nct_id,title,status,phase,enrollment,start_date,completion_date,enrollment_rate_monthly,enrollment_rate_tier,enrollment_success_pct,success_tier,status_success_score,composite_success_score,success_percentile
NCT03447535,Better Understand Children and Adolescents' Intrafamilial Oppositional Defiant Disorder,COMPLETED,,75.0,2017-12-01,2017-12-31,75.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,64.3,77.265
NCT05836935,Role of Imaging in Complications of Sinusitis,UNKNOWN,NA,30.0,2023-05-01,2023-12-01,4.267289719626168,Adequate (1-10/month),42.67289719626169,Significantly Below (<50%),50,37.4,18.62
NCT03551535,Monitored Home Exercise in Pregnancy,WITHDRAWN,NA,0.0,2018-11-01,2019-10-08,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT02889835,Clinical Performance of Incremental and Bulk Fill Composites in Class II Restorations,COMPLETED,NA,53.0,2016-03-22,2021-07-03,0.8363504406428202,Slow (<1/month),8.363504406428202,Significantly Below (<50%),100,49.2,46.035
NCT04802135,Creation of a Register of Patients With Neonatal-onset Epileptic Encephalopathy,RECRUITING,,200.0,2021-03-06,2032-09-01,1.450559923755063,Adequate (1-10/month),14.505599237550632,Significantly Below (<50%),60,47.3,40.475
NCT01081535,The Effect of Intravenous (IV) Patient Controlled Analgesic (PCA) With Ketorolac or Fentanyl Combined With Caudal Block for Postoperative Analgesia in Small Children Undergoing Intravesical Ureteroneocystostomy,COMPLETED,NA,50.0,2009-05-01,2010-02-01,5.5144927536231885,Adequate (1-10/month),55.14492753623188,Below (50-75%),100,54.0,58.72500000000001
NCT05775835,Effects of Whole Body Vibration and Resistance Exercise on Carotis Intima Media and Muscle Architecture in Hypertension,COMPLETED,NA,43.0,2023-02-10,2024-03-15,3.280501253132832,Adequate (1-10/month),32.80501253132832,Significantly Below (<50%),100,53.4,57.35
NCT03012035,The Role of Treatment Expectation in Exposure Training With Spider Fearful Participants,COMPLETED,NA,70.0,2017-05-18,2018-03-12,7.150335570469799,Adequate (1-10/month),71.503355704698,Below (50-75%),100,55.6,62.905
NCT06986135,The Effect of Breathing on Cognitive Performance and Stress,COMPLETED,NA,66.0,2024-08-01,2025-05-01,7.35912087912088,Adequate (1-10/month),73.5912087912088,Below (50-75%),100,55.3,62.36000000000001
NCT02897635,Integrative Approaches For Cancer Survivorship 2: Project 1,COMPLETED,NA,20.0,2016-09-01,2018-09-21,0.8117333333333334,Slow (<1/month),8.117333333333333,Significantly Below (<50%),100,46.6,37.375
NCT02687035,PARTNER II Trial: S3iCAP,COMPLETED,NA,1822.0,2015-01-01,2018-12-01,38.78439160839161,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT00575835,Oral Vitamin D Supplementation in Elderly Women,COMPLETED,NA,40.0,2006-10-01,2007-10-01,3.3358904109589043,Adequate (1-10/month),33.35890410958904,Significantly Below (<50%),100,53.2,56.665
NCT01076335,Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer,COMPLETED,PHASE2,40.0,2005-05-01,2015-06-01,0.3306000543035569,Slow (<1/month),3.306000543035569,Significantly Below (<50%),100,48.2,43.665
NCT00789035,12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients,COMPLETED,PHASE2,408.0,2008-10-01,,,Slow (<1/month),,Significantly Below (<50%),100,72.6,83.28
NCT04790435,Acute-On-Chronic Liver Failure In Cirrhotic Patients,COMPLETED,,109.0,2021-03-01,2022-02-01,9.845578635014837,Adequate (1-10/month),98.45578635014839,Met (75-100%),100,62.1,74.595
NCT02636335,"Light, Exercise Intensity and Mood in Overweight",COMPLETED,NA,26.0,2016-01-01,2017-06-01,1.5308317214700196,Adequate (1-10/month),15.308317214700196,Significantly Below (<50%),100,47.1,39.64
NCT04990635,Evaluation of Caudal Block Success With Perfusion Index,UNKNOWN,,55.0,2021-08-17,2021-09-30,38.050000000000004,Good (10-50/month),200.0,Exceeded (≥100%),50,42.7,25.77
NCT06077435,Comparative Analysis of AI Software for Enhanced Polyp Detection and Diagnosis,RECRUITING,NA,915.0,2023-03-01,2026-06-01,23.444949494949498,Good (10-50/month),200.0,Exceeded (≥100%),60,83.0,89.505
NCT06762535,fMRI Study of the Neural Mechanism of rTMS in the Treatment of Nicotine Dependence,ACTIVE_NOT_RECRUITING,NA,50.0,2023-04-01,2025-08-01,1.784290738569754,Adequate (1-10/month),17.84290738569754,Significantly Below (<50%),85,49.5,46.58
NCT02983435,Osteopathic Treatment for Chronic Low Back Pain,COMPLETED,NA,10.0,2016-12-01,2017-04-01,2.515702479338843,Adequate (1-10/month),25.157024793388434,Significantly Below (<50%),100,50.8,49.18
NCT03629535,Accuracy of Non-invasive Non-oscillometric Blood Pressure Wristband,COMPLETED,NA,8.0,2019-04-01,2019-09-10,1.5032098765432098,Adequate (1-10/month),15.032098765432098,Significantly Below (<50%),100,45.6,32.08
NCT00532935,MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066),COMPLETED,PHASE3,517.0,2008-01-26,2009-10-23,24.74446540880503,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT06354608,The Effect of Audio Book and Local Vibration on Pain and Fear in Intramuscular Injection in Children,RECRUITING,NA,120.0,2023-10-25,2024-07-01,14.6112,Good (10-50/month),146.112,Exceeded (≥100%),60,52.6,54.684999999999995
NCT04580108,Highly Sensitive Serum Cardiac Troponin T and Cardiovascular Events in Patients With Systemic Lupus Erythematosus,COMPLETED,,446.0,2007-07-03,2019-06-26,3.1024314442413163,Adequate (1-10/month),31.024314442413164,Significantly Below (<50%),100,84.0,90.595
NCT07252908,A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder,RECRUITING,PHASE2,195.0,2025-12-22,2026-06-01,36.86832298136646,Good (10-50/month),200.0,Exceeded (≥100%),60,58.6,69.51
NCT04711408,Virtual Reality During Ultrasound Examination of Women With Endometriosis,UNKNOWN,NA,100.0,2022-06-14,2023-12-01,5.689719626168224,Adequate (1-10/month),56.89719626168224,Below (50-75%),50,43.0,26.465
NCT00963508,"Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice",COMPLETED,PHASE3,403.0,2009-08-01,2010-03-01,57.86471698113208,Excellent (>50/month),200.0,Exceeded (≥100%),100,92.2,93.825
NCT02380508,Heterologous Effects of BCG in Healthy UK Adults,COMPLETED,NA,36.0,2015-02-01,2016-11-01,1.7149295774647888,Adequate (1-10/month),17.14929577464789,Significantly Below (<50%),100,52.9,55.55
NCT01304108,Improving Venous Thromboembolism Prophylaxis,COMPLETED,PHASE4,3000.0,2009-01-01,2010-05-01,188.28865979381445,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT02368808,"Adolescent Bereavement Initiative in the Free State, South Africa",COMPLETED,NA,843.0,2015-01-01,2015-11-01,84.41092105263158,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT06979908,A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer,RECRUITING,PHASE2,46.0,2025-01-22,2027-01-22,1.91813698630137,Adequate (1-10/month),19.1813698630137,Significantly Below (<50%),60,41.7,24.36
NCT06318208,Pulmonary Function in Non-hospitalized Adults and Children After Mild COVID-19,COMPLETED,,110.0,2021-04-20,2022-01-03,12.97829457364341,Good (10-50/month),129.7829457364341,Exceeded (≥100%),100,62.1,74.595
NCT01495208,Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment,WITHDRAWN,PHASE4,0.0,2011-12-01,2012-10-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT03221608,Clinical Analysis of HIPEC for T4 Colorectal Cancer After Surgery,UNKNOWN,PHASE3,300.0,2017-08-01,2024-08-01,3.5713727023856086,Adequate (1-10/month),35.71372702385609,Significantly Below (<50%),50,59.0,70.365
NCT03352908,Yale Swallow Protocol in Extubated Patients,COMPLETED,,166.0,2017-10-25,2020-10-29,4.593672727272728,Adequate (1-10/month),45.93672727272728,Significantly Below (<50%),100,61.6,74.0
NCT06921408,Retrospective Identification of Scintigraphic Cardiac Amyloidosis (RISCA),NOT_YET_RECRUITING,,57.0,2025-06-01,2027-12-01,1.9004162102957285,Adequate (1-10/month),19.004162102957284,Significantly Below (<50%),30,31.9,11.295
NCT06444308,Community Health Worker-led Hypertension Management,RECRUITING,NA,460.0,2024-09-09,2026-09-01,19.393905817174517,Good (10-50/month),193.93905817174516,Exceeded (≥100%),60,79.8,87.27000000000001
NCT04645108,Coached or Non-Coached Weight Loss Intervention,COMPLETED,NA,246.0,2020-11-20,2021-06-10,37.07049504950495,Good (10-50/month),200.0,Exceeded (≥100%),100,74.7,84.33500000000001
NCT00004108,DX-8951f in Treating Patients With Liver Cancer,COMPLETED,PHASE2,,1999-09-01,2005-04-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,30.330000000000002
NCT00359008,PHP Home Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization (CNV),COMPLETED,,336.0,2006-07-01,2007-09-01,23.952786885245903,Good (10-50/month),200.0,Exceeded (≥100%),100,80.2,88.045
NCT00704808,Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739),COMPLETED,,180.0,2006-05-01,2008-12-01,5.798095238095239,Adequate (1-10/month),57.98095238095239,Below (50-75%),100,62.7,75.42
NCT01590108,The Study of Apelin-APJ System on Pulmonary Hypertension Patients and Healthy Subjects,COMPLETED,PHASE1,12.0,2012-03-01,2014-09-01,0.39964989059080963,Slow (<1/month),3.996498905908097,Significantly Below (<50%),100,46.0,34.1
NCT03625908,Optical CoherenCe Tomography-gUided Coronary Intervention in Patients With Complex lesIons: a Randomized Controlled Trial (OCCUPI Trial),COMPLETED,NA,1604.0,2019-01-09,2023-10-12,28.10924582613702,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT00823108,Rapid Administration of Insulin in Sepsis,COMPLETED,PHASE1,20.0,2009-03-01,2010-10-01,1.05146804835924,Adequate (1-10/month),10.5146804835924,Significantly Below (<50%),100,46.6,37.375
NCT00609908,The Technique of Skin Stretching for Acute Burn Treatment and Scar Reconstruction,COMPLETED,PHASE3,30.0,2007-12-01,2011-06-01,0.7145539906103286,Slow (<1/month),7.145539906103286,Significantly Below (<50%),100,47.4,40.98
NCT00582608,Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9,TERMINATED,NA,12.0,2001-10-01,2009-05-01,0.13191765980498377,Slow (<1/month),1.3191765980498376,Significantly Below (<50%),10,19.0,4.84
NCT03991208,Malarone Pharmacokinetics Under Simulated Physiologic Stressors of Deployment,WITHDRAWN,PHASE4,0.0,2019-05-24,2021-05-23,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT04673825,Monitoring Spondyloarthritis With SpA-Net,COMPLETED,NA,200.0,2020-12-02,2023-07-01,6.46971307120085,Adequate (1-10/month),64.69713071200852,Below (50-75%),100,66.0,78.99000000000001
NCT03909425,Defining Disease Activity in Neovascular AMD With Optical Coherence Tomography Angiography,COMPLETED,,35.0,2019-09-02,2021-08-16,1.4921568627450983,Adequate (1-10/month),14.921568627450982,Significantly Below (<50%),100,46.1,34.695
NCT01117025,Combined Treatment of Resistant Hypertension and Atrial Fibrillation,COMPLETED,PHASE2,26.0,2010-04-01,2012-04-01,1.0826812585499317,Adequate (1-10/month),10.826812585499317,Significantly Below (<50%),100,47.1,39.64
NCT01566825,The Influence of Amitriptyline on Learning in a Visual Discrimination Task,COMPLETED,NA,32.0,2008-08-01,2009-05-01,3.5680586080586085,Adequate (1-10/month),35.68058608058608,Significantly Below (<50%),100,52.6,54.684999999999995
NCT04443725,Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19,UNKNOWN,PHASE2,100.0,2020-07-01,2020-12-01,19.895424836601308,Good (10-50/month),198.95424836601308,Exceeded (≥100%),50,48.0,42.945
NCT05980325,Exercise for Fighting Oncology Repercussions After Treatment,NOT_YET_RECRUITING,NA,45.0,2025-01-08,2026-07-01,2.541372912801484,Adequate (1-10/month),25.413729128014843,Significantly Below (<50%),30,32.6,12.31
NCT00433225,Efficacy of Topical Ketorolac Versus Placebo for Improving Visual Outcomes Following Multifocal IOL Implantation,COMPLETED,PHASE4,,,,,Slow (<1/month),,Significantly Below (<50%),100,40.0,21.87
NCT05501925,GlideSheath Slender® Versus Conventional 6 French Arterial Sheath: Impact on the Distal Radial Artery Occlusion (SMART),UNKNOWN,NA,600.0,2022-09-15,2024-02-28,34.3954802259887,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT03574025,NEUROlogical Prognosis After Cardiac Arrest in Kids,UNKNOWN,,150.0,2018-01-01,2019-08-01,7.913344887348354,Adequate (1-10/month),79.13344887348354,Met (75-100%),50,45.3,31.169999999999998
NCT05043376,Study to Investigate the Treatment Benefits of Probiotic Streptococcus Salivarius K12 for Hospitalised Patients (Non-ICU) With COVID-19,COMPLETED,NA,50.0,2021-09-10,2021-11-21,21.13888888888889,Good (10-50/month),200.0,Exceeded (≥100%),100,59.0,70.365
NCT00672776,Effects of Paxil CR on Neural Circuits in Posttraumatic Stress Disorder (PTSD),COMPLETED,PHASE4,40.0,2003-05-01,2007-09-01,0.7686868686868688,Slow (<1/month),7.686868686868687,Significantly Below (<50%),100,48.2,43.665
NCT00016276,"Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer",TERMINATED,PHASE3,396.0,2001-05-01,,,Slow (<1/month),,Significantly Below (<50%),10,44.7,29.67
NCT02929576,"Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer",WITHDRAWN,PHASE3,0.0,2016-09-01,,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT01459276,A Study to Evaluate Safety and Immunogenicity of FluvalAB-like Influenza Vaccine in Non-Elderly Adult and Elderly Subjects,COMPLETED,NA,1206.0,2011-10-01,2012-03-01,241.51736842105262,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT06092476,Trial to Evaluate Efficacy+Safety of Revita DMR Treatment Paradigm 1 and Retreatment in Type 2 Diabetes Patients,RECRUITING,NA,18.0,2024-08-09,2027-07-01,0.5188636363636363,Slow (<1/month),5.188636363636364,Significantly Below (<50%),60,34.4,14.430000000000001
NCT05308576,A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 Years,ACTIVE_NOT_RECRUITING,PHASE3,10000.0,2022-12-26,2024-04-01,658.8744588744589,Excellent (>50/month),200.0,Exceeded (≥100%),85,95.5,96.55
NCT06722976,Digital Health and Exercise for Autonomous Longevity Program,ENROLLING_BY_INVITATION,NA,120.0,2024-11-05,2025-07-01,15.347899159663866,Good (10-50/month),153.47899159663868,Exceeded (≥100%),55,51.1,50.129999999999995
NCT05645276,A Study of AK129 in Patients With Advanced Malignant Tumors,RECRUITING,PHASE1,182.0,2023-03-02,2026-06-01,4.667295703454086,Adequate (1-10/month),46.672957034540865,Significantly Below (<50%),60,52.6,54.684999999999995
NCT00588276,Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors,COMPLETED,PHASE1,15.0,2005-06-01,2012-06-01,0.17856863511928042,Slow (<1/month),1.7856863511928043,Significantly Below (<50%),100,46.2,35.089999999999996
NCT04271176,Jaundice as Initial Presentation of Liver Hydatidosis (ICTEHIDA),UNKNOWN,,35.0,2009-01-01,2021-04-30,0.23665037760995114,Slow (<1/month),2.3665037760995116,Significantly Below (<50%),50,31.1,10.084999999999999
NCT02878876,Incidence of Lactose Intolerance Among Self-reported Lactose Intolerant People,COMPLETED,PHASE4,600.0,2016-01-01,2016-03-01,304.40000000000003,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT01821976,Transtibial Amputation Outcomes Study,COMPLETED,NA,250.0,2013-03-01,2020-03-01,2.9761439186546736,Adequate (1-10/month),29.76143918654674,Significantly Below (<50%),100,70.0,81.89999999999999
NCT06981676,The Developmental Origins of Obesity,RECRUITING,NA,160.0,2023-07-25,2027-03-30,3.623809523809524,Adequate (1-10/month),36.23809523809524,Significantly Below (<50%),60,50.8,49.18
NCT02644876,Preventive Effects of Penehyclidine Hydrochloride Inhalation on Postoperative Pulmonary Complications,COMPLETED,PHASE4,864.0,2015-09-01,2018-12-10,21.99010033444816,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT04648176,Application of MOSES Technology in BPH,UNKNOWN,NA,400.0,2020-03-06,2023-06-30,10.054500412881916,Good (10-50/month),100.54500412881917,Exceeded (≥100%),50,72.0,82.92
NCT04334876,Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers,COMPLETED,NA,571.0,2020-04-01,2021-01-01,63.2045090909091,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT00003617,Chlorambucil Compared With No Further Therapy Following Anti-Helicobacter Therapy in Treating Patients With Low-Grade Lymphoma of the Stomach,UNKNOWN,PHASE3,200.0,1995-03-01,,,Slow (<1/month),,Significantly Below (<50%),50,41.0,23.01
NCT01298817,Use of a Soy-based Meal Replacement Weight Loss Intervention to Impact Ectopic Fat,COMPLETED,NA,24.0,2011-03-01,2012-12-01,1.1397191887675506,Adequate (1-10/month),11.397191887675506,Significantly Below (<50%),100,46.9,38.96
NCT07146217,Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection,NOT_YET_RECRUITING,PHASE2,30.0,2025-08-01,2026-10-01,2.143661971830986,Adequate (1-10/month),21.43661971830986,Significantly Below (<50%),30,31.4,10.47
NCT06852417,Qigong and Executive Attention in Older Adults with Depressive Symptoms,NOT_YET_RECRUITING,NA,200.0,2026-01-01,2028-12-31,5.559817351598174,Adequate (1-10/month),55.59817351598174,Below (50-75%),30,45.0,30.330000000000002
NCT02272517,Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder,COMPLETED,PHASE3,101.0,2014-12-01,2016-03-01,6.742192982456141,Adequate (1-10/month),67.42192982456142,Below (50-75%),100,58.1,68.595
NCT05107817,Aquatic Exercise and Reactive Balance,NOT_YET_RECRUITING,NA,44.0,2026-01-01,2027-09-01,2.2028947368421052,Adequate (1-10/month),22.028947368421054,Significantly Below (<50%),30,32.5,12.235
NCT04821817,Peribulbar Rocuronium in Adult Strabismus Surgery,COMPLETED,NA,52.0,2021-04-03,2025-02-09,1.1242045454545455,Adequate (1-10/month),11.242045454545455,Significantly Below (<50%),100,49.2,46.035
NCT01833117,Efficacy and Safety Study of FID 119515A,COMPLETED,NA,75.0,2013-05-01,2013-06-01,73.64516129032258,Excellent (>50/month),200.0,Exceeded (≥100%),100,66.0,78.99000000000001
NCT03391817,FAECAL MICROBIOTA TRANSPLANTATION IN OBESITY,UNKNOWN,NA,40.0,2018-01-19,2021-02-28,1.0718309859154929,Adequate (1-10/month),10.718309859154928,Significantly Below (<50%),50,33.2,12.989999999999998
NCT05059717,An Investigational Scan (MR DENSE) in Detecting Early Chemotherapy-Related Liver Injury Before Surgery in Patients With Resectable Colorectal Liver Metastases,WITHDRAWN,NA,0.0,2018-07-12,2022-06-24,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT05599217,Association Between Dietary Factors and Chronic Subdural Hematoma (DISH),RECRUITING,,420.0,2023-03-13,2025-03-31,17.069158878504673,Good (10-50/month),170.69158878504675,Exceeded (≥100%),60,74.9,84.425
NCT02082717,The Impact of Neut During Potassium Chloride Replacement on Pain and Incidence of Phlebitis,TERMINATED,PHASE4,17.0,2014-02-25,2018-08-03,0.3194320987654321,Slow (<1/month),3.194320987654321,Significantly Below (<50%),10,19.4,5.2299999999999995
NCT05999617,Effectiveness of Dual Task Exercise Training in Children With Cerebral Palsy,COMPLETED,NA,30.0,2023-05-12,2023-08-31,8.227027027027027,Adequate (1-10/month),82.27027027027027,Met (75-100%),100,52.4,53.949999999999996
NCT03190317,Health Information for Infected Veterans,ACTIVE_NOT_RECRUITING,,123.0,2019-06-24,2025-09-30,1.6349868995633188,Adequate (1-10/month),16.349868995633187,Significantly Below (<50%),85,48.7,44.93
NCT01222117,A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion,COMPLETED,PHASE2,174.0,2010-12-01,2016-01-01,2.8522132471728594,Adequate (1-10/month),28.52213247172859,Significantly Below (<50%),100,63.9,76.9
NCT05300217,Evaluation of a Website to Improve Depression Literacy in Adoldescents,COMPLETED,NA,79.0,2021-01-04,2022-05-02,4.97879917184265,Adequate (1-10/month),49.7879917184265,Significantly Below (<50%),100,56.3,64.5
NCT05275140,Adapted Taekwondo on Health Status in Older Women,COMPLETED,NA,56.0,2023-05-01,2024-01-30,6.221313868613138,Adequate (1-10/month),62.21313868613139,Below (50-75%),100,54.5,60.12
NCT00874640,Patient Characteristics in Daily Radiological Practice of Gadovist® Application (PATRON),COMPLETED,,3711.0,2009-03-01,2011-11-01,115.85932307692309,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02307240,"Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors",COMPLETED,PHASE1,43.0,2014-11-01,2019-05-31,0.7828468899521531,Slow (<1/month),7.828468899521532,Significantly Below (<50%),100,48.4,44.22
NCT01154140,A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung,COMPLETED,PHASE3,343.0,2011-01-13,2016-11-30,4.8607635009311,Adequate (1-10/month),48.60763500931099,Significantly Below (<50%),100,77.4,85.835
NCT03592940,The Management of Neuroendocrine Tumours: A Nutritional Viewpoint.,COMPLETED,,100.0,2017-11-01,2018-06-30,12.630705394190873,Good (10-50/month),126.30705394190873,Exceeded (≥100%),100,61.3,73.56
NCT05331040,Radiomics in Rectal Cancer,UNKNOWN,,350.0,2020-05-01,2025-05-01,5.83461117196057,Adequate (1-10/month),58.346111719605695,Below (50-75%),50,61.3,73.56
NCT04855240,Evaluate the Efficacy and Safety of ACP-044 for the Treatment of Acute Postoperative Pain Following Bunionectomy,COMPLETED,PHASE2,239.0,2021-03-29,2022-03-14,20.78617142857143,Good (10-50/month),200.0,Exceeded (≥100%),100,74.1,84.10499999999999
NCT00544440,An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma,COMPLETED,PHASE2,57.0,2007-10-01,2012-08-01,0.9824915062287657,Slow (<1/month),9.824915062287657,Significantly Below (<50%),100,49.6,46.785
NCT00430040,Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.,TERMINATED,PHASE4,14.0,2007-02-01,2013-05-01,0.1868303375712407,Slow (<1/month),1.868303375712407,Significantly Below (<50%),10,19.1,4.9799999999999995
NCT04742140,Magnesium Sulphate Injection in Treatment of Myofascial Trigger Points,COMPLETED,PHASE4,180.0,2021-02-20,2021-09-01,28.389637305699484,Good (10-50/month),200.0,Exceeded (≥100%),100,69.4,81.52000000000001
NCT02021240,Ketamine in Post-operative Dental Pain and Recovery,COMPLETED,PHASE3,150.0,2014-02-10,2016-04-18,5.7218045112781954,Adequate (1-10/month),57.21804511278196,Below (50-75%),100,62.0,74.42
NCT01126840,Survivorship in Lynch Syndrome Families,COMPLETED,,303.0,2010-06-20,2022-09-19,2.061537773804202,Adequate (1-10/month),20.615377738042024,Significantly Below (<50%),100,72.6,83.28
NCT05710289,A Blood Collection Study to Assess the Immunogenicity of Nationally Authorized Homologous COVID-19 Booster Vaccines Among Adult Vaccinees.,WITHDRAWN,,0.0,2023-02-01,2024-02-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT03222089,Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC,WITHDRAWN,PHASE2,0.0,2017-07-20,2020-07-20,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT06356389,"A Clinical Trial to Evaluate Safety, Tolerance and Pharmacokinetics of JX11502MA Capsule in Patients With Schizophrenia.",COMPLETED,PHASE1,60.0,2022-03-02,2023-01-28,5.501204819277109,Adequate (1-10/month),55.012048192771076,Below (50-75%),100,54.8,61.095
NCT00778089,Open-Label Study to Evaluate the Immunogenicity of Bovine Collagen in ArteFill® by Skin Testing,TERMINATED,NA,498.0,2008-07-01,2008-12-03,97.80077419354839,Excellent (>50/month),200.0,Exceeded (≥100%),10,72.8,83.36
NCT07279389,Comparative Study Between One-Shot Dilatation Versus Serial Dilatation Techniques for Access in Percutaneous Nephrolithotomy in Adult Patients,COMPLETED,NA,60.0,2022-02-27,2023-08-05,3.4854961832061067,Adequate (1-10/month),34.85496183206107,Significantly Below (<50%),100,54.8,61.095
NCT00176189,Clinical Performance of Extended All-Ceramic Fixed Partial Dentures Based on Zircon-Oxide Ceramics.,COMPLETED,NA,30.0,2005-02-01,2006-12-01,1.367065868263473,Adequate (1-10/month),13.670658682634729,Significantly Below (<50%),100,47.4,40.98
NCT04337489,Remote Monitoring Use In Cases Of Suspected COVID-19 (Coronavirus),COMPLETED,,15.0,2020-07-28,2021-03-26,1.8946058091286309,Adequate (1-10/month),18.94605809128631,Significantly Below (<50%),100,49.5,46.58
NCT02904889,Stimulating Engagement in Daily and Physical Activities Among Older Adults Receiving Homecare Services (Part of Basic Care Revisited),COMPLETED,NA,40.0,2016-09-01,2017-07-01,4.018481848184819,Adequate (1-10/month),40.18481848184819,Significantly Below (<50%),100,53.2,56.665
NCT04594889,Comparison of Sirolimus vs Paclitaxel Drug Eluting Balloon for Below-the-knee Angioplasty in Critical Limb Ischemia,UNKNOWN,NA,170.0,2020-10-14,2022-12-31,6.404455445544555,Adequate (1-10/month),64.04455445544556,Below (50-75%),50,48.6,44.685
NCT00358189,Effects of Deep Brain Stimulation for the Treatment of Parkinson's Disease,COMPLETED,,20.0,2006-10-01,2008-05-01,1.053287197231834,Adequate (1-10/month),10.53287197231834,Significantly Below (<50%),100,44.9,30.025000000000002
NCT06011889,Study of the Efficacy and Safety of Etanercept Treatment in Patients With SAPHO Syndrome,RECRUITING,PHASE2,60.0,2024-09-04,2028-10-18,1.2135548172757475,Adequate (1-10/month),12.135548172757476,Significantly Below (<50%),60,37.8,19.015
NCT04285489,A Study on the Safety of Hakim Programmable Shunt System,COMPLETED,,130.0,2020-05-02,2020-07-28,45.48505747126437,Good (10-50/month),200.0,Exceeded (≥100%),100,68.7,81.065
NCT00836589,Long-term Evaluation of the Linox Family ICD Leads Registry (GALAXY),COMPLETED,,1997.0,2008-12-01,2016-12-01,20.803791923340178,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT01936389,A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma,COMPLETED,PHASE2,10.0,2013-09-01,2014-10-01,0.7706329113924052,Slow (<1/month),7.706329113924052,Significantly Below (<50%),100,45.8,33.03
NCT04302389,Single Arm Trial of a Multi-component Commercial Digital Weight Loss Program,COMPLETED,NA,153.0,2021-02-10,2021-11-01,17.641363636363636,Good (10-50/month),176.41363636363636,Exceeded (≥100%),100,67.2,79.94
NCT04039789,Impact of Physical Activity as a Coadjuvant Treatment in the Healing of Venous Ulcers in Primary Health Care.,COMPLETED,NA,44.0,2021-05-17,2023-12-31,1.398079331941545,Adequate (1-10/month),13.980793319415449,Significantly Below (<50%),100,48.5,44.47
NCT04908189,A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment,ACTIVE_NOT_RECRUITING,PHASE3,729.0,2021-07-15,2026-11-12,11.403268242548819,Good (10-50/month),114.03268242548819,Exceeded (≥100%),85,90.5,93.4
NCT03946189,Comparison of the PaO2/FiO2 Ratio to Other Oxygenation Indexes for the Classification of Severity of Acute Respiratory Distress Syndrome,COMPLETED,,150.0,2018-03-14,2019-05-01,11.055690072639225,Good (10-50/month),110.55690072639226,Exceeded (≥100%),100,65.3,78.32000000000001
NCT06365489,"Comparison of Brachial Wrist Index Before and After Implantation of Arteriovenous Fistulas, Based on Brachial Artery",COMPLETED,,78.0,2022-12-11,2024-09-15,3.686832298136646,Adequate (1-10/month),36.86832298136646,Significantly Below (<50%),100,54.6,60.39
NCT00281489,Study Evaluating Ways of Preventing Patients From Being Awake During High-Risk Surgery and Anesthesia,COMPLETED,PHASE2,2000.0,2005-08-01,,,Slow (<1/month),,Significantly Below (<50%),100,80.0,87.67
NCT03077789,Prospective Study of the Diagnostic and Therapeutic Management of Congenital Glaucoma in France,COMPLETED,NA,250.0,2013-04-01,2021-11-01,2.4266581632653064,Adequate (1-10/month),24.266581632653065,Significantly Below (<50%),100,70.0,81.89999999999999
NCT00094289,Interactions Between Cocaine and Ethanol and Disulfiram - 1,UNKNOWN,PHASE1,16.0,2004-08-01,2005-07-01,1.4582035928143713,Adequate (1-10/month),14.58203592814371,Significantly Below (<50%),50,31.3,10.299999999999999
NCT05814289,"The Association of Telephone Head Tilt With Cervical, Thoracic, and Lumbar Spine Mobility and Disorders in Young Adults",COMPLETED,NA,40.0,2023-04-01,2024-07-01,2.664332603938731,Adequate (1-10/month),26.64332603938731,Significantly Below (<50%),100,53.2,56.665
NCT02826889,Assessing the Diagnostic Accuracy of Corrected Flow Time (FTc) and Pleth Variability Index (PVI) as Predictors of Fluid Responsiveness in Patients in the Prone Position Using the Jackson Table,COMPLETED,NA,58.0,2016-05-24,2017-07-27,4.1154312354312355,Adequate (1-10/month),41.15431235431235,Significantly Below (<50%),100,54.6,60.39
NCT07028489,Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer,RECRUITING,,130.0,2025-06-05,2029-04-01,2.8346704871060173,Adequate (1-10/month),28.346704871060176,Significantly Below (<50%),60,46.7,37.895
NCT04282889,Rotational Thromboelastometry (ROTEM) TRUE-NATEM Reference Value Validation in Liver Transplantation,COMPLETED,,40.0,2020-10-06,2021-02-01,10.31864406779661,Good (10-50/month),103.18644067796612,Exceeded (≥100%),100,56.5,65.18
NCT04666389,The Role of Statins in the Prevention of Contrast-induced Acute Kidney Injury in Patients With Cardiovascular Diseases,COMPLETED,NA,150.0,2020-10-15,2023-01-10,5.588739290085679,Adequate (1-10/month),55.88739290085679,Below (50-75%),100,62.0,74.42
NCT07097389,In Vivo Human Study on Commercial Cellobiose as a Potential Prebiotic Candidate,COMPLETED,NA,37.0,2024-07-31,2025-06-01,3.69272131147541,Adequate (1-10/month),36.9272131147541,Significantly Below (<50%),100,53.0,55.80500000000001
NCT02312089,GnRHa for Luteal Phase Support in GnRH Antagonist Protocol Cycles,UNKNOWN,PHASE4,200.0,2016-08-07,2024-12-31,1.9843546284224252,Adequate (1-10/month),19.84354628422425,Significantly Below (<50%),50,51.0,49.714999999999996
NCT01615289,Neural Effects of Green Tea Extract on Dorsolateral Prefrontal Cortex,COMPLETED,NA,12.0,2010-07-01,2012-01-01,0.6653551912568307,Slow (<1/month),6.6535519125683065,Significantly Below (<50%),100,46.0,34.1
NCT01369368,Treatment of Acute Leukemia Relapse After Allotransplantation,UNKNOWN,PHASE1,20.0,2013-08-01,2020-10-01,0.23254392666157372,Slow (<1/month),2.3254392666157373,Significantly Below (<50%),50,31.6,10.905
NCT01427868,Bioequivalence of LB80380 Free Base and Maleate Salt Tablets,COMPLETED,PHASE1,32.0,2010-09-01,2010-12-01,10.704175824175824,Good (10-50/month),107.04175824175823,Exceeded (≥100%),100,57.6,67.36999999999999
NCT05421468,Timing of Thyroxine Dose In Ramadan,UNKNOWN,NA,250.0,2022-03-14,2022-10-30,33.08695652173913,Good (10-50/month),200.0,Exceeded (≥100%),50,60.0,71.97
NCT03240068,Angiotensin-(1-7) in Peripheral Arterial Disease,TERMINATED,EARLY_PHASE1,6.0,2017-09-01,2020-03-09,0.1985217391304348,Slow (<1/month),1.9852173913043478,Significantly Below (<50%),10,18.5,4.02
NCT06347068,Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells,RECRUITING,PHASE1,42.0,2024-06-27,2028-05-01,0.9105982905982907,Slow (<1/month),9.105982905982907,Significantly Below (<50%),60,36.4,17.14
NCT00607568,Atomoxetine Effects in Humans,COMPLETED,PHASE1,10.0,2006-06-01,2009-09-01,0.25622895622895625,Slow (<1/month),2.5622895622895623,Significantly Below (<50%),100,45.8,33.03
NCT01507168,A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma,COMPLETED,PHASE2,185.0,2012-02-02,2015-08-20,4.348571428571429,Adequate (1-10/month),43.48571428571429,Significantly Below (<50%),100,64.8,77.865
NCT02551068,High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib,RECRUITING,NA,88.0,2015-12-01,2026-12-01,0.6666799402687905,Slow (<1/month),6.666799402687906,Significantly Below (<50%),60,40.0,21.87
NCT00043368,PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909),COMPLETED,PHASE2,31.0,2002-09-01,2007-06-01,0.5441983852364476,Slow (<1/month),5.4419838523644755,Significantly Below (<50%),100,47.5,41.415
NCT06324968,Ro60 Expression in Macrophages in Sjogren's Disease,ACTIVE_NOT_RECRUITING,NA,20.0,2024-02-09,2025-05-09,1.338021978021978,Adequate (1-10/month),13.380219780219782,Significantly Below (<50%),85,42.1,25.019999999999996
NCT00218868,Cytodiagnosis of Basal Cell Carcinoma and Actinic Keratosis Using Papanicolaou and May-grunwald-giemsa Stained Tissue Smear,COMPLETED,,66.0,2000-01-01,2007-11-01,0.7022160083886754,Slow (<1/month),7.022160083886753,Significantly Below (<50%),100,48.6,44.685
NCT05227768,Safety and Pharmacokinetics Study of Single Ascending Doses of VV116 in Healthy Volunteers,COMPLETED,PHASE1,38.0,2021-11-11,2022-01-13,18.36063492063492,Good (10-50/month),183.6063492063492,Exceeded (≥100%),100,58.0,68.245
NCT01101568,A Study to Investigate the Interaction of GSK1292263 With Rosuvastatin and Simvastatin in Healthy Subjects,COMPLETED,PHASE1,28.0,2010-04-14,2010-06-24,12.004507042253522,Good (10-50/month),120.0450704225352,Exceeded (≥100%),100,57.2,66.465
NCT03071068,A Study to Evaluate the Safety and Efficacy of THR-317 for the Treatment of Diabetic Macular Oedema (DME),COMPLETED,PHASE2,49.0,2016-12-22,2018-04-01,3.2076559139784946,Adequate (1-10/month),32.07655913978494,Significantly Below (<50%),100,53.9,58.34
NCT03095768,Lifestyle Education and Nutrition Demonstration,COMPLETED,NA,37.0,2017-04-13,2017-06-15,17.877460317460315,Good (10-50/month),178.77460317460316,Exceeded (≥100%),100,58.0,68.245
NCT06951568,Study of the Effect of Peripheral Somatosensory Stimulation on the Functionality of Patients With Cerebral Palsy and Reduced Mobility,RECRUITING,NA,20.0,2025-05-02,2025-09-30,4.031788079470199,Adequate (1-10/month),40.317880794701985,Significantly Below (<50%),60,39.6,21.115000000000002
NCT05642468,Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis,COMPLETED,PHASE2,18.0,2023-01-09,2025-07-10,0.60013143483023,Slow (<1/month),6.001314348302301,Significantly Below (<50%),100,46.4,36.26
NCT00169468,Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma,COMPLETED,PHASE2,48.0,2005-01-01,2006-01-01,4.0030684931506855,Adequate (1-10/month),40.030684931506855,Significantly Below (<50%),100,53.8,58.065
NCT04101968,The GBA Multimodal Study in Parkinson's Disease,RECRUITING,,25.0,2019-05-01,2025-12-30,0.3125256673511294,Slow (<1/month),3.1252566735112937,Significantly Below (<50%),60,33.3,13.200000000000001
NCT02826668,Influence of Lumbar Ultrasound on Resident Learning Curve for Lateral Labor Epidural Placement,TERMINATED,NA,28.0,2014-06-01,2021-03-01,0.3457687626774848,Slow (<1/month),3.4576876267748484,Significantly Below (<50%),10,20.2,5.845000000000001
NCT06990568,Impact of Probiotics on Antibiotic-associated Diarrhea in Community-acquired Pneumonia,NOT_YET_RECRUITING,PHASE4,100.0,2025-06-01,2026-12-31,5.26643598615917,Adequate (1-10/month),52.664359861591706,Below (50-75%),30,37.0,17.955
NCT03403868,Right Ventricular Haemodynamic Evaluation and Response to Treatment,UNKNOWN,NA,100.0,2016-01-01,2021-12-01,1.4086071263304025,Adequate (1-10/month),14.086071263304026,Significantly Below (<50%),50,38.0,19.255
NCT00732368,A Long-term Study of Mometasone Furoate in Patients With Perennial Allergic Rhinitis (Study P04459),COMPLETED,PHASE3,98.0,2005-05-01,2006-01-01,12.176,Good (10-50/month),121.76,Exceeded (≥100%),100,62.8,75.53999999999999
NCT05736068,Is Casting of Displaced Pediatric Distal Forearm Fractures Non-inferior to Reduction in General Anesthesia?,ACTIVE_NOT_RECRUITING,NA,40.0,2023-09-07,2026-01-01,1.4375442739079103,Adequate (1-10/month),14.375442739079103,Significantly Below (<50%),85,43.7,27.744999999999997
NCT03992768,Feature Detection Study for Validation of Hamamatsu NanoZoomer S360MD Digital Slide Scanner System,COMPLETED,NA,540.0,2019-06-12,2021-09-30,19.545303210463732,Good (10-50/month),195.45303210463732,Exceeded (≥100%),100,95.0,95.7
NCT02146768,Low-dose-contrast Cardiac Computed Tomography,COMPLETED,,142.0,2014-01-01,,,Slow (<1/month),,Significantly Below (<50%),100,49.7,46.949999999999996
NCT02161068,Clinical Care of Autosomal Polycystic Kidney Disease: Retrospective Analysis and Prospective PKD Genotyping,COMPLETED,,79.0,2013-12-01,2021-11-01,0.8315214384508991,Slow (<1/month),8.315214384508991,Significantly Below (<50%),100,49.7,46.949999999999996
NCT02829268,A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome,COMPLETED,PHASE1,21.0,2017-01-01,2023-02-01,0.2876867686768677,Slow (<1/month),2.876867686768677,Significantly Below (<50%),100,46.7,37.895
NCT01115868,Prevascar in African Continental Group Scarring,UNKNOWN,PHASE1,56.0,2010-04-01,2012-08-01,1.9984056271981243,Adequate (1-10/month),19.984056271981242,Significantly Below (<50%),50,39.5,21.044999999999998
NCT00409968,BATTLE Program: Umbrella Protocol for Patients With Non-Small Cell Lung Cancer (NSCLC),COMPLETED,,341.0,2006-11-27,2019-10-31,2.1986951916966744,Adequate (1-10/month),21.986951916966742,Significantly Below (<50%),100,75.6,84.735
NCT06194968,"Treatment of Acute Ischemic StroKe With Intravenous UroKinase Real-world Research: a Multicenter, Prospective Study",RECRUITING,,1800.0,2023-12-30,2026-12-01,51.3514526710403,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT04272268,Feasibility and Safety of Using Nasal High Flow Oxygen Postoperatively to Reduce Respiratory Complications,WITHDRAWN,,0.0,2019-10-01,2020-03-31,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT05668468,A Bifido Bacteria to Improve Lactose Digestion and Tolerance,UNKNOWN,NA,35.0,2022-05-01,2024-05-01,1.4574555403556773,Adequate (1-10/month),14.574555403556774,Significantly Below (<50%),50,32.8,12.425
NCT00153868,A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer,COMPLETED,PHASE4,43.0,2003-10-01,2007-08-17,0.9243785310734464,Slow (<1/month),9.243785310734463,Significantly Below (<50%),100,48.4,44.22
NCT03835468,The Role of the Microbiota-gut-brain Axis in Brain Development and Mental Health,UNKNOWN,NA,120.0,2019-02-01,2023-03-01,2.4531900604432506,Adequate (1-10/month),24.531900604432508,Significantly Below (<50%),50,44.6,29.42
NCT00905450,Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery,COMPLETED,PHASE2,415.0,2009-06-01,2010-05-01,37.82215568862276,Good (10-50/month),200.0,Exceeded (≥100%),100,88.2,92.62
NCT06963450,NeoSCB App for Screening Jaundice in Newborns,RECRUITING,,405.0,2025-09-23,2027-03-31,22.253068592057762,Good (10-50/month),200.0,Exceeded (≥100%),60,73.7,83.825
NCT06173050,PAP Systems Internal Clinical Studies (ICS),NOT_YET_RECRUITING,NA,30.0,2024-10-01,2029-12-01,0.4839427662957075,Slow (<1/month),4.839427662957075,Significantly Below (<50%),30,26.4,7.865
NCT00936650,A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT),COMPLETED,PHASE2,78.0,1999-11-01,2001-06-01,4.107820069204153,Adequate (1-10/month),41.07820069204153,Significantly Below (<50%),100,56.2,64.21
NCT04415450,Effect of Nutrition Education on Knowledge and Healthy Dietary Practice Among Pregnant Women,COMPLETED,NA,226.0,2018-08-31,2018-09-24,226.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,78.1,86.195
NCT01730950,Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,COMPLETED,PHASE2,182.0,2012-12-20,2022-12-22,1.5161685823754791,Adequate (1-10/month),15.161685823754793,Significantly Below (<50%),100,59.6,71.17999999999999
NCT02590250,A Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in India,COMPLETED,,250.0,2015-12-16,2017-08-07,12.683333333333334,Good (10-50/month),126.83333333333333,Exceeded (≥100%),100,73.3,83.61
NCT05766150,Oral Microbioma and Oral Malignant Disease,UNKNOWN,,300.0,2021-12-01,2024-12-01,8.332116788321168,Adequate (1-10/month),83.32116788321167,Met (75-100%),50,57.3,66.74
NCT01434550,Phase II Study of First-line SBRT in Patients With Non-Metastatic Unresectable Pancreatic Cancer,WITHDRAWN,NA,0.0,2012-03-01,2015-08-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT07235150,A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body in Healthy Adults,RECRUITING,PHASE1,76.0,2025-12-11,2027-07-27,3.9012478920741995,Adequate (1-10/month),39.01247892074199,Significantly Below (<50%),60,44.1,28.425
NCT02261350,Post-hospitalisation Nutritional Support and Gait Speed in COPD,TERMINATED,PHASE3,22.0,2014-01-01,2015-09-01,1.1014473684210526,Adequate (1-10/month),11.014473684210527,Significantly Below (<50%),10,19.8,5.465
NCT01533350,Receptivity Assessment of Homogeneous Endometrium in Late Follicle Phase,COMPLETED,,28.0,2010-09-01,2012-01-01,1.7501437371663244,Adequate (1-10/month),17.501437371663243,Significantly Below (<50%),100,50.6,48.705
NCT00661050,"Treatment of Interstitial Cystitis/Painful Bladder Syndrome Using Alternative Techniques: Exercise, Meditation, Tai Chi",WITHDRAWN,,0.0,2008-04-01,2008-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT04635150,National Evaluation of the Close Collaboration With Parents Training,COMPLETED,NA,768.0,2012-05-30,2018-09-30,10.102817631806396,Good (10-50/month),101.02817631806396,Exceeded (≥100%),100,95.0,95.7
NCT02380950,Effect of Moderate Alcohol Consumption to Cognitive Functioning After Roux-en Y Gastric Bypass,COMPLETED,NA,28.0,2013-06-01,,,Slow (<1/month),,Significantly Below (<50%),100,42.2,25.155
NCT00778050,Bioequivalence Study of Amoxicillin Dispersible 600 mg Tablets Under Fasting Conditions,COMPLETED,NA,26.0,2002-10-01,2002-12-01,12.974426229508197,Good (10-50/month),129.74426229508197,Exceeded (≥100%),100,57.1,66.27
NCT05172050,"Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients.",COMPLETED,PHASE2,61.0,2021-01-22,2021-06-12,13.169078014184397,Good (10-50/month),131.69078014184396,Exceeded (≥100%),100,59.9,71.86
NCT07010991,Effectiveness of Artificial Intelligence Based Educational Approach in Developing Clinical Reasoning Skills,RECRUITING,NA,40.0,2025-05-14,2025-09-10,10.231932773109245,Good (10-50/month),102.31932773109244,Exceeded (≥100%),60,46.2,35.089999999999996
NCT01069991,Asthma Self-Management For Adolescents,COMPLETED,PHASE2,345.0,2002-01-01,2007-02-01,5.655250403877221,Adequate (1-10/month),56.55250403877221,Below (50-75%),100,77.6,85.89
NCT05231291,"Association Between Handgrip Strength, Skinfold Thickness and Trunk Strength",COMPLETED,,40.0,2021-11-12,2022-01-05,22.54814814814815,Good (10-50/month),200.0,Exceeded (≥100%),100,56.5,65.18
NCT02949791,HIPEC Using High Intra-abdominal Pressure,COMPLETED,PHASE2,38.0,2014-12-01,2017-11-01,1.0851031894934335,Adequate (1-10/month),10.851031894934335,Significantly Below (<50%),100,48.0,42.945
NCT06301191,The Effect of Semaglutide on Cardiovascular Markers and Liver Function,RECRUITING,,50.0,2022-03-01,2024-05-01,1.9217171717171717,Adequate (1-10/month),19.21717171717172,Significantly Below (<50%),60,40.3,22.21
NCT01961791,Lymph Node Staging System With a Novel Concept for Gastric Cancer: a Hybrid Type of Topographic and Numeric Ones,COMPLETED,,6025.0,2000-01-01,2013-09-01,36.73898237179487,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT06347991,Alberta Chiropractic SelfBack Study,RECRUITING,NA,100.0,2024-05-24,2026-03-15,4.612121212121212,Adequate (1-10/month),46.121212121212125,Significantly Below (<50%),60,46.0,34.1
NCT01071291,Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069),COMPLETED,PHASE1,37.0,2010-02-01,2010-09-01,5.312641509433963,Adequate (1-10/month),53.12641509433963,Below (50-75%),100,53.0,55.80500000000001
NCT06831591,Dubousset Functional Test: An Investigation of Its Validity and Reliability in Children With GMFCS I-II Spastic Cerebral Palsy,COMPLETED,,33.0,2025-01-24,2025-03-01,27.903333333333332,Good (10-50/month),200.0,Exceeded (≥100%),100,56.0,63.71
NCT04930991,High Dose Omeprazole in Patients With Pancreatic Cancer,RECRUITING,EARLY_PHASE1,60.0,2021-09-07,2027-09-01,0.8358810068649887,Slow (<1/month),8.358810068649886,Significantly Below (<50%),60,37.8,19.015
NCT07029191,Screening for Alterations in the Autonomic Nervous System,COMPLETED,NA,12.0,2025-11-21,2025-12-12,12.0,Good (10-50/month),120.0,Exceeded (≥100%),100,56.0,63.71
NCT02921191,"Descriptive Analysis of G-CSF Use in Patients With Breast Cancer, Lung Cancer, or Lymphoma Treated",COMPLETED,,57725.0,2008-01-01,2019-02-01,433.9711039762904,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT03458091,Evaluation of Lung Atelectasis During Apneic Oxygenation Using THRIVE in Adults During Laryngeal Surgery.,COMPLETED,NA,30.0,2018-01-22,2020-10-10,0.9205645161290322,Slow (<1/month),9.205645161290322,Significantly Below (<50%),100,47.4,40.98
NCT00536991,Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer,TERMINATED,PHASE1,51.0,2006-10-01,2016-10-01,0.4249767314535998,Slow (<1/month),4.249767314535998,Significantly Below (<50%),10,22.1,6.254999999999999
NCT01088191,Safety and Efficacy Study of MSB-CAR001 in Subjects 6 Weeks Post an Anterior Cruciate Ligament Reconstruction,COMPLETED,PHASE1,17.0,2009-03-01,2014-10-01,0.2536666666666667,Slow (<1/month),2.5366666666666666,Significantly Below (<50%),100,46.4,36.26
NCT04585191,Reducing Treatment Risk in Older Adults With Diabetes,COMPLETED,NA,450.0,2020-11-02,2024-09-01,9.791279485346676,Adequate (1-10/month),97.91279485346675,Met (75-100%),100,91.0,93.56
NCT03815591,Implementation and Dissemination of an Evidence-Based Tobacco Product Use Prevention Videogame Intervention With Adolescents,COMPLETED,NA,560.0,2019-02-01,2021-12-31,16.021052631578947,Good (10-50/month),160.21052631578948,Exceeded (≥100%),100,95.0,95.7
NCT00952991,The Effects of LAF237 on Gastric Function in Type 2 Diabetes,COMPLETED,PHASE3,18.0,2005-05-01,2006-02-01,1.9852173913043478,Adequate (1-10/month),19.852173913043476,Significantly Below (<50%),100,51.4,50.92
NCT05622591,ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML,WITHDRAWN,PHASE1,0.0,2024-06-07,2024-06-07,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT03729791,The Effect of tDCS on Schizophrenia With Negative Symptoms,UNKNOWN,NA,44.0,2019-12-01,2020-12-01,3.6594535519125686,Adequate (1-10/month),36.594535519125685,Significantly Below (<50%),50,38.5,19.895
NCT06431191,Does Medial Raw Anchor Necessary During Tendon Repair Combined With Microfracture,ENROLLING_BY_INVITATION,NA,50.0,2023-01-01,2026-12-31,1.0424657534246577,Adequate (1-10/month),10.424657534246576,Significantly Below (<50%),55,35.5,15.950000000000001
NCT04914091,Quality Of Life and Drug Use in Patients With CAR-T Cells,RECRUITING,,70.0,2021-03-31,2033-01-31,0.49278445883441263,Slow (<1/month),4.927844588344126,Significantly Below (<50%),60,36.9,17.735
NCT04201574,Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease,COMPLETED,PHASE1,138.0,2019-12-16,2020-09-15,15.331094890510949,Good (10-50/month),153.31094890510948,Exceeded (≥100%),100,66.0,78.99000000000001
NCT02290574,Efficacy of NeoThermo-Radio-chemotherapy for LA Rectal Cancer Before Laparoscopic TME: Prospective Phase II Trial,TERMINATED,NA,14.0,2014-11-01,2016-03-01,0.8768724279835391,Slow (<1/month),8.768724279835393,Significantly Below (<50%),10,19.1,4.9799999999999995
NCT07012174,Impact of Body Mass Index and Lipid Metabolism on Anti-PD-1 Immunotherapy Outcomes in Colorectal Cancer,COMPLETED,,142.0,2019-01-01,2025-04-30,1.8703937689311987,Adequate (1-10/month),18.70393768931199,Significantly Below (<50%),100,59.7,71.355
NCT04794374,Effects of Telerehabilitation After Discharge in COVID-19 Survivors,COMPLETED,NA,20.0,2020-11-16,2022-03-31,1.2176,Adequate (1-10/month),12.176,Significantly Below (<50%),100,46.6,37.375
NCT06546774,The Effect of Melatonin Supplementation on Cumulus Cells and IVF Outcomes,RECRUITING,NA,200.0,2021-05-01,2025-12-31,3.5706744868035196,Adequate (1-10/month),35.706744868035194,Significantly Below (<50%),60,54.0,58.72500000000001
NCT03840174,Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003),COMPLETED,PHASE1,18.0,2019-03-08,2019-11-07,2.245573770491803,Adequate (1-10/month),22.45573770491803,Significantly Below (<50%),100,51.4,50.92
NCT04728074,Effects of Vocational Rehabilitation Group Intervention on Motivation and Occupational Self-Awareness in Individuals With Intellectual Disabilities,COMPLETED,NA,49.0,2020-02-06,2020-05-12,15.537083333333333,Good (10-50/month),155.37083333333334,Exceeded (≥100%),100,58.9,70.10499999999999
NCT00152074,Salt Reduction on Blood Pressure and Cardiovascular Organ Damage,COMPLETED,PHASE3,210.0,2004-04-01,2007-12-01,4.774010455563854,Adequate (1-10/month),47.74010455563854,Significantly Below (<50%),100,66.8,79.55
NCT04106674,Two- Part Proximal Humerus - Conservative vs Operative,RECRUITING,NA,50.0,2020-10-01,2034-10-31,0.295936223993778,Slow (<1/month),2.9593622399377804,Significantly Below (<50%),60,37.0,17.955
NCT02475174,Manual Lymphatic Drainage in the Superior Member in Women in Post-surgery for Breast Cancer,UNKNOWN,NA,30.0,2015-06-01,2016-03-01,3.332846715328467,Adequate (1-10/month),33.32846715328467,Significantly Below (<50%),50,37.4,18.62
NCT00001574,A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients With Primary and Metastatic Brain Tumors,COMPLETED,,40.0,1997-03-14,2019-05-06,0.15054401582591492,Slow (<1/month),1.5054401582591495,Significantly Below (<50%),100,46.5,36.815
NCT00665574,ActaVisc and ActaVisc Mx Intra-articular Injection for Pain Associated With Osteoarthritis in the Knee,TERMINATED,NA,23.0,2008-03-01,2009-06-01,1.5319912472647703,Adequate (1-10/month),15.319912472647705,Significantly Below (<50%),10,19.8,5.465
NCT00685074,Computer-based Brief Intervention for Perinatal Substance Abuse,COMPLETED,PHASE1,143.0,2007-09-01,2011-03-01,3.4087079091620986,Adequate (1-10/month),34.087079091620986,Significantly Below (<50%),100,61.4,73.735
NCT00392574,Safety and Efficacy of Prulifloxacin Versus Placebo in Traveler's Diarrhea,COMPLETED,PHASE3,282.0,2006-08-01,2008-03-01,14.85134948096886,Good (10-50/month),148.5134948096886,Exceeded (≥100%),100,77.6,85.89
NCT05781074,Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （CASTLE-08）,UNKNOWN,PHASE2,25.0,2023-03-23,2025-12-30,0.751233958538993,Slow (<1/month),7.512339585389931,Significantly Below (<50%),50,32.0,11.425
NCT06427174,Analgesic Efficacy of Us Guided Fascia Iliaca Block Versus Caudal Block in Pediatric Graft Surgeries,NOT_YET_RECRUITING,NA,60.0,2025-03-01,2026-05-01,4.287323943661972,Adequate (1-10/month),42.87323943661972,Significantly Below (<50%),30,33.8,13.694999999999999
NCT06272318,Vital Signs Blood Pressure Trial,NOT_YET_RECRUITING,,50.0,2025-09-01,2026-09-30,3.8629441624365484,Adequate (1-10/month),38.629441624365484,Significantly Below (<50%),30,31.3,10.299999999999999
NCT05212818,Evaluate the Efficacy and Safety of TF0023 in Treatments for COVID-19 in Hospitalized Adults,TERMINATED,PHASE2,19.0,2022-05-10,2023-03-08,1.9150993377483443,Adequate (1-10/month),19.15099337748344,Significantly Below (<50%),10,24.5,6.925000000000001
NCT02068118,Optimization of the Ambulatory Monitoring for Patients With Heart Failure by Tele-cardiology,COMPLETED,NA,990.0,2013-05-01,2018-09-28,15.250809716599191,Good (10-50/month),152.5080971659919,Exceeded (≥100%),100,95.0,95.7
NCT05855018,A Study of Atropine Sulfate in Healthy Chinese Volunteers,UNKNOWN,PHASE1,30.0,2023-05-09,2023-06-01,30.0,Good (10-50/month),200.0,Exceeded (≥100%),50,42.4,25.45
NCT00073918,"Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",COMPLETED,PHASE2,111.0,1999-02-01,2011-10-02,0.7304020752269781,Slow (<1/month),7.30402075226978,Significantly Below (<50%),100,53.9,58.34
NCT00000818,Evaluation of the Changes in HIV-1 Burden in Peripheral Blood and Lymphoid Tissue Following Zidovudine ( AZT ) Treatment in HIV-1-Infected Patients With CD4+ Cells Between 100 and 500 Cells/mm3.,COMPLETED,PHASE1,18.0,,,,Slow (<1/month),,Significantly Below (<50%),100,41.4,24.04
NCT02655718,Short and Long Term Outcomes of Acute Coronary Syndrome in Patients With Non Obstructive Coronary Atherosclerosis,UNKNOWN,NA,200.0,2015-10-01,2018-09-01,5.711069418386492,Adequate (1-10/month),57.11069418386492,Below (50-75%),50,51.0,49.714999999999996
NCT07149818,A Single-arm Phase 2 Prospective Clinical Study of Linprixel in the Treatment of Relapsed/Refractory Autoimmune Hemolytic Anemia,NOT_YET_RECRUITING,,22.0,2025-09-01,2027-01-01,1.3751129363449692,Adequate (1-10/month),13.751129363449694,Significantly Below (<50%),30,24.1,6.805
NCT00001890,Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections,COMPLETED,PHASE2,80.0,1999-05-01,2001-03-01,3.6346268656716423,Adequate (1-10/month),36.34626865671642,Significantly Below (<50%),100,56.4,64.88000000000001
NCT06135090,Testing a Peer-led Trauma-focused Intervention for Significant Others of Those With BPD,UNKNOWN,PHASE1,60.0,2024-02-01,2026-01-01,2.609142857142857,Adequate (1-10/month),26.091428571428573,Significantly Below (<50%),50,39.8,21.47
NCT04478890,Hemodynamic Assessment of the Right Ventricle Using Pressure-volume Loop Catheter and Pulmonary Artery Catheter in Patients Undergoing Left Ventricular Assist Device Placement,COMPLETED,,4.0,2021-08-01,2024-12-31,0.09756410256410257,Slow (<1/month),0.9756410256410256,Significantly Below (<50%),100,43.7,27.744999999999997
NCT06413290,Doppler Evaluation of Ultrasound-guided Pectointercostal Fascial Plane Block in Cardiac Surgery,COMPLETED,,40.0,2024-05-15,2025-12-30,2.04983164983165,Adequate (1-10/month),20.4983164983165,Significantly Below (<50%),100,51.5,51.245
NCT00370890,A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy,COMPLETED,PHASE3,104.0,2006-09-04,2021-10-26,0.572366660640029,Slow (<1/month),5.72366660640029,Significantly Below (<50%),100,53.3,57.14
NCT03147690,Contrast-Enhanced Ultrasound in the Evaluation of Abdominal Injuries in Children,TERMINATED,PHASE1,74.0,2017-11-01,2019-10-07,3.1951205673758865,Adequate (1-10/month),31.951205673758864,Significantly Below (<50%),10,28.9,8.709999999999999
NCT01808690,EMERALD: Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes,COMPLETED,PHASE3,52.0,2013-03-01,2016-12-02,1.1537026239067056,Adequate (1-10/month),11.537026239067057,Significantly Below (<50%),100,49.2,46.035
NCT03427190,Suicide Prevention Algorithm in the French Overseas Territories,COMPLETED,NA,259.0,2017-10-09,2020-10-16,7.1477425203989124,Adequate (1-10/month),71.47742520398913,Below (50-75%),100,70.7,82.25
NCT00626990,Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH),ACTIVE_NOT_RECRUITING,PHASE3,751.0,2007-12-01,2029-12-01,2.844753608760578,Adequate (1-10/month),28.44753608760578,Significantly Below (<50%),85,85.5,91.42
NCT03966690,Rate of Leg Curl to Leg Press During Isokinetic Testing,COMPLETED,NA,28.0,2018-08-15,2019-05-15,3.1220512820512822,Adequate (1-10/month),31.220512820512823,Significantly Below (<50%),100,52.2,53.22
NCT06038890,"The Learning Curve of Transurethral Holmium Laser Enucleation of the Prostate, Prospective Assessment",UNKNOWN,NA,200.0,2023-08-01,2025-12-01,7.137162954279016,Adequate (1-10/month),71.37162954279016,Below (50-75%),50,51.0,49.714999999999996
NCT07299890,An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer,NOT_YET_RECRUITING,PHASE2,90.0,2025-12-20,2027-11-01,4.022907488986784,Adequate (1-10/month),40.22907488986784,Significantly Below (<50%),30,36.2,16.84
NCT01963390,Metabolomics During Testosterone Therapy,COMPLETED,,60.0,2012-07-01,2017-12-01,0.9228903486609399,Slow (<1/month),9.228903486609399,Significantly Below (<50%),100,48.1,43.275000000000006
NCT01596790,COLOSPOT Study : Assessment by EPISPOT of Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer,COMPLETED,NA,168.0,2012-04-01,2019-09-01,1.887751937984496,Adequate (1-10/month),18.877519379844962,Significantly Below (<50%),100,63.4,76.375
NCT04350190,Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma,COMPLETED,PHASE2,25.0,2021-01-14,2022-09-15,1.2495894909688012,Adequate (1-10/month),12.495894909688012,Significantly Below (<50%),100,47.0,39.33
NCT03142490,Acupuncture as a Complementary Therapy for in Vitro Fertilization Patients: a Randomized Controlled Trial,UNKNOWN,NA,100.0,2016-12-01,2018-12-31,4.005263157894737,Adequate (1-10/month),40.05263157894737,Significantly Below (<50%),50,43.0,26.465
NCT07279090,Spatiotemporal Single-cell Atlas of Peri-implant Soft Tissue Healing,NOT_YET_RECRUITING,NA,5.0,2025-12-20,2026-12-31,0.4047872340425532,Slow (<1/month),4.047872340425532,Significantly Below (<50%),30,24.4,6.890000000000001
NCT01669590,Nutrient Regulation of Amino Acid Transporters in Aging Human Skeletal Muscle,COMPLETED,,28.0,2011-12-01,2016-09-01,0.49096774193548387,Slow (<1/month),4.909677419354838,Significantly Below (<50%),100,45.6,32.08
NCT04233190,"A Multicenter, Randomized, Parallel, Two-period, Non-inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment",COMPLETED,PHASE3,472.0,2023-04-19,2024-10-30,25.65657142857143,Good (10-50/month),200.0,Exceeded (≥100%),100,92.8,93.865
NCT06322290,Epidemiological Study on Invasive Bacterial Diseases,RECRUITING,,5000.0,2021-12-09,2032-03-30,40.435706695005315,Good (10-50/month),200.0,Exceeded (≥100%),60,81.3,88.58
NCT03018990,Alcohol Challenge On Liver and Gut Measured by Liver Vein Catheterization. A Pathophysiological Intervention Trial,UNKNOWN,NA,40.0,2016-11-09,2024-12-01,0.41358695652173916,Slow (<1/month),4.135869565217392,Significantly Below (<50%),50,33.2,12.989999999999998
NCT04625790,Speech Therapy and Repetitive Transcranial Magnetic Stimulation Therapy in Post-stroke Anomic Aphasia,COMPLETED,NA,25.0,2020-11-06,2021-11-06,2.0849315068493155,Adequate (1-10/month),20.84931506849315,Significantly Below (<50%),100,52.0,52.86
NCT01815190,IgA-positive Versus IgA-negative Immune Complex Vasculitis,UNKNOWN,,300.0,2011-01-01,2016-12-01,4.225821378991208,Adequate (1-10/month),42.25821378991208,Significantly Below (<50%),50,57.3,66.74
NCT06916897,A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers,COMPLETED,PHASE1,42.0,2025-01-08,2025-02-22,28.410666666666668,Good (10-50/month),200.0,Exceeded (≥100%),100,58.4,69.175
NCT04909697,Treatment of ARDS With Sivelestat Sodium,RECRUITING,PHASE4,324.0,2022-04-18,2026-03-30,6.839500693481276,Adequate (1-10/month),68.39500693481277,Below (50-75%),60,63.9,76.9
NCT05927597,"A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Caucasian Participants",COMPLETED,PHASE1,82.0,2019-01-09,2019-08-01,12.235686274509805,Good (10-50/month),122.35686274509806,Exceeded (≥100%),100,61.6,74.0
NCT04145297,Ulixertinib (BVD-523) and Hydroxychloroquine in Patients W Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas,COMPLETED,PHASE1,16.0,2020-03-17,2022-08-18,0.550950226244344,Slow (<1/month),5.50950226244344,Significantly Below (<50%),100,46.3,35.66
NCT06331897,Bronchial Asthma & Its Exacerbation,NOT_YET_RECRUITING,,50.0,2025-01-01,2026-06-01,2.949612403100775,Adequate (1-10/month),29.496124031007753,Significantly Below (<50%),30,31.3,10.299999999999999
NCT07247097,ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma,NOT_YET_RECRUITING,PHASE2,160.0,2026-04-15,2035-12-01,1.3848166050611317,Adequate (1-10/month),13.848166050611315,Significantly Below (<50%),30,36.8,17.630000000000003
NCT04719897,Life Experiences in Adolescents and the Development of Skills,COMPLETED,NA,88.0,2021-05-19,2025-10-10,1.6689844236760125,Adequate (1-10/month),16.689844236760127,Significantly Below (<50%),100,57.0,66.12
NCT07054697,Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder,COMPLETED,PHASE4,54.0,2017-01-01,2025-01-15,0.5598637602179837,Slow (<1/month),5.598637602179837,Significantly Below (<50%),100,49.3,46.265
NCT04870697,Acceptance and Commitment Therapy for Parents of Children With Cancer,UNKNOWN,NA,142.0,2021-06-28,2022-01-01,23.11486631016043,Good (10-50/month),200.0,Exceeded (≥100%),50,51.4,50.92
NCT06402097,TRIP-patch vs Duplex,COMPLETED,,20.0,2020-06-05,2020-09-25,5.435714285714286,Adequate (1-10/month),54.35714285714286,Below (50-75%),100,49.9,47.425
NCT03427697,Effect of VR and Accommdation Relax on Controlling Myopia in Children,UNKNOWN,NA,1000.0,2020-09-18,2022-12-31,36.49880095923261,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT01560897,"Investigating Project of the Functional C13 Test ""Pilot Study""",UNKNOWN,PHASE1,10.0,2012-01-01,,,Slow (<1/month),,Significantly Below (<50%),50,25.8,7.670000000000001
NCT06379997,Oral Supplementation Compared With Hyaluronic Acid Infiltration in Rotator Cuff Tendinopathies,RECRUITING,NA,50.0,2024-08-10,2025-12-31,2.9960629921259843,Adequate (1-10/month),29.96062992125984,Significantly Below (<50%),60,42.0,24.825
NCT02303197,Clinical Trial on the Efficacy and Safety of Chining Decoction in the Treatment of Radiation Stomatitis,COMPLETED,PHASE3,70.0,2014-05-01,2015-12-01,3.6801381692573405,Adequate (1-10/month),36.8013816925734,Significantly Below (<50%),100,55.6,62.905
NCT06491797,"Booster of the ""More Time for Patients"" Program",NOT_YET_RECRUITING,NA,764.0,2024-08-01,2025-10-01,54.59192488262911,Excellent (>50/month),200.0,Exceeded (≥100%),30,79.0,86.96000000000001
NCT03015597,Pilot Study of Contingency Management for Smoking Cessation,COMPLETED,NA,40.0,2016-10-01,2017-09-01,3.6346268656716423,Adequate (1-10/month),36.34626865671642,Significantly Below (<50%),100,53.2,56.665
NCT00566397,A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease,COMPLETED,PHASE2,402.0,2007-12-01,2010-12-01,11.165036496350364,Good (10-50/month),111.65036496350365,Exceeded (≥100%),100,87.2,92.21000000000001
NCT01365897,Effectiveness of Modafinil in Improving Cognitive Performance of University Students,COMPLETED,PHASE4,128.0,2010-09-01,2011-01-01,31.937049180327868,Good (10-50/month),200.0,Exceeded (≥100%),100,65.2,78.23
NCT03090997,Effect of Resveratrol and Vitamin C on Insulin Resistance Among Postmenopausal Women,UNKNOWN,NA,45.0,2018-02-15,2022-02-28,0.9293080054274084,Slow (<1/month),9.293080054274084,Significantly Below (<50%),50,33.6,13.375
NCT01234597,Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day,COMPLETED,PHASE4,219.0,2012-12-01,2015-04-01,7.833560517038778,Adequate (1-10/month),78.33560517038778,Met (75-100%),100,67.5,80.08
NCT01256697,The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions im Patients With Retinitis Pigmentosa,COMPLETED,NA,34.0,2008-08-01,2011-01-01,1.1720951302378257,Adequate (1-10/month),11.720951302378255,Significantly Below (<50%),100,47.7,42.17
NCT05623397,A Deep Learning Method to Evaluate QT on Ribociclib,COMPLETED,,70.0,2023-07-28,2025-10-08,2.653549190535492,Adequate (1-10/month),26.535491905354924,Significantly Below (<50%),100,53.9,58.34
NCT02656797,Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis,COMPLETED,PHASE2,13.0,2018-01-30,2021-10-01,0.2953134328358209,Slow (<1/month),2.953134328358209,Significantly Below (<50%),100,46.0,34.1
NCT07183397,Impact of Fluid Resuscitation on Venous Congestion in Cardiac Critically-ill Patients,NOT_YET_RECRUITING,,250.0,2025-09-15,2027-12-01,9.429987608426272,Adequate (1-10/month),94.2998760842627,Met (75-100%),30,52.3,53.515
NCT05128097,Preventive Approach for the Management of the Main Geriatric Risks,UNKNOWN,,107.0,2020-06-01,2021-12-31,5.635086505190312,Adequate (1-10/month),56.35086505190312,Below (50-75%),50,41.9,24.585
NCT03666897,Markers of Recovery in StrokE Study (MORSE),COMPLETED,NA,21.0,2018-10-01,2022-04-01,0.5001877934272301,Slow (<1/month),5.001877934272301,Significantly Below (<50%),100,46.7,37.895
NCT05377697,The Effect of Lavender Scent on Sleep,COMPLETED,NA,90.0,2022-04-23,2023-09-15,5.371764705882353,Adequate (1-10/month),53.71764705882352,Below (50-75%),100,57.2,66.465
NCT00375297,Study of Sildenafil for Treatment of SSRI-Antidepressant Sexual Dysfunction in Women,COMPLETED,PHASE4,100.0,2001-01-01,2005-06-01,1.8883374689826302,Adequate (1-10/month),18.8833746898263,Significantly Below (<50%),100,58.0,68.245
NCT04249297,Predictors of Pregnancy Rate in Assisted Reproductive Technology According to Actual Guidelines,UNKNOWN,,1150.0,2020-03-03,2022-12-01,34.901296111665005,Good (10-50/month),200.0,Exceeded (≥100%),50,78.3,86.48
NCT04192097,Impact of a Curriculum About Professionalism on Stress Response During a Critical Situation,COMPLETED,NA,20.0,2019-12-15,2021-03-01,1.3773755656108597,Adequate (1-10/month),13.7737556561086,Significantly Below (<50%),100,46.6,37.375
NCT01772797,Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer,COMPLETED,PHASE1,22.0,2013-06-01,2016-01-01,0.709406779661017,Slow (<1/month),7.094067796610171,Significantly Below (<50%),100,46.8,38.440000000000005
NCT06031597,Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy,UNKNOWN,PHASE3,105.0,2023-09-15,2025-12-31,3.8140811455847254,Adequate (1-10/month),38.14081145584725,Significantly Below (<50%),50,43.4,27.265
NCT00800397,Evaluation of the Noga System: Detecting of Respiratory Related Sleep Disorders in Cardiac Patients,COMPLETED,,80.0,2007-12-01,2008-12-01,6.6535519125683065,Adequate (1-10/month),66.53551912568307,Below (50-75%),100,54.7,60.629999999999995
NCT05681897,Comparing Platelet-Rich Plasma (PRP) Centrifugation Methods on Thrombocyte Concentration and Clinical Improvement of Androgenetic Alopecia,UNKNOWN,NA,30.0,2023-02-01,2023-02-01,30.0,Good (10-50/month),200.0,Exceeded (≥100%),50,27.4,8.225
NCT05789797,Remaxol® in Patients With Drug-induced Liver Injuries During Cancer Chemotherapy,COMPLETED,,368.0,2022-05-12,2024-12-16,11.803919915700739,Good (10-50/month),118.03919915700737,Exceeded (≥100%),100,82.8,89.19500000000001
NCT02660697,3D Radiographic Evaluation of a Novel Implant Site Development Technique,COMPLETED,PHASE4,43.0,2007-12-01,2014-12-01,0.5118967540086039,Slow (<1/month),5.1189675400860395,Significantly Below (<50%),100,48.4,44.22
NCT01373697,Study to Assess the Efficacy and Safety of Ibuprofen 50 mg/g Gel Compared to Profenid 25mg/g Gel,UNKNOWN,PHASE3,144.0,2011-06-01,2011-08-01,71.8583606557377,Excellent (>50/month),200.0,Exceeded (≥100%),50,56.5,65.18
NCT00776997,LINX Reflux Management System Clinical Study Protocol,COMPLETED,NA,100.0,2008-11-01,2011-09-01,2.9439071566731143,Adequate (1-10/month),29.439071566731144,Significantly Below (<50%),100,58.0,68.245
NCT04890197,Tahini and Dermatitis in Breast Cancer,UNKNOWN,NA,50.0,2021-05-08,2021-07-15,22.38235294117647,Good (10-50/month),200.0,Exceeded (≥100%),50,44.0,28.249999999999996
NCT00679497,A Phase I Study of Modified Vaccinia Virus Ankara (MVA-B) in Healthy Volunteers at Low Risk of HIV Infection,COMPLETED,PHASE1,30.0,2008-06-01,2010-12-01,1.0002190580503834,Adequate (1-10/month),10.002190580503836,Significantly Below (<50%),100,47.4,40.98
NCT00006110,"Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer",COMPLETED,PHASE2,82.0,1998-12-01,2013-04-01,0.47680611270296086,Slow (<1/month),4.7680611270296085,Significantly Below (<50%),100,51.6,51.644999999999996
NCT00539110,Differential Effects of Zolpidem Versus Ramelteon in Burned Children,COMPLETED,PHASE2,10.0,2009-12-01,2013-11-01,0.2127183787561146,Slow (<1/month),2.127183787561146,Significantly Below (<50%),100,45.8,33.03
NCT01291810,Clinical Efficacy of TNFa Kinoid in Crohn's Disease Patients,COMPLETED,PHASE2,66.0,2011-02-01,2014-05-01,1.6953924050632911,Adequate (1-10/month),16.953924050632914,Significantly Below (<50%),100,55.3,62.36000000000001
NCT07206810,"A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients",COMPLETED,,419.0,2018-08-01,2025-02-01,5.3679966329966335,Adequate (1-10/month),53.679966329966334,Below (50-75%),100,81.9,89.01
NCT06793410,Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation,RECRUITING,PHASE2,100.0,2025-05-12,2029-10-31,1.8640538885486835,Adequate (1-10/month),18.640538885486837,Significantly Below (<50%),60,46.0,34.1
NCT03700710,Remote Dietary Counseling to Promote Healthy Diet and Blood Pressure,COMPLETED,NA,187.0,2019-01-16,2021-06-30,6.352991071428572,Adequate (1-10/month),63.529910714285705,Below (50-75%),100,65.0,78.065
NCT00601510,"Imatinib, Capecitabine, and Cisplatin in Treating Patients With Unresectable or Metastatic Stomach Cancer",COMPLETED,PHASE1,38.0,2007-11-01,2012-01-01,0.76,Slow (<1/month),7.6,Significantly Below (<50%),100,48.0,42.945
NCT06718010,The Association Between Age-related Peripheral Blood Components and Treatment Efficacy in Breast Cancer,RECRUITING,,120.0,2024-12-05,2026-03-31,7.594178794178794,Adequate (1-10/month),75.94178794178794,Met (75-100%),60,45.9,33.495000000000005
NCT05670210,[Trial of device that is not approved or cleared by the U.S. FDA],WITHHELD,,,,,,Slow (<1/month),,Significantly Below (<50%),50,20.0,5.695
NCT00372710,Safety/Efficacy of Intravenous Zoledronic Acid When Added to Standard Therapies in Patients With Breast Cancer and Metastatic Bone Lesions,TERMINATED,PHASE3,30.0,2002-08-01,,,Slow (<1/month),,Significantly Below (<50%),10,15.4,2.5100000000000002
NCT01542710,Bimatoprost/Timolol Versus Travoprost/Timolol,COMPLETED,NA,80.0,2011-01-01,2011-12-01,7.291017964071856,Adequate (1-10/month),72.91017964071857,Below (50-75%),100,56.4,64.88000000000001
NCT00002810,High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis,COMPLETED,PHASE2,,1996-05-01,2006-05-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,30.330000000000002
NCT00752310,TMC114-TiDP29-C169: Bioavailability and Pharmacokinetics Trial Comparing Darunavir Pediatric Suspension Formulation to Current Darunavir Tablet,COMPLETED,PHASE1,23.0,2008-04-01,2008-08-01,5.738688524590164,Adequate (1-10/month),57.38688524590163,Below (50-75%),100,51.8,52.17
NCT00994110,"Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess",COMPLETED,PHASE3,439.0,2009-10-01,2014-09-01,7.440512249443207,Adequate (1-10/month),74.40512249443208,Below (50-75%),100,85.1,91.29
NCT07169110,Study of the Interprofessional Reproducibility of a Clinical Observation Scale for the Development of Very Premature Infants,NOT_YET_RECRUITING,,35.0,2025-12-22,2026-12-30,2.856300268096515,Adequate (1-10/month),28.56300268096515,Significantly Below (<50%),30,30.1,9.19
NCT03964610,Multimodal Retinal Imaging of Cerebrovascular Stroke,COMPLETED,,62.0,2019-11-15,2022-02-15,2.2931713244228433,Adequate (1-10/month),22.931713244228433,Significantly Below (<50%),100,53.3,57.14
NCT00584610,The Effect of a Levonorgestrel-releasing Intrauterine Device (IUD) Versus a Copper Containing IUD on Risk of Blood Clots,UNKNOWN,NA,50.0,2007-12-01,2012-07-01,0.9091995221027479,Slow (<1/month),9.091995221027478,Significantly Below (<50%),50,34.0,14.02
NCT01778010,Modafinil for Smoked Cocaine Self-Administration,COMPLETED,PHASE2,8.0,2009-03-01,2013-06-01,0.15680618158403092,Slow (<1/month),1.5680618158403092,Significantly Below (<50%),100,45.6,32.08
NCT03348410,Joint Coordination to Facilitate the Transition From Sick Leave to Employment,COMPLETED,NA,193.0,2017-11-14,2019-12-14,7.730157894736842,Adequate (1-10/month),77.30157894736843,Met (75-100%),100,65.4,78.415
NCT07083310,"The Effect of Health Education Conducted Using Two Different Methods on Women's Knowledge of Breast Cancer, Health Beliefs, Mammography Self-Efficacy, and Participation in Screening Programs",NOT_YET_RECRUITING,NA,78.0,2025-07-01,2025-10-01,25.807826086956524,Good (10-50/month),200.0,Exceeded (≥100%),30,40.2,22.115000000000002
NCT02200510,Patient-Provider Tools to Improve the Transition to Adult Care in Sickle Cell Disease,COMPLETED,NA,78.0,2011-06-01,2015-08-01,1.56,Adequate (1-10/month),15.6,Significantly Below (<50%),100,51.2,50.375
NCT00992810,Medial Versus Lateral Approach in Ultrasound (US)-Guided Supraclavicular Block,COMPLETED,NA,78.0,2009-08-01,2010-09-01,5.995757575757576,Adequate (1-10/month),59.95757575757575,Below (50-75%),100,56.2,64.21
NCT02251210,Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid Arthritis,COMPLETED,PHASE2,404.0,2001-05-01,,,Slow (<1/month),,Significantly Below (<50%),100,72.3,83.065
NCT04920513,Universal- Versus Guidelines-Directed Genetic Testing for Germline Pathogenic Variants Utilizing a Multi-Gene Panel for Inherited Cancers in Non-Western Society.,COMPLETED,,3000.0,2021-05-01,2025-02-01,66.5597667638484,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT03773913,Integrated Community Based Health Systems Strengthening Preliminary Study in Kozah Togo,UNKNOWN,,1500.0,2015-01-01,2021-08-31,18.75924404272802,Good (10-50/month),187.5924404272802,Exceeded (≥100%),50,78.3,86.48
NCT05298813,Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 Illness,COMPLETED,PHASE1,162.0,2021-09-29,2023-01-04,10.673766233766234,Good (10-50/month),106.73766233766233,Exceeded (≥100%),100,68.0,80.56
NCT03838913,Whole-Exome Sequencing (WES) of Intraductal Neoplasms of the Bile Duct (IPNB),UNKNOWN,,60.0,2019-02-15,2019-12-31,5.725391849529781,Adequate (1-10/month),57.2539184952978,Below (50-75%),50,38.1,19.425
NCT01064713,Phase II Study of Tesetaxel in Metastatic Melanoma,COMPLETED,PHASE2,17.0,2010-02-01,2014-10-01,0.3038637698179683,Slow (<1/month),3.0386376981796825,Significantly Below (<50%),100,46.4,36.26
NCT05157113,"Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population",RECRUITING,PHASE4,70.0,2022-05-31,2026-06-01,1.4574555403556773,Adequate (1-10/month),14.574555403556774,Significantly Below (<50%),60,38.6,20.015
NCT03874013,Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency,COMPLETED,PHASE3,44.0,2017-12-07,2020-03-06,1.6333658536585367,Adequate (1-10/month),16.333658536585364,Significantly Below (<50%),100,48.5,44.47
NCT03309813,Feasibility Study of ExAblate Thalamotomy for Treatment of Chronic Trigeminal Neuropathic Pain,UNKNOWN,NA,10.0,2017-12-01,2023-10-01,0.14291079812206572,Slow (<1/month),1.4291079812206575,Significantly Below (<50%),50,30.8,9.745
NCT04295213,The Inside Study II: Oligosaccharides Versus Placebo and Hard Stools,UNKNOWN,NA,196.0,2021-04-28,2023-09-01,6.9699065420560755,Adequate (1-10/month),69.69906542056074,Below (50-75%),50,50.7,48.915
NCT01333813,Hepatitis B Antibody Persistence and Immune Response to Hepatitis B Vaccine Challenge in Previously Vaccinated Children,COMPLETED,PHASE4,300.0,2011-04-26,2011-09-28,58.91612903225806,Excellent (>50/month),200.0,Exceeded (≥100%),100,84.0,90.595
NCT02809313,Clinical and Microbiological Effects of Lactobacillus Rhamnosus in Treatment of Gingivitis,UNKNOWN,PHASE2,36.0,2016-03-01,2016-11-01,4.472816326530612,Adequate (1-10/month),44.72816326530612,Significantly Below (<50%),50,37.9,19.139999999999997
NCT03354013,Genetic Screening and Assisted Oocyte Activation in Couples with Diminished/aberrant Embryonic Development.,COMPLETED,NA,42.0,2018-01-15,2022-09-09,0.7529328621908127,Slow (<1/month),7.529328621908128,Significantly Below (<50%),100,48.4,44.22
NCT01609413,The COMparison of CALcium Bioavailability Between AlgaeCal® and a Proprietary Supplement,COMPLETED,PHASE1,20.0,2009-10-01,2010-04-01,3.345054945054945,Adequate (1-10/month),33.45054945054945,Significantly Below (<50%),100,51.6,51.644999999999996
NCT02570113,The Peregrine Post-Market Study for the Treatment of Hypertension,COMPLETED,NA,45.0,2015-11-01,2019-07-01,1.0237668161434976,Adequate (1-10/month),10.237668161434978,Significantly Below (<50%),100,48.6,44.685
NCT03204513,Impact of Powered Knee-Ankle Prosthesis Leg on Everyday Community Mobility and Social Interaction,ACTIVE_NOT_RECRUITING,NA,15.0,2016-12-01,2025-12-01,0.13891086096744754,Slow (<1/month),1.3891086096744754,Significantly Below (<50%),85,41.7,24.36
NCT03335813,Endoesophageal Brachytherapy for Patients With Esophageal Cancer,COMPLETED,NA,7.0,2018-03-06,2020-12-08,0.21138888888888888,Slow (<1/month),2.113888888888889,Significantly Below (<50%),100,45.6,32.08
NCT00397813,Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders,COMPLETED,PHASE2,77.0,2006-01-01,2018-03-01,0.5276632147681225,Slow (<1/month),5.276632147681225,Significantly Below (<50%),100,51.2,50.375
NCT05939960,Application of a New Type of Whole Blood Coagulation Time Measurement in Evaluating the Hypercoagulable State of Malignant Tumors,UNKNOWN,,354.0,2023-07-01,2024-09-30,23.579343544857768,Good (10-50/month),200.0,Exceeded (≥100%),50,66.7,79.47999999999999
NCT07069660,Compass 3: A Novel Transition Program to Reduce Disability After Stroke,RECRUITING,NA,520.0,2025-09-29,2030-03-01,9.807187112763321,Adequate (1-10/month),98.07187112763323,Met (75-100%),60,83.0,89.505
NCT04552860,vEAET for Older Veterans With Chronic Musculoskeletal Pain Pilot,COMPLETED,NA,16.0,2020-08-15,2021-08-16,1.3307103825136612,Adequate (1-10/month),13.307103825136613,Significantly Below (<50%),100,46.3,35.66
NCT01691560,Exploratory Study to Evaluate an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity,COMPLETED,PHASE2,140.0,2012-08-01,2012-11-01,46.321739130434786,Good (10-50/month),200.0,Exceeded (≥100%),100,71.2,82.59
NCT05400460,Prognosis Study of Different Anterior Cruciate Ligament Surgery Methods,COMPLETED,NA,406.0,2016-06-01,2021-01-17,7.308480189237138,Adequate (1-10/month),73.08480189237137,Below (50-75%),100,82.5,89.165
NCT00427960,Study of Asian Patients With Hypercholesterolaemia in the UK - Rosuvastatin 5mg Versus Atorvastatin 10mg,TERMINATED,PHASE4,55.0,2006-12-01,2008-02-01,3.9208430913348944,Adequate (1-10/month),39.20843091334895,Significantly Below (<50%),10,27.4,8.225
NCT04073160,TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer,WITHDRAWN,PHASE1,0.0,2020-06-01,2026-01-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT03272360,Endometriosis Biomarker Discovery Study,WITHDRAWN,,0.0,2016-09-01,2017-06-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT04308460,Arthrocentesis Versus Operative Arthroscopy Treatment of TMJ Internal Derangement (TMJ),COMPLETED,NA,40.0,2017-01-10,2019-12-16,1.137943925233645,Adequate (1-10/month),11.379439252336448,Significantly Below (<50%),100,48.2,43.665
NCT06246760,"Differences in Ventilatory Function, Body Composition, and Cardiorrespiratory Fitness According to Training Status",RECRUITING,NA,1272.0,2000-01-01,2030-01-01,3.533462310640628,Adequate (1-10/month),35.33462310640628,Significantly Below (<50%),60,78.0,86.075
NCT00251160,Electrothermal Arthroscopic Capsulorrhaphy (ETAC) and Open Inferior Capsular Shift in Patients With Shoulder Instability,COMPLETED,NA,58.0,1999-12-01,2010-02-01,0.4752409152086137,Slow (<1/month),4.752409152086138,Significantly Below (<50%),100,49.6,46.785
NCT03833960,SLNB After Neoadjuvant Treatment in Node Positive Patients,COMPLETED,,65.0,2016-05-01,2019-06-01,1.7571936056838366,Adequate (1-10/month),17.571936056838368,Significantly Below (<50%),100,53.5,57.555
NCT02975960,ADMSCs for the Treatment of Systemic Sclerosis,COMPLETED,NA,7.0,2016-10-25,2018-01-20,0.47141592920353986,Slow (<1/month),4.714159292035399,Significantly Below (<50%),100,45.6,32.08
NCT06825260,PEG3350 vs Senna After Urogyn Surgery,RECRUITING,PHASE4,254.0,2025-04-23,2027-07-01,9.676795994993743,Adequate (1-10/month),96.76795994993745,Met (75-100%),60,63.3,76.235
NCT00548860,Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients,COMPLETED,PHASE3,2018.0,2007-10-01,2009-07-01,96.13133020344289,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT04766060,Indocyanine Green Fluorescent Imaging in Robotic Assisted Rectosigmoidal Resection; a Multicenter Assessment of Interobserver Variation and Comparison With Computer-based Pixel Analysis,COMPLETED,,55.0,2017-04-01,2018-11-30,2.7536184210526318,Adequate (1-10/month),27.536184210526315,Significantly Below (<50%),100,52.7,55.04
NCT02357160,The Value of Integrating Visual Arts: Evaluating the Benefits of Hospital Room Artwork on Inpatient Wellbeing,COMPLETED,NA,184.0,2014-11-01,2016-08-01,8.765195618153365,Adequate (1-10/month),87.65195618153365,Met (75-100%),100,69.7,81.73
NCT00213460,Small Bowel Motor Impairment in Scleroderma: Results of a Prospective 5-year Manometric Follow-up,COMPLETED,,,2001-08-01,2003-07-01,,Slow (<1/month),,Significantly Below (<50%),100,43.3,27.05
NCT03194360,Risk Factors of Delirium in Sequential Sedation Patients in Intensive Care Unit,COMPLETED,,141.0,2015-12-01,2017-01-15,10.442919708029196,Good (10-50/month),104.42919708029197,Exceeded (≥100%),100,64.6,77.59
NCT03765060,The Efficacy and Security of the Small Stitch Technique in Emergency Surgery,UNKNOWN,NA,105.0,2018-10-01,2021-12-01,2.7624891961970612,Adequate (1-10/month),27.624891961970615,Significantly Below (<50%),50,43.4,27.265
NCT07237360,Impact of Prevention of Safe Sleeping and Unexpected Infant Death,NOT_YET_RECRUITING,,100.0,2025-11-30,2026-06-30,14.358490566037737,Good (10-50/month),143.58490566037736,Exceeded (≥100%),30,40.3,22.21
NCT03325660,Whole Body Vibration and Pelvic Floor Exercises on Urinary Incontinence,COMPLETED,NA,61.0,2016-07-03,2017-10-27,3.8603742203742204,Adequate (1-10/month),38.6037422037422,Significantly Below (<50%),100,54.9,61.55500000000001
NCT01895660,Children With Hemiparesis Arm and Hand Movement Project (CHAMP Study),COMPLETED,PHASE2,124.0,2013-07-01,2019-12-01,1.610307167235495,Adequate (1-10/month),16.10307167235495,Significantly Below (<50%),100,54.9,61.55500000000001
NCT01668160,Stability of Revision Total Hip Arthroplasty Implants Using Radiostereometric Analysis,WITHDRAWN,NA,0.0,2012-02-01,2020-01-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT04100460,A Double Blind Study on the Gastrointestinal Effects of Arabinoxylan (Leaf Fiber Extract).,UNKNOWN,NA,45.0,2019-09-01,2020-05-01,5.637037037037038,Adequate (1-10/month),56.37037037037038,Below (50-75%),50,38.6,20.015
NCT02163460,Repair of Large Incisional Hernias - To Drain or Not to Drain Randomised Clinical Trial,COMPLETED,PHASE2,42.0,2012-05-01,2014-01-01,2.0958688524590166,Adequate (1-10/month),20.958688524590166,Significantly Below (<50%),100,53.4,57.35
NCT06517160,Comparison of MedBook Portal and Usual Care in Medication Reconciliation at Primary Healthcare Upon Hospital Discharge,COMPLETED,NA,398.0,2023-05-02,2024-07-24,26.982449888641426,Good (10-50/month),200.0,Exceeded (≥100%),100,86.8,92.06
NCT06930560,HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms,RECRUITING,NA,300.0,2025-10-15,2027-12-31,11.315985130111525,Good (10-50/month),113.15985130111525,Exceeded (≥100%),60,67.0,79.725
NCT02283060,Sleep and Cognition After Atripla to Stribild Switch,UNKNOWN,PHASE4,30.0,2014-09-01,2016-08-01,1.3045714285714285,Adequate (1-10/month),13.045714285714286,Significantly Below (<50%),50,32.4,12.025
NCT05104060,The Effects of Manual Therapy and Scapular Exercise for the Pectoralis Minor in Individuals With Shoulder Pain,COMPLETED,NA,100.0,2021-11-17,2023-03-22,6.212244897959184,Adequate (1-10/month),62.12244897959184,Below (50-75%),100,58.0,68.245
NCT03427060,Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms,COMPLETED,PHASE2,1.0,2018-05-14,2021-02-03,0.030562248995983938,Slow (<1/month),0.3056224899598393,Significantly Below (<50%),100,45.1,30.605
NCT07271160,The Effect of Aromatherapy Foot Massage on Neuropathic Pain in Patients With Type2 Diabetes,NOT_YET_RECRUITING,NA,78.0,2025-12-01,2026-05-15,14.389818181818182,Good (10-50/month),143.89818181818183,Exceeded (≥100%),30,40.2,22.115000000000002
NCT03523260,Comparison of High-Flow Hemodialysis Catheters Placed From the Left Internal Jugular Vein(R12-022),WITHDRAWN,NA,0.0,2013-08-27,2020-01-22,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT04659460,RIC as an Adjunct Therapy for Severe COVID-19 Disease: a Prospective Randomized Pilot Study,UNKNOWN,NA,30.0,2020-12-15,2021-09-01,3.5123076923076924,Adequate (1-10/month),35.123076923076916,Significantly Below (<50%),50,37.4,18.62
NCT04482660,Characterization of Cerebral Tau Aggregates With 18F-RO6958948 PET in the ALFA Population,ENROLLING_BY_INVITATION,NA,100.0,2021-03-29,2025-12-31,1.7514384349827388,Adequate (1-10/month),17.514384349827385,Significantly Below (<50%),55,44.5,29.160000000000004
NCT00003720,SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma,COMPLETED,PHASE1,,1998-07-01,,,Slow (<1/month),,Significantly Below (<50%),100,40.0,21.87
NCT03533920,Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma,COMPLETED,NA,62.0,2017-10-25,2018-09-03,6.02964856230032,Adequate (1-10/month),60.29648562300319,Below (50-75%),100,55.0,61.834999999999994
NCT04698720,Contribution of Psychological Factors in the Healing of the Diabetic Foot Ulcer,COMPLETED,NA,69.0,2019-02-01,2022-07-25,1.6538267716535433,Adequate (1-10/month),16.538267716535433,Significantly Below (<50%),100,50.5,48.515
NCT04163120,Effects of a Ketogenic Diet on PCOS Outcomes,COMPLETED,NA,14.0,2017-01-01,2017-05-01,3.5513333333333335,Adequate (1-10/month),35.513333333333335,Significantly Below (<50%),100,51.1,50.129999999999995
NCT03418220,Comparison of Cytokine Profiles in Aqueous Humor of Patients With Age Related Macular Degeneration (AMD),COMPLETED,NA,82.0,2017-11-22,2020-09-08,2.4447404505386876,Adequate (1-10/month),24.447404505386878,Significantly Below (<50%),100,56.6,65.34
NCT06660420,Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel),RECRUITING,PHASE1,39.0,2025-02-25,2031-12-31,0.474864,Slow (<1/month),4.74864,Significantly Below (<50%),60,36.1,16.665
NCT00961220,O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma,COMPLETED,PHASE1,17.0,2010-02-01,2014-04-08,0.3388867059593975,Slow (<1/month),3.3888670595939754,Significantly Below (<50%),100,46.4,36.26
NCT02729220,Respiratory and Cardiovascular Effects in COPD,COMPLETED,NA,52.0,2012-01-01,,,Slow (<1/month),,Significantly Below (<50%),100,44.2,28.549999999999997
NCT00501020,Comparison of the Efficacy and Tolerability of the Addition of AVANDIA to Submaximal Doses of Metformin,COMPLETED,PHASE4,750.0,2001-06-05,2003-02-13,36.94174757281554,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT06183320,Can Flowable Bulk Fill Composites be Used in Proximal Area of Class II Restorations,ACTIVE_NOT_RECRUITING,NA,38.0,2019-08-05,2026-12-30,0.4277810650887574,Slow (<1/month),4.277810650887575,Significantly Below (<50%),85,43.5,27.400000000000002
NCT03367520,"Helping Veterans With SMI ""StayQuit"" From Smoking After Inpatient Hospitalization",COMPLETED,NA,29.0,2017-06-07,2018-12-31,1.5432867132867132,Adequate (1-10/month),15.43286713286713,Significantly Below (<50%),100,47.3,40.475
NCT02505620,Neurocognitive Function After Therapy of OSAS,COMPLETED,,80.0,2014-09-01,2016-09-01,3.331326949384405,Adequate (1-10/month),33.31326949384405,Significantly Below (<50%),100,54.7,60.629999999999995
NCT01958320,Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus,COMPLETED,PHASE2,202.0,2013-12-01,2017-06-01,4.811330203442879,Adequate (1-10/month),48.1133020344288,Significantly Below (<50%),100,66.2,79.2
NCT03806920,Isomaltulose VS Sucrose - Postprandial Effect on Incretin Profile and Second Meal Effect,COMPLETED,NA,50.0,2016-11-05,2019-07-30,1.5265797392176528,Adequate (1-10/month),15.26579739217653,Significantly Below (<50%),100,49.0,45.61
NCT03979820,A Study in Healthy People to Test How Combining BI 1467335 and Tyramine Affects Blood Pressure,TERMINATED,PHASE1,53.0,2019-07-31,2020-04-08,6.402063492063492,Adequate (1-10/month),64.0206349206349,Below (50-75%),10,27.2,8.115
NCT05056220,Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites,RECRUITING,PHASE3,240.0,2024-02-26,2026-09-01,7.958169934640523,Adequate (1-10/month),79.58169934640523,Met (75-100%),60,57.2,66.465
NCT02308020,"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain",COMPLETED,PHASE2,162.0,2015-04-20,2019-11-08,2.9652916416115453,Adequate (1-10/month),29.652916416115456,Significantly Below (<50%),100,63.0,75.845
NCT00504582,Fibrin Melanoma Axillary Node Study in Patients With Melanoma,COMPLETED,NA,121.0,2002-05-15,2020-04-09,0.5632726716623336,Slow (<1/month),5.632726716623337,Significantly Below (<50%),100,54.7,60.629999999999995
NCT05963282,Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients,COMPLETED,,9870.0,2021-11-29,2022-07-19,1295.0120689655173,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT04964882,Gastric Insufflation During Positive Pressure Ventilation,UNKNOWN,NA,78.0,2021-07-20,2022-03-05,10.413684210526316,Good (10-50/month),104.13684210526317,Exceeded (≥100%),50,46.2,35.089999999999996
NCT02493582,The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR,ACTIVE_NOT_RECRUITING,PHASE2,400.0,2015-07-01,2033-07-01,1.8518631178707226,Adequate (1-10/month),18.518631178707228,Significantly Below (<50%),85,77.5,85.87
NCT03742882,"A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects",COMPLETED,PHASE1,40.0,2018-12-06,2019-06-10,6.5462365591397855,Adequate (1-10/month),65.46236559139786,Below (50-75%),100,53.2,56.665
NCT03334682,Randomized Double-blind Study on the Benefit of Spironolactone for Treating Acne of Adult Woman.,COMPLETED,PHASE3,158.0,2018-01-31,2023-07-04,2.429050505050505,Adequate (1-10/month),24.29050505050505,Significantly Below (<50%),100,62.6,75.325
NCT02436382,Hypothermia and the Effect of Ambient Temperature,COMPLETED,NA,846.0,2015-02-01,2015-09-01,121.47283018867925,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT01105182,Radiofrequency Ablation Combined With Chemotherapy for Pulmonary Tumors,UNKNOWN,,48.0,2009-11-01,2011-06-01,2.5322703639514734,Adequate (1-10/month),25.32270363951474,Significantly Below (<50%),50,37.2,18.17
NCT04028882,Immune Activation as a Cause of Insulin Resistance in Adults Living With HIV-1 on Effective Antiretroviral Therapy,TERMINATED,,148.0,2020-03-03,2024-02-09,3.1329068150208625,Adequate (1-10/month),31.329068150208627,Significantly Below (<50%),10,33.2,12.989999999999998
NCT01818882,Diagnostic Value of Portable Ultrasound for Dyspneic Patient Support in the Emergency Department,TERMINATED,NA,85.0,2014-04-01,2016-01-01,4.0428125,Adequate (1-10/month),40.428125,Significantly Below (<50%),10,29.8,8.98
NCT06084182,Cognitive Function in Multiple Sclerosis,COMPLETED,NA,76.0,2021-11-15,2022-11-15,6.338191780821918,Adequate (1-10/month),63.38191780821918,Below (50-75%),100,56.1,63.99
NCT05114382,An Evaluation of the Safety and Performance of the CathVision Cube® System,COMPLETED,NA,24.0,2020-10-02,2021-08-01,2.4110891089108915,Adequate (1-10/month),24.110891089108915,Significantly Below (<50%),100,51.9,52.55499999999999
NCT06905782,"Artificial Intelligence (AI) Technology May Help Patients to Understand Bowel Preparation Better Before They go for Colonoscopy.This Study Attempts to Leverage AI Chatbot in Counselling Patients to Improve Bowel Cleanliness, Reduce Anxiety as Well as Increase Procedural Satisfaction",NOT_YET_RECRUITING,NA,96.0,2025-04-01,2026-02-02,9.51869706840391,Adequate (1-10/month),95.1869706840391,Met (75-100%),30,41.7,24.36
NCT06842082,The Videolaryngoscopy Versus Direct Laringoscopy for Residents Intubation Study,RECRUITING,NA,1008.0,2025-06-16,2025-12-29,156.54857142857142,Excellent (>50/month),200.0,Exceeded (≥100%),60,88.0,92.495
NCT04491682,Megestrol Acetate Plus Rosuvastatin in Young Women With Atypical Endometrial Hyperplasia,COMPLETED,PHASE2,36.0,2020-09-01,2022-06-20,1.667945205479452,Adequate (1-10/month),16.67945205479452,Significantly Below (<50%),100,52.9,55.55
NCT00713882,Health and Psychosocial Outcomes in Long-Term Lymphoma Survivors,COMPLETED,,130.0,2008-04-01,2008-11-01,18.49158878504673,Good (10-50/month),184.9158878504673,Exceeded (≥100%),100,63.7,76.655
NCT00531882,Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy Volunteers,COMPLETED,NA,25.0,2007-09-01,2009-02-01,1.466281310211946,Adequate (1-10/month),14.662813102119463,Significantly Below (<50%),100,47.0,39.33
NCT02887482,GLS-5700 in Dengue Virus Seropositive Adults,COMPLETED,PHASE1,160.0,2016-08-01,2018-06-01,7.280119581464873,Adequate (1-10/month),72.80119581464872,Below (50-75%),100,62.8,75.53999999999999
NCT07141082,Expressive Art Therapy for Elder Adults With Chronic Low Back Pain,RECRUITING,NA,30.0,2025-08-02,2027-12-01,1.073090481786134,Adequate (1-10/month),10.73090481786134,Significantly Below (<50%),60,35.4,15.765
NCT02613182,Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis,TERMINATED,PHASE2,34.0,2016-02-01,2018-05-01,1.2621463414634146,Adequate (1-10/month),12.621463414634146,Significantly Below (<50%),10,20.7,6.02
NCT06636682,FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer,RECRUITING,PHASE2,100.0,2024-10-14,2027-05-04,3.2660944206008584,Adequate (1-10/month),32.66094420600859,Significantly Below (<50%),60,46.0,34.1
NCT04018482,Povidone Iodine vs AVEnova: A Pre-injection Disinfection Study (PAVE Study),COMPLETED,PHASE4,50.0,2019-07-16,2019-08-14,50.0,Good (10-50/month),200.0,Exceeded (≥100%),100,64.0,77.025
NCT03709082,Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer,TERMINATED,PHASE1,3.0,2018-10-15,2021-02-03,0.10845605700712589,Slow (<1/month),1.0845605700712588,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT05731882,First in Man Study of Left Atrial Appendage Pulsed Field Ablation Occluder,UNKNOWN,NA,10.0,2022-07-17,2024-08-01,0.4080428954423593,Slow (<1/month),4.080428954423593,Significantly Below (<50%),50,30.8,9.745
NCT05417282,MW151 and Whole-brain Radiotherapy in Patients With Intracranial Metastases,COMPLETED,PHASE1,27.0,2022-07-01,2025-07-31,0.729911190053286,Slow (<1/month),7.299111900532859,Significantly Below (<50%),100,47.2,40.035
NCT04403282,Topical Eflornithine for Pseudofolliculitis Barbae: Randomized Controlled Trial,TERMINATED,PHASE4,9.0,2020-09-27,2023-06-22,0.27450901803607214,Slow (<1/month),2.7450901803607217,Significantly Below (<50%),10,18.7,4.455
NCT00540982,Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction,COMPLETED,PHASE1,47.0,1997-02-20,2010-05-20,0.2957783750258425,Slow (<1/month),2.9577837502584248,Significantly Below (<50%),100,48.8,45.184999999999995
NCT05915624,Tele Nursing Counseling on Anxiety and Patient Satisfaction in Same Day Surgery,COMPLETED,NA,160.0,2022-09-01,2023-05-30,17.971955719557197,Good (10-50/month),179.71955719557195,Exceeded (≥100%),100,67.8,80.285
NCT00099424,Exercise Training in Sarcoidosis (EXTRAS Study),COMPLETED,NA,30.0,2004-02-01,2005-08-01,1.6694698354661792,Adequate (1-10/month),16.694698354661792,Significantly Below (<50%),100,52.4,53.949999999999996
NCT02182024,"Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With and Without Renal Impairment",COMPLETED,PHASE1,35.0,2005-04-01,,,Slow (<1/month),,Significantly Below (<50%),100,42.8,25.929999999999996
NCT04306224,A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas,COMPLETED,PHASE1,12.0,2020-06-05,2022-10-07,0.427728337236534,Slow (<1/month),4.27728337236534,Significantly Below (<50%),100,46.0,34.1
NCT05776524,Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer,RECRUITING,PHASE2,46.0,2023-06-13,2029-07-01,0.6335927601809955,Slow (<1/month),6.3359276018099555,Significantly Below (<50%),60,36.7,17.544999999999998
NCT04457024,Tennis Elbow Patients Undergoing Closed Therapy Can Easily Cause Tendon Tear,COMPLETED,,108.0,2020-01-01,2020-04-01,36.12659340659341,Good (10-50/month),200.0,Exceeded (≥100%),100,62.0,74.42
NCT03385824,Self-Advocacy for Independent Life (SAIL) After TBI,COMPLETED,NA,76.0,2018-02-01,2020-03-31,2.9321166032953103,Adequate (1-10/month),29.321166032953105,Significantly Below (<50%),100,56.1,63.99
NCT06356324,The Effects of Music and Television on Intraoperative Hypertensive Events in Cataract Surgery,COMPLETED,NA,650.0,2021-10-18,2024-04-01,22.08258928571429,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT07336524,Ankle Isometric Strength and Proprioception in Young Ice Hockey Players,NOT_YET_RECRUITING,,70.0,2025-12-15,2026-03-15,23.675555555555555,Good (10-50/month),200.0,Exceeded (≥100%),30,37.9,19.139999999999997
NCT01873924,Clinical and Neuropsychological Investigations in Batten Disease,RECRUITING,,500.0,2004-08-01,2035-08-01,1.3442854619325209,Adequate (1-10/month),13.442854619325207,Significantly Below (<50%),60,71.3,82.655
NCT02252224,Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance,COMPLETED,,3123.0,2014-09-23,2016-11-30,118.97887359199,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT05831124,A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults,COMPLETED,PHASE1,90.0,2023-04-19,2024-06-26,6.312442396313364,Adequate (1-10/month),63.12442396313364,Below (50-75%),100,57.2,66.465
NCT01534624,Stem Cell Study of Genetics and Drug Addiction,COMPLETED,,49.0,2012-02-07,2014-07-30,1.6499557522123895,Adequate (1-10/month),16.499557522123894,Significantly Below (<50%),100,47.3,40.475
NCT00869024,Stem Cell Therapy in Patients With Severe Heart Failure & Undergoing Left Ventricular Assist Device Placement,COMPLETED,PHASE1,25.0,2011-11-10,2016-03-29,0.4753279200499688,Slow (<1/month),4.753279200499688,Significantly Below (<50%),100,47.0,39.33
NCT04778124,HAL-RAR Technique for Treating Hemorrhoids,COMPLETED,NA,105.0,2010-01-01,2019-11-01,0.8900584795321639,Slow (<1/month),8.900584795321638,Significantly Below (<50%),100,53.4,57.35
NCT06366724,LIFT: Life Improvement Trial,RECRUITING,PHASE2,160.0,2024-09-10,2026-11-01,6.2281329923273665,Adequate (1-10/month),62.28132992327367,Below (50-75%),60,50.8,49.18
NCT01420224,Study of the Effects of Commercial Air Travel on the Lungs,COMPLETED,,9.0,2011-05-01,2011-06-01,8.83741935483871,Adequate (1-10/month),88.3741935483871,Met (75-100%),100,54.1,59.11
NCT01090024,Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids,COMPLETED,PHASE2,108.0,2010-03-01,2011-02-18,9.286779661016949,Adequate (1-10/month),92.86779661016949,Met (75-100%),100,63.6,76.545
NCT03129724,Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - Axitinib,UNKNOWN,,100.0,2016-09-01,2017-07-01,10.046204620462047,Good (10-50/month),100.46204620462046,Exceeded (≥100%),50,46.3,35.66
NCT06088524,The Effects of Mental Fatigue Created by Social Media on Upper Extremity Performance,COMPLETED,,29.0,2023-01-05,2023-10-01,3.2816356877323423,Adequate (1-10/month),32.81635687732342,Significantly Below (<50%),100,50.7,48.915
NCT00798824,The Impact of Nasogastric Indwelling Versus Oral Intermittent Tube Feeding Methods on Premature Infants,COMPLETED,NA,24.0,2008-08-01,2009-12-01,1.500123203285421,Adequate (1-10/month),15.001232032854212,Significantly Below (<50%),100,46.9,38.96
NCT01243723,Study Assessing the Efficacy of Eductyl® for the Treatment of Patients With Dyschesia,COMPLETED,PHASE4,306.0,2010-11-01,2012-06-01,16.11529411764706,Good (10-50/month),161.15294117647062,Exceeded (≥100%),100,79.5,87.195
NCT00088023,Safety Study of PT-523 in Cancer Patients to Treat Solid Tumors Including a Preliminary Assessment of Effectiveness,TERMINATED,PHASE1,40.0,2004-03-01,2005-12-01,1.9025,Adequate (1-10/month),19.025,Significantly Below (<50%),10,26.2,7.775
NCT01612923,Safety and Efficacy of Medical Abortion Provided by Midlevel Providers or Physicians,COMPLETED,PHASE3,1180.0,2011-04-01,2012-07-01,78.59781181619256,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT01511523,Study to Evaluate the Effect of RGMA001 on Patients With Non Alcoholic Fatty Liver Disease (NAFLD),UNKNOWN,NA,40.0,2012-01-01,2012-10-01,4.443795620437956,Adequate (1-10/month),44.43795620437956,Significantly Below (<50%),50,38.2,19.645000000000003
NCT07030023,Diagnosis of Wire Syndrome,ENROLLING_BY_INVITATION,,40.0,2025-03-28,2025-07-31,9.7408,Adequate (1-10/month),97.408,Met (75-100%),55,43.0,26.465
NCT05332223,The Epidemiology of Sleep Disordered Breathing in Patients With Congestive Heart Failure,COMPLETED,,116.0,2022-04-15,2023-12-31,5.649664,Adequate (1-10/month),56.49664,Below (50-75%),100,57.6,67.36999999999999
NCT07243223,Urinary Incontinence in Older Hong Kong Women: A Cross-sectional Study,NOT_YET_RECRUITING,,1100.0,2025-11-30,2027-03-01,73.4298245614035,Excellent (>50/month),200.0,Exceeded (≥100%),30,77.3,85.67
NCT04363723,The Influence of an Acute Exacerbation During Pulmonary Rehabilitation in COPD Patients Awaiting Lung Transplantation,COMPLETED,,559.0,2020-04-23,2020-05-10,559.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT05230823,Behavioural Weight Loss Treatment for Patients with Atrial Fibrillation and Obesity in Cardiac Rehabilitation,COMPLETED,NA,14.0,2022-01-24,2023-01-31,1.1455913978494625,Adequate (1-10/month),11.455913978494623,Significantly Below (<50%),100,46.1,34.695
NCT03075423,Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC,COMPLETED,PHASE2,316.0,2017-11-01,2023-11-23,4.34660641662901,Adequate (1-10/month),43.4660641662901,Significantly Below (<50%),100,75.3,84.60499999999999
NCT01737723,Electroencephalograph for Detection of Acute Ischemic Stroke,UNKNOWN,,20.0,2011-08-01,,,Slow (<1/month),,Significantly Below (<50%),50,24.9,7.12
NCT03016923,Functional Electrical Stimulation (FES) for Upper Extremity Hemiplegia in Children With Cerebral Palsy,COMPLETED,NA,3.0,2016-03-01,2017-08-25,0.1684870848708487,Slow (<1/month),1.6848708487084874,Significantly Below (<50%),100,45.2,30.830000000000002
NCT02652923,Contrast Ultrasound Detection of Sentinel Lymph Nodes,COMPLETED,PHASE1,98.0,2016-01-01,2022-01-12,1.3541171130276894,Adequate (1-10/month),13.541171130276897,Significantly Below (<50%),100,52.8,55.31
NCT06329323,SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours,NOT_YET_RECRUITING,,24.0,2024-04-14,2028-04-01,0.5045303867403315,Slow (<1/month),5.045303867403315,Significantly Below (<50%),30,24.3,6.855
NCT02272023,Randomized Trial of Intensive Motivational Interviewing (IMI) to Improve Drinking Outcomes Among Women,COMPLETED,NA,215.0,2015-02-01,2019-03-07,4.377658862876254,Adequate (1-10/month),43.77658862876254,Significantly Below (<50%),100,67.2,79.94
NCT04916223,Study to Determine Therapeutic Massage Dosing to Improve Quality of Life in Hospitalized Patients Receiving Palliative Care,COMPLETED,NA,405.0,2017-11-01,2019-03-26,24.17294117647059,Good (10-50/month),200.0,Exceeded (≥100%),100,87.4,92.28
NCT03722823,A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects,COMPLETED,PHASE1,37.0,2018-10-10,2019-05-07,5.3888995215311,Adequate (1-10/month),53.888995215311006,Below (50-75%),100,53.0,55.80500000000001
NCT04228523,Therapeutic Education in Parkinson's Disease: What Impact on Drug Representations of Patients? (ETPARK-REMED),COMPLETED,NA,24.0,2020-02-24,2021-01-01,2.3415384615384616,Adequate (1-10/month),23.415384615384617,Significantly Below (<50%),100,51.9,52.55499999999999
NCT06616623,Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer,SUSPENDED,PHASE1,24.0,2024-12-31,2026-12-31,1.0007671232876714,Adequate (1-10/month),10.007671232876714,Significantly Below (<50%),20,22.9,6.3549999999999995
NCT04675723,The Role of Mucosal Microbiome in Recurrence of Clostridioides Difficile Infection,COMPLETED,,52.0,2019-09-23,2022-05-05,1.6574659685863875,Adequate (1-10/month),16.574659685863875,Significantly Below (<50%),100,47.5,41.415
NCT06208423,Physician Reasoning on Management Cases With Large Language Models,COMPLETED,NA,92.0,2023-12-28,2024-04-19,24.783008849557522,Good (10-50/month),200.0,Exceeded (≥100%),100,62.4,75.095
NCT04462523,DEXTENZA for the Treatment of Postoperative Pain and Inflammation Following Vitreo-retinal Surgery,COMPLETED,PHASE4,40.0,2020-01-03,2022-03-31,1.4885085574572128,Adequate (1-10/month),14.885085574572127,Significantly Below (<50%),100,48.2,43.665
NCT04023123,Anterior Corneal Striae in Hypotony,COMPLETED,,98.0,2019-09-17,2020-03-23,15.867659574468085,Good (10-50/month),158.67659574468087,Exceeded (≥100%),100,61.2,73.43499999999999
NCT00610623,Azithromycin as a Quorum-Sensing Inhibitor for the Prevention of Pseudomonas Aeruginosa Ventilator-Associated Pneumonia,TERMINATED,PHASE2,92.0,2003-04-01,2005-10-01,3.0639824945295406,Adequate (1-10/month),30.63982494529541,Significantly Below (<50%),10,30.4,9.345
NCT00796523,An Intervention to Decrease Infant Crying,COMPLETED,NA,51.0,2005-08-01,2006-05-01,5.686593406593407,Adequate (1-10/month),56.86593406593408,Below (50-75%),100,54.1,59.11
NCT01589523,GlycoCholic Acid Treatment for Patients With Inborn Errors in Bile Acid Synthesis,COMPLETED,PHASE3,5.0,2006-02-01,2019-01-22,0.03212325875897003,Slow (<1/month),0.3212325875897003,Significantly Below (<50%),100,45.4,31.455
NCT03408223,Total Marrow and Lymphoid Irradiation and Chemotherapy for High-Risk Acute Leukemia,UNKNOWN,NA,100.0,2014-03-01,2022-12-01,0.9521426337191118,Slow (<1/month),9.521426337191118,Significantly Below (<50%),50,38.0,19.255
NCT00225823,Study In Adults And Adolescents With Seasonal Allergic Rhinitis.,COMPLETED,PHASE3,288.0,2005-05-01,2005-08-01,95.2904347826087,Excellent (>50/month),200.0,Exceeded (≥100%),100,83.0,89.505
NCT06786923,The Effect of taVNS on the Prognosis of Patients Undergoing Pancreatoduodenectomy,COMPLETED,NA,84.0,2025-01-08,2025-10-31,8.638378378378379,Adequate (1-10/month),86.38378378378378,Met (75-100%),100,61.7,74.1
NCT01964859,Feasibility Study for Fibroblast Autologous Skin Grafts,RECRUITING,PHASE2,80.0,2015-01-07,2028-11-01,0.48250445809391723,Slow (<1/month),4.825044580939172,Significantly Below (<50%),60,39.4,20.94
NCT01290159,The Development Of A Novel Biomarker For Early Identification Of The Individual's State Of Tolerance To Heat,COMPLETED,,10.0,2011-05-01,2013-07-01,0.3843434343434344,Slow (<1/month),3.8434343434343434,Significantly Below (<50%),100,44.1,28.425
NCT06092359,The Eye in Orbit: UCF Adaption,COMPLETED,,1.0,2022-03-01,2022-07-31,0.20026315789473684,Slow (<1/month),2.0026315789473683,Significantly Below (<50%),100,43.4,27.265
NCT02262559,Bioequivalence of BIBR 277 Tablet Compared With Capsule in Healthy Male Volunteers,COMPLETED,PHASE1,30.0,2002-07-01,,,Slow (<1/month),,Significantly Below (<50%),100,42.4,25.45
NCT06356259,"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy Participants",TERMINATED,PHASE1,83.0,2023-06-07,2025-01-23,4.239127516778524,Adequate (1-10/month),42.39127516778524,Significantly Below (<50%),10,29.6,8.885
NCT06916559,Comparison of Different Methods for Measuring Urinary Oxalate and Citrate: An Observational Study,COMPLETED,,122.0,2025-03-01,2025-04-01,119.79612903225807,Excellent (>50/month),200.0,Exceeded (≥100%),100,68.1,80.715
NCT05084859,"A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors",TERMINATED,PHASE1,30.0,2021-11-03,2022-10-20,2.601709401709402,Adequate (1-10/month),26.017094017094017,Significantly Below (<50%),10,25.4,7.470000000000001
NCT03121859,Analgesic Current Therapies for Chronic Neck Pain,COMPLETED,NA,81.0,2015-10-01,2017-04-01,4.499343065693431,Adequate (1-10/month),44.99343065693431,Significantly Below (<50%),100,56.5,65.18
NCT01026259,Local Warming of Surgical Incisions,COMPLETED,PHASE3,146.0,2005-10-01,2009-11-01,2.978713136729223,Adequate (1-10/month),29.78713136729223,Significantly Below (<50%),100,61.7,74.1
NCT00273559,A Study Comparing Outcomes of Kidney Transplants in Patients on Steroids Versus Those Who Discontinue Steroids,UNKNOWN,,60.0,2006-01-01,2008-12-01,1.7149295774647888,Adequate (1-10/month),17.14929577464789,Significantly Below (<50%),50,38.1,19.425
NCT00497159,A Study of the Novel Drug Dimebon in Patients With Huntington's Disease,COMPLETED,PHASE2,91.0,2007-07-01,2008-06-01,8.244166666666667,Adequate (1-10/month),82.44166666666666,Met (75-100%),100,57.3,66.74
NCT01459159,Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome,TERMINATED,PHASE2,162.0,2011-10-01,2013-02-01,10.084417177914112,Good (10-50/month),100.8441717791411,Exceeded (≥100%),10,41.0,23.01
NCT06488859,Affect Treatment for Depression and Anxiety (TAD Pilot),COMPLETED,NA,10.0,2024-03-25,2025-03-25,0.8339726027397261,Slow (<1/month),8.33972602739726,Significantly Below (<50%),100,45.8,33.03
NCT02981459,Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women,WITHDRAWN,PHASE4,0.0,2017-12-08,2018-06-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT06934759,Impact and Lived Experience of Parents of a Child With a Large or Giant Congenital Melanocytic Nevus,ENROLLING_BY_INVITATION,,30.0,2025-12-01,2026-08-31,3.345054945054945,Adequate (1-10/month),33.45054945054945,Significantly Below (<50%),55,37.2,18.17
NCT04203459,The Mechanism of Enhancing the Anti-tumor Effects of CAR-T on PC by Gut Microbiota Regulation,UNKNOWN,,80.0,2019-10-20,2022-12-31,2.084931506849315,Adequate (1-10/month),20.849315068493148,Significantly Below (<50%),50,39.7,21.21
NCT01498380,The Bolus Dose of Dexmedetomidine (ED50) That Avoids Hemodynamic Compromise in Children,COMPLETED,NA,21.0,2012-01-01,2013-09-01,1.049655172413793,Adequate (1-10/month),10.49655172413793,Significantly Below (<50%),100,46.7,37.895
NCT00558480,Vitamin A Supplementation for Modulation of Mycobacterium Tuberculosis Immune Responses in Latent Tuberculosis,WITHDRAWN,NA,0.0,2009-07-01,2012-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT04110080,Enhanced Recovery After Surgery in Kidney Transplant Donors,UNKNOWN,NA,42.0,2019-09-12,2023-06-12,0.9338787436084734,Slow (<1/month),9.338787436084734,Significantly Below (<50%),50,33.4,13.29
NCT03175380,Biological Samples Obtained by Leukapheresis Induced by Two BCG Vaccinations in BCG-naïve Healthy Adults in the US,COMPLETED,EARLY_PHASE1,15.0,2017-08-08,2019-01-10,0.8780769230769231,Slow (<1/month),8.780769230769229,Significantly Below (<50%),100,46.2,35.089999999999996
NCT06794580,The DUAL-SYSTEM HYPOTHESIS of ANOSOGNOSIA: the Interplay Between Emotional Processing and Self-Monitoring in Neurodegenerative Patients,COMPLETED,,100.0,2019-01-22,2020-07-30,5.484684684684685,Adequate (1-10/month),54.84684684684685,Below (50-75%),100,56.3,64.5
NCT04825080,Carotid Asymptomatic Stenosis,UNKNOWN,,300.0,2019-01-01,2025-01-01,4.166058394160584,Adequate (1-10/month),41.660583941605836,Significantly Below (<50%),50,57.3,66.74
NCT06169280,Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma,RECRUITING,PHASE1,20.0,2025-06-27,2030-12-31,0.30243417784401394,Slow (<1/month),3.024341778440139,Significantly Below (<50%),60,34.6,14.729999999999999
NCT01177280,Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions Among Chronic Low Back Pain Patients Taking Opioid Analgesics and Associated Economic Outcomes,COMPLETED,,10000.0,2010-09-01,2011-01-01,2495.0819672131147,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02488980,An Evaluation of Weekly Tafenoquine,COMPLETED,PHASE2,306.0,2000-05-01,2003-03-01,9.00835589941973,Adequate (1-10/month),90.0835589941973,Met (75-100%),100,79.5,87.195
NCT04169880,Effects of High Intensity Laser Therapy (HILT) in Patients With Subacromial Impingement Syndrome,COMPLETED,NA,30.0,2014-05-05,2016-05-27,1.2127490039840638,Adequate (1-10/month),12.127490039840637,Significantly Below (<50%),100,47.4,40.98
NCT00121680,"A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma",COMPLETED,PHASE1,115.0,2005-07-01,2015-05-01,0.9748259537733223,Slow (<1/month),9.748259537733222,Significantly Below (<50%),100,54.2,59.330000000000005
NCT02418780,Tai Chi for Enhancing Motor and Cognitive Function in Parkinson's Disease,COMPLETED,NA,32.0,2014-05-01,2016-04-01,1.3895577746077032,Adequate (1-10/month),13.89557774607703,Significantly Below (<50%),100,47.6,41.775
NCT04770480,Non-pharmacological Treatment for Pain After Spine Surgery,ACTIVE_NOT_RECRUITING,NA,267.0,2021-12-10,2026-03-30,5.173443666454488,Adequate (1-10/month),51.73443666454488,Below (50-75%),85,66.9,79.60000000000001
NCT00676780,Green Tea Extract and Prostate Cancer,COMPLETED,PHASE2,33.0,2004-05-01,2008-12-01,0.5997134328358209,Slow (<1/month),5.997134328358209,Significantly Below (<50%),100,47.6,41.775
NCT02219880,Kava for the Treatment of Generalised Anxiety Disorder: A Double-Blind Randomised Placebo-Controlled Trial,COMPLETED,PHASE4,178.0,2015-10-13,2018-05-31,5.638210197710718,Adequate (1-10/month),56.38210197710718,Below (50-75%),100,64.2,77.18
NCT05347680,A Comparison Between the Intubating Laryngeal Tube Suction and the Ambu AuraGain,COMPLETED,NA,80.0,2019-09-19,2021-01-18,5.00041067761807,Adequate (1-10/month),50.0041067761807,Below (50-75%),100,56.4,64.88000000000001
NCT04366180,Evaluation of the Probiotic Lactobacillus Coryniformis K8 on COVID-19 Prevention in Healthcare Workers,UNKNOWN,NA,314.0,2020-04-24,2020-10-01,59.7385,Excellent (>50/month),200.0,Exceeded (≥100%),50,70.1,81.955
NCT05482880,"Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region",COMPLETED,,78.0,2022-02-28,2024-12-01,2.3578152929493545,Adequate (1-10/month),23.578152929493548,Significantly Below (<50%),100,54.6,60.39
NCT03075280,Pre-ERCP High Carbohydrate Drinks Improve Patients Recovery,COMPLETED,NA,1292.0,2017-04-01,2021-04-17,26.627271496276236,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT00044980,Diet and Exercise-Based Counseling Program Compared With a Standard Counseling Program in Patients With Early-Stage Prostate Cancer,COMPLETED,NA,,2002-07-01,2006-12-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,30.330000000000002
NCT05488080,PAINED: Project Addressing INequities in the Emergency Department,RECRUITING,NA,22032.0,2023-02-27,2026-08-23,526.8295993715633,Excellent (>50/month),200.0,Exceeded (≥100%),60,88.0,92.495
NCT06652880,Digital Support Intervention for Pregnant People with Opioid Use Disorders,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,32.0,2024-06-04,2025-12-31,1.6940521739130436,Adequate (1-10/month),16.940521739130435,Significantly Below (<50%),85,48.1,43.275000000000006
NCT01642680,Optimal Timing of Physical Activity in Cancer Treatment,COMPLETED,NA,266.0,2013-01-24,2020-10-22,2.8631683168316835,Adequate (1-10/month),28.631683168316833,Significantly Below (<50%),100,71.3,82.655
NCT04186780,Effects of Lentinula Edodes Bars on Dyslipidemia and Oxidative Stress in Cholesterol Individuals: Randomized Study,COMPLETED,NA,68.0,2018-09-26,2019-09-20,5.765793871866296,Adequate (1-10/month),57.65793871866296,Below (50-75%),100,55.4,62.56
NCT05775380,The Role of Pioglitazone in Vascular Transcriptional Remodeling,UNKNOWN,PHASE4,20.0,2023-06-15,2024-12-22,1.0949640287769784,Adequate (1-10/month),10.949640287769785,Significantly Below (<50%),50,31.6,10.905
NCT02075580,Totally Implantable Venous Access Devices: Quality of Life and Body Image,COMPLETED,NA,128.0,2013-09-01,2018-12-01,2.032509128847157,Adequate (1-10/month),20.325091288471572,Significantly Below (<50%),100,60.2,72.2
NCT03497780,Longitudinal Assessment of Cartilage Injury and Remodeling After Anterior Cruciate Ligament Rupture and Reconstruction:,TERMINATED,,13.0,2018-11-08,2021-03-25,0.4558986175115208,Slow (<1/month),4.558986175115208,Significantly Below (<50%),10,17.4,2.8049999999999997
NCT01387880,"Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer",COMPLETED,PHASE2,100.0,2010-01-01,2012-03-01,3.853164556962026,Adequate (1-10/month),38.53164556962025,Significantly Below (<50%),100,58.0,68.245
NCT04919980,TVMR With the INNOVALVE System Trial - Early Feasibility Study,RECRUITING,NA,65.0,2022-09-01,2031-07-01,0.6135193798449612,Slow (<1/month),6.135193798449612,Significantly Below (<50%),60,38.2,19.645000000000003
NCT04732780,Avoidance of Hyperglycaemia in People With Type 1 Diabetes,COMPLETED,,253.0,2021-03-02,2022-04-20,18.602222222222224,Good (10-50/month),186.0222222222222,Exceeded (≥100%),100,73.6,83.775
NCT05434780,Kinesiology Taping on Calf Tightness,UNKNOWN,NA,20.0,2022-08-15,2022-12-15,4.99016393442623,Adequate (1-10/month),49.901639344262286,Significantly Below (<50%),50,36.6,17.41
NCT06580379,Spine Surgery Video Observation Study. The Creation of a Benchmark Video (RGB-Depth) Dataset to Investigate the Feasibility of Developing a Markerless Tracking System for Spine Surgery.,NOT_YET_RECRUITING,,25.0,2024-10-01,2027-10-01,0.6949771689497718,Slow (<1/month),6.949771689497718,Significantly Below (<50%),30,24.3,6.855
NCT06437379,Infection Control Measures for Patients Undergoing Percutaneous Nephrolithotomy,COMPLETED,NA,30.0,2023-09-01,2025-01-01,1.871311475409836,Adequate (1-10/month),18.71311475409836,Significantly Below (<50%),100,52.4,53.949999999999996
NCT06133179,Super-Resolution Ultrasound of the Brain in 3D,RECRUITING,NA,20.0,2024-03-22,2025-02-01,1.9265822784810127,Adequate (1-10/month),19.265822784810126,Significantly Below (<50%),60,39.6,21.115000000000002
NCT02084979,A Controlled Trial of Patient Centered Telepsychiatry Interventions,COMPLETED,NA,185.0,2014-04-01,2019-04-29,3.0374325782092777,Adequate (1-10/month),30.374325782092775,Significantly Below (<50%),100,64.8,77.865
NCT03020979,A Clinical Trial With Apatinib for Subjects With Refractory Malignant Ascites,UNKNOWN,PHASE2,120.0,2017-01-01,2019-12-01,3.433082706766917,Adequate (1-10/month),34.330827067669176,Significantly Below (<50%),50,44.6,29.42
NCT02532179,Subcutaneous Immunotherapy for Mouse in Adults,COMPLETED,PHASE1,12.0,2015-10-01,2016-10-01,0.9980327868852459,Slow (<1/month),9.98032786885246,Significantly Below (<50%),100,46.0,34.1
NCT02559479,A Study to Assess the Effect of a Normal vs. High Protein Diets in Carbohydrates Metabolism in Obese Subjects With Diabetes or Prediabetes,UNKNOWN,NA,100.0,2015-09-01,2017-06-01,4.763693270735525,Adequate (1-10/month),47.63693270735524,Significantly Below (<50%),50,43.0,26.465
NCT02534779,"Assessing the Disintegration, Safety, and Acceptability of Placebo Vaginal Inserts for the Delivery of Vaginal Products",COMPLETED,NA,49.0,2015-08-01,2016-03-01,7.002629107981221,Adequate (1-10/month),70.02629107981221,Below (50-75%),100,53.9,58.34
NCT05419479,Switch Maintenance in Pancreatic,SUSPENDED,PHASE1,46.0,2022-11-30,2028-09-30,0.6570811825434069,Slow (<1/month),6.570811825434069,Significantly Below (<50%),20,24.7,6.995
NCT02906579,"A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension",COMPLETED,PHASE2,11.0,2016-09-01,2017-03-17,1.6996954314720814,Adequate (1-10/month),16.996954314720814,Significantly Below (<50%),100,50.9,49.370000000000005
NCT00894179,Safety and Accuracy Study of Regadenoson Atropine Combination for Stress Echocardiography in Identification of Coronary Artery Disease,UNKNOWN,,110.0,2009-05-01,2011-12-01,3.547033898305085,Adequate (1-10/month),35.47033898305085,Significantly Below (<50%),50,42.1,25.019999999999996
NCT02590679,Multi-center Trial of Percutaneous Pulmonary Valve Implantation With Venus-p,UNKNOWN,PHASE2,44.0,2013-05-01,2017-02-01,0.9762099125364433,Slow (<1/month),9.762099125364433,Significantly Below (<50%),50,33.5,13.34
NCT02775279,Association Between Telomere Length and Risk of Acute Coronary Syndrome,COMPLETED,,400.0,2016-01-01,2016-05-01,100.62809917355372,Excellent (>50/month),200.0,Exceeded (≥100%),100,90.3,93.28
NCT04573179,Effectiveness of 68Ga-PSMA PET/MRI for Improving the Detection of csPCa in Lesions With PI-RADS Score 3,UNKNOWN,,60.0,2020-07-01,2021-07-01,5.003835616438357,Adequate (1-10/month),50.03835616438357,Below (50-75%),50,38.1,19.425
NCT06039579,Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults,COMPLETED,PHASE2,44.0,2023-10-25,2024-06-24,5.511769547325104,Adequate (1-10/month),55.11769547325104,Below (50-75%),100,53.5,57.555
NCT06072196,A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC),COMPLETED,,3017.0,2023-10-04,2024-12-18,208.24825396825398,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT07136896,"Nutritional Assessment in Patient of Mucopolysaccharide """,NOT_YET_RECRUITING,NA,40.0,2025-08-16,2026-08-30,3.2126649076517153,Adequate (1-10/month),32.126649076517154,Significantly Below (<50%),30,32.2,11.635
NCT02374996,Pharmacoepigenetics of Bipolar Disorder Treatment,COMPLETED,,40.0,2015-11-01,2017-09-01,1.8173134328358211,Adequate (1-10/month),18.17313432835821,Significantly Below (<50%),100,51.5,51.245
NCT04193696,RT+ Anti-PD-1 for Patients With Advanced HCC (RT+PD-1-HCC),UNKNOWN,PHASE2,39.0,2020-01-10,2020-07-30,5.877029702970297,Adequate (1-10/month),58.77029702970298,Below (50-75%),50,38.1,19.425
NCT02465996,Gastric Barrier Dysfunction of Functional Dyspepsia and Therapeutic Response to Puyuanhewei Detected by Endomicroscopy,UNKNOWN,NA,200.0,2014-07-01,2015-06-01,18.17313432835821,Good (10-50/month),181.73134328358208,Exceeded (≥100%),50,56.0,63.71
NCT02545296,HIV Point-of-Care Test Evaluation in Infants,COMPLETED,NA,604.0,2015-07-01,2017-08-01,24.128293963254595,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT00788996,Reduction of Environmental Tobacco Smoke (ETS) Exposure at Home: the BIBE Study,UNKNOWN,PHASE2,552.0,2009-01-01,2011-01-01,23.01764383561644,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT03096496,Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy,UNKNOWN,,161.0,2017-03-27,2022-01-01,2.814956921309592,Adequate (1-10/month),28.14956921309592,Significantly Below (<50%),50,46.2,35.089999999999996
NCT06073496,The Effectiveness of Electroacupuncture and Standard Therapy Compared to Standard Therapy in Gynecological Cancer Pain,COMPLETED,NA,58.0,2023-08-30,2023-12-19,15.905585585585586,Good (10-50/month),159.05585585585587,Exceeded (≥100%),100,59.6,71.17999999999999
NCT04006496,AML Expressive Writing,TERMINATED,NA,15.0,2019-11-04,2022-01-19,0.5657992565055763,Slow (<1/month),5.657992565055762,Significantly Below (<50%),10,19.2,5.055
NCT04488796,STAND UP to SARS-CoV-2 (COVID-19): Using Behavioural Economics to Reduce Sedentary Behaviour in At-home Office Workers,COMPLETED,NA,148.0,2020-09-07,2020-12-16,45.0512,Good (10-50/month),200.0,Exceeded (≥100%),100,71.8,82.83
NCT05472896,TACE With Dicycloplatin(TP21) in Unresectable HCC,UNKNOWN,PHASE3,332.0,2022-06-09,2024-06-30,13.438936170212767,Good (10-50/month),134.38936170212767,Exceeded (≥100%),50,66.6,79.43
NCT01788696,Pilot Study To Assess Effect of Treatment and Adherence in PD Subjects,COMPLETED,PHASE1,20.0,2012-06-01,2015-06-01,0.5559817351598174,Slow (<1/month),5.559817351598174,Significantly Below (<50%),100,46.6,37.375
NCT06619496,Health in Motion Pragmatic Clinical Trial - WRAPAROUND,COMPLETED,NA,63.0,2022-10-24,2024-07-01,3.1131818181818183,Adequate (1-10/month),31.131818181818183,Significantly Below (<50%),100,55.0,61.834999999999994
NCT05130996,Observational Study Evaluating Safety and Performance of IDI Dental Implant Systems in Subjects Followed for 18 Months.,RECRUITING,,121.0,2022-05-09,2024-06-01,4.884933687002653,Adequate (1-10/month),48.84933687002653,Significantly Below (<50%),60,46.0,34.1
NCT01021696,Pain in Patients With Dementia and Behavioural Disturbances,COMPLETED,PHASE2,352.0,2009-11-01,2010-10-01,32.08047904191617,Good (10-50/month),200.0,Exceeded (≥100%),100,83.2,89.815
NCT05743296,Differences in Brain Activity in the Application of Upper Limb Exercise Tasks Through Virtual Reality,COMPLETED,,25.0,2022-12-27,2023-02-20,13.836363636363638,Good (10-50/month),138.36363636363637,Exceeded (≥100%),100,55.3,62.36000000000001
NCT00005596,Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia,COMPLETED,PHASE3,1076.0,2000-04-01,2007-07-01,12.373796751038913,Good (10-50/month),123.73796751038913,Exceeded (≥100%),100,95.0,95.7
NCT01050296,Molecular Analysis Of Solid Tumors,RECRUITING,,1000.0,2010-02-10,2026-09-30,5.009874917709019,Adequate (1-10/month),50.0987491770902,Below (50-75%),60,76.3,85.1
NCT03737396,Pre-Anaesthesia CompuTerized Health Assessment,COMPLETED,NA,402.0,2018-05-03,2021-01-02,12.550646153846156,Good (10-50/month),125.50646153846155,Exceeded (≥100%),100,87.2,92.21000000000001
NCT06632496,BD Prevue(TM) II Peripheral Vascular Access System With Cue(TM) Needle Tracking Technology Clinical Study,COMPLETED,,156.0,2025-03-28,2025-09-23,26.528715083798883,Good (10-50/month),200.0,Exceeded (≥100%),100,65.8,78.745
NCT01923896,D-cycloserine and Treatment of Feeding Disorders,COMPLETED,PHASE1,16.0,2013-03-01,2013-11-01,1.987918367346939,Adequate (1-10/month),19.879183673469388,Significantly Below (<50%),100,51.3,50.62
NCT02363296,Main Study: Influence on Plasticity of Brain Temperature Sub-Study: Phase Triggered Paired Associative Stimulation (PAS),COMPLETED,NA,45.0,2016-05-03,2025-08-07,0.40490688737806685,Slow (<1/month),4.049068873780668,Significantly Below (<50%),100,48.6,44.685
NCT05972096,DBT Skills Expanded With Contextual Intervention for Long Lasting Symptoms in Borderline Personality Disorder,UNKNOWN,NA,60.0,2022-03-01,2023-10-01,3.1544041450777205,Adequate (1-10/month),31.5440414507772,Significantly Below (<50%),50,39.8,21.47
NCT05366296,"Safety, Reactogenicity, and Immunogenicity Study of a Lyophilized COVID-19 mRNA Vaccine",WITHDRAWN,PHASE1,0.0,2022-07-01,2023-01-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT03502096,Portion Size and To-go Container on Dinner Intake,COMPLETED,NA,58.0,2016-10-01,2017-12-01,4.1444131455399065,Adequate (1-10/month),41.44413145539907,Significantly Below (<50%),100,54.6,60.39
NCT04941196,Bioequivalence Study of Anplag® 90mg (Ticagrelor) Tablet & Brilinta® 90 mg (Ticagrelor) Tablet in Healthy Adult Male Pakistani Subjects Under Fasting Condition,COMPLETED,PHASE1,30.0,2020-10-16,2020-11-25,22.830000000000002,Good (10-50/month),200.0,Exceeded (≥100%),100,57.4,67.05499999999999
NCT01133496,Bioequivalence Study of Alendronate Sodium Tablets 70 mg of Dr. Reddy's Under Fasting Conditions,COMPLETED,PHASE1,80.0,2006-12-01,2007-04-01,20.125619834710744,Good (10-50/month),200.0,Exceeded (≥100%),100,61.4,73.735
NCT05675462,Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma,UNKNOWN,PHASE1,25.0,2023-03-01,2025-12-30,0.7352657004830918,Slow (<1/month),7.352657004830918,Significantly Below (<50%),50,32.0,11.425
NCT03328962,Smoking Cessation in Cancer Treatment,UNKNOWN,NA,1200.0,2017-09-15,2021-06-01,26.957933579335794,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT01212562,Treatment of Primary Basal Cell Carcinomas of the Skin With Combination of Topical Imiquimod and Cryosurgery,COMPLETED,,70.0,2007-04-01,2011-08-01,1.3460518003790272,Adequate (1-10/month),13.46051800379027,Significantly Below (<50%),100,48.9,45.4
NCT02201862,Non-Invasive Chromosomal Evaluation of Trisomy Study,COMPLETED,,2000.0,2014-04-01,2019-08-01,31.252566735112936,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT06571162,A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients,RECRUITING,NA,400.0,2025-01-30,2028-09-01,9.294656488549618,Adequate (1-10/month),92.94656488549619,Met (75-100%),60,75.0,84.49
NCT01973062,Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma,TERMINATED,PHASE2,1.0,2014-03-01,2015-06-01,0.06660831509846828,Slow (<1/month),0.6660831509846827,Significantly Below (<50%),10,18.1,3.105
NCT02580162,Success in Health: Impacting Families Together,COMPLETED,NA,242.0,2015-12-01,2020-12-20,3.990509209100759,Adequate (1-10/month),39.90509209100758,Significantly Below (<50%),100,69.4,81.52000000000001
NCT02901262,Continuous Quantified EEG in NeuroIntensive Care,COMPLETED,,30.0,2016-01-01,2017-01-01,2.495081967213115,Adequate (1-10/month),24.950819672131146,Significantly Below (<50%),100,50.7,48.915
NCT00748462,Fractional CO2 Treatment of Acne Scars in Asians,COMPLETED,PHASE4,12.0,2008-07-01,2008-12-01,2.387450980392157,Adequate (1-10/month),23.87450980392157,Significantly Below (<50%),100,51.0,49.714999999999996
NCT01248962,"Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer",COMPLETED,PHASE2,146.0,2010-11-01,2018-08-01,1.5704028268551236,Adequate (1-10/month),15.704028268551237,Significantly Below (<50%),100,56.7,65.53
NCT06636162,Window of Opportunity Study of DSP-0390 in Gliomas,RECRUITING,EARLY_PHASE1,20.0,2025-04-03,2026-05-17,1.4885085574572128,Adequate (1-10/month),14.885085574572127,Significantly Below (<50%),60,34.6,14.729999999999999
NCT02853162,Ablative tReatment of Inoperable REnal Cell Carcinoma Using STereotactic Body Radiotherapy (ARREST-study),TERMINATED,PHASE2,30.0,2016-06-01,2020-04-01,0.6522857142857142,Slow (<1/month),6.522857142857143,Significantly Below (<50%),10,20.4,5.885
NCT00002062,"Open-Label ""Compassionate"" Use Study of Spiramycin for the Treatment of Diarrhea Due to Chronic Cryptosporidiosis in Immunocompromised Patients",COMPLETED,NA,,,,,Slow (<1/month),,Significantly Below (<50%),100,40.0,21.87
NCT01867762,An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease,COMPLETED,PHASE2,211.0,2013-09-09,2014-09-01,17.991148459383755,Good (10-50/month),179.91148459383754,Exceeded (≥100%),100,71.9,82.86
NCT02753062,Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma,UNKNOWN,PHASE2,22.0,2015-08-01,2023-08-01,0.2291854893908282,Slow (<1/month),2.291854893908282,Significantly Below (<50%),50,31.8,11.19
NCT01641562,Diagnosis and Prediction of Taxanes Induced Cardiac Dysfunction,COMPLETED,,60.0,2012-01-01,2017-01-31,0.9835218093699515,Slow (<1/month),9.835218093699515,Significantly Below (<50%),100,48.1,43.275000000000006
NCT03941262,Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy,COMPLETED,PHASE1,27.0,2019-07-15,2023-02-17,0.625955826351866,Slow (<1/month),6.2595582635186595,Significantly Below (<50%),100,47.2,40.035
NCT03746262,Changes in Circulating Tumor-Specific DNA in Patients With Non-Metastatic Non-Small Cell Lung Cancer,COMPLETED,,40.0,2016-05-13,2018-08-10,1.4866910866910867,Adequate (1-10/month),14.866910866910867,Significantly Below (<50%),100,46.5,36.815
NCT02893462,Setting up a Warehouse of Physiological Data and Biomedical Signals in Adult Intensive Care,RECRUITING,,1500.0,2015-01-01,2027-01-01,10.417522245037645,Good (10-50/month),104.17522245037645,Exceeded (≥100%),60,81.3,88.58
NCT04040062,Spectral Correlation Coefficient-based TMS,ENROLLING_BY_INVITATION,NA,10.0,2019-06-25,2027-10-01,0.10079470198675497,Slow (<1/month),1.0079470198675495,Significantly Below (<50%),55,32.3,11.799999999999999
NCT07033962,Fractional CO₂ Laser or 40% Urea With Topical Fluconazole Microemulsion in Onychomycosis,NOT_YET_RECRUITING,NA,40.0,2025-06-01,2026-07-01,3.082531645569621,Adequate (1-10/month),30.825316455696207,Significantly Below (<50%),30,32.2,11.635
NCT04180462,Increasing Optimal Use of HPV Vaccination in Primary Care,COMPLETED,NA,20.0,2020-01-07,2024-04-29,0.3867852604828463,Slow (<1/month),3.8678526048284625,Significantly Below (<50%),100,46.6,37.375
NCT05453162,Circadian Influence on Prolonged Exposure Therapy for PTSD,ACTIVE_NOT_RECRUITING,NA,52.0,2022-07-01,2026-04-01,1.1553868613138687,Adequate (1-10/month),11.553868613138686,Significantly Below (<50%),85,44.7,29.67
NCT06224062,Virus and Bronchial Epithelium in Children and the Elderly,UNKNOWN,NA,200.0,2022-10-28,2025-04-28,6.668127053669223,Adequate (1-10/month),66.68127053669222,Below (50-75%),50,51.0,49.714999999999996
NCT01853462,Effects of Two Supervised Training Programs for the Rehabilitation of Ankle Sprains,COMPLETED,NA,22.0,2014-12-01,2016-09-01,1.046375,Adequate (1-10/month),10.463750000000001,Significantly Below (<50%),100,46.8,38.440000000000005
NCT05512962,Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema,COMPLETED,PHASE2,25.0,2022-08-31,2023-11-30,1.6688596491228072,Adequate (1-10/month),16.688596491228072,Significantly Below (<50%),100,52.0,52.86
NCT05282862,Guided Surgery for Horizontal Bone Augmentation,UNKNOWN,NA,28.0,2019-05-28,2023-03-01,0.6207720320466132,Slow (<1/month),6.207720320466132,Significantly Below (<50%),50,32.2,11.635
NCT00836862,Arteriovenous Fistula Tissue Bank for Pre- and Post-Fistula Placement Specimens,COMPLETED,,43.0,2009-02-01,2017-09-07,0.41685350318471337,Slow (<1/month),4.168535031847134,Significantly Below (<50%),100,46.8,38.440000000000005
NCT02335762,Dietary Conjugated Linoleic Acid (CLA) Intake Among Students in Italy,COMPLETED,,40.0,2012-01-01,2012-10-01,4.443795620437956,Adequate (1-10/month),44.43795620437956,Significantly Below (<50%),100,51.5,51.245
NCT06797362,Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors,AVAILABLE,,,,,,Slow (<1/month),,Significantly Below (<50%),50,23.3,6.569999999999999
NCT00016562,Cause and Pathogenesis of Neurometabolic Disorders,COMPLETED,,20.0,2001-05-13,2008-03-03,0.24489139179404668,Slow (<1/month),2.448913917940467,Significantly Below (<50%),100,44.9,30.025000000000002
NCT01368562,Compassionate Use Study of Methylnaltrexone,COMPLETED,NA,26.0,2003-01-24,2008-06-02,0.4046216768916156,Slow (<1/month),4.046216768916155,Significantly Below (<50%),100,47.1,39.64
NCT03657446,A Study in Healthy Subjects to Investigate Whether Administration of Clazosentan Can Affect Normal Heart Function,COMPLETED,PHASE1,36.0,2018-09-18,2018-10-26,28.837894736842106,Good (10-50/month),200.0,Exceeded (≥100%),100,57.9,67.83
NCT05763446,Predictive Factors for Massive Transfusion During Liver Transplantation,RECRUITING,,400.0,2021-07-31,2026-10-31,6.348279457768509,Adequate (1-10/month),63.482794577685084,Below (50-75%),60,68.3,80.875
NCT00204646,Neoadjuvant Adriamycin and Ifosfamide Plus High-Dose ICE in Patients With Soft Tissue Sarcoma (STS),COMPLETED,PHASE2,,1999-02-01,2006-12-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,30.330000000000002
NCT05086146,Prognostic Impact of Cardiac Imaging During Suspected Immune Checkpoint Inhibitor Myocarditis,UNKNOWN,,100.0,2021-08-10,2024-03-01,3.259100642398287,Adequate (1-10/month),32.59100642398287,Significantly Below (<50%),50,41.3,23.74
NCT04720846,Categorized PT for Non-arthritic Hip and Groin Pain,RECRUITING,NA,70.0,2020-12-02,2026-02-01,1.1291997880233176,Adequate (1-10/month),11.291997880233176,Significantly Below (<50%),60,38.6,20.015
NCT04830046,Covid-19 Vaccine Responsiveness in MM and Waldenstrom,COMPLETED,,146.0,2021-04-15,2022-09-14,8.596208897485495,Adequate (1-10/month),85.96208897485495,Met (75-100%),100,65.0,78.065
NCT00000346,Cognitive Correlates of Substance Abuse - 11,UNKNOWN,PHASE4,80.0,,,,Slow (<1/month),,Significantly Below (<50%),50,31.4,10.47
NCT05572346,Digital App for Telerehabilitation in Respiratory Diseases,UNKNOWN,,30.0,2022-10-17,2024-01-01,2.0707482993197277,Adequate (1-10/month),20.707482993197278,Significantly Below (<50%),50,35.7,16.18
NCT04468646,To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients,UNKNOWN,PHASE3,100.0,2020-06-15,2020-08-30,40.05263157894737,Good (10-50/month),200.0,Exceeded (≥100%),50,48.0,42.945
NCT04363346,Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia,COMPLETED,PHASE1,5.0,2020-05-14,2021-02-18,0.5435714285714286,Slow (<1/month),5.435714285714286,Significantly Below (<50%),100,45.4,31.455
NCT03238846,Operations Research of the 'Real World' Effectiveness of Multi-Month Dispensing of ART for Stable Patients in CARGs in Zimbabwe,UNKNOWN,NA,4676.0,2017-07-28,2019-09-30,179.26629722921916,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT07313046,CAREGİVER TRAİNİNG AND PRESSURE ULCER PREVENTİON İN HOME CARE,COMPLETED,NA,57.0,2024-07-12,2025-06-20,5.058542274052479,Adequate (1-10/month),50.58542274052479,Below (50-75%),100,54.6,60.39
NCT01690546,Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence,COMPLETED,PHASE2,38.0,2012-09-01,2015-02-01,1.3099886749716876,Adequate (1-10/month),13.099886749716875,Significantly Below (<50%),100,48.0,42.945
NCT04406246,Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide,COMPLETED,PHASE4,150.0,2020-05-21,2020-12-31,20.383928571428573,Good (10-50/month),200.0,Exceeded (≥100%),100,67.0,79.725
NCT06795646,Clinical Classification of MAFLD Based Liver Biopsy,NOT_YET_RECRUITING,,2000.0,2025-02-08,2038-12-31,11.998423334647223,Good (10-50/month),119.98423334647224,Exceeded (≥100%),30,72.3,83.065
NCT05149846,Pre-conditioning by Balloon-inflation on Myocardial Injury,WITHDRAWN,NA,0.0,2023-01-01,2024-12-31,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT05772546,Avatrombopag vs. Placebo for CIT in GI Malignancies,ACTIVE_NOT_RECRUITING,PHASE2,60.0,2023-11-01,2026-07-31,1.8209371884346959,Adequate (1-10/month),18.209371884346957,Significantly Below (<50%),85,50.3,48.215
NCT05517746,"Study on the Safety of the Drug BAY2395840 at Different Doses, the Way the Body Absorbs, Distributes and Excretes the Drug Including the Effect of Its Formulation (Tablet or Liquid) and the Effect of Food on the Absorption, Distribution or Excretion of the Drug in Healthy Male Participants",COMPLETED,PHASE1,63.0,2019-12-18,2021-03-11,4.271091314031181,Adequate (1-10/month),42.7109131403118,Significantly Below (<50%),100,55.0,61.834999999999994
NCT05318846,A Study to Evaluate the Efficacy and Safety of HRS4800 Tablets for Postoperative Analgesia After Impacted Teeth Removal Surgery.,COMPLETED,PHASE2,38.0,2022-01-14,2022-03-22,17.264477611940297,Good (10-50/month),172.64477611940296,Exceeded (≥100%),100,58.0,68.245
NCT03830346,Instrument-assisted Soft Tissue Mobilization in CrossFitters,UNKNOWN,NA,21.0,2019-02-01,2019-07-01,4.2616,Adequate (1-10/month),42.616,Significantly Below (<50%),50,36.7,17.544999999999998
NCT04436146,The Effect of Laryngeal Manual Therapy as a Management of Globus,UNKNOWN,NA,70.0,2022-03-01,2023-07-01,4.375359342915811,Adequate (1-10/month),43.753593429158116,Significantly Below (<50%),50,40.6,22.575
NCT06904846,To Evaluate the Change in Glucose Parameters in Adult Patients With Type 1 or Type 2 Diabetes From Europe Using the iCan o3 CGM System for 60 Days Period,ENROLLING_BY_INVITATION,NA,70.0,2025-04-23,2026-06-30,4.921016166281755,Adequate (1-10/month),49.21016166281755,Significantly Below (<50%),55,42.1,25.019999999999996
NCT07303946,Deep Brain Stimulation of the Anterior Cingulate Bundle (ACB) and the Ventral Anterior Limb of the Internal Capsule (vALIC) in Patients With Intractable Obsessive Compulsive Disorder (OCD),NOT_YET_RECRUITING,NA,4.0,2026-01-01,2031-01-01,0.06668127053669222,Slow (<1/month),0.6668127053669223,Significantly Below (<50%),30,24.3,6.855
NCT02057146,Endoscopic Evaluation of Premalignant Lesions in the Biliary Tract and Pancreatic Ducts,COMPLETED,NA,50.0,2013-10-01,2019-08-22,0.7075778707577871,Slow (<1/month),7.075778707577871,Significantly Below (<50%),100,49.0,45.61
NCT05281146,Production of Fortified Biscuit With Chickpea and Crushed Peanut for Improving Cognitive Performance,COMPLETED,NA,80.0,2018-11-26,2021-07-05,2.557983193277311,Adequate (1-10/month),25.57983193277311,Significantly Below (<50%),100,56.4,64.88000000000001
NCT07342946,The Effects of the Mediterranean Diet and Synbiotics in Polycystic Ovary Syndrome,NOT_YET_RECRUITING,NA,32.0,2025-12-20,2027-08-01,1.6537860780984721,Adequate (1-10/month),16.53786078098472,Significantly Below (<50%),30,26.6,8.01
NCT07292246,A Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study),RECRUITING,NA,15.0,2025-09-09,2029-10-01,0.3078894133513149,Slow (<1/month),3.078894133513149,Significantly Below (<50%),60,34.2,14.305000000000001
NCT04042246,"Effect of Knowledge on Vaccine Take-up in Adamawa State, Northeastern Nigeria",COMPLETED,NA,400.0,2019-09-15,2020-02-09,82.82993197278911,Excellent (>50/month),200.0,Exceeded (≥100%),100,92.0,93.78999999999999
NCT03549546,Expression of the Inhibitory Receptors on Lymphocytes T Cells After Lung Cancer Surgery.,COMPLETED,NA,31.0,2018-06-14,2019-02-12,3.883292181069959,Adequate (1-10/month),38.832921810699595,Significantly Below (<50%),100,52.5,54.345
NCT02249546,Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection,UNKNOWN,PHASE4,654.0,2014-09-01,2016-10-01,26.16,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT03125746,A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors,UNKNOWN,PHASE1,72.0,2017-06-12,2021-10-28,1.370656660412758,Adequate (1-10/month),13.706566604127582,Significantly Below (<50%),50,35.8,16.325
NCT02805946,Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections,COMPLETED,PHASE4,21.0,2017-04-28,2019-09-07,0.7415777262180975,Slow (<1/month),7.415777262180974,Significantly Below (<50%),100,46.7,37.895
NCT06338046,SMosE Safety and Efficacy Evaluation as a Skin Adaptogen,COMPLETED,NA,40.0,2023-10-01,2023-12-22,14.848780487804879,Good (10-50/month),148.4878048780488,Exceeded (≥100%),100,58.2,68.795
NCT00594646,HIV Non Occupational Post-Exposure Prophylaxis (PEP),COMPLETED,PHASE4,100.0,2008-02-01,2010-08-01,3.3377192982456143,Adequate (1-10/month),33.377192982456144,Significantly Below (<50%),100,58.0,68.245
NCT06059846,A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP),COMPLETED,PHASE3,1690.0,2023-12-21,2025-02-06,124.56077481840194,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT04689646,Mind Body Syndrome Therapy for Chronic Pain,RECRUITING,NA,150.0,2021-05-20,2026-06-01,2.4842219804134933,Adequate (1-10/month),24.84221980413493,Significantly Below (<50%),60,50.0,47.675
NCT07288346,Effect of Predictive Model on Double-Balloon Enteroscopy,RECRUITING,NA,338.0,2026-01-12,2027-08-31,17.26295302013423,Good (10-50/month),172.62953020134228,Exceeded (≥100%),60,70.0,81.89999999999999
NCT00043888,Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR,COMPLETED,PHASE3,60.0,2002-01-01,2003-05-01,3.765773195876289,Adequate (1-10/month),37.65773195876289,Significantly Below (<50%),100,54.8,61.095
NCT03107988,NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922),COMPLETED,PHASE1,65.0,2017-09-05,2025-01-31,0.731460258780037,Slow (<1/month),7.31460258780037,Significantly Below (<50%),100,50.2,48.04
NCT06499688,A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines,COMPLETED,PHASE3,529.0,2023-12-28,2024-05-31,103.88877419354839,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT04544488,Descriptive Evaluation of Expulsive Efforts During Pregnancy in Term Nulliparous Women by Measurement of Intra Bladder Pressure: Pilot Observational Study.,UNKNOWN,NA,45.0,2021-12-28,2022-10-01,4.945126353790614,Adequate (1-10/month),49.451263537906144,Significantly Below (<50%),50,38.6,20.015
NCT00289588,An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection in Soldiers,COMPLETED,NA,3000.0,2005-01-01,2005-12-01,273.41317365269464,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT02546388,Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis,COMPLETED,NA,17.0,2015-10-01,2018-08-01,0.4999806763285024,Slow (<1/month),4.999806763285024,Significantly Below (<50%),100,46.4,36.26
NCT03742388,A Genomic Analysis of Evolution of Epithelia Ovarian Tumors,UNKNOWN,,40.0,2018-11-10,2020-12-23,1.5731266149870802,Adequate (1-10/month),15.731266149870804,Significantly Below (<50%),50,31.5,10.635
NCT04968288,Natural History of KSHV-Associated Multicentric Castleman s Disease,RECRUITING,,195.0,2021-11-17,2035-01-01,1.2384310452743583,Adequate (1-10/month),12.384310452743584,Significantly Below (<50%),60,46.9,38.96
NCT06941688,"Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell Lymphoma",TERMINATED,PHASE2,17.0,2020-11-13,2024-12-30,0.3431564986737401,Slow (<1/month),3.431564986737401,Significantly Below (<50%),10,19.4,5.2299999999999995
NCT02194088,Combined Medication for Improved Analgesia in Superficial Pain,COMPLETED,PHASE3,100.0,2014-04-01,2017-06-01,2.630942091616249,Adequate (1-10/month),26.30942091616249,Significantly Below (<50%),100,58.0,68.245
NCT04484688,Prestilol(Perindopril+Bisoprolol) in Therapy of Patients With Atrial Fibrilation,UNKNOWN,,50.0,2020-08-01,2021-12-01,3.1252566735112937,Adequate (1-10/month),31.252566735112943,Significantly Below (<50%),50,37.3,18.35
NCT02656888,Efficacy and Safety of Irlanda-1-Association on the Treatment of Common Cold in Children,WITHDRAWN,PHASE3,0.0,2019-06-01,2020-09-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT02625688,The Risk of Hyperbilirubinemia in Term Newborns After Placental Transfusion,COMPLETED,NA,400.0,2013-08-01,2016-12-01,9.99671592775041,Adequate (1-10/month),99.9671592775041,Met (75-100%),100,87.0,92.135
NCT04712903,Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer,COMPLETED,PHASE3,101.0,2020-12-16,2023-06-21,3.352715376226827,Adequate (1-10/month),33.52715376226827,Significantly Below (<50%),100,58.1,68.595
NCT05565703,The Use of PARO to Decrease Agitation in Persons With Dementia and/or Delirium,COMPLETED,NA,104.0,2018-10-30,2023-10-30,1.733713033953998,Adequate (1-10/month),17.33713033953998,Significantly Below (<50%),100,58.3,68.99499999999999
NCT06673303,Investigating The Role of Noise Correlations in Learning,RECRUITING,NA,40.0,2024-12-14,2025-09-01,4.665134099616859,Adequate (1-10/month),46.651340996168585,Significantly Below (<50%),60,41.2,23.425
NCT00654303,OLE Study to Evaluate Safety / Efficacy of ZD4522,COMPLETED,PHASE3,3500.0,1999-08-01,2005-02-01,52.97861760318249,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT03498703,Azathioprine in Recurrent Implantation Failure,COMPLETED,PHASE2,64.0,2018-04-25,2019-07-01,4.50962962962963,Adequate (1-10/month),45.096296296296295,Significantly Below (<50%),100,55.1,62.085
NCT04822103,A Real-World Study of Immune Checkpoint Inhibitors and Chemotherapy for Advanced Esophageal Cancer,COMPLETED,,155.0,2021-01-01,2021-10-31,15.571617161716173,Good (10-50/month),155.7161716171617,Exceeded (≥100%),100,65.7,78.66499999999999
NCT07088003,Yoga as Mindful Movement: A Randomized Controlled Trial,COMPLETED,NA,47.0,2021-10-04,2022-03-02,9.601879194630872,Adequate (1-10/month),96.01879194630872,Met (75-100%),100,58.8,69.89999999999999
NCT06054503,Pilot Clinical Investigation to Evaluate a Prototype of Sensor Measuring Ventilator-derived Parameters,COMPLETED,NA,59.0,2023-09-26,2024-06-06,7.0707086614173225,Adequate (1-10/month),70.70708661417322,Below (50-75%),100,54.7,60.629999999999995
NCT07059403,"A Study of SN2001 Dose, Safety & Immunogenicity in Healthy Adults",RECRUITING,PHASE1,36.0,2025-08-19,2027-04-01,1.85735593220339,Adequate (1-10/month),18.5735593220339,Significantly Below (<50%),60,40.9,22.82
NCT05673603,A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment,COMPLETED,PHASE1,28.0,2021-07-20,2023-02-14,1.484878048780488,Adequate (1-10/month),14.848780487804877,Significantly Below (<50%),100,47.2,40.035
NCT01050803,Effectiveness of the Farsi Diabetes Self-management Education (FDSME) Program for People With Type 2 Diabetes,COMPLETED,NA,280.0,2009-08-01,2011-04-01,14.01842105263158,Good (10-50/month),140.1842105263158,Exceeded (≥100%),100,77.4,85.835
NCT06603103,Prospective Randomized Study Comparing the SpheriKA® (MEDACTA) and Origin® (SYMBIOS) Prostheses During Total Knee Replacement Using the Kinematic Alignment Technique,RECRUITING,NA,120.0,2024-10-03,2028-04-30,2.7990804597701153,Adequate (1-10/month),27.990804597701153,Significantly Below (<50%),60,47.6,41.775
NCT03034603,The Safety and Efficacy Test of Nutri-PEITC Jelly in Head and Neck Cancer Patients,COMPLETED,NA,96.0,2014-08-01,2023-01-01,0.9503219512195121,Slow (<1/month),9.503219512195123,Significantly Below (<50%),100,52.7,55.04
NCT02482103,The Dutch National Renal Denervation Registry,UNKNOWN,,1000.0,2013-04-01,2020-04-01,11.904575674618695,Good (10-50/month),119.04575674618695,Exceeded (≥100%),50,78.3,86.48
NCT01295203,Internet-based Physical Activity Intervention,COMPLETED,PHASE3,12287.0,2008-05-01,2009-05-01,1024.7021369863014,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT03899103,Compare Efficacy and Safety of Repeated Courses of Rituximab to That of Maintenance Mycophenolate Mofetil Following Single Course of Rituximab Among Children With Steroid Dependent Nephrotic Syndrome,COMPLETED,PHASE3,100.0,2019-05-15,2023-12-24,1.8076009501187649,Adequate (1-10/month),18.07600950118765,Significantly Below (<50%),100,58.0,68.245
NCT06141603,Comparison of Upper and Lower Limb Maximal Exercise Capacities and Muscle Oxygenation in Patients With ILD,UNKNOWN,,30.0,2023-11-25,2024-12-30,2.2773067331670824,Adequate (1-10/month),22.77306733167082,Significantly Below (<50%),50,35.7,16.18
NCT05568303,the Role of Problem Solving in Cognitive Behavioral Therapy for Mothers With Autistic Children,COMPLETED,NA,60.0,2022-06-01,2023-01-01,8.534579439252337,Adequate (1-10/month),85.34579439252337,Met (75-100%),100,59.8,71.61
NCT07158203,Optical Diagnosis of Neoplasia Using Artificial Intelligence,NOT_YET_RECRUITING,NA,70.0,2025-09-01,2025-12-01,23.415384615384617,Good (10-50/month),200.0,Exceeded (≥100%),30,39.6,21.115000000000002
NCT02786303,Interest of Whole-body MRI Correlated to Spreading Sequences for Staging Neuroendocrine Tumors,UNKNOWN,NA,100.0,2014-04-01,2017-04-01,2.7773722627737225,Adequate (1-10/month),27.773722627737225,Significantly Below (<50%),50,43.0,26.465
NCT04191603,TWO DİFFERENT ELECTROSURGERY DEVICES AS MONOPOLAR HOOC AND PLASMAKINETIC BIPOLAR SPATULA EFFECTIVENESS DURING COLPOTOMY,UNKNOWN,NA,100.0,2020-10-30,2021-12-30,7.145539906103287,Adequate (1-10/month),71.45539906103286,Below (50-75%),50,43.0,26.465
NCT02020603,Efficacy of Hemostasis by Soft Coagulation Using Endoscopic Hemostatic Forceps for Acute Peptic Ulcer Bleeding,COMPLETED,NA,151.0,2012-01-01,2014-06-01,5.211383219954649,Adequate (1-10/month),52.113832199546486,Below (50-75%),100,62.1,74.595
NCT03184103,Acute Post Streptococcal Glomerulonephritis,UNKNOWN,,50.0,2017-06-27,2019-12-27,1.6670317634173057,Adequate (1-10/month),16.670317634173056,Significantly Below (<50%),50,37.3,18.35
NCT01916603,"Diet, Physical Activity and Breastfeeding Intervention on Maternal Nutrition, Offspring Growth and Development",UNKNOWN,NA,2400.0,2013-09-01,2017-03-01,57.20908379013312,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT00684203,Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016),COMPLETED,PHASE2,120.0,2006-12-01,2007-10-01,12.01578947368421,Good (10-50/month),120.15789473684211,Exceeded (≥100%),100,64.6,77.59
NCT05337527,Neuromuscular Responses to Acute Beetroot Ingestion in Women Older Adults,COMPLETED,NA,9.0,2022-03-01,2022-04-10,6.849,Adequate (1-10/month),68.49000000000001,Below (50-75%),100,50.7,48.915
NCT03248427,Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.,COMPLETED,PHASE2,106.0,2017-07-13,2019-07-20,4.3780732700135685,Adequate (1-10/month),43.78073270013568,Significantly Below (<50%),100,58.5,69.34
NCT01026727,A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy,TERMINATED,PHASE2,2.0,2009-11-01,2010-06-01,0.28716981132075475,Slow (<1/month),2.8716981132075476,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT05856227,Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age,COMPLETED,PHASE3,9.0,2023-08-06,2024-12-18,0.54792,Slow (<1/month),5.4792,Significantly Below (<50%),100,45.7,32.5
NCT03187327,Feasibility of Opportunistic Salpingectomy at the Time of Vaginal Hysterectomy for Benign Pathology,COMPLETED,,69.0,2013-09-01,2015-01-01,4.312854209445585,Adequate (1-10/month),43.12854209445586,Significantly Below (<50%),100,53.9,58.34
NCT03975127,Cervical Cytology - Do SMS Reminders Increase Participation in the Cervical Screening Programme?,UNKNOWN,NA,50000.0,2019-12-01,2021-03-01,3337.719298245614,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT06716827,Bleaching Procedures Performed During Treatment With Brackets and Clear Aligners,COMPLETED,NA,56.0,2022-11-09,2024-11-09,2.3319288645690834,Adequate (1-10/month),23.319288645690836,Significantly Below (<50%),100,54.5,60.12
NCT05917327,Performance and Safety of MEX-CD1 Low-volume Continuous Veno-venous Haemodialysis Medical Device for Copper-extraction in Patients With Wilson's Disease,TERMINATED,NA,1.0,2024-01-24,2025-09-15,0.05073333333333333,Slow (<1/month),0.5073333333333333,Significantly Below (<50%),10,18.1,3.105
NCT05877027,Exercise vs. Topical Diclofenac vs. PRP,COMPLETED,NA,82.0,2024-03-20,2025-05-18,5.886981132075472,Adequate (1-10/month),58.869811320754714,Below (50-75%),100,56.6,65.34
NCT01873027,OPtical Frequency Domain Imaging vs. INtravascular Ultrasound in Percutaneous Coronary InterventiON,COMPLETED,PHASE3,829.0,2013-06-01,2016-07-01,22.410976909413854,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT02343627,Safety and Efficacy of NVXT Solution in Mild-to-Moderate Fungal Infection of the Toe Nail,COMPLETED,PHASE2,47.0,2014-12-01,2016-01-01,3.612828282828283,Adequate (1-10/month),36.12828282828283,Significantly Below (<50%),100,53.8,58.065
NCT03137927,"A Phase I Clinical Study of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine",COMPLETED,PHASE1,36.0,2017-06-13,2017-12-27,5.56263959390863,Adequate (1-10/month),55.626395939086294,Below (50-75%),100,52.9,55.55
NCT04703127,Effectiveness and Tolerability of the On-demand Use of Combined Dapoxetine With Tadalafil and Combined Dapoxetine With Lidocaine 5% Spray in Treatment of Patients With Lifelong Premature Ejaculation and Non-responding to Dapoxetine Alone.,UNKNOWN,PHASE3,60.0,2020-03-30,2021-01-30,5.968627450980392,Adequate (1-10/month),59.68627450980393,Below (50-75%),50,39.8,21.47
NCT06764927,Fibrinogen in Liver Transplant Subjects,NOT_YET_RECRUITING,PHASE4,30.0,2025-10-31,2026-03-01,7.547107438016529,Adequate (1-10/month),75.4710743801653,Met (75-100%),30,31.4,10.47
NCT01996527,3T MRI Biomarkers of Glioma Treatment Response,TERMINATED,EARLY_PHASE1,7.0,2012-05-01,2016-01-01,0.15901492537313433,Slow (<1/month),1.5901492537313433,Significantly Below (<50%),10,18.6,4.25
NCT03937427,Unified Airway Model,UNKNOWN,,24.0,2017-01-16,2020-04-01,0.6238770281810418,Slow (<1/month),6.238770281810417,Significantly Below (<50%),50,30.3,9.295
NCT00418327,Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma,COMPLETED,PHASE1,48.0,2005-06-01,,,Slow (<1/month),,Significantly Below (<50%),100,43.8,27.965
NCT00532727,Triple Negative Breast Cancer Trial,UNKNOWN,PHASE3,400.0,2008-01-01,2020-03-01,2.7404906594643257,Adequate (1-10/month),27.404906594643258,Significantly Below (<50%),50,67.0,79.725
NCT06192927,Efficacy and Safety of TenoMiR in Lateral Epicondylitis,COMPLETED,PHASE2,123.0,2024-04-10,2025-06-12,8.747943925233646,Adequate (1-10/month),87.47943925233645,Met (75-100%),100,64.8,77.865
NCT06381427,"Perioperative Interdisciplinary, Intersectoral Process Optimization in Heart Failure",RECRUITING,NA,1057.0,2024-09-01,2027-03-01,35.3184193194292,Good (10-50/month),200.0,Exceeded (≥100%),60,83.0,89.505
NCT02944227,Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration,COMPLETED,PHASE4,20.0,2016-03-03,2017-08-21,1.135820895522388,Adequate (1-10/month),11.35820895522388,Significantly Below (<50%),100,46.6,37.375
NCT00774527,Comparison of Cy-Atg Vs Cy-Flu-Atg for the Conditioning Therapy in Allo-HCT,COMPLETED,PHASE3,82.0,2003-03-01,2011-01-01,0.8718407265106531,Slow (<1/month),8.718407265106531,Significantly Below (<50%),100,51.6,51.644999999999996
NCT06629727,The Effect Of Virtual Reality Glasses On Pain And Anxiety During The Kidney Stone Lithotripsy Procedure,ACTIVE_NOT_RECRUITING,NA,60.0,2021-07-25,2024-11-10,1.5169435215946845,Adequate (1-10/month),15.169435215946844,Significantly Below (<50%),85,45.3,31.169999999999998
NCT03370627,Effect of Anti-CD303 Antibodies in Autoimmune Diseases,COMPLETED,NA,138.0,2017-12-20,2019-05-25,8.062802303262957,Adequate (1-10/month),80.62802303262957,Met (75-100%),100,61.0,73.17
NCT01854827,Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia,COMPLETED,PHASE1,30.0,2013-10-01,2016-07-01,0.9095617529880479,Slow (<1/month),9.095617529880478,Significantly Below (<50%),100,47.4,40.98
NCT06940427,Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis,RECRUITING,PHASE2,50.0,2025-11-19,2027-09-01,2.337941628264209,Adequate (1-10/month),23.37941628264209,Significantly Below (<50%),60,42.0,24.825
NCT04163627,Changing Trends in HCC Procedures,UNKNOWN,,1000.0,2019-11-30,2021-03-25,63.28482328482328,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT02009527,Arginase Inhibition in Ischemia-reperfusion Injury,COMPLETED,PHASE1,24.0,2012-01-01,2013-09-01,1.1996059113300492,Adequate (1-10/month),11.996059113300491,Significantly Below (<50%),100,46.9,38.96
NCT06741761,12-hour Time Limited Feeding in Critical Care,RECRUITING,NA,20.0,2025-03-25,2026-06-01,1.4060046189376443,Adequate (1-10/month),14.060046189376443,Significantly Below (<50%),60,34.6,14.729999999999999
NCT00309361,"Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Mandibular Procedures",COMPLETED,PHASE3,240.0,2006-02-01,2006-07-01,48.704,Good (10-50/month),200.0,Exceeded (≥100%),100,79.2,87.095
NCT05904561,Effect of Low Level Laser Therapy Versus Pulsed Ultrasound,COMPLETED,NA,48.0,2023-04-01,2023-08-20,10.362553191489361,Good (10-50/month),103.62553191489361,Exceeded (≥100%),100,58.8,69.89999999999999
NCT04540861,Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active Disease,NO_LONGER_AVAILABLE,,,,,,Slow (<1/month),,Significantly Below (<50%),50,23.3,6.569999999999999
NCT03184961,Lung Recruitment Maneuver for Predicting Fluid Responsiveness in Children,COMPLETED,NA,30.0,2017-06-15,2019-05-31,1.2772027972027973,Adequate (1-10/month),12.772027972027974,Significantly Below (<50%),100,47.4,40.98
NCT06459661,The Bowel Movement Monitoring (BoMoMo) Study,RECRUITING,,24.0,2024-05-01,2024-06-30,12.176,Good (10-50/month),121.76,Exceeded (≥100%),60,43.3,27.05
NCT06371261,Pathogenicity of Species of the Achromobacter Genus in Patients From Reunion Island With Cystic Fibrosis,RECRUITING,,35.0,2024-03-12,2028-03-01,0.7347586206896551,Slow (<1/month),7.347586206896552,Significantly Below (<50%),60,34.1,14.19
NCT02406261,A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants,COMPLETED,PHASE1,82.0,2015-04-30,2015-08-31,20.293333333333333,Good (10-50/month),200.0,Exceeded (≥100%),100,61.6,74.0
NCT01947361,Heart Rate and Initial Presentation of Cardiovascular Diseases (Caliber),UNKNOWN,,1961286.0,2012-01-01,2014-12-01,56057.78952112676,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT00448461,Antithrombotic Regimens and Outcome,COMPLETED,PHASE4,850.0,2007-03-01,2008-06-01,56.49344978165939,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT02276261,The Effect of Vertical Versus Horizontal Vaginal Cuff Closure on Vaginal Length After Laparoscopic Hysterectomy,COMPLETED,NA,43.0,2014-11-01,2016-06-01,2.264567474048443,Adequate (1-10/month),22.645674740484434,Significantly Below (<50%),100,53.4,57.35
NCT05732961,Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms,RECRUITING,PHASE2,70.0,2023-02-21,2026-09-01,1.6543478260869566,Adequate (1-10/month),16.543478260869566,Significantly Below (<50%),60,38.6,20.015
NCT03617861,Effect of Secretin in Functional Dyspepsia and Healthy Subjects,COMPLETED,PHASE1,20.0,2018-11-07,2019-08-01,2.2801498127340825,Adequate (1-10/month),22.801498127340828,Significantly Below (<50%),100,51.6,51.644999999999996
NCT02848261,Remote Monitoring of Diabetes in Young Children With Type 1 Diabetes,COMPLETED,NA,92.0,2016-08-15,2019-04-01,2.9202085505735145,Adequate (1-10/month),29.20208550573514,Significantly Below (<50%),100,57.4,67.05499999999999
NCT06252961,A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects,RECRUITING,PHASE2,99.0,2024-06-21,2026-02-01,5.107728813559323,Adequate (1-10/month),51.07728813559322,Below (50-75%),60,45.9,33.495000000000005
NCT06167161,Clinical Investigation and Validation of a Self-fitted Air-conduction Hearing Aid,COMPLETED,NA,21.0,2023-01-30,2023-05-30,5.327,Adequate (1-10/month),53.269999999999996,Below (50-75%),100,51.7,51.94
NCT05567861,Virtual Reality for Fibromyalgia,ACTIVE_NOT_RECRUITING,,60.0,2022-10-11,2025-09-01,1.7295454545454545,Adequate (1-10/month),17.295454545454543,Significantly Below (<50%),85,48.6,44.685
NCT00673361,"Pilot Trial of ""Chemo-Switch"" Regimen to Treat Advanced Melanoma",TERMINATED,PHASE2,9.0,2007-03-01,2009-01-01,0.40767857142857145,Slow (<1/month),4.076785714285715,Significantly Below (<50%),10,18.7,4.455
NCT01333761,Cardiox Shunt Detection Technology Study,TERMINATED,PHASE3,71.0,2011-04-01,2012-07-01,4.729190371991248,Adequate (1-10/month),47.291903719912476,Significantly Below (<50%),10,28.7,8.63
NCT03847961,Efficacy and Safety Study of CA330 Hemoadsorption Device on IL-6 Removal in Septic Patients,UNKNOWN,NA,144.0,2018-12-17,2020-10-01,6.702385321100918,Adequate (1-10/month),67.02385321100918,Below (50-75%),50,46.5,36.815
NCT07177261,Inter-Brain Synchrony in Schizophrenia,RECRUITING,NA,100.0,2025-12-01,2027-11-30,4.175582990397805,Adequate (1-10/month),41.755829903978054,Significantly Below (<50%),60,46.0,34.1
NCT03413761,"Antioxidant Supplements, Genetics and Chemotherapy Outcomes",COMPLETED,,1771.0,2004-12-18,2013-11-12,16.582356198092896,Good (10-50/month),165.82356198092893,Exceeded (≥100%),100,93.3,94.325
NCT04370561,Outcome Following Semitubular Plate vs. Polyaxial Locking Plates,COMPLETED,NA,45.0,2016-01-01,2019-01-01,1.2498175182481752,Adequate (1-10/month),12.498175182481752,Significantly Below (<50%),100,48.6,44.685
NCT03550261,"Salt Wasting, Hydro-sodium Balance and Fludrocortisone Requirement in Congenital Adrenal Hyperplasia",COMPLETED,,30.0,2018-05-17,2021-11-15,0.7145539906103286,Slow (<1/month),7.145539906103286,Significantly Below (<50%),100,45.7,32.5
NCT06940661,Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis,NOT_YET_RECRUITING,PHASE2,33.0,2025-06-01,2028-07-01,0.892113676731794,Slow (<1/month),8.92113676731794,Significantly Below (<50%),30,26.6,8.01
NCT00174161,The Symptom Experience of Women With Perimenstrual Syndrome;Women's Health Related Quality of Life.,UNKNOWN,,1000.0,2005-08-01,2005-12-01,249.50819672131146,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT01251861,Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer,ACTIVE_NOT_RECRUITING,PHASE2,108.0,2010-12-23,2026-03-18,0.5908554996405464,Slow (<1/month),5.908554996405464,Significantly Below (<50%),85,49.1,45.83
NCT03967561,Progressive vs. Non-progressive Water-based Aerobic Training on Type 2 Diabetes Control: a Randomized Clinical Trial,UNKNOWN,NA,50.0,2019-06-10,2019-11-15,9.632911392405063,Adequate (1-10/month),96.32911392405063,Met (75-100%),50,44.0,28.249999999999996
NCT05008861,Gut Microbiota Reconstruction for NSCLC Immunotherapy,UNKNOWN,PHASE1,20.0,2021-09-01,2022-12-30,1.255257731958763,Adequate (1-10/month),12.552577319587629,Significantly Below (<50%),50,31.6,10.905
NCT07255742,Role of Lactoferrin in Prevention of Ventilator Associated Pneumonia in Neonates.,COMPLETED,NA,50.0,2025-08-01,2025-12-04,12.176,Good (10-50/month),121.76,Exceeded (≥100%),100,59.0,70.365
NCT06578442,Effectiveness of Electromagnetic Field Therapy in Chronic Constipation,COMPLETED,NA,40.0,2019-02-01,2020-01-31,3.345054945054945,Adequate (1-10/month),33.45054945054945,Significantly Below (<50%),100,53.2,56.665
NCT02101242,Regional Cerebral Oxygen Saturation Under General Anesthesia A Pilot Study,TERMINATED,,42.0,2014-05-11,2014-09-17,9.910697674418603,Adequate (1-10/month),99.10697674418604,Met (75-100%),10,29.7,8.92
NCT00521742,Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease,COMPLETED,PHASE3,300.0,2001-03-01,2003-01-01,13.609538002980626,Good (10-50/month),136.09538002980625,Exceeded (≥100%),100,79.0,86.96000000000001
NCT00981942,Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec,COMPLETED,PHASE3,10.0,2009-09-01,2010-12-01,0.6675438596491229,Slow (<1/month),6.675438596491229,Significantly Below (<50%),100,45.8,33.03
NCT04170842,"Music During Paediatric Outpatient Wound Dressing Changes: Impact on Anxiety, Pain and Patient Satisfaction",COMPLETED,NA,48.0,2016-12-23,2019-03-28,1.7710545454545454,Adequate (1-10/month),17.710545454545453,Significantly Below (<50%),100,53.8,58.065
NCT06978842,Seizure Prediction Using Wearable EEG,RECRUITING,,150.0,2025-06-19,2026-03-01,17.905882352941177,Good (10-50/month),179.05882352941177,Exceeded (≥100%),60,53.3,57.14
NCT03866642,Two Year Follow up of Cadence Total Ankle Replacement,UNKNOWN,,40.0,2018-09-01,2019-07-01,4.018481848184819,Adequate (1-10/month),40.18481848184819,Significantly Below (<50%),50,36.5,17.285
NCT01134042,Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics,COMPLETED,PHASE3,587.0,2010-06-01,2011-10-01,36.69051334702259,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT04432142,Immune Profiling of Stage III Non-small Cell Lung Cancer Patients Treated With Concurrent Chemoradiation and Adjuvant Durvalumab: A Prospective Observational Phase II Trial,ACTIVE_NOT_RECRUITING,,45.0,2021-04-01,2026-12-01,0.6617391304347826,Slow (<1/month),6.6173913043478265,Significantly Below (<50%),85,42.4,25.45
NCT02418442,Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry,RECRUITING,,20000.0,2015-07-01,2028-12-01,124.19420644634845,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT01735942,Ingenol Mebutate Compared to Cryotherapy for the Treatment of Skin Lesions,WITHDRAWN,EARLY_PHASE1,0.0,2012-10-01,2016-05-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT03791242,Ketogenic Diet and CPAP Previous Bariatric Surgery,COMPLETED,NA,66.0,2019-03-21,2021-05-19,2.543088607594937,Adequate (1-10/month),25.430886075949367,Significantly Below (<50%),100,55.3,62.36000000000001
NCT02205242,BACE Trial Substudy 1 - PROactive Substudy,COMPLETED,PHASE3,60.0,2014-09-01,2020-04-01,0.8957332025502698,Slow (<1/month),8.957332025502698,Significantly Below (<50%),100,49.8,47.17
NCT05547542,Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing,COMPLETED,PHASE1,19.0,2023-03-02,2024-08-06,1.10585086042065,Adequate (1-10/month),11.058508604206502,Significantly Below (<50%),100,46.5,36.815
NCT05115942,Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.,COMPLETED,PHASE3,248.0,2021-12-30,2024-10-22,7.350652385589094,Adequate (1-10/month),73.50652385589095,Below (50-75%),100,69.8,81.785
NCT00079742,A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic Fibrosis,COMPLETED,PHASE2,68.0,2003-09-01,2007-05-01,1.5470254110612855,Adequate (1-10/month),15.470254110612855,Significantly Below (<50%),100,50.4,48.355
NCT03680742,Contour Neurovascular System - European Pre-Market Unruptured Aneurysm,COMPLETED,NA,34.0,2018-09-18,2021-02-02,1.1923502304147466,Adequate (1-10/month),11.923502304147465,Significantly Below (<50%),100,47.7,42.17
NCT02288442,Whole Muscle Exercise Training (WHOLEi+12) in Pulmonary Hypertension,COMPLETED,NA,40.0,2015-01-01,2016-06-01,2.3551257253384916,Adequate (1-10/month),23.551257253384918,Significantly Below (<50%),100,53.2,56.665
NCT03882242,Effect of a Prevention Program on Program Facilitators,UNKNOWN,NA,50.0,2016-08-01,2022-11-01,0.6666666666666666,Slow (<1/month),6.666666666666667,Significantly Below (<50%),50,34.0,14.02
NCT03364686,Transfusion of Biotin-Labeled Red Blood Cells,TERMINATED,PHASE2,6.0,2019-09-16,2021-06-29,0.2801226993865031,Slow (<1/month),2.801226993865031,Significantly Below (<50%),10,18.5,4.02
NCT06508086,Pilonidal Sinus Disease,RECRUITING,NA,30.0,2024-06-10,2025-06-01,2.5651685393258425,Adequate (1-10/month),25.65168539325843,Significantly Below (<50%),60,40.4,22.34
NCT06729086,Propofol vs Sevoflurane in Cardiac Surgery,NOT_YET_RECRUITING,NA,100.0,2025-01-04,2025-05-31,20.707482993197278,Good (10-50/month),200.0,Exceeded (≥100%),30,42.0,24.825
NCT02689986,Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease,COMPLETED,PHASE2,43.0,2013-01-01,2016-12-01,0.9153286713286714,Slow (<1/month),9.153286713286715,Significantly Below (<50%),100,48.4,44.22
NCT05562986,Impacts of Oral Irrigation in Orthodontic Patients,COMPLETED,NA,30.0,2018-03-01,2018-12-27,3.033887043189369,Adequate (1-10/month),30.33887043189369,Significantly Below (<50%),100,52.4,53.949999999999996
NCT05193786,Low Versus High PEEP in Noninvasive Ventilation for Hypoxemic Respiratory Failure,COMPLETED,NA,380.0,2022-01-11,2024-08-31,12.011630321910697,Good (10-50/month),120.11630321910698,Exceeded (≥100%),100,85.4,91.38
NCT03115086,The REPLACE Registry for Cholbam® (Cholic Acid),ACTIVE_NOT_RECRUITING,,55.0,2017-07-10,2039-07-01,0.2085970595564416,Slow (<1/month),2.0859705955644157,Significantly Below (<50%),85,43.2,26.840000000000003
NCT04213586,Effects of Whey Protein and Collagen Supplementation,COMPLETED,NA,22.0,2019-09-01,2019-12-05,7.049263157894737,Adequate (1-10/month),70.49263157894737,Below (50-75%),100,51.8,52.17
NCT05796986,Endovascular Treatment of Wide Neck Saccular Cerebral Aneurysms,RECRUITING,NA,40.0,2022-01-01,2024-12-01,1.1432863849765258,Adequate (1-10/month),11.43286384976526,Significantly Below (<50%),60,36.2,16.84
NCT03943186,"Application of Ectoin Containing Lozenges (EHT02) in Patients With Acute, Viral Pharyngitis.",COMPLETED,,102.0,2018-12-13,2019-05-13,20.562119205298014,Good (10-50/month),200.0,Exceeded (≥100%),100,61.5,73.905
NCT00364286,Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825),COMPLETED,PHASE2,17.0,2006-08-01,2012-11-01,0.2265674255691769,Slow (<1/month),2.265674255691769,Significantly Below (<50%),100,46.4,36.26
NCT02089386,Tamoxifen to Treat Barrett's Metaplasia,TERMINATED,EARLY_PHASE1,7.0,2014-07-09,2016-06-21,0.2988499298737728,Slow (<1/month),2.988499298737728,Significantly Below (<50%),10,18.6,4.25
NCT07018986,The MIND-BC Study: MIND Diet for Breast Cancer Cognition,RECRUITING,NA,200.0,2025-07-09,2030-03-01,3.5896226415094343,Adequate (1-10/month),35.89622641509434,Significantly Below (<50%),60,54.0,58.72500000000001
NCT06860386,Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC,SUSPENDED,PHASE2,75.0,2025-02-25,2028-02-01,2.131652661064426,Adequate (1-10/month),21.31652661064426,Significantly Below (<50%),20,32.0,11.425
NCT03648086,Intestinal Microbiota Transplantation for Nonalcoholic Fatty Liver Disease,UNKNOWN,NA,30.0,2017-11-14,2020-11-01,0.843213296398892,Slow (<1/month),8.43213296398892,Significantly Below (<50%),50,32.4,12.025
NCT06840886,A Study of PHST001 in Advanced Solid Tumors,RECRUITING,PHASE1,155.0,2025-03-31,2031-04-01,2.152463503649635,Adequate (1-10/month),21.52463503649635,Significantly Below (<50%),60,50.4,48.355
NCT06855186,Symptom-Targeted Approach to Rehabilitation for Concussion (STAR-C),RECRUITING,NA,222.0,2025-09-18,2028-08-31,6.268719851576995,Adequate (1-10/month),62.68719851576995,Below (50-75%),60,55.8,63.245
NCT06079086,Evaluation of the Clinical Evolution of Breast Increase Using Prostheses,UNKNOWN,NA,60.0,2014-05-01,2024-05-30,0.4960347637153721,Slow (<1/month),4.9603476371537205,Significantly Below (<50%),50,34.8,15.040000000000001
NCT03121586,Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia,TERMINATED,PHASE3,995.0,2017-01-01,2024-05-30,11.192830746489284,Good (10-50/month),111.92830746489284,Exceeded (≥100%),10,68.0,80.56
NCT01417286,Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer,COMPLETED,PHASE2,69.0,2010-12-21,2020-02-20,0.6273476702508961,Slow (<1/month),6.273476702508961,Significantly Below (<50%),100,50.5,48.515
NCT04036370,Continuous Pectoral Nerve Block in Breast Cancer Surgery,COMPLETED,NA,48.0,2019-07-30,2019-11-15,13.52888888888889,Good (10-50/month),135.2888888888889,Exceeded (≥100%),100,58.8,69.89999999999999
NCT03650270,Childhood Convulsive Status Epilepticus Management In A Resource Limited Setting,COMPLETED,PHASE3,198.0,2015-03-01,2018-03-01,5.499197080291971,Adequate (1-10/month),54.99197080291971,Below (50-75%),100,65.8,78.745
NCT01139970,Veliparib and Temozolomide in Treating Patients With Acute Leukemia,COMPLETED,PHASE1,66.0,2010-06-04,2018-12-01,0.6476595744680851,Slow (<1/month),6.476595744680851,Significantly Below (<50%),100,50.3,48.215
NCT00372970,Placebo Controlled Trial of Botulinum Toxin for Gastroparesis,COMPLETED,NA,32.0,2003-07-01,2008-12-01,0.491959595959596,Slow (<1/month),4.91959595959596,Significantly Below (<50%),100,47.6,41.775
NCT06551870,Xbox Kinect Sports Versus Nintendo Switch Sports,RECRUITING,NA,45.0,2024-04-14,2024-12-14,5.613934426229508,Adequate (1-10/month),56.139344262295076,Below (50-75%),60,41.6,24.29
NCT05463770,A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia,COMPLETED,PHASE1,15.0,2022-08-30,2023-08-22,1.2789915966386556,Adequate (1-10/month),12.789915966386555,Significantly Below (<50%),100,46.2,35.089999999999996
NCT01172470,Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients,COMPLETED,PHASE2,34.0,2005-06-01,2010-07-01,0.5576293103448277,Slow (<1/month),5.5762931034482754,Significantly Below (<50%),100,47.7,42.17
NCT00362570,Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma,COMPLETED,PHASE2,1.0,2005-05-01,2011-03-01,0.014291079812206573,Slow (<1/month),0.14291079812206575,Significantly Below (<50%),100,45.1,30.605
NCT00729170,Milk Supplementation and Energy Balance.,COMPLETED,NA,41.0,2006-10-01,2009-02-01,1.4614051522248244,Adequate (1-10/month),14.614051522248245,Significantly Below (<50%),100,48.3,43.985
NCT03248570,Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects,COMPLETED,PHASE2,26.0,2018-02-20,2023-09-28,0.3868230694037146,Slow (<1/month),3.8682306940371456,Significantly Below (<50%),100,47.1,39.64
NCT02489370,CHF Home Telemonitoring: A Home Telemonitoring Service for Chronic Heart Failure Patients on Trial,UNKNOWN,NA,40.0,2014-10-01,2016-12-01,1.5373737373737375,Adequate (1-10/month),15.373737373737374,Significantly Below (<50%),50,33.2,12.989999999999998
NCT00294970,Cognitive Characteristics of PTSD Patients With OCD,COMPLETED,,76.0,2006-02-01,2006-08-01,12.781436464088397,Good (10-50/month),127.81436464088398,Exceeded (≥100%),100,59.4,70.905
NCT02551770,Emdogain Minimally Invasive Surgical Technique,COMPLETED,NA,51.0,2015-10-01,2019-08-30,1.0863820853743877,Adequate (1-10/month),10.863820853743876,Significantly Below (<50%),100,49.1,45.83
NCT03782870,Cardiovascular Involvement in Patients With Granulomatosis With Polyangiitis,UNKNOWN,,100.0,2010-02-01,2019-12-30,0.8411163304780326,Slow (<1/month),8.411163304780326,Significantly Below (<50%),50,36.3,17.0
NCT06806670,Exercise and Diet Effects in Reducing Cardiovascular Risk in Kidney Transplant Recipients,RECRUITING,NA,275.0,2025-01-07,2031-01-01,3.8311212814645312,Adequate (1-10/month),38.311212814645316,Significantly Below (<50%),60,60.0,71.97
NCT02823470,A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation,TERMINATED,PHASE4,24.0,2016-06-01,2017-08-01,1.7149295774647888,Adequate (1-10/month),17.14929577464789,Significantly Below (<50%),10,24.9,7.12
NCT04860570,Are Double-ring Wound-edge Protectors Effective for Preventing Superficial Surgical Site Infection After Open Appendectomy?,UNKNOWN,,671.0,2024-10-25,2024-12-31,304.85432835820893,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT03446170,Effect of Cigarette Pack Warnings and Packaging Among Young Adult Smokers,COMPLETED,NA,400.0,2014-09-01,2020-08-31,5.557279780921954,Adequate (1-10/month),55.572797809219544,Below (50-75%),100,82.0,89.05499999999999
NCT04083170,Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers,TERMINATED,PHASE2,1.0,2022-10-06,2022-11-30,0.5534545454545455,Slow (<1/month),5.534545454545455,Significantly Below (<50%),10,18.1,3.105
NCT04405570,"Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19",COMPLETED,PHASE2,204.0,2020-06-19,2021-02-21,25.140728744939274,Good (10-50/month),200.0,Exceeded (≥100%),100,71.3,82.655
NCT04020770,Influence of Upper Extremity Vibration on Spasticity and Function in Persons With Tetraplegia,COMPLETED,NA,12.0,2018-10-28,2019-02-20,3.176347826086957,Adequate (1-10/month),31.763478260869565,Significantly Below (<50%),100,51.0,49.714999999999996
NCT04321070,Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris,COMPLETED,PHASE1,550.0,2019-09-09,2020-03-06,93.53072625698324,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT04833270,Pragmatic Randomized Controlled Trial of Non-pharmacological Treatment for Lumbar Disc Herniation : A Pilot Study,COMPLETED,NA,30.0,2021-07-09,2022-06-28,2.5796610169491525,Adequate (1-10/month),25.796610169491522,Significantly Below (<50%),100,52.4,53.949999999999996
NCT03915470,Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection,COMPLETED,PHASE2,124.0,2019-08-29,2021-03-29,6.530380622837371,Adequate (1-10/month),65.30380622837372,Below (50-75%),100,59.9,71.86
NCT04907370,PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma,ACTIVE_NOT_RECRUITING,PHASE3,532.0,2021-08-01,2027-03-01,7.9460647693817466,Adequate (1-10/month),79.46064769381746,Met (75-100%),85,85.5,91.42
NCT00395473,Ezetimibe Added to Statin Therapy (EASY) Study (0653-087)(COMPLETED),COMPLETED,PHASE3,141.0,2005-03-01,2005-11-01,17.5185306122449,Good (10-50/month),175.185306122449,Exceeded (≥100%),100,66.3,79.3
NCT03884673,Dolutegravir Plus Lamivudine Simplified Therapy,RECRUITING,,300.0,2019-01-01,2030-12-31,2.083979917845733,Adequate (1-10/month),20.83979917845733,Significantly Below (<50%),60,60.3,72.34
NCT03112473,Effect of Bilateral TENS With TOT on Upper Limb Function in Patients With Chronic Stroke,COMPLETED,NA,120.0,2016-11-24,2020-10-24,2.5544055944055946,Adequate (1-10/month),25.54405594405595,Significantly Below (<50%),100,59.6,71.17999999999999
NCT05273073,Effects of Probiotics on Gut Microbiota Composition and Metabolic Outcomes in Post- Gestational Diabetes Women,COMPLETED,NA,166.0,2018-03-01,2021-04-26,4.386319444444444,Adequate (1-10/month),43.863194444444446,Significantly Below (<50%),100,63.3,76.235
NCT04628273,Treatment Strategy of Pancreatic Radiolucent Stone,COMPLETED,,52.0,2011-03-01,2020-01-30,0.4859932453177771,Slow (<1/month),4.8599324531777714,Significantly Below (<50%),100,47.5,41.415
NCT05106673,Clinical Implementation and Evaluation for the Family-oriented Care CHIMPS-NET,UNKNOWN,NA,798.0,2020-01-01,2023-09-01,18.141239731142644,Good (10-50/month),181.41239731142645,Exceeded (≥100%),50,80.0,87.67
NCT05655273,Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients,ENROLLING_BY_INVITATION,PHASE4,40.0,2024-01-01,2026-02-28,1.5432192648922687,Adequate (1-10/month),15.432192648922689,Significantly Below (<50%),55,34.7,14.899999999999999
NCT07107373,A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US,ACTIVE_NOT_RECRUITING,,150.0,2023-12-22,2025-12-31,6.1702702702702705,Adequate (1-10/month),61.70270270270271,Below (50-75%),85,55.8,63.245
NCT02543073,MSC for Treatment of Interstitial Lung Disease After Allo-HSCT,UNKNOWN,PHASE1,60.0,2014-09-01,2018-06-01,1.3341124908692477,Adequate (1-10/month),13.341124908692478,Significantly Below (<50%),50,34.8,15.040000000000001
NCT03352973,Regulation of Craving in Internet Gamers,COMPLETED,NA,20.0,2018-07-20,2018-10-20,6.6173913043478265,Adequate (1-10/month),66.17391304347827,Below (50-75%),100,51.6,51.644999999999996
NCT05833373,Vagal Nerve Stimulation for the Treatment of Persistent AF,UNKNOWN,NA,120.0,2023-11-06,2025-12-20,4.7132903225806455,Adequate (1-10/month),47.13290322580646,Significantly Below (<50%),50,44.6,29.42
NCT00782873,Balanced Propofol Sedation During Upper Endoscopy in Morbidly Obese Patients,COMPLETED,,65.0,2008-03-01,2008-09-01,10.753260869565217,Good (10-50/month),107.53260869565217,Exceeded (≥100%),100,58.5,69.34
NCT00810173,Phone Call in Type 2 Diabetes Patient,COMPLETED,NA,48.0,2008-01-01,2008-10-01,5.332554744525547,Adequate (1-10/month),53.325547445255474,Below (50-75%),100,53.8,58.065
NCT02531373,"A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)",COMPLETED,PHASE1,338.0,2015-09-15,2017-04-14,17.83140381282496,Good (10-50/month),178.3140381282496,Exceeded (≥100%),100,82.0,89.05499999999999
NCT00869973,Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients,TERMINATED,PHASE3,580.0,2009-09-01,2012-07-01,17.074661508704065,Good (10-50/month),170.74661508704062,Exceeded (≥100%),10,68.0,80.56
NCT05564273,Viome Nutritional Programs to Improve Clinical Outcomes for Metabolic Conditions,RECRUITING,NA,150.0,2023-10-13,2026-12-01,3.9877729257641925,Adequate (1-10/month),39.877729257641924,Significantly Below (<50%),60,50.0,47.675
NCT04179773,Chemotherapy and Liver Cirrhosis in Frequently-associated Cancers,TERMINATED,,7.0,2019-01-24,2019-10-25,0.7776642335766423,Slow (<1/month),7.776642335766423,Significantly Below (<50%),10,16.9,2.735
NCT05894473,Effects of Telerehabilitation-Based Motor and Cognitive Dual-Task Exercise in Patients With Parkinson's Disease,COMPLETED,NA,30.0,2023-05-30,2023-08-01,14.495238095238095,Good (10-50/month),144.95238095238093,Exceeded (≥100%),100,57.4,67.05499999999999
NCT01141673,Development of a Diagnostic Kit for FLT3-ITD in Acute Myeloid Leukemia,UNKNOWN,,100.0,2010-06-01,2011-06-01,8.339726027397262,Adequate (1-10/month),83.3972602739726,Met (75-100%),50,46.3,35.66
NCT05885373,A Clinical Study to Evaluate the Effect of SIM01 in Female With NAFLD,COMPLETED,NA,40.0,2023-03-01,2023-12-31,3.992131147540984,Adequate (1-10/month),39.921311475409844,Significantly Below (<50%),100,53.2,56.665
NCT03450473,A Prospective Case Series Evaluating Surgimend Mp® In Patients Undergoing Complex Abdominal Hernia Repair,COMPLETED,NA,24.0,2018-01-03,2022-12-31,0.4007460230389468,Slow (<1/month),4.007460230389468,Significantly Below (<50%),100,46.9,38.96
NCT05371873,A Study of Chromosomal Abnormalities as a Predictor of Staging and Prognosis in Patients With Liver Cancer,UNKNOWN,,250.0,2021-03-01,2025-03-01,5.208761122518823,Adequate (1-10/month),52.087611225188226,Below (50-75%),50,53.3,57.14
NCT00336973,A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent,COMPLETED,PHASE4,73.0,2006-05-01,,,Slow (<1/month),,Significantly Below (<50%),100,45.8,33.03
NCT05269173,Efficacy and Safety of Flos Gossypii Flavonoids Tablet in the Treatment of Alzheimer's Disease,COMPLETED,PHASE2,240.0,2020-10-29,2024-11-05,4.976566757493188,Adequate (1-10/month),49.76566757493188,Significantly Below (<50%),100,69.2,81.28
NCT07026773,Validity of ICU Clinician's Appraisal of Proportionality in CPR,RECRUITING,,1000.0,2025-05-18,2026-12-30,51.50592216582064,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT05943873,Successful Microsurgical Breast Reconstruction in Minimally Invasive Mastectomy,COMPLETED,,63.0,2023-06-30,2023-07-05,63.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,63.4,76.375
NCT01956669,Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors,COMPLETED,PHASE2,57.0,2014-10-08,2019-11-05,0.9358576051779937,Slow (<1/month),9.358576051779938,Significantly Below (<50%),100,49.6,46.785
NCT04524169,Immunotherapy for Elderly Patients With Chronic Osteoporotic Pain,UNKNOWN,PHASE4,100.0,2020-11-01,2021-12-31,7.16235294117647,Adequate (1-10/month),71.62352941176471,Below (50-75%),50,43.0,26.465
NCT04876469,Radiocontrast Media in the Pulsed Radiofrequency Treatment,UNKNOWN,NA,60.0,2021-03-01,2021-07-01,14.970491803278687,Good (10-50/month),149.70491803278688,Exceeded (≥100%),50,44.8,29.845
NCT03329469,The Value of CT-FFR Compared to CCTA or CCTA and Stress MPI in Low to Intermediate Risk ED Patients With Toshiba CT-FFR,UNKNOWN,,1142.0,2018-04-18,2024-03-31,15.990101195952164,Good (10-50/month),159.9010119595216,Exceeded (≥100%),50,78.3,86.48
NCT07289269,Prevalence of Violence Against Infertile Women Attending Infertility Treatment,NOT_YET_RECRUITING,,233.0,2025-12-01,2027-12-01,9.715780821917809,Adequate (1-10/month),97.1578082191781,Met (75-100%),30,51.0,49.714999999999996
NCT02396069,"The Evaluation of Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of JPI-289 in Healthy Male Volunteers",COMPLETED,PHASE1,24.0,2015-03-01,2015-08-01,4.774901960784314,Adequate (1-10/month),47.74901960784314,Significantly Below (<50%),100,51.9,52.55499999999999
NCT05981469,Can Cervical Stiffness Predict Successful Vaginal Delivery After Induction of Labour?,COMPLETED,,100.0,2023-09-29,2024-11-29,7.128805620608899,Adequate (1-10/month),71.288056206089,Below (50-75%),100,56.3,64.5
NCT05622669,Understanding Patterns of Fatigue in Health and Disease,ACTIVE_NOT_RECRUITING,,40.0,2021-12-07,2024-03-30,1.442654028436019,Adequate (1-10/month),14.42654028436019,Significantly Below (<50%),85,42.0,24.825
NCT06670469,Flipped Learning and Escape Room Method on Nursing Students,COMPLETED,,110.0,2024-10-24,2024-12-15,64.3923076923077,Excellent (>50/month),200.0,Exceeded (≥100%),100,67.1,79.86999999999999
NCT01281969,Intravenous Immunoglobulin for PANDAS,COMPLETED,PHASE3,48.0,2011-01-01,2018-08-13,0.525393743257821,Slow (<1/month),5.253937432578209,Significantly Below (<50%),100,48.8,45.184999999999995
NCT06801769,Study for the Identification of a Score to Assess Intrapancreatic Fat Through Eco-Elastography and Its Correlation with Metabolic Syndrome and Insulin-Secreting Cells.,NOT_YET_RECRUITING,NA,100.0,2025-02-01,2026-12-01,4.5568862275449105,Adequate (1-10/month),45.5688622754491,Significantly Below (<50%),30,37.0,17.955
NCT06752369,Adapting Single Sessions Interventions for Type 1 Diabetes,NOT_YET_RECRUITING,NA,80.0,2026-03-02,2029-02-01,2.282286785379569,Adequate (1-10/month),22.82286785379569,Significantly Below (<50%),30,35.4,15.765
NCT00839969,Cystoscopy Plus Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired Voiding,UNKNOWN,NA,30.0,2009-01-01,2009-10-01,3.345054945054945,Adequate (1-10/month),33.45054945054945,Significantly Below (<50%),50,37.4,18.62
NCT03618069,Diagnosis by Comprehensive Cardiovascular Imaging for Stroke and TIA,UNKNOWN,NA,100.0,2018-09-01,2019-08-30,8.385674931129477,Adequate (1-10/month),83.85674931129478,Met (75-100%),50,48.0,42.945
NCT04226183,Natural Antioxidant Intake After Exercise Can Oxidative Stress in the Third Trimester of Pragnancy,COMPLETED,NA,24.0,2016-02-03,2016-10-17,2.842645914396887,Adequate (1-10/month),28.426459143968874,Significantly Below (<50%),100,51.9,52.55499999999999
NCT05738083,Multi-Center Registry Cohort Study on Prognostic Factors and Prediction Model Construction in Aneurysmal SAH,RECRUITING,,5000.0,2018-10-01,2029-12-30,37.04965920155794,Good (10-50/month),200.0,Exceeded (≥100%),60,81.3,88.58
NCT03110783,Bioseal Dural Sealing Study BIOS-14-001,COMPLETED,PHASE3,200.0,2017-09-14,2019-09-20,8.271739130434783,Adequate (1-10/month),82.71739130434783,Met (75-100%),100,66.0,78.99000000000001
NCT04738383,Feasibility and Acceptance of Changes in Medical Supervision of Exercise Groups in Cardiac Rehabilitation,COMPLETED,NA,446.0,2018-11-05,2020-05-21,24.114103019538188,Good (10-50/month),200.0,Exceeded (≥100%),100,90.7,93.49
NCT00214383,Internet Telehealth for Pediatric Asthma Case Management,COMPLETED,NA,301.0,2004-05-01,2009-05-01,5.01776560788609,Adequate (1-10/month),50.1776560788609,Below (50-75%),100,74.1,84.10499999999999
NCT05380583,Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) and Substance Use: A Pilot Study,RECRUITING,NA,80.0,2022-05-19,2026-03-30,1.72586817859674,Adequate (1-10/month),17.2586817859674,Significantly Below (<50%),60,44.4,28.95
NCT06541483,Multicentre Clinical Study of Ultra-Fast-Track Anaesthesia for Minimally Invasive Heart Valve Surgery,NOT_YET_RECRUITING,NA,1200.0,2024-12-01,2028-12-01,25.00205338809035,Good (10-50/month),200.0,Exceeded (≥100%),30,74.0,83.985
NCT01545583,A Study of LY3016859 in Healthy Volunteers,COMPLETED,PHASE1,56.0,2012-04-01,2012-09-01,11.141437908496732,Good (10-50/month),111.41437908496732,Exceeded (≥100%),100,59.5,71.0
NCT01055483,"A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia",COMPLETED,PHASE1,59.0,2009-09-01,2012-02-01,2.0339297848244624,Adequate (1-10/month),20.339297848244623,Significantly Below (<50%),100,54.7,60.629999999999995
NCT04978883,Interstitial Lung Diseases in Primary Sjogren's Syndrome,COMPLETED,,170.0,2016-01-01,2018-07-31,5.493418259023355,Adequate (1-10/month),54.93418259023354,Below (50-75%),100,61.9,74.265
NCT00963183,AZD5423 Single Ascending Dose Study,COMPLETED,PHASE1,72.0,2009-08-01,2009-11-01,23.822608695652175,Good (10-50/month),200.0,Exceeded (≥100%),100,60.8,72.99
NCT01047683,Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL,COMPLETED,PHASE3,229.0,2009-12-01,2011-07-01,12.08103986135182,Good (10-50/month),120.81039861351822,Exceeded (≥100%),100,73.3,83.61
NCT03460483,Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care,COMPLETED,NA,1001.0,2018-03-30,2025-06-15,11.568124525436598,Good (10-50/month),115.68124525436599,Exceeded (≥100%),100,95.0,95.7
NCT01845883,Perceptual Decision Making Under Conditions of Visual Uncertainty,UNKNOWN,NA,120.0,2013-04-01,2016-12-01,2.725970149253732,Adequate (1-10/month),27.259701492537314,Significantly Below (<50%),50,44.6,29.42
NCT06525883,Analysis of Patients With Post-traumatic Vertebral Fracture and Accompanying Rib Fracture,COMPLETED,,151.0,2023-01-01,2024-02-01,11.607171717171717,Good (10-50/month),116.07171717171718,Exceeded (≥100%),100,65.4,78.415
NCT03054883,Observational Study for Patients With Newly Diagnosed (MCL) Not Eligible for High-dose Therapy,COMPLETED,,73.0,2012-04-01,2016-12-31,1.2807608069164265,Adequate (1-10/month),12.807608069164267,Significantly Below (<50%),100,49.2,46.035
NCT03320083,Behavioral Insomnia of Childhood: Impact of Parent Education,COMPLETED,NA,157.0,2016-02-01,2016-10-30,17.57014705882353,Good (10-50/month),175.70147058823528,Exceeded (≥100%),100,67.6,80.15
NCT01269983,Effectiveness of Fascial Manipulation for Chronic Low Back Pain,UNKNOWN,NA,50.0,2009-04-01,2010-12-01,2.4991789819376025,Adequate (1-10/month),24.991789819376024,Significantly Below (<50%),50,39.0,20.505000000000003
NCT06674083,Reliability of the Gyko Inertial Sensor System in Evaluating Jumping and Postural Stability Parameters in Healthy Adults,NOT_YET_RECRUITING,,55.0,2025-02-01,2025-05-01,18.81123595505618,Good (10-50/month),188.1123595505618,Exceeded (≥100%),30,36.7,17.544999999999998
NCT02863783,EUS Fiducial for Pancreas Surgery,UNKNOWN,NA,20.0,2016-11-23,2024-02-01,0.23183549124143185,Slow (<1/month),2.318354912414318,Significantly Below (<50%),50,31.6,10.905
NCT02303483,"The Effect of Vitamin B3 on Substrate Metabolism, Insulin Sensitivity, and Body Composition in Obese Men",COMPLETED,NA,40.0,2016-01-04,2017-04-04,2.6701754385964915,Adequate (1-10/month),26.701754385964914,Significantly Below (<50%),100,53.2,56.665
NCT03450083,Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis,COMPLETED,PHASE2,33.0,2017-07-01,2020-02-01,1.062984126984127,Adequate (1-10/month),10.629841269841272,Significantly Below (<50%),100,47.6,41.775
NCT00055783,Monoclonal Antibody Therapy in Treating Patients With Recurrent Hodgkin's Lymphoma,COMPLETED,PHASE2,,2002-07-01,2003-04-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,30.330000000000002
NCT05369741,"TIME™ at Home Feasibility Study: Evaluation of a Virtually Delivered, Community-based, Task-oriented Exercise Program",COMPLETED,NA,20.0,2022-01-22,2022-07-31,3.2042105263157894,Adequate (1-10/month),32.04210526315789,Significantly Below (<50%),100,51.6,51.644999999999996
NCT05017441,TOcilizumab and Covid-19 : Risk of Severe INfection,UNKNOWN,,1200.0,2021-08-16,2024-01-31,40.67706013363029,Good (10-50/month),200.0,Exceeded (≥100%),50,78.3,86.48
NCT00379041,Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma,ACTIVE_NOT_RECRUITING,PHASE3,1158.0,1993-09-01,,,Slow (<1/month),,Significantly Below (<50%),85,75.5,84.68
NCT03938441,"Biweekly Interval Intermittent Fasting for Type 2 Diabetes, a Safety Study",TERMINATED,NA,24.0,2019-07-31,2021-05-28,1.0952923538230885,Adequate (1-10/month),10.952923538230886,Significantly Below (<50%),10,19.9,5.555000000000001
NCT00232141,Study of Pregabalin Versus Placebo in the Treatment of Nerve Pain Associated With HIV Neuropathy,COMPLETED,PHASE3,302.0,2005-10-01,2007-11-01,12.08,Good (10-50/month),120.8,Exceeded (≥100%),100,79.2,87.095
NCT04334941,Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker,ACTIVE_NOT_RECRUITING,PHASE2,103.0,2020-07-20,2027-01-21,1.3195791245791246,Adequate (1-10/month),13.195791245791247,Significantly Below (<50%),85,48.7,44.93
NCT01836341,Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation,WITHDRAWN,PHASE1,0.0,2013-04-01,2015-04-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT05272241,Registry of Asthma Characterization and Recruitment 3 (RACR3),RECRUITING,,1500.0,2022-04-15,2028-05-01,20.679347826086957,Good (10-50/month),200.0,Exceeded (≥100%),60,81.3,88.58
NCT05476341,A Phase I Clinical Trial of Bevacizumab Injection,COMPLETED,PHASE1,98.0,2017-04-06,2017-08-18,22.262089552238805,Good (10-50/month),200.0,Exceeded (≥100%),100,62.8,75.53999999999999
NCT06442241,"A Safety and Immunogenicity Trial of a Respiratory Syncytial Virus Vaccine, LYB005 in Healthy Adults",ACTIVE_NOT_RECRUITING,PHASE1,84.0,2024-07-31,2025-12-30,4.945764023210832,Adequate (1-10/month),49.457640232108325,Significantly Below (<50%),85,52.2,53.22
NCT02533141,Effect of Simvastatin Withdrawal on Ocular Endothelial Function,WITHDRAWN,PHASE4,0.0,2019-10-01,2020-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT02466841,Prospective Comparison of Techniques for Cubital Tunnel Release,WITHDRAWN,,0.0,2015-08-01,2019-11-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT05092854,The Effect of AMP Human Sodium Bicarbonate Lotion on Dehydrated Heat Stress,COMPLETED,NA,18.0,2021-09-03,2022-08-01,1.6503614457831326,Adequate (1-10/month),16.503614457831326,Significantly Below (<50%),100,46.4,36.26
NCT00527254,Telemedicine Influence in the Follow up of the Type 2 Diabetes Patient,COMPLETED,NA,328.0,2003-10-01,2005-06-01,16.394614121510674,Good (10-50/month),163.9461412151067,Exceeded (≥100%),100,81.2,88.265
NCT01060254,"A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain",TERMINATED,PHASE2,31.0,2010-04-06,2011-06-24,2.1253153153153153,Adequate (1-10/month),21.253153153153153,Significantly Below (<50%),10,25.5,7.5200000000000005
NCT05805254,Neurofunctional Study of Preterm Infants' Brain Activity,COMPLETED,,30.0,2018-03-25,2022-08-08,0.5718221665623043,Slow (<1/month),5.718221665623044,Significantly Below (<50%),100,45.7,32.5
NCT02024854,Skin-to-skin After Delivery in Preterm Infants Born at 28-32 Weeks of Gestation,ACTIVE_NOT_RECRUITING,NA,108.0,2014-02-01,2025-12-01,0.7608238833603334,Slow (<1/month),7.608238833603334,Significantly Below (<50%),85,49.1,45.83
NCT03626454,Norepinephrine Addition in Spinal Anesthesia of Caesarean Section,COMPLETED,NA,300.0,2020-10-16,2024-02-01,7.5910224438902745,Adequate (1-10/month),75.91022443890274,Met (75-100%),100,74.0,83.985
NCT03148054,Computed Tomography Vs. Endoscopy Study,RECRUITING,,400.0,2017-02-17,2025-12-31,3.7591849336214884,Adequate (1-10/month),37.59184933621489,Significantly Below (<50%),60,68.3,80.875
NCT00821054,A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients,COMPLETED,PHASE1,24.0,2009-03-06,2011-03-22,0.9793029490616623,Slow (<1/month),9.793029490616622,Significantly Below (<50%),100,46.9,38.96
NCT04743154,In-hospital Versus After-discharge Complete Revascularization,COMPLETED,NA,250.0,2018-01-20,2022-12-21,4.237193763919822,Adequate (1-10/month),42.371937639198215,Significantly Below (<50%),100,70.0,81.89999999999999
NCT05567354,A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-103),COMPLETED,PHASE1,27.0,2022-06-10,2022-08-31,10.022926829268293,Good (10-50/month),100.22926829268293,Exceeded (≥100%),100,57.2,66.465
NCT04489654,Immediate Implant Using Socket Shield Technique With Xenogenic Bone Graft,UNKNOWN,NA,16.0,2019-07-20,2020-10-01,1.1094305239179953,Adequate (1-10/month),11.094305239179954,Significantly Below (<50%),50,31.3,10.299999999999999
NCT03729154,Preschool First Step to Success: An Efficacy Replication Study,COMPLETED,NA,162.0,2015-10-01,2023-06-30,1.7431177094379642,Adequate (1-10/month),17.431177094379642,Significantly Below (<50%),100,63.0,75.845
NCT03515954,AS-OCT Guided Treatment of Diffuse CSCC,COMPLETED,,15.0,2014-03-01,2018-10-01,0.27259701492537314,Slow (<1/month),2.7259701492537314,Significantly Below (<50%),100,44.5,29.160000000000004
NCT03682354,ESPB Versus INB With PCIA in Video-assisted Thoracic Surgery,COMPLETED,NA,70.0,2018-09-27,2019-03-15,12.60828402366864,Good (10-50/month),126.0828402366864,Exceeded (≥100%),100,60.6,72.785
NCT03112954,Floral Remedies for Sleep-bruxism Patients,COMPLETED,NA,74.0,2014-05-29,2014-06-20,74.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,65.9,78.83
NCT03638154,Regenerative Potential of Cultured Gingival Fibroblast- Mesenchymal Stem Cells in Treatment of Periodontitis,COMPLETED,NA,20.0,2016-03-15,2018-02-22,0.8586741889985896,Slow (<1/month),8.586741889985895,Significantly Below (<50%),100,46.6,37.375
NCT02997254,COMparison of Physiological Algorithms for Real-time Evaluation of Atrial Fibrillation,RECRUITING,,1000.0,2016-12-01,2027-06-30,7.8798860988868755,Adequate (1-10/month),78.79886098886875,Met (75-100%),60,76.3,85.1
NCT03157154,Bleeding Risk Evaluation in Haemophilia Patients Under Antiplatelet Therapies,COMPLETED,,259.0,2017-06-27,2017-07-30,238.9078787878788,Excellent (>50/month),200.0,Exceeded (≥100%),100,79.1,87.06
NCT00594854,Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec,TERMINATED,PHASE3,20.0,2007-09-01,2008-09-01,1.6633879781420766,Adequate (1-10/month),16.633879781420767,Significantly Below (<50%),10,19.6,5.365
NCT07002554,Bright Light Therapy for Depressed Geriatric Inpatients,ENROLLING_BY_INVITATION,PHASE2,20.0,2025-11-14,2026-04-30,3.645508982035928,Adequate (1-10/month),36.455089820359284,Significantly Below (<50%),55,38.1,19.425
NCT00000354,Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 3,COMPLETED,PHASE1,0.0,1996-07-01,1997-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),100,43.3,27.05
NCT06434454,EFT AND SLEEP QUALITY,NOT_YET_RECRUITING,NA,74.0,2024-06-20,2024-09-20,24.484347826086957,Good (10-50/month),200.0,Exceeded (≥100%),30,39.9,21.695
NCT05020054,Effect of Tecartherapy in the Treatment of Localized Fat and Sagging Abdominal Skin - Clinical and Experimental Study,COMPLETED,NA,60.0,2019-02-08,2021-07-01,2.0897025171624715,Adequate (1-10/month),20.897025171624712,Significantly Below (<50%),100,54.8,61.095
NCT00852254,Validation of Minimally Invasive Ultrasound Indicator Dilution Technique in Critically Ill Children,COMPLETED,,9.0,2008-06-01,2011-05-01,0.2574812030075188,Slow (<1/month),2.5748120300751878,Significantly Below (<50%),100,44.1,28.425
NCT03107754,Buffered Lidocaine in Paracervical Blocks,COMPLETED,PHASE4,98.0,2017-05-15,2018-10-25,5.6498484848484845,Adequate (1-10/month),56.49848484848485,Below (50-75%),100,57.8,67.635
NCT01205854,Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial,COMPLETED,PHASE4,238.0,2010-09-01,2015-04-01,4.330376569037657,Adequate (1-10/month),43.30376569037657,Significantly Below (<50%),100,69.0,81.185
NCT03694054,"Care Coordination in Oncology, Quality Among Patients With Lung Cancer and Their Caregivers",COMPLETED,NA,57.0,2018-06-04,2019-03-31,5.7836,Adequate (1-10/month),57.836,Below (50-75%),100,54.6,60.39
NCT03785054,"Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242",COMPLETED,PHASE1,71.0,2018-11-14,2021-03-11,2.5486320754716982,Adequate (1-10/month),25.486320754716985,Significantly Below (<50%),100,55.7,63.09
NCT04374305,Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2),ACTIVE_NOT_RECRUITING,PHASE2,100.0,2020-06-20,2030-12-01,0.7976939203354297,Slow (<1/month),7.9769392033542985,Significantly Below (<50%),85,48.5,44.47
NCT01198405,Study of Enahnced External Counterpulsation to Treat Coronary Heart Disease,UNKNOWN,NA,1050.0,2008-09-01,2013-09-01,17.50383351588171,Good (10-50/month),175.0383351588171,Exceeded (≥100%),50,80.0,87.67
NCT04873505,Functional Validation of Lactobacillus Containing Oral Tablet,COMPLETED,NA,50.0,2020-10-30,2022-04-29,2.787545787545788,Adequate (1-10/month),27.875457875457883,Significantly Below (<50%),100,54.0,58.72500000000001
NCT01762605,Treatment of Distal Radius Buckle Fractures,TERMINATED,NA,11.0,2010-03-01,2012-11-01,0.34307377049180326,Slow (<1/month),3.4307377049180325,Significantly Below (<50%),10,18.9,4.6899999999999995
NCT01368705,Nitrogen Balance in Infants After Post Cardiothoracic Surgery,COMPLETED,PHASE4,24.0,2009-08-01,2012-06-01,0.7058550724637681,Slow (<1/month),7.058550724637682,Significantly Below (<50%),100,46.9,38.96
NCT07186205,A Study to Collect Data to Build Artificial Intelligence Derived Algorithms for Estimating Risk of Iron Deficiency and Anaemia in African Children,COMPLETED,,126.0,2025-10-13,2026-01-09,43.584545454545456,Good (10-50/month),200.0,Exceeded (≥100%),100,68.4,80.97
NCT04568005,Evaluation of Lymphedema Patients Status During Covid-19 Pandemic,COMPLETED,,60.0,2020-06-01,2020-08-01,29.940983606557374,Good (10-50/month),200.0,Exceeded (≥100%),100,58.1,68.595
NCT04313205,A Pharmacokinetic Study of JKB-122 Tablets Compared to Capsule,UNKNOWN,PHASE1,8.0,2020-08-01,2020-12-01,1.9960655737704918,Adequate (1-10/month),19.960655737704915,Significantly Below (<50%),50,35.6,16.03
NCT04045405,"Clinical Study to Assess Safety, PK and PD Parameters of CDR132L",COMPLETED,PHASE1,28.0,2019-06-21,2020-06-26,2.297358490566038,Adequate (1-10/month),22.97358490566038,Significantly Below (<50%),100,52.2,53.22
NCT00508105,Comparing Two Surgical Methods of Fixation of Subscapularis During Shoulder Arthroplasty,COMPLETED,NA,87.0,2006-11-01,2011-12-01,1.4268750000000001,Adequate (1-10/month),14.268749999999999,Significantly Below (<50%),100,52.0,52.86
NCT06580405,A Feasibility Study to Evaluate the Safety of the KNP-1000 Apheresis System in Severe Preeclampsia,NOT_YET_RECRUITING,NA,13.0,2025-05-31,2028-06-30,0.35143872113676733,Slow (<1/month),3.5143872113676733,Significantly Below (<50%),30,25.0,7.23
NCT07213505,This Clinical Investigation Assesses the Safety and Performance of a New Beamformer for MED-EL Cochlear Implant Recipients.,RECRUITING,NA,40.0,2025-09-29,2026-09-29,3.3358904109589043,Adequate (1-10/month),33.35890410958904,Significantly Below (<50%),60,41.2,23.425
NCT00332605,N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence,COMPLETED,PHASE2,45.0,2006-06-01,2010-01-01,1.0456488549618321,Adequate (1-10/month),10.45648854961832,Significantly Below (<50%),100,48.6,44.685
NCT02736305,Use of Regorafenib in Recurrent Epithelial Ovarian Cancer,COMPLETED,PHASE2,21.0,2016-02-03,2019-11-18,0.461878612716763,Slow (<1/month),4.61878612716763,Significantly Below (<50%),100,46.7,37.895
NCT06220305,DNA Methylation Combined With Artificial Intelligence Imaging to Identify Lung Nodules,UNKNOWN,,100.0,2022-12-01,2024-12-31,4.0,Adequate (1-10/month),40.0,Significantly Below (<50%),50,41.3,23.74
NCT04324905,"Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP1802 to HGP1705 in Healthy Volunteers",COMPLETED,PHASE1,49.0,2020-04-29,2020-10-30,8.106304347826088,Adequate (1-10/month),81.06304347826088,Met (75-100%),100,53.9,58.34
NCT04158505,Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer,UNKNOWN,,3000.0,2020-02-28,2023-11-15,67.34513274336284,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT05903105,Diversity in Patients With OAB,NOT_YET_RECRUITING,,1000.0,2025-01-01,2025-12-01,91.1377245508982,Excellent (>50/month),200.0,Exceeded (≥100%),30,77.3,85.67
NCT00976105,Effects of Repeat Dosing of GSK1521498,COMPLETED,PHASE1,49.0,2009-09-22,2010-03-09,8.878333333333334,Adequate (1-10/month),88.78333333333333,Met (75-100%),100,58.9,70.10499999999999
NCT05203705,Clinical Study on the Efficacy and Safety of Multiple Oral Administrations of SHR2285 Tablets in Patients Undergoing Elective Total Knee Arthroplasty,TERMINATED,PHASE2,64.0,2022-03-07,2023-03-14,5.236989247311828,Adequate (1-10/month),52.369892473118284,Below (50-75%),10,28.1,8.42
NCT06891105,Effect of Probiotic and Synbiotic Administration on Nutritional Status in Hemodialysis Patients,NOT_YET_RECRUITING,NA,60.0,2025-04-15,2025-11-01,9.132,Adequate (1-10/month),91.32000000000001,Met (75-100%),30,38.8,20.244999999999997
NCT01802905,Utilization of Genomic Information to Augment Chemotherapy Decision-making for People With Incurable Malignancies,COMPLETED,NA,100.0,2012-06-01,2015-02-01,3.1220512820512822,Adequate (1-10/month),31.220512820512823,Significantly Below (<50%),100,58.0,68.245
NCT05465005,Perception of Electrical Stimuli in Individuals with Stroke,ACTIVE_NOT_RECRUITING,NA,45.0,2022-02-01,2026-03-01,0.919946272666219,Slow (<1/month),9.19946272666219,Significantly Below (<50%),85,44.1,28.425
NCT00159705,Trial of Efficacy and Safety of Pregabalin in Subjects With Neuropathic Pain Associated With Lumbo-Sacral Radiculopathy,COMPLETED,PHASE3,276.0,2005-04-01,2007-06-01,10.621289506953225,Good (10-50/month),106.21289506953224,Exceeded (≥100%),100,77.1,85.5
NCT02978105,Effects of Self-conditioning Techniques in Promoting Weight Loss in Patients With Obesity. A Randomized Controlled Trial,COMPLETED,PHASE3,120.0,2015-02-01,2017-09-01,3.8735949098621423,Adequate (1-10/month),38.735949098621425,Significantly Below (<50%),100,59.6,71.17999999999999
NCT03902405,Computerized Exercise to Alter Stimulant Approach Responses,UNKNOWN,NA,60.0,2018-06-11,2022-03-31,1.314902807775378,Adequate (1-10/month),13.14902807775378,Significantly Below (<50%),50,34.8,15.040000000000001
NCT01190605,Evaluating Factors That Impact Loss to Follow-up Among Postpartum HIV-infected Women in Mississippi,COMPLETED,,53.0,2010-07-01,2013-07-01,1.472007299270073,Adequate (1-10/month),14.72007299270073,Significantly Below (<50%),100,47.6,41.775
NCT05264805,Effectiveness of Port Site Bupivacaine Injection in Postoperative Pain Reduction After Lap. Chole,UNKNOWN,PHASE3,166.0,2022-03-01,2022-09-01,27.46217391304348,Good (10-50/month),200.0,Exceeded (≥100%),50,53.3,57.14
NCT02456805,Alternate Formula Feedings in Formula Intolerant Infants,COMPLETED,NA,113.0,1996-08-01,1997-06-01,11.314868421052632,Good (10-50/month),113.14868421052633,Exceeded (≥100%),100,64.0,77.025
NCT04586205,Task Augmentation of Transcranial Magnetic Stimulation (TMS),COMPLETED,,17.0,2019-04-07,2024-03-11,0.2874888888888889,Slow (<1/month),2.8748888888888895,Significantly Below (<50%),100,44.7,29.67
NCT01763905,Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2,COMPLETED,PHASE3,307.0,2013-01-24,2013-11-19,31.25444816053512,Good (10-50/month),200.0,Exceeded (≥100%),100,79.6,87.22
NCT07279194,Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes,RECRUITING,PHASE3,825.0,2025-10-14,2026-12-13,59.08941176470588,Excellent (>50/month),200.0,Exceeded (≥100%),60,88.0,92.495
NCT05947994,Elucidate Outcomes of Elective High-grade/Total Occlusion Intracranial Arteries Using Low-profile Self-expanding Stent,COMPLETED,NA,156.0,2022-01-01,2024-04-20,5.653142857142857,Adequate (1-10/month),56.53142857142858,Below (50-75%),100,62.5,75.21
NCT01248494,PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer,COMPLETED,PHASE1,72.0,2010-11-01,2016-05-01,1.0914741035856574,Adequate (1-10/month),10.914741035856574,Significantly Below (<50%),100,50.8,49.18
NCT06011694,The Jinling Cohort,RECRUITING,,15000.0,2022-06-15,2027-05-15,254.37325905292482,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT01647594,Pilot Study for Young Women's Intervention,COMPLETED,NA,93.0,2011-03-01,2012-07-01,5.801065573770492,Adequate (1-10/month),58.01065573770491,Below (50-75%),100,57.4,67.05499999999999
NCT06483594,Prediction and Prognostic Analysis of Liver Abscess Formation After Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma (CHANCE 2407),NOT_YET_RECRUITING,,400.0,2024-06-30,2025-06-30,33.35890410958905,Good (10-50/month),200.0,Exceeded (≥100%),30,64.3,77.265
NCT03810794,Clinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease,RECRUITING,NA,180.0,2019-03-01,2026-12-30,1.915134568332751,Adequate (1-10/month),19.15134568332751,Significantly Below (<50%),60,52.4,53.949999999999996
NCT04069494,Descriptors and Predictors of Burden and Information Needs,COMPLETED,,112.0,2019-10-01,2020-02-29,22.578013245033112,Good (10-50/month),200.0,Exceeded (≥100%),100,62.3,74.94
NCT02474394,Effects of Videolaryngoscope on Intraocular Pressure,COMPLETED,PHASE4,80.0,2013-02-01,2015-06-01,2.8649411764705883,Adequate (1-10/month),28.649411764705885,Significantly Below (<50%),100,56.4,64.88000000000001
NCT03462394,Increasing Patient Engagement in the Annual Well Visits Program,COMPLETED,,5475.0,2018-02-19,2019-07-24,320.4980769230769,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02086994,Prevention of Postpartum Hemorrhage in Patients With Severe Preeclampsia Using Carbetocin Versus Misoprostol,COMPLETED,PHASE3,60.0,2013-03-01,2015-08-01,2.068403171007928,Adequate (1-10/month),20.684031710079275,Significantly Below (<50%),100,54.8,61.095
NCT07353294,Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC,NOT_YET_RECRUITING,PHASE1,12.0,2026-01-01,2029-06-30,0.28626959247648903,Slow (<1/month),2.8626959247648904,Significantly Below (<50%),30,25.0,7.23
NCT00857194,Cardiovascular Disease Study,COMPLETED,,170.0,2007-03-01,2017-06-21,1.374448871181939,Adequate (1-10/month),13.744488711819388,Significantly Below (<50%),100,56.9,65.89500000000001
NCT02216994,A New Scoring System Improves Diagnostic Accuracy of Intestinal Dysganglionosis --a Prospective Study,UNKNOWN,NA,80.0,2013-01-01,2015-06-01,2.7641316685584565,Adequate (1-10/month),27.641316685584567,Significantly Below (<50%),50,41.4,24.04
NCT04229394,2ccPA Study in Patients With Symptomatic Knee Osteoarthritis,COMPLETED,PHASE1,40.0,2018-02-13,2021-03-22,1.0746690203000882,Adequate (1-10/month),10.746690203000881,Significantly Below (<50%),100,48.2,43.665
NCT04723394,Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults,COMPLETED,PHASE3,910.0,2021-01-28,2022-10-19,44.03879173290938,Good (10-50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT05955794,Vocal Pattern Assessment as a New Key to Identifying Rare Syndromes,UNKNOWN,NA,500.0,2023-09-01,2025-09-20,20.293333333333337,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT06504394,A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65),ACTIVE_NOT_RECRUITING,PHASE2,66.0,2024-10-14,2028-11-08,1.3519784656796772,Adequate (1-10/month),13.519784656796771,Significantly Below (<50%),85,45.8,33.03
NCT02720094,Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men,COMPLETED,PHASE2,4570.0,2016-12-19,2025-03-31,46.00224867724868,Good (10-50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT00765466,"A Phase II Open Label, Multi-Center Study With AVR118 in Anorectic Patients With Recurrent or Advanced Malignancies",TERMINATED,PHASE2,30.0,2007-10-01,2010-05-01,0.9683987274655356,Slow (<1/month),9.683987274655356,Significantly Below (<50%),10,20.4,5.885
NCT01679366,The Effectiveness of Probiotics for the Therapy of Acute Pharyngotonsillitis in Adult Patients,COMPLETED,PHASE3,57.0,2012-10-01,2013-10-01,4.7536438356164386,Adequate (1-10/month),47.53643835616439,Significantly Below (<50%),100,54.6,60.39
NCT03530566,Study to Evaluate Effectiveness of a Weight Loss Program in Obese Patients During 3 Months Prior to Bariatric Surgery,UNKNOWN,,25.0,2018-05-01,2019-03-01,2.5032894736842106,Adequate (1-10/month),25.032894736842103,Significantly Below (<50%),50,35.3,15.534999999999998
NCT00064766,Norplant and Irregular Bleeding/Spotting,UNKNOWN,PHASE4,50.0,2003-02-01,2005-02-01,2.0820793433652534,Adequate (1-10/month),20.820793433652533,Significantly Below (<50%),50,39.0,20.505000000000003
NCT02153866,The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine,UNKNOWN,PHASE4,2800.0,2013-12-01,2014-08-01,350.7489711934157,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT06061666,Treatment of Insomnia in Patients With Breast Cancer,UNKNOWN,NA,80.0,2023-06-01,2024-06-30,6.165063291139242,Adequate (1-10/month),61.650632911392414,Below (50-75%),50,41.4,24.04
NCT01788566,A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer,COMPLETED,PHASE2,61.0,2013-03-01,2015-12-01,1.8476019900497511,Adequate (1-10/month),18.476019900497512,Significantly Below (<50%),100,54.9,61.55500000000001
NCT06939166,Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases,RECRUITING,EARLY_PHASE1,12.0,2025-06-17,2027-10-01,0.43693779904306224,Slow (<1/month),4.369377990430623,Significantly Below (<50%),60,34.0,14.02
NCT05224466,Characteristics and Clinical Outcomes of Peritoneal Dialysis Patients,UNKNOWN,,400.0,2022-03-01,2024-12-01,12.103379721669981,Good (10-50/month),121.0337972166998,Exceeded (≥100%),50,70.3,82.09
NCT05633056,An Adaptive Randomized Controlled Trial,RECRUITING,NA,360.0,2023-03-07,2029-04-01,4.942895805142085,Adequate (1-10/month),49.42895805142085,Significantly Below (<50%),60,66.8,79.55
NCT04518956,Shockwave Therapy Versus LIPUS on Mandibular Fracture Bone Healing,COMPLETED,NA,21.0,2016-12-18,2018-06-23,1.1580434782608695,Adequate (1-10/month),11.580434782608695,Significantly Below (<50%),100,46.7,37.895
NCT07282756,EVALUATION OF THE EFFECTIVNESS OF SUBGINGIVAL APPLICATION OF 1.2% LOVASTATIN GEL AS AN ADJUNCT TO NON-SURGICAL TREATMENT OF PERIODONTITIS IN GENERALLY HEALTHY SMOKERS AND NON-SMOKERS PATIENTS FROM CENTAL EUROPE- A SPLIT-MOUTH RANDOMIZED CONTROLLED TRIAL.,RECRUITING,NA,44.0,2025-07-11,2026-12-01,2.636535433070866,Adequate (1-10/month),26.365354330708655,Significantly Below (<50%),60,41.5,24.215
NCT02448056,MiRNA as a Diagnostic and Prognostic Biomarker of Hepatocellular Carcinoma,UNKNOWN,,150.0,2015-06-01,2025-05-01,1.2606294864715628,Adequate (1-10/month),12.606294864715629,Significantly Below (<50%),50,40.3,22.21
NCT01939756,Intravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract Symptoms,COMPLETED,PHASE1,50.0,2012-01-01,2013-06-01,2.9439071566731143,Adequate (1-10/month),29.439071566731144,Significantly Below (<50%),100,54.0,58.72500000000001
NCT01610856,Single Dose Versus Split Dose Polyethylene Glycol-based Colonic Lavage for Colonoscopy,COMPLETED,NA,250.0,2010-03-01,2010-06-01,82.71739130434783,Excellent (>50/month),200.0,Exceeded (≥100%),100,80.0,87.67
NCT04877756,Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery,COMPLETED,PHASE2,22.0,2021-08-19,2023-07-12,0.9677456647398844,Slow (<1/month),9.677456647398843,Significantly Below (<50%),100,46.8,38.440000000000005
NCT02093156,A Predictive Score Identifies Patients With Inadequate Bowel Preparation for Colonoscopy,COMPLETED,,605.0,2013-09-01,2013-12-01,202.3758241758242,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT01402856,Teenage Driving Safety Study: An Emergency Medicine-Trauma Collaborative Study,COMPLETED,,3750.0,2007-11-01,2012-05-01,69.47656725502131,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT01318356,The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment,COMPLETED,PHASE4,156.0,2011-04-01,2015-09-01,2.9421561338289965,Adequate (1-10/month),29.421561338289965,Significantly Below (<50%),100,62.5,75.21
NCT02910856,Infective Endocarditis in the Elderly,COMPLETED,,120.0,2015-03-01,2017-07-01,4.282297772567409,Adequate (1-10/month),42.82297772567409,Significantly Below (<50%),100,57.9,67.83
NCT01934556,A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema,COMPLETED,PHASE1,150.0,2013-11-01,2018-04-01,2.832506203473945,Adequate (1-10/month),28.32506203473945,Significantly Below (<50%),100,62.0,74.42
NCT02198456,"Imaging Control Study, 3D Echo, MR and RHC.",UNKNOWN,,12.0,2014-07-01,2019-12-01,0.18457806973218796,Slow (<1/month),1.8457806973218798,Significantly Below (<50%),50,29.3,8.825
NCT00871156,Tafenoquine/Chloroquine DDI Study,COMPLETED,PHASE1,68.0,2009-03-24,2009-08-26,13.354322580645162,Good (10-50/month),133.5432258064516,Exceeded (≥100%),100,60.4,72.54
NCT05558956,Total Body PET-CT Imaging of Prostate Cancer Using Illuccix,UNKNOWN,EARLY_PHASE1,100.0,2022-11-01,2023-12-01,7.706329113924052,Adequate (1-10/month),77.0632911392405,Met (75-100%),50,43.0,26.465
NCT07332156,Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas,COMPLETED,,21692.0,2009-01-01,2023-12-31,120.55951798429797,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT03252756,Effects of Cannabidiol in Alcohol Use Disorder,COMPLETED,PHASE1,27.0,2019-09-01,2022-03-16,0.8866019417475729,Slow (<1/month),8.86601941747573,Significantly Below (<50%),100,47.2,40.035
NCT05323656,A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN),COMPLETED,PHASE2,55.0,2022-04-06,2025-08-21,1.3578264395782644,Adequate (1-10/month),13.578264395782647,Significantly Below (<50%),100,49.4,46.42
NCT03592056,Hemidiaphragmatic Paralysis With Diluted Continuous Interscalene Plexus Infusions,TERMINATED,,30.0,2018-08-10,2019-07-23,2.6317002881844385,Adequate (1-10/month),26.31700288184438,Significantly Below (<50%),10,23.7,6.74
NCT00042822,"FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma",COMPLETED,PHASE2,,2002-05-01,,,Slow (<1/month),,Significantly Below (<50%),100,40.0,21.87
NCT06576622,"PERIodontal Disease, Microbiota and Miscarriage",RECRUITING,,30.0,2024-11-29,2026-12-30,1.2,Adequate (1-10/month),12.0,Significantly Below (<50%),60,33.7,13.465
NCT02633722,"Intermittent Fasting for Metabolic Health, Does Meal Timing Matter?",COMPLETED,NA,15.0,2016-01-01,2018-07-30,0.4852284803400638,Slow (<1/month),4.8522848034006385,Significantly Below (<50%),100,46.2,35.089999999999996
NCT07082322,European Prospective Bloodstream Infection Cohort,NOT_YET_RECRUITING,,40000.0,2025-09-01,2031-01-01,625.0513347022587,Excellent (>50/month),200.0,Exceeded (≥100%),30,77.3,85.67
NCT05536622,Hi-Res IR Thermography for the Diagnosis of Toddler's Fractures,UNKNOWN,NA,50.0,2021-02-11,2022-09-30,2.553691275167785,Adequate (1-10/month),25.536912751677853,Significantly Below (<50%),50,39.0,20.505000000000003
NCT04969822,eValuating iDA Selection Ability. The VISA Study.,COMPLETED,NA,1066.0,2020-02-20,2023-11-01,24.036325925925926,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT00512122,Impact of Early Parenteral Nutrition Completing Enteral Nutrition in Adult Critically Ill Patients,ACTIVE_NOT_RECRUITING,PHASE4,4640.0,2007-08-01,2026-12-01,20.00022656471255,Good (10-50/month),200.0,Exceeded (≥100%),85,90.5,93.4
NCT00451022,Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies,RECRUITING,,750.0,2004-09-13,,,Slow (<1/month),,Significantly Below (<50%),60,66.3,79.3
NCT06369922,TENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence.,RECRUITING,NA,100.0,2024-07-01,2026-06-01,4.348571428571429,Adequate (1-10/month),43.48571428571428,Significantly Below (<50%),60,46.0,34.1
NCT04523922,Oxytocin to Enhance Integrated Treatment for AUD and PTSD,RECRUITING,PHASE2,180.0,2021-03-29,2026-12-01,2.643125904486252,Adequate (1-10/month),26.43125904486252,Significantly Below (<50%),60,52.4,53.949999999999996
NCT01168622,Impact of Race/Ethnicity on Platelet Function,COMPLETED,,625.0,2010-06-01,2013-03-30,18.41723136495644,Good (10-50/month),184.17231364956436,Exceeded (≥100%),100,93.3,94.325
NCT06824922,"""Educational Intervention 'Be Yourself': Digital Innovation to Prevent Teenage Pregnancy""",NOT_YET_RECRUITING,NA,150.0,2025-02-06,2025-06-06,38.050000000000004,Good (10-50/month),200.0,Exceeded (≥100%),30,46.0,34.1
NCT04332822,"A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma",RECRUITING,PHASE3,300.0,2020-08-19,2028-12-28,2.991156239764167,Adequate (1-10/month),29.911562397641667,Significantly Below (<50%),60,62.0,74.42
NCT01968122,Registry Study of Stenting for Symptomatic Intracranial Artery Stenosis in China,COMPLETED,,300.0,2013-09-01,2015-12-01,11.123020706455542,Good (10-50/month),111.23020706455542,Exceeded (≥100%),100,77.3,85.67
NCT01747122,The Effects of Local Infiltration Versus Epidural Following Liver Resection 2,COMPLETED,NA,97.0,2012-12-01,2014-08-01,4.856381578947368,Adequate (1-10/month),48.563815789473686,Significantly Below (<50%),100,57.8,67.635
NCT05041322,Improving Ventilatory Capacity in Those With Chronic High Level SCI,COMPLETED,PHASE2,13.0,2020-11-29,2024-11-01,0.2761479413817167,Slow (<1/month),2.761479413817167,Significantly Below (<50%),100,46.0,34.1
NCT06713122,Effects of Symptom Management Education With Mobile Application in Gynecological Cancer Patients Receiving Chemotherapy,ENROLLING_BY_INVITATION,NA,70.0,2025-01-01,2026-02-02,5.367254408060454,Adequate (1-10/month),53.67254408060453,Below (50-75%),55,42.1,25.019999999999996
NCT00136422,Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia,COMPLETED,PHASE1,30.0,2000-01-01,2006-03-01,0.40568636161705907,Slow (<1/month),4.056863616170591,Significantly Below (<50%),100,47.4,40.98
NCT03444922,Effects of BPA on Insulin and Glucose Responses,COMPLETED,NA,11.0,2016-09-01,2019-02-14,0.3737053571428572,Slow (<1/month),3.737053571428571,Significantly Below (<50%),100,45.9,33.495000000000005
NCT06425822,Characterization of Left Atrial Substrate in Patients With Ventricular Arrhythmias,RECRUITING,,50.0,2023-11-08,2027-10-31,1.0474879559532002,Adequate (1-10/month),10.474879559532004,Significantly Below (<50%),60,35.3,15.534999999999998
NCT00985322,Angiotensin-converting-enzyme (ACE) Inhibitors in Hemodialysis,COMPLETED,PHASE3,269.0,2009-05-01,2016-04-01,3.240348239018599,Adequate (1-10/month),32.40348239018599,Significantly Below (<50%),100,71.5,82.72
NCT03022851,The Prophet Trial -Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Patients With Pulmonary Hypertension,COMPLETED,NA,32.0,2017-07-19,2024-01-08,0.41204737732656516,Slow (<1/month),4.120473773265652,Significantly Below (<50%),100,47.6,41.775
NCT04872751,Immune Response of Haemodialysis Patients Post Covid-19 Vaccination,UNKNOWN,,425.0,2021-04-27,2022-04-01,38.16224188790561,Good (10-50/month),200.0,Exceeded (≥100%),50,72.3,83.065
NCT03583151,Corticosteroid vs. Amniotic Fluid Injections in Patients With Trigger Finger,UNKNOWN,PHASE3,100.0,2018-05-10,2019-12-01,5.340350877192983,Adequate (1-10/month),53.40350877192983,Below (50-75%),50,43.0,26.465
NCT05565651,Retrospective Study of Intestinal Microbiota in Association With Diabetes,COMPLETED,,334.0,2020-01-01,2022-06-30,11.160219538968168,Good (10-50/month),111.60219538968168,Exceeded (≥100%),100,80.1,88.02499999999999
NCT04162951,Retrolaminar Thoracic Paravertebral Block,COMPLETED,NA,93.0,2019-11-10,2023-10-19,1.9672828353022933,Adequate (1-10/month),19.67282835302293,Significantly Below (<50%),100,57.4,67.05499999999999
NCT01492751,Effectiveness of Localized Prostate Cancer Treatments,ACTIVE_NOT_RECRUITING,,500.0,2003-04-01,2025-12-01,1.8381642512077294,Adequate (1-10/month),18.381642512077292,Significantly Below (<50%),85,83.8,90.505
NCT00920751,Comparison of on Demand Sedation With Study Method Versus on Demand Sedation With Conventional Method for Performing Colonoscopy for Colorectal Cancer Screening and Surveillance,UNKNOWN,NA,100.0,2009-03-01,,,Slow (<1/month),,Significantly Below (<50%),50,33.0,12.695
NCT02518451,Bioequivalence Evaluation of Two Film-Coated Formulations of Valsartan 160 mg,COMPLETED,NA,48.0,2013-06-01,2014-03-01,5.352087912087913,Adequate (1-10/month),53.52087912087913,Below (50-75%),100,53.8,58.065
NCT00277251,Alendronate Osteoporosis Study,COMPLETED,PHASE2,20.0,2003-03-01,2006-06-01,0.5124579124579125,Slow (<1/month),5.124579124579125,Significantly Below (<50%),100,46.6,37.375
NCT04602351,Communication in ICU During COVID-19,COMPLETED,,296.0,2021-03-22,2021-05-01,225.256,Excellent (>50/month),200.0,Exceeded (≥100%),100,82.0,89.05499999999999
NCT06159751,PROGNOSTIC ROLE OF SERUM ALBUMIN LEVEL IN RADIOLOGICAL PROGRESSION OF GONARTHROSIS: IS IT A BIOMARKER IN ITSELF? A BIOMARKER ASSOCIATED WITH SYSTEMIC INFLAMMATION?,COMPLETED,,375.0,2023-02-01,2023-03-01,375.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,88.3,92.705
NCT07194551,Assessing Uterine Cancer Risk in Lynch Syndrome Carriers Using Vaginal Self-sampling and a Health Questionnaire,RECRUITING,NA,30.0,2025-08-29,2027-04-01,1.5744827586206895,Adequate (1-10/month),15.744827586206897,Significantly Below (<50%),60,35.4,15.765
NCT02389751,"Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer",COMPLETED,PHASE1,3.0,2015-04-10,2019-07-16,0.05861360718870347,Slow (<1/month),0.5861360718870348,Significantly Below (<50%),100,45.2,30.830000000000002
NCT00086151,Identifying Low-Risk Patients With Pulmonary Embolism,COMPLETED,,,2004-07-01,2007-06-01,,Slow (<1/month),,Significantly Below (<50%),100,43.3,27.05
NCT00229151,Sleep Deprivation and Advancement of Sleep Period as Treatment for Bipolar Depression.,TERMINATED,NA,5.0,2005-10-01,2011-12-01,0.06758436944937833,Slow (<1/month),0.6758436944937833,Significantly Below (<50%),10,18.4,3.855
NCT01621451,Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD?,UNKNOWN,PHASE4,400.0,2012-06-01,2014-06-01,16.679452054794524,Good (10-50/month),166.7945205479452,Exceeded (≥100%),50,72.0,82.92
NCT03928951,General Practitioner Reassessment of Urinary Infection Antibiotherapy Prescribed by Emergency Departments,COMPLETED,,50.0,2019-06-14,2019-09-12,16.91111111111111,Good (10-50/month),169.11111111111111,Exceeded (≥100%),100,57.3,66.74
NCT03618251,Automated Volume Assessment of Acute Stroke,COMPLETED,,406.0,2018-03-15,2020-12-04,12.420743718592965,Good (10-50/month),124.20743718592963,Exceeded (≥100%),100,85.8,91.495
NCT07147751,Characterization of Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL) by Multiomic Approach,NOT_YET_RECRUITING,,100.0,2026-04-01,2029-12-01,2.271641791044776,Adequate (1-10/month),22.71641791044776,Significantly Below (<50%),30,35.3,15.534999999999998
NCT04471051,An Observational Cohort Trial of Outcomes and Antibody Responses Following Treatment With COVID19 Convalescent Plasma in Hospitalized COVID-19 Patients,COMPLETED,,255.0,2020-04-30,2020-08-20,69.30535714285715,Excellent (>50/month),200.0,Exceeded (≥100%),100,78.7,86.835
NCT01877551,Tauroursodeoxycholic Acid for Protease-inhibitor Associated Insulin Resistance,COMPLETED,NA,27.0,2013-09-01,2018-05-01,0.48260716382853786,Slow (<1/month),4.826071638285379,Significantly Below (<50%),100,47.2,40.035
NCT00369629,Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome,TERMINATED,PHASE1,14.0,2006-08-28,2013-06-04,0.17239482200647252,Slow (<1/month),1.723948220064725,Significantly Below (<50%),10,19.1,4.9799999999999995
NCT01582529,SVRII Family Factors Study,COMPLETED,,187.0,2012-06-01,2019-11-14,2.0912123438648056,Adequate (1-10/month),20.912123438648056,Significantly Below (<50%),100,63.3,76.235
NCT03943329,Trial of a Distal Targeting System for Cephalomedullary Nails as Part of Surgical Repair of Hip and Femoral Shaft Fractures,COMPLETED,NA,60.0,2019-12-17,2021-03-07,4.095067264573991,Adequate (1-10/month),40.950672645739914,Significantly Below (<50%),100,54.8,61.095
NCT00884429,Effectiveness of Chest Physiotherapy in Infants With Acute Viral Bronchiolitis,COMPLETED,NA,33.0,2009-04-01,2010-04-01,2.7521095890410963,Adequate (1-10/month),27.52109589041096,Significantly Below (<50%),100,52.6,54.684999999999995
NCT05615129,Sequence and Time-of-day Infusion of immunoCHemotherapy Affect Response in Oesophageal Cancer in the NeOadjuvant Setting,COMPLETED,,350.0,2021-10-01,2022-10-30,27.04060913705584,Good (10-50/month),200.0,Exceeded (≥100%),100,81.3,88.58
NCT00377429,Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy,COMPLETED,PHASE2,47.0,2006-09-01,2008-02-01,2.761930501930502,Adequate (1-10/month),27.619305019305024,Significantly Below (<50%),100,53.8,58.065
NCT02510729,SPG Neurostimulation in Cluster Patients,COMPLETED,NA,21.0,2015-07-01,2016-10-01,1.3957205240174673,Adequate (1-10/month),13.957205240174671,Significantly Below (<50%),100,46.7,37.895
NCT04081129,Effect of Early Mobilization on Regional Lung Ventilation Assessed by EIT,UNKNOWN,,40.0,2019-01-01,2019-12-31,3.345054945054945,Adequate (1-10/month),33.45054945054945,Significantly Below (<50%),50,36.5,17.285
NCT06321029,Electronic Diabetes Tune-Up Group (eDTU) for African Americans,ACTIVE_NOT_RECRUITING,NA,60.0,2023-10-19,2026-03-31,2.0429530201342283,Adequate (1-10/month),20.42953020134228,Significantly Below (<50%),85,50.3,48.215
NCT06969729,Evaluation of Clinical Efficacy and Safety of Aortal Stent-Graft Created Using 3D Printing Technology,RECRUITING,PHASE2,100.0,2022-11-01,2027-04-30,1.8549664838513102,Adequate (1-10/month),18.549664838513106,Significantly Below (<50%),60,46.0,34.1
NCT01139229,Hybrid-everted Versus Hand-sewn or Stapled Esophagogastrostomy in Prevention of Anastomotic Stricture,COMPLETED,NA,144.0,2007-11-01,2008-09-01,14.371672131147543,Good (10-50/month),143.71672131147542,Exceeded (≥100%),100,66.5,79.405
NCT05414929,Acceptability of HPV Self-sampling Among Canadian Women Aged 21 to 65,UNKNOWN,NA,400.0,2022-04-04,2022-06-30,139.95402298850576,Excellent (>50/month),200.0,Exceeded (≥100%),50,77.0,85.475
NCT06414629,An Implementation Research of Simulation Based Mentorship Program,COMPLETED,NA,326.0,2020-11-01,2023-12-31,8.591722943722944,Adequate (1-10/month),85.91722943722944,Met (75-100%),100,81.1,88.24499999999999
NCT04836429,Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease,TERMINATED,PHASE1,5.0,2022-03-10,2025-01-03,0.14776699029126214,Slow (<1/month),1.4776699029126212,Significantly Below (<50%),10,18.4,3.855
NCT06243029,A Study to Assess Multidomain Endpoints of an ECG Patch,ACTIVE_NOT_RECRUITING,,67.0,2024-01-08,2026-02-27,2.611370038412292,Adequate (1-10/month),26.11370038412292,Significantly Below (<50%),85,49.2,46.035
NCT00922129,Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer,WITHDRAWN,PHASE2,0.0,2009-09-01,2011-01-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT06558929,Evaluating the Effectiveness of Intervention Based on the Model of Occupational Harmony in Patients With Sleep Disorders,ACTIVE_NOT_RECRUITING,NA,40.0,2024-11-01,2026-07-31,1.9114599686028257,Adequate (1-10/month),19.114599686028257,Significantly Below (<50%),85,48.7,44.93
NCT04498429,Effect of Integrated Cueing on Functional Transfers in Chronic Stroke Survivors,COMPLETED,NA,21.0,2020-11-06,2022-08-24,0.9744512195121952,Slow (<1/month),9.74451219512195,Significantly Below (<50%),100,46.7,37.895
NCT02851329,Therapeutic Resistance Prediction of Tyrosine Kinase Inhibitors,UNKNOWN,,500.0,2015-02-01,2017-07-01,17.275822928490353,Good (10-50/month),172.75822928490354,Exceeded (≥100%),50,78.3,86.48
NCT04603729,Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease,COMPLETED,PHASE3,100.0,2020-05-30,2020-07-01,95.125,Excellent (>50/month),200.0,Exceeded (≥100%),100,68.0,80.56
NCT00558129,Effects of X-STOP® Versus Laminectomy Study,WITHDRAWN,PHASE4,0.0,2007-11-01,2011-11-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT05602129,"A Clinical Study to Evaluate the Efficacy, Safety and PK/PD Profiles of Anticoagulation of HSK36273 for Injection in Continuous Renal Replacement Therapy Subjects",UNKNOWN,PHASE2,156.0,2022-11-01,2023-10-01,14.21748502994012,Good (10-50/month),142.17485029940121,Exceeded (≥100%),50,52.5,54.345
NCT02818829,Biological and Clinical Database for Pancreatic Adenocarcinoma,ACTIVE_NOT_RECRUITING,,1700.0,2014-05-01,2029-01-01,9.656279156559059,Adequate (1-10/month),96.56279156559059,Met (75-100%),85,88.8,92.89
NCT05050929,RAPid SimPLE Targeted Radiation Treatment for Brain Metastases,RECRUITING,PHASE2,100.0,2022-07-01,2027-12-30,1.51593625498008,Adequate (1-10/month),15.159362549800798,Significantly Below (<50%),60,41.0,23.01
NCT00967629,Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy,COMPLETED,PHASE1,20.0,2009-06-01,2010-02-01,2.4848979591836735,Adequate (1-10/month),24.848979591836738,Significantly Below (<50%),100,51.6,51.644999999999996
NCT00143429,Corneal Versus Conjunctival Delivery Using a Delivery Device,WITHDRAWN,PHASE2,0.0,,,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT00688129,KITS: School Readiness in Foster Care Efficacy Trial,COMPLETED,NA,192.0,2005-09-01,2016-12-31,1.4120512201014739,Adequate (1-10/month),14.120512201014737,Significantly Below (<50%),100,60.4,72.54
NCT06733129,Best Hypnotic Drug Choice for Rapid Sequence Induction in the Operating Room,RECRUITING,PHASE3,1218.0,2025-04-14,2027-04-30,49.69962466487936,Good (10-50/month),200.0,Exceeded (≥100%),60,88.0,92.495
NCT00568529,Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer,SUSPENDED,PHASE2,30.0,2007-10-01,2010-02-01,1.0693208430913348,Adequate (1-10/month),10.69320843091335,Significantly Below (<50%),20,23.4,6.7
NCT00602329,MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer,TERMINATED,PHASE2,5.0,2006-02-01,2009-10-01,0.11375186846038864,Slow (<1/month),1.1375186846038863,Significantly Below (<50%),10,18.4,3.855
NCT03357029,Neuromodulation in Patients With Painful Chronic Pancreatitis,COMPLETED,NA,28.0,2018-01-11,2019-04-30,1.7981434599156119,Adequate (1-10/month),17.981434599156117,Significantly Below (<50%),100,52.2,53.22
NCT05401929,Transcranial Magnetic Brain Stimulation to Reduce Cannabis Use in Heavy Cannabis Users,SUSPENDED,NA,50.0,2022-06-01,2029-07-01,0.5883262466177039,Slow (<1/month),5.883262466177039,Significantly Below (<50%),20,25.0,7.23
NCT03810131,Study Protocol for a Feasibility Study of a Novel ACT-based eHealth Psychoeducational Intervention for Students With Mental Distress,COMPLETED,NA,60.0,2022-07-01,2023-11-01,3.742622950819672,Adequate (1-10/month),37.42622950819672,Significantly Below (<50%),100,54.8,61.095
NCT02538731,Laser Lithotripsy for Difficult Large Bile Duct Stones,UNKNOWN,NA,150.0,2015-08-01,2016-12-01,9.35655737704918,Adequate (1-10/month),93.5655737704918,Met (75-100%),50,52.0,52.86
NCT05055531,"""Effects of the Vaccin Against COVID 19 in a Cohort of Dialysis Patients: Adverse Events and Immunological Response""",UNKNOWN,,60.0,2021-08-08,2023-06-01,2.7589123867069487,Adequate (1-10/month),27.589123867069492,Significantly Below (<50%),50,38.1,19.425
NCT04540731,Multicenter Registry of Nonalcoholic Fatty Liver Disease,UNKNOWN,,2000.0,2020-10-01,2025-10-01,33.34063526834611,Good (10-50/month),200.0,Exceeded (≥100%),50,78.3,86.48
NCT03599531,Utility of the SomaLogic Cardiovascular Disease (CVD) Secondary Risk Panel for Cardiovascular Risk,COMPLETED,,244.0,2017-06-13,2020-10-10,6.113053497942388,Adequate (1-10/month),61.13053497942387,Below (50-75%),100,67.9,80.36999999999999
NCT01726231,Evaluation of Abdominal Wall Lifting During Laparoscopic Direct Trocar Insertion,COMPLETED,,40.0,2012-11-01,2013-12-01,3.082531645569621,Adequate (1-10/month),30.825316455696207,Significantly Below (<50%),100,51.5,51.245
NCT00437931,Color Flow Doppler Ultrasound in Subclinical Thyroid Dysfunction,COMPLETED,,60.0,2007-02-01,2008-02-01,5.003835616438357,Adequate (1-10/month),50.03835616438357,Below (50-75%),100,53.1,56.105000000000004
NCT06267131,Transcutaneous Pulse Oximetry Brain Monitoring Study (US),RECRUITING,NA,15.0,2023-10-27,2024-11-01,1.2307277628032347,Adequate (1-10/month),12.307277628032347,Significantly Below (<50%),60,34.2,14.305000000000001
NCT02989831,The Effect of Random Vibrations on Perception and Balance,COMPLETED,NA,40.0,2014-04-01,2015-10-01,2.221897810218978,Adequate (1-10/month),22.21897810218978,Significantly Below (<50%),100,53.2,56.665
NCT06810531,Comparison Between Intravenous Ondanosteron and Metclopromide Versus Ondanesteron and Dexamethasone Effects on the Prevention of Postoperative Nausea and Vomiting in Cesarean Section,COMPLETED,PHASE4,108.0,2025-02-05,2025-07-01,22.517260273972603,Good (10-50/month),200.0,Exceeded (≥100%),100,63.6,76.545
NCT06702631,Nitrous Oxide Neuroimaging,RECRUITING,EARLY_PHASE1,60.0,2025-01-13,2026-06-01,3.623809523809524,Adequate (1-10/month),36.238095238095234,Significantly Below (<50%),60,42.8,25.929999999999996
NCT01021631,TRACS STUDY: Transfusion Requirements After Cardiac Surgery,UNKNOWN,PHASE3,500.0,2009-02-01,2010-04-01,35.89622641509434,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT05093231,Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer,RECRUITING,PHASE2,20.0,2025-02-26,2028-01-01,0.5859480269489895,Slow (<1/month),5.859480269489895,Significantly Below (<50%),60,34.6,14.729999999999999
NCT02489331,"Post Marketing Surveillance of Safety and Efficacy for Cholib in Korean Patients Under the ""New Drug Re-examination"".",COMPLETED,,193.0,2015-07-01,2020-11-10,2.9989382337927513,Adequate (1-10/month),29.989382337927513,Significantly Below (<50%),100,63.8,76.78
NCT03600831,Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma,COMPLETED,PHASE2,434.0,2018-08-20,2023-12-31,6.743726391015825,Adequate (1-10/month),67.43726391015824,Below (50-75%),100,84.7,90.78500000000001
NCT01732731,Effects of Intensive Locomotor Treadmill Training on Gross Motor Function in Young Children With Neuromotor Impairment,COMPLETED,NA,12.0,2009-04-01,2012-09-01,0.2924579663730985,Slow (<1/month),2.924579663730985,Significantly Below (<50%),100,46.0,34.1
NCT03028831,Fiber to Reduce Colon Cancer in Alaska Native People,COMPLETED,NA,48.0,2017-12-11,2022-12-31,0.7915059588299026,Slow (<1/month),7.915059588299026,Significantly Below (<50%),100,48.8,45.184999999999995
NCT00199602,Prophylaxis of Thrombosis With Implantable Devices for Central Venous Access in Cancer Patients,COMPLETED,PHASE3,420.0,1999-08-01,2010-12-01,3.0881159420289856,Adequate (1-10/month),30.881159420289855,Significantly Below (<50%),100,83.6,90.435
NCT05581602,Actimetry Monitoring of the Paretic Upper Limb in Chronic Post Stroke.,UNKNOWN,NA,66.0,2023-02-13,2025-08-20,2.1861153427638738,Adequate (1-10/month),21.861153427638737,Significantly Below (<50%),50,40.3,22.21
NCT00532402,Continuous and Discontinuous Determination of Propofol Concentration in Breathing Gas,COMPLETED,,16.0,2007-09-01,2010-12-01,0.4103117101937658,Slow (<1/month),4.103117101937658,Significantly Below (<50%),100,44.6,29.42
NCT00905502,Intraoperative Fluid Management in Laparoscopic Bariatric Surgery,COMPLETED,NA,107.0,2007-04-01,2008-12-01,5.339475409836066,Adequate (1-10/month),53.394754098360664,Below (50-75%),100,58.6,69.51
NCT00645502,Bioequivalence Study Comparing 2 Formulations for 4 mg Risperidone Tablet.,COMPLETED,PHASE1,40.0,2003-06-01,2003-07-01,40.0,Good (10-50/month),200.0,Exceeded (≥100%),100,58.2,68.795
NCT01672502,Fire Fighter Fatigue Management Program: Operation Fight Fatigue,COMPLETED,NA,620.0,2012-09-01,2014-05-01,31.09192751235585,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT03257202,Topical Treatment and Prevalence of P. Acnes,COMPLETED,PHASE2,12.0,2017-09-11,2018-01-01,3.2614285714285716,Adequate (1-10/month),32.614285714285714,Significantly Below (<50%),100,51.0,49.714999999999996
NCT04705402,Mannitol Use During Cadaveric Kidney Transplantation,UNKNOWN,NA,32.0,2022-02-01,2022-02-01,32.0,Good (10-50/month),200.0,Exceeded (≥100%),50,27.6,8.295
NCT05919602,Effectiveness of Images in Reducing Preoperative Anxiety,NOT_YET_RECRUITING,NA,167.0,2026-03-01,2027-05-01,11.933051643192488,Good (10-50/month),119.33051643192489,Exceeded (≥100%),30,47.4,40.98
NCT00311402,JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme,COMPLETED,PHASE3,1295.0,2006-04-01,,,Slow (<1/month),,Significantly Below (<50%),100,80.0,87.67
NCT05954702,Supercharged TRAM Evaluation in Cervical Esophagogastroplasty After Esophagectomy,RECRUITING,NA,60.0,2023-07-21,2026-10-01,1.5636986301369864,Adequate (1-10/month),15.636986301369863,Significantly Below (<50%),60,37.8,19.015
NCT02611102,Effect of Butter & MCT Oil on Lipoproteins - A RCT,COMPLETED,NA,80.0,2016-03-08,2022-03-01,1.115018315018315,Adequate (1-10/month),11.150183150183151,Significantly Below (<50%),100,51.4,50.92
NCT02290002,Calcium Dobesilate Versus Coasting for Prevention of Ovarian Hyperstimulation Syndrome,COMPLETED,PHASE2,200.0,2014-06-01,2016-12-01,6.660831509846827,Adequate (1-10/month),66.60831509846827,Below (50-75%),100,66.0,78.99000000000001
NCT03081702,"A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer",COMPLETED,PHASE1,13.0,2017-07-25,2019-08-27,0.5186369593709044,Slow (<1/month),5.186369593709044,Significantly Below (<50%),100,46.0,34.1
NCT00001202,Treatment of Boys With Precocious Puberty,COMPLETED,PHASE2,80.0,1985-01-01,2004-01-01,0.3509439400489984,Slow (<1/month),3.5094394004899847,Significantly Below (<50%),100,51.4,50.92
NCT00119002,The Effectiveness of Oral Dexamethasone for Acute Bronchiolitis,COMPLETED,PHASE4,598.0,2004-01-01,2006-04-01,22.171887941534713,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT06767202,Relationship Between Exposure to Phenols and Pregnancy Outcomes After Embryo Transfer,COMPLETED,,1200.0,2025-03-14,2025-07-01,335.1192660550459,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT06660602,Perioperative Cerebral Function Assessment for Cardiac Surgery,RECRUITING,,1845.0,2025-02-08,2028-07-01,45.32832929782083,Good (10-50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT02999802,Nutrient Sensing & Signaling in Aging Muscle,COMPLETED,NA,19.0,2015-10-01,2016-12-21,1.293870246085011,Adequate (1-10/month),12.938702460850113,Significantly Below (<50%),100,46.5,36.815
NCT05308602,A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 Years,WITHDRAWN,PHASE2,0.0,2022-04-01,2023-08-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT01941602,A Comparative Study of Prophylactic Anticoagulation in Meningioma Surgery,COMPLETED,,979.0,2013-08-01,2015-10-01,37.67479140328698,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT07161102,Effect of Foot Reflexology on Anxiety,ENROLLING_BY_INVITATION,NA,44.0,2025-07-30,2025-12-05,10.46375,Good (10-50/month),104.6375,Exceeded (≥100%),55,45.0,30.330000000000002
NCT00984802,Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy,COMPLETED,PHASE2,142.0,2010-02-01,2011-04-01,10.194528301886793,Good (10-50/month),101.94528301886794,Exceeded (≥100%),100,66.4,79.36999999999999
NCT06639802,Effects of Hand Arm Bimanual Intensive Therapy Including Lower Extremity on Balance and Coordination in Ataxic Cerebral Palsy,RECRUITING,NA,23.0,2024-04-10,2024-12-01,2.9792340425531916,Adequate (1-10/month),29.792340425531915,Significantly Below (<50%),60,39.8,21.47
NCT03941002,Continuous Evaluation of Diaphragm Function,UNKNOWN,NA,25.0,2019-09-30,2021-06-30,1.1909233176838812,Adequate (1-10/month),11.90923317683881,Significantly Below (<50%),50,32.0,11.425
NCT05242302,AIN Transfer for Cubital Tunnel Syndrome,COMPLETED,PHASE1,65.0,2019-01-01,2023-02-28,1.3025674786043449,Adequate (1-10/month),13.025674786043451,Significantly Below (<50%),100,50.2,48.04
NCT06288802,Study of Wilms Tumors Among Patients of Shefa Al-Orman Children Cancer Hospital,RECRUITING,,50.0,2020-06-15,2024-12-01,0.9337423312883436,Slow (<1/month),9.337423312883436,Significantly Below (<50%),60,35.3,15.534999999999998
NCT07237802,Online Pain Neuroscience Education for Women With Primary Dysmenorrhea,ENROLLING_BY_INVITATION,NA,82.0,2025-09-01,2026-02-28,13.867111111111111,Good (10-50/month),138.67111111111112,Exceeded (≥100%),55,48.1,43.275000000000006
NCT01152502,Paracetamol Metabolism in Post Operative Conditions,COMPLETED,,30.0,2008-06-01,2010-06-01,1.2509589041095892,Adequate (1-10/month),12.509589041095893,Significantly Below (<50%),100,45.7,32.5
NCT05398302,Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy,RECRUITING,PHASE1,30.0,2024-04-26,2026-12-31,0.9327885597548519,Slow (<1/month),9.327885597548518,Significantly Below (<50%),60,35.4,15.765
NCT01591902,Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®,TERMINATED,PHASE4,129.0,2012-06-01,2018-08-01,1.743676731793961,Adequate (1-10/month),17.43676731793961,Significantly Below (<50%),10,33.3,13.200000000000001
NCT04688502,Effects of Wearing a Face Mask During CrossFit Exercise,WITHDRAWN,NA,0.0,2022-06-11,2023-02-15,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT00481702,A Study to Evaluate the Safety and Effectiveness of Ertapenem Versus Ceftriaxone/Metronidazole in the Treatment of Intra-abdominal Infections in Adults (0826-802),COMPLETED,PHASE3,300.0,2001-12-01,2003-06-01,16.694698354661792,Good (10-50/month),166.94698354661793,Exceeded (≥100%),100,79.0,86.96000000000001
NCT00948402,"PED/PEA-15 Protein, PCOS, Obesity, Insulin Sensitivity Indexes, Metformin, Oral Contraceptives",COMPLETED,PHASE3,20.0,2006-12-01,2009-01-01,0.7989501312335959,Slow (<1/month),7.989501312335959,Significantly Below (<50%),100,46.6,37.375
NCT02113202,"Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CW",COMPLETED,PHASE1,17.0,2014-03-01,2015-10-01,0.8937478411053541,Slow (<1/month),8.93747841105354,Significantly Below (<50%),100,46.4,36.26
NCT05813002,Impact of Order of Movement on Nerve Root Function,UNKNOWN,NA,75.0,2023-04-01,2023-05-01,75.0,Excellent (>50/month),200.0,Exceeded (≥100%),50,51.0,49.714999999999996
NCT01321502,Bioequivalency Study of Famciclovir 500 mg Tablets Under Fed Conditions,COMPLETED,NA,31.0,2007-07-01,2007-07-01,31.0,Good (10-50/month),200.0,Exceeded (≥100%),100,42.5,25.585
NCT00860002,The Benefits and Limits of Laparoscopic Surgery for Uterine Fibroids,UNKNOWN,,1200.0,2009-01-01,2014-12-01,16.91111111111111,Good (10-50/month),169.11111111111111,Exceeded (≥100%),50,78.3,86.48
NCT01773902,Protein for Premies,COMPLETED,NA,60.0,2012-10-01,2016-07-01,1.3341124908692477,Adequate (1-10/month),13.341124908692478,Significantly Below (<50%),100,49.8,47.17
NCT06695702,Cancer Symptom Management in Nursing Students,COMPLETED,,100.0,2024-11-15,2025-01-01,64.76595744680851,Excellent (>50/month),200.0,Exceeded (≥100%),100,66.3,79.3
NCT04886102,"Molecular Epidemiology of Hepatitis B in Cayenne General Hospital, French Guiana",UNKNOWN,,400.0,2021-02-11,2022-02-01,34.29859154929578,Good (10-50/month),200.0,Exceeded (≥100%),50,70.3,82.09
NCT00505102,Safe Renal Function In Long Term Heart Transplanted Patients,UNKNOWN,PHASE4,200.0,2007-01-01,2009-07-01,6.675438596491229,Adequate (1-10/month),66.75438596491229,Below (50-75%),50,51.0,49.714999999999996
NCT03463902,Transcranial Direct Current Stimulation (tDCS) to Improve Gesture Control,TERMINATED,NA,32.0,2018-01-29,2024-03-22,0.43408199643493767,Slow (<1/month),4.340819964349377,Significantly Below (<50%),10,20.6,5.965
NCT01477502,Clinical Value of Homeopathic Prophylaxis of Recurrent Urinary Tract Infections in Persons With Spinal Cord Injury,COMPLETED,NA,46.0,2011-11-01,2016-10-01,0.7796436525612472,Slow (<1/month),7.796436525612473,Significantly Below (<50%),100,48.7,44.93
NCT01809002,Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve Repair,COMPLETED,PHASE3,220.0,2015-06-01,2021-08-30,2.934618755477651,Adequate (1-10/month),29.34618755477651,Significantly Below (<50%),100,67.6,80.15
NCT07134153,Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases,RECRUITING,PHASE1,139.0,2025-04-18,2027-02-28,6.213157121879589,Adequate (1-10/month),62.13157121879589,Below (50-75%),60,49.1,45.83
NCT01499953,Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux,COMPLETED,PHASE3,472.0,2012-04-01,2016-05-01,9.636270959087861,Adequate (1-10/month),96.36270959087861,Met (75-100%),100,92.8,93.865
NCT02260453,Coronary Angiography Before Elective Carotid Endarterectomy in Patients With Asymptomatic Coronary Artery Disease,COMPLETED,PHASE3,426.0,2005-01-01,2012-06-01,4.788567208271787,Adequate (1-10/month),47.885672082717875,Significantly Below (<50%),100,84.1,90.64999999999999
NCT05103553,What is the Optimal Follow-up for Patients With Systemic Sclerosis?,UNKNOWN,NA,250.0,2022-01-01,2026-01-01,5.208761122518823,Adequate (1-10/month),52.087611225188226,Below (50-75%),50,55.0,61.834999999999994
NCT02582853,sCD163 as a Potential Biomarker in Guillain- Barré Syndrome,UNKNOWN,,60.0,2015-09-01,2018-01-01,2.1411488862837045,Adequate (1-10/month),21.411488862837047,Significantly Below (<50%),50,38.1,19.425
NCT01960153,Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure: Extent of Renal Damage,WITHDRAWN,PHASE3,0.0,2013-10-01,2018-05-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT05856253,Enhanced Recovery in Esophageal Surgery,COMPLETED,,40.0,2019-06-01,2021-11-30,1.3336254107338446,Adequate (1-10/month),13.336254107338446,Significantly Below (<50%),100,46.5,36.815
NCT01169753,Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients,TERMINATED,NA,1.0,2011-05-01,2013-02-01,0.04741433021806854,Slow (<1/month),0.47414330218068546,Significantly Below (<50%),10,18.1,3.105
NCT04941053,Seroprevalence of COVID-19,COMPLETED,,300.0,2021-06-03,2021-12-30,43.48571428571429,Good (10-50/month),200.0,Exceeded (≥100%),100,82.3,89.115
NCT02906553,The Role of Nitric Oxide in Cognition in Schizophrenia,COMPLETED,NA,19.0,2016-09-01,2019-04-01,0.6139702760084925,Slow (<1/month),6.139702760084925,Significantly Below (<50%),100,46.5,36.815
NCT02798653,Evaluation of Different Luteal Phase Support Methods in Patients With Poor Ovarian Response,UNKNOWN,PHASE3,210.0,2015-11-01,2019-12-01,4.287323943661972,Adequate (1-10/month),42.87323943661972,Significantly Below (<50%),50,51.8,52.17
NCT06697353,An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan,COMPLETED,,4936.0,2024-11-01,2025-09-19,466.6206211180124,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT06074653,Effects of Mulligans BLR and CR on Hamstrings Flexibility in Office Workers,COMPLETED,NA,52.0,2023-10-03,2024-04-30,7.53752380952381,Adequate (1-10/month),75.3752380952381,Met (75-100%),100,54.2,59.330000000000005
NCT00245453,Outpatient Registry Trial of Respiratory Tract Infections in Adults,WITHDRAWN,PHASE4,0.0,2005-10-01,2006-07-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT05760053,Toripalimab Plus Etoposide and Platinum-based Chemotherapy for Genitourinary Small Cell Carcinoma,RECRUITING,PHASE2,33.0,2023-02-18,2026-02-18,0.9165328467153284,Slow (<1/month),9.165328467153284,Significantly Below (<50%),60,35.6,16.03
NCT05905653,Pharmacokinetic Study of STN1012600 Ophthalmic Solution in Healthy Adult Males Volunteers,COMPLETED,PHASE1,8.0,2023-05-25,2023-06-21,8.0,Adequate (1-10/month),80.0,Met (75-100%),100,55.6,62.905
NCT05061953,Development of a Novel Functional Eye-Tracking Software Application for Multiple Sclerosis,RECRUITING,,168.0,2021-10-18,2027-10-18,2.334057507987221,Adequate (1-10/month),23.34057507987221,Significantly Below (<50%),60,49.8,47.17
NCT06264453,A Study to Evaluate the Efficacy and Safety of KH001 in Patients with Dentin Hypersensitivity,COMPLETED,PHASE2,171.0,2024-03-19,2024-09-25,27.396,Good (10-50/month),200.0,Exceeded (≥100%),100,68.7,81.065
NCT05334953,"Efficacy of Extracorporeal Shock Wave Therapy, Ultrasound and Phonophoresis Treatments in Lateral Epicondylitis",COMPLETED,NA,68.0,2022-06-01,2023-01-06,9.451689497716895,Adequate (1-10/month),94.51689497716896,Met (75-100%),100,60.4,72.54
NCT03689153,A Study of JNJ-63733657 in Healthy Japanese Participants,COMPLETED,PHASE1,24.0,2018-09-28,2019-07-11,2.5544055944055946,Adequate (1-10/month),25.544055944055945,Significantly Below (<50%),100,51.9,52.55499999999999
NCT01113853,Daily Monitoring of Exhaled Nitric Oxide in Asthmatic Patients,COMPLETED,,40.0,2007-01-01,2010-01-01,1.110948905109489,Adequate (1-10/month),11.10948905109489,Significantly Below (<50%),100,46.5,36.815
NCT01100437,Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients,TERMINATED,PHASE4,14.0,2010-04-01,2011-03-01,1.275928143712575,Adequate (1-10/month),12.759281437125747,Significantly Below (<50%),10,19.1,4.9799999999999995
NCT07258537,Modified Sims Versus Lumbar Roll Manipulation in Patients With Sacroiliac Joint Dysfunction,ENROLLING_BY_INVITATION,NA,60.0,2024-08-22,2025-12-22,3.7503080082135525,Adequate (1-10/month),37.503080082135526,Significantly Below (<50%),55,41.3,23.74
NCT03354637,A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata,TERMINATED,PHASE2,129.0,2017-11-29,2019-09-10,6.041169230769231,Adequate (1-10/month),60.41169230769231,Below (50-75%),10,33.3,13.200000000000001
NCT03547037,"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers",COMPLETED,PHASE1,22.0,2018-08-31,2022-07-04,0.477320028510335,Slow (<1/month),4.77320028510335,Significantly Below (<50%),100,46.8,38.440000000000005
NCT03038737,Comparative Study of Biting Force of Injection Molded PEEK and Bre.Flex for Removable Partial Dentures.,UNKNOWN,NA,20.0,2017-03-01,2017-10-01,2.8448598130841125,Adequate (1-10/month),28.448598130841123,Significantly Below (<50%),50,36.6,17.41
NCT03667937,Effectiveness of a Hydrophobic Dressing for Microorganisms' Colonization and Infection Control of Vascular Ulcers,UNKNOWN,PHASE4,204.0,2019-05-15,2021-04-30,8.672849162011174,Adequate (1-10/month),86.72849162011174,Met (75-100%),50,56.3,64.5
NCT05325437,The Effect of Laparoscopic Splenectomy and Azygoportal Disconnection on Liver Reserve Function for Cirrhosis Patients,RECRUITING,NA,20.0,2022-03-01,2025-07-31,0.4878205128205128,Slow (<1/month),4.878205128205129,Significantly Below (<50%),60,34.6,14.729999999999999
NCT02618837,Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers,UNKNOWN,PHASE4,2520.0,2015-12-14,2022-08-01,31.671676300578035,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT03878537,Recurrence Monitoring in NSCLC Using Circulating Tumor DNA,UNKNOWN,,50.0,2019-03-14,2021-12-31,1.4877810361681332,Adequate (1-10/month),14.877810361681329,Significantly Below (<50%),50,32.3,11.799999999999999
NCT02243137,Study of Platelet Function After Administration of Aspirin Versus Lysine Acetylsalicylate,COMPLETED,PHASE1,30.0,2013-05-01,2014-06-01,2.306060606060606,Adequate (1-10/month),23.060606060606062,Significantly Below (<50%),100,52.4,53.949999999999996
NCT01506037,Bioequivalence Study for Desloratadine OD Tablets 5 mg Under Fed Condition,COMPLETED,PHASE1,36.0,2006-01-01,2006-02-01,35.34967741935484,Good (10-50/month),200.0,Exceeded (≥100%),100,57.9,67.83
NCT05940337,FIT to Grow Old - Functionality of the Immune System and Healthy Aging,COMPLETED,,156.0,2020-11-11,2023-07-31,4.786935483870968,Adequate (1-10/month),47.869354838709675,Significantly Below (<50%),100,60.8,72.99
NCT00394537,Labetalol to Prevent Hypertension and Tachycardia During Fiberoptic Bronchoscopy,COMPLETED,PHASE4,72.0,,2007-05-01,,Slow (<1/month),,Significantly Below (<50%),100,45.8,33.03
NCT04813237,Clinical Implications of Fetal Positioning During Delivery,UNKNOWN,,300.0,2021-03-31,2021-12-30,33.32846715328467,Good (10-50/month),200.0,Exceeded (≥100%),50,62.3,74.94
NCT00728637,Evaluating the Effectiveness of a Family Heart Health Educational Program (The FIT-Heart Study),COMPLETED,NA,501.0,2005-01-01,2008-06-01,12.22970328789094,Good (10-50/month),122.2970328789094,Exceeded (≥100%),100,95.0,95.7
NCT02573337,Perception of Facial Expressions Following Correction of Wrinkles and Folds,COMPLETED,PHASE4,63.0,2015-10-01,2017-01-01,4.187161572052402,Adequate (1-10/month),41.87161572052402,Significantly Below (<50%),100,55.0,61.834999999999994
NCT02536937,A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate,COMPLETED,PHASE1,32.0,2015-09-01,2017-01-01,1.9960655737704918,Adequate (1-10/month),19.960655737704915,Significantly Below (<50%),100,52.6,54.684999999999995
NCT04004637,"CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia",UNKNOWN,PHASE1,10.0,2019-08-25,2021-06-01,0.47120743034055734,Slow (<1/month),4.712074303405573,Significantly Below (<50%),50,30.8,9.745
NCT01976637,Compression Treatment of Superficial Vein Thrombosis,COMPLETED,NA,80.0,2009-12-01,2013-11-01,1.7017470300489168,Adequate (1-10/month),17.01747030048917,Significantly Below (<50%),100,56.4,64.88000000000001
NCT06275737,"POP-UP: a Single-arm, Two-cohort Study: Trimodal Prehab for Upper GI and Pancreatic Cancer",RECRUITING,NA,72.0,2024-06-24,2028-06-01,1.5241168289290683,Adequate (1-10/month),15.241168289290682,Significantly Below (<50%),60,38.8,20.244999999999997
NCT04637737,Effect of Anterioposterior Weight Shifting Training With Visual Biofeedback in Subacute Stroke,UNKNOWN,NA,50.0,2014-10-01,2021-06-01,0.6250513347022588,Slow (<1/month),6.250513347022587,Significantly Below (<50%),50,34.0,14.02
NCT04059237,Pilot Study of a Decision Aid Intervention for Family-building After Cancer,COMPLETED,NA,102.0,2020-01-06,2022-12-11,2.9017570093457943,Adequate (1-10/month),29.017570093457945,Significantly Below (<50%),100,58.2,68.795
NCT06516237,Development of Novel Imaging and Molecular Biomarkers of Fibrosis in Patient With Ulcerative Colitis,RECRUITING,NA,50.0,2024-11-21,2026-07-31,2.46677471636953,Adequate (1-10/month),24.6677471636953,Significantly Below (<50%),60,42.0,24.825
NCT01760837,Oral Immunotherapy With Baked Milk Products for Patients Allergic to Cow's Milk - A Multicenter Study,COMPLETED,NA,75.0,2013-02-01,2015-11-01,2.2761714855433697,Adequate (1-10/month),22.7617148554337,Significantly Below (<50%),100,56.0,63.71
NCT05351437,To Assess the Safety and Tolerability of MTx-COVAB36 as a Therapeutic and Prophylactic Treatment Against COVID-19.,COMPLETED,PHASE1,32.0,2022-04-26,2022-11-02,5.126736842105263,Adequate (1-10/month),51.26736842105263,Below (50-75%),100,52.6,54.684999999999995
NCT04429737,"The Effects of Freshwater Clam Extract on Blood Sugar, and Lipid Profile in Prediabetes Patients",UNKNOWN,NA,180.0,2017-03-01,2022-03-01,3.0006571741511503,Adequate (1-10/month),30.0065717415115,Significantly Below (<50%),50,49.4,46.42
NCT07188337,Characteristics of Diabetic Foot Ulcer Patients,RECRUITING,,200.0,2025-07-27,2025-11-01,62.76288659793815,Excellent (>50/month),200.0,Exceeded (≥100%),60,62.3,74.94
NCT00038337,Improving Functional Health Literacy in Older Veterans,COMPLETED,PHASE2,240.0,2001-04-01,2004-05-01,6.48809946714032,Adequate (1-10/month),64.88099467140319,Below (50-75%),100,69.2,81.28
NCT00464945,Wyeth Study To Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants,COMPLETED,PHASE3,269.0,2007-06-01,2008-09-01,17.878515283842795,Good (10-50/month),178.78515283842796,Exceeded (≥100%),100,76.5,85.3
NCT04598945,Acquisition and Retention of Motor Memories in Adults and Typically Developing Children,UNKNOWN,NA,60.0,2020-10-20,2022-11-01,2.4614555256064694,Adequate (1-10/month),24.614555256064694,Significantly Below (<50%),50,39.8,21.47
NCT03408145,Stem Cell and Growth Factor Injury and Arthritis Clinical Research Study,COMPLETED,NA,88.0,2018-01-04,2020-10-10,2.6521980198019803,Adequate (1-10/month),26.521980198019808,Significantly Below (<50%),100,57.0,66.12
NCT01684345,Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis,TERMINATED,PHASE3,200.0,2012-08-01,,,Slow (<1/month),,Significantly Below (<50%),10,29.0,8.76
NCT06606145,Reduction of Arm Volume and Improvement in Lymphedema Via Surgery,COMPLETED,NA,179.0,2011-01-01,2022-12-01,1.2520128676470588,Adequate (1-10/month),12.520128676470588,Significantly Below (<50%),100,59.3,70.815
NCT06296745,Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.,RECRUITING,PHASE2,36.0,2025-09-01,2027-03-20,1.9395398230088499,Adequate (1-10/month),19.3953982300885,Significantly Below (<50%),60,40.9,22.82
NCT06017245,The Bone-Myoregulation Reflex and Development of Sarcopenia in Osteoporosis,COMPLETED,NA,60.0,2023-08-29,2023-12-29,14.970491803278687,Good (10-50/month),149.70491803278688,Exceeded (≥100%),100,59.8,71.61
NCT04052945,"Efficacy, Safety and Underlying Mechanisms of Sphenopalatine Ganglion Acupuncture for Seasonal Allergic Rhinitis",UNKNOWN,NA,70.0,2020-03-25,2022-12-31,2.107616221562809,Adequate (1-10/month),21.07616221562809,Significantly Below (<50%),50,40.6,22.575
NCT01655745,Positron Emission Tomography (PET) Study for Staging of Muscle Invasive Bladder Cancer,COMPLETED,NA,22.0,2012-07-24,2019-02-01,0.2810239194292908,Slow (<1/month),2.810239194292908,Significantly Below (<50%),100,46.8,38.440000000000005
NCT06169345,The Long-term Course of Moderate Tricuspid Regurgitation,COMPLETED,,250.0,2021-05-01,2023-02-01,11.872074882995319,Good (10-50/month),118.72074882995318,Exceeded (≥100%),100,73.3,83.61
NCT02563145,Real-time fMRI for the Treatment of Aggressive Behavior in Adolescents,COMPLETED,NA,37.0,2015-10-01,2019-07-01,0.8227027027027027,Slow (<1/month),8.227027027027027,Significantly Below (<50%),100,48.0,42.945
NCT03835845,A Clinical Study to Assess the Safety and Clinical Performance of a New Dressing (PICO7Y) in Breast Surgery Patients,COMPLETED,NA,40.0,2019-03-08,2020-02-29,3.4011173184357544,Adequate (1-10/month),34.011173184357546,Significantly Below (<50%),100,53.2,56.665
NCT05485545,Asynchrony in Operated Tetralogy of Fallot,UNKNOWN,NA,30.0,2022-09-01,2024-09-01,1.249247606019152,Adequate (1-10/month),12.49247606019152,Significantly Below (<50%),50,32.4,12.025
NCT03620045,An Exercise Intervention to Improve the Eating Patterns of Preadolescent Children at High Risk for Obesity,COMPLETED,NA,92.0,2017-06-14,2021-08-04,1.8521693121693121,Adequate (1-10/month),18.521693121693122,Significantly Below (<50%),100,57.4,67.05499999999999
NCT03348345,"Efficacy of Eat Breathe Thrive, a Yoga-Based Program",COMPLETED,NA,266.0,2018-01-31,2019-10-04,13.252111292962358,Good (10-50/month),132.52111292962357,Exceeded (≥100%),100,76.3,85.1
NCT00640445,Military to Civilian: Trial of an Intervention to Promote Postdeployment Reintegration,COMPLETED,PHASE2,1292.0,2011-06-01,2013-09-01,47.78673147023087,Good (10-50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT06091345,Midodrine Plus Albumin Versus Midodrine Alone to Prevent Cirrhosis Related Complications in Children With Cirrhosis and Ascites,RECRUITING,NA,60.0,2023-11-02,2025-12-31,2.3118987341772153,Adequate (1-10/month),23.11898734177215,Significantly Below (<50%),60,42.8,25.929999999999996
NCT04650945,"In-hospital Diabetes Management With Flash Glucose Monitoring (isCGM) - the INDIGO Study, Part A",TERMINATED,NA,13.0,2021-01-04,2022-11-16,0.5810866372980911,Slow (<1/month),5.81086637298091,Significantly Below (<50%),10,19.0,4.84
NCT03162445,Bone Mass Accrual in Children With Autism Spectrum Disorder,COMPLETED,,49.0,2010-01-11,2016-01-01,0.6838881247134342,Slow (<1/month),6.838881247134341,Significantly Below (<50%),100,47.3,40.475
NCT03610945,"Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers",COMPLETED,PHASE1,48.0,2018-07-19,2018-08-21,44.276363636363634,Good (10-50/month),200.0,Exceeded (≥100%),100,63.8,76.78
NCT01923545,Phase II Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia,COMPLETED,PHASE2,61.0,2010-07-01,2011-05-01,6.108026315789473,Adequate (1-10/month),61.08026315789474,Below (50-75%),100,54.9,61.55500000000001
NCT03254745,Evaluation of Pharmacist's Intervention in Improving Treatment Outcomes of Rheumatoid Arthritis: A Randomized Controlled Trial,COMPLETED,NA,400.0,2017-12-19,2018-08-17,50.52282157676349,Excellent (>50/month),200.0,Exceeded (≥100%),100,92.0,93.78999999999999
NCT06214845,Early-goal Directed Automated Red Blood Cell Exchange for Acute Chest Syndrome in Sickle Cell Disease,NOT_YET_RECRUITING,NA,130.0,2024-03-01,2026-09-01,4.3295404814004375,Adequate (1-10/month),43.29540481400438,Significantly Below (<50%),30,39.4,20.94
NCT02923245,POCUS Assessment of Bladder Fullness for Girls Awaiting Radiology-Performed Transabdominal Pelvic Ultrasound,COMPLETED,NA,120.0,2015-09-01,2016-11-05,8.475174013921114,Adequate (1-10/month),84.75174013921114,Met (75-100%),100,64.6,77.59
NCT06157645,Prophylactic Mesh Reinforcement for Stoma Closure,COMPLETED,NA,62.0,2024-09-01,2025-09-01,5.1706301369863015,Adequate (1-10/month),51.70630136986302,Below (50-75%),100,55.0,61.834999999999994
NCT03874845,Neural Mechanisms of Mindfulness-based Cognitive Therapy (MBCT) for Posttraumatic Stress Disorder (PTSD)_VA Only,WITHDRAWN,NA,0.0,2022-01-29,2023-06-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT07045545,A Multicenter Randomized Controlled Trial Comparing Platelet-Rich Fibrin and Ventral Dartos Flap as Intermediate Layers in Tabularized Incised Plate (TIP) Urethroplasty for Distal Hypospadias With Mild Penile Curvature,ENROLLING_BY_INVITATION,NA,5.0,2025-06-05,2026-06-05,0.41698630136986303,Slow (<1/month),4.16986301369863,Significantly Below (<50%),55,31.9,11.295
NCT01916772,Natural History of Cherubism Observational Study,COMPLETED,,33.0,2013-07-01,2016-09-01,0.8674611398963731,Slow (<1/month),8.67461139896373,Significantly Below (<50%),100,46.0,34.1
NCT02309372,Depression Therapy to Improve Cardiovascular Risk in HIV,COMPLETED,NA,54.0,2015-04-01,2019-04-01,1.1250924024640656,Adequate (1-10/month),11.250924024640657,Significantly Below (<50%),100,49.3,46.265
NCT07287072,Pain Reprocessing Therapy for Chronic Primary Pain,NOT_YET_RECRUITING,NA,12.0,2026-02-01,2026-12-31,1.096936936936937,Adequate (1-10/month),10.969369369369371,Significantly Below (<50%),30,25.0,7.23
NCT05017272,Technology for MAT in Primary Care - Phase 2,COMPLETED,NA,246.0,2021-05-01,2023-08-31,8.789014084507043,Adequate (1-10/month),87.89014084507043,Met (75-100%),100,74.7,84.33500000000001
NCT04629872,Fingolimod in Endovascular Treatment of Ischemic Stroke,UNKNOWN,PHASE2,30.0,2020-11-12,2023-12-30,0.7989501312335959,Slow (<1/month),7.989501312335959,Significantly Below (<50%),50,32.4,12.025
NCT02873572,Vulnerability Markers in Pathological Gambling,UNKNOWN,NA,80.0,2010-04-01,2017-12-01,0.8694037843627277,Slow (<1/month),8.694037843627276,Significantly Below (<50%),50,36.4,17.14
NCT06525272,"A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of OsrhCT in Patients With Pleurisy",NOT_YET_RECRUITING,PHASE1,72.0,2024-07-01,2025-12-01,4.231042471042471,Adequate (1-10/month),42.31042471042471,Significantly Below (<50%),30,34.8,15.040000000000001
NCT02750072,INfrapatellar Versus SUprapatellar Reamed Intramedullary Nailing for Fractures of the Tibia,COMPLETED,NA,248.0,2016-09-13,2023-10-12,2.9203558994197296,Adequate (1-10/month),29.203558994197294,Significantly Below (<50%),100,69.8,81.785
NCT02157272,Rivaroxaban in Thrombotic Antiphospholipid Syndrome,TERMINATED,PHASE3,121.0,2014-12-01,2018-01-25,3.200034752389227,Adequate (1-10/month),32.00034752389227,Significantly Below (<50%),10,32.7,12.370000000000001
NCT05428072,"Alcohol, Gut Leakiness, & Liver Disease",COMPLETED,EARLY_PHASE1,195.0,2003-01-01,2015-03-01,1.336289959477713,Adequate (1-10/month),13.362899594777128,Significantly Below (<50%),100,60.6,72.785
NCT01372072,A Study to Investigate the Effects of Heated Humidification During Non-Invasive Ventilation,COMPLETED,NA,15.0,2012-02-01,2014-09-30,0.4697530864197531,Slow (<1/month),4.697530864197532,Significantly Below (<50%),100,46.2,35.089999999999996
NCT01580072,Telemonitoring of Patients With COPD in Carinthia,COMPLETED,NA,65.0,2010-02-01,2014-02-01,1.354277891854894,Adequate (1-10/month),13.54277891854894,Significantly Below (<50%),100,50.2,48.04
NCT01320072,Diagnosis of Aspirin Hypersensitivity in Aspirin Exacerbated Respiratory Disease,TERMINATED,,29.0,2010-05-01,2022-05-26,0.20026315789473684,Slow (<1/month),2.0026315789473688,Significantly Below (<50%),10,18.7,4.455
NCT00946972,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of JNJ-38431055 in Volunteers With Type 2 Diabetes Mellitus",TERMINATED,PHASE1,33.0,2009-07-01,2009-11-01,8.166829268292682,Adequate (1-10/month),81.66829268292683,Met (75-100%),10,25.6,7.595000000000001
NCT04195672,NIPE as an Indicator of Pain in Sedated/Ventilated Patient Under 3 Years-old Hospitalized in Intensive Care Unit,COMPLETED,,32.0,2017-11-01,2019-04-30,1.7873027522935783,Adequate (1-10/month),17.873027522935782,Significantly Below (<50%),100,50.9,49.370000000000005
NCT05079672,"Efficacy and Safety of Dexmedetomidine in the Analgesic Prophylaxis , in Patients Undergoing Cardiovascular Surgery",UNKNOWN,PHASE4,102.0,2021-10-07,2023-10-10,4.235852660300137,Adequate (1-10/month),42.35852660300136,Significantly Below (<50%),50,43.2,26.840000000000003
NCT02708472,Safety and Efficacy of Synchronized Transcranial Magnetic Stimulation for the Treatment of Generalized Anxiety Disorder,WITHDRAWN,NA,0.0,2016-04-01,2018-01-22,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT00044772,Study Evaluating Venlafaxine ER in Patients With Panic Disorder,COMPLETED,PHASE3,653.0,2001-11-01,2003-04-01,38.52193798449612,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT02075372,CrossBoss and Hybrid Registry on Coronary Chronic Total Occlusions,COMPLETED,,1177.0,2014-01-01,2017-01-01,32.68967153284672,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT05132595,Esketamine vs. Ketorolac for Prevention of Postoperative Pain and Cognitive Dysfunction After Total Knee Arthroplasty,UNKNOWN,NA,160.0,2021-11-30,2022-07-30,20.125619834710744,Good (10-50/month),200.0,Exceeded (≥100%),50,52.8,55.31
NCT03898895,COmbination of Radiotherapy With Anti-PD-1 Antibody for unREseCtable Biliary Tract Cancer,UNKNOWN,PHASE2,36.0,2019-12-10,2024-11-01,0.6128859060402685,Slow (<1/month),6.128859060402685,Significantly Below (<50%),50,32.9,12.53
NCT06831695,Comparison of Surgical Outcomes of Craniotomy and Craniectomy in Posterior Fossa Lesions,NOT_YET_RECRUITING,NA,80.0,2025-03-04,2026-03-01,6.72707182320442,Adequate (1-10/month),67.2707182320442,Below (50-75%),30,35.4,15.765
NCT04437095,Positive Suggestions Via MP3 Messages,COMPLETED,NA,149.0,2020-08-17,2025-02-07,2.7740428134556576,Adequate (1-10/month),27.740428134556574,Significantly Below (<50%),100,61.9,74.265
NCT06754995,Diagnostic Feasibility of 100 Hz Tetanic Stimulation,RECRUITING,,40.0,2025-01-06,2027-12-31,1.1180899908172637,Adequate (1-10/month),11.180899908172636,Significantly Below (<50%),60,34.5,14.52
NCT00150995,Tetrathiomolybdate in Hormone Refractory Prostate Cancer,COMPLETED,PHASE2,19.0,2001-05-01,2006-04-01,0.32202672605790644,Slow (<1/month),3.2202672605790648,Significantly Below (<50%),100,46.5,36.815
NCT06195995,Brain Mechanism and Intervention of Executive-control Dysfunction Among Gambling Disorder,UNKNOWN,NA,20.0,2024-01-15,2025-12-31,0.8502793296089386,Slow (<1/month),8.502793296089386,Significantly Below (<50%),50,31.6,10.905
NCT03335995,Stroke Prognosis in Intensive CarE,COMPLETED,,364.0,2017-10-18,2020-11-18,9.831552795031056,Adequate (1-10/month),98.31552795031058,Met (75-100%),100,82.5,89.165
NCT06047795,Endurance Training in Patients With Post-TB Lung Disease,COMPLETED,NA,36.0,2023-09-11,2024-06-30,3.740068259385666,Adequate (1-10/month),37.40068259385666,Significantly Below (<50%),100,52.9,55.55
NCT04793295,Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects,COMPLETED,PHASE1,112.0,2021-03-23,2022-02-04,10.721006289308177,Good (10-50/month),107.21006289308175,Exceeded (≥100%),100,64.0,77.025
NCT00338195,Assessment and Treatment of Caffeine Dependence,COMPLETED,PHASE1,94.0,2001-05-01,2009-12-01,0.9124234693877551,Slow (<1/month),9.124234693877552,Significantly Below (<50%),100,52.5,54.345
NCT03519295,A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma,COMPLETED,PHASE2,97.0,2018-07-03,2023-09-20,1.5499632545931759,Adequate (1-10/month),15.499632545931757,Significantly Below (<50%),100,52.8,55.31
NCT06897995,Aerobic Exercise on Platelet Mitochondrial Function,COMPLETED,NA,36.0,2023-07-01,2024-05-31,3.271164179104478,Adequate (1-10/month),32.71164179104478,Significantly Below (<50%),100,52.9,55.55
NCT00023595,Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease,COMPLETED,PHASE3,2136.0,2002-01-01,2015-11-01,12.870118764845607,Good (10-50/month),128.70118764845606,Exceeded (≥100%),100,95.0,95.7
NCT02368795,Non-inferiority of Pharmacological Prevention Alone Versus Pancreatic Stents to Prevent Post-ERCP Pancreatitis,UNKNOWN,NA,400.0,2015-02-01,,,Slow (<1/month),,Significantly Below (<50%),50,57.0,66.12
NCT04695795,Sea Water in Allergic Conjunctivitis,UNKNOWN,,50.0,2021-02-01,2022-12-01,2.2784431137724552,Adequate (1-10/month),22.78443113772455,Significantly Below (<50%),50,37.3,18.35
NCT01439295,Ascorbyl Peroxide Association With Bronchopulmonary Dysplasia,COMPLETED,,51.0,2010-08-01,2015-11-01,0.809405630865485,Slow (<1/month),8.094056308654848,Significantly Below (<50%),100,47.4,40.98
NCT00880139,Study Investigating the Levels and Effects of Low-grade Inflammation in Diabetic Retinopathy of Type 1 Diabetes,TERMINATED,,33.0,2009-06-01,2012-09-01,0.8455555555555556,Slow (<1/month),8.455555555555556,Significantly Below (<50%),10,19.0,4.84
NCT07218939,Universal Biospecimen Collection Protocol for Extra Material From Clinical Pulmonary Procedures,RECRUITING,,12000.0,2025-10-08,2032-12-01,139.9004212945232,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT05921539,Does Axillary Nerve and Inferior Capsule Release Add Extra Benefit in Treating Patients With Adhesive Capsulitis,UNKNOWN,NA,72.0,2021-12-01,2025-03-01,1.8479595278246208,Adequate (1-10/month),18.479595278246208,Significantly Below (<50%),50,40.8,22.745
NCT00327639,Factors Promoting Increased Rate and Success of Pregnancy in the Thalassemia Population in Toronto,UNKNOWN,,50.0,2005-07-01,,,Slow (<1/month),,Significantly Below (<50%),50,27.3,8.155
NCT03832439,Probiotic Supplementation on Weight Loss,COMPLETED,NA,18.0,2019-01-17,2021-04-28,0.6585576923076923,Slow (<1/month),6.585576923076923,Significantly Below (<50%),100,46.4,36.26
NCT02788539,Our Whole Lives: Online Chronic Pain Management,COMPLETED,NA,43.0,2016-06-01,2018-01-01,2.2606563039723664,Adequate (1-10/month),22.606563039723664,Significantly Below (<50%),100,53.4,57.35
NCT07291739,A Clinical Evaluation of a Phakic Intraocular Lens,COMPLETED,NA,47.0,2022-08-22,2024-10-18,1.8155837563451778,Adequate (1-10/month),18.155837563451776,Significantly Below (<50%),100,53.8,58.065
NCT04400539,The IMmunotherapy Pleural 5-ALA PDT,RECRUITING,PHASE2,20.0,2022-05-09,2026-05-09,0.4167008898015058,Slow (<1/month),4.167008898015058,Significantly Below (<50%),60,34.6,14.729999999999999
NCT06624839,Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV,RECRUITING,PHASE2,120.0,2025-03-15,2028-01-01,3.5741682974559685,Adequate (1-10/month),35.74168297455969,Significantly Below (<50%),60,47.6,41.775
NCT04573439,Protein Requirements for Active Children,RECRUITING,NA,30.0,2021-08-16,2026-07-01,0.5130337078651686,Slow (<1/month),5.130337078651685,Significantly Below (<50%),60,35.4,15.765
NCT02603939,Understanding Pain Perception in Osteoarthritis,UNKNOWN,,250.0,2013-06-01,2022-12-01,2.1930835734870318,Adequate (1-10/month),21.930835734870318,Significantly Below (<50%),50,53.3,57.14
NCT05228639,COVID-19 Surveillance in Rural Mozambique for Prompt and Effective Response,COMPLETED,,6494.0,2020-12-01,2022-08-31,309.8391222570533,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT01238939,Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer,COMPLETED,PHASE1,35.0,2010-08-01,2014-03-01,0.8145259938837921,Slow (<1/month),8.14525993883792,Significantly Below (<50%),100,47.8,42.42
NCT04518839,"The Comparison of Cognition, Depression and Anxiety, and Quality of Life After Hip Fracture Surgery Under General or Regional Anesthesia",UNKNOWN,,140.0,2020-08-01,2021-09-01,10.761616161616162,Good (10-50/month),107.6161616161616,Exceeded (≥100%),50,49.5,46.58
NCT01976039,Rhinopharyngeal Retrograde Clearance is Effective to Adequate Upper Airways Function in Adults,COMPLETED,NA,24.0,2012-07-01,2012-08-01,23.566451612903226,Good (10-50/month),200.0,Exceeded (≥100%),100,56.9,65.89500000000001
NCT00176839,Stem Cell Transplantation for Hematological Malignancies,TERMINATED,PHASE2,11.0,2000-06-07,2012-02-01,0.07867481203007519,Slow (<1/month),0.7867481203007518,Significantly Below (<50%),10,18.9,4.6899999999999995
NCT06231277,Phase I Clinical Trial of BH002 in Patients With Advanced Solid Tumors,COMPLETED,PHASE1,12.0,2022-04-26,2023-03-31,1.0775221238938053,Adequate (1-10/month),10.775221238938054,Significantly Below (<50%),100,46.0,34.1
NCT06903377,Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer,RECRUITING,PHASE1,50.0,2025-05-23,2027-05-01,2.1497175141242937,Adequate (1-10/month),21.497175141242938,Significantly Below (<50%),60,42.0,24.825
NCT00750477,Efficacy & Safety Study Evaluating Natural Eggshell Membrane (NEM) in the Treatment of Osteoarthritis,COMPLETED,NA,67.0,2004-12-01,2006-05-01,3.9524806201550384,Adequate (1-10/month),39.52480620155039,Significantly Below (<50%),100,55.4,62.56
NCT02596477,Evaluation of Vepoloxamer in Chronic Heart Failure,TERMINATED,PHASE2,10.0,2015-10-01,,,Slow (<1/month),,Significantly Below (<50%),10,13.8,0.83
NCT02339077,Group B Streptococcus (GBS) Associated Stillbirths in a High Burden Setting,COMPLETED,,354.0,2014-10-01,2015-12-01,25.295211267605634,Good (10-50/month),200.0,Exceeded (≥100%),100,81.7,88.97
NCT03026777,Preventing Cardiovascular collaPse With Administration of Fluid Resuscitation Before Endotracheal Intubation,COMPLETED,PHASE4,337.0,2017-01-01,2018-01-01,28.10487671232877,Good (10-50/month),200.0,Exceeded (≥100%),100,82.0,89.05499999999999
NCT06068777,The Impact of Aromatherapy on Alleviating Dental Anxiety in Children,COMPLETED,NA,45.0,2022-03-23,2022-08-21,9.071523178807947,Adequate (1-10/month),90.71523178807946,Met (75-100%),100,58.6,69.51
NCT06296277,Mechanical Ventilation in Surgical Patients,NOT_YET_RECRUITING,,10000.0,2025-09-01,2027-03-01,557.5091575091576,Excellent (>50/month),200.0,Exceeded (≥100%),30,77.3,85.67
NCT00877877,Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.,COMPLETED,PHASE3,632.0,2009-05-07,2015-01-06,9.29375845410628,Adequate (1-10/month),92.9375845410628,Met (75-100%),100,95.0,95.7
NCT06025877,Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey,ACTIVE_NOT_RECRUITING,,400.0,2023-11-15,2025-04-30,22.887218045112782,Good (10-50/month),200.0,Exceeded (≥100%),85,80.8,88.215
NCT00001477,Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy,COMPLETED,,300.0,1995-08-01,2000-10-01,4.836864406779661,Adequate (1-10/month),48.36864406779661,Significantly Below (<50%),100,72.3,83.065
NCT01117077,The Immune Tolerance Mechanism Induced by IL-17-producing Regulatory T Cells in the Orthotopic Liver Transplant Recipients With Aspergillosis,UNKNOWN,,50.0,2010-05-01,,,Slow (<1/month),,Significantly Below (<50%),50,27.3,8.155
NCT04712877,Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers,RECRUITING,,1000.0,2022-06-15,2026-06-15,20.83504449007529,Good (10-50/month),200.0,Exceeded (≥100%),60,81.3,88.58
NCT03239977,Social Intelligence Training for Custodial Grandfamilies,UNKNOWN,PHASE2,680.0,2018-05-31,2022-10-31,12.824783147459728,Good (10-50/month),128.2478314745973,Exceeded (≥100%),50,80.0,87.67
NCT07108777,L-Carnitine Protective Effect in Nephrotoxicity,RECRUITING,PHASE2,46.0,2025-08-10,2026-11-01,3.1255357142857143,Adequate (1-10/month),31.255357142857143,Significantly Below (<50%),60,41.7,24.36
NCT02333877,Comparison of Skinlink With Suture for ED Patients,COMPLETED,NA,49.0,2015-01-01,2016-04-01,3.270964912280702,Adequate (1-10/month),32.70964912280702,Significantly Below (<50%),100,53.9,58.34
NCT00222677,Aspirin for the Prevention of Recurrent Venous Thromboembolism,UNKNOWN,PHASE2,70.0,2004-05-01,,,Slow (<1/month),,Significantly Below (<50%),50,30.6,9.475
NCT06164977,Chronic Total Coronary Occlusion Treatment Results 6 Years After Bioresorbable Scaffold Implantation,COMPLETED,NA,34.0,2017-02-01,2023-12-01,0.4149799518845229,Slow (<1/month),4.149799518845229,Significantly Below (<50%),100,47.7,42.17
NCT00803777,In-Clinic and Home-Use Study of a New Blood Glucose Monitoring System,COMPLETED,NA,147.0,2008-12-01,2009-03-01,49.71866666666667,Good (10-50/month),200.0,Exceeded (≥100%),100,71.8,82.83
NCT04036877,Mood Disorders Bladder Cancer,COMPLETED,,358.0,2019-09-19,2021-08-04,15.908788321167883,Good (10-50/month),159.08788321167881,Exceeded (≥100%),100,82.0,89.05499999999999
NCT00066677,Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer,TERMINATED,PHASE2,32.0,2003-10-01,2009-04-01,0.4848581383773022,Slow (<1/month),4.8485813837730225,Significantly Below (<50%),10,20.6,5.965
NCT00585377,"Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer",COMPLETED,PHASE2,50.0,2007-08-01,2013-05-01,0.7247619047619048,Slow (<1/month),7.2476190476190485,Significantly Below (<50%),100,49.0,45.61
NCT01426477,Veritas in Non-Bridging Ventral Hernia Repair,TERMINATED,,20.0,2011-08-01,2017-08-01,0.27773722627737224,Slow (<1/month),2.7773722627737225,Significantly Below (<50%),10,17.9,2.87
NCT06226077,Project SHINE (Sleep Health INitiative for Equity): Culturally Informing a Sleep Extension Intervention for African American Adults,RECRUITING,PHASE1,90.0,2023-10-01,2026-11-01,2.4308784383318547,Adequate (1-10/month),24.30878438331855,Significantly Below (<50%),60,45.2,30.830000000000002
NCT06080477,Enhancing Mental Health Outcomes for Patients With Psychosis in Malawi Through Community-based Rehabilitation,COMPLETED,NA,60.0,2023-12-04,2025-08-31,2.871698113207547,Adequate (1-10/month),28.71698113207547,Significantly Below (<50%),100,54.8,61.095
NCT04729777,Assessment of Cardiac Function Using Combined Cardiovascular Magnetic Resonance and Cardiopulmonary Exercise Testing (CMR-CPET),UNKNOWN,,100.0,2019-03-01,2021-10-01,3.221164021164021,Adequate (1-10/month),32.211640211640216,Significantly Below (<50%),50,41.3,23.74
NCT07064577,Novel ROS-scavenging Nanoenzymes for the Treatment of Radiation Dermatitis in Patients With Head and Neck Cancer,RECRUITING,NA,30.0,2025-07-15,2025-10-15,9.92608695652174,Adequate (1-10/month),99.2608695652174,Met (75-100%),60,45.4,31.455
NCT00966277,Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients,COMPLETED,PHASE4,87.0,2010-04-01,2014-09-01,1.6408178438661711,Adequate (1-10/month),16.408178438661714,Significantly Below (<50%),100,52.0,52.86
NCT06560177,[Trial of device that is not approved or cleared by the U.S. FDA],WITHHELD,,,,,,Slow (<1/month),,Significantly Below (<50%),50,20.0,5.695
NCT02907177,Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®),TERMINATED,PHASE3,136.0,2017-03-30,2020-03-26,3.7910622710622714,Adequate (1-10/month),37.91062271062272,Significantly Below (<50%),10,33.9,13.865
NCT05923177,Molecular Imaging of HER2 Expression in Breast Cancer Using [123I] I-(HE)3-G3,COMPLETED,PHASE1,10.0,2023-09-01,2024-09-01,0.8316939890710383,Slow (<1/month),8.316939890710383,Significantly Below (<50%),100,45.8,33.03
NCT00476177,Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic Transplant,COMPLETED,PHASE1,25.0,2003-07-01,2009-07-01,0.3471715328467153,Slow (<1/month),3.471715328467153,Significantly Below (<50%),100,47.0,39.33
NCT06798077,Chronic Airway Disease and Multimorbidity Cohort,RECRUITING,,2000.0,2025-02-01,2028-07-31,47.711598746081506,Good (10-50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT00169975,Efficacy of the CMI Magnetocardiograph in Diagnosing Acute Coronary Syndromes in Patients Presenting With High Risk Unstable Angina.,COMPLETED,,137.0,2004-08-01,2008-02-01,3.260578577013292,Adequate (1-10/month),32.60578577013292,Significantly Below (<50%),100,59.3,70.815
NCT04394975,Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer,COMPLETED,PHASE3,421.0,2020-08-20,2024-04-02,9.701165783497352,Adequate (1-10/month),97.01165783497352,Met (75-100%),100,88.7,92.84
NCT06810375,Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery,RECRUITING,PHASE3,120.0,2025-03-01,2029-02-28,2.5019178082191784,Adequate (1-10/month),25.019178082191786,Significantly Below (<50%),60,47.6,41.775
NCT04535375,Sonographic QUantification of Venous Circulation In the Preterm Brain,COMPLETED,NA,47.0,2021-01-01,2024-05-16,1.1622095857026808,Adequate (1-10/month),11.622095857026808,Significantly Below (<50%),100,48.8,45.184999999999995
NCT05191875,Saccharomyces Boulardii as Pretreatment Before Rescue Therapy of Helicobacter Pylori,COMPLETED,NA,106.0,2021-12-01,2022-04-23,22.563916083916084,Good (10-50/month),200.0,Exceeded (≥100%),100,63.5,76.465
NCT05128175,Comparative Bioavailability Study of Carbidopa/Levodopa Extended-Release Tablets Under Fasting and Fed Conditions,UNKNOWN,PHASE1,15.0,2021-10-29,2022-03-25,3.1061224489795918,Adequate (1-10/month),31.06122448979592,Significantly Below (<50%),50,36.2,16.84
NCT05726175,Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer,UNKNOWN,PHASE2,20.0,2023-03-01,2024-08-31,1.1089253187613846,Adequate (1-10/month),11.089253187613844,Significantly Below (<50%),50,31.6,10.905
NCT02400775,A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.,WITHDRAWN,PHASE4,0.0,2015-03-01,2016-04-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT03380975,Role of Montelukast in Asthma and Allergic Rhinitis Patients,COMPLETED,PHASE4,600.0,2018-08-28,2019-06-30,59.68627450980392,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT04680975,Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis,TERMINATED,PHASE2,10.0,2021-03-03,2022-12-19,0.46402439024390246,Slow (<1/month),4.640243902439025,Significantly Below (<50%),10,18.8,4.58
NCT04142775,Predictors of Intracranial Hemorrhage in ARDS Patients on ECMO,UNKNOWN,,1000.0,2019-02-01,2020-03-31,71.79245283018868,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT02512575,"A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567.",COMPLETED,PHASE1,72.0,2015-11-18,2016-09-26,7.002172523961662,Adequate (1-10/month),70.02172523961661,Below (50-75%),100,55.8,63.245
NCT02711475,Evaluation of Colonic Diminutive Polyps With Electronic Filters,UNKNOWN,,800.0,2017-01-10,2018-01-01,68.40449438202248,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT01248975,Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid/Long Acting Beta Agonist Combination Treatment for Asthma,COMPLETED,PHASE2,145.0,2010-12-01,2011-10-01,14.51907894736842,Good (10-50/month),145.19078947368422,Exceeded (≥100%),100,66.6,79.43
NCT05364775,The Experiences of International Nurses,WITHDRAWN,,0.0,2023-08-01,2024-02-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT03802175,The Application Of Lung Ultrasound In Postoperative Hypoxemia Patients,UNKNOWN,,113.0,2019-01-10,2019-08-01,16.944433497536945,Good (10-50/month),169.4443349753695,Exceeded (≥100%),50,47.4,40.98
NCT07004075,FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration,NOT_YET_RECRUITING,PHASE3,102.0,2025-06-30,2029-04-30,2.2177714285714285,Adequate (1-10/month),22.177714285714284,Significantly Below (<50%),30,37.2,18.17
NCT01726075,Trial to Assess the Efficacy of Neuroprotective Drugs Administered Topically to Prevent or Arrest Diabetic Retinopathy,COMPLETED,PHASE2,450.0,2013-02-01,2015-11-01,13.65702891326022,Good (10-50/month),136.5702891326022,Exceeded (≥100%),100,91.0,93.56
NCT03482375,Prospective Evaluation of Residual Bile Duct Stone by Peroral Cholangioscopy After Conventional ERCP,COMPLETED,,140.0,2015-12-17,2019-02-10,3.7025195482189406,Adequate (1-10/month),37.025195482189396,Significantly Below (<50%),100,59.5,71.0
NCT02632175,Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis,COMPLETED,PHASE3,59.0,2015-11-26,2025-04-08,0.5249809997076877,Slow (<1/month),5.249809997076878,Significantly Below (<50%),100,49.7,46.949999999999996
NCT01723657,Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML),COMPLETED,PHASE2,862.0,2003-10-01,2012-03-01,8.535875081327262,Adequate (1-10/month),85.35875081327261,Met (75-100%),100,95.0,95.7
NCT04111757,A Study With Technolas® TENEO 317 Model 2 Excimer Laser to Treat Participants With Myopia or Myopic Astigmatism,COMPLETED,NA,168.0,2019-07-25,2021-08-06,6.8827994616419925,Adequate (1-10/month),68.82799461641993,Below (50-75%),100,63.4,76.375
NCT00509457,GV 1001 Immunotherapy in Patients With Non-small Cell Lung Cancer (NSCLC),COMPLETED,NA,20.0,2006-11-01,2009-08-01,0.6063745019920319,Slow (<1/month),6.063745019920319,Significantly Below (<50%),100,46.6,37.375
NCT00311857,"Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT)",UNKNOWN,PHASE1,46.0,2006-02-01,,,Slow (<1/month),,Significantly Below (<50%),50,28.7,8.63
NCT03747757,Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue,ACTIVE_NOT_RECRUITING,PHASE2,48.0,2018-11-29,2027-09-11,0.4554613466334165,Slow (<1/month),4.554613466334164,Significantly Below (<50%),85,44.3,28.715000000000003
NCT02216357,Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease,COMPLETED,PHASE2,19.0,2014-08-01,2016-01-01,1.1165250965250966,Adequate (1-10/month),11.165250965250967,Significantly Below (<50%),100,46.5,36.815
NCT01160757,A Study to Determine the Safety and Efficacy of an Ultrasound Device in the Management of Acute Acne Lesions,COMPLETED,PHASE1,35.0,2008-10-01,,,Slow (<1/month),,Significantly Below (<50%),100,42.8,25.929999999999996
NCT04717557,Hyperbaric Oxygen and Outcome After Below Knee Amputations,TERMINATED,PHASE1,4.0,2021-01-01,2023-10-31,0.1178702807357212,Slow (<1/month),1.1787028073572121,Significantly Below (<50%),10,18.3,3.74
NCT00657657,Safety and Immunogenicity of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine,COMPLETED,PHASE4,29.0,2008-04-01,2008-08-01,7.235737704918033,Adequate (1-10/month),72.35737704918033,Below (50-75%),100,52.3,53.515
NCT07009457,Phase I Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer,RECRUITING,PHASE1,48.0,2025-06-16,2028-09-01,1.245626598465473,Adequate (1-10/month),12.456265984654731,Significantly Below (<50%),60,36.8,17.630000000000003
NCT06583057,Multicenter Comparison of Thermal Ablation Versus Thyroid Lobectomy for Subcapsular Papillary Thyroid Microcarcinoma,COMPLETED,,2000.0,2019-01-01,2024-07-31,29.87242394504416,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT04777357,A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.,RECRUITING,PHASE3,380.0,2021-04-28,2027-03-01,5.422972339428036,Adequate (1-10/month),54.22972339428035,Below (50-75%),60,68.4,80.97
NCT00385957,Immunological and Viral Response to Antiretrovirals in HIV Patients With CD4 Cell Count Below 100,COMPLETED,PHASE4,70.0,,,,Slow (<1/month),,Significantly Below (<50%),100,45.6,32.08
NCT04886557,Retrospective Image Analysis of Degenerative Lumbar Disease Patients,COMPLETED,,139.0,2007-01-01,2018-12-01,0.9722334558823529,Slow (<1/month),9.72233455882353,Significantly Below (<50%),100,54.5,60.12
NCT03691857,Feasibility and Accuracy of an Ultrasound Algorithm for Acute Dyspnea Diagnosis in the Emergency Department,RECRUITING,NA,225.0,2020-12-14,2025-04-14,4.329329962073325,Adequate (1-10/month),43.29329962073325,Significantly Below (<50%),60,56.0,63.71
NCT00145457,IGF1 Generation Test,COMPLETED,PHASE4,82.0,2001-04-01,2005-01-01,1.8206272793581328,Adequate (1-10/month),18.20627279358133,Significantly Below (<50%),100,56.6,65.34
NCT04618757,Trial Evaluating Hedonic vs Cash Incentives,COMPLETED,NA,310.0,2022-11-18,2023-08-31,32.99440559440559,Good (10-50/month),200.0,Exceeded (≥100%),100,79.8,87.27000000000001
NCT04443257,REassessement After Hospitalization for Sars-COV-2 disordER,TERMINATED,,119.0,2020-07-08,2022-02-18,6.139593220338983,Adequate (1-10/month),61.39593220338983,Below (50-75%),10,30.9,9.875
NCT01438957,Clinical Study to Investigate the Efficacy and the Safety of DA-9501 in Sedation During the Surgery With Epidural Anesthesia or Spinal Anesthesia Without Intubation,COMPLETED,PHASE3,119.0,2011-06-03,2011-11-18,21.561666666666667,Good (10-50/month),200.0,Exceeded (≥100%),100,64.5,77.44
NCT02263157,Evaluate the Association Between Infection and Thrombocytopenia,COMPLETED,,390.0,2013-01-01,2014-06-01,23.006976744186044,Good (10-50/month),200.0,Exceeded (≥100%),100,84.5,90.745
NCT06472557,Spinocerebellar Ataxia Type 27B Natural History Study (SCA27B-NHS),RECRUITING,,300.0,2024-06-04,2028-12-31,5.4649910233393175,Adequate (1-10/month),54.649910233393186,Below (50-75%),60,60.3,72.34
NCT04730557,Reducing Obesity and Cartilage Compression in Knees,COMPLETED,NA,88.0,2020-06-05,2024-05-17,1.8576421636615812,Adequate (1-10/month),18.576421636615812,Significantly Below (<50%),100,57.0,66.12
NCT03105557,Rickets Device - Feasibility Study,UNKNOWN,,10.0,2020-01-27,2024-03-01,0.20361204013377926,Slow (<1/month),2.0361204013377923,Significantly Below (<50%),50,29.1,8.799999999999999
NCT02380157,Blood Pressure Regulation - Role of Potassium,COMPLETED,PHASE4,25.0,2015-03-01,2016-12-01,1.187207488299532,Adequate (1-10/month),11.872074882995319,Significantly Below (<50%),100,47.0,39.33
NCT04204057,Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL),COMPLETED,PHASE2,21.0,2019-11-28,2020-10-02,2.06873786407767,Adequate (1-10/month),20.687378640776704,Significantly Below (<50%),100,51.7,51.94
NCT00021957,ESCAPE Mechanistic Substudies - Ancillary to ESCAPE,COMPLETED,,,2001-04-01,2005-03-01,,Slow (<1/month),,Significantly Below (<50%),100,43.3,27.05
NCT01503801,Inhaled Nitric Oxide to Prevent and Treat Bronchopulmonary Dysplasia,COMPLETED,PHASE2,400.0,2011-05-01,2012-12-01,20.99310344827586,Good (10-50/month),200.0,Exceeded (≥100%),100,87.0,92.135
NCT05685901,Oropharyngeal Immunoprophylaxis With High Polyphenolic Olive Oil as Clinical Spectrum Mitigating Factor in COVID-19.,COMPLETED,NA,88.0,2021-07-01,2022-09-30,5.874385964912281,Adequate (1-10/month),58.74385964912281,Below (50-75%),100,57.0,66.12
NCT00003701,Combination Chemotherapy in Treating Patients With Bladder Cancer,COMPLETED,PHASE3,490.0,1999-04-02,2007-06-15,4.978504672897197,Adequate (1-10/month),49.78504672897196,Significantly Below (<50%),100,89.2,92.985
NCT01397201,Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS),TERMINATED,PHASE2,30.0,2011-07-01,2011-12-23,5.218285714285714,Adequate (1-10/month),52.182857142857145,Below (50-75%),10,25.4,7.470000000000001
NCT00734201,Safety and Efficacy of Low Doses of V24343 in Obese Subjects,COMPLETED,PHASE1,32.0,2008-10-01,2009-03-01,6.450860927152318,Adequate (1-10/month),64.50860927152317,Below (50-75%),100,52.6,54.684999999999995
NCT00626301,Lopinavir/Ritonavir Monotherapy in Children,COMPLETED,PHASE4,40.0,2007-11-01,2009-09-01,1.8173134328358211,Adequate (1-10/month),18.17313432835821,Significantly Below (<50%),100,53.2,56.665
NCT03018301,Intravenous Ketamine and Postoperative Pain Following Cesarean Section.,UNKNOWN,PHASE2,80.0,2017-01-01,2017-10-01,8.92014652014652,Adequate (1-10/month),89.20146520146521,Met (75-100%),50,46.4,36.26
NCT02598401,The British Osteonecrosis Study,UNKNOWN,,50.0,2017-08-21,2022-10-10,0.8113006396588486,Slow (<1/month),8.113006396588487,Significantly Below (<50%),50,32.3,11.799999999999999
NCT05896501,Role of FFR in ACS Patients: Pressure ACS Registry,ACTIVE_NOT_RECRUITING,,500.0,2020-01-01,2026-12-31,5.954616588419405,Adequate (1-10/month),59.54616588419406,Below (50-75%),85,83.8,90.505
NCT02071901,Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy,UNKNOWN,PHASE2,31.0,2014-08-14,2023-09-26,0.2833753753753754,Slow (<1/month),2.833753753753754,Significantly Below (<50%),50,32.5,12.235
NCT05617001,Clinical Validation and Safety of the AC 12L ECG System Against a Standard of Care 12-Lead ECG (AC 12L ECG),RECRUITING,NA,200.0,2022-10-04,2024-12-01,7.716096324461343,Adequate (1-10/month),77.16096324461344,Met (75-100%),60,54.0,58.72500000000001
NCT00038701,"Study of Gemcitabine Chemoradiation and TNP-470 Patients Locally Advanced, Nonmetastatic Adenocarcinoma of Pancreas",TERMINATED,PHASE2,6.0,1999-08-01,2004-05-11,0.10466475644699141,Slow (<1/month),1.046647564469914,Significantly Below (<50%),10,18.5,4.02
NCT02970201,Improving Adherence in Renal Dialysis Patients Through Electronic Interventions,COMPLETED,NA,26.0,2015-02-01,2016-12-01,1.1830194319880418,Adequate (1-10/month),11.830194319880418,Significantly Below (<50%),100,47.1,39.64
NCT04569201,Endoscopic and Endoscopic-Assisted Microsurgery of Intraventricular Lesions,UNKNOWN,,20.0,2020-11-01,2022-12-01,0.8010526315789473,Slow (<1/month),8.010526315789473,Significantly Below (<50%),50,29.9,9.07
NCT00990301,A Study to Compare the Relative Bioavailability of Moexipril HCl/Hydrochlorothiazide in Healthy Adult Volunteers Under Fasting Conditions,COMPLETED,PHASE1,48.0,,,,Slow (<1/month),,Significantly Below (<50%),100,43.8,27.965
NCT07353801,Oral Mini Pulse Dexamethasone in Pediatric Vitiligo,RECRUITING,PHASE4,22.0,2026-01-01,2026-06-01,4.434966887417218,Adequate (1-10/month),44.34966887417218,Significantly Below (<50%),60,39.8,21.47
NCT02767401,The Success of Opening Single CTO Lesions to Improve Myocardial Viability Study (SOS-comedy),COMPLETED,PHASE4,200.0,2015-09-15,2018-12-15,5.128896377422072,Adequate (1-10/month),51.28896377422073,Below (50-75%),100,66.0,78.99000000000001
NCT00886301,Fatty Liver and Ectopic Fat in Overweight and Obese Patients,COMPLETED,NA,56.0,2010-03-01,2014-10-02,1.01708830548926,Adequate (1-10/month),10.1708830548926,Significantly Below (<50%),100,49.5,46.58
NCT00021801,Islet Cell Transplantation Alone and CD34+ Enriched Bone Marrow Cell Infusion in Patients With Diabetes Mellitus: Steroid-Free Regimen,COMPLETED,PHASE2,,2000-03-01,2000-09-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,30.330000000000002
NCT02476201,Quartet Lead and Resynchronization Therapy Options III (QUARTO_III),COMPLETED,NA,105.0,2016-02-01,2019-07-01,2.565168539325843,Adequate (1-10/month),25.65168539325843,Significantly Below (<50%),100,58.4,69.175
NCT06055101,Regional Anaesthesia,COMPLETED,NA,54.0,2019-01-03,2023-04-04,1.0591237113402063,Adequate (1-10/month),10.591237113402062,Significantly Below (<50%),100,49.3,46.265
NCT06287801,Annual Wellness Visits vs GRACE-augmented Annual Wellness Visits For Older Adults With High Needs - Phase 1,COMPLETED,NA,110.0,2024-08-29,2025-07-18,10.366563467492261,Good (10-50/month),103.66563467492263,Exceeded (≥100%),100,63.8,76.78
NCT01741701,A Pilot Study of Oxaloacetate in Subjects With Treated PD,COMPLETED,PHASE2,33.0,2012-12-01,2014-10-01,1.50152466367713,Adequate (1-10/month),15.015246636771298,Significantly Below (<50%),100,47.6,41.775
NCT02621801,Evaluation of a Mind-body Education Program to Enhance Resiliency and Reduce Burnout in Residents,UNKNOWN,NA,173.0,2015-08-01,2016-07-01,15.719761194029852,Good (10-50/month),157.19761194029851,Exceeded (≥100%),50,53.8,58.065
NCT04590001,Effect of the MobiusHD® in Patients With Heart Failure,RECRUITING,NA,50.0,2020-10-02,2026-06-01,0.7359767891682786,Slow (<1/month),7.359767891682786,Significantly Below (<50%),60,37.0,17.955
NCT04148001,Identifying and Genotyping Homozygous Familial Hypercholesterolemia (HoFH) Patients,COMPLETED,,4.0,2019-12-04,2020-04-08,0.9663492063492063,Slow (<1/month),9.663492063492063,Significantly Below (<50%),100,43.7,27.744999999999997
NCT06569901,Strengthening Hope After ICU Discharge,RECRUITING,NA,75.0,2024-09-10,2030-09-01,1.046287809349221,Adequate (1-10/month),10.46287809349221,Significantly Below (<50%),60,39.0,20.505000000000003
NCT01844401,Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients With Asthma,COMPLETED,PHASE1,15.0,2013-04-01,2013-10-01,2.495081967213115,Adequate (1-10/month),24.950819672131146,Significantly Below (<50%),100,51.2,50.375
NCT06939101,Self-efficacy for Interprofessional Experiential Learning Through an International Service Trip,COMPLETED,,14.0,2024-05-07,2024-08-16,4.21940594059406,Adequate (1-10/month),42.1940594059406,Significantly Below (<50%),100,49.5,46.58
NCT02905201,A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC),WITHDRAWN,,0.0,2016-09-01,2018-04-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT05232812,Validation of 3-[11C]-OHB,COMPLETED,NA,6.0,2022-06-01,2023-03-29,0.6067774086378738,Slow (<1/month),6.067774086378738,Significantly Below (<50%),100,45.5,31.705
NCT01731912,Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer,COMPLETED,NA,16.0,2013-05-01,2016-09-01,0.3995406070549631,Slow (<1/month),3.9954060705496306,Significantly Below (<50%),100,46.3,35.66
NCT06700512,Standard Post Market Clinical Follow-up (PMCF) Study WSA @ HZO,COMPLETED,NA,20.0,2024-06-14,2024-08-26,8.33972602739726,Adequate (1-10/month),83.39726027397259,Met (75-100%),100,56.6,65.34
NCT04780412,Efficacy of Misoprostol in Prevention of Neonatal Respiratory Morbidity in Parturient at Early Term Elective Caesarian Section,UNKNOWN,PHASE3,210.0,2020-09-01,2021-03-01,35.31712707182321,Good (10-50/month),200.0,Exceeded (≥100%),50,56.8,65.69500000000001
NCT03629912,Bingocize: A Novel Mobile Application for Older Adult Health,COMPLETED,NA,241.0,2018-08-13,2022-05-13,5.358685171658145,Adequate (1-10/month),53.58685171658145,Below (50-75%),100,69.3,81.395
NCT02848612,Evaluation of the Amiens University Hospital Neuroradiology Anticoagulation Protocol,COMPLETED,,459.0,2015-11-20,2016-07-15,58.705714285714286,Excellent (>50/month),200.0,Exceeded (≥100%),100,95.1,96.5
NCT04331912,PFS and OS of Patients With Advanced Neuroendocrine Cancer (NEN) After Systemic Treatment,UNKNOWN,,100.0,2019-07-01,2023-12-31,1.8515815085158152,Adequate (1-10/month),18.515815085158152,Significantly Below (<50%),50,41.3,23.74
NCT00512512,Transoral Endoscopic Liver Biopsy During Laparoscopic Gastric Bypass,COMPLETED,,4.0,2007-06-01,2009-06-01,0.16656634746922025,Slow (<1/month),1.6656634746922028,Significantly Below (<50%),100,43.7,27.744999999999997
NCT01604512,A Comparison of MRI Perfusion and FDG PET/CT to Distinguish Between Radiation Injury and Tumor Progression,COMPLETED,NA,148.0,2012-05-01,2023-12-29,1.057788213195586,Adequate (1-10/month),10.57788213195586,Significantly Below (<50%),100,56.8,65.69500000000001
NCT01890512,INGENIO MRI/ FINELINE II Pacing System Data Collection in Patients Undergoing MRI,COMPLETED,,20.0,2013-06-01,2014-01-01,2.8448598130841125,Adequate (1-10/month),28.448598130841123,Significantly Below (<50%),100,49.9,47.425
NCT06540612,"Effects of Aerobic Exercise on Cancer-Related Biomarkers, Functional Capacity, Cognitive Status and Quality of Life in Women With Breast Cancer",ENROLLING_BY_INVITATION,NA,69.0,2024-05-15,2025-08-15,4.59597374179431,Adequate (1-10/month),45.95973741794311,Significantly Below (<50%),55,42.0,24.825
NCT02990312,Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant Recipients,WITHDRAWN,PHASE4,0.0,2017-05-01,2019-07-17,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT00533312,MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED),COMPLETED,PHASE2,407.0,2005-04-01,2007-01-01,19.3579375,Good (10-50/month),193.579375,Exceeded (≥100%),100,87.6,92.335
NCT03631212,Avatar-led Acceptance and Commitment Therapy Smoking Cessation,UNKNOWN,NA,300.0,2017-09-15,2020-07-30,8.705433746425168,Adequate (1-10/month),87.05433746425167,Met (75-100%),50,64.0,77.025
NCT06704412,Effects of a Floss Band on Ankle in Stroke,COMPLETED,NA,40.0,2021-11-23,2022-08-31,4.333096085409253,Adequate (1-10/month),43.330960854092524,Significantly Below (<50%),100,53.2,56.665
NCT04552912,Physical Activity to Improve Patient Reported Outcomes for Adults With Acute Leukemia,COMPLETED,NA,49.0,2021-01-15,2022-09-15,2.4532236842105264,Adequate (1-10/month),24.532236842105267,Significantly Below (<50%),100,53.9,58.34
NCT05235412,"A Cohort Study on Milk Composition, Health Outcomes, and Feeding Practices of Chinese Mothers and Infants",COMPLETED,,769.0,2021-11-19,2025-07-31,17.339525925925926,Good (10-50/month),173.39525925925926,Exceeded (≥100%),100,93.3,94.325
NCT05205512,"Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS Trial",COMPLETED,NA,10.0,2022-09-14,2025-06-09,0.30470470470470473,Slow (<1/month),3.0470470470470477,Significantly Below (<50%),100,45.8,33.03
NCT04504812,A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain,COMPLETED,PHASE3,1937.0,2021-02-01,2025-04-08,38.61314996725606,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT06441812,"A Study to Evaluate the Long-term Safety, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma Patients",RECRUITING,PHASE2,200.0,2024-07-19,2028-09-01,4.045182724252492,Adequate (1-10/month),40.45182724252492,Significantly Below (<50%),60,54.0,58.72500000000001
NCT03672812,The Use of Liraglutide in Brain Death,COMPLETED,PHASE3,50.0,2018-09-01,2022-02-10,1.2098569157392687,Adequate (1-10/month),12.098569157392687,Significantly Below (<50%),100,49.0,45.61
NCT07134881,Navigating Advanced Illness Goals And Treatment With Digital Engagement (NAVIGATE),RECRUITING,NA,200.0,2025-08-27,2027-07-31,8.660028449502134,Adequate (1-10/month),86.60028449502134,Met (75-100%),60,59.0,70.365
NCT02782481,"A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations",WITHDRAWN,PHASE3,0.0,2016-08-01,2018-10-15,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT05387681,"Preoperative Short Course Radiotherapy With Envafolimab, Endostatin and SOX Regimen in Locally Advanced Gastric",UNKNOWN,PHASE2,35.0,2022-05-30,2025-12-30,0.8132824427480917,Slow (<1/month),8.132824427480918,Significantly Below (<50%),50,32.8,12.425
NCT03968081,Exploration of Theory of Mind in a Situation of Social Rejection in Borderline Personality Disorder,TERMINATED,NA,10.0,2019-06-26,2021-10-31,0.3547785547785548,Slow (<1/month),3.5477855477855478,Significantly Below (<50%),10,18.8,4.58
NCT05226481,Investigating the Effect of Evidence-based Treatment for Post-traumatic Stress Disorder Among Youth,COMPLETED,,216.0,2018-01-01,2021-12-21,4.534510344827586,Adequate (1-10/month),45.345103448275864,Significantly Below (<50%),100,65.6,78.56
NCT06870981,Optimizing Nutrition and Milk (Opti-NuM) Project,RECRUITING,,1100.0,2010-10-01,2027-12-01,5.340350877192982,Adequate (1-10/month),53.40350877192983,Below (50-75%),60,76.3,85.1
NCT07320781,Role of Preoperative Tapentadol in Reduction of Perioperative Analgesic Requirement After Breast Conservative Surgery in Cancer Patients.,COMPLETED,NA,70.0,2024-11-15,2025-10-10,6.476595744680852,Adequate (1-10/month),64.76595744680851,Below (50-75%),100,55.6,62.905
NCT00923481,"A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...",COMPLETED,PHASE2,37.0,2009-04-01,2012-01-01,1.1206766169154228,Adequate (1-10/month),11.206766169154228,Significantly Below (<50%),100,48.0,42.945
NCT07068581,Effect of Maternal Voice on Physiological Indicators and Feeding Performance,RECRUITING,NA,50.0,2025-08-10,2026-07-23,4.3861671469740635,Adequate (1-10/month),43.861671469740635,Significantly Below (<50%),60,42.0,24.825
NCT05214781,The Significance of Radiologically Detected Intramammary Lymph Nodes in Prediction of Axillary Lymph Nodes Status in Breast Cancer Patients,UNKNOWN,,30.0,2021-09-14,2023-03-04,1.7037313432835821,Adequate (1-10/month),17.03731343283582,Significantly Below (<50%),50,35.7,16.18
NCT02136381,Lifestyle Interventions at Retirement,UNKNOWN,NA,90.0,2014-05-01,2015-02-01,9.92608695652174,Adequate (1-10/month),99.26086956521739,Met (75-100%),50,47.2,40.035
NCT05366881,cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease,RECRUITING,,7000.0,2022-05-03,2027-03-01,120.8621667612025,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT03783481,Distress Reduction by Activity Tracking and Activity Enhancement by Mobile Support Group in Oncology,COMPLETED,NA,202.0,2019-01-07,2020-11-16,9.05578792341679,Adequate (1-10/month),90.5578792341679,Met (75-100%),100,71.2,82.59
NCT01140581,Optimal Timing of Dronedarone Initiation After Conversion in Patients With Persistent Atrial Fibrillation,COMPLETED,PHASE4,402.0,2010-09-01,2011-12-01,26.835263157894737,Good (10-50/month),200.0,Exceeded (≥100%),100,87.2,92.21000000000001
NCT04078581,Profiling Fecal Samples for Selection of Donors of Feces,WITHDRAWN,NA,0.0,2020-03-01,2021-06-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT01196481,Carvedilol + VSL#3 Versus Endoscopic Variceal Ligation for Primary Prophylaxis of Esophageal Variceal Bleeding in Cirrhotic Patients Non Responder to Carvedilol.,COMPLETED,NA,40.0,2012-12-01,2015-08-01,1.251387461459404,Adequate (1-10/month),12.51387461459404,Significantly Below (<50%),100,48.2,43.665
NCT01066481,A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease,WITHDRAWN,PHASE2,0.0,2010-04-01,2012-04-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT03038581,Comparison of Self-inflicted Deep Wrist Injuries to Traumatic Deep Wrist Injuries,COMPLETED,,183.0,2015-10-01,2018-09-01,5.22562851782364,Adequate (1-10/month),52.2562851782364,Below (50-75%),100,63.0,75.845
NCT00698581,"A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures",TERMINATED,PHASE3,88.0,2008-08-01,2010-02-01,4.879271402550092,Adequate (1-10/month),48.79271402550091,Significantly Below (<50%),10,30.0,9.145
NCT06579781,Evaluation of Parent Toolkit 2.0 (Morehouse Family Health Study),RECRUITING,NA,2000.0,2024-10-21,2028-09-29,42.30715774843641,Good (10-50/month),200.0,Exceeded (≥100%),60,88.0,92.495
NCT04991181,"Absorption, Distribution, Metabolism and Excretion of BIA 5-1058",COMPLETED,PHASE1,15.0,2017-03-31,2017-05-24,8.455555555555556,Adequate (1-10/month),84.55555555555556,Met (75-100%),100,56.2,64.21
NCT01524081,Antibiotic Prophylaxis in the Prevention of Surgical Site Infections After Selected Urgent Abdominal Surgical Procedures,COMPLETED,PHASE3,187.0,2008-07-01,2011-11-01,4.673464696223316,Adequate (1-10/month),46.734646962233164,Significantly Below (<50%),100,65.0,78.065
NCT04875481,Precise Objective Automated Assessment System of Autism Spectrum Disorder From an Existing Big Cohort,COMPLETED,,214.0,2018-08-01,2022-07-31,4.461753424657535,Adequate (1-10/month),44.617534246575346,Significantly Below (<50%),100,65.5,78.48
NCT01599481,"Career Management to Improve Education, Employment and Retention for People With Anxiety and Depression",COMPLETED,PHASE2,261.0,2011-10-01,2014-04-01,8.701905805038335,Adequate (1-10/month),87.01905805038336,Met (75-100%),100,75.9,84.885
NCT02510781,A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs,UNKNOWN,PHASE2,200.0,2015-01-01,2017-12-01,5.716431924882629,Adequate (1-10/month),57.1643192488263,Below (50-75%),50,51.0,49.714999999999996
NCT07003581,Cardiometabolic Risk Factors Associated With Multidrug-Resistant Tuberculosis,COMPLETED,,183.0,2024-09-04,2025-01-30,37.63864864864865,Good (10-50/month),200.0,Exceeded (≥100%),100,68.0,80.56
NCT02407119,Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD,ACTIVE_NOT_RECRUITING,PHASE3,470.0,2003-06-01,2030-06-01,1.4506996552423443,Adequate (1-10/month),14.506996552423443,Significantly Below (<50%),85,78.1,86.195
NCT04479319,Decision Support System Algorithm for COVID-19 Diagnosis,COMPLETED,,3215.0,2020-12-31,2022-04-01,214.615350877193,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT01601119,Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients,COMPLETED,,545.0,2012-01-01,2014-07-01,18.190570175438598,Good (10-50/month),181.90570175438597,Exceeded (≥100%),100,93.3,94.325
NCT04870619,FIRST-Oslo Long-term Follow-up,COMPLETED,,69.0,2021-06-20,2023-09-04,2.6059057071960297,Adequate (1-10/month),26.059057071960297,Significantly Below (<50%),100,53.9,58.34
NCT03253419,HotShOT: Home Safety Occupational Therapy,WITHDRAWN,NA,0.0,2017-08-15,2020-02-28,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT04320719,Optimizing Statin Tratment in People Living With Diabetes,COMPLETED,,387.0,2018-11-01,2020-05-01,21.536160877513712,Good (10-50/month),200.0,Exceeded (≥100%),100,84.3,90.71000000000001
NCT04935619,Extended Effects of Cannabis Abstinence on Clinical Symptoms and Cognition in Depression,RECRUITING,NA,52.0,2021-07-21,2027-08-31,0.7091756272401434,Slow (<1/month),7.091756272401434,Significantly Below (<50%),60,37.2,18.17
NCT04844619,KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial,ACTIVE_NOT_RECRUITING,PHASE1,40.0,2021-04-19,2024-12-31,0.9005917159763314,Slow (<1/month),9.005917159763314,Significantly Below (<50%),85,43.7,27.744999999999997
NCT02071719,Prediction of Response to Kinase Inhibitors Based on Protein Phosphorylation Profiles in Tumor Tissue From Advanced Renal Cell Cancer Patients,TERMINATED,,6.0,2012-04-01,2017-10-01,0.09091090094574417,Slow (<1/month),0.9091090094574418,Significantly Below (<50%),10,16.8,2.715
NCT02167919,Efficacy of Prostatic Artery Embolization (PAE) in Patients With Severe Benign Prostatic Hyperplasia (BPH),COMPLETED,NA,15.0,2014-07-01,2017-05-01,0.44115942028985505,Slow (<1/month),4.41159420289855,Significantly Below (<50%),100,46.2,35.089999999999996
NCT06897319,High-Flow Tracheal Therapy on Tracheobronchial Secretions in Tracheostomized Patients,NOT_YET_RECRUITING,NA,15.0,2025-03-20,2026-08-01,0.9150300601202405,Slow (<1/month),9.150300601202405,Significantly Below (<50%),30,25.2,7.359999999999999
NCT00838019,Intrabone Cord Blood Transplantation,UNKNOWN,PHASE4,10.0,2009-02-01,2011-02-01,0.41698630136986303,Slow (<1/month),4.16986301369863,Significantly Below (<50%),50,30.8,9.745
NCT04501419,Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria,RECRUITING,NA,600.0,2019-10-05,2026-06-30,7.424390243902439,Adequate (1-10/month),74.2439024390244,Below (50-75%),60,78.0,86.075
NCT00381719,Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy,COMPLETED,PHASE2,330.0,2006-10-01,2007-11-01,25.366666666666667,Good (10-50/month),200.0,Exceeded (≥100%),100,81.4,88.9
NCT04008719,ATtention Test and Executive Functions After STroke to Predict Depression.,COMPLETED,NA,74.0,2017-05-16,2019-09-30,2.598108419838524,Adequate (1-10/month),25.98108419838524,Significantly Below (<50%),100,55.9,63.42
NCT07070219,A Study of CTD402 in T-ALL/LBL Patients,RECRUITING,PHASE1,54.0,2025-10-07,2028-12-30,1.3930169491525426,Adequate (1-10/month),13.930169491525424,Significantly Below (<50%),60,37.3,18.35
NCT00436319,Duration of GnRH-analogue Downregulation and Pregnancy Rates,TERMINATED,PHASE4,300.0,2006-05-01,,,Slow (<1/month),,Significantly Below (<50%),10,37.0,17.955
NCT02412319,The Clinical Trial of the Anti Hepatitis B Placenta Transfer Factor Injection,UNKNOWN,PHASE4,288.0,2014-10-01,2017-12-01,7.577113223854797,Adequate (1-10/month),75.77113223854796,Met (75-100%),50,58.0,68.245
NCT04968119,Telehealth Exercise Platform to Reduce Frailty After Bone Marrow Transplant,COMPLETED,NA,21.0,2021-07-12,2024-10-08,0.5398986486486487,Slow (<1/month),5.3989864864864865,Significantly Below (<50%),100,46.7,37.895
NCT07345819,Dexamethasone vs. Placebo in Children and Youth Hospitalized for Orbital Cellulitis,NOT_YET_RECRUITING,NA,30.0,2026-04-01,2027-12-31,1.4291079812206573,Adequate (1-10/month),14.291079812206572,Significantly Below (<50%),30,26.4,7.865
NCT01468519,Exploratory CSII Trial on Erectile Dysfunction in T2DM Patients,COMPLETED,PHASE4,20.0,2012-01-01,2014-11-01,0.5882125603864734,Slow (<1/month),5.882125603864734,Significantly Below (<50%),100,46.6,37.375
NCT01989819,Primary Sjögren Syndrome,COMPLETED,,44.0,2012-09-01,2017-06-01,0.772410611303345,Slow (<1/month),7.724106113033449,Significantly Below (<50%),100,46.9,38.96
NCT05163119,Randomized Trial on Mobile Technology and Young Drivers' Cellphone Use,RECRUITING,NA,1200.0,2022-11-09,2026-06-30,27.485327313769755,Good (10-50/month),200.0,Exceeded (≥100%),60,83.0,89.505
NCT04814719,Treatment and Duration Effect of Pentosan Polysulfate Sodium (PPS) in Participants With Knee Osteoarthritis Pain,COMPLETED,,133.0,2023-06-24,2024-12-24,7.374353369763207,Adequate (1-10/month),73.74353369763207,Below (50-75%),100,59.0,70.365
NCT05614219,Familial Hypercholesterolemia Interpretive Comment - Nudging to Detection.,RECRUITING,NA,2000.0,2023-12-01,2027-05-01,48.82117080994387,Good (10-50/month),200.0,Exceeded (≥100%),60,88.0,92.495
NCT03756519,The Effect of Exercise on Recent Onset Low Back Pain in the Emergency Department,COMPLETED,NA,69.0,2018-05-01,2018-11-30,9.860845070422537,Adequate (1-10/month),98.60845070422536,Met (75-100%),100,60.5,72.685
NCT03626519,Effects of Menthol on Dyspnoea in COPD Patients,COMPLETED,NA,63.0,2019-09-23,2021-03-12,3.577835820895522,Adequate (1-10/month),35.778358208955225,Significantly Below (<50%),100,55.0,61.834999999999994
NCT04045119,Effect of a Facial Cream Containing Cannabidiol and Hemp Oil on Skin Hydration and Acne-prone Skin,COMPLETED,NA,54.0,2019-10-01,2020-01-02,17.67483870967742,Good (10-50/month),176.7483870967742,Exceeded (≥100%),100,59.3,70.815
NCT06887530,Hand-10 Questionnaire in Children With Unilateral Cerebral Palsy,COMPLETED,,63.0,2025-03-21,2025-05-30,27.396,Good (10-50/month),200.0,Exceeded (≥100%),100,58.4,69.175
NCT04598230,Partners in Caring for Anxious Youth,ACTIVE_NOT_RECRUITING,PHASE3,468.0,2021-02-09,2026-12-31,6.6229288702928875,Adequate (1-10/month),66.22928870292887,Below (50-75%),85,82.9,89.21
NCT03524430,RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy,RECRUITING,NA,801.0,2018-04-26,2031-03-31,5.163583227445998,Adequate (1-10/month),51.63583227445998,Below (50-75%),60,78.0,86.075
NCT02264730,ClotFoam as an Adjunct to Hemostasis in Abdominal Surgery - Liver Bleeding is Encountered,UNKNOWN,PHASE1,20.0,2014-07-01,2015-01-01,3.3086956521739133,Adequate (1-10/month),33.08695652173913,Significantly Below (<50%),50,36.6,17.41
NCT05046730,SEAM Trial: Sutureless End to End Anastomosis by Magnetic Compression,TERMINATED,NA,128.0,2022-02-01,2023-12-30,5.59012912482066,Adequate (1-10/month),55.9012912482066,Below (50-75%),10,33.2,12.989999999999998
NCT06038630,129Xe MRI Cardiopulmonary,RECRUITING,PHASE2,125.0,2024-01-12,2028-06-30,2.3329245861434704,Adequate (1-10/month),23.329245861434703,Significantly Below (<50%),60,48.0,42.945
NCT01079130,Efficacy and Safety of Different Doses of Indacaterol,COMPLETED,PHASE3,511.0,2010-02-01,,,Slow (<1/month),,Significantly Below (<50%),100,80.0,87.67
NCT01887730,Hand Hygiene Intervention Study in Finnish Garrison,SUSPENDED,NA,1120.0,2012-01-01,2020-12-01,10.467546822229044,Good (10-50/month),104.67546822229046,Exceeded (≥100%),20,71.0,82.44
NCT04128930,Ambulatory CPAP Titration in Moderate Obstructive Sleep Apnea,COMPLETED,NA,100.0,2019-10-14,2021-12-31,3.762669962917182,Adequate (1-10/month),37.626699629171824,Significantly Below (<50%),100,58.0,68.245
NCT01730430,Cerebrospinal Fluid (CSF) Biomarkers Alzheimer's Disease (AD) and Non-AD Dementias,COMPLETED,,40.0,2012-07-01,2013-12-01,2.3505791505791507,Adequate (1-10/month),23.50579150579151,Significantly Below (<50%),100,51.5,51.245
NCT05054530,"Assessment of the Safety, Tolerability, and Pharmacokinetic of GMA106",COMPLETED,PHASE1,73.0,2021-11-11,2023-11-17,3.0191847826086957,Adequate (1-10/month),30.19184782608696,Significantly Below (<50%),100,55.8,63.245
NCT04075630,Observatory on Artificial Labour-induction Methods and Measuring Immediate Postpartum Maternal Satisfaction,COMPLETED,,260.0,2019-10-02,2024-01-09,5.073333333333333,Adequate (1-10/month),50.73333333333334,Below (50-75%),100,69.1,81.22
NCT06796530,High Intensity Exercise in Children with MCADD,NOT_YET_RECRUITING,NA,8.0,2025-01-20,2026-05-01,0.5225751072961373,Slow (<1/month),5.225751072961373,Significantly Below (<50%),30,24.6,6.959999999999999
NCT04581330,The Effects of Fractional CO2 Laser on Poikiloderma of Civatte,COMPLETED,NA,10.0,2021-04-01,2022-01-01,1.106909090909091,Adequate (1-10/month),11.06909090909091,Significantly Below (<50%),100,45.8,33.03
NCT06275230,Establishment of Human Lung Stem Cell Proliferation System and Organoid Construction in COPD,RECRUITING,,30.0,2024-03-20,2025-12-31,1.4027649769585253,Adequate (1-10/month),14.027649769585254,Significantly Below (<50%),60,33.7,13.465
NCT00611130,Vigabatrin for Treatment of Cocaine Dependence,COMPLETED,PHASE2,186.0,2008-01-01,2012-10-01,3.2633083573487034,Adequate (1-10/month),32.633083573487035,Significantly Below (<50%),100,64.9,77.985
NCT04898530,Diet Patterns in IBD in Central Texas,SUSPENDED,,500.0,2021-06-08,2024-12-31,11.689708141321045,Good (10-50/month),116.89708141321044,Exceeded (≥100%),20,69.3,81.395
NCT02035930,Effect of Dexmedetomidine on Bispectral Index and Propofol Requirements During Different Menstrual Cycle,COMPLETED,PHASE4,110.0,2010-11-01,2012-11-01,4.580574555403557,Adequate (1-10/month),45.80574555403557,Significantly Below (<50%),100,58.8,69.89999999999999
NCT06470230,RESPECT: (REsearching Stigma in PEdiatric Cancer Tool),RECRUITING,,1320.0,2024-07-08,2026-02-01,70.1235602094241,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT03101930,Cardiovascular Effects of GLP-1 Receptor Activation,COMPLETED,PHASE4,329.0,2017-05-01,2021-06-24,6.610402640264026,Adequate (1-10/month),66.10402640264027,Below (50-75%),100,76.3,85.1
NCT01159730,Study to Assess the Safety and Efficacy of Multiple Doses of VB-201 on Biomarkers,COMPLETED,PHASE2,320.0,2010-10-01,2011-10-01,26.687123287671234,Good (10-50/month),200.0,Exceeded (≥100%),100,80.6,88.14999999999999
NCT03137030,A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults,WITHDRAWN,PHASE1,0.0,2017-09-01,2018-01-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT06526130,Influence of Anaesthesia Type on Multiple Sclerosis Relapse,COMPLETED,,56.0,2012-01-01,2024-05-16,0.3772161982739544,Slow (<1/month),3.772161982739544,Significantly Below (<50%),100,47.8,42.42
NCT04047030,The Mobility Toolkit: Electronically Augmented Assessment of Functional Recovery Following Lower-extremity Trauma,COMPLETED,,244.0,2019-01-01,2024-08-31,3.5898308361527307,Adequate (1-10/month),35.898308361527306,Significantly Below (<50%),100,67.9,80.36999999999999
NCT03394430,Comparison of Midazolam or Dexmedetomidine on Epileptiform EEG During Sevoflurane Mask Induction,UNKNOWN,PHASE4,45.0,2018-10-01,2019-02-01,11.136585365853659,Good (10-50/month),111.3658536585366,Exceeded (≥100%),50,43.6,27.54
NCT03229330,Low-level Light Therapy on Treatment of Venous Ulcers Assesed by Nursing Outcome Classification (NOC),COMPLETED,NA,40.0,2016-04-01,2018-12-01,1.2501026694045174,Adequate (1-10/month),12.501026694045175,Significantly Below (<50%),100,48.2,43.665
NCT01735630,Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease,COMPLETED,PHASE2,350.0,2012-11-01,2015-05-01,11.69484083424808,Good (10-50/month),116.94840834248079,Exceeded (≥100%),100,83.0,89.505
NCT01184430,Effect of Perioperative Hemodynamic Optimization on the Immune Function Parameters of Peripheral Blood Monocytes After Cardiac Surgery,UNKNOWN,NA,40.0,2013-08-01,2014-12-01,2.500205338809035,Adequate (1-10/month),25.00205338809035,Significantly Below (<50%),50,38.2,19.645000000000003
NCT02451930,A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC,COMPLETED,PHASE1,71.0,2015-09-04,2019-09-17,1.4662415196743555,Adequate (1-10/month),14.662415196743552,Significantly Below (<50%),100,50.7,48.915
NCT05932030,Assessment of Knowledge and Perceptions of Artificial Intelligence in Solid Organ Transplantation,UNKNOWN,NA,6750.0,2023-07-01,2023-12-01,1342.9411764705883,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT04698330,Effects Of Berberine Plus Inulin On Diabetes Care in Patients With LADA,NOT_YET_RECRUITING,PHASE4,240.0,2022-05-01,2026-12-01,4.36155223880597,Adequate (1-10/month),43.6155223880597,Significantly Below (<50%),30,48.2,43.665
NCT04723030,The Transformation of Locally Advanced Pancreatic Cancer.,UNKNOWN,PHASE2,30.0,2021-04-01,2023-04-01,1.2509589041095892,Adequate (1-10/month),12.509589041095893,Significantly Below (<50%),50,32.4,12.025
NCT00384930,Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia,COMPLETED,PHASE2,1058.0,2006-08-01,2008-10-01,40.66353535353536,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT02516228,Transcranial Electrical Neuromodulation for Suppressing Epileptiform Discharges,TERMINATED,NA,6.0,2016-08-01,2018-05-01,0.28626959247648903,Slow (<1/month),2.8626959247648904,Significantly Below (<50%),10,18.5,4.02
NCT05865028,A Proof of Concept Trial Investigating Safety and Efficacy of APG-157 in Oral Dysplasia,RECRUITING,PHASE2,32.0,2023-05-24,2028-05-24,0.5331581828133553,Slow (<1/month),5.331581828133554,Significantly Below (<50%),60,35.6,16.03
NCT05833828,Differential Regulation of RAAS-axis in Patients Undergoing Cardiac Surgery,RECRUITING,,40.0,2023-08-24,2025-08-01,1.719774011299435,Adequate (1-10/month),17.19774011299435,Significantly Below (<50%),60,39.5,21.044999999999998
NCT06212128,RAPIDO vs LCRT vs Upfront Surgery - a Prospective Cohort Study,ACTIVE_NOT_RECRUITING,,57.0,2016-01-01,2024-12-30,0.5280219111381619,Slow (<1/month),5.28021911138162,Significantly Below (<50%),85,43.4,27.265
NCT03292328,Yoga for Symptoms of Nerve Damage Caused by Chemotherapy,COMPLETED,NA,51.0,2017-09-18,2020-09-15,1.4203476669716377,Adequate (1-10/month),14.203476669716379,Significantly Below (<50%),100,49.1,45.83
NCT06083428,Erector Spinae vs. PENG Block for Total Hip Arthroplasty,COMPLETED,PHASE4,90.0,2023-10-17,2024-06-11,11.5109243697479,Good (10-50/month),115.10924369747899,Exceeded (≥100%),100,62.2,74.74499999999999
NCT03266328,Procedure and In-hospital Outcome of Patients Under 40 Years Old Undergoing Primary Percutaneous Coronary Intervention for Acute ST Elevated Myocardial Infarction in Assiut University,UNKNOWN,,117.0,2017-09-01,2018-08-01,10.66311377245509,Good (10-50/month),106.63113772455088,Exceeded (≥100%),50,47.7,42.17
NCT06151028,An Observational Study of Menopausal Symptom in Patients With Gynecological Malignancy After Oophorectomy,RECRUITING,,490.0,2023-12-01,2033-12-31,4.049850665218572,Adequate (1-10/month),40.498506652185725,Significantly Below (<50%),60,75.5,84.68
NCT04212728,Treatment of Knee Osteoarthritis With Autologous Adipose-derived Mesenchymal Stem Cells,UNKNOWN,NA,60.0,2019-12-29,2024-12-01,1.015230683713174,Adequate (1-10/month),10.15230683713174,Significantly Below (<50%),50,34.8,15.040000000000001
NCT07279428,A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors,NOT_YET_RECRUITING,PHASE1,33.0,2025-12-01,2027-12-01,1.3760547945205481,Adequate (1-10/month),13.76054794520548,Significantly Below (<50%),30,26.6,8.01
NCT02386228,Micro Ribonucleic Acid (miRNA) Markers of Hydrocephalus in Intraventricular Hemorrhage (IVH),TERMINATED,,1.0,2015-03-01,2016-12-01,0.047488299531981276,Slow (<1/month),0.47488299531981276,Significantly Below (<50%),10,16.4,2.595
NCT01346228,Using Smart Phone Technology To Rural Veterans,UNKNOWN,NA,15.0,2011-04-01,2013-08-01,0.5352872215709261,Slow (<1/month),5.352872215709262,Significantly Below (<50%),50,31.2,10.165000000000001
NCT02252328,Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients,UNKNOWN,PHASE2,50.0,2015-09-01,2019-08-01,1.0643356643356645,Adequate (1-10/month),10.643356643356643,Significantly Below (<50%),50,34.0,14.02
NCT05766228,Web-Based Intercultural Midwifery Training Given to Midwifery Students,COMPLETED,NA,1113.0,2022-10-15,2023-05-15,159.81,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT00953628,Endometrial Advancement After Rec or u-HCG Triggering,COMPLETED,PHASE4,130.0,2005-08-01,2008-12-01,3.248932676518883,Adequate (1-10/month),32.48932676518883,Significantly Below (<50%),100,60.4,72.54
NCT06880328,18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia,COMPLETED,PHASE1,35.0,2018-11-07,2019-09-04,3.5395348837209304,Adequate (1-10/month),35.395348837209305,Significantly Below (<50%),100,52.8,55.31
NCT02143128,Efficacy Side-effect Score (ESS): Development and Evaluation of a New Tool for Patients After Surgery,COMPLETED,NA,1152.0,2014-03-01,2015-05-01,82.31661971830987,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT00432328,Juvista (Avotermin) in Breast Reduction Surgery Scars,TERMINATED,PHASE2,39.0,2006-10-01,,,Slow (<1/month),,Significantly Below (<50%),10,16.1,2.55
NCT06815328,Efficacy of Shock Wave Therapy in Post-Stroke Muscle Spasticity Management,NOT_YET_RECRUITING,NA,50.0,2025-03-15,2025-04-30,33.08695652173913,Good (10-50/month),200.0,Exceeded (≥100%),30,38.0,19.255
NCT06002165,Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle,ENROLLING_BY_INVITATION,NA,4000.0,2023-10-04,2027-06-01,91.1377245508982,Excellent (>50/month),200.0,Exceeded (≥100%),55,86.5,91.97999999999999
NCT02004665,Incidence and Prognostic Value of DELIRIUM in Patients With Acute CORonary synDrome: an observatIonal Study,UNKNOWN,,400.0,2013-12-01,2016-11-01,11.422138836772984,Good (10-50/month),114.22138836772984,Exceeded (≥100%),50,70.3,82.09
NCT01719965,Evaluation of Tak Community Advisory Board,COMPLETED,,20.0,2012-10-01,2014-08-01,0.9100149476831091,Slow (<1/month),9.10014947683109,Significantly Below (<50%),100,44.9,30.025000000000002
NCT00884065,Effectiveness of Diacutaneous Fibrolysis in Painful Shoulder,COMPLETED,NA,50.0,2007-06-01,2008-01-01,7.112149532710281,Adequate (1-10/month),71.1214953271028,Below (50-75%),100,54.0,58.72500000000001
NCT01999465,NMES Efficacy on Patients With NBPP,COMPLETED,NA,20.0,2013-11-01,2018-01-31,0.3922680412371134,Slow (<1/month),3.9226804123711343,Significantly Below (<50%),100,46.6,37.375
NCT02537665,Heating Precondition of Epidural Catheter Decrease the Incidence of Injury to Blood Vessel During Epidural Catheter Placement,UNKNOWN,NA,200.0,2015-06-01,,,Slow (<1/month),,Significantly Below (<50%),50,41.0,23.01
NCT06154265,Intraoperative Echocardiography in Low-Risk CABG Surgery,ACTIVE_NOT_RECRUITING,NA,40.0,2024-01-22,2025-12-31,1.7173483779971792,Adequate (1-10/month),17.17348377997179,Significantly Below (<50%),85,48.7,44.93
NCT06827665,Clinical and Radiographic Evaluation of Allogenic Dentin Grafts for Alveolar Ridge Preservation,RECRUITING,PHASE1,10.0,2025-01-01,2027-12-30,0.2784995425434584,Slow (<1/month),2.7849954254345834,Significantly Below (<50%),60,33.8,13.694999999999999
NCT05651165,Drug-Eluting Balloons vs Mimetic Stents for Popliteal Artery Disease,UNKNOWN,NA,110.0,2021-12-01,2024-01-01,4.4,Adequate (1-10/month),44.0,Significantly Below (<50%),50,43.8,27.965
NCT04620265,Differential Air Pressure Technology for Treatment of Diabetic Elderly Patients,COMPLETED,NA,110.0,2020-03-01,2020-10-01,15.646728971962618,Good (10-50/month),156.46728971962617,Exceeded (≥100%),100,63.8,76.78
NCT00916565,Evaluation of Cow Milk-Based Formulas - Functional Proteins,COMPLETED,,139.0,2009-07-01,,,Slow (<1/month),,Significantly Below (<50%),100,49.5,46.58
NCT06708065,Effects of Armeo Power Robot Therapy on Upper Limb Recovery in Hemiplegic Stroke Patients,COMPLETED,NA,84.0,2023-07-01,2024-08-30,6.002253521126761,Adequate (1-10/month),60.022535211267616,Below (50-75%),100,56.7,65.53
NCT07027865,Sip and Snack Better (SSB) Study: Improving Added Sugar in Adolescents,RECRUITING,NA,70.0,2025-06-24,2026-07-31,5.300497512437811,Adequate (1-10/month),53.004975124378106,Below (50-75%),60,43.6,27.54
NCT00059865,Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer,COMPLETED,PHASE1,68.0,2004-01-01,2008-02-01,1.3873458445040217,Adequate (1-10/month),13.873458445040216,Significantly Below (<50%),100,50.4,48.355
NCT03524365,Bariatric Surgery Versus Non-alcoholic Steato-hepatitis,COMPLETED,NA,288.0,2018-12-06,2022-07-20,6.631406959152798,Adequate (1-10/month),66.314069591528,Below (50-75%),100,73.0,83.44
NCT04215965,Efficacy and Safety of a Citrate-based Anticoagulation With Calcium-free Phosphate-containing Fluid in Renal Replacement Therapy,UNKNOWN,PHASE4,100.0,2020-05-02,2022-08-01,3.707673568818514,Adequate (1-10/month),37.07673568818514,Significantly Below (<50%),50,43.0,26.465
NCT01050465,MedlinePlus Health Prescriptions: Developing a Pragmatic Approach for Clinic Use,COMPLETED,NA,907.0,2009-05-01,2010-12-01,47.68407599309154,Good (10-50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT01534065,Barricaid EU Post Market Study for Primary Lumbar Disc Herniation,COMPLETED,NA,45.0,2009-04-01,2013-03-01,0.957902097902098,Slow (<1/month),9.57902097902098,Significantly Below (<50%),100,48.6,44.685
NCT05999565,Investigation of the Effect of Motor Imagery Training in Individuals with Cervical Discogenic Pain,COMPLETED,NA,40.0,2024-01-04,2024-09-02,5.031404958677686,Adequate (1-10/month),50.31404958677687,Below (50-75%),100,53.2,56.665
NCT04475965,The Effectiveness of Isometric Exercise on the Management of Chronic Shoulder Pain,COMPLETED,NA,82.0,2018-12-01,2019-10-05,8.104155844155844,Adequate (1-10/month),81.04155844155844,Met (75-100%),100,56.6,65.34
NCT04725565,Genetics Adviser: Evaluating a Digital Decision Support Tool for Genetic Results,COMPLETED,NA,133.0,2021-06-22,2024-04-06,3.9730323846908733,Adequate (1-10/month),39.73032384690873,Significantly Below (<50%),100,60.6,72.785
NCT01857765,Breast Augmentation Rehabilitation Program,WITHDRAWN,NA,0.0,2013-05-01,2014-09-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT00107965,Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses,COMPLETED,PHASE2,60.0,2005-03-01,2005-09-01,9.92608695652174,Adequate (1-10/month),99.2608695652174,Met (75-100%),100,59.8,71.61
NCT06367465,Feasibility and Acceptability of HCV Treatment in Pregnancy,RECRUITING,,50.0,2024-02-01,2026-02-28,2.007915567282322,Adequate (1-10/month),20.07915567282322,Significantly Below (<50%),60,40.3,22.21
NCT00029965,Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders,RECRUITING,,200.0,2002-02-06,,,Slow (<1/month),,Significantly Below (<50%),60,42.3,25.295
NCT03007667,The Impact of Colorectal Cancer Surgery on Localization of Ureters; Prospective Clinical Trail,COMPLETED,,30.0,2016-10-01,2017-09-30,2.5087912087912088,Adequate (1-10/month),25.08791208791209,Significantly Below (<50%),100,50.7,48.915
NCT06500767,Psycho-emotional Impact of Preoperative Counselling in Cervico-carcinoma Screening Programs,RECRUITING,,300.0,2022-06-01,2025-07-01,8.1101243339254,Adequate (1-10/month),81.101243339254,Met (75-100%),60,60.3,72.34
NCT04006067,The Impact of Changing Gloves During Cesarean Section on Post-operative Wound Complication,UNKNOWN,NA,600.0,2019-06-20,2020-10-01,38.94243070362474,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT04838067,Validation of Therapeutic Effects of Cefaly on Insomnia,COMPLETED,NA,19.0,2018-07-26,2020-07-14,0.8043949930458971,Slow (<1/month),8.043949930458972,Significantly Below (<50%),100,46.5,36.815
NCT06578767,Decompression of Pudendal and Inferior Cluneal Nerves Using Robot-assisted Laparoscopy for Entrapment Neuralgias : the X-DECO Study,RECRUITING,,20.0,2024-07-31,2025-07-01,1.8173134328358211,Adequate (1-10/month),18.17313432835821,Significantly Below (<50%),60,37.9,19.139999999999997
NCT06022367,Activation Technique in cVEMPs,COMPLETED,NA,24.0,2022-12-15,2023-02-24,10.289577464788731,Good (10-50/month),102.89577464788732,Exceeded (≥100%),100,56.9,65.89500000000001
NCT07094867,Customized z Shaped Miniplate Versus Standard 2 Miniplates for Fixation of Parasymphyseal/Body Mandibular Fractures,COMPLETED,NA,22.0,2024-04-01,2024-12-30,2.453040293040293,Adequate (1-10/month),24.530402930402932,Significantly Below (<50%),100,51.8,52.17
NCT02057367,Scalp Nerve Block and Opioid Consumption in Brain Surgery,COMPLETED,PHASE4,100.0,2013-03-01,2016-04-01,2.7009760425909497,Adequate (1-10/month),27.009760425909494,Significantly Below (<50%),100,58.0,68.245
NCT05793567,A Study of Microcirculatory Function in Type 2 Myocardial Infarction (T2MI),NOT_YET_RECRUITING,,52.0,2026-08-01,2027-04-01,6.513909465020577,Adequate (1-10/month),65.13909465020576,Below (50-75%),30,31.5,10.635
NCT06407167,Neuropathic Pain in Patients With Degenerative Lumbar Stenosis,ACTIVE_NOT_RECRUITING,,120.0,2024-05-13,2026-05-13,5.003835616438357,Adequate (1-10/month),50.03835616438357,Below (50-75%),85,53.4,57.35
NCT01131767,Bioequivalence Study of Naproxen Sodium 220 mg & Pseudoephedrine HCl 120 mg ER Tablets of Dr. Reddy's Under Fed Conditions,COMPLETED,PHASE1,26.0,2004-07-01,2004-09-01,12.76516129032258,Good (10-50/month),127.6516129032258,Exceeded (≥100%),100,57.1,66.27
NCT01690767,A Study to Assess the Ability of 2% Lidocaine Gel to Reduce the Discomfort of Urethral Catheterization,COMPLETED,PHASE2,133.0,2011-12-01,2014-12-01,3.693905109489051,Adequate (1-10/month),36.939051094890516,Significantly Below (<50%),100,60.6,72.785
NCT05707767,A Prospective Study of Surgical Treatment Strategies for Chordoma,UNKNOWN,NA,100.0,2023-02-01,2024-09-30,5.0148270181219115,Adequate (1-10/month),50.14827018121911,Below (50-75%),50,43.0,26.465
NCT05437367,Effect of Scapular Stabilization Exercises on Scapular Muscles Strength and Kyphosis Index in Smartphone Users,UNKNOWN,NA,88.0,2022-06-01,2023-07-01,6.7815696202531655,Adequate (1-10/month),67.81569620253165,Below (50-75%),50,42.0,24.825
NCT04501367,"Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker.",UNKNOWN,PHASE4,60.0,2021-04-27,2024-12-31,1.3589285714285715,Adequate (1-10/month),13.589285714285715,Significantly Below (<50%),50,34.8,15.040000000000001
NCT04435067,"Evaluation of Clinical, Radiomics and Molecular Features of Lung Metastasis in PDAC Patients (LUMACA Trial)",UNKNOWN,,44.0,2020-05-27,2021-12-31,2.297358490566038,Adequate (1-10/month),22.97358490566038,Significantly Below (<50%),50,36.9,17.735
NCT02351700,Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors,COMPLETED,PHASE4,62.0,2015-02-01,2016-04-01,4.440658823529412,Adequate (1-10/month),44.40658823529412,Significantly Below (<50%),100,55.0,61.834999999999994
NCT01094600,Comparison of Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) to Endoscopic Pancreatic Function Test (ePFT) in Diagnosing Pancreatic Exocrine Insufficiency,WITHDRAWN,NA,0.0,2012-06-01,2012-06-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT02860000,"Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE2,96.0,2017-07-06,2026-12-31,0.8433593073593074,Slow (<1/month),8.433593073593073,Significantly Below (<50%),85,48.2,43.665
NCT02865200,The Effectiveness of Dry Needling and Classic Physiotherapy Programs in The Patients Suffering From Chronic Low Back Pain Caused by Lumbar Disc Hernia,COMPLETED,NA,34.0,2015-02-01,2015-12-01,3.415709570957096,Adequate (1-10/month),34.15709570957096,Significantly Below (<50%),100,52.7,55.04
NCT04188600,Study to Evaluate the Effectiveness and Safety of Libicare® in Women With Low Arousal and Sexual Desire Levels,WITHDRAWN,NA,0.0,2019-11-14,2023-11-30,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT04648800,Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland,UNKNOWN,PHASE3,1000.0,2020-07-07,2021-04-01,113.5820895522388,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT01391000,Laser CO2 Versus TENS After Reconstruction of the Rotator Cuff,COMPLETED,NA,70.0,2011-07-01,2013-11-01,2.495081967213115,Adequate (1-10/month),24.95081967213115,Significantly Below (<50%),100,55.6,62.905
NCT03749200,Motivational Approach to Treat Childhood Obesity,COMPLETED,NA,319.0,2016-01-01,2021-12-31,4.431930625285259,Adequate (1-10/month),44.319306252852584,Significantly Below (<50%),100,75.5,84.68
NCT07124000,DESTINY-PANTUMOUR04,RECRUITING,,100.0,2025-09-18,2028-03-30,3.2943722943722946,Adequate (1-10/month),32.94372294372294,Significantly Below (<50%),60,44.3,28.715000000000003
NCT04963400,Impact of Hospitalization on High-sensitivity Cardiac Troponin T Concentrations Depending on Disease Severity,COMPLETED,,177.0,2021-07-14,2024-01-17,5.875550708833152,Adequate (1-10/month),58.75550708833151,Below (50-75%),100,62.5,75.21
NCT07260500,"A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and Pharmacokinetics",RECRUITING,PHASE2,72.0,2025-11-11,2027-01-31,4.9140807174887895,Adequate (1-10/month),49.14080717488789,Significantly Below (<50%),60,43.8,27.965
NCT05097300,Treatment of Tension Headache Using Soft Tissue Techniques VS Vagus Stimulation Techniques.,UNKNOWN,NA,42.0,2021-11-01,2021-12-01,42.0,Good (10-50/month),200.0,Exceeded (≥100%),50,48.4,44.22
NCT04591600,Effectiveness of Ivermectin and Doxycycline on COVID-19 Patients,COMPLETED,PHASE1,140.0,2020-07-01,2020-10-14,40.586666666666666,Good (10-50/month),200.0,Exceeded (≥100%),100,66.2,79.2
NCT04481100,CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer,UNKNOWN,PHASE2,38.0,2020-10-01,2023-07-31,1.1197676669893515,Adequate (1-10/month),11.197676669893514,Significantly Below (<50%),50,33.0,12.695
NCT03993600,New Markers of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Function in Sweat,UNKNOWN,NA,30.0,2018-12-04,2021-12-31,0.8131789848619768,Slow (<1/month),8.131789848619768,Significantly Below (<50%),50,32.4,12.025
NCT03777800,Body Therapy for War Veterans With Post Traumatic Stress Disorder (PTSD),COMPLETED,NA,42.0,2019-01-14,2022-01-01,1.1804986149584487,Adequate (1-10/month),11.804986149584488,Significantly Below (<50%),100,48.4,44.22
NCT06656000,Digital Analysis of Mesiodistal Tooth Width,NOT_YET_RECRUITING,,20.0,2024-12-01,2025-10-01,2.0026315789473683,Adequate (1-10/month),20.026315789473685,Significantly Below (<50%),30,28.9,8.709999999999999
NCT02204800,Active Surveillance of the Small Renal Mass,COMPLETED,,4.0,2014-12-01,2020-08-31,0.05798095238095239,Slow (<1/month),0.5798095238095239,Significantly Below (<50%),100,43.7,27.744999999999997
NCT06496100,"Effect of Triticum Aestivum on Appetite, Ghrelin, Leptin, Adiponectin Hormonal Axis in Patients With Obesity",RECRUITING,PHASE3,38.0,2024-01-03,2024-12-24,3.2492134831460673,Adequate (1-10/month),32.492134831460675,Significantly Below (<50%),60,41.0,23.01
NCT07356700,Deciphering the Factors of Longevity Through a Multi-Omics Study in Long-Lived Individuals in Hong Kong,NOT_YET_RECRUITING,,2500.0,2026-03-01,2031-02-28,41.6986301369863,Good (10-50/month),200.0,Exceeded (≥100%),30,77.3,85.67
NCT03702400,Norepinephrine or Phenylephrine in Bolus for Hypotension in Cesarean Delivery,COMPLETED,PHASE2,72.0,2018-10-01,2020-10-01,2.9981942544459645,Adequate (1-10/month),29.98194254445965,Significantly Below (<50%),100,55.8,63.245
NCT03729700,The Effect of Almonds on Facial Aesthetics and Modulation of the Microbiome and Lipidome,COMPLETED,NA,60.0,2018-10-22,2021-06-22,1.8751540041067762,Adequate (1-10/month),18.751540041067763,Significantly Below (<50%),100,54.8,61.095
NCT03126500,Post - Hospital Syndrome: Profile of Functional Status by Malnutrition,UNKNOWN,,200.0,2017-05-31,2021-06-30,4.083165660630449,Adequate (1-10/month),40.83165660630449,Significantly Below (<50%),50,49.3,46.265
NCT03017300,Transdiaphragmatic Pressure and Neural Respiratory Drive Measured During Inspiratory Muscle Training in COPD,COMPLETED,NA,12.0,2016-01-01,2016-12-01,1.0903880597014926,Adequate (1-10/month),10.903880597014926,Significantly Below (<50%),100,46.0,34.1
NCT03949400,Effects of Exercise Therapy and Soft Brace on Knee Osteoarthritis,RECRUITING,,40.0,2018-04-24,2029-05-20,0.30108803165182985,Slow (<1/month),3.010880316518299,Significantly Below (<50%),60,34.5,14.52
NCT04098900,"Clinical Evaluation of the Click Sexual Health Test for the Detection of Neisseria Gonorrhoeae (NG), Trichomonas Vaginalis (TV), and Chlamydia Trachomatis (CT) in Women",COMPLETED,,309.0,2019-09-16,2019-12-03,120.58923076923077,Excellent (>50/month),200.0,Exceeded (≥100%),100,83.1,89.8
NCT02603107,Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults,COMPLETED,PHASE3,578.0,2015-11-20,2019-12-23,11.77665327978581,Good (10-50/month),117.76653279785812,Exceeded (≥100%),100,95.0,95.7
NCT03840707,"LIFEwithIBD: Living With Intention, Fullness and Engagement With Inflammatory Bowel Disease",COMPLETED,NA,76.0,2019-05-27,2021-02-28,3.5978849144634526,Adequate (1-10/month),35.97884914463453,Significantly Below (<50%),100,56.1,63.99
NCT05561907,Enteral Anastomosis for the Treatment of Gastric Outlet Obstruction: A Randomized Controlled Study Comparing Endoscopic Versus Surgical Gastrojejunostomy,RECRUITING,NA,32.0,2022-10-28,2025-06-01,1.028595564941922,Adequate (1-10/month),10.285955649419218,Significantly Below (<50%),60,35.6,16.03
NCT03331107,Correlation of the Objective and Subjective Measures of the Nasal Obstruction Before and After Surgery of the Nasal Septum,COMPLETED,,80.0,2016-12-05,2019-01-01,3.216908850726552,Adequate (1-10/month),32.16908850726553,Significantly Below (<50%),100,54.7,60.629999999999995
NCT05665907,Evaluation of Executive Functions in Children With Cochleovestibular Deficit,UNKNOWN,,60.0,2023-01-01,2024-01-01,5.003835616438357,Adequate (1-10/month),50.03835616438357,Below (50-75%),50,38.1,19.425
NCT00839007,Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure,COMPLETED,PHASE2,77.0,2009-06-01,2010-07-01,5.93387341772152,Adequate (1-10/month),59.338734177215194,Below (50-75%),100,56.2,64.21
NCT07202507,Proof-of-Concept Study of the SNOEZELEN Device on Anxiety Symptoms in Patients Hospitalized for Chemotherapy in a Pediatric Oncology Department,NOT_YET_RECRUITING,NA,20.0,2025-09-30,2027-10-31,0.8,Slow (<1/month),8.0,Significantly Below (<50%),30,25.6,7.595000000000001
NCT05750407,Feasibility of Cardiovascular Health Intervention Within Evidence-based Home Visiting,COMPLETED,NA,15.0,2023-05-15,2024-07-30,1.033031674208145,Adequate (1-10/month),10.330316742081449,Significantly Below (<50%),100,46.2,35.089999999999996
NCT03949907,Early IntraVenous Administration of Nutritional Support,TERMINATED,NA,34.0,2020-04-14,2024-07-30,0.6600510204081633,Slow (<1/month),6.600510204081633,Significantly Below (<50%),10,20.7,6.02
NCT00315107,Estrogen Treatment in Acromegalic Women,UNKNOWN,PHASE2,30.0,2006-05-01,2007-08-01,1.9982494529540482,Adequate (1-10/month),19.98249452954048,Significantly Below (<50%),50,37.4,18.62
NCT02093507,Effectiveness of Parent's Manipulation in Newborn With Metatarsus Adducts. a Randomized Controlled Trial,UNKNOWN,NA,200.0,2013-05-01,2014-12-01,10.514680483592402,Good (10-50/month),105.146804835924,Exceeded (≥100%),50,56.0,63.71
NCT03002207,Repairing the Defect of Intervertebral Disc With Autologous BMSC and Gelatin Sponge After Microendoscopic Discectomy for Lumbar Disc Herniation,COMPLETED,NA,25.0,2016-10-01,2024-12-22,0.2533288948069241,Slow (<1/month),2.533288948069241,Significantly Below (<50%),100,47.0,39.33
NCT06855407,Hypertension and Cerebrovascular Hemodynamics in General Anaesthesia,RECRUITING,NA,30.0,2024-12-06,2027-06-01,1.0068357221609703,Adequate (1-10/month),10.068357221609702,Significantly Below (<50%),60,35.4,15.765
NCT02509507,Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611,COMPLETED,PHASE1,127.0,2016-02-05,2023-07-11,1.4249465536306671,Adequate (1-10/month),14.249465536306671,Significantly Below (<50%),100,55.2,62.195
NCT06321107,Long-term Follow-up Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference,ACTIVE_NOT_RECRUITING,,158.0,2024-03-01,2025-10-31,7.897405582922824,Adequate (1-10/month),78.97405582922823,Met (75-100%),85,56.5,65.18
NCT02250807,Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection,COMPLETED,PHASE3,40.0,2015-01-01,2015-12-01,3.645508982035928,Adequate (1-10/month),36.455089820359284,Significantly Below (<50%),100,53.2,56.665
NCT01219907,Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer,WITHDRAWN,PHASE1,0.0,2012-06-01,,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT05169892,Aquablation in Benign Prostatic Hyperplasia in Canada,RECRUITING,,25.0,2019-10-09,2026-12-31,0.28825757575757577,Slow (<1/month),2.882575757575758,Significantly Below (<50%),60,33.3,13.200000000000001
NCT04669392,The Effect of Using 70% Ethanol Alcohol as a Root Canal Irrigant on Increasing the Success Rate of Metapex in Pulpectomy Compared to Normal Saline in Primary Molars,UNKNOWN,EARLY_PHASE1,20.0,2021-12-01,2023-01-01,1.5373737373737375,Adequate (1-10/month),15.373737373737374,Significantly Below (<50%),50,31.6,10.905
NCT01171092,A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma,COMPLETED,EARLY_PHASE1,21.0,2010-09-01,2014-12-01,0.4118814432989691,Slow (<1/month),4.118814432989691,Significantly Below (<50%),100,46.7,37.895
NCT03967392,Comparison of Bupivacaine Versus Bupivacaine-dexamethasone Infiltration for Postoperative Analgesia in Skin Graft Donor Sites,COMPLETED,PHASE4,100.0,2018-10-10,2019-02-10,24.747967479674795,Good (10-50/month),200.0,Exceeded (≥100%),100,63.0,75.845
NCT03417492,Cerebrovascular Reactivity in American Football Players,TERMINATED,PHASE1,7.0,2018-03-01,2022-06-30,0.13469026548672566,Slow (<1/month),1.3469026548672567,Significantly Below (<50%),10,18.6,4.25
NCT05054192,Reliability and Validity of Modified Four Square Step Test,UNKNOWN,,28.0,2021-09-01,2023-09-01,1.1675616438356167,Adequate (1-10/month),11.675616438356165,Significantly Below (<50%),50,30.6,9.475
NCT03327792,Mavoglurant in Alcohol Drinking,COMPLETED,PHASE1,34.0,2018-02-07,2023-07-13,0.5221796165489405,Slow (<1/month),5.221796165489406,Significantly Below (<50%),100,47.7,42.17
NCT04168892,Anti-Müllerian Hormone (AMH) Measured With Fully Automated Assay Versus AFC in the Prediction of Ovarian Response,COMPLETED,,160.0,2019-09-20,2023-01-31,3.9628966639544343,Adequate (1-10/month),39.628966639544345,Significantly Below (<50%),100,61.1,73.31
NCT02854592,Intravenous Thrombolysis Registry for Chinese Ischemic Stroke Within 4.5 h Onset,COMPLETED,,4000.0,2017-04-01,2019-10-30,129.25690021231424,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT01563692,Immune Response to Respiratory Syncytial Virus (RSV) in Health Care Workers,COMPLETED,,30.0,2012-03-01,,,Slow (<1/month),,Significantly Below (<50%),100,40.7,22.675
NCT00063492,Angiotensinogen Gene and Human Hypertension,COMPLETED,,,2003-01-01,2007-12-01,,Slow (<1/month),,Significantly Below (<50%),100,43.3,27.05
NCT06853392,Socket Preservation Using Dentin Graft Autogenous Dentin Graft With Collagen Sponge on Dental Implant Stability AUTOGENOUS TOOTH GRAFT WITH COLLAGEN SPONGE ON DENTAL IMPLANT STABILITY,COMPLETED,PHASE3,16.0,2023-09-15,2024-06-01,1.8732307692307693,Adequate (1-10/month),18.73230769230769,Significantly Below (<50%),100,51.3,50.62
NCT04367792,Cardiac Injury in COVID-19: a Pathology Study,UNKNOWN,,60.0,2020-04-23,2021-03-01,5.8538461538461535,Adequate (1-10/month),58.53846153846154,Below (50-75%),50,38.1,19.425
NCT05581992,Study to Evaluate the Drug-drug Interaction Effect of Omeprazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants,COMPLETED,PHASE1,14.0,2020-01-06,2020-01-26,14.0,Good (10-50/month),140.0,Exceeded (≥100%),100,56.1,63.99
NCT05130892,Effect of Inflammasome Inhibitor on hsCRP in Patients After PCI,COMPLETED,PHASE4,132.0,2021-11-15,2023-02-01,9.070158013544019,Adequate (1-10/month),90.70158013544018,Met (75-100%),100,65.6,78.56
NCT00761592,Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm,COMPLETED,PHASE4,65.0,2006-07-01,2008-01-01,3.6040072859744994,Adequate (1-10/month),36.040072859744996,Significantly Below (<50%),100,55.2,62.195
NCT00810992,Traditional Tibetan Medicine for Patients With Coronary Artery Disease,COMPLETED,NA,524.0,2009-01-01,2011-04-01,19.45190243902439,Good (10-50/month),194.5190243902439,Exceeded (≥100%),100,95.0,95.7
NCT04554992,Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019),UNKNOWN,PHASE1,350.0,2020-03-20,2022-06-01,13.26774595267746,Good (10-50/month),132.6774595267746,Exceeded (≥100%),50,68.0,80.56
NCT04428892,Simulation in Physical Therapy Students,COMPLETED,NA,40.0,2019-03-01,2019-12-20,4.141496598639455,Adequate (1-10/month),41.414965986394556,Significantly Below (<50%),100,53.2,56.665
NCT06724692,Acute Effects of Ultra-processed Versus Unprocessed Foods on Glucocorticoid Secretion in Healthy Individuals,RECRUITING,NA,20.0,2024-10-30,2026-02-01,1.3263616557734206,Adequate (1-10/month),13.263616557734206,Significantly Below (<50%),60,34.6,14.729999999999999
NCT00005592,Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma,COMPLETED,PHASE2,23.0,1999-11-01,2005-11-01,0.3193978102189781,Slow (<1/month),3.193978102189781,Significantly Below (<50%),100,46.8,38.440000000000005
NCT03598192,The Effect and Safety of the Four Points Transversus Abdominis Plane Block,COMPLETED,NA,30.0,2018-08-15,2020-07-30,1.2772027972027973,Adequate (1-10/month),12.772027972027974,Significantly Below (<50%),100,47.4,40.98
NCT02298192,A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms,COMPLETED,PHASE3,420.0,2014-11-21,2015-12-23,32.20352644836272,Good (10-50/month),200.0,Exceeded (≥100%),100,88.6,92.825
NCT02879292,Post-operative Outcomes in the Pyloromyotomy Procedure Under Spinal Anesthesia,UNKNOWN,,92.0,2016-12-01,2017-02-01,45.16903225806451,Good (10-50/month),200.0,Exceeded (≥100%),50,50.7,48.915
NCT05992792,Evaluation of the International Diffusion of the European Code Against Cancer Through Mobile Telephony,TERMINATED,NA,1990.0,2018-01-01,2022-07-10,36.690248334342826,Good (10-50/month),200.0,Exceeded (≥100%),10,68.0,80.56
NCT03191292,Bacterial Epidemiology and Empirical Antibiotherapy in Patients With Prosthetic Joint Infection,COMPLETED,,567.0,2016-06-01,2017-04-30,51.830270270270276,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT01048892,"Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features",COMPLETED,PHASE1,22.0,2009-09-01,,,Slow (<1/month),,Significantly Below (<50%),100,41.8,24.445
NCT00261092,GEMOX: Oxaliplatin in Pancreatic Cancer,COMPLETED,PHASE2,48.0,2005-10-01,,,Slow (<1/month),,Significantly Below (<50%),100,43.8,27.965
NCT04778592,Efficacy and Safety of ETX-018810 in Subjects With Lumbosacral Radicular Pain,COMPLETED,PHASE2,149.0,2021-01-19,2022-05-25,9.237393075356415,Adequate (1-10/month),92.37393075356415,Met (75-100%),100,66.9,79.60000000000001
NCT03223792,Acceptance Of A Partially-Hydrolyzed Infant Formula,COMPLETED,NA,100.0,2017-08-21,2018-12-31,6.124748490945675,Adequate (1-10/month),61.24748490945675,Below (50-75%),100,58.0,68.245
NCT01064492,A Phase 1 Study To Estimate The Relative Bioavailability And Food Effect Of PF-04620110 In Healthy Adult Subjects,COMPLETED,PHASE1,12.0,2010-02-01,2010-03-01,12.0,Good (10-50/month),120.0,Exceeded (≥100%),100,56.0,63.71
NCT05271292,Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.,RECRUITING,PHASE1,36.0,2022-08-26,2025-05-01,1.1193462717058222,Adequate (1-10/month),11.193462717058221,Significantly Below (<50%),60,35.9,16.445
NCT06610292,Effects of Pharmacist-led Medication Reconciliation Services on Geriatric Patients,COMPLETED,NA,128.0,2018-06-24,2018-10-13,35.101981981981986,Good (10-50/month),200.0,Exceeded (≥100%),100,65.2,78.23
NCT01350492,Impact of Exercise Training on Pain and Brain Function in Gulf War Veterans,COMPLETED,NA,77.0,2013-04-16,2019-06-18,1.0398757763975157,Adequate (1-10/month),10.398757763975157,Significantly Below (<50%),100,51.2,50.375
NCT04662892,An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca,UNKNOWN,,200.0,2020-08-01,2022-12-15,7.030023094688222,Adequate (1-10/month),70.30023094688221,Below (50-75%),50,49.3,46.265
NCT01918436,"RCT, Proof of Concept Study of TEAMS (Training Executive, Attention and Motor Skills) Intervention Program",UNKNOWN,NA,160.0,2012-10-01,2014-12-01,6.157269279393174,Adequate (1-10/month),61.572692793931736,Below (50-75%),50,47.8,42.42
NCT02010736,Loading Gait in Spatic Cerebral Palsy,COMPLETED,NA,20.0,2012-09-01,2012-11-01,9.98032786885246,Adequate (1-10/month),99.80327868852457,Met (75-100%),100,56.6,65.34
NCT06378736,Electroencephalogram Recording in Patients With Systemic Lupus Erythematosus,RECRUITING,,40.0,2024-01-22,2026-03-23,1.5393173198482935,Adequate (1-10/month),15.393173198482934,Significantly Below (<50%),60,34.5,14.52
NCT00033436,Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer,COMPLETED,PHASE3,330.0,2000-10-01,2008-11-01,3.401693193362682,Adequate (1-10/month),34.01693193362682,Significantly Below (<50%),100,76.4,85.25
NCT01714336,Does Tranexamic Acid Reduce the Need for Blood Transfusions in Patients Undergoing Hip Fracture Surgery?,COMPLETED,PHASE4,138.0,2012-09-01,2015-10-01,3.733973333333333,Adequate (1-10/month),37.339733333333335,Significantly Below (<50%),100,61.0,73.17
NCT03436836,Nalbuphine as an Adjuvant to Local Anaesthetic Mixture in Peribulbar Cataract Surgery,COMPLETED,NA,40.0,2018-01-14,2018-02-28,27.05777777777778,Good (10-50/month),200.0,Exceeded (≥100%),100,58.2,68.795
NCT06510036,Assessment of Pancreatic Physiological and Pathological Characteristics Based on Spectral CT,RECRUITING,,1500.0,2021-01-21,2028-06-21,16.86115214180207,Good (10-50/month),168.61152141802066,Exceeded (≥100%),60,81.3,88.58
NCT00966836,Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy,UNKNOWN,PHASE3,100.0,2009-04-01,,,Slow (<1/month),,Significantly Below (<50%),50,33.0,12.695
NCT03730636,Procalcitonin and Duration of AntiBiotherapy In Late Onset Sepsis of Neonate,COMPLETED,NA,511.0,2019-02-15,2023-03-07,10.50293045239703,Good (10-50/month),105.0293045239703,Exceeded (≥100%),100,95.0,95.7
NCT01744236,SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies,COMPLETED,PHASE4,70.0,2013-04-01,2015-08-01,2.5009389671361504,Adequate (1-10/month),25.009389671361504,Significantly Below (<50%),100,55.6,62.905
NCT02305836,Effect of Electroacupuncture Combined With Donepezil for Treating Alzheimer's Disease,UNKNOWN,PHASE2,334.0,2017-06-01,2019-12-01,11.135772179627601,Good (10-50/month),111.35772179627604,Exceeded (≥100%),50,66.7,79.47999999999999
NCT05380336,Medico-economic Evaluation Comparing the Impact of the New Fixed-dose Nivolumab Regimen With the Old mg/kg Regimen in the Management of Patients With Metastatic Cancer,COMPLETED,,40000.0,2014-01-01,2021-12-31,416.8435467305717,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT06188936,Home Semen Analysis Tests As a Screening Tool for Fertility Patients,COMPLETED,EARLY_PHASE1,200.0,2023-11-08,2024-10-29,17.10112359550562,Good (10-50/month),171.01123595505618,Exceeded (≥100%),100,71.0,82.44
NCT02526836,Complete Mesocolic Excision With Central Vessel Ligation Compared With Conventional Surgery for Colon Cancer,UNKNOWN,PHASE2,40.0,2014-09-01,2018-10-01,0.8166331321260899,Slow (<1/month),8.166331321260898,Significantly Below (<50%),50,33.2,12.989999999999998
NCT06052436,Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Control the Immune Hyperactivation Associated With COVID-19 and/or Acute Respiratory Distress Syndrome (THYTECH2),RECRUITING,PHASE1,24.0,2023-06-27,2027-12-31,0.44330097087378645,Slow (<1/month),4.433009708737864,Significantly Below (<50%),60,34.9,15.215
NCT00476736,The Effect of N-Acetylcystein on Quality of Life and Air Trapping During Rest and After Exercise,UNKNOWN,PHASE4,30.0,2007-05-01,2007-05-01,30.0,Good (10-50/month),200.0,Exceeded (≥100%),50,27.4,8.225
NCT02621736,Copeptin for Prediction of Treatment Response in Children With Monosymptomatic Nocturnal Enuresis (MEN).,COMPLETED,,28.0,2016-01-01,2021-06-30,0.4246736422521176,Slow (<1/month),4.246736422521176,Significantly Below (<50%),100,45.6,32.08
NCT01365936,hMG or Recombinant FSH on OHSS Prevention in PCOS Patients Undergoing IVF,COMPLETED,PHASE4,80.0,2008-01-01,2008-06-01,16.021052631578947,Good (10-50/month),160.21052631578948,Exceeded (≥100%),100,61.4,73.735
NCT03263936,Epigenetic Reprogramming in Relapse/Refractory AML,COMPLETED,PHASE1,37.0,2017-07-11,2022-02-10,0.6724059701492537,Slow (<1/month),6.724059701492538,Significantly Below (<50%),100,48.0,42.945
NCT03549611,Pre-induction Analgesia: Multimodel Regimen vs Aceteminophen for Post Ureteroscopy Pain,WITHDRAWN,PHASE4,0.0,2018-08-01,2019-06-30,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT06999811,Technology-Enhanced Therapy vs. Medication Monitoring for Buprenorphine Retention in Pregnant Persons,RECRUITING,NA,37.0,2025-11-05,2028-10-15,1.0477023255813953,Adequate (1-10/month),10.477023255813954,Significantly Below (<50%),60,36.0,16.564999999999998
NCT02518711,Effectiveness Study of a Behavioral Teacher Program Targeting ADHD Symptoms,COMPLETED,NA,114.0,2011-09-01,2014-07-01,3.3560541586073507,Adequate (1-10/month),33.560541586073505,Significantly Below (<50%),100,59.1,70.6
NCT02754011,Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 Negative,COMPLETED,PHASE1,18.0,2017-02-02,2022-12-23,0.254846511627907,Slow (<1/month),2.5484651162790697,Significantly Below (<50%),100,46.4,36.26
NCT00940511,Effects of Coordinated Care for Disabled Medicaid Recipients,COMPLETED,NA,2618.0,2009-08-01,2013-01-01,63.80457966373099,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT02908711,Adductor Canal Block (ACB) Before and After Primary Total Knee Arthroplasty (TKA),COMPLETED,PHASE4,50.0,2016-10-01,2018-01-01,3.3304157549234135,Adequate (1-10/month),33.304157549234134,Significantly Below (<50%),100,54.0,58.72500000000001
NCT05537311,Reducing Isolation and Feeling of Loneliness During Critical Illness,COMPLETED,NA,13.0,2022-07-27,2023-07-01,1.167315634218289,Adequate (1-10/month),11.673156342182892,Significantly Below (<50%),100,46.0,34.1
NCT00191711,Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk.,COMPLETED,PHASE2,43.0,2004-02-01,2005-10-01,2.152828947368421,Adequate (1-10/month),21.52828947368421,Significantly Below (<50%),100,53.4,57.35
NCT03610711,REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer,ACTIVE_NOT_RECRUITING,PHASE1,21.0,2019-03-06,2026-12-01,0.22611956137247965,Slow (<1/month),2.2611956137247966,Significantly Below (<50%),85,42.2,25.155
NCT01040611,Effectiveness of Music Therapy,UNKNOWN,NA,66.0,2009-10-01,2010-09-01,5.99713432835821,Adequate (1-10/month),59.97134328358209,Below (50-75%),50,40.3,22.21
NCT06851611,The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus,COMPLETED,PHASE1,40.0,2025-01-21,2025-06-26,7.805128205128205,Adequate (1-10/month),78.05128205128206,Met (75-100%),100,53.2,56.665
NCT04926311,Efficiency of Speech and Language Intervention on Achievement of Children With Developmental Language Disorder,COMPLETED,,130.0,2021-06-08,2022-06-01,11.053631284916202,Good (10-50/month),110.53631284916202,Exceeded (≥100%),100,63.7,76.655
NCT00002611,Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer,COMPLETED,PHASE3,3031.0,1995-07-01,2003-08-01,31.244036572976633,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT04545411,Combination GRA and SGLT-2i Treatment in Type 1 Diabetes,COMPLETED,PHASE1,12.0,2021-02-22,2022-10-31,0.592987012987013,Slow (<1/month),5.92987012987013,Significantly Below (<50%),100,46.0,34.1
NCT00358111,Study of LUMA Cervical Imaging System as Adjunct to Colposcopy,TERMINATED,PHASE4,10.0,2006-07-01,2010-11-01,0.1921717171717172,Slow (<1/month),1.9217171717171717,Significantly Below (<50%),10,18.8,4.58
NCT04862611,"Tracking Attempts of CSE, Epidural and Spinal Insertions (TRACES)",COMPLETED,,220.0,2021-01-05,2021-05-05,55.80666666666667,Excellent (>50/month),200.0,Exceeded (≥100%),100,75.9,84.885
NCT04236011,BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma,UNKNOWN,EARLY_PHASE1,15.0,2020-01-16,2022-12-31,0.42277777777777775,Slow (<1/month),4.227777777777778,Significantly Below (<50%),50,31.2,10.165000000000001
NCT06057311,Equine Assisted Therapy in Autism Spectrum Disorder,COMPLETED,NA,33.0,2019-12-24,2020-08-24,4.116885245901639,Adequate (1-10/month),41.16885245901639,Significantly Below (<50%),100,52.6,54.684999999999995
NCT02332811,"An Open Label, Dose Titration Study of Sevelamer Carbonate Tablets & Powder in Hyperphosphatemic CKD Patients",COMPLETED,PHASE3,96.0,2013-10-01,2014-07-01,10.704175824175826,Good (10-50/month),107.04175824175826,Exceeded (≥100%),100,62.7,75.42
NCT06206811,Phase 1 Study to Investigate OD-07656 in Healthy Adult Participants,COMPLETED,PHASE1,101.0,2024-02-12,2024-11-25,10.71233449477352,Good (10-50/month),107.12334494773519,Exceeded (≥100%),100,63.1,76.03
NCT05732311,Intermittent Theta Burst Stimulation for Maintenance Therapy in Depression,RECRUITING,NA,60.0,2023-04-25,2026-02-28,1.7561538461538462,Adequate (1-10/month),17.561538461538458,Significantly Below (<50%),60,42.8,25.929999999999996
NCT05636111,Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer,RECRUITING,PHASE1,34.0,2023-07-12,2026-12-31,0.8162145110410095,Slow (<1/month),8.162145110410094,Significantly Below (<50%),60,35.7,16.18
NCT04568811,The Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine,COMPLETED,PHASE1,89.0,2020-09-26,2021-09-11,7.740457142857143,Adequate (1-10/month),77.40457142857142,Met (75-100%),100,57.1,66.27
NCT05700071,MRS of Glioma Genomics,RECRUITING,NA,80.0,2023-03-06,2028-03-02,1.3358200767964894,Adequate (1-10/month),13.358200767964892,Significantly Below (<50%),60,39.4,20.94
NCT01200771,Impact of the PET in the Diagnosis Strategy of FUO or Inflammatory Syndrome in Immunocompetent Patients FUO-TEP,COMPLETED,NA,116.0,2008-05-01,2014-02-01,1.679847764034253,Adequate (1-10/month),16.798477640342533,Significantly Below (<50%),100,59.3,70.815
NCT06555471,"A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer",RECRUITING,PHASE2,40.0,2024-08-06,2027-12-31,0.980354267310789,Slow (<1/month),9.80354267310789,Significantly Below (<50%),60,36.2,16.84
NCT03434171,Effect of Aerobic Exercises With Selected Phytoestrogens on Hot Flushes in Menopausal Women,UNKNOWN,NA,50.0,2016-01-01,2018-03-01,1.926582278481013,Adequate (1-10/month),19.265822784810126,Significantly Below (<50%),50,39.0,20.505000000000003
NCT01465971,Monitoring of the Cerebral Tissue Oxygenation and Perfusion in the Adapting Climber During Sleep in High Altitude,COMPLETED,,6.0,2011-05-01,2011-12-01,0.8534579439252337,Slow (<1/month),8.534579439252337,Significantly Below (<50%),100,43.8,27.965
NCT00539071,High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone,COMPLETED,PHASE4,160.0,2008-03-01,2012-05-01,3.2,Adequate (1-10/month),32.0,Significantly Below (<50%),100,62.8,75.53999999999999
NCT01381471,Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,,11060.0,2009-08-01,2010-05-01,1233.2102564102565,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT01069471,Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella,COMPLETED,PHASE1,40.0,2010-02-01,2010-10-01,5.031404958677686,Adequate (1-10/month),50.31404958677687,Below (50-75%),100,53.2,56.665
NCT06238271,Evaluation of the Long-term Efficacy and Safety of Monofocal Plate Haptic Intraocular Lens,UNKNOWN,NA,300.0,2022-11-23,2025-05-01,10.26067415730337,Good (10-50/month),102.60674157303372,Exceeded (≥100%),50,64.0,77.025
NCT05386771,Effects of Whey and Collagen Protein Blend on Protein Synthesis Rates,COMPLETED,NA,36.0,2022-09-06,2023-04-03,5.243253588516747,Adequate (1-10/month),52.432535885167475,Below (50-75%),100,52.9,55.55
NCT07217171,"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas",RECRUITING,PHASE1,160.0,2025-11-13,2031-01-29,2.559327377824488,Adequate (1-10/month),25.593273778244875,Significantly Below (<50%),60,50.8,49.18
NCT02658071,Measurement of Ocular Tensional Fluctuation by Triggerfish Lens Before and After Cataract Surgery in Patients With Exfoliative Glaucoma,UNKNOWN,,10.0,2016-03-15,2018-09-15,0.33304157549234137,Slow (<1/month),3.330415754923414,Significantly Below (<50%),50,29.1,8.799999999999999
NCT05219071,TRIP-Patch vs the Rigiscan,COMPLETED,,10.0,2022-06-20,2022-09-14,3.5395348837209304,Adequate (1-10/month),35.395348837209305,Significantly Below (<50%),100,49.1,45.83
NCT02555371,Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients,COMPLETED,PHASE3,306.0,2016-01-07,2019-07-24,7.1983307573415765,Adequate (1-10/month),71.98330757341577,Below (50-75%),100,74.5,84.28999999999999
NCT02889744,Comparison of Cerebral SctO2 Between 36℃ and 33℃ of TTM After Cardiac Arrest,UNKNOWN,NA,66.0,2016-03-01,2021-03-01,1.1002409638554218,Adequate (1-10/month),11.002409638554218,Significantly Below (<50%),50,35.3,15.534999999999998
NCT06421844,A Prospective Study: Smart Phone Application for Measure Serum Bilirubin Through Sclera Images,RECRUITING,,270.0,2024-04-20,2024-07-10,101.46666666666667,Excellent (>50/month),200.0,Exceeded (≥100%),60,67.9,80.36999999999999
NCT06269744,Proactive Outreach With FIT,ENROLLING_BY_INVITATION,NA,3000.0,2024-03-13,2026-04-30,117.37789203084834,Excellent (>50/month),200.0,Exceeded (≥100%),55,86.5,91.97999999999999
NCT03193944,"Vitamin D Supplementation on Metabolic Syndrome Indicators Among Older Adults, Alborz Province, Iran",COMPLETED,PHASE2,120.0,2017-02-10,2017-07-10,24.352,Good (10-50/month),200.0,Exceeded (≥100%),100,64.6,77.59
NCT06807944,"Association Between Salivary Soluble RANKL, OPG Concentration and Mandibular Resorption to Clinically Predict Severe Residual Ridge Resorption Risk",COMPLETED,,140.0,2021-11-30,2024-04-01,4.9960140679953104,Adequate (1-10/month),49.960140679953106,Significantly Below (<50%),100,59.5,71.0
NCT07239544,Generation of Reactive T Cells Based on Tumor Whole Cell Antigen Nanovaccines,ACTIVE_NOT_RECRUITING,,50.0,2025-07-10,2026-07-10,4.169863013698631,Adequate (1-10/month),41.6986301369863,Significantly Below (<50%),85,47.8,42.42
NCT02826044,The Pharmacokinetics Study of Single and Multiple Dose of SP2086 in Healthy Volunteers,UNKNOWN,PHASE1,30.0,2016-07-01,,,Slow (<1/month),,Significantly Below (<50%),50,27.4,8.225
NCT00313144,Aralast alpha1-proteinase Inhibitor Surveillance Study,TERMINATED,PHASE4,127.0,2006-06-09,2009-05-01,3.657407757805109,Adequate (1-10/month),36.57407757805109,Significantly Below (<50%),10,33.2,12.989999999999998
NCT01861444,An Observational Study on the Prevalence of Chronic Hepatitis D in Romania and the Efficacy of Treatment With Pegasys (Peginterferon Alfa-2a),TERMINATED,,45.0,2011-03-01,2015-03-01,0.9375770020533881,Slow (<1/month),9.37577002053388,Significantly Below (<50%),10,19.9,5.555000000000001
NCT06420544,"Japi: Cognitive, Emotional and Social Stimulation for Preschool Children",RECRUITING,NA,120.0,2024-06-01,2024-12-31,17.14929577464789,Good (10-50/month),171.49295774647888,Exceeded (≥100%),60,52.6,54.684999999999995
NCT03122444,Imipramine on ER+ve and Triple Negative Breast Cancer,COMPLETED,EARLY_PHASE1,17.0,2019-07-05,2022-05-01,0.5019204655674103,Slow (<1/month),5.019204655674104,Significantly Below (<50%),100,46.4,36.26
NCT04857944,Improving Depressive Symptoms Through Personalised Exercise and Activation,COMPLETED,NA,121.0,2021-06-07,2024-07-08,3.268181011535049,Adequate (1-10/month),32.68181011535049,Significantly Below (<50%),100,59.7,71.355
NCT06940544,Uppsala Self-SCREENing of Heart Failure Study,RECRUITING,NA,500.0,2023-02-01,2026-08-01,11.918559122944401,Good (10-50/month),119.18559122944401,Exceeded (≥100%),60,83.0,89.505
NCT02800044,Studying the Effectiveness of Non-Invasive Glucose Sensors in Patients With Diabetes: The SENSOR Study,TERMINATED,NA,6.0,2017-03-14,2018-03-27,0.4831746031746032,Slow (<1/month),4.831746031746032,Significantly Below (<50%),10,18.5,4.02
NCT00487344,Research Study of Nutritional Methods to Reduce Body Fat Percentages in Overweight and Obese Populations,UNKNOWN,PHASE1,32.0,2007-06-01,2007-11-01,6.366535947712419,Adequate (1-10/month),63.665359477124184,Below (50-75%),50,37.6,18.845
NCT02948244,Effect of Creatine Monohydrate on Functional Muscle Strength in Children With FSHD,COMPLETED,NA,11.0,2017-10-31,2022-07-01,0.1965023474178404,Slow (<1/month),1.965023474178404,Significantly Below (<50%),100,45.9,33.495000000000005
NCT02441244,Probiotic Visbiome for Inflammation and Translocation in HIV Ι,TERMINATED,PHASE2,1.0,2015-11-15,2016-12-19,0.0761,Slow (<1/month),0.761,Significantly Below (<50%),10,18.1,3.105
NCT06723444,Improving Learning and Memory in Portuguese Patients With Multiple Sclerosis,RECRUITING,NA,80.0,2024-12-05,2028-08-01,1.8241198501872662,Adequate (1-10/month),18.24119850187266,Significantly Below (<50%),60,44.4,28.95
NCT01570244,Drug-drug Interaction of BI 201335 and Microgynon,COMPLETED,PHASE1,16.0,2012-04-01,2012-08-01,3.9921311475409835,Adequate (1-10/month),39.92131147540983,Significantly Below (<50%),100,51.3,50.62
NCT01797744,Vestibular Rehabilitation for Strokepatients With Dizziness,COMPLETED,NA,31.0,2013-02-01,2018-06-01,0.48491264131551903,Slow (<1/month),4.849126413155191,Significantly Below (<50%),100,47.5,41.415
NCT03388944,PCT Guided Stopping of Antibiotic Therapy in Children With Sepsis,COMPLETED,NA,561.0,2019-10-21,2023-02-28,13.928907014681892,Good (10-50/month),139.28907014681891,Exceeded (≥100%),100,95.0,95.7
NCT03520244,A 12-week Exercise Program for Adults With Celiac Disease,COMPLETED,NA,48.0,2016-11-15,2018-03-30,2.92224,Adequate (1-10/month),29.222399999999997,Significantly Below (<50%),100,53.8,58.065
NCT05722834,Self-regulation for Older Adults With Asthma Through Remote Education,COMPLETED,NA,20.0,2023-06-13,2024-05-31,1.7246458923512749,Adequate (1-10/month),17.24645892351275,Significantly Below (<50%),100,51.6,51.644999999999996
NCT06042634,A Feasibility Study of Online Psychoeducation for Family Caregivers of People With Dementia,COMPLETED,NA,60.0,2022-07-15,2023-01-31,9.132,Adequate (1-10/month),91.32000000000001,Met (75-100%),100,59.8,71.61
NCT03029234,Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma,COMPLETED,PHASE3,126.0,2017-03-31,2021-06-04,2.5133944954128444,Adequate (1-10/month),25.133944954128445,Significantly Below (<50%),100,60.1,72.085
NCT04534634,Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL）,UNKNOWN,PHASE2,60.0,2019-04-01,2025-07-31,0.7896238651102465,Slow (<1/month),7.896238651102465,Significantly Below (<50%),50,34.8,15.040000000000001
NCT01539434,Behavioral Intervention to Maintain Physical Capacity and Activity in Patients With Chronic Obstructive Pulmonary Disease (COPD),UNKNOWN,PHASE2,100.0,2010-09-01,2020-12-01,0.813034188034188,Slow (<1/month),8.130341880341883,Significantly Below (<50%),50,38.0,19.255
NCT05448534,Electroencephalographic Patterns of Septic Patients and Its Correlation With Cognitive Outcomes,COMPLETED,,160.0,2021-11-01,2023-02-24,10.146666666666667,Good (10-50/month),101.46666666666665,Exceeded (≥100%),100,66.1,79.125
NCT03189134,Utilization of Confocal Microscopy During Cardiac Surgery,COMPLETED,PHASE1,6.0,2018-04-02,2019-04-26,0.46951156812339334,Slow (<1/month),4.695115681233934,Significantly Below (<50%),100,45.5,31.705
NCT00853034,Effects of Arabinoxylan-Oligosaccharides Compared to Other Prebiotics in Healthy Subjects,COMPLETED,PHASE4,20.0,2006-10-01,2007-09-01,1.8173134328358211,Adequate (1-10/month),18.17313432835821,Significantly Below (<50%),100,51.6,51.644999999999996
NCT01410734,Fluorescence Imaging on the da Vinci Surgical System for Intra-operative Near Infrared Imaging of the Biliary Tree (up to 2-weeks Post-operatively),COMPLETED,NA,72.0,2011-07-01,2012-12-01,4.222890173410405,Adequate (1-10/month),42.22890173410405,Significantly Below (<50%),100,55.8,63.245
NCT02202434,Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement,TERMINATED,NA,1425.0,2014-09-22,2021-05-21,17.828606658446365,Good (10-50/month),178.28606658446364,Exceeded (≥100%),10,68.0,80.56
NCT00691834,Safety and Efficacy on Cell-based Therapy in Patients With Recent Large Acute Myocardial Infarction,WITHDRAWN,PHASE2,0.0,2009-08-01,2009-08-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT05993234,A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY),RECRUITING,,257.0,2023-12-05,2027-09-01,5.726998535871157,Adequate (1-10/month),57.26998535871157,Below (50-75%),60,56.9,65.89500000000001
NCT05860634,Urinary Catheter Self-Discontinuation After Urogynecology Surgery,UNKNOWN,NA,118.0,2023-08-01,2025-11-01,4.36442284325638,Adequate (1-10/month),43.64422843256379,Significantly Below (<50%),50,44.4,28.95
NCT06372834,Adjuvant Accelerated piTBS for Reducing Suicidal Ideation in TRD Patients,COMPLETED,NA,100.0,2023-03-29,2024-12-20,4.8164556962025316,Adequate (1-10/month),48.164556962025316,Significantly Below (<50%),100,58.0,68.245
NCT01269034,New Onset Type 1 Diabetes: Role of Exenatide,COMPLETED,PHASE4,13.0,2010-12-01,2017-01-31,0.17564136706613406,Slow (<1/month),1.7564136706613405,Significantly Below (<50%),100,46.0,34.1
NCT03724864,Edulcorants Effect in Caries Risk Schoolchildren,COMPLETED,NA,271.0,2017-02-01,2018-05-08,17.894229934924077,Good (10-50/month),178.94229934924078,Exceeded (≥100%),100,76.7,85.385
NCT04903964,Growth and Development of Children With Congenital Heart Disease (CHD),COMPLETED,NA,42.0,2021-02-01,2021-09-15,5.656991150442479,Adequate (1-10/month),56.56991150442479,Below (50-75%),100,53.4,57.35
NCT01873664,Functional Magnetic Resonance Imaging Study of Jaw-tapping Movement on Memory Function,UNKNOWN,NA,30.0,2009-05-01,2013-07-01,0.6,Slow (<1/month),6.0,Significantly Below (<50%),50,32.4,12.025
NCT03512964,"Rapid HIV Treatment Initiation, Access and Engagement in Care",COMPLETED,NA,32.0,2016-11-29,2020-09-13,0.7038150289017341,Slow (<1/month),7.038150289017341,Significantly Below (<50%),100,47.6,41.775
NCT02328664,SCar-biopsies After Malignant Colorectal Polypectomy of Uncertain RAdicality,TERMINATED,NA,246.0,2015-08-01,2019-05-01,5.469861212563916,Adequate (1-10/month),54.69861212563916,Below (50-75%),10,42.7,25.77
NCT02175264,Genetic Basis of Non Syndromic Congenital Diaphragmatic Hernia,COMPLETED,,73.0,2014-06-01,2016-05-01,3.174457142857143,Adequate (1-10/month),31.744571428571426,Significantly Below (<50%),100,54.2,59.330000000000005
NCT03376464,Xeomin Cosmetic in the Management of Masseter,COMPLETED,PHASE4,30.0,2015-11-06,2017-10-11,1.2953191489361702,Adequate (1-10/month),12.953191489361702,Significantly Below (<50%),100,47.4,40.98
NCT00296764,Characterization of Angelman Syndrome,COMPLETED,,302.0,2006-02-01,2014-08-01,2.9625781501772477,Adequate (1-10/month),29.625781501772476,Significantly Below (<50%),100,72.5,83.23
NCT01429064,Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001,COMPLETED,PHASE2,76.0,2011-06-01,2015-11-01,1.4333581164807931,Adequate (1-10/month),14.333581164807931,Significantly Below (<50%),100,51.1,50.129999999999995
NCT05040464,Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial,RECRUITING,PHASE3,166.0,2021-08-26,2027-05-01,2.436374156219865,Adequate (1-10/month),24.363741562198648,Significantly Below (<50%),60,51.3,50.62
NCT00847964,Safety and Feasibility of Algisyl-LVR™ as a Method of Left Ventricular Restoration in Patients With DCM Undergoing Open-heart Surgery,COMPLETED,PHASE2,11.0,2009-02-01,2012-11-01,0.2445872899926954,Slow (<1/month),2.445872899926954,Significantly Below (<50%),100,45.9,33.495000000000005
NCT00660764,Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS),COMPLETED,,,2003-05-01,2005-04-01,,Slow (<1/month),,Significantly Below (<50%),100,43.3,27.05
NCT01776164,Early and Longitudinal Assessment of Neurodegeneration in the Brain and Spinal Cord in Friedreich's Ataxia,COMPLETED,,85.0,2013-01-01,2022-02-08,0.7781654135338346,Slow (<1/month),7.781654135338346,Significantly Below (<50%),100,50.1,47.89
NCT01969864,University Student Intervention to Increase Organ Donation,COMPLETED,NA,2261.0,2013-10-01,2016-12-01,59.48560069144339,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT03386864,Metabolic Determinants of Cardiac Function,COMPLETED,,400.0,2016-04-01,2020-04-01,8.334017796030116,Adequate (1-10/month),83.34017796030116,Met (75-100%),100,80.3,88.075
NCT06661564,Identification of Diagnosis Biomarkers in the Tears of Alzheimer's Disease Patients: The COG-EYE Pilot Study,RECRUITING,NA,90.0,2025-07-09,2027-07-01,3.794459833795014,Adequate (1-10/month),37.94459833795014,Significantly Below (<50%),60,45.2,30.830000000000002
NCT01150409,Hemodynamic and Inflammatory Effects of Abrupt Versus Tapered Corticosteroid Discontinuation in Septic Shock,TERMINATED,PHASE4,11.0,2008-05-01,2010-08-01,0.4073479318734793,Slow (<1/month),4.073479318734793,Significantly Below (<50%),10,18.9,4.6899999999999995
NCT01496209,REgenerative CardiOsphere iNjection to STRengthen dysfUnCTional Hearts,WITHDRAWN,PHASE1,0.0,2015-07-01,2017-09-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT01982409,Immune Persistence After Inoculated With One-dose Freeze-Dried Live Attenuated Varicella Vaccine in Children Vaccine in Children,UNKNOWN,PHASE4,350.0,2013-06-01,2018-12-01,5.303135888501743,Adequate (1-10/month),53.03135888501743,Below (50-75%),50,63.0,75.845
NCT06692309,Exploring the Predictive Value of Electroencephalography Features in Perioperative Neurocognitive Disorders Following Cardiovascular Surgery,RECRUITING,,100.0,2023-03-01,2026-02-28,2.779908675799087,Adequate (1-10/month),27.79908675799087,Significantly Below (<50%),60,44.3,28.715000000000003
NCT04772209,Comparison of Effectiveness and Complications of Catheter Lock Solutions in Non-tunneled Hemodialysis Catheters,COMPLETED,NA,441.0,2021-02-01,2022-03-30,31.810521327014218,Good (10-50/month),200.0,Exceeded (≥100%),100,90.3,93.28
NCT06974409,This Study Will Compare Force Production in Double-leg Squats of College Students Before and After a Standardized Foam Rolling Session,COMPLETED,NA,21.0,2025-06-11,2025-09-30,5.758918918918919,Adequate (1-10/month),57.58918918918919,Below (50-75%),100,51.7,51.94
NCT01653509,An Exploratory Study to Investigate the Inflammatory Response During a Cold Sore Episode,COMPLETED,PHASE1,60.0,2012-07-01,2012-09-01,29.45806451612903,Good (10-50/month),200.0,Exceeded (≥100%),100,59.8,71.61
NCT00115609,Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129),COMPLETED,PHASE3,70.0,2006-01-01,2009-11-01,1.522,Adequate (1-10/month),15.22,Significantly Below (<50%),100,50.6,48.705
NCT01201109,Carpal Tunnel Release in Diabetic Patients,UNKNOWN,,66.0,2010-11-01,2011-12-01,5.086177215189874,Adequate (1-10/month),50.861772151898734,Below (50-75%),50,38.6,20.015
NCT02001909,Effect of Neomycin on the Pharmacokinetics of Regorafenib,COMPLETED,PHASE1,27.0,2013-12-01,2014-04-01,6.792396694214877,Adequate (1-10/month),67.92396694214877,Below (50-75%),100,52.2,53.22
NCT05800509,Gestational Diabetes and Perinatal Depression: an Intervention Program,UNKNOWN,NA,226.0,2023-04-01,2024-07-01,15.05347921225383,Good (10-50/month),150.5347921225383,Exceeded (≥100%),50,58.1,68.595
NCT05342909,Two Time a Week vs. Five Time a Week Blood Flow Restriction Training Program for the Lower Extremity.,UNKNOWN,NA,55.0,2020-09-01,2022-06-30,2.5100449775112446,Adequate (1-10/month),25.100449775112445,Significantly Below (<50%),50,39.4,20.94
NCT01864109,Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma,ACTIVE_NOT_RECRUITING,PHASE2,83.0,2013-05-01,2027-05-01,0.494136514766282,Slow (<1/month),4.941365147662821,Significantly Below (<50%),85,47.1,39.64
NCT04592809,Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents,COMPLETED,PHASE3,50.0,2022-10-03,2025-08-31,1.431796801505174,Adequate (1-10/month),14.317968015051743,Significantly Below (<50%),100,49.0,45.61
NCT06124209,Use of Fibrin Sealant Patch for Vein Anastomosis During Deceased Donor Liver Transplantation- Randomized Clinical Trial,RECRUITING,PHASE4,170.0,2023-11-04,2026-03-01,6.102358490566038,Adequate (1-10/month),61.02358490566038,Below (50-75%),60,51.6,51.644999999999996
NCT05264909,Assessment of Transcranial Electrical Stimulation and Auditory Stimulation During Walking in Parkinson Patients,UNKNOWN,NA,5.0,2021-08-01,2022-12-31,0.29439071566731145,Slow (<1/month),2.9439071566731148,Significantly Below (<50%),50,30.4,9.345
NCT05701709,Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors,RECRUITING,PHASE1,395.0,2023-04-06,2025-08-31,13.694533029612757,Good (10-50/month),136.94533029612754,Exceeded (≥100%),60,74.6,84.31
NCT06626009,[Trial of device that is not approved or cleared by the U.S. FDA],WITHHELD,,,,,,Slow (<1/month),,Significantly Below (<50%),50,20.0,5.695
NCT05476809,Upgraded Smart Cloth Home Care System for Persons With Dementia,COMPLETED,NA,60.0,2022-11-01,2024-12-31,2.3089759797724403,Adequate (1-10/month),23.089759797724398,Significantly Below (<50%),100,54.8,61.095
NCT06678009,Isokinetic Training Combined with Blood Flow Restriction on Muscle Strength and Endurance,COMPLETED,NA,42.0,2022-07-15,2024-06-15,1.8237945791726105,Adequate (1-10/month),18.237945791726105,Significantly Below (<50%),100,53.4,57.35
NCT07227909,NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy,NOT_YET_RECRUITING,PHASE2,83.0,2026-05-04,2031-01-31,1.4578880553952684,Adequate (1-10/month),14.578880553952683,Significantly Below (<50%),30,30.6,9.475
NCT05782309,Healthy Aging Through Dietary Intervention,COMPLETED,NA,68.0,2019-04-01,2023-02-05,1.4722048364153628,Adequate (1-10/month),14.722048364153629,Significantly Below (<50%),100,50.4,48.355
NCT04048109,The Point of View of Adolescents Who Have Undergone a Suicidal Act: What Do They Expect from Their Relationship with Their Doctor?,COMPLETED,,10.0,2019-07-26,2019-09-19,5.534545454545455,Adequate (1-10/month),55.34545454545455,Below (50-75%),100,49.1,45.83
NCT00166309,The FEIBA NovoSeven Comparative Study,COMPLETED,NA,60.0,2000-07-01,2005-06-01,1.0169265033407573,Adequate (1-10/month),10.169265033407573,Significantly Below (<50%),100,49.8,47.17
NCT01203709,Low-dose Combination of Mycophenolate Mofetil (MMF) and Tacrolimus (Tac) for Refractory Lupus Nephritis,COMPLETED,PHASE4,20.0,2010-08-01,2013-02-01,0.6653551912568306,Slow (<1/month),6.6535519125683065,Significantly Below (<50%),100,46.6,37.375
NCT06234709,Long-term Mortality After Intensive Care Considering Comorbidity and Admission Diagnoses,COMPLETED,,200000.0,2005-01-01,2016-12-31,1389.3199452304887,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT05514509,A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories,COMPLETED,PHASE4,162.0,2022-10-28,2025-09-02,4.741615384615384,Adequate (1-10/month),47.41615384615384,Significantly Below (<50%),100,63.0,75.845
NCT04800809,The Afolabi Stroke Registry for Children and Young Adults With SCD in Northern Nigeria,COMPLETED,,350.0,2020-04-01,2023-12-31,7.782322863403945,Adequate (1-10/month),77.82322863403945,Met (75-100%),100,76.3,85.1
NCT01154309,Group CBT for Depression and AOD Disorders,COMPLETED,PHASE1,73.0,2006-09-01,2009-09-01,2.0274817518248174,Adequate (1-10/month),20.274817518248174,Significantly Below (<50%),100,55.8,63.245
NCT03377309,Safety and Tolerability of Perampanel in Amyotrophic Lateral Sclerosis Patients,TERMINATED,PHASE2,6.0,2019-12-01,2021-07-01,0.3159861591695502,Slow (<1/month),3.159861591695502,Significantly Below (<50%),10,18.5,4.02
NCT06784609,"Correlation of Euroscore-II, STS Risk Scoring Systems and Frailty Tests with Cardiac Histopathological Findings in Coronary Bypass Surgery",ACTIVE_NOT_RECRUITING,,50.0,2024-09-05,2025-04-01,7.3173076923076925,Adequate (1-10/month),73.17307692307692,Below (50-75%),85,47.8,42.42
NCT02837809,Early Lung Cancer Detection in High Risk Individuals,COMPLETED,NA,4099.0,2005-09-01,2016-10-01,30.823507905138342,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT00458809,Intraperitoneal Hyperthermic Perfusion With Oxaliplatin in Treating Patients With Stage IV Peritoneal Cancer Due to Appendix Cancer or Colorectal Cancer,COMPLETED,PHASE1,16.0,2007-03-01,2007-11-01,1.987918367346939,Adequate (1-10/month),19.879183673469388,Significantly Below (<50%),100,51.3,50.62
NCT06002009,SupraScapular Cuff Study: Assessing the Effects of Size and Type of Rotator Cuff Tear on Suprascapular Nerve Function,RECRUITING,,250.0,2025-06-23,2029-09-30,4.878205128205129,Adequate (1-10/month),48.782051282051285,Significantly Below (<50%),60,56.3,64.5
NCT06263309,Mid-Term Radiological Outcomes of Femoral Neck Fractures Treated With Osteosynthesis: A Comparative Analysis,COMPLETED,,10.0,2022-06-01,2023-09-01,0.6660831509846827,Slow (<1/month),6.660831509846828,Significantly Below (<50%),100,44.1,28.425
NCT07334509,Clinical Evaluation of a Simplified-Shade Nano-Hybrid Composite With Full-Coverage Silane Coating and High-Performance Pulverized Fillers,NOT_YET_RECRUITING,NA,50.0,2026-01-15,2027-01-15,4.169863013698631,Adequate (1-10/month),41.6986301369863,Significantly Below (<50%),30,33.0,12.695
NCT03652909,Personal Sound Amplification Smartphone Application Feasibility,COMPLETED,,32.0,2021-02-26,2021-09-20,4.7285436893203885,Adequate (1-10/month),47.28543689320389,Significantly Below (<50%),100,50.9,49.370000000000005
NCT00022009,Gemcitabine Plus Supportive Care in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer,UNKNOWN,PHASE2,,2001-07-01,,,Slow (<1/month),,Significantly Below (<50%),50,25.0,7.23
NCT06685809,A Phase 1 Study of FZ008-145 in Healthy Subjects.,RECRUITING,PHASE1,168.0,2024-11-25,2025-12-26,12.913939393939394,Good (10-50/month),129.13939393939393,Exceeded (≥100%),60,56.4,64.88000000000001
NCT07251309,"A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia",RECRUITING,PHASE3,420.0,2024-12-23,2026-11-01,18.856637168141596,Good (10-50/month),188.56637168141594,Exceeded (≥100%),60,76.6,85.35000000000001
NCT04263909,The Impact of Sublingual Sufentanil on Postoperative Pain and Analgesic Requirements in Spine Surgery Patients,COMPLETED,PHASE4,199.0,2020-12-01,2023-12-30,5.389288256227759,Adequate (1-10/month),53.89288256227758,Below (50-75%),100,65.9,78.83
NCT03666299,Lidocaine Infusion for Postthoracotomy Pain Syndrome,UNKNOWN,NA,72.0,2018-11-06,2019-06-30,9.286779661016949,Adequate (1-10/month),92.86779661016949,Met (75-100%),50,45.8,33.03
NCT03115099,A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes,COMPLETED,PHASE1,80.0,2017-05-31,2018-04-05,7.880906148867314,Adequate (1-10/month),78.80906148867315,Met (75-100%),100,56.4,64.88000000000001
NCT02441699,"Assessing the Health Impact of a Combined Water and Sanitation Intervention in Rural Odisha, India",UNKNOWN,,2940.0,2015-04-01,2019-12-01,52.48891495601173,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT04940299,"Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma",ACTIVE_NOT_RECRUITING,PHASE2,35.0,2021-09-23,2027-12-31,0.4652401746724891,Slow (<1/month),4.652401746724891,Significantly Below (<50%),85,43.3,27.05
NCT03923699,"Telemedicine Control Tower for the Operating Room: Navigating Information, Care and Safety",COMPLETED,PHASE3,79560.0,2019-07-01,2023-01-31,1848.7071755725192,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT06357299,Assessing Better Bottles for Babies,RECRUITING,NA,76.0,2025-05-28,2026-05-01,6.8444970414201185,Adequate (1-10/month),68.4449704142012,Below (50-75%),60,44.1,28.425
NCT01217099,Methylprednisolone Pulse Macrolide Therapy for Refractory Mycoplasma Pneumoniae Pneumonia in Children,TERMINATED,NA,47.0,2007-05-01,2010-05-01,1.3053649635036495,Adequate (1-10/month),13.053649635036496,Significantly Below (<50%),10,21.8,6.205
NCT03004599,Safety and Efficacy of SYM-SV/DS-002 in Patients With Severe Aortic Stenosis,TERMINATED,NA,11.0,2016-11-01,2017-10-01,1.0025149700598803,Adequate (1-10/month),10.025149700598803,Significantly Below (<50%),10,18.9,4.6899999999999995
NCT07003399,Diaphragmatic Function and Respiratory Drive in OSA and COPD,RECRUITING,,80.0,2025-01-01,2025-08-31,10.062809917355372,Good (10-50/month),100.62809917355374,Exceeded (≥100%),60,47.7,42.17
NCT06367699,Conversational Agents to Improve HPV Vaccine Acceptance in Primary Care (ECA-HPV)- Clinical Trial,TERMINATED,NA,29.0,2024-11-13,2025-04-01,6.350791366906475,Adequate (1-10/month),63.507913669064756,Below (50-75%),10,25.3,7.414999999999999
NCT03754699,Preoperative Education for Less Outpatient Pain After Surgery (PELOPS),COMPLETED,NA,412.0,2019-01-22,2025-09-15,5.165271828665569,Adequate (1-10/month),51.652718286655684,Below (50-75%),100,83.0,89.505
NCT01730599,A Longitudinal Study in Parkinson's Disease (PD) Patients,UNKNOWN,,200.0,2012-11-01,,,Slow (<1/month),,Significantly Below (<50%),50,39.3,20.810000000000002
NCT06063499,HMP for Addictions Study,WITHDRAWN,NA,0.0,2025-05-01,2025-08-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT06890299,"A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fed Conditions",COMPLETED,PHASE1,40.0,2024-12-05,2025-01-12,32.04210526315789,Good (10-50/month),200.0,Exceeded (≥100%),100,58.2,68.795
NCT00382499,Intraoperative Lidocaine Infusion for Analgesia (ILIA),COMPLETED,NA,93.0,2006-11-01,2008-12-01,3.72,Adequate (1-10/month),37.2,Significantly Below (<50%),100,57.4,67.05499999999999
NCT06521099,A Novel Conditioning Approach to Counter Loneliness in Adults,RECRUITING,NA,136.0,2025-08-19,2026-06-01,14.474965034965035,Good (10-50/month),144.74965034965032,Exceeded (≥100%),60,53.9,58.34
NCT05038332,Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT]),RECRUITING,PHASE2,136.0,2021-11-12,2029-11-01,1.4221367227756785,Adequate (1-10/month),14.221367227756785,Significantly Below (<50%),60,43.9,28.12
NCT04111432,Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Expanded Programme on Immunization Vaccines,COMPLETED,PHASE4,372.0,2019-07-26,2020-03-25,46.59950617283951,Good (10-50/month),200.0,Exceeded (≥100%),100,89.8,93.065
NCT00826332,Transvaginal vs Transabdominal Ultrasound Guided Embryo Transfer,UNKNOWN,PHASE1,200.0,2009-01-01,2010-12-01,8.70958512160229,Adequate (1-10/month),87.09585121602291,Met (75-100%),50,56.0,63.71
NCT02417532,Safety and Feasibility Evaluation of Robot Assisted Physiotherapy Exercises With REX,COMPLETED,NA,56.0,2015-05-01,2016-12-01,2.9390344827586206,Adequate (1-10/month),29.39034482758621,Significantly Below (<50%),100,54.5,60.12
NCT03601832,Non-invasive Ablation of Ventricular Tachycardia,COMPLETED,NA,10.0,2018-08-01,2020-01-31,0.5554744525547445,Slow (<1/month),5.554744525547445,Significantly Below (<50%),100,45.8,33.03
NCT07236632,Hyaluronic Acid vs Botulinum Toxin Injection in Treatment of Lifelong Drug-Resistant Premature Ejaculation: Randomized Study,NOT_YET_RECRUITING,NA,80.0,2025-12-15,2026-12-15,6.6717808219178085,Adequate (1-10/month),66.71780821917808,Below (50-75%),30,35.4,15.765
NCT02411032,Fresh Start Experiment,COMPLETED,NA,13323.0,2015-04-01,2015-10-01,2216.1318032786885,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT03223532,Randomized Trial Comparing PrePex Day 7 Foreskin Removal Procedure (FRP) to a Day 0 PrePex FRP .,COMPLETED,NA,152.0,2017-04-26,2017-11-15,22.792512315270937,Good (10-50/month),200.0,Exceeded (≥100%),100,67.2,79.94
NCT05212532,A Proof-of-Concept Study Evaluating EOM613 in COVID-19 Infected Patients With Severe Symptoms,UNKNOWN,PHASE1,40.0,2021-08-09,2022-03-30,5.225751072961374,Adequate (1-10/month),52.257510729613735,Below (50-75%),50,38.2,19.645000000000003
NCT01139632,The Contribution of Lp-PLA2 Level to the Presence of Coronary Plaques in Patients With Non Alcoholic Fatty Liver Disease,UNKNOWN,,60.0,2010-07-01,2011-03-01,7.51604938271605,Adequate (1-10/month),75.16049382716051,Met (75-100%),50,38.1,19.425
NCT01982032,Edwards SAPIEN-3 Periprosthetic Leakage Evaluation Versus Medtronic CoreValve in Transfemoral Aortic Valve Implantation,TERMINATED,NA,56.0,2013-11-01,2017-05-01,1.3348786217697728,Adequate (1-10/month),13.34878621769773,Significantly Below (<50%),10,22.5,6.305
NCT07149532,Biofeedback Therapy Alone Versus Biofeedback Therapy With Medical Treatment for Dysfunctional Voiding in Children,RECRUITING,NA,124.0,2025-02-26,2026-01-01,12.215404530744337,Good (10-50/month),122.15404530744338,Exceeded (≥100%),60,52.9,55.55
NCT04363632,Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection,COMPLETED,,1231.0,2020-04-02,2020-06-30,421.02966292134835,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT04351932,Bone Marrow Versus Adipose Autologous Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis,UNKNOWN,PHASE3,54.0,2020-06-07,2021-09-07,3.5968490153172867,Adequate (1-10/month),35.96849015317287,Significantly Below (<50%),50,39.3,20.810000000000002
NCT03802032,Topical Analgesia for Pain Relief in Hysterosalpingography,COMPLETED,NA,120.0,2019-02-01,2019-12-22,11.274074074074074,Good (10-50/month),112.74074074074075,Exceeded (≥100%),100,64.6,77.59
NCT05715632,New Adjuvant Treatment of Locally Advanced Resectable Gastric Cancer With Carelizumab and XELOX,UNKNOWN,NA,46.0,2023-02-01,2025-03-01,1.844848484848485,Adequate (1-10/month),18.448484848484846,Significantly Below (<50%),50,38.7,20.145
NCT02854098,The Comorbidity of Benign Hypermobility Joint Syndrome and Functional Constipation in Children,UNKNOWN,,400.0,2015-04-01,2017-10-01,13.321663019693654,Good (10-50/month),133.21663019693653,Exceeded (≥100%),50,70.3,82.09
NCT04528498,Embryo Health Study,RECRUITING,,500.0,2020-12-01,2025-12-01,8.335158817086528,Adequate (1-10/month),83.35158817086528,Met (75-100%),60,81.3,88.58
NCT07209098,Propensity-Matched Study of Cardiac Contractility Modulation Therapy in Heart Failure,RECRUITING,,4200.0,2025-11-01,2031-04-01,64.66767830045524,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT01901198,Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase I Study in Chinese Healthy Volunteers,COMPLETED,PHASE1,34.0,2013-04-01,2013-12-01,4.241639344262295,Adequate (1-10/month),42.41639344262295,Significantly Below (<50%),100,52.7,55.04
NCT03955198,A Trial Evaluating Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous Oligometastatic Disease Under Durvalumab Consolidation Following Chemoradiation,COMPLETED,PHASE2,4.0,2021-05-27,2024-08-26,0.10257792754844144,Slow (<1/month),1.0257792754844146,Significantly Below (<50%),100,45.3,31.169999999999998
NCT02612298,Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate,COMPLETED,PHASE4,198.0,2015-08-01,2018-09-13,5.291589113257244,Adequate (1-10/month),52.91589113257243,Below (50-75%),100,65.8,78.745
NCT05816798,Photobiomodulation in Chronic Knee Pain in Patients Who Are in PreRehabilitation for Bariatric Surgery,RECRUITING,PHASE2,62.0,2023-07-28,2026-02-01,2.053623503808488,Adequate (1-10/month),20.536235038084875,Significantly Below (<50%),60,43.0,26.465
NCT06694298,A Study of SYS6020 Injection in Refractory Active Systemic Lupus Erythematosus,NOT_YET_RECRUITING,PHASE1,50.0,2024-12-26,2029-01-29,1.0180602006688964,Adequate (1-10/month),10.180602006688963,Significantly Below (<50%),30,28.0,8.38
NCT04293198,Evaluating the Performance of the KODEX-EPD CRyOballoon Occlusion Feature in Patients With Atrial Fibrillation,COMPLETED,,63.0,2020-11-04,2023-01-31,2.34440097799511,Adequate (1-10/month),23.444009779951102,Significantly Below (<50%),100,53.4,57.35
NCT03435198,Biomarkers in Exhaled Breath of Glucose Fluctuation in Type 1 Diabetes,COMPLETED,,10.0,2018-03-01,2018-08-30,1.6725274725274726,Adequate (1-10/month),16.725274725274726,Significantly Below (<50%),100,49.1,45.83
NCT04012398,Validation of the German Version of the Amsterdam Instrumental Activities of Daily Living Questionnaire®,COMPLETED,,96.0,2018-02-01,2019-09-30,4.822178217821783,Adequate (1-10/month),48.22178217821783,Significantly Below (<50%),100,56.0,63.71
NCT02235298,Dapagliflozin Effects on Epicardial Fat,COMPLETED,PHASE4,100.0,2015-09-01,2020-09-10,1.6579520697167756,Adequate (1-10/month),16.57952069716776,Significantly Below (<50%),100,53.0,55.80500000000001
NCT06925698,Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease,NOT_YET_RECRUITING,PHASE3,110.0,2025-04-30,2028-04-01,3.138144329896907,Adequate (1-10/month),31.38144329896907,Significantly Below (<50%),30,37.8,19.015
NCT04219098,Pain After Preoperative UltraSound Guided Hip Injections for Total Hip Arthroplasty (PUSH),COMPLETED,NA,75.0,2020-02-01,2021-08-30,3.9635416666666665,Adequate (1-10/month),39.635416666666664,Significantly Below (<50%),100,56.0,63.71
NCT03080298,Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire,COMPLETED,PHASE2,119.0,2016-03-14,2017-07-25,7.273815261044177,Adequate (1-10/month),72.73815261044176,Below (50-75%),100,59.5,71.0
NCT03142698,"Evaluation of 4 MRI Methods (PDFF 3, 6 and 11 Gradient Echoes and Spectroscopy) Compared to the Reference Method (Liver Biopsy) in Quantification of Hepatic Steatosis",UNKNOWN,NA,60.0,2017-05-01,2018-09-01,3.742622950819672,Adequate (1-10/month),37.42622950819672,Significantly Below (<50%),50,39.8,21.47
NCT02370498,A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061),COMPLETED,PHASE3,592.0,2015-05-11,2021-06-10,8.11002700270027,Adequate (1-10/month),81.10027002700271,Met (75-100%),100,90.0,93.17
NCT00971763,"Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma",COMPLETED,PHASE2,62.0,2006-03-01,2011-07-01,0.968829568788501,Slow (<1/month),9.688295687885011,Significantly Below (<50%),100,50.0,47.675
NCT05151263,Prevalence of Aspirin Resistance in Ischemic Stroke Patients at Assiut University Hospital,UNKNOWN,,133.0,2023-11-01,2024-04-01,26.635,Good (10-50/month),200.0,Exceeded (≥100%),50,49.0,45.61
NCT05584163,Pilot Study to Evaluate the Prevention and Safety of Doxorubicin-induced Cardiomyopathy Using Extracorporeal Shock Waves,UNKNOWN,NA,72.0,2020-10-01,2023-06-01,2.252497430626927,Adequate (1-10/month),22.52497430626927,Significantly Below (<50%),50,40.8,22.745
NCT05762263,"The Effect of Flexitarian, Time-restricted Eating on Cardiometabolic Traits in Normal Weight, Young Men",UNKNOWN,NA,96.0,2023-04-01,2023-12-01,11.97639344262295,Good (10-50/month),119.7639344262295,Exceeded (≥100%),50,47.7,42.17
NCT05649163,Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy,UNKNOWN,,306.0,2023-01-01,2025-05-01,10.945522914218568,Good (10-50/month),109.45522914218566,Exceeded (≥100%),50,62.8,75.53999999999999
NCT07242963,Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study,RECRUITING,,300.0,2025-09-30,2035-12-30,2.439754207854662,Adequate (1-10/month),24.397542078546618,Significantly Below (<50%),60,60.3,72.34
NCT01519063,Naltrexone and Memantine Effects on Alcohol Drinking Behaviors,COMPLETED,PHASE2,75.0,2012-01-01,2017-05-01,1.1725731895223421,Adequate (1-10/month),11.72573189522342,Significantly Below (<50%),100,51.0,49.714999999999996
NCT00628563,REALL: A Retrospective Observational Study to Compare the Effectiveness and Cost-Effectiveness Between Different Step-3 Asthma Treatment Strategies,COMPLETED,,50000.0,2007-09-01,2015-12-01,505.14437437769664,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT00152763,Psychological Support for Patients With an Implantable Cardioverter Defibrillator,COMPLETED,PHASE3,193.0,2003-10-01,2007-11-01,3.937613941018767,Adequate (1-10/month),39.37613941018767,Significantly Below (<50%),100,65.4,78.415
NCT06486363,Comparison of the Antiplatelet Efficacy of Aspirin Combined With Clopidogrel and Aspirin Combined With Half-dose Ticagrelor in Patients With Unruptured Intracranial Aneurysms With Normal CYP2C19 Metabolizer Phenotype,NOT_YET_RECRUITING,PHASE4,196.0,2024-08-01,2027-07-31,5.453601462522852,Adequate (1-10/month),54.536014625228525,Below (50-75%),30,44.7,29.67
NCT01950663,RETeval Study for Diabetic Retinopathy,COMPLETED,NA,468.0,2013-09-01,2014-04-01,67.19773584905661,Excellent (>50/month),200.0,Exceeded (≥100%),100,97.4,96.63000000000001
NCT00973063,Effectiveness of Routine Sterile Gloving in Blood Culture,COMPLETED,NA,1854.0,2009-03-01,2009-12-01,205.22094545454547,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT02646163,Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients,COMPLETED,PHASE1,8.0,2009-01-01,2012-12-01,0.1702937062937063,Slow (<1/month),1.702937062937063,Significantly Below (<50%),100,45.6,32.08
NCT02765763,Clinical Evaluation of Day and Night Skin Care Creams Supplemented With MediCell Technology (MCT)'s Composition of Defensins and Supportive Molecules,COMPLETED,PHASE4,45.0,2016-05-01,2017-06-01,3.4590909090909094,Adequate (1-10/month),34.590909090909086,Significantly Below (<50%),100,53.6,57.705
NCT07096063,Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk,COMPLETED,,887132.0,2024-10-01,2025-07-15,94091.63094076655,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT01208363,Improving Iron Status Through Consumption Of Iron Fortified Cowpea: An Intervention Study,COMPLETED,NA,240.0,2010-09-01,2011-07-01,24.110891089108915,Good (10-50/month),200.0,Exceeded (≥100%),100,74.2,84.15
NCT06591663,Can Cognitive Therapy Rating Scale (CTRS) be Used Across Cultures? Enhancing Cultural Relevance of CTRS,RECRUITING,NA,20.0,2024-09-08,2024-12-31,5.340350877192983,Adequate (1-10/month),53.40350877192983,Below (50-75%),60,39.6,21.115000000000002
NCT05719363,Portable Oxygen Concentrator in Non-hospitalized Patients With Chronic Heart Failure,COMPLETED,NA,20.0,2023-10-11,2023-11-21,14.848780487804879,Good (10-50/month),148.4878048780488,Exceeded (≥100%),100,56.6,65.34
NCT03144063,Improving the Assessment of SLE Disease Activity,COMPLETED,,247.0,2017-07-11,2020-06-04,7.099792256846081,Adequate (1-10/month),70.99792256846081,Below (50-75%),100,68.1,80.715
NCT06638463,My Health Coach App RCT,RECRUITING,NA,200.0,2025-04-01,2026-12-31,9.52738654147105,Adequate (1-10/month),95.27386541471049,Met (75-100%),60,59.0,70.365
NCT07353463,Shanghai Clinical Cohort - Parkinson's Disease (Reserve),RECRUITING,,700.0,2025-04-01,2026-12-31,33.345852895148674,Good (10-50/month),200.0,Exceeded (≥100%),60,81.3,88.58
NCT04087863,Administration for Placebo Group and Evalution the Safety and Efficacy in Atopic Dermatitis Patients,UNKNOWN,,99.0,2019-08-29,2024-12-31,1.5446232701178886,Adequate (1-10/month),15.446232701178886,Significantly Below (<50%),50,36.3,17.0
NCT03457363,Double Trunk Mask and Standard Nasal Cannula During Acute Hypoxia,COMPLETED,NA,15.0,2018-06-20,2018-11-20,2.984313725490196,Adequate (1-10/month),29.843137254901965,Significantly Below (<50%),100,51.2,50.375
NCT02903563,Knowledge Attitudes Beliefs and Practices Relative to HIV Among Sex Workers in French Guiana,COMPLETED,,256.0,2009-01-01,2010-12-01,11.14826895565093,Good (10-50/month),111.48268955650931,Exceeded (≥100%),100,73.8,83.865
NCT01476163,Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease,AVAILABLE,,,,,,Slow (<1/month),,Significantly Below (<50%),50,23.3,6.569999999999999
NCT00617487,Pulmonary Arterial Hypertension in Systemic Sclerosis,UNKNOWN,,200.0,2007-12-01,2020-01-01,1.3792478477571364,Adequate (1-10/month),13.792478477571363,Significantly Below (<50%),50,44.3,28.715000000000003
NCT05302687,Probiotic Modulates Vaginal Microflora,COMPLETED,PHASE2,112.0,2022-01-15,2024-03-18,4.29921815889029,Adequate (1-10/month),42.9921815889029,Significantly Below (<50%),100,59.0,70.365
NCT03968887,Correlation Between Plasma Oxidized Low Density Lipoprotein Levels And Postoperative Delirium,UNKNOWN,,300.0,2019-05-20,2019-09-20,74.24390243902438,Excellent (>50/month),200.0,Exceeded (≥100%),50,67.3,80.00500000000001
NCT04003987,ESP Block VS TAP in Laparoscopic Hysterectomy,COMPLETED,PHASE3,78.0,2019-05-01,2021-03-04,3.527964338781575,Adequate (1-10/month),35.279643387815746,Significantly Below (<50%),100,56.2,64.21
NCT02794987,Cholangioscopic Classification of Bile Duct Lesions,COMPLETED,,130.0,2015-12-01,2016-12-01,10.812021857923497,Good (10-50/month),108.12021857923497,Exceeded (≥100%),100,63.7,76.655
NCT04352387,Montessori Based Activities for Dementia,COMPLETED,NA,108.0,2018-08-24,2019-12-31,6.654898785425102,Adequate (1-10/month),66.54898785425102,Below (50-75%),100,58.6,69.51
NCT00352287,"Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults",COMPLETED,PHASE4,60.0,2003-03-01,2005-04-01,2.3968503937007877,Adequate (1-10/month),23.968503937007878,Significantly Below (<50%),100,54.8,61.095
NCT00759187,Evaluate Clinical Research From Commerical Oral Care Products,COMPLETED,PHASE3,25.0,2008-01-01,2008-04-01,8.362637362637363,Adequate (1-10/month),83.62637362637363,Met (75-100%),100,57.0,66.12
NCT02759887,Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD),COMPLETED,NA,19.0,2016-11-01,2018-12-01,0.761,Slow (<1/month),7.61,Significantly Below (<50%),100,46.5,36.815
NCT07120087,Evaluation of an Online Intervention to Educate Women at High Risk of Breast Cancer on How to Help Reduce Their Risk.,NOT_YET_RECRUITING,NA,1508.0,2025-10-01,2027-06-01,75.49921052631579,Excellent (>50/month),200.0,Exceeded (≥100%),30,79.0,86.96000000000001
NCT03977987,Maternal Antiviral Treatment and Infants Immunoprophylaxis in the Prevention of Mother-to-child Transmission,COMPLETED,,233.0,2011-01-01,2018-12-30,2.4289452054794523,Adequate (1-10/month),24.289452054794523,Significantly Below (<50%),100,67.0,79.725
NCT03645187,Celecoxib as Adjuvant Therapy to Chemotherapy in Patients With Metastatic Colorectal Cancer,UNKNOWN,PHASE4,50.0,2018-08-01,2025-12-01,0.5681224337439343,Slow (<1/month),5.681224337439343,Significantly Below (<50%),50,34.0,14.02
NCT04315987,NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia,COMPLETED,PHASE2,90.0,2020-06-30,2021-02-28,11.274074074074075,Good (10-50/month),112.74074074074076,Exceeded (≥100%),100,62.2,74.74499999999999
NCT03504787,Upper Extremity Selective Voluntary Motor Control in Children With Unilateral Cerebral Palsy,COMPLETED,,24.0,2017-04-25,2018-03-25,2.187305389221557,Adequate (1-10/month),21.87305389221557,Significantly Below (<50%),100,50.3,48.215
NCT07048587,Beta-HCG Levels in Uterine Cavity Lavage for Pregnancies of Unknown Location,COMPLETED,NA,121.0,2020-06-12,2023-11-03,2.972752219531881,Adequate (1-10/month),29.727522195318805,Significantly Below (<50%),100,59.7,71.355
NCT00081887,Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia,TERMINATED,PHASE1,8.0,2004-05-01,2007-06-01,0.21626998223801067,Slow (<1/month),2.1626998223801066,Significantly Below (<50%),10,18.6,4.25
NCT05189587,Home-based Transcranial Electrical Stimulation (TES) in Patients With Chronic Tinnitus,UNKNOWN,NA,60.0,2022-03-01,2023-06-30,3.758024691358025,Adequate (1-10/month),37.580246913580254,Significantly Below (<50%),50,39.8,21.47
NCT04458987,Addictology Expert Patients' Fields of Intervention,COMPLETED,NA,69.0,2020-06-19,2021-05-19,6.288502994011976,Adequate (1-10/month),62.88502994011975,Below (50-75%),100,55.5,62.71
NCT05976087,Improving Grasp Function in People With Sensorimotor Impairments by Combining Electrical Stimulation With a Robotic Hand Orthosis,ACTIVE_NOT_RECRUITING,NA,20.0,2023-07-01,2030-06-30,0.23818466353677623,Slow (<1/month),2.3818466353677623,Significantly Below (<50%),85,42.1,25.019999999999996
NCT03542487,Blood Glucose Monitoring in Electronic Health Records,COMPLETED,NA,7052.0,2018-05-01,2018-10-31,1173.0212021857924,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT05608187,Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers,TERMINATED,PHASE2,1.0,2022-09-26,2024-12-20,0.037303921568627454,Slow (<1/month),0.3730392156862745,Significantly Below (<50%),10,18.1,3.105
NCT03060187,Proposal and Clinical Evaluation of a Comprehensive Airway Exam Score,COMPLETED,,2000.0,2010-02-01,2011-01-01,182.2754491017964,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT05612087,The Clinical Significance of Gut Permeability in Gastrointestinal Post Acute COVID-19 Syndrome,UNKNOWN,,40.0,2022-11-08,2023-12-31,2.9129186602870814,Adequate (1-10/month),29.129186602870817,Significantly Below (<50%),50,36.5,17.285
NCT04201587,The Preliminary Effects of Henna on CIPN,COMPLETED,NA,60.0,2018-05-28,2019-11-29,3.320727272727273,Adequate (1-10/month),33.20727272727273,Significantly Below (<50%),100,54.8,61.095
NCT01734187,Efficacy and Safety of Fermented Cinnamon Vine Powder on Decrement of Body Fat,COMPLETED,NA,60.0,2012-01-02,2014-05-29,2.0801822323462416,Adequate (1-10/month),20.801822323462414,Significantly Below (<50%),100,54.8,61.095
NCT04395287,Prospective Associations Between Screen Media Use and Physical Activity in Preschool Children,COMPLETED,,887.0,2020-05-04,2021-07-08,62.791348837209306,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT01289587,Promoting Physical Activity in Patients With Type 2 Diabetes (DIAfit),COMPLETED,NA,185.0,2011-02-01,2017-10-01,2.3136400986031225,Adequate (1-10/month),23.136400986031227,Significantly Below (<50%),100,64.8,77.865
NCT02558387,Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck,UNKNOWN,PHASE2,20.0,2014-11-01,2017-01-01,0.7686868686868688,Slow (<1/month),7.686868686868687,Significantly Below (<50%),50,31.6,10.905
NCT05698693,Social Determinants of Sleep and Obesity,RECRUITING,EARLY_PHASE1,90.0,2023-11-01,2026-06-01,2.905196182396607,Adequate (1-10/month),29.051961823966067,Significantly Below (<50%),60,45.2,30.830000000000002
NCT02916693,Mirabegron For Erectile Dysfunction,COMPLETED,PHASE1,20.0,2017-08-01,2020-01-01,0.6894677236693092,Slow (<1/month),6.8946772366930915,Significantly Below (<50%),100,46.6,37.375
NCT06343493,Effect of Hot Saline Irrigation on the Operative Field During Endoscopic Sinus Surgery,COMPLETED,NA,60.0,2023-06-16,2023-12-31,9.224242424242425,Adequate (1-10/month),92.24242424242425,Met (75-100%),100,59.8,71.61
NCT00043693,Family Intervention for Mental Illness and Substance Abuse,COMPLETED,NA,108.0,2002-04-01,2008-12-01,1.3495566502463054,Adequate (1-10/month),13.495566502463053,Significantly Below (<50%),100,53.6,57.705
NCT01135693,Service Users' Perspective of Reasons for Detention Under Section 136 of the Mental Health Act 1983,UNKNOWN,,20.0,2010-08-01,2011-01-01,3.9790849673202615,Adequate (1-10/month),39.790849673202615,Significantly Below (<50%),50,34.9,15.215
NCT05269693,A BHI to Increase Hope Level and Stress Level of Parents With a CMC,COMPLETED,NA,40.0,2021-12-01,2023-02-01,2.8515222482435596,Adequate (1-10/month),28.515222482435597,Significantly Below (<50%),100,53.2,56.665
NCT06105593,Effect of Balneotherapy and Physiotherapy Treatment in Female Infertility: a Retrospective Study,ACTIVE_NOT_RECRUITING,,577.0,2023-09-01,2024-05-01,72.27934156378602,Excellent (>50/month),200.0,Exceeded (≥100%),85,93.8,94.80499999999999
NCT05787093,ROLE OF PELVIC ULTRASOUND IN THE TREATMENT MONITORING OF CHILDREN WITH CHRONIC Idiopathic Constipation,UNKNOWN,,123.0,2022-09-01,2024-09-01,5.121915184678523,Adequate (1-10/month),51.21915184678522,Below (50-75%),50,43.2,26.840000000000003
NCT07266493,Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma,RECRUITING,PHASE2,26.0,2023-12-01,2026-12-01,0.7221167883211679,Slow (<1/month),7.221167883211679,Significantly Below (<50%),60,35.1,15.384999999999998
NCT00003293,SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme,COMPLETED,PHASE3,,1998-02-01,2001-05-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,30.330000000000002
NCT00814593,Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery,WITHDRAWN,PHASE2,0.0,2008-11-01,2011-09-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT01259193,Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCC,UNKNOWN,PHASE2,50.0,2010-10-01,2012-07-01,2.3818466353677623,Adequate (1-10/month),23.81846635367762,Significantly Below (<50%),50,39.0,20.505000000000003
NCT01844193,Early Postoperative Compex Rehab NMES Use for Total Knee Arthroplasty Patients,COMPLETED,NA,60.0,2013-01-01,2016-12-31,1.2509589041095892,Adequate (1-10/month),12.509589041095893,Significantly Below (<50%),100,49.8,47.17
NCT00912093,A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3),COMPLETED,PHASE3,98.0,2009-07-16,2010-10-01,6.749140271493213,Adequate (1-10/month),67.49140271493212,Below (50-75%),100,57.8,67.635
NCT03349593,Prevalence of Hypovolemia and Heart Failure in Non-cardiac Surgery,COMPLETED,,100.0,2017-12-01,2019-12-30,4.0105401844532285,Adequate (1-10/month),40.10540184453228,Significantly Below (<50%),100,56.3,64.5
NCT06846593,The Comparison of Semiconductor Embedded Therapeutic Arm Sleeves for the Treatment of ECRB Tendinopathy,ENROLLING_BY_INVITATION,NA,80.0,2024-11-01,2025-11-01,6.6717808219178085,Adequate (1-10/month),66.71780821917808,Below (50-75%),55,42.9,26.145000000000003
NCT05946993,Linking In With Advice and Supports for Men Impacted by Metastatic Cancer,RECRUITING,NA,72.0,2023-05-08,2026-04-01,2.06957507082153,Adequate (1-10/month),20.695750708215296,Significantly Below (<50%),60,43.8,27.965
NCT06503393,SENOVIE France - Therapeutic Mobility and Breast Cancer,RECRUITING,,1000.0,2024-03-25,2025-03-31,82.04851752021564,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT02617693,Development of Pre-pregnancy Intervention to Reduce the Risk of Diabetes and Prediabetes,COMPLETED,PHASE4,552.0,2015-11-23,2017-12-09,22.49381526104418,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT01845493,Sulforaphane Supplementation in Atopic Asthmatics,COMPLETED,PHASE1,16.0,2013-04-01,2014-10-01,0.8887591240875912,Slow (<1/month),8.887591240875912,Significantly Below (<50%),100,46.3,35.66
NCT03865693,Effects of Pain Scrambler Therapy for the Alterations of Cerebral Blood,UNKNOWN,NA,40.0,2019-07-01,2020-11-30,2.3505791505791507,Adequate (1-10/month),23.50579150579151,Significantly Below (<50%),50,38.2,19.645000000000003
NCT02182193,"Safety and Relative Bioavailability of BIBF 1120 Soft Gelatine Capsules Charge 1, BIBF 1120 Soft Gelatine Capsules Charge 2 and BIBF 1120 Drinking Solution in Healthy Male Volunteers",COMPLETED,PHASE1,54.0,2006-09-01,,,Slow (<1/month),,Significantly Below (<50%),100,44.3,28.715000000000003
NCT03344393,Effect of Intraoperative IV Ketamine on Postoperative Morphine Consumption During Intestinal Surgery,UNKNOWN,NA,60.0,2017-12-01,2019-03-01,4.014065934065934,Adequate (1-10/month),40.14065934065935,Significantly Below (<50%),50,39.8,21.47
NCT07310693,External Validation of the CLOVER Score for Detecting Occult Cancer in Venous Thromboembolism Patients,RECRUITING,,500.0,2025-12-01,2028-12-31,13.516873889875667,Good (10-50/month),135.16873889875666,Exceeded (≥100%),60,81.3,88.58
NCT05072093,Parrying the Pitfalls of PrEP: Project PEACH,COMPLETED,PHASE4,240.0,2021-11-20,2025-03-31,5.954034229828851,Adequate (1-10/month),59.54034229828851,Below (50-75%),100,69.2,81.28
NCT03929393,Mindful Movement for Physical Activity and Wellbeing in Older Adults- A Hybrid Effectiveness-Implementation Study,COMPLETED,NA,176.0,2019-07-17,2022-03-31,5.42251012145749,Adequate (1-10/month),54.2251012145749,Below (50-75%),100,64.1,77.12
NCT01780493,The Long Term Follow-Up Results Of The Direct Nipple Ureteroneocystostomy Technique,COMPLETED,NA,19.0,2004-03-01,2011-08-01,0.21349575489110373,Slow (<1/month),2.1349575489110375,Significantly Below (<50%),100,46.5,36.815
NCT05798793,Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma,RECRUITING,PHASE3,309.0,2023-11-21,2026-10-01,9.00091866028708,Adequate (1-10/month),90.00918660287081,Met (75-100%),60,67.7,80.22
NCT04626193,LOAD VS Levofloxacine Concomitant,UNKNOWN,PHASE4,80.0,2020-10-31,2024-05-30,1.8631981637337414,Adequate (1-10/month),18.631981637337418,Significantly Below (<50%),50,41.4,24.04
NCT03484221,Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer,UNKNOWN,PHASE2,30.0,2018-04-01,2022-04-01,0.6250513347022587,Slow (<1/month),6.250513347022587,Significantly Below (<50%),50,32.4,12.025
NCT03108521,SNP Study of DPP-4 and GLP-1R in Chinese People (Including Diabetes Patients),COMPLETED,PHASE4,119.0,2016-04-21,2018-10-08,4.024844444444445,Adequate (1-10/month),40.24844444444445,Significantly Below (<50%),100,59.5,71.0
NCT01579721,Prospective Randomized Study of SILS Versus CLS for Rectal Cancer,COMPLETED,PHASE4,40.0,2011-09-01,2012-10-01,3.074747474747475,Adequate (1-10/month),30.747474747474747,Significantly Below (<50%),100,53.2,56.665
NCT03190421,Expanded Quantitative Urinary Culture (EQUC) vs Standard Culture (SUC) Techniques in the Clinical Care,COMPLETED,NA,225.0,2017-06-15,2020-04-30,6.522857142857144,Adequate (1-10/month),65.22857142857144,Below (50-75%),100,68.0,80.56
NCT06101121,Performance and Safety of Lubri-cream for Pain Minimization During Urethral Catheterization and Cystoscopy,UNKNOWN,,120.0,2023-12-01,2024-10-01,11.976393442622951,Good (10-50/month),119.76393442622953,Exceeded (≥100%),50,47.9,42.64
NCT04006821,PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma,UNKNOWN,PHASE2,30.0,2019-07-25,2022-08-01,0.8279238440616501,Slow (<1/month),8.279238440616501,Significantly Below (<50%),50,32.4,12.025
NCT06393621,Investigate the Effectiveness of KEFPEP® on Regulating High Blood Pressure,COMPLETED,NA,46.0,2018-07-26,2023-08-28,0.7532221624529317,Slow (<1/month),7.532221624529317,Significantly Below (<50%),100,48.7,44.93
NCT01192321,Visual Outcomes After Bilateral Surgical Cataract Phacoemulsification: AcrySof Toric IOL Implantation Compared to Monofocal IOL Implantation,TERMINATED,PHASE4,9.0,2010-06-01,2010-12-01,1.497049180327869,Adequate (1-10/month),14.970491803278687,Significantly Below (<50%),10,18.7,4.455
NCT02453321,Continuous Adductor Canal Blocks Vs. Low Dose Femoral Nerve Blocks For Early Rehabilitation After Total Knee Arthroplasty,COMPLETED,PHASE4,62.0,2015-06-01,2016-08-31,4.129715536105032,Adequate (1-10/month),41.29715536105033,Significantly Below (<50%),100,55.0,61.834999999999994
NCT00175721,"Trial Comparing Care in Multiple Clinics Versus Care in a Cardiac, Diabetes and Kidney Care Clinic",COMPLETED,NA,150.0,2005-12-01,2013-01-01,1.7642967542503865,Adequate (1-10/month),17.642967542503865,Significantly Below (<50%),100,62.0,74.42
NCT04759521,Evaluation of Liver Fibrosis With 2D-Shear Wave Elastography,COMPLETED,,253.0,2019-01-03,2020-12-18,10.771076923076924,Good (10-50/month),107.71076923076923,Exceeded (≥100%),100,73.6,83.775
NCT06389721,Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy,RECRUITING,,45.0,2024-07-16,2027-01-31,1.4744886975242197,Adequate (1-10/month),14.744886975242197,Significantly Below (<50%),60,34.9,15.215
NCT04698421,Collection of Biological Samples from Patients with Rare Neurological Diseases,RECRUITING,,1000.0,2020-10-12,2030-09-03,8.425131469692776,Adequate (1-10/month),84.25131469692775,Met (75-100%),60,81.3,88.58
NCT06011421,Wound Catheter Vs LA Bolus in Renal Transplant: RCT,UNKNOWN,,88.0,2022-01-31,2023-11-01,4.192050078247261,Adequate (1-10/month),41.920500782472615,Significantly Below (<50%),50,40.4,22.34
NCT05092321,Aquatic Therapy for ASD,COMPLETED,NA,60.0,2021-09-14,2024-08-31,1.6879852125693162,Adequate (1-10/month),16.879852125693166,Significantly Below (<50%),100,54.8,61.095
NCT05829421,Addressing Problems in Managing Daily Tasks Due to Poststroke Cognitive Impairments,COMPLETED,NA,8.0,2023-05-25,2025-10-01,0.2831627906976744,Slow (<1/month),2.831627906976744,Significantly Below (<50%),100,45.6,32.08
NCT06089421,Genetic Information Assistant in Telegenetics,RECRUITING,NA,96.0,2025-04-01,2027-08-01,3.4298591549295776,Adequate (1-10/month),34.29859154929578,Significantly Below (<50%),60,45.7,32.5
NCT00079521,Therapeutic Touch for Wrist Fractures in Postmenopausal Women,COMPLETED,PHASE2,125.0,2003-03-01,2006-04-01,3.3762200532386872,Adequate (1-10/month),33.76220053238687,Significantly Below (<50%),100,60.0,71.97
NCT06700421,Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis,ACTIVE_NOT_RECRUITING,PHASE2,32.0,2024-08-13,2026-12-31,1.1196321839080459,Adequate (1-10/month),11.196321839080458,Significantly Below (<50%),85,43.1,26.724999999999998
NCT01769521,Relationship Between 24-hour IOP Pattern and the 24-hour Blood Pressure Pattern in Patients With POAG,COMPLETED,NA,20.0,2012-10-01,2013-04-01,3.345054945054945,Adequate (1-10/month),33.45054945054945,Significantly Below (<50%),100,51.6,51.644999999999996
NCT07007221,Clinical Trials to Evaluate Metformin to Treat Depression in People Living With HIV,NOT_YET_RECRUITING,PHASE2,600.0,2026-07-01,2030-12-01,11.315985130111525,Good (10-50/month),113.15985130111525,Exceeded (≥100%),30,74.0,83.985
NCT02361021,Lung Aeration During WEANing From Mechanical Ventilation Determined by Electrical Impedance Tomography and Lung Ultrasound,UNKNOWN,,60.0,2015-07-01,2015-08-01,58.91612903225806,Excellent (>50/month),200.0,Exceeded (≥100%),50,48.1,43.275000000000006
NCT06729021,Predictive Value of Modified Caprini Score and D-Dimer in Managing Lower Limb Venous Thrombosis in Cardiothoracic Patients,RECRUITING,,112.0,2025-01-20,2025-07-30,17.849633507853405,Good (10-50/month),178.49633507853403,Exceeded (≥100%),60,50.3,48.215
NCT04871321,Biomarker Discovery in Patients With Advanced Biliary Tract Cancer,COMPLETED,,119.0,2021-04-14,2023-12-31,3.6552573158425834,Adequate (1-10/month),36.55257315842584,Significantly Below (<50%),100,57.9,67.83
NCT06067321,Gastric Residual Volumes in Infants Fed at 4 and 6 Hours Prior to General Anaesthesia,UNKNOWN,NA,70.0,2024-05-01,2025-07-01,5.001877934272301,Adequate (1-10/month),50.01877934272301,Below (50-75%),50,40.6,22.575
NCT05338814,Conventional Neck Exercise With and Without Scapular Corrective Exercises in Patients With Forward Head Posture,COMPLETED,NA,50.0,2021-10-01,2022-07-31,5.023102310231024,Adequate (1-10/month),50.23102310231023,Below (50-75%),100,54.0,58.72500000000001
NCT06152614,MIND Foods and Aerobic Training in Black Adults With HTN,RECRUITING,NA,128.0,2023-11-28,2028-01-30,2.556640419947507,Adequate (1-10/month),25.566404199475066,Significantly Below (<50%),60,48.2,43.665
NCT07288814,Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL),NOT_YET_RECRUITING,PHASE1,43.0,2025-12-08,2027-12-31,1.738273572377158,Adequate (1-10/month),17.38273572377158,Significantly Below (<50%),30,32.4,12.025
NCT04952714,RRT With a Cytokine Absorption Filter (oXiris ®) in Patients With Septic Shock,COMPLETED,,93.0,2021-09-01,2023-11-10,3.53865,Adequate (1-10/month),35.3865,Significantly Below (<50%),100,55.8,63.245
NCT02725814,Sucrose Practices for Pain in Neonates Part B,COMPLETED,NA,172.0,2016-03-01,2022-04-01,2.3562916291629166,Adequate (1-10/month),23.562916291629165,Significantly Below (<50%),100,63.8,76.78
NCT00199914,Efficacy Study of Shortwave Diathermy for the Treatment of Patients With Knee Osteoarthritis,COMPLETED,PHASE3,113.0,2004-01-01,2004-06-01,22.629736842105263,Good (10-50/month),200.0,Exceeded (≥100%),100,64.0,77.025
NCT00332514,Post-Discharge Follow-Up Phone Call by a Pharmacist and Impact on Patient Care,COMPLETED,PHASE2,200.0,2004-03-01,2008-01-01,4.3454675231977165,Adequate (1-10/month),43.45467523197716,Significantly Below (<50%),100,66.0,78.99000000000001
NCT00413114,Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS),COMPLETED,PHASE2,24.0,2006-12-01,2009-11-01,0.6853283302063791,Slow (<1/month),6.853283302063791,Significantly Below (<50%),100,46.9,38.96
NCT03122314,Comparison of Efficacy of Intravenous Paracetamol and Dexketoprofen for Acute Nontraumatic Musculoskeletal Pain,COMPLETED,PHASE4,200.0,2015-08-01,2016-09-01,15.33501259445844,Good (10-50/month),153.3501259445844,Exceeded (≥100%),100,71.0,82.44
NCT05462314,"Intestinal Microbiome, Oral Microbiome, and Whole Blood Transcriptome Analyses in Gastrointestinal Malignancies",COMPLETED,,24.0,2022-03-29,2025-01-21,0.7099708454810495,Slow (<1/month),7.099708454810496,Significantly Below (<50%),100,45.3,31.169999999999998
NCT01516814,Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients,COMPLETED,PHASE3,40.0,2012-02-01,2013-11-01,1.9054773082942098,Adequate (1-10/month),19.0547730829421,Significantly Below (<50%),100,53.2,56.665
NCT01956214,Functional Electrical Stimulation (FES) Exercise Training in Hemodialysis Patients,TERMINATED,NA,9.0,2012-12-01,2016-11-01,0.19144654088050314,Slow (<1/month),1.9144654088050315,Significantly Below (<50%),10,18.7,4.455
NCT06597214,Intraoperative Warming: Comparison of Two Temperature Management Systems,COMPLETED,NA,90.0,2023-06-01,2025-05-15,3.836974789915967,Adequate (1-10/month),38.36974789915967,Significantly Below (<50%),100,57.2,66.465
NCT01489514,Evaluation of Allergenicity of Hypoallergenic Peanut Product in Peanut Allergic Subjects,COMPLETED,,22.0,2011-12-01,2015-01-01,0.594214729370009,Slow (<1/month),5.942147293700089,Significantly Below (<50%),100,45.1,30.605
NCT02793414,Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia,WITHDRAWN,,0.0,2016-09-01,2018-01-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT00553514,AS900672-Enriched in Ovulation Induction,TERMINATED,PHASE2,71.0,2007-12-01,2009-03-01,4.739561403508772,Adequate (1-10/month),47.395614035087725,Significantly Below (<50%),10,28.7,8.63
NCT05442814,Anterior and Posterior Approaches of Suprascapular Nerve Block,COMPLETED,NA,60.0,2022-03-15,2023-03-15,5.003835616438357,Adequate (1-10/month),50.03835616438357,Below (50-75%),100,54.8,61.095
NCT04145414,Cerebrospinal Fluid Movements Through Interventricular Foramina in Phase Contrast Magnetic Resonance Imaging (PC-MRI),COMPLETED,NA,28.0,2019-06-13,2020-01-14,3.964279069767442,Adequate (1-10/month),39.64279069767442,Significantly Below (<50%),100,52.2,53.22
NCT07308314,Taining Golden Lake Comprehensive Chronic Disease Management Initiative,RECRUITING,,20000.0,2025-08-01,2028-07-01,571.6431924882629,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT00637416,Dietary Control Alone Versus Dietary Control Plus Use of Proton Pump Inhibitors to Treat Pediatric Hoarseness,TERMINATED,PHASE4,9.0,2008-03-01,2009-07-01,0.5625462012320328,Slow (<1/month),5.625462012320329,Significantly Below (<50%),10,18.7,4.455
NCT04880616,"Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor",COMPLETED,PHASE2,31.0,2021-04-20,2022-06-08,2.279323671497585,Adequate (1-10/month),22.793236714975844,Significantly Below (<50%),100,52.5,54.345
NCT04676516,"A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer",COMPLETED,PHASE2,40.0,2021-06-08,2022-08-15,2.8120092378752886,Adequate (1-10/month),28.120092378752886,Significantly Below (<50%),100,53.2,56.665
NCT05083416,Effect of Prolonged Nightly Fasting on Immunotherapy Outcomes in HNSCC - Role of Gut Microbiome,COMPLETED,NA,29.0,2021-10-20,2024-02-08,1.049655172413793,Adequate (1-10/month),10.49655172413793,Significantly Below (<50%),100,47.3,40.475
NCT02274116,Acute Intermittent Hypoxia on Leg Function Following Spinal Cord Injury,ACTIVE_NOT_RECRUITING,NA,30.0,2014-10-01,2027-11-01,0.1910860012554928,Slow (<1/month),1.9108600125549282,Significantly Below (<50%),85,42.9,26.145000000000003
NCT01074216,Vitamin D Levels in Stage IV Colorectal Cancer Patients,COMPLETED,PHASE2,45.0,2010-02-01,2014-10-01,0.8043452730475631,Slow (<1/month),8.04345273047563,Significantly Below (<50%),100,48.6,44.685
NCT05720416,Effects of a Multi-intervention Programme for the Elderly,COMPLETED,NA,207.0,2023-08-22,2024-12-31,12.678229376257546,Good (10-50/month),126.78229376257548,Exceeded (≥100%),100,71.6,82.755
NCT05242016,Structured Individiual Reminiscence on Self Transcendence of Palliative Care Patients,UNKNOWN,NA,48.0,2021-11-04,2023-05-25,2.576931216931217,Adequate (1-10/month),25.76931216931217,Significantly Below (<50%),50,38.8,20.244999999999997
NCT06934616,"A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors",NOT_YET_RECRUITING,PHASE1,330.0,2025-04-24,2028-03-01,9.640307101727448,Adequate (1-10/month),96.40307101727447,Met (75-100%),30,60.4,72.54
NCT03756116,Effect of Papillary Epinephrine Spraying for the Prevention of Post-ERCP Pancreatitis in Patients Received Octreotide,UNKNOWN,NA,2000.0,2018-10-01,2020-10-01,83.28317373461013,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT01318616,The Effect of Strength Training on the Hip Adduction Strength Measured With Hand-held Dynamometry,COMPLETED,NA,34.0,2011-01-01,2011-06-01,6.854039735099338,Adequate (1-10/month),68.54039735099337,Below (50-75%),100,52.7,55.04
NCT07384416,"Single-Arm Trial of QL1706, Lenvatinib, and Nab-Paclitaxel for Advanced Refractory Penile Cancer",NOT_YET_RECRUITING,PHASE2,47.0,2026-02-10,2031-01-31,0.787819383259912,Slow (<1/month),7.87819383259912,Significantly Below (<50%),30,27.8,8.32
NCT06565416,Opioid and Pain Treatment in Indigenous Communities (OPTIC) Trial,RECRUITING,NA,225.0,2023-06-01,2028-07-01,3.6882067851373184,Adequate (1-10/month),36.88206785137318,Significantly Below (<50%),60,56.0,63.71
NCT00532116,PK Comparison of 6mg and 12mg EMSAM in Elderly vs. Non-Elderly,COMPLETED,PHASE4,32.0,2007-04-01,2007-08-01,7.984262295081967,Adequate (1-10/month),79.84262295081966,Met (75-100%),100,52.6,54.684999999999995
NCT03827616,Moderately Hypofractionated Radiotherapy for Prostate Cancer.,ENROLLING_BY_INVITATION,PHASE2,200.0,2019-01-25,2030-02-01,1.512546583850932,Adequate (1-10/month),15.125465838509319,Significantly Below (<50%),55,47.5,41.415
NCT02887716,Mapping the Lumbar Spine Marrow Adiposity,COMPLETED,,50.0,2015-08-01,2015-11-01,16.543478260869566,Good (10-50/month),165.43478260869566,Exceeded (≥100%),100,57.3,66.74
NCT05517616,"The Absorption, Metabolism and Excretion of [14C]APG-2575 in Healthy Subjects",COMPLETED,PHASE1,6.0,2022-09-14,2023-04-20,0.8377981651376147,Slow (<1/month),8.377981651376148,Significantly Below (<50%),100,45.5,31.705
NCT07085416,Sensor Ankle Brace for Special Operations Rehabilitation,RECRUITING,NA,60.0,2025-10-16,2026-06-18,7.454693877551021,Adequate (1-10/month),74.54693877551021,Below (50-75%),60,42.8,25.929999999999996
NCT03133416,Platelet-rich Plasma Injections and Physiotherapy in the Treatment of Chronic Rotator Cuff Tendinopathy,COMPLETED,NA,95.0,2016-08-01,2018-07-31,3.966803840877915,Adequate (1-10/month),39.66803840877915,Significantly Below (<50%),100,57.6,67.36999999999999
NCT02709616,Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC),COMPLETED,PHASE1,10.0,2016-03-01,2019-06-30,0.25032894736842104,Slow (<1/month),2.5032894736842106,Significantly Below (<50%),100,45.8,33.03
NCT03095716,Laparoscopic Surgery in Elderly Patients,UNKNOWN,,20.0,2016-10-01,2018-12-01,0.7696586599241467,Slow (<1/month),7.696586599241467,Significantly Below (<50%),50,29.9,9.07
NCT04495816,COVID-19 Anosmia Study,COMPLETED,PHASE2,139.0,2020-07-15,2021-12-31,7.923520599250937,Adequate (1-10/month),79.23520599250938,Met (75-100%),100,61.1,73.31
NCT06345716,Paracetamol-Tramadol and Paracetamol-caffeine Versus Placebo in the Emergency Discharge Treatment of Renal Colic,RECRUITING,PHASE2,1500.0,2024-04-10,2025-11-30,76.22704507512522,Excellent (>50/month),200.0,Exceeded (≥100%),60,88.0,92.495
NCT01019616,Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy,UNKNOWN,PHASE3,400.0,2011-03-04,2022-06-30,2.9439071566731143,Adequate (1-10/month),29.439071566731144,Significantly Below (<50%),50,67.0,79.725
NCT02161016,A Clinical Study of Outcomes in Foot and Ankle Bone Grafting Using map3® Cellular Allogeneic Bone Graft,TERMINATED,PHASE4,1.0,2014-06-01,2015-01-01,0.14224299065420562,Slow (<1/month),1.422429906542056,Significantly Below (<50%),10,18.1,3.105
NCT02571816,"A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215",COMPLETED,PHASE1,24.0,2015-10-23,2016-03-05,5.451940298507463,Adequate (1-10/month),54.51940298507463,Below (50-75%),100,51.9,52.55499999999999
NCT04191616,"Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet",COMPLETED,PHASE2,54.0,2020-08-06,2024-10-01,1.0835596572181938,Adequate (1-10/month),10.835596572181938,Significantly Below (<50%),100,49.3,46.265
NCT01613716,Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study),COMPLETED,PHASE4,30.0,2012-07-01,2017-02-01,0.5448687350835322,Slow (<1/month),5.448687350835322,Significantly Below (<50%),100,47.4,40.98
NCT03529916,Endothelial Cell Gene Networks of CVD,WITHDRAWN,,0.0,2018-05-21,2021-09-30,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT02059616,A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension,UNKNOWN,PHASE2,384.0,2014-02-01,2015-12-01,17.498443113772456,Good (10-50/month),174.98443113772456,Exceeded (≥100%),50,70.7,82.25
NCT06222216,The Effect of Chilled Needle on the Development of Pain and Ecchymosis in Subcutaneous Injection in Adults,RECRUITING,NA,60.0,2024-03-01,2024-10-01,8.534579439252337,Adequate (1-10/month),85.34579439252337,Met (75-100%),60,47.8,42.42
NCT01599416,Influence of U-relax on Vaginal Health Promotion and HPV DNA Test Change From Positive to Negative,COMPLETED,NA,80.0,2011-06-01,2013-12-01,2.664332603938731,Adequate (1-10/month),26.64332603938731,Significantly Below (<50%),100,56.4,64.88000000000001
NCT00740506,Behavioral and Environmetal Factors and Time to Delivery,COMPLETED,PHASE4,510.0,2008-08-20,2009-07-13,47.47522935779817,Good (10-50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT05290506,Linagliptin Response to OGTT in Prediabetes and Type 2 Diabetes Mellitus,COMPLETED,PHASE3,50.0,2020-08-01,2021-03-01,7.179245283018869,Adequate (1-10/month),71.79245283018868,Below (50-75%),100,54.0,58.72500000000001
NCT05485506,Multimodal Exercises on Sprint Performance of Rugby Players,COMPLETED,NA,24.0,2022-08-08,2022-09-25,15.22,Good (10-50/month),152.2,Exceeded (≥100%),100,56.9,65.89500000000001
NCT04467606,Motivational Interview Based Discharge Planning for Patients With Diabetic Foot Ulcers,COMPLETED,NA,132.0,2020-08-01,2022-11-30,4.72159811985899,Adequate (1-10/month),47.215981198589894,Significantly Below (<50%),100,60.6,72.785
NCT02647606,Comparison of the Videolaryngoscopes With Manual In-line Stabilization,COMPLETED,NA,120.0,2016-01-01,2017-02-01,9.201007556675064,Adequate (1-10/month),92.01007556675063,Met (75-100%),100,64.6,77.59
NCT04207606,Post Epidural Steroid Injection Follow-up,COMPLETED,,100.0,2020-01-03,2020-12-01,9.141141141141143,Adequate (1-10/month),91.41141141141142,Met (75-100%),100,61.3,73.56
NCT02031406,Impact of Pharmacist Post-discharge Phone Calls on Hospital Readmission and Patient Medication Literacy and Adherence,TERMINATED,NA,155.0,2014-01-01,2014-07-01,26.06740331491713,Good (10-50/month),200.0,Exceeded (≥100%),10,40.4,22.34
NCT04582006,Changes of Oral and Intestinal Microbiota After Bariatric Surgery,COMPLETED,,30.0,2018-12-01,2020-12-30,1.201578947368421,Adequate (1-10/month),12.01578947368421,Significantly Below (<50%),100,45.7,32.5
NCT05380206,Functional Knee Phenotypes of Patients Operated on for Total Knee Arthroplasty,COMPLETED,,500.0,2021-03-15,2022-09-15,27.723132969034612,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT06509906,M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511),TERMINATED,PHASE1,3.0,2024-10-08,2025-12-02,0.21742857142857144,Slow (<1/month),2.174285714285715,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT01126606,Comparative Safety and Efficacy Evaluation Between Dermacyd Silver and Glycerine Vegetal Soap Granado Traditional,COMPLETED,PHASE3,70.0,2010-08-01,2010-11-01,23.160869565217393,Good (10-50/month),200.0,Exceeded (≥100%),100,60.6,72.785
NCT03800706,A Phase II Study to Evaluate the Safety and Efficacy of TQB2450 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma,UNKNOWN,PHASE2,85.0,2019-03-25,2021-12-31,2.556719367588933,Adequate (1-10/month),25.56719367588933,Significantly Below (<50%),50,41.8,24.445
NCT04502706,Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma,TERMINATED,PHASE1,9.0,2020-11-17,2022-03-31,0.5490180360721443,Slow (<1/month),5.490180360721443,Significantly Below (<50%),10,18.7,4.455
NCT06043206,Bariatric Surgery in Patients With Schizophrenia,COMPLETED,,100.0,2022-10-01,2023-06-30,11.191176470588236,Good (10-50/month),111.91176470588235,Exceeded (≥100%),100,61.3,73.56
NCT03114306,Evaluation of a Fast-track Knee Arthroplasty Concept,COMPLETED,NA,40.0,2017-04-05,2017-08-30,8.28299319727891,Adequate (1-10/month),82.82993197278911,Met (75-100%),100,53.2,56.665
NCT03644706,Study Evaluating Subjects With Distal Renal Tubular Acidosis,TERMINATED,PHASE3,3.0,2021-09-20,2023-12-20,0.11123020706455543,Slow (<1/month),1.1123020706455542,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT06474806,"Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer",RECRUITING,PHASE2,168.0,2024-06-01,2025-09-01,11.19019693654267,Good (10-50/month),111.90196936542671,Exceeded (≥100%),60,56.4,64.88000000000001
NCT04037306,Measurements From Stool to Support Dietary Change,TERMINATED,NA,7.0,2019-07-30,2020-03-10,0.95125,Slow (<1/month),9.5125,Significantly Below (<50%),10,18.6,4.25
NCT00228306,The Effect of Aerobic Exercise on Learning After Stroke,COMPLETED,PHASE1,38.0,2005-09-01,2009-12-01,0.7453092783505155,Slow (<1/month),7.453092783505156,Significantly Below (<50%),100,48.0,42.945
NCT03982706,"Examination of Focal Therapies- MRI-Fusion, HIFU, NanoKnife and Cryotherapy",UNKNOWN,,1000.0,2015-10-28,2020-06-06,18.086749851455735,Good (10-50/month),180.86749851455735,Exceeded (≥100%),50,78.3,86.48
NCT07223606,Fecal Microbiota Transplant for Neuroblastoma in a Single Patient,NO_LONGER_AVAILABLE,,,,,,Slow (<1/month),,Significantly Below (<50%),50,23.3,6.569999999999999
NCT02438306,CardiAMP™ Cell Therapy for Heart Failure Trial,COMPLETED,PHASE3,125.0,2016-12-01,2025-06-01,1.2258376288659794,Adequate (1-10/month),12.258376288659793,Significantly Below (<50%),100,55.0,61.834999999999994
NCT00397306,Evaluation of a Bioimpedance Method for Determination of Dry Weight in Dialysis Patients,COMPLETED,NA,16.0,2006-11-01,2008-09-01,0.7269253731343285,Slow (<1/month),7.269253731343284,Significantly Below (<50%),100,46.3,35.66
NCT06157606,Prediction Model for Inadequate Weight Loss After Sleeve Gastrectomy,COMPLETED,,1000.0,2017-09-01,2024-09-30,11.77107501933488,Good (10-50/month),117.7107501933488,Exceeded (≥100%),100,93.3,94.325
NCT05770206,Hydrogen-Oxygen Generator With Nebulizer for Adjuvant Treatment of Novel Coronavirus Disease 2019 (COVID-19),UNKNOWN,NA,218.0,2023-04-01,2024-12-31,10.368625,Good (10-50/month),103.68625,Exceeded (≥100%),50,57.4,67.05499999999999
NCT06847906,Evaluating the Reach of Clinical Decision Support for Patients With Heart Failure,RECRUITING,NA,500.0,2025-02-25,2026-01-01,49.096774193548384,Good (10-50/month),200.0,Exceeded (≥100%),60,88.0,92.495
NCT05375006,Tropism and Pathogenesis of Influenza Virus and Coronavirus in Human Brain Explant Culture,UNKNOWN,,80.0,2022-05-26,2024-09-30,2.8382284382284384,Adequate (1-10/month),28.382284382284382,Significantly Below (<50%),50,39.7,21.21
NCT02229006,Sodium Fluoride Imaging of Abdominal Aortic Aneurysms,COMPLETED,,96.0,2014-09-01,2017-02-01,3.3057013574660634,Adequate (1-10/month),33.05701357466064,Significantly Below (<50%),100,56.0,63.71
NCT00750906,"ECT/Succinylcholine: Biochemical, Serum and Cardiovascular Changes",TERMINATED,,13.0,2008-10-01,2015-04-30,0.16474604496253123,Slow (<1/month),1.6474604496253127,Significantly Below (<50%),10,17.4,2.8049999999999997
NCT04028206,Resistance Exercise or Vibration With HMB for Sarcopenia,UNKNOWN,NA,144.0,2019-09-04,2023-07-29,3.0782022471910113,Adequate (1-10/month),30.782022471910114,Significantly Below (<50%),50,46.5,36.815
NCT05516706,Dynamic Stretching Versus Plyometric Push up Training on Upper Body Performance in Cricketers,COMPLETED,NA,22.0,2021-04-22,2022-07-30,1.4432758620689656,Adequate (1-10/month),14.432758620689656,Significantly Below (<50%),100,46.8,38.440000000000005
NCT07078006,Injectable Platelet Rich Fibrin Versus Platelet Rich Plasma Injection in Degenerative Temporomandibular Joint,COMPLETED,NA,20.0,2023-02-22,2024-07-23,1.1775628626692458,Adequate (1-10/month),11.775628626692459,Significantly Below (<50%),100,46.6,37.375
NCT07248306,Temporomandibular Joint Dysfunction in Sjögren's Syndrome,COMPLETED,,27.0,2025-05-15,2025-09-15,6.681951219512195,Adequate (1-10/month),66.81951219512196,Below (50-75%),100,50.5,48.515
NCT05213104,Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Arrhythmia or Tachycardia,ACTIVE_NOT_RECRUITING,PHASE3,186.0,2022-03-23,2026-07-01,3.6270595771941068,Adequate (1-10/month),36.27059577194106,Significantly Below (<50%),85,60.4,72.54
NCT07352904,Exploration Strategies in Night Vision Sensors,NOT_YET_RECRUITING,,10.0,2026-02-01,2026-12-25,0.9308868501529053,Slow (<1/month),9.308868501529052,Significantly Below (<50%),30,23.1,6.404999999999999
NCT05890404,SGM Evidenced-Based Mental Healthcare Implementation,RECRUITING,NA,1410.0,2024-02-08,2028-06-30,26.758354114713217,Good (10-50/month),200.0,Exceeded (≥100%),60,83.0,89.505
NCT00247104,The Use of Cranberries in Women With Preterm Premature Rupture of Membranes,UNKNOWN,NA,200.0,2007-05-01,2008-02-01,22.057971014492754,Good (10-50/month),200.0,Exceeded (≥100%),50,56.0,63.71
NCT07004504,MEnstrual Cycle pHase ANd dIabeteS Management,COMPLETED,,77.0,2023-12-14,2024-12-29,6.151916010498688,Adequate (1-10/month),61.51916010498688,Below (50-75%),100,54.5,60.12
NCT01679704,Determination of Glycemic Index (GI) of Ten Food Products,COMPLETED,NA,15.0,2012-02-01,2012-04-01,7.61,Adequate (1-10/month),76.1,Met (75-100%),100,51.2,50.375
NCT00030004,Pilot Study of Spinal Manipulation for Chronic Neck Pain,TERMINATED,PHASE1,30.0,2000-05-01,2001-04-01,2.725970149253732,Adequate (1-10/month),27.259701492537314,Significantly Below (<50%),10,25.4,7.470000000000001
NCT05614804,[Trial of device that is not approved or cleared by the U.S. FDA],WITHHELD,,,,,,Slow (<1/month),,Significantly Below (<50%),50,20.0,5.695
NCT03490604,Ambulatory Measurement of Physical Activity in Pancreatic Cancer Patients,COMPLETED,,30.0,2018-07-02,2021-10-01,0.7693344566133109,Slow (<1/month),7.693344566133109,Significantly Below (<50%),100,45.7,32.5
NCT03528304,Native Women's Wellness: Contingency Management for Tobacco Cessation and Weight Loss,COMPLETED,NA,125.0,2010-09-01,2015-01-01,2.4036639292482627,Adequate (1-10/month),24.036639292482626,Significantly Below (<50%),100,60.0,71.97
NCT05462704,Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy,RECRUITING,PHASE3,300.0,2023-01-17,2027-03-31,5.953063885267276,Adequate (1-10/month),59.53063885267276,Below (50-75%),60,62.0,74.42
NCT04916704,Subclinical Cytomegalovirus Reactivation in Acute ANCA-associated Vasculitis,ACTIVE_NOT_RECRUITING,,70.0,2022-04-19,2025-12-22,1.5865971705137754,Adequate (1-10/month),15.865971705137753,Significantly Below (<50%),85,44.4,28.95
NCT06821204,Detection of Pathogenic Bacteria in Make-up Tools,COMPLETED,NA,64.0,2025-03-20,2025-04-18,64.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,65.1,78.14
NCT00852904,National Children s Health Study,COMPLETED,,9942.0,2009-02-25,2020-05-29,73.61578204816345,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT06714604,Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC,RECRUITING,PHASE3,432.0,2023-10-18,2033-12-31,3.5283284142742155,Adequate (1-10/month),35.283284142742154,Significantly Below (<50%),60,72.6,83.28
NCT00919204,Axitinib Pharmacokinetics in Chinese Healthy Volunteers,COMPLETED,PHASE1,14.0,2009-08-01,2009-08-01,14.0,Good (10-50/month),140.0,Exceeded (≥100%),100,41.1,23.225
NCT01502904,Neointimal Coverage After Implantation of Biolimus Eluting Stent With Biodegradable Polymer: Optical Coherence Tomographic Assessment According to the Treatment of Dyslipidemia and Hypertension and the Types of Implanted Drug-eluting Stents,COMPLETED,PHASE4,120.0,2010-07-01,2015-06-01,2.0338530066815146,Adequate (1-10/month),20.338530066815146,Significantly Below (<50%),100,59.6,71.17999999999999
NCT03320304,A Study to Assess Effectiveness and Efficiency of VNS Therapy in Patients With Difficult to Treat Depression.,RECRUITING,,500.0,2017-12-14,2031-12-01,2.984313725490196,Adequate (1-10/month),29.843137254901965,Significantly Below (<50%),60,76.3,85.1
NCT00674804,Communicating a Cancer Diagnosis-Current Methods and Their Effects,COMPLETED,,1100.0,2008-04-24,2009-07-16,74.74107142857143,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT03455504,"Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia",ACTIVE_NOT_RECRUITING,PHASE2,124.0,2018-10-26,2025-01-01,1.6708986277113769,Adequate (1-10/month),16.70898627711377,Significantly Below (<50%),85,55.4,62.56
NCT04549584,Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast Cancer,TERMINATED,,3.0,2020-10-01,2020-12-16,1.201578947368421,Adequate (1-10/month),12.015789473684212,Significantly Below (<50%),10,16.6,2.645
NCT06847984,Antimicrobial Effect of Curcumin Versus Chlorohexidine on Oral Microbiome,NOT_YET_RECRUITING,NA,54.0,2025-03-01,2026-03-01,4.503452054794521,Adequate (1-10/month),45.03452054794521,Significantly Below (<50%),30,33.3,13.200000000000001
NCT05421884,Impact of Five Love Languages on Cancer Patients,UNKNOWN,NA,50.0,2022-05-03,2022-09-30,10.146666666666667,Good (10-50/month),101.46666666666665,Exceeded (≥100%),50,44.0,28.249999999999996
NCT03972384,A Problem Solving Intervention for Post-ICU Cognitive Impairment in Older Adults,COMPLETED,NA,19.0,2022-01-21,2023-03-01,1.4315841584158417,Adequate (1-10/month),14.315841584158417,Significantly Below (<50%),100,46.5,36.815
NCT05510284,Post-partum Care in the NICU,COMPLETED,NA,37.0,2022-11-29,2024-05-14,2.117067669172932,Adequate (1-10/month),21.170676691729323,Significantly Below (<50%),100,53.0,55.80500000000001
NCT02186184,Effect of Orthokeratology Versus Spectacles on Myopia Progression in Chinese Children: A Crossover Trial,COMPLETED,PHASE4,100.0,2014-06-01,2017-10-01,2.4991789819376025,Adequate (1-10/month),24.991789819376024,Significantly Below (<50%),100,58.0,68.245
NCT00865384,A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Non-fasting Conditions,COMPLETED,PHASE1,24.0,2001-09-01,2001-09-01,24.0,Good (10-50/month),200.0,Exceeded (≥100%),100,41.9,24.585
NCT04834284,HEMS for Mechanical Thrombectomy,UNKNOWN,,60.0,2020-06-01,2023-12-31,1.3963302752293578,Adequate (1-10/month),13.963302752293579,Significantly Below (<50%),50,33.1,12.814999999999998
NCT00396084,"Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis",COMPLETED,PHASE1,70.0,2004-02-10,2007-12-28,1.503740296400847,Adequate (1-10/month),15.03740296400847,Significantly Below (<50%),100,50.6,48.705
NCT01322984,Cognitive and Emotional Processing of Social Stimuli in Children and Youth With Autism Spectrum Disorder,UNKNOWN,NA,60.0,2011-03-01,,,Slow (<1/month),,Significantly Below (<50%),50,29.8,8.98
NCT06455384,The Genetics Navigator: Evaluating a Digital Platform for Genomics Health Services,RECRUITING,NA,170.0,2025-10-28,2027-07-01,8.469394435351882,Adequate (1-10/month),84.69394435351883,Met (75-100%),60,56.6,65.34
NCT01424384,Emotional Processing in Healthy Volunteers in the Presence of an Investigational Anxiolytic,COMPLETED,PHASE1,54.0,2008-09-19,2009-04-30,7.371121076233185,Adequate (1-10/month),73.71121076233183,Below (50-75%),100,54.3,59.62
NCT01164384,"A Phase 1b, Single Center, Clinical Study to Investigate the Safety and Biological Responses to Baminercept in Patients With Chronic HCV Hepatitis.",UNKNOWN,PHASE1,,2010-10-01,2013-02-01,,Slow (<1/month),,Significantly Below (<50%),50,30.0,9.145
NCT03843684,Effects of 3D-printed on Lower Extremity Biomechanics in Individuals With Knee Osteoarthritis,COMPLETED,NA,15.0,2019-04-20,2019-12-10,1.9512820512820515,Adequate (1-10/month),19.512820512820518,Significantly Below (<50%),100,51.2,50.375
NCT01742884,Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz,COMPLETED,PHASE4,50.0,2012-12-01,2014-06-01,2.7824497257769654,Adequate (1-10/month),27.824497257769654,Significantly Below (<50%),100,54.0,58.72500000000001
NCT04361084,Community Simulation Utilising Mixed Reality (MR),UNKNOWN,NA,68.0,2020-11-01,2021-04-30,11.499555555555556,Good (10-50/month),114.99555555555557,Exceeded (≥100%),50,45.4,31.455
NCT02862184,"Female Sexual Dysfunction, Risks and Outcomes (FSFI)",WITHDRAWN,,0.0,2016-07-01,2017-01-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT05676684,Dapagliflozin With or Without Spironolactone for HFpEF,COMPLETED,PHASE2,108.0,2022-09-15,2024-11-29,4.078808933002481,Adequate (1-10/month),40.78808933002481,Significantly Below (<50%),100,58.6,69.51
NCT02083484,Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030),NO_LONGER_AVAILABLE,,,,,,Slow (<1/month),,Significantly Below (<50%),50,23.3,6.569999999999999
NCT07143084,Investigation of the Relationship Between Nutritional Status Assessment and Frailty in Critical Care Patients,ENROLLING_BY_INVITATION,,100.0,2025-05-15,2026-05-01,8.672364672364674,Adequate (1-10/month),86.72364672364672,Met (75-100%),55,47.8,42.42
NCT05947084,Comparison of Growth and Tolerance of Healthy Term Infants Fed Iron-Fortified Infant Formulas,COMPLETED,NA,518.0,2023-08-31,2025-06-30,23.569387144992525,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT06545084,Evaluation of Periapical Healing Following Endodontic Microsurgery With Leukocyte and Platelet Rich Fibrin (L-PRF),RECRUITING,,50.0,2024-08-01,2026-06-30,2.1805157593123212,Adequate (1-10/month),21.805157593123212,Significantly Below (<50%),60,40.3,22.21
NCT05958784,"PKU Carriers Trial (Pilot Study): Impact on Cognition, Mental Health, Blood Pressure and Metabolism",COMPLETED,NA,7.0,2023-07-01,2023-12-01,1.3926797385620915,Adequate (1-10/month),13.926797385620915,Significantly Below (<50%),100,45.6,32.08
NCT06359184,"Yoga, Mother's Stress and Baby",COMPLETED,NA,55.0,2023-11-01,2024-02-15,15.79433962264151,Good (10-50/month),157.9433962264151,Exceeded (≥100%),100,59.4,70.905
NCT05560984,Cervical Internal os Plasty in Management of Placenta Previa and Focal Accreta,UNKNOWN,NA,40.0,2022-10-01,2023-02-01,9.899186991869918,Adequate (1-10/month),98.9918699186992,Met (75-100%),50,43.2,26.840000000000003
NCT01996384,"Provoked, Localized Vulvodynia Treatment With Acupuncture and Lidocaine Pilot Study",COMPLETED,PHASE1,19.0,2013-11-01,2016-03-01,0.6796239717978849,Slow (<1/month),6.796239717978849,Significantly Below (<50%),100,46.5,36.815
NCT00076284,GW873140 to Treat HIV-1 Infected Adults,COMPLETED,PHASE2,20.0,2004-01-01,2005-03-01,1.4324705882352942,Adequate (1-10/month),14.324705882352943,Significantly Below (<50%),100,46.6,37.375
NCT03800784,Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer,WITHDRAWN,PHASE2,0.0,2019-10-01,2021-10-21,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT06086184,Inpatient Group Acceptance and Commitment Therapy (ACT) for Psychosis Spectrum Disorder,UNKNOWN,NA,32.0,2023-10-16,2025-02-01,2.0550210970464136,Adequate (1-10/month),20.550210970464136,Significantly Below (<50%),50,37.6,18.845
NCT05337384,Sonographic Venous Doppler Imaging in End-Stage Renal Disease,COMPLETED,,40.0,2022-04-01,2022-12-01,4.99016393442623,Adequate (1-10/month),49.901639344262286,Significantly Below (<50%),100,51.5,51.245
NCT05651984,Communication Strategies for Mechanically Ventilated Patients in Intensive Care Units,COMPLETED,NA,44.0,2019-02-09,2019-06-27,9.705507246376811,Adequate (1-10/month),97.05507246376811,Met (75-100%),100,58.5,69.34
NCT01805284,"Pharmacokinetic and Pharmacodynamic Evaluation of Linezolid Administered Intravenously in MRSA-positive, Morbidly Obese Patients With Pneumonia",COMPLETED,PHASE4,15.0,2013-02-01,2016-09-30,0.3415108451757667,Slow (<1/month),3.415108451757667,Significantly Below (<50%),100,46.2,35.089999999999996
NCT02238184,Postmarketing Surveillance Study of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,,105.0,2001-01-01,,,Slow (<1/month),,Significantly Below (<50%),100,46.7,37.895
NCT03090984,Evaluation of Contact Phase Activation During Hemodialysis,COMPLETED,NA,10.0,2017-05-08,2017-07-24,3.9532467532467535,Adequate (1-10/month),39.53246753246753,Significantly Below (<50%),100,50.8,49.18
NCT04205084,[Trial of device that is not approved or cleared by the U.S. FDA],WITHHELD,,,,,,Slow (<1/month),,Significantly Below (<50%),50,20.0,5.695
NCT05519384,Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia,UNKNOWN,EARLY_PHASE1,12.0,2022-09-14,2025-12-01,0.31114139693356047,Slow (<1/month),3.111413969335605,Significantly Below (<50%),50,31.0,9.985
NCT07083284,Acute Kidney Injury in Neonatal ICU in Assuit University,NOT_YET_RECRUITING,,100.0,2025-08-01,2026-09-01,7.686868686868687,Adequate (1-10/month),76.86868686868688,Met (75-100%),30,35.3,15.534999999999998
NCT02187133,Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,COMPLETED,PHASE1,10.0,2015-05-05,2021-03-31,0.14112192860454337,Slow (<1/month),1.4112192860454338,Significantly Below (<50%),100,45.8,33.03
NCT00116233,Pediatric Multicenter Study of REPEL-CV,UNKNOWN,PHASE2,,,,,Slow (<1/month),,Significantly Below (<50%),50,25.0,7.23
NCT01231633,Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO),COMPLETED,NA,27.0,2010-09-01,2014-09-01,0.5625462012320328,Slow (<1/month),5.6254620123203285,Significantly Below (<50%),100,47.2,40.035
NCT06579833,Histotripsy (HistoSonics®) for Liver Tumours,ACTIVE_NOT_RECRUITING,NA,60.0,2024-08-29,2028-09-01,1.2475409836065574,Adequate (1-10/month),12.475409836065573,Significantly Below (<50%),85,45.3,31.169999999999998
NCT06276933,A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC),NOT_YET_RECRUITING,PHASE4,104.0,2024-02-22,2026-11-22,3.153147410358566,Adequate (1-10/month),31.531474103585662,Significantly Below (<50%),30,37.3,18.35
NCT05539833,KSH01-TCRT Solid Tumors,RECRUITING,EARLY_PHASE1,50.0,2022-08-19,2027-07-31,0.8422800221361373,Slow (<1/month),8.422800221361374,Significantly Below (<50%),60,37.0,17.955
NCT05100433,Effect of Passive Ultrasonic Irrigation on Bacteria That Persist After Root Canal Preparation,COMPLETED,NA,30.0,2018-03-05,2022-11-25,0.5290845886442642,Slow (<1/month),5.290845886442643,Significantly Below (<50%),100,47.4,40.98
NCT00007033,Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease,COMPLETED,NA,25.0,2000-10-01,,,Slow (<1/month),,Significantly Below (<50%),100,42.0,24.825
NCT04052633,Success of Intraoperative Cholangiography,COMPLETED,,201.0,2018-01-01,2019-03-26,13.626815144766146,Good (10-50/month),136.26815144766147,Exceeded (≥100%),100,69.4,81.52000000000001
NCT01399333,Comparison of Meal Replacements Versus Protein Supplements and Utilizing the Protein Digestibility Corrected Amino Acid Score (PDCAAS) Method,UNKNOWN,PHASE4,60.0,2010-01-01,2012-01-01,2.5019178082191784,Adequate (1-10/month),25.019178082191786,Significantly Below (<50%),50,39.8,21.47
NCT06062433,A Study of Remote Asthma Management Using an Integrated Artificial Intelligence-assisted EHR Dashboard and Mobile Device Compared With Usual Asthma Care to Treat 6-17 Year Old Patients,COMPLETED,NA,47.0,2023-12-05,2025-06-05,2.610729927007299,Adequate (1-10/month),26.107299270072993,Significantly Below (<50%),100,53.8,58.065
NCT06926933,Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty,RECRUITING,PHASE4,50.0,2024-12-12,2027-10-30,1.4467680608365021,Adequate (1-10/month),14.467680608365018,Significantly Below (<50%),60,37.0,17.955
NCT06525233,Interval Aerobic Training and Continious Training,COMPLETED,,40.0,2018-05-05,2019-05-20,3.2042105263157894,Adequate (1-10/month),32.04210526315789,Significantly Below (<50%),100,51.5,51.245
NCT01678833,Understanding Drug Abuse Treatment Outcomes,COMPLETED,,7.0,2012-07-19,2016-03-07,0.16057272042200454,Slow (<1/month),1.6057272042200452,Significantly Below (<50%),100,43.9,28.12
NCT00498433,Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension,TERMINATED,PHASE2,46.0,2007-06-01,2012-03-01,0.8070547550432277,Slow (<1/month),8.070547550432277,Significantly Below (<50%),10,21.7,6.175
NCT04482933,HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma,SUSPENDED,PHASE2,35.0,2025-09-01,2030-02-15,0.6544226044226044,Slow (<1/month),6.544226044226044,Significantly Below (<50%),20,23.8,6.76
NCT06663033,Anastomotic Leak in Covid-19,COMPLETED,,390.0,2020-04-01,2024-10-01,7.221167883211678,Adequate (1-10/month),72.21167883211679,Below (50-75%),100,79.5,87.195
NCT00096733,Adult-to-Adult Living Donor Liver Transplantation Study,COMPLETED,,2470.0,2004-10-01,2010-08-01,35.29896713615024,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT06315933,Anesthesia Neurodevelopmental Impact in Congenital Scoliosis Children,RECRUITING,,150.0,2020-07-13,2026-12-01,1.9579759862778732,Adequate (1-10/month),19.579759862778733,Significantly Below (<50%),60,48.3,43.985
NCT01927133,LIVER FIBROSIS PREVALENCE IN FRANCE,UNKNOWN,,10000.0,1997-01-01,2020-01-01,36.23809523809524,Good (10-50/month),200.0,Exceeded (≥100%),50,78.3,86.48
NCT01946633,Remote-controlled Capsule Endoscopy: a Feasibility Study,UNKNOWN,NA,80.0,2013-10-01,,,Slow (<1/month),,Significantly Below (<50%),50,31.4,10.47
NCT00000433,Blocking Tumor Necrosis Factor in Ankylosing Spondylitis,COMPLETED,PHASE2,42.0,1999-10-01,2002-03-01,1.4495238095238094,Adequate (1-10/month),14.495238095238097,Significantly Below (<50%),100,48.4,44.22
NCT01288833,Clinical Study of Real Time Colorectal Polyp Diagnosis During Colonoscopy - the VALID Colonoscopy Study,COMPLETED,NA,558.0,2011-03-01,2015-10-01,10.14060895522388,Good (10-50/month),101.40608955223883,Exceeded (≥100%),100,95.0,95.7
NCT06665633,Treatment of U.S. Veterans With Mild Traumatic Brain Injury With Hyperbaric Oxygen Therapy,COMPLETED,PHASE1,40.0,2021-09-07,2025-07-01,0.8740847092605887,Slow (<1/month),8.740847092605888,Significantly Below (<50%),100,48.2,43.665
NCT04858633,Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19,UNKNOWN,PHASE3,1000.0,2021-03-22,2021-06-30,304.40000000000003,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT05070052,MBCT and CBT for Youth at High Risk for Mood and Psychotic Disorders: a Randomized Controlled Trial,COMPLETED,NA,66.0,2020-01-14,2022-03-09,2.5592866242038217,Adequate (1-10/month),25.59286624203822,Significantly Below (<50%),100,55.3,62.36000000000001
NCT00018252,The Effect of Exercise Training on Mental Stress-Induced Silent Ischemia,COMPLETED,NA,,1997-04-01,2000-03-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,30.330000000000002
NCT01868152,The Realtime Detection for Prediction of Opioid Analgesic,COMPLETED,,131.0,2013-04-01,2014-04-01,10.925041095890412,Good (10-50/month),109.25041095890413,Exceeded (≥100%),100,63.8,76.78
NCT00295152,Effects of Community Occupational Therapy in Older Patients With Dementia and Their Caregivers.,UNKNOWN,NA,135.0,2001-04-01,2005-02-01,2.9310984308131243,Adequate (1-10/month),29.31098430813124,Significantly Below (<50%),50,45.8,33.03
NCT02278952,Tacrolimus Adjustment by NFAT-related Gene Expression in Lung Allograft Recipients.,COMPLETED,,50.0,2014-12-01,2018-01-01,1.3504880212954748,Adequate (1-10/month),13.504880212954747,Significantly Below (<50%),100,47.3,40.475
NCT01212952,"Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",COMPLETED,PHASE1,50.0,2011-09-01,2018-03-22,0.6357560568086884,Slow (<1/month),6.357560568086884,Significantly Below (<50%),100,49.0,45.61
NCT04654052,VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome,ACTIVE_NOT_RECRUITING,PHASE4,634.0,2021-07-02,2026-12-04,9.742029278142352,Adequate (1-10/month),97.42029278142354,Met (75-100%),85,90.5,93.4
NCT01378052,DNA Methylation and Urothelial Carcinoma,UNKNOWN,,200.0,2011-06-01,,,Slow (<1/month),,Significantly Below (<50%),50,39.3,20.810000000000002
NCT03365752,Chloroprocaine Spinal for Outpatient Knee Surgery,TERMINATED,PHASE2,39.0,2018-06-24,2021-02-04,1.2417991631799163,Adequate (1-10/month),12.417991631799163,Significantly Below (<50%),10,21.1,6.140000000000001
NCT05458752,Pneumocystis Jirovecii Pneumonia in Non-HIV-infected Immunocompromised Patients,COMPLETED,,133.0,2020-04-01,2023-07-01,3.4135919055649246,Adequate (1-10/month),34.135919055649246,Significantly Below (<50%),100,59.0,70.365
NCT02541552,Effect of Volume of Local Anesthetic for Adductor Canal Block on Quadriceps Muscle Function: A Dose Finding Study,COMPLETED,PHASE3,26.0,2015-04-01,2015-11-01,3.698317757009346,Adequate (1-10/month),36.98317757009345,Significantly Below (<50%),100,52.1,53.03
NCT02438852,Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer,WITHDRAWN,PHASE3,0.0,2019-02-25,2022-02-25,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT04656652,Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01),ACTIVE_NOT_RECRUITING,PHASE3,605.0,2020-12-21,2026-01-31,9.864059989287629,Adequate (1-10/month),98.64059989287628,Met (75-100%),85,90.5,93.4
NCT00331747,Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate,UNKNOWN,NA,20.0,2006-05-01,,,Slow (<1/month),,Significantly Below (<50%),50,26.6,8.01
NCT02280447,"3 Adjuvated Reduced Dose IPV-Al SSI Vaccines and Non-adjuvated Full Dose IPV SSI, as Booster Vaccination to Adolescents",COMPLETED,PHASE1,240.0,2014-11-13,2015-03-05,65.22857142857143,Excellent (>50/month),200.0,Exceeded (≥100%),100,79.2,87.095
NCT00001747,Racial Differences in Control of Blood Vessel Tone and Blood Flow,COMPLETED,,108.0,1998-05-01,2001-03-01,3.1763478260869564,Adequate (1-10/month),31.763478260869565,Significantly Below (<50%),100,57.0,66.12
NCT02669147,A Study to Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPC,COMPLETED,,160.0,2016-01-26,2021-03-01,2.617087587318646,Adequate (1-10/month),26.17087587318646,Significantly Below (<50%),100,61.1,73.31
NCT06526247,Evaluating Interventions for Intimate Partner Violence Use in Washington State,RECRUITING,NA,800.0,2024-11-18,2027-07-01,25.499476439790577,Good (10-50/month),200.0,Exceeded (≥100%),60,83.0,89.505
NCT02267447,Cardiovascular Disease Population Risk Tool,COMPLETED,,104219.0,2000-09-01,2016-04-01,557.4462062906343,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT04909047,"The Effectiveness of Parassacral Transcutaneous Stimulation Compared to Tibial Transcutaneous Stimulation, Home Protocol and Behavioral Therapy in the Treatment of Female Hyperative Bladder: Randomized Clinical Trial",RECRUITING,NA,120.0,2021-07-01,2025-12-01,2.263197026022305,Adequate (1-10/month),22.63197026022305,Significantly Below (<50%),60,47.6,41.775
NCT04529447,Response of Korean Medicine Hospital to COVID-19,COMPLETED,,485.0,2020-06-10,2020-08-10,242.02295081967213,Excellent (>50/month),200.0,Exceeded (≥100%),100,97.1,96.61
NCT02120547,Phase 1 Study of Multiple-Dose Pharmacokinetics of Cenicriviroc in Subjects With Mild and Moderate Hepatic Impairment,COMPLETED,PHASE1,31.0,2014-03-01,2014-08-01,6.167581699346405,Adequate (1-10/month),61.67581699346405,Below (50-75%),100,52.5,54.345
NCT01059747,Therapeutic Drug Monitoring and Pharmacogenomics Study of Methadone Therapy,UNKNOWN,,500.0,2008-12-01,,,Slow (<1/month),,Significantly Below (<50%),50,63.3,76.235
NCT01765647,Oral AGY for Celiac Disease,COMPLETED,PHASE1,10.0,2014-05-01,2015-08-01,0.6660831509846827,Slow (<1/month),6.660831509846828,Significantly Below (<50%),100,45.8,33.03
NCT06376747,The Influence of Blood Sampling Technique on the Total Amount of Blood Collected for Laboratory Testing Critically Ill Pediatric Patients,NOT_YET_RECRUITING,NA,100.0,2024-05-01,2025-08-31,6.250513347022587,Adequate (1-10/month),62.505133470225886,Below (50-75%),30,37.0,17.955
NCT06372847,DISE-HNS Effect Study,RECRUITING,NA,58.0,2025-10-21,2028-03-31,1.9792825112107624,Adequate (1-10/month),19.79282511210762,Significantly Below (<50%),60,42.6,25.679999999999996
NCT05403047,"Efficacy of Tenofovir Disoproxil on Mother-to-child Transmission of HBV in Tokombéré, Cameroon in Pregnant Women",UNKNOWN,PHASE4,150.0,2022-07-01,2025-10-01,3.843434343434344,Adequate (1-10/month),38.43434343434344,Significantly Below (<50%),50,47.0,39.33
NCT04309747,"A Prospective, Multicenter Clinical Trial of Safety and Effectiveness of Nanosecond Knife Ablation for Liver Cancer",UNKNOWN,NA,190.0,2020-04-01,2022-12-01,5.937987679671458,Adequate (1-10/month),59.37987679671458,Below (50-75%),50,50.2,48.04
NCT01345747,The Laryngeal Tube Suction Versus Endotracheal Tube for Ventilation in Gynecological Laparoscopic Surgery,COMPLETED,NA,120.0,2008-06-01,2009-07-01,9.247594936708861,Adequate (1-10/month),92.4759493670886,Met (75-100%),100,64.6,77.59
NCT06856447,The Role of Coenzyme Q10 in the Prophylaxis of Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer,RECRUITING,PHASE1,22.0,2024-06-01,2026-01-10,1.1389115646258503,Adequate (1-10/month),11.389115646258505,Significantly Below (<50%),60,34.8,15.040000000000001
NCT04671147,Short-Term Preoperative Traction Method for Rigid and Severe Scoliosis,COMPLETED,,30.0,2016-01-01,2019-12-31,0.6254794520547946,Slow (<1/month),6.2547945205479465,Significantly Below (<50%),100,45.7,32.5
NCT01353547,Genes and Environment in Multiple Sclerosis,RECRUITING,,5000.0,2017-10-01,2040-10-01,18.116890846327816,Good (10-50/month),181.16890846327817,Exceeded (≥100%),60,81.3,88.58
NCT03506347,Regional Prophylactic Vancomycin With Restricted Tourniquet Time in Primary Total Knee Replacement,COMPLETED,PHASE2,24.0,2018-09-24,2019-01-17,6.352695652173914,Adequate (1-10/month),63.52695652173913,Below (50-75%),100,51.9,52.55499999999999
NCT05949047,Smartphone-based Cognitive Emotion Regulation Training for Unpaid Primary Caregivers of Persons With Alzheimer's Disease,RECRUITING,NA,270.0,2023-09-14,2027-05-31,6.065535055350554,Adequate (1-10/month),60.655350553505535,Below (50-75%),60,59.6,71.17999999999999
NCT07167147,Survival Outcomes by Tumor-Node Stage and Recurrence Patterns in Colon Cancer After Radical Surgery,COMPLETED,,7259.0,2025-04-09,2025-08-01,1938.280350877193,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT06003647,Educational Intervention Among Informal Caregivers of Person With Dementia,UNKNOWN,NA,174.0,2023-12-15,2024-09-01,20.293333333333337,Good (10-50/month),200.0,Exceeded (≥100%),50,53.9,58.34
NCT00486447,Perfusion Imaging and CT -Understanding Relative Efficacy,TERMINATED,NA,249.0,2007-06-01,2009-12-01,8.2927352297593,Adequate (1-10/month),82.927352297593,Met (75-100%),10,42.9,26.145000000000003
NCT01135147,Obesity and Obstructive Sleep Apnea (OSA) in Children,UNKNOWN,NA,100.0,2010-06-01,,,Slow (<1/month),,Significantly Below (<50%),50,33.0,12.695
NCT04775147,Intensive Control of Blood Pressure in Acute Ischemic Stroke After Endovascular Therapy on Clinical Outcome (CRISIS I),TERMINATED,NA,205.0,2020-07-03,2023-01-03,6.827352297592998,Adequate (1-10/month),68.27352297592998,Below (50-75%),10,39.4,20.94
NCT02106247,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Healthy Male Volunteers",COMPLETED,PHASE1,36.0,2014-04-01,2014-06-01,17.964590163934425,Good (10-50/month),179.64590163934423,Exceeded (≥100%),100,57.9,67.83
NCT01294449,Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy Post Approval Registry,COMPLETED,,394.0,2011-03-01,2013-11-01,12.28827868852459,Good (10-50/month),122.88278688524589,Exceeded (≥100%),100,84.9,90.85
NCT03887949,Comparison of Three Modes of Ventilation During Robot-assisted Hysterectomy in Trendelenburg Position,UNKNOWN,NA,60.0,2018-05-01,2019-05-31,4.6237974683544305,Adequate (1-10/month),46.2379746835443,Significantly Below (<50%),50,39.8,21.47
NCT07326449,Test-Retest Reliability And Validation For End-Tidal Carbon Dioxide Measurement (PetCO2) During Rest And Low-Loaded Steady State Work Using A Portable Capnograph.,ENROLLING_BY_INVITATION,,20.0,2025-06-06,2026-02-01,2.5366666666666666,Adequate (1-10/month),25.366666666666664,Significantly Below (<50%),55,36.4,17.14
NCT00531349,Regional Anesthesia and Endometrial Cancer Recurrence,WITHDRAWN,PHASE3,0.0,2007-11-01,2007-11-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT04554849,Demographic Characteristics and Psychosocial Health of Transgender People,UNKNOWN,,320.0,2020-07-24,2022-01-01,18.518631178707224,Good (10-50/month),185.18631178707224,Exceeded (≥100%),50,63.9,76.9
NCT03687749,Presentation of First Time Attenders at Lymphedema Clinics,COMPLETED,,46.0,2017-02-01,2020-12-31,0.9798740377886634,Slow (<1/month),9.798740377886633,Significantly Below (<50%),100,47.0,39.33
NCT05948449,To Evaluate the Efficacy and Safety of Cadonilimab With SOX as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.,UNKNOWN,PHASE2,37.0,2023-07-01,2025-07-01,1.5407387140902873,Adequate (1-10/month),15.407387140902875,Significantly Below (<50%),50,33.0,12.695
NCT00403949,A Study of Azelaic Acid (AzA) 15% in Topical Treatment of Mild to Moderate Perioral Dermatitis,COMPLETED,PHASE2,48.0,2006-11-01,2007-03-01,12.176,Good (10-50/month),121.76,Exceeded (≥100%),100,58.8,69.89999999999999
NCT06591949,Cognitive Exercise Therapy Approach (BETY) in JIA,COMPLETED,NA,52.0,2025-01-15,2025-09-12,6.5953333333333335,Adequate (1-10/month),65.95333333333333,Below (50-75%),100,54.2,59.330000000000005
NCT00630149,Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy,COMPLETED,PHASE2,35.0,2007-11-01,2012-01-01,0.7,Slow (<1/month),7.000000000000001,Significantly Below (<50%),100,47.8,42.42
NCT02140749,"Trial on Short-chain Fructooligosaccharides, Microbiota, and Constipation in Adults",COMPLETED,NA,120.0,2014-04-01,2014-12-01,14.970491803278687,Good (10-50/month),149.70491803278688,Exceeded (≥100%),100,64.6,77.59
NCT06248749,Effect of Intravenously Iron Infusion on the Prevention and Treatment of Anemia in Ovarian Cancer,NOT_YET_RECRUITING,PHASE3,200.0,2024-02-29,2029-12-01,2.896289248334919,Adequate (1-10/month),28.96289248334919,Significantly Below (<50%),30,45.0,30.330000000000002
NCT03145649,Breast Milk Hormones and Early Infant Growth of Women With Gestational Diabetes Mellitus,COMPLETED,,96.0,2010-01-12,2011-07-16,5.313163636363637,Adequate (1-10/month),53.13163636363637,Below (50-75%),100,56.0,63.71
NCT00908349,Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy,COMPLETED,PHASE3,214.0,2009-06-01,2011-11-01,7.377304643261609,Adequate (1-10/month),73.77304643261608,Below (50-75%),100,67.1,79.86999999999999
NCT00023049,Genetic Analysis of Hereditary Disorders of Hearing and Balance,COMPLETED,,335.0,2002-12-23,,,Slow (<1/month),,Significantly Below (<50%),100,65.1,78.14
NCT04692649,Comparison of Pragmatic Posterior Capsular Stretch and Crossbody Stretch on the Shoulder Mobility,COMPLETED,NA,60.0,2021-01-05,2021-04-15,18.264,Good (10-50/month),182.64000000000001,Exceeded (≥100%),100,59.8,71.61
NCT05620849,Young Adult Education on Alcohol & Health,RECRUITING,NA,300.0,2023-09-15,2026-01-31,10.508630609896432,Good (10-50/month),105.08630609896431,Exceeded (≥100%),60,67.0,79.725
NCT01139749,Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea,UNKNOWN,PHASE4,50.0,2011-10-01,2012-12-01,3.5644028103044496,Adequate (1-10/month),35.6440281030445,Significantly Below (<50%),50,39.0,20.505000000000003
NCT03178149,"A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration",RECRUITING,PHASE1,42.0,2018-07-13,2026-06-30,0.4394912341010657,Slow (<1/month),4.394912341010657,Significantly Below (<50%),60,36.4,17.14
NCT05736549,Yale Steroid Enhanced Versus Exparel Nerveblock TKA Part 2,RECRUITING,PHASE2,66.0,2023-02-07,2028-03-01,1.0865548945375878,Adequate (1-10/month),10.865548945375878,Significantly Below (<50%),60,38.3,19.785
NCT01130649,Remote Tracking of Epilepsy Patients,WITHDRAWN,,0.0,2010-07-01,2013-07-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT05782049,Ultrasound Characteristics of the Salivary Glands in Patients With Rheumatoid Arthritis,UNKNOWN,NA,210.0,2023-02-02,2026-02-02,5.832481751824817,Adequate (1-10/month),58.324817518248175,Below (50-75%),50,51.8,52.17
NCT04947449,Potential Benefits of Laser Treatment on Skin Blood Flow and Sweating in Burn Survivors,TERMINATED,,4.0,2021-07-29,2025-03-01,0.09287566742944318,Slow (<1/month),0.928756674294432,Significantly Below (<50%),10,16.7,2.68
NCT02013349,DESolve Post-Approval Study,COMPLETED,NA,102.0,2014-04-22,2019-04-01,1.7201551246537397,Adequate (1-10/month),17.2015512465374,Significantly Below (<50%),100,58.2,68.795
NCT01573949,A Pilot Study: Metformin Therapy in Heart Failure Patients With Early Diabetes or at High Risk of Developing Diabetes (Pre-Diabetes),COMPLETED,NA,7.0,2011-12-01,2012-12-01,0.5821857923497268,Slow (<1/month),5.821857923497268,Significantly Below (<50%),100,45.6,32.08
NCT03932149,The Effect of Intermittent Theta Burst Stimulation (iTBS) in Patients With Alcohol Use Disorder,UNKNOWN,NA,60.0,2019-12-06,2021-03-01,4.049667405764967,Adequate (1-10/month),40.49667405764967,Significantly Below (<50%),50,39.8,21.47
NCT01945749,Exercise and Steroid in Knee Osteoarthritis,COMPLETED,NA,100.0,2012-10-01,2014-04-01,5.564899451553931,Adequate (1-10/month),55.64899451553931,Below (50-75%),100,58.0,68.245
NCT05402449,To Evaluate the Beneficial Effect of Probiotics on NAFLD Patients and the Role of Gut Microbiota Modulation,COMPLETED,NA,70.0,2022-07-14,2024-05-31,3.101601164483261,Adequate (1-10/month),31.01601164483261,Significantly Below (<50%),100,55.6,62.905
NCT01208649,Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH),COMPLETED,PHASE4,13.0,2008-07-01,2010-09-01,0.49964646464646467,Slow (<1/month),4.996464646464647,Significantly Below (<50%),100,46.0,34.1
NCT04690049,Therapeutic Progressive Exercise on Shoulder Impingement Syndrome,NOT_YET_RECRUITING,NA,60.0,2025-04-01,2026-02-01,5.968627450980392,Adequate (1-10/month),59.68627450980393,Below (50-75%),30,33.8,13.694999999999999
NCT03144349,Diagnosis Accuracy of Hemoconcentration to Detect Hypovolemia During CRRT,UNKNOWN,,52.0,2016-12-01,2019-12-01,1.4455525114155252,Adequate (1-10/month),14.455525114155254,Significantly Below (<50%),50,32.5,12.235
NCT03587038,OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma,ACTIVE_NOT_RECRUITING,PHASE1,27.0,2018-09-03,2026-11-01,0.27570613887957063,Slow (<1/month),2.757061388795706,Significantly Below (<50%),85,42.7,25.77
NCT06036238,The Outreach and Prevention at ALcohol Venues in East Africa Study (OPAL-East Africa- Aim 2) (OPAL-Aim 2),RECRUITING,NA,400.0,2024-05-17,2027-06-01,10.96936936936937,Good (10-50/month),109.6936936936937,Exceeded (≥100%),60,75.0,84.49
NCT05937438,Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma,RECRUITING,PHASE1,70.0,2023-09-01,2026-12-31,1.750862777321282,Adequate (1-10/month),17.50862777321282,Significantly Below (<50%),60,43.6,27.54
NCT00335738,"Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma",COMPLETED,PHASE3,331.0,2005-12-01,2020-09-30,1.8600036920804874,Adequate (1-10/month),18.600036920804875,Significantly Below (<50%),100,76.5,85.3
NCT07085338,A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma,RECRUITING,PHASE2,54.0,2025-11-10,2029-02-01,1.3941984732824428,Adequate (1-10/month),13.941984732824428,Significantly Below (<50%),60,37.3,18.35
NCT06228638,CognivAiD Real-World Evidence Clinical Registry (CONNECT Registry),UNKNOWN,,100.0,2023-12-12,2025-01-31,7.3173076923076925,Adequate (1-10/month),73.17307692307692,Below (50-75%),50,41.3,23.74
NCT03717038,Sym004 Versus TAS-102 in Patients With mCRC,WITHDRAWN,PHASE3,0.0,2019-02-01,2025-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT00808938,A Pilot Study of the Use of Magnetic Seizure Therapy for Depression,COMPLETED,PHASE2,15.0,2009-01-01,2011-01-01,0.6254794520547946,Slow (<1/month),6.2547945205479465,Significantly Below (<50%),100,46.2,35.089999999999996
NCT05186038,Mass Screening for the Early Detection of Patients With Celiac Disease.,COMPLETED,,1000.0,2021-12-18,2022-12-31,80.52910052910053,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT00240838,An Effectiveness and Safety Study Comparing Acetaminophen (3900 mg/Day) to Ibuprofen (1200 mg/Day) in the Treatment of Post-Race Muscle Soreness.,COMPLETED,PHASE4,483.0,2003-05-01,2003-06-01,474.2748387096774,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.6,98.36
NCT00312338,Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora,COMPLETED,PHASE4,137.0,2006-06-01,2007-06-01,11.425424657534247,Good (10-50/month),114.25424657534249,Exceeded (≥100%),100,66.0,78.99000000000001
NCT02891538,Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,51.0,2017-01-31,2025-12-02,0.4810784009916331,Slow (<1/month),4.810784009916331,Significantly Below (<50%),85,44.6,29.42
NCT07063238,A Clinical Study of MK-8527 in Healthy Adult Participants (MK-8527-014),COMPLETED,PHASE1,42.0,2025-08-12,2025-12-29,9.197697841726619,Adequate (1-10/month),91.9769784172662,Met (75-100%),100,58.4,69.175
NCT02904538,Perineural Versus Systemic Dexamethasone to Prolong Regional Anesthesia in Front Foot Surgery,COMPLETED,PHASE3,100.0,2016-11-22,2017-05-23,16.725274725274726,Good (10-50/month),167.25274725274727,Exceeded (≥100%),100,63.0,75.845
NCT06258538,"Effects of Circuit Training Combining Different Types of Distal Robot-assisted and Task-oriented Therapy on Motor Control, Motor and Daily Functions, and Quality of Life After Stroke",RECRUITING,NA,87.0,2024-06-01,2026-12-31,2.8083563096500535,Adequate (1-10/month),28.08356309650053,Significantly Below (<50%),60,45.0,30.330000000000002
NCT05933538,Effectiveness of Cariprazine Monotherapy for Treatment of Major Depressive Disorder,NOT_YET_RECRUITING,PHASE4,110.0,2024-08-01,2030-12-01,1.4476437527021186,Adequate (1-10/month),14.476437527021185,Significantly Below (<50%),30,32.8,12.425
NCT03190538,Nonalcoholic Steatohepatitis in Chinese Children,RECRUITING,,400.0,2017-05-01,2028-05-31,3.0079051383399213,Adequate (1-10/month),30.079051383399214,Significantly Below (<50%),60,68.3,80.875
NCT02262338,Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome,COMPLETED,PHASE1,6.0,2015-04-01,2017-03-27,0.25157024793388433,Slow (<1/month),2.515702479338843,Significantly Below (<50%),100,45.5,31.705
NCT05128838,"RISE (Reinvent, Integrate, Strengthen, Expand) Self-Management Program for Cancer Survivors: A Feasibility Study",COMPLETED,EARLY_PHASE1,23.0,2022-05-25,2024-10-09,0.8065898617511521,Slow (<1/month),8.06589861751152,Significantly Below (<50%),100,46.8,38.440000000000005
NCT06297538,Parkinson's Disease and Gamma-transcranial Alternating Current Stimulation,RECRUITING,NA,84.0,2023-04-29,2026-04-29,2.332992700729927,Adequate (1-10/month),23.32992700729927,Significantly Below (<50%),60,44.7,29.67
NCT03207438,Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression,COMPLETED,PHASE4,1790.0,2006-04-01,2019-10-01,11.050010139931048,Good (10-50/month),110.50010139931048,Exceeded (≥100%),100,95.0,95.7
NCT05386238,Engaging Men From Blue-collar Industries in Weight Loss,COMPLETED,NA,28.0,2022-09-28,2023-11-15,2.063728813559322,Adequate (1-10/month),20.63728813559322,Significantly Below (<50%),100,52.2,53.22
NCT03133338,Effect of Early Pelvic Binder Use in Emergency Management of Suspected Pelvic Trauma: a Retrospective Cohort Study,COMPLETED,,204.0,2013-08-01,2014-07-31,17.05978021978022,Good (10-50/month),170.5978021978022,Exceeded (≥100%),100,69.7,81.73
NCT02322658,"Bioequivalence Study of Eszopiclone Tablets, 3 mg Under Fed Conditions",COMPLETED,PHASE1,46.0,2008-09-01,2008-10-01,46.0,Good (10-50/month),200.0,Exceeded (≥100%),100,63.7,76.655
NCT04286958,A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC,UNKNOWN,PHASE2,40.0,2020-04-22,2023-03-01,1.1674017257909874,Adequate (1-10/month),11.674017257909874,Significantly Below (<50%),50,33.2,12.989999999999998
NCT05343858,Pilot Study to Evaluate the Effect of Two Microalgae Consumption on Metabolic Syndrome,COMPLETED,NA,30.0,2019-09-09,2021-01-31,1.7905882352941178,Adequate (1-10/month),17.905882352941177,Significantly Below (<50%),100,52.4,53.949999999999996
NCT07260058,Immune Cell Therapy for Advanced Solid Tumors,NOT_YET_RECRUITING,PHASE1,48.0,2025-12-01,2027-12-31,1.9225263157894739,Adequate (1-10/month),19.225263157894737,Significantly Below (<50%),30,32.8,12.425
NCT05302258,Attenuation Imaging in Hepatic Steatosis,UNKNOWN,,120.0,2022-04-14,2022-12-14,14.970491803278687,Good (10-50/month),149.70491803278688,Exceeded (≥100%),50,47.9,42.64
NCT04112758,Exercise Intervention on Conflict Monitoring in Children With Attention-deficit Hyperactivity Disorder,COMPLETED,NA,110.0,2020-06-01,2022-01-23,5.571381031613976,Adequate (1-10/month),55.713810316139764,Below (50-75%),100,58.8,69.89999999999999
NCT04480658,Effectiveness of Bryophyllum in Nocturia-Therapy,COMPLETED,NA,50.0,2018-01-01,2022-01-14,1.0325644504748983,Adequate (1-10/month),10.325644504748983,Significantly Below (<50%),100,49.0,45.61
NCT04275258,Collaborative Opioid Taper After Trauma: Preventing Opioid Misuse and Opioid Use Disorder,UNKNOWN,NA,100.0,2020-06-01,2022-01-31,4.998357963875205,Adequate (1-10/month),49.98357963875205,Significantly Below (<50%),50,43.0,26.465
NCT04757558,C-MAC Video-stylet for Double- Lumen Tracheal Intubation,UNKNOWN,NA,80.0,2020-12-20,2021-06-01,14.939877300613498,Good (10-50/month),149.39877300613497,Exceeded (≥100%),50,46.4,36.26
NCT02399358,Factors Associated With Hyponatremia Induced by High-dose Cyclophosphamide,UNKNOWN,,200.0,2015-12-01,2017-11-01,8.684736091298145,Adequate (1-10/month),86.84736091298146,Met (75-100%),50,54.3,59.62
NCT06396858,Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke,NOT_YET_RECRUITING,PHASE4,4500.0,2025-07-01,2026-12-01,264.44015444015446,Excellent (>50/month),200.0,Exceeded (≥100%),30,79.0,86.96000000000001
NCT04973358,Clinical Trial to Determine the Effect of a Mouthwash on the Preservation of the Ecology of the Oral Microbiome and Its Compatibility With Health,UNKNOWN,NA,220.0,2021-09-01,2023-09-01,9.173698630136988,Adequate (1-10/month),91.73698630136987,Met (75-100%),50,57.6,67.36999999999999
NCT02434458,Sudoscan in Patients With Autoimmune Disorders,COMPLETED,,85.0,2015-05-01,2015-09-01,21.035772357723577,Good (10-50/month),200.0,Exceeded (≥100%),100,60.1,72.085
NCT00006058,Study of the Pathobiology of Bronchopulmonary Dysplasia in Newborns,COMPLETED,,200.0,1996-09-01,,,Slow (<1/month),,Significantly Below (<50%),100,54.3,59.62
NCT00006358,Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor,COMPLETED,PHASE2,44.0,2000-06-13,2006-07-20,0.601149012567325,Slow (<1/month),6.01149012567325,Significantly Below (<50%),100,48.5,44.47
NCT05926258,Efficacy and Safety of Chloroprocaine 3% Gel and Oxybuprocaine 0.4% Eye Drops Anesthesia in Pediatric Population,COMPLETED,PHASE3,74.0,2024-05-23,2025-03-13,7.661768707482993,Adequate (1-10/month),76.61768707482993,Met (75-100%),100,55.9,63.42
NCT02928458,Clinical and Financial Impact of an Evidenced-Based Adhesive Small Bowel Obstruction Management Protocol,WITHDRAWN,NA,0.0,2015-09-01,2017-09-13,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT00948558,Citrate Pharmacokinetics and Regional Citrate Anticoagulation in CRRT,UNKNOWN,,40.0,2009-03-01,2011-09-01,1.3321663019693655,Adequate (1-10/month),13.321663019693656,Significantly Below (<50%),50,31.5,10.635
NCT01970358,A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma,COMPLETED,PHASE1,15.0,2014-04-01,2018-06-01,0.3,Slow (<1/month),3.0,Significantly Below (<50%),100,46.2,35.089999999999996
NCT01501058,Parent-supported Social Skills Training for Teens With Autism Spectrum Disorders (PEERS-K),UNKNOWN,NA,40.0,2011-12-01,2013-09-01,1.9025,Adequate (1-10/month),19.025,Significantly Below (<50%),50,38.2,19.645000000000003
NCT03838458,Molecular and Structural Comparison of Hypospadic and Normal Children Prepuces,COMPLETED,,52.0,2019-01-07,2020-03-10,3.698317757009346,Adequate (1-10/month),36.98317757009345,Significantly Below (<50%),100,52.5,54.345
NCT00975858,Long-term Comparison of Stenting Versus Off-pump Coronary Bypass Surgery,COMPLETED,NA,280.0,1998-01-01,2001-02-01,7.5627329192546595,Adequate (1-10/month),75.6273291925466,Met (75-100%),100,72.4,83.17999999999999
NCT02136758,Cardiovascular Risk Clinic,TERMINATED,NA,207.0,2009-04-01,2013-07-01,4.0599742268041235,Adequate (1-10/month),40.59974226804124,Significantly Below (<50%),10,39.6,21.115000000000002
NCT04393558,Wearable Sensor to Monitor COVID-19 Like Signs and Symptoms,COMPLETED,,75.0,2020-04-20,2020-10-26,12.079365079365079,Good (10-50/month),120.79365079365081,Exceeded (≥100%),100,59.3,70.815
NCT04129658,Heart Failure in Southern Sweden,COMPLETED,,563.0,2021-05-26,2024-01-31,17.4874693877551,Good (10-50/month),174.87469387755104,Exceeded (≥100%),100,93.3,94.325
NCT01908348,Dose-Dependent Effects of Erythritol on Endothelial Function in Type 2 Diabetes Mellitus,COMPLETED,NA,27.0,2013-07-18,2016-12-01,0.6671103896103896,Slow (<1/month),6.6711038961038955,Significantly Below (<50%),100,47.2,40.035
NCT05475548,Effect of Skeletally Anchored Reversed PowerScope Appliance in Orthodontic Treatment of Patients With Class III Malocclusion,UNKNOWN,NA,16.0,2022-12-01,2023-12-01,1.3343561643835617,Adequate (1-10/month),13.343561643835619,Significantly Below (<50%),50,31.3,10.299999999999999
NCT07286448,Personalized Digital Training for COGnitive FITness in Mild Cognitive Impairment,RECRUITING,NA,100.0,2025-11-28,2026-11-30,8.294277929155314,Adequate (1-10/month),82.94277929155314,Met (75-100%),60,46.0,34.1
NCT07086248,A Study to Determine if RADIESSE® Dilute Treatment in Décolleté of Adult Women Affects Radiographic Imaging Assessments,ACTIVE_NOT_RECRUITING,NA,30.0,2025-07-22,2026-10-01,2.094495412844037,Adequate (1-10/month),20.94495412844037,Significantly Below (<50%),85,47.9,42.64
NCT00770848,AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer,COMPLETED,PHASE1,162.0,2008-11-01,2012-04-01,3.9545148356054534,Adequate (1-10/month),39.54514835605454,Significantly Below (<50%),100,63.0,75.845
NCT03264248,Daily Weight Feedback for Wheelchair Users to Promote Weight Loss,COMPLETED,NA,9.0,2017-07-01,2018-02-09,1.2285201793721974,Adequate (1-10/month),12.285201793721972,Significantly Below (<50%),100,45.7,32.5
NCT05037448,Exploring Telehealth to Deliver Me & My Wishes During Coronavirus-19,COMPLETED,NA,17.0,2020-08-17,2021-02-28,2.65374358974359,Adequate (1-10/month),26.537435897435902,Significantly Below (<50%),100,51.4,50.92
NCT06646848,"Effects of Vibration, Heel Warming and Shotblocker on Pain Levels During Heel Blood Collection",COMPLETED,NA,192.0,2024-06-03,2025-05-28,16.279888579387187,Good (10-50/month),162.79888579387188,Exceeded (≥100%),100,70.4,82.17
NCT05670548,Early Prediction of Postpartum Glucose Metabolism Abnormalities in Gestational Diabetes Mellitus,UNKNOWN,,2000.0,2023-01-01,2025-12-31,55.59817351598174,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT06418048,INfectious DIsease REgistry BIObank,RECRUITING,,10000.0,2024-02-01,2044-07-31,40.662570130911035,Good (10-50/month),200.0,Exceeded (≥100%),60,81.3,88.58
NCT00116948,A Comparison of Two Total Hip Replacements: Hip Resurfacing System Versus Mallory-Head/Exeter,COMPLETED,PHASE4,50.0,2005-01-01,2012-01-01,0.5954616588419406,Slow (<1/month),5.954616588419405,Significantly Below (<50%),100,49.0,45.61
NCT05573048,A Study of Optical Fusion Trans-Perineal Grid,ENROLLING_BY_INVITATION,NA,20.0,2022-10-04,2026-12-01,0.4007899934167215,Slow (<1/month),4.007899934167216,Significantly Below (<50%),55,33.1,12.814999999999998
NCT05626348,The Clinical Efficacy of Immunomodulators in RA Patients,RECRUITING,PHASE4,400.0,2021-12-22,2026-12-31,6.635422343324251,Adequate (1-10/month),66.35422343324252,Below (50-75%),60,70.0,81.89999999999999
NCT04877548,Powdered Fermented Fruits for Glycemia Reduction,UNKNOWN,NA,20.0,2021-09-07,2022-08-01,1.8560975609756099,Adequate (1-10/month),18.5609756097561,Significantly Below (<50%),50,36.6,17.41
NCT00153348,South Central Foundation - WISEWOMAN Project,COMPLETED,NA,,2001-01-01,2008-06-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,30.330000000000002
NCT02008448,Endomyocardial Botulinum Toxin Injection in Patients With Persistent Atrial Fibrillation,UNKNOWN,PHASE2,160.0,2013-06-01,2016-01-01,5.159322033898305,Adequate (1-10/month),51.59322033898306,Below (50-75%),50,47.8,42.42
NCT03235648,Evaluation of Surgical Excision of Cardiophrenic Lymph Nodes in Patients With Advanced Ovarian Cancer,UNKNOWN,NA,25.0,2017-06-01,2023-06-01,0.34732998630762213,Slow (<1/month),3.4732998630762215,Significantly Below (<50%),50,32.0,11.425
NCT07170748,Clinical Performance Evaluation of MagIA IVD-MD Multiplex Testing (HIV/HBV/HCV/Syphilis),RECRUITING,,2950.0,2025-07-29,2026-04-01,365.0325203252032,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT05800548,Health Literacy of Postpartum Women and Family Planing,COMPLETED,,2.0,2022-03-01,2022-08-31,0.3326775956284153,Slow (<1/month),3.3267759562841532,Significantly Below (<50%),100,43.5,27.400000000000002
NCT02271048,The Feasibility and Effectiveness Study for Tele-ultrasonography,COMPLETED,NA,12.0,2014-11-01,2015-03-01,3.044,Adequate (1-10/month),30.44,Significantly Below (<50%),100,51.0,49.714999999999996
NCT04339348,Comparative Safety and Efficacy of Vaginal Misoprostol Versus Lidocaine-prilocaine Cream in Levonorgestrel IUD Insertion,COMPLETED,PHASE3,210.0,2020-04-30,2021-03-01,20.958688524590166,Good (10-50/month),200.0,Exceeded (≥100%),100,71.8,82.83
NCT00869648,Head Positions to Open the Upper Airway,COMPLETED,NA,60.0,2009-04-01,2009-08-01,14.970491803278687,Good (10-50/month),149.70491803278688,Exceeded (≥100%),100,59.8,71.61
NCT00353548,Determining the Response to Sipping Beverages Without Swallowing in People With Eating Disorders,COMPLETED,,80.0,2005-04-01,2011-07-01,1.067134092900964,Adequate (1-10/month),10.67134092900964,Significantly Below (<50%),100,49.7,46.949999999999996
NCT03719248,Thoracic Epidural Reduces Risks of Increased Left Ventricular Mass Index During Coronary Artery Bypass Graft Surgery,COMPLETED,NA,80.0,2017-01-01,2018-01-01,6.6717808219178085,Adequate (1-10/month),66.71780821917808,Below (50-75%),100,56.4,64.88000000000001
NCT05675748,Real-world Study Evaluating the Efficacy and Safety of Azvudine in Nursing Home Patients,UNKNOWN,,400.0,2023-01-15,2023-04-15,135.2888888888889,Excellent (>50/month),200.0,Exceeded (≥100%),50,75.3,84.60499999999999
NCT05791448,AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease,RECRUITING,PHASE1,36.0,2023-03-29,2027-03-29,0.7500616016427105,Slow (<1/month),7.500616016427104,Significantly Below (<50%),60,35.9,16.445
NCT07367555,Effect Of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors on Body Mass Index After 3 Months of Use in Diabetic Patients,COMPLETED,PHASE1,360.0,2024-10-01,2025-03-31,60.543646408839784,Excellent (>50/month),200.0,Exceeded (≥100%),100,88.8,92.89
NCT05569655,Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAH,UNKNOWN,NA,100.0,2021-04-06,2022-12-31,4.801261829652997,Adequate (1-10/month),48.01261829652997,Significantly Below (<50%),50,43.0,26.465
NCT02437955,Fe Absorption in Mother and Child Pairs From Wheat Fortified With Iron With and Without Phenolic Containing Beverages,COMPLETED,NA,34.0,2015-04-01,2015-10-01,5.65551912568306,Adequate (1-10/month),56.5551912568306,Below (50-75%),100,52.7,55.04
NCT02526355,Development and Assessment of a Mobile Phone Based Intervention to Reduce Maternal Depression and Improve Child Health,COMPLETED,NA,208.0,2016-01-01,2019-08-01,4.840611620795108,Adequate (1-10/month),48.40611620795107,Significantly Below (<50%),100,66.6,79.43
NCT04423055,Nexplanon Use in Women Primarily Choosing a Combined Oral Contraceptive,COMPLETED,PHASE4,120.0,2020-08-13,2024-04-09,2.7361797752808994,Adequate (1-10/month),27.361797752808993,Significantly Below (<50%),100,59.6,71.17999999999999
NCT04712955,Bloodflow Restricted Exercise in Healthy Ageing,UNKNOWN,NA,24.0,2021-01-19,2025-07-01,0.4498522167487685,Slow (<1/month),4.498522167487685,Significantly Below (<50%),50,31.9,11.295
NCT00322855,Chart Review of Treatments Received by Patients Diagnosed With Soft Tissue Sarcoma,TERMINATED,,1.0,2005-08-01,2007-08-01,0.041698630136986305,Slow (<1/month),0.4169863013698631,Significantly Below (<50%),10,16.4,2.595
NCT00003955,Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma,COMPLETED,PHASE2,77.0,1999-09-01,2009-10-01,0.636405104534347,Slow (<1/month),6.36405104534347,Significantly Below (<50%),100,51.2,50.375
NCT04829955,Eccentric Manual Resistance Training in Patients With Ischemic CMP,COMPLETED,NA,16.0,2022-06-29,2023-12-12,0.9172128060263653,Slow (<1/month),9.172128060263654,Significantly Below (<50%),100,46.3,35.66
NCT04371055,Intensive Rhythm Monitoring to Decrease Ischemic Stroke and Systemic Embolism - the Find-AF 2 Study,ACTIVE_NOT_RECRUITING,NA,5227.0,2020-07-07,2026-12-31,67.1916722972973,Excellent (>50/month),200.0,Exceeded (≥100%),85,95.5,96.55
NCT04096755,Targeted Metabolic Profiling in Deep Vein Thrombosis,UNKNOWN,,80.0,2019-10-01,2025-05-01,1.194310936733693,Adequate (1-10/month),11.943109367336929,Significantly Below (<50%),50,34.7,14.899999999999999
NCT04845555,Association Between Individual Clotting Factor Level Monitoring and the Risk of Bleeding Whilst Physical Active Conditions,UNKNOWN,,30.0,2019-09-01,2022-12-30,0.7509868421052631,Slow (<1/month),7.509868421052632,Significantly Below (<50%),50,30.7,9.585
NCT01988155,Eccentric Exercise Versus Eccentric Exercise and Astym for Insertional Achilles Tendinopathy,COMPLETED,NA,16.0,2013-12-01,2015-12-01,0.6671780821917809,Slow (<1/month),6.671780821917809,Significantly Below (<50%),100,46.3,35.66
NCT05274555,Reliability and Validity of the Turkish Version of the Upper Limb Short Questionnaire in Duchenne Muscular Dystrophy,COMPLETED,,41.0,2019-03-27,2021-06-29,1.5127757575757577,Adequate (1-10/month),15.127757575757576,Significantly Below (<50%),100,46.6,37.375
NCT05845255,"Evaluation of the Epilepsy-related Quality of Life, Seizure-related Accidents and Validation of the Mjn-SERAS Solution in the Normalised Patient Environment with Real-World Data",RECRUITING,,130.0,2023-05-01,2025-06-30,5.002781289506953,Adequate (1-10/month),50.02781289506954,Below (50-75%),60,46.7,37.895
NCT04982055,Intravenous Versus Subcutaneous Administration of Low Molecular Weight Heparin for Thromboprophylaxis in Critically Ill Patients,COMPLETED,PHASE4,60.0,2015-04-08,2020-12-31,0.8722063037249285,Slow (<1/month),8.722063037249283,Significantly Below (<50%),100,49.8,47.17
NCT00848055,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis",COMPLETED,PHASE1,40.0,2008-12-01,,,Slow (<1/month),,Significantly Below (<50%),100,43.2,26.840000000000003
NCT05261555,Mixed Methods Feasibility Study of an App for Childhood Obesity Prevention and Management,COMPLETED,NA,231.0,2020-06-27,2021-08-23,16.66265402843602,Good (10-50/month),166.6265402843602,Exceeded (≥100%),100,73.5,83.74000000000001
NCT00045955,Long-Term Safety Performance of Fexofenadine in Asthma,COMPLETED,PHASE3,1200.0,2002-02-01,2003-11-01,57.25391849529781,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT06501755,Effects of Individualized Theta-tACS on a Working Memory Training at SCD,NOT_YET_RECRUITING,NA,36.0,2024-07-19,2025-07-31,2.9067374005305044,Adequate (1-10/month),29.06737400530504,Significantly Below (<50%),30,31.9,11.295
NCT01504555,Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome?,UNKNOWN,,300.0,2011-10-01,2017-09-01,4.223866790009251,Adequate (1-10/month),42.23866790009251,Significantly Below (<50%),50,57.3,66.74
NCT06679855,Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial,RECRUITING,PHASE3,316.0,2025-06-13,2029-06-30,6.508146143437077,Adequate (1-10/month),65.08146143437077,Below (50-75%),60,63.3,76.235
NCT05643755,Preoperative Image-based Education Effect on Postoperative Satisfaction of Patients Undergoing First-time Dermatologic Surgery,WITHDRAWN,NA,0.0,2025-12-01,2025-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT00005855,Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma,COMPLETED,PHASE1,48.0,2000-07-01,2006-10-01,0.64,Slow (<1/month),6.4,Significantly Below (<50%),100,48.8,45.184999999999995
NCT07259655,Management of Post-Induction Hypotension in Emergency Abdominal Surgery,TERMINATED,PHASE4,100.0,2025-03-06,2025-05-06,49.90163934426229,Good (10-50/month),200.0,Exceeded (≥100%),10,41.0,23.01
NCT06898255,A Phase I Study to Evaluate GFS202A in Advanced Solid Tumor Patients With Pre-cachexia or Cachexia,RECRUITING,PHASE1,36.0,2025-04-24,2026-07-06,2.5019178082191784,Adequate (1-10/month),25.019178082191786,Significantly Below (<50%),60,40.9,22.82
NCT03952455,Deep Brain Stimulation of the Bilateral Nucleus Accumbens for Patients With Methadone Maintenance Treatment,UNKNOWN,NA,12.0,2019-05-13,2021-06-01,0.48704000000000003,Slow (<1/month),4.8704,Significantly Below (<50%),50,31.0,9.985
NCT03243955,Transcutaneous Electrical Acupoint Stimulation (TEAS) for Chronic Constipation,RECRUITING,NA,100.0,2017-02-28,2026-03-01,0.9257907542579076,Slow (<1/month),9.257907542579076,Significantly Below (<50%),60,41.0,23.01
NCT06629155,Studying Eye Movement Deficits and Cognitive Impairment in Patients with Multiple Sclerosis Using Infrared Eye Tracking and Cognitive Tests,NOT_YET_RECRUITING,,50.0,2025-03-01,2027-02-01,2.1680911680911685,Adequate (1-10/month),21.68091168091168,Significantly Below (<50%),30,31.3,10.299999999999999
NCT06769555,BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy,NOT_YET_RECRUITING,NA,20.0,2025-01-01,2028-08-01,0.46544342507645264,Slow (<1/month),4.654434250764526,Significantly Below (<50%),30,25.6,7.595000000000001
NCT00978055,Fasting Study of Liothyronine Sodium Tablets (50 Mcg) to Cytomel® Tablets (50 Mcg),COMPLETED,PHASE1,31.0,2007-10-01,2007-12-01,15.46950819672131,Good (10-50/month),154.6950819672131,Exceeded (≥100%),100,57.5,67.27
NCT03428555,Integrated Care Pathway for Youth Depression,UNKNOWN,NA,60.0,2018-03-29,2020-02-21,2.6317002881844385,Adequate (1-10/month),26.31700288184438,Significantly Below (<50%),50,39.8,21.47
NCT07211555,The LARC Robot Simplifies Renal Access In Percutaneous Nephrolithotomy,NOT_YET_RECRUITING,NA,45.0,2025-11-01,2026-01-01,22.455737704918032,Good (10-50/month),200.0,Exceeded (≥100%),30,37.6,18.845
NCT07167355,Comparison of Balloon Dilatation and Per Oral Endoscopic Myotomy in Children With Achalasia Cardia,NOT_YET_RECRUITING,NA,70.0,2025-09-03,2028-07-15,2.037093690248566,Adequate (1-10/month),20.370936902485663,Significantly Below (<50%),30,34.6,14.729999999999999
NCT02951455,Community Wise: An Innovative Multi-level Intervention to Reduce Alcohol and Illegal Drug Use,COMPLETED,NA,602.0,2017-01-17,2020-01-20,16.689326047358836,Good (10-50/month),166.89326047358836,Exceeded (≥100%),100,95.0,95.7
NCT05946226,A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors,UNKNOWN,PHASE1,18.0,2023-09-07,2025-12-31,0.6476595744680851,Slow (<1/month),6.476595744680852,Significantly Below (<50%),50,31.4,10.47
NCT05773326,Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG,RECRUITING,EARLY_PHASE1,12.0,2023-05-15,2028-05-01,0.20147821290678433,Slow (<1/month),2.0147821290678434,Significantly Below (<50%),60,34.0,14.02
NCT04511026,Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer,TERMINATED,PHASE2,6.0,2021-01-20,2021-06-10,1.2953191489361702,Adequate (1-10/month),12.953191489361702,Significantly Below (<50%),10,18.5,4.02
NCT00370526,HEAL-HF: A Cardiac Resynchronization Therapy (CRT) Outcomes Study,TERMINATED,PHASE4,100.0,2007-02-01,2007-12-01,10.046204620462047,Good (10-50/month),100.46204620462046,Exceeded (≥100%),10,36.0,16.564999999999998
NCT02342626,Devel. and Eval. of an Active Surveillance Decision Aid for Men With Low or Intermediate Grade Prostate Cancer,COMPLETED,NA,140.0,2015-01-01,2017-12-01,4.001502347417841,Adequate (1-10/month),40.015023474178406,Significantly Below (<50%),100,61.2,73.43499999999999
NCT02437526,Analytic Treatment Interruption (ATI) to Assess HIV Cure,ENROLLING_BY_INVITATION,NA,10.0,2015-05-01,2035-05-01,0.04167008898015059,Slow (<1/month),0.41670088980150577,Significantly Below (<50%),55,32.3,11.799999999999999
NCT02806726,Clinical Investigation iDesign System With 1.3-PRESBY Treatment and STAR S4 IR™ Excimer Laser System,TERMINATED,NA,42.0,2016-07-13,2017-11-09,2.6414876033057855,Adequate (1-10/month),26.414876033057855,Significantly Below (<50%),10,26.4,7.865
NCT00119626,Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke,COMPLETED,PHASE3,1700.0,2003-06-01,2005-02-01,84.69394435351883,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT05973526,Comparison of the Effects of Electric Current With Needles and Surface Electrodes on the Abdominal Contour of Women,UNKNOWN,NA,20.0,2023-05-16,2024-10-30,1.1422138836772984,Adequate (1-10/month),11.422138836772984,Significantly Below (<50%),50,31.6,10.905
NCT06669026,The Proposed Study Aims to Investigate the Impact of Adjunctive Vitamin D Gel Application on Gingival Crevicular Fluid Levels of Alkaline Phosphatase and Interleukin-8 in Periodontitis Patients Undergoing Phase 1 Periodontal Therapy. By Elucidating the Molecular Mechanisms Underlying the Therapeutic,COMPLETED,PHASE2,50.0,2023-09-01,2024-09-20,3.9532467532467535,Adequate (1-10/month),39.53246753246754,Significantly Below (<50%),100,54.0,58.72500000000001
NCT04641026,Discovery of Biological Signatures for Cruciferous Vegetable Intake (Single Serving),ACTIVE_NOT_RECRUITING,NA,83.0,2021-02-22,2026-12-01,1.19853889943074,Adequate (1-10/month),11.985388994307401,Significantly Below (<50%),85,47.1,39.64
NCT03289026,Pharmacologic Treatment of Acute Episode of Schizophrenia: a Real World Study,COMPLETED,PHASE4,770.0,2017-09-01,2021-02-02,18.75104,Good (10-50/month),187.5104,Exceeded (≥100%),100,95.0,95.7
NCT06572826,Cardiac Rehabilitation in Patients Acutely Managed for Cardiogenic Shock (ENIGMA),RECRUITING,,2000.0,2024-08-31,2026-08-31,83.3972602739726,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT05314426,Mayo Clinic Phage Program Biobank,ENROLLING_BY_INVITATION,,100.0,2022-04-19,2027-04-01,1.6836283185840708,Adequate (1-10/month),16.83628318584071,Significantly Below (<50%),55,42.8,25.929999999999996
NCT05968326,A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC,RECRUITING,PHASE2,260.0,2023-10-18,2031-01-01,3.0069908814589668,Adequate (1-10/month),30.06990881458967,Significantly Below (<50%),60,58.8,69.89999999999999
NCT07385326,Umbilical Cord Clamping Methods and Stem Cell Counts in Preterm Infants,COMPLETED,NA,49.0,2015-01-01,2015-06-01,9.877880794701987,Adequate (1-10/month),98.77880794701987,Met (75-100%),100,58.9,70.10499999999999
NCT02631226,Multi-resistant Enterobacteriaceae Colonisation in Less Than 32 Weeks Pregnant Women Admitted to the Hospital.,UNKNOWN,,580.0,2016-02-01,2017-12-01,26.390433482810163,Good (10-50/month),200.0,Exceeded (≥100%),50,78.3,86.48
NCT03655626,Implementation and Evaluations of Sepsis Watch,COMPLETED,NA,32003.0,2018-11-05,2019-07-05,4025.50132231405,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT02778126,A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer,COMPLETED,PHASE1,6.0,2016-09-22,2017-07-27,0.592987012987013,Slow (<1/month),5.92987012987013,Significantly Below (<50%),100,45.5,31.705
NCT05842226,SYMPTOM MANAGEMENT EDUCATION GIVEN WITH MICRO TEACHING METHOD ENRICHED WITH STANDARD PATIENT IN PALLIATIVE CARE,UNKNOWN,NA,40.0,2023-04-17,2023-07-01,16.234666666666666,Good (10-50/month),162.34666666666666,Exceeded (≥100%),50,43.2,26.840000000000003
NCT05447026,The Effect of Adjunctive Therapies in Regenerative Treatment of Stage III Grade C Periodontitis,COMPLETED,NA,48.0,2018-01-01,2022-09-15,0.8504772991850991,Slow (<1/month),8.50477299185099,Significantly Below (<50%),100,48.8,45.184999999999995
NCT01710826,"A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Genz-682452 in Healthy Volunteers",COMPLETED,PHASE1,36.0,2012-10-01,2013-02-01,8.909268292682926,Adequate (1-10/month),89.09268292682927,Met (75-100%),100,57.9,67.83
NCT03208426,Sequential Versus Quadruple Therapy in the Second-line Treatment,UNKNOWN,PHASE4,240.0,2017-10-01,2020-12-31,6.154675652906487,Adequate (1-10/month),61.54675652906487,Below (50-75%),50,54.2,59.330000000000005
NCT06546826,Alveolar Ridge Preservation After Tooth Extraction,ACTIVE_NOT_RECRUITING,,60.0,2024-01-06,2026-01-31,2.415873015873016,Adequate (1-10/month),24.15873015873016,Significantly Below (<50%),85,48.6,44.685
NCT02772978,Dopamine Responsivity in Gamblers,COMPLETED,NA,19.0,2014-08-01,2015-09-01,1.4605050505050505,Adequate (1-10/month),14.605050505050505,Significantly Below (<50%),100,46.5,36.815
NCT03077178,Impact of Locoregional Treatment of Soft Tissue Sarcoma on Status of Patients Aged 70 Years and Over,ACTIVE_NOT_RECRUITING,NA,25.0,2017-11-30,2026-03-01,0.25257218718884833,Slow (<1/month),2.525721871888483,Significantly Below (<50%),85,42.5,25.585
NCT04491578,An Advance Care Planning Programme for Persons With Early Stage Dementia in the Community,COMPLETED,NA,100.0,2021-01-09,2022-10-31,4.612121212121212,Adequate (1-10/month),46.121212121212125,Significantly Below (<50%),100,58.0,68.245
NCT02139878,Short-term Health Effects of Wild Blueberry Juice Consumption,COMPLETED,NA,20.0,2014-05-01,2015-06-01,1.5373737373737375,Adequate (1-10/month),15.373737373737374,Significantly Below (<50%),100,46.6,37.375
NCT00752778,Magnetic Resonance Imaging (MRI) Follow-up of Macrophagic Infiltration in MS Patients Treated With Tysabri,TERMINATED,PHASE4,8.0,2008-12-01,2011-03-01,0.29697560975609755,Slow (<1/month),2.9697560975609756,Significantly Below (<50%),10,18.6,4.25
NCT03485378,Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease,ACTIVE_NOT_RECRUITING,NA,39.0,2018-09-20,2026-09-20,0.40628336755646816,Slow (<1/month),4.062833675564682,Significantly Below (<50%),85,43.6,27.54
NCT06903078,A Study That Collects Participant Data and Biospecimens to Analyze Pathogenic Exosomes That Mediate Increased Vascular Dementia Risk in Individuals With Herpes Zoster.,RECRUITING,,375.0,2025-02-13,2030-08-01,5.7218045112781954,Adequate (1-10/month),57.21804511278196,Below (50-75%),60,66.3,79.3
NCT03148678,Scrutinizing and Promoting Mindfulness Via New Technologies,COMPLETED,NA,84.0,2017-03-31,2019-03-05,3.632045454545455,Adequate (1-10/month),36.32045454545455,Significantly Below (<50%),100,56.7,65.53
NCT07091578,Supervised Toothbrushing and Oral Health Education in Primary Schools in Saudi Arabia,ACTIVE_NOT_RECRUITING,NA,202.0,2024-08-18,2025-11-30,13.110618336886994,Good (10-50/month),131.10618336886992,Exceeded (≥100%),85,66.7,79.47999999999999
NCT05470478,iBCI Optimization for Veterans With Paralysis,NOT_YET_RECRUITING,NA,2.0,2026-01-16,2026-06-30,0.36896969696969695,Slow (<1/month),3.68969696969697,Significantly Below (<50%),30,24.2,6.825
NCT00297778,Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms,COMPLETED,PHASE4,296.0,2006-03-01,,,Slow (<1/month),,Significantly Below (<50%),100,63.7,76.655
NCT01361178,Immunoglobulin Levels and Occurrence of Infections After Lung Transplantation and Impact of IgG Replacement,COMPLETED,NA,133.0,2011-01-01,2016-01-01,2.2171522453450163,Adequate (1-10/month),22.171522453450166,Significantly Below (<50%),100,60.6,72.785
NCT01045278,"Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy",COMPLETED,PHASE4,277.0,2008-04-01,2013-09-01,4.260677109651339,Adequate (1-10/month),42.606771096513384,Significantly Below (<50%),100,72.2,82.98
NCT03443778,Dexamethasone-bupivacaine Versus Bupivacaine for Tonsillectomy Pain.,UNKNOWN,PHASE4,120.0,2017-12-15,2018-04-15,30.188429752066117,Good (10-50/month),200.0,Exceeded (≥100%),50,49.6,46.785
NCT05583578,HOMEStudy: Development of a Home-based Self-delivered Prehabilitation Intervention to Proactively Reduce Fall Risk in Older Adults,COMPLETED,NA,34.0,2023-01-01,2024-02-07,2.57452736318408,Adequate (1-10/month),25.745273631840792,Significantly Below (<50%),100,52.7,55.04
NCT05994378,To Compare the Efficacy and Safety of Oral SHR 7280 Tablets With Ganirelix Acetate Injection in Infertile Female Subjects,COMPLETED,PHASE3,317.0,2023-08-29,2025-05-02,15.767124183006535,Good (10-50/month),157.67124183006536,Exceeded (≥100%),100,80.4,88.105
NCT04139278,The Dynamics of Frailty in Older People,UNKNOWN,,300000.0,2020-07-21,2022-02-28,15557.069846678025,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT06182878,Tender Loving Care for Recurrent Pregnancy Loss,RECRUITING,NA,60.0,2024-01-01,2025-12-01,2.609142857142857,Adequate (1-10/month),26.091428571428573,Significantly Below (<50%),60,42.8,25.929999999999996
NCT00644878,Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib,TERMINATED,PHASE2,18.0,2008-10-01,2012-03-01,0.43939053728949484,Slow (<1/month),4.393905372894949,Significantly Below (<50%),10,19.4,5.2299999999999995
NCT00722878,Long-term Lung Function and Disease Progression in Children With Early Onset Primary Ciliary Dyskinesia Lung Disease,COMPLETED,,48.0,2008-07-01,2019-08-01,0.36094861660079053,Slow (<1/month),3.609486166007905,Significantly Below (<50%),100,47.2,40.035
NCT01831778,Breast Cancer Surveillance Consortium,COMPLETED,,2345817.0,1994-01-01,2009-12-01,12283.961720282128,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT07238478,JDS-HF3.0 Supplementation on Menopause Related Quality of Life Outcomes in Postmenopausal Women,RECRUITING,NA,250.0,2025-05-14,2026-10-01,15.069306930693072,Good (10-50/month),150.6930693069307,Exceeded (≥100%),60,63.0,75.845
NCT02892578,Systematic Screening With Electrocardiogram for Unknown Atrial Fibrillation in 65 Years Old and Above People in Nursing Home,TERMINATED,NA,287.0,2015-07-22,2016-05-25,28.364545454545453,Good (10-50/month),200.0,Exceeded (≥100%),10,51.0,49.714999999999996
NCT06321978,Mepilex Border Flex Utilization Pilot Spain,RECRUITING,,40.0,2024-02-16,2024-05-31,11.596190476190477,Good (10-50/month),115.96190476190478,Exceeded (≥100%),60,44.5,29.160000000000004
NCT01353378,Use of Dexmedetomidine in Children Undergoing Oral Maxillofacial Surgery to Decrease Emergence Delirium,WITHDRAWN,PHASE4,0.0,2011-06-01,2011-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT05644678,Evaluation of the Periodontal Status After the Treatment of Palatally Impacted Canines Using Acceleration Procedures,COMPLETED,NA,46.0,2018-09-23,2022-11-15,0.9248612945838838,Slow (<1/month),9.248612945838838,Significantly Below (<50%),100,48.7,44.93
NCT01040078,Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month,UNKNOWN,PHASE3,900.0,2009-12-01,2010-06-01,150.52747252747253,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT02187978,Early Total Enteral Feeding Versus Conventional Enteral Feeding in Stable Very Low Birth Weight Infants,COMPLETED,NA,180.0,2014-07-01,2015-07-01,15.01150684931507,Good (10-50/month),150.11506849315072,Exceeded (≥100%),100,69.4,81.52000000000001
NCT04257578,Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma,ACTIVE_NOT_RECRUITING,PHASE1,23.0,2020-12-02,2031-03-01,0.18714782143811814,Slow (<1/month),1.8714782143811817,Significantly Below (<50%),85,42.3,25.295
NCT07017985,Prevalence of Diabetes in Patients Who Are Candidates for Spine Surgery,RECRUITING,,500.0,2024-03-28,2026-06-30,18.47087378640777,Good (10-50/month),184.70873786407768,Exceeded (≥100%),60,81.3,88.58
NCT01863485,Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China,COMPLETED,PHASE1,44.0,2013-05-01,2016-05-01,1.222043795620438,Adequate (1-10/month),12.220437956204378,Significantly Below (<50%),100,48.5,44.47
NCT02527785,"Study of Oxaliplatin, Irinotecan, and S-1 in Gastric Cancer",COMPLETED,PHASE2,44.0,2015-02-01,2017-04-01,1.6953924050632914,Adequate (1-10/month),16.953924050632914,Significantly Below (<50%),100,53.5,57.555
NCT01333085,"Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery",COMPLETED,PHASE1,49.0,2009-10-01,2013-05-01,1.140336391437309,Adequate (1-10/month),11.40336391437309,Significantly Below (<50%),100,48.9,45.4
NCT06497985,A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients,RECRUITING,PHASE3,430.0,2024-11-27,2028-09-30,9.32943692088382,Adequate (1-10/month),93.29436920883822,Met (75-100%),60,77.4,85.835
NCT05664685,Optimized Bismuth Quadruple Therapy vs Triple Standard Therapy for Helicobacter Pylori Eradication,COMPLETED,PHASE4,127.0,2022-10-17,2024-01-30,8.225276595744681,Adequate (1-10/month),82.25276595744681,Met (75-100%),100,60.2,72.2
NCT04164485,Functional Collagen Scaffold for Laryngeal Soft Tissue Regeneration,UNKNOWN,PHASE1,60.0,2019-07-01,2022-12-01,1.4622898318654924,Adequate (1-10/month),14.622898318654926,Significantly Below (<50%),50,34.8,15.040000000000001
NCT01338285,"Association of Formaldehyde Exposure to Myeloid Leukemia in Workers in Guangdong, China",COMPLETED,,94.0,2006-06-10,2020-11-06,0.5436747102413072,Slow (<1/month),5.436747102413072,Significantly Below (<50%),100,50.9,49.370000000000005
NCT03757585,Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD),COMPLETED,PHASE4,54.0,2019-05-20,2024-05-06,0.9066519580805296,Slow (<1/month),9.066519580805295,Significantly Below (<50%),100,49.3,46.265
NCT07345585,Probiotics for Autism Spectrum Disorders: a Randomized Controlled Trial (The PASD Study),RECRUITING,NA,50.0,2023-01-01,2026-03-01,1.3177489177489177,Adequate (1-10/month),13.177489177489177,Significantly Below (<50%),60,37.0,17.955
NCT00471185,ACY-6 Oral Administration of Acyline,COMPLETED,PHASE1,9.0,2007-06-01,2007-08-01,4.491147540983606,Adequate (1-10/month),44.91147540983606,Significantly Below (<50%),100,50.7,48.915
NCT04070885,Cohort Follow-up: Progression and Consequences of Chronic Kidney Disease.,COMPLETED,,210.0,2011-01-05,2015-03-20,4.1644299674267105,Adequate (1-10/month),41.644299674267096,Significantly Below (<50%),100,65.1,78.14
NCT03351985,The Study of Post-operation Delirium and Prognosis of Cardiac Surgery Patients,UNKNOWN,,56.0,2017-12-01,2018-08-31,6.2441025641025645,Adequate (1-10/month),62.44102564102565,Below (50-75%),50,37.8,19.015
NCT01716585,A Study to Evaluate Chronic Hepatitis C Infection,COMPLETED,PHASE3,636.0,2012-11-01,2014-10-01,27.69648068669528,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT07170085,Positioning of Children With Acute Respiratory Insufficiency,RECRUITING,NA,40.0,2025-11-24,2027-04-01,2.469776876267749,Adequate (1-10/month),24.697768762677484,Significantly Below (<50%),60,41.2,23.425
NCT07154485,Investigator Initiated Study for the Safety and Efficacy in Frontotemporal Dementia,NOT_YET_RECRUITING,PHASE2,15.0,2025-10-01,2028-08-01,0.44115942028985505,Slow (<1/month),4.41159420289855,Significantly Below (<50%),30,25.2,7.359999999999999
NCT04069585,RHA® Redensity With New Anesthetic Agent - Perioral Rhytids,COMPLETED,NA,30.0,2019-10-30,2020-11-09,2.428723404255319,Adequate (1-10/month),24.287234042553195,Significantly Below (<50%),100,52.4,53.949999999999996
NCT06197685,A Novel Combinatory Approach to Maximize Functional Recovery of Learning and Memory in Multiple Sclerosis,RECRUITING,NA,78.0,2024-02-12,2026-06-30,2.7322439585730725,Adequate (1-10/month),27.322439585730724,Significantly Below (<50%),60,44.2,28.549999999999997
NCT03675243,Quality of Life After Transanal Endoscopic Microsurgery (TEM),COMPLETED,,100.0,2018-04-01,2021-03-30,2.7824497257769654,Adequate (1-10/month),27.824497257769654,Significantly Below (<50%),100,56.3,64.5
NCT03039543,Neuromuscular Blockade During Transurethral Resection of Bladder Cancer,COMPLETED,PHASE4,108.0,2017-06-01,2017-11-10,20.293333333333333,Good (10-50/month),200.0,Exceeded (≥100%),100,63.6,76.545
NCT01226043,Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus,COMPLETED,PHASE4,405.0,2010-10-01,2012-05-01,21.32906574394464,Good (10-50/month),200.0,Exceeded (≥100%),100,87.4,92.28
NCT04804943,Pilot Clinical Study of NOA-001 for ARDS (Acute Respiratory Distress Syndrome),RECRUITING,NA,45.0,2021-05-22,2025-09-04,0.874712643678161,Slow (<1/month),8.74712643678161,Significantly Below (<50%),60,36.6,17.41
NCT05105243,Phase 1 SAD/MAD Study of CVN766 in Healthy Volunteers,COMPLETED,PHASE1,64.0,2022-01-17,2022-11-21,6.325194805194805,Adequate (1-10/month),63.25194805194805,Below (50-75%),100,55.1,62.085
NCT04720443,"A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects",COMPLETED,PHASE1,56.0,2019-11-22,2022-07-14,1.7664663212435234,Adequate (1-10/month),17.664663212435233,Significantly Below (<50%),100,54.5,60.12
NCT03923543,Is Neutrophil to Lymphocyte Ratio a Prognostic Factor of Sepsis in Newborns With Operated Congenital Heart Disease,COMPLETED,,60.0,2015-01-01,2018-12-31,1.2509589041095892,Adequate (1-10/month),12.509589041095893,Significantly Below (<50%),100,48.1,43.275000000000006
NCT04057443,Nutritional and Physical Exercise Intervention in Older Patients With Malignant Hemopathies,UNKNOWN,NA,80.0,2019-04-11,2023-06-01,1.6105820105820106,Adequate (1-10/month),16.105820105820108,Significantly Below (<50%),50,36.4,17.14
NCT02951143,Abuse Liability of Reduced Nicotine Content Cigarettes Within a Complex Tobacco Marketplace,COMPLETED,NA,305.0,2017-01-01,2019-11-01,8.978916827852998,Adequate (1-10/month),89.78916827853,Met (75-100%),100,79.4,87.155
NCT02744443,Leucine Supplementation in Young Subjects Undergoing Resistance Training,COMPLETED,NA,60.0,2015-01-01,2016-04-01,4.005263157894737,Adequate (1-10/month),40.05263157894737,Significantly Below (<50%),100,54.8,61.095
NCT04457843,The Mobile COPD Status Test (mCST),COMPLETED,,130.0,2020-08-21,2023-07-31,3.684543761638734,Adequate (1-10/month),36.845437616387336,Significantly Below (<50%),100,58.7,69.69
NCT05959343,Enhanced Recovery After Surgery in Oblique Lumbar Interbody Fusion,COMPLETED,NA,38.0,2023-07-12,2024-02-28,5.007445887445888,Adequate (1-10/month),50.07445887445887,Below (50-75%),100,53.0,55.80500000000001
NCT00041743,Treatment of Binge Eating Disorder,COMPLETED,NA,200.0,2002-07-01,2007-12-01,3.0763011622031327,Adequate (1-10/month),30.76301162203133,Significantly Below (<50%),100,66.0,78.99000000000001
NCT03400943,Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3),TERMINATED,PHASE3,93.0,2018-01-17,2022-04-06,1.8382597402597405,Adequate (1-10/month),18.382597402597405,Significantly Below (<50%),10,30.4,9.345
NCT04570943,Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer,RECRUITING,PHASE2,103.0,2021-06-16,2030-06-01,0.9582273838630807,Slow (<1/month),9.582273838630808,Significantly Below (<50%),60,41.2,23.425
NCT06196515,Anti-bacterial Potential of Nano Calcium Hydroxide as an Intracanal Medication,RECRUITING,PHASE2,54.0,2024-08-01,2025-12-01,3.3752772073921973,Adequate (1-10/month),33.752772073921975,Significantly Below (<50%),60,42.3,25.295
NCT05238415,ASAP - Assisted Immediate Augmented Post-/Long-COVID Plan for Patients Infected With COVID-19,COMPLETED,NA,192.0,2021-12-15,2023-06-30,10.399430604982207,Good (10-50/month),103.99430604982207,Exceeded (≥100%),100,70.4,82.17
NCT02466815,A Study to Assess the Relative Bioavailability of JNJ-42756493 Tablets,COMPLETED,PHASE1,12.0,2015-06-01,2015-08-01,5.988196721311475,Adequate (1-10/month),59.88196721311475,Below (50-75%),100,51.0,49.714999999999996
NCT06093815,Prospective Study to Assess Tissue Responses After Injection With Biostimulatory Products,COMPLETED,NA,20.0,2023-09-08,2024-11-01,1.4495238095238097,Adequate (1-10/month),14.495238095238097,Significantly Below (<50%),100,46.6,37.375
NCT00284115,Efficacy of a Mechanical Gait Repetitive Training Technique in Hemiparetic Stroke Patients (AVC),TERMINATED,NA,122.0,2006-03-01,2011-05-01,1.9680339162692104,Adequate (1-10/month),19.680339162692103,Significantly Below (<50%),10,32.8,12.425
NCT01364415,Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs),COMPLETED,PHASE1,29.0,2011-08-01,2016-04-01,0.5177478005865103,Slow (<1/month),5.177478005865104,Significantly Below (<50%),100,47.3,40.475
NCT03453515,Reducing HIV Risk Among Adolescents: Evaluating HEART for Teens,COMPLETED,NA,226.0,2018-03-01,2019-04-30,16.186917647058824,Good (10-50/month),161.86917647058826,Exceeded (≥100%),100,73.1,83.515
NCT05282615,Impact of Daily Use of The Emanate Tray Adjunct to Full Mouth Debridement Compared to Full Mouth Debridement Alone,COMPLETED,NA,45.0,2022-02-01,2023-01-18,3.902564102564103,Adequate (1-10/month),39.02564102564103,Significantly Below (<50%),100,53.6,57.705
NCT04094415,"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice",COMPLETED,,581.0,2019-10-28,2021-07-28,27.6770579029734,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT03951415,Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer,UNKNOWN,PHASE2,55.0,2019-07-08,2021-08-01,2.2174834437086095,Adequate (1-10/month),22.174834437086094,Significantly Below (<50%),50,39.4,20.94
NCT00873015,Safety and Pharmacokinetic Evaluation of Nitrite for Prevention of Cerebral Vasospasm,COMPLETED,PHASE2,19.0,2010-04-01,2012-08-01,0.6780304806565065,Slow (<1/month),6.780304806565065,Significantly Below (<50%),100,46.5,36.815
NCT06898515,Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258),RECRUITING,PHASE3,400.0,2025-07-14,2027-12-01,13.995402298850575,Good (10-50/month),139.95402298850576,Exceeded (≥100%),60,75.0,84.49
NCT03588715,Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2),UNKNOWN,PHASE1,15.0,2020-06-18,2022-10-30,0.5284722222222222,Slow (<1/month),5.284722222222222,Significantly Below (<50%),50,31.2,10.165000000000001
NCT02056015,A Phase I Study of MLN6907 in Patients With Metastatic Colorectal,COMPLETED,PHASE1,20.0,2015-06-01,2015-09-01,6.6173913043478265,Adequate (1-10/month),66.17391304347827,Below (50-75%),100,51.6,51.644999999999996
NCT01147315,ORN Study: Curative Treatment of Osteoradionecrosis (ORN) With Hybrid Bone Substitution,COMPLETED,NA,13.0,2009-11-18,2016-11-16,0.15488062622309198,Slow (<1/month),1.5488062622309198,Significantly Below (<50%),100,46.0,34.1
NCT05827315,"Incidence, Impact and Mechanisms of Perioperative Right VEntricular Dysfunction (IMPRoVE)",NOT_YET_RECRUITING,,175.0,2023-04-01,2026-04-01,4.860401459854015,Adequate (1-10/month),48.60401459854015,Significantly Below (<50%),30,41.3,23.74
NCT07127315,Assessing Gonadotropin-Releasing Hormone Agonists Benefit in Preserving the Ovarian Function in Premenopausal Breast Cancer Patients During Chemotherapy,COMPLETED,,100.0,2022-07-01,2024-07-01,4.164158686730507,Adequate (1-10/month),41.641586867305065,Significantly Below (<50%),100,56.3,64.5
NCT04276415,DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST),TERMINATED,PHASE1,34.0,2020-05-08,2022-03-11,1.5401190476190476,Adequate (1-10/month),15.401190476190477,Significantly Below (<50%),10,20.7,6.02
NCT06506435,Radiotherapy Patient Education With Virtual Reality,RECRUITING,NA,150.0,2024-12-04,2026-12-31,6.031704095112286,Adequate (1-10/month),60.317040951122856,Below (50-75%),60,50.0,47.675
NCT01818635,To Investigate the Effect of Montelukast on Behavior Problems in Children With Asthma,COMPLETED,,600.0,2013-03-01,2015-01-01,27.219076005961252,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT00457535,"Study of the Relationship Between rHuEPO Dose, Serum ADPN, and Mortality in Patients Beginning HD",TERMINATED,,,2000-08-01,2004-07-01,,Slow (<1/month),,Significantly Below (<50%),10,16.3,2.5700000000000003
NCT06226935,Comparative Analysis of Glaucoma Screening Uptake Among First-Degree Relatives in Community-Based and Hospital-Based Approaches,COMPLETED,,1304.0,2022-01-01,2023-05-31,77.07526213592233,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT01650935,Comparison of DASH With Oxalate Restricted Diet on Urine in Recurrent Stone Formers With Hyperoxaluria,COMPLETED,NA,48.0,2012-09-01,2013-04-01,6.892075471698114,Adequate (1-10/month),68.92075471698114,Below (50-75%),100,53.8,58.065
NCT04851535,Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment.,COMPLETED,PHASE2,34.0,2021-07-28,2022-11-01,2.2450325379609546,Adequate (1-10/month),22.450325379609545,Significantly Below (<50%),100,52.7,55.04
NCT00391235,White Matter in Pediatric Bipolar Disorder: A DTI Study,COMPLETED,,28.0,2005-09-01,2008-10-01,0.7569449378330373,Slow (<1/month),7.569449378330373,Significantly Below (<50%),100,45.6,32.08
NCT05032235,Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Kidney Function,COMPLETED,PHASE1,24.0,2021-11-09,2023-12-05,0.9663492063492064,Slow (<1/month),9.663492063492065,Significantly Below (<50%),100,46.9,38.96
NCT02908035,Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO),UNKNOWN,PHASE2,100.0,2017-03-03,2021-09-01,1.8527084601339014,Adequate (1-10/month),18.527084601339016,Significantly Below (<50%),50,43.0,26.465
NCT02523235,Effects of Catheter Location on Postoperative Analgesia for Continuous Adductor Canal and Popliteal-Sciatic Nerve Blocks,COMPLETED,PHASE4,117.0,2015-08-01,2018-03-01,3.776755037115589,Adequate (1-10/month),37.76755037115589,Significantly Below (<50%),100,59.4,70.905
NCT04959435,Understanding the Role of Oral Microbiota in Behçet's Disease (BEHCETBIOT),COMPLETED,,66.0,2022-01-10,2024-06-21,2.24976483762598,Adequate (1-10/month),22.4976483762598,Significantly Below (<50%),100,53.6,57.705
NCT03950635,Dietary Intervention in Patients with a History of Melanoma,TERMINATED,PHASE1,13.0,2019-04-16,2024-11-27,0.19284600389863552,Slow (<1/month),1.928460038986355,Significantly Below (<50%),10,19.0,4.84
NCT02870335,Manual Therapy and Proprioceptive Neuromuscular Facilitation in Field Hockey Players.,COMPLETED,NA,47.0,2016-08-01,2016-10-01,23.453770491803276,Good (10-50/month),200.0,Exceeded (≥100%),100,58.8,69.89999999999999
NCT06697535,A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD),RECRUITING,PHASE2,35.0,2023-05-24,2026-07-30,0.9160791057609631,Slow (<1/month),9.160791057609629,Significantly Below (<50%),60,35.8,16.325
NCT02473835,Effects of a Short Term Caloric Restriction on T Cell Activation in Fat,COMPLETED,NA,12.0,2013-01-01,2014-11-01,0.5460089686098655,Slow (<1/month),5.460089686098654,Significantly Below (<50%),100,46.0,34.1
NCT06353035,Biodiversity Interventions for Well-Being,ACTIVE_NOT_RECRUITING,NA,30.0,2022-03-30,2027-09-30,0.4543283582089552,Slow (<1/month),4.543283582089551,Significantly Below (<50%),85,42.9,26.145000000000003
NCT05127135,Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies,UNKNOWN,PHASE1,30.0,2020-01-22,2023-12-24,0.6377094972067039,Slow (<1/month),6.377094972067039,Significantly Below (<50%),50,32.4,12.025
NCT00709735,A Psychophysiologic Study of Weakening Traumatic Combat Memories With Post-Reactivation Propranolol,COMPLETED,PHASE4,23.0,2007-05-01,2010-08-01,0.5893265993265994,Slow (<1/month),5.893265993265993,Significantly Below (<50%),100,46.8,38.440000000000005
NCT02948608,Clinical Characteristics of Importance to Outcome in Patients With Spondyloarthritis,UNKNOWN,,60.0,2017-03-01,2019-09-30,1.9367974549310711,Adequate (1-10/month),19.367974549310713,Significantly Below (<50%),50,38.1,19.425
NCT02257008,Effect of Different Boosting Agents on Pharmacokinetics of BILR 355 BS Dissolved in Polyethylene Glycol 400 (PEG 400) in Healthy Male Volunteers,COMPLETED,PHASE1,44.0,2003-03-01,,,Slow (<1/month),,Significantly Below (<50%),100,43.5,27.400000000000002
NCT03141008,Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet,COMPLETED,,54.0,2017-09-15,2020-02-27,1.8366033519553073,Adequate (1-10/month),18.36603351955307,Significantly Below (<50%),100,52.7,55.04
NCT06349408,"IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors",RECRUITING,PHASE1,250.0,2025-01-10,2027-12-31,7.013824884792626,Adequate (1-10/month),70.13824884792626,Below (50-75%),60,58.0,68.245
NCT06540508,Application of Integrated Proteomic and Serum Metabolomic Analysis in Assessing the Efficacy and Prognosis of TACE Combined With Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma,ENROLLING_BY_INVITATION,,30.0,2023-02-01,2025-05-01,1.113658536585366,Adequate (1-10/month),11.136585365853659,Significantly Below (<50%),55,32.2,11.635
NCT04827108,Psychometric Properties of the Chinese Version of PeNAT,UNKNOWN,,150.0,2022-09-01,2024-08-31,6.254794520547946,Adequate (1-10/month),62.54794520547946,Below (50-75%),50,45.3,31.169999999999998
NCT02164708,Healthy Student Initiative,COMPLETED,NA,71.0,2012-07-01,2013-07-01,5.921205479452055,Adequate (1-10/month),59.212054794520554,Below (50-75%),100,55.7,63.09
NCT05943808,Teaching Acupuncture Points With Recorded VR Courses Versus Traditional Text,UNKNOWN,,200.0,2022-11-01,2024-06-30,10.029654036243823,Good (10-50/month),100.29654036243822,Exceeded (≥100%),50,54.3,59.62
NCT02361008,A Randomized Controlled Trial:Treatments on Infundibular Ventricular Septal Defect,COMPLETED,NA,20121212.0,2012-12-01,2014-12-01,839026.9770958904,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT01980108,Quantitative Ultrasound Assessment of Gastric Volume in Pregnant Women at Term,COMPLETED,NA,60.0,2013-10-01,2016-02-01,2.1411488862837045,Adequate (1-10/month),21.411488862837047,Significantly Below (<50%),100,54.8,61.095
NCT04170608,PEFCATII Expanded Safety and Feasibility Study of the FARAPULSE Endocardial Multi Ablation System to Treat Paroxysmal Atrial Fibrillation,COMPLETED,NA,10.0,2019-10-18,2020-12-07,0.7317307692307693,Slow (<1/month),7.3173076923076925,Significantly Below (<50%),100,45.8,33.03
NCT04781608,In It Together: Using Acceptance and Commitment Therapy to Treat Distress Among Older Adults With Sensory Loss and Their Spouses,COMPLETED,NA,662.0,2021-11-22,2022-06-30,91.59672727272728,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT04273308,The Effect of Whole-body Vibration Training,COMPLETED,NA,42.0,2016-03-18,2016-06-25,12.913939393939394,Good (10-50/month),129.13939393939393,Exceeded (≥100%),100,58.4,69.175
NCT00238108,Melatonin Supplements for Improving Sleep in Individuals With Hypertension,COMPLETED,PHASE2,16.0,2005-10-01,2010-08-01,0.27594334277620397,Slow (<1/month),2.7594334277620396,Significantly Below (<50%),100,46.3,35.66
NCT04941508,Mother's Recorded Voice Versus Dexmedetomidine on Postoperative Agitation,COMPLETED,PHASE3,90.0,2021-06-25,2021-11-05,20.598496240601502,Good (10-50/month),200.0,Exceeded (≥100%),100,62.2,74.74499999999999
NCT05588908,A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout,UNKNOWN,PHASE1,120.0,2022-06-29,2023-11-01,7.454693877551021,Adequate (1-10/month),74.54693877551021,Below (50-75%),50,44.6,29.42
NCT05262608,The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation,UNKNOWN,PHASE2,30.0,2021-12-07,2024-04-26,1.0484500574052813,Adequate (1-10/month),10.484500574052815,Significantly Below (<50%),50,32.4,12.025
NCT04754308,COPD and Socially Vulnerable Individuals,COMPLETED,NA,513.0,2021-04-19,2024-04-18,14.260931506849317,Good (10-50/month),142.60931506849317,Exceeded (≥100%),100,95.0,95.7
NCT04760808,Evaluation of Cerebrospinal Fluid Flow in Adolescent Idiopathic Scoliosis,COMPLETED,,72.0,2021-02-10,2022-05-04,4.892142857142858,Adequate (1-10/month),48.92142857142857,Significantly Below (<50%),100,54.1,59.11
NCT03108508,Non-inferiority Bioavailabilty Study of 3 Silicon-rich Supplements,COMPLETED,NA,5.0,2017-05-01,2017-07-30,1.6911111111111112,Adequate (1-10/month),16.91111111111111,Significantly Below (<50%),100,50.4,48.355
NCT03953508,Perceptions of Cigarette Smoking in Young Adults,COMPLETED,NA,199.0,2020-08-01,2023-01-31,6.634786418400877,Adequate (1-10/month),66.34786418400877,Below (50-75%),100,65.9,78.83
NCT02218008,A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study,COMPLETED,PHASE3,407.0,2014-07-01,2016-10-01,15.05356014580802,Good (10-50/month),150.5356014580802,Exceeded (≥100%),100,87.6,92.335
NCT01646008,Correlation Between Carbon Dioxide Measured in End of Exhalation and Arterial Blood,COMPLETED,,32.0,2012-04-01,2013-08-01,2.000164271047228,Adequate (1-10/month),20.001642710472282,Significantly Below (<50%),100,50.9,49.370000000000005
NCT04789408,Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia,TERMINATED,PHASE1,15.0,2021-07-19,2024-05-18,0.4415860735009672,Slow (<1/month),4.415860735009672,Significantly Below (<50%),10,19.2,5.055
NCT02225808,Neural Mechanisms of CBT for Anxiety in Autism (Open Pilot Study),COMPLETED,NA,10.0,2014-08-01,2016-12-01,0.35685814771395075,Slow (<1/month),3.5685814771395075,Significantly Below (<50%),100,45.8,33.03
NCT05752825,"Acromegaly: Balance, Falls and Fracture Risk",COMPLETED,,34.0,2023-06-02,2024-05-15,2.974022988505747,Adequate (1-10/month),29.740229885057474,Significantly Below (<50%),100,51.1,50.129999999999995
NCT05399225,Platelets to Lymphocytes Ratio in Sepsis,UNKNOWN,,50.0,2022-09-01,2023-06-01,5.575091575091576,Adequate (1-10/month),55.750915750915766,Below (50-75%),50,37.3,18.35
NCT02021825,Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders,UNKNOWN,PHASE4,50.0,2009-03-01,2015-12-01,0.6171938361719385,Slow (<1/month),6.171938361719384,Significantly Below (<50%),50,34.0,14.02
NCT03436225,Steroid Therapy in Acute Bronchiolitis A New Old Line of Therapy.,UNKNOWN,PHASE1,80.0,2019-02-01,2019-03-01,80.0,Excellent (>50/month),200.0,Exceeded (≥100%),50,51.4,50.92
NCT07048925,Iliac Stent-Grafts in TASC C-D Lesions,ACTIVE_NOT_RECRUITING,,52.0,2024-01-01,2025-08-30,2.607710049423394,Adequate (1-10/month),26.07710049423394,Significantly Below (<50%),85,48.0,42.945
NCT01031225,"A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)",COMPLETED,PHASE2,113.0,2009-11-01,2014-02-01,2.214887314874437,Adequate (1-10/month),22.148873148744368,Significantly Below (<50%),100,59.0,70.365
NCT01854125,Autologous Mesenchymal Stem Cell Transplantation in Cirrhosis Patients With Refractory Ascites,UNKNOWN,PHASE3,30.0,2013-05-01,,,Slow (<1/month),,Significantly Below (<50%),50,27.4,8.225
NCT05416125,Vyvanse in Children Aged 6 to 12 Years,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,44.0,2023-12-20,2027-07-31,1.0154359363153906,Adequate (1-10/month),10.154359363153906,Significantly Below (<50%),85,44.0,28.249999999999996
NCT00638625,Correlation of X-ray and Pathology With Needle Biopsy of Lung Tumors,WITHDRAWN,,0.0,2010-01-01,2011-02-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT05713825,Multidimensional Evaluation of Patients With Ruptured or Unruptured Cerebral Aneurysm Undergoing Endovascular or Surgical Treatment,UNKNOWN,,500.0,2023-01-31,2023-12-31,45.5688622754491,Good (10-50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT02799225,Prevalence of Clinical Strains of Enterobacteria With Reduced Susceptibility to Carbapenems in the North-West Region of France,COMPLETED,,287.0,2012-06-01,2014-02-02,14.298330605564649,Good (10-50/month),142.9833060556465,Exceeded (≥100%),100,76.3,85.1
NCT05546125,a Non-interventional Study of Sildenafil in the Treatment of Pulmonary Arterial Hypertension (PAH) in Adults From China,COMPLETED,,100.0,2021-12-23,2023-02-27,7.062645011600928,Adequate (1-10/month),70.62645011600928,Below (50-75%),100,56.3,64.5
NCT05063825,Understanding Reactions to Emotional Material in the Media During COVID-19 - Study 2,COMPLETED,NA,98.0,2021-10-06,2021-12-13,43.86941176470588,Good (10-50/month),200.0,Exceeded (≥100%),100,67.8,80.285
NCT00236925,Efficacy Study of Low-Dose Hydrocortisone Treatment for Fibromyalgia,COMPLETED,EARLY_PHASE1,30.0,2003-05-01,2007-06-01,0.612064343163539,Slow (<1/month),6.120643431635389,Significantly Below (<50%),100,47.4,40.98
NCT04407325,Tuberculosis Screening in Paraguayan Prisons,UNKNOWN,NA,5000.0,2021-10-18,2023-12-01,196.64082687338504,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT03636425,Musculoskeletal Disorders in Mountain Runners,COMPLETED,,200.0,2018-08-30,2019-01-30,39.790849673202615,Good (10-50/month),200.0,Exceeded (≥100%),100,69.3,81.395
NCT05582525,COVID-19 Vaccines and the Development of New LUTS,COMPLETED,,341.0,2022-02-01,2022-04-01,175.9328813559322,Excellent (>50/month),200.0,Exceeded (≥100%),100,85.6,91.465
NCT03064425,Understanding HIV Susceptibility in the Female Genital Tract,COMPLETED,,98.0,2015-01-01,2017-01-01,4.080875512995896,Adequate (1-10/month),40.80875512995896,Significantly Below (<50%),100,56.2,64.21
NCT03809325,"A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly",COMPLETED,,225.0,2018-11-21,2019-07-12,29.39484978540773,Good (10-50/month),200.0,Exceeded (≥100%),100,71.3,82.655
NCT01578525,Medication Safety of Elderly Patients in Hospital and Ambulatory Setting,COMPLETED,NA,61.0,2012-04-01,2014-04-01,2.543616438356165,Adequate (1-10/month),25.43616438356165,Significantly Below (<50%),100,54.9,61.55500000000001
NCT07331025,Ultrasound Detection of Early Facial Muscle Changes in FSHD: Thickness and Echo Intensity Findings,COMPLETED,,39.0,2023-09-01,2024-02-15,7.10874251497006,Adequate (1-10/month),71.08742514970061,Below (50-75%),100,51.5,51.245
NCT04872725,The Effect of Covid-19 Process,COMPLETED,,531.0,2020-03-01,2020-07-30,107.04397350993378,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT05793125,Pulmonary Artery Doppler And Neonatal Outcome In Hypertensive Disorders Of Pregnancy,COMPLETED,,72.0,2023-04-03,2024-06-07,5.085104408352668,Adequate (1-10/month),50.85104408352669,Below (50-75%),100,54.1,59.11
NCT06002425,Treatment Recommendations for Gastrointestinal Cancers Via Large Language Models,RECRUITING,NA,400.0,2023-08-29,2028-12-31,6.240902101486418,Adequate (1-10/month),62.40902101486419,Below (50-75%),60,70.0,81.89999999999999
NCT05457725,Modulating Neurocognitive Processes of Learning to Trust and Distrust in Aging,RECRUITING,NA,68.0,2024-10-08,2027-04-30,2.2161884368308353,Adequate (1-10/month),22.161884368308353,Significantly Below (<50%),60,43.4,27.265
NCT03879525,EMR Outcomes: Anxiety and Depression in Epilepsy,COMPLETED,NA,30.0,2019-12-16,2021-09-27,1.4027649769585253,Adequate (1-10/month),14.027649769585254,Significantly Below (<50%),100,47.4,40.98
NCT02756325,Quantitative MRI for Functional Imaging of the Testis: A New Methodology for Evaluation of the Infertile Male,WITHDRAWN,NA,0.0,2016-06-01,2019-01-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT04199325,"Probiotics for Gout / Hyperuricemia: A Randomized, Intervention, Parallel Controlled, Multicenter Clinical Trial",UNKNOWN,NA,300.0,2018-11-01,2024-03-01,4.6902927580893685,Adequate (1-10/month),46.90292758089368,Significantly Below (<50%),50,59.0,70.365
NCT00728325,Impact of Supported Employment Versus Standard Vocational Rehabilitation in Veterans With Post-traumatic Stress Disorder,UNKNOWN,NA,100.0,2008-05-01,2014-05-01,1.3893199452304885,Adequate (1-10/month),13.893199452304886,Significantly Below (<50%),50,38.0,19.255
NCT06171425,Evaluation of Patients With Diffuse Parenchymal Lung Diseases Regarding Frailty,UNKNOWN,,28.0,2023-12-25,2024-02-22,14.446101694915255,Good (10-50/month),144.46101694915257,Exceeded (≥100%),50,40.6,22.575
NCT02725125,Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer,UNKNOWN,NA,19.0,2015-11-01,2019-11-01,0.39586584531143054,Slow (<1/month),3.9586584531143054,Significantly Below (<50%),50,31.5,10.635
NCT07340125,Pistachio Snacking and Metabolic Flexibility,RECRUITING,NA,60.0,2025-09-01,2026-12-31,3.758024691358025,Adequate (1-10/month),37.580246913580254,Significantly Below (<50%),60,42.8,25.929999999999996
NCT02222025,Injury Prevention in Children´s Football,COMPLETED,NA,3895.0,2014-08-01,2015-11-01,259.4393873085339,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT07377825,Accuracy and Periodontal Outcomes of Three Interproximal Enamel Reduction Techniques During Clear Aligner Therapy,NOT_YET_RECRUITING,NA,75.0,2026-03-01,2026-11-01,9.318367346938777,Adequate (1-10/month),93.18367346938776,Met (75-100%),30,40.0,21.87
NCT02293525,Clinical Evaluation of the ReLeaf Analgesic Infusion Catheter & Wound Drain,WITHDRAWN,NA,0.0,,2016-01-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT03147625,Salutogenic Healthy Aging Program Embracement (SHAPE) for Elderly-only Households,UNKNOWN,NA,154.0,2017-08-01,2020-07-31,4.281059360730594,Adequate (1-10/month),42.81059360730594,Significantly Below (<50%),50,47.3,40.475
NCT03653325,ORI to Reduce Hyperoxia After Out Hospital Cardiac Arrest,COMPLETED,NA,100.0,2018-11-08,2022-01-31,2.579661016949153,Adequate (1-10/month),25.796610169491522,Significantly Below (<50%),100,58.0,68.245
NCT07129525,Health Oriented Protocol for Epidermal Radiodermatitis,NOT_YET_RECRUITING,,80.0,2025-09-01,2026-09-30,6.180710659898478,Adequate (1-10/month),61.807106598984774,Below (50-75%),30,33.7,13.465
NCT02797925,Mechanisms Behind Development of Tendinopathy,UNKNOWN,,400.0,2016-06-01,2020-06-01,8.334017796030116,Adequate (1-10/month),83.34017796030116,Met (75-100%),50,65.3,78.32000000000001
NCT04720625,Adapt2Quit - An Adaptive Motivational System for Socio-Economically Disadvantaged Smokers,COMPLETED,NA,757.0,2021-06-28,2025-03-31,16.79524781341108,Good (10-50/month),167.9524781341108,Exceeded (≥100%),100,95.0,95.7
NCT06233825,Nutritional Intervention to Enhance Recovery After Arthroscopic Knee Surgery in Adults,COMPLETED,NA,30.0,2024-02-01,2025-10-14,1.4705314009661836,Adequate (1-10/month),14.705314009661835,Significantly Below (<50%),100,47.4,40.98
NCT07261176,Effect of Smoking on Retinal Vessel Morphology and Functionality,COMPLETED,NA,40.0,2021-04-01,2024-12-01,0.9086567164179106,Slow (<1/month),9.086567164179105,Significantly Below (<50%),100,48.2,43.665
NCT01114776,Multi-Center Study of Iron Overload: Pilot Study,COMPLETED,,20.0,2009-11-01,2013-09-30,0.42603219034289713,Slow (<1/month),4.260321903428972,Significantly Below (<50%),100,44.9,30.025000000000002
NCT02975076,Sanchitongtshu Plus Asprine for Minor Ischemic Stroke or Transient Ischemic Attack: A Randomized Double-blind Study,UNKNOWN,NA,120.0,2016-12-01,2019-11-01,3.4298591549295776,Adequate (1-10/month),34.29859154929578,Significantly Below (<50%),50,44.6,29.42
NCT05887076,Postoperative Delirium After Kidney Transplantation,COMPLETED,,362.0,2023-05-24,2023-12-19,52.723827751196175,Excellent (>50/month),200.0,Exceeded (≥100%),100,87.3,92.25
NCT04255576,Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone,UNKNOWN,PHASE1,139.0,2019-10-10,2023-10-01,2.9140220385674933,Adequate (1-10/month),29.140220385674937,Significantly Below (<50%),50,46.1,34.695
NCT00006476,Suramin in Treating Patients With Recurrent Bladder Cancer,COMPLETED,PHASE1,15.0,2000-10-01,2007-10-01,0.17863849765258216,Slow (<1/month),1.7863849765258215,Significantly Below (<50%),100,46.2,35.089999999999996
NCT07076576,Effects of Yoga in Children With Attention Deficit Hyperactivity Disorder,COMPLETED,NA,34.0,2022-12-01,2024-12-31,1.36,Adequate (1-10/month),13.600000000000001,Significantly Below (<50%),100,47.7,42.17
NCT01890876,"Altitude, Exercise and Glucose Metabolism in Pre-diabetic Men",COMPLETED,NA,32.0,2013-06-01,2015-12-01,1.0669003285870755,Adequate (1-10/month),10.669003285870756,Significantly Below (<50%),100,47.6,41.775
NCT03768076,an Istitution Experience on Parosteal OsTeosarcoma,COMPLETED,,220.0,2018-11-30,2019-02-28,74.4088888888889,Excellent (>50/month),200.0,Exceeded (≥100%),100,75.9,84.885
NCT02370576,The Effect of Traumatic Childbirth on the Incidence of PTSD and Other Major Postpartum Psychopathology,UNKNOWN,,500.0,2015-03-01,2018-03-01,13.886861313868613,Good (10-50/month),138.86861313868613,Exceeded (≥100%),50,78.3,86.48
NCT02496676,Magnesium Supplementation in People With XMEN Syndrome,COMPLETED,PHASE1,8.0,2016-05-17,2020-04-23,0.16946416144746,Slow (<1/month),1.6946416144746,Significantly Below (<50%),100,45.6,32.08
NCT06383676,Effect Of Functional Balance Exercise İn Elderly,COMPLETED,NA,31.0,2023-04-20,2024-10-30,1.6880858676207513,Adequate (1-10/month),16.880858676207513,Significantly Below (<50%),100,52.5,54.345
NCT01808976,Can Mental Health Apps Work in the Real World? A Feasibility Pilot Study.,COMPLETED,NA,1000.0,2013-04-01,2017-02-01,21.711840228245364,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT06453876,"Percutaneous Embolectomy, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism",NOT_YET_RECRUITING,PHASE3,210.0,2025-06-01,2029-10-31,3.963050216986981,Adequate (1-10/month),39.63050216986981,Significantly Below (<50%),30,45.8,33.03
NCT04576676,Environmental Epidemiology of Essential Tremor,COMPLETED,,1497.0,2020-07-02,2023-07-19,40.97902877697842,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT00752076,Detection of EGFR Mutation in Malignant Pleural Effusion of Lung Cancer Patients and Cancer Cell Lines Establishment,UNKNOWN,NA,100.0,2008-04-01,2011-03-01,2.8609022556390977,Adequate (1-10/month),28.60902255639098,Significantly Below (<50%),50,43.0,26.465
NCT01940276,Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer,COMPLETED,PHASE2,100.0,2013-10-01,2019-10-08,1.3848953594176525,Adequate (1-10/month),13.848953594176525,Significantly Below (<50%),100,53.0,55.80500000000001
NCT07015476,Retrospective Observational Evaluation of the Bone Mineral Density Outcome in Young Women With Amenorrhea,RECRUITING,,180.0,2020-11-09,2026-11-01,2.5099404489235,Adequate (1-10/month),25.099404489235,Significantly Below (<50%),60,50.7,48.915
NCT05578976,"A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)",ACTIVE_NOT_RECRUITING,PHASE3,900.0,2023-02-08,2029-12-01,11.011254019292606,Good (10-50/month),110.11254019292605,Exceeded (≥100%),85,90.5,93.4
NCT04466176,A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers,COMPLETED,PHASE1,34.0,2020-07-01,2020-12-31,5.65551912568306,Adequate (1-10/month),56.5551912568306,Below (50-75%),100,52.7,55.04
NCT04839276,Administration of Platelet-rich Fibrin to Autologous Fat Tissue in Injection Laryngoplasty for Vocal Cord Paralysis,COMPLETED,PHASE4,19.0,2018-01-01,2019-02-01,1.4605050505050505,Adequate (1-10/month),14.605050505050505,Significantly Below (<50%),100,46.5,36.815
NCT05322317,Advance Care Planning (ACP) in Primary Care for Dementia,COMPLETED,NA,17.0,2022-04-21,2022-11-09,2.561782178217822,Adequate (1-10/month),25.61782178217822,Significantly Below (<50%),100,51.4,50.92
NCT02194517,"Impact of ELKa, the Toolset for Food Exchanges Calculation on Metabolic Control in Pediatric Diabetic Patients.",COMPLETED,NA,106.0,2013-04-01,2014-11-01,5.572780656303973,Adequate (1-10/month),55.72780656303973,Below (50-75%),100,58.5,69.34
NCT06474117,Muscle-tendon Interaction in the Spastic Sural Triceps During Gait,RECRUITING,,80.0,2024-11-15,2026-11-15,3.3358904109589043,Adequate (1-10/month),33.35890410958904,Significantly Below (<50%),60,42.7,25.77
NCT04667117,A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab,COMPLETED,PHASE4,63.0,2021-01-14,2023-07-06,2.123720930232558,Adequate (1-10/month),21.237209302325585,Significantly Below (<50%),100,55.0,61.834999999999994
NCT03367117,"Results of Peripheral Blood Stem Cells According to Stimulatory Molecule,: Zarzio Versus Granocytes",COMPLETED,,70.0,2016-10-10,2017-01-23,20.293333333333333,Good (10-50/month),200.0,Exceeded (≥100%),100,58.9,70.10499999999999
NCT07194317,A Feasibility Study to Determine the Most Appropriate Digital Dietary Assessment Tool in Patients With Obesity Initiating GLP-1 Receptor Agonist Treatment,ENROLLING_BY_INVITATION,NA,50.0,2025-09-01,2026-04-01,7.179245283018869,Adequate (1-10/month),71.79245283018868,Below (50-75%),55,40.5,22.46
NCT00365417,"Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer",COMPLETED,PHASE2,45.0,2006-08-01,2009-11-01,1.153030303030303,Adequate (1-10/month),11.530303030303031,Significantly Below (<50%),100,48.6,44.685
NCT06775717,"Motor Imagery and Mirror Therapy on Synkinesis, Facial Asymmetry, Facial Function and QoF in Bell's Palsy Patients.",ENROLLING_BY_INVITATION,NA,42.0,2024-10-01,2025-05-01,6.030566037735849,Adequate (1-10/month),60.30566037735849,Below (50-75%),55,39.9,21.695
NCT01241617,ENDO GIA Stapler With Duet Tissue Reinforcement System (TRS) Used in Pulmonary Resections,TERMINATED,NA,100.0,2010-08-01,2012-01-01,5.876447876447877,Adequate (1-10/month),58.76447876447877,Below (50-75%),10,31.0,9.985
NCT02490917,ACT™ Balloons Versus Artificial Urinary Sphincter (AMS800™) for the Treatment of Female Stress Urinary Incontinence,UNKNOWN,NA,300.0,2015-09-01,2019-12-01,5.884020618556701,Adequate (1-10/month),58.84020618556701,Below (50-75%),50,59.0,70.365
NCT00256217,Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women,COMPLETED,PHASE2,42.0,2004-09-21,2018-12-12,0.2460981713185756,Slow (<1/month),2.460981713185756,Significantly Below (<50%),100,48.4,44.22
NCT06030817,99mTc-CNDG Injection in the Diagnosis of Malignant Tumors,UNKNOWN,NA,100.0,2023-08-11,2025-12-31,3.486827033218786,Adequate (1-10/month),34.86827033218786,Significantly Below (<50%),50,43.0,26.465
NCT07354217,Workflow Optimization During Pulse Field Ablation for Atrial Fibrillation,NOT_YET_RECRUITING,PHASE4,60.0,2026-01-01,2030-12-31,1.0007671232876711,Adequate (1-10/month),10.007671232876712,Significantly Below (<50%),30,28.8,8.665000000000001
NCT02974517,The Application of Time-lapse System in IVF/ICSI,UNKNOWN,,300.0,2016-11-01,,,Slow (<1/month),,Significantly Below (<50%),50,47.3,40.475
NCT05613517,Study of the Angle Lambda and Ocular Dominance,COMPLETED,,76.0,2022-11-25,2024-02-28,5.029217391304348,Adequate (1-10/month),50.292173913043484,Below (50-75%),100,54.4,59.89
NCT04901117,Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days,UNKNOWN,PHASE4,1300.0,2021-06-01,2023-08-01,50.02781289506954,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT05249517,Telerehabilitation Based Pain Neuroscience Education on Patients With Non-specific Chronic Neck Pain,COMPLETED,NA,20.0,2022-02-01,2022-12-08,1.9638709677419355,Adequate (1-10/month),19.638709677419357,Significantly Below (<50%),100,51.6,51.644999999999996
NCT03280017,Ketamine With Multilevel Paravertebral Block for Post Video-assisted Thoracic Surgery Pain,COMPLETED,PHASE4,32.0,2017-09-25,2018-12-31,2.1083982683982687,Adequate (1-10/month),21.083982683982686,Significantly Below (<50%),100,52.6,54.684999999999995
NCT05843617,Comparison of Bioavailability of Liposomal and Traditional Formulation of Vitamin C,COMPLETED,NA,10.0,2022-02-28,2022-06-09,3.013861386138614,Adequate (1-10/month),30.138613861386144,Significantly Below (<50%),100,50.8,49.18
NCT05968040,Point Of Care Ultrasound For Prediction Of Fluid Responsiveness in Off Pump Coronary Artery Bypass Grafting Surgery,UNKNOWN,NA,40.0,2023-08-01,2024-06-30,3.645508982035928,Adequate (1-10/month),36.455089820359284,Significantly Below (<50%),50,38.2,19.645000000000003
NCT02901340,Fetal Renal Artery Doppler Indices in Borderline Isolated Oligohydramnios,UNKNOWN,,140.0,2016-08-01,2016-12-01,34.9311475409836,Good (10-50/month),200.0,Exceeded (≥100%),50,49.5,46.58
NCT04761640,The Impact of Polynuclear Neutrophils' Intra-tumoral Rate and the Mutational Status in Pulmonary Adenocarcinomas on Survival,UNKNOWN,,100.0,2021-02-01,2021-09-01,14.358490566037737,Good (10-50/month),143.58490566037736,Exceeded (≥100%),50,46.3,35.66
NCT00726440,Are the Continuous Glucose Monitoring Systems Able to Improve Long Term Glycaemic Control in Type 1 Diabetic Patients?,COMPLETED,NA,180.0,2008-02-01,2010-06-01,6.438542890716804,Adequate (1-10/month),64.38542890716803,Below (50-75%),100,64.4,77.37
NCT04245540,Effects of Pau d' Arco in Primary Dysmenorrhea,COMPLETED,EARLY_PHASE1,12.0,2019-07-30,2022-12-15,0.29601296596434357,Slow (<1/month),2.960129659643436,Significantly Below (<50%),100,46.0,34.1
NCT03648840,Human Alcohol Seeking Despite Aversion,TERMINATED,NA,84.0,2018-04-04,2022-05-04,1.7149295774647888,Adequate (1-10/month),17.14929577464789,Significantly Below (<50%),10,29.7,8.92
NCT02855840,Auto-immune Diseases and Quality of Life,COMPLETED,,77.0,2015-03-02,2017-03-01,3.2107945205479456,Adequate (1-10/month),32.10794520547945,Significantly Below (<50%),100,54.5,60.12
NCT05585840,The Effect of Biofeedback-Based Virtual Reality Game on Children,COMPLETED,NA,62.0,2023-07-15,2023-12-31,11.167337278106508,Good (10-50/month),111.67337278106508,Exceeded (≥100%),100,60.0,71.97
NCT03413540,Effects of Jumping on Bone Health in Young Women,COMPLETED,NA,357.0,2008-09-28,2012-06-13,8.025908419497783,Adequate (1-10/month),80.25908419497785,Met (75-100%),100,78.6,86.81
NCT04483440,Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia,ACTIVE_NOT_RECRUITING,PHASE1,13.0,2020-06-02,2027-08-31,0.14955404383975812,Slow (<1/month),1.4955404383975812,Significantly Below (<50%),85,41.5,24.215
NCT02008240,Salpingectomy Versus Aspiration of Hydrosalpingeal Fluid Prior to IVF-ET,COMPLETED,PHASE2,160.0,2011-08-01,2014-05-01,4.850996015936255,Adequate (1-10/month),48.50996015936255,Significantly Below (<50%),100,62.8,75.53999999999999
NCT02585440,"A Multiple Dose Study of the Safety, Tolerability and PK of CMX157 in Healthy Subjects",COMPLETED,PHASE1,50.0,2016-04-01,2016-09-01,9.947712418300654,Adequate (1-10/month),99.47712418300654,Met (75-100%),100,59.0,70.365
NCT01949740,Patient Preferences in Making Treatment Decisions in Patients With Stage I-IVA Oropharyngeal Cancer,TERMINATED,,37.0,2013-06-01,2015-08-01,1.4238685208596713,Adequate (1-10/month),14.238685208596713,Significantly Below (<50%),10,19.3,5.125
NCT01797640,Intramedullary Nailing of Tibia Fractures,COMPLETED,,90.0,2012-10-01,2015-04-01,3.003947368421053,Adequate (1-10/month),30.039473684210527,Significantly Below (<50%),100,55.5,62.71
NCT05416840,Effects and Safety of Clonidine Patch on Young and Middle-aged Smokers With Mild Hypertension,NOT_YET_RECRUITING,PHASE4,92.0,2024-01-01,2026-12-01,2.6295586854460096,Adequate (1-10/month),26.295586854460097,Significantly Below (<50%),30,36.4,17.14
NCT00002040,"Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis",COMPLETED,NA,,,,,Slow (<1/month),,Significantly Below (<50%),100,40.0,21.87
NCT04913740,Nursing Study of Skin Lesions Related to Health Care Protection in Novel Nursing Study of Skin Lesions Related to Health Care Protection in Novel Coronavirus Epidemic,UNKNOWN,NA,170.0,2021-06-01,2022-01-01,24.181308411214953,Good (10-50/month),200.0,Exceeded (≥100%),50,53.6,57.705
NCT04951440,Study on the Effectiveness and Safety of Nitrone for Injection in Patients With Acute Ischemic Stroke,UNKNOWN,NA,200.0,2018-06-01,2021-12-01,4.75996872556685,Adequate (1-10/month),47.59968725566849,Significantly Below (<50%),50,51.0,49.714999999999996
NCT04242940,Assessing Listening Effort at Different Signal-to-noise Ratios in Bone-anchored Users,TERMINATED,NA,14.0,2020-02-21,2022-05-17,0.5222549019607844,Slow (<1/month),5.222549019607844,Significantly Below (<50%),10,19.1,4.9799999999999995
NCT06208540,Clinical Characteristics and Treatment of Anosmia and Ageusia Due to SARS-CoV2 Variants,COMPLETED,PHASE4,160.0,2021-08-30,2024-05-30,4.850996015936255,Adequate (1-10/month),48.50996015936255,Significantly Below (<50%),100,62.8,75.53999999999999
NCT03329040,Is Primiparity a Risk Factor for Neonatal Hyperbilirubinemia?,COMPLETED,,4369.0,2018-01-01,2018-09-20,507.604427480916,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT03308240,Magic Therapy to Relieve Pediatric Patient Anxiety and Improve the Hospitalization Experience,UNKNOWN,NA,260.0,2017-07-26,2018-07-26,21.68328767123288,Good (10-50/month),200.0,Exceeded (≥100%),50,60.8,72.99
NCT05306340,"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)",ACTIVE_NOT_RECRUITING,PHASE3,373.0,2022-08-03,2026-10-15,7.401642764015646,Adequate (1-10/month),74.01642764015645,Below (50-75%),85,75.3,84.60499999999999
NCT04990440,A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis,TERMINATED,PHASE2,6.0,2021-09-02,2022-03-09,0.9714893617021277,Slow (<1/month),9.714893617021277,Significantly Below (<50%),10,18.5,4.02
NCT02515240,Immune Response to Pneumococcal Vaccination in HIV Infected Individuals,COMPLETED,EARLY_PHASE1,124.0,2010-07-01,2015-03-01,2.215117370892019,Adequate (1-10/month),22.151173708920187,Significantly Below (<50%),100,59.9,71.86
NCT06761040,Intrinsic Foot Muscle With and Without Hip Abductor Muscle Strengthening Training in Overweight Females,RECRUITING,NA,48.0,2024-09-15,2025-01-15,11.97639344262295,Good (10-50/month),119.7639344262295,Exceeded (≥100%),60,46.8,38.440000000000005
NCT04272840,The Impact of Glycemic Index Education on Lowering Dietary GI in Gestational Diabetes Mellitus,UNKNOWN,NA,60.0,2019-10-24,2022-08-30,1.7544668587896255,Adequate (1-10/month),17.544668587896258,Significantly Below (<50%),50,39.8,21.47
NCT01291940,The Effects of Emollient Therapy on the Skin Barrier,COMPLETED,NA,25.0,2011-01-01,2014-12-01,0.5321678321678323,Slow (<1/month),5.321678321678322,Significantly Below (<50%),100,47.0,39.33
NCT05555940,Effect of Individualized Precise TMS on Emotional Blunting in Depression and Its Brain Imaging Mechanism,UNKNOWN,NA,80.0,2022-10-01,2024-06-30,3.8169278996865206,Adequate (1-10/month),38.16927899686521,Significantly Below (<50%),50,41.4,24.04
NCT06598540,Comparison of Two Nutrition-Based Interventions on Physician Well-being,ACTIVE_NOT_RECRUITING,NA,177.0,2025-03-15,2025-07-20,42.42425196850394,Good (10-50/month),200.0,Exceeded (≥100%),85,69.7,81.73
NCT03249740,A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration,COMPLETED,PHASE1,32.0,2017-08-29,2019-01-16,1.928871287128713,Adequate (1-10/month),19.28871287128713,Significantly Below (<50%),100,52.6,54.684999999999995
NCT01020240,Physiotherapy in Postpartum After a Cesarean,COMPLETED,NA,45.0,2009-03-01,2009-06-01,14.88913043478261,Good (10-50/month),148.8913043478261,Exceeded (≥100%),100,58.6,69.51
NCT01662089,The Efficacy in Treatment of Female Pattern Hair Loss Using 5% Minoxidil Solution Combinded With Zinc Supplement,UNKNOWN,PHASE1,20.0,2012-01-01,2012-12-01,1.8173134328358211,Adequate (1-10/month),18.17313432835821,Significantly Below (<50%),50,36.6,17.41
NCT03491189,Blade vs Screw Intertrochanteric Hip Fracture Fixation Study,WITHDRAWN,NA,0.0,2018-04-01,2018-06-19,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT02726789,Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B,COMPLETED,PHASE2,5.0,2012-10-01,2016-12-01,0.1,Slow (<1/month),1.0,Significantly Below (<50%),100,45.4,31.455
NCT04317989,STUN (STop UNhealthy) Alcohol Use Now! Implementing Evidence-Based Services for Unhealthy Alcohol Use in Primary Care,COMPLETED,NA,32.0,2020-01-22,2023-10-31,0.7068795355587808,Slow (<1/month),7.06879535558781,Significantly Below (<50%),100,47.6,41.775
NCT00681889,Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV),COMPLETED,PHASE1,9.0,2008-04-01,2010-09-01,0.31026047565118914,Slow (<1/month),3.1026047565118913,Significantly Below (<50%),100,45.7,32.5
NCT02669589,Investigating Different Anticoagulants for Renal Replacement Therapy,COMPLETED,PHASE4,638.0,2016-03-01,2020-01-03,13.842280826799715,Good (10-50/month),138.42280826799714,Exceeded (≥100%),100,95.0,95.7
NCT02731989,Comparison Between the Clinical Assessment of the Undescended Testis and Its' Ultrasonographic Size,UNKNOWN,,60.0,2017-07-24,2019-07-24,2.5019178082191784,Adequate (1-10/month),25.019178082191786,Significantly Below (<50%),50,38.1,19.425
NCT02074189,Adjuvant Chemotherapy Following Radical Cystectomy to Treat Locally Advanced Bladder Cancer,UNKNOWN,PHASE3,200.0,2014-03-01,2019-04-01,3.2784060312331715,Adequate (1-10/month),32.78406031233171,Significantly Below (<50%),50,51.0,49.714999999999996
NCT04840589,Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors,RECRUITING,PHASE1,66.0,2022-02-02,2026-01-01,1.4059062281315606,Adequate (1-10/month),14.059062281315605,Significantly Below (<50%),60,38.3,19.785
NCT01626989,Evaluation of the Philips Respironics BiPAP autoSV Devices in Subjects With Sleep Disorders,COMPLETED,NA,44.0,2010-06-01,2012-06-01,1.8322298221614228,Adequate (1-10/month),18.32229822161423,Significantly Below (<50%),100,53.5,57.555
NCT06490289,Clinical Efficiency of Natural Herbal Based Gel.,COMPLETED,NA,202.0,2023-06-15,2024-01-16,28.599441860465117,Good (10-50/month),200.0,Exceeded (≥100%),100,71.2,82.59
NCT00869089,Safety and Efficacy of CC-10004 for Prurigo Nodularis,COMPLETED,PHASE2,5.0,2008-09-01,2011-01-01,0.17863849765258216,Slow (<1/month),1.7863849765258215,Significantly Below (<50%),100,45.4,31.455
NCT06668389,Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial,RECRUITING,PHASE4,106.0,2025-05-12,2026-12-31,5.395719063545151,Adequate (1-10/month),53.95719063545151,Below (50-75%),60,46.5,36.815
NCT03925389,Outcome Analysis in Septorhinoplasty,RECRUITING,,750.0,2019-05-07,2025-12-10,9.476961394769615,Adequate (1-10/month),94.76961394769616,Met (75-100%),60,81.3,88.58
NCT02462889,IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD,COMPLETED,PHASE2,128.0,2015-06-01,2019-03-01,2.8461066471877285,Adequate (1-10/month),28.461066471877285,Significantly Below (<50%),100,60.2,72.2
NCT01412489,Intrauterine Adhesion Rate After Hysteroscopic Myomectomy and Application of HYALOBARRIER Gel,COMPLETED,NA,189.0,2011-08-01,2016-12-01,2.951852231913802,Adequate (1-10/month),29.518522319138018,Significantly Below (<50%),100,65.1,78.14
NCT06981689,Association of Breast Reconstruction Method With Long-term Risk of Psychiatric Disorders,COMPLETED,,24930.0,2015-01-01,2023-12-31,230.9401095556908,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02249689,Three-month Clinical Evaluation of Silicone Hydrogel Definitive 65 Contact Lenses,COMPLETED,NA,60.0,2014-01-01,2014-05-01,15.22,Good (10-50/month),152.2,Exceeded (≥100%),100,59.8,71.61
NCT06592989,A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET,RECRUITING,,20.0,2024-09-30,2026-09-30,0.8339726027397261,Slow (<1/month),8.33972602739726,Significantly Below (<50%),60,32.9,12.53
NCT03334968,Prolidase Enzyme Activity in Stroke Patients,COMPLETED,,74.0,2016-05-01,2017-05-01,6.171397260273973,Adequate (1-10/month),61.71397260273973,Below (50-75%),100,54.3,59.62
NCT00416468,Bioavailability of Aliskiren and Valsartan Combined as a Single Tablet vs. the Same Medications Given Separately to Healthy Subjects.,COMPLETED,PHASE1,32.0,2006-11-01,,,Slow (<1/month),,Significantly Below (<50%),100,42.6,25.679999999999996
NCT06766968,Prolonged Compression Following Foam Sclerotherapy,RECRUITING,NA,140.0,2024-12-16,2026-07-31,7.198648648648649,Adequate (1-10/month),71.98648648648648,Below (50-75%),60,49.2,46.035
NCT01292668,Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer,COMPLETED,PHASE1,21.0,2011-03-01,2014-09-01,0.49940625,Slow (<1/month),4.9940625,Significantly Below (<50%),100,46.7,37.895
NCT06461468,Hypertrophic Cardiomyopathy Federated Learning Implementation Platform,ENROLLING_BY_INVITATION,,1000.0,2024-06-05,2026-01-01,52.93913043478261,Excellent (>50/month),200.0,Exceeded (≥100%),55,84.8,90.815
NCT05674968,Managing Challenging Behaviors-ADHD,COMPLETED,NA,47.0,2022-10-10,2024-06-01,2.3844666666666665,Adequate (1-10/month),23.844666666666665,Significantly Below (<50%),100,53.8,58.065
NCT01855568,Methotrexate Treatment for Ectopic Pregnancy,COMPLETED,PHASE3,92.0,2013-05-01,2015-04-01,4.000685714285714,Adequate (1-10/month),40.00685714285714,Significantly Below (<50%),100,57.4,67.05499999999999
NCT03472768,The Impact of Age-dependent Haptoglobin Deficiency on Plasma Free Hemoglobin Levels During Extracorporeal Membrane Oxygenation Support,UNKNOWN,,90.0,2018-09-25,2024-09-01,1.2636531365313655,Adequate (1-10/month),12.636531365313653,Significantly Below (<50%),50,35.5,15.950000000000001
NCT04758468,Effects of Telerehabilitation-Based Pelvic Floor Muscle Training in People With Multiple Sclerosis,COMPLETED,NA,45.0,2021-02-18,2021-11-15,5.073333333333333,Adequate (1-10/month),50.73333333333333,Below (50-75%),100,53.6,57.705
NCT05156268,A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma,ACTIVE_NOT_RECRUITING,PHASE2,26.0,2022-01-27,2026-01-01,0.5515261324041812,Slow (<1/month),5.515261324041813,Significantly Below (<50%),85,42.6,25.679999999999996
NCT03012568,Clinical Study to Confirm MRI Safety and Effectiveness Using St. Jude Medical (SJM) Cardiac Rhythm Management Systems,COMPLETED,,119.0,2016-11-10,2018-03-29,7.187222222222222,Adequate (1-10/month),71.87222222222222,Below (50-75%),100,57.9,67.83
NCT03570268,Preventing Falls and Participation Restrictions in Neurological Diseases,COMPLETED,NA,90.0,2015-01-01,2017-01-15,3.6773154362416105,Adequate (1-10/month),36.77315436241611,Significantly Below (<50%),100,57.2,66.465
NCT00095368,APC-111 Once a Day (QD) for 7 Days vs. Penicillin Taken Four Times a Day (QID) for 10 Days in Patients With Strep Throat,COMPLETED,PHASE3,500.0,2004-10-01,2005-05-01,71.79245283018868,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT05751668,Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II),RECRUITING,PHASE2,98.0,2023-11-02,2032-03-15,0.976151832460733,Slow (<1/month),9.76151832460733,Significantly Below (<50%),60,40.8,22.745
NCT02974868,Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata,COMPLETED,PHASE2,142.0,2016-12-15,2019-05-15,4.90633371169126,Adequate (1-10/month),49.06333711691261,Significantly Below (<50%),100,61.4,73.735
NCT01275950,A Study to Evaluate the Impact of Direct and Surrogate Advertising and Compliance With the Bill With the Respect to Sale of Tobacco Products Around Educational Institutes,UNKNOWN,NA,480.0,2010-05-01,2011-04-01,43.61552238805971,Good (10-50/month),200.0,Exceeded (≥100%),50,83.4,90.405
NCT02643550,Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,COMPLETED,PHASE1,143.0,2015-12-01,2023-03-28,1.6278683620044878,Adequate (1-10/month),16.27868362004488,Significantly Below (<50%),100,56.4,64.88000000000001
NCT01699750,Comparative In-Vivo Wetting Characteristics of Silicone Hydrogel Materials With Selected Lens Care Systems,COMPLETED,NA,109.0,2012-12-01,2013-11-01,9.904358208955225,Adequate (1-10/month),99.04358208955225,Met (75-100%),100,63.7,76.655
NCT06507150,"AI-assisted Migraine Education: Efficacy, Safety and Patients' Acceptance",RECRUITING,NA,140.0,2024-09-01,2026-08-31,5.845816186556927,Adequate (1-10/month),58.45816186556927,Below (50-75%),60,49.2,46.035
NCT00082550,Serotonin Transporters in Obsessive-Compulsive-Related Disorders,COMPLETED,,30.0,2004-05-10,2007-04-09,0.8582706766917293,Slow (<1/month),8.582706766917294,Significantly Below (<50%),100,45.7,32.5
NCT00121550,The CLARICOR Trial: Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease,COMPLETED,PHASE3,4372.0,1999-10-01,2002-09-01,124.84397748592872,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT03888950,Interim FDG PET-CT in Melanoma Metastatic Patient's Treated by Anti-PD1 Therapy,RECRUITING,NA,20.0,2020-11-24,2027-11-01,0.2403474141334386,Slow (<1/month),2.403474141334386,Significantly Below (<50%),60,34.6,14.729999999999999
NCT00511550,Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation With Unrelated Donors,COMPLETED,,15.0,2005-08-01,2007-11-01,0.5554744525547445,Slow (<1/month),5.554744525547446,Significantly Below (<50%),100,44.5,29.160000000000004
NCT05825950,Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC),RECRUITING,,600.0,2024-01-25,2026-09-01,19.225263157894737,Good (10-50/month),192.2526315789474,Exceeded (≥100%),60,81.3,88.58
NCT03214250,Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma,COMPLETED,PHASE1,129.0,2017-07-21,2022-02-25,2.337357142857143,Adequate (1-10/month),23.37357142857143,Significantly Below (<50%),100,60.3,72.34
NCT05963191,CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome,RECRUITING,NA,272.0,2024-04-18,2026-04-18,11.342027397260274,Good (10-50/month),113.42027397260274,Exceeded (≥100%),60,64.8,77.865
NCT05895591,Clinical and Biological Anti-aging Efficacy of a Cosmetic Cream,COMPLETED,NA,33.0,2021-10-12,2021-12-14,15.944761904761904,Good (10-50/month),159.44761904761904,Exceeded (≥100%),100,57.6,67.36999999999999
NCT06702891,Integrative Analysis of Exosome-Mediated Single-Cell Transcriptomics and Proteomics in Gastric Cardia Cancer,RECRUITING,,20.0,2024-12-17,2027-10-01,0.5980353634577604,Slow (<1/month),5.980353634577605,Significantly Below (<50%),60,32.9,12.53
NCT06493591,"Atrial Fibrillation Ablation and Autonomic Modulation Via Thoracoscopic Surgery, 10 Year Follow up.",NOT_YET_RECRUITING,,200.0,2024-09-01,2025-08-01,18.227544910179642,Good (10-50/month),182.2754491017964,Exceeded (≥100%),30,48.3,43.985
NCT06112691,ARTIFICIAL INTELLIGENCE FOR MASS SCREENING OF THE DIABETIC RETINOPATHY IN THE CHERNIVTSI REGION (Pilot Study),UNKNOWN,,660.0,2022-02-01,2024-11-01,20.010358565737054,Good (10-50/month),200.0,Exceeded (≥100%),50,78.3,86.48
NCT02311491,Nano-Crystalline Ceramic Coating of Orthodontic Archwires,WITHDRAWN,NA,0.0,2016-12-01,2017-08-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT02406391,Adherence to Preventive Care for Cervical Cancer,UNKNOWN,,400.0,2015-04-01,2017-12-01,12.488205128205129,Good (10-50/month),124.8820512820513,Exceeded (≥100%),50,70.3,82.09
NCT00003191,Fenretinide in Treating Children With Solid Tumors,COMPLETED,PHASE1,18.0,1998-03-01,,,Slow (<1/month),,Significantly Below (<50%),100,41.4,24.04
NCT04282291,"Serratus Intercostal Plane Block,New Analgesia in Supraumbilical Surgery",COMPLETED,,105.0,2016-02-18,2019-08-30,2.479596586501164,Adequate (1-10/month),24.795965865011638,Significantly Below (<50%),100,56.7,65.53
NCT05645991,Coconut Sugar Lowers Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults,COMPLETED,NA,22.0,2018-03-08,2022-01-20,0.47360678925035365,Slow (<1/month),4.736067892503536,Significantly Below (<50%),100,46.8,38.440000000000005
NCT02615691,A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A,COMPLETED,PHASE3,120.0,2015-11-12,2024-10-29,1.1156994502138058,Adequate (1-10/month),11.156994502138057,Significantly Below (<50%),100,54.6,60.39
NCT03785691,Validating the Effect og Ondansetron and Mirtazapine in Treating Hyperemesis Gravidarum,TERMINATED,PHASE2,58.0,2019-03-01,2022-07-31,1.4146794871794872,Adequate (1-10/month),14.14679487179487,Significantly Below (<50%),10,22.6,6.329999999999999
NCT01415791,"Oral Mucosal Absorption of ICI176,334-1",COMPLETED,PHASE1,8.0,2011-08-01,2011-09-01,7.855483870967742,Adequate (1-10/month),78.55483870967743,Met (75-100%),100,50.6,48.705
NCT06522191,Cross Education for Upper Extremity Motor Function and Strength in Stroke,COMPLETED,NA,26.0,2024-07-29,2025-05-15,2.729103448275862,Adequate (1-10/month),27.29103448275862,Significantly Below (<50%),100,52.1,53.03
NCT02046291,Safety of Romiplostim (Nplate®) Following UCBT,COMPLETED,PHASE1,21.0,2015-04-10,2021-06-01,0.28486631016042785,Slow (<1/month),2.8486631016042785,Significantly Below (<50%),100,46.7,37.895
NCT00638391,Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer,COMPLETED,,1600.0,2005-05-01,2007-03-01,72.80119581464872,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT04124991,Safety and Efficacy Study of Radioembolization in Combination With Durvalumab in Locally Advanced and Unresectable HCC,COMPLETED,PHASE1,24.0,2020-06-12,2022-07-28,0.9414432989690722,Slow (<1/month),9.414432989690722,Significantly Below (<50%),100,46.9,38.96
NCT02850991,Different Radiation Dose With Concurrent Chemotherapy for Thoracic Esophageal Carcinoma,COMPLETED,NA,167.0,2016-04-01,2022-04-01,2.320164308534916,Adequate (1-10/month),23.20164308534916,Significantly Below (<50%),100,63.4,76.375
NCT01118091,Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...,COMPLETED,PHASE2,12.0,2010-04-01,2012-04-01,0.4996990424076608,Slow (<1/month),4.996990424076608,Significantly Below (<50%),100,46.0,34.1
NCT03343691,Blood Test for Early Detection of Breast Cancer Using Todos Medical -Breast 1(TM-B1) Assay,UNKNOWN,,200.0,2018-01-22,2019-07-01,11.596190476190477,Good (10-50/month),115.96190476190478,Exceeded (≥100%),50,54.3,59.62
NCT00990691,Pilot Study of the Effects of the Desipramine on the Neurovegetative Parameters of the Child With Rett Syndrome,COMPLETED,PHASE2,36.0,2009-02-17,2017-08-21,0.35270035403926614,Slow (<1/month),3.5270035403926614,Significantly Below (<50%),100,47.9,42.64
NCT04494191,"Bioequivalence Study of Flibanserin From AphroFemine 100 mg F.C.T (Bio Med for Pharmaceuticals Industries (BIOMED), Egypt) Versus Addyi 100 mg Tablets (Sprout Pharmaceuticals, Inc., USA)",COMPLETED,PHASE1,26.0,2018-12-12,2019-02-27,10.278441558441559,Good (10-50/month),102.78441558441558,Exceeded (≥100%),100,57.1,66.27
NCT03972891,Influence - Intervention Break - Children - Speech Sound Disorders,WITHDRAWN,NA,0.0,2024-02-01,2025-02-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT01981291,Duration of Sciatic Nerve Block After Injection of Local Anesthetic In or Around the Nerve,COMPLETED,PHASE4,120.0,2012-10-01,2013-10-01,10.007671232876714,Good (10-50/month),100.07671232876714,Exceeded (≥100%),100,64.6,77.59
NCT02060591,Comparison of Two Periarticular Injection Medications for Adjunctive Pain Management Following Total Knee Arthroplasty (TKA),UNKNOWN,NA,,2014-01-01,,,Slow (<1/month),,Significantly Below (<50%),50,25.0,7.23
NCT06721091,"Safety, Tolerability, and Dose Response of VNA-318 in Healthy Males",COMPLETED,PHASE1,92.0,2024-12-03,2025-11-27,7.800779944289695,Adequate (1-10/month),78.00779944289694,Met (75-100%),100,57.4,67.05499999999999
NCT06359691,Multi-ethnic Multi-level Strategies and Behavioral Economics to Eliminate Hypertension Disparities in Los Angeles County,ACTIVE_NOT_RECRUITING,NA,540.0,2024-08-08,2027-10-01,14.306005221932114,Good (10-50/month),143.06005221932116,Exceeded (≥100%),85,90.5,93.4
NCT03185091,Neuromonitoring During Rapid Ventricular Pacing in Patients Undergoing Cerebral Aneurysm Surgery,COMPLETED,NA,7.0,2013-01-14,2017-12-01,0.11957351290684624,Slow (<1/month),1.1957351290684624,Significantly Below (<50%),100,45.6,32.08
NCT04087291,Veterans Response to Dosage in Chiropractic Therapy,COMPLETED,NA,766.0,2021-02-22,2025-05-20,15.062687338501293,Good (10-50/month),150.62687338501294,Exceeded (≥100%),100,95.0,95.7
NCT05691491,Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness,RECRUITING,PHASE1,58.0,2023-09-28,2027-03-01,1.412416,Adequate (1-10/month),14.12416,Significantly Below (<50%),60,37.6,18.845
NCT01485874,Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer,TERMINATED,PHASE1,11.0,2011-11-01,2015-12-01,0.22457411133467473,Slow (<1/month),2.245741113346747,Significantly Below (<50%),10,18.9,4.6899999999999995
NCT01246674,"Thigh Swelling, Hip-muscle Strength, and Functional Performance Following Total Hip Arthroplasty",COMPLETED,,30.0,2011-01-01,2012-07-01,1.6694698354661792,Adequate (1-10/month),16.694698354661792,Significantly Below (<50%),100,50.7,48.915
NCT04638374,Adaptation of Lumbar Spine to a Mattress: a MRI Evaluation.,UNKNOWN,,20.0,2020-11-04,2021-10-31,1.6864265927977842,Adequate (1-10/month),16.86426592797784,Significantly Below (<50%),50,34.9,15.215
NCT02096874,Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema,COMPLETED,PHASE4,50.0,2013-06-01,2015-06-01,2.0849315068493155,Adequate (1-10/month),20.84931506849315,Significantly Below (<50%),100,54.0,58.72500000000001
NCT03767374,Risk-factors for Multidrug-resistant Bacteria Colonization Among Patients at High Risk of STIs,COMPLETED,,2186.0,2018-05-11,2020-12-31,68.95527461139896,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT03641274,Implementing a Case-management Intervention for Frequent Users of the Emergency Department in French-speaking Switzerland,UNKNOWN,,120.0,2018-11-20,2020-10-01,5.363876651982379,Adequate (1-10/month),53.63876651982379,Below (50-75%),50,42.9,26.145000000000003
NCT06520774,Concave Supra-arch Branched Stent-Graft System for Endovascular Treatment of Aortic Arch Diseases,RECRUITING,NA,103.0,2024-05-30,2031-06-30,1.21195206803247,Adequate (1-10/month),12.119520680324701,Significantly Below (<50%),60,41.2,23.425
NCT06061874,Ga68-FAPI-46 PET/CT for Preoperative Assessment of Peritoneal Carcinomatosis,RECRUITING,NA,80.0,2023-05-30,2025-12-01,2.658515283842795,Adequate (1-10/month),26.585152838427952,Significantly Below (<50%),60,44.4,28.95
NCT07030374,Effects of Conscious Connected Breathing Exercises on Fibromyalgia,COMPLETED,NA,60.0,2024-12-09,2025-04-21,13.732330827067669,Good (10-50/month),137.3233082706767,Exceeded (≥100%),100,59.8,71.61
NCT00178074,The Effects of Sleep Deprivation on Antidepressant Response,COMPLETED,PHASE4,80.0,1999-02-01,2003-04-01,1.6021052631578947,Adequate (1-10/month),16.021052631578947,Significantly Below (<50%),100,51.4,50.92
NCT06688474,A Sensor-enhanced Mouth Guard to Quantitatively Measure Bite Compression Forces.,COMPLETED,,2.0,2024-08-05,2024-10-31,0.6997701149425287,Slow (<1/month),6.9977011494252865,Significantly Below (<50%),100,43.5,27.400000000000002
NCT05344274,Retinal Blood Flow and Autoregulation,RECRUITING,PHASE4,90.0,2022-05-23,2027-09-01,1.421691748832382,Adequate (1-10/month),14.216917488323821,Significantly Below (<50%),60,40.2,22.115000000000002
NCT00902174,Imatinib (QTI571) in Pulmonary Arterial Hypertension,COMPLETED,PHASE3,202.0,2009-09-01,2011-05-01,10.12995057660626,Good (10-50/month),101.29950576606261,Exceeded (≥100%),100,71.2,82.59
NCT00293774,Alberta Hip Improvement Project,COMPLETED,,1632.0,2004-06-01,2021-07-16,7.943409018228334,Adequate (1-10/month),79.43409018228334,Met (75-100%),100,88.3,92.705
NCT04205474,Aortic Valve Dynamics During Exercise After Valve Sparing Root Replacement Surgery,COMPLETED,NA,20.0,2019-12-16,2021-01-01,1.593717277486911,Adequate (1-10/month),15.93717277486911,Significantly Below (<50%),100,46.6,37.375
NCT04416074,An Online 5-week Professional Identity Group Psychotherapy,COMPLETED,NA,110.0,2020-05-10,2020-06-20,81.66829268292683,Excellent (>50/month),200.0,Exceeded (≥100%),100,68.8,81.105
NCT04874974,Feasibility of a Novel Process-based Treatment for Patients With Psychosis,COMPLETED,NA,37.0,2021-05-10,2023-09-23,1.300554272517321,Adequate (1-10/month),13.00554272517321,Significantly Below (<50%),100,48.0,42.945
NCT02137174,Home and School Visits Intervention for Children With DM TYPE 1,COMPLETED,PHASE2,92.0,2012-01-01,2014-02-01,3.675170603674541,Adequate (1-10/month),36.75170603674541,Significantly Below (<50%),100,57.4,67.05499999999999
NCT03374774,A Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus (T2DM),COMPLETED,,516.0,2017-11-13,2018-07-04,67.41218884120173,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT05149118,Effect of PDRN in Post-operative Scars,COMPLETED,PHASE4,22.0,2019-02-01,2021-10-31,0.6676769690927218,Slow (<1/month),6.676769690927219,Significantly Below (<50%),100,46.8,38.440000000000005
NCT01459718,Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload,TERMINATED,PHASE2,32.0,2011-01-01,2014-06-01,0.781138732959102,Slow (<1/month),7.81138732959102,Significantly Below (<50%),10,20.6,5.965
NCT04444518,Increasing Influenza and Tdap Vaccination of Pregnant Women,COMPLETED,NA,12760.0,2019-07-01,2022-06-30,354.7163470319635,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT05418218,International Headache Registry Study,RECRUITING,,200000.0,2021-07-12,2082-12-31,271.15624443256723,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT00161018,New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia,COMPLETED,PHASE3,150.0,2003-11-01,2004-11-01,12.475409836065575,Good (10-50/month),124.75409836065575,Exceeded (≥100%),100,67.0,79.725
NCT04756518,COVID-19 Infection and Machine Learning Using Artificial Intelligence (AI),COMPLETED,,215.0,2020-07-06,2022-03-31,10.339020537124803,Good (10-50/month),103.39020537124802,Exceeded (≥100%),100,70.5,82.19999999999999
NCT01927718,Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT),TERMINATED,NA,10.0,2014-01-01,2016-11-01,0.2941062801932367,Slow (<1/month),2.941062801932367,Significantly Below (<50%),10,18.8,4.58
NCT00051818,Immune and Viral Outcomes of HIV-1 Therapy Interruption,COMPLETED,PHASE1,20.0,2000-09-01,2003-07-01,0.5893514036786061,Slow (<1/month),5.89351403678606,Significantly Below (<50%),100,46.6,37.375
NCT00006018,Paclitaxel and BMS-214662 in Treating Patients With Advanced Solid Tumors,COMPLETED,PHASE1,5.0,2000-07-01,2002-04-01,0.23818466353677623,Slow (<1/month),2.3818466353677623,Significantly Below (<50%),100,45.4,31.455
NCT02547818,Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease,COMPLETED,PHASE3,620.0,2015-09-15,2020-11-18,9.98032786885246,Adequate (1-10/month),99.80327868852459,Met (75-100%),100,95.0,95.7
NCT05359718,The Psychological Impact of COVID-19 on Patients with Solid Malignancies: a Single-Institution Survey Study,COMPLETED,,312.0,2021-03-01,2023-09-13,10.256241900647948,Good (10-50/month),102.56241900647949,Exceeded (≥100%),100,78.3,86.48
NCT03275818,Trial of Nab-paclitaxel in Patients With Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing Sarcoma,COMPLETED,PHASE2,69.0,2017-05-09,2021-09-30,1.3086355140186916,Adequate (1-10/month),13.086355140186917,Significantly Below (<50%),100,50.5,48.515
NCT04497818,Correlation Fear of COVID-19 & Dental Treatment Anxiety,COMPLETED,,385.0,2020-06-16,2020-07-25,300.4974358974359,Excellent (>50/month),200.0,Exceeded (≥100%),100,89.1,92.965
NCT00503490,"Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis",COMPLETED,PHASE1,40.0,2007-06-01,2007-12-01,6.6535519125683065,Adequate (1-10/month),66.53551912568307,Below (50-75%),100,53.2,56.665
NCT02406690,Endometrial Receptivity Profile in Patients With Endometrial Proliferation Defects,COMPLETED,,1.0,2015-07-31,2015-09-17,0.6341666666666667,Slow (<1/month),6.341666666666668,Significantly Below (<50%),100,43.4,27.265
NCT05635890,Effect of Vestibular Rehabilitation on Trunk Kinetic and Kinematic Parameters in Patients With Multiple Sclerosis,COMPLETED,NA,30.0,2022-05-06,2022-09-20,6.665693430656934,Adequate (1-10/month),66.65693430656934,Below (50-75%),100,52.4,53.949999999999996
NCT05737290,Effects of Clear Aligners Versus Fixed Appliances on Occlusion After Treatment of Mild Anterior Crowding,UNKNOWN,NA,16.0,2023-12-01,2024-06-01,2.6614207650273225,Adequate (1-10/month),26.614207650273226,Significantly Below (<50%),50,36.3,17.0
NCT04646590,A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19,UNKNOWN,PHASE3,28904.0,2020-12-16,2022-12-01,1230.5423216783217,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT03889990,Acute Effects of a Heat-not-burn Tobacco Product on Pulmonary Function,COMPLETED,NA,40.0,2018-01-01,2019-01-01,3.3358904109589043,Adequate (1-10/month),33.35890410958904,Significantly Below (<50%),100,53.2,56.665
NCT02792790,Carpal Tunnel Syndrome and Amyloid Cardiomyopathy,COMPLETED,,96.0,2016-03-01,2021-12-02,1.3902188392007613,Adequate (1-10/month),13.902188392007611,Significantly Below (<50%),100,51.0,49.714999999999996
NCT01464190,"A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients",COMPLETED,PHASE3,659.0,2011-09-01,2013-04-01,34.70581314878893,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT04710290,A Cohort Study of Beta-Glucan or Beta-Glucan Compound in Metastatic Cancers,UNKNOWN,PHASE2,90.0,2018-01-04,2021-12-31,1.880301990391215,Adequate (1-10/month),18.803019903912148,Significantly Below (<50%),50,42.2,25.155
NCT05713890,Home-based Action Observation Treatment With Virtual-reality for Arm Rehabilitation in People With Multiple Sclerosis,RECRUITING,NA,60.0,2023-11-02,2026-12-01,1.6234666666666666,Adequate (1-10/month),16.234666666666666,Significantly Below (<50%),60,37.8,19.015
NCT05551390,Effect of One-time Versus Three-times of Umbilical Cord Milking on Neonatal Hemoglobin in Late Preterm,COMPLETED,NA,162.0,2022-05-01,2022-09-01,40.09170731707317,Good (10-50/month),200.0,Exceeded (≥100%),100,68.0,80.56
NCT02878590,Clinical Study for the BONGO Device in the Treatment of Obstructive Sleep Apnea (OSA),COMPLETED,NA,23.0,2016-09-01,2017-11-30,1.5387252747252746,Adequate (1-10/month),15.38725274725275,Significantly Below (<50%),100,46.8,38.440000000000005
NCT06093490,Detecting Absence Seizures Using Hyperventilation and Eye Movement Recordings,COMPLETED,,65.0,2023-12-01,2025-07-30,3.2596375617792424,Adequate (1-10/month),32.596375617792425,Significantly Below (<50%),100,53.5,57.555
NCT03081390,Migraine and CVD Risk in Women,ACTIVE_NOT_RECRUITING,NA,30.0,2017-04-01,2026-06-30,0.2704175303523838,Slow (<1/month),2.704175303523838,Significantly Below (<50%),85,42.9,26.145000000000003
NCT01193790,Evaluation of Coblation Channeling in Treating Chronic Tonsillitis,UNKNOWN,PHASE2,60.0,2011-01-01,,,Slow (<1/month),,Significantly Below (<50%),50,29.8,8.98
NCT05797090,Comparative Study Between Conventional Crystalloid Cardioplegic Solution With Modified Del Nido Cardioplegia,COMPLETED,NA,80.0,2022-07-01,2023-03-15,9.475486381322957,Adequate (1-10/month),94.75486381322959,Met (75-100%),100,61.4,73.735
NCT03675490,ABLE (Arts-Based Exercise Enhancing LongEvity),UNKNOWN,NA,25.0,2018-10-01,2020-01-01,1.6652078774617067,Adequate (1-10/month),16.652078774617067,Significantly Below (<50%),50,32.0,11.425
NCT07038590,Use of Immersive Virtual Reality and Therapeutic Exercise as Complementary Therapy in Mild to Moderate Parkinson's Disease (InViPark),COMPLETED,NA,100.0,2024-09-05,2024-12-15,30.13861386138614,Good (10-50/month),200.0,Exceeded (≥100%),100,63.0,75.845
NCT04103190,Multiparametric Imaging for Analysis of MVNT (Multinodular and Vacuolating Neuronal Tumor),COMPLETED,,71.0,2019-12-10,2025-07-10,1.0599509563511527,Adequate (1-10/month),10.599509563511525,Significantly Below (<50%),100,49.0,45.61
NCT04198090,Sexual & Gender Minority Competency in Oncology,COMPLETED,NA,62.0,2020-02-17,2021-12-31,2.763221083455344,Adequate (1-10/month),27.632210834553444,Significantly Below (<50%),100,55.0,61.834999999999994
NCT05300490,Prednisolone Urinary Excretion Kinetics,WITHDRAWN,,0.0,2023-05-01,2024-01-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT02882490,Parent Behavioral Training for Disruptive Behaviors in Tourette Syndrome,UNKNOWN,NA,42.0,2014-06-01,2017-06-01,1.1664963503649635,Adequate (1-10/month),11.664963503649634,Significantly Below (<50%),50,33.4,13.29
NCT06837090,Retrospective Analysis of the Experience With Larotrectinib in Patients With Solid Neoplasms With NTRK Fusion in Spain (SPAINTRK),RECRUITING,,19.0,2025-02-11,2026-01-01,1.7850617283950618,Adequate (1-10/month),17.85061728395062,Significantly Below (<50%),60,37.9,19.139999999999997
NCT00581490,Biochemical and Radiological Indicators of Cardiovascular Morbidity in Children With Premature Pubarche,COMPLETED,,52.0,2003-08-01,2011-06-01,0.5532610975183503,Slow (<1/month),5.532610975183502,Significantly Below (<50%),100,47.5,41.415
NCT05044390,Lung Transplantation for Pleuroparenchymal Fibroelastosis,UNKNOWN,,30.0,2021-04-01,2021-11-01,4.267289719626168,Adequate (1-10/month),42.67289719626169,Significantly Below (<50%),50,35.7,16.18
NCT01081990,Use of Cyclobenzaprine After Vaginal Surgery,COMPLETED,NA,63.0,2010-04-01,2014-08-01,1.2114466203411245,Adequate (1-10/month),12.114466203411244,Significantly Below (<50%),100,50.0,47.675
NCT03372590,NEO Rehab for Infants at Risk of Cerebral Palsy,COMPLETED,NA,14.0,2018-09-02,2019-06-30,1.4158139534883722,Adequate (1-10/month),14.158139534883722,Significantly Below (<50%),100,46.1,34.695
NCT04428190,Prebiotic Therapy to Improve Outcomes of Renal Transplant,UNKNOWN,EARLY_PHASE1,60.0,2022-02-23,2024-12-15,1.7801169590643278,Adequate (1-10/month),17.80116959064328,Significantly Below (<50%),50,39.8,21.47
NCT01761890,Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib,UNKNOWN,,147.0,2014-01-28,2022-12-01,1.3857788789098793,Adequate (1-10/month),13.857788789098793,Significantly Below (<50%),50,40.1,22.05
NCT04229797,Mandibular First Molar Distalization,NOT_YET_RECRUITING,NA,20.0,2024-12-01,2025-03-01,6.764444444444445,Adequate (1-10/month),67.64444444444445,Below (50-75%),30,30.6,9.475
NCT02691897,Melatonin's Effects on Treatment Of Diabetes Mellitus,UNKNOWN,EARLY_PHASE1,60.0,2019-07-01,2020-07-01,4.99016393442623,Adequate (1-10/month),49.90163934426229,Significantly Below (<50%),50,39.8,21.47
NCT00793897,Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors,COMPLETED,PHASE1,21.0,2009-04-01,2012-06-01,0.5524978392394122,Slow (<1/month),5.5249783923941225,Significantly Below (<50%),100,46.7,37.895
NCT07315997,The Coronary Artery Calcium and Troponins in Rheumatoid Arthritis (CAT-RA) Study,RECRUITING,,120.0,2024-09-04,2028-03-04,2.860454189506656,Adequate (1-10/month),28.604541895066564,Significantly Below (<50%),60,45.9,33.495000000000005
NCT02580097,MR-based Stroke Mechanism and Future Risk Score,COMPLETED,,961.0,2015-08-01,2021-03-31,14.138637022716287,Good (10-50/month),141.3863702271629,Exceeded (≥100%),100,93.3,94.325
NCT05658497,Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate),RECRUITING,,908.0,2023-10-27,2032-07-06,8.70536062992126,Adequate (1-10/month),87.0536062992126,Met (75-100%),60,81.3,88.58
NCT01698697,Comparison of Two Insulin Aspart Formulations in Healthy Volunteers,COMPLETED,PHASE1,24.0,2002-09-02,2002-10-18,15.881739130434783,Good (10-50/month),158.81739130434784,Exceeded (≥100%),100,56.9,65.89500000000001
NCT05070897,Health Literacy and Digital Health in Cancer Patients.,COMPLETED,,1518.0,2021-09-27,2021-12-16,577.599,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT04570397,Ravulizumab and COVID-19,UNKNOWN,PHASE3,32.0,2020-12-18,2023-11-01,0.9294656488549619,Slow (<1/month),9.294656488549618,Significantly Below (<50%),50,32.6,12.31
NCT01703897,Esophageal Manometry and Impedance Study in Obese Patients Before and During Anesthesia,WITHDRAWN,,0.0,2012-10-01,,,Slow (<1/month),0.0,Significantly Below (<50%),5,8.2,0.03
NCT06125197,Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE1,22.0,2024-07-23,2026-05-30,0.9906508875739645,Slow (<1/month),9.906508875739645,Significantly Below (<50%),85,42.3,25.295
NCT04812197,Microbial Diversity Between Inflamed and Non-inflamed Skin of Patients With Immune Checkpoint Inhibitor-Induced Dermatitis,COMPLETED,NA,2.0,2021-03-08,2021-10-08,0.28448598130841124,Slow (<1/month),2.844859813084112,Significantly Below (<50%),100,45.2,30.830000000000002
NCT06199297,Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma,COMPLETED,,188.0,2021-03-02,2023-07-25,6.5402514285714295,Adequate (1-10/month),65.4025142857143,Below (50-75%),100,63.4,76.375
NCT07137897,Telerehabilitation for Knee Osteoarthritis: Study Protocol,COMPLETED,NA,118.0,2024-06-27,2025-11-10,7.1695009980039925,Adequate (1-10/month),71.69500998003993,Below (50-75%),100,59.4,70.905
NCT01242397,Mitral Insufficiency Reduction With Biventricular Pacing,UNKNOWN,PHASE1,50.0,2011-01-01,2013-01-01,2.0820793433652534,Adequate (1-10/month),20.820793433652533,Significantly Below (<50%),50,39.0,20.505000000000003
NCT03998397,Self-estimates and Objective Blood Alcohol Concentration in Emergency Department,COMPLETED,NA,34.0,2019-06-18,2020-06-18,2.82775956284153,Adequate (1-10/month),28.2775956284153,Significantly Below (<50%),100,52.7,55.04
NCT01425697,Eliminate Risk of Cardiac Surgical Site Events,COMPLETED,NA,739.0,2008-11-01,2012-09-01,16.06797142857143,Good (10-50/month),160.67971428571428,Exceeded (≥100%),100,95.0,95.7
NCT00878397,Impact of School-based Delivery of Long Lasting Insecticide Nets,COMPLETED,NA,5113.0,2009-05-01,2010-11-01,283.49675774134795,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT00441597,Does Atorvastatin Reduce Ischemia-Reperfusion Injury in Humans in-Vivo?,COMPLETED,PHASE4,30.0,2007-02-01,2009-03-01,1.2031620553359685,Adequate (1-10/month),12.031620553359684,Significantly Below (<50%),100,47.4,40.98
NCT03417297,A Pilot Study: Focused Ultrasound Thalamotomy for the Prevention of Secondary Generalization in Focal Onset Epilepsy,ACTIVE_NOT_RECRUITING,NA,10.0,2018-04-24,2028-05-01,0.08316939890710383,Slow (<1/month),0.8316939890710383,Significantly Below (<50%),85,41.3,23.74
NCT05131997,A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A,COMPLETED,PHASE3,290.0,2021-11-16,2022-06-08,43.272549019607844,Good (10-50/month),200.0,Exceeded (≥100%),100,83.2,89.815
NCT01932697,Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer,COMPLETED,PHASE2,81.0,2013-09-04,2021-12-28,0.8118669739874878,Slow (<1/month),8.118669739874877,Significantly Below (<50%),100,51.5,51.245
NCT04688697,Prepectoral and Subpectoral Implant-based Breast Reconstruction,ACTIVE_NOT_RECRUITING,NA,300.0,2021-05-12,2025-12-31,5.3907910271546635,Adequate (1-10/month),53.90791027154664,Below (50-75%),85,69.5,81.62
NCT02045797,Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections,COMPLETED,PHASE2,126.0,2014-03-24,2015-06-29,8.301818181818183,Adequate (1-10/month),83.01818181818183,Met (75-100%),100,60.1,72.085
NCT06142110,The Relationship Between Functional Movement and Respiratory Muscle Strength,COMPLETED,NA,45.0,2023-01-01,2023-03-30,15.565909090909091,Good (10-50/month),155.6590909090909,Exceeded (≥100%),100,58.6,69.51
NCT00218010,Methadone Levels in Breast Milk of Women Taking Methadone for Opiate Addiction - 2,COMPLETED,,25.0,2000-11-01,2005-09-01,0.4311614730878187,Slow (<1/month),4.311614730878187,Significantly Below (<50%),100,45.3,31.169999999999998
NCT05951010,Cerebellar Transcranial Direct Current Stimulation in Spinocerebellar Ataxia 38,COMPLETED,NA,7.0,2022-11-01,2023-06-01,1.0050943396226415,Adequate (1-10/month),10.050943396226415,Significantly Below (<50%),100,45.6,32.08
NCT04128410,A Study on Central Transport Characteristics of Flurbiprofen Axetil in Elderly Patients,UNKNOWN,,77.0,2019-10-01,2019-10-01,77.0,Excellent (>50/month),200.0,Exceeded (≥100%),50,29.5,8.86
NCT00695110,Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men,COMPLETED,PHASE2,29.0,2008-06-01,2009-08-01,2.0722065727699532,Adequate (1-10/month),20.722065727699533,Significantly Below (<50%),100,52.3,53.515
NCT04935710,Prevention and Early Identification for High Risk Youth in School-based Clinics,COMPLETED,PHASE1,219.0,2022-01-03,2024-03-31,8.14958435207824,Adequate (1-10/month),81.4958435207824,Met (75-100%),100,67.5,80.08
NCT01546610,Rheumatoid Foot Insole,UNKNOWN,NA,80.0,2011-11-01,2012-11-01,6.6535519125683065,Adequate (1-10/month),66.53551912568307,Below (50-75%),50,41.4,24.04
NCT02473510,Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season,COMPLETED,PHASE4,301.0,2015-06-01,2016-01-01,42.81514018691589,Good (10-50/month),200.0,Exceeded (≥100%),100,84.1,90.64999999999999
NCT03364010,"Dyslexia, Motor Control and Proprioception",TERMINATED,NA,56.0,2018-01-04,2021-06-02,1.3691887550200803,Adequate (1-10/month),13.691887550200802,Significantly Below (<50%),10,22.5,6.305
NCT06339710,Short Benznidazole Regimen for Chronic Phase Chagas Disease Patients,WITHDRAWN,PHASE3,0.0,2025-01-30,2026-10-30,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT03331510,Prospective Strength Measurement Involving Muscles Altered In Arthroscopic Latarjet,UNKNOWN,,50.0,2018-02-01,2022-12-01,0.86281179138322,Slow (<1/month),8.6281179138322,Significantly Below (<50%),50,32.3,11.799999999999999
NCT03728010,Electrical Impedance Tomography in One-Lung Ventilation,UNKNOWN,,20.0,2018-12-07,2024-01-01,0.32890329551593733,Slow (<1/month),3.289032955159374,Significantly Below (<50%),50,29.9,9.07
NCT02751710,Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer,COMPLETED,NA,369.0,2016-12-06,2023-03-31,4.870928013876843,Adequate (1-10/month),48.70928013876843,Significantly Below (<50%),100,79.5,87.195
NCT04931810,Urban and Reservation Implementation of All Nations Breath of Life,RECRUITING,NA,576.0,2021-04-08,2027-02-28,8.147509293680297,Adequate (1-10/month),81.47509293680298,Met (75-100%),60,78.0,86.075
NCT07240610,Abscopal Effect of Ultra-Hypofractionated Radiation Plus Immunotherapy in Metastatic Renal Cell Carcinoma,RECRUITING,,145.0,2025-11-10,2029-09-30,3.10830985915493,Adequate (1-10/month),31.0830985915493,Significantly Below (<50%),60,47.9,42.64
NCT04381910,Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer,COMPLETED,PHASE2,66.0,2020-09-28,2023-03-04,2.2649830890642617,Adequate (1-10/month),22.649830890642615,Significantly Below (<50%),100,55.3,62.36000000000001
NCT02135510,"MEtoclopramide, DExamethasone or Axoli to Prevent or Delay Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy",COMPLETED,PHASE3,249.0,2013-06-01,2019-03-01,3.611033825631253,Adequate (1-10/month),36.11033825631254,Significantly Below (<50%),100,69.9,81.83
NCT02169310,Neural Basis of Decision-Making Deficits in Traumatic Brain Injury,COMPLETED,PHASE1,45.0,2014-11-18,2024-02-13,0.4059869590989923,Slow (<1/month),4.059869590989923,Significantly Below (<50%),100,48.6,44.685
NCT02971410,Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma,WITHDRAWN,EARLY_PHASE1,0.0,2017-04-01,2021-11-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT01367210,Switch to Darunavir/r + Maraviroc Quaque Die in Patients With R5 Tropism by Viral DNA Genotyping (GUSTA),TERMINATED,PHASE4,165.0,2011-06-01,2015-06-01,3.437782340862423,Adequate (1-10/month),34.37782340862423,Significantly Below (<50%),10,36.2,16.84
NCT01027910,PCI-24781 in Combination With Doxorubicin to Treat Sarcoma,COMPLETED,PHASE1,20.0,2009-02-01,2015-03-01,0.2743578188373141,Slow (<1/month),2.743578188373141,Significantly Below (<50%),100,46.6,37.375
NCT00267410,"Adopting and Demonstrating the Adaptation of Prevention Techniques (ADAPT), Harlem United Community AIDS Center",COMPLETED,NA,33.0,2005-11-01,2009-06-01,0.7679816513761468,Slow (<1/month),7.679816513761469,Significantly Below (<50%),100,47.6,41.775
NCT04524910,A Study to Learn More About How Drug Aflibercept Works in Canadian Patients With Reduced Vision Caused by New Blood Vessels Growing in the Eye (Myopic Choroidal Neovascularization or mCNV),COMPLETED,,28.0,2021-06-16,2022-11-11,1.661442495126706,Adequate (1-10/month),16.61442495126706,Significantly Below (<50%),100,45.6,32.08
NCT07321210,Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma (T-LND UTUC): A Randomized Clinical Trial,RECRUITING,NA,150.0,2026-01-01,2032-08-30,1.8766954377311962,Adequate (1-10/month),18.76695437731196,Significantly Below (<50%),60,50.0,47.675
NCT03740113,"Kids SipSmartER, an Intervention to Reduce Sugar-sweetened Beverages",COMPLETED,NA,1013.0,2018-08-15,2024-06-07,14.524597268016956,Good (10-50/month),145.2459726801696,Exceeded (≥100%),100,95.0,95.7
NCT02024113,LC-NMR Study Biomarkers to Detect Lung Cancer,COMPLETED,,646.0,2013-02-01,2015-01-01,28.131959942775396,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT01849913,Laser Therapy on Neck Pain in Adolescents,UNKNOWN,NA,75.0,2013-02-01,2014-01-01,6.835329341317365,Adequate (1-10/month),68.35329341317366,Below (50-75%),50,41.0,23.01
NCT04521413,Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies,ACTIVE_NOT_RECRUITING,PHASE1,170.0,2020-08-31,2025-12-01,2.6980187695516165,Adequate (1-10/month),26.98018769551616,Significantly Below (<50%),85,59.1,70.6
NCT00890513,Family Satisfaction in the Intensive Care Unit - a Multicentre Assessment,COMPLETED,,1200.0,2007-04-01,2007-12-01,149.70491803278688,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT05245513,Enhancing Recovery Capital Amid Opioid Use Disorder Pharmacotherapy: A Pilot Randomized Trial,NOT_YET_RECRUITING,NA,145.0,2025-12-01,2027-02-28,9.722026431718062,Adequate (1-10/month),97.22026431718062,Met (75-100%),30,45.6,32.08
NCT04121013,PREhospital Routage of Acute STroke Patients With Suspected Large Vessel Occlusion: Mothership Versus Drip and Ship,UNKNOWN,NA,800.0,2021-01-30,2022-01-01,72.47619047619048,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT00146913,AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year,UNKNOWN,PHASE2,30.0,2004-03-01,,,Slow (<1/month),,Significantly Below (<50%),50,27.4,8.225
NCT00057213,An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder,COMPLETED,PHASE2,367.0,2003-03-01,2007-04-01,7.487587131367293,Adequate (1-10/month),74.87587131367293,Below (50-75%),100,79.4,87.155
NCT06939413,Diabetes Management Using Continuous Glucose Monitors and Remote Patient Monitoring in Underserved Populations,RECRUITING,NA,40.0,2025-03-18,2026-10-01,2.1665480427046266,Adequate (1-10/month),21.665480427046262,Significantly Below (<50%),60,41.2,23.425
NCT05042713,The Effect of Using Different Single File Systems With Coronal Flaring Instruments on Postoperative Pain,UNKNOWN,NA,80.0,2021-09-01,2022-07-01,8.036963696369638,Adequate (1-10/month),80.36963696369638,Met (75-100%),50,41.4,24.04
NCT04582513,Impact of an Anesthesia Care Handover-Checklist on Adverse Perioperative Outcome,UNKNOWN,,300.0,2020-10-29,2021-11-01,24.815217391304348,Good (10-50/month),200.0,Exceeded (≥100%),50,62.3,74.94
NCT01853813,"First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer",COMPLETED,PHASE2,85.0,2013-05-01,2015-07-01,3.2710493046776237,Adequate (1-10/month),32.710493046776236,Significantly Below (<50%),100,56.8,65.69500000000001
NCT02867813,Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension,COMPLETED,PHASE3,5035.0,2016-09-02,2022-03-21,75.6492596248766,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT06467513,To Investigate the Effect of Esketamine Hydrochloride on Pulmonary Complications,RECRUITING,PHASE4,102.0,2024-01-01,2025-05-01,6.3886419753086425,Adequate (1-10/month),63.88641975308643,Below (50-75%),60,46.2,35.089999999999996
NCT04219813,Urinary Gluten Immunogenic Peptides Detection in Non-celiac Gluten/Wheat Sensitivity,RECRUITING,NA,40.0,2021-01-01,2026-12-31,0.5559817351598174,Slow (<1/month),5.559817351598174,Significantly Below (<50%),60,36.2,16.84
NCT02558413,Phase 1 Safety and Pharmacokinetics Study of Single Ascending Doses of BTA-C585 in Healthy Volunteers,COMPLETED,PHASE1,60.0,2015-08-01,2015-12-01,14.970491803278687,Good (10-50/month),149.70491803278688,Exceeded (≥100%),100,59.8,71.61
NCT06094413,Effects of Multicomponent Training in Older Adults,COMPLETED,NA,20.0,2024-03-04,2024-12-17,2.113888888888889,Adequate (1-10/month),21.13888888888889,Significantly Below (<50%),100,51.6,51.644999999999996
NCT04424160,Effects of Platelet Rich Plasma on Endometrium,COMPLETED,NA,150.0,2020-09-15,2021-04-19,21.13888888888889,Good (10-50/month),200.0,Exceeded (≥100%),100,67.0,79.725
NCT06761560,Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia,NOT_YET_RECRUITING,PHASE2,29.0,2025-01-15,2027-11-25,0.8455555555555556,Slow (<1/month),8.455555555555556,Significantly Below (<50%),30,26.3,7.8
NCT04316260,Smoking Cessation E-Visit,COMPLETED,NA,51.0,2019-05-01,2020-02-28,5.123564356435644,Adequate (1-10/month),51.23564356435644,Below (50-75%),100,54.1,59.11
NCT02025660,Efficacy of Mw Vaccine in Treatment of Severe Sepsis,COMPLETED,PHASE2,50.0,2013-08-01,2014-03-01,7.179245283018869,Adequate (1-10/month),71.79245283018868,Below (50-75%),100,54.0,58.72500000000001
NCT02641860,Clinical Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis,COMPLETED,PHASE1,22.0,2015-12-01,2018-03-01,0.8156881851400731,Slow (<1/month),8.156881851400732,Significantly Below (<50%),100,46.8,38.440000000000005
NCT04573660,Abbott Vascular Medical Device Registry,RECRUITING,,3784.0,2020-10-25,2031-11-01,28.624493041749503,Good (10-50/month),200.0,Exceeded (≥100%),60,81.3,88.58
NCT00477360,Humeral Resurfacing Hemiarthroplasty,UNKNOWN,NA,30.0,2007-01-01,2013-02-01,0.41079622132253707,Slow (<1/month),4.107962213225371,Significantly Below (<50%),50,32.4,12.025
NCT02848560,Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI,ACTIVE_NOT_RECRUITING,,38.0,2016-03-01,2025-10-31,0.32758991787029174,Slow (<1/month),3.2758991787029172,Significantly Below (<50%),85,41.9,24.585
NCT04829760,The Effect of Psyllium and Wheat Bran on Body Weight in People With Parkinson's Disease and Constipation Symptoms,COMPLETED,NA,35.0,2021-05-13,2024-04-28,0.9855689176688253,Slow (<1/month),9.855689176688252,Significantly Below (<50%),100,47.8,42.42
NCT03788460,Correlation Between PT and INR to Factor 7,UNKNOWN,,60.0,2019-01-07,2020-01-01,5.087465181058496,Adequate (1-10/month),50.87465181058496,Below (50-75%),50,38.1,19.425
NCT03052660,Impact of Preoperative Midazolam on Outcome of Elderly Patients,COMPLETED,PHASE4,782.0,2017-10-12,2019-06-24,38.39367741935484,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT02338960,2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder,COMPLETED,PHASE3,714.0,2015-01-01,2017-06-29,23.883692307692307,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT06838260,Assessment of Endotracheal Tube Temperature Effects in Children Undergoing Adenotonsillectomy,RECRUITING,NA,250.0,2025-03-02,2026-02-01,22.648809523809526,Good (10-50/month),200.0,Exceeded (≥100%),60,63.0,75.845
NCT03793660,Biologic National Registry,COMPLETED,,439.0,2018-05-23,2022-06-30,8.914716477651769,Adequate (1-10/month),89.14716477651768,Met (75-100%),100,88.5,92.81
NCT05598060,"Preoperative Stereotactic Body Radiotherapy (SBRT) Followed by Hepatectomy for Centrally Located Hepatocellular Carcinoma: a Prospective, Single-center, Phase I Study",UNKNOWN,NA,15.0,2022-11-01,2024-02-01,0.9991247264770241,Slow (<1/month),9.99124726477024,Significantly Below (<50%),50,31.2,10.165000000000001
NCT06487260,Mental Health and Symptoms of Energy Deficiency (REDs) in Young Biathletes,COMPLETED,,28.0,2024-08-21,2024-12-10,7.678558558558559,Adequate (1-10/month),76.7855855855856,Met (75-100%),100,50.6,48.705
NCT00002460,Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer,UNKNOWN,PHASE3,,1987-09-01,,,Slow (<1/month),,Significantly Below (<50%),50,25.0,7.23
NCT00775060,Maastricht IBS Cohort,UNKNOWN,,600.0,2009-09-01,2024-09-01,3.3334550100383282,Adequate (1-10/month),33.33455010038329,Significantly Below (<50%),50,73.3,83.61
NCT01946360,Role of 13C Methacetin Breath Test in Predicting Prognosis Among Patients With Acute or Acute on Chronic Liver Failure (ACLF).,COMPLETED,NA,24.0,2014-04-01,2015-01-01,2.6565818181818184,Adequate (1-10/month),26.565818181818184,Significantly Below (<50%),100,51.9,52.55499999999999
NCT02114060,Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine,COMPLETED,PHASE2,310.0,2014-07-01,2016-02-01,16.269655172413792,Good (10-50/month),162.69655172413792,Exceeded (≥100%),100,79.8,87.27000000000001
NCT05115760,Pea Protein Oral Nutrition Supplement for the Reduction of Gastrostomy Tube Placement Rate in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemoradiation Therapy,RECRUITING,NA,60.0,2022-04-05,2027-06-01,0.9699415825809878,Slow (<1/month),9.699415825809877,Significantly Below (<50%),60,37.8,19.015
NCT04327960,Risk Assessment Strategies in Pulmonary Embolism,UNKNOWN,,100.0,2021-09-01,2023-10-01,4.005263157894737,Adequate (1-10/month),40.05263157894737,Significantly Below (<50%),50,41.3,23.74
NCT05465460,Effect of Banana Blossom on Breast Milk Volume in Mothers of Preterm Newborns,COMPLETED,PHASE4,70.0,2022-07-13,2023-08-31,5.1468599033816425,Adequate (1-10/month),51.46859903381642,Below (50-75%),100,55.6,62.905
NCT03858660,Clinical Applications of a Smart Physical Examination System for the Health Management in Elderly,UNKNOWN,,600.0,2018-10-23,2019-09-18,55.345454545454544,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT04158960,Motor Skill Proficiency After Equine-assisted Activities and Brain-building Tasks,COMPLETED,NA,25.0,2015-02-01,2018-05-31,0.6263374485596709,Slow (<1/month),6.263374485596708,Significantly Below (<50%),100,47.0,39.33
NCT00369720,Use of Blended Oxygen for Delivery Room Resuscitation of Very Low Birth Weight Infants,COMPLETED,NA,40.0,2005-01-01,2008-06-01,0.9764234161988774,Slow (<1/month),9.764234161988774,Significantly Below (<50%),100,48.2,43.665
NCT01697020,Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions,COMPLETED,PHASE1,70.0,2012-09-01,2012-11-01,34.9311475409836,Good (10-50/month),200.0,Exceeded (≥100%),100,60.6,72.785
NCT04083820,"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)",COMPLETED,,521.0,2019-09-16,2021-09-27,21.373638814016175,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT00005420,Prediction of Quality of Life in Cardiovascular Disease,COMPLETED,,,1992-04-01,1995-03-01,,Slow (<1/month),,Significantly Below (<50%),100,43.3,27.05
NCT00374920,Safety and Efficacy of MEM 1003 Versus Placebo for the Treatment of Patients With Bipolar I Disorder,COMPLETED,PHASE2,60.0,2006-09-01,2007-03-01,10.09060773480663,Good (10-50/month),100.90607734806629,Exceeded (≥100%),100,59.8,71.61
NCT06375720,Efficacy of Different Doses of Tai Chi Chuan on Cognitive Function in Persons With Mild Cognitive Impairment,NOT_YET_RECRUITING,NA,350.0,2024-05-05,2025-12-15,18.08828522920204,Good (10-50/month),180.8828522920204,Exceeded (≥100%),30,62.0,74.42
NCT02855320,Efficiency of a Nurse-led Self-management Education Intervention in Promoting Safety Knowledge and Skills of Patients With Arthritis Treated Par Biologics,COMPLETED,NA,129.0,2017-01-27,2018-11-26,5.878383233532934,Adequate (1-10/month),58.783832335329336,Below (50-75%),100,60.3,72.34
NCT00655720,The Effects on Growth of a Non-Routine Infant Formula,COMPLETED,NA,293.0,2006-03-01,2007-05-01,20.93643192488263,Good (10-50/month),200.0,Exceeded (≥100%),100,78.4,86.75
NCT02023320,Effects of Blueberry Dry Powder on Glycemic Status in Subjects With Prediabetes,COMPLETED,NA,50.0,2013-11-01,2014-07-01,6.289256198347108,Adequate (1-10/month),62.89256198347108,Below (50-75%),100,54.0,58.72500000000001
NCT06790420,RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study,COMPLETED,,1.0,2025-01-31,2025-03-14,0.7247619047619048,Slow (<1/month),7.2476190476190485,Significantly Below (<50%),100,43.4,27.265
NCT02068820,Detection of SLN in Patients With Endometrial Cancer Undergoing Robotic Assisted Staging: Comparison of ISB and ICG,COMPLETED,NA,200.0,2012-09-01,2015-01-01,7.145539906103287,Adequate (1-10/month),71.45539906103286,Below (50-75%),100,66.0,78.99000000000001
NCT02076620,L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours,COMPLETED,PHASE1,29.0,2013-01-16,2018-01-25,0.48106811989100823,Slow (<1/month),4.810681198910082,Significantly Below (<50%),100,47.3,40.475
NCT05519020,Inhaled Therapy Adherence and Outcomes to Kaftrio in Cystic Fibrosis,COMPLETED,,1385.0,2022-07-27,2024-10-31,50.978718258766634,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT01667120,The Use of Ketorolac in Surgical Neonates,WITHDRAWN,PHASE2,0.0,2012-07-01,2018-12-31,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT01321320,Investigation of the Role of FHL-1 and Myostatin in Intensive Care Unit Acquired Paresis (ICUAP),COMPLETED,NA,13.0,2011-04-01,2013-10-01,0.4329540481400438,Slow (<1/month),4.329540481400438,Significantly Below (<50%),100,46.0,34.1
NCT04813120,Digital Mirror Therapy With Uni- and Bilateral Mirror Visual Feedback After Stroke: Treatment Effects and EEG Evidence,COMPLETED,NA,47.0,2021-08-01,2024-07-31,1.3065570776255708,Adequate (1-10/month),13.065570776255708,Significantly Below (<50%),100,48.8,45.184999999999995
NCT03868020,Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease,COMPLETED,EARLY_PHASE1,16.0,2019-04-24,2024-03-22,0.2714827201783724,Slow (<1/month),2.7148272017837236,Significantly Below (<50%),100,46.3,35.66
NCT01313520,A Study to Evaluate the Effectiveness of Infliximab and Changes in Hand and Wrist Magnetic Resonance Imaging (MRI) in Participants With Active Rheumatoid Arthritis (RA) (P08136),COMPLETED,PHASE2,61.0,2011-03-01,2012-03-01,5.073333333333333,Adequate (1-10/month),50.73333333333333,Below (50-75%),100,54.9,61.55500000000001
NCT06899620,BC179 Relieves Discomfort After Drinking,COMPLETED,NA,60.0,2024-07-01,2025-07-20,4.7562500000000005,Adequate (1-10/month),47.5625,Significantly Below (<50%),100,54.8,61.095
NCT04989920,Brain and Behavior Correlates of Arm Rehabilitation,COMPLETED,NA,23.0,2003-04-28,2011-07-15,0.23337333333333335,Slow (<1/month),2.3337333333333334,Significantly Below (<50%),100,46.8,38.440000000000005
NCT05547620,Modulating Cerebellar Activity With Low-intensity Focused Ultrasound Stimulation for Primary Orthostatic Tremor,ACTIVE_NOT_RECRUITING,NA,15.0,2021-03-08,2026-09-01,0.22795806290564155,Slow (<1/month),2.2795806290564156,Significantly Below (<50%),85,41.7,24.36
NCT05420220,Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer,RECRUITING,PHASE2,54.0,2022-07-15,2027-12-26,0.8260100502512563,Slow (<1/month),8.260100502512563,Significantly Below (<50%),60,37.3,18.35
NCT00755820,Food Exposure Therapy in Anorexia Nervosa,COMPLETED,,32.0,2008-01-01,2012-01-01,0.6667214236824093,Slow (<1/month),6.667214236824092,Significantly Below (<50%),100,45.9,33.495000000000005
NCT06951620,Optimizing Aerobic Fitness in Older Adults,RECRUITING,NA,114.0,2025-04-17,2029-06-30,2.260690553745928,Adequate (1-10/month),22.606905537459284,Significantly Below (<50%),60,47.1,39.64
NCT06118320,The Effective of Potassium Sodium Hydrogen Citrate in Treating Uric Acid Stones Using Gut Microbiota and Metabolomics.,UNKNOWN,,30.0,2022-03-01,2024-06-30,1.071830985915493,Adequate (1-10/month),10.71830985915493,Significantly Below (<50%),50,30.7,9.585
NCT05667220,Sitagliptin in Combination With Beidougen Capsule for Type 2 Diabetes,UNKNOWN,PHASE4,20.0,2022-12-01,2023-12-31,1.5412658227848104,Adequate (1-10/month),15.412658227848103,Significantly Below (<50%),50,31.6,10.905
NCT02479620,Lower-Limb Adventitial Infusion of DexaMethasone Via Bullfrog to Reduce Occurrence of Restenosis After Atherectomy (ATX)-Based Revascularization,UNKNOWN,PHASE2,120.0,2016-06-01,2020-03-01,2.6682249817384953,Adequate (1-10/month),26.682249817384957,Significantly Below (<50%),50,44.6,29.42
NCT02925520,Expanded Access Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Liver Injury in Children,NO_LONGER_AVAILABLE,,,,,,Slow (<1/month),,Significantly Below (<50%),50,23.3,6.569999999999999
NCT02293720,"An Open-Label Extension to Protocol 09-1, Efficacy and Safety Study of the EndoBarrier® Gastrointestinal Liner System",WITHDRAWN,NA,0.0,2015-04-01,2016-07-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT02604420,Identification and Treatment of Thrombotic Microangiopathies in Allogeneic Stem Cell Transplants,COMPLETED,,200.0,2014-09-01,2018-03-28,4.668711656441718,Adequate (1-10/month),46.68711656441718,Significantly Below (<50%),100,64.3,77.265
NCT02349620,Effect of Platelet-rich Factor on Implant Stability and Bone Resorption in the Lower Posterior Mandible,UNKNOWN,PHASE2,30.0,2014-09-01,2015-10-01,2.3118987341772153,Adequate (1-10/month),23.11898734177215,Significantly Below (<50%),50,37.4,18.62
NCT05476120,The Effect of the Use of BATHE Interview Technique on Treatment Compliance in Hypertension Patients in Primary Care,COMPLETED,NA,2.0,2020-10-01,2021-04-30,0.2885308056872038,Slow (<1/month),2.8853080568720384,Significantly Below (<50%),100,45.2,30.830000000000002
NCT02343120,Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies,COMPLETED,PHASE1,385.0,2014-09-04,2021-03-31,4.883083333333333,Adequate (1-10/month),48.83083333333333,Significantly Below (<50%),100,80.8,88.215
NCT02536482,Free Amino Acid-based Formula to Treat Children Cow's Milk Protein Allergy,COMPLETED,PHASE2,15.0,2013-08-01,2015-06-01,0.6825112107623318,Slow (<1/month),6.825112107623318,Significantly Below (<50%),100,46.2,35.089999999999996
NCT05133882,A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML,RECRUITING,PHASE1,133.0,2022-10-31,2026-08-15,2.9252312138728325,Adequate (1-10/month),29.252312138728325,Significantly Below (<50%),60,48.6,44.685
NCT06188182,D-index as a Predictor of Complication of Treatment of Patients With Acute Myeloid Leukemia,NOT_YET_RECRUITING,,60.0,2024-06-01,2026-06-01,2.5019178082191784,Adequate (1-10/month),25.019178082191786,Significantly Below (<50%),30,32.1,11.5
NCT00854282,The Role of Regulatory T Cell in Ovarian Cancer: Focus on Relationship Between Clinical Prognosis and Regulatory T Cell Expression,UNKNOWN,NA,50.0,2009-01-01,2012-12-01,1.0643356643356645,Adequate (1-10/month),10.643356643356643,Significantly Below (<50%),50,34.0,14.02
NCT05504382,Effect of Electroacupuncture on Refractory Pain in Juvenile Rheumatoid Arthritis: Randomized Controlled Trial,UNKNOWN,NA,42.0,2022-08-01,2023-05-01,4.683076923076923,Adequate (1-10/month),46.830769230769235,Significantly Below (<50%),50,38.4,19.835
NCT04598282,Evaluating Adjunctive Cryopreserved Amniotic Membrane Treatment in Herpes Simplex Dendritic Keratitis,WITHDRAWN,NA,0.0,2021-01-21,2022-07-28,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT04723082,Impacts of Sugar-Sweetened Beverage on Body Weight,COMPLETED,,128.0,2021-09-10,2022-07-22,12.369269841269842,Good (10-50/month),123.69269841269843,Exceeded (≥100%),100,63.6,76.545
NCT06738082,Influenza Vaccine Elicited Immune Response in Immunocompromised Patients,COMPLETED,,147.0,2024-10-15,2025-01-31,41.43222222222222,Good (10-50/month),200.0,Exceeded (≥100%),100,65.1,78.14
NCT06917482,A Study to Assess the Safety and Effects of the Investigational Drug BW-40202 in Healthy Volunteers,RECRUITING,PHASE1,40.0,2025-06-30,2026-12-31,2.217850637522769,Adequate (1-10/month),22.178506375227688,Significantly Below (<50%),60,41.2,23.425
NCT06715982,"JAK Inhibitors for Solid Malignant Tumor Patients With Immune Checkpoint Inhibitors-related Dermatitis: A Open-lable, Single Arm, Phase IIa Trial",RECRUITING,PHASE2,35.0,2024-12-31,2025-12-01,3.180298507462687,Adequate (1-10/month),31.802985074626868,Significantly Below (<50%),60,40.8,22.745
NCT04321382,Subjective Perception of Ocular Prosthesis Wear,COMPLETED,,100.0,2019-01-01,2020-02-01,7.686868686868687,Adequate (1-10/month),76.86868686868688,Met (75-100%),100,56.3,64.5
NCT00550082,3 Screen Electronic Alert,COMPLETED,,880.0,2007-07-01,2009-11-01,31.366744730679155,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT04130282,VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M Vaccine,TERMINATED,PHASE1,1.0,2019-09-27,2020-09-22,0.08432132963988921,Slow (<1/month),0.843213296398892,Significantly Below (<50%),10,18.1,3.105
NCT02159482,Pilot Study of Interferon Alfa for Patients Who Have Received Cancer Vaccines,TERMINATED,PHASE2,11.0,2005-11-01,2008-05-01,0.36714912280701756,Slow (<1/month),3.6714912280701757,Significantly Below (<50%),10,18.9,4.6899999999999995
NCT00873782,Safety Study of Transvenous Limb Perfusion in Human Muscular Dystrophy,COMPLETED,PHASE1,16.0,2009-03-01,2014-02-01,0.2708787541713015,Slow (<1/month),2.708787541713015,Significantly Below (<50%),100,46.3,35.66
NCT03044782,Barriers to Care and QOL for CCCA Patients,COMPLETED,,34.0,2016-08-01,2017-09-01,2.6135353535353536,Adequate (1-10/month),26.135353535353534,Significantly Below (<50%),100,51.1,50.129999999999995
NCT00431782,Study of a New Anticoagulant Drug in Patients With Atrial Fibrillation,COMPLETED,PHASE2,60.0,2006-12-01,2007-10-01,6.007894736842105,Adequate (1-10/month),60.078947368421055,Below (50-75%),100,54.8,61.095
NCT02540382,Comparison of Covered and Bare Stent in TIPS,COMPLETED,NA,258.0,2006-01-01,2014-12-01,2.4120147420147418,Adequate (1-10/month),24.12014742014742,Significantly Below (<50%),100,70.6,82.22500000000001
NCT06197282,Impact of COVID-19 on Surgical Outcomes,COMPLETED,,7696.0,2020-05-05,2022-12-01,249.21940425531918,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT00189982,Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101,COMPLETED,PHASE2,4.0,2004-12-17,2006-11-10,0.1756998556998557,Slow (<1/month),1.756998556998557,Significantly Below (<50%),100,45.3,31.169999999999998
NCT00387582,Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema,COMPLETED,PHASE2,49.0,2006-07-01,2009-02-01,1.5767019027484144,Adequate (1-10/month),15.767019027484144,Significantly Below (<50%),100,48.9,45.4
NCT01410682,Oral Care and Gram-negative Pathogen in Children,COMPLETED,NA,74.0,2005-06-01,2007-06-01,3.0856986301369864,Adequate (1-10/month),30.856986301369865,Significantly Below (<50%),100,55.9,63.42
NCT06141824,Performance Evaluation of the Lucira COVID-19 & Flu Test,COMPLETED,NA,1361.0,2022-10-11,2023-02-16,323.6628125,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT06586424,The Prognostic Value of Anion Gap in Predicting Major Adverse Cardiovascular Events Among Patients With ST-Segment Elevation Myocardial Infarction,RECRUITING,,80.0,2024-01-01,2024-10-05,8.759712230215827,Adequate (1-10/month),87.59712230215828,Met (75-100%),60,47.7,42.17
NCT04758624,Elucidating the Temporality of Structural and Functional Connectivity Changes in Essential Tremor After Successful Deep Brain Stimulation to the Dentato-rubro-thalamic Tract,RECRUITING,NA,72.0,2021-12-04,2026-08-31,1.2661351819757367,Adequate (1-10/month),12.661351819757366,Significantly Below (<50%),60,38.8,20.244999999999997
NCT05551624,Evaluation of the Effect in Platelet Count of Atorvastatin and N-acetyl Cysteine,COMPLETED,EARLY_PHASE1,15.0,2018-07-04,2020-01-23,0.8038732394366197,Slow (<1/month),8.038732394366196,Significantly Below (<50%),100,46.2,35.089999999999996
NCT04544124,Delivering Contingency Management in Outpatient Addiction Treatment,COMPLETED,NA,88.0,2021-01-25,2023-12-08,2.55847182425979,Adequate (1-10/month),25.584718242597898,Significantly Below (<50%),100,57.0,66.12
NCT02065024,Food Matrix and Genetic Variability as Determinants of Bioavailability and Biological Effects of Beta-cryptoxanthin and Phytosterols,COMPLETED,PHASE1,40.0,2014-03-01,2015-08-01,2.3505791505791507,Adequate (1-10/month),23.50579150579151,Significantly Below (<50%),100,53.2,56.665
NCT01629524,Influence of Tumor Associated Immunity on the Number of Lymph Node Retrieved After Colorectal Cancer Surgery (Preliminary Study),COMPLETED,,25.0,2012-06-01,2012-12-01,4.158469945355192,Adequate (1-10/month),41.58469945355191,Significantly Below (<50%),100,50.3,48.215
NCT05924724,Treatment Satisfaction and Treatment Adherence of Diabetic Women Through the Use of FGM,UNKNOWN,NA,100.0,2023-06-01,2024-12-31,5.257340241796201,Adequate (1-10/month),52.573402417962,Below (50-75%),50,43.0,26.465
NCT05819424,EpiCor Clinical Study on Rapid Immune Modulating Effects,COMPLETED,NA,30.0,2023-05-16,2023-11-17,4.936216216216216,Adequate (1-10/month),49.362162162162164,Significantly Below (<50%),100,52.4,53.949999999999996
NCT06713824,"Neoadjuvant Radiotherapy Before Surgery for Rectal Cancer, Surgical and Oncological Outcome Analysis, Retrospective Case Control Study in a Single Institute.",ACTIVE_NOT_RECRUITING,,1000.0,2017-01-01,2025-11-30,9.351766513056836,Adequate (1-10/month),93.51766513056837,Met (75-100%),85,88.8,92.89
NCT01565824,Web-based Support During Pregnancy and Early Motherhood in Women With Type 1 Diabetes (MODIAB-web),COMPLETED,NA,174.0,2011-11-01,2016-03-01,3.3480151706700383,Adequate (1-10/month),33.480151706700376,Significantly Below (<50%),100,63.9,76.9
NCT02380924,Recovery and Survival of EryDex in Non-patient Volunteers,COMPLETED,PHASE1,10.0,2015-01-01,2015-06-01,2.0158940397350995,Adequate (1-10/month),20.158940397350992,Significantly Below (<50%),100,50.8,49.18
NCT00995124,"Trial of the Ovicidal Activity of Three Head Lice Products (NeutraLice Lotion®, NeutraLice Advance® and Moov Head Lice Solution®) After a Single Application",COMPLETED,PHASE4,90.0,2009-10-01,2009-12-01,44.911475409836065,Good (10-50/month),200.0,Exceeded (≥100%),100,67.2,79.94
NCT06444724,The Effect of Smartphone Application on the Quality of Bowel Preparation for Colonoscopy,COMPLETED,PHASE4,488.0,2022-07-01,2025-02-28,15.266927029804728,Good (10-50/month),152.66927029804728,Exceeded (≥100%),100,94.0,94.84
NCT07315724,"The Efficacy of a Technology-Assisted Block Training Program on Cognitive Function, Hand Dexterity, and Grip Strength in Community-Dwelling Older Adults: A Mixed-Methods Research",RECRUITING,NA,40.0,2025-03-28,2026-03-27,3.345054945054945,Adequate (1-10/month),33.45054945054945,Significantly Below (<50%),60,41.2,23.425
NCT03305224,The Combination Therapy With Ra-223 and Enzalutamide,UNKNOWN,PHASE2,10.0,2017-10-27,2022-03-31,0.18836633663366337,Slow (<1/month),1.883663366336634,Significantly Below (<50%),50,30.8,9.745
NCT06404424,Combined Hemoperfusion and Therapeutic Plasma Exchange for Treatment of Patients With Septic Shock,COMPLETED,,82.0,2022-05-01,2024-03-01,3.7254925373134333,Adequate (1-10/month),37.25492537313433,Significantly Below (<50%),100,54.9,61.55500000000001
NCT03133624,A Study on a Multidimensional Prediction Model for Rupture Risk of Unruptured Intracranial Aneurysms,UNKNOWN,,500.0,2017-05-01,2021-12-31,8.926686217008799,Adequate (1-10/month),89.26686217008799,Met (75-100%),50,78.3,86.48
NCT05117424,CArdioMetabolism and Atherosclerotic PlaqUe progreSsion,RECRUITING,,3000.0,2017-01-01,2025-12-31,27.790626902008523,Good (10-50/month),200.0,Exceeded (≥100%),60,81.3,88.58
NCT06693024,Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer,RECRUITING,,2806.0,2019-01-01,2031-12-31,17.99339372235096,Good (10-50/month),179.9339372235096,Exceeded (≥100%),60,81.3,88.58
NCT00393224,"Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families",TERMINATED,,952.0,2005-07-05,2020-06-02,5.321131105398458,Adequate (1-10/month),53.21131105398459,Below (50-75%),10,61.3,73.56
NCT06867523,Eye Masks and Earplugs for Delirium and Pain Prevention in Pediatric Intensive Care Unit,COMPLETED,NA,74.0,2024-08-25,2025-06-30,7.289838187702266,Adequate (1-10/month),72.89838187702266,Below (50-75%),100,55.9,63.42
NCT00429923,Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a),COMPLETED,PHASE3,219.0,,,,Slow (<1/month),,Significantly Below (<50%),100,57.5,67.27
NCT03741023,Disorders of the Acute Phase Response Following Trauma and Invasive Surgery,ENROLLING_BY_INVITATION,NA,320.0,2019-12-12,2026-12-31,3.7813664596273293,Adequate (1-10/month),37.81366459627329,Significantly Below (<50%),55,62.1,74.595
NCT05533723,Comparison Between Endoscopic Epidural Neuroplasty and Percutaneous Epidural Neuroplasty in Low Back and Radicular Pain,COMPLETED,,107.0,2018-10-10,2022-08-24,2.3034512022630835,Adequate (1-10/month),23.034512022630835,Significantly Below (<50%),100,56.9,65.89500000000001
NCT02703623,"Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer",ACTIVE_NOT_RECRUITING,PHASE2,196.0,2016-05-18,2026-03-31,1.655449500554939,Adequate (1-10/month),16.554495005549388,Significantly Below (<50%),85,56.2,64.21
NCT01216423,Pulmonary Embolism and Stroke in Patient With Patent Foramen Ovale,COMPLETED,,374.0,2009-11-01,2017-01-01,4.348571428571429,Adequate (1-10/month),43.48571428571428,Significantly Below (<50%),100,78.3,86.48
NCT00940823,The AVB Study: Prospective Study Comparing the Ahmed Valve and the Baerveldt Implant for Treating Refractory Glaucoma,COMPLETED,NA,238.0,2005-07-01,2015-04-01,2.0344622297107553,Adequate (1-10/month),20.344622297107552,Significantly Below (<50%),100,69.0,81.185
NCT04895423,Evaluation of the Effectiveness and Safety of Immunosuppressive and Biological Therapy of Atopic Dermatitis in Childhood,UNKNOWN,PHASE4,160.0,2021-11-25,2023-07-25,8.023723228995058,Adequate (1-10/month),80.23723228995058,Met (75-100%),50,47.8,42.42
NCT02418923,HemoSonics-UVA Spinal Surgery,COMPLETED,,51.0,2015-04-01,2015-08-01,12.724918032786885,Good (10-50/month),127.24918032786886,Exceeded (≥100%),100,57.4,67.05499999999999
NCT00775723,Melatonin Production Delay in Preterm Infants,COMPLETED,,46.0,2008-01-01,2008-05-01,11.572231404958679,Good (10-50/month),115.7223140495868,Exceeded (≥100%),100,57.0,66.12
NCT06789523,Friendship Bench for Women Who Use Methamphetamine in Vietnam,RECRUITING,NA,100.0,2025-06-11,2029-08-31,1.9740596627756162,Adequate (1-10/month),19.74059662775616,Significantly Below (<50%),60,46.0,34.1
NCT04626323,Randomized Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease,UNKNOWN,PHASE2,60.0,2021-05-25,2024-12-01,1.4202177293934681,Adequate (1-10/month),14.202177293934682,Significantly Below (<50%),50,34.8,15.040000000000001
NCT02403323,Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144,TERMINATED,PHASE3,790.0,2015-06-08,2023-10-09,7.897405582922825,Adequate (1-10/month),78.97405582922825,Met (75-100%),10,63.0,75.845
NCT04329559,COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study,COMPLETED,,21.0,2020-03-30,2021-02-10,2.016529968454259,Adequate (1-10/month),20.16529968454259,Significantly Below (<50%),100,50.0,47.675
NCT06452459,Glymphatic MRI Study,NOT_YET_RECRUITING,,10.0,2024-07-01,2028-07-01,0.2083504449007529,Slow (<1/month),2.083504449007529,Significantly Below (<50%),30,23.1,6.404999999999999
NCT02244359,Improving Decision Making On Location of Care With the Frail Elderly and Their Caregivers,COMPLETED,NA,455.0,2014-09-01,2016-08-01,19.786,Good (10-50/month),197.85999999999999,Exceeded (≥100%),100,91.4,93.64
NCT01070459,The Effect of an Aerobic Exercise Programme in Stroke Patients,UNKNOWN,PHASE3,50.0,2010-02-01,2011-12-01,2.2784431137724552,Adequate (1-10/month),22.78443113772455,Significantly Below (<50%),50,39.0,20.505000000000003
NCT03799159,Renal Arterial Resistive Index Versus Novel Biomarkers for Early Prediction of Sepsis Associated-acute Kidney Injury,COMPLETED,,75.0,2019-05-15,2021-02-28,3.485496183206107,Adequate (1-10/month),34.85496183206107,Significantly Below (<50%),100,54.3,59.62
NCT02287259,Olanzapine Versus Lithium in the Treatment of Acute Depression in Patients With Bipolar II or Bipolar Not Otherwise Specified(OL Study),COMPLETED,PHASE4,50.0,2014-11-01,2019-03-31,0.9447548106765984,Slow (<1/month),9.447548106765984,Significantly Below (<50%),100,49.0,45.61
NCT03656159,Evaluation of a New CBT for People With Alzheimer's Disease and Their Caregivers,COMPLETED,NA,46.0,2017-01-01,2019-06-01,1.5893757094211125,Adequate (1-10/month),15.893757094211125,Significantly Below (<50%),100,48.7,44.93
NCT05476159,Indocyanine Green Test in Bariatric Surgery,COMPLETED,,30.0,2020-01-01,2021-12-31,1.2509589041095892,Adequate (1-10/month),12.509589041095893,Significantly Below (<50%),100,45.7,32.5
NCT03483259,To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers,COMPLETED,PHASE1,30.0,2018-04-02,2018-05-18,19.85217391304348,Good (10-50/month),198.5217391304348,Exceeded (≥100%),100,57.4,67.05499999999999
NCT03258359,Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN),UNKNOWN,PHASE1,12.0,2018-01-01,2020-12-01,0.34298591549295776,Slow (<1/month),3.429859154929578,Significantly Below (<50%),50,31.0,9.985
NCT03107559,Perfusion Index and Labor Analgesia,UNKNOWN,,30.0,2017-05-30,2017-08-01,14.495238095238095,Good (10-50/month),144.95238095238093,Exceeded (≥100%),50,40.7,22.675
NCT02661659,A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy,WITHDRAWN,PHASE1,0.0,2016-06-12,2017-10-03,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT06156059,Oral Bedtime Melatonin in Critically Ill Patients,NOT_YET_RECRUITING,PHASE4,160.0,2025-02-01,2026-04-01,11.486792452830189,Good (10-50/month),114.8679245283019,Exceeded (≥100%),30,46.8,38.440000000000005
NCT06352359,"Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors",RECRUITING,PHASE1,30.0,2024-08-23,2027-09-30,0.8060017652250662,Slow (<1/month),8.06001765225066,Significantly Below (<50%),60,35.4,15.765
NCT04763759,Study to Evaluate Safety and Activity of TRL1068 in Prosthetic Joint Infections,COMPLETED,PHASE1,15.0,2021-02-08,2024-03-13,0.40442869796279896,Slow (<1/month),4.04428697962799,Significantly Below (<50%),100,46.2,35.089999999999996
NCT05597059,The Diagnostic Value of the First Clinical Impression of Patients Presenting to the Emergency Department (PREKEYDIA),COMPLETED,,1506.0,2019-09-01,2021-02-01,88.32878612716763,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT04733859,Using Red Djulis Products Can Improve Skin Conditions,COMPLETED,NA,30.0,2017-10-01,2018-10-31,2.3118987341772153,Adequate (1-10/month),23.11898734177215,Significantly Below (<50%),100,52.4,53.949999999999996
NCT06100159,Short-term Effects of Ventilation Tubes in Children With Chronic Otitis Media With Effusion,COMPLETED,NA,60.0,2017-01-20,2022-08-30,0.8917968749999999,Slow (<1/month),8.91796875,Significantly Below (<50%),100,49.8,47.17
NCT07307859,Pain Neuroscience Education Combined With Lumbar Stabilization Exercises on Disability and Kinesiophobia Among Patients With Chronic Low Back Pain,NOT_YET_RECRUITING,NA,40.0,2026-01-20,2026-09-01,5.435714285714286,Adequate (1-10/month),54.35714285714286,Below (50-75%),30,32.2,11.635
NCT00927459,"Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol",TERMINATED,PHASE1,23.0,2009-06-01,2010-01-01,3.2715887850467293,Adequate (1-10/month),32.71588785046729,Significantly Below (<50%),10,24.8,7.06
NCT00718159,Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia,COMPLETED,PHASE1,23.0,2008-08-01,2011-12-01,0.5752834839769927,Slow (<1/month),5.7528348397699265,Significantly Below (<50%),100,46.8,38.440000000000005
NCT02587559,Effectiveness of Manual Therapy and Exercise in Shoulder OA,WITHDRAWN,NA,0.0,2016-05-01,2020-06-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT00816959,Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma,UNKNOWN,PHASE3,1200.0,2011-07-01,2014-04-01,36.34626865671642,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT04425759,Prevalence and Risk Factors of SARS-CoV-2 Antibody Responses (COVID-19),UNKNOWN,,2400.0,2020-06-08,2021-06-30,188.77519379844964,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT02887859,Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD,COMPLETED,PHASE2,15.0,2016-12-20,2023-12-01,0.17997635001970833,Slow (<1/month),1.7997635001970835,Significantly Below (<50%),100,46.2,35.089999999999996
NCT06897280,Clinical Trial of MED HF10™ Spinal Cord Stimulation for the Treatment of Chronic Pain,ACTIVE_NOT_RECRUITING,PHASE4,25.0,2021-11-16,2026-12-01,0.4133623030961434,Slow (<1/month),4.1336230309614335,Significantly Below (<50%),85,42.5,25.585
NCT01513980,Life-long Monitoring of COPD in Veneto Region,COMPLETED,NA,750.0,2011-11-01,2014-05-01,25.032894736842106,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT01374880,Diagnostic and Prognostic Value of New Biomarkers in Patients With Heart Disease,UNKNOWN,,3000.0,2009-06-01,2014-01-01,54.51940298507463,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT06253780,Multidisciplinary Study to Verify Blood Pressure Documentation and Response to Titration of Intravenous Medications,COMPLETED,,30.0,2024-01-12,2025-01-31,2.3719480519480522,Adequate (1-10/month),23.719480519480523,Significantly Below (<50%),100,50.7,48.915
NCT06209580,AMT-253 in Patients With Advanced Solid Tumours,RECRUITING,PHASE1,96.0,2024-01-31,2026-12-31,2.743887323943662,Adequate (1-10/month),27.438873239436624,Significantly Below (<50%),60,45.7,32.5
NCT07321080,Central Sensitisation in Nociceptive and Neuropathic Pain,ACTIVE_NOT_RECRUITING,,185.0,2025-12-15,2027-12-20,7.661768707482993,Adequate (1-10/month),76.61768707482993,Met (75-100%),85,58.6,69.51
NCT01810380,Brexpiprazole in Patients With Acute Schizophrenia,COMPLETED,PHASE3,468.0,2013-03-01,2014-12-01,22.25925,Good (10-50/month),200.0,Exceeded (≥100%),100,92.4,93.845
NCT06795880,"""Artificial Intelligence-Based Data Analysis Results and Mortality Prediction in Covid-19 Patients in Intensive Care""",ACTIVE_NOT_RECRUITING,,400.0,2020-04-01,2025-04-01,6.668127053669223,Adequate (1-10/month),66.68127053669222,Below (50-75%),85,75.8,84.83500000000001
NCT03609580,Post-operative Urinary Retention (POUR) Following Thoracic Surgery,RECRUITING,PHASE1,127.0,2018-05-07,2026-03-30,1.3404576976421636,Adequate (1-10/month),13.404576976421637,Significantly Below (<50%),60,43.2,26.840000000000003
NCT00735280,Reduced Dose of Unfractionated Heparin in Patients Undergoing PCI,COMPLETED,PHASE4,2505.0,2008-08-01,2011-03-01,80.94713375796178,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT05910580,"Improving Alcohol and Substance Use Care Access, Outcome, Equity During the Reproductive Years",RECRUITING,NA,400.0,2025-07-03,2027-05-31,17.469153515064562,Good (10-50/month),174.69153515064562,Exceeded (≥100%),60,75.0,84.49
NCT00363480,Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data,COMPLETED,PHASE4,221.0,2006-05-17,2007-09-14,13.87059793814433,Good (10-50/month),138.70597938144329,Exceeded (≥100%),100,72.7,83.325
NCT01649180,NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma,TERMINATED,PHASE2,3.0,2012-07-01,2016-03-01,0.06820014936519792,Slow (<1/month),0.6820014936519792,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT03094780,Quality of Life Intervention for Patients Receiving Radiation Therapy for Advanced Cancer Treatment and Their Caregivers,COMPLETED,NA,20.0,2016-07-01,2019-02-21,0.6308808290155441,Slow (<1/month),6.30880829015544,Significantly Below (<50%),100,46.6,37.375
NCT05403580,Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer,WITHDRAWN,PHASE3,0.0,2022-06-03,2024-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT06515080,"Predicting Outcomes Using Infra-red SEnsors, a Feasibility Study.",NOT_YET_RECRUITING,,500.0,2025-03-31,2026-07-31,31.252566735112936,Good (10-50/month),200.0,Exceeded (≥100%),30,72.3,83.065
NCT05816980,Re-irradiation for Pelvic Recurrences in Rectal Cancer Patients,COMPLETED,PHASE2,16.0,2015-01-01,2023-01-01,0.16668035592060232,Slow (<1/month),1.666803559206023,Significantly Below (<50%),100,46.3,35.66
NCT05051280,Left Atrial Appendage Occlusion Under Cone-beam Computed Tomography Fusion Image Guidance,UNKNOWN,NA,80.0,2020-08-01,2024-12-31,1.5097334159950404,Adequate (1-10/month),15.097334159950403,Significantly Below (<50%),50,36.4,17.14
NCT05475080,Carotid Web and Stroke Registry.,UNKNOWN,,100.0,2022-07-15,2025-07-15,2.7773722627737225,Adequate (1-10/month),27.773722627737225,Significantly Below (<50%),50,41.3,23.74
NCT06225180,Review of Breast Abscess Management,UNKNOWN,,500.0,2023-06-29,2024-06-29,41.58469945355191,Good (10-50/month),200.0,Exceeded (≥100%),50,78.3,86.48
NCT05147480,Online Mother-Baby Yoga With Preterm Infants and Their Mothers,COMPLETED,NA,29.0,2021-01-07,2021-09-27,3.3565019011406845,Adequate (1-10/month),33.56501901140685,Significantly Below (<50%),100,52.3,53.515
NCT01875380,Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE2,46.0,2013-06-01,2016-04-01,1.3528888888888888,Adequate (1-10/month),13.528888888888888,Significantly Below (<50%),100,48.7,44.93
NCT02059980,Developing Effective Response Inhibition Training for Symptom Relief in OCD and Trichotillomania,COMPLETED,NA,45.0,2014-08-01,2017-08-01,1.2498175182481752,Adequate (1-10/month),12.498175182481752,Significantly Below (<50%),100,48.6,44.685
NCT03885180,Randomized Evaluation of D-dimer Guiding dUration of Oral antiCoagulation thErapy,UNKNOWN,NA,500.0,2019-03-20,2021-03-30,20.539811066126855,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT01361880,Reduce African-American Infant Mortality,COMPLETED,NA,1200.0,2011-06-01,2015-12-01,22.21897810218978,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT00074880,The Role of Heart Stiff and Weak Atrium on Exercise Capacity in Patients With Hypertrophic Cardiomyopathy,COMPLETED,,50.0,2003-12-01,2005-03-01,3.3377192982456143,Adequate (1-10/month),33.377192982456144,Significantly Below (<50%),100,52.3,53.515
NCT06983080,Efficacy of Trazodone to Treat Insomnia in Older Adults (TRADITION Study),RECRUITING,PHASE2,40.0,2025-11-10,2027-12-01,1.6213049267643143,Adequate (1-10/month),16.213049267643143,Significantly Below (<50%),60,36.2,16.84
NCT05112380,Fatigue Test With an XCo,COMPLETED,,50.0,2021-11-22,2022-03-01,15.373737373737374,Good (10-50/month),153.73737373737376,Exceeded (≥100%),100,57.3,66.74
NCT02713880,Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP),WITHDRAWN,,0.0,2018-08-20,2019-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT04168879,Sphenopalatine Ganglion Block for Nasal Surery,COMPLETED,NA,110.0,2021-11-10,2023-12-10,4.4057894736842105,Adequate (1-10/month),44.05789473684211,Significantly Below (<50%),100,58.8,69.89999999999999
NCT05272579,PrePhage - Faecal Bacteriophage Transfer for Enhanced Gastrointestinal Tract Maturation in Preterm Infants,RECRUITING,EARLY_PHASE1,20.0,2023-11-07,2025-12-31,0.7755414012738854,Slow (<1/month),7.755414012738854,Significantly Below (<50%),60,34.6,14.729999999999999
NCT03401879,Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis,RECRUITING,NA,50.0,2018-02-01,2026-03-01,0.5159322033898305,Slow (<1/month),5.159322033898305,Significantly Below (<50%),60,37.0,17.955
NCT07069179,Feasibility of Choose to Move Replacement Ready,RECRUITING,NA,60.0,2025-07-14,2028-03-01,1.9005202913631634,Adequate (1-10/month),19.00520291363163,Significantly Below (<50%),60,42.8,25.929999999999996
NCT00561379,Diffuse Large B Cell Lymphoma of the Adult: Randomization Between High Dose Chemotherapy With Rituximab and CHOP 14-Rituximab,COMPLETED,NA,350.0,2005-04-01,2013-05-01,3.6090785907859084,Adequate (1-10/month),36.090785907859086,Significantly Below (<50%),100,78.0,86.075
NCT05487079,Identification and Characterization of Diabetes in Low-resource Populations,UNKNOWN,,11700.0,2022-01-17,2023-05-31,713.7234468937876,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT03027479,Skeletal Muscle Energy Metabolism in Women With Weight Loss and Ovarian and/or Endometrial Cancer With Weight Loss,COMPLETED,NA,70.0,2017-03-01,2019-07-16,2.4576701268742793,Adequate (1-10/month),24.576701268742795,Significantly Below (<50%),100,55.6,62.905
NCT03854279,Comparison of Bizact With Electroscissor for Tonsillectomy,UNKNOWN,PHASE4,60.0,2019-02-20,2020-12-31,2.6858823529411766,Adequate (1-10/month),26.85882352941176,Significantly Below (<50%),50,39.8,21.47
NCT03707379,The Effect of Share Care Model in the Improvement of Diabetes Management,RECRUITING,,3500.0,2016-03-01,2026-03-31,28.935361216730037,Good (10-50/month),200.0,Exceeded (≥100%),60,81.3,88.58
NCT03559179,Clinical Decision Support for Opioid Use Disorders in Medical Settings: Usability Testing in an EMR,COMPLETED,NA,55.0,2018-04-30,2019-02-14,5.773103448275862,Adequate (1-10/month),57.73103448275862,Below (50-75%),100,54.4,59.89
NCT06016179,Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer,RECRUITING,PHASE1,12.0,2024-01-30,2027-01-01,0.3423430178069353,Slow (<1/month),3.4234301780693532,Significantly Below (<50%),60,34.0,14.02
NCT05188079,"Effect of Acute Nitrate Supplementation on Vascular Function in Hispanic, Black and White Population",RECRUITING,NA,90.0,2021-10-01,2028-01-31,1.1844357976653699,Adequate (1-10/month),11.844357976653699,Significantly Below (<50%),60,40.2,22.115000000000002
NCT02086279,AMH Levels Change During Treatment With GnRh Agonist,COMPLETED,NA,67.0,2014-03-01,2014-11-01,8.324408163265307,Adequate (1-10/month),83.24408163265306,Met (75-100%),100,55.4,62.56
NCT06871579,Study of the Esophageal String Test (EST) for the Diagnosis of Helicobacter Pylori,RECRUITING,NA,25.0,2025-06-11,2026-03-30,2.606164383561644,Adequate (1-10/month),26.061643835616437,Significantly Below (<50%),60,40.0,21.87
NCT04462679,COMMIT HIV Trial Nepal,UNKNOWN,NA,86.0,2020-02-25,2021-07-01,5.320813008130081,Adequate (1-10/month),53.20813008130082,Below (50-75%),50,41.9,24.585
NCT02256579,Utility of Urinary beta2 Microglobulin as an Early Marker of Renal Dysfunction in Vietnamese HIV-Infected Patients,UNKNOWN,,1800.0,2014-10-01,2017-03-01,62.12244897959184,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT06709079,Study on the Effect and Mechanism of Aescine Sodium in the Treatment of Allergic Rhinitis,NOT_YET_RECRUITING,NA,60.0,2024-12-01,2026-09-01,2.8582159624413146,Adequate (1-10/month),28.582159624413144,Significantly Below (<50%),30,33.8,13.694999999999999
NCT00406679,"Analgesic Efficacy, Safety and Tolerability of Two Paracetamol-containing Solutions in Post-Surgical Dental Pain",COMPLETED,PHASE3,135.0,2006-11-01,2007-10-01,12.303592814371259,Good (10-50/month),123.03592814371255,Exceeded (≥100%),100,65.8,78.745
NCT04877379,VNRX-7145 Drug-Drug Interaction in Healthy Adult Volunteers,COMPLETED,PHASE1,53.0,2021-06-08,2021-11-10,10.408516129032257,Good (10-50/month),104.08516129032259,Exceeded (≥100%),100,59.2,70.7
NCT07057479,Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin,WITHDRAWN,PHASE3,0.0,2026-09-01,2028-02-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT01988779,Oral Versus Topical Antibiotics for Chronic Rhinosinusitis Exacerbations,COMPLETED,PHASE3,33.0,2013-10-01,2020-12-31,0.37935045317220545,Slow (<1/month),3.793504531722055,Significantly Below (<50%),100,47.6,41.775
NCT03135379,Comparison of Patient Satisfaction Using Heated Versus Room Temperature Ultrasound Gel,COMPLETED,NA,124.0,2016-04-01,2017-04-01,10.341260273972603,Good (10-50/month),103.41260273972604,Exceeded (≥100%),100,64.9,77.985
NCT01467596,Ultrasound-guided Supraclavicular Brachial Plexus Block in Elderly,COMPLETED,NA,44.0,2011-11-01,2012-11-01,3.6594535519125686,Adequate (1-10/month),36.594535519125685,Significantly Below (<50%),100,53.5,57.555
NCT05466396,Lung Health of Early COPD: A Multi-center Cohort Study,RECRUITING,,1550.0,2022-08-01,2027-12-31,23.853387259858447,Good (10-50/month),200.0,Exceeded (≥100%),60,81.3,88.58
NCT05624996,"Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer",RECRUITING,PHASE3,474.0,2023-07-12,2031-10-15,4.7824196221412,Adequate (1-10/month),47.824196221411995,Significantly Below (<50%),60,75.9,84.885
NCT03925896,Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC Patients,UNKNOWN,PHASE1,27.0,2019-08-07,2022-08-01,0.7540183486238533,Slow (<1/month),7.540183486238533,Significantly Below (<50%),50,32.2,11.635
NCT01975896,Mindfulness Training to Promote Healthy Diet and Physical Activity in Teens,COMPLETED,NA,53.0,2014-09-01,2015-06-01,5.90959706959707,Adequate (1-10/month),59.0959706959707,Below (50-75%),100,54.2,59.330000000000005
NCT02261896,Antibiotic Prophylaxis for Endoscopic Ultrasound Guided Fine Needle Aspiration of Pancreatic Cystic Lesions,COMPLETED,PHASE4,226.0,2014-10-01,2018-07-01,5.025157048940833,Adequate (1-10/month),50.25157048940832,Below (50-75%),100,68.1,80.715
NCT00000496,Platelet Drug Trial in Coronary Disease Progression,COMPLETED,PHASE3,,1979-12-01,1982-12-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,30.330000000000002
NCT05163496,Frontline Clinician Psilocybin Study,COMPLETED,PHASE3,30.0,2022-03-03,2024-06-30,1.0743529411764705,Adequate (1-10/month),10.743529411764706,Significantly Below (<50%),100,47.4,40.98
NCT00785096,"How do Patients, Nurses and Physicians Perceive Negative Postoperative Events?",COMPLETED,,615.0,2009-01-01,2009-12-01,56.049700598802396,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT00000696,A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV Disease,COMPLETED,PHASE1,48.0,,1993-11-01,,Slow (<1/month),,Significantly Below (<50%),100,43.8,27.965
NCT04812496,Tenofovir-DF Versus Hydroxychloroquine in the Treatment of Hospitalized Patients With COVID-19 (TEDHICOV),COMPLETED,,100.0,2020-03-01,2021-01-15,9.5125,Adequate (1-10/month),95.125,Met (75-100%),100,61.3,73.56
NCT05878496,Short Term Outcome of Pediatric Fracture of Neck Femur Fixation by Plate and Screws,UNKNOWN,NA,20.0,2023-04-01,2023-10-01,3.3267759562841532,Adequate (1-10/month),33.26775956284153,Significantly Below (<50%),50,36.6,17.41
NCT06436196,Video Laryngoscopy vs Direct Laryngoscopy in Paediatric Patients,NOT_YET_RECRUITING,NA,88.0,2024-06-01,2025-01-30,11.023539094650207,Good (10-50/month),110.23539094650208,Exceeded (≥100%),30,41.0,23.01
NCT02709096,BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes,COMPLETED,PHASE2,33.0,2016-04-01,2016-06-01,16.467540983606558,Good (10-50/month),164.67540983606557,Exceeded (≥100%),100,57.6,67.36999999999999
NCT02126462,Safety and Immunogenicity of Co-Administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 in Gabonese Adults,COMPLETED,PHASE1,32.0,2014-11-01,2016-06-01,1.6852595155709345,Adequate (1-10/month),16.852595155709345,Significantly Below (<50%),100,52.6,54.684999999999995
NCT00130962,ALGRX 4975 in the Treatment of Patients With Morton's Neuroma,COMPLETED,PHASE2,60.0,2004-09-01,2006-02-01,3.525868725868726,Adequate (1-10/month),35.25868725868726,Significantly Below (<50%),100,54.8,61.095
NCT01481662,"Epidemiological, Clinical and Etiological Features of SUSAC's Syndrome",UNKNOWN,,100.0,2011-11-01,2021-05-01,0.877486307293168,Slow (<1/month),8.77486307293168,Significantly Below (<50%),50,36.3,17.0
NCT03479762,In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database,COMPLETED,,105.0,2018-04-20,2022-09-12,1.9901618929016192,Adequate (1-10/month),19.901618929016195,Significantly Below (<50%),100,56.7,65.53
NCT07026162,Oliceridine on Postoperative Nausea and Vomiting in Gynecological Laparoscopic Surgery,RECRUITING,PHASE4,96.0,2025-07-21,2026-01-31,15.063092783505155,Good (10-50/month),150.63092783505155,Exceeded (≥100%),60,50.7,48.915
NCT01068262,Safety and Tolerability of Odanacatib (0822-059),COMPLETED,PHASE1,44.0,2009-12-08,2010-05-02,9.23696551724138,Adequate (1-10/month),92.36965517241379,Met (75-100%),100,58.5,69.34
NCT01079962,"An Active-controlled, Clinical Trial to Assess Central Hemodynamic Effects of Bisoprolol in Hypertensive Patients (Central Hemodynamic Assessment Measured in Patient With HypertensION [CHAMPION])",COMPLETED,PHASE4,209.0,2009-12-01,2011-10-01,9.50965620328849,Adequate (1-10/month),95.0965620328849,Met (75-100%),100,71.7,82.78999999999999
NCT00428662,Evaluation of a New Nanotechnology Based Drug-Eluting Stent for Opening of Narrowed Arteries of the Heart,UNKNOWN,NA,200.0,2007-01-01,2007-10-01,22.300366300366303,Good (10-50/month),200.0,Exceeded (≥100%),50,56.0,63.71
NCT06857162,Comparison of Maternal Hemodynamics During Spinal Anesthesia with Different Cesarean Delivery Positioning,NOT_YET_RECRUITING,NA,216.0,2025-04-25,2025-09-01,50.969302325581396,Excellent (>50/month),200.0,Exceeded (≥100%),30,56.3,64.5
NCT04557462,A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy,RECRUITING,PHASE3,540.0,2021-09-20,2032-10-25,4.055662472242783,Adequate (1-10/month),40.556624722427834,Significantly Below (<50%),60,78.0,86.075
NCT02821962,Sedentary Intervention Trial in Cardiac Rehabilitation,COMPLETED,NA,40.0,2016-08-01,2017-09-01,3.074747474747475,Adequate (1-10/month),30.747474747474747,Significantly Below (<50%),100,53.2,56.665
NCT02191462,A Study of the Pharmacokinetics of Three Dosages of Niagen in Healthy Subjects,COMPLETED,PHASE1,12.0,2014-07-01,2014-08-01,11.783225806451613,Good (10-50/month),117.83225806451614,Exceeded (≥100%),100,56.0,63.71
NCT03653962,Video-Assisted Presentation Before Bariatric Surgery Enhanced Understanding of Informed Consent Content,COMPLETED,NA,77.0,2016-10-01,2017-03-01,15.522384105960265,Good (10-50/month),155.22384105960262,Exceeded (≥100%),100,61.2,73.43499999999999
NCT04342962,Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia,TERMINATED,PHASE2,25.0,2021-02-16,2024-01-18,0.7138836772983115,Slow (<1/month),7.138836772983115,Significantly Below (<50%),10,20.0,5.695
NCT04509362,An 8-Day Initiation of Advanced Hybrid Closed Loop System In Children and Adolescents,COMPLETED,,34.0,2020-10-01,2021-09-01,3.089432835820896,Adequate (1-10/month),30.894328358208956,Significantly Below (<50%),100,51.1,50.129999999999995
NCT02966262,Korea University Anam Hospital Optical Coherence Tomography Registry,UNKNOWN,,2000.0,2016-04-01,2021-12-01,29.41062801932367,Good (10-50/month),200.0,Exceeded (≥100%),50,78.3,86.48
NCT02977962,Treatment of Anxiety in Late Adolescents With Autism,UNKNOWN,NA,44.0,2017-01-01,2021-08-01,0.8005738194859534,Slow (<1/month),8.005738194859534,Significantly Below (<50%),50,33.5,13.34
NCT06627062,A Modified-simple Technique for Managing Moderate and Severe Subluxated Lens Extraction,COMPLETED,,9.0,2023-01-01,2024-02-28,0.6476595744680851,Slow (<1/month),6.476595744680852,Significantly Below (<50%),100,44.1,28.425
NCT06911762,The Effects of a Structured Hand Exercise Program on Trigger Finger: A Randomized Controlled Trial,NOT_YET_RECRUITING,NA,76.0,2025-04-15,2026-08-01,4.890993657505286,Adequate (1-10/month),48.90993657505286,Significantly Below (<50%),30,35.1,15.384999999999998
NCT05174962,"National Stigma Survey About Mental Illness, Intellectual Disability and Homelessness in Spain",UNKNOWN,,2750.0,2022-01-01,2022-02-01,2700.322580645161,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT02920346,Prospective Maternal Surveillance of SSA (Sjögren Syndrome A) Positive Pregnancies Using a Hand-held Fetal Heart Rate Monitor,COMPLETED,,700.0,2014-03-01,2020-06-16,9.268377555458896,Adequate (1-10/month),92.68377555458895,Met (75-100%),100,93.3,94.325
NCT05212246,Basal Cell Carcinoma Chemoprevention Trial,NOT_YET_RECRUITING,PHASE3,1630.0,2026-05-01,2032-05-03,22.614949863263448,Good (10-50/month),200.0,Exceeded (≥100%),30,74.0,83.985
NCT01457846,Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer,TERMINATED,PHASE2,960.0,2011-11-01,2015-02-01,24.5979797979798,Good (10-50/month),200.0,Exceeded (≥100%),10,68.0,80.56
NCT04993846,Pancreatic Cancer and Oral Microbiome,UNKNOWN,,120.0,2021-07-26,2023-12-31,4.113513513513514,Adequate (1-10/month),41.13513513513514,Significantly Below (<50%),50,42.9,26.145000000000003
NCT05528146,Effects of Psyllium on Constipation in Schizo-phrenic: A Randomized Controlled Crossover Trial,COMPLETED,NA,42.0,2023-03-01,2023-07-07,9.988125,Adequate (1-10/month),99.88125,Met (75-100%),100,58.4,69.175
NCT05223946,Treatment and Companion Diagnostics of Lower Back Pain Using SCENAR and Passive Medical Radiometry (MWR),COMPLETED,NA,55.0,2020-09-01,2021-08-04,4.967952522255193,Adequate (1-10/month),49.67952522255194,Significantly Below (<50%),100,54.4,59.89
NCT03056846,Probiotics on Stress-associated Gastrointestinal Function in University Students,COMPLETED,NA,634.0,2017-09-05,2018-02-05,126.13699346405228,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT05183646,A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB,RECRUITING,PHASE3,286.0,2022-05-30,2029-12-01,3.174996353026988,Adequate (1-10/month),31.749963530269877,Significantly Below (<50%),60,60.9,73.06
NCT04988646,Pharmacokinetic Properties of 200 and 400 mg Acyclovir Tablet in Indonesia Healthy Subject,COMPLETED,NA,56.0,2020-02-21,2020-04-28,25.442388059701493,Good (10-50/month),200.0,Exceeded (≥100%),100,59.5,71.0
NCT00602446,Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant,TERMINATED,PHASE2,4.0,2007-08-01,2009-12-01,0.1427432590855803,Slow (<1/month),1.4274325908558032,Significantly Below (<50%),10,18.3,3.74
NCT06830746,ASCEND CSP IDE Study,RECRUITING,NA,414.0,2025-04-11,2028-05-01,11.29225806451613,Good (10-50/month),112.9225806451613,Exceeded (≥100%),60,76.1,84.94500000000001
NCT06644846,Spatially Fractionated Radiation Treatment for Gynaecological Cancers,RECRUITING,NA,20.0,2024-10-04,2029-02-28,0.3786069651741294,Slow (<1/month),3.7860696517412933,Significantly Below (<50%),60,34.6,14.729999999999999
NCT00039546,Combination Chemotherapy in Treating Women With Breast Cancer Who Have Undergone Surgery,UNKNOWN,PHASE3,,2001-08-01,,,Slow (<1/month),,Significantly Below (<50%),50,25.0,7.23
NCT07323446,The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation,NOT_YET_RECRUITING,EARLY_PHASE1,120.0,2026-01-01,2030-01-01,2.500205338809035,Adequate (1-10/month),25.00205338809035,Significantly Below (<50%),30,38.6,20.015
NCT05229146,Improving Future Thinking Among Mothers to Reduce Harsh Parenting and Improve Child Outcomes,COMPLETED,NA,48.0,2022-06-02,2023-11-21,2.7208938547486037,Adequate (1-10/month),27.208938547486035,Significantly Below (<50%),100,53.8,58.065
NCT02619188,Nutritional Markers in Normal and Hyperemesis Pregnancies,UNKNOWN,,60.0,2015-09-01,2018-07-01,1.7663442940038687,Adequate (1-10/month),17.66344294003869,Significantly Below (<50%),50,38.1,19.425
NCT03183388,Brain Emotion Circuitry-Targeted Self-Monitoring and Regulation Therapy (BE-SMART),COMPLETED,NA,76.0,2017-10-17,2022-06-30,1.347373325567851,Adequate (1-10/month),13.47373325567851,Significantly Below (<50%),100,51.1,50.129999999999995
NCT04651088,Comparing Alkalinizing Agents Efficacy on Stone Risk in Patients on a Metabolically Controlled Diet,NOT_YET_RECRUITING,EARLY_PHASE1,15.0,2026-01-01,2027-07-01,0.8362637362637363,Slow (<1/month),8.362637362637363,Significantly Below (<50%),30,25.2,7.359999999999999
NCT03354988,Effect of Assisted Exercise on Musculoskeletal System and Growth in Preterm Infants,UNKNOWN,NA,36.0,2015-01-01,2018-08-01,0.8377981651376147,Slow (<1/month),8.377981651376148,Significantly Below (<50%),50,32.9,12.53
NCT07327788,QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT,RECRUITING,PHASE2,38.0,2025-12-25,2028-12-30,1.0506085376930063,Adequate (1-10/month),10.506085376930063,Significantly Below (<50%),60,36.0,16.564999999999998
NCT00376688,Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer,COMPLETED,PHASE2,31.0,2006-07-11,2019-12-16,0.19234406848756624,Slow (<1/month),1.9234406848756627,Significantly Below (<50%),100,47.5,41.415
NCT04103788,Evaluation of Increased Absorption of a Curcumin Emulsion (CurQ+) in Healthy Volunteers,COMPLETED,NA,10.0,2018-03-27,2018-12-13,1.1662835249042147,Adequate (1-10/month),11.662835249042146,Significantly Below (<50%),100,45.8,33.03
NCT02122588,OVArian Cancer Non-Interventional Study - OVATAR,COMPLETED,,503.0,2014-06-30,2018-05-31,10.699734451432564,Good (10-50/month),106.99734451432565,Exceeded (≥100%),100,93.3,94.325
NCT00003888,Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer,COMPLETED,PHASE3,359.0,1999-04-01,2015-03-01,1.8799174264579392,Adequate (1-10/month),18.799174264579392,Significantly Below (<50%),100,78.7,86.835
NCT06567288,Effect of Spencer Muscle Energy Technique on Pain in Diabetic Stiff Shoulder,NOT_YET_RECRUITING,NA,30.0,2024-10-01,2024-12-01,14.970491803278687,Good (10-50/month),149.70491803278688,Exceeded (≥100%),30,36.4,17.14
NCT04569188,Convalescent Plasma in COVID-19 Elderly Patients,COMPLETED,PHASE2,21.0,2020-05-15,2020-09-03,5.758918918918919,Adequate (1-10/month),57.58918918918919,Below (50-75%),100,51.7,51.94
NCT01815788,"Evaluation of Efficacy and Patient Acceptance of Sound Amplifier Téo First, in Mild and Moderate Presbycusis Patient 60 Years of Age and Older, With no Previous Hearing Aid",COMPLETED,NA,31.0,2013-04-01,2014-06-01,2.215117370892019,Adequate (1-10/month),22.151173708920187,Significantly Below (<50%),100,52.5,54.345
NCT01709188,Musical Dual Task Training to Improve Attention Control for Dementia,UNKNOWN,NA,30.0,2012-10-01,2013-10-01,2.5019178082191784,Adequate (1-10/month),25.019178082191786,Significantly Below (<50%),50,37.4,18.62
NCT04843488,Effectiveness of Different Membrane Applications in Vertical Ridge Augmentation,COMPLETED,NA,30.0,2021-04-15,2023-05-02,1.2224899598393575,Adequate (1-10/month),12.224899598393575,Significantly Below (<50%),100,47.4,40.98
NCT06702488,Dexmedetomidine and Magnesium Sulfate in the Reduction Cognitive Dysfunction in Geriatrics,RECRUITING,PHASE1,58.0,2024-11-21,2025-05-15,10.088685714285715,Good (10-50/month),100.88685714285714,Exceeded (≥100%),60,47.6,41.775
NCT03998488,Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Dietary Fiber in Patients With Ulcerative Colitis,COMPLETED,PHASE2,27.0,2020-01-31,2024-04-12,0.5361252446183953,Slow (<1/month),5.361252446183953,Significantly Below (<50%),100,47.2,40.035
NCT06448988,Evaluation of Respiratory Mechanics in Supine and PARK-bench Positions (SPARK),ENROLLING_BY_INVITATION,,22.0,2024-06-06,2025-07-31,1.5944761904761906,Adequate (1-10/month),15.944761904761906,Significantly Below (<50%),55,31.6,10.905
NCT04432688,The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients,COMPLETED,,3192.0,2020-12-01,2023-06-18,104.59039827771798,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02439788,3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA,WITHDRAWN,PHASE1,0.0,2017-08-01,2030-10-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT03369288,Assessing Cement-bone Incorporation and Adjacent Segment Degeneration Following Cement Augmentation; an MRI-PET Follow-up,UNKNOWN,NA,30.0,2017-12-05,2019-11-28,1.2630705394190873,Adequate (1-10/month),12.630705394190873,Significantly Below (<50%),50,32.4,12.025
NCT02325388,Pressure Sensing to Reduce the Risk of Pressure Ulcer Formation,COMPLETED,NA,678.0,2014-12-01,2018-05-10,16.431783439490445,Good (10-50/month),164.31783439490445,Exceeded (≥100%),100,95.0,95.7
NCT05741203,Lung Ultrasound in Pediatric CAP,UNKNOWN,,1000.0,2023-05-01,2025-04-30,41.6986301369863,Good (10-50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT01917903,Cognitive-motor Training for PD,UNKNOWN,NA,24.0,2020-10-26,2022-12-15,0.9366153846153846,Slow (<1/month),9.366153846153848,Significantly Below (<50%),50,31.9,11.295
NCT02488603,Decision Aids for Tamoxifen Treatment in Breast Cancer Patients,UNKNOWN,NA,360.0,2015-08-01,,,Slow (<1/month),,Significantly Below (<50%),50,53.8,58.065
NCT01160003,"A Blinded, Dose Ascending Study to Assess the Pharmacokinetics, Safety and Tollerability of Repeat Inhaled Doses of Nebulised GW870086X in Healthy Adult Male Volunteers.",COMPLETED,PHASE1,12.0,2010-07-29,2010-11-05,3.68969696969697,Adequate (1-10/month),36.89696969696969,Significantly Below (<50%),100,51.0,49.714999999999996
NCT05990803,"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies",RECRUITING,PHASE2,130.0,2023-11-06,2027-12-01,2.6629878869448187,Adequate (1-10/month),26.629878869448188,Significantly Below (<50%),60,48.4,44.22
NCT02690103,Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV,COMPLETED,PHASE2,37.0,2012-07-01,2015-06-01,1.0575399061032864,Adequate (1-10/month),10.575399061032865,Significantly Below (<50%),100,48.0,42.945
NCT05712603,The Nijmegen-Leiden-Amsterdam 2-tiered Care Path Study,COMPLETED,,655.0,2022-10-01,2024-10-15,26.762684563758388,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT03212703,Mindfulness for Parents of OCD-affected Children,COMPLETED,NA,39.0,2015-07-01,2020-09-01,0.6284595023822128,Slow (<1/month),6.284595023822128,Significantly Below (<50%),100,48.1,43.275000000000006
NCT01371903,The Effects of Patient Features on Opioid Induced End-Tidal CO2,COMPLETED,,278.0,2010-08-01,2012-11-01,10.28228432563791,Good (10-50/month),102.82284325637909,Exceeded (≥100%),100,75.6,84.735
NCT02599103,The Effects of Various Cooking Oils on Health Related Biomarkers in Healthy Subjects,COMPLETED,NA,17.0,2013-09-01,2015-09-01,0.7088767123287671,Slow (<1/month),7.0887671232876714,Significantly Below (<50%),100,46.4,36.26
NCT06523803,A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers,TERMINATED,PHASE1,32.0,2024-09-30,2025-10-01,2.6614207650273225,Adequate (1-10/month),26.614207650273226,Significantly Below (<50%),10,25.6,7.595000000000001
NCT05554003,Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study,RECRUITING,PHASE2,46.0,2022-01-14,2024-12-31,1.2941219963031425,Adequate (1-10/month),12.941219963031426,Significantly Below (<50%),60,36.7,17.544999999999998
NCT00221403,Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders,COMPLETED,PHASE3,46.0,2004-09-01,2011-05-01,0.5755199342375668,Slow (<1/month),5.755199342375668,Significantly Below (<50%),100,48.7,44.93
NCT00446303,A Phase II Study of Maintenance With Azacitidine in MDS Patients,TERMINATED,PHASE2,39.0,2006-07-01,2010-07-01,0.8125667351129363,Slow (<1/month),8.125667351129364,Significantly Below (<50%),10,21.1,6.140000000000001
NCT04575103,Monitoring of Arrhythmias in Patients Treated With Antipsychotics,UNKNOWN,NA,600.0,2021-01-01,2024-12-31,12.509589041095891,Good (10-50/month),125.09589041095892,Exceeded (≥100%),50,80.0,87.67
NCT03080103,Appendectomy Versus Conservative Treatment for Uncomplicated Acute Appendicitis,COMPLETED,,300.0,2017-06-01,2019-12-31,9.683987274655356,Adequate (1-10/month),96.83987274655355,Met (75-100%),100,77.3,85.67
NCT05700903,Contributions to Hypertension With Androgen Deprivation Therapy,COMPLETED,PHASE4,10.0,2023-09-20,2025-07-16,0.4577443609022556,Slow (<1/month),4.5774436090225565,Significantly Below (<50%),100,45.8,33.03
NCT06344403,Clinical Efficacy and Safety of Tender Point Infiltration (TPI) for Acute and Subacute Zoster Associated Pain,ACTIVE_NOT_RECRUITING,NA,136.0,2025-06-01,2027-12-01,4.5343263964950715,Adequate (1-10/month),45.343263964950715,Significantly Below (<50%),85,56.4,64.88000000000001
NCT01420003,"Kinetics of IgE Memory B Cells, Plasmablasts and Plasma Cells After Whole Lung Allergen Challenge in Mild Asthmatics",COMPLETED,NA,12.0,2011-11-01,2014-07-01,0.3754162384378212,Slow (<1/month),3.7541623843782124,Significantly Below (<50%),100,46.0,34.1
NCT02422303,Effects of Low Dose Ketamine Given at Induction of Anesthesia on Postoperative Mood in Patients With Depressive Symptoms,TERMINATED,NA,12.0,2015-12-01,2016-09-01,1.3282909090909092,Adequate (1-10/month),13.282909090909092,Significantly Below (<50%),10,19.0,4.84
NCT05365503,Dissemination Strategies and Implementation Outcomes of Adolescent Character Strength Interventions.,COMPLETED,NA,3000.0,2022-05-16,2022-10-31,543.5714285714286,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT02781103,Guided Imagery and Transcranial Direct Current Stimulation (tDCS) in Women With Chronic Pelvic Pain,TERMINATED,NA,1.0,2017-01-20,2019-09-26,0.031092951991828394,Slow (<1/month),0.31092951991828394,Significantly Below (<50%),10,18.1,3.105
NCT06971003,Mohala Na Pua: Community-driven Drug Prevention,ACTIVE_NOT_RECRUITING,NA,130.0,2025-04-01,2030-05-31,2.098197242841994,Adequate (1-10/month),20.981972428419937,Significantly Below (<50%),85,55.9,63.42
NCT01095003,Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer,COMPLETED,PHASE3,770.0,2009-05-01,2015-10-01,9.99948805460751,Adequate (1-10/month),99.9948805460751,Met (75-100%),100,95.0,95.7
NCT04824703,Comparative Study Between Liberal and Conservative Oxygen Therapy in Mechanically Ventilated Intensive Care Patients,COMPLETED,NA,106.0,2021-04-05,2023-05-11,4.212323759791123,Adequate (1-10/month),42.12323759791123,Significantly Below (<50%),100,58.5,69.34
NCT04202003,"A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)",COMPLETED,PHASE1,105.0,2020-03-25,2023-12-15,2.3501470588235294,Adequate (1-10/month),23.501470588235293,Significantly Below (<50%),100,58.4,69.175
NCT00043927,Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults,COMPLETED,PHASE3,760.0,2001-04-01,,,Slow (<1/month),,Significantly Below (<50%),100,80.0,87.67
NCT00500227,Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery,COMPLETED,,55.0,2007-09-01,2012-07-01,0.9485552407932012,Slow (<1/month),9.485552407932012,Significantly Below (<50%),100,47.7,42.17
NCT06590727,Psychological Well-being in Patients With Breast Cancer,RECRUITING,,2400.0,2024-03-31,2029-07-31,37.503080082135526,Good (10-50/month),200.0,Exceeded (≥100%),60,81.3,88.58
NCT04296227,Comparison of Non-Invasive Blood Pressure Methods,COMPLETED,NA,85.0,2020-02-04,2020-03-03,85.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,66.8,79.55
NCT04983927,Evaluation of Clinical Decision Support System for Scoring of ASPECT Score Using Brain CT Images,COMPLETED,,326.0,2021-08-11,2021-12-06,84.8157264957265,Excellent (>50/month),200.0,Exceeded (≥100%),100,84.4,90.73
NCT00306527,"Comparison of Safety, Tolerability and Immunogenicity of Influenza Vaccines in Adults and Elderly",COMPLETED,PHASE3,2235.0,2005-09-01,2006-04-01,320.91226415094343,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT02954627,Ultrasound Assessment of the Carotid Intimal Medial Thickness in Obese Subjects; Weight Loss,COMPLETED,,200.0,2016-11-01,2019-03-01,7.16235294117647,Adequate (1-10/month),71.62352941176471,Below (50-75%),100,64.3,77.265
NCT03459027,Nitrate Supplementation and Muscle Blood Flow,COMPLETED,NA,10.0,2017-10-10,2018-02-08,2.515702479338843,Adequate (1-10/month),25.157024793388434,Significantly Below (<50%),100,50.8,49.18
NCT02162927,Dietary Nitrate Supplementation and Crossfit Athletes,COMPLETED,NA,12.0,2014-08-01,2014-11-01,3.9704347826086956,Adequate (1-10/month),39.70434782608696,Significantly Below (<50%),100,51.0,49.714999999999996
NCT04614727,Desensitizing Efficacy of Polymeric Nano Calcium Fluoride Containing Varnish,UNKNOWN,NA,50.0,2021-02-10,2021-06-10,12.683333333333334,Good (10-50/month),126.83333333333333,Exceeded (≥100%),50,44.0,28.249999999999996
NCT05414227,The Association of Gut Microbes and Their Metabolites With Post-stroke Depression,UNKNOWN,,200.0,2022-06-06,2023-05-31,16.95821727019499,Good (10-50/month),169.58217270194987,Exceeded (≥100%),50,54.3,59.62
NCT02571127,"Evaluate the Efficacy, Safety and Tolerability of a Non-hormonal Intravaginal Gel in Postmenopausal Women With Symptoms of Vaginal Dryness.",UNKNOWN,PHASE4,46.0,2015-10-01,2016-03-01,9.212105263157895,Adequate (1-10/month),92.12105263157895,Met (75-100%),50,43.7,27.744999999999997
NCT04138927,A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia,ENROLLING_BY_INVITATION,PHASE3,90.0,2019-10-30,2024-04-01,1.6963467492260063,Adequate (1-10/month),16.96346749226006,Significantly Below (<50%),55,43.7,27.744999999999997
NCT06473727,Evaluation of the Initial Color Match of Different Single-shade Composites,COMPLETED,NA,60.0,2023-05-24,2024-06-16,4.695115681233934,Adequate (1-10/month),46.951156812339335,Significantly Below (<50%),100,54.8,61.095
NCT06888427,Sleep Longitudinal Exploration of the Experience of Patients,RECRUITING,,1000.0,2025-04-23,2025-12-31,120.79365079365078,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT02608827,Sympathetic and Blood Pressure Responses to Aerobic Exercise and Guided Respiration in Hypertensives,COMPLETED,NA,29.0,2011-01-01,2015-12-01,0.4917883008356546,Slow (<1/month),4.917883008356546,Significantly Below (<50%),100,47.3,40.475
NCT03368027,Effectiveness of a Cognitive-behavioral Program of Coping With Psychological Stress in People With Retinitis Pigmentosa,COMPLETED,NA,30.0,2017-06-01,2018-12-03,1.6603636363636365,Adequate (1-10/month),16.603636363636365,Significantly Below (<50%),100,47.4,40.98
NCT01888627,Integrated Care in Psychotic Disorders With Severe Mental Illness,UNKNOWN,NA,400.0,2007-05-01,2025-12-01,1.7934894682574753,Adequate (1-10/month),17.934894682574754,Significantly Below (<50%),50,67.0,79.725
NCT05610527,Hormonal Influences on Inflammatory Bowel Diseases,NOT_YET_RECRUITING,NA,200.0,2024-12-01,2027-03-01,7.424390243902439,Adequate (1-10/month),74.2439024390244,Below (50-75%),30,45.0,30.330000000000002
NCT05753527,"The Effect of Progressive Relaxation Exercises on Anxiety, Satisfaction and Stress Levels Before Simulation Education",UNKNOWN,NA,54.0,2023-10-01,2023-12-01,26.946885245901637,Good (10-50/month),200.0,Exceeded (≥100%),50,44.3,28.715000000000003
NCT01176227,Efficacy of a Multi-strain Probiotic in the Treatment of Irritable Bowel Syndrome (IBS),COMPLETED,PHASE1,128.0,2010-05-01,2011-02-01,14.117101449275362,Good (10-50/month),141.1710144927536,Exceeded (≥100%),100,65.2,78.23
NCT04738227,"Effect of Low-level Laser Therapy on Salivary Flow, pH and Quality of Life in Irradiated Oropharyngeal Cancer Patients",COMPLETED,NA,34.0,2020-11-06,2021-02-03,11.62876404494382,Good (10-50/month),116.2876404494382,Exceeded (≥100%),100,57.7,67.51
NCT01874327,Biomarkers of Developmental Trajectories and Treatment in Autism Spectrum Disorder (ASD),COMPLETED,NA,110.0,2013-01-01,2018-09-01,1.6183663605606573,Adequate (1-10/month),16.183663605606576,Significantly Below (<50%),100,53.8,58.065
NCT01709227,Peritoneal Dialysis vs Furosemide for Acute Kidney Injury After Cardiopulmonary Bypass,COMPLETED,NA,73.0,2011-10-01,2015-06-01,1.6595369678864824,Adequate (1-10/month),16.595369678864827,Significantly Below (<50%),100,50.8,49.18
NCT01701427,Pain After Deep Electrical Stimulation in the Groin in Pain Free Subjects,COMPLETED,,21.0,2012-06-01,2013-01-01,2.987102803738318,Adequate (1-10/month),29.87102803738318,Significantly Below (<50%),100,50.0,47.675
NCT03479827,Measuring the Peripheral Optical Quality of The Eye,COMPLETED,,24.0,2018-08-31,2020-11-29,0.8898416565164434,Slow (<1/month),8.898416565164434,Significantly Below (<50%),100,45.3,31.169999999999998
NCT00218127,Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens,COMPLETED,PHASE2,142.0,2001-11-01,2005-07-01,3.2305530642750373,Adequate (1-10/month),32.30553064275038,Significantly Below (<50%),100,61.4,73.735
NCT03136627,Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC,COMPLETED,PHASE1,28.0,2017-03-22,2021-06-18,0.5502388637830858,Slow (<1/month),5.502388637830859,Significantly Below (<50%),100,47.2,40.035
NCT01255761,A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects,COMPLETED,PHASE4,736.0,2010-11-01,2012-12-01,29.44,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT03669861,Safety and Efficacy of Abatacept in IgG4-Related Disease,COMPLETED,PHASE2,10.0,2018-11-13,2020-11-10,0.41813186813186815,Slow (<1/month),4.181318681318682,Significantly Below (<50%),100,45.8,33.03
NCT02605161,Imaging Blood Brain Imaging Dysfunction in Parkinson's Disease,COMPLETED,,17.0,2015-11-01,2020-09-08,0.2918668922729837,Slow (<1/month),2.918668922729837,Significantly Below (<50%),100,44.7,29.67
NCT05896761,A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants,COMPLETED,PHASE3,118.0,2021-10-28,2022-08-23,12.013110367892978,Good (10-50/month),120.13110367892979,Exceeded (≥100%),100,64.4,77.37
NCT02368561,Treatment of Insertional Achilles Tendinopathy by Hyaluronic Acid Injection,UNKNOWN,EARLY_PHASE1,20.0,2015-03-01,2016-07-01,1.2475409836065574,Adequate (1-10/month),12.475409836065571,Significantly Below (<50%),50,31.6,10.905
NCT02823561,Garcinia Mangostana Extracts in the Management of Weight Loss,COMPLETED,PHASE4,40.0,2015-11-01,2016-05-01,6.69010989010989,Adequate (1-10/month),66.9010989010989,Below (50-75%),100,53.2,56.665
NCT05441761,Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL,UNKNOWN,PHASE1,60.0,2022-05-01,2025-05-01,1.6664233576642336,Adequate (1-10/month),16.664233576642335,Significantly Below (<50%),50,34.8,15.040000000000001
NCT04832061,Respiratory Supports and COVID-19 Mortality,COMPLETED,,2300.0,2021-04-01,2021-04-20,2300.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT04109261,Analysis of Palbociclib Treatment in Patients With Advanced Breast Cancer Within a Compassionate Use Programe,COMPLETED,,237.0,2018-09-18,2019-09-01,20.730689655172416,Good (10-50/month),200.0,Exceeded (≥100%),100,72.3,83.065
NCT00005861,Liposomal Doxorubicin in Treating Patients With Advanced or Recurrent Endometrial Cancer,COMPLETED,PHASE2,,2000-05-01,,,Slow (<1/month),,Significantly Below (<50%),100,40.0,21.87
NCT02801461,The Effect of ESWT for Cubital Tunnel Syndrome,COMPLETED,NA,7.0,2016-10-01,2017-12-31,0.467280701754386,Slow (<1/month),4.672807017543859,Significantly Below (<50%),100,45.6,32.08
NCT04232761,"Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone",COMPLETED,,194.0,2020-07-07,2024-04-29,4.242356321839081,Adequate (1-10/month),42.423563218390804,Significantly Below (<50%),100,63.9,76.9
NCT02731261,Chronic Effects of Exercise on Motor Memory Consolidation in Elderly People,COMPLETED,NA,38.0,2013-01-01,2013-09-01,4.760164609053498,Adequate (1-10/month),47.601646090534985,Significantly Below (<50%),100,53.0,55.80500000000001
NCT03915561,Effect of Intravenous Dynastat on Postoperative Sore Throat,UNKNOWN,PHASE2,140.0,2019-03-01,2020-11-30,6.65875,Adequate (1-10/month),66.5875,Below (50-75%),50,46.2,35.089999999999996
NCT01449461,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)",COMPLETED,PHASE1,137.0,2011-09-20,2020-02-18,1.3570712658639768,Adequate (1-10/month),13.570712658639767,Significantly Below (<50%),100,56.0,63.71
NCT01763242,Study of the Effect of Synchronised Anaemia Management in Chronic Kidney Disease,COMPLETED,PHASE4,102.0,2011-12-01,2012-12-01,8.48327868852459,Adequate (1-10/month),84.83278688524591,Met (75-100%),100,63.2,76.11
NCT06328842,Effect of Multifunctional Nutrition Tube on Cerebral Small Vessel Disease Patients,NOT_YET_RECRUITING,NA,88.0,2024-03-01,2024-12-01,9.7408,Adequate (1-10/month),97.40800000000002,Met (75-100%),30,41.0,23.01
NCT04787042,"Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067",RECRUITING,PHASE1,316.0,2021-08-06,2025-12-31,5.981990049751244,Adequate (1-10/month),59.819900497512435,Below (50-75%),60,63.3,76.235
NCT00045942,PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2),COMPLETED,PHASE1,144.0,2002-01-30,2008-03-27,1.9498932384341638,Adequate (1-10/month),19.49893238434164,Significantly Below (<50%),100,61.5,73.905
NCT01683942,A New Reproducible Method of Measuring C/D Ratio of Digital Stereo Images of Optic Disc,COMPLETED,,250.0,2012-08-01,,,Slow (<1/month),,Significantly Below (<50%),100,58.3,68.99499999999999
NCT03450642,Complement Diagnosis of Acute Appendicitis,COMPLETED,,70.0,2012-01-01,2014-10-01,2.122310756972112,Adequate (1-10/month),21.223107569721115,Significantly Below (<50%),100,53.9,58.34
NCT03988842,Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism,TERMINATED,PHASE4,4.0,2019-07-25,2020-04-05,0.4774901960784314,Slow (<1/month),4.774901960784314,Significantly Below (<50%),10,18.3,3.74
NCT05241886,Evaluation of Sarcopenia With SARC-F and Anthropometric Measurement,COMPLETED,,190.0,2018-07-01,2019-05-30,17.368168168168168,Good (10-50/month),173.6816816816817,Exceeded (≥100%),100,68.5,81.01
NCT02825186,Dexamethasone (Sterodex) Versus Loteprendol (Lotemax) Eye Drops Following Strabismus Surgery,UNKNOWN,NA,100.0,2016-07-01,2018-06-01,4.348571428571429,Adequate (1-10/month),43.48571428571428,Significantly Below (<50%),50,43.0,26.465
NCT06189586,Comparison of Aerosol Inhalation and Intravenous Glucocorticoid in the Treatment of Severe AECOPD,UNKNOWN,NA,100.0,2021-10-01,2025-07-31,2.1758398856325947,Adequate (1-10/month),21.758398856325947,Significantly Below (<50%),50,43.0,26.465
NCT00322686,Study of Oglemilast for the Treatment of Asthma,COMPLETED,PHASE2,6.0,2006-05-01,,,Slow (<1/month),,Significantly Below (<50%),100,40.5,22.46
NCT01150786,"Effect of Selenium on Serum Adiponectin, Homocystein and Malnutrition-inflammation Complex Syndrome in Hemodialysis Patients",COMPLETED,PHASE3,80.0,2009-04-01,2009-09-01,15.916339869281046,Good (10-50/month),159.16339869281046,Exceeded (≥100%),100,61.4,73.735
NCT06474286,Prucalopride for Cognitive Functioning in Schizophrenia,NOT_YET_RECRUITING,NA,34.0,2026-07-31,2026-12-31,6.764444444444444,Adequate (1-10/month),67.64444444444445,Below (50-75%),30,31.7,11.14
NCT03026686,Postpartum Readmission,TERMINATED,,335.0,2017-01-01,2017-09-01,41.964609053497945,Good (10-50/month),200.0,Exceeded (≥100%),10,58.1,68.595
NCT03294486,"Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients",UNKNOWN,PHASE1,78.0,2017-10-12,2021-09-01,1.6720563380281692,Adequate (1-10/month),16.720563380281693,Significantly Below (<50%),50,41.2,23.425
NCT02107586,Comparison of Outcomes Between Biceps Tenotomy and Tenodesis in the Treatment of the Long Head of the Biceps Pathology,COMPLETED,NA,6.0,2013-05-13,2014-04-08,0.5534545454545454,Slow (<1/month),5.534545454545454,Significantly Below (<50%),100,45.5,31.705
NCT03826186,CompuFlo Thoracic Epidural Study,COMPLETED,NA,120.0,2019-03-26,2022-06-01,3.140842648323302,Adequate (1-10/month),31.408426483233015,Significantly Below (<50%),100,59.6,71.17999999999999
NCT06515886,"Characterizing the Inflammation Around Dental Implants: Bacterial Infection, Hypersensitivity or Both?",RECRUITING,,40.0,2022-09-22,2025-12-01,1.044253859348199,Adequate (1-10/month),10.442538593481991,Significantly Below (<50%),60,34.5,14.52
NCT06531486,A Study of XS-02 Capsules in Patients With Advanced Solid Tumors,NOT_YET_RECRUITING,PHASE1,96.0,2024-07-29,2027-08-30,2.5929370008873116,Adequate (1-10/month),25.92937000887312,Significantly Below (<50%),30,36.7,17.544999999999998
NCT06836986,COMPARISON BETWEEN EFFICACY OF NOREPINEPHRINE AND PHENYLEPHRINE BOLUSES for PREVENTION OF SPINAL ANAESTHESIA INDUCED HYPOTENSION IN OBSTETRICAL PATIENTS UNDERGOING EMERGENCY CESAREAN SECTION-A Double Blind Randomized Controlled Trial,RECRUITING,NA,124.0,2024-12-31,2025-03-31,41.93955555555556,Good (10-50/month),200.0,Exceeded (≥100%),60,57.9,67.83
NCT05510986,The Effect of Oxycodone Hydrochloride on CRBD After TURBT Under General Anesthesia,UNKNOWN,NA,196.0,2022-10-01,2024-11-01,7.82971128608924,Adequate (1-10/month),78.2971128608924,Met (75-100%),50,50.7,48.915
NCT03651986,Diagnostic and Monitoring Significance of ctDNA Methylation Analysis by NGS in Benign and Malignant Pulmonary Nodules,UNKNOWN,,10560.0,2018-11-26,2025-06-01,135.11828499369483,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT05952986,A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults,UNKNOWN,PHASE1,22.0,2023-05-03,2024-03-26,2.0417073170731705,Adequate (1-10/month),20.417073170731708,Significantly Below (<50%),50,36.8,17.630000000000003
NCT00742586,Autonomic Failure Patients for RNA Blood Sampling,COMPLETED,,30.0,2008-07-01,2009-02-01,4.247441860465116,Adequate (1-10/month),42.47441860465116,Significantly Below (<50%),100,50.7,48.915
NCT00339586,First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene,UNKNOWN,PHASE2,40.0,2006-01-01,,,Slow (<1/month),,Significantly Below (<50%),50,28.2,8.469999999999999
NCT04606186,"Influence of Probiotics on Clinical Parameters, the Oral Microbiome and the Immune System During an Orthodontic Treatment in Adult Patients",UNKNOWN,NA,34.0,2020-10-19,2023-11-01,0.9340794223826716,Slow (<1/month),9.340794223826714,Significantly Below (<50%),50,32.7,12.370000000000001
NCT00554086,"Open Label,Phase II Trial of MAB Dose Escalation OF Bicalutamide For Biochemical Failure In Prostate Cancer Patients.",COMPLETED,PHASE2,65.0,2005-11-01,2010-09-01,1.1210198300283287,Adequate (1-10/month),11.210198300283286,Significantly Below (<50%),100,50.2,48.04
NCT06237686,Clinical Investigation Exploring Two Ostomy Product Prototypes,COMPLETED,NA,11.0,2024-01-09,2024-02-02,11.0,Good (10-50/month),110.00000000000001,Exceeded (≥100%),100,55.9,63.42
NCT06708286,A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component),ACTIVE_NOT_RECRUITING,PHASE2,1820.0,2024-12-20,2025-05-30,344.10434782608695,Excellent (>50/month),200.0,Exceeded (≥100%),85,95.5,96.55
NCT00004286,Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy,COMPLETED,PHASE3,120.0,1996-02-01,1999-11-01,2.6682249817384953,Adequate (1-10/month),26.682249817384957,Significantly Below (<50%),100,59.6,71.17999999999999
NCT06627686,"Predictive Value of Airway Occlusion Pressure, Maximal Inspiratory Pressure and Their Ratio for Successful Extubation in Patients With Traumatic Brain Injury",RECRUITING,,60.0,2023-09-01,2024-10-05,4.566,Adequate (1-10/month),45.660000000000004,Significantly Below (<50%),60,41.1,23.225
NCT06249386,Adapting and Piloting Behavioral Activation for Veterans With Alcohol Use Disorder and Posttraumatic Stress Disorder,COMPLETED,NA,10.0,2025-01-17,2025-10-06,1.1618320610687023,Adequate (1-10/month),11.618320610687023,Significantly Below (<50%),100,45.8,33.03
NCT06833086,Influence of Thoracic Paravertebral Block on Atrioventricular Conduction,COMPLETED,,60.0,2025-02-20,2025-03-31,46.83076923076923,Good (10-50/month),200.0,Exceeded (≥100%),100,63.1,76.03
NCT03951870,Characterization of the Relationship Between the Human Mesolimbic Reward System and Immune Functioning,COMPLETED,NA,85.0,2019-01-20,2022-08-28,1.9661094224924014,Adequate (1-10/month),19.661094224924014,Significantly Below (<50%),100,56.8,65.69500000000001
NCT05374070,Antiviral Activity of Oral Probiotics,UNKNOWN,NA,20.0,2022-05-23,2022-08-15,7.247619047619048,Adequate (1-10/month),72.47619047619048,Below (50-75%),50,36.6,17.41
NCT00272870,Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy,TERMINATED,PHASE1,1.0,2005-12-01,2012-08-01,0.012501026694045176,Slow (<1/month),0.12501026694045175,Significantly Below (<50%),10,18.1,3.105
NCT05692570,A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers,COMPLETED,PHASE1,21.0,2022-09-09,2022-11-12,9.988125,Adequate (1-10/month),99.88125,Met (75-100%),100,56.7,65.53
NCT00730470,"Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors",COMPLETED,PHASE1,60.0,2008-08-01,2010-07-01,2.612875536480687,Adequate (1-10/month),26.12875536480687,Significantly Below (<50%),100,54.8,61.095
NCT03990870,Wiring Adolescents With Social Anxiety Via Behavioral Interventions,COMPLETED,NA,34.0,2020-06-11,2021-11-24,1.9490772128060263,Adequate (1-10/month),19.490772128060264,Significantly Below (<50%),100,52.7,55.04
NCT05367570,"24-hour Movement Behaviors Among Normal Weight, Overweight and Obese Adults",COMPLETED,,250.0,2022-04-18,2023-10-31,13.565062388591802,Good (10-50/month),135.650623885918,Exceeded (≥100%),100,73.3,83.61
NCT06476470,Taiwan Interstitial Lung Disease Multi-center Investigation and Registry,RECRUITING,,10000.0,2024-03-10,2035-12-31,70.5773243681892,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT06828770,Minima Stent System Post- Approval Study (PAS),RECRUITING,,100.0,2025-05-21,2031-12-01,1.2763102725366877,Adequate (1-10/month),12.763102725366876,Significantly Below (<50%),60,39.3,20.810000000000002
NCT02360670,Penumbra and Recanalisation Acute Computed Tomography in Ischaemic Stroke Evaluation,UNKNOWN,NA,400.0,2015-02-01,2018-11-01,8.894083272461652,Adequate (1-10/month),88.94083272461651,Met (75-100%),50,72.0,82.92
NCT04909970,Impact of a Self-hyPnOsis Practice on Chronic StresS Among Caregivers of Elderly People With Loss of Autonomy at Home,RECRUITING,NA,60.0,2025-04-10,2025-12-01,7.771914893617022,Adequate (1-10/month),77.71914893617023,Met (75-100%),60,42.8,25.929999999999996
NCT01241370,"Skin and Retina Microvascular Endothelial Function in Healthy, Insulin Resistant and Type 2 Diabetic Subjects",COMPLETED,,78.0,2009-05-01,2010-04-01,7.0875223880597025,Adequate (1-10/month),70.87522388059702,Below (50-75%),100,54.6,60.39
NCT05592470,commd7 Gene Expression in ALL,UNKNOWN,,102.0,2022-11-01,2024-11-01,4.247441860465116,Adequate (1-10/month),42.47441860465116,Significantly Below (<50%),50,41.5,24.215
NCT07376070,The Role of Inflammatory Biomarkers in Preventing Deep Sternal Wound Infections After Sternotomy,ACTIVE_NOT_RECRUITING,,30.0,2025-04-14,2028-04-14,0.8332116788321168,Slow (<1/month),8.332116788321168,Significantly Below (<50%),85,41.2,23.425
NCT02365870,Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment,TERMINATED,PHASE4,4.0,2016-08-01,2019-07-01,0.1144360902255639,Slow (<1/month),1.1443609022556391,Significantly Below (<50%),10,18.3,3.74
NCT02124070,Therapeutic Effect of Recombinant Human Growth Hormone (rhGH) on the Myopathy of Cystinosis,WITHDRAWN,PHASE1,0.0,2014-03-26,2015-11-06,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT04655170,"Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD",UNKNOWN,PHASE4,60.0,2020-12-09,2023-03-30,2.1717003567181927,Adequate (1-10/month),21.717003567181926,Significantly Below (<50%),50,39.8,21.47
NCT06306170,Advanced Radiotherapy (ART) in Gynecological Cancer Patients (GYN-ART),RECRUITING,,1000.0,2024-02-15,2029-02-15,16.66119321291735,Good (10-50/month),166.61193212917354,Exceeded (≥100%),60,81.3,88.58
NCT03122470,Correlation of Imaging Findings With Clinical Findings and Patient Outcomes in Prostate Cancer,WITHDRAWN,NA,0.0,2017-08-01,2023-06-20,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT02766270,CCRT With Temozolomide Versus RT Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas,UNKNOWN,EARLY_PHASE1,30.0,2016-09-26,2018-12-01,1.1472361809045226,Adequate (1-10/month),11.472361809045225,Significantly Below (<50%),50,32.4,12.025
NCT03399370,Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol,COMPLETED,PHASE3,1561.0,2017-12-21,2019-09-17,74.82966929133859,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT07147270,Impact of Patient Position on Chemical Pleurodesis by Chest Ultrasound,RECRUITING,NA,30.0,2025-05-01,2026-02-01,3.308695652173913,Adequate (1-10/month),33.08695652173913,Significantly Below (<50%),60,40.4,22.34
NCT06992570,Risk Assessment of Mild Traumatic Brain Injury in Military Training,ENROLLING_BY_INVITATION,NA,50.0,2025-11-04,2026-09-30,4.612121212121212,Adequate (1-10/month),46.121212121212125,Significantly Below (<50%),55,40.5,22.46
NCT06753370,Experiences of Managing Sleep Disordered Breathing in Children With Cerebral Palsy.,RECRUITING,,20.0,2025-02-28,2026-08-01,1.1730250481695568,Adequate (1-10/month),11.73025048169557,Significantly Below (<50%),60,32.9,12.53
NCT02172170,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 10773 in Healthy Male Subjects",COMPLETED,PHASE1,72.0,2007-01-01,,,Slow (<1/month),,Significantly Below (<50%),100,45.8,33.03
NCT04064970,Patient Satisfaction Survey of Non-surgical Urinary Incontinence Treatment,COMPLETED,,125.0,2019-03-14,2020-07-01,8.010526315789473,Adequate (1-10/month),80.10526315789474,Met (75-100%),100,58.3,68.99499999999999
NCT06599970,Improving Disease Prevention Strategies by Integrating Socio-spatial Characterization of Human Mobility,RECRUITING,,810.0,2024-06-01,2027-06-30,21.936298932384343,Good (10-50/month),200.0,Exceeded (≥100%),60,81.3,88.58
NCT00002973,Melphalan and Whole-Body Hyperthermia in Treating Patients With Advanced Melanoma,COMPLETED,PHASE2,34.0,1995-12-01,2000-12-01,0.56648056923919,Slow (<1/month),5.6648056923919,Significantly Below (<50%),100,47.7,42.17
NCT05616273,Stimulated Glucagon as a Biomarker of Hypoglycemic Risk in Type 1 Diabetes,COMPLETED,,62.0,2023-05-03,2025-09-30,2.1422020431328037,Adequate (1-10/month),21.422020431328036,Significantly Below (<50%),100,53.3,57.14
NCT01605773,Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes,COMPLETED,PHASE4,51.0,2001-11-08,2003-03-13,3.168244897959184,Adequate (1-10/month),31.682448979591836,Significantly Below (<50%),100,54.1,59.11
NCT06826573,Analysis of Risk Factors for High Intraocular Pressure and Retinal Detachment Recurrence After Vitrectomy with Silicone Oil Tamponade in Retinal Detachment Patients,RECRUITING,,65.0,2024-09-01,2026-06-30,2.966416791604198,Adequate (1-10/month),29.664167916041983,Significantly Below (<50%),60,41.5,24.215
NCT04528173,Opioid-Free Anesthetic for Tonsillectomy,TERMINATED,PHASE4,35.0,2020-07-22,2023-08-22,0.9461811722912966,Slow (<1/month),9.461811722912966,Significantly Below (<50%),10,20.8,6.055
NCT05318573,"A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer",ACTIVE_NOT_RECRUITING,PHASE2,120.0,2022-06-01,2029-11-01,1.3478966789667897,Adequate (1-10/month),13.478966789667895,Significantly Below (<50%),85,50.1,47.89
NCT02618473,Effect of Snapshot Freeze on Cardiac CT Image Quality,COMPLETED,NA,140.0,2013-01-01,2015-08-01,4.523991507430998,Adequate (1-10/month),45.23991507430998,Significantly Below (<50%),100,61.2,73.43499999999999
NCT05483673,Analyzing Orthopedic Patient Experience Patterns in Medical Trials,NOT_YET_RECRUITING,,500.0,2024-08-01,2026-08-01,20.84931506849315,Good (10-50/month),200.0,Exceeded (≥100%),30,72.3,83.065
NCT05130073,4-Point Therapy Response Score With PET/CT for Anal Squamous Cell Cancer,COMPLETED,,41.0,2019-07-31,2023-12-14,0.7814902943018159,Slow (<1/month),7.81490294301816,Significantly Below (<50%),100,46.6,37.375
NCT03035773,Simplifying Survivorship Care Planning,COMPLETED,NA,378.0,2015-10-01,2021-03-31,5.730239043824701,Adequate (1-10/month),57.302390438247016,Below (50-75%),100,80.2,88.045
NCT00001873,The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers,COMPLETED,PHASE2,102.0,1999-02-22,2017-06-13,0.46438528268022733,Slow (<1/month),4.643852826802274,Significantly Below (<50%),100,53.2,56.665
NCT02900573,Withdrawal of Artificial Nutrition at the End of Life (PERCEPAL),COMPLETED,,289.0,2010-05-01,2010-08-01,95.62130434782608,Excellent (>50/month),200.0,Exceeded (≥100%),100,81.5,88.92999999999999
NCT01396473,Study on Out of School Nutrition and Physical Activity Environments,COMPLETED,NA,590.0,2010-09-01,2011-06-01,65.78608058608059,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT03380273,AO Multicenter Intervention Trial for Prevention of Surgical Site Infection,TERMINATED,NA,222.0,2019-12-06,2021-12-31,8.93873015873016,Adequate (1-10/month),89.3873015873016,Met (75-100%),10,45.8,33.03
NCT01614873,Comparison of Breathing Pattern During Neurally Adjusted Ventilatory Assist Ventilation and Pressure Support Ventilation,COMPLETED,NA,10.0,2012-05-01,2012-08-01,3.3086956521739133,Adequate (1-10/month),33.08695652173913,Significantly Below (<50%),100,50.8,49.18
NCT04972773,Spinal Cord Injury Mental Health Functional Outcomes Improved by Mindfulness,COMPLETED,NA,10.0,2021-10-04,2023-03-27,0.5647495361781076,Slow (<1/month),5.647495361781076,Significantly Below (<50%),100,45.8,33.03
NCT06748573,Compression Device to Reduce Pocket Hematoma After Cardiac Implantable Electronic Device Implantation in a High Bleeding Risk Population,COMPLETED,NA,65.0,2023-06-01,2024-09-01,4.3200873362445416,Adequate (1-10/month),43.20087336244542,Significantly Below (<50%),100,55.2,62.195
NCT01145573,Bone Health in Pregnancy,COMPLETED,NA,65.0,2010-05-01,2013-12-01,1.510381679389313,Adequate (1-10/month),15.10381679389313,Significantly Below (<50%),100,50.2,48.04
NCT03397173,TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid,COMPLETED,PHASE2,12.0,2018-03-16,2021-01-21,0.3505566218809981,Slow (<1/month),3.5055662188099808,Significantly Below (<50%),100,46.0,34.1
NCT03633773,Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma,UNKNOWN,PHASE1,9.0,2018-07-01,2024-12-31,0.11535157894736843,Slow (<1/month),1.1535157894736843,Significantly Below (<50%),50,30.7,9.585
NCT00208273,Concomitant and Sequential Radiohormonotherapy in Adjuvant Breast Cancer,COMPLETED,PHASE2,150.0,2005-01-01,2007-02-01,6.0,Adequate (1-10/month),60.0,Below (50-75%),100,62.0,74.42
NCT00594373,Interventional Study of Mucosal and Antimicrobial Responses to Repeated Vaginal Applications of Tenofovir Gel in HIV Uninfected Women,COMPLETED,PHASE1,30.0,,2010-04-01,,Slow (<1/month),,Significantly Below (<50%),100,42.4,25.45
NCT03251573,The Cohort Study of Cognitive Impairment in Chinese Hemodialysis Patients,COMPLETED,,613.0,2017-09-01,2019-06-18,28.48812213740458,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT00001673,Screening Evaluation for Studies of the National Institute on Alcohol Abuse and Alcoholism (NIAAA),COMPLETED,,2220.0,1997-10-02,2015-12-15,10.164981949458484,Good (10-50/month),101.64981949458482,Exceeded (≥100%),100,93.3,94.325
NCT02986373,A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171),COMPLETED,PHASE2,145.0,2016-12-15,2018-07-30,7.455743243243243,Adequate (1-10/month),74.55743243243244,Below (50-75%),100,61.6,74.0
NCT03846869,Major Cations Targeted Fluid Therapy In Renal Transplantation.,UNKNOWN,NA,50.0,2019-02-01,2021-12-01,1.4719535783365572,Adequate (1-10/month),14.719535783365572,Significantly Below (<50%),50,34.0,14.02
NCT06422169,Interventistic Clinical Investigation on the Use of Medical Device in Subjects With Mild-moderate Osteoarticular Pain,RECRUITING,NA,35.0,2024-05-08,2025-05-08,2.9189041095890413,Adequate (1-10/month),29.189041095890417,Significantly Below (<50%),60,40.8,22.745
NCT04758169,Exploring Enhanced HFP to Reduce Child Marriage in Bangladesh,UNKNOWN,NA,1200.0,2021-02-01,2023-03-15,47.31606217616581,Good (10-50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT06878469,SIMPLIFication of Care Pathways for Patients with Rare Brain Tumors Through Artificial Intelligence,RECRUITING,NA,200.0,2025-01-27,2026-07-01,11.707692307692307,Good (10-50/month),117.07692307692308,Exceeded (≥100%),60,59.0,70.365
NCT01723969,Screening Platform for Clinical Trials in Advanced Colorectal Cancer,COMPLETED,,668.0,2013-09-01,2020-03-10,8.53649034424853,Adequate (1-10/month),85.36490344248531,Met (75-100%),100,93.3,94.325
NCT07168369,Early Nutritional Intervention in Patients Undergoing Liver Transplantation,COMPLETED,NA,30.0,2021-02-15,2025-01-06,0.6426460239268121,Slow (<1/month),6.426460239268121,Significantly Below (<50%),100,47.4,40.98
NCT01086969,"A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India",COMPLETED,PHASE3,300.0,2010-06-01,2011-06-01,25.019178082191782,Good (10-50/month),200.0,Exceeded (≥100%),100,79.0,86.96000000000001
NCT01081769,Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics,COMPLETED,PHASE3,769.0,2010-02-01,2013-02-01,21.357992700729927,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT01548469,Study to Evaluate Clinical Efficacy and Safety of Bio Mineral Toothpaste in Patients With Mild Periodontitis,COMPLETED,PHASE4,60.0,2012-03-01,2012-06-01,19.85217391304348,Good (10-50/month),198.5217391304348,Exceeded (≥100%),100,59.8,71.61
NCT04138069,Imposed Pursed Lip Breathing at Rest and During Exercise In COPD,COMPLETED,NA,29.0,2017-07-01,2017-12-30,4.85032967032967,Adequate (1-10/month),48.503296703296705,Significantly Below (<50%),100,52.3,53.515
NCT01114269,PRE-DETERMINE Cohort Study,ACTIVE_NOT_RECRUITING,,5764.0,2007-07-01,2026-11-01,24.841591391759877,Good (10-50/month),200.0,Exceeded (≥100%),85,88.8,92.89
NCT02268669,Comparison of Primary PCI vs. Post-thrombolysis PCI as Reperfusion Strategies in STEMI,UNKNOWN,PHASE4,1444.0,2010-05-01,2016-03-01,20.626635382449557,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT03269669,"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma",ACTIVE_NOT_RECRUITING,PHASE2,73.0,2018-01-23,2027-01-21,0.6764444444444445,Slow (<1/month),6.764444444444444,Significantly Below (<50%),85,46.3,35.66
NCT06724783,Comparison of Two Collagen Membranes for Bone Augmentation Around Dental Implants Restored with Monolithic Zirconia Single Crowns,RECRUITING,PHASE4,68.0,2023-06-30,2030-09-30,0.7813967534918838,Slow (<1/month),7.813967534918836,Significantly Below (<50%),60,38.4,19.835
NCT03976583,Remineralization Potential of Pearl Powder Compared to CPP-ACP on Enamel White Spot Lesions,UNKNOWN,PHASE2,62.0,2019-09-01,2021-09-01,2.581778385772914,Adequate (1-10/month),25.817783857729143,Significantly Below (<50%),50,40.0,21.87
NCT05097183,Validation of Accurate Commissural Alignment During Transcatheter Aortic Valve Implantation,UNKNOWN,,274.0,2021-12-01,2024-12-31,7.407246891651865,Adequate (1-10/month),74.07246891651866,Below (50-75%),50,55.3,62.36000000000001
NCT07041983,24-h Energy Expenditure and Anti-obesity Medication,NOT_YET_RECRUITING,,30.0,2025-07-01,2026-12-01,1.762934362934363,Adequate (1-10/month),17.62934362934363,Significantly Below (<50%),30,29.7,8.92
NCT00423683,Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism,TERMINATED,PHASE3,64.0,2007-01-01,2010-11-01,1.3915428571428572,Adequate (1-10/month),13.91542857142857,Significantly Below (<50%),10,23.1,6.404999999999999
NCT07195383,GUSS-ICU Safe Nutrition Program After Extubation in ICU Patients,RECRUITING,NA,82.0,2025-03-05,2026-06-30,5.178589211618258,Adequate (1-10/month),51.78589211618259,Below (50-75%),60,44.6,29.42
NCT02822183,Online Survey of Clinicians to Learn About Their Interpretation of Capnography Waveforms,COMPLETED,,75.0,2013-08-01,2016-07-01,2.143661971830986,Adequate (1-10/month),21.436619718309863,Significantly Below (<50%),100,54.3,59.62
NCT01214083,N-acetylcysteine Plus Naltrexone for the Treatment of Alcohol Dependence,COMPLETED,PHASE2,111.0,2010-10-15,2016-10-30,1.5309651110104212,Adequate (1-10/month),15.30965111010421,Significantly Below (<50%),100,53.9,58.34
NCT07151183,"Diagnosis, Prognosis, and Mechanisms in Panvascular Disease",RECRUITING,,1000.0,2024-12-01,2030-12-31,13.70553804592526,Good (10-50/month),137.05538045925258,Exceeded (≥100%),60,81.3,88.58
NCT02325583,Intraoral 30% Glucose Effect In Newborns,COMPLETED,PHASE3,19.0,2014-01-01,2014-10-01,2.1185347985347986,Adequate (1-10/month),21.18534798534799,Significantly Below (<50%),100,51.5,51.245
NCT06958783,Chemotherapy-induced Lipid Profile Changes in Women With Early Breast Cancer,COMPLETED,,56.0,2023-03-05,2025-02-28,2.3479889807162535,Adequate (1-10/month),23.47988980716254,Significantly Below (<50%),100,52.8,55.31
NCT03652883,ImpleMentAll - Towards Evidence-based Tailored Implementation Strategies for eHealth,COMPLETED,NA,456.0,2018-06-01,2020-12-31,14.70406779661017,Good (10-50/month),147.04067796610173,Exceeded (≥100%),100,91.5,93.67
NCT05030883,The Effect of a Protective Message on Critical Evaluation of Fake News,COMPLETED,NA,400.0,2019-05-10,2019-07-01,234.15384615384616,Excellent (>50/month),200.0,Exceeded (≥100%),100,92.0,93.78999999999999
NCT02233283,Effect of Modifications of Nutritional Intake Upon Reproductive Hormones in Normal Women,COMPLETED,NA,9.0,2014-01-01,2015-06-01,0.5309302325581395,Slow (<1/month),5.309302325581395,Significantly Below (<50%),100,45.7,32.5
NCT03333083,"Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen",TERMINATED,PHASE3,17.0,2018-05-03,2020-06-25,0.6600510204081633,Slow (<1/month),6.600510204081633,Significantly Below (<50%),10,19.4,5.2299999999999995
NCT03305783,The Influence of Cholecystectomy on Secretion of Incretin Hormones,COMPLETED,,40.0,2017-11-01,2022-04-01,0.7553349875930521,Slow (<1/month),7.553349875930521,Significantly Below (<50%),100,46.5,36.815
NCT01054183,The Use of the GlideScope Ranger in Pediatric Critical Care Transport,COMPLETED,NA,22.0,2010-07-01,2011-12-01,1.2928185328185329,Adequate (1-10/month),12.928185328185329,Significantly Below (<50%),100,46.8,38.440000000000005
NCT05990283,Socket Shield Technique and Guided Bone Regeneration,COMPLETED,NA,24.0,2019-11-01,2023-01-20,0.6212244897959184,Slow (<1/month),6.212244897959184,Significantly Below (<50%),100,46.9,38.96
NCT00756483,Stability Plus - Outcomes From Extended Continuum of Care,UNKNOWN,,200.0,2008-10-01,2009-10-01,16.679452054794524,Good (10-50/month),166.7945205479452,Exceeded (≥100%),50,54.3,59.62
NCT03101683,Radiotherapy After Mastectomy for Breast Cancer Patients at Increased Risk of Local Recurrence,UNKNOWN,NA,28.0,2017-10-01,2019-09-30,1.1691632373113854,Adequate (1-10/month),11.691632373113855,Significantly Below (<50%),50,32.2,11.635
NCT03597841,Turkish Prospective Cohort Study on Carbapenem Resistant Klebsiella Pneumonia Bacteremia,COMPLETED,,278.0,2018-06-25,2019-07-22,21.587551020408164,Good (10-50/month),200.0,Exceeded (≥100%),100,75.6,84.735
NCT04089241,Fusion of CT Angiography With 3D Contrast Ultrasound as a Method for Follow up for Endovascular Aneurysm Repair,UNKNOWN,NA,20.0,2020-09-01,2023-04-01,0.6462845010615711,Slow (<1/month),6.46284501061571,Significantly Below (<50%),50,31.6,10.905
NCT03216941,Randomised Trial Ketiapine Olanzapine Fast Sedation Agitated Patients Emergency Ward,COMPLETED,PHASE4,500.0,2015-01-01,2016-01-31,38.53164556962026,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT06210841,[Trial of device that is not approved or cleared by the U.S. FDA],WITHHELD,,,,,,Slow (<1/month),,Significantly Below (<50%),50,20.0,5.695
NCT03647241,Evaluation of Self-ligating Brackets Plus Minor Surgery in Treating Crowded Cases of Malocclusion,COMPLETED,NA,60.0,2018-08-15,2020-06-19,2.7097922848664693,Adequate (1-10/month),27.09792284866469,Significantly Below (<50%),100,54.8,61.095
NCT07096141,Improving Emotional Wellbeing of University Students: Emotion Regulation,RECRUITING,NA,40.0,2025-03-05,2027-12-31,1.1809893307468478,Adequate (1-10/month),11.80989330746848,Significantly Below (<50%),60,36.2,16.84
NCT00670241,Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris,COMPLETED,PHASE3,458.0,2008-04-01,2009-04-01,38.195945205479454,Good (10-50/month),200.0,Exceeded (≥100%),100,91.6,93.695
NCT03769441,Effect of Ferric Carboxymaltose on Exercise Capacity After Kidney Transplantation,COMPLETED,PHASE3,148.0,2019-08-02,2024-08-19,2.443123644251627,Adequate (1-10/month),24.43123644251627,Significantly Below (<50%),100,61.8,74.19
NCT03868241,Coated Devices to Decrease Infection in the Intensive Care Unit,COMPLETED,PHASE1,103.0,2019-04-06,2020-02-28,9.55890243902439,Adequate (1-10/month),95.5890243902439,Met (75-100%),100,63.2,76.11
NCT03755141,Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer,COMPLETED,PHASE2,109.0,2018-12-15,2022-06-30,2.5660943542150036,Adequate (1-10/month),25.66094354215004,Significantly Below (<50%),100,58.7,69.69
NCT07058441,Clinical and Mechanistic Research on Autogenous Arteriovenous Fistula in Hemodialysis Patients,ACTIVE_NOT_RECRUITING,,100.0,2024-10-01,2027-01-01,3.7031630170316303,Adequate (1-10/month),37.031630170316305,Significantly Below (<50%),85,51.8,52.17
NCT06677541,Vibrator Use to Improve Sexual and Pelvic Floor Function Among Urogynecology Patients,RECRUITING,NA,84.0,2024-11-01,2026-01-31,5.607368421052632,Adequate (1-10/month),56.073684210526324,Below (50-75%),60,44.7,29.67
NCT02457741,Validation of a Simple Approach to Estimate Alveolar Recruitability in ARDS Patients,COMPLETED,,45.0,2015-06-01,2017-12-01,1.4986870897155362,Adequate (1-10/month),14.986870897155363,Significantly Below (<50%),100,46.9,38.96
NCT05042141,Safety and Efficacy of KOVIR in the Combination Regimen With Background Treatment in COVID-19 Patients (KOVIR),COMPLETED,NA,66.0,2021-07-28,2021-09-12,43.67478260869565,Good (10-50/month),200.0,Exceeded (≥100%),100,65.3,78.32000000000001
NCT06518941,An Open Trial of a Novel Pharmacotherapy for Habit Modification in Anorexia Nervosa,NOT_YET_RECRUITING,PHASE2,10.0,2026-06-01,2027-12-01,0.5554744525547445,Slow (<1/month),5.554744525547445,Significantly Below (<50%),30,24.8,7.06
NCT04565041,Social Support and Enhanced Fear Extinction,RECRUITING,NA,100.0,2022-02-01,2026-01-01,2.128671328671329,Adequate (1-10/month),21.286713286713287,Significantly Below (<50%),60,46.0,34.1
NCT07080541,Protocol for a Natural-Based Intervention to Promote Quality of Life and Healthy Habits on Children and Adolescents.,ACTIVE_NOT_RECRUITING,NA,728.0,2025-04-28,2025-11-01,118.50438502673798,Excellent (>50/month),200.0,Exceeded (≥100%),85,95.5,96.55
NCT02270541,Prehospital Study at the Universitair Ziekenhuis Brussel II,UNKNOWN,NA,140.0,2014-11-01,2017-02-01,5.17812879708384,Adequate (1-10/month),51.7812879708384,Below (50-75%),50,46.2,35.089999999999996
NCT06121141,Comparison of Two Different Concentrations of Local Anesthetic in Patient Reported Pain in Oculoplastic Surgery,COMPLETED,PHASE4,30.0,2023-08-07,2024-05-27,3.1061224489795918,Adequate (1-10/month),31.06122448979592,Significantly Below (<50%),100,52.4,53.949999999999996
NCT03788941,Left Atrial Appendage Closure in Combination With Catheter Ablation,UNKNOWN,,1200.0,2017-01-01,2024-12-31,12.505306401917151,Good (10-50/month),125.05306401917152,Exceeded (≥100%),50,78.3,86.48
NCT07081841,AB-1005 Long-Term Follow-up Study,ENROLLING_BY_INVITATION,,132.0,2025-09-04,2038-03-30,0.8753986928104576,Slow (<1/month),8.753986928104576,Significantly Below (<50%),55,40.4,22.34
NCT03625141,A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases,COMPLETED,PHASE2,80.0,2018-12-13,2023-04-13,1.5393173198482935,Adequate (1-10/month),15.393173198482934,Significantly Below (<50%),100,51.4,50.92
NCT05737641,Gastric Volume After Water or Jelly Ingestion,COMPLETED,NA,25.0,2022-12-01,2024-08-25,1.202211690363349,Adequate (1-10/month),12.02211690363349,Significantly Below (<50%),100,47.0,39.33
NCT04801641,A Pilot Trial of Nabilone for the Treatment of Obesity,TERMINATED,PHASE2,24.0,2021-09-17,2023-08-14,1.049655172413793,Adequate (1-10/month),10.496551724137932,Significantly Below (<50%),10,19.9,5.555000000000001
NCT05148741,Evaluation of Capsular Bag Shape Changes After Plate-haptic Intraocular Lens Implantation by SS-OCT,COMPLETED,,60.0,2020-07-01,2021-07-01,5.003835616438357,Adequate (1-10/month),50.03835616438357,Below (50-75%),100,53.1,56.105000000000004
NCT02167841,Comparison of Efficiency Between Practicing of Knee Chest Position and External Cephalic Version in Cases of Breech Presentation.,UNKNOWN,NA,100.0,2014-06-01,2016-04-01,4.543283582089552,Adequate (1-10/month),45.43283582089552,Significantly Below (<50%),50,43.0,26.465
NCT02912741,One Year Clinical Evaluation of White Spot Lesions Treated With Newly Introduced Resin Modified Glass Ionomer in Comparison to Resin Infiltration in Anterior Teeth Split Mouth Technique,UNKNOWN,PHASE2,35.0,2017-01-01,2018-05-01,2.196701030927835,Adequate (1-10/month),21.967010309278347,Significantly Below (<50%),50,37.8,19.015
NCT03850041,The Impact of Fluid Volume Shifts on Upper Airway Collapse and Obstructive Sleep Apnea in Surgical Patients,TERMINATED,,50.0,2019-07-22,2020-12-14,2.9784735812133074,Adequate (1-10/month),29.78473581213307,Significantly Below (<50%),10,25.3,7.414999999999999
NCT03630341,Adding L-Carnitine to Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovary Syndrome,COMPLETED,PHASE4,150.0,2016-02-01,2018-05-01,5.568292682926829,Adequate (1-10/month),55.6829268292683,Below (50-75%),100,62.0,74.42
NCT03964441,"ANDDI-PRENATOME - Feasibility Study for a "" Fast "" Pangenomic High Throughput Sequencing Analysis in Prenatal Diagnosis",COMPLETED,,149.0,2019-06-20,2024-01-25,2.699738095238095,Adequate (1-10/month),26.997380952380958,Significantly Below (<50%),100,60.3,72.34
NCT02687841,A Uremic Toxin Absorbent (AST-120) to Treat Hospital Acquired Acute Kidney Injury,UNKNOWN,PHASE3,206.0,2016-01-01,2017-12-01,8.958057142857143,Adequate (1-10/month),89.58057142857142,Met (75-100%),50,56.5,65.18
NCT05225441,National Investigation in College and High School Among Adolescents on Health and Substances at the FSEF,COMPLETED,,598.0,2022-03-01,2022-06-24,158.288,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT06053541,Morbid Rates After Spiriva Chronic Obstructive Pulmonary Disease (COPD) Protocol Change,COMPLETED,,3015000.0,2021-04-01,2021-07-01,1008534.065934066,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT03627741,A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors,COMPLETED,PHASE1,10.0,2018-06-07,2022-07-05,0.20443250503693755,Slow (<1/month),2.0443250503693755,Significantly Below (<50%),100,45.8,33.03
NCT01732341,Stentys Coronary Stent System Clinical Trial in Patients With Acute Myocardial Infarction,TERMINATED,PHASE3,318.0,2013-05-01,2017-03-01,6.914228571428572,Adequate (1-10/month),69.1422857142857,Below (50-75%),10,48.4,44.22
NCT06450041,"NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial",RECRUITING,PHASE2,62.0,2024-12-16,2038-12-01,0.37020007846214203,Slow (<1/month),3.7020007846214202,Significantly Below (<50%),60,38.0,19.255
NCT02474654,Implementation of a Pain Management Protocol for Total Knee Arthroplasty,COMPLETED,PHASE4,220.0,2015-07-01,2019-01-14,5.179273008507347,Adequate (1-10/month),51.792730085073465,Below (50-75%),100,67.6,80.15
NCT01346254,Glucose Control in Pre-Diabetic Renal Transplant Patients,COMPLETED,PHASE2,51.0,2009-12-01,2011-11-01,2.2177714285714285,Adequate (1-10/month),22.177714285714284,Significantly Below (<50%),100,54.1,59.11
NCT04649554,Study of MRgFUS Exablate Treatment Following the Neuropathic Pain,TERMINATED,NA,2.0,2020-10-08,2023-08-03,0.059164237123420796,Slow (<1/month),0.591642371234208,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT06604754,Effects of VR Training on Balance and Fall Risk of Patients With COPD,RECRUITING,NA,56.0,2025-06-12,2025-12-30,8.480796019900497,Adequate (1-10/month),84.80796019900497,Met (75-100%),60,47.5,41.415
NCT03860454,The Deep Phenotype of Lamin A/C Cardiomyopathy,UNKNOWN,,150.0,2019-03-07,2025-02-01,2.1158480074142725,Adequate (1-10/month),21.158480074142727,Significantly Below (<50%),50,45.3,31.169999999999998
NCT01593254,Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib,COMPLETED,PHASE2,262.0,2012-09-12,2022-04-12,2.279302657902258,Adequate (1-10/month),22.793026579022584,Significantly Below (<50%),100,71.0,82.44
NCT03569254,"Effectiveness, Safety and Perceptions With the Use of One LED Blanket Device in the Ambulatory Treatment of Jaundice",COMPLETED,NA,64.0,2016-03-01,2017-10-05,3.3416123499142367,Adequate (1-10/month),33.41612349914237,Significantly Below (<50%),100,55.1,62.085
NCT06664554,Predictive Value of Maternal Blood Protein Signatures in Preterm Birth,COMPLETED,,18000.0,2021-01-01,2024-06-30,429.40438871473356,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT03424954,The Effect of a 30-day Automated Text Messaging Intervention on Hospital Based Acute Care Encounters Following Ileostomy,TERMINATED,NA,9.0,2018-03-01,2019-03-31,0.6935696202531646,Slow (<1/month),6.935696202531645,Significantly Below (<50%),10,18.7,4.455
NCT01694654,Epidemiology and Outcome of Solitary Fibrous Tumors of the Pleura.,UNKNOWN,,300.0,2012-09-01,2016-12-01,5.884020618556701,Adequate (1-10/month),58.84020618556701,Below (50-75%),50,57.3,66.74
NCT05896254,Study of MAR001 in Adults With Metabolic Dysfunction,COMPLETED,PHASE1,55.0,2023-07-22,2024-12-13,3.282745098039216,Adequate (1-10/month),32.82745098039216,Significantly Below (<50%),100,54.4,59.89
NCT05281354,Development of a Personalised Therapeutic Approach for Cancer Patients With Resting Hypermetabolism,UNKNOWN,NA,120.0,2022-12-01,2023-08-01,15.0320987654321,Good (10-50/month),150.32098765432102,Exceeded (≥100%),50,49.6,46.785
NCT00772954,"Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study, Safety, Tolerability and Immunogenicity",TERMINATED,PHASE1,36.0,2006-03-01,2006-06-01,11.911304347826087,Good (10-50/month),119.11304347826088,Exceeded (≥100%),10,30.9,9.875
NCT00013754,Pesticide Exposure Pathways for Farmworker Children,COMPLETED,,40.0,2001-03-01,2003-10-01,1.2898305084745763,Adequate (1-10/month),12.898305084745765,Significantly Below (<50%),100,46.5,36.815
NCT06911554,A Study of Recombinant Human Albumin Injection to Treat Hypoalbuminemia in Cirrhotic Patients With Ascites,COMPLETED,PHASE3,416.0,2023-06-16,2024-09-27,27.00008528784648,Good (10-50/month),200.0,Exceeded (≥100%),100,88.3,92.705
NCT04191954,Fasudil Eye Drop in Retinopathy Of Prematurity(ROP),UNKNOWN,PHASE2,184.0,2019-06-02,2020-09-01,12.255929978118163,Good (10-50/month),122.55929978118164,Exceeded (≥100%),50,54.7,60.629999999999995
NCT01166854,Characterization of Familial Myopathy and Paget Disease of Bone,RECRUITING,,25.0,2010-06-18,2030-06-01,0.10441822173435786,Slow (<1/month),1.0441822173435786,Significantly Below (<50%),60,33.3,13.200000000000001
NCT00779454,Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma,COMPLETED,PHASE2,72.0,2008-09-01,2016-03-01,0.8004674945215486,Slow (<1/month),8.004674945215488,Significantly Below (<50%),100,50.8,49.18
NCT01706354,Local Anaesthesia vs Regional Block for Arteriovenous Fistulae,UNKNOWN,NA,126.0,2012-10-01,2015-10-01,3.50268493150685,Adequate (1-10/month),35.026849315068496,Significantly Below (<50%),50,45.1,30.605
NCT05935254,Plaque Removal Efficacy of Electric Toothbrushes in ADHD,COMPLETED,NA,52.0,2022-01-29,2022-12-15,4.9465,Adequate (1-10/month),49.465,Significantly Below (<50%),100,54.2,59.330000000000005
NCT02811354,Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA,UNKNOWN,PHASE2,108.0,2017-02-24,2020-02-24,3.002301369863014,Adequate (1-10/month),30.02301369863014,Significantly Below (<50%),50,43.6,27.54
NCT02479854,"Bioequivalence Study of Montelukast From Asmakast 5mg Chewable Tab.(Sandoz, Egypt) & Singulair 5mg Chewable Tab.(Merck)",COMPLETED,PHASE1,24.0,2014-04-01,2014-04-01,24.0,Good (10-50/month),200.0,Exceeded (≥100%),100,41.9,24.585
NCT04029454,Neovac 2 Burkina Faso: Impact of the Integration of Hepatitis B Birth Dose Vaccine Into the Infant Immunization Schedule,COMPLETED,NA,10000.0,2020-10-19,2023-12-15,264.2361111111111,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT01812954,Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis,COMPLETED,,1.0,2013-03-01,2014-06-01,0.06660831509846828,Slow (<1/month),0.6660831509846827,Significantly Below (<50%),100,43.4,27.265
NCT02121054,Research of Resistance to Antiplatelet Agents and Development of Tailored Treatment Model for Patients With Coronary Artery Disease,COMPLETED,,1527.0,2013-10-19,2020-10-29,18.107471756914688,Good (10-50/month),181.07471756914688,Exceeded (≥100%),100,93.3,94.325
NCT00831454,Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection,COMPLETED,,51.0,2008-09-01,2011-12-01,1.3089713322091063,Adequate (1-10/month),13.089713322091065,Significantly Below (<50%),100,47.4,40.98
NCT02707354,Early Detection of Mucosal Abnormalities in Graft-versus-host Disease,COMPLETED,NA,19.0,2016-06-03,2018-08-20,0.7157920792079209,Slow (<1/month),7.157920792079208,Significantly Below (<50%),100,46.5,36.815
NCT01837654,Plantarflexion Reduces Urgency and Peak Detrusor Pressure in Patients With Detrusor Overactivity,COMPLETED,NA,22.0,2012-06-01,2012-08-01,10.978360655737704,Good (10-50/month),109.78360655737704,Exceeded (≥100%),100,56.8,65.69500000000001
NCT06687954,Activation of the Ankle Musculature in Basketball Players With Chronic Ankle Instability,COMPLETED,,58.0,2023-12-27,2024-07-22,8.488076923076923,Adequate (1-10/month),84.88076923076923,Met (75-100%),100,58.0,68.245
NCT01851954,Pharmacokinetic Study of Clarithromycin in Very Low Birth Weight (VLBW),TERMINATED,PHASE2,6.0,2013-02-01,2014-04-01,0.4307547169811321,Slow (<1/month),4.307547169811321,Significantly Below (<50%),10,18.5,4.02
NCT05659654,The Application of Ursodeoxycholic Acid for the Prevention of SARS-CoV-2 Infection (COVID-19),COMPLETED,PHASE1,95.0,2022-12-16,2023-03-08,35.265853658536585,Good (10-50/month),200.0,Exceeded (≥100%),100,62.6,75.325
NCT05980754,Clinical Study on Exploring High Risk Factors Inducing the Progress of Diabetes,NOT_YET_RECRUITING,,90.0,2024-05-20,2025-12-30,4.651273344651953,Adequate (1-10/month),46.512733446519526,Significantly Below (<50%),30,34.5,14.52
NCT05656105,Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients With Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Infection,RECRUITING,EARLY_PHASE1,60.0,2023-11-10,2028-06-01,1.096936936936937,Adequate (1-10/month),10.96936936936937,Significantly Below (<50%),60,37.8,19.015
NCT00822705,Inhibition of Food Intake in Response to Oral GLP-1 and Peptide YY3-36,COMPLETED,PHASE1,16.0,2008-08-01,2009-01-01,3.1832679738562093,Adequate (1-10/month),31.832679738562092,Significantly Below (<50%),100,51.3,50.62
NCT02010905,Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System,UNKNOWN,PHASE2,120.0,2013-12-01,2018-01-01,2.448257372654156,Adequate (1-10/month),24.482573726541556,Significantly Below (<50%),50,44.6,29.42
NCT06750705,PechaKucha as a Reinforcement Tool for Teaching Vital Signs Skills in Nursing Students,NOT_YET_RECRUITING,NA,100.0,2024-12-30,2025-01-10,100.0,Excellent (>50/month),200.0,Exceeded (≥100%),30,47.0,39.33
NCT05686005,Tranexamic Acid in Functional Endoscopic Sinus Surgery,COMPLETED,PHASE4,159.0,2022-12-03,2023-04-30,32.70243243243243,Good (10-50/month),200.0,Exceeded (≥100%),100,67.7,80.22
NCT00002705,Topotecan in Treating Children With Refractory Leukemia,COMPLETED,PHASE1,3.0,1996-04-01,,,Slow (<1/month),,Significantly Below (<50%),100,40.2,22.115000000000002
NCT03750305,Evaluating the Effectiveness of Imagery Focussed Therapy,COMPLETED,NA,62.0,2018-10-01,2020-12-30,2.2987576126674787,Adequate (1-10/month),22.98757612667479,Significantly Below (<50%),100,55.0,61.834999999999994
NCT03452605,The Effect of Cocoa Flavanol on the BOLD Response and Cognitive Function in Type 1 Diabetes,COMPLETED,NA,22.0,2015-11-20,2017-03-15,1.3922661122661122,Adequate (1-10/month),13.922661122661124,Significantly Below (<50%),100,46.8,38.440000000000005
NCT06528405,The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease,RECRUITING,PHASE2,264.0,2024-11-21,2027-12-01,7.27254298642534,Adequate (1-10/month),72.7254298642534,Below (50-75%),60,59.1,70.6
NCT05966805,Impact of Exercise Intervention on Well-being in Shift-working Acute Care Nurses,COMPLETED,NA,21.0,2023-09-13,2025-05-13,1.0513815789473684,Adequate (1-10/month),10.513815789473686,Significantly Below (<50%),100,46.7,37.895
NCT00604305,Comperative Trial Between an Accommodative Iol and Monofocal Iol,WITHDRAWN,NA,0.0,2008-03-01,2012-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT00777205,Improving Depression Management Through Peer Support,COMPLETED,NA,443.0,2010-02-01,2013-09-01,10.309571865443425,Good (10-50/month),103.09571865443425,Exceeded (≥100%),100,90.4,93.305
NCT03773705,Impact of Nasoseptal Flap Harvest Technique on Olfaction Following Endoscopic Transsphenoidal Pituitary Surgery,UNKNOWN,NA,20.0,2019-02-25,2019-12-31,1.9702265372168286,Adequate (1-10/month),19.702265372168288,Significantly Below (<50%),50,36.6,17.41
NCT05341505,Outcomes of Emotion Regulation Therapy in Young Autistic Adults,UNKNOWN,NA,5.0,2022-07-15,2023-01-30,0.7648241206030151,Slow (<1/month),7.648241206030152,Significantly Below (<50%),50,30.4,9.345
NCT03351205,The Efficacy of Estrogen Therapy Against Adhesion Reformation After Hysteroscopic Adhesiolysis,UNKNOWN,NA,100.0,2017-11-21,2018-11-22,8.316939890710383,Adequate (1-10/month),83.16939890710383,Met (75-100%),50,43.0,26.465
NCT00679705,Influence of Tocolytical Medications on Hemodynamics (Central and Peripheral) and Vascular Function in a Pilot Study to Determine the Design of the Final Study and the Final Study Itself,COMPLETED,PHASE1,23.0,2008-05-01,2008-11-01,3.805,Adequate (1-10/month),38.05,Significantly Below (<50%),100,51.8,52.17
NCT00193505,Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma,COMPLETED,PHASE2,40.0,2003-10-01,2005-08-01,1.8173134328358211,Adequate (1-10/month),18.17313432835821,Significantly Below (<50%),100,53.2,56.665
NCT02737605,A Study to Evaluate the Effects of Esketamine on Cardiac Repolarization in Healthy Participants,COMPLETED,PHASE1,62.0,2016-07-01,2017-02-23,7.9632067510548525,Adequate (1-10/month),79.63206751054854,Met (75-100%),100,55.0,61.834999999999994
NCT01484405,Anterolateral Versus Posterior Approach for Total Hip Arthroplasty After Displaced Femoral Neck Fracture,TERMINATED,NA,16.0,2010-06-01,2013-11-01,0.38994395516413133,Slow (<1/month),3.8994395516413127,Significantly Below (<50%),10,19.3,5.125
NCT03845205,Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH,RECRUITING,NA,200.0,2020-11-20,2027-06-01,2.553691275167785,Adequate (1-10/month),25.536912751677853,Significantly Below (<50%),60,54.0,58.72500000000001
NCT04937205,Motivation for Exercise and Physical Activity Adherence,COMPLETED,,39.0,2019-02-13,2021-04-14,1.5008343868520861,Adequate (1-10/month),15.00834386852086,Significantly Below (<50%),100,46.5,36.815
NCT02702505,Success and Color Stability of MTA Pulpotomized Primary Molars: an RCT,UNKNOWN,PHASE4,50.0,2014-11-01,2017-12-01,1.3516873889875667,Adequate (1-10/month),13.516873889875667,Significantly Below (<50%),50,34.0,14.02
NCT06463405,Patient Perception and Oral Function of Implant Restorations,RECRUITING,NA,20.0,2024-03-01,2028-01-31,0.4254367575122292,Slow (<1/month),4.254367575122292,Significantly Below (<50%),60,34.6,14.729999999999999
NCT00981305,Impact of Lactate-Containing Vaginal Lubricant on Sexual Dysfunction in Young Breast Cancer Survivors,COMPLETED,PHASE3,136.0,2009-09-01,2015-07-01,1.9444997651479567,Adequate (1-10/month),19.44499765147957,Significantly Below (<50%),100,60.9,73.06
NCT06100705,Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC,RECRUITING,PHASE2,26.0,2023-12-20,2028-03-01,0.5162687540769733,Slow (<1/month),5.162687540769733,Significantly Below (<50%),60,35.1,15.384999999999998
NCT01667705,To Examine the Effect of a View of Nature on Patient's Stress and Anxiety,COMPLETED,,120.0,2012-03-01,2013-12-01,5.7075000000000005,Adequate (1-10/month),57.074999999999996,Below (50-75%),100,57.9,67.83
NCT00697905,Combination of Gemcitabine and Carboplatin in Metastatic or Recurrent Nasopharyngeal Carcinoma,COMPLETED,PHASE2,18.0,2008-01-01,2011-05-01,0.4505921052631579,Slow (<1/month),4.505921052631579,Significantly Below (<50%),100,46.4,36.26
NCT05027594,Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma,TERMINATED,PHASE1,5.0,2022-09-09,2024-01-08,0.3131687242798354,Slow (<1/month),3.131687242798354,Significantly Below (<50%),10,18.4,3.855
NCT04706494,A Study to Investigate the Efficacy of AlphaWave® L-Theanine on Stress,COMPLETED,PHASE1,16.0,2020-02-02,2020-09-25,2.0637288135593224,Adequate (1-10/month),20.63728813559322,Significantly Below (<50%),100,51.3,50.62
NCT06829394,Transitional Housing and HIV Health,RECRUITING,,200.0,2025-02-25,2028-08-01,4.858739026336791,Adequate (1-10/month),48.58739026336792,Significantly Below (<50%),60,52.3,53.515
NCT00149994,Cyclosporine A C-2h Monitoring Versus Tacrolimus C-0h Monitoring in de Novo Liver Transplant Recipients,COMPLETED,PHASE4,171.0,2002-12-01,2007-12-01,2.850624315443593,Adequate (1-10/month),28.50624315443593,Significantly Below (<50%),100,63.7,76.655
NCT05633394,Subcostal Temporary Extravascular Pacing V Study,COMPLETED,NA,29.0,2023-01-23,2025-06-30,0.9929808773903263,Slow (<1/month),9.929808773903263,Significantly Below (<50%),100,47.3,40.475
NCT01643694,Individualized Electronic Intervention to Promote Work Engagement,COMPLETED,NA,288.0,2012-07-01,2013-05-01,28.837894736842106,Good (10-50/month),200.0,Exceeded (≥100%),100,78.0,86.075
NCT01962194,Mapping and Stimulating the Limbic Areas of the Subthalamic Nucleus,UNKNOWN,NA,10.0,2013-12-01,2015-12-01,0.41698630136986303,Slow (<1/month),4.16986301369863,Significantly Below (<50%),50,30.8,9.745
NCT04326894,Methorexate and Knee Osteoarthritis,COMPLETED,PHASE4,128.0,2011-12-01,2012-12-01,10.64568306010929,Good (10-50/month),106.4568306010929,Exceeded (≥100%),100,65.2,78.23
NCT03267394,Role of Thymus-And Activation-Regulated Chemokine (TARC) In Diagnosis Of Allergic Bronchopulmonary Aspergillosis,UNKNOWN,,75.0,2017-10-01,2018-11-01,5.765151515151516,Adequate (1-10/month),57.651515151515156,Below (50-75%),50,39.3,20.810000000000002
NCT07331194,Pharmacokinetics and Bioequivalence Study of HMPL-523 Acetate Tablets in Humans,RECRUITING,PHASE1,54.0,2025-10-28,2026-03-31,10.673766233766234,Good (10-50/month),106.73766233766233,Exceeded (≥100%),60,47.3,40.475
NCT00057694,The Value of Genetic Information to Adult Adopted Individuals,COMPLETED,,40.0,2003-04-01,2004-01-01,4.427636363636364,Adequate (1-10/month),44.27636363636364,Significantly Below (<50%),100,51.5,51.245
NCT05375994,Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients,ACTIVE_NOT_RECRUITING,PHASE1,85.0,2022-08-01,2026-01-01,2.071577261809448,Adequate (1-10/month),20.715772618094476,Significantly Below (<50%),85,52.3,53.515
NCT05438394,Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM,UNKNOWN,PHASE1,24.0,2022-10-13,2023-12-31,1.6454054054054055,Adequate (1-10/month),16.454054054054055,Significantly Below (<50%),50,31.9,11.295
NCT06625294,Comparative Effects of Constraint-Induced Movement Therapy With Bilateral Functional Task Training On Hand Function In Patients With Stroke,ENROLLING_BY_INVITATION,NA,34.0,2024-06-20,2024-12-20,5.65551912568306,Adequate (1-10/month),56.5551912568306,Below (50-75%),55,39.2,20.715
NCT05257694,Clinical Decision Biological Biomarker and Prognosis Prediction of Hepatocellular Carcinoma by Deep Learning,UNKNOWN,,1.0,2022-01-01,2025-12-31,0.020849315068493152,Slow (<1/month),0.20849315068493154,Significantly Below (<50%),50,28.4,8.52
NCT03332394,COPD Care Model on Clinical and Patient-Reported Outcomes,COMPLETED,,58.0,2017-11-15,2020-05-30,1.904552319309601,Adequate (1-10/month),19.045523193096013,Significantly Below (<50%),100,53.0,55.80500000000001
NCT06731894,Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors,RECRUITING,PHASE2,120.0,2025-10-03,2028-01-07,4.42227602905569,Adequate (1-10/month),44.2227602905569,Significantly Below (<50%),60,47.6,41.775
NCT03587194,Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis,COMPLETED,PHASE4,50.0,2018-07-23,2019-07-01,4.43731778425656,Adequate (1-10/month),44.3731778425656,Significantly Below (<50%),100,54.0,58.72500000000001
NCT06712394,Knee Osteoarthritis and IPACK,NOT_YET_RECRUITING,,120.0,2025-01-01,2025-07-01,20.18121546961326,Good (10-50/month),200.0,Exceeded (≥100%),30,41.9,24.585
NCT04508894,Ketamine Versus Dexmedetomidine in Supraclavicular Brachial Plexus Block,COMPLETED,NA,75.0,2019-04-21,2020-12-30,3.6882067851373184,Adequate (1-10/month),36.882067851373186,Significantly Below (<50%),100,56.0,63.71
NCT06353594,Reduced Stent Strategy Versus Conventional Percutaneous Coronary Revascularization in Patients Presenting With STEMI,RECRUITING,NA,1272.0,2024-03-11,2035-09-01,9.238768790264853,Adequate (1-10/month),92.38768790264854,Met (75-100%),60,83.0,89.505
NCT01637194,Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer,COMPLETED,PHASE1,12.0,2008-11-01,2011-07-01,0.3758024691358025,Slow (<1/month),3.758024691358025,Significantly Below (<50%),100,46.0,34.1
NCT01370694,Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001),TERMINATED,PHASE1,7.0,2011-08-19,2014-12-01,0.17756666666666668,Slow (<1/month),1.7756666666666667,Significantly Below (<50%),10,18.6,4.25
NCT03704194,Adapted Lifestyle-integrated Functional Exercise Program for Medically Underserved Older Adults,COMPLETED,NA,17.0,2018-08-01,2019-01-31,2.82775956284153,Adequate (1-10/month),28.2775956284153,Significantly Below (<50%),100,51.4,50.92
NCT06396494,An Automated Navigation System for Deep Brain Electrode Implantation,ACTIVE_NOT_RECRUITING,,30.0,2024-01-01,2025-12-31,1.2509589041095892,Adequate (1-10/month),12.509589041095893,Significantly Below (<50%),85,41.2,23.425
NCT04146194,"OTTAPE : Observatory on the Use of New Therapies (LED Photobiomodulation, Radiofrequency, Laser and Injectable Hyaluronic Acid) in the Treatment of Women's Pelvic-perineal Pathologies After Failure, Partial or Total, of First-line Medical Treatment",COMPLETED,,173.0,2019-12-30,2022-10-07,5.203675889328063,Adequate (1-10/month),52.036758893280634,Below (50-75%),100,62.2,74.74499999999999
NCT04872894,Familial Hypocalciuric Hypercalcemia: Clinical Aspects and Evolution,COMPLETED,,70.0,2021-02-01,2023-04-01,2.70063371356147,Adequate (1-10/month),27.006337135614704,Significantly Below (<50%),100,53.9,58.34
NCT06772194,Taiwan Post-Stroke Disability Study,RECRUITING,,2000.0,2024-10-21,2028-09-30,42.27777777777778,Good (10-50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT07355166,Suzetrigine Versus Usual-care Opioids for Postop Pain in Sports,NOT_YET_RECRUITING,PHASE4,140.0,2026-02-01,2026-07-01,28.410666666666668,Good (10-50/month),200.0,Exceeded (≥100%),30,45.2,30.830000000000002
NCT01376466,Impact of CT on Diagnosis of Acute Appendicitis,COMPLETED,,102.0,2009-02-01,2012-10-01,2.320538116591928,Adequate (1-10/month),23.20538116591928,Significantly Below (<50%),100,56.5,65.18
NCT04280666,Next-generation Sequencing of Colorectal Cancer Somatic Cells to Guide Genetic Susceptibility Gene Mutations Screening.,UNKNOWN,,100.0,2019-06-20,2022-12-31,2.3596899224806203,Adequate (1-10/month),23.5968992248062,Significantly Below (<50%),50,41.3,23.74
NCT03262766,Daily Intermittent Hypoxia and Task-Specific Upper Limb Training in Persons With Chronic Incomplete SCI,UNKNOWN,NA,80.0,2017-06-24,2020-10-30,1.9895424836601308,Adequate (1-10/month),19.895424836601308,Significantly Below (<50%),50,41.4,24.04
NCT00005566,Cognitive Aspects of Adolescent Suicide,UNKNOWN,NA,,,,,Slow (<1/month),,Significantly Below (<50%),50,25.0,7.23
NCT03074266,Clinical Performance of the Investigational GEM Hemochron® 100 in Populations Ages 18 Years and Older,UNKNOWN,,140.0,2017-06-08,2018-12-01,7.877264325323476,Adequate (1-10/month),78.77264325323476,Met (75-100%),50,44.5,29.160000000000004
NCT04613466,The Prevelance of Pulmonary Manifestation in Patients With Inflammatory Bowel Disease,UNKNOWN,,60.0,2020-12-01,2022-06-01,3.3389396709323584,Adequate (1-10/month),33.389396709323584,Significantly Below (<50%),50,38.1,19.425
NCT01416766,CONtrolling Disease Using Inexpensive IT - Hypertension in Diabetes,COMPLETED,NA,196.0,2011-08-01,2015-07-01,4.1721958041958045,Adequate (1-10/month),41.72195804195805,Significantly Below (<50%),100,65.7,78.66499999999999
NCT01601366,LNG-IUS for Treatment of Dysmenorrhea,COMPLETED,PHASE2,62.0,2012-04-01,2015-04-01,1.723543378995434,Adequate (1-10/month),17.235433789954342,Significantly Below (<50%),100,55.0,61.834999999999994
NCT00418366,A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008),COMPLETED,PHASE1,24.0,2003-01-01,2003-03-01,12.382372881355932,Good (10-50/month),123.82372881355934,Exceeded (≥100%),100,56.9,65.89500000000001
NCT05713266,Using Data From a Multisensor Rapid Health Assessment Device to Predict Decompensation in Long COVID (AIDI),COMPLETED,,204.0,2022-10-31,2024-02-29,12.777283950617285,Good (10-50/month),127.77283950617286,Exceeded (≥100%),100,69.7,81.73
NCT00171366,A Study Comparing the Response of Patients With Hypertension to Amlodipine or Amlodipine Plus Benazepril.,COMPLETED,PHASE3,1422.0,2004-07-01,2005-07-01,118.59090410958905,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT06493266,"The Effect of Neurolingualistik Programming (NLP) on Pain Score, Fear of Pain and Pain Catastrophizing Before Colposcopy",COMPLETED,NA,100.0,2024-07-02,2025-04-04,11.028985507246377,Good (10-50/month),110.28985507246377,Exceeded (≥100%),100,63.0,75.845
NCT06893666,Effects of Play Based Therapy on Attention Level of Children With Down Syndrome,COMPLETED,NA,20.0,2025-03-28,2025-07-09,5.910679611650486,Adequate (1-10/month),59.10679611650485,Below (50-75%),100,51.6,51.644999999999996
NCT04545866,The Budesonide in Babies (BiB) Trial,ACTIVE_NOT_RECRUITING,PHASE3,642.0,2021-04-01,2026-12-17,9.368398849472674,Adequate (1-10/month),93.68398849472675,Met (75-100%),85,90.5,93.4
NCT00175266,Islet Transplantation Using Campath-1H and Infliximab Induction,COMPLETED,PHASE2,12.0,,,,Slow (<1/month),,Significantly Below (<50%),100,41.0,23.01
NCT06406166,Lifei Xiaoji Wan in Treatment of Advanced NSCLC,RECRUITING,NA,100.0,2022-06-01,2024-12-31,3.2245762711864407,Adequate (1-10/month),32.245762711864415,Significantly Below (<50%),60,46.0,34.1
NCT07014566,Effectiveness of Digital Physiotherapy in the Short and Long-Term Management of Lower Extremity Lymphedema,COMPLETED,NA,82.0,2019-02-05,2024-11-22,1.1790647142182333,Adequate (1-10/month),11.790647142182333,Significantly Below (<50%),100,51.6,51.644999999999996
NCT00649766,Tailored Messages to Increase Eye Examination Behavior,UNKNOWN,NA,330.0,2006-06-01,2008-05-01,14.350285714285715,Good (10-50/month),143.50285714285712,Exceeded (≥100%),50,66.4,79.36999999999999
NCT00488566,GSK Drug Single Dose Escalation And Their Effect On Resting Motor Threshold In Healthy Volunteers,COMPLETED,PHASE1,50.0,2007-05-31,2008-05-31,4.158469945355192,Adequate (1-10/month),41.58469945355191,Significantly Below (<50%),100,54.0,58.72500000000001
NCT06559566,Evaluation of Postoperative Intracranial Pressure in Patients Undergoing Intracranial Tumor Surgery,NOT_YET_RECRUITING,NA,50.0,2024-09-15,2025-05-01,6.675438596491229,Adequate (1-10/month),66.75438596491229,Below (50-75%),30,33.0,12.695
NCT05341466,The Effect of Acute Intermittent Hypoxia on Motor Learning,COMPLETED,NA,56.0,2022-05-27,2025-02-24,1.6978486055776894,Adequate (1-10/month),16.978486055776894,Significantly Below (<50%),100,54.5,60.12
NCT06078566,Long-Term Follow-Up Study of Unilateral Microtia Patients Implanted With AUR-201,TERMINATED,PHASE1,1.0,2024-01-26,2025-11-14,0.046261398176291796,Slow (<1/month),0.4626139817629179,Significantly Below (<50%),10,18.1,3.105
NCT02615366,Tranexamic Acid for Bleeding in Breast Surgery,UNKNOWN,PHASE4,800.0,2016-02-01,2019-02-01,22.21897810218978,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT05657366,Peritoneal Lavage on the Incidence of Pancreatic Fistula and Related Complications After Pancreatoduodenectomy,NOT_YET_RECRUITING,NA,260.0,2023-05-01,2027-06-30,5.203418803418804,Adequate (1-10/month),52.03418803418805,Below (50-75%),30,49.8,47.17
NCT04723966,Safety and Efficacy Evaluation of TPN in Preterm Neonates in NICU of Cairo University Children Hospital,UNKNOWN,,200.0,2019-04-07,2021-12-07,6.2441025641025645,Adequate (1-10/month),62.44102564102565,Below (50-75%),50,49.3,46.265
NCT00939666,Minimal Invasive Strategies for Good and Complete Response to Chemoradiation in Rectal Cancer,COMPLETED,NA,28.0,2009-07-01,2014-09-01,0.4514406779661017,Slow (<1/month),4.514406779661018,Significantly Below (<50%),100,47.2,40.035
NCT07320066,"IMT in Asthma: Activity, Coping, Self-Management",RECRUITING,,15.0,2026-01-05,2027-12-19,0.6403927068723703,Slow (<1/month),6.403927068723703,Significantly Below (<50%),60,32.5,12.235
NCT06334666,The Efficacy of Pedometer-motivated Physical Activity for the Management of Patients With MASLD.,ENROLLING_BY_INVITATION,NA,86.0,2024-08-01,2026-06-01,3.913064275037369,Adequate (1-10/month),39.13064275037369,Significantly Below (<50%),55,43.4,27.265
NCT00838266,Study of Growing Biofilm by an Antiplaque Mouthrinse,COMPLETED,PHASE3,50.0,2009-02-01,2009-03-01,50.0,Good (10-50/month),200.0,Exceeded (≥100%),100,64.0,77.025
NCT04627766,Validation of Continuous Monitoring of Vital Signs in Children With a Connected Patch,RECRUITING,NA,48.0,2025-02-02,2026-12-31,2.0962984218077474,Adequate (1-10/month),20.962984218077473,Significantly Below (<50%),60,41.8,24.445
NCT05006066,The Effect of the Nature And Frequency of a Stimulation on the Amplitude of the Temporal Summation of Pain,UNKNOWN,,34.0,2021-07-12,2022-08-30,2.499903381642512,Adequate (1-10/month),24.99903381642512,Significantly Below (<50%),50,36.1,16.665
NCT05321056,Exposure Measurements and Interventions for Aerosol Produced by Gastrointestinal Endoscopy,COMPLETED,NA,130.0,2022-06-17,2024-12-01,4.406681514476615,Adequate (1-10/month),44.066815144766146,Significantly Below (<50%),100,60.4,72.54
NCT03875456,Needle Aspiration for Large Cephalohematoma,COMPLETED,,67.0,2018-12-01,2019-03-01,22.660888888888888,Good (10-50/month),200.0,Exceeded (≥100%),100,58.7,69.69
NCT02271256,Functional Intimate Apparel for Adolescents With Early Scoliosis,COMPLETED,NA,20.0,2017-07-15,2021-12-31,0.37349693251533744,Slow (<1/month),3.734969325153375,Significantly Below (<50%),100,46.6,37.375
NCT01372956,Cholesterol Goal Attainment Rate and Its Associated Factors Among Dyslipidemic Patients on Lipid-lowering Drug Therapy in Korea,COMPLETED,,4950.0,2011-08-01,2011-10-01,2470.1311475409834,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02801656,Fecal Microbiota Transplantation for Primary Clostridium Difficile Diarrhea,WITHDRAWN,PHASE3,0.0,2020-12-01,2022-09-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT05023356,Non-contact Vital Signs Monitoring in Anesthesia,UNKNOWN,,30.0,2021-09-10,2022-05-23,3.5811764705882356,Adequate (1-10/month),35.811764705882354,Significantly Below (<50%),50,35.7,16.18
NCT04804956,Mesorectal Microbiome as a Prognostic Factor in Patients With Rectal Cancer,RECRUITING,,100.0,2021-04-01,2026-04-01,1.6670317634173057,Adequate (1-10/month),16.670317634173056,Significantly Below (<50%),60,44.3,28.715000000000003
NCT02597556,The Impact of Anthelmintic Treatment on the Incidence of Diarrheal Disease in Vietnamese School Children,WITHDRAWN,PHASE4,0.0,2016-02-01,2016-05-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT06591156,Gingival Recessions Treated by CAF with or Without PRF,COMPLETED,NA,19.0,2020-05-01,2024-09-01,0.36512626262626263,Slow (<1/month),3.651262626262626,Significantly Below (<50%),100,46.5,36.815
NCT01335256,Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies,COMPLETED,PHASE1,10.0,2010-12-01,2011-09-01,1.110948905109489,Adequate (1-10/month),11.10948905109489,Significantly Below (<50%),100,45.8,33.03
NCT07017556,Views on Information Resources for Kidney Transplantation Patients,NOT_YET_RECRUITING,NA,60.0,2025-06-01,2026-02-01,7.454693877551021,Adequate (1-10/month),74.54693877551021,Below (50-75%),30,33.8,13.694999999999999
NCT04208256,Food Intake and the Adolescent Brain,COMPLETED,,63.0,2019-12-30,2024-09-30,1.1046774193548388,Adequate (1-10/month),11.046774193548387,Significantly Below (<50%),100,48.4,44.22
NCT06328556,Ultrasound-guided Botulinum Toxin Injection on Cricopharyngeal Muscle Dysfunction,NOT_YET_RECRUITING,NA,30.0,2024-03-01,2024-12-01,3.320727272727273,Adequate (1-10/month),33.20727272727273,Significantly Below (<50%),30,31.4,10.47
NCT05496556,Influence of Food Preferences on the Occurrence of Undernutrition in Treated Patients for Bronchopulmonary Carcinoma Non-small Cell Stage IV,ACTIVE_NOT_RECRUITING,NA,190.0,2023-11-01,2026-10-01,5.430610328638498,Adequate (1-10/month),54.30610328638499,Below (50-75%),85,60.7,72.89999999999999
NCT04210856,Effects of Landscapes on the Brain,COMPLETED,NA,95.0,2019-02-28,2021-07-09,3.354756380510441,Adequate (1-10/month),33.54756380510441,Significantly Below (<50%),100,57.6,67.36999999999999
NCT06734156,CARE-CRC: Microbiome Insights and Correlations for Risk and Outcomes in Colorectal Cancer,NOT_YET_RECRUITING,,400.0,2025-12-02,2029-12-02,8.334017796030116,Adequate (1-10/month),83.34017796030116,Met (75-100%),30,59.3,70.815
NCT06275256,Outcomes of MIST for BPH: A Single-Institution Prospective Study,NOT_YET_RECRUITING,PHASE3,20.0,2024-03-01,2025-03-01,1.6679452054794521,Adequate (1-10/month),16.67945205479452,Significantly Below (<50%),30,30.6,9.475
NCT03196856,Brock Exercise And Supplement Trials,COMPLETED,NA,30.0,2017-07-01,2019-05-30,1.3083094555873926,Adequate (1-10/month),13.083094555873927,Significantly Below (<50%),100,47.4,40.98
NCT03766256,Shared Decision Making in Diabetes Prevention for Women With a History of GDM,COMPLETED,NA,33.0,2019-03-01,2019-12-28,3.326225165562914,Adequate (1-10/month),33.262251655629136,Significantly Below (<50%),100,52.6,54.684999999999995
NCT01729156,Effects of Metformin on Hepatic FFA Metabolism,COMPLETED,PHASE4,36.0,2013-01-01,2017-05-05,0.6913817034700316,Slow (<1/month),6.913817034700316,Significantly Below (<50%),100,47.9,42.64
NCT06363656,Assessment of Smartwatch SAMSUNG to Monitor Sleep Quality: an Observational Prospective Study - SleepEx2 Protocol,COMPLETED,,158.0,2024-02-15,2024-06-28,35.891940298507464,Good (10-50/month),200.0,Exceeded (≥100%),100,66.0,78.99000000000001
NCT00711256,Sunscreen: Persistence of Sun Protection Factor and the Influence on Vitamin D,UNKNOWN,NA,80.0,2008-07-01,2008-11-01,19.798373983739836,Good (10-50/month),197.9837398373984,Exceeded (≥100%),50,46.4,36.26
NCT03373656,Vaccination for Children of H&O and Their Parents,UNKNOWN,NA,300.0,2017-05-01,2025-09-01,2.9990147783251233,Adequate (1-10/month),29.99014778325123,Significantly Below (<50%),50,59.0,70.365
NCT07299656,Outcome of Active Aspiration Versus Simple Compression to Remove Residual Gas From Abdominal Cavity in Reducing Pain After Laparoscopic Cholecystectomy,NOT_YET_RECRUITING,NA,62.0,2025-12-11,2027-01-30,4.547662650602409,Adequate (1-10/month),45.4766265060241,Significantly Below (<50%),30,34.0,14.02
NCT00986856,Fucidin® Cream in the Treatment of Impetigo,TERMINATED,PHASE4,58.0,2004-05-01,2005-03-01,5.807631578947368,Adequate (1-10/month),58.07631578947369,Below (50-75%),10,27.6,8.295
NCT03029156,Effectiveness of the Aeroneb in Acute Severe Asthma,COMPLETED,NA,31.0,2015-08-01,2019-08-01,0.645886379192334,Slow (<1/month),6.45886379192334,Significantly Below (<50%),100,47.5,41.415
NCT06468956,Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis,ACTIVE_NOT_RECRUITING,PHASE3,652.0,2024-06-14,2026-03-31,30.300580152671756,Good (10-50/month),200.0,Exceeded (≥100%),85,90.5,93.4
NCT00946556,Examining the Ability of Herpes Simplex Virus Type 2 (HSV2) Therapy to Reduce HIV Target Cell Numbers in the Cervix,COMPLETED,NA,30.0,2010-04-01,2011-05-01,2.3118987341772153,Adequate (1-10/month),23.11898734177215,Significantly Below (<50%),100,52.4,53.949999999999996
NCT00163956,Failed Retrieval of Inferior Vena Cava (IVC) Filters: Long-Term Outcomes,UNKNOWN,,20.0,2005-08-01,2010-12-01,0.31252566735112935,Slow (<1/month),3.1252566735112937,Significantly Below (<50%),50,29.9,9.07
NCT01131156,Prevention of Postpartum Smoking Relapse in Mothers of Infants in the Neonatal Intensive Care Unit (NICU),COMPLETED,NA,54.0,2009-05-01,2010-06-01,4.150909090909091,Adequate (1-10/month),41.509090909090915,Significantly Below (<50%),100,54.3,59.62
NCT04739722,Colorectal Cancer and Pre-Cancerous Adenoma Non-Invasive Detection Test Study,COMPLETED,NA,14263.0,2021-04-12,2024-01-31,423.9899609375,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT04720222,Detectability of the Bladder With an Early Prototype of the Bladder Sensor,COMPLETED,NA,91.0,2021-04-29,2021-10-19,16.01179190751445,Good (10-50/month),160.11791907514453,Exceeded (≥100%),100,62.3,74.94
NCT03318822,Usability and Tolerability of Novel Protection Device Against Potential Brain Injury During Competitive Sport,COMPLETED,,200.0,2017-08-01,2020-12-31,4.878205128205129,Adequate (1-10/month),48.782051282051285,Significantly Below (<50%),100,64.3,77.265
NCT05856422,Respiratory Rate Validation Study,COMPLETED,,24.0,2022-12-05,2022-12-29,24.0,Good (10-50/month),200.0,Exceeded (≥100%),100,55.3,62.36000000000001
NCT04071522,Validation of the Back Beliefs Questionnaire to the Turkish,COMPLETED,,110.0,2018-06-01,2019-02-12,13.0796875,Good (10-50/month),130.796875,Exceeded (≥100%),100,62.1,74.595
NCT05466422,A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002),COMPLETED,PHASE1,34.0,2022-09-20,2025-07-03,1.0176597836774828,Adequate (1-10/month),10.176597836774828,Significantly Below (<50%),100,47.7,42.17
NCT05222022,Engineering Evaluation of an Eye Movement Monitor Device,COMPLETED,NA,39.0,2022-02-18,2023-10-10,1.9819031719532556,Adequate (1-10/month),19.819031719532553,Significantly Below (<50%),100,53.1,56.105000000000004
NCT05527522,Nutritional Intervention in Malnourished Patients With Chronic Heart Failure,COMPLETED,NA,86.0,2019-01-01,2022-11-01,1.8698857142857144,Adequate (1-10/month),18.698857142857143,Significantly Below (<50%),100,56.9,65.89500000000001
NCT01437722,Dose-ranging Study of SPL7013 Gel for the Prevention of Bacterial Vaginosis (BV),COMPLETED,PHASE2,205.0,2011-08-01,,,Slow (<1/month),,Significantly Below (<50%),100,56.4,64.88000000000001
NCT02685722,UC-MSCs Gel Treatment Difficult Healing of Skin Ulcers,COMPLETED,PHASE1,20.0,2012-01-01,2015-12-01,0.42573426573426576,Slow (<1/month),4.257342657342657,Significantly Below (<50%),100,46.6,37.375
NCT01923922,CT Perfusion in the Prognostication of Cerebral High Grade Glioma,COMPLETED,NA,48.0,2013-09-09,2019-10-22,0.6540376007162041,Slow (<1/month),6.540376007162041,Significantly Below (<50%),100,48.8,45.184999999999995
NCT01531322,A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Subjects,COMPLETED,PHASE1,72.0,2011-10-01,2012-01-01,23.822608695652175,Good (10-50/month),200.0,Exceeded (≥100%),100,60.8,72.99
NCT00001922,Sensory Function in Idiopathic Voice Disorders,COMPLETED,,370.0,1998-11-05,,,Slow (<1/month),,Significantly Below (<50%),100,67.9,80.36999999999999
NCT04629222,Tracheobronchitis in Respiratory Involvement on the Lung SPECT/CT Images of Coronavirus Disease (COVID-19) Patients,COMPLETED,,10.0,2020-03-11,2020-07-23,2.271641791044776,Adequate (1-10/month),22.71641791044776,Significantly Below (<50%),100,49.1,45.83
NCT01475422,Effectiveness of the Self Monitoring of Capillary Blood Glucose at Home,UNKNOWN,NA,91.0,2011-09-01,2012-03-01,15.22,Good (10-50/month),152.2,Exceeded (≥100%),50,47.3,40.475
NCT00913822,To Demonstrate the Relative Bioavailability of Desipramine Hydrochloride Tablets,COMPLETED,PHASE1,36.0,1987-12-01,1987-12-01,36.0,Good (10-50/month),200.0,Exceeded (≥100%),100,42.9,26.145000000000003
NCT06540222,Sustained Cord Circulation at Emergency Cesarean Section,RECRUITING,NA,2200.0,2025-09-08,2031-11-01,29.829844097995544,Good (10-50/month),200.0,Exceeded (≥100%),60,83.0,89.505
NCT00649922,Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid Arthritis,COMPLETED,PHASE4,226.0,2003-10-01,2005-02-01,14.06838445807771,Good (10-50/month),140.6838445807771,Exceeded (≥100%),100,73.1,83.515
NCT05697822,Using Advanced Data Systems to Improve Health in Early Life in Rural Nepal,UNKNOWN,NA,360.0,2023-03-01,2024-12-01,17.09578783151326,Good (10-50/month),170.95787831513258,Exceeded (≥100%),50,68.8,81.105
NCT00604422,Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) in Detection & Classification of Ulcerative Colitis,COMPLETED,,97.0,2007-04-01,2010-03-01,2.7724694835680754,Adequate (1-10/month),27.72469483568075,Significantly Below (<50%),100,56.1,63.99
NCT07103122,Virtual Reality Therapy for Arm Recovery (VVITA) Stroke,ACTIVE_NOT_RECRUITING,NA,24.0,2022-03-01,2027-06-01,0.38089676746611056,Slow (<1/month),3.808967674661105,Significantly Below (<50%),85,42.4,25.45
NCT04748822,Quality of Life in Patients With Alcohol Use Disorder,COMPLETED,NA,167.0,2021-03-25,2025-01-21,3.636251788268956,Adequate (1-10/month),36.36251788268956,Significantly Below (<50%),100,63.4,76.375
NCT05855122,Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients,UNKNOWN,PHASE4,48.0,2023-04-17,2024-12-31,2.3415384615384616,Adequate (1-10/month),23.415384615384617,Significantly Below (<50%),50,38.8,20.244999999999997
NCT05671822,Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer,ACTIVE_NOT_RECRUITING,PHASE2,76.0,2023-03-14,2026-07-30,1.8747487844408428,Adequate (1-10/month),18.74748784440843,Significantly Below (<50%),85,51.6,51.644999999999996
NCT03079622,Manual Versus Electric Vacuum Aspiration for Pregnancy Termination Between 10-14 Weeks,COMPLETED,NA,146.0,2015-11-01,2016-06-01,20.864976525821596,Good (10-50/month),200.0,Exceeded (≥100%),100,66.7,79.47999999999999
NCT06986122,Virtual Contexts for Affective Modulation,RECRUITING,NA,20.0,2025-10-28,2029-06-15,0.4591251885369533,Slow (<1/month),4.591251885369532,Significantly Below (<50%),60,34.6,14.729999999999999
NCT03686722,Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin,COMPLETED,PHASE1,20.0,2017-09-09,2017-12-06,6.918181818181818,Adequate (1-10/month),69.18181818181819,Below (50-75%),100,51.6,51.644999999999996
NCT07126522,Virtual Support Platform (HERCaRE Application) for the Improvement of Survivorship Among Black Breast Cancer Survivors,RECRUITING,NA,200.0,2025-07-18,2027-08-01,8.182795698924732,Adequate (1-10/month),81.82795698924731,Met (75-100%),60,54.0,58.72500000000001
NCT03062722,Efficacy of Keyhole Approach to Carpal Tunnel Syndrome Under Ambulatory Strategy,COMPLETED,NA,55.0,2015-01-01,2016-07-01,3.060694698354662,Adequate (1-10/month),30.606946983546617,Significantly Below (<50%),100,54.4,59.89
NCT02941822,Ambroxol in Disease Modification in Parkinson Disease,COMPLETED,PHASE2,23.0,2016-12-01,2018-05-01,1.3568217054263565,Adequate (1-10/month),13.568217054263565,Significantly Below (<50%),100,46.8,38.440000000000005
NCT00799422,Evaluation of Contact Lenses and Conjunctival Staining in Normal Patients,COMPLETED,NA,26.0,2008-11-01,2009-03-01,6.5953333333333335,Adequate (1-10/month),65.95333333333333,Below (50-75%),100,52.1,53.03
NCT04344951,"Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial",TERMINATED,PHASE2,29.0,2020-04-06,2020-11-30,3.709075630252101,Adequate (1-10/month),37.09075630252101,Significantly Below (<50%),10,25.3,7.414999999999999
NCT06956651,18-Month Clinical Evaluation of Self-Adhesive Flowable Giomer Compared to Conventional Flowable Giomer in Conservative Occlusal Restorations,NOT_YET_RECRUITING,NA,40.0,2025-09-01,2027-04-01,2.1102253032928946,Adequate (1-10/month),21.102253032928946,Significantly Below (<50%),30,32.2,11.635
NCT04044651,Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection,WITHDRAWN,PHASE2,0.0,2019-10-30,2022-09-30,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT00526851,Oral Cancer Screening Among Nursing Home Dentists in Ohio,COMPLETED,,37.0,2007-03-01,2009-01-01,1.6760119047619049,Adequate (1-10/month),16.76011904761905,Significantly Below (<50%),100,51.3,50.62
NCT06101251,A Randomized Field Trial of Smartphone-based Feedback to Encourage Safe Driving,COMPLETED,NA,1449.0,2024-01-25,2024-09-30,177.1387951807229,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT01612351,Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery,COMPLETED,PHASE2,40.0,2012-06-01,2025-05-19,0.25714889123548046,Slow (<1/month),2.5714889123548046,Significantly Below (<50%),100,48.2,43.665
NCT06912451,Sport Mouthguards: Devices for Preventing Dental Injuries in Sports,RECRUITING,NA,136.0,2024-06-01,2025-12-26,7.224851657940664,Adequate (1-10/month),72.24851657940665,Below (50-75%),60,48.9,45.4
NCT04643951,Pain in Pediatric Dentistry - a Grounded Theory Study on the Experiences of Dental Professionals and Students,RECRUITING,,35.0,2020-12-01,2026-12-30,0.47990990990990995,Slow (<1/month),4.7990990990991,Significantly Below (<50%),60,34.1,14.19
NCT06941051,Food Sustainability Knowledge and EAT-Lancet Adherence in Turkish Adults,COMPLETED,,3446.0,2024-12-30,2025-04-15,989.5871698113208,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02164851,Non-Invasive Shock: Differentiating Shock in the Emergency Department,COMPLETED,,500.0,2012-11-28,2020-01-01,5.876447876447877,Adequate (1-10/month),58.76447876447877,Below (50-75%),100,88.3,92.705
NCT01795651,Identification of Take Home Message in Lecture Based Learning,COMPLETED,,77.0,2013-02-01,2013-04-01,39.72677966101695,Good (10-50/month),200.0,Exceeded (≥100%),100,59.5,71.0
NCT00437151,Analysis of Adherence & Associated Factors in Teenagers Undergoing Treatment of Acne Vulgaris With Differin® Gel 0.1%,COMPLETED,PHASE4,61.0,2006-06-01,2007-06-01,5.08723287671233,Adequate (1-10/month),50.8723287671233,Below (50-75%),100,54.9,61.55500000000001
NCT02428751,R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma,UNKNOWN,PHASE3,216.0,2015-09-01,2020-05-01,3.8585915492957747,Adequate (1-10/month),38.58591549295775,Significantly Below (<50%),50,52.3,53.515
NCT03145051,Efficacy of Nasal Irrigation With Respimer® Netiflow® vs Saline Among Patients With Cystic Fibrosis and Chronic Rhinosinusitis,UNKNOWN,NA,50.0,2015-01-01,2017-12-01,1.4291079812206573,Adequate (1-10/month),14.291079812206576,Significantly Below (<50%),50,34.0,14.02
NCT04737551,"Adjuvant Chemoradiation Following Radical Resection of Pancreatic Ductal Adenocarcinoma, a Prospective Cohort Study",UNKNOWN,,400.0,2020-01-01,2023-12-31,8.339726027397262,Adequate (1-10/month),83.3972602739726,Met (75-100%),50,70.3,82.09
NCT06346951,Survey on the Current Status of IFD Diagnosis and Treatment by Intensive Care Physicians in Sichuan Province (IFS),NOT_YET_RECRUITING,,300.0,2024-06-01,2024-09-30,75.47107438016529,Excellent (>50/month),200.0,Exceeded (≥100%),30,61.3,73.56
NCT02610751,Maternal Smoking During Pregnancy and Female Fetal Testosterone Levels,COMPLETED,,80.0,2016-01-01,2019-08-26,1.8268567141785446,Adequate (1-10/month),18.268567141785446,Significantly Below (<50%),100,54.7,60.629999999999995
NCT02167451,Maraviroc as GVHD Prophylaxis in Transplant Recipients,TERMINATED,PHASE1,31.0,2014-07-01,2018-09-01,0.6195929087327643,Slow (<1/month),6.195929087327643,Significantly Below (<50%),10,20.5,5.92
NCT04073251,"Efficacy, Safety and Palatability of the Syrup ""KalobaTuss® Children"" for the Treatment of Cough in Children",COMPLETED,NA,106.0,2019-02-15,2019-05-10,38.41238095238095,Good (10-50/month),200.0,Exceeded (≥100%),100,63.5,76.465
NCT01926951,Renal Denervation Using Externally Focused Therapeutic Ultrasound,COMPLETED,NA,27.0,2013-09-01,2015-06-01,1.2882131661442007,Adequate (1-10/month),12.882131661442006,Significantly Below (<50%),100,47.2,40.035
NCT04718051,S.P.PRO LIVER POWDER is Used to Improve Liver and Metabolic Indexes in People With Non-alcoholic Fatty Liver Disease,UNKNOWN,PHASE4,60.0,2021-01-13,2021-12-31,5.1886363636363635,Adequate (1-10/month),51.88636363636364,Below (50-75%),50,39.8,21.47
NCT06174051,Flashforward EMDR Treatment for Patients With an ICD,UNKNOWN,NA,33.0,2024-02-01,2025-07-01,1.9467441860465116,Adequate (1-10/month),19.467441860465115,Significantly Below (<50%),50,37.6,18.845
NCT07033351,The Effect of Platelet Rich Fibrin Layers on Peri-implant Tissue Phenotype,COMPLETED,NA,31.0,2025-02-01,2025-06-06,7.549119999999999,Adequate (1-10/month),75.49119999999999,Met (75-100%),100,52.5,54.345
NCT05936151,A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes,COMPLETED,PHASE2,146.0,2023-07-20,2025-10-21,5.393495145631068,Adequate (1-10/month),53.93495145631068,Below (50-75%),100,61.7,74.1
NCT03486951,"Outpatient Orthognathic Surgery: ""AMBOST"" a One Year Study",UNKNOWN,,100.0,2018-09-01,2019-10-01,7.706329113924052,Adequate (1-10/month),77.0632911392405,Met (75-100%),50,41.3,23.74
NCT05322551,"Molecular, Metabolomic and Nutritional Changes After Metabolic Surgery",UNKNOWN,,102.0,2022-06-24,2024-12-01,3.484713804713805,Adequate (1-10/month),34.847138047138046,Significantly Below (<50%),50,41.5,24.215
NCT05807451,Anatomic Relationship Of the Popliteal Vessels In Open Wedge Osteotomy,UNKNOWN,,36.0,2023-12-01,2024-12-01,2.994098360655738,Adequate (1-10/month),29.940983606557374,Significantly Below (<50%),50,36.2,16.84
NCT02756429,Quantification of Endothelial Thrombogenicity in Patients With Atrial Fibrillation,COMPLETED,NA,200.0,2014-02-01,2018-01-01,4.257342657342658,Adequate (1-10/month),42.57342657342657,Significantly Below (<50%),100,66.0,78.99000000000001
NCT02163629,Impact of Stress Management Training After Cardiac Transplantation,UNKNOWN,PHASE3,60.0,2015-04-01,2020-12-01,0.8818928054080155,Slow (<1/month),8.818928054080155,Significantly Below (<50%),50,34.8,15.040000000000001
NCT02119429,Pumpkin Seed Oil Supplementation in Premenopausal Women,COMPLETED,PHASE2,50.0,2014-04-01,2015-05-01,3.853164556962026,Adequate (1-10/month),38.53164556962025,Significantly Below (<50%),100,54.0,58.72500000000001
NCT05526729,Special Drug Use Observational Study With Beovu Kit for Intravitreal Injection,COMPLETED,,222.0,2022-09-02,2024-06-29,10.146666666666668,Good (10-50/month),101.46666666666668,Exceeded (≥100%),100,71.1,82.54
NCT01353729,A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers,COMPLETED,PHASE1,40.0,2011-05-19,2011-08-02,16.234666666666666,Good (10-50/month),162.34666666666666,Exceeded (≥100%),100,58.2,68.795
NCT07232329,The Effect of Chronic Breathing Exercises on Pulmonary Functions: A Study on Combined Aerobic Exercise and Synchronized Breathing Exercises,COMPLETED,NA,45.0,2024-03-01,2025-01-01,4.476470588235294,Adequate (1-10/month),44.76470588235294,Significantly Below (<50%),100,53.6,57.705
NCT04800029,Telehealth to Improve Prevention of Suicide (TIPS),COMPLETED,NA,32406.0,2021-07-12,2025-11-30,615.754456928839,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT00144729,Conditioning Regimens for Patients With Severe Aplastic Anemia Transplanted With Marrow From an Unrelated Donor,COMPLETED,PHASE1,85.0,1993-05-01,2007-07-01,0.5000773096250484,Slow (<1/month),5.000773096250484,Significantly Below (<50%),100,51.8,52.17
NCT05637229,"A Serosurvey Study of Hand, Foot, and Mouth Disease in Indonesia",COMPLETED,,600.0,2022-11-28,2022-12-19,600.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02935829,Short-term Effects of a Carob Snack on Postprandial Glycemic Responses and Energy Intake and Satiety,COMPLETED,NA,140.0,2014-03-01,2016-09-01,4.657486338797814,Adequate (1-10/month),46.57486338797814,Significantly Below (<50%),100,61.2,73.43499999999999
NCT01386229,A Comparison of Etomidate and Ketamine for Anesthesia Induction in Coronary Artery Bypass Graft Surgery,UNKNOWN,PHASE4,40.0,2011-03-01,2012-03-01,3.3267759562841532,Adequate (1-10/month),33.26775956284153,Significantly Below (<50%),50,38.2,19.645000000000003
NCT04768829,Antifungal Potential of Moringa Olifera Against Otomycosis,COMPLETED,EARLY_PHASE1,10.0,2021-02-18,2021-12-01,1.0643356643356643,Adequate (1-10/month),10.643356643356643,Significantly Below (<50%),100,45.8,33.03
NCT05427929,Measuring Diaphragm Electrical Activity in Neonates Using a Smaller Inter-electrode Distance,ACTIVE_NOT_RECRUITING,NA,10.0,2023-01-12,2025-08-01,0.32660944206008585,Slow (<1/month),3.2660944206008584,Significantly Below (<50%),85,41.3,23.74
NCT00519129,Improving Quality of Colonoscopy Using a 3D-imager,COMPLETED,PHASE3,800.0,2007-08-01,2010-08-01,22.21897810218978,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT04330729,The Effect of Salicylate on Platelet Function in CKD (Chronic Kidney Disease) Patients Treated With Aranesp,RECRUITING,NA,60.0,2020-04-15,2026-12-31,0.7451652386780907,Slow (<1/month),7.451652386780906,Significantly Below (<50%),60,37.8,19.015
NCT05121129,Treatment of Major Depression by rTMS on Dorsolateral Prefrontal Cortex: Study of Underlying Mechanisms,UNKNOWN,NA,30.0,2021-10-13,2023-04-09,1.681767955801105,Adequate (1-10/month),16.81767955801105,Significantly Below (<50%),50,37.4,18.62
NCT00088829,Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer,TERMINATED,PHASE2,22.0,2001-04-01,2012-12-01,0.15712810886907558,Slow (<1/month),1.5712810886907556,Significantly Below (<50%),10,19.8,5.465
NCT00198029,An Open Label Trial for Treating Carpometacarpal Osteoarthritis of the Thumb: Pilot Study,COMPLETED,NA,32.0,2004-10-01,2009-12-01,0.516205617382088,Slow (<1/month),5.162056173820879,Significantly Below (<50%),100,47.6,41.775
NCT01982929,Post Caesarean-Section Pain Control Regimens: Oral Regimen With and Without Transversus Abdominis Plane Block,COMPLETED,NA,180.0,2013-11-01,2014-06-01,25.845283018867924,Good (10-50/month),200.0,Exceeded (≥100%),100,69.4,81.52000000000001
NCT01275729,The Effect of Loop Diuretics on Severity and Outcome of Acute Kidney Injury,COMPLETED,NA,96.0,2010-12-01,2022-06-01,0.6957714285714287,Slow (<1/month),6.957714285714286,Significantly Below (<50%),100,52.7,55.04
NCT00606229,A Multicenter Investigative Study of the Safety and Efficacy of Long-term Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode,COMPLETED,PHASE3,41.0,2008-01-01,2010-11-01,1.2058357487922706,Adequate (1-10/month),12.058357487922706,Significantly Below (<50%),100,48.3,43.985
NCT00824629,Embryo Transfer: Direct Versus Afterloading Trial,COMPLETED,NA,400.0,2008-10-01,2010-09-01,17.394285714285715,Good (10-50/month),173.94285714285712,Exceeded (≥100%),100,87.0,92.135
NCT04538729,Use of Alternative Therapy in Acne Vulgaris Patients,COMPLETED,,1571.0,2020-03-01,2020-11-30,174.53007299270072,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT01655329,Reader Study to Demonstrate That Use of ClearRead Confirm is Superior to the Use Standard AP/PA X-ray Image,COMPLETED,,10.0,2012-08-01,2013-02-01,1.6543478260869566,Adequate (1-10/month),16.543478260869566,Significantly Below (<50%),100,44.1,28.425
NCT01804829,Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.,COMPLETED,PHASE3,80.0,2013-06-01,2016-06-01,2.221897810218978,Adequate (1-10/month),22.21897810218978,Significantly Below (<50%),100,56.4,64.88000000000001
NCT01404429,Study of Two Different Starting Doses of Methotrexate When Starting Treatment in Rheumatoid Arthritis,COMPLETED,PHASE4,100.0,2011-05-01,2012-07-01,7.128805620608899,Adequate (1-10/month),71.288056206089,Below (50-75%),100,58.0,68.245
NCT04542629,Comparative Study of Dietary and Immunological Management of Refractory Epilepsy in Children,UNKNOWN,PHASE4,140.0,2020-10-01,2022-08-20,6.194186046511628,Adequate (1-10/month),61.941860465116285,Below (50-75%),50,46.2,35.089999999999996
NCT07101029,Effect of Bio-C Temp Versus Calcium Ydroxide as Intracanal Dressings on Postoperative Pain Intensity and Periapical MMP-9 Level in Patients With Necrotic Pulp,NOT_YET_RECRUITING,EARLY_PHASE1,30.0,2025-08-01,2026-07-01,2.734131736526946,Adequate (1-10/month),27.341317365269457,Significantly Below (<50%),30,31.4,10.47
NCT05868629,Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors,RECRUITING,,40.0,2024-02-06,2028-03-03,0.8188298587760592,Slow (<1/month),8.188298587760592,Significantly Below (<50%),60,34.5,14.52
NCT00768729,Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation,COMPLETED,PHASE1,7.0,2009-05-01,2012-12-01,0.16265648854961834,Slow (<1/month),1.6265648854961834,Significantly Below (<50%),100,45.6,32.08
NCT04822129,A Comparison of Two Approaches to Developing Brain Health Programs,COMPLETED,NA,18.0,2021-04-26,2022-03-31,1.616283185840708,Adequate (1-10/month),16.16283185840708,Significantly Below (<50%),100,46.4,36.26
NCT02610231,Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease,COMPLETED,PHASE3,239.0,2015-12-01,2017-12-20,9.700213333333334,Adequate (1-10/month),97.00213333333335,Met (75-100%),100,74.1,84.10499999999999
NCT01936831,High-Dose Isoniazid Among Adult Patients With Different Genetic Variants of INH-Resistant Tuberculosis (TB),COMPLETED,PHASE2,282.0,2014-08-13,2021-10-06,3.287659900421295,Adequate (1-10/month),32.87659900421295,Significantly Below (<50%),100,72.6,83.28
NCT02484131,Bone Health Management for Women Diagnosed With Breast Cancer,COMPLETED,NA,54.0,2015-11-01,2017-03-20,3.254970297029703,Adequate (1-10/month),32.549702970297034,Significantly Below (<50%),100,54.3,59.62
NCT03386331,VDR Gene Polymorphisms and Weight Loss in Non-diabetic Overweight and Obese Subjects,COMPLETED,NA,110.0,2016-03-16,2019-03-30,3.0192966636609557,Adequate (1-10/month),30.192966636609558,Significantly Below (<50%),100,58.8,69.89999999999999
NCT05175131,Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders,COMPLETED,PHASE3,465.0,2020-11-27,2021-05-18,82.29418604651163,Excellent (>50/month),200.0,Exceeded (≥100%),100,97.2,96.61999999999999
NCT04136431,Effects of Programmed Cryotherapy and Continuous Passive Motion After Computer-Assisted Total Knee Arthroplasty,COMPLETED,NA,60.0,2012-03-07,2013-03-05,5.031404958677687,Adequate (1-10/month),50.31404958677687,Below (50-75%),100,54.8,61.095
NCT03837431,Cutaneous Leishmaniasis Diagnostic Study,COMPLETED,,351.0,2019-02-13,2023-01-31,7.378756906077348,Adequate (1-10/month),73.78756906077348,Below (50-75%),100,76.4,85.25
NCT03247231,Banding Without Resection in Small Subepithelial Tumours,TERMINATED,,157.0,2017-03-31,2021-03-30,3.273342465753425,Adequate (1-10/month),32.73342465753425,Significantly Below (<50%),10,33.9,13.865
NCT00571831,The Effect of a Blue Light Filtering IOL,COMPLETED,NA,50.0,2003-02-01,2005-03-01,2.0052700922266142,Adequate (1-10/month),20.05270092226614,Significantly Below (<50%),100,54.0,58.72500000000001
NCT04048031,Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Peri-menopausal and Menopausal Women With Thinning Hair,COMPLETED,NA,70.0,2019-06-19,2020-09-30,4.543283582089552,Adequate (1-10/month),45.43283582089552,Significantly Below (<50%),100,55.6,62.905
NCT07101731,Effects of Hypopressive Exercises on Urinary Incontinence and Erectile Dysfunction After Radical Prostatectomy,RECRUITING,NA,30.0,2024-06-01,2025-11-15,1.7165413533834586,Adequate (1-10/month),17.165413533834588,Significantly Below (<50%),60,40.4,22.34
NCT03170531,A Custom-Designed MR Coil for Spine Radiotherapy Treatment Planning,COMPLETED,,8.0,2017-05-23,2021-04-26,0.1698186889818689,Slow (<1/month),1.698186889818689,Significantly Below (<50%),100,44.0,28.249999999999996
NCT04568031,Study of AZD1222 for the Prevention of COVID-19 in Japan,COMPLETED,PHASE1,256.0,2020-08-23,2021-11-22,17.089122807017546,Good (10-50/month),170.89122807017546,Exceeded (≥100%),100,75.5,84.68
NCT02854631,Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH),COMPLETED,PHASE2,104.0,2016-09-01,2018-05-31,4.969795918367347,Adequate (1-10/month),49.69795918367347,Significantly Below (<50%),100,58.3,68.99499999999999
NCT01264731,Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma,COMPLETED,PHASE1,4.0,2011-01-01,2012-06-01,0.23551257253384916,Slow (<1/month),2.3551257253384916,Significantly Below (<50%),100,45.3,31.169999999999998
NCT02759731,"Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation",COMPLETED,PHASE1,24.0,2016-11-01,2024-05-30,0.26402602096132993,Slow (<1/month),2.6402602096132997,Significantly Below (<50%),100,46.9,38.96
NCT06338631,"Early Detection of Renal Abnormalities in Metabolically Healthy and Unhealthy Weight Excess""",RECRUITING,,1000.0,2023-08-01,2025-12-31,34.473386183465465,Good (10-50/month),200.0,Exceeded (≥100%),60,81.3,88.58
NCT06859931,Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE),NOT_YET_RECRUITING,PHASE2,120.0,2025-03-01,2026-12-01,5.7075000000000005,Adequate (1-10/month),57.074999999999996,Below (50-75%),30,38.6,20.015
NCT04800731,Study of Lymphopenia as a Specific Biomarker or Prognostic Risk Factor for Disease Severity in Elderly Patients With COVID-19,COMPLETED,,227.0,2021-06-30,2022-06-30,18.93117808219178,Good (10-50/month),189.3117808219178,Exceeded (≥100%),100,71.5,82.72
NCT06661902,"Buffered Lidocaine for Reducing Pain in Patients Undergoing Prostate Biopsy, BURN Trial",RECRUITING,PHASE1,350.0,2025-01-09,2026-01-01,29.843137254901965,Good (10-50/month),200.0,Exceeded (≥100%),60,71.0,82.44
NCT06351202,Impact Assessment of Abdominal Massage on Feeding Tolerance of Preterms,RECRUITING,NA,120.0,2024-05-16,2026-06-01,4.896514745308312,Adequate (1-10/month),48.96514745308311,Significantly Below (<50%),60,47.6,41.775
NCT06388902,A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies,SUSPENDED,PHASE1,120.0,2024-02-19,2028-12-01,2.0908986834573557,Adequate (1-10/month),20.908986834573557,Significantly Below (<50%),20,35.6,16.03
NCT05475002,A Care Empowerment Program Using Virtual Reality for Family Caregivers of People With Dementia,COMPLETED,NA,92.0,2022-08-01,2023-07-01,8.384670658682635,Adequate (1-10/month),83.84670658682634,Met (75-100%),100,62.4,75.095
NCT06156202,Evaluating a Comprehensive Multimodal Outpatient Rehabilitation Program for PASC Program to Improve Functioning of Persons Suffering From Post-COVID-19 Syndrome: A Randomized Controlled Trial,COMPLETED,NA,125.0,2023-11-15,2025-11-30,5.100536193029491,Adequate (1-10/month),51.00536193029491,Below (50-75%),100,60.0,71.97
NCT01279902,Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL,UNKNOWN,PHASE2,32.0,2010-08-01,2017-01-01,0.41538592750533054,Slow (<1/month),4.153859275053306,Significantly Below (<50%),50,32.6,12.31
NCT03582202,Organization of the Dietetic Service in a Hospital,COMPLETED,NA,33.0,2015-04-18,2017-04-22,1.3666938775510205,Adequate (1-10/month),13.666938775510204,Significantly Below (<50%),100,47.6,41.775
NCT05316402,Sun Exposure for Outdoor Athletes in Mayotte and Reunion Island,UNKNOWN,NA,400.0,2022-04-01,2023-12-01,19.99343185550082,Good (10-50/month),199.9343185550082,Exceeded (≥100%),50,72.0,82.92
NCT04516902,Effects of MDMA Co-administration on the Response to LSD in Healthy Subjects,COMPLETED,PHASE1,24.0,2021-01-01,2022-08-22,1.2216722408026757,Adequate (1-10/month),12.216722408026758,Significantly Below (<50%),100,46.9,38.96
NCT04827602,Drug Allergy Labels After Drug Allergy Investigation,COMPLETED,,849.0,2021-04-15,2021-07-15,283.99516483516487,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT05523102,Paracetamol Compared With Ketorolac for Post-operative Analgetic,COMPLETED,PHASE4,85.0,2022-03-31,2022-08-02,20.866129032258062,Good (10-50/month),200.0,Exceeded (≥100%),100,61.8,74.19
NCT03181802,Are Paraspinous Intramuscular Injections of Botulinum Toxin A (BoNT-A) Efficient in the Treatment of Chronic Low-back Pain (LBP)?,COMPLETED,PHASE3,19.0,2003-11-18,2005-05-08,1.0770204841713222,Adequate (1-10/month),10.770204841713223,Significantly Below (<50%),100,46.5,36.815
NCT06392802,Effectiveness of a Rehabilitation Exercise Plan at Home to Treat Post-stroke Patients in the Chronic Phase,RECRUITING,NA,50.0,2023-03-01,2025-03-01,2.0820793433652534,Adequate (1-10/month),20.820793433652533,Significantly Below (<50%),60,42.0,24.825
NCT06755502,Garlic Oil As Root Filling Material in Primary Molars,NOT_YET_RECRUITING,NA,40.0,2025-08-08,2026-11-08,2.664332603938731,Adequate (1-10/month),26.64332603938731,Significantly Below (<50%),30,32.2,11.635
NCT01090102,Mesalamine to Reduce T Cell Activation in HIV Infection,COMPLETED,PHASE4,33.0,2010-06-01,2012-12-01,1.0990371991247265,Adequate (1-10/month),10.990371991247265,Significantly Below (<50%),100,47.6,41.775
NCT04048902,Shortwave Diathermy and Pilates Exercises in Patients With Chronic Non-specific Low Back,COMPLETED,NA,36.0,2018-03-06,2020-09-30,1.1670287539936104,Adequate (1-10/month),11.670287539936105,Significantly Below (<50%),100,47.9,42.64
NCT04058002,Project Arthritis Recovering Quality of Life Through Education 70+,UNKNOWN,NA,34.0,2019-08-15,2020-10-15,2.4237939110070257,Adequate (1-10/month),24.237939110070258,Significantly Below (<50%),50,37.7,18.915000000000003
NCT06530602,3-Dimensional Shoulder Complex Pain Alignment (3-D SPA) Mobilization on Frozen Shoulder.,RECRUITING,NA,36.0,2024-08-09,2025-01-10,7.115844155844155,Adequate (1-10/month),71.15844155844155,Below (50-75%),60,40.9,22.82
NCT04402502,Dynamic 4DCT to Examine Wrist Carpal Mechanics,COMPLETED,NA,57.0,2018-09-26,2022-02-02,1.416391836734694,Adequate (1-10/month),14.16391836734694,Significantly Below (<50%),100,49.6,46.785
NCT05629702,ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids,RECRUITING,PHASE2,120.0,2023-02-03,2027-04-01,2.406324110671937,Adequate (1-10/month),24.063241106719367,Significantly Below (<50%),60,47.6,41.775
NCT06843902,Improving Coronary Vascular Health in Women,RECRUITING,PHASE2,80.0,2025-04-17,2029-06-01,1.6169986719787517,Adequate (1-10/month),16.16998671978752,Significantly Below (<50%),60,39.4,20.94
NCT04328402,Factors Correlated With Obstructive Sleep Apnea in Children and Adolescents,COMPLETED,,187.0,2020-04-01,2021-03-15,16.35712643678161,Good (10-50/month),163.57126436781607,Exceeded (≥100%),100,68.3,80.875
NCT04847102,A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above,UNKNOWN,PHASE3,28000.0,2021-07-22,2023-05-30,1258.9660265878877,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT03210402,REmodeling the Left Ventricle With Atrial Modulated Pacing,COMPLETED,NA,22.0,2017-09-15,2021-03-15,0.5244166014095536,Slow (<1/month),5.244166014095537,Significantly Below (<50%),100,46.8,38.440000000000005
NCT07361302,A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well,NOT_YET_RECRUITING,PHASE3,1325.0,2026-02-17,2027-10-02,68.13006756756756,Excellent (>50/month),200.0,Exceeded (≥100%),30,79.0,86.96000000000001
NCT06146153,Intra Oral Scanning of Edentulous Arches,COMPLETED,,30.0,2023-11-01,2024-01-15,12.176,Good (10-50/month),121.76,Exceeded (≥100%),100,55.7,63.09
NCT06508853,Transforming Care Experiences of Support Workers and Managers,NOT_YET_RECRUITING,,12.0,2024-08-01,2025-05-01,1.3380219780219782,Adequate (1-10/month),13.380219780219782,Significantly Below (<50%),30,23.3,6.569999999999999
NCT04970953,Diastolic Exercise Stress Testing in Heart Failure,TERMINATED,,19.0,2021-08-09,2023-02-20,1.0327857142857142,Adequate (1-10/month),10.327857142857143,Significantly Below (<50%),10,17.9,2.87
NCT03637153,Acute Exposure to High Altitude on Exercise Capacity,COMPLETED,NA,28.0,2018-07-01,2019-01-01,4.632173913043478,Adequate (1-10/month),46.321739130434786,Significantly Below (<50%),100,52.2,53.22
NCT03527953,A 24-month Clinical Evaluation of Different Bulk-fill Restorative Resins in Class II Restorations,COMPLETED,NA,40.0,2013-11-01,2016-01-01,1.5393173198482935,Adequate (1-10/month),15.393173198482934,Significantly Below (<50%),100,48.2,43.665
NCT00179153,Improving The Nutritional Status Of The Malnourished Chronic Hemodialysis Patients In The State Of Tennessee,COMPLETED,PHASE2,352.0,2005-02-01,2009-05-01,6.912825806451614,Adequate (1-10/month),69.12825806451613,Below (50-75%),100,78.2,86.215
NCT05329753,Effectiveness of a Mobile Health Intervention for the Prevention of Overweight and Obesity in Adolescents,COMPLETED,NA,305.0,2019-09-15,2021-06-30,14.196024464831806,Good (10-50/month),141.96024464831805,Exceeded (≥100%),100,79.4,87.155
NCT04458753,Effect of Lumbar Stabilization on Knee OA,COMPLETED,NA,80.0,2020-06-10,2021-11-30,4.52639405204461,Adequate (1-10/month),45.2639405204461,Significantly Below (<50%),100,56.4,64.88000000000001
NCT02476253,Sodium Bicarbonate to Treat Severe Acidosis in the Critically Ill,COMPLETED,PHASE3,400.0,2015-05-05,2017-05-29,16.127152317880796,Good (10-50/month),161.27152317880794,Exceeded (≥100%),100,87.0,92.135
NCT01515553,Bioequivalence of Two Liraglutide Formulations in Healthy Volunteers,COMPLETED,PHASE1,22.0,2007-01-01,2007-04-01,7.440888888888889,Adequate (1-10/month),74.4088888888889,Below (50-75%),100,51.8,52.17
NCT07023653,Comparison of Clinical Outcomes Between All-Inside and Complete Tibial Tunnel Techniques in Anterior Cruciate Ligament Reconstruction Among Patients With ACL Ruptures,RECRUITING,NA,40.0,2024-10-15,2026-12-01,1.567052767052767,Adequate (1-10/month),15.67052767052767,Significantly Below (<50%),60,36.2,16.84
NCT01750853,A Study of LY3045697 in Healthy Participants,COMPLETED,PHASE1,27.0,2013-01-01,2013-07-01,4.540773480662984,Adequate (1-10/month),45.40773480662983,Significantly Below (<50%),100,52.2,53.22
NCT00673153,Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia,TERMINATED,PHASE2,31.0,2008-03-01,,,Slow (<1/month),,Significantly Below (<50%),10,15.5,2.53
NCT05992753,"Mothers' Breast Milk Expression Experiences, Infant Feeding Attitudes and Perceived Social Support Levels",COMPLETED,,455.0,2022-09-01,2023-01-05,109.92222222222222,Excellent (>50/month),200.0,Exceeded (≥100%),100,94.7,94.895
NCT00227253,Chromosome 18 Clinical Research Center,RECRUITING,,4000.0,1993-09-01,2040-12-01,7.055278711322286,Adequate (1-10/month),70.55278711322286,Below (50-75%),60,76.3,85.1
NCT06291753,Characteristics and Tumor Staging Proposal for Primary Malignant Melanoma of the Esophagus,COMPLETED,,25.0,2023-09-22,2024-02-18,5.10738255033557,Adequate (1-10/month),51.07382550335571,Below (50-75%),100,50.3,48.215
NCT04792853,Tablet-based Cognitive Behavioral Intervention for Older Adults With Arthritis Fatigue,COMPLETED,NA,40.0,2021-01-21,2023-04-30,1.46875753920386,Adequate (1-10/month),14.687575392038601,Significantly Below (<50%),100,48.2,43.665
NCT04371653,"A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally in Subjects With Nonalcoholic Fatty Liver Disease",WITHDRAWN,PHASE2,0.0,2023-12-01,2024-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT02276053,Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumors,COMPLETED,,93.0,2014-11-27,2017-12-04,2.5665639165911154,Adequate (1-10/month),25.665639165911152,Significantly Below (<50%),100,55.8,63.245
NCT05097053,A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19,UNKNOWN,PHASE4,200.0,2021-10-07,2022-07-01,22.801498127340825,Good (10-50/month),200.0,Exceeded (≥100%),50,56.0,63.71
NCT05594953,Outcomes Using MARS for Patients With ALF,UNKNOWN,,30.0,2021-04-23,2024-12-31,0.6774480712166173,Slow (<1/month),6.774480712166173,Significantly Below (<50%),50,30.7,9.585
NCT05652153,Inhibitory Mechanisms of Negative Urgency in Adolescent Suicidal Behavior,RECRUITING,NA,80.0,2024-05-25,2028-01-01,1.8504559270516718,Adequate (1-10/month),18.50455927051672,Significantly Below (<50%),60,44.4,28.95
NCT02294253,Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone,COMPLETED,PHASE2,30.0,2014-09-01,2017-12-01,0.7693344566133109,Slow (<1/month),7.693344566133109,Significantly Below (<50%),100,47.4,40.98
NCT06294353,Study of Efficacy and Safety of WELT-ED for Eating Disorder (WCTP-ED-B-01),RECRUITING,NA,134.0,2023-03-29,2024-08-30,7.844153846153846,Adequate (1-10/month),78.44153846153846,Met (75-100%),60,48.7,44.93
NCT04981353,Thoracic Erector Spinae Plane Block for Painless 1st Stage Normal Vaginal Delivery: Randomized Controlled Study,UNKNOWN,NA,30.0,2021-07-05,2021-10-05,9.92608695652174,Adequate (1-10/month),99.2608695652174,Met (75-100%),50,42.4,25.45
NCT02273453,Study to Evaluate the Presence of a Hangover Effect in Healthy Adults After Administration of Songha® Night Tablets,COMPLETED,PHASE1,54.0,2003-02-01,,,Slow (<1/month),,Significantly Below (<50%),100,44.3,28.715000000000003
NCT05700253,Comparing Pain Outcomes of Treatment Strategies for Osteoarthritis Knee Patients,UNKNOWN,NA,76.0,2023-02-01,2024-09-01,4.0024913494809695,Adequate (1-10/month),40.024913494809695,Significantly Below (<50%),50,41.1,23.225
NCT00452153,Evaluation of Legionella PCR Techniques for the Routine Diagnosis of Legionellosis,TERMINATED,NA,200.0,2007-03-01,2010-07-01,4.998357963875205,Adequate (1-10/month),49.98357963875205,Significantly Below (<50%),10,39.0,20.505000000000003
NCT05540353,Transvaginal Low-level Laser Therapy to Improve Pelvic Pain and Sexual Function in Patients with Endometriosis.,TERMINATED,NA,6.0,2023-05-02,2024-07-01,0.4287323943661972,Slow (<1/month),4.287323943661972,Significantly Below (<50%),10,18.5,4.02
NCT02454153,Hyperglycemic Profiles in Obstructive Sleep Apnea: Effects of PAP Therapy,COMPLETED,NA,184.0,2014-12-01,2020-03-15,2.9005489383738996,Adequate (1-10/month),29.005489383738997,Significantly Below (<50%),100,64.7,77.75999999999999
NCT04908553,Study on the Safety and Effectiveness of Remimazolam Tosilate for Injection for Short-term Elective Surgery in Adults,COMPLETED,PHASE4,650.0,2021-07-01,2025-05-31,13.836363636363638,Good (10-50/month),138.36363636363637,Exceeded (≥100%),100,95.0,95.7
NCT03915353,Evaluation Of Vestibular Functions and Balance in Edirne Band Musicians,COMPLETED,,44.0,2017-03-01,2018-06-30,2.755884773662552,Adequate (1-10/month),27.55884773662552,Significantly Below (<50%),100,51.9,52.55499999999999
NCT01464853,Effect of Enteral Nutrition Support for Critically Ill Patients,TERMINATED,PHASE3,84.0,2010-04-01,2011-05-01,6.473316455696203,Adequate (1-10/month),64.73316455696204,Below (50-75%),10,29.7,8.92
NCT04797637,Post-operative Patient Positioning Device for Improvement of Post-Operative Pain,COMPLETED,NA,278.0,2021-04-01,2022-07-20,17.81541052631579,Good (10-50/month),178.1541052631579,Exceeded (≥100%),100,77.2,85.52499999999999
NCT00852137,"A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis",COMPLETED,PHASE2,16.0,2009-03-01,2009-06-01,5.293913043478261,Adequate (1-10/month),52.93913043478261,Below (50-75%),100,51.3,50.62
NCT00815737,Effectiveness and Safety of Rhubarb for the Treatment of Patients Who Have Suffered From Cerebral Hemorrhage,UNKNOWN,PHASE2,100.0,2009-01-01,,,Slow (<1/month),,Significantly Below (<50%),50,33.0,12.695
NCT03886337,Impact of Germicidal Light,WITHDRAWN,NA,0.0,2022-05-01,2024-12-31,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT06942637,"Effectiveness of Integrated Network for Student Psychosocial Intervention, Resilience, and Education (INSPIRE) on Mental Health Outcomes Among Indonesian Adolescents in Bandung",ACTIVE_NOT_RECRUITING,NA,680.0,2025-04-28,2026-03-31,61.4219584569733,Excellent (>50/month),200.0,Exceeded (≥100%),85,95.5,96.55
NCT02848937,Calcium Mass Balance and Dialytic Efficiency of a New cITRate-containing and Acetate-free Dialysis flUidS: CITRUS Study,UNKNOWN,,62.0,2013-03-01,2016-12-01,1.3765718453683444,Adequate (1-10/month),13.765718453683442,Significantly Below (<50%),50,33.3,13.200000000000001
NCT06461637,Stepped Care Treatment for Common Mental Disorders Among Foreign Domestic Helpers,NOT_YET_RECRUITING,NA,240.0,2024-07-01,2025-06-01,21.807761194029855,Good (10-50/month),200.0,Exceeded (≥100%),30,53.2,56.665
NCT05981937,ICG Anastomosis Control in Colon Surgery,COMPLETED,,115.0,2023-07-20,2024-02-01,17.860204081632652,Good (10-50/month),178.60204081632654,Exceeded (≥100%),100,62.5,75.21
NCT05871437,Randomized Controlled Clinical Study on the Reduction of Tumor Marker Levels in Breast Cancer Patients by Huaier Granules,NOT_YET_RECRUITING,PHASE4,232.0,2025-09-01,2028-01-01,8.288826291079813,Adequate (1-10/month),82.88826291079813,Met (75-100%),30,47.6,41.775
NCT00065637,Once Weekly Parathyroid Hormone for Osteoporosis,COMPLETED,PHASE3,50.0,2003-12-01,2005-09-01,2.378125,Adequate (1-10/month),23.78125,Significantly Below (<50%),100,54.0,58.72500000000001
NCT07311837,"Investigating the Relationships Between Body Composition, Peripheral Muscle Strength, and Cough Force in Healthy Young Adults",NOT_YET_RECRUITING,,46.0,2026-02-15,2026-03-15,46.0,Good (10-50/month),200.0,Exceeded (≥100%),30,41.0,23.01
NCT01183637,Evaluation of an Acellular Osteochondral Graft for Cartilage LEsions Pilot Trial,TERMINATED,PHASE2,2.0,2010-06-01,2014-05-01,0.042573426573426575,Slow (<1/month),0.42573426573426576,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT01918137,The Effect of a Deep-fried Chocolate Bar or Porridge on Cerebral Blood Flow,UNKNOWN,NA,24.0,2013-08-01,2013-09-01,23.566451612903226,Good (10-50/month),200.0,Exceeded (≥100%),50,41.9,24.585
NCT06368037,Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy,NOT_YET_RECRUITING,NA,10.0,2024-08-01,2026-06-01,0.45500747384155454,Slow (<1/month),4.550074738415545,Significantly Below (<50%),30,24.8,7.06
NCT02444637,Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD,COMPLETED,PHASE4,100.0,2015-04-01,2019-03-01,2.128671328671329,Adequate (1-10/month),21.286713286713287,Significantly Below (<50%),100,58.0,68.245
NCT04375137,Correlation Between Oxidative Stress Status and COVID-19 Severity,COMPLETED,,90.0,2020-04-20,2022-05-30,3.557922077922078,Adequate (1-10/month),35.57922077922078,Significantly Below (<50%),100,55.5,62.71
NCT01511237,Perinatal Antiretroviral Intensification for PMTCT of HIV in Late Comers,COMPLETED,PHASE3,379.0,2011-12-01,2017-03-01,6.018132498695879,Adequate (1-10/month),60.18132498695879,Below (50-75%),100,80.3,88.075
NCT00220337,A Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Diabetic Neuropathy,COMPLETED,PHASE3,371.0,2004-12-21,2007-10-31,10.81727969348659,Good (10-50/month),108.1727969348659,Exceeded (≥100%),100,84.7,90.78500000000001
NCT04151537,Personal Activity Intelligence in the Treatment of High Blood Pressure,COMPLETED,NA,26.0,2019-10-21,2020-05-19,3.7509004739336493,Adequate (1-10/month),37.5090047393365,Significantly Below (<50%),100,52.1,53.03
NCT06660537,Effects of Balloon-blowing Exercises in 90/90 Bridge Position With a Ball on Pulmonary Function Among Asthmatic Patients,RECRUITING,NA,41.0,2024-08-15,2025-02-01,7.3414117647058825,Adequate (1-10/month),73.41411764705882,Below (50-75%),60,41.3,23.74
NCT02490137,Brain Changes With Game Training in Aging,COMPLETED,NA,20.0,2015-06-15,2017-08-15,0.7686868686868688,Slow (<1/month),7.686868686868687,Significantly Below (<50%),100,46.6,37.375
NCT07200037,Effects of IMT on Weaning and Diaphragmatic Function in PMV Patients,NOT_YET_RECRUITING,NA,120.0,2025-10-01,2026-09-01,10.903880597014927,Good (10-50/month),109.03880597014926,Exceeded (≥100%),30,43.6,27.54
NCT02365337,Influence of Serum Vitamin D Levels on Embryo Morphokinetic Parameters,UNKNOWN,,100.0,2015-04-01,2016-07-01,6.660831509846827,Adequate (1-10/month),66.60831509846827,Below (50-75%),50,41.3,23.74
NCT00017537,Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer,WITHDRAWN,PHASE1,0.0,2000-03-01,2005-03-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT06628037,SN514-066b Enzyme in Deep Partial Thickness Burns,ENROLLING_BY_INVITATION,PHASE1,27.0,2025-05-08,2026-05-01,2.2957541899441343,Adequate (1-10/month),22.957541899441342,Significantly Below (<50%),55,38.7,20.145
NCT04691037,CCTA Improves Clinical Management of Stable Chest Pain,RECRUITING,,50000.0,2016-01-01,2030-01-01,297.6143918654674,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT03888937,bnP for pRediction of Outcome FollowIng Lung rEsection Surgery,UNKNOWN,,250.0,2018-10-01,2020-10-01,10.410396716826266,Good (10-50/month),104.10396716826267,Exceeded (≥100%),50,58.3,68.99499999999999
NCT07257237,Sleep Hygiene Education and Blood Pressure Control in Essential Hypertension in Primary Care,COMPLETED,NA,138.0,2024-01-01,2024-07-31,19.814716981132076,Good (10-50/month),198.14716981132077,Exceeded (≥100%),100,66.0,78.99000000000001
NCT05001737,"Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE",COMPLETED,PHASE3,33.0,2021-12-15,2025-06-04,0.7928334648776638,Slow (<1/month),7.928334648776639,Significantly Below (<50%),100,47.6,41.775
NCT01949337,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,UNKNOWN,PHASE3,1311.0,2014-01-22,2024-08-31,10.30119772844605,Good (10-50/month),103.01197728446053,Exceeded (≥100%),50,80.0,87.67
NCT06554145,Development and Evaluation of AI Program for Predicting Bacterial Species From Urine Gram Stain Specimens,RECRUITING,,15000.0,2023-09-25,2028-08-01,257.6749435665914,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT01285245,Effect of Anakinra on Insulin Sensitivity in Type 1 Diabetes Mellitus,UNKNOWN,PHASE2,16.0,2011-04-01,2011-12-01,1.9960655737704918,Adequate (1-10/month),19.960655737704915,Significantly Below (<50%),50,36.3,17.0
NCT00351845,Clinical Study to Test the Effects of a Low-Carbohydrate Diet on Body Weight,COMPLETED,NA,86.0,2004-04-01,2004-12-01,10.728852459016393,Good (10-50/month),107.28852459016392,Exceeded (≥100%),100,61.9,74.265
NCT01482845,"A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease",COMPLETED,PHASE1,20.0,2011-11-01,2012-03-01,5.031404958677686,Adequate (1-10/month),50.31404958677687,Below (50-75%),100,51.6,51.644999999999996
NCT03366545,Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices,RECRUITING,,3000.0,2018-05-14,2026-03-01,32.06460674157304,Good (10-50/month),200.0,Exceeded (≥100%),60,81.3,88.58
NCT01335945,Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer,TERMINATED,PHASE1,14.0,2011-08-01,2015-01-01,0.3412009607686149,Slow (<1/month),3.4120096076861492,Significantly Below (<50%),10,19.1,4.9799999999999995
NCT06503445,The Impact of Video-based Cardiac Rehabilitation Education in Patients With CIEDs- a Randomized Controlled Trial,COMPLETED,NA,85.0,2021-03-03,2022-07-20,5.133730158730159,Adequate (1-10/month),51.33730158730159,Below (50-75%),100,56.8,65.69500000000001
NCT00836745,Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent,COMPLETED,,36.0,2009-03-01,2012-07-01,0.8997044334975369,Slow (<1/month),8.997044334975367,Significantly Below (<50%),100,46.2,35.089999999999996
NCT05567445,Outcome of Cardiomyopathic Adults Admission in ICU.,UNKNOWN,,45.0,2023-09-01,2024-10-01,3.4590909090909094,Adequate (1-10/month),34.590909090909086,Significantly Below (<50%),50,36.9,17.735
NCT06847945,Observation on the Curative Effect of Acupuncture At Sensitized Points on Gallbladder Meridian in the Treatment of Neck Type Cervical Spondylopathy,NOT_YET_RECRUITING,NA,80.0,2025-03-05,2025-12-31,8.090365448504985,Adequate (1-10/month),80.90365448504984,Met (75-100%),30,35.4,15.765
NCT02625545,Study of Median Lobe Prostatic UroLift Procedure,COMPLETED,NA,45.0,2016-02-17,2017-12-19,2.041430700447094,Adequate (1-10/month),20.414307004470942,Significantly Below (<50%),100,53.6,57.705
NCT00832572,Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy,TERMINATED,PHASE4,5.0,2009-01-01,2009-06-01,1.0079470198675498,Adequate (1-10/month),10.079470198675496,Significantly Below (<50%),10,18.4,3.855
NCT04156672,Real World Study Of The Clinical Profile And Treatment Outcomes Of Advanced Therapies For Ulcerative Colitis In Portugal,WITHDRAWN,,0.0,2020-10-06,2021-04-30,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT05573672,Dietary Counselling Plus Omega-3 Supplementation in the Treatment of Generalized Anxiety Disorder,COMPLETED,PHASE2,50.0,2022-08-12,2023-11-30,3.2042105263157894,Adequate (1-10/month),32.04210526315789,Significantly Below (<50%),100,54.0,58.72500000000001
NCT02284672,The Effect of Dexmedetomidine on Propofol Requirement for Insertion of Laryngeal Mask Airway,COMPLETED,PHASE4,39.0,2014-11-01,2016-01-01,2.7867605633802817,Adequate (1-10/month),27.867605633802818,Significantly Below (<50%),100,53.1,56.105000000000004
NCT04315272,Gut and Azithromycin Mechanisms in Infants and Children II,COMPLETED,PHASE4,449.0,2020-08-21,2022-06-01,21.059414483821264,Good (10-50/month),200.0,Exceeded (≥100%),100,90.9,93.53
NCT03565172,"Efficacy of a Long Term, High Intensity and Long Time Stretch Training Program on Viscoelasticity Plantarflexors Muscle in Children With Cerebral Palsy (CP).",TERMINATED,NA,1.0,2018-07-02,2018-07-26,1.0,Adequate (1-10/month),10.0,Significantly Below (<50%),10,18.1,3.105
NCT04193072,Imagery Ability in Obstetric Brachial Plexus Palsy,COMPLETED,,40.0,2017-10-02,2018-03-25,6.997701149425287,Adequate (1-10/month),69.97701149425288,Below (50-75%),100,51.5,51.245
NCT03284372,Safer Food Allergy Management for Adolescents,COMPLETED,NA,138.0,2018-01-18,2020-07-31,4.541318918918919,Adequate (1-10/month),45.41318918918919,Significantly Below (<50%),100,61.0,73.17
NCT06763172,Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI,RECRUITING,PHASE4,12.0,2023-05-17,2026-12-31,0.27589123867069487,Slow (<1/month),2.7589123867069487,Significantly Below (<50%),60,34.0,14.02
NCT04235972,Evaluation of Staple Watson Wrist Arthrodesis,COMPLETED,NA,41.0,2020-08-03,2021-01-07,7.9492993630573245,Adequate (1-10/month),79.49299363057325,Met (75-100%),100,53.3,57.14
NCT04031872,LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615),WITHDRAWN,PHASE1,0.0,2020-01-01,2020-01-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT00878072,Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis,COMPLETED,PHASE2,53.0,2009-03-25,2010-06-02,3.7173271889400925,Adequate (1-10/month),37.17327188940092,Significantly Below (<50%),100,54.2,59.330000000000005
NCT02679872,Video-assisted Thoracoscopic Surgery Teams' Perception of Non-technical Skills,COMPLETED,,21.0,2016-02-01,2016-12-01,2.102763157894737,Adequate (1-10/month),21.02763157894737,Significantly Below (<50%),100,50.0,47.675
NCT04349072,A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy,COMPLETED,PHASE3,112.0,2020-07-06,2024-05-20,2.4110891089108915,Adequate (1-10/month),24.110891089108915,Significantly Below (<50%),100,59.0,70.365
NCT01625572,Ultrasound-assisted Bilateral Transversus Abdominis Plane Block for Open Prostatectomy,COMPLETED,NA,66.0,2012-07-01,2015-12-01,1.6098076923076923,Adequate (1-10/month),16.098076923076924,Significantly Below (<50%),100,50.3,48.215
NCT02978872,Quantra Determination of Coagulation Parameters in Arterial and Venous Blood,COMPLETED,,30.0,2016-07-01,2017-01-01,4.96304347826087,Adequate (1-10/month),49.6304347826087,Significantly Below (<50%),100,50.7,48.915
NCT00111072,Dexamethasone to Treat Oral Lichen Planus,COMPLETED,PHASE2,70.0,2005-05-01,2006-03-01,7.00921052631579,Adequate (1-10/month),70.0921052631579,Below (50-75%),100,55.6,62.905
NCT01515072,Remote Ischemic Preconditioning in Neurological Death Organ Donors,COMPLETED,NA,321.0,2011-07-01,2015-04-01,7.132291970802919,Adequate (1-10/month),71.3229197080292,Below (50-75%),100,75.7,84.785
NCT03518372,Myocardial Injury and Intraoperative Tissue Oximetry in Patients Undergoing Spine Surgery,COMPLETED,,70.0,2018-01-02,2018-07-24,10.496551724137932,Good (10-50/month),104.96551724137933,Exceeded (≥100%),100,58.9,70.10499999999999
NCT05724472,Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health,COMPLETED,PHASE1,36.0,2023-06-19,2024-01-09,5.371764705882353,Adequate (1-10/month),53.71764705882354,Below (50-75%),100,52.9,55.55
NCT01853072,Nepafenac Once Daily for Macular Edema - Study 1,COMPLETED,PHASE3,881.0,2013-06-01,2015-05-01,38.365722460658084,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT03575572,Colchicine in Postoperative Fontan Patients,TERMINATED,PHASE2,11.0,2018-08-29,2021-01-13,0.3857603686635945,Slow (<1/month),3.857603686635944,Significantly Below (<50%),10,18.9,4.6899999999999995
NCT04005872,Clinical and Radiographic Evaluation of Nano Silver Fluoride Versus Calcium Hydroxide in Indirect Pulp Treatment,COMPLETED,NA,40.0,2019-10-01,2022-11-30,1.053287197231834,Adequate (1-10/month),10.53287197231834,Significantly Below (<50%),100,48.2,43.665
NCT05981872,EFFECT OF COGNITIVE BEHAVIORAL THERAPY ON DEPRESSION AND QUALITY OF LIFE IN PATIENTS WITH POST COVID-19,UNKNOWN,NA,36.0,2023-05-04,2024-01-01,4.528264462809918,Adequate (1-10/month),45.28264462809918,Significantly Below (<50%),50,37.9,19.139999999999997
NCT05564572,Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology,UNKNOWN,NA,3000.0,2022-09-07,2023-12-07,200.26315789473685,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT02875795,Carcinologic Speech Severity Index,COMPLETED,NA,124.0,2015-01-01,2017-12-31,3.447086757990868,Adequate (1-10/month),34.470867579908685,Significantly Below (<50%),100,59.9,71.86
NCT02552095,Triathlon PKR Study in Japan,COMPLETED,NA,63.0,2013-06-01,2018-09-01,0.9998540145985403,Slow (<1/month),9.998540145985402,Significantly Below (<50%),100,50.0,47.675
NCT04050995,Evaluation of the MuSICCA for Measuring Awareness,RECRUITING,,80.0,2022-04-01,2027-12-01,1.1764251207729468,Adequate (1-10/month),11.764251207729467,Significantly Below (<50%),60,37.7,18.915000000000003
NCT03485495,Clinical Trial of Efficacy and Safety of Divaza for Adjustment of Oxidative Disorders in Patients With Cerebral Atherosclerosis,COMPLETED,PHASE4,124.0,2018-04-12,2019-04-11,10.36967032967033,Good (10-50/month),103.6967032967033,Exceeded (≥100%),100,64.9,77.985
NCT03251495,Immunologic Responses to a Live Attenuated Oral Cholera Vaccine,ACTIVE_NOT_RECRUITING,PHASE2,34.0,2017-08-29,2025-12-01,0.3431564986737401,Slow (<1/month),3.431564986737401,Significantly Below (<50%),85,43.2,26.840000000000003
NCT03013595,The MILESTONE Study: Improving Transition From Child to Adult Mental Health Care,UNKNOWN,NA,1000.0,2015-10-01,2018-12-01,26.309420916162487,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT06358495,Improving Sleep to Prevent Depression & Anxiety in Adolescents at High Risk,RECRUITING,NA,50.0,2024-11-01,2025-08-30,5.039735099337748,Adequate (1-10/month),50.39735099337748,Below (50-75%),60,42.0,24.825
NCT04342195,Acquiring Convalescent Specimens for COVID-19 Antibodies,COMPLETED,,15.0,2020-03-25,2021-03-12,1.2971590909090909,Adequate (1-10/month),12.97159090909091,Significantly Below (<50%),100,44.5,29.160000000000004
NCT00769795,Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer,COMPLETED,PHASE2,29.0,2008-10-01,2011-11-01,0.7839786856127886,Slow (<1/month),7.839786856127887,Significantly Below (<50%),100,47.3,40.475
NCT04208295,24-hour Blood Pressure Dynamics and Autonomic Adrenergic Regulation in Type 2 Diabetics,UNKNOWN,,80.0,2019-05-01,2021-06-01,3.1958005249343837,Adequate (1-10/month),31.958005249343834,Significantly Below (<50%),50,39.7,21.21
NCT05991895,Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer,RECRUITING,,5000.0,2023-07-24,2026-07-01,141.8452935694315,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT06275295,A Retrospective Study of Transbronchial Cryobiopsy in the Diagnosis of Progressive Pulmonary Fibrosis,NOT_YET_RECRUITING,,300.0,2024-03-20,2024-12-31,31.93006993006993,Good (10-50/month),200.0,Exceeded (≥100%),30,56.3,64.5
NCT05176795,Host-microbiota-environment Interactions,RECRUITING,,60.0,2022-03-16,2026-09-01,1.1204907975460123,Adequate (1-10/month),11.204907975460124,Significantly Below (<50%),60,36.1,16.665
NCT06025695,"Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks",COMPLETED,PHASE3,2000.0,2023-09-01,2024-10-23,145.64593301435409,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT00687895,Improved Clinical and Microscopy Diagnosis at Primary Health Care in Tanzania,COMPLETED,PHASE4,3131.0,2003-07-01,2004-03-01,390.6050819672131,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT00672295,"PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer",COMPLETED,PHASE1,11.0,2007-08-01,2012-11-01,0.17448671182907766,Slow (<1/month),1.7448671182907767,Significantly Below (<50%),100,45.9,33.495000000000005
NCT00577395,Bone Microarchitecture in Osteopenic Postmenopausal Women,TERMINATED,PHASE4,13.0,2008-07-01,2009-02-01,1.8405581395348838,Adequate (1-10/month),18.40558139534884,Significantly Below (<50%),10,24.0,6.79
NCT00620295,Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors,COMPLETED,PHASE1,17.0,2007-03-01,2009-10-01,0.5475978835978836,Slow (<1/month),5.475978835978836,Significantly Below (<50%),100,46.4,36.26
NCT04902495,Clinical and Radiographic Evaluation of Pulpotomies in Primary Molars Using Tricalcium Silicate Cements,RECRUITING,NA,61.0,2017-01-12,2024-12-12,0.642282947077136,Slow (<1/month),6.42282947077136,Significantly Below (<50%),60,37.9,19.139999999999997
NCT03881995,Effects of Insulin Glargine and Lixisenatide on the Brain,TERMINATED,PHASE4,1.0,2019-03-18,2020-06-29,0.0649040511727079,Slow (<1/month),0.6490405117270789,Significantly Below (<50%),10,18.1,3.105
NCT03943095,Study to Characterize the Efficacy of a Dual Active Dentifrice for the Relief of Dentin Hypersensitivity,COMPLETED,PHASE2,123.0,2019-05-13,2019-08-28,34.99177570093458,Good (10-50/month),200.0,Exceeded (≥100%),100,64.8,77.865
NCT04738695,SARS-CoV-2 Seroprevalence Among Nursing Home Staff and Residents (COVID-19),COMPLETED,,3008.0,2021-02-01,2022-12-31,131.17982808022924,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02604095,"Effect of Melatonin on Body Composition, Glucose Metabolism and Lipid Metabolism",COMPLETED,NA,16.0,2014-05-01,2015-10-01,0.9402316602316603,Slow (<1/month),9.402316602316603,Significantly Below (<50%),100,46.3,35.66
NCT03390595,Avelumab Plus Carboplatin-gemcitabine in Urothelial Carcinoma,COMPLETED,PHASE2,85.0,2018-05-17,2022-08-31,1.6511805998723676,Adequate (1-10/month),16.511805998723673,Significantly Below (<50%),100,51.8,52.17
NCT04860895,Detection of SARS-CoV-2 in Nasopharyngeal Swabs by Using Multi-Spectral Screening System,UNKNOWN,NA,4400.0,2021-02-11,2021-05-15,1440.1720430107528,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT03026595,The Profile of the Depression and it's Intervention Strategy in Patients With Parkinson's Disease in China,UNKNOWN,,500.0,2017-01-01,2018-12-01,21.773962804005723,Good (10-50/month),200.0,Exceeded (≥100%),50,78.3,86.48
NCT03870295,Technique to Measure Type C Fibre Nerve Conduction Velocitynerve Fibers in Polyneuropathies,COMPLETED,NA,45.0,2019-09-30,2020-09-29,3.7528767123287676,Adequate (1-10/month),37.52876712328768,Significantly Below (<50%),100,53.6,57.705
NCT03235895,Evaluation of Internet-Based CME for Wet-cupping Providers,UNKNOWN,NA,90.0,2017-09-25,2017-12-10,36.04736842105263,Good (10-50/month),200.0,Exceeded (≥100%),50,47.2,40.035
NCT03324139,Treatment of Intrauterine Growth Restriction With Low Molecular Heparin.,COMPLETED,PHASE3,48.0,2018-01-25,2023-02-19,0.7893679092382496,Slow (<1/month),7.893679092382497,Significantly Below (<50%),100,48.8,45.184999999999995
NCT00942539,Midazolam Sedation for Neonatal Lumbar Puncture,TERMINATED,PHASE2,12.0,2009-07-01,2011-07-01,0.5003835616438357,Slow (<1/month),5.003835616438357,Significantly Below (<50%),10,19.0,4.84
NCT05018039,Feasibility and Acceptability of Collaborative Care for People With Musculoskeletal and Mental Problems,UNKNOWN,NA,40.0,2022-01-30,2023-12-30,1.7419170243204578,Adequate (1-10/month),17.41917024320458,Significantly Below (<50%),50,38.2,19.645000000000003
NCT02840539,"Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma",COMPLETED,PHASE2,19.0,2016-10-11,2022-12-31,0.25455985915492957,Slow (<1/month),2.545598591549296,Significantly Below (<50%),100,46.5,36.815
NCT01219439,Evaluation of Discarded Laboratory Pathological Specimens and Media,COMPLETED,,10000.0,2007-07-01,2022-12-01,54.04829545454545,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT04015739,Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse,UNKNOWN,PHASE2,74.0,2019-03-01,2024-01-29,1.254908077994429,Adequate (1-10/month),12.54908077994429,Significantly Below (<50%),50,35.9,16.445
NCT05367739,Real World Study on the Efficacy and Safety of Anti-HER2 Therapy,COMPLETED,,200.0,2020-06-01,2023-07-01,5.411555555555555,Adequate (1-10/month),54.11555555555555,Below (50-75%),100,64.3,77.265
NCT06607939,ORB-021 In Patients With Advanced Solid Tumors,RECRUITING,PHASE1,36.0,2024-11-21,2027-02-28,1.321881785283474,Adequate (1-10/month),13.218817852834741,Significantly Below (<50%),60,35.9,16.445
NCT04945239,Amplification of Positivity to Enhance Social Connections in Anxiety and Depression,COMPLETED,NA,134.0,2021-03-29,2024-03-25,3.7353113553113557,Adequate (1-10/month),37.35311355311356,Significantly Below (<50%),100,60.7,72.89999999999999
NCT00037739,Chronic Obstructive Pulmonary Disease Gene Localization,COMPLETED,,,2001-04-01,2004-03-01,,Slow (<1/month),,Significantly Below (<50%),100,43.3,27.05
NCT00847639,Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma,COMPLETED,PHASE2,30.0,2009-02-01,2014-03-01,0.49255663430420715,Slow (<1/month),4.925566343042072,Significantly Below (<50%),100,47.4,40.98
NCT05079139,Musset's Surgical Technique: Evaluation of Long-term Results (LONGOMUSSET),COMPLETED,NA,11.0,2022-01-20,2022-03-24,5.314920634920635,Adequate (1-10/month),53.149206349206345,Below (50-75%),100,50.9,49.370000000000005
NCT02531139,The Effect of Blood Pressure on Cerebral Perfusion During Vascular Surgery,WITHDRAWN,NA,0.0,2017-03-01,2017-11-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT07170839,Combined Isotonic Exercise in the Treatment of Lateral Epicondylitis,COMPLETED,NA,40.0,2025-01-20,2025-05-30,9.366153846153846,Adequate (1-10/month),93.66153846153846,Met (75-100%),100,58.2,68.795
NCT01168739,"Effect of Combined Exercise, Heat, and Quercetin Supplementation on Whole Body Stress Response",COMPLETED,NA,9.0,2009-09-01,2010-03-01,1.5135911602209946,Adequate (1-10/month),15.135911602209944,Significantly Below (<50%),100,45.7,32.5
NCT05865639,Time Restricted Fasting and Aerobic Exercise Interventions Among Sedentary Adults,COMPLETED,NA,56.0,2022-02-01,2022-12-01,5.625874587458746,Adequate (1-10/month),56.258745874587454,Below (50-75%),100,54.5,60.12
NCT00396539,Hydrogen Sulfide Production by Oral Microflora,COMPLETED,,60.0,2007-01-01,2008-09-01,2.999014778325123,Adequate (1-10/month),29.990147783251224,Significantly Below (<50%),100,53.1,56.105000000000004
NCT07342439,Study of Serine Supplementation to Protect Vision in MacTel,NOT_YET_RECRUITING,PHASE3,120.0,2026-09-01,2030-02-01,2.924579663730985,Adequate (1-10/month),29.24579663730985,Significantly Below (<50%),30,38.6,20.015
NCT03026439,Searching Clinical Chronic Obstructive Pulmonary Disease Onset,COMPLETED,,240.0,2014-09-01,2018-09-30,4.903087248322148,Adequate (1-10/month),49.03087248322148,Significantly Below (<50%),100,67.5,80.08
NCT00269139,Outcome of Crisis Intervention for Subjects With Borderline Personality Disorder or Post-Traumatic Stress Disorder,UNKNOWN,PHASE1,40.0,,,,Slow (<1/month),,Significantly Below (<50%),50,28.2,8.469999999999999
NCT01350739,The Umbilical Access in Laparoscopic Surgery,WITHDRAWN,NA,0.0,2015-05-01,2017-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT01691339,Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.,COMPLETED,PHASE4,200.0,2012-09-01,2013-02-01,39.790849673202615,Good (10-50/month),200.0,Exceeded (≥100%),100,71.0,82.44
NCT03913039,Reduction of Prostate Biopsy Morbidity,COMPLETED,,157.0,2019-05-01,2021-12-31,4.9016205128205135,Adequate (1-10/month),49.01620512820513,Significantly Below (<50%),100,60.9,73.06
NCT00439439,"ACHAT-STUDY, Alternative Treatment of Chronic Globus Sensations",COMPLETED,NA,40.0,2006-10-01,2008-05-01,2.106574394463668,Adequate (1-10/month),21.06574394463668,Significantly Below (<50%),100,53.2,56.665
NCT05495139,Gastric Bypass Stent Small-Sample-Size Study For Nonalcoholic Fatty Liver Disease,RECRUITING,NA,10.0,2022-12-15,2026-06-30,0.2354215003866976,Slow (<1/month),2.354215003866976,Significantly Below (<50%),60,33.8,13.694999999999999
NCT05287139,QOL of Women With HR-Positive Metastatic BC Treated in the First-line Setting: Comparison Between Public and Private Institutions.,UNKNOWN,,202.0,2021-07-14,2022-07-30,16.13879265091864,Good (10-50/month),161.38792650918637,Exceeded (≥100%),50,54.5,60.12
NCT04547439,"Sleep, Diabetic Retinopathy and Melatonin",RECRUITING,PHASE2,42.0,2021-02-03,2026-06-01,0.6576543209876544,Slow (<1/month),6.576543209876544,Significantly Below (<50%),60,36.4,17.14
NCT01635439,Prostin and Propess in Induction of Labor,COMPLETED,PHASE3,200.0,2010-12-01,2011-12-01,16.679452054794524,Good (10-50/month),166.7945205479452,Exceeded (≥100%),100,71.0,82.44
NCT05765877,Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer,RECRUITING,PHASE2,26.0,2023-03-01,2029-03-01,0.36105839416058394,Slow (<1/month),3.6105839416058396,Significantly Below (<50%),60,35.1,15.384999999999998
NCT02280577,[Trial of device that is not approved or cleared by the U.S. FDA],WITHHELD,,,,,,Slow (<1/month),,Significantly Below (<50%),50,20.0,5.695
NCT03762577,Effects of Ground-based Walking Training in Pulmonary Hypertension,COMPLETED,NA,24.0,2018-12-10,2020-03-04,1.6234666666666668,Adequate (1-10/month),16.23466666666667,Significantly Below (<50%),100,46.9,38.96
NCT04785677,Researching Resiliency in Stressful Experiences (RISE) Program for Men Leaving Incarceration,COMPLETED,NA,403.0,2021-02-09,2024-06-30,9.916992724333063,Adequate (1-10/month),99.16992724333063,Met (75-100%),100,87.2,92.21000000000001
NCT02934477,Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis,RECRUITING,,650.0,2016-11-01,2027-10-01,4.9638735574510795,Adequate (1-10/month),49.63873557451079,Significantly Below (<50%),60,76.3,85.1
NCT01761877,NSAID Effects on Clinical and Imaging Breast Biomarkers,COMPLETED,PHASE2,114.0,2012-12-01,2019-03-11,1.5146922741161066,Adequate (1-10/month),15.146922741161067,Significantly Below (<50%),100,54.1,59.11
NCT04515277,"Study to Evaluate the Effect of Gum Acacia (FibregumTM) on Post-prandial Glucose, Insulin Levels and Food Intake",COMPLETED,NA,36.0,2019-06-28,2019-09-27,12.042197802197803,Good (10-50/month),120.42197802197802,Exceeded (≥100%),100,57.9,67.83
NCT06599177,The Impact of Psychosocial Interventions in Patients with COPD,ACTIVE_NOT_RECRUITING,NA,160.0,2024-09-08,2026-02-28,9.05278810408922,Adequate (1-10/month),90.5278810408922,Met (75-100%),85,63.3,76.235
NCT00052377,Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides,TERMINATED,PHASE1,46.0,2002-09-01,,,Slow (<1/month),,Significantly Below (<50%),10,16.7,2.68
NCT02033577,"Effects of Long Biliopancreatic Limb Versus Long Alimentary Limb in Superobesity, a Randomized Study",UNKNOWN,NA,200.0,2011-08-01,2016-08-01,3.3322386425834702,Adequate (1-10/month),33.32238642583471,Significantly Below (<50%),50,51.0,49.714999999999996
NCT00118677,Long-Term Supervised Treatment Interruption in HIV-Infected Patients,COMPLETED,PHASE3,130.0,2003-02-01,2007-05-01,2.5530322580645164,Adequate (1-10/month),25.530322580645166,Significantly Below (<50%),100,60.4,72.54
NCT00879177,Smoking Study With Behavioral Therapy for Hypertensive Patients,COMPLETED,PHASE4,203.0,2009-04-01,2014-11-01,3.0290784313725494,Adequate (1-10/month),30.29078431372549,Significantly Below (<50%),100,66.2,79.2
NCT00517777,Continuous Positive Airway Pressure in Sleep Apnea Syndrome: Effects on Metabolic Syndrome and Cardiac Damage,UNKNOWN,PHASE4,100.0,2007-08-01,2010-08-01,2.7773722627737225,Adequate (1-10/month),27.773722627737225,Significantly Below (<50%),50,43.0,26.465
NCT04611477,Effect of Synbiotic 365 on Body Composition in Overweight and Obese Individuals,COMPLETED,NA,180.0,2020-09-28,2021-10-29,13.836363636363638,Good (10-50/month),138.36363636363635,Exceeded (≥100%),100,69.4,81.52000000000001
NCT03584477,Robotic Rehabilitation of the Upper Limb After a Stroke,TERMINATED,NA,54.0,2014-10-30,2022-07-11,0.5847598719316969,Slow (<1/month),5.847598719316969,Significantly Below (<50%),10,22.3,6.279999999999999
NCT01830777,Brentuximab Vedotin + Re-induction Chemotherapy for AML,COMPLETED,PHASE1,22.0,2013-05-01,2019-05-01,0.3056503879507075,Slow (<1/month),3.0565038795070754,Significantly Below (<50%),100,46.8,38.440000000000005
NCT04109677,AIM CONTROL and SWECON - Handball The SWEdish CONcussion Study in Elite Handball,UNKNOWN,,126.0,2019-09-25,2021-07-31,5.682133333333334,Adequate (1-10/month),56.821333333333335,Below (50-75%),50,43.4,27.265
NCT06318377,Peanuts and Neurocognitive / Cardiovascular Health in Black Individuals,COMPLETED,NA,40.0,2022-09-01,2024-07-31,1.7419170243204578,Adequate (1-10/month),17.41917024320458,Significantly Below (<50%),100,53.2,56.665
NCT05572177,Feasibility of a Smartphone Application for Asthma Self-management,RECRUITING,NA,50.0,2023-06-26,2025-07-31,1.986945169712794,Adequate (1-10/month),19.86945169712794,Significantly Below (<50%),60,42.0,24.825
NCT03002077,Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder,COMPLETED,PHASE3,617.0,2017-02-03,2018-12-06,27.990283159463488,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT03414775,"Influences of High-fiber, Organic Whole-food Formula on the Gut Microbiome in Critically Ill Children",COMPLETED,NA,32.0,2018-02-02,2025-07-01,0.35997043606799706,Slow (<1/month),3.599704360679971,Significantly Below (<50%),100,47.6,41.775
NCT06291675,"Gender-Affirming Hormone Therapy and Its Impact on Myocardial Mass and Cardiac Function, Heart, Liver and Pancreatic Fat Content",RECRUITING,,50.0,2023-03-03,2033-03-03,0.4166438543662743,Slow (<1/month),4.166438543662744,Significantly Below (<50%),60,35.3,15.534999999999998
NCT00376675,Methylphenidate in Treating Patients With Fatigue Caused by Cancer,COMPLETED,PHASE3,148.0,2008-02-01,2010-06-01,5.293913043478262,Adequate (1-10/month),52.93913043478261,Below (50-75%),100,61.8,74.19
NCT04357275,The RIsk Stratification in COVID-19 Patients in the ICU Registry,UNKNOWN,,10000.0,2020-03-13,2025-12-01,145.7156534226903,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT05501275,Evaluation of Life Quality in Post Stroke Patients,COMPLETED,NA,447.0,2021-09-14,2023-06-30,20.805321100917432,Good (10-50/month),200.0,Exceeded (≥100%),100,90.8,93.51
NCT00543075,"Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function",COMPLETED,PHASE1,23.0,2006-05-01,2009-09-01,0.5743396226415094,Slow (<1/month),5.743396226415094,Significantly Below (<50%),100,46.8,38.440000000000005
NCT01090375,Regulation of Intraarticular and Synovium-related Biomarkers of Osteoarthritis. Effect of Acute Mechanical Joint Loading,COMPLETED,EARLY_PHASE1,,2008-08-01,,,Slow (<1/month),,Significantly Below (<50%),100,40.0,21.87
NCT06890975,"""F!reF!ghterF!t"": Lifestyle Coaching Interventions for Obese Firefighters (FireFit)",RECRUITING,NA,50.0,2025-01-21,2026-01-01,4.411594202898551,Adequate (1-10/month),44.11594202898551,Significantly Below (<50%),60,42.0,24.825
NCT05493475,Evaluation of a Novel Intervention to Prevent Polysubstance Overdoses Involving Illicit Stimulants,COMPLETED,NA,653.0,2022-11-10,2025-09-29,18.858937381404175,Good (10-50/month),188.58937381404175,Exceeded (≥100%),100,95.0,95.7
NCT02444975,The Effect of Increased Water Intake on the Frequency of the Clinical Recurrent Urinary Tract Infections in Pre-menopausal Women: S-HYDRACYST,COMPLETED,NA,140.0,2013-12-01,2016-07-01,4.519194061505833,Adequate (1-10/month),45.19194061505833,Significantly Below (<50%),100,61.2,73.43499999999999
NCT00054275,Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer,COMPLETED,PHASE2,39.0,2002-12-01,2012-11-01,0.32767319900634834,Slow (<1/month),3.276731990063484,Significantly Below (<50%),100,48.1,43.275000000000006
NCT05228275,"Evaluation of Immunologic Response Following COVID-19 Vaccination in Children, Adolescents, and Young Adults With Cancer",ACTIVE_NOT_RECRUITING,,549.0,2022-04-08,2027-09-30,8.35160419790105,Adequate (1-10/month),83.51604197901051,Met (75-100%),85,88.8,92.89
NCT04646057,DuraSorb® in Prosthetic Breast Reconstruction,UNKNOWN,NA,168.0,2021-01-15,2024-12-01,3.6115254237288137,Adequate (1-10/month),36.115254237288134,Significantly Below (<50%),50,48.4,44.22
NCT01731457,Limitation of Ischemic Injury of a Kidney Stored in Machine Perfusion in Hypothermia - Evaluation of the Impact on Kidney Allograft Function,COMPLETED,PHASE2,94.0,2011-04-01,2016-02-01,1.6193322014714204,Adequate (1-10/month),16.193322014714205,Significantly Below (<50%),100,52.5,54.345
NCT04423757,A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression,TERMINATED,PHASE2,45.0,2020-06-22,2022-05-08,1.9997080291970804,Adequate (1-10/month),19.9970802919708,Significantly Below (<50%),10,26.6,8.01
NCT02768857,Effects of Early Sensory Reeducation Programs Using Mirror Therapy for Patients With Peripheral Nerve Injuries,COMPLETED,NA,12.0,2014-12-01,2015-10-01,1.201578947368421,Adequate (1-10/month),12.015789473684212,Significantly Below (<50%),100,46.0,34.1
NCT06464757,"Laryngomalacia, Examinations and Quality of Life in Children Before and After Treatment With Follow-up After 1 Year",RECRUITING,,50.0,2024-01-01,2034-12-31,0.37888971869554394,Slow (<1/month),3.7888971869554386,Significantly Below (<50%),60,35.3,15.534999999999998
NCT07357857,High Five! - School-based Prevention of Overweight and Obesity Among 6 to 9 Year Olds,COMPLETED,NA,659.0,2025-04-23,2025-11-28,91.59799086757991,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT03580057,Effect of Weight Loss and Lactation (the EVA-trial),COMPLETED,NA,156.0,2018-01-30,2023-12-15,2.2138181818181817,Adequate (1-10/month),22.138181818181817,Significantly Below (<50%),100,62.5,75.21
NCT02241057,Investigational Air-Activated Adhesive-Backed Heat Patch (3-Cell),COMPLETED,NA,60.0,2014-09-01,2014-10-01,60.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,64.8,77.865
NCT01464957,Skin Cancer Prevention in a Pediatric Population,COMPLETED,PHASE2,867.0,2003-11-01,2008-09-01,14.944212910532277,Good (10-50/month),149.44212910532278,Exceeded (≥100%),100,95.0,95.7
NCT04486157,Bioequivalence and Safety Study of IN-A012 and Akynzeo Capsules in Male and Female Healthy Korean Subjects,COMPLETED,PHASE1,44.0,2021-03-18,2021-05-10,25.270943396226418,Good (10-50/month),200.0,Exceeded (≥100%),100,58.5,69.34
NCT01509157,MDRS for Prevention of Nocturnal Hypoglycemia,COMPLETED,PHASE1,38.0,2012-01-01,2013-04-01,2.5366666666666666,Adequate (1-10/month),25.36666666666667,Significantly Below (<50%),100,53.0,55.80500000000001
NCT04821401,Rejuvant™ Safety and Biomarker Study,COMPLETED,NA,100.0,2020-02-07,2022-02-14,4.124661246612466,Adequate (1-10/month),41.24661246612467,Significantly Below (<50%),100,58.0,68.245
NCT04612101,Check Brain Temp Trial,COMPLETED,,12.0,2018-10-01,2020-10-01,0.4996990424076608,Slow (<1/month),4.996990424076608,Significantly Below (<50%),100,44.3,28.715000000000003
NCT04228601,A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer,COMPLETED,PHASE1,39.0,2020-01-21,2023-01-15,1.0891376146788991,Adequate (1-10/month),10.891376146788993,Significantly Below (<50%),100,48.1,43.275000000000006
NCT05444101,Optimizing Psychological Treatment for Pain After Breast Cancer,UNKNOWN,NA,185.0,2022-09-01,2024-10-01,7.4,Adequate (1-10/month),74.0,Below (50-75%),50,49.8,47.17
NCT06060301,Topical Sulfasalazine and Oral Lichen Planus,ACTIVE_NOT_RECRUITING,PHASE3,46.0,2023-03-01,2024-10-20,2.33762938230384,Adequate (1-10/month),23.376293823038395,Significantly Below (<50%),85,49.2,46.035
NCT02413801,"Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients",COMPLETED,,103.0,2015-03-19,2023-12-01,0.9862598301352627,Slow (<1/month),9.862598301352628,Significantly Below (<50%),100,51.6,51.644999999999996
NCT01554501,"The Role of Stress in Self-Control, Coping, and Emotion Regulation",COMPLETED,,855.0,2007-11-01,2015-12-01,8.816463414634148,Adequate (1-10/month),88.16463414634148,Met (75-100%),100,93.3,94.325
NCT05697601,Predictors of Ovarian Cancer and Endometrial Cancer for Artificial-Intelligence-Based Screening Tools,UNKNOWN,,2905.0,2023-02-28,2024-06-30,181.20532786885246,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT01592201,A Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug,TERMINATED,PHASE4,13.0,2012-07-01,2013-06-01,1.1812537313432836,Adequate (1-10/month),11.812537313432836,Significantly Below (<50%),10,19.0,4.84
NCT07219901,"Early Intervention in Infants With Unrepaired Cleft Palate: Language, Palatal Function, and Articulation.",NOT_YET_RECRUITING,NA,200.0,2025-10-21,2027-01-31,13.036402569593148,Good (10-50/month),130.36402569593147,Exceeded (≥100%),30,50.0,47.675
NCT00609401,Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC),COMPLETED,PHASE2,90.0,2006-11-01,2008-05-01,5.008409506398538,Adequate (1-10/month),50.08409506398538,Below (50-75%),100,57.2,66.465
NCT04850001,Cognitive Decline in Asymptomatic Intracranial Stenosis Patients: A 1-Year Follow-Up Study,UNKNOWN,,40.0,2020-09-10,2025-12-31,0.6282765737874098,Slow (<1/month),6.282765737874096,Significantly Below (<50%),50,31.5,10.635
NCT02953301,Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS),COMPLETED,PHASE2,201.0,2016-11-01,2024-08-01,2.1619929328621907,Adequate (1-10/month),21.619929328621907,Significantly Below (<50%),100,66.1,79.125
NCT01384201,Confocal Endomicroscopy Detection of Gastric Preneoplasia and Neoplasia,COMPLETED,,100.0,2007-08-01,2010-10-01,2.630942091616249,Adequate (1-10/month),26.30942091616249,Significantly Below (<50%),100,56.3,64.5
NCT03291301,Group Cognitive Behavioral Therapy and Acupressure for Insomnia,COMPLETED,NA,40.0,2017-12-11,2018-05-31,7.12046783625731,Adequate (1-10/month),71.2046783625731,Below (50-75%),100,53.2,56.665
NCT05839301,A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age,UNKNOWN,PHASE3,1200.0,2023-04-27,2024-04-30,98.9918699186992,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT03854201,Personalized Exercise Counseling to Promote Workability,UNKNOWN,NA,190.0,2018-12-10,2023-12-20,3.150108932461874,Adequate (1-10/month),31.501089324618736,Significantly Below (<50%),50,50.2,48.04
NCT00721201,Glucocorticoid Receptor Antagonism in Subclinical Cushings,COMPLETED,PHASE1,6.0,2008-11-01,2010-03-01,0.37657731958762886,Slow (<1/month),3.7657731958762883,Significantly Below (<50%),100,45.5,31.705
NCT03167801,Melatonin Secretion and Sleep Quality in Spinal Cord Injury Patients,COMPLETED,,18.0,2017-07-11,2018-07-31,1.4231688311688313,Adequate (1-10/month),14.231688311688314,Significantly Below (<50%),100,44.8,29.845
NCT04213001,Diagnostic Contribution of Ultrasonography in Breast Cancer-Related Lymphedema,COMPLETED,NA,34.0,2020-01-02,2020-01-31,34.0,Good (10-50/month),200.0,Exceeded (≥100%),100,57.7,67.51
NCT04352101,Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits,COMPLETED,PHASE4,18.0,2020-09-23,2022-07-25,0.8177910447761195,Slow (<1/month),8.177910447761194,Significantly Below (<50%),100,46.4,36.26
NCT01659801,Evaluation of the BunnyLens TR Intraocular Lens,COMPLETED,NA,25.0,2012-05-21,2015-05-01,0.707906976744186,Slow (<1/month),7.079069767441861,Significantly Below (<50%),100,47.0,39.33
NCT03716401,Prognostic Imaging Biomarkers for Diabetic Kidney Disease,RECRUITING,,500.0,2018-09-01,2038-09-01,2.0835044490075294,Adequate (1-10/month),20.83504449007529,Significantly Below (<50%),60,76.3,85.1
NCT00387712,Inflammatory Abnormalities in Muscle After Stroke: Effects of Exercise,COMPLETED,NA,99.0,2006-10-01,2014-08-01,1.053324012583013,Adequate (1-10/month),10.53324012583013,Significantly Below (<50%),100,52.9,55.55
NCT00438412,Vasoactive Hormones and Oxygen Saturation During Apneic Events in Patients With Obstructive Sleep Apnea,SUSPENDED,,40.0,2006-10-01,,,Slow (<1/month),,Significantly Below (<50%),20,17.5,2.82
NCT02410512,A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors,COMPLETED,PHASE1,610.0,2015-04-24,2019-11-22,11.098864315600718,Good (10-50/month),110.98864315600719,Exceeded (≥100%),100,95.0,95.7
NCT03476512,Treatment Adherence and Blood Pressure Outcome Among Hypertensive Out-patients,COMPLETED,,605.0,2017-02-01,2017-05-30,156.06949152542373,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT00104312,Osteoarthritis: Weakness From Inflammation,COMPLETED,,88.0,2001-04-01,2009-05-01,0.9074254742547426,Slow (<1/month),9.074254742547428,Significantly Below (<50%),100,50.4,48.355
NCT03974412,Syncope Trial to Understand Tilt Testing Early or Recorders Study,COMPLETED,NA,40.0,2019-05-28,2024-12-31,0.5956947162426615,Slow (<1/month),5.956947162426615,Significantly Below (<50%),100,48.2,43.665
NCT00794612,Dermacyd Femina Pocket BR (Lactic Acid)- Acceptability.,COMPLETED,PHASE3,30.0,2008-11-01,,,Slow (<1/month),,Significantly Below (<50%),100,42.4,25.45
NCT00702312,A Bengali Dietary Salt Study to Control Blood Pressure,COMPLETED,PHASE3,56.0,2008-06-01,2009-07-01,4.315544303797469,Adequate (1-10/month),43.155443037974685,Significantly Below (<50%),100,54.5,60.12
NCT02708212,Optimal Procedural Sequence in Same-day Bidirectional Endoscopy: A Prospective Randomized Controlled Study,COMPLETED,NA,121.0,2016-04-01,2016-07-01,40.47516483516484,Good (10-50/month),200.0,Exceeded (≥100%),100,64.7,77.75999999999999
NCT07038512,Evaluation of Hyivy Floora in Managing Interstitial Cystitis/Bladder Pain Syndrome/High-tone Pelvic Floor Dysfunction,NOT_YET_RECRUITING,NA,10.0,2026-05-01,2026-10-01,1.9895424836601308,Adequate (1-10/month),19.895424836601308,Significantly Below (<50%),30,29.8,8.98
NCT03262012,"Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®",COMPLETED,PHASE3,416.0,2016-08-09,2018-06-15,18.76005925925926,Good (10-50/month),187.60059259259262,Exceeded (≥100%),100,88.3,92.705
NCT00469612,Evaluating NeuroVision's Neural Vision Correction (NVC) Myopia Treatment,TERMINATED,NA,2.0,2007-06-01,2009-12-01,0.06660831509846828,Slow (<1/month),0.6660831509846827,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT04019912,The Novel Use of Treadmill Plus Music in MS Patients Gate Rehabilitation,UNKNOWN,NA,40.0,2019-10-01,2020-05-01,5.716431924882629,Adequate (1-10/month),57.16431924882629,Below (50-75%),50,38.2,19.645000000000003
NCT02142881,Treatment of Masked Hypertension,COMPLETED,PHASE3,4.0,2014-06-01,2017-12-07,0.09475486381322958,Slow (<1/month),0.9475486381322957,Significantly Below (<50%),100,45.3,31.169999999999998
NCT02085681,Study of Effectiveness of Telemedicine in Identifying Diabetic Retinopathy Cases,COMPLETED,NA,801.0,2014-05-01,2015-03-01,80.20539473684211,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT06115681,Real-world Study of Dedifferentiated Liposarcoma Patients in China,COMPLETED,,1390.0,2024-03-13,2024-05-15,671.6126984126984,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT00118781,Trial of Iseganan in Prevention of Ventilator-Associated Pneumonia,TERMINATED,PHASE2,900.0,2003-09-01,2004-06-01,99.98540145985402,Excellent (>50/month),200.0,Exceeded (≥100%),10,73.0,83.44
NCT04250181,High Power vs Standard Power RF Ablation of Atrial Fibrillation in Conscious Patients,COMPLETED,,30.0,2019-11-15,2020-02-08,10.743529411764706,Good (10-50/month),107.43529411764705,Exceeded (≥100%),100,55.7,63.09
NCT02619981,The Effect of Parental Presence on Dental Fear,COMPLETED,PHASE4,150.0,2012-11-01,2015-02-01,5.554744525547445,Adequate (1-10/month),55.54744525547446,Below (50-75%),100,62.0,74.42
NCT06591481,Retrospective Case-Control Study for Developing an Artificial Intelligence (AI) Tool for Lesion Detection Using Magnetic Resonance Imaging (MRI) and Clinical Variables for Early Diagnosis of Axial Spondyloarthritis (axSpA),COMPLETED,,925.0,2023-02-19,2025-04-03,36.378552971576234,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT01227681,Study of the Neuro-protective Effect of Granulocyte-colony Stimulating Factor on Early Stage Parkinson's Disease,TERMINATED,PHASE2,4.0,2010-06-01,2013-12-01,0.09519937451133699,Slow (<1/month),0.9519937451133699,Significantly Below (<50%),10,18.3,3.74
NCT05212181,Clinic to Home Robotics-assisted Telerehabilitation for Upper Limb (CHISEL),COMPLETED,,12.0,2022-02-10,2022-12-31,1.1274074074074074,Adequate (1-10/month),11.274074074074074,Significantly Below (<50%),100,44.3,28.715000000000003
NCT06285981,Retrospective Study Chimaera Long Nail in Adult Patient,COMPLETED,,44.0,2023-11-27,2024-12-18,3.4608785529715766,Adequate (1-10/month),34.60878552971577,Significantly Below (<50%),100,51.9,52.55499999999999
NCT02190981,Point of Care Ultrasound for Suspected Small Bowel Obstruction in the Emergency Department,COMPLETED,,217.0,2014-07-01,2019-02-01,3.941217183770883,Adequate (1-10/month),39.412171837708826,Significantly Below (<50%),100,65.7,78.66499999999999
NCT04330781,Radiotherapy of Head and Neck Cancer Using an Intraoral Stent,COMPLETED,PHASE2,220.0,2020-01-01,2025-07-08,3.3234739454094298,Adequate (1-10/month),33.234739454094296,Significantly Below (<50%),100,67.6,80.15
NCT01434381,Initial Study of Malaria Vaccine Pfs25-EPA/Alhydrogel(Registered Trademark),COMPLETED,PHASE1,30.0,2011-08-01,2013-08-01,1.249247606019152,Adequate (1-10/month),12.49247606019152,Significantly Below (<50%),100,47.4,40.98
NCT05037981,Effect of Early Systemic Stabilization Therapy on Recent Onset Vitiligo,COMPLETED,,25.0,2015-10-10,2021-08-20,0.35544138253152735,Slow (<1/month),3.5544138253152733,Significantly Below (<50%),100,45.3,31.169999999999998
NCT05842681,Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis,RECRUITING,NA,30.0,2023-06-01,2026-04-30,0.8582706766917293,Slow (<1/month),8.582706766917294,Significantly Below (<50%),60,35.4,15.765
NCT01236781,Comparison of Full-Field Digital Mammography With Digital Breast Tomography for Screening Call-Back Rates,COMPLETED,NA,558.0,2011-01-04,2013-12-31,15.554505494505495,Good (10-50/month),155.54505494505497,Exceeded (≥100%),100,95.0,95.7
NCT00497081,Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors,COMPLETED,PHASE2,60.0,2007-05-01,2010-03-01,1.7646376811594202,Adequate (1-10/month),17.6463768115942,Significantly Below (<50%),100,54.8,61.095
NCT03748381,Comparison of 2 Diffractive Trifocal IOLs,UNKNOWN,NA,44.0,2018-04-01,2020-04-01,1.8322298221614228,Adequate (1-10/month),18.32229822161423,Significantly Below (<50%),50,38.5,19.895
NCT06709781,Cardiovascular Responses in Burn Survivors During Exercise,RECRUITING,NA,36.0,2025-01-08,2027-01-01,1.5156846473029046,Adequate (1-10/month),15.156846473029045,Significantly Below (<50%),60,35.9,16.445
NCT02509481,Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study,COMPLETED,PHASE2,2712.0,2015-06-01,2015-12-01,451.1108196721312,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT01698281,Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer,TERMINATED,PHASE2,7.0,2012-12-01,2014-10-01,0.3185052316890882,Slow (<1/month),3.1850523168908818,Significantly Below (<50%),10,18.6,4.25
NCT04031781,The Role of Left Prefrontal Transcranial Magnetic Stimulation in Episodic Migraine Prophylaxis,COMPLETED,NA,33.0,2013-05-01,2015-02-01,1.5671138845553823,Adequate (1-10/month),15.67113884555382,Significantly Below (<50%),100,47.6,41.775
NCT00240981,TOM: Testosterone in Older Men With Sarcopenia,TERMINATED,PHASE4,209.0,2005-01-01,2009-12-01,3.5442674094707525,Adequate (1-10/month),35.44267409470752,Significantly Below (<50%),10,39.7,21.21
NCT00692081,Social Competence Training for Adolescents With Borderline Intellectual Functioning,COMPLETED,PHASE2,77.0,,,,Slow (<1/month),,Significantly Below (<50%),100,46.2,35.089999999999996
NCT02571881,Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section,UNKNOWN,PHASE4,57.0,2012-10-01,2023-12-01,0.4254732712113781,Slow (<1/month),4.254732712113781,Significantly Below (<50%),50,34.6,14.729999999999999
NCT02323581,Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts,RECRUITING,NA,520.0,2013-11-01,2033-12-01,2.157982276755283,Adequate (1-10/month),21.57982276755283,Significantly Below (<50%),60,78.0,86.075
NCT07167381,xDRIVE for Florida-based Cancer Patients,RECRUITING,NA,210.0,2025-11-01,2027-04-01,12.388372093023255,Good (10-50/month),123.88372093023254,Exceeded (≥100%),60,59.8,71.61
NCT04839081,Neuropathic Hand Pain in Rheumatoid Arthritis,ACTIVE_NOT_RECRUITING,,300.0,2021-04-26,2026-06-15,4.867803837953092,Adequate (1-10/month),48.67803837953091,Significantly Below (<50%),85,67.8,80.285
NCT06756581,Tolerability of Baked Dairy Protein in Eosinophilic Esophagitis Patients With Cow Milk Protein Trigger,ENROLLING_BY_INVITATION,NA,20.0,2025-03-01,2030-12-01,0.2897667777248929,Slow (<1/month),2.897667777248929,Significantly Below (<50%),55,33.1,12.814999999999998
NCT03554681,Prediction of Preeclampsia (PE) at 11-13 Week,COMPLETED,,10935.0,2016-12-01,2019-09-01,331.53525896414345,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT05312281,Study Comparing Postoperative Treatment After Surgical Decompression for Lumbar Spinal Stenosis.,UNKNOWN,NA,100.0,2022-06-28,2025-12-01,2.431309904153355,Adequate (1-10/month),24.313099041533548,Significantly Below (<50%),50,43.0,26.465
NCT04176419,Perioperative Analgesia on Postoperative Opioid Usage and Pain Control in H&N Cancer Surgery,TERMINATED,PHASE3,30.0,2020-01-17,2021-06-23,1.7460803059273422,Adequate (1-10/month),17.460803059273424,Significantly Below (<50%),10,25.4,7.470000000000001
NCT00210119,Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response,TERMINATED,PHASE2,19.0,2006-07-12,2009-03-01,0.6005815160955349,Slow (<1/month),6.005815160955349,Significantly Below (<50%),10,19.5,5.315
NCT04202419,Nonablative Fractional Diode Laser for Treatment of Pigmented Lesions,COMPLETED,NA,30.0,2020-01-09,2021-04-26,1.9306553911205073,Adequate (1-10/month),19.306553911205075,Significantly Below (<50%),100,52.4,53.949999999999996
NCT03790319,Emotional Competence and Compassion Training,UNKNOWN,,50.0,2019-01-01,2020-07-31,2.6377816291161182,Adequate (1-10/month),26.37781629116118,Significantly Below (<50%),50,37.3,18.35
NCT02608619,Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement,COMPLETED,,3.0,2015-11-01,2018-08-01,0.09095617529880479,Slow (<1/month),0.9095617529880479,Significantly Below (<50%),100,43.6,27.54
NCT02530619,Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia,UNKNOWN,NA,26.0,2015-10-09,2022-05-01,0.3303171953255426,Slow (<1/month),3.303171953255426,Significantly Below (<50%),50,32.1,11.5
NCT01615419,An Observational Study of RoActemra/Actemra (Tocilizumab) in Rheumatoid Arthritis Patients,COMPLETED,,60.0,2012-05-01,2013-11-01,3.3267759562841532,Adequate (1-10/month),33.26775956284153,Significantly Below (<50%),100,53.1,56.105000000000004
NCT05070819,Atrial Natriuretic Peptide in Assessing Fluid Status,COMPLETED,NA,30.0,2021-09-23,2022-04-07,4.659183673469388,Adequate (1-10/month),46.59183673469388,Significantly Below (<50%),100,52.4,53.949999999999996
NCT02405819,Patient and Provider Initiated Survivorship Care Planning,COMPLETED,NA,41.0,2015-02-01,2016-02-01,3.419287671232877,Adequate (1-10/month),34.19287671232877,Significantly Below (<50%),100,53.3,57.14
NCT03327519,Solving Insomnia Electronically: Sleep Treatment for Asthma,TERMINATED,NA,34.0,2018-05-29,2022-08-15,0.6724886289798571,Slow (<1/month),6.724886289798571,Significantly Below (<50%),10,20.7,6.02
NCT01070719,"Pharmacokinetic, Immunological and Biochemical Sample Collection and Analysis of a Tysabri Patient Cohort",COMPLETED,,270.0,2010-02-01,2010-05-01,92.34606741573035,Excellent (>50/month),200.0,Exceeded (≥100%),100,79.9,87.315
NCT06936319,Counterpressure Maneuvers in Postural Orthostatic Tachycardia Syndrome,RECRUITING,NA,40.0,2025-01-15,2025-12-31,3.478857142857143,Adequate (1-10/month),34.78857142857143,Significantly Below (<50%),60,41.2,23.425
NCT04992819,The Effect of Oral Feeding Model With a Chronobiological Approach in Preterm Infants,COMPLETED,NA,80.0,2020-12-29,2021-07-03,13.092473118279571,Good (10-50/month),130.9247311827957,Exceeded (≥100%),100,61.4,73.735
NCT05836519,Effects of Pes Planus on Quality of Life,UNKNOWN,,32.0,2023-05-01,2023-12-01,4.55177570093458,Adequate (1-10/month),45.51775700934579,Significantly Below (<50%),50,35.9,16.445
NCT01746719,Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fasting Condition,COMPLETED,PHASE1,36.0,2012-10-01,2012-12-01,17.964590163934425,Good (10-50/month),179.64590163934423,Exceeded (≥100%),100,57.9,67.83
NCT01928719,Reduced Nicotine Content Cigarettes in Smokers of Lower Socioeconomic Status,COMPLETED,NA,280.0,2015-09-09,2018-02-23,9.491314031180401,Adequate (1-10/month),94.91314031180401,Met (75-100%),100,77.4,85.835
NCT06374719,WiTNNess - TNNT1 Myopathy Natural History Study,RECRUITING,,40.0,2018-09-23,2027-06-01,0.3837377875827293,Slow (<1/month),3.837377875827293,Significantly Below (<50%),60,34.5,14.52
NCT03561519,FMT in the Treatment of IBS,COMPLETED,NA,52.0,2015-08-27,2018-07-01,1.5234648700673725,Adequate (1-10/month),15.234648700673725,Significantly Below (<50%),100,49.2,46.035
NCT02338219,Effects of Pregnancy and Childbirth on Pelvic Floor Morphology and Sexual Function in Egyptian Women,COMPLETED,PHASE1,120.0,2013-05-01,2014-02-01,13.234782608695651,Good (10-50/month),132.34782608695653,Exceeded (≥100%),100,64.6,77.59
NCT01387919,Time Course and Nature of Nutrient Sensing During Fasting in Humans,COMPLETED,NA,12.0,2011-02-01,2011-03-01,12.0,Good (10-50/month),120.0,Exceeded (≥100%),100,56.0,63.71
NCT07321119,Correlation Between Cervical Deep Flexors Endurance and Proprioception Function in Cervical Radiculopathy,NOT_YET_RECRUITING,,80.0,2026-01-01,2026-03-01,41.27457627118644,Good (10-50/month),200.0,Exceeded (≥100%),30,38.7,20.145
NCT05394519,A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight,COMPLETED,PHASE3,1200.0,2023-02-01,2025-02-03,49.83356070941337,Good (10-50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT03370419,The Pick Two to Stick To Habit Development Intervention,COMPLETED,NA,40.0,2016-01-13,2017-12-30,1.698186889818689,Adequate (1-10/month),16.98186889818689,Significantly Below (<50%),100,53.2,56.665
NCT00286819,Dose Density FU 75 and FU 90 as Adjuvant Therapy for Early Breast Cancer,COMPLETED,PHASE2,50.0,2005-04-01,2006-09-01,2.9382239382239383,Adequate (1-10/month),29.382239382239383,Significantly Below (<50%),100,54.0,58.72500000000001
NCT02047019,Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil,WITHDRAWN,PHASE3,0.0,2017-12-01,2019-12-08,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT07037719,Automatic Detection of Eligible Patients to RAUC Protocol (RAUCISABLE),RECRUITING,,300000.0,2025-01-17,2026-01-17,25019.178082191782,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT04736719,Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data,COMPLETED,,19002.0,2020-09-22,2021-02-18,3882.0193288590604,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT05574530,Vitamin (VIT) for Vigilance Study,UNKNOWN,NA,90.0,2022-10-12,2023-07-01,10.45648854961832,Good (10-50/month),104.56488549618321,Exceeded (≥100%),50,47.2,40.035
NCT03355430,Simultaneous Corneal Wavefront-Guided Trans-PRK and Corneal Collagen Crosslinking After ICRS Implantation for Moderate Keratoconus,COMPLETED,,23.0,2016-07-07,2017-01-02,3.9112849162011174,Adequate (1-10/month),39.11284916201117,Significantly Below (<50%),100,50.2,48.04
NCT06739330,Thyroid Dysfunction and Its Association With Metabolic Dysfunction-Associated Fatty Liver Disease,RECRUITING,,150.0,2024-12-19,2025-05-01,34.33082706766917,Good (10-50/month),200.0,Exceeded (≥100%),60,53.3,57.14
NCT05417230,RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2,UNKNOWN,PHASE2,29.0,2022-08-01,2025-08-01,0.8054379562043795,Slow (<1/month),8.054379562043795,Significantly Below (<50%),50,32.3,11.799999999999999
NCT01562730,Myovista iECG for Detecting Ischemic Heart Disease: Comparison With Computed Tomography Coronary Angiography,UNKNOWN,,1000.0,2012-04-01,2013-04-01,83.3972602739726,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT03597230,Per-operative Exploration of the Peri-pancreatic Lymphatic Pathways During Pancreatic Surgical Resection,UNKNOWN,NA,20.0,2018-10-22,2020-10-22,0.8328317373461013,Slow (<1/month),8.328317373461012,Significantly Below (<50%),50,31.6,10.905
NCT03382730,De-adoption of Oral Chlorhexidine Prophylaxis and Implementation of an Oral Care Bundle (CHORAL),COMPLETED,NA,3260.0,2017-12-01,2020-01-01,130.4,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT07159230,PCOT for Outpatients With Acute Respiratory Tract Infection at Risk of Severe Disease in Primary Healthcare,NOT_YET_RECRUITING,NA,16868.0,2025-09-15,2028-01-31,591.5459907834102,Excellent (>50/month),200.0,Exceeded (≥100%),30,79.0,86.96000000000001
NCT05883930,The Effect of the Mobile Software Let's Move Program on Changing Sedentary Behaviors of University Students,UNKNOWN,NA,194.0,2023-10-30,2024-04-30,32.269726775956286,Good (10-50/month),200.0,Exceeded (≥100%),50,55.5,62.71
NCT04080830,Registration Study of Acute Ischemic Stroke/Transient Ischemic Attack (TIA) With Atrial Fibrillation,UNKNOWN,,1000.0,2016-01-01,2021-12-30,13.899543378995435,Good (10-50/month),138.99543378995435,Exceeded (≥100%),50,78.3,86.48
NCT07285330,Dietitian-Nutritionist vs. Day Hospital in the Metabolic Control of Patients With Type 2 Diabetes,RECRUITING,,140.0,2025-06-30,2026-04-30,14.01842105263158,Good (10-50/month),140.1842105263158,Exceeded (≥100%),60,52.5,54.345
NCT02679430,Analysis of Prostatic Arterial Embolization for Benign Prostatic Hyperplasia Using Embosphere Microspheres,WITHDRAWN,NA,0.0,2013-05-01,2015-12-31,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT02457130,Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM),UNKNOWN,PHASE4,30.0,2015-04-01,2017-02-01,1.3589285714285715,Adequate (1-10/month),13.589285714285715,Significantly Below (<50%),50,32.4,12.025
NCT01717430,Metabolic and Endocrine Effects of Repeated Epidural and Sacroiliac Joint Corticosteroid Injections,UNKNOWN,,126.0,2012-10-01,2016-12-01,2.52,Adequate (1-10/month),25.2,Significantly Below (<50%),50,43.4,27.265
NCT02437630,Intrinsic PEEP and Laryngeal Aperture in COPD,UNKNOWN,,30.0,2016-04-01,2018-05-01,1.201578947368421,Adequate (1-10/month),12.01578947368421,Significantly Below (<50%),50,30.7,9.585
NCT04252430,RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Subjects,TERMINATED,PHASE1,24.0,2019-10-09,2020-03-17,4.566,Adequate (1-10/month),45.660000000000004,Significantly Below (<50%),10,24.9,7.12
NCT06249230,The Analysis of Risk Factors for Recurrent Pregnancy Loss and Prediction of Pregnancy Loss Risk,NOT_YET_RECRUITING,,1000.0,2024-01-31,2024-12-31,90.86567164179105,Excellent (>50/month),200.0,Exceeded (≥100%),30,77.3,85.67
NCT06658028,[Trial of device that is not approved or cleared by the U.S. FDA],WITHHELD,,,,,,Slow (<1/month),,Significantly Below (<50%),50,20.0,5.695
NCT06535828,AIM4 AI and Mechanistic Modeling in Molecular Medicine,WITHDRAWN,,0.0,2024-11-30,2025-01-15,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT05325528,Study of Tislelizumab in Combination With SOX for the Treatment of Gastric Cancer With Liver Metastases,UNKNOWN,PHASE2,40.0,2022-04-10,2025-12-31,0.8946362968405585,Slow (<1/month),8.946362968405586,Significantly Below (<50%),50,33.2,12.989999999999998
NCT02238028,Short-term Cardiovascular Benefits of Wearing Particulate-filtering Respirators,COMPLETED,NA,28.0,2014-03-01,2014-12-01,3.0993454545454546,Adequate (1-10/month),30.99345454545455,Significantly Below (<50%),100,52.2,53.22
NCT02713828,"Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung",TERMINATED,PHASE1,13.0,2016-04-10,2018-09-26,0.4401779755283649,Slow (<1/month),4.401779755283649,Significantly Below (<50%),10,19.0,4.84
NCT03479528,The Predictive Value of Alarm Symptoms in Patients With Dyspepsia Based on Roman IV,UNKNOWN,,800.0,2018-03-01,2019-01-31,72.47619047619048,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT00668928,Effect of Dietary Polyphenols on Insulin Sensitivity,COMPLETED,PHASE1,20.0,2006-01-01,2007-12-01,0.8709585121602289,Slow (<1/month),8.70958512160229,Significantly Below (<50%),100,46.6,37.375
NCT02670928,Interventional Study of Active Weight Management in Patients With Type 2 Diabetes and Obesity in Routine Clinical Practice During 12 Months.,COMPLETED,PHASE4,130.0,2015-07-20,2017-04-06,6.321405750798722,Adequate (1-10/month),63.21405750798722,Below (50-75%),100,60.4,72.54
NCT04020328,Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal Insufficiency,UNKNOWN,PHASE4,70.0,2019-09-12,2022-05-31,2.147983870967742,Adequate (1-10/month),21.47983870967742,Significantly Below (<50%),50,40.6,22.575
NCT04904328,A Proof of Concept Alleviating the Symptoms of Photosensitive Migraine.,UNKNOWN,NA,77.0,2021-06-30,2022-04-04,8.431223021582733,Adequate (1-10/month),84.31223021582734,Met (75-100%),50,46.2,35.089999999999996
NCT05387928,A Study of KL340399 in Patients With Advanced Solid Tumors,COMPLETED,PHASE1,21.0,2022-06-07,2025-04-02,0.620621359223301,Slow (<1/month),6.20621359223301,Significantly Below (<50%),100,46.7,37.895
NCT06405828,Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer,RECRUITING,NA,67.0,2024-05-01,2026-11-30,2.1627571580063627,Adequate (1-10/month),21.627571580063627,Significantly Below (<50%),60,43.4,27.265
NCT06647628,A Clinical Study of MK-1708 in Healthy Elderly Participants (MK-1708-005),COMPLETED,PHASE1,16.0,2024-11-04,2025-03-31,3.3131972789115647,Adequate (1-10/month),33.13197278911565,Significantly Below (<50%),100,51.3,50.62
NCT06784128,Impact of TECAR Therapy on Pain and Function in Adhesive Capsulitis:,COMPLETED,NA,60.0,2023-12-01,2024-07-20,7.872413793103449,Adequate (1-10/month),78.72413793103448,Met (75-100%),100,54.8,61.095
NCT05348928,A Pilot Study of the Feasibility and Accuracy of the TrueVie CGM System - A Non-Significant Risk Study,COMPLETED,,16.0,2022-05-04,2022-06-16,11.326511627906976,Good (10-50/month),113.26511627906977,Exceeded (≥100%),100,54.6,60.39
NCT05111028,Reversal of Aspirin Antiplatelet Therapy With Cold Stored Platelets,UNKNOWN,PHASE1,10.0,2020-11-20,2021-11-01,0.8797687861271677,Slow (<1/month),8.797687861271676,Significantly Below (<50%),50,30.8,9.745
NCT02065128,The Efficacy of Capsaicin Sensitivity Testing in Patients With Irritable Larynx Syndrome,WITHDRAWN,,0.0,2017-08-01,2017-08-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,8.2,0.03
NCT00217828,Effects of Citalopram on Hostility and CHD Risk,COMPLETED,NA,,2002-03-01,2003-02-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,30.330000000000002
NCT06040528,Early Discharge Pathway Registry,RECRUITING,,20000.0,2023-11-11,2026-12-31,531.2390924956371,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT06859528,Step Up to PD: A Community-based Walking Program for People With Parkinson's Disease,RECRUITING,NA,40.0,2025-04-01,2027-09-30,1.3350877192982458,Adequate (1-10/month),13.350877192982457,Significantly Below (<50%),60,36.2,16.84
NCT05686928,Healing Ointment Usage Post-surgical Procedure,COMPLETED,PHASE4,15.0,2022-08-17,2022-11-30,4.348571428571429,Adequate (1-10/month),43.48571428571429,Significantly Below (<50%),100,51.2,50.375
NCT05055128,"A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole",COMPLETED,PHASE2,248.0,2021-08-11,2022-09-01,19.557305699481866,Good (10-50/month),195.57305699481867,Exceeded (≥100%),100,74.8,84.385
NCT06550128,Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB).,ACTIVE_NOT_RECRUITING,PHASE2,86.0,2024-07-10,2026-06-30,3.635888888888889,Adequate (1-10/month),36.35888888888889,Significantly Below (<50%),85,52.4,53.949999999999996
NCT00821028,Local Paclitaxel Delivery for SFA Disease,COMPLETED,NA,27.0,2009-01-01,2012-04-01,0.6929848229342328,Slow (<1/month),6.929848229342328,Significantly Below (<50%),100,47.2,40.035
NCT06043128,Proprioceptive Awareness in Stroke Patients With Different Trunk Impact Levels,UNKNOWN,,98.0,2023-09-01,2024-08-15,8.547621776504299,Adequate (1-10/month),85.47621776504299,Met (75-100%),50,46.2,35.089999999999996
NCT00037128,Study of GL701 in Men With Systemic Lupus Erythematosus,UNKNOWN,PHASE3,40.0,1998-03-01,,,Slow (<1/month),,Significantly Below (<50%),50,28.2,8.469999999999999
NCT05757128,Optimizing Mental Health for Young People at Clinical High Risk for Psychosis (CHR),COMPLETED,NA,30.0,2023-08-24,2024-12-19,1.8906832298136647,Adequate (1-10/month),18.906832298136646,Significantly Below (<50%),100,52.4,53.949999999999996
NCT03630328,Angelica Gigas Dietary Supplements and Human Immune Cells,ACTIVE_NOT_RECRUITING,NA,40.0,2019-02-06,2026-05-01,0.46103748580083304,Slow (<1/month),4.61037485800833,Significantly Below (<50%),85,43.7,27.744999999999997
NCT04316728,Clinical Performance of the VivaDiag ™ COVID-19 lgM / IgG Rapid Test in Early Detecting the Infection of COVID-19,UNKNOWN,NA,200.0,2020-03-01,2020-11-01,24.848979591836738,Good (10-50/month),200.0,Exceeded (≥100%),50,56.0,63.71
NCT01958528,Study Of Circulating Multiple Myeloma Cells As A Biomarker of MGUS And SMM,COMPLETED,,52.0,2013-05-23,2019-01-22,0.7646763285024154,Slow (<1/month),7.646763285024154,Significantly Below (<50%),100,47.5,41.415
NCT04345328,Impact of Bariatric Surgery on the Gut Environment,COMPLETED,,151.0,2017-03-23,2021-09-01,2.832064078866297,Adequate (1-10/month),28.32064078866297,Significantly Below (<50%),100,60.4,72.54
NCT05519228,"PMCF Study on the Safety, Performance and Clinical Benefits Data of the ToggleLoc™ 2.9mm in the Elbow",COMPLETED,,83.0,2022-09-12,2024-02-20,4.803269961977187,Adequate (1-10/month),48.03269961977186,Significantly Below (<50%),100,55.0,61.834999999999994
NCT01599065,"Comparison of a MAGNET Protocol Versus ""off-on"" Protocol for Patients With Implantable Cardioverter Defibrillators",COMPLETED,,80.0,2011-12-01,2013-10-01,3.6346268656716423,Adequate (1-10/month),36.34626865671642,Significantly Below (<50%),100,54.7,60.629999999999995
NCT02873065,Efficacy and Safety of 1-week Triple Therapy With Ilaprazole for the Eradication of Helicobacter Pylori,COMPLETED,PHASE4,,2014-09-01,2015-06-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,30.330000000000002
NCT02447965,Pilot Study: Rectus Sheath Blocks for Improving Abdominal Surgery Conditions,TERMINATED,NA,6.0,2016-01-01,2016-12-01,0.5451940298507463,Slow (<1/month),5.451940298507463,Significantly Below (<50%),10,18.5,4.02
NCT01539265,A Dose-finding Study of Silodosin in Patients With Urinary Calculi,COMPLETED,PHASE2,300.0,,,,Slow (<1/month),,Significantly Below (<50%),100,64.0,77.025
NCT03117465,Scalp Acupuncture Combined rTMS on Brain White Matter Microstructure of Hemiplegic Patients With Stroke,COMPLETED,NA,28.0,2015-07-01,2018-04-01,0.8480796019900497,Slow (<1/month),8.480796019900497,Significantly Below (<50%),100,47.2,40.035
NCT07348965,Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis,NOT_YET_RECRUITING,NA,42.0,2026-01-01,2028-12-31,1.1675616438356167,Adequate (1-10/month),11.675616438356167,Significantly Below (<50%),30,27.4,8.225
NCT04687865,Constitution of a Biobank for Studies Related to Organ Transplantation (Lyon Centaure Biocollection),RECRUITING,,4000.0,2020-01-08,2040-01-08,16.668035592060235,Good (10-50/month),166.68035592060232,Exceeded (≥100%),60,81.3,88.58
NCT00405665,The Short Term Safety and Efficacy of Inhaled L-arginine in Patients With Cystic Fibrosis,COMPLETED,PHASE2,20.0,2006-11-01,2009-06-01,0.6455991516436904,Slow (<1/month),6.455991516436904,Significantly Below (<50%),100,46.6,37.375
NCT00516165,RAD001 in Advanced Hepatocellular Carcinoma,COMPLETED,PHASE1,28.0,2007-08-01,2011-11-01,0.5488216355441082,Slow (<1/month),5.488216355441082,Significantly Below (<50%),100,47.2,40.035
NCT02167165,Role of SNP and DIGOXIN Response in Atrial Fibrillation Patients,COMPLETED,,150.0,2013-07-01,2016-12-01,3.6557245796637314,Adequate (1-10/month),36.55724579663731,Significantly Below (<50%),100,60.3,72.34
NCT00418665,A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid,COMPLETED,PHASE2,39.0,2006-12-01,2010-10-01,0.8479714285714286,Slow (<1/month),8.479714285714286,Significantly Below (<50%),100,48.1,43.275000000000006
NCT06854965,Cohort Study on Factors Associated with the Evolution of Quality of Life Among Transgender Individuals in the French Population,NOT_YET_RECRUITING,,1500.0,2025-02-28,2027-02-28,62.54794520547946,Excellent (>50/month),200.0,Exceeded (≥100%),30,77.3,85.67
NCT04611165,Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCC,COMPLETED,PHASE2,50.0,2019-11-15,2023-12-15,1.0207914151576123,Adequate (1-10/month),10.207914151576123,Significantly Below (<50%),100,49.0,45.61
NCT02828865,A Clinical Trial Using Irreversible Electroporation for the Treatment of Liver Cancers,COMPLETED,NA,18.0,2012-11-01,2020-05-27,0.1982344428364689,Slow (<1/month),1.982344428364689,Significantly Below (<50%),100,46.4,36.26
NCT01505465,"Study of Melatonin on Sleep, Pain, and Confusion After Joint Replacement Surgery",COMPLETED,NA,50.0,2012-02-01,2013-06-01,3.131687242798354,Adequate (1-10/month),31.316872427983544,Significantly Below (<50%),100,54.0,58.72500000000001
NCT06163365,Inherited Cancer Early Diagnosis (ICED) Study,UNKNOWN,,100.0,2022-07-26,2025-07-26,2.7773722627737225,Adequate (1-10/month),27.773722627737225,Significantly Below (<50%),50,41.3,23.74
NCT04898465,Improving Family's Adherence to Dental Care After DGA (HECC-CAN-study),COMPLETED,NA,89.0,2021-02-26,2024-01-01,2.6074687199230033,Adequate (1-10/month),26.074687199230027,Significantly Below (<50%),100,57.1,66.27
NCT07381465,Efficacy and Safety of IL-1 Inhibitors in Mild to Moderate Systemic Lupus Erythematosus,NOT_YET_RECRUITING,PHASE4,15.0,2026-04-15,2027-12-31,0.73056,Slow (<1/month),7.305599999999999,Significantly Below (<50%),30,25.2,7.359999999999999
NCT07312565,Occurrence of Abdominal Aortic Aneurysms in Patients With Aneurysmal Subarachnoid Hemorrhage,NOT_YET_RECRUITING,,233.0,2026-01-01,2026-12-01,21.23508982035928,Good (10-50/month),200.0,Exceeded (≥100%),30,51.0,49.714999999999996
NCT04496765,Early-onset Rectal Cancer,COMPLETED,,244.0,2008-01-01,2020-04-30,1.6494248278925163,Adequate (1-10/month),16.494248278925163,Significantly Below (<50%),100,62.9,75.655
NCT07351565,Chemotherapy Plus Pitavastatin Guided by Patient-Derived Tumor-like Cell Clusters in Refractory Non-Small Cell Lung Cancer,NOT_YET_RECRUITING,PHASE1,22.0,2026-01-10,2026-12-31,1.8864225352112678,Adequate (1-10/month),18.86422535211268,Significantly Below (<50%),30,30.8,9.745
NCT04556565,MIND/COVID-19: Mental Health Impact and NeeDs Associated With COVID-19: a Comprehensive National Evaluation in Spain,UNKNOWN,,16000.0,2020-05-08,2022-11-01,536.9790518191842,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT05005065,Evaluation of the Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of IN-C005 and IN-A001 in Healthy Caucasians,COMPLETED,PHASE1,20.0,2021-09-06,2021-11-30,7.16235294117647,Adequate (1-10/month),71.62352941176471,Below (50-75%),100,51.6,51.644999999999996
NCT05970965,Periodontitis and Inflammation in Children With Down Syndrome/Trisomy 21: Study on Biological Samples,RECRUITING,NA,18.0,2025-04-30,2027-04-30,0.7505753424657535,Slow (<1/month),7.505753424657535,Significantly Below (<50%),60,34.4,14.430000000000001
NCT06964165,A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C),TERMINATED,PHASE2,36.0,2022-04-14,2025-03-31,1.0127911275415897,Adequate (1-10/month),10.127911275415899,Significantly Below (<50%),10,20.9,6.075
NCT06629467,Cognitive Behavioral Treatment with Activity Trackers for Smoking Cessation,RECRUITING,NA,128.0,2023-05-10,2025-12-01,4.162735042735043,Adequate (1-10/month),41.627350427350436,Significantly Below (<50%),60,48.2,43.665
NCT06093867,Early Detection of Infectious and Noninfectious Lung Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation,RECRUITING,,40.0,2024-04-08,2029-10-01,0.6081918081918082,Slow (<1/month),6.081918081918083,Significantly Below (<50%),60,34.5,14.52
NCT01365767,Contrast Ultrasound of the Small Intestine in Patients With Crohns Disease,COMPLETED,,5.0,2011-05-01,2011-09-01,1.2373983739837398,Adequate (1-10/month),12.3739837398374,Significantly Below (<50%),100,43.7,27.744999999999997
NCT00455767,Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients,COMPLETED,PHASE2,84.0,2006-07-01,2007-09-01,5.988196721311476,Adequate (1-10/month),59.88196721311476,Below (50-75%),100,56.7,65.53
NCT02408367,Intensity Depended Impacts on Cognitive Functions in Persons With Multiple Sclerosis - a Pilot Study,UNKNOWN,,20.0,2015-02-01,2015-05-01,6.840449438202247,Adequate (1-10/month),68.40449438202248,Below (50-75%),50,34.9,15.215
NCT05523167,A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.,ACTIVE_NOT_RECRUITING,PHASE2,265.0,2022-10-12,2027-02-01,5.1281627463445645,Adequate (1-10/month),51.281627463445645,Below (50-75%),85,66.7,79.47999999999999
NCT04488367,Blood Loss After Early TXA in Hip Fractures.,UNKNOWN,EARLY_PHASE1,120.0,2020-07-06,2023-07-01,3.351192660550459,Adequate (1-10/month),33.51192660550459,Significantly Below (<50%),50,44.6,29.42
NCT04531267,Ratio of Dietary Calcium to Magnesium on Cardiovascular Risk,UNKNOWN,NA,42.0,2021-01-01,2021-12-01,3.8277844311377245,Adequate (1-10/month),38.277844311377244,Significantly Below (<50%),50,38.4,19.835
NCT05988567,Efficacy Testing of Melon Oil Olive Pressed Candy Products,COMPLETED,NA,60.0,2023-05-09,2023-12-31,7.738983050847458,Adequate (1-10/month),77.38983050847457,Met (75-100%),100,54.8,61.095
NCT03874767,Can Mobility Technicians Provide Value to Hospitalized Patients?,WITHDRAWN,NA,0.0,2022-12-01,2023-09-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT06741267,The Assessment of the Feasibility and Operational Performance of Automated System Bronchoscopy in a Simulated Environment,UNKNOWN,NA,30.0,2024-01-01,2024-12-31,2.5019178082191784,Adequate (1-10/month),25.019178082191786,Significantly Below (<50%),50,37.4,18.62
NCT03989167,Clinical Decision Support for Familial Hypercholesterolemia,RECRUITING,NA,460000.0,2022-12-06,2025-12-06,12775.912408759124,Excellent (>50/month),200.0,Exceeded (≥100%),60,88.0,92.495
NCT02641067,A Study Evaluating the Pharmacokinetics of Doravirine (MK-1439) in Participants With Severe Renal Impairment (MK-1439-051),COMPLETED,PHASE1,16.0,2016-01-26,2016-05-25,4.058666666666667,Adequate (1-10/month),40.586666666666666,Significantly Below (<50%),100,51.3,50.62
NCT00600067,A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults,COMPLETED,PHASE2,130.0,2008-01-01,2008-11-01,12.974426229508198,Good (10-50/month),129.74426229508197,Exceeded (≥100%),100,65.4,78.415
NCT00418067,Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent and PacliTaxel-Eluting Stent for Coronary Lesions,COMPLETED,PHASE4,2645.0,2006-10-01,2009-01-01,97.82964763061969,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT01309867,A Study to Evaluate the Performance of Two Designs of Soft Toric Lenses,COMPLETED,NA,302.0,2010-12-01,2011-04-01,75.97421487603306,Excellent (>50/month),200.0,Exceeded (≥100%),100,84.2,90.685
NCT05154500,Iron and Zinc Bioavailability From Biofortified Potatoes,COMPLETED,NA,179.0,2018-08-29,2022-03-31,4.159358778625954,Adequate (1-10/month),41.59358778625955,Significantly Below (<50%),100,64.3,77.265
NCT02302300,Interest of the Not Invasive Ventilation Used in Meadow and Post-operative of Cardiac Surgery,COMPLETED,NA,216.0,2014-05-27,2019-02-26,3.787465437788019,Adequate (1-10/month),37.874654377880184,Significantly Below (<50%),100,67.3,80.00500000000001
NCT00235300,"An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.",COMPLETED,PHASE2,240.0,2000-05-01,2005-06-01,3.934087237479806,Adequate (1-10/month),39.34087237479806,Significantly Below (<50%),100,69.2,81.28
NCT03187600,Submucosa/Mucosal Pharyngeal Flap Trial,UNKNOWN,NA,20.0,2017-07-18,2020-06-10,0.5754253308128545,Slow (<1/month),5.754253308128545,Significantly Below (<50%),50,31.6,10.905
NCT01453400,Evaluate the Time of Pain Relief of Fast Acting Aspirin Versus Acetaminophen in Subjects Diagnosed With Sore Throat Pain,COMPLETED,PHASE3,177.0,2011-09-27,2012-04-06,28.061875,Good (10-50/month),200.0,Exceeded (≥100%),100,69.2,81.28
NCT03822000,Risk Factors and Complications Contributing to Mortality in Elderly Patients With Fall-Induced Femoral Fracture,COMPLETED,,2407.0,2019-01-11,2019-01-28,2407.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT00425100,A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients,COMPLETED,PHASE3,516.0,2007-01-01,2007-10-01,57.53494505494506,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT03590600,A Single Ascending Dose Study of BTZ043,COMPLETED,PHASE1,30.0,2018-06-07,2019-03-05,3.3697416974169743,Adequate (1-10/month),33.69741697416974,Significantly Below (<50%),100,52.4,53.949999999999996
NCT02017600,"A Phase II Trial of Induction Chemotherapy With ND-420, Cisplatin and Fluorouracil Followed by Surgery in the Treatment of Patients With Localized Squamous Cell Carcinoma of the Esophagus",TERMINATED,PHASE2,48.0,2013-08-01,2015-04-04,2.3913584288052374,Adequate (1-10/month),23.913584288052373,Significantly Below (<50%),10,26.8,8.08
NCT00715000,"Oral Versus Intravenous Rehydration for Prevention of Dehydration in Premature Babies, During the First Days of Life.",COMPLETED,PHASE4,49.0,2008-07-01,2011-08-01,1.3246536412078154,Adequate (1-10/month),13.246536412078152,Significantly Below (<50%),100,48.9,45.4
NCT02416700,Evaluation of Peri Implant Bone Loss of Immediately Versus Conventionally Loaded Implants With a Single Prosthesis,COMPLETED,NA,17.0,2016-05-01,2018-03-01,0.7735127055306428,Slow (<1/month),7.735127055306427,Significantly Below (<50%),100,46.4,36.26
NCT06097000,A Study of the Safety and Efficacy of Intelligent Powered Exoskeletons in Postoperative Spinal Rehabilitation,RECRUITING,NA,80.0,2023-10-20,2025-11-20,3.1958005249343837,Adequate (1-10/month),31.958005249343834,Significantly Below (<50%),60,44.4,28.95
NCT04193800,Specialist Paramedic Rotations And Their Impact on Non-conveyancE Decisions,UNKNOWN,,33600.0,2020-01-01,2020-04-01,11239.384615384615,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT06927700,Effects of FDA Authorized Smokeless Tobacco Claims Among US Adults Who Smoke Cigarettes,COMPLETED,NA,1257.0,2025-04-24,2025-05-04,1257.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT02553200,The Efficacy of Breathing Exercise With BreatheMAX Device on Airway Secretion Clearance and Lung Function,COMPLETED,NA,28.0,2016-01-01,2018-02-28,1.080253485424588,Adequate (1-10/month),10.80253485424588,Significantly Below (<50%),100,47.2,40.035
NCT04130100,Clinical Study of Pulp Mesenchymal Stem Cells in the Treatment of Primary Mild to Moderate Knee Osteoarthritis,UNKNOWN,EARLY_PHASE1,60.0,2019-04-04,2021-12-30,1.8245754245754247,Adequate (1-10/month),18.24575424575425,Significantly Below (<50%),50,39.8,21.47
NCT00130000,Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria,COMPLETED,PHASE3,87.0,2005-08-09,2007-06-25,3.8661021897810217,Adequate (1-10/month),38.661021897810215,Significantly Below (<50%),100,57.0,66.12
NCT01037400,Biochemical Approach to Measuring Surgical Trauma,WITHDRAWN,,0.0,2010-02-01,,,Slow (<1/month),0.0,Significantly Below (<50%),5,8.2,0.03
NCT02843100,Diet for Induction and Maintenance of Remission and Re-biosis in Crohn's Disease,COMPLETED,NA,63.0,2018-04-10,2022-05-29,1.2700132450331127,Adequate (1-10/month),12.700132450331125,Significantly Below (<50%),100,50.0,47.675
NCT07374900,Hybrid Versus Fully In-person Physiotherapy for Non-traumatic Shoulder Pain in Routine Care.,COMPLETED,,129.0,2025-03-17,2025-11-11,16.429958158995817,Good (10-50/month),164.29958158995817,Exceeded (≥100%),100,63.7,76.655
NCT07096700,VR and Orthoses for Rehabilitation in Multiple Sclerosis,NOT_YET_RECRUITING,NA,12.0,2025-10-01,2026-05-01,1.7230188679245284,Adequate (1-10/month),17.230188679245284,Significantly Below (<50%),30,30.0,9.145
NCT02401100,Anastomotic Leakage After Anterior Resection for Rectal Cancer - Predictive Biomarkers and Rectal Blood Flow,COMPLETED,,36.0,2015-05-01,2018-09-01,0.898966365873667,Slow (<1/month),8.98966365873667,Significantly Below (<50%),100,46.2,35.089999999999996
NCT00089700,TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced Subjects With HIV-1,UNKNOWN,PHASE2,80.0,2004-03-01,,,Slow (<1/month),,Significantly Below (<50%),50,31.4,10.47
NCT00198900,Diabetes Knowledge Assessment,COMPLETED,,350.0,2000-01-01,2000-03-01,177.5666666666667,Excellent (>50/month),200.0,Exceeded (≥100%),100,86.3,91.725
NCT00765700,Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury,COMPLETED,PHASE3,364.0,2008-09-01,2009-09-01,30.356602739726032,Good (10-50/month),200.0,Exceeded (≥100%),100,84.1,90.64999999999999
NCT06201000,Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients,RECRUITING,,282.0,2023-12-27,2024-09-01,34.474216867469885,Good (10-50/month),200.0,Exceeded (≥100%),60,63.9,76.9
NCT06606600,Impacts of Kebbi Robot Intervention for Older Adults With Mild Dementia,RECRUITING,NA,136.0,2025-02-03,2025-07-30,23.388926553672317,Good (10-50/month),200.0,Exceeded (≥100%),60,53.9,58.34
NCT05822700,Outcome Of Using Transfixing K Wire ln DDH With Hypoplastic Head And Severe Generalised Ligamentous Laxity,UNKNOWN,NA,50.0,2023-05-01,2025-03-01,2.271641791044776,Adequate (1-10/month),22.71641791044776,Significantly Below (<50%),50,39.0,20.505000000000003
NCT06298500,Clinical Performance of HISTOACRYL® LAPFIX - CANNULA for Laparoscopic Inguinal Hernia Repair,COMPLETED,,443.0,2024-03-15,2025-05-07,32.260574162679426,Good (10-50/month),200.0,Exceeded (≥100%),100,88.8,92.89
NCT05278000,Improving Adherence to Controller Medication in Children With Asthma,COMPLETED,,201.0,2022-08-25,2025-07-18,5.783024574669188,Adequate (1-10/month),57.83024574669188,Below (50-75%),100,64.4,77.37
NCT03549000,A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.,TERMINATED,PHASE1,127.0,2018-07-18,2022-10-17,2.49090206185567,Adequate (1-10/month),24.909020618556703,Significantly Below (<50%),10,33.2,12.989999999999998
NCT06843200,Conversations With Caregivers About Health and Appearance,RECRUITING,NA,240.0,2025-01-27,2026-07-01,14.04923076923077,Good (10-50/month),140.49230769230766,Exceeded (≥100%),60,62.2,74.74499999999999
NCT06675500,Evaluation of the Role of Magnesium in Prevention of AF Post Cardiac Surgery,COMPLETED,PHASE3,130.0,2024-11-01,2025-04-30,21.984444444444446,Good (10-50/month),200.0,Exceeded (≥100%),100,65.4,78.415
NCT03110900,Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation,TERMINATED,PHASE4,2.0,2017-09-30,2018-04-04,0.32731182795698927,Slow (<1/month),3.2731182795698928,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT01941407,First Line Metastatic Breast Cancer Treatment (ESMERALDA),COMPLETED,PHASE2,61.0,2013-11-01,2016-03-01,2.1819506462984726,Adequate (1-10/month),21.819506462984727,Significantly Below (<50%),100,54.9,61.55500000000001
NCT03723707,Enhanced Quality in Primary Care for Elders With Diabetes and Dementia,COMPLETED,NA,355.0,2018-12-03,2022-10-20,7.626111503175724,Adequate (1-10/month),76.26111503175723,Met (75-100%),100,78.4,86.75
NCT04485507,COgnitive Intervention to Restore Attention Using Nature Environment,COMPLETED,NA,74.0,2020-07-01,2022-06-08,3.1860820367751064,Adequate (1-10/month),31.860820367751064,Significantly Below (<50%),100,55.9,63.42
NCT05334407,Effect of Implant Treatment and/or Dietary Advice on the Nutrition of Edentulous Ageing Subjects,UNKNOWN,NA,120.0,2022-04-18,2024-12-31,3.697165991902834,Adequate (1-10/month),36.97165991902834,Significantly Below (<50%),50,44.6,29.42
NCT00529607,Diagnostics for the Reperfusion Injury Following MI,COMPLETED,,200.0,2007-09-01,2009-03-01,11.129798903107861,Good (10-50/month),111.29798903107861,Exceeded (≥100%),100,69.3,81.395
NCT04047407,Suprathreshold Pressure Pain Stimulation in Fibromyalgia,UNKNOWN,,52.0,2019-06-03,2019-09-18,14.793271028037385,Good (10-50/month),147.9327102803738,Exceeded (≥100%),50,42.5,25.585
NCT00607607,A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer,COMPLETED,PHASE2,44.0,2008-01-01,2012-01-01,0.9167419575633128,Slow (<1/month),9.167419575633128,Significantly Below (<50%),100,48.5,44.47
NCT02720107,Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01),COMPLETED,PHASE4,133.0,2016-05-12,2016-11-14,21.766236559139784,Good (10-50/month),200.0,Exceeded (≥100%),100,65.6,78.56
NCT07024407,A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.,RECRUITING,PHASE1,10.0,2025-05-14,2026-01-01,1.3120689655172415,Adequate (1-10/month),13.120689655172413,Significantly Below (<50%),60,33.8,13.694999999999999
NCT05291507,Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System,RECRUITING,EARLY_PHASE1,34.0,2023-01-23,2028-08-01,0.5131184928111056,Slow (<1/month),5.131184928111056,Significantly Below (<50%),60,35.7,16.18
NCT02766907,Optimizing the Ocular Surface Prior to Cataract Surgery,COMPLETED,NA,20.0,2016-03-01,2018-04-01,0.8,Slow (<1/month),8.0,Significantly Below (<50%),100,46.6,37.375
NCT01599507,Study of FG-4592 in Subjects With Chronic Kidney Disease in China,COMPLETED,PHASE2,91.0,2011-12-01,2013-01-01,6.9774307304785905,Adequate (1-10/month),69.77430730478589,Below (50-75%),100,57.3,66.74
NCT02484807,Effect of Pharmacologic Interaction Between ERAs and PDE-5 Inhibitors on Medication Serum Levels and Clinical Disease Status in Patients With PAH,COMPLETED,,125.0,2015-05-01,2016-12-01,6.560344827586206,Adequate (1-10/month),65.60344827586206,Below (50-75%),100,58.3,68.99499999999999
NCT01147107,Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection,COMPLETED,PHASE4,80.0,2014-02-01,2021-06-01,0.9096750093388121,Slow (<1/month),9.096750093388122,Significantly Below (<50%),100,51.4,50.92
NCT02838407,"Identification and Characterization of Bacteria in the Lungs of Children From 6 Months up to 6 Years Old, With Suspected Infection of the Lungs, in Spain.",COMPLETED,NA,197.0,2013-09-23,2015-09-23,8.214630136986303,Adequate (1-10/month),82.14630136986301,Met (75-100%),100,65.8,78.745
NCT01258907,"A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)",COMPLETED,PHASE2,147.0,2010-03-01,,,Slow (<1/month),,Significantly Below (<50%),100,51.8,52.17
NCT02783807,Clinical Equivalency Validation Protocol Clinical Equivalency Eyenez Retina Camera v200 and Optomed Smartscope M5 EY3,COMPLETED,NA,34.0,2015-10-01,2016-05-01,4.858967136150235,Adequate (1-10/month),48.589671361502354,Significantly Below (<50%),100,52.7,55.04
NCT07050407,Impact of Deferred Clinic Visits on Patients With Cardiovascular Comorbidities: A Prospective Cohort Study,COMPLETED,,458.0,2020-04-01,2024-06-30,8.988729851708575,Adequate (1-10/month),89.88729851708575,Met (75-100%),100,90.0,93.17
NCT05487807,Adapting and Evaluating a Tobacco Use Cessation Program for People Living With HIV in Uganda and Zambia,RECRUITING,PHASE1,800.0,2023-09-13,2026-08-31,22.48568790397045,Good (10-50/month),200.0,Exceeded (≥100%),60,83.0,89.505
NCT03641807,Different Modes of Assessment on Acupuncture Effect on Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome,UNKNOWN,NA,60.0,2018-11-01,2021-10-30,1.6694698354661792,Adequate (1-10/month),16.694698354661792,Significantly Below (<50%),50,39.8,21.47
NCT01421407,Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Device to Treat Secondary Hyperparathyroidism,WITHDRAWN,NA,0.0,2011-08-01,2014-01-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT04831307,68Ga-HTK03149 for Use as a Diagnostic Radiopharmaceutical,UNKNOWN,NA,10.0,2021-08-30,2022-08-01,0.905952380952381,Slow (<1/month),9.05952380952381,Significantly Below (<50%),50,30.8,9.745
NCT06422507,A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema,ACTIVE_NOT_RECRUITING,PHASE3,333.0,2024-05-29,2026-03-22,15.311963746223567,Good (10-50/month),153.11963746223566,Exceeded (≥100%),85,77.1,85.5
NCT02027792,Cabbage Leaf Wraps in Osteoarthritis of the Knee,COMPLETED,NA,81.0,2014-01-01,2014-08-01,11.630377358490566,Good (10-50/month),116.30377358490567,Exceeded (≥100%),100,61.5,73.905
NCT04072692,Investigation of the Relation Between Trigger Digit and Carpal Tunnel Syndrome,COMPLETED,NA,59.0,2016-04-26,2019-06-13,1.571268591426072,Adequate (1-10/month),15.71268591426072,Significantly Below (<50%),100,49.7,46.949999999999996
NCT01498692,The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions in Small Vessels,COMPLETED,NA,94.0,2009-02-01,2015-05-01,1.254982456140351,Adequate (1-10/month),12.549824561403511,Significantly Below (<50%),100,52.5,54.345
NCT04278092,Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure,COMPLETED,PHASE2,57.0,2020-02-10,2024-10-31,1.0058434782608696,Adequate (1-10/month),10.058434782608696,Significantly Below (<50%),100,49.6,46.785
NCT02781792,Temozolomide Chronotherapy for High Grade Glioma,COMPLETED,PHASE2,42.0,2016-08-11,2024-07-18,0.4411594202898551,Slow (<1/month),4.411594202898551,Significantly Below (<50%),100,48.4,44.22
NCT03715192,A Safety Study of LY3462817 in Healthy Participants,COMPLETED,PHASE1,64.0,2018-12-13,2019-12-11,5.366831955922866,Adequate (1-10/month),53.668319559228664,Below (50-75%),100,55.1,62.085
NCT00834392,Exercise in Men With Prostate Cancer,COMPLETED,NA,30.0,2008-10-01,2010-12-01,1.1544879898862201,Adequate (1-10/month),11.544879898862199,Significantly Below (<50%),100,47.4,40.98
NCT01774292,Effect of Intracuff Alkalinized Lidocaine on Coughing Incidence at Extubation,COMPLETED,PHASE4,80.0,2013-01-01,2014-11-01,3.6400597907324364,Adequate (1-10/month),36.40059790732436,Significantly Below (<50%),100,56.4,64.88000000000001
NCT01705392,Bevacizumab vs Dacarbazine in Metastatic Melanoma,TERMINATED,PHASE2,2.0,2013-01-01,2017-02-20,0.04029119788219722,Slow (<1/month),0.40291197882197216,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT04296292,The Lived Experience of Participants in an African Randomised Trial,COMPLETED,,89.0,2020-02-05,2021-06-11,5.506422764227642,Adequate (1-10/month),55.06422764227642,Below (50-75%),100,55.5,62.71
NCT05975892,Transplantation of Bone Marrow Mesenchymal Stromal Cells for Periodontal Regeneration,UNKNOWN,PHASE1,30.0,2018-08-30,2024-08-30,0.4166058394160584,Slow (<1/month),4.166058394160584,Significantly Below (<50%),50,32.4,12.025
NCT03963492,Intermittent vs Continuous Walking in People With Multiple Sclerosis,SUSPENDED,NA,24.0,2019-07-01,2023-02-28,0.5460089686098655,Slow (<1/month),5.460089686098654,Significantly Below (<50%),20,22.9,6.3549999999999995
NCT04024592,Reliability and Validity of Strength Measurement of the Lower Limbs in Typically Developing Children,COMPLETED,NA,20.0,2017-11-30,2018-04-30,4.031788079470199,Adequate (1-10/month),40.317880794701985,Significantly Below (<50%),100,51.6,51.644999999999996
NCT00584792,"Diet, Genetic Variation and Prostate Cancer Among African Americans",COMPLETED,,102.0,2006-08-01,2007-12-01,6.375523613963039,Adequate (1-10/month),63.7552361396304,Below (50-75%),100,56.5,65.18
NCT07128992,Need-driven Treatment of the Patients With Type 1 Diabetes,NOT_YET_RECRUITING,,125.0,2025-10-06,2028-12-31,3.21912013536379,Adequate (1-10/month),32.19120135363791,Significantly Below (<50%),30,37.3,18.35
NCT06125392,Multicenter Registry on Microvascular Dysfunction - Searching a New Ach Spasm Definition,RECRUITING,,1000.0,2023-09-30,2028-08-31,16.939343350027826,Good (10-50/month),169.39343350027823,Exceeded (≥100%),60,81.3,88.58
NCT07296692,Effect of a Nutritional Formula Composed of Proteins and Carbohydrates on Gastric Emptying in Elderly Individuals,NOT_YET_RECRUITING,NA,25.0,2026-01-01,2027-05-01,1.5690721649484536,Adequate (1-10/month),15.690721649484535,Significantly Below (<50%),30,26.0,7.735
NCT04497792,Safety and Efficacy of Empagliflozin for Patients With Diabetes Mellitus and Planned Percutaneous Coronary Interventions,COMPLETED,PHASE4,40.0,2016-11-01,2019-11-01,1.1119634703196348,Adequate (1-10/month),11.119634703196349,Significantly Below (<50%),100,48.2,43.665
NCT03067792,FOLFIRI Versus Docetaxel and Cisplatin as a Second-line Chemotherapy After Failure of First-line Chemotherapy in Advanced Gastric Cancer,COMPLETED,PHASE3,52.0,2014-12-01,2016-10-17,2.3074052478134113,Adequate (1-10/month),23.074052478134114,Significantly Below (<50%),100,54.2,59.330000000000005
NCT00324792,I3LTE4: Intensive Insulin Therapy and Production of LTE4 in Patients With Diabetes,COMPLETED,NA,45.0,2006-05-01,2007-10-01,2.6444015444015445,Adequate (1-10/month),26.444015444015445,Significantly Below (<50%),100,53.6,57.705
NCT03006692,Diagnostic Value of Arterial Blood Gas Analysis in Prehospital Patients,COMPLETED,,300.0,2016-06-01,2018-04-01,13.650224215246636,Good (10-50/month),136.50224215246635,Exceeded (≥100%),100,77.3,85.67
NCT05877092,Comparative Evaluation of Masticatory Efficiency of Implant Supported Overdenture,COMPLETED,NA,24.0,2022-03-01,2023-01-01,2.387450980392157,Adequate (1-10/month),23.87450980392157,Significantly Below (<50%),100,51.9,52.55499999999999
NCT02175992,Quality of Life After Surgery for Pancreatic Carcinoma,COMPLETED,,300.0,2012-03-01,2017-06-30,4.6902927580893685,Adequate (1-10/month),46.90292758089368,Significantly Below (<50%),100,72.3,83.065
NCT01858792,A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies,COMPLETED,,1.0,2011-05-01,2011-06-01,0.9819354838709677,Slow (<1/month),9.819354838709678,Significantly Below (<50%),100,43.4,27.265
NCT02987192,Minimally Invasive Lumbar Aneasthesia Used for Cesarean Section,UNKNOWN,NA,200.0,2016-11-01,2017-11-01,16.679452054794524,Good (10-50/month),166.7945205479452,Exceeded (≥100%),50,56.0,63.71
NCT02359292,Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers,COMPLETED,PHASE1,50.0,2015-02-01,2015-07-01,10.146666666666667,Good (10-50/month),101.46666666666665,Exceeded (≥100%),100,59.0,70.365
NCT00322192,Evaluation of Whether Functional Strength Training Can Enhance Recovery of Mobility After Stroke,COMPLETED,PHASE2,300.0,2004-01-01,2006-12-01,8.574647887323945,Adequate (1-10/month),85.74647887323945,Met (75-100%),100,79.0,86.96000000000001
NCT04968392,Single-shot Adductor Canal Block With Levobupivacaine and Dexmedetomidine in Total Knee Arthroplasty,COMPLETED,PHASE2,60.0,2019-03-01,2020-05-01,4.277283372365339,Adequate (1-10/month),42.7728337236534,Significantly Below (<50%),100,54.8,61.095
NCT01210092,Comparison of Different Video Laryngoscopes in a Manikin With Immobilized Cervical Spine,COMPLETED,,25.0,2010-08-01,2011-01-01,4.973856209150327,Adequate (1-10/month),49.73856209150327,Significantly Below (<50%),100,50.3,48.215
NCT06844292,Evaluation of Microinvasive Glaucoma Surgery: MINIject® Versus Hydrus® Microstent in Combination With Cataract Surgery,RECRUITING,NA,152.0,2025-03-03,2031-03-03,2.1117663167503427,Adequate (1-10/month),21.117663167503427,Significantly Below (<50%),60,50.2,48.04
NCT03037736,Outpatient Performed Pterygium Surgery Study,WITHDRAWN,PHASE4,0.0,2020-03-01,2020-03-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT06252636,Evaluation of the Efficacy and Safety of A2 Milk on Digestion,ACTIVE_NOT_RECRUITING,NA,40.0,2023-04-07,2025-04-30,1.6148541114058357,Adequate (1-10/month),16.148541114058357,Significantly Below (<50%),85,43.7,27.744999999999997
NCT05132036,Lung Ultrasound Assessment of Fluid Overload in Haemodialysis Patients,COMPLETED,NA,46.0,2021-11-09,2022-06-01,6.863921568627451,Adequate (1-10/month),68.63921568627451,Below (50-75%),100,53.7,57.84
NCT04007536,A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome,COMPLETED,,18.0,2019-10-23,2024-03-01,0.34438717787554995,Slow (<1/month),3.4438717787555,Significantly Below (<50%),100,44.8,29.845
NCT04033536,Involved Versus Elective Target SSRS for Spinal Metastases,UNKNOWN,NA,114.0,2019-08-01,2024-06-01,1.9649830124575314,Adequate (1-10/month),19.649830124575313,Significantly Below (<50%),50,44.1,28.425
NCT04599036,EMG Controlled Device in Acute Rehabilitation After Acute Stroke,RECRUITING,NA,10.0,2020-10-07,2027-09-30,0.11941938014907807,Slow (<1/month),1.1941938014907807,Significantly Below (<50%),60,33.8,13.694999999999999
NCT02450136,"Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors",COMPLETED,NA,2.0,2015-10-08,2018-02-01,0.07187721369539551,Slow (<1/month),0.7187721369539551,Significantly Below (<50%),100,45.2,30.830000000000002
NCT04569136,Physical Therapy Intervention for Puerperal Mastitis,COMPLETED,NA,37.0,2020-12-01,2023-04-27,1.2842417331812999,Adequate (1-10/month),12.842417331813,Significantly Below (<50%),100,48.0,42.945
NCT01477736,A Comparison Study of Oxybutynin and Botulinum Toxin for Neurogenic Detrusor Overactivity,COMPLETED,NA,68.0,2009-01-01,2010-11-01,3.094050822122571,Adequate (1-10/month),30.94050822122571,Significantly Below (<50%),100,55.4,62.56
NCT04557436,TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL),COMPLETED,PHASE1,9.0,2020-08-12,2024-03-05,0.21057647963105303,Slow (<1/month),2.10576479631053,Significantly Below (<50%),100,45.7,32.5
NCT04348136,An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II,ACTIVE_NOT_RECRUITING,PHASE2,27.0,2019-09-01,2030-03-31,0.21270186335403726,Slow (<1/month),2.1270186335403727,Significantly Below (<50%),85,42.7,25.77
NCT06435936,"A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With Placebo",ACTIVE_NOT_RECRUITING,PHASE1,28.0,2024-04-22,2025-02-01,2.9905964912280703,Adequate (1-10/month),29.9059649122807,Significantly Below (<50%),85,47.7,42.17
NCT06480136,SHR-A1921 Combined With Adebrelimab in the Treatment of Advanced NSCLC Who Failed the Previous Standard First-line Treatment,NOT_YET_RECRUITING,PHASE2,32.0,2024-07-15,2028-02-15,0.7435725190839695,Slow (<1/month),7.435725190839696,Significantly Below (<50%),30,26.6,8.01
NCT04612036,"In Vivo Kinematics for Subjects With Smith & Nephew Journey II BCS TKA, Journey II CR TKA, Or Journey II XR TKA",COMPLETED,,60.0,2020-10-22,2022-05-16,3.198598949211909,Adequate (1-10/month),31.985989492119092,Significantly Below (<50%),100,53.1,56.105000000000004
NCT01953536,Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004),WITHDRAWN,PHASE2,0.0,2014-04-01,2016-11-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT05596136,Novel Blood Biomarker for Peripheral Arterial Disease,UNKNOWN,NA,548.0,2022-10-01,2025-08-01,16.117024154589373,Good (10-50/month),161.17024154589373,Exceeded (≥100%),50,80.0,87.67
NCT03200236,"The Lung Screening, Tobacco and Health Project",COMPLETED,PHASE3,1114.0,2017-05-03,2022-01-30,19.56731679169071,Good (10-50/month),195.67316791690712,Exceeded (≥100%),100,95.0,95.7
NCT03828136,Novum Vitrium® Cervical Cage in Anterior Cervical Discectomy and Fusion,TERMINATED,NA,25.0,2019-04-24,2022-03-21,0.716572504708098,Slow (<1/month),7.165725047080978,Significantly Below (<50%),10,20.0,5.695
NCT01510236,Self-help Program Via Internet for Adolescents With Cancer,WITHDRAWN,PHASE2,0.0,2013-01-01,2018-05-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT03006536,"Low-Intensity Extracorporeal Shock Wave Treatment for Erectile Dysfunction: A Randomized, Controlled, Double Blind Trial",COMPLETED,NA,100.0,2017-10-01,2022-03-13,1.874384236453202,Adequate (1-10/month),18.74384236453202,Significantly Below (<50%),100,58.0,68.245
NCT00752336,Prospective Intervention Study to Improve HRQoL and Exercise Tolerance After Heart Transplantation,UNKNOWN,NA,87.0,2002-01-01,2009-09-01,0.9458142857142857,Slow (<1/month),9.458142857142857,Significantly Below (<50%),50,37.0,17.955
NCT06212336,ISTH/ANRS 0409s INTEGRATE Lassa Fever Study,RECRUITING,PHASE2,1755.0,2025-05-02,2027-06-01,70.29236842105263,Excellent (>50/month),200.0,Exceeded (≥100%),60,88.0,92.495
NCT04745936,Comparison of Different Stylet Angles for Orotracheal Intubation Using C-MAC® Video Laryngoscopes in Infants,COMPLETED,NA,114.0,2021-03-03,2022-05-20,7.833318284424379,Adequate (1-10/month),78.3331828442438,Met (75-100%),100,59.1,70.6
NCT05395936,Mastectomy Flap Temperature Study,TERMINATED,NA,19.0,2022-09-29,2024-03-17,1.0810467289719627,Adequate (1-10/month),10.810467289719625,Significantly Below (<50%),10,19.5,5.315
NCT03375736,Whole Body Vibration for Children and Young Adults With Moderate Severity of Cerebral Palsy,COMPLETED,NA,14.0,2018-02-20,2018-09-28,1.9370909090909092,Adequate (1-10/month),19.37090909090909,Significantly Below (<50%),100,51.1,50.129999999999995
NCT03539536,Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE2,270.0,2018-10-10,2026-08-01,2.881767180925666,Adequate (1-10/month),28.817671809256662,Significantly Below (<50%),85,67.1,79.86999999999999
NCT06496711,IMPLEMENT - Model Project for Quality-assured Exercise Therapy for Cancer Patients,RECRUITING,NA,600.0,2023-09-01,2026-02-28,20.048298572996707,Good (10-50/month),200.0,Exceeded (≥100%),60,83.0,89.505
NCT01138111,Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients,COMPLETED,PHASE1,45.0,2008-06-01,2011-12-01,1.071830985915493,Adequate (1-10/month),10.71830985915493,Significantly Below (<50%),100,48.6,44.685
NCT00345111,ACRYSOF® Restor Apodized Diffractive IOL Postmarket Evaluation of Clinical Outcomes and Life-Style Visual Performance RESTOR IOL SN60WF IOL (Control Group),WITHDRAWN,PHASE4,0.0,2005-07-01,2007-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT04029311,Comparison of Two Techniques of Combination Therapy for Treatment of Obstructive Sleep Apnea (OSA),COMPLETED,NA,28.0,2017-06-08,2019-05-07,1.2210888252149,Adequate (1-10/month),12.210888252148997,Significantly Below (<50%),100,47.2,40.035
NCT02722811,Efficacy of Subcutaneous Injection of Etanercept for Moderate and Severe Knee Osteoarthritis,UNKNOWN,NA,60.0,2016-02-01,2017-08-01,3.3389396709323584,Adequate (1-10/month),33.389396709323584,Significantly Below (<50%),50,39.8,21.47
NCT01931111,"Cardiovascular Risk Factors, Maximal Oxygen Uptake and Sedentariness: an Observational Study",COMPLETED,,874.0,2012-08-01,2014-09-01,34.96,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT04485611,Prehabilitation of Veterans With Exercise and Nutrition,COMPLETED,NA,20.0,2021-05-27,2024-03-29,0.5870781099324975,Slow (<1/month),5.870781099324975,Significantly Below (<50%),100,46.6,37.375
NCT04776811,Evaluation of Accuracy of Guardian Sensor 3 in Diabetes Patients on Peritoneal Dialysis,COMPLETED,,30.0,2021-03-01,2022-09-30,1.579930795847751,Adequate (1-10/month),15.79930795847751,Significantly Below (<50%),100,45.7,32.5
NCT04727411,Analysis of Conjunctival Changes as Indicators for Ab-interno Gelatin Microstent Implantation Surgery Outcomes,COMPLETED,NA,39.0,2021-01-01,2022-10-17,1.8152293577981653,Adequate (1-10/month),18.152293577981652,Significantly Below (<50%),100,53.1,56.105000000000004
NCT04762511,"A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years",TERMINATED,PHASE1,17.0,2021-03-02,2021-05-26,6.088,Adequate (1-10/month),60.88,Below (50-75%),10,24.4,6.890000000000001
NCT05740111,The PREPAIRD Study: Personalized Surveillance for Early Detection of Pancreatic Cancer in High Risk Individuals,ENROLLING_BY_INVITATION,NA,200.0,2022-09-01,2042-12-31,0.8198222461621331,Slow (<1/month),8.19822246162133,Significantly Below (<50%),55,47.5,41.415
NCT03115411,Prospective Evaluation of Winged Biliary Stent Patency in Patients With Benign Biliary Obstruction,COMPLETED,NA,23.0,2011-09-06,2018-04-10,0.2907475083056479,Slow (<1/month),2.907475083056479,Significantly Below (<50%),100,46.8,38.440000000000005
NCT07124611,A Brief Psychological Intervention to Improve Emotional Well-Being During Neoadjuvant Therapy for Pancreatic Cancer,NOT_YET_RECRUITING,NA,25.0,2026-01-10,2026-12-31,2.143661971830986,Adequate (1-10/month),21.436619718309863,Significantly Below (<50%),30,31.0,9.985
NCT06538311,Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease,RECRUITING,EARLY_PHASE1,30.0,2023-05-01,2026-03-31,0.8574647887323944,Slow (<1/month),8.574647887323945,Significantly Below (<50%),60,35.4,15.765
NCT01409811,Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid,TERMINATED,NA,9.0,2012-09-14,2015-02-01,0.31489655172413794,Slow (<1/month),3.148965517241379,Significantly Below (<50%),10,18.7,4.455
NCT01509911,A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment,UNKNOWN,PHASE2,99.0,2012-01-01,2017-01-01,1.6494581280788179,Adequate (1-10/month),16.494581280788182,Significantly Below (<50%),50,37.9,19.139999999999997
NCT02287571,Skin Traction Versus Position Splint in Patients With Hip Fracture,COMPLETED,NA,68.0,2013-03-01,2014-07-01,4.250349075975359,Adequate (1-10/month),42.503490759753596,Significantly Below (<50%),100,55.4,62.56
NCT03188471,Preventive Application of GnRH Antagonist on Early OHSS,UNKNOWN,PHASE4,175.0,2017-01-01,2018-03-01,12.56367924528302,Good (10-50/month),125.63679245283019,Exceeded (≥100%),50,54.0,58.72500000000001
NCT03414671,The Effect of Standardizing the Definition of a Clinically Significant Cardiopulmonary Event on Length of Stay,COMPLETED,,160.0,2018-06-01,2021-09-21,4.031788079470199,Adequate (1-10/month),40.317880794701985,Significantly Below (<50%),100,61.1,73.31
NCT01017471,Carpal Tunnel Syndrome Release Using PSU Retractor,UNKNOWN,PHASE3,60.0,2009-09-01,2012-12-01,1.5386689132266218,Adequate (1-10/month),15.386689132266218,Significantly Below (<50%),50,34.8,15.040000000000001
NCT00813371,Airway Pressure Release Ventilation as a Preventative Strategy,WITHDRAWN,NA,0.0,2008-12-01,2011-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT04429971,Pre-Exposure Prophylaxis in the Emergency Department,COMPLETED,NA,26.0,2020-03-18,2023-07-31,0.6434471544715448,Slow (<1/month),6.434471544715448,Significantly Below (<50%),100,47.1,39.64
NCT01742871,Nutritional Status of Patients Victims of Haemorragic Accidents With Antivitamins K,UNKNOWN,,300.0,2012-08-01,2014-01-01,17.62934362934363,Good (10-50/month),176.29343629343632,Exceeded (≥100%),50,62.3,74.94
NCT00576771,"Effects of Different Assisted Mechanical Ventilation in Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) Patients: Pressure Support Ventilation (PSV), Neurally Adjusted Ventilatory Assist (NAVA) and Controlled by Patient",COMPLETED,NA,15.0,2013-08-01,2014-11-01,0.9991247264770241,Slow (<1/month),9.99124726477024,Significantly Below (<50%),100,46.2,35.089999999999996
NCT01211171,"COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-I Treatment Due to couGH in Poland",COMPLETED,,2498.0,2009-05-01,2009-12-01,355.3229906542056,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02687971,Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨,COMPLETED,PHASE2,130.0,2016-12-01,2019-09-10,3.9064165844027636,Adequate (1-10/month),39.064165844027634,Significantly Below (<50%),100,60.4,72.54
NCT06988371,Responses of Adults Smoking Nondaily and Daily in the Experimental Tobacco Marketplace,COMPLETED,NA,695.0,2025-08-18,2025-08-29,695.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT00297271,Prospective Research in Memory Clinics (PRIME),COMPLETED,,970.0,2005-08-01,2011-08-01,13.47640346873574,Good (10-50/month),134.7640346873574,Exceeded (≥100%),100,93.3,94.325
NCT02563171,Gingival Crevicular Fluid Vaspin and Omentin Levels in Obese Patients With Chronic Periodontitis,COMPLETED,EARLY_PHASE1,76.0,2014-07-01,2015-05-01,7.61,Adequate (1-10/month),76.1,Met (75-100%),100,56.1,63.99
NCT02401971,Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer,UNKNOWN,PHASE4,900.0,2014-08-01,2018-08-01,18.751540041067763,Good (10-50/month),187.51540041067761,Exceeded (≥100%),50,80.0,87.67
NCT01155271,OBese Patients With Obstructive Sleep Apnea Syndrome(OSAS) and EXercise Training,UNKNOWN,NA,60.0,2010-07-01,2018-12-01,0.5939512195121951,Slow (<1/month),5.939512195121951,Significantly Below (<50%),50,34.8,15.040000000000001
NCT00004471,Phase I Pilot Study of Gene Therapy for Cystic Fibrosis Using Cationic Liposome Mediated Gene Transfer,COMPLETED,PHASE1,9.0,1995-08-01,,,Slow (<1/month),,Significantly Below (<50%),100,40.7,22.675
NCT00245271,Safety of OMS103HP in Patients Undergoing Anterior Cruciate Ligament (ACL) Reconstruction,COMPLETED,PHASE3,480.0,2004-10-01,2011-03-01,6.238770281810418,Adequate (1-10/month),62.38770281810419,Below (50-75%),100,88.4,92.795
NCT05505071,DANTE SPACE for Evaluation of Subjects With Intracranial Vascular Disease,WITHDRAWN,NA,0.0,2022-12-01,2023-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT05039671,Feedback and Outcomes for Clinically Useful Student Services (FOCUSS),COMPLETED,NA,92.0,2021-08-17,2023-08-31,3.7640860215053764,Adequate (1-10/month),37.64086021505376,Significantly Below (<50%),100,57.4,67.05499999999999
NCT04709471,E-cigarette Nicotine Study,COMPLETED,PHASE2,77.0,2021-01-20,2022-06-01,4.71605633802817,Adequate (1-10/month),47.1605633802817,Significantly Below (<50%),100,56.2,64.21
NCT02936271,Efficacy of Vasculera in Prevention on Post-op Pain and Edema Following Lower Extremity Venous Treatment in the Outpatient Setting,WITHDRAWN,NA,0.0,2016-10-01,2017-04-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT03918044,Obesity Among Young Adult Males Born With Cesarean Section.,COMPLETED,,97291.0,2019-04-30,2019-08-30,24274.901967213114,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT03164044,Improved Basophil Activation Test (BAT) in the Diagnostics of Drug Allergy,UNKNOWN,,45.0,2017-01-03,2019-06-30,1.508590308370044,Adequate (1-10/month),15.085903083700442,Significantly Below (<50%),50,31.9,11.295
NCT06551844,Adaptive Dengue Antiviral Platform Trial,NOT_YET_RECRUITING,PHASE2,500.0,2025-09-01,2030-12-31,7.817154596815614,Adequate (1-10/month),78.17154596815614,Met (75-100%),30,69.0,81.185
NCT04837144,Evaluation of the Safety and Usability of the MAK Exoskeleton in Patients With Stroke,COMPLETED,NA,6.0,2020-10-06,2021-06-23,0.7024615384615385,Slow (<1/month),7.024615384615385,Significantly Below (<50%),100,45.5,31.705
NCT04211844,Metabolic Changes in Chronic HCV Patients Receiving DAAS,UNKNOWN,,100.0,2019-10-01,2020-04-01,16.633879781420767,Good (10-50/month),166.33879781420765,Exceeded (≥100%),50,46.3,35.66
NCT04733144,Bioequivalence Study of Prednisolone and Dexamethasone,UNKNOWN,PHASE1,24.0,2021-03-04,2022-05-31,1.6127152317880795,Adequate (1-10/month),16.127152317880793,Significantly Below (<50%),50,31.9,11.295
NCT04384744,To Explore the Effect of GH on Outcomes of IVF and Telomerase Activity of Granulosa Cells in Women With POR,UNKNOWN,,40.0,2020-05-26,2021-11-30,2.201808318264015,Adequate (1-10/month),22.018083182640147,Significantly Below (<50%),50,36.5,17.285
NCT05862844,Promise Women Project,COMPLETED,NA,20.0,2023-09-25,2023-10-15,20.0,Good (10-50/month),200.0,Exceeded (≥100%),100,56.6,65.34
NCT03684044,Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza,COMPLETED,PHASE3,363.0,2019-01-08,2020-03-16,25.518983833718245,Good (10-50/month),200.0,Exceeded (≥100%),100,84.0,90.595
NCT03356444,Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate,UNKNOWN,PHASE2,140.0,2017-11-01,2020-12-01,3.7847246891651865,Adequate (1-10/month),37.847246891651864,Significantly Below (<50%),50,46.2,35.089999999999996
NCT01294644,Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat,COMPLETED,PHASE3,360.0,2011-01-01,2012-02-01,27.672727272727276,Good (10-50/month),200.0,Exceeded (≥100%),100,83.8,90.505
NCT06826144,Chronic Remote Ischemic Conditioning in Small Infarctions Associated with Stent-assisted Coiling of Unruptured Intracranial Aneurysms,NOT_YET_RECRUITING,NA,84.0,2025-02-20,2026-06-01,5.487038626609443,Adequate (1-10/month),54.870386266094414,Below (50-75%),30,35.7,16.18
NCT04675944,Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil,COMPLETED,PHASE1,20.0,2018-02-28,2018-05-25,7.079069767441861,Adequate (1-10/month),70.79069767441861,Below (50-75%),100,51.6,51.644999999999996
NCT00203944,International Adoption and Stress Response Study,COMPLETED,,39.0,2002-07-01,2009-01-01,0.49964646464646467,Slow (<1/month),4.996464646464647,Significantly Below (<50%),100,46.5,36.815
NCT01755234,Propofol Versus Sevoflurane Recovery After Gynecological Surgery,COMPLETED,PHASE4,90.0,2012-11-01,2014-04-01,5.309302325581395,Adequate (1-10/month),53.093023255813954,Below (50-75%),100,57.2,66.465
NCT06233734,Robot-Assisted Gait Training in Early-Subacute Stroke,RECRUITING,,60.0,2024-04-30,2024-12-01,8.494883720930233,Adequate (1-10/month),84.94883720930233,Met (75-100%),60,46.1,34.695
NCT04922034,Outcome of Patients After a Negative Oral Challenge to Amoxicillin,COMPLETED,,190.0,2022-01-13,2022-07-18,31.09462365591398,Good (10-50/month),200.0,Exceeded (≥100%),100,68.5,81.01
NCT04318834,Molecular Profiling of Advanced Biliary Tract Cancers,RECRUITING,NA,40.0,2020-04-01,2025-01-01,0.7013824884792627,Slow (<1/month),7.0138248847926254,Significantly Below (<50%),60,36.2,16.84
NCT06227234,Evaluation of Foreign Body Airway Obstruction Interventions Through Simulation,UNKNOWN,NA,132.0,2024-08-07,2025-12-31,7.863170254403132,Adequate (1-10/month),78.63170254403131,Met (75-100%),50,45.6,32.08
NCT01165034,Development of King's College Hospital Breathlessness Service,UNKNOWN,PHASE3,110.0,2010-07-01,2013-05-01,3.235169082125604,Adequate (1-10/month),32.351690821256035,Significantly Below (<50%),50,43.8,27.965
NCT03856034,Laparotomy Versus Percutaneous Endoscopic Correction of Myelomeningocele,RECRUITING,NA,12.0,2018-11-02,2027-12-31,0.10916915720263001,Slow (<1/month),1.0916915720263,Significantly Below (<50%),60,34.0,14.02
NCT04855734,FACE for Children With Rare Diseases,COMPLETED,NA,42.0,2021-07-06,2024-06-01,1.2049764373232799,Adequate (1-10/month),12.049764373232799,Significantly Below (<50%),100,48.4,44.22
NCT00003834,Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer,COMPLETED,PHASE2,44.0,1999-03-01,2005-12-01,0.5429104175111472,Slow (<1/month),5.429104175111473,Significantly Below (<50%),100,48.5,44.47
NCT07202234,Bacteriophage Cocktail Therapy for Multidrug-Resistant Gram-Negative Ventilator-Associated Pneumonia,NOT_YET_RECRUITING,NA,248.0,2025-11-01,2028-05-31,8.013927813163482,Adequate (1-10/month),80.13927813163481,Met (75-100%),30,48.8,45.184999999999995
NCT04818034,The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study,COMPLETED,PHASE2,10.0,2021-08-30,2022-04-28,1.2630705394190873,Adequate (1-10/month),12.630705394190873,Significantly Below (<50%),100,45.8,33.03
NCT01711034,"A Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer",COMPLETED,PHASE1,145.0,2012-06-01,2015-12-01,3.4536776212832554,Adequate (1-10/month),34.53677621283256,Significantly Below (<50%),100,61.6,74.0
NCT03390634,Physiological Predictors of Clinical Outcomes After Anti-reflux Surgery,COMPLETED,,343.0,2018-03-05,2019-08-19,19.62578947368421,Good (10-50/month),196.2578947368421,Exceeded (≥100%),100,80.8,88.215
NCT01581034,"Effect of PADMA 28 on Endothelial Function, Autonomic Nervous System and Biomarkers in Patients With Coronary Artery Disease",COMPLETED,PHASE2,80.0,2012-04-01,2013-05-01,6.165063291139242,Adequate (1-10/month),61.650632911392414,Below (50-75%),100,56.4,64.88000000000001
NCT05811234,"A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults",COMPLETED,,291.0,2023-06-13,2024-10-01,18.60932773109244,Good (10-50/month),186.09327731092438,Exceeded (≥100%),100,76.6,85.35000000000001
NCT06669234,Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults,RECRUITING,PHASE1,40.0,2025-03-06,2026-07-30,2.382778864970646,Adequate (1-10/month),23.82778864970646,Significantly Below (<50%),60,41.2,23.425
NCT03015064,"Post-Myocardial Infarction Patients in Santa Catarina, Brazil - Catarina Heart Study",ACTIVE_NOT_RECRUITING,,1426.0,2016-07-01,2025-12-01,12.618441860465117,Good (10-50/month),126.18441860465117,Exceeded (≥100%),85,88.8,92.89
NCT03636464,Pharmacokinetics of Antibiotics in Patients Undergoing Renal Replacement Therapies,RECRUITING,,200.0,2018-04-01,2026-07-01,2.0205774975107866,Adequate (1-10/month),20.205774975107865,Significantly Below (<50%),60,52.3,53.515
NCT02102464,Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers,COMPLETED,NA,55.0,2014-04-01,2015-09-01,3.232046332046332,Adequate (1-10/month),32.32046332046332,Significantly Below (<50%),100,54.4,59.89
NCT06560164,Restrictive Versus Liberal Thresholds for RBC Transfusion in ECMO,RECRUITING,NA,526.0,2024-11-26,2029-10-01,9.046011299435028,Adequate (1-10/month),90.46011299435028,Met (75-100%),60,83.0,89.505
NCT03035864,A 8 Weeks Study to Evaluate Efficacy & Safety of rhNGF vs Vehicle in Patients After Cataract and Refractive Surgery,COMPLETED,PHASE2,180.0,2017-01-12,2017-09-04,23.315744680851065,Good (10-50/month),200.0,Exceeded (≥100%),100,69.4,81.52000000000001
NCT00495664,Titanium Nitride Oxide Coated Stents and Paclitaxel Eluting Stents for Acute Myocardial Infarction,COMPLETED,NA,425.0,2005-12-01,2009-11-01,9.04053109713487,Adequate (1-10/month),90.40531097134871,Met (75-100%),100,89.0,92.945
NCT03297164,Incidence Rate of Heart Failure After Acute Myocardial Infarction With Optimal Treatment,COMPLETED,,12043.0,2017-12-21,2021-06-30,284.8398756798757,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT04100564,LITES Task Order 0005 Prehospital Airway Control Trial (PACT),RECRUITING,NA,2009.0,2021-04-01,2027-01-01,29.10707282246549,Good (10-50/month),200.0,Exceeded (≥100%),60,83.0,89.505
NCT05624164,Microfracture at Proximal Humerus Lateral to Footprint Could Enhance the Rotator Cuff Healing,RECRUITING,NA,88.0,2022-10-01,2026-12-31,1.725979381443299,Adequate (1-10/month),17.25979381443299,Significantly Below (<50%),60,45.0,30.330000000000002
NCT01165164,An Evaluation of the Nighttime Retention of Effect of an Investigational Lubricant Eye Drop (FID 115958D),COMPLETED,NA,89.0,2010-06-01,2010-07-01,89.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,67.1,79.86999999999999
NCT04133064,Assessment of the Pivot Breath Sensor: Single-Arm Cohort Study,COMPLETED,NA,234.0,2019-09-25,2020-10-01,19.14774193548387,Good (10-50/month),191.4774193548387,Exceeded (≥100%),100,73.7,83.825
NCT00000264,Subjective/Psychomotor/ Effects of Combined Alcohol & Nitrous Oxide - 16,COMPLETED,NA,8.0,1997-09-01,1999-10-01,0.32042105263157894,Slow (<1/month),3.2042105263157894,Significantly Below (<50%),100,45.6,32.08
NCT04962464,The Impact of a Fast Diet and Calorie Mimetic Supplements on Epigenetic Aging,UNKNOWN,PHASE2,100.0,2021-03-10,2022-09-01,5.637037037037037,Adequate (1-10/month),56.37037037037036,Below (50-75%),50,43.0,26.465
NCT03245164,The Effects of Group Exercise and Basketball on Obese Children,COMPLETED,NA,45.0,2015-09-01,2016-07-01,4.505921052631579,Adequate (1-10/month),45.05921052631579,Significantly Below (<50%),100,53.6,57.705
NCT05862064,"A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer",RECRUITING,PHASE3,606.0,2023-06-01,2028-07-01,9.93357027463651,Adequate (1-10/month),99.3357027463651,Met (75-100%),60,83.0,89.505
NCT05044364,Clinical Study of Clevidipine Butyrate Injection in the Treatment of Hypertensive Emergency and Sub-emergency,UNKNOWN,PHASE3,10.0,2021-10-11,2022-10-10,0.8362637362637363,Slow (<1/month),8.362637362637363,Significantly Below (<50%),50,30.8,9.745
NCT05131464,The Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyps,COMPLETED,PHASE2,46.0,2021-11-30,2024-01-31,1.767979797979798,Adequate (1-10/month),17.67979797979798,Significantly Below (<50%),100,53.7,57.84
NCT05741164,Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer,RECRUITING,PHASE2,37.0,2024-10-22,2027-12-15,0.9802262837249782,Slow (<1/month),9.802262837249783,Significantly Below (<50%),60,36.0,16.564999999999998
NCT00819364,Early Intervention Program for Children With Autism (BCRI Model),UNKNOWN,NA,200.0,2009-08-01,2016-08-01,2.3809151349237387,Adequate (1-10/month),23.80915134923739,Significantly Below (<50%),50,51.0,49.714999999999996
NCT04409964,the Effect of Opioid-free General Anesthesia,COMPLETED,NA,78.0,2020-06-01,2021-09-20,4.988067226890757,Adequate (1-10/month),49.88067226890757,Significantly Below (<50%),100,56.2,64.21
NCT04018664,Oral Abuse Potential Study of Nalbuphine,COMPLETED,PHASE1,56.0,2018-05-29,2020-06-02,2.3192380952380955,Adequate (1-10/month),23.192380952380955,Significantly Below (<50%),100,54.5,60.12
NCT04214964,Clinical Characters of the Diagnosis and Treatment of Gynecological Malignant Tumors in China : A Real World Study,UNKNOWN,,10000.0,2020-04-11,2024-12-01,179.58702064896755,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT06885164,Remote Monitoring of Cardiac Mechanics in Heart Failure Patients,RECRUITING,,200.0,2025-06-11,2027-01-01,10.699472759226715,Good (10-50/month),106.99472759226714,Exceeded (≥100%),60,57.3,66.74
NCT01504464,The Effects of Intra-articular Injection of Mesenchymal Stem Cells in Knee Joint Osteoarthritis,COMPLETED,PHASE2,40.0,2012-10-01,2015-10-01,1.1119634703196348,Adequate (1-10/month),11.119634703196349,Significantly Below (<50%),100,48.2,43.665
NCT02762864,Post-operative Treatment of Diabetic Peripheral Arterial Disease Guided by Platelet Reactivity Unit,UNKNOWN,NA,200.0,2016-05-01,2019-04-01,5.716431924882629,Adequate (1-10/month),57.1643192488263,Below (50-75%),50,51.0,49.714999999999996
NCT05608109,A Social Media Personalized Normative Feedback Intervention for Heavy Drinking College Students,COMPLETED,NA,401.0,2022-01-09,2024-12-28,11.260553505535055,Good (10-50/month),112.60553505535056,Exceeded (≥100%),100,87.1,92.17999999999999
NCT01218009,A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed Dosing,TERMINATED,PHASE3,331.0,2010-10-01,2010-12-01,165.17442622950819,Excellent (>50/month),200.0,Exceeded (≥100%),10,59.5,71.0
NCT03346109,To Study the Feasibility and Quality of Life of Medial Group Retropharyngeal Node Sparing in Nasopharyngeal Carcinoma,UNKNOWN,NA,568.0,2017-11-16,2022-12-30,9.245946524064172,Adequate (1-10/month),92.45946524064172,Met (75-100%),50,80.0,87.67
NCT02060409,Prognostic Molecular Markers in Patients With Myelodysplastic Syndrome,COMPLETED,,58.0,2012-01-01,2014-02-01,2.316955380577428,Adequate (1-10/month),23.16955380577428,Significantly Below (<50%),100,53.0,55.80500000000001
NCT04904809,Perclose Multi-Access Duplex Ultrasound (DUS) Study,COMPLETED,NA,36.0,2021-09-01,2022-05-27,4.088955223880597,Adequate (1-10/month),40.88955223880596,Significantly Below (<50%),100,52.9,55.55
NCT01680809,Compliance of Compression Therapy in Healed Venous Ulcerations,WITHDRAWN,NA,0.0,2012-09-01,2014-06-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT04769609,Reconstructive Surgical Therapy of Peri-implantitis,COMPLETED,,52.0,2020-09-01,2021-02-12,9.651707317073171,Adequate (1-10/month),96.51707317073172,Met (75-100%),100,57.5,67.27
NCT06639009,Effect of Laser Photobiomodulation in Improving Mouth Opening in Oral Submucous Fibrosis,RECRUITING,NA,315.0,2024-09-01,2027-12-31,7.885361842105263,Adequate (1-10/month),78.85361842105263,Met (75-100%),60,63.2,76.11
NCT03801109,Transcranial Magnetic Stimulation and Hyperbaric Chamber for Women Fibromyalgia,COMPLETED,NA,69.0,2019-02-01,2020-06-26,4.1102935420743645,Adequate (1-10/month),41.10293542074364,Significantly Below (<50%),100,55.5,62.71
NCT04292509,Risk for Ketonaemia in Type 1 Diabetes Pregnancies With Sensor-augmented Pump Therapy,COMPLETED,NA,12.0,2020-02-15,2020-07-15,2.419072847682119,Adequate (1-10/month),24.190728476821192,Significantly Below (<50%),100,51.0,49.714999999999996
NCT04275609,The Efficiency of Writing Endoscopic Reports by Artificial Intelligence and Physicians: a Randomized Controlled Trial,UNKNOWN,NA,80.0,2020-02-20,2020-03-30,62.44102564102564,Excellent (>50/month),200.0,Exceeded (≥100%),50,51.4,50.92
NCT05372809,"Multi-Center, Prospective, Randomized Controlled Trial Evaluating SkinTE® in the Treatment of Wagner 2 DFUs",TERMINATED,PHASE3,42.0,2022-04-28,2024-02-21,1.925421686746988,Adequate (1-10/month),19.25421686746988,Significantly Below (<50%),10,26.4,7.865
NCT02761109,Postoperative Complications After Liver Transplantation,COMPLETED,,1600.0,2011-01-01,2020-01-01,14.817158503194403,Good (10-50/month),148.17158503194403,Exceeded (≥100%),100,93.3,94.325
NCT01017809,Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian Cancer,WITHDRAWN,NA,0.0,2010-12-01,2013-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT06542809,Evaluation of the Propensity of Patients Under rhGH to Envision a Modification of Their Treatment Regimen Toward LAGH,RECRUITING,NA,500.0,2024-04-15,2026-03-01,22.21897810218978,Good (10-50/month),200.0,Exceeded (≥100%),60,83.0,89.505
NCT00002309,A Study of Azithromycin in the Prevention of Mycobacterium Avium Complex Disease (MAC) in HIV-Infected Patients,COMPLETED,NA,,,,,Slow (<1/month),,Significantly Below (<50%),100,40.0,21.87
NCT06675409,Expert Guided Training Versus Self Learning with Virtual Patients,ENROLLING_BY_INVITATION,NA,93.0,2024-08-15,2024-11-15,30.770869565217392,Good (10-50/month),200.0,Exceeded (≥100%),55,48.9,45.4
NCT06132009,Predictive Value of Preoperative Evaluation in Cases of Recurrent Endometriosis,UNKNOWN,,64.0,2022-02-22,2024-02-01,2.7477574047954865,Adequate (1-10/month),27.477574047954867,Significantly Below (<50%),50,38.5,19.895
NCT05700409,Evaluating a Telemedicine-based Intensive Treatment Program for Children and Adolescents With Obesity,RECRUITING,NA,100.0,2023-01-01,2024-12-31,4.169863013698631,Adequate (1-10/month),41.6986301369863,Significantly Below (<50%),60,46.0,34.1
NCT00912509,Cross Linking for Treatment of Corneal Infection,TERMINATED,NA,30.0,2009-05-01,2013-06-01,0.612064343163539,Slow (<1/month),6.120643431635389,Significantly Below (<50%),10,20.4,5.885
NCT01198509,Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA),COMPLETED,NA,178.0,2010-01-01,2013-01-01,4.943722627737226,Adequate (1-10/month),49.43722627737226,Significantly Below (<50%),100,64.2,77.18
NCT03075709,"The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan",UNKNOWN,,800.0,2017-09-30,2021-09-30,16.66803559206023,Good (10-50/month),166.68035592060232,Exceeded (≥100%),50,78.3,86.48
NCT02810509,Quality of Anticoagulation With Warfarin in Patient With Atrial Fibrillation for Secondary Stroke Prevention in Korea,COMPLETED,,1814.0,2015-06-01,2016-10-01,113.15196721311474,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT07151209,"Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Potentially Resectable MSI-H, dMMR Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma",NOT_YET_RECRUITING,PHASE2,20.0,2025-09-01,2028-12-01,0.5128896377422073,Slow (<1/month),5.128896377422072,Significantly Below (<50%),30,25.6,7.595000000000001
NCT05049499,Long-term Academic and Psychosocial Impact of Child's Sleep: Parental Influences,ACTIVE_NOT_RECRUITING,,104.0,2021-01-08,2025-12-31,1.7413421342134214,Adequate (1-10/month),17.413421342134217,Significantly Below (<50%),85,52.2,53.22
NCT02730299,"Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS",COMPLETED,PHASE3,125.0,2016-12-16,2025-02-07,1.2789915966386554,Adequate (1-10/month),12.789915966386554,Significantly Below (<50%),100,55.0,61.834999999999994
NCT04064099,Speech Adaptation When Using Mouthguards,COMPLETED,NA,35.0,2017-10-04,2019-03-08,2.0488461538461538,Adequate (1-10/month),20.488461538461536,Significantly Below (<50%),100,52.8,55.31
NCT01085799,Education Intervention to Reduce Helminth Infections and Absenteeism in Grade 5 School-children,COMPLETED,NA,1101.0,2010-04-01,2010-10-01,183.13901639344263,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT03729999,Ultrasound to Verify Lung-isolation During Single-lung Ventilation,COMPLETED,NA,40.0,2018-12-12,2023-11-27,0.6723357261181668,Slow (<1/month),6.723357261181667,Significantly Below (<50%),100,48.2,43.665
NCT05093699,Dual-plane Ultrasound Imaging During Vascular Access Procedures,COMPLETED,NA,98.0,2022-05-01,2024-03-01,4.452417910447761,Adequate (1-10/month),44.52417910447761,Significantly Below (<50%),100,57.8,67.635
NCT04135599,A Study of the Effectiveness of Direct Current Stimulation for Alcohol Use Disorders,UNKNOWN,NA,40.0,2019-10-31,2020-04-30,6.69010989010989,Adequate (1-10/month),66.9010989010989,Below (50-75%),50,38.2,19.645000000000003
NCT02721199,EMG in COPD - Factor Analysis,COMPLETED,,11.0,2016-01-01,2016-06-01,2.2028947368421052,Adequate (1-10/month),22.028947368421054,Significantly Below (<50%),100,49.2,46.035
NCT06394999,"Efficacy, Safety, and Acceptability of Mifepristone 50 mg Once-weekly as a Contraceptive",RECRUITING,PHASE3,1186.0,2025-05-02,2030-04-01,20.112445682451256,Good (10-50/month),200.0,Exceeded (≥100%),60,83.0,89.505
NCT03369899,FreeStyle Libre Flash Glucose Monitoring System in Pediatric Populations,COMPLETED,,72.0,2017-12-11,2018-05-23,13.445889570552147,Good (10-50/month),134.45889570552148,Exceeded (≥100%),100,59.1,70.6
NCT01033799,Effect of the Consumption of a Fermented Milk on Common Infections in Shift-workers,COMPLETED,NA,1000.0,2006-10-01,2007-08-01,100.13157894736842,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT00556699,"A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma",COMPLETED,PHASE1,22.0,2007-12-01,2010-11-01,0.6282176360225141,Slow (<1/month),6.282176360225142,Significantly Below (<50%),100,46.8,38.440000000000005
NCT02614599,Neurocognitive and Neurobiological Improvement in ADHD Children With High Protein Diet,COMPLETED,EARLY_PHASE1,100.0,2015-06-01,2015-11-01,19.895424836601308,Good (10-50/month),198.95424836601308,Exceeded (≥100%),100,63.0,75.845
NCT01448499,Clozapine Versus Amisulpride in Treatment-resistant Schizophrenia Patients,WITHDRAWN,NA,0.0,2011-10-01,,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT01545999,Paired Associative Stimulation in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia,ACTIVE_NOT_RECRUITING,NA,72.0,2012-03-01,2025-12-01,0.4363288871192515,Slow (<1/month),4.363288871192514,Significantly Below (<50%),85,46.3,35.66
NCT00828399,Prevention of Acute Radiation Enteritis With Glutamine,COMPLETED,PHASE4,70.0,2009-01-01,2011-05-01,2.506823529411765,Adequate (1-10/month),25.068235294117645,Significantly Below (<50%),100,55.6,62.905
NCT04832399,Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants,COMPLETED,,60.0,2013-11-12,2023-10-02,0.5057878703960123,Slow (<1/month),5.057878703960122,Significantly Below (<50%),100,48.1,43.275000000000006
NCT06498999,4-STEP-Training Program for Social Media Addiction (4-STEP-TPS) Among Young Adults,RECRUITING,NA,90.0,2024-05-15,2024-11-01,16.11529411764706,Good (10-50/month),161.1529411764706,Exceeded (≥100%),60,50.2,48.04
NCT04555499,"A Diagnosis Study of a New Prehospital Strokeidentification Test, the PreHospitalt Ambulans Stroke Test (PreHAST), to be Used to Triage Patients With Suspected Stroke",COMPLETED,,78.0,2014-01-01,2020-01-01,1.083669557279781,Adequate (1-10/month),10.836695572797812,Significantly Below (<50%),100,49.6,46.785
NCT02086799,Thyroid Hormones Treatment in Asthma Exacerbation,UNKNOWN,NA,100.0,2014-07-01,2016-12-01,3.4434389140271495,Adequate (1-10/month),34.43438914027149,Significantly Below (<50%),50,43.0,26.465
NCT05187299,Use of an Observer Tool to Improve Learning Outcomes for Cardiac Arrest Management,UNKNOWN,NA,120.0,2022-01-10,2022-12-31,10.289577464788733,Good (10-50/month),102.89577464788732,Exceeded (≥100%),50,49.6,46.785
NCT02223299,Pilot Study: Combining Nutritional Supplements With Standard Antidepressant to Treat Depression.,WITHDRAWN,NA,0.0,2015-11-01,2015-11-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT01445899,"PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)",COMPLETED,PHASE2,258.0,2012-02-01,2013-11-01,12.290328638497654,Good (10-50/month),122.90328638497654,Exceeded (≥100%),100,75.6,84.735
NCT02329899,Standardisation of Investigations of Mild Bleeding Disorders,COMPLETED,,208.0,2012-07-01,2016-09-01,4.157268548916612,Adequate (1-10/month),41.57268548916612,Significantly Below (<50%),100,65.0,78.065
NCT07251699,EFFECT OF EARLY WEIGHT BEARING AND ACTIVE KNEE EXERCISES IN TREATMENT OF TIBIAL PLATEAU FRACTURES,ENROLLING_BY_INVITATION,NA,28.0,2024-11-01,2026-11-01,1.1675616438356167,Adequate (1-10/month),11.675616438356165,Significantly Below (<50%),55,33.7,13.465
NCT05420532,Designing Virtual Reality-based Software for People With Multiple Sclerosis,UNKNOWN,NA,15.0,2022-01-30,2023-08-30,0.7913344887348355,Slow (<1/month),7.913344887348354,Significantly Below (<50%),50,31.2,10.165000000000001
NCT00857532,Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients,COMPLETED,PHASE2,31.0,2009-01-01,2011-11-01,0.9126112185686654,Slow (<1/month),9.126112185686654,Significantly Below (<50%),100,47.5,41.415
NCT05440032,LE as a Marker for Periprosthetic Joint Infection,UNKNOWN,,160.0,2023-12-07,2024-03-01,57.29882352941176,Excellent (>50/month),200.0,Exceeded (≥100%),50,56.1,63.99
NCT03963232,A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine,COMPLETED,PHASE3,520.0,2019-07-30,2022-03-11,16.574659685863875,Good (10-50/month),165.74659685863875,Exceeded (≥100%),100,95.0,95.7
NCT05397132,Mechanisms of Disease R/R in CAR-T for Hematologic Malignancies,RECRUITING,,50.0,2022-05-27,2026-11-01,0.9400864731315628,Slow (<1/month),9.400864731315627,Significantly Below (<50%),60,35.3,15.534999999999998
NCT02676232,DARWeb: an Online Psychosocial Intervention for Children With Recurrent Abdominal Pain and Their Families.,COMPLETED,NA,61.0,2014-09-01,2019-03-01,1.1308404384896469,Adequate (1-10/month),11.308404384896468,Significantly Below (<50%),100,49.9,47.425
NCT05983432,Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors,RECRUITING,PHASE1,470.0,2023-08-08,2028-03-21,8.480616478956728,Adequate (1-10/month),84.80616478956729,Met (75-100%),60,80.6,88.14999999999999
NCT03938532,Feasibility and Impact of Volume Targeted Ventilation in the Delivery Room,TERMINATED,NA,20.0,2019-07-11,2024-12-31,0.3044,Slow (<1/month),3.044,Significantly Below (<50%),10,19.6,5.365
NCT01183832,Radiotherapy - Anastrazole Concomitant : Evaluation of the Side Effects,COMPLETED,,490.0,2005-08-01,2016-01-01,3.92,Adequate (1-10/month),39.2,Significantly Below (<50%),100,87.5,92.305
NCT04472832,"A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult Participants",COMPLETED,PHASE1,32.0,2020-06-17,2020-11-23,6.1262893081761005,Adequate (1-10/month),61.26289308176101,Below (50-75%),100,52.6,54.684999999999995
NCT03777332,Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy,COMPLETED,PHASE1,19.0,2018-11-05,2021-04-01,0.6587243735763098,Slow (<1/month),6.5872437357630975,Significantly Below (<50%),100,46.5,36.815
NCT05027932,"Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine",COMPLETED,PHASE1,45.0,2022-06-27,2025-02-25,1.4063655030800821,Adequate (1-10/month),14.063655030800822,Significantly Below (<50%),100,48.6,44.685
NCT02461732,Trial of a Novel Cognitive-Behavioral Treatment for Posttraumatic Stress and Substance Dependence,COMPLETED,NA,60.0,2014-08-01,2016-11-01,2.219198055893074,Adequate (1-10/month),22.19198055893074,Significantly Below (<50%),100,54.8,61.095
NCT07011732,A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1),RECRUITING,PHASE3,352.0,2025-07-10,2028-12-08,8.592526062550121,Adequate (1-10/month),85.92526062550122,Met (75-100%),60,71.2,82.59
NCT05850832,Efficacy of Esmolol Versus Magnesium Sulphate on Quality of Recovery in Patients Undergoing Laparoscopic Cholecystectomy: Randomized Controlled Study,COMPLETED,PHASE2,60.0,2022-10-05,2023-04-10,9.766844919786097,Adequate (1-10/month),97.66844919786098,Met (75-100%),100,59.8,71.61
NCT06983132,Natural History of Familial Cerebral Cavernous Malformations: the CCM_Italia Cohort Study,RECRUITING,,100.0,2024-11-18,2027-02-28,3.6586538461538463,Adequate (1-10/month),36.58653846153846,Significantly Below (<50%),60,44.3,28.715000000000003
NCT02249832,The General Use of Robots in Stroke Recovery: the Anklebot,COMPLETED,NA,55.0,2013-06-01,2019-05-01,0.7750925925925926,Slow (<1/month),7.750925925925925,Significantly Below (<50%),100,49.4,46.42
NCT04715932,Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN),COMPLETED,PHASE2,216.0,2021-02-18,2021-06-07,60.32146788990826,Excellent (>50/month),200.0,Exceeded (≥100%),100,77.3,85.67
NCT00424632,Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors,COMPLETED,PHASE1,57.0,2006-11-01,2009-06-01,1.8399575821845178,Adequate (1-10/month),18.399575821845175,Significantly Below (<50%),100,54.6,60.39
NCT01530698,Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients,COMPLETED,PHASE1,28.0,2010-04-01,2014-11-01,0.5088477611940299,Slow (<1/month),5.088477611940299,Significantly Below (<50%),100,47.2,40.035
NCT01981798,Effect of an Outpatient Intervention Program in Patients With Chronic Back or Neck Pain,COMPLETED,NA,121.0,2006-03-01,2008-02-01,5.246780626780628,Adequate (1-10/month),52.467806267806274,Below (50-75%),100,59.7,71.355
NCT05875298,Implementation Of Physical Therapy Protocol In Management Of Chronic Maxillary Sinusitis,UNKNOWN,NA,66.0,2023-06-01,2023-09-01,21.837391304347825,Good (10-50/month),200.0,Exceeded (≥100%),50,45.3,31.169999999999998
NCT00126698,Prophylactic Antibiotics on Urethral Catheter Withdrawal,COMPLETED,PHASE4,100.0,2005-01-01,2007-04-01,3.7121951219512197,Adequate (1-10/month),37.1219512195122,Significantly Below (<50%),100,58.0,68.245
NCT00006298,Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa,COMPLETED,,125.0,,,,Slow (<1/month),,Significantly Below (<50%),100,48.3,43.985
NCT00949598,Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer,COMPLETED,PHASE3,177.0,2008-12-01,2010-10-01,8.053632286995516,Adequate (1-10/month),80.53632286995516,Met (75-100%),100,64.2,77.18
NCT02269098,The Synergy to Control Emergency Department Hyperglycemia Program for Type 2 Diabetes,COMPLETED,NA,101.0,2012-02-01,2013-12-01,4.595575485799701,Adequate (1-10/month),45.95575485799701,Significantly Below (<50%),100,58.1,68.595
NCT06081998,Investigation of the Effects of Sleep Deprivation on Itch and Pain Sensitivity,RECRUITING,NA,30.0,2023-11-01,2026-12-31,0.7899653979238755,Slow (<1/month),7.899653979238755,Significantly Below (<50%),60,35.4,15.765
NCT01435798,Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan Dose Response Clinical Trial,COMPLETED,PHASE2,26.0,2003-04-01,2008-01-01,0.4558986175115208,Slow (<1/month),4.558986175115208,Significantly Below (<50%),100,47.1,39.64
NCT00774098,Improving Glycogen Liver Content Will Improve Post-operative Liver Function in Patients Undergoing Major Liver Resections,COMPLETED,NA,60.0,2007-01-01,2009-09-01,1.8751540041067762,Adequate (1-10/month),18.751540041067763,Significantly Below (<50%),100,54.8,61.095
NCT03397498,Computerized Cognitive Intervention in the Oldest-Old,COMPLETED,NA,69.0,2011-03-10,2014-12-16,1.5253159041394337,Adequate (1-10/month),15.253159041394337,Significantly Below (<50%),100,50.5,48.515
NCT01494298,Study of Cholesterol Levels and Types in African Americans With Type 2 Diabetes,COMPLETED,,111.0,2011-12-01,2013-03-01,7.409736842105263,Adequate (1-10/month),74.09736842105264,Below (50-75%),100,57.2,66.465
NCT05097898,Chronic Heart Failure With Preserved Ejection Fraction - COngestion eValuation,RECRUITING,NA,200.0,2022-08-10,2029-06-10,2.4391025641025643,Adequate (1-10/month),24.391025641025642,Significantly Below (<50%),60,54.0,58.72500000000001
NCT03452098,Post-Operative Rehabilitation of Knee Osteochondral Defect: A Case Series,COMPLETED,,5.0,2011-01-01,2018-11-01,0.05319818245368753,Slow (<1/month),0.5319818245368753,Significantly Below (<50%),100,43.7,27.744999999999997
NCT01404598,Pharmacokinetics Study: Determination of Naproxcinod and Its Metabolites After Oral Administration in Male,COMPLETED,PHASE1,24.0,2010-01-01,2010-02-01,23.566451612903226,Good (10-50/month),200.0,Exceeded (≥100%),100,56.9,65.89500000000001
NCT02280798,Endometrial Gene Expression in Different Protocols of Endometrial Preparation for Embryo Transfer',COMPLETED,,5.0,2014-12-01,2015-04-01,1.2578512396694215,Adequate (1-10/month),12.578512396694217,Significantly Below (<50%),100,43.7,27.744999999999997
NCT00181298,Memantine in Systemic Lupus Erythematosus,COMPLETED,NA,61.0,2006-03-01,2007-05-01,4.358779342723005,Adequate (1-10/month),43.58779342723005,Significantly Below (<50%),100,54.9,61.55500000000001
NCT05529498,High Intensity Interval Gait Training in Multiple Sclerosis,UNKNOWN,NA,30.0,2022-09-02,2023-12-31,1.8828865979381444,Adequate (1-10/month),18.828865979381444,Significantly Below (<50%),50,37.4,18.62
NCT05873998,Detecting Lung's Closing Pressure by Capnography,COMPLETED,,20.0,2023-02-28,2025-05-10,0.7591022443890274,Slow (<1/month),7.5910224438902745,Significantly Below (<50%),100,44.9,30.025000000000002
NCT02031198,"18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease",COMPLETED,PHASE1,25.0,2014-01-01,2016-12-01,0.7145539906103286,Slow (<1/month),7.145539906103288,Significantly Below (<50%),100,47.0,39.33
NCT02717598,Cold Snare Polypectomy Versus Hot Snare Polypectomy for Diminutive and Small Colorectal Polyps,COMPLETED,NA,198.0,2016-02-01,2017-06-01,12.401481481481483,Good (10-50/month),124.01481481481483,Exceeded (≥100%),100,70.8,82.295
NCT02322463,Ethnicity and Analgesic Practice in a Pediatric Emergency Department,UNKNOWN,,5000.0,2014-12-01,2015-10-01,500.6578947368421,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT01143363,Effect of High-intensity Intermittent Sprinting on Appetite Control on Obese Volunteers,COMPLETED,NA,12.0,2010-05-01,2014-06-01,0.24482573726541557,Slow (<1/month),2.4482573726541554,Significantly Below (<50%),100,46.0,34.1
NCT05372263,Safety Surveillance of Targeted Drugs for Pulmonary Hypertension Using a Computerized Follow-up System: a Nationwide Cohort Study,RECRUITING,,700.0,2021-08-26,2026-12-31,10.910394265232975,Good (10-50/month),109.10394265232975,Exceeded (≥100%),60,81.3,88.58
NCT04337463,ATG-008 Combined With Toripalimab in Advanced Solid Tumors,UNKNOWN,PHASE1,60.0,2020-04-23,2022-12-01,1.9184873949579833,Adequate (1-10/month),19.184873949579835,Significantly Below (<50%),50,39.8,21.47
NCT02197663,Clinical Evaluation of Acupuncture on the Complications of Cerebral Vascular Accident,TERMINATED,PHASE1,60.0,2013-04-01,2015-07-01,2.2246041412911084,Adequate (1-10/month),22.246041412911087,Significantly Below (<50%),10,27.8,8.32
NCT01364363,Unrelated Donor Stem Cell Transplantation,COMPLETED,NA,64.0,2005-03-01,2015-07-01,0.516205617382088,Slow (<1/month),5.162056173820879,Significantly Below (<50%),100,50.1,47.89
NCT03940963,Study of AxoGuard® Nerve Cap and Neurectomy for Treatment of Symptomatic Neuroma & Prevention of Recurrent Neuroma Pain,COMPLETED,NA,86.0,2018-10-10,2023-07-17,1.5036415852958072,Adequate (1-10/month),15.03641585295807,Significantly Below (<50%),100,51.9,52.55499999999999
NCT00900263,"S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma",COMPLETED,,375.0,2002-06-01,,,Slow (<1/month),,Significantly Below (<50%),100,68.3,80.875
NCT05898763,TEIPP Immunotherapy in Patients With NSCLC,COMPLETED,PHASE1,26.0,2021-09-29,2024-04-30,0.8383898305084746,Slow (<1/month),8.383898305084747,Significantly Below (<50%),100,47.1,39.64
NCT01901263,Patients With Behavioural Symptoms and Hospitalized in Cognitive and Behavioural Units,COMPLETED,,306.0,2012-10-01,2015-10-01,8.506520547945206,Adequate (1-10/month),85.06520547945206,Met (75-100%),100,77.8,85.93499999999999
NCT05953363,Prospective Clinical Evaluation of BD NRFit™ Devices and Accessories.,COMPLETED,,161.0,2023-07-24,2024-06-07,15.363134796238246,Good (10-50/month),153.63134796238245,Exceeded (≥100%),100,66.2,79.2
NCT05993663,Effectiveness of an Intervention Based on Arts In Health in the Quality of Life of People With Fibromyalgia.,UNKNOWN,NA,121.0,2023-10-02,2025-12-30,4.491756097560976,Adequate (1-10/month),44.91756097560976,Significantly Below (<50%),50,44.7,29.67
NCT01031563,Risk Perception in Drug-Dependent Adults With and Without Schizophrenia,COMPLETED,,120.0,2009-08-18,2012-05-03,3.6934277047522754,Adequate (1-10/month),36.934277047522755,Significantly Below (<50%),100,57.9,67.83
NCT00003963,Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation,COMPLETED,PHASE2,14.0,1999-05-01,2005-02-01,0.20264384213029007,Slow (<1/month),2.0264384213029007,Significantly Below (<50%),100,46.1,34.695
NCT05448963,Pilot Study of Single-port Robot-assisted Nipple-sparing Mastectomy,UNKNOWN,NA,30.0,2022-07-30,2023-08-01,2.488283378746594,Adequate (1-10/month),24.88283378746594,Significantly Below (<50%),50,37.4,18.62
NCT03827863,Acute CorPulmonale and ARDS Circulation Protection China Study China (ACPC),UNKNOWN,,300.0,2019-04-01,2020-03-31,25.019178082191782,Good (10-50/month),200.0,Exceeded (≥100%),50,62.3,74.94
NCT03367663,The Effect of Prednisone on Atherogenesis as Studied in the Macrophage Foam Cell Formation Model System.,COMPLETED,EARLY_PHASE1,10.0,2018-01-17,2018-09-30,1.1890625,Adequate (1-10/month),11.890625,Significantly Below (<50%),100,45.8,33.03
NCT00568763,Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma,COMPLETED,PHASE1,11.0,2005-11-25,2018-05-24,0.07338154722770107,Slow (<1/month),0.7338154722770108,Significantly Below (<50%),100,45.9,33.495000000000005
NCT05146063,LNK in Polycystic Ovary Syndrome With Insulin Resistance,UNKNOWN,,80.0,2021-11-05,2023-12-31,3.0982188295165396,Adequate (1-10/month),30.982188295165397,Significantly Below (<50%),50,39.7,21.21
NCT04849663,Comparative Evaluation of Buccal Fat Pad and Subepithelial Connective Tissue Graft,COMPLETED,EARLY_PHASE1,16.0,2018-06-24,2021-01-24,0.5153862433862434,Slow (<1/month),5.153862433862434,Significantly Below (<50%),100,46.3,35.66
NCT00922363,"Trial on the Safety of a New Liposomal Adjuvant System, CAF01, When Given With the Tuberculosis Subunit Vaccine Ag85B-ESAT-6 as Two Injections With Two Months Interval to Healthy Adult Volunteers",COMPLETED,PHASE1,38.0,2009-10-01,2011-10-01,1.5845479452054796,Adequate (1-10/month),15.845479452054795,Significantly Below (<50%),100,48.0,42.945
NCT00897663,Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies,COMPLETED,,56.0,2006-11-01,2018-01-01,0.41790634959548906,Slow (<1/month),4.179063495954891,Significantly Below (<50%),100,47.8,42.42
NCT03250663,Eucrisa for Atopic Dermatitis,COMPLETED,PHASE1,28.0,2017-10-01,2022-07-27,0.4842727272727273,Slow (<1/month),4.842727272727273,Significantly Below (<50%),100,47.2,40.035
NCT00230763,Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure,COMPLETED,PHASE3,396.0,2005-09-01,2007-10-01,15.860842105263158,Good (10-50/month),158.60842105263157,Exceeded (≥100%),100,86.7,92.035
NCT03922763,Fixed Inclination Humeral Cut,UNKNOWN,NA,100.0,2019-02-02,2020-05-02,6.69010989010989,Adequate (1-10/month),66.9010989010989,Below (50-75%),50,43.0,26.465
NCT02777463,The Prediction Using Diffusion MRI of the Response Evaluation in BRPC in NAT.,COMPLETED,,28.0,2016-06-01,2020-01-01,0.6511229946524064,Slow (<1/month),6.511229946524064,Significantly Below (<50%),100,45.6,32.08
NCT02250963,Prognostic Accuracy of Coronary CT and Dobutamine Stress Echocardiography in Patient Undergoing Non-cardiac Surgery,TERMINATED,,220.0,2014-07-01,2016-06-01,9.55320970042796,Adequate (1-10/month),95.53209700427959,Met (75-100%),10,43.9,28.12
NCT05855863,Clinical Study of GKT in Diabetes Related Dementia,NOT_YET_RECRUITING,PHASE4,370.0,2023-12-01,2026-06-30,11.956263269639066,Good (10-50/month),119.56263269639065,Exceeded (≥100%),30,63.6,76.545
NCT04571463,Ethyl Glucuronide in Urine Samples of Pregnant Women Within the HUS ja PHHYKY Area,COMPLETED,,505.0,2020-10-01,2021-07-30,50.90132450331126,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT04774263,The Acceptability of a Real-time Localization for Patients and Caregivers,COMPLETED,,19.0,2021-02-01,2021-03-01,19.0,Good (10-50/month),190.0,Exceeded (≥100%),100,54.9,61.55500000000001
NCT04026763,MR/TRUS Fusion Guided Prostate Biopsy,UNKNOWN,NA,520.0,2018-05-11,2021-12-01,12.176000000000002,Good (10-50/month),121.76,Exceeded (≥100%),50,80.0,87.67
NCT02691663,"Dietary Acid Load, Kidney Function and Disability in Elderly",COMPLETED,NA,196.0,2016-02-01,2018-06-15,6.897387283236994,Adequate (1-10/month),68.97387283236995,Below (50-75%),100,65.7,78.66499999999999
NCT03706287,Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC,UNKNOWN,PHASE1,62.0,2018-12-06,2021-03-10,2.2876121212121214,Adequate (1-10/month),22.876121212121213,Significantly Below (<50%),50,40.0,21.87
NCT04657887,Registry of Patients With Von WilLEbrand Disease Treated With Voncento®,COMPLETED,,135.0,2015-11-23,2023-12-31,1.3883108108108109,Adequate (1-10/month),13.883108108108107,Significantly Below (<50%),100,54.1,59.11
NCT05445687,Rehabilitation of Narrative Language in Children With Hearing Impairment and Developmental Language Disorder,COMPLETED,NA,88.0,2022-04-19,2024-05-19,3.52,Adequate (1-10/month),35.199999999999996,Significantly Below (<50%),100,57.0,66.12
NCT05140187,CMV-TCR-T Cells for CMV Infection After Allogenic HSCT,UNKNOWN,PHASE1,12.0,2021-10-15,2024-12-31,0.31140664961636827,Slow (<1/month),3.114066496163683,Significantly Below (<50%),50,31.0,9.985
NCT05205187,Gut Microbiota and Metabonomics,UNKNOWN,,450.0,2022-02-28,2025-12-31,9.770328102710414,Adequate (1-10/month),97.70328102710413,Met (75-100%),50,74.3,84.205
NCT01792687,"Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate",COMPLETED,PHASE1,6.0,2013-02-05,2024-02-13,0.04537639751552796,Slow (<1/month),0.4537639751552796,Significantly Below (<50%),100,45.5,31.705
NCT02568787,The Effect of an RBAC Supplement (BRM4) on NAFLD,COMPLETED,NA,23.0,2016-05-01,2017-06-10,1.7286913580246914,Adequate (1-10/month),17.286913580246914,Significantly Below (<50%),100,51.8,52.17
NCT05673187,Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status,ACTIVE_NOT_RECRUITING,PHASE2,68.0,2023-06-12,2026-03-01,2.0845115810674724,Adequate (1-10/month),20.845115810674724,Significantly Below (<50%),85,50.9,49.370000000000005
NCT02276287,HIV Patients Illness Perception and Adherence,COMPLETED,,187.0,2013-03-01,2014-04-01,14.374444444444444,Good (10-50/month),143.74444444444444,Exceeded (≥100%),100,68.3,80.875
NCT04076787,Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib,COMPLETED,,1769.0,2018-09-01,2018-09-02,1769.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02512887,Caudal vs Local Anesthesia in Hypospadias,UNKNOWN,NA,224.0,2016-07-01,2024-01-01,2.4885255474452554,Adequate (1-10/month),24.885255474452553,Significantly Below (<50%),50,52.9,55.55
NCT05566587,Designing a Personalized Diet to Reduce the Risk of Crohn's Disease Onset,UNKNOWN,NA,30.0,2022-10-01,2024-03-01,1.7663442940038687,Adequate (1-10/month),17.66344294003869,Significantly Below (<50%),50,37.4,18.62
NCT05705687,Validation of a Treatment Algorithm for Poor-Risk NSGCTnon Seminomatous Germ-cell Tumors,RECRUITING,NA,150.0,2023-05-05,2037-02-01,0.9093806014738101,Slow (<1/month),9.093806014738101,Significantly Below (<50%),60,45.0,30.330000000000002
NCT03286387,Contextual Associations During Episodic Recall of Everyday or Virtual Reality,COMPLETED,NA,95.0,2018-10-11,2019-08-13,9.450326797385621,Adequate (1-10/month),94.50326797385621,Met (75-100%),100,62.6,75.325
NCT01493687,Phase 3 Papulopustular Rosacea Study,COMPLETED,PHASE3,683.0,2011-12-01,2013-08-01,34.13878489326765,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT03220087,Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NETs in Spain,COMPLETED,,142.0,2017-07-21,2018-04-30,15.273780918727917,Good (10-50/month),152.73780918727917,Exceeded (≥100%),100,64.7,77.75999999999999
NCT01966887,AAV1-CMV-Serca2a GENe Therapy Trial in Heart Failure,TERMINATED,PHASE2,10.0,2013-12-01,2016-02-01,0.3843434343434344,Slow (<1/month),3.8434343434343434,Significantly Below (<50%),10,18.8,4.58
NCT07068087,Silodosin in Facilitating Flexible Uretroscopy,ACTIVE_NOT_RECRUITING,NA,42.0,2025-02-01,2025-09-01,6.030566037735849,Adequate (1-10/month),60.30566037735849,Below (50-75%),85,48.9,45.4
NCT02545387,Hepatitis C Virus in Neutrophil Granulocyte Progenitor Cells,WITHDRAWN,,0.0,2015-01-01,2018-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT06103487,Long Term Follow-Up for RGX-111,ENROLLING_BY_INVITATION,,7.0,2023-07-24,2027-09-01,0.14205333333333334,Slow (<1/month),1.4205333333333334,Significantly Below (<50%),55,30.4,9.345
NCT00302887,Connective Tissue Manipulation and Combined Ultrasound Therapy in Patients with Fibromyalgia,COMPLETED,,20.0,2003-08-01,2004-12-01,1.2475409836065574,Adequate (1-10/month),12.475409836065571,Significantly Below (<50%),100,44.9,30.025000000000002
NCT00770887,Self Administration of Subcutaneous Depot Medroxyprogesterone Acetate,COMPLETED,,50.0,2010-05-01,2011-06-01,3.8434343434343434,Adequate (1-10/month),38.43434343434344,Significantly Below (<50%),100,52.3,53.515
NCT05488587,Serum Levels of Some Trace Elements in Hepatocellular Carcinoma Patients,UNKNOWN,,100.0,2022-08-01,2023-08-01,8.339726027397262,Adequate (1-10/month),83.3972602739726,Met (75-100%),50,46.3,35.66
NCT04059887,Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY],COMPLETED,PHASE4,100.0,2019-12-18,2022-06-30,3.290810810810811,Adequate (1-10/month),32.90810810810811,Significantly Below (<50%),100,58.0,68.245
NCT04180787,Effects of a Caffeine- and Protein-Containing Coffee Beverage on Metabolism and Muscular Performance,COMPLETED,NA,19.0,2019-12-05,2020-03-09,6.088,Adequate (1-10/month),60.88,Below (50-75%),100,51.5,51.245
NCT03942887,Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis,UNKNOWN,PHASE3,100.0,2019-05-03,2025-04-01,1.4092592592592592,Adequate (1-10/month),14.09259259259259,Significantly Below (<50%),50,38.0,19.255
NCT02368587,Intracoronary or Intravenous Infusion Human Wharton' Jelly-derived Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy,UNKNOWN,PHASE2,160.0,2020-01-01,2021-07-01,8.90383912248629,Adequate (1-10/month),89.03839122486289,Met (75-100%),50,52.8,55.31
NCT05405387,Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant,SUSPENDED,PHASE2,120.0,2023-05-03,2027-09-01,2.3089759797724403,Adequate (1-10/month),23.089759797724398,Significantly Below (<50%),20,35.6,16.03
NCT02429193,Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA,COMPLETED,PHASE2,16.0,2016-03-01,2019-09-01,0.38079749804534796,Slow (<1/month),3.8079749804534795,Significantly Below (<50%),100,46.3,35.66
NCT06338293,Effects of Inclisiran Combined With Statins on the Morphology of Coronary Vulnerable Plaques,RECRUITING,PHASE4,40.0,2024-03-15,2025-12-31,1.8560975609756099,Adequate (1-10/month),18.5609756097561,Significantly Below (<50%),60,41.2,23.425
NCT04454593,Novel Method for Diagnosing Lateral Patellar Compression Syndrome Using X-ray: a Retrospective Case-Control Study,COMPLETED,,87.0,2020-03-22,2020-05-22,43.414426229508194,Good (10-50/month),200.0,Exceeded (≥100%),100,65.3,78.32000000000001
NCT01924793,An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection,COMPLETED,PHASE2,23.0,2013-08-01,2017-05-01,0.5114097881665449,Slow (<1/month),5.11409788166545,Significantly Below (<50%),100,46.8,38.440000000000005
NCT07347093,Reversal of Roux-en-Y Gastric Bypass: A Swedish National Cohort Study,ACTIVE_NOT_RECRUITING,,199.0,2025-11-01,2026-05-31,28.70881516587678,Good (10-50/month),200.0,Exceeded (≥100%),85,64.8,77.865
NCT06940193,A Self-test Home-use Blood Phenylalanine Monitoring System Under the Brand Name Egoo Phe System Has Been Developed for Measurement of Phenylalanine (Phe) in Individuals Diagnosed With Phenylketonuria (PKU): The Study Purpose is to Evaluate Accuracy and Usability,ENROLLING_BY_INVITATION,,20.0,2025-04-15,2025-10-31,3.0592964824120603,Adequate (1-10/month),30.592964824120607,Significantly Below (<50%),55,36.4,17.14
NCT06203093,Charcot-Marie-Tooth Disease (CMT) Biological Sample Collection for IPSC Generation and Biobanking,RECRUITING,,50.0,2022-09-22,2025-09-22,1.3886861313868613,Adequate (1-10/month),13.886861313868613,Significantly Below (<50%),60,35.3,15.534999999999998
NCT05255393,Survey on Lymphedema After Sentinel Lymph Node Biopsy in People With Cervical or Vulvar Cancer,COMPLETED,,111.0,2022-02-15,2025-11-19,2.4609176984705026,Adequate (1-10/month),24.609176984705027,Significantly Below (<50%),100,57.2,66.465
NCT00221793,"Weight Changes in Parkinsonian Patients, Treated With Deep Brain Stimulation",COMPLETED,NA,20.0,2002-12-01,2006-12-01,0.4167008898015058,Slow (<1/month),4.167008898015058,Significantly Below (<50%),100,46.6,37.375
NCT06667193,Cold Water Exposure's Effects on Physical and Mental Health,ENROLLING_BY_INVITATION,NA,75.0,2024-10-10,2025-10-01,6.412921348314607,Adequate (1-10/month),64.12921348314606,Below (50-75%),55,42.5,25.585
NCT02075593,"ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection",COMPLETED,PHASE3,4.0,2014-12-17,2021-09-15,0.04941558441558441,Slow (<1/month),0.4941558441558441,Significantly Below (<50%),100,45.3,31.169999999999998
NCT02877693,A Post-market Clinical Evaluation of St. Jude Medical™ MR Conditional ICD System on Patients Undergoing Magnetic Resonance Imaging,COMPLETED,NA,205.0,2016-10-10,2020-03-23,4.952539682539683,Adequate (1-10/month),49.52539682539683,Significantly Below (<50%),100,66.4,79.36999999999999
NCT05980793,Denervation for Osteoarthritis in the PIP-joint Efficacy Study (DOPS),RECRUITING,NA,90.0,2023-09-25,2029-07-15,1.2922641509433963,Adequate (1-10/month),12.922641509433962,Significantly Below (<50%),60,40.2,22.115000000000002
NCT01004393,Methylnaltrexone for Opioid-induced Constipation in Cancer Patients,COMPLETED,PHASE2,12.0,2009-10-01,2013-12-01,0.24,Slow (<1/month),2.4,Significantly Below (<50%),100,46.0,34.1
NCT00323193,Using MOVE! With Seriously Mentally Ill Veterans,COMPLETED,NA,109.0,2006-07-01,2011-08-01,1.7867312870220786,Adequate (1-10/month),17.867312870220783,Significantly Below (<50%),100,58.7,69.69
NCT01889693,Imaging of Atherosclerosis With 68Ga-MSA,COMPLETED,,60.0,2012-08-01,2013-08-01,5.003835616438357,Adequate (1-10/month),50.03835616438357,Below (50-75%),100,53.1,56.105000000000004
NCT04821921,The Impact of the COVID-19 Pandemic on Diabetes Management,COMPLETED,,1503.0,2021-04-09,2022-09-15,87.31167938931297,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02753621,Parkinsonics: A Controlled Study of Group Singing in Parkinson Disease,COMPLETED,PHASE2,32.0,2015-12-01,2016-12-31,2.45979797979798,Adequate (1-10/month),24.5979797979798,Significantly Below (<50%),100,52.6,54.684999999999995
NCT05982821,Artificial Intelligent Accelerates the Learning Curve for Mastering Contrast-enhanced Ultrasound of Thyroid Nodules,RECRUITING,,1000.0,2024-01-03,2026-12-31,27.849954254345835,Good (10-50/month),200.0,Exceeded (≥100%),60,81.3,88.58
NCT00902421,Efficacy and Safety of Selective Serotonin Reuptake Inhibitor (SSRI) in Overactive Bladder Patients,COMPLETED,PHASE4,40.0,2007-01-01,2009-07-01,1.3350877192982458,Adequate (1-10/month),13.350877192982457,Significantly Below (<50%),100,48.2,43.665
NCT05682521,Scoliosis and Postural Deformity Evaluation in Famagusta Region Secondary Schools,COMPLETED,,440.0,2022-12-01,2023-08-01,55.11769547325103,Excellent (>50/month),200.0,Exceeded (≥100%),100,93.5,94.76
NCT01350921,Evaluation of the Drug-drug Interaction Between Ticagrelor and Venlafaxine When Taken Together in Healthy Volunteers,COMPLETED,PHASE1,22.0,2011-05-01,2012-03-01,2.1956721311475413,Adequate (1-10/month),21.956721311475413,Significantly Below (<50%),100,51.8,52.17
NCT01256021,The Efficacy and Safety of MEDITOXIN® in Children With Cerebral Palsy,COMPLETED,PHASE4,212.0,2010-08-01,2011-05-01,23.63838827838828,Good (10-50/month),200.0,Exceeded (≥100%),100,72.0,82.92
NCT04949321,Acceleration of the Kinetics of Diffusion of Gadolinium in the Perilymphatic Structures of the Inner Ear.,UNKNOWN,NA,80.0,2021-07-31,2023-05-31,3.6400597907324364,Adequate (1-10/month),36.40059790732436,Significantly Below (<50%),50,41.4,24.04
NCT04779021,Caracterisation of COVID-19 Patients Hospitalized in Infectious Disease Department,UNKNOWN,,1300.0,2020-02-15,2022-12-31,37.68761904761905,Good (10-50/month),200.0,Exceeded (≥100%),50,78.3,86.48
NCT06842121,"A Bioequivalence Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Inorganic Phosphate (Sodium Phosphates Injection, USP)",COMPLETED,PHASE1,42.0,2025-01-27,2025-05-22,11.117217391304349,Good (10-50/month),111.17217391304348,Exceeded (≥100%),100,58.4,69.175
NCT05730621,A Study to Compare the Effects of Sarpogrelate Sustained Release /Aspirin Combination Therapy Versus Aspirin on Blood Viscosity in the Patients With Peripheral Arterial Disease and Coronary Artery Disease,COMPLETED,PHASE4,68.0,2023-01-11,2024-02-28,5.011912832929782,Adequate (1-10/month),50.11912832929782,Below (50-75%),100,55.4,62.56
NCT05396521,BFR Therapy Following DRF,COMPLETED,NA,4.0,2022-05-26,2023-05-08,0.3508933717579251,Slow (<1/month),3.508933717579251,Significantly Below (<50%),100,45.3,31.169999999999998
NCT02812121,UC-MSC Infusion for HBV-Related Acute-on-Chronic Liver Failure,UNKNOWN,PHASE2,261.0,2016-06-01,2018-06-01,10.883342465753426,Good (10-50/month),108.83342465753425,Exceeded (≥100%),50,60.9,73.06
NCT06985121,Scalp Care Efficacy Evaluation for Premium Scalp Revitalizing Essence,COMPLETED,NA,60.0,2025-04-08,2025-07-31,16.021052631578947,Good (10-50/month),160.21052631578948,Exceeded (≥100%),100,59.8,71.61
NCT04096521,"Serum Folic Acid Status, Genotyping MTHFR 677C-->T, Plasma Homocysteine, DNA Methylation of IGF2 Gene and Microbiota of the Children: Mother-Children Cohort Study",COMPLETED,,254.0,2018-08-02,2019-03-16,34.21132743362832,Good (10-50/month),200.0,Exceeded (≥100%),100,73.7,83.825
NCT06658821,The Effect of LDL557 on Improving Degenerative Arthritis in the Elderly,ENROLLING_BY_INVITATION,NA,100.0,2025-02-27,2026-06-30,6.237704918032787,Adequate (1-10/month),62.37704918032786,Below (50-75%),55,44.5,29.160000000000004
NCT03716921,Short 3-week Antibiotic Treatment Versus 6 Weeks in Adults With Septic Arthritis of Native Joint,COMPLETED,NA,332.0,2019-02-05,2024-01-25,5.568088154269972,Adequate (1-10/month),55.68088154269972,Below (50-75%),100,76.6,85.35000000000001
NCT06584721,Short Foot Exercises and Anti-pronation Taping on Low Back Pain Associated With Hyper Pronation,RECRUITING,NA,40.0,2024-10-02,2025-08-27,3.7009118541033437,Adequate (1-10/month),37.00911854103344,Significantly Below (<50%),60,41.2,23.425
NCT02865421,Adipose Tissue Derived Stem Cell Based Hair Restoration Therapy for Androgenetic Alopecia,COMPLETED,PHASE2,22.0,2017-06-10,2017-12-31,3.2827450980392157,Adequate (1-10/month),32.82745098039216,Significantly Below (<50%),100,51.8,52.17
NCT00860821,A Methodology Study in Healthy Subjects to Evaluate the Effect of AZD8309 After Nasal Administration of Lipopolysaccharide (LPS),COMPLETED,NA,20.0,2009-03-01,2009-10-01,2.8448598130841125,Adequate (1-10/month),28.448598130841123,Significantly Below (<50%),100,51.6,51.644999999999996
NCT02866721,Safety and Tolerability Study of Allogeneic Mesenchymal Stem Cell Infusion in Adults With Cystic Fibrosis,COMPLETED,PHASE1,14.0,2016-08-01,2020-08-01,0.29169062286105407,Slow (<1/month),2.9169062286105407,Significantly Below (<50%),100,46.1,34.695
NCT04482114,Detection and Volumetry of Pulmonary Nodules on Ultra-low Dose Chest CT Scan With Deeplearning Image Reconstruction Algorithm (DLIR),UNKNOWN,NA,70.0,2020-07-22,2023-07-01,1.9839851024208568,Adequate (1-10/month),19.839851024208567,Significantly Below (<50%),50,40.6,22.575
NCT01446614,Mesenchymal Stem Cells Transplantation to Patients With Parkinson's Disease,UNKNOWN,PHASE1,20.0,2011-10-01,2014-06-01,0.6250513347022587,Slow (<1/month),6.250513347022587,Significantly Below (<50%),50,31.6,10.905
NCT01954914,Plerixafor as a Salvage Regimen to Mobilize Allogeneic Stem Cells in Healthy Volunteers,COMPLETED,PHASE2,39.0,2013-12-01,2016-01-01,1.56,Adequate (1-10/month),15.6,Significantly Below (<50%),100,48.1,43.275000000000006
NCT04261114,Exploring the Link Between Pain and Distress in Adolescent Patients with Chronic Pain,COMPLETED,,77.0,2022-06-13,2024-03-28,3.5839143730886853,Adequate (1-10/month),35.83914373088685,Significantly Below (<50%),100,54.5,60.12
NCT03843814,Pilot Study Using Amide Proton Transfer Magnetic Resonance Imaging Distinguishing Glioma,TERMINATED,NA,13.0,2014-08-01,2017-12-13,0.3217235772357724,Slow (<1/month),3.217235772357724,Significantly Below (<50%),10,19.0,4.84
NCT05431114,Quantitative MRI of Glenohumeral Cartilage & Labrum in Shoulder Instability,COMPLETED,,20.0,2022-08-02,2025-04-01,0.625693730729702,Slow (<1/month),6.25693730729702,Significantly Below (<50%),100,44.9,30.025000000000002
NCT04721314,Personalized Pacing: A New Paradigm for Patients With Diastolic Dysfunction or Heart Failure With Preserved Ejection Fraction,COMPLETED,NA,123.0,2019-07-17,2021-12-05,4.2937155963302756,Adequate (1-10/month),42.93715596330276,Significantly Below (<50%),100,59.8,71.61
NCT06658314,Comparison of Kinesiotaping and Graded Exposure Therapy on Kinesiophobia in Post-Mastectomy Patients,COMPLETED,NA,32.0,2024-11-01,2025-06-19,4.235130434782609,Adequate (1-10/month),42.351304347826094,Significantly Below (<50%),100,52.6,54.684999999999995
NCT02429414,Video Double-Lumen Tube Prospective Randomized Study,COMPLETED,PHASE3,83.0,2015-09-01,2020-12-18,1.3056950904392766,Adequate (1-10/month),13.056950904392767,Significantly Below (<50%),100,51.6,51.644999999999996
NCT06298214,Testing the Effectiveness of the Her Health Program to Add Healthcare Value in the Fourth Trimester,ENROLLING_BY_INVITATION,NA,500.0,2024-05-29,2026-06-01,20.763983628922237,Good (10-50/month),200.0,Exceeded (≥100%),55,81.5,88.92999999999999
NCT01566214,Vet-Harts Pilot Intervention for Veterans With Coronary Heart Disease,COMPLETED,PHASE2,12.0,2012-04-30,2012-10-31,1.9852173913043478,Adequate (1-10/month),19.85217391304348,Significantly Below (<50%),100,51.0,49.714999999999996
NCT01022814,Development of a Diagnostic Device for Identifying Between Amniotic Fluid to Urine,UNKNOWN,,300.0,2010-01-01,,,Slow (<1/month),,Significantly Below (<50%),50,47.3,40.475
NCT01470014,Cardiac Computed Tomography: Characteristics of Isolated Left Ventricular Non-compaction,COMPLETED,,39.0,2011-10-01,2014-12-01,1.026067415730337,Adequate (1-10/month),10.26067415730337,Significantly Below (<50%),100,46.5,36.815
NCT05065814,Connective Tissue Diseases and Vitamin D Deficiency,UNKNOWN,NA,60.0,2020-10-01,2022-07-01,2.8626959247648904,Adequate (1-10/month),28.6269592476489,Significantly Below (<50%),50,39.8,21.47
NCT06372314,"Isoleucine, Leucine, Valine and Tryptophan Requirements in TPN Fed Neonates",NOT_YET_RECRUITING,NA,80.0,2025-08-01,2027-12-01,2.8582159624413146,Adequate (1-10/month),28.582159624413144,Significantly Below (<50%),30,35.4,15.765
NCT04509414,Intranasal Dexmedetomidine for Deep-sedated Pediatric Dental Patients,COMPLETED,PHASE4,100.0,2020-04-10,2022-05-31,3.8975672215108834,Adequate (1-10/month),38.97567221510884,Significantly Below (<50%),100,58.0,68.245
NCT02640014,Oral Immunotherapy in Food Allergy in Finland,UNKNOWN,NA,250.0,2015-12-01,2021-12-01,3.471715328467153,Adequate (1-10/month),34.71715328467153,Significantly Below (<50%),50,55.0,61.834999999999994
NCT03526614,REpetitive Assessement of SCOREs in Patients on Dual Antiplatelet Therapy,COMPLETED,,480.0,2017-06-01,2019-12-31,15.494379639448569,Good (10-50/month),154.9437963944857,Exceeded (≥100%),100,91.7,93.72500000000001
NCT00476814,NPD Measurements in PSC Patients,UNKNOWN,,,,,,Slow (<1/month),,Significantly Below (<50%),50,23.3,6.569999999999999
NCT02222714,Safety Evaluation of 3K3A-APC in Ischemic Stroke,COMPLETED,PHASE2,110.0,2014-10-01,2017-06-29,3.341716566866268,Adequate (1-10/month),33.417165668662676,Significantly Below (<50%),100,58.8,69.89999999999999
NCT01194414,A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis,COMPLETED,PHASE3,1262.0,2010-09-01,2013-08-01,36.07068544600939,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT07200414,Strengthening HPV Vaccination and Adolescent Health Research Program in Nigeria (SHARP),ACTIVE_NOT_RECRUITING,NA,14768.0,2024-10-01,2026-03-31,823.3295238095238,Excellent (>50/month),200.0,Exceeded (≥100%),85,95.5,96.55
NCT02151214,Efficacy of Parenteral Nutrition in Patients at the Palliative Phase of Cancer.,COMPLETED,NA,106.0,2012-07-27,2017-12-11,1.6437289862455424,Adequate (1-10/month),16.437289862455426,Significantly Below (<50%),100,53.5,57.555
NCT02521714,Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral Suspension,COMPLETED,PHASE1,28.0,2015-08-14,2015-09-23,21.308,Good (10-50/month),200.0,Exceeded (≥100%),100,57.2,66.465
NCT05939414,An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.,RECRUITING,PHASE3,450.0,2024-03-12,2031-10-03,4.961245925389352,Adequate (1-10/month),49.61245925389351,Significantly Below (<50%),60,74.0,83.985
NCT01387516,Motivation and Skills for Detained Teen Smokers,COMPLETED,NA,314.0,2007-07-01,2014-05-01,3.8293910256410255,Adequate (1-10/month),38.29391025641026,Significantly Below (<50%),100,75.1,84.56
NCT06603116,Evaluation of the Clinical Performance of Bioactive Giomer Restoration in Class II Cavities After One Year,COMPLETED,NA,24.0,2022-11-15,2024-03-25,1.4729032258064516,Adequate (1-10/month),14.729032258064517,Significantly Below (<50%),100,46.9,38.96
NCT04117516,Safety and Efficacy of Percutaneous Carpal Tunnel Release Versus Open Surgery,COMPLETED,NA,60.0,2019-06-05,2021-11-30,2.0092409240924094,Adequate (1-10/month),20.092409240924095,Significantly Below (<50%),100,54.8,61.095
NCT06532916,Color Stability and Wear Resistance of Direct Flowable and Preheated Composite Using the Injectable Technique,RECRUITING,NA,142.0,2014-03-01,2026-03-01,0.9861921058635639,Slow (<1/month),9.861921058635637,Significantly Below (<50%),60,44.4,28.95
NCT02519816,Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid-refractory or Dependent Chronic GVHD,UNKNOWN,PHASE2,17.0,2016-03-01,2020-01-01,0.36936473947180587,Slow (<1/month),3.693647394718059,Significantly Below (<50%),50,31.4,10.47
NCT04105816,Ultrasound for Rectus Femoris Measurement,WITHDRAWN,NA,0.0,2020-12-01,2021-12-31,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT05633316,Automated Intracytoplasmic Sperm Injection (ICSIA),UNKNOWN,NA,10.0,2022-12-05,2024-11-30,0.4192837465564739,Slow (<1/month),4.192837465564739,Significantly Below (<50%),50,30.8,9.745
NCT05296616,"Sleep Quality, Stress Level and Heart Rate Variability of University Students",UNKNOWN,NA,60.0,2022-05-18,2023-01-18,7.454693877551021,Adequate (1-10/month),74.54693877551021,Below (50-75%),50,39.8,21.47
NCT02746016,Effect of Formula on Infant Behavior,COMPLETED,NA,69.0,2016-04-01,2016-10-01,11.477377049180328,Good (10-50/month),114.77377049180329,Exceeded (≥100%),100,60.5,72.685
NCT02436616,"microEEG for Neonatal Apnea, Bradycardia and Desaturation",UNKNOWN,,50.0,2013-01-01,2016-07-01,1.19185591229444,Adequate (1-10/month),11.918559122944401,Significantly Below (<50%),50,32.3,11.799999999999999
NCT06243016,Breaking Sitting with High-intensity Interval Training for Brain Health,RECRUITING,NA,54.0,2024-05-07,2025-07-31,3.6528,Adequate (1-10/month),36.528000000000006,Significantly Below (<50%),60,42.3,25.295
NCT04390516,Respiratory Decompensation and Model for the Triage of COVID-19 Patients,COMPLETED,NA,197.0,2020-03-24,2020-05-30,89.50268656716418,Excellent (>50/month),200.0,Exceeded (≥100%),100,75.8,84.83500000000001
NCT01937416,Autologous Bone Marrow Mononuclear Cells Therapy in Diabetic Lower Limb Ischemia,UNKNOWN,PHASE1,10.0,2012-01-01,2014-12-01,0.28582159624413145,Slow (<1/month),2.858215962441315,Significantly Below (<50%),50,30.8,9.745
NCT01487616,Prevalence of Congenital Uterine Malformations,UNKNOWN,,246.0,2012-09-01,2016-03-01,5.863931088488645,Adequate (1-10/month),58.639310884886456,Below (50-75%),50,53.0,55.80500000000001
NCT04233216,Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019),COMPLETED,PHASE3,35.0,2020-03-18,2023-11-01,0.8052910052910053,Slow (<1/month),8.052910052910054,Significantly Below (<50%),100,47.8,42.42
NCT05252416,(VELA) Study of BLU-222 in Advanced Solid Tumors,TERMINATED,PHASE1,50.0,2022-04-07,2025-07-04,1.285472972972973,Adequate (1-10/month),12.85472972972973,Significantly Below (<50%),10,22.0,6.239999999999999
NCT04906616,An Economic and Relationship-strengthening Intervention for HIV-affected Couples Who Drink Alcohol in Malawi,COMPLETED,NA,156.0,2021-05-31,2023-07-13,6.143130659767141,Adequate (1-10/month),61.43130659767141,Below (50-75%),100,62.5,75.21
NCT06207916,International Survey of Childbirth-Related Trauma - Swedish Part,COMPLETED,,619.0,2021-09-01,2022-01-31,123.9628947368421,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT03953716,"Traditional Chinese Medicine, Western Medicine and Low-level Light Therapy（LLLT） for Primary Dysmenorrhea（PD）",UNKNOWN,PHASE4,480.0,2019-06-22,2020-06-30,39.06737967914439,Good (10-50/month),200.0,Exceeded (≥100%),50,78.4,86.75
NCT01504516,Bioequivalence Study for Donepezil Hydrochloride Tablets 10 mg Under Fed Condition,COMPLETED,PHASE1,25.0,2009-10-01,2009-12-01,12.475409836065573,Good (10-50/month),124.75409836065572,Exceeded (≥100%),100,57.0,66.12
NCT00289016,A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma,COMPLETED,PHASE2,50.0,2005-12-01,2009-05-01,1.2205292702485968,Adequate (1-10/month),12.205292702485968,Significantly Below (<50%),100,49.0,45.61
NCT06751316,Clinical and Radiographic Evaluation of MTA Pulpotomy Versus Conventional Pulpectomy in Primary Molars With Irreversible Pulpitis,NOT_YET_RECRUITING,NA,42.0,2025-01-01,2026-01-01,3.50268493150685,Adequate (1-10/month),35.026849315068496,Significantly Below (<50%),30,32.4,12.025
NCT03519516,"Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects",COMPLETED,PHASE1,30.0,2018-01-25,2018-06-10,6.714705882352941,Adequate (1-10/month),67.14705882352942,Below (50-75%),100,52.4,53.949999999999996
NCT01030016,Study of Atenolol Influence on Blood Pressure During Resistance Exercise,COMPLETED,PHASE4,10.0,2007-05-01,2009-05-01,0.41641586867305064,Slow (<1/month),4.164158686730506,Significantly Below (<50%),100,45.8,33.03
NCT04737616,Continuous Monitoring and Management of Vaginal Health Via Multifunctional OCT/OCTA/OCE Endoscopy,ACTIVE_NOT_RECRUITING,NA,90.0,2020-07-16,2026-07-01,1.2590073529411765,Adequate (1-10/month),12.590073529411766,Significantly Below (<50%),85,47.7,42.17
NCT00693316,Safety and Tolerability Study With Single Ascending Doses of ORM-12741,COMPLETED,PHASE1,120.0,2008-07-01,2009-10-01,7.992997811816193,Adequate (1-10/month),79.92997811816193,Met (75-100%),100,59.6,71.17999999999999
NCT05862116,Impact of Health Literacy on Chronic Non-specific Low Back Pain,UNKNOWN,,300.0,2023-07-01,2023-12-01,59.68627450980392,Excellent (>50/month),200.0,Exceeded (≥100%),50,67.3,80.00500000000001
NCT01639716,Lymphoma and T Helper 2 Cytokines Relationship With Prognostic Markers,COMPLETED,,58.0,2011-05-01,2012-06-01,4.447153652392948,Adequate (1-10/month),44.47153652392947,Significantly Below (<50%),100,53.0,55.80500000000001
NCT05845216,Effect of Transcranial Near InfraRed Light on Cerebral Function in Young and Healthy Older Subjects: a FMRI Study (TIROC),ACTIVE_NOT_RECRUITING,NA,64.0,2023-09-01,2026-05-15,1.973819655521783,Adequate (1-10/month),19.738196555217833,Significantly Below (<50%),85,50.6,48.705
NCT04618016,Evaluation of Medium Cross-linked Polyethylene With and Without Vitamin E for Total Knee Arthroplasty,ACTIVE_NOT_RECRUITING,,605.0,2021-03-08,2034-10-01,3.7166902119071645,Adequate (1-10/month),37.16690211907164,Significantly Below (<50%),85,83.8,90.505
NCT02192216,The Effect of Resistance Training and Aerobic Training on Body Composition During Chemotherapy,TERMINATED,NA,16.0,2014-02-01,2016-12-01,0.4710251450676983,Slow (<1/month),4.710251450676983,Significantly Below (<50%),10,19.3,5.125
NCT01529216,Efficacy Study of the DIAMOND System to Treat Type 2 Diabetes Mellitus,COMPLETED,NA,2.0,2012-05-01,2015-01-01,0.062441025641025646,Slow (<1/month),0.6244102564102565,Significantly Below (<50%),100,45.2,30.830000000000002
NCT05687916,A Study of TAK-861 in Participants With Narcolepsy Type 2,COMPLETED,PHASE2,71.0,2023-01-09,2023-12-25,6.174971428571428,Adequate (1-10/month),61.74971428571428,Below (50-75%),100,55.7,63.09
NCT06139406,A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer,ACTIVE_NOT_RECRUITING,PHASE1,70.0,2023-12-06,2026-08-31,2.132932932932933,Adequate (1-10/month),21.329329329329333,Significantly Below (<50%),85,51.1,50.129999999999995
NCT05692206,"In Chronic Neck Pain; Kinesiophobia, Neck Awareness Examination of Cognitive and Cognitive Functions at Different Levels of Functionality",UNKNOWN,,106.0,2023-02-13,2023-04-07,60.88,Excellent (>50/month),200.0,Exceeded (≥100%),50,51.8,52.17
NCT02884206,Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction,COMPLETED,PHASE3,592.0,2016-11-23,2022-05-16,9.01024,Adequate (1-10/month),90.10239999999999,Met (75-100%),100,95.0,95.7
NCT01043406,Seizure Advisory System Feasibility Study,TERMINATED,PHASE1,15.0,2010-03-01,2012-10-01,0.4831746031746032,Slow (<1/month),4.831746031746032,Significantly Below (<50%),10,19.2,5.055
NCT05602506,"Safety, Tolerability, and Efficacy of a Dose Reduction Strategy Based on Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-infected Adults",COMPLETED,PHASE4,40.0,2022-11-15,2024-06-05,2.1436619718309857,Adequate (1-10/month),21.436619718309856,Significantly Below (<50%),100,53.2,56.665
NCT00617006,Potential Nosocomial Infection Prevention Via Modification of Anesthesia Intraoperative Aseptic Practice,COMPLETED,,114.0,2007-07-01,2007-10-01,37.71913043478261,Good (10-50/month),200.0,Exceeded (≥100%),100,62.5,75.21
NCT03159806,Detecting Markers of Kidney Function With Intravenous Microdialysis,WITHDRAWN,,0.0,2019-07-01,2019-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT07110506,Comparison of Hemodynamic Variables Between Using Conventional Invasive Catheter Monitoring and Non-invasive Piezoelectric Sensor,NOT_YET_RECRUITING,NA,30.0,2025-08-22,2026-12-18,1.8906832298136647,Adequate (1-10/month),18.906832298136646,Significantly Below (<50%),30,31.4,10.47
NCT07382206,"Effect of Acute Exercise on Sleep Patterns in Patients With PLMS, Using a Wearable Device, Compared With a Control Group ( SONEX )",RECRUITING,NA,150.0,2024-12-24,2026-04-30,9.280487804878048,Adequate (1-10/month),92.8048780487805,Met (75-100%),60,55.0,61.834999999999994
NCT00844506,p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer,COMPLETED,PHASE2,19.0,2008-10-01,2009-07-01,2.1185347985347986,Adequate (1-10/month),21.18534798534799,Significantly Below (<50%),100,51.5,51.245
NCT02486406,A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects,COMPLETED,PHASE2,64.0,2015-10-28,2020-11-19,1.0536289886425094,Adequate (1-10/month),10.536289886425093,Significantly Below (<50%),100,50.1,47.89
NCT00198406,A FRENCH SURVEY OF THE DIAGNOSTIC AND THERAPEUTIC MANAGEMENT OF ELDERLY PEOPLE WITH HISTOLOGICALLY/CYTOLOGICALLY CONFIRMED LUNG CANCER.,COMPLETED,,1653.0,2002-09-01,2005-12-01,42.39032855939343,Good (10-50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT00178906,Acoustical Properties of Speech as Indicators of Suicidal Risk,COMPLETED,,124.0,1999-12-01,2008-04-01,1.24,Adequate (1-10/month),12.4,Significantly Below (<50%),100,53.3,57.14
NCT00347906,Photodynamic Therapy (PDT) Versus Transpupillary Thermotherapy (TTT) in Occult Choroidal Neovascularization (CNV) in Age-related Macular Degeneration (AMD),TERMINATED,NA,,2003-11-01,2005-09-01,,Slow (<1/month),,Significantly Below (<50%),10,18.0,2.92
NCT00306306,COOL RCN: Cooling to Prevent Radiocontrast Nephropathy,TERMINATED,PHASE2,400.0,2006-03-01,2007-08-01,23.505791505791507,Good (10-50/month),200.0,Exceeded (≥100%),10,60.0,71.97
NCT06695806,Measurement of the Intolerance to Uncertainty in Osteopaths,ENROLLING_BY_INVITATION,,400.0,2024-10-15,2025-05-31,53.40350877192983,Excellent (>50/month),200.0,Exceeded (≥100%),55,76.8,85.42
NCT05424406,Role of Sleep Reactivity in Shift Work Disorder,RECRUITING,NA,150.0,2023-01-01,2027-10-01,2.633217993079585,Adequate (1-10/month),26.332179930795853,Significantly Below (<50%),60,50.0,47.675
NCT01471106,Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer,COMPLETED,PHASE2,26.0,2014-01-21,2024-05-30,0.2092649391856161,Slow (<1/month),2.0926493918561606,Significantly Below (<50%),100,47.1,39.64
NCT06260306,Hip Activation vs. Hip Activation + Core Stabilization,COMPLETED,NA,34.0,2024-01-24,2024-04-12,13.100759493670886,Good (10-50/month),131.00759493670887,Exceeded (≥100%),100,57.7,67.51
NCT06193304,A Study to Evaluate Pharmacokinetic Parameters and Safety of Eliglustat Absorption Through the Mouth,COMPLETED,PHASE1,6.0,2014-08-25,2014-09-21,6.0,Adequate (1-10/month),60.0,Below (50-75%),100,50.5,48.515
NCT06206304,Relationship of Eye Colour With Anesthetic Success and Post-Operative Pain,COMPLETED,,110.0,2023-06-18,2023-12-11,19.025000000000002,Good (10-50/month),190.25,Exceeded (≥100%),100,62.1,74.595
NCT07144904,Assessing the Efficacy of Indocyanine Green for Ureter Identification During Robot-Assisted Surgery in Advanced-Stage Endometriosis,NOT_YET_RECRUITING,PHASE4,40.0,2025-10-01,2026-03-15,7.37939393939394,Adequate (1-10/month),73.79393939393938,Below (50-75%),30,32.2,11.635
NCT07005804,Calcium Pyrophosphate Deposition (CPPD) Disease,NOT_YET_RECRUITING,NA,137.0,2025-10-01,2027-11-01,5.48,Adequate (1-10/month),54.800000000000004,Below (50-75%),30,40.0,21.87
NCT01794104,Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas,COMPLETED,PHASE1,21.0,2013-02-15,2017-10-27,0.37273469387755104,Slow (<1/month),3.727346938775511,Significantly Below (<50%),100,46.7,37.895
NCT03100604,The Effect of General Anesthesia on the Middle Ear Pressure,COMPLETED,NA,50.0,2013-08-01,2016-03-01,1.613997879109226,Adequate (1-10/month),16.13997879109226,Significantly Below (<50%),100,49.0,45.61
NCT04576104,Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer,ACTIVE_NOT_RECRUITING,PHASE2,51.0,2021-11-29,2026-06-30,0.9273835125448029,Slow (<1/month),9.273835125448029,Significantly Below (<50%),85,44.6,29.42
NCT03846804,Next-Generation Sequencing for Pathogen Detection and Quantification in Children With Musculoskeletal Infections,COMPLETED,NA,38.0,2019-09-01,2022-06-02,1.1509651741293532,Adequate (1-10/month),11.509651741293531,Significantly Below (<50%),100,48.0,42.945
NCT04274504,Osteopontin in Metastatic Breast Cancer Patients,COMPLETED,,119.0,2015-01-01,2019-11-01,2.0523286118980173,Adequate (1-10/month),20.52328611898017,Significantly Below (<50%),100,57.9,67.83
NCT04201704,Effect of Giving Reduced Fluid in Children After Trauma,RECRUITING,NA,250.0,2018-08-27,2026-09-01,2.5999316706525453,Adequate (1-10/month),25.999316706525455,Significantly Below (<50%),60,58.0,68.245
NCT07307404,Web-based Platform for Nutrition Management in Patients With Cancer,RECRUITING,NA,84.0,2025-12-30,2027-04-30,5.261234567901235,Adequate (1-10/month),52.61234567901235,Below (50-75%),60,44.7,29.67
NCT04569604,QoL and Cognitive Function in Patients With Hypoparathyroidism,COMPLETED,,64.0,2019-10-01,2021-12-01,2.45979797979798,Adequate (1-10/month),24.5979797979798,Significantly Below (<50%),100,53.5,57.555
NCT04160104,Pre-procedure Modle Predicts Bowel Preparation Quality Prior Colonoscopy,UNKNOWN,,1600.0,2019-04-01,2019-12-31,177.75182481751824,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT01809704,Clinical Validation of New OCT System,COMPLETED,,87.0,2013-02-25,2013-07-03,20.689687499999998,Good (10-50/month),200.0,Exceeded (≥100%),100,60.3,72.34
NCT04511104,Effects of Exercise During the Acute Phase of Burns,UNKNOWN,PHASE2,40.0,2020-05-04,2022-04-01,1.7469153515064562,Adequate (1-10/month),17.469153515064562,Significantly Below (<50%),50,38.2,19.645000000000003
NCT04348604,Improving Adherence in Adolescents and Young Adults With Bipolar Disorder,COMPLETED,NA,36.0,2021-03-15,2023-09-01,1.2176,Adequate (1-10/month),12.176000000000002,Significantly Below (<50%),100,47.9,42.64
NCT07267104,Mathematical Analysis of Signals and Clinical Parameters Provided by Non-invasive Home Ventilation Devices,RECRUITING,,75.0,2025-03-25,2026-12-01,3.706168831168831,Adequate (1-10/month),37.061688311688314,Significantly Below (<50%),60,42.3,25.295
NCT04257604,A Study of Perampanel as Add-on Therapy in Adult and Adolescent Participants With Focal Seizures,COMPLETED,,243.0,2016-01-03,2019-04-30,6.098037922506183,Adequate (1-10/month),60.98037922506183,Below (50-75%),100,67.8,80.285
NCT07182604,Effectiveness of a Prenatal Educational Intervention to Prevent Positional Occipital Plagiocephaly,COMPLETED,NA,400.0,2023-01-01,2024-04-30,25.105154639175257,Good (10-50/month),200.0,Exceeded (≥100%),100,87.0,92.135
NCT03264404,Azacitidine and Pembrolizumab in Pancreatic Cancer,COMPLETED,PHASE2,36.0,2017-10-01,2024-12-03,0.41825954198473286,Slow (<1/month),4.1825954198473285,Significantly Below (<50%),100,47.9,42.64
NCT03720704,Post-Market Registry of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis Implanted in Peripheral Vessels,ACTIVE_NOT_RECRUITING,,280.0,2018-12-18,2027-07-01,2.734424125761951,Adequate (1-10/month),27.344241257619505,Significantly Below (<50%),85,66.2,79.2
NCT02523404,HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA）for Lung Cancer,COMPLETED,PHASE1,60.0,2015-05-01,2016-08-01,3.9877729257641925,Adequate (1-10/month),39.877729257641924,Significantly Below (<50%),100,54.8,61.095
NCT00830804,Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults,COMPLETED,PHASE2,113.0,2009-04-01,2010-09-01,6.640386100386101,Adequate (1-10/month),66.40386100386101,Below (50-75%),100,59.0,70.365
NCT05445284,Group Education Trial to Improve Transition for Parents of Adolescents With T1D,ACTIVE_NOT_RECRUITING,NA,34.0,2023-10-10,2026-03-01,1.1855211912943873,Adequate (1-10/month),11.855211912943874,Significantly Below (<50%),85,43.2,26.840000000000003
NCT06658184,Effects of Sleep Restriction and Stimulus Control in Chronic Insomnia Patients,RECRUITING,NA,88.0,2024-12-01,2025-12-01,7.33895890410959,Adequate (1-10/month),73.38958904109589,Below (50-75%),60,45.0,30.330000000000002
NCT04359784,Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy,COMPLETED,PHASE2,27.0,2021-12-27,2024-12-23,0.7526373626373627,Slow (<1/month),7.526373626373628,Significantly Below (<50%),100,47.2,40.035
NCT06448884,Accuracy of ICCMS Versus Simplified Cariogram,NOT_YET_RECRUITING,,323.0,2024-06-15,2025-04-01,33.903862068965516,Good (10-50/month),200.0,Exceeded (≥100%),30,58.2,68.795
NCT03692884,Chongqing Diabetes Registry Study,RECRUITING,,5000.0,2018-07-01,2030-07-01,34.72507415012549,Good (10-50/month),200.0,Exceeded (≥100%),60,81.3,88.58
NCT04285684,The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women,COMPLETED,EARLY_PHASE1,4.0,2019-12-20,2021-01-05,0.3187434554973822,Slow (<1/month),3.1874345549738217,Significantly Below (<50%),100,45.3,31.169999999999998
NCT02195284,"To Study Device Attributes by Investigating Errors Made in Use, Ease of Use and Preference Among Different Inhalers in Subjects With Asthma",COMPLETED,PHASE4,162.0,2014-11-01,2015-05-01,27.2446408839779,Good (10-50/month),200.0,Exceeded (≥100%),100,68.0,80.56
NCT03449784,Assessment of Compliance With European and French Guidelines for the Management of Dyslipidaemias,RECRUITING,,977.0,2012-05-01,2041-05-01,2.807768126888218,Adequate (1-10/month),28.077681268882177,Significantly Below (<50%),60,76.3,85.1
NCT05501184,SYNCHRONOUS AND ASYNCHRONOUS TELEREHABILITATION METHODS IN PATIENTS WITH CERVICAL DISC HERNIATION,COMPLETED,NA,60.0,2022-02-01,2022-08-11,9.562303664921465,Adequate (1-10/month),95.62303664921465,Met (75-100%),100,59.8,71.61
NCT03214484,The Evolution of Visual Acuity Measured by Electronic Tablet / Computer of Exudative AMD Patients,UNKNOWN,NA,80.0,2017-06-02,2018-06-01,6.69010989010989,Adequate (1-10/month),66.9010989010989,Below (50-75%),50,41.4,24.04
NCT03777384,EValuating the Safety of De-escaLated Head and Neck Irradiation in HPV PositivE Oropharynx Cancer in Non-smokers/minimal Smokers,ACTIVE_NOT_RECRUITING,,75.0,2018-10-12,2026-12-01,0.7681695827725438,Slow (<1/month),7.681695827725439,Significantly Below (<50%),85,44.8,29.845
NCT06678984,Treated Umbilical Vein Allograft (UVT) Versus Autologous Fascial Pubovaginal Sling in the Treatment of Female Stress Urinary Incontinence,NOT_YET_RECRUITING,PHASE3,96.0,2025-10-01,2028-05-01,3.098875927889714,Adequate (1-10/month),30.988759278897138,Significantly Below (<50%),30,36.7,17.544999999999998
NCT00864084,Does Pulmonary Rehabilitation Improve Balance in People With Respiratory Disease?,COMPLETED,PHASE1,14.0,2009-04-01,2009-12-01,1.7465573770491802,Adequate (1-10/month),17.4655737704918,Significantly Below (<50%),100,51.1,50.129999999999995
NCT00379184,Sensitization in Osteoarthritic Knees,COMPLETED,,72.0,2006-09-01,2009-06-01,2.182948207171315,Adequate (1-10/month),21.829482071713148,Significantly Below (<50%),100,54.1,59.11
NCT01718184,Piggyback Sulcoflex Toric IOL for Correcting Refractive Error Following Corneal Transplantation,UNKNOWN,NA,25.0,2012-10-01,2014-10-01,1.0424657534246577,Adequate (1-10/month),10.424657534246576,Significantly Below (<50%),50,32.0,11.425
NCT02105584,"Prospective, Non-randomized, Safety and Efficacy Study of a New Occluder Design for Minimally Invasive Closure of the Left Atrial Appendage (LAA) in Patients With Atrial Fibrillation",COMPLETED,NA,78.0,2014-04-01,2017-09-01,1.9009767814251401,Adequate (1-10/month),19.0097678142514,Significantly Below (<50%),100,56.2,64.21
NCT05035784,RCE With FMT in the Treatment of Childhood Constipation,COMPLETED,NA,110.0,2020-11-10,2022-05-13,6.099089253187614,Adequate (1-10/month),60.99089253187615,Below (50-75%),100,58.8,69.89999999999999
NCT06156384,"Study to Assess the Pain, Satisfaction, and Quality of Life of Patients With FITBONE® Lengthening Nail",RECRUITING,,45.0,2024-06-18,2029-06-30,0.7452665941240479,Slow (<1/month),7.452665941240479,Significantly Below (<50%),60,34.9,15.215
NCT05878184,Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT),ACTIVE_NOT_RECRUITING,PHASE1,16.0,2023-05-02,2038-11-04,0.08597352162400707,Slow (<1/month),0.8597352162400707,Significantly Below (<50%),85,41.8,24.445
NCT02301884,"Pilot Study of Intralymphatic Immunotherapy (ILIT) for House Dust Mite, Cat, and Dog Allergen in Allergic Rhinitis",COMPLETED,PHASE1,12.0,2013-11-01,2015-03-01,0.7531546391752577,Slow (<1/month),7.531546391752577,Significantly Below (<50%),100,46.0,34.1
NCT03330184,Effectiveness and Safety of Berberine Hydrochloride and Bifidobacterium in People With Abnormal Glucose Level,COMPLETED,NA,300.0,2015-10-01,2018-04-01,10.002190580503834,Good (10-50/month),100.02190580503833,Exceeded (≥100%),100,79.0,86.96000000000001
NCT06701084,Molecular Genetic Mechanisms of Infantile Epilepsies and the Impact of Genetic Diagnosis,RECRUITING,NA,600.0,2021-09-02,2029-11-01,6.124748490945675,Adequate (1-10/month),61.24748490945674,Below (50-75%),60,78.0,86.075
NCT02128984,Clinical Study With an Enteral Formula With Symbiotic and DHA for Malnourished Children,COMPLETED,NA,109.0,2012-01-01,2015-05-01,2.7285855263157894,Adequate (1-10/month),27.28585526315789,Significantly Below (<50%),100,58.7,69.69
NCT03062384,AT-001 for Long-term Preservation of Brain Health in Aging,COMPLETED,NA,95.0,2016-05-01,2018-12-31,2.968993839835729,Adequate (1-10/month),29.68993839835729,Significantly Below (<50%),100,57.6,67.36999999999999
NCT00303784,Prostate Adenocarcinoma TransCutaneous Hormones,UNKNOWN,PHASE3,2200.0,2006-03-01,2021-08-01,11.890625,Good (10-50/month),118.90625000000001,Exceeded (≥100%),50,80.0,87.67
NCT06327984,Barts Sex-CAD Database - Sex Hormones and Inflammatory Status in Coronary Artery Disease,RECRUITING,,6000.0,2023-11-21,2033-01-31,54.37332539446264,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT03414684,Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE2,78.0,2018-01-30,2026-07-30,0.765169191105382,Slow (<1/month),7.6516919110538195,Significantly Below (<50%),85,46.7,37.895
NCT05156333,Probiotics and GBS Colonization in Pregnancy,SUSPENDED,NA,402.0,2020-10-15,2022-12-31,15.163420074349444,Good (10-50/month),151.63420074349446,Exceeded (≥100%),20,63.2,76.11
NCT05780333,Effect of Different Plane Blocks on Quality of Recovery and Postoperative Pain After Laparoscopic Hysterectomy,UNKNOWN,NA,60.0,2023-01-27,2023-07-01,11.783225806451613,Good (10-50/month),117.83225806451614,Exceeded (≥100%),50,44.8,29.845
NCT06906133,Sleep Quality and the Menstrual Cycle,ACTIVE_NOT_RECRUITING,,60.0,2025-03-01,2026-08-31,3.332846715328467,Adequate (1-10/month),33.32846715328467,Significantly Below (<50%),85,48.6,44.685
NCT01689233,Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease,COMPLETED,PHASE3,800.0,2012-10-01,2016-05-01,18.617737003058107,Good (10-50/month),186.17737003058105,Exceeded (≥100%),100,95.0,95.7
NCT00922233,Pericoital Oral Contraception With Levonorgestrel,COMPLETED,PHASE3,72.0,2010-01-01,2010-11-01,7.2094736842105265,Adequate (1-10/month),72.09473684210526,Below (50-75%),100,55.8,63.245
NCT05818033,Safety and Effectiveness of CARE1.02 Spectacle Lens in Myopia Control,ACTIVE_NOT_RECRUITING,NA,760.0,2023-04-25,2025-06-30,29.02685069008783,Good (10-50/month),200.0,Exceeded (≥100%),85,90.5,93.4
NCT05742633,Comparative Effect of Active Release Technique Versus Self-myofascial Release in Improving Piriformis Syndrome,COMPLETED,NA,82.0,2023-02-03,2023-06-15,18.90969696969697,Good (10-50/month),189.0969696969697,Exceeded (≥100%),100,61.6,74.0
NCT01720433,Reduction of Pain Following Laparoscopic Surgery: A Double Blind Prospective Randomized Controlled Trial,COMPLETED,NA,127.0,2010-08-01,2012-02-01,7.0416757741347915,Adequate (1-10/month),70.41675774134791,Below (50-75%),100,60.2,72.2
NCT04741633,Multi Dimensional Precise Exploration of Immunoconsolidation Therapy for Locally Advanced NSCLC After Chemo-radiotherapy,UNKNOWN,,25.0,2020-04-01,2022-12-31,0.75796812749004,Slow (<1/month),7.579681274900399,Significantly Below (<50%),50,30.3,9.295
NCT04992533,Tourniquet vs. no Tourniquet During High Tibial Osteotomy,UNKNOWN,NA,50.0,2019-11-30,2021-12-30,2.0,Adequate (1-10/month),20.0,Significantly Below (<50%),50,39.0,20.505000000000003
NCT06202833,Tongyuan Acupuncture on Consciousness Disorder After Stroke,RECRUITING,NA,174.0,2024-03-20,2025-12-31,8.136036866359447,Adequate (1-10/month),81.36036866359447,Met (75-100%),60,51.9,52.55499999999999
NCT03572933,Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder,COMPLETED,PHASE3,101.0,2018-06-30,2021-05-28,2.8922295390404518,Adequate (1-10/month),28.922295390404518,Significantly Below (<50%),100,58.1,68.595
NCT03307733,Walking in Pregnancy (WiP) - a Social Networking Physical Activity Intervention for Pregnant Obese Women,COMPLETED,NA,40.0,2016-09-01,2017-07-01,4.018481848184819,Adequate (1-10/month),40.18481848184819,Significantly Below (<50%),100,53.2,56.665
NCT02349633,Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M),TERMINATED,PHASE1,65.0,2015-05-14,2020-05-28,1.074741988049973,Adequate (1-10/month),10.747419880499729,Significantly Below (<50%),10,23.2,6.444999999999999
NCT00268333,Combination Chemotherapy and Radiation Therapy in Treating Patients With Recurrent Metastatic Colorectal Cancer,COMPLETED,PHASE2,39.0,2005-08-01,,,Slow (<1/month),,Significantly Below (<50%),100,43.1,26.724999999999998
NCT03465033,"Early Physiotherapy, Mandibular Motion and Sensorial Recovery After Orthognathic Surgery",UNKNOWN,NA,50.0,2018-03-30,2021-03-12,1.411873840445269,Adequate (1-10/month),14.11873840445269,Significantly Below (<50%),50,34.0,14.02
NCT00003152,Chemotherapy Plus Interferon Alfa Alone or With Radiation Therapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma,TERMINATED,PHASE3,469.0,1997-03-01,,,Slow (<1/month),,Significantly Below (<50%),10,50.5,48.515
NCT06983652,Validation of the Use of Terahertz Scanning System on Corneal Scars and Corneal Edema,RECRUITING,,150.0,2024-07-01,2026-08-31,5.7724399494311,Adequate (1-10/month),57.724399494310994,Below (50-75%),60,48.3,43.985
NCT01392352,HYPAZ: Hypertension Induced by Pazopanib,TERMINATED,PHASE2,31.0,2011-04-01,2015-09-01,0.5846592317224288,Slow (<1/month),5.846592317224288,Significantly Below (<50%),10,20.5,5.92
NCT02507752,An Observational Quality of Life Study in Participants With Rheumatoid Arthritis Treated With Rituximab,COMPLETED,,94.0,2009-07-01,2012-06-01,2.6842026266416514,Adequate (1-10/month),26.842026266416514,Significantly Below (<50%),100,55.9,63.42
NCT00404352,REbif FLEXible Dosing in Early Multiple Sclerosis (MS),COMPLETED,PHASE3,517.0,2006-11-01,2011-07-01,9.241033470346448,Adequate (1-10/month),92.41033470346447,Met (75-100%),100,95.0,95.7
NCT07146152,Empowering Women - Shared Decision Making in Managing Cervical Precancer,NOT_YET_RECRUITING,NA,138.0,2025-10-01,2030-04-30,2.512392344497608,Adequate (1-10/month),25.123923444976082,Significantly Below (<50%),30,40.0,21.87
NCT02847052,"Study of the Role of Soluble Inhibitor of Interleukin 22, Interleukin 22 Binding Protein (IL-22BP), in Chronic Inflammatory Bowel Disease",TERMINATED,,52.0,2014-08-01,2022-03-16,0.5685632183908046,Slow (<1/month),5.685632183908046,Significantly Below (<50%),10,20.5,5.92
NCT05041452,Multiparametric Cardio-hepatic MRI in Patients With Noncirrhotic Portal Hypertension,UNKNOWN,,60.0,2021-04-29,2023-12-31,1.871311475409836,Adequate (1-10/month),18.71311475409836,Significantly Below (<50%),50,38.1,19.425
NCT04206852,Safety and Efficacy of Balloon Pulmonary Angioplasty in China,RECRUITING,,200.0,2018-05-11,2028-05-11,1.6665754174650973,Adequate (1-10/month),16.665754174650974,Significantly Below (<50%),60,47.3,40.475
NCT03610152,Does a Theory-Based Intervention to Improve Accountability Reduce Low-Value Preoperative Investigations in Patients Undergoing Ambulatory Surgery,UNKNOWN,NA,22.0,2019-10-01,2021-09-30,0.9173698630136987,Slow (<1/month),9.173698630136986,Significantly Below (<50%),50,31.8,11.19
NCT03963752,Clinical Trial of Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western Medicine,COMPLETED,PHASE4,126.0,2019-08-15,2022-09-30,3.3585288966725044,Adequate (1-10/month),33.585288966725045,Significantly Below (<50%),100,60.1,72.085
NCT01822652,"3rd Generation GD-2 Chimeric Antigen Receptor and ICaspase Suicide Safety Switch, Neuroblastoma, GRAIN",ACTIVE_NOT_RECRUITING,PHASE1,11.0,2013-08-01,2030-10-01,0.05340350877192983,Slow (<1/month),0.5340350877192983,Significantly Below (<50%),85,41.4,24.04
NCT01543152,Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T,COMPLETED,PHASE1,26.0,2011-12-01,2017-07-07,0.3870122249388753,Slow (<1/month),3.8701222493887535,Significantly Below (<50%),100,47.1,39.64
NCT04609852,A Study to Assess the Safety and Tolerability of E8001 in Healthy Male Participants,COMPLETED,PHASE1,36.0,2020-10-28,2023-08-18,1.07015625,Adequate (1-10/month),10.7015625,Significantly Below (<50%),100,47.9,42.64
NCT03571152,Efficacy of the Use of Educational Videos for Caregivers of Patients in Subacute Phase of Stroke,COMPLETED,NA,10.0,2018-09-01,2018-12-10,3.044,Adequate (1-10/month),30.44,Significantly Below (<50%),100,50.8,49.18
NCT06693752,CEUS Evaluation of Hydrocephalus in Neonates and Infants,RECRUITING,PHASE2,20.0,2026-02-28,2027-08-01,1.1730250481695568,Adequate (1-10/month),11.73025048169557,Significantly Below (<50%),60,34.6,14.729999999999999
NCT06592352,MODAFIMS: A Trial to Evaluate Predictors of Response to MODAFinil in Patients With Multiple Sclerosis,RECRUITING,PHASE2,64.0,2024-08-27,2026-09-01,2.650557823129252,Adequate (1-10/month),26.50557823129252,Significantly Below (<50%),60,43.1,26.724999999999998
NCT05499052,Trial to Assess the Pattern of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation (IVF) or Intracytoplasmic Sperm Injection (ICSI) Procedures in Routine Clinical Practice,COMPLETED,,201.0,2022-08-28,2024-03-14,10.848297872340426,Good (10-50/month),108.48297872340424,Exceeded (≥100%),100,69.4,81.52000000000001
NCT03257852,A Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate,COMPLETED,PHASE2,66.0,2017-09-29,2018-10-16,5.259267015706807,Adequate (1-10/month),52.59267015706806,Below (50-75%),100,55.3,62.36000000000001
NCT02408952,Screening for Youth Alcohol and Drug Use: A Study of Primary Care Providers,UNKNOWN,NA,9084.0,2011-10-01,2025-12-31,53.12525648414986,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT01437852,StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns,COMPLETED,PHASE1,30.0,2011-09-01,2014-10-01,0.81101243339254,Slow (<1/month),8.110124333925398,Significantly Below (<50%),100,47.4,40.98
NCT00112047,Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects,COMPLETED,PHASE3,517.0,2003-07-01,2009-06-01,7.279130434782609,Adequate (1-10/month),72.79130434782608,Below (50-75%),100,90.0,93.17
NCT03469947,California Prehospital and In Hospital Antifibrinolytic Therapy Via TXA,COMPLETED,PHASE3,200.0,2015-03-01,2024-07-29,1.7707969749854566,Adequate (1-10/month),17.70796974985457,Significantly Below (<50%),100,66.0,78.99000000000001
NCT01412047,Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study,COMPLETED,,75.0,2012-03-01,2013-06-30,4.697530864197531,Adequate (1-10/month),46.97530864197532,Significantly Below (<50%),100,54.3,59.62
NCT02030847,Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia,COMPLETED,PHASE2,42.0,2014-02-27,2018-04-26,0.8416589861751151,Slow (<1/month),8.416589861751152,Significantly Below (<50%),100,48.4,44.22
NCT04444947,Influencing Factors in Patients With Colorectal and Gastric Polyps a Retrospective Study,COMPLETED,,64889.0,2019-02-20,2020-06-01,4229.595631691649,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT03207347,A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001),COMPLETED,PHASE2,37.0,2018-08-13,2022-08-30,0.7620297699594046,Slow (<1/month),7.620297699594046,Significantly Below (<50%),100,48.0,42.945
NCT04576247,Combined Modality Exercise and Appetite in Breast Cancer Survivors,TERMINATED,NA,3.0,2020-06-05,2021-09-20,0.19347457627118644,Slow (<1/month),1.9347457627118647,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT06436547,Subiculum Electrical Stimulation for Temporal Lobe Epilepsy With Biliteral Hippocampus Sclerosis(SESTB),ACTIVE_NOT_RECRUITING,NA,6.0,2024-06-01,2026-03-30,0.27382308845577213,Slow (<1/month),2.7382308845577215,Significantly Below (<50%),85,41.0,23.01
NCT05374447,Diagnostic Yield of Intranodal Forceps Biopsies in Mediastinal Adenopathy,RECRUITING,NA,55.0,2022-06-10,2026-03-01,1.2310294117647058,Adequate (1-10/month),12.310294117647057,Significantly Below (<50%),60,37.4,18.62
NCT03980847,"Evaluation, the Histomorphometric Study of Nanocrystalline Hydroxyapatite (Nano Bone) Wif Alendronate in the Preservation of the Tooth Socket",COMPLETED,PHASE2,20.0,2018-02-23,2019-04-25,1.4291079812206573,Adequate (1-10/month),14.291079812206572,Significantly Below (<50%),100,46.6,37.375
NCT03589547,Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung,ACTIVE_NOT_RECRUITING,PHASE2,11.0,2019-05-13,2026-10-01,0.1241067457375834,Slow (<1/month),1.241067457375834,Significantly Below (<50%),85,41.4,24.04
NCT00941447,Development of Self-Regulation in Individuals With Type 2 Diabetes,COMPLETED,NA,15.0,2009-04-01,2011-02-01,0.6804769001490313,Slow (<1/month),6.804769001490313,Significantly Below (<50%),100,46.2,35.089999999999996
NCT01415947,V-Chordal Adjustable System for Chordal Replacement in Mitral Valve Insufficiency Due to Leaflet Prolapse,TERMINATED,PHASE2,5.0,2010-11-01,2013-03-01,0.17884841363102233,Slow (<1/month),1.7884841363102235,Significantly Below (<50%),10,18.4,3.855
NCT06827249,Peginterferon α-2b Injection for the Treatment of Pediatric RSV Bronchiolitis,RECRUITING,NA,90.0,2025-03-01,2027-06-01,3.332846715328467,Adequate (1-10/month),33.32846715328468,Significantly Below (<50%),60,45.2,30.830000000000002
NCT03941249,Blod Biomarkers for Stroke,UNKNOWN,,150.0,2017-11-01,2023-12-01,2.055830706888789,Adequate (1-10/month),20.55830706888789,Significantly Below (<50%),50,45.3,31.169999999999998
NCT01662349,Safety Study of Plasma Treatment System to Treat Back Acne,TERMINATED,NA,8.0,2012-08-01,2013-06-01,0.8010526315789473,Slow (<1/month),8.010526315789473,Significantly Below (<50%),10,18.6,4.25
NCT05657249,Alternative Surveillance Program for Patients With High Risk Group of HCC,ACTIVE_NOT_RECRUITING,NA,199.0,2023-01-06,2026-12-31,4.16327147766323,Adequate (1-10/month),41.6327147766323,Significantly Below (<50%),85,61.4,73.735
NCT03643549,Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17),RECRUITING,PHASE1,63.0,2018-08-30,2025-12-31,0.7155671641791046,Slow (<1/month),7.155671641791045,Significantly Below (<50%),60,38.0,19.255
NCT06784349,ALN-APOC3 in Adult Participants With Dyslipidemia,ACTIVE_NOT_RECRUITING,PHASE1,32.0,2025-01-27,2026-02-25,2.472284263959391,Adequate (1-10/month),24.72284263959391,Significantly Below (<50%),85,48.1,43.275000000000006
NCT04966949,Lateral Prostate Capsule Sparing Versus Nerve Sparing Robot-assisted Radical Cystectomy-orthotopic Ileal Neobladder for Bladder Cancer in the Male,UNKNOWN,NA,100.0,2021-09-01,2023-08-31,4.175582990397805,Adequate (1-10/month),41.755829903978054,Significantly Below (<50%),50,43.0,26.465
NCT01286649,Safety and Efficacy Study of Human Autologous Hair Follicle Cells to Treat Androgenetic Alopecia,COMPLETED,PHASE1,19.0,2010-12-01,2017-02-23,0.2541124780316345,Slow (<1/month),2.541124780316345,Significantly Below (<50%),100,46.5,36.815
NCT01038349,Applications for Methotrexate Optimization in Rheumatoid Arthritis,COMPLETED,,256.0,2009-06-01,2010-02-01,31.806693877551023,Good (10-50/month),200.0,Exceeded (≥100%),100,73.8,83.865
NCT03022149,Remote Ischemic Preconditioning for Subcortical Vascular Dementia,UNKNOWN,NA,52.0,2016-02-01,2017-06-01,3.2569547325102883,Adequate (1-10/month),32.56954732510288,Significantly Below (<50%),50,39.2,20.715
NCT06737549,Effect of Specific Mode Electroacupuncture Stimulation Combined with NGF on Dysphagia After Ischaemic Stroke: a Pilot Randomized Controlled Trial,RECRUITING,PHASE4,144.0,2024-12-01,2027-12-01,4.0030684931506855,Adequate (1-10/month),40.030684931506855,Significantly Below (<50%),60,49.5,46.58
NCT00923949,Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung Cancer,TERMINATED,PHASE2,1.0,2008-08-01,2010-03-01,0.05275563258232236,Slow (<1/month),0.5275563258232236,Significantly Below (<50%),10,18.1,3.105
NCT05659849,Effectiveness of Manual Therapy and Neuromuscular Training in the Management of Knee Osteoarthritis,COMPLETED,NA,60.0,2022-06-16,2024-06-30,2.451543624161074,Adequate (1-10/month),24.51543624161074,Significantly Below (<50%),100,54.8,61.095
NCT06372249,A Clinical Trial of Soluble Fiber for Asthma,NOT_YET_RECRUITING,PHASE2,105.0,2025-12-01,2027-04-01,6.576543209876544,Adequate (1-10/month),65.76543209876544,Below (50-75%),30,37.4,18.62
NCT02689349,Esteem New Subject Enrollment Post Approval Study,COMPLETED,NA,117.0,2010-08-01,2021-09-01,0.8795949617189429,Slow (<1/month),8.79594961718943,Significantly Below (<50%),100,54.4,59.89
NCT05665049,Social Transfers for Exclusive Breastfeeding,ACTIVE_NOT_RECRUITING,NA,300.0,2022-08-01,2027-12-31,4.616784630940344,Adequate (1-10/month),46.16784630940345,Significantly Below (<50%),85,69.5,81.62
NCT01310049,LEO 32731 - A Study in Healthy Male Subjects,COMPLETED,PHASE1,111.0,2011-03-01,2012-11-01,5.530016366612111,Adequate (1-10/month),55.300163666121115,Below (50-75%),100,58.9,70.10499999999999
NCT04911049,Prevalence and Pathophysiology of Systemic Arterial Pressure Abnormalities in Childhood Sickle Cell Disease,UNKNOWN,,200.0,2021-06-01,2023-06-01,8.339726027397262,Adequate (1-10/month),83.3972602739726,Met (75-100%),50,54.3,59.62
NCT05043649,Camsirubicin + Pegfilgrastim to Determine MTD in ASTS,TERMINATED,PHASE1,14.0,2021-09-22,2024-05-13,0.44207468879668055,Slow (<1/month),4.420746887966805,Significantly Below (<50%),10,19.1,4.9799999999999995
NCT05321849,Echocardiography-guided Percutaneous Patent Ductus Arteriosus Closure,COMPLETED,,60.0,2019-03-12,2020-06-23,3.8942430703624735,Adequate (1-10/month),38.94243070362473,Significantly Below (<50%),100,53.1,56.105000000000004
NCT05601349,TeleEducation for Implementing a Clinical Practice Guideline For Amputees,COMPLETED,NA,7.0,2020-01-01,2022-05-01,0.2503877790834313,Slow (<1/month),2.503877790834313,Significantly Below (<50%),100,45.6,32.08
NCT02457949,The Impact of Alternative Social Assistance Disbursement on Drug-related Harm,TERMINATED,NA,194.0,2015-10-27,2019-09-30,4.118103207810321,Adequate (1-10/month),41.18103207810321,Significantly Below (<50%),10,38.5,19.895
NCT05678049,Evaluation and Characterisation of Microplastics and Nanoplastics in Joint Synovial Liquid,UNKNOWN,,50.0,2023-01-15,2024-12-15,2.1742857142857144,Adequate (1-10/month),21.74285714285714,Significantly Below (<50%),50,37.3,18.35
NCT02104349,Mindfulness Meditation for Spine Surgery Pain,TERMINATED,NA,38.0,2014-02-01,2020-09-02,0.48096465696465696,Slow (<1/month),4.80964656964657,Significantly Below (<50%),10,21.0,6.105
NCT03085849,SGI-110 Plus Durvalumab/Tremelimumab in SCLC,COMPLETED,PHASE1,2.0,2017-12-15,2018-11-26,0.17595375722543352,Slow (<1/month),1.7595375722543352,Significantly Below (<50%),100,45.2,30.830000000000002
NCT02417649,Advanced Immunological Approach in COPD Exacerbation,COMPLETED,PHASE4,288.0,2009-09-01,2013-07-01,6.266418870621872,Adequate (1-10/month),62.664188706218724,Below (50-75%),100,73.0,83.44
NCT06287138,"The Effect of Ciprofol on Breathing Patterns, Respiratory Drive, and Inspiratory Effort in Mechanically Ventilated Patients",UNKNOWN,NA,20.0,2023-05-10,2025-03-31,0.881041968162084,Slow (<1/month),8.81041968162084,Significantly Below (<50%),50,31.6,10.905
NCT02258438,Effect of Breaking up Prolonged Sitting on Metabolic Flexibility,COMPLETED,NA,28.0,2014-10-08,2017-09-01,0.8048347497639282,Slow (<1/month),8.048347497639282,Significantly Below (<50%),100,47.2,40.035
NCT00145938,Sildenafil and Pulmonary Artery Pressure,TERMINATED,PHASE2,10.0,2003-09-01,2006-09-01,0.27773722627737224,Slow (<1/month),2.7773722627737225,Significantly Below (<50%),10,18.8,4.58
NCT07380438,A Clinical Study to Evaluate the Efficacy of a Nutritional Supplement to Improve Carotenoid Content as Measured by a Non-invasive Hyperspectral Absorption Device,COMPLETED,NA,84.0,2025-10-20,2026-01-08,31.962,Good (10-50/month),200.0,Exceeded (≥100%),100,61.7,74.1
NCT03382938,Dexmedetomidine Wound Infiltration in Cesarean Section,RECRUITING,NA,100.0,2019-08-23,2026-11-20,1.1504157218442934,Adequate (1-10/month),11.504157218442932,Significantly Below (<50%),60,41.0,23.01
NCT03801538,The Optimizing Treatment of Peginterferon Alpha in Chronic Hepatitis B Patients With Low Level HBsAg,UNKNOWN,PHASE4,200.0,2019-01-01,2020-12-01,8.697142857142858,Adequate (1-10/month),86.97142857142856,Met (75-100%),50,56.0,63.71
NCT05026138,"Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)",RECRUITING,,850.0,2021-11-17,2047-03-31,2.7926605504587156,Adequate (1-10/month),27.926605504587158,Significantly Below (<50%),60,76.3,85.1
NCT06720038,"A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants",ACTIVE_NOT_RECRUITING,PHASE2,905.0,2024-11-25,2027-12-01,25.021071752951862,Good (10-50/month),200.0,Exceeded (≥100%),85,90.5,93.4
NCT04244838,Gait Analysis in Patients Underwent Total Knee Arthroplasty With a Medial Pivot Design.,COMPLETED,NA,25.0,2019-07-29,2024-05-19,0.43337129840546695,Slow (<1/month),4.333712984054669,Significantly Below (<50%),100,47.0,39.33
NCT00985738,Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer,TERMINATED,PHASE2,16.0,2009-09-01,2013-01-01,0.3998686371100164,Slow (<1/month),3.9986863711001637,Significantly Below (<50%),10,19.3,5.125
NCT06991738,"177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer",NOT_YET_RECRUITING,PHASE1,18.0,2026-02-03,2032-08-01,0.2310923660902573,Slow (<1/month),2.310923660902573,Significantly Below (<50%),30,25.4,7.470000000000001
NCT01427738,Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis,COMPLETED,PHASE3,221.0,2011-06-01,2014-01-01,7.118772486772487,Adequate (1-10/month),71.18772486772488,Below (50-75%),100,67.7,80.22
NCT01926938,Endothelial Function in Young Hispanic Adults at Risk for Type 2 Diabetes,COMPLETED,,44.0,2003-05-01,2013-01-01,0.3790999150863289,Slow (<1/month),3.790999150863289,Significantly Below (<50%),100,46.9,38.96
NCT06768138,Intra-Arterial Thrombolysis After SUCCESSful Reperfusion in Anterior Circulation Ischemic Stroke,RECRUITING,PHASE3,626.0,2025-06-01,2029-07-01,12.780308517773307,Good (10-50/month),127.80308517773307,Exceeded (≥100%),60,83.0,89.505
NCT07100938,A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis,RECRUITING,PHASE2,90.0,2025-08-21,2026-10-18,6.476595744680851,Adequate (1-10/month),64.76595744680851,Below (50-75%),60,45.2,30.830000000000002
NCT05886738,"Investigating the Effect of Short-term Fasting on T Cell Metabolism, Function, and Phenotype in Obesity",UNKNOWN,NA,20.0,2023-06-01,2023-08-30,6.764444444444445,Adequate (1-10/month),67.64444444444445,Below (50-75%),50,36.6,17.41
NCT01405638,Faith-based Approaches to Treating Hypertension and Colon Cancer Prevention,COMPLETED,NA,451.0,2011-03-01,2015-06-01,8.839948486799743,Adequate (1-10/month),88.39948486799743,Met (75-100%),100,91.1,93.58999999999999
NCT06744738,Pharmacist-led Intervention on Hemodialysis Patients' Therapy Adherence,COMPLETED,NA,72.0,2024-02-02,2024-06-25,15.22,Good (10-50/month),152.2,Exceeded (≥100%),100,60.8,72.99
NCT05494658,Impact of Preoperative Oral Branched-chain Amino Acids on Reducing Postoperative Insulin Resistance.,RECRUITING,NA,224.0,2022-08-26,2024-12-01,8.234975845410629,Adequate (1-10/month),82.34975845410628,Met (75-100%),60,55.9,63.42
NCT01819558,Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy,COMPLETED,PHASE1,2.0,2013-03-01,2015-03-01,0.08339726027397261,Slow (<1/month),0.8339726027397262,Significantly Below (<50%),100,45.2,30.830000000000002
NCT00740558,Heart Rate Variability Modulation Following a Manipulation in Pain Free Patients Versus Patients in Pain,COMPLETED,NA,53.0,2004-07-01,2006-07-01,2.210027397260274,Adequate (1-10/month),22.10027397260274,Significantly Below (<50%),100,54.2,59.330000000000005
NCT04264858,Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients,UNKNOWN,NA,10.0,2020-03-17,2020-05-31,4.058666666666666,Adequate (1-10/month),40.586666666666666,Significantly Below (<50%),50,35.8,16.325
NCT03744858,The Role of Pyroptosis in Chronic Venous Disease,UNKNOWN,,400.0,2018-11-12,2020-11-12,16.656634746922027,Good (10-50/month),166.56634746922026,Exceeded (≥100%),50,70.3,82.09
NCT04879758,Intervention Study: Genetic Risk Communication and Wearables,UNKNOWN,NA,150.0,2021-07-07,2024-05-01,4.437317784256559,Adequate (1-10/month),44.373177842565596,Significantly Below (<50%),50,47.0,39.33
NCT05206058,To Exam the Effects of Phyllanthus Niruri Extracts on Human Neutrophils,COMPLETED,,240.0,2022-01-01,2023-07-31,12.683333333333334,Good (10-50/month),126.83333333333333,Exceeded (≥100%),100,72.5,83.23
NCT02492958,"SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults",COMPLETED,PHASE2,136.0,2015-06-01,2016-09-01,9.038951965065502,Adequate (1-10/month),90.38951965065503,Met (75-100%),100,65.9,78.83
NCT06857058,Standardized Procedure for Intracranial Drug-Eluting Stenting in the Treatment of Intracranial Atherosclerotic Stenosis,RECRUITING,NA,300.0,2024-03-08,2026-06-08,11.10948905109489,Good (10-50/month),111.09489051094891,Exceeded (≥100%),60,67.0,79.725
NCT06810258,BIOmarkers Before and After Kidney Transplantation,RECRUITING,,1000.0,2024-10-08,2035-10-08,7.577794373910879,Adequate (1-10/month),75.77794373910878,Met (75-100%),60,76.3,85.1
NCT04823858,3Spine Lumbar Fusion Real World Evidence Study,ACTIVE_NOT_RECRUITING,,176.0,2021-05-25,2029-11-15,1.7304392764857883,Adequate (1-10/month),17.304392764857884,Significantly Below (<50%),85,57.9,67.83
NCT00269958,A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo to Reduce the Need for Blood Transfusions and Reduce the Occurrence of Severe Anemia During the Time Period Surrounding Total Hip Replacement Surgery,COMPLETED,PHASE2,208.0,,1991-12-01,,Slow (<1/month),,Significantly Below (<50%),100,56.6,65.34
NCT00251758,Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn,COMPLETED,PHASE3,908.0,2005-12-01,2006-05-01,183.04317880794702,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT00702858,Trial of Blue Citrus Compared to Placebo in Patients Receiving Aromatase Inhibitor Therapy for Estrogen Receptor Positive Post-Menopausal Breast Cancer,COMPLETED,NA,30.0,2008-04-01,2011-06-01,0.7899653979238755,Slow (<1/month),7.899653979238755,Significantly Below (<50%),100,47.4,40.98
NCT00808158,"Examining the Relationship Between Tobacco Exposure, Abdominal Obesity, and Metabolic Syndrome in Adolescents (The STRONG Kids Study)",COMPLETED,,117.0,2008-10-01,2012-05-01,2.722844036697248,Adequate (1-10/month),27.228440366972478,Significantly Below (<50%),100,57.7,67.51
NCT05726058,Ocular Blood Flow Imaging for Glaucoma Assessment,RECRUITING,NA,150.0,2023-03-30,2027-04-30,3.0603217158176945,Adequate (1-10/month),30.60321715817695,Significantly Below (<50%),60,50.0,47.675
NCT03841058,Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery,RECRUITING,PHASE2,96.0,2019-08-14,2026-09-01,1.1348504854368933,Adequate (1-10/month),11.348504854368931,Significantly Below (<50%),60,40.7,22.675
NCT04428658,Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes,RECRUITING,NA,82.0,2022-09-15,2025-07-01,2.447137254901961,Adequate (1-10/month),24.47137254901961,Significantly Below (<50%),60,44.6,29.42
NCT01806558,Pilot Study: Combined Molecular Breast Imaging/Ultrasound System for Diagnostic Evaluation of MBI-detected Lesions,COMPLETED,NA,12.0,2012-09-01,2017-06-01,0.2106574394463668,Slow (<1/month),2.106574394463668,Significantly Below (<50%),100,46.0,34.1
NCT04883658,A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(2),COMPLETED,PHASE1,62.0,2021-06-04,2021-08-19,24.832631578947368,Good (10-50/month),200.0,Exceeded (≥100%),100,60.0,71.97
NCT00017758,The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs,COMPLETED,PHASE1,56.0,,,,Slow (<1/month),,Significantly Below (<50%),100,44.5,29.160000000000004
NCT02756858,An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease,COMPLETED,PHASE2,21.0,2016-03-01,2020-11-01,0.3747010550996483,Slow (<1/month),3.747010550996483,Significantly Below (<50%),100,46.7,37.895
NCT00002058,A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease,COMPLETED,NA,,,,,Slow (<1/month),,Significantly Below (<50%),100,40.0,21.87
NCT04739358,CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC,TERMINATED,PHASE1,2.0,2022-05-25,2023-06-23,0.15451776649746193,Slow (<1/month),1.5451776649746194,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT04985058,Real-world Data in Patients With Breast Cancer Treated With Abemaciclib,RECRUITING,,108.0,2021-10-06,2027-07-01,1.5699713467048713,Adequate (1-10/month),15.699713467048712,Significantly Below (<50%),60,40.0,21.87
NCT05632848,Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients,COMPLETED,PHASE2,47.0,2022-06-15,2025-02-21,1.4569042769857434,Adequate (1-10/month),14.569042769857434,Significantly Below (<50%),100,48.8,45.184999999999995
NCT03030248,Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients,COMPLETED,PHASE2,9.0,2018-06-01,2020-06-30,0.36047368421052634,Slow (<1/month),3.6047368421052632,Significantly Below (<50%),100,45.7,32.5
NCT05996848,A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight,COMPLETED,PHASE3,300.0,2023-08-15,2025-02-22,16.394973070017954,Good (10-50/month),163.94973070017954,Exceeded (≥100%),100,79.0,86.96000000000001
NCT04518748,Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.,RECRUITING,PHASE1,70.0,2020-09-16,2028-11-01,0.7179245283018869,Slow (<1/month),7.179245283018869,Significantly Below (<50%),60,38.6,20.015
NCT05852548,"Parent-Mediated Intervention for Families With Children With Autism and Feeding Challenges, Australia Cohort",COMPLETED,NA,20.0,2023-06-24,2024-05-08,1.9084639498432603,Adequate (1-10/month),19.084639498432605,Significantly Below (<50%),100,51.6,51.644999999999996
NCT01467648,The Pharmacodynamics of Doripenem Between 4-hour and 1-hour Infusion in Patients With Ventilator-associated Pneumonia,COMPLETED,PHASE4,12.0,2010-10-01,2011-10-01,1.0007671232876714,Adequate (1-10/month),10.007671232876714,Significantly Below (<50%),100,46.0,34.1
NCT00610948,"Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment",COMPLETED,PHASE1,74.0,2008-03-01,2016-01-01,0.787058001397624,Slow (<1/month),7.87058001397624,Significantly Below (<50%),100,50.9,49.370000000000005
NCT04625348,A Multicentre Clinical Test of the Ultracore Repose® Mattress to Prevent Pressure Ulcers Cat. II-IV in Nursing Homes,COMPLETED,NA,40.0,2020-02-15,2020-11-05,4.612121212121212,Adequate (1-10/month),46.121212121212125,Significantly Below (<50%),100,53.2,56.665
NCT04548648,A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas,ACTIVE_NOT_RECRUITING,PHASE2,10.0,2020-10-15,2030-03-14,0.08856560954320629,Slow (<1/month),0.8856560954320629,Significantly Below (<50%),85,41.3,23.74
NCT03290248,"Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis",COMPLETED,PHASE1,71.0,2017-09-19,2018-12-21,4.718864628820961,Adequate (1-10/month),47.18864628820961,Significantly Below (<50%),100,55.7,63.09
NCT01102348,Enhanced Protein-Energy Provision Via the Enteral Route in Critically Ill Patients,COMPLETED,NA,50.0,2008-06-01,2009-07-01,3.853164556962026,Adequate (1-10/month),38.53164556962025,Significantly Below (<50%),100,54.0,58.72500000000001
NCT02967848,Liver Function Investigation With SPECT,UNKNOWN,,20.0,2016-10-19,2024-12-31,0.2032721202003339,Slow (<1/month),2.032721202003339,Significantly Below (<50%),50,29.9,9.07
NCT04689048,Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery,RECRUITING,PHASE1,20.0,2022-04-04,2026-12-01,0.35769682726204466,Slow (<1/month),3.576968272620447,Significantly Below (<50%),60,34.6,14.729999999999999
NCT03529448,TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma,ACTIVE_NOT_RECRUITING,PHASE1,33.0,2023-08-18,2025-12-01,1.201578947368421,Adequate (1-10/month),12.015789473684213,Significantly Below (<50%),85,43.1,26.724999999999998
NCT06120348,Study of Application of Pulse Electrical Stimulation Around Eye in Dry Eye Disease Patients Who Are Scheduled for Laser Epithelial Keratomileusis (LASEK) Surgery,UNKNOWN,NA,178.0,2023-08-31,2024-08-31,14.804153005464482,Good (10-50/month),148.0415300546448,Exceeded (≥100%),50,54.2,59.330000000000005
NCT02159248,"Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation",WITHDRAWN,PHASE1,0.0,2014-03-01,2019-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT00009048,EMD 128130 for the Treatment of Parkinson's Disease,COMPLETED,PHASE2,30.0,2001-01-01,2003-12-01,0.8582706766917293,Slow (<1/month),8.582706766917294,Significantly Below (<50%),100,47.4,40.98
NCT07209748,sCD163 in HELLP Syndrome,NOT_YET_RECRUITING,,70.0,2025-12-01,2027-02-01,4.99016393442623,Adequate (1-10/month),49.9016393442623,Significantly Below (<50%),30,32.9,12.53
NCT00035048,Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED),COMPLETED,PHASE3,540.0,2001-11-21,2003-12-31,21.34753246753247,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT01283048,Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma,COMPLETED,PHASE1,32.0,2011-09-01,2016-09-01,0.5331581828133553,Slow (<1/month),5.331581828133554,Significantly Below (<50%),100,47.6,41.775
NCT05214248,Multimedia Admission Orientation in NICU,UNKNOWN,NA,132.0,2021-08-31,2023-07-31,5.748326180257511,Adequate (1-10/month),57.483261802575115,Below (50-75%),50,45.6,32.08
NCT00406848,A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients,COMPLETED,PHASE4,370.0,2006-11-01,2009-11-01,10.276277372262774,Good (10-50/month),102.76277372262774,Exceeded (≥100%),100,84.6,90.765
NCT03760848,Study of Potential for Drug Interactions Mediated by CYP3A4 Inhibition With Aramchol in Healthy Volunteers,COMPLETED,PHASE1,15.0,2018-11-12,2019-02-02,5.568292682926829,Adequate (1-10/month),55.6829268292683,Below (50-75%),100,51.2,50.375
NCT04974255,Association of TTGA (Tissue Transglutaminase Antibody) and Histopathologic Findings in Thyroidectomy Patients,UNKNOWN,NA,198.0,2019-05-01,2021-07-30,7.341193666260658,Adequate (1-10/month),73.41193666260658,Below (50-75%),50,50.8,49.18
NCT03536455,Effect of Acetazolamide on Maximal Exercise Performance in Lowlanders Older Than 40 Years at Altitude,COMPLETED,PHASE4,92.0,2018-05-15,2018-08-02,35.449113924050636,Good (10-50/month),200.0,Exceeded (≥100%),100,62.4,75.095
NCT03692455,Effect of Laparoscopic Sleeve Gastrectomy Versus Roux-en-Y Gastric Bypass on Gastroesophageal Reflux Disease: An 8-Year Prospective Cohort Study,ENROLLING_BY_INVITATION,,75.0,2025-09-17,2025-11-08,43.90384615384615,Good (10-50/month),200.0,Exceeded (≥100%),55,50.8,49.18
NCT02528955,De-Intensification Radiotherapy Postoperative Head Neck,UNKNOWN,PHASE2,200.0,2014-10-01,2021-10-01,2.3809151349237387,Adequate (1-10/month),23.80915134923739,Significantly Below (<50%),50,51.0,49.714999999999996
NCT02127255,Acupuncture for Chemical Therapy Induced Nausea and Vomiting: a Cross-over Trail,COMPLETED,NA,39.0,2014-04-01,2015-12-01,1.94935960591133,Adequate (1-10/month),19.4935960591133,Significantly Below (<50%),100,53.1,56.105000000000004
NCT01784055,NeoChord TACT Post-Market Surveillance Registry,COMPLETED,,126.0,2013-03-01,2016-07-01,3.148965517241379,Adequate (1-10/month),31.489655172413787,Significantly Below (<50%),100,58.4,69.175
NCT06488755,SIM0718 Treatment of Asthma Clinical Study,RECRUITING,PHASE3,418.0,2024-07-23,2027-09-30,10.931202749140894,Good (10-50/month),109.31202749140895,Exceeded (≥100%),60,76.4,85.25
NCT05734755,Dietary Programme and Exercise Training in Combination or Separately on Managing Sarcopenic Obesity in Older Adults,RECRUITING,NA,380.0,2023-03-15,2026-03-15,10.554014598540146,Good (10-50/month),105.54014598540147,Exceeded (≥100%),60,73.4,83.7
NCT02021955,Integrating Care After Exacerbation of COPD,COMPLETED,NA,717.0,2015-02-11,2019-01-31,15.052055172413793,Good (10-50/month),150.52055172413793,Exceeded (≥100%),100,95.0,95.7
NCT03164655,Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network,COMPLETED,PHASE2,20.0,2018-07-25,2021-11-15,0.5035566583953681,Slow (<1/month),5.035566583953681,Significantly Below (<50%),100,46.6,37.375
NCT03025555,Patient Satisfaction and Dimensional Accuracy of Bre Flex and Peek for Removable Partial Dentures,UNKNOWN,NA,12.0,2017-03-30,2017-10-01,1.9744864864864866,Adequate (1-10/month),19.744864864864866,Significantly Below (<50%),50,36.0,16.564999999999998
NCT01141855,Smoking Termination Opportunity for inPatients,COMPLETED,PHASE2,392.0,2008-05-01,2011-12-01,9.11572192513369,Adequate (1-10/month),91.1572192513369,Met (75-100%),100,86.4,91.94
NCT01548755,The Western Galilee Hospital in Nahariya Home Monitoring Registry,UNKNOWN,,20.0,2012-04-01,2015-01-01,0.6057711442786069,Slow (<1/month),6.057711442786069,Significantly Below (<50%),50,29.9,9.07
NCT04307355,Continuous Diffusion of Oxygen Treatment for Incision Wounds,COMPLETED,NA,23.0,2021-06-01,2023-08-28,0.8558924205378973,Slow (<1/month),8.558924205378974,Significantly Below (<50%),100,46.8,38.440000000000005
NCT04293055,Phone Coaching for Weight Loss Maintenance,COMPLETED,NA,77.0,2020-03-04,2023-08-23,1.8499447513812155,Adequate (1-10/month),18.499447513812157,Significantly Below (<50%),100,56.2,64.21
NCT01786655,Safety Study of Long-Acting Local Anesthetic,COMPLETED,PHASE1,105.0,2013-05-01,2014-04-01,9.54089552238806,Adequate (1-10/month),95.4089552238806,Met (75-100%),100,63.4,76.375
NCT03604055,Can Recurrence of Hamartomas be Prevented?,COMPLETED,NA,21.0,2012-05-01,2017-07-01,0.33875993640699525,Slow (<1/month),3.387599364069952,Significantly Below (<50%),100,46.7,37.895
NCT04972955,Predicting Dysglycemia in Individuals With Gestational Diabetes Immediately Postpartum Using Continuous Glucose Monitoring,ACTIVE_NOT_RECRUITING,,240.0,2023-07-04,2030-12-01,2.6987809383080905,Adequate (1-10/month),26.9878093830809,Significantly Below (<50%),85,63.0,75.845
NCT06176755,Treadmill Training With and Without Weighted Ankle Cuffs on Gait Parameters,COMPLETED,NA,46.0,2023-10-26,2023-12-28,22.226031746031744,Good (10-50/month),200.0,Exceeded (≥100%),100,58.7,69.69
NCT07162155,A Hybrid Program to Prevent Substance Use Risk Among Upper Elementary School Students Using a Positive Youth Development Approach,NOT_YET_RECRUITING,NA,3000.0,2026-01-01,2028-08-01,96.83987274655357,Excellent (>50/month),200.0,Exceeded (≥100%),30,79.0,86.96000000000001
NCT03038555,China Obstetrics Alliance Cohort Study,UNKNOWN,,900.0,2017-01-01,2022-01-01,15.00328587075575,Good (10-50/month),150.03285870755752,Exceeded (≥100%),50,78.3,86.48
NCT06461455,Clinical Performance Evaluation of Two Frequent Replacement Silicone Hydrogel Multifocal Toric Contact Lenses,COMPLETED,NA,95.0,2024-07-26,2024-12-31,18.30253164556962,Good (10-50/month),183.02531645569618,Exceeded (≥100%),100,62.6,75.325
NCT05292755,Effects of Carboxymethylcellulose Artificial Tears on the Eye Microbiome,COMPLETED,PHASE4,80.0,2022-04-22,2022-07-01,34.78857142857143,Good (10-50/month),200.0,Exceeded (≥100%),100,61.4,73.735
NCT06369155,Azenosertib in Uterine Serous Carcinoma: Biomarker Study,RECRUITING,PHASE2,25.0,2025-03-05,2027-01-31,1.0918220946915351,Adequate (1-10/month),10.918220946915351,Significantly Below (<50%),60,35.0,15.305
NCT03245255,Noninvasive Real-time Intracardiac Pressure Measurements Using Subharmonic Ultrasound,COMPLETED,PHASE2,80.0,2017-12-04,2023-06-07,1.2109398309298856,Adequate (1-10/month),12.109398309298856,Significantly Below (<50%),100,51.4,50.92
NCT00874055,The Presence of Friends Increases Food Intake in Youth,COMPLETED,,72.0,2007-10-01,2008-10-01,5.988196721311476,Adequate (1-10/month),59.88196721311475,Below (50-75%),100,54.1,59.11
NCT05533255,Preheated Composites Vs. Conventional Composites in Noncarious Cervical Lesions,UNKNOWN,NA,46.0,2022-06-30,2023-06-30,3.83627397260274,Adequate (1-10/month),38.3627397260274,Significantly Below (<50%),50,38.7,20.145
NCT02255955,Postoperative Analgesia in Laminectomy,UNKNOWN,PHASE4,75.0,2014-10-01,2014-12-01,37.42622950819672,Good (10-50/month),200.0,Exceeded (≥100%),50,46.0,34.1
NCT07176455,Temporal Transformation Mechanism and Intervention Strategies of Frail-related Dietary Behaviors in Older Gastric Cancer Survivors,ENROLLING_BY_INVITATION,,438.0,2025-07-01,2026-06-30,36.62835164835165,Good (10-50/month),200.0,Exceeded (≥100%),55,74.9,84.425
NCT04989855,Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune Score,UNKNOWN,PHASE2,48.0,2021-08-01,2024-02-01,1.5985995623632385,Adequate (1-10/month),15.985995623632387,Significantly Below (<50%),50,33.8,13.694999999999999
NCT07258355,Occupation-Based Multicomponent Intervention to Reduce Fall Risk in Older Adults,ENROLLING_BY_INVITATION,NA,40.0,2025-11-01,2026-03-30,8.171812080536913,Adequate (1-10/month),81.71812080536913,Met (75-100%),55,39.7,21.21
NCT00594555,A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia,WITHDRAWN,PHASE2,20.0,2007-11-01,2008-11-01,1.6633879781420766,Adequate (1-10/month),16.633879781420767,Significantly Below (<50%),5,18.1,3.105
NCT05240755,Effectiveness of Cannabidiol vs. Narcotics for Post Operative Pain Control in Elective Shoulder Arthroscopic Surgery,COMPLETED,EARLY_PHASE1,40.0,2022-07-01,2024-08-20,1.5590268886043535,Adequate (1-10/month),15.590268886043535,Significantly Below (<50%),100,48.2,43.665
NCT04438655,Prospective Randomized Clinical Trial on Oral and Intravenous Antibiotic Prophylaxis in Colorectal Surgery.,COMPLETED,NA,130.0,2019-05-01,2021-11-01,4.324808743169399,Adequate (1-10/month),43.248087431693996,Significantly Below (<50%),100,60.4,72.54
NCT03294655,A Resilience Building Intervention to Promote Successful Aging,COMPLETED,NA,61.0,2018-04-13,2019-03-31,5.275113636363637,Adequate (1-10/month),52.75113636363636,Below (50-75%),100,54.9,61.55500000000001
NCT06728826,Prevention of Atrial Fibrillation After Cardiac Surgery by Posterior Pericardiotomy,NOT_YET_RECRUITING,NA,648.0,2025-01-01,2026-06-01,38.22697674418605,Good (10-50/month),200.0,Exceeded (≥100%),30,74.0,83.985
NCT04745026,Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder,COMPLETED,PHASE2,103.0,2021-05-31,2023-12-21,3.3568736616702357,Adequate (1-10/month),33.56873661670235,Significantly Below (<50%),100,58.2,68.795
NCT04430426,Heterozygous Individuals for AGXT and Kidney Stones,NOT_YET_RECRUITING,NA,4.0,2026-07-01,2032-08-01,0.05477282950967161,Slow (<1/month),0.5477282950967162,Significantly Below (<50%),30,24.3,6.855
NCT04576026,Exogenous Ketone Supplementation and Cognitive Function During Exercise,UNKNOWN,NA,15.0,2020-10-01,2021-10-01,1.2509589041095892,Adequate (1-10/month),12.509589041095893,Significantly Below (<50%),50,31.2,10.165000000000001
NCT06120426,En Bloc Resection Versus Separation Surgery Combined With Radiotherapy for the Treatment of Spinal Oligometastatic Tumor.,RECRUITING,,182.0,2023-07-01,2027-07-01,3.791978097193703,Adequate (1-10/month),37.91978097193703,Significantly Below (<50%),60,50.9,49.370000000000005
NCT00109226,A Study to Evaluate Avastin in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE2,,2000-08-01,2003-09-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,30.330000000000002
NCT06818526,Huandao Conditioning Application for Allergic Rhinitis Treatment,NOT_YET_RECRUITING,NA,95.0,2025-03-01,2026-12-31,4.316119402985075,Adequate (1-10/month),43.16119402985075,Significantly Below (<50%),30,36.6,17.41
NCT00169026,Alcoholism and Schizophrenia: Effects of Clozapine,TERMINATED,PHASE4,64.0,1999-05-01,2004-01-01,1.1419460726846424,Adequate (1-10/month),11.419460726846426,Significantly Below (<50%),10,23.1,6.404999999999999
NCT01532726,Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA),COMPLETED,,56.0,2012-03-01,2014-09-01,1.8650328227571116,Adequate (1-10/month),18.650328227571116,Significantly Below (<50%),100,52.8,55.31
NCT05099926,The Reducing Exercise Sensitivity With Exposure Training (RESET) Study,TERMINATED,NA,4.0,2021-10-13,2023-02-03,0.2547280334728034,Slow (<1/month),2.5472803347280335,Significantly Below (<50%),10,18.3,3.74
NCT02250326,"Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer",COMPLETED,PHASE2,240.0,2015-01-07,2023-08-17,2.323664122137405,Adequate (1-10/month),23.236641221374047,Significantly Below (<50%),100,69.2,81.28
NCT04475926,"A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice",ACTIVE_NOT_RECRUITING,,205.0,2021-04-22,2030-09-05,1.823020742039147,Adequate (1-10/month),18.23020742039147,Significantly Below (<50%),85,60.2,72.2
NCT02575326,Teen Asthma Control Encouraging a Healthier Lifestyle,COMPLETED,NA,44.0,2015-08-01,2018-02-01,1.4637814207650275,Adequate (1-10/month),14.637814207650274,Significantly Below (<50%),100,48.5,44.47
NCT01164826,Bioequivalence Study of Nabumetone 750 mg Tablets of Dr. Reddy's Under Fed Conditions,COMPLETED,PHASE1,30.0,2006-03-01,2006-03-01,30.0,Good (10-50/month),200.0,Exceeded (≥100%),100,42.4,25.45
NCT05163626,Combined Aerobic Exercise and Cognitive Training in Seniors at Increased Risk for Alzheimer's Disease,NOT_YET_RECRUITING,NA,200.0,2024-12-01,2034-12-01,1.6670317634173057,Adequate (1-10/month),16.670317634173056,Significantly Below (<50%),30,45.0,30.330000000000002
NCT02299726,Early Aldosterone Blockade in Acute Heart Failure: An Exploratory Safety Study,WITHDRAWN,PHASE2,0.0,2015-05-01,2018-11-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT03903926,Efficacy Trial of a Commercial EV71 Vaccine,COMPLETED,PHASE4,15500.0,2019-03-26,2020-10-30,807.9109589041096,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT01918826,Evaluation of the Analgesic Efficiency of the Transcutaneous Neurostimulation in the Charcot Syndrome Marie Tooth on the Pains of Lower Limbs,UNKNOWN,NA,40.0,2012-06-01,2013-08-01,2.8582159624413146,Adequate (1-10/month),28.582159624413144,Significantly Below (<50%),50,38.2,19.645000000000003
NCT01095926,Pharmacokinetic Study of Doxorubicin in Children With Cancer,COMPLETED,PHASE2,101.0,2010-05-01,2013-05-01,2.80514598540146,Adequate (1-10/month),28.0514598540146,Significantly Below (<50%),100,58.1,68.595
NCT01978626,Enhancing Performance of Cognitive Behavioral Therapy for Insomnia With an Integrative Mobile Platform,UNKNOWN,NA,120.0,2014-03-01,2016-07-01,4.282297772567409,Adequate (1-10/month),42.82297772567409,Significantly Below (<50%),50,44.6,29.42
NCT05909826,"Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM",NOT_YET_RECRUITING,PHASE2,49.0,2023-07-01,2027-06-30,1.0216164383561646,Adequate (1-10/month),10.216164383561646,Significantly Below (<50%),30,27.9,8.344999999999999
NCT02597426,Nasopharyngeal Carcinoma Post IMRT,ACTIVE_NOT_RECRUITING,,108.0,2015-06-01,2027-12-01,0.72,Slow (<1/month),7.199999999999999,Significantly Below (<50%),85,47.5,41.415
NCT07269626,PULSAR in Systemic Therapy for Pancreatic Cancer,RECRUITING,PHASE2,47.0,2025-11-14,2028-12-31,1.2516885389326335,Adequate (1-10/month),12.516885389326335,Significantly Below (<50%),60,36.8,17.630000000000003
NCT01587326,The Effects of Escitalopram on Cytokines,UNKNOWN,NA,25.0,2012-04-01,2013-04-01,2.0849315068493155,Adequate (1-10/month),20.84931506849315,Significantly Below (<50%),50,37.0,17.955
NCT05682326,Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P),COMPLETED,PHASE3,4.0,2023-09-06,2025-03-17,0.2182078853046595,Slow (<1/month),2.182078853046595,Significantly Below (<50%),100,45.3,31.169999999999998
NCT03095378,Evaluation of Root Coverage by Connective Graft and Different Root Conditioning Methods,COMPLETED,NA,14.0,2014-03-10,2017-03-10,0.38883211678832114,Slow (<1/month),3.8883211678832117,Significantly Below (<50%),100,46.1,34.695
NCT04465578,Incidence of Short-term Urinary Retention After Fascial Retropubic Sling: Prospective and Randomized Analysis.,UNKNOWN,NA,56.0,2020-02-10,2020-11-30,5.798095238095238,Adequate (1-10/month),57.98095238095239,Below (50-75%),50,39.5,21.044999999999998
NCT03682978,Arbaclofen in Children and Adolescents With ASD,COMPLETED,PHASE2,124.0,2019-09-19,2023-01-27,3.0787601957585644,Adequate (1-10/month),30.787601957585643,Significantly Below (<50%),100,59.9,71.86
NCT04826978,Auditory Environment by Parents of Preterm Infants,UNKNOWN,,116.0,2017-01-01,2023-03-30,1.5493813075910488,Adequate (1-10/month),15.493813075910486,Significantly Below (<50%),50,37.6,18.845
NCT07057778,Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP,NOT_YET_RECRUITING,PHASE2,120.0,2025-07-01,2027-07-01,5.003835616438357,Adequate (1-10/month),50.03835616438357,Below (50-75%),30,38.6,20.015
NCT01374178,A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects,COMPLETED,PHASE1,16.0,2011-06-01,2011-07-01,16.0,Good (10-50/month),160.0,Exceeded (≥100%),100,56.3,64.5
NCT06702878,Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections,RECRUITING,PHASE3,4514.0,2024-12-27,2025-12-01,405.32790560471983,Excellent (>50/month),200.0,Exceeded (≥100%),60,88.0,92.495
NCT00165178,Treatment of Acute Lymphoblastic Leukemia in Children,COMPLETED,PHASE3,498.0,2000-09-01,2011-05-01,3.892942989214176,Adequate (1-10/month),38.92942989214176,Significantly Below (<50%),100,89.8,93.065
NCT00596778,Chest Physiotherapy on Immediate Postoperative in Patients Submitted to High Abdominal Surgery,TERMINATED,NA,31.0,2004-02-01,2004-12-01,3.104078947368421,Adequate (1-10/month),31.04078947368421,Significantly Below (<50%),10,25.5,7.5200000000000005
NCT00365378,Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005),COMPLETED,PHASE2,2409.0,1999-09-01,2009-07-01,20.42048454469507,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT03277378,Evaluating Anatomic Versus Targeted Lead Placement for Burst Stimulation Therapy During the Trial,COMPLETED,NA,270.0,2017-09-22,2018-10-12,21.34753246753247,Good (10-50/month),200.0,Exceeded (≥100%),100,76.6,85.35000000000001
NCT03690778,The PK Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male Volunteers.,COMPLETED,PHASE1,42.0,2018-10-04,2019-02-01,10.654,Good (10-50/month),106.53999999999999,Exceeded (≥100%),100,58.4,69.175
NCT03758378,Evaluation of Food Additive Contributions to Obesity - Feasibility Study 2,TERMINATED,NA,2.0,2018-11-12,2019-05-01,0.35811764705882354,Slow (<1/month),3.5811764705882356,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT02546778,Effects of Radiofrequency on Located Adiposity,COMPLETED,NA,30.0,2014-05-01,2014-08-01,9.92608695652174,Adequate (1-10/month),99.2608695652174,Met (75-100%),100,57.4,67.05499999999999
NCT00499278,JOINTS Study - Joint Replacement Outcome in Inpatient Rehabilitation Facilities and Nursing Treatment Sites,COMPLETED,,2384.0,2005-11-01,2007-02-01,158.79422319474835,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT00533078,"Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies",COMPLETED,PHASE2,14.0,2007-11-01,2009-12-01,0.56,Slow (<1/month),5.6000000000000005,Significantly Below (<50%),100,46.1,34.695
NCT04104178,Optimal Treatment of MRSA Throat Carriers,COMPLETED,PHASE3,53.0,2020-05-20,2025-09-18,0.8286183872624552,Slow (<1/month),8.28618387262455,Significantly Below (<50%),100,49.2,46.035
NCT05656378,A Repository to Study Host-Microbiome Interactions in Health and Disease,RECRUITING,,600.0,2023-03-09,2032-01-01,5.6720496894409935,Adequate (1-10/month),56.72049689440993,Below (50-75%),60,76.3,85.1
NCT02419378,Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential,COMPLETED,PHASE4,15.0,2015-06-01,2020-11-01,0.23060606060606062,Slow (<1/month),2.3060606060606057,Significantly Below (<50%),100,46.2,35.089999999999996
NCT00369278,Intensified vs. Standard Dose Therapy With Mycophenolate Sodium Plus Cyclosporin Microemulsion and Corticosteroid Combination in Patients With de Novo Renal Transplant Patients,COMPLETED,PHASE3,128.0,2006-06-01,2008-12-01,4.26293216630197,Adequate (1-10/month),42.629321663019695,Significantly Below (<50%),100,60.2,72.2
NCT02070978,Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II),TERMINATED,PHASE2,253.0,2014-07-29,2018-02-09,5.965391169635941,Adequate (1-10/month),59.65391169635941,Below (50-75%),10,43.2,26.840000000000003
NCT05229185,Error-enhancement for Arm Rehabilitation Post Stroke,COMPLETED,EARLY_PHASE1,22.0,2022-01-25,2022-11-23,2.217483443708609,Adequate (1-10/month),22.17483443708609,Significantly Below (<50%),100,51.8,52.17
NCT03667885,Non-Invasive Diagnostics of Small Renal Masses,UNKNOWN,,160.0,2019-03-01,2020-09-01,8.855272727272729,Adequate (1-10/month),88.55272727272728,Met (75-100%),50,51.1,50.129999999999995
NCT04766385,Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal Dialysis,COMPLETED,PHASE3,54.0,2021-03-03,2021-12-01,6.021098901098902,Adequate (1-10/month),60.210989010989024,Below (50-75%),100,54.3,59.62
NCT03423485,Safety and Performance of the CG-100 in Patients Undergoing Colorectal Surgery.,UNKNOWN,NA,137.0,2018-01-01,2019-07-31,7.240069444444444,Adequate (1-10/month),72.40069444444444,Below (50-75%),50,46.0,34.1
NCT06682585,Nutritional Status and Therapy in DMD Patients,COMPLETED,NA,9.0,2024-11-18,2025-02-21,2.8837894736842107,Adequate (1-10/month),28.837894736842106,Significantly Below (<50%),100,50.7,48.915
NCT05273385,Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma,UNKNOWN,NA,40.0,2022-10-10,2024-12-10,1.5373737373737375,Adequate (1-10/month),15.373737373737374,Significantly Below (<50%),50,33.2,12.989999999999998
NCT00302185,Acupuncture in Palliative Cancer Care,COMPLETED,PHASE3,20.0,2007-06-01,2008-03-01,2.221897810218978,Adequate (1-10/month),22.21897810218978,Significantly Below (<50%),100,51.6,51.644999999999996
NCT02109185,"A Comparison of Mometasone Nasal Spray, Nasonex Nasal Spray, Nasonex Nasal Spray Suspension, & Placebo for Treatment of Seasonal Allergies for Safety, Efficacy, & Superiority in 1520 Male & Female Volunteers",COMPLETED,PHASE1,1307.0,2013-09-01,2013-11-01,652.2144262295081,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT01257685,Selenoprotein P and Non-alcoholic Fatty Liver Disease,COMPLETED,,120.0,2007-09-01,2008-08-01,10.903880597014927,Good (10-50/month),109.03880597014926,Exceeded (≥100%),100,62.9,75.655
NCT02478385,Birth Environment of the Future,COMPLETED,NA,680.0,2015-05-01,2018-08-01,17.423569023569026,Good (10-50/month),174.23569023569024,Exceeded (≥100%),100,95.0,95.7
NCT04411485,Sexual Dysfunction in Partner of Patients With Ankylosing Spondylitis,UNKNOWN,,80.0,2018-02-15,2020-07-15,2.7641316685584565,Adequate (1-10/month),27.641316685584567,Significantly Below (<50%),50,39.7,21.21
NCT06023485,The Effect of Stress Ball Use on Procedural Pain Caused by Subcutaneous Injection in Orthopedic Patients,UNKNOWN,NA,134.0,2023-03-01,2023-10-31,16.71704918032787,Good (10-50/month),167.17049180327868,Exceeded (≥100%),50,50.7,48.915
NCT00315185,"Study of Paclitaxel, Carboplatin, and Cetuximab for Advanced Lung Cancer",COMPLETED,PHASE2,53.0,2004-12-01,2008-06-01,1.262378716744914,Adequate (1-10/month),12.62378716744914,Significantly Below (<50%),100,49.2,46.035
NCT04709185,AVS After 1mg DST to Determine Subtype in PA,COMPLETED,NA,110.0,2021-01-08,2022-12-30,4.644105409153953,Adequate (1-10/month),46.44105409153953,Significantly Below (<50%),100,58.8,69.89999999999999
NCT01695785,Perception of Physical Exertion in Healthy Weight and Obese Adolescents,UNKNOWN,,40.0,2012-06-01,2016-08-01,0.8,Slow (<1/month),8.0,Significantly Below (<50%),50,31.5,10.635
NCT06815185,Rehabilitation Counselling for Patients with Interstitial Lung Disease,RECRUITING,,40.0,2022-12-15,2027-07-15,0.7277943813508668,Slow (<1/month),7.277943813508668,Significantly Below (<50%),60,34.5,14.52
NCT04537585,"COVID-19: Collecting Measurements of Renin-angiotensin-system Markers, Such as Angiotensin-2 and Angiotensin 1-7",UNKNOWN,NA,2000.0,2020-11-01,2022-12-01,80.10526315789474,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT03158285,A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis,COMPLETED,PHASE3,741.0,2017-07-12,2020-11-10,18.534133114215283,Good (10-50/month),185.34133114215282,Exceeded (≥100%),100,95.0,95.7
NCT03447015,Effects of Ambulation During First Stage of Labour on Maternal and Neonatal Outcomes,COMPLETED,NA,290.0,2018-03-01,2019-02-20,24.796629213483147,Good (10-50/month),200.0,Exceeded (≥100%),100,78.2,86.215
NCT04968015,Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission,ACTIVE_NOT_RECRUITING,PHASE2,134.0,2022-05-25,2029-01-31,1.6696520671305772,Adequate (1-10/month),16.69652067130577,Significantly Below (<50%),85,56.2,64.21
NCT04219215,Acute Hyperbaric Oxygen Treatment Increases Hepatic Insulin Sensitivity and Muscle Reactive Oxygen Species in T2D,COMPLETED,NA,12.0,2020-02-01,2022-09-20,0.3797089397089397,Slow (<1/month),3.7970893970893966,Significantly Below (<50%),100,46.0,34.1
NCT05848115,BiPAP in Pediatric Moderate to Severe Asthma Randomized Control Trial,TERMINATED,NA,67.0,2023-06-23,2025-07-07,2.7375570469798656,Adequate (1-10/month),27.37557046979866,Significantly Below (<50%),10,28.4,8.52
NCT05593315,Efficacy of the Combination of Mindfulness and Buteyko Techniques for the Improvement of Poorly Controlled Asthma.,UNKNOWN,NA,40.0,2023-03-01,2025-12-31,1.1752895752895753,Adequate (1-10/month),11.752895752895755,Significantly Below (<50%),50,33.2,12.989999999999998
NCT03192215,AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke,TERMINATED,PHASE3,1015.0,2018-01-19,2023-04-17,16.142424242424244,Good (10-50/month),161.42424242424244,Exceeded (≥100%),10,68.0,80.56
NCT03084315,Changes in Biomarkers Associated With Use of Electronic Cigarettes,COMPLETED,NA,234.0,2016-11-15,2019-03-08,8.449537366548043,Adequate (1-10/month),84.49537366548043,Met (75-100%),100,73.7,83.825
NCT02641015,Study to Assess Management and Outcomes of Hospitalised Patients With Complicated UTI (RESCUING),COMPLETED,,1028.0,2015-12-01,2016-08-01,128.2472131147541,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT01870115,Melatonin-Micronutrients for Osteopenia Treatment Study,COMPLETED,PHASE1,23.0,2013-08-01,2017-02-09,0.5435714285714286,Slow (<1/month),5.435714285714286,Significantly Below (<50%),100,46.8,38.440000000000005
NCT07180615,Gut Decolonisation With Neomycin/Metronidazole or Rifaximin Before Colon Surgery,NOT_YET_RECRUITING,PHASE4,458.0,2026-06-01,2029-06-30,12.392462222222221,Good (10-50/month),123.92462222222223,Exceeded (≥100%),30,70.6,82.22500000000001
NCT03844815,Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia,ACTIVE_NOT_RECRUITING,PHASE1,26.0,2019-11-18,2025-12-10,0.3574706413730804,Slow (<1/month),3.5747064137308033,Significantly Below (<50%),85,42.6,25.679999999999996
NCT00100815,"Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer",COMPLETED,PHASE2,50.0,2004-08-01,,,Slow (<1/month),,Significantly Below (<50%),100,44.0,28.249999999999996
NCT04028115,Bone Healing During Ninlaro Exposure,COMPLETED,PHASE2,30.0,2019-10-24,2024-04-01,0.5633559531153609,Slow (<1/month),5.633559531153609,Significantly Below (<50%),100,47.4,40.98
NCT04115215,"Pre-FRONTal Brain STability, Key for Action Against Disability in AGing",UNKNOWN,NA,93.0,2020-03-23,2023-03-23,2.5853150684931507,Adequate (1-10/month),25.85315068493151,Significantly Below (<50%),50,42.4,25.45
NCT07067515,Effectiveness of Omega-3 Poly Unsaturated Fatty Acids on The Treatment of Gingival Hyperpigmentation,ACTIVE_NOT_RECRUITING,PHASE1,30.0,2024-01-03,2025-08-28,1.5144278606965176,Adequate (1-10/month),15.144278606965175,Significantly Below (<50%),85,42.9,26.145000000000003
NCT05933135,Factor XIII Activity in Gastrointestinal Bleedings,COMPLETED,,97.0,2021-01-08,2023-12-31,2.7163569457221715,Adequate (1-10/month),27.16356945722171,Significantly Below (<50%),100,56.1,63.99
NCT00583635,Early Pregnancy Antioxidant Supplementation in the Prevention of Preeclampsia,COMPLETED,,684.0,2004-05-01,2011-08-01,7.862900302114804,Adequate (1-10/month),78.62900302114805,Met (75-100%),100,88.3,92.705
NCT07214935,A TQT Study of Effect of M2951 on Cardiac Repolarization,COMPLETED,PHASE1,36.0,2022-11-08,2023-08-25,3.778758620689655,Adequate (1-10/month),37.78758620689655,Significantly Below (<50%),100,52.9,55.55
NCT06600035,Gastric Ultrasound in Elective Surgical Diabetic Patients,RECRUITING,,130.0,2024-09-17,2025-04-01,20.18979591836735,Good (10-50/month),200.0,Exceeded (≥100%),60,51.7,51.94
NCT00016835,Treating Periodontal Infection: Effects on Glycemic,COMPLETED,PHASE2,46.0,2001-10-17,2004-09-03,1.3310266159695818,Adequate (1-10/month),13.31026615969582,Significantly Below (<50%),100,48.7,44.93
NCT01151735,C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation,WITHDRAWN,PHASE4,0.0,2010-07-01,2012-07-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT01324635,Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors,TERMINATED,PHASE1,17.0,2012-05-01,2016-10-01,0.3206195786864932,Slow (<1/month),3.206195786864932,Significantly Below (<50%),10,19.4,5.2299999999999995
NCT01770535,Oxford Ovarian Cancer Predict Chemotherapy Response 01,UNKNOWN,,35.0,2012-11-01,2015-06-01,1.1309978768577496,Adequate (1-10/month),11.309978768577494,Significantly Below (<50%),50,31.1,10.084999999999999
NCT05175235,Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements,UNKNOWN,PHASE1,10.0,2021-08-19,2023-08-01,0.42752808988764046,Slow (<1/month),4.275280898876405,Significantly Below (<50%),50,30.8,9.745
NCT03701035,Moderate Intensity Aerobic Training in Sub-acute and Chronic Stroke Patients - the Influence on Brain Derived Neurotrophic Factor (BDNF) and Upper-limb Rehabilitation. A Protocol for a Randomized Control Trial and Health Economic Evaluation,COMPLETED,NA,17.0,2018-10-08,2020-09-01,0.7456484149855909,Slow (<1/month),7.456484149855909,Significantly Below (<50%),100,46.4,36.26
NCT05937035,Histological and Volumetric Evaluation of Customized Allograft Bone Blocks,RECRUITING,NA,10.0,2024-05-25,2025-07-25,0.7145539906103286,Slow (<1/month),7.145539906103286,Significantly Below (<50%),60,33.8,13.694999999999999
NCT02232035,Diazepam at the Active Phase of Labor,UNKNOWN,PHASE2,400.0,2014-09-01,2015-09-01,33.35890410958905,Good (10-50/month),200.0,Exceeded (≥100%),50,72.0,82.92
NCT06152835,The BuKoBc Project: Building a Deeper Knowledge on Breast Milk Composition,RECRUITING,,100.0,2023-07-24,2026-07-24,2.7773722627737225,Adequate (1-10/month),27.773722627737225,Significantly Below (<50%),60,44.3,28.715000000000003
NCT07199335,Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs,NOT_YET_RECRUITING,PHASE4,100.0,2025-11-01,2027-09-01,4.550074738415545,Adequate (1-10/month),45.50074738415545,Significantly Below (<50%),30,37.0,17.955
NCT00564135,Postoperative Urinary Retention and Urinary Track Infection (UTI) After Laparoscopic Assisted Vaginal Hysterectomy (LAVH) for Benign Disease,COMPLETED,NA,150.0,2007-03-01,2008-07-01,9.35655737704918,Adequate (1-10/month),93.5655737704918,Met (75-100%),100,67.0,79.725
NCT05326035,A Study of WJ05129 in Advanced Malignant Solid Tumors,TERMINATED,PHASE1,26.0,2022-04-19,2023-12-26,1.2848051948051948,Adequate (1-10/month),12.848051948051948,Significantly Below (<50%),10,20.1,5.81
NCT05743335,"A Phase 1 Study to Assess the Safety and Immunogenicity of JCXH-221, an MRNA-based Broadly Protective COVID-19 Vaccine",COMPLETED,PHASE1,73.0,2023-03-07,2023-12-01,8.260669144981414,Adequate (1-10/month),82.60669144981414,Met (75-100%),100,55.8,63.245
NCT03846635,Handheld Infrared Thermometer to Evaluate Cellulitis,COMPLETED,,52.0,2018-08-28,2020-01-31,3.038157389635317,Adequate (1-10/month),30.38157389635317,Significantly Below (<50%),100,52.5,54.345
NCT06499935,The Effect of Taping on Plantar Pressure Distribution in Players With Chronic Ankle Instability,RECRUITING,NA,88.0,2024-05-24,2024-10-25,17.394285714285715,Good (10-50/month),173.94285714285712,Exceeded (≥100%),60,50.0,47.675
NCT06037135,Dexmedetomidine Infusion During Laparoscopic Adrenalectomy,COMPLETED,NA,40.0,2012-12-03,2021-03-26,0.4011861614497529,Slow (<1/month),4.011861614497529,Significantly Below (<50%),100,48.2,43.665
NCT07032935,The Effect of Virtual Reality Glasses on Vital Signs and State Anxiety in Patients Undergoing Coronary Angiography,COMPLETED,NA,84.0,2025-07-15,2025-08-15,82.48258064516129,Excellent (>50/month),200.0,Exceeded (≥100%),100,66.7,79.47999999999999
NCT00981435,Steroids After Laser Trabeculoplasty for Glaucoma,COMPLETED,PHASE4,97.0,2009-09-01,2015-09-01,1.3476403468735738,Adequate (1-10/month),13.47640346873574,Significantly Below (<50%),100,52.8,55.31
NCT05366335,Colonoscopic Probiotics Infusion for Functional Gastrointestinal Disease,UNKNOWN,PHASE4,160.0,2022-07-04,2023-01-01,26.90828729281768,Good (10-50/month),200.0,Exceeded (≥100%),50,52.8,55.31
NCT06189235,Ultrasonography-guided Real-time Modular Systems for Hand Therapy,UNKNOWN,NA,149.0,2023-06-28,2024-07-31,11.367318295739349,Good (10-50/month),113.67318295739348,Exceeded (≥100%),50,51.9,52.55499999999999
NCT03983135,Revisional Bariatric Surgery Experience,COMPLETED,NA,48.0,2012-03-01,2018-12-01,0.5925060827250609,Slow (<1/month),5.925060827250609,Significantly Below (<50%),100,48.8,45.184999999999995
NCT06176235,Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia,WITHDRAWN,PHASE2,0.0,2023-12-19,2025-05-12,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT02213835,Treatment With the Specific Carbohydrate Diet for Children With Active Crohns Disease and Ulcerative Colitis,COMPLETED,NA,9.0,2014-06-01,2017-09-01,0.23060606060606062,Slow (<1/month),2.3060606060606057,Significantly Below (<50%),100,45.7,32.5
NCT01431235,CBT for Patients With Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders,COMPLETED,NA,184.0,2011-08-01,2016-12-01,2.873760903027194,Adequate (1-10/month),28.737609030271933,Significantly Below (<50%),100,64.7,77.75999999999999
NCT02386735,Reduction of Corticosteroid Use in Outpatient Treatment of Exacerbated COPD,TERMINATED,NA,133.0,2015-03-01,2024-07-31,1.1768953488372094,Adequate (1-10/month),11.768953488372093,Significantly Below (<50%),10,28.6,8.58
NCT03308435,"Effect of TF-TAVR on Emotional Status, Quality of Life, Frailty and Inflammation",TERMINATED,,18.0,2017-11-06,2020-12-31,0.4760382276281495,Slow (<1/month),4.7603822762814945,Significantly Below (<50%),10,17.8,2.835
NCT03140735,Interest of Pulse Wave Velocity Measurement as a Predictor of Severity of Aortic Stenosis,WITHDRAWN,NA,0.0,2017-07-03,2023-06-20,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT02292108,"Hypnosis, Self-hypnosis and Weight Loss in Obese Patients",COMPLETED,NA,82.0,2014-09-01,2016-04-01,4.31847750865052,Adequate (1-10/month),43.1847750865052,Significantly Below (<50%),100,56.6,65.34
NCT01259908,Laparoscopic Surgical Treatment of Aorto-iliac Occlusive Disease,COMPLETED,,80.0,2010-09-01,2023-05-01,0.5265297297297298,Slow (<1/month),5.265297297297297,Significantly Below (<50%),100,49.7,46.949999999999996
NCT03122808,Uterine Activity in Moderate-Severe Neonatal Encephalopathy: A Case Control Study,COMPLETED,,264.0,2016-09-01,2021-10-18,4.290528563801388,Adequate (1-10/month),42.905285638013886,Significantly Below (<50%),100,69.5,81.62
NCT07333508,Fospropofol Disodium ED95 for Elderly Spinal Anesthesia Sedation,NOT_YET_RECRUITING,PHASE4,60.0,2026-01-01,2027-03-01,4.307547169811321,Adequate (1-10/month),43.07547169811321,Significantly Below (<50%),30,33.8,13.694999999999999
NCT01170208,Insulin Dosage Software Program for People With Type 1 and Type 2 Diabetes,COMPLETED,NA,46.0,2010-06-01,2011-03-01,5.12908424908425,Adequate (1-10/month),51.2908424908425,Below (50-75%),100,53.7,57.84
NCT01838408,Evaluation of Proposed EZ2go Complete Bowel Cleansing System,COMPLETED,NA,185.0,2013-04-01,2014-06-01,13.21924882629108,Good (10-50/month),132.1924882629108,Exceeded (≥100%),100,69.8,81.785
NCT07070908,Modifications to Gastric Sleeve: Implications for GRED and Quality of Life,ACTIVE_NOT_RECRUITING,NA,120.0,2020-04-06,2025-12-31,1.7435799522673034,Adequate (1-10/month),17.435799522673033,Significantly Below (<50%),85,55.1,62.085
NCT07167108,Mulligan Technique for Chronic Neck Pain in Adults,COMPLETED,NA,76.0,2025-03-02,2025-06-05,24.352,Good (10-50/month),200.0,Exceeded (≥100%),100,61.1,73.31
NCT02420808,An Epidemiological Cohort Study of Acute Coronary Syndromes in The Greek Population. The PHAETHON Study,COMPLETED,,800.0,2012-03-01,2014-01-01,36.29210134128167,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT01813708,Intensive Life-Style Intervention in Type 2 Diabetes Patients,COMPLETED,NA,200.0,2004-11-01,2007-12-01,5.411555555555555,Adequate (1-10/month),54.11555555555555,Below (50-75%),100,66.0,78.99000000000001
NCT01501708,Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection,UNKNOWN,PHASE2,55.0,2011-12-01,2017-12-01,0.7637773722627738,Slow (<1/month),7.637773722627737,Significantly Below (<50%),50,34.4,14.430000000000001
NCT02426008,Improving Embryogenesis by Adding Growth Factors to In Vitro Human Culture Media,COMPLETED,NA,426.0,2015-05-01,2016-03-01,42.51619672131148,Good (10-50/month),200.0,Exceeded (≥100%),100,94.1,94.85
NCT00958308,Efficacy and Safety Study in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection,COMPLETED,PHASE3,255.0,2008-12-01,2009-04-01,64.1504132231405,Excellent (>50/month),200.0,Exceeded (≥100%),100,80.4,88.105
NCT00496808,Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast,COMPLETED,NA,69.0,2005-03-01,2010-11-01,1.0141767262192178,Adequate (1-10/month),10.141767262192177,Significantly Below (<50%),100,50.5,48.515
NCT06769308,Effect of Goal-directed Analgesia and Sedation Using EEG Derived QCON/qNOX in ICU Patients,RECRUITING,NA,174.0,2024-01-01,2027-07-31,4.052456006120888,Adequate (1-10/month),40.524560061208874,Significantly Below (<50%),60,51.9,52.55499999999999
NCT01326208,Strategies to Optimize Positive End-expiratory Pressure (PEEP) in Patients With Acute Lung Injury,UNKNOWN,PHASE2,40.0,2011-03-01,2013-06-01,1.4794653705953829,Adequate (1-10/month),14.794653705953827,Significantly Below (<50%),50,33.2,12.989999999999998
NCT01492608,Magnesium Sulphate for Preterm Birth (MASP Study),COMPLETED,PHASE3,560.0,2011-12-16,2019-08-12,6.096709585121602,Adequate (1-10/month),60.96709585121602,Below (50-75%),100,90.0,93.17
NCT02309008,"A Study to Assess the Safety, Tolerability and Pharmacokinetics of PAC-14028 Cream in Healthy Male Subjects",COMPLETED,PHASE1,24.0,2014-11-01,,,Slow (<1/month),,Significantly Below (<50%),100,41.9,24.585
NCT01596608,"Magnetic Seizure Therapy (MST) for Treatment Resistant Depression, Schizophrenia, and Obsessive Compulsive Disorder",COMPLETED,NA,224.0,2012-02-01,2019-06-01,2.5470900261486737,Adequate (1-10/month),25.47090026148674,Significantly Below (<50%),100,67.9,80.36999999999999
NCT00785408,"Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects",COMPLETED,PHASE2,273.0,2008-12-01,2009-09-01,30.32890510948905,Good (10-50/month),200.0,Exceeded (≥100%),100,76.8,85.42
NCT06482008,"HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-label, Single-arm, Phase II Study",NOT_YET_RECRUITING,PHASE2,33.0,2024-06-19,2026-02-01,1.6968243243243244,Adequate (1-10/month),16.968243243243244,Significantly Below (<50%),30,31.6,10.905
NCT01969708,Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2),COMPLETED,PHASE3,362.0,2014-09-01,2021-03-01,4.643607248209018,Adequate (1-10/month),46.43607248209018,Significantly Below (<50%),100,79.0,86.96000000000001
NCT04419025,Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease,COMPLETED,PHASE2,165.0,2020-09-23,2021-05-14,21.556223175965666,Good (10-50/month),200.0,Exceeded (≥100%),100,68.2,80.77
NCT06298825,S-ADHF：Sarcopenia in Patients With ADHF,NOT_YET_RECRUITING,,500.0,2024-04-01,2026-06-01,19.24146649810367,Good (10-50/month),192.41466498103668,Exceeded (≥100%),30,72.3,83.065
NCT03737825,Computerized Cognitive Training in MS,COMPLETED,NA,2.0,2019-04-25,2025-02-12,0.028716981132075475,Slow (<1/month),0.28716981132075475,Significantly Below (<50%),100,45.2,30.830000000000002
NCT02033525,Mesenchymal Stromal Cells for Degenerative Meniscus Injury,COMPLETED,PHASE1,20.0,2014-01-31,2017-05-02,0.5128896377422073,Slow (<1/month),5.128896377422072,Significantly Below (<50%),100,46.6,37.375
NCT04654325,Prevalence of SARS-CoV-2 Genome in Tears of Asymptomatic and Moderately Symptomatic COVID-19 Patients,TERMINATED,NA,534.0,2021-01-19,2021-04-29,162.5496,Excellent (>50/month),200.0,Exceeded (≥100%),10,73.0,83.44
NCT00003125,"Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors",COMPLETED,PHASE2,24.0,1998-01-01,2004-11-01,0.2926923076923077,Slow (<1/month),2.926923076923077,Significantly Below (<50%),100,46.9,38.96
NCT00392925,A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects,COMPLETED,PHASE2,177.0,2006-10-01,2007-09-01,16.083223880597018,Good (10-50/month),160.83223880597015,Exceeded (≥100%),100,69.2,81.28
NCT03190525,"Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma",ACTIVE_NOT_RECRUITING,,530.0,2017-11-13,2025-12-01,5.487482993197279,Adequate (1-10/month),54.87482993197279,Below (50-75%),85,83.8,90.505
NCT02088125,Dynamic Ventilatory and Asymmetry of the Chest Wall During Breath Stacking and Volume-oriented Incentive Spirometer,UNKNOWN,NA,12.0,2013-09-01,2014-08-01,1.0936526946107785,Adequate (1-10/month),10.936526946107785,Significantly Below (<50%),50,31.0,9.985
NCT01413425,A Long-Term Study of Cholesterol Supplements for Smith-Lemli-Opitz Syndrome,WITHDRAWN,,0.0,2011-06-29,2014-10-20,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT00005625,Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma,COMPLETED,PHASE2,,1999-12-01,2003-09-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,30.330000000000002
NCT02704325,Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2,WITHDRAWN,PHASE1,0.0,2016-04-01,2020-02-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT00002325,A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common,COMPLETED,NA,,,,,Slow (<1/month),,Significantly Below (<50%),100,40.0,21.87
NCT03511625,The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis,UNKNOWN,PHASE3,6.0,2018-10-02,2024-12-03,0.08102928127772849,Slow (<1/month),0.810292812777285,Significantly Below (<50%),50,30.5,9.395000000000001
NCT01219725,Cardiovascular Prophylaxis for Postmenopausal Women,UNKNOWN,PHASE2,100.0,2005-07-01,2011-12-01,1.2986348122866895,Adequate (1-10/month),12.986348122866895,Significantly Below (<50%),50,38.0,19.255
NCT05468125,Maternal Care Bundle to Attenuate Hypotension in Cesarean Section,UNKNOWN,NA,144.0,2022-08-01,2022-12-01,35.92918032786885,Good (10-50/month),200.0,Exceeded (≥100%),50,51.5,51.245
NCT06561425,A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma,RECRUITING,PHASE1,274.0,2022-03-09,2029-07-01,3.12263571695994,Adequate (1-10/month),31.2263571695994,Significantly Below (<50%),60,59.9,71.86
NCT02487225,Pentoxifylline Treatment in Acute Pancreatitis (AP),COMPLETED,PHASE3,83.0,2015-05-01,2017-10-31,2.7642450765864335,Adequate (1-10/month),27.642450765864336,Significantly Below (<50%),100,56.6,65.34
NCT06153576,The Value of Systematic Biopsies During Vertebroplasty for the Treatment of Osteoporotic Vertebral Fractures,COMPLETED,,1120.0,2016-01-01,2022-03-01,15.145624167036873,Good (10-50/month),151.45624167036874,Exceeded (≥100%),100,93.3,94.325
NCT01584076,Treatment of Residual Amblyopia With Donepezil,COMPLETED,PHASE1,18.0,2012-08-01,2021-01-01,0.17818536585365854,Slow (<1/month),1.7818536585365852,Significantly Below (<50%),100,46.4,36.26
NCT02162576,Asthma Data Innovation Demonstration Project,COMPLETED,NA,95.0,2012-06-01,2014-01-01,4.99447322970639,Adequate (1-10/month),49.9447322970639,Significantly Below (<50%),100,57.6,67.36999999999999
NCT04044976,Caffeine Treatment in in the Delivery Room,COMPLETED,NA,42.0,2019-08-01,2021-08-31,1.68,Adequate (1-10/month),16.8,Significantly Below (<50%),100,53.4,57.35
NCT07201376,"Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically",NOT_YET_RECRUITING,,125.0,2025-11-01,2027-11-01,5.212328767123288,Adequate (1-10/month),52.12328767123289,Below (50-75%),30,37.3,18.35
NCT02015676,A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer,COMPLETED,PHASE1,69.0,2001-07-01,2009-09-01,0.7038739946380698,Slow (<1/month),7.038739946380698,Significantly Below (<50%),100,50.5,48.515
NCT02781376,Evidence-based Diagnosis and Management of Pediatric Obstructive Sleep Apnea in Primary Care,COMPLETED,NA,1500.0,2017-01-01,2019-01-01,62.54794520547946,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT04020276,"OAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases",RECRUITING,NA,32.0,2019-11-04,2028-12-01,0.29384012066365006,Slow (<1/month),2.9384012066365006,Significantly Below (<50%),60,35.6,16.03
NCT05143476,Serum-Protein-Based Indices for the Progression of Fracture Healing and Nonunion,ACTIVE_NOT_RECRUITING,,45.0,2021-06-26,2025-09-29,0.8803341902313626,Slow (<1/month),8.803341902313626,Significantly Below (<50%),85,42.4,25.45
NCT02136576,Caries Prevention Products & Dentinal Hypersensitivity,COMPLETED,NA,39.0,2014-05-01,2018-10-01,0.7355390334572491,Slow (<1/month),7.355390334572491,Significantly Below (<50%),100,48.1,43.275000000000006
NCT01148576,Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients,UNKNOWN,PHASE4,1200.0,2010-06-01,2012-02-01,59.88196721311476,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT05923476,Electroconvulsive Therapy and Concomitant Lithium in Depressive Disorder: A Pilot Study,UNKNOWN,EARLY_PHASE1,20.0,2023-06-01,2025-06-30,0.8010526315789473,Slow (<1/month),8.010526315789473,Significantly Below (<50%),50,31.6,10.905
NCT07363876,The Efficacy of Ultrasonication in Combination With Corticosteroid Intraarticular Injection for Arthritis,NOT_YET_RECRUITING,NA,100.0,2025-12-29,2026-12-31,8.294277929155314,Adequate (1-10/month),82.94277929155314,Met (75-100%),30,37.0,17.955
NCT06015776,Purinergic Signaling and the Postmenopausal Heart,RECRUITING,,100.0,2019-07-01,2025-06-01,1.4079555966697503,Adequate (1-10/month),14.079555966697502,Significantly Below (<50%),60,39.3,20.810000000000002
NCT00882076,"Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias",TERMINATED,PHASE1,22.0,2009-03-01,2011-03-01,0.9173698630136987,Slow (<1/month),9.173698630136986,Significantly Below (<50%),10,19.8,5.465
NCT02120976,"Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252",TERMINATED,PHASE1,85.0,2014-04-01,2015-03-01,7.746706586826347,Adequate (1-10/month),77.46706586826348,Met (75-100%),10,29.8,8.98
NCT00242476,A Study to Assess the Effectiveness of an Investigational Drug in Elderly Subjects With Low Vitamin D Levels (0822A-009),COMPLETED,PHASE2,216.0,2005-09-01,2006-07-01,21.69980198019802,Good (10-50/month),200.0,Exceeded (≥100%),100,72.3,83.065
NCT01521676,Predictive Clinical and Biological Parameters in Breast Cancer,RECRUITING,NA,750.0,2010-12-01,2029-12-01,3.2896253602305476,Adequate (1-10/month),32.89625360230548,Significantly Below (<50%),60,78.0,86.075
NCT01971476,Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known,COMPLETED,PHASE1,22.0,2013-10-22,2017-01-27,0.5613411567476949,Slow (<1/month),5.613411567476949,Significantly Below (<50%),100,46.8,38.440000000000005
NCT02703376,Oral Prednisolone in the Treatment of Esophageal Stricture After Esophageal Surgery,UNKNOWN,PHASE1,8.0,2016-01-01,2019-10-01,0.17788166544923303,Slow (<1/month),1.7788166544923303,Significantly Below (<50%),50,30.6,9.475
NCT00005976,Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma,COMPLETED,PHASE2,60.0,2000-05-01,2007-04-01,0.723040380047506,Slow (<1/month),7.23040380047506,Significantly Below (<50%),100,49.8,47.17
NCT01502176,A Retrospective Register Study to Map the Frequency of Short Duration Atrial Fibrillation (AF) Among All Patients Admitted to Roskilde Sygehus in Denmark in 2010,UNKNOWN,,1600.0,2011-12-01,2012-12-01,133.07103825136613,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT01196676,"Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451",COMPLETED,PHASE1,63.0,2010-08-01,2011-04-01,7.891851851851852,Adequate (1-10/month),78.91851851851854,Met (75-100%),100,55.0,61.834999999999994
NCT02752776,A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.,COMPLETED,PHASE4,1660.0,2016-03-17,2018-03-28,68.19217273954116,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT01731717,Cluster Randomized Trial of Stepped Care Intervention vs. Treatment as Usual for Patients With Depression,COMPLETED,NA,737.0,2012-09-01,2015-05-01,23.08053497942387,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT02587117,"A Clinical Trial to Study the Effects of Two Drugs, Lycopene and Prednisolone in Patients With Oral Lichen Planus",COMPLETED,PHASE4,28.0,2013-02-01,2014-03-01,2.168753180661578,Adequate (1-10/month),21.68753180661578,Significantly Below (<50%),100,52.2,53.22
NCT00483717,Efficacy and Safety of Intranasal Ketorolac for the Acute Treatment of Migraine,COMPLETED,PHASE2,173.0,2007-07-01,2008-01-01,28.620217391304347,Good (10-50/month),200.0,Exceeded (≥100%),100,68.8,81.105
NCT02804217,Acquired Resistant Mechanism of the First-generation EGFR TKIs,UNKNOWN,,60.0,2016-06-01,,,Slow (<1/month),,Significantly Below (<50%),50,28.1,8.42
NCT04973917,A Comparison of Intellivent-ASV Mode With Conventional Modes in Patients With BMI >35,COMPLETED,NA,32.0,2021-12-20,2023-02-01,2.387450980392157,Adequate (1-10/month),23.87450980392157,Significantly Below (<50%),100,52.6,54.684999999999995
NCT01020617,"The Effect of Probiotics on Low-grade Inflammation, Microbiota and Risk Factors for Metabolic Syndrome in Obese Children",COMPLETED,NA,51.0,2009-04-01,2011-01-01,2.4256875,Adequate (1-10/month),24.256875,Significantly Below (<50%),100,54.1,59.11
NCT03517917,Prospective Tissue Collection Research Protocol,COMPLETED,,221.0,2018-02-08,2024-10-08,2.7638619556285953,Adequate (1-10/month),27.63861955628595,Significantly Below (<50%),100,66.0,78.99000000000001
NCT00434317,Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases,COMPLETED,PHASE4,80.0,2005-08-01,,,Slow (<1/month),,Significantly Below (<50%),100,46.4,36.26
NCT02897817,Treatment Adherence to Injectable Methotrexate in Rheumatoid Arthritis,COMPLETED,,471.0,2016-06-01,2017-12-01,26.162846715328467,Good (10-50/month),200.0,Exceeded (≥100%),100,91.0,93.56
NCT06865417,A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis,RECRUITING,PHASE3,80.0,2025-09-29,2028-06-01,2.495081967213115,Adequate (1-10/month),24.950819672131143,Significantly Below (<50%),60,44.4,28.95
NCT06965517,Effect of Digital Versus Static Jaw Relation Record on Crestal Bone Changes Around Implants Supporting Maxillary Single Overdenture,COMPLETED,NA,14.0,2022-11-30,2025-04-15,0.49153402537485585,Slow (<1/month),4.915340253748559,Significantly Below (<50%),100,46.1,34.695
NCT06306417,A Randomized Controlled Trial of Acupuncture for Insulin Resistance in Patients With Polycystic Ovary Syndrome,COMPLETED,NA,144.0,2023-09-28,2025-04-30,7.55751724137931,Adequate (1-10/month),75.5751724137931,Met (75-100%),100,61.5,73.905
NCT06407817,Comparative Effects Of Spencer and Reverse Distraction Technique In Patients With Adhesive Capsulitis,RECRUITING,NA,50.0,2024-02-01,2025-01-01,4.543283582089552,Adequate (1-10/month),45.43283582089552,Significantly Below (<50%),60,42.0,24.825
NCT05889117,Brain Stimulation for Concussion,ACTIVE_NOT_RECRUITING,NA,15.0,2023-10-30,2026-05-01,0.49956236323851205,Slow (<1/month),4.99562363238512,Significantly Below (<50%),85,41.7,24.36
NCT06462417,Efficacy and Safety of Arbidol in the Treatment of Allergic Rhinitis,RECRUITING,NA,15.0,2024-07-11,2025-06-30,1.2898305084745763,Adequate (1-10/month),12.898305084745761,Significantly Below (<50%),60,34.2,14.305000000000001
NCT03530917,A Study to Assess the Safety and Tolerability of Single and Multiple Ascending Doses of Oral RO7020531 in Chinese Healthy Participants.,COMPLETED,PHASE1,70.0,2018-05-15,2019-05-15,5.837808219178083,Adequate (1-10/month),58.378082191780834,Below (50-75%),100,55.6,62.905
NCT06309017,Pre-operative Nutrition for Elective Resection Surgery in Inflammatory Bowel Disease,RECRUITING,NA,150.0,2025-01-07,2027-07-01,5.045303867403315,Adequate (1-10/month),50.453038674033145,Below (50-75%),60,50.0,47.675
NCT03797417,Gut Microbiome and Metabolic Pathways Changes in Vitiligo,UNKNOWN,,200.0,2018-09-18,2020-12-31,7.291017964071857,Adequate (1-10/month),72.91017964071858,Below (50-75%),50,49.3,46.265
NCT06847217,Effect of Applying Oral Hygiene Care on Swallowing in Stroke Patients With Oropharyngeal Dysphagia,ENROLLING_BY_INVITATION,NA,260.0,2025-05-21,2027-10-31,8.862709966405376,Adequate (1-10/month),88.62709966405376,Met (75-100%),55,62.3,74.94
NCT05765617,Effect Of Calcitriol On Neutrophil To Lymphocytes Ratio And High Sensitivity C-Reactive Protein Covid-19 Patients,COMPLETED,PHASE2,16.0,2021-07-01,2021-09-30,5.352087912087912,Adequate (1-10/month),53.520879120879115,Below (50-75%),100,51.3,50.62
NCT02606617,A Clinical Trial Analyzing Effects of Prokinetic Drug on the Blood Glucose in Patients With Type 2 Diabetes,UNKNOWN,PHASE4,200.0,2015-12-01,2016-12-01,16.633879781420767,Good (10-50/month),166.33879781420765,Exceeded (≥100%),50,56.0,63.71
NCT03703817,Rheumatoid Arthritis Satisfaction Outcome Research,COMPLETED,,421.0,2018-07-02,2020-03-12,20.70313408723748,Good (10-50/month),200.0,Exceeded (≥100%),100,87.0,92.135
NCT01725217,"Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia",COMPLETED,PHASE3,198.0,2012-11-01,2013-03-01,50.226000000000006,Excellent (>50/month),200.0,Exceeded (≥100%),100,75.8,84.83500000000001
NCT05807217,A Pharmacokinetics Study of Meropenem and Piperacillin in Patients With Sepsis,UNKNOWN,,44.0,2022-10-26,2023-12-31,3.1075638051044083,Adequate (1-10/month),31.075638051044084,Significantly Below (<50%),50,36.9,17.735
NCT01467817,Obesity/Overweight in Persons With Early and Chronic Spinal Cord Injury (SCI),COMPLETED,NA,29.0,2010-09-01,2016-09-01,0.40271897810218976,Slow (<1/month),4.027189781021898,Significantly Below (<50%),100,47.3,40.475
NCT05978817,Clinical Effectiveness of Damon Ultima Vs Conventional Brackets Trial),UNKNOWN,NA,34.0,2023-08-01,2025-05-01,1.6196557120500783,Adequate (1-10/month),16.196557120500785,Significantly Below (<50%),50,32.7,12.370000000000001
NCT07161817,Effect of Postural Changes on Postoperative Hypoxemia,NOT_YET_RECRUITING,NA,1200.0,2026-02-01,2028-10-01,37.54162384378212,Good (10-50/month),200.0,Exceeded (≥100%),30,74.0,83.985
NCT00754117,Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET),COMPLETED,,8.0,2008-05-01,2012-12-08,0.14478002378121285,Slow (<1/month),1.4478002378121282,Significantly Below (<50%),100,44.0,28.249999999999996
NCT00737217,"Executive, Activities of Daily Living, and Cholinergic Functions in Parkinson's Disease",COMPLETED,,74.0,2006-03-01,2009-04-01,1.9987222715173028,Adequate (1-10/month),19.98722271517303,Significantly Below (<50%),100,54.3,59.62
NCT04643340,Imaging During Subliminal Perception,COMPLETED,,70.0,2020-03-15,2022-12-01,2.150151362260343,Adequate (1-10/month),21.501513622603436,Significantly Below (<50%),100,53.9,58.34
NCT04401540,Characteristics of Neonatal Covid-19 in Turkey,UNKNOWN,,90.0,2020-05-01,2020-12-30,11.274074074074075,Good (10-50/month),112.74074074074076,Exceeded (≥100%),50,45.5,31.705
NCT05662540,PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma,RECRUITING,NA,40.0,2023-05-26,2026-10-01,0.9947712418300654,Slow (<1/month),9.947712418300654,Significantly Below (<50%),60,36.2,16.84
NCT04772040,Impact of Fish Oil Dose on Tissue Content and Function,COMPLETED,NA,28.0,2021-11-01,2023-06-15,1.4421658206429782,Adequate (1-10/month),14.42165820642978,Significantly Below (<50%),100,47.2,40.035
NCT06958640,Da Qing Offspring Study,ENROLLING_BY_INVITATION,,5000.0,2025-04-01,2026-12-31,238.1846635367762,Excellent (>50/month),200.0,Exceeded (≥100%),55,84.8,90.815
NCT03696940,Clinical Trial to Evaluate the Efficacy of a Dyslipidemic Therapy in Mexican Population,UNKNOWN,PHASE3,120.0,2018-05-28,2019-08-31,7.940869565217392,Adequate (1-10/month),79.4086956521739,Met (75-100%),50,44.6,29.42
NCT03694340,Optimization of Cochlear Implant MAP-parameters in Children,COMPLETED,NA,15.0,2018-10-25,2020-06-30,0.7436482084690554,Slow (<1/month),7.436482084690555,Significantly Below (<50%),100,46.2,35.089999999999996
NCT06439940,Oncoliq: Early Breast Cancer Detection Based on Liquid Biopsies and microRNAs,RECRUITING,,364.0,2021-07-14,2025-03-31,8.171209439528024,Adequate (1-10/month),81.71209439528025,Met (75-100%),60,65.5,78.48
NCT03199040,Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy,TERMINATED,PHASE1,18.0,2019-07-23,2023-05-01,0.3976197387518142,Slow (<1/month),3.9761973875181424,Significantly Below (<50%),10,19.4,5.2299999999999995
NCT05505240,Influence of Ambient Temperature on Resting Energy Expenditure of Healthy Adults,COMPLETED,NA,32.0,2022-11-21,2023-04-06,7.16235294117647,Adequate (1-10/month),71.62352941176471,Below (50-75%),100,52.6,54.684999999999995
NCT05663840,Effects of Exercise on Dystonia Pathophysiology,RECRUITING,NA,56.0,2022-10-13,2027-12-31,0.8948241469816273,Slow (<1/month),8.948241469816272,Significantly Below (<50%),60,37.5,18.775
NCT05077540,"Oxytocin Versus, Sublingual Misoprostol in the Secondary Prevention of Postpartum Hemorrhage After Vaginal Delivery",UNKNOWN,NA,150.0,2021-11-01,2023-12-31,5.779746835443039,Adequate (1-10/month),57.79746835443038,Below (50-75%),50,47.0,39.33
NCT04336540,Increasing Availability of Lower Energy Meals vs. Menu Energy Labelling on Food Choice,COMPLETED,NA,2091.0,2019-08-01,2019-11-30,526.0333884297521,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT01921140,To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours,COMPLETED,PHASE1,60.0,2013-09-24,2022-03-15,0.5903038138332256,Slow (<1/month),5.903038138332256,Significantly Below (<50%),100,49.8,47.17
NCT07229040,A Double-blind Non Inferiority Clinical Trial to Compare the Nephroprotection of Cilastatn Versus Thiosulfate in Patients Undergoing Debulking Surgery With Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Cisplatin.,RECRUITING,PHASE2,90.0,2025-02-21,2028-10-21,2.0475336322869953,Adequate (1-10/month),20.475336322869957,Significantly Below (<50%),60,45.2,30.830000000000002
NCT04151940,PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer,RECRUITING,NA,80.0,2019-09-26,2027-11-30,0.8152661533311015,Slow (<1/month),8.152661533311015,Significantly Below (<50%),60,39.4,20.94
NCT00405340,Rituximab in the Treatment of Idiopathic Membranous Nephropathy,COMPLETED,EARLY_PHASE1,20.0,2006-10-01,2012-04-01,0.30303633648581385,Slow (<1/month),3.030363364858139,Significantly Below (<50%),100,46.6,37.375
NCT04385940,Vitamin D and COVID-19 Management,COMPLETED,PHASE3,11.0,2021-03-19,2024-07-02,0.27880099916736056,Slow (<1/month),2.7880099916736056,Significantly Below (<50%),100,45.9,33.495000000000005
NCT06367140,Effects of Electromyography-Triggered Constraint-Induced Movement Cycling Therapy on Patients With Chronic Stroke,COMPLETED,NA,58.0,2020-01-01,2023-12-31,1.2092602739726028,Adequate (1-10/month),12.09260273972603,Significantly Below (<50%),100,49.6,46.785
NCT01674140,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,1939.0,2013-09-12,2030-01-01,9.911529806884971,Adequate (1-10/month),99.11529806884971,Met (75-100%),85,90.5,93.4
NCT01559389,Incontinence & Intimate Partners: Assessing the Contribution of Treatment,COMPLETED,PHASE4,138.0,2012-03-09,2017-06-29,2.1675541795665634,Adequate (1-10/month),21.675541795665634,Significantly Below (<50%),100,61.0,73.17
NCT03129789,Volumetric Bladder Ultrasound Training for Pediatric Residents,COMPLETED,NA,14.0,2017-04-03,2017-11-12,1.9110313901345293,Adequate (1-10/month),19.11031390134529,Significantly Below (<50%),100,51.1,50.129999999999995
NCT04154189,"A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma",COMPLETED,PHASE2,81.0,2020-03-23,2023-08-17,1.9852173913043478,Adequate (1-10/month),19.852173913043476,Significantly Below (<50%),100,56.5,65.18
NCT04679168,Study on Kidney Disease and EnviromenTal Chemical,UNKNOWN,,310.0,2020-06-01,2021-12-31,16.325951557093425,Good (10-50/month),163.25951557093427,Exceeded (≥100%),50,63.1,76.03
NCT02259868,Study of New Tablet Formulations and Suspension Formulation Compared to Current (1B) Formulation of BILR 355 BS in Healthy Male Volunteer Subjects,COMPLETED,PHASE1,88.0,2005-06-01,,,Slow (<1/month),,Significantly Below (<50%),100,47.0,39.33
NCT05593068,Iron Deposits in the Pancreas by MRI Method of Dialysis Patients With Hemosiderosis Iatrogenic (ERDFP),UNKNOWN,,185.0,2022-11-01,2023-09-01,18.52434210526316,Good (10-50/month),185.2434210526316,Exceeded (≥100%),50,53.1,56.105000000000004
NCT02774668,A Short Term Evaluation of a Structured Weight Loss Plan in Overweight and Obese Adults,COMPLETED,NA,20.0,2016-05-01,2017-04-01,1.8173134328358211,Adequate (1-10/month),18.17313432835821,Significantly Below (<50%),100,51.6,51.644999999999996
NCT03245268,International BPA Registry,COMPLETED,,500.0,2018-03-02,2022-03-31,10.21476510067114,Good (10-50/month),102.14765100671141,Exceeded (≥100%),100,93.3,94.325
NCT00351468,EXTEND (Eltrombopag Extended Dosing Study),COMPLETED,PHASE3,302.0,2006-06-01,2015-07-01,2.7714440759722643,Adequate (1-10/month),27.714440759722642,Significantly Below (<50%),100,74.2,84.15
NCT05148468,Effects of Spinal Cord Stimulation on Gait in Patients With Parkinson´s Disease,TERMINATED,NA,8.0,2021-11-30,2024-03-01,0.2962530413625304,Slow (<1/month),2.9625304136253043,Significantly Below (<50%),10,18.6,4.25
NCT00909168,"Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)",COMPLETED,PHASE2,130.0,2008-03-01,2013-03-01,2.1671412924424973,Adequate (1-10/month),21.671412924424974,Significantly Below (<50%),100,60.4,72.54
NCT03178968,Can Surface Roughness Predict Progression of Tooth Wear?,COMPLETED,NA,30.0,2017-01-10,2017-05-29,6.56978417266187,Adequate (1-10/month),65.6978417266187,Below (50-75%),100,52.4,53.949999999999996
NCT03579368,Prospective Evaluation of the Tecnis Symfony Intraocular Lens (IOL),UNKNOWN,NA,200.0,2018-07-05,2019-05-15,19.388535031847134,Good (10-50/month),193.88535031847135,Exceeded (≥100%),50,56.0,63.71
NCT04605068,Transverse Preputial Island Flap Versus Double Faced Preputial Flap for Repair of Penoscrotal Hypospadias With Chordee,COMPLETED,NA,144.0,2014-03-01,2020-03-01,1.9997080291970804,Adequate (1-10/month),19.997080291970804,Significantly Below (<50%),100,61.5,73.905
NCT04775368,Fibromyalgia Syndrome in France: The Role of Assessment and Management of Sleep Disorders,COMPLETED,NA,601.0,2021-04-01,2023-03-07,25.949560283687944,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT06599268,Analyzing the Barriers and Enablers for Women Reaching Top Executive Positions in the Pharmaceutical Sector,COMPLETED,,275.0,2024-07-15,2024-12-30,49.827380952380956,Good (10-50/month),200.0,Exceeded (≥100%),100,80.3,88.075
NCT05294068,"Barriers to Physical Activity in Patients With Cognitive, Neuromotor or Sensory Impairments During Aging",RECRUITING,,1000.0,2022-04-01,2034-02-01,7.039777983348752,Adequate (1-10/month),70.39777983348752,Below (50-75%),60,76.3,85.1
NCT02190968,Reducing Residual Depressive Symptoms With Web-based Mindful Mood Balance,COMPLETED,NA,460.0,2015-03-01,2018-11-01,10.441759880686055,Good (10-50/month),104.41759880686057,Exceeded (≥100%),100,91.8,93.755
NCT03133468,"Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJM347 in Healthy Male Caucasian and Japanese Subjects in the Fasted and Fed State",COMPLETED,PHASE1,200.0,2017-07-25,2018-07-06,17.595375722543352,Good (10-50/month),175.95375722543355,Exceeded (≥100%),100,71.0,82.44
NCT01329068,Patient Empowerment by Group Medical Consultations,UNKNOWN,NA,320.0,2011-04-01,2014-02-01,9.39324975891996,Adequate (1-10/month),93.9324975891996,Met (75-100%),50,65.6,78.56
NCT05521568,Diagnostic Accuracy of Rapid Molecular Tests for Group A Streptococcal Pharyngitis Using Saliva Samples,COMPLETED,,800.0,2023-01-31,2025-02-28,32.08432147562583,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT02532868,A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002),TERMINATED,PHASE1,27.0,2005-05-01,2008-01-01,0.8429538461538463,Slow (<1/month),8.429538461538462,Significantly Below (<50%),10,20.2,5.845000000000001
NCT07195968,Comparative Analysis of NTG-Pd/Pa and Saline-Pd/Pa (CANS),ENROLLING_BY_INVITATION,,50.0,2025-09-17,2029-12-31,0.9719029374201789,Slow (<1/month),9.719029374201789,Significantly Below (<50%),55,33.8,13.694999999999999
NCT02344368,The Effect of Sucrose on Pain Relief During Venous Blood Sampling in Preterm Infants,COMPLETED,NA,50.0,2015-01-01,2016-06-01,2.9439071566731143,Adequate (1-10/month),29.439071566731144,Significantly Below (<50%),100,54.0,58.72500000000001
NCT03089268,Molecular and Histological Characteristics of Serrated Lesions of the Colon,ACTIVE_NOT_RECRUITING,,700.0,2017-06-01,2028-01-01,5.511639937920331,Adequate (1-10/month),55.116399379203315,Below (50-75%),85,83.8,90.505
NCT03457168,Treatment of Hypertension During Sleep,RECRUITING,NA,5320.0,2019-02-01,2032-12-31,31.865564738292015,Good (10-50/month),200.0,Exceeded (≥100%),60,83.0,89.505
NCT04026568,A Single Dose Pharmaco-Diagnostic for Peripheral Nerve Continuity After Trauma,TERMINATED,PHASE2,1.0,2021-08-17,2022-07-18,0.09086567164179106,Slow (<1/month),0.9086567164179105,Significantly Below (<50%),10,18.1,3.105
NCT00420368,Efficacy Trial on Alleviation of Infant Malnutrition With Fortified Spread or Maize-soy Flour Food Supplements,COMPLETED,PHASE3,189.0,2007-02-01,2007-07-01,38.3544,Good (10-50/month),200.0,Exceeded (≥100%),100,70.1,81.955
NCT01897350,Myocardial Oedema in ST Segment Elevation Myocardial Infarction Myocardial,COMPLETED,,30.0,2013-07-01,,,Slow (<1/month),,Significantly Below (<50%),100,40.7,22.675
NCT00629850,Respiratory Resistance Training on Sleep Quality in Persons With Spinal Cord Injury,TERMINATED,NA,1.0,2008-02-01,2009-09-01,0.0526643598615917,Slow (<1/month),0.526643598615917,Significantly Below (<50%),10,18.1,3.105
NCT04756050,Comparison of Different Approaches for Supraclavicular Block and Their Effects on Diaphragm Muscle Function,COMPLETED,PHASE4,90.0,2021-02-16,2022-03-02,7.22849604221636,Adequate (1-10/month),72.2849604221636,Below (50-75%),100,57.2,66.465
NCT01052350,PET Imaging in Parkinson Disease Dementia,ACTIVE_NOT_RECRUITING,,320.0,2006-08-01,2030-07-01,1.1151459645105897,Adequate (1-10/month),11.151459645105897,Significantly Below (<50%),85,64.4,77.37
NCT00008450,Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant,COMPLETED,PHASE1,6.0,1997-08-11,2018-12-26,0.023394389650313825,Slow (<1/month),0.2339438965031382,Significantly Below (<50%),100,45.5,31.705
NCT05454150,Balloon-Expandable Versus Self-expanding Transcatheter Heart Valve for Treatment of Symptomatic Native Aortic Valve Stenosis (BEST),ACTIVE_NOT_RECRUITING,NA,1960.0,2023-04-19,2035-12-29,12.866594781108475,Good (10-50/month),128.66594781108475,Exceeded (≥100%),85,90.5,93.4
NCT01347450,Protective Effects of Cocoa Ingestion Over Healthy Males Plasma Lipids Subjected to Peroxidative Conditions,COMPLETED,NA,136.0,2007-10-01,2008-08-01,13.573245901639346,Good (10-50/month),135.73245901639345,Exceeded (≥100%),100,65.9,78.83
NCT06821750,A Study to Learn How Different Amounts of the Study Medicine Called PF-07314470 Are Tolerated and Act in the Body in Healthy Adults,TERMINATED,PHASE1,23.0,2025-02-11,2025-08-18,3.7240425531914894,Adequate (1-10/month),37.240425531914894,Significantly Below (<50%),10,24.8,7.06
NCT03043950,Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE),COMPLETED,,647.0,2017-01-25,2024-01-17,7.729466248037676,Adequate (1-10/month),77.29466248037676,Met (75-100%),100,88.3,92.705
NCT05686850,Non-Invasive Ventilation Versus High-flow Nasal Oxygen in Intensive Care Units,RECRUITING,NA,670.0,2023-02-02,2028-08-27,10.031874077717658,Good (10-50/month),100.31874077717657,Exceeded (≥100%),60,83.0,89.505
NCT05295550,Reliability of the Smartphone Inclinometer App and Flexicurve,COMPLETED,NA,60.0,2021-09-01,2021-12-31,15.094214876033059,Good (10-50/month),150.9421487603306,Exceeded (≥100%),100,59.8,71.61
NCT04548050,Impact of the Training of Nursing Staff on the Practice of Manual Expression of Early Colostrum in Neonatal Medicine,COMPLETED,,82.0,2020-09-14,2022-04-21,4.274109589041096,Adequate (1-10/month),42.74109589041096,Significantly Below (<50%),100,54.9,61.55500000000001
NCT06854250,Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer,RECRUITING,PHASE2,104.0,2025-03-01,2030-03-01,1.733713033953998,Adequate (1-10/month),17.33713033953998,Significantly Below (<50%),60,46.3,35.66
NCT05177250,"Association of Bisphenol A,Paraben Exposure and Type 2 Diabetes",UNKNOWN,NA,100.0,2022-02-20,2023-01-01,9.663492063492065,Adequate (1-10/month),96.63492063492065,Met (75-100%),50,48.0,42.945
NCT01650350,"Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer",TERMINATED,PHASE2,7.0,2012-11-01,2013-10-01,0.6379640718562875,Slow (<1/month),6.379640718562873,Significantly Below (<50%),10,18.6,4.25
NCT06791850,Sustaining Home Heart Failure Palliative Care in Rural Appalachia,RECRUITING,NA,208.0,2025-04-01,2028-05-01,5.623019538188277,Adequate (1-10/month),56.23019538188277,Below (50-75%),60,54.6,60.39
NCT04848350,Use of Inhaler Aromatherapy During SWL,COMPLETED,NA,120.0,2020-06-01,2020-09-01,39.70434782608696,Good (10-50/month),200.0,Exceeded (≥100%),100,64.6,77.59
NCT03030950,Perineural Dexmedetomidine in Adductor Canal Block,COMPLETED,PHASE4,40.0,2018-01-25,2018-12-05,3.877707006369427,Adequate (1-10/month),38.77707006369427,Significantly Below (<50%),100,53.2,56.665
NCT01685450,NIMIP: Non Invasive Measurement of the Intracranial Pressure,UNKNOWN,PHASE4,25.0,2010-06-01,2012-09-01,0.9246658566221143,Slow (<1/month),9.246658566221143,Significantly Below (<50%),50,32.0,11.425
NCT06608550,"Pre-procedure Short Movie Video Training on the Child's Fear, Anxiety and Satisfaction",COMPLETED,NA,90.0,2025-05-16,2025-12-31,11.963318777292578,Good (10-50/month),119.63318777292578,Exceeded (≥100%),100,62.2,74.74499999999999
NCT00810550,Carotid Ultrasound in the Evaluation of Heart Failure,COMPLETED,NA,150.0,2005-10-01,2008-12-01,3.9464131374243734,Adequate (1-10/month),39.464131374243735,Significantly Below (<50%),100,62.0,74.42
NCT01067950,Pancreas Allotransplantation for Diabetic Nephropathy and Mild Chronic REnal fAilure Stage Study,UNKNOWN,PHASE3,180.0,2010-03-01,,,Slow (<1/month),,Significantly Below (<50%),50,39.4,20.94
NCT05662150,Low-frequency Repetitive Nerve Stimulation in Myotonic Dystrophy Type 1,COMPLETED,NA,9.0,2021-09-01,2022-06-20,0.9382191780821918,Slow (<1/month),9.382191780821918,Significantly Below (<50%),100,45.7,32.5
NCT00203450,Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial,COMPLETED,PHASE4,20.0,2003-05-01,2006-03-01,0.5882125603864734,Slow (<1/month),5.882125603864734,Significantly Below (<50%),100,46.6,37.375
NCT05668650,"Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC",RECRUITING,PHASE3,174.0,2023-08-15,2024-12-01,11.174177215189873,Good (10-50/month),111.74177215189873,Exceeded (≥100%),60,56.9,65.89500000000001
NCT02752750,Longitudinal Quantitative Susceptibility Mapping (QSM) in Alzheimer 's Disease,UNKNOWN,,50.0,2016-05-01,2025-05-01,0.4630362032248251,Slow (<1/month),4.630362032248251,Significantly Below (<50%),50,32.3,11.799999999999999
NCT02345850,Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301),COMPLETED,PHASE3,346.0,2015-08-01,2020-10-05,5.566723044397463,Adequate (1-10/month),55.66723044397464,Below (50-75%),100,77.7,85.91499999999999
NCT04466891,A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers,COMPLETED,PHASE2,87.0,2020-10-01,2024-07-11,1.9204350978970268,Adequate (1-10/month),19.204350978970268,Significantly Below (<50%),100,57.0,66.12
NCT06843291,UNIVERSAL GENETIC TESTING OF PATIENTS WITH HEMATOLOGICAL MALIGNANCIES (UGT),NOT_YET_RECRUITING,NA,100.0,2025-02-01,2029-02-01,2.083504449007529,Adequate (1-10/month),20.83504449007529,Significantly Below (<50%),30,37.0,17.955
NCT07260591,VSV-02 Compassionate Use in Advanced Solid Tumors,RECRUITING,PHASE1,6.0,2025-09-22,2027-09-30,0.24747967479674798,Slow (<1/month),2.47479674796748,Significantly Below (<50%),60,33.5,13.34
NCT00711191,A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas,COMPLETED,PHASE1,22.0,2008-06-01,2011-01-01,0.709406779661017,Slow (<1/month),7.094067796610171,Significantly Below (<50%),100,46.8,38.440000000000005
NCT07189091,CReep and Maintenance flUid Sodium Chloride ADministration rEduction in cRitically Ill adultS,RECRUITING,PHASE4,640.0,2025-10-07,2028-07-30,18.969425511197663,Good (10-50/month),189.69425511197664,Exceeded (≥100%),60,83.0,89.505
NCT04659291,Prospective Study on Patients With Obstructive Sleep Apnea in Hong Kong (PrOSA),RECRUITING,,1000.0,2020-08-30,2028-08-29,10.421088668264293,Good (10-50/month),104.21088668264294,Exceeded (≥100%),60,81.3,88.58
NCT00830791,A Single Dose Study to Investigate the Pharmacokinetics of MK-0941 in Participants With Renal Insufficiency (MK-0941-015-02),TERMINATED,PHASE1,32.0,2009-01-01,2009-09-01,4.008559670781893,Adequate (1-10/month),40.08559670781893,Significantly Below (<50%),10,25.6,7.595000000000001
NCT00958191,Trident® X3 Polyethylene Insert Study,COMPLETED,NA,250.0,2005-05-01,2016-12-01,1.7982041587901703,Adequate (1-10/month),17.982041587901705,Significantly Below (<50%),100,70.0,81.89999999999999
NCT01622491,"Effectiveness of H1N1 Influenza Vaccines in Manitoba, Canada",UNKNOWN,,1860.0,2012-06-01,2013-12-01,103.31824817518248,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT01251991,Cholesterol Lowering Treatment With Psyllium Husks and Isolated Soy Protein in Hypercholesterolemia,COMPLETED,PHASE4,41.0,2011-01-01,2012-01-01,3.419287671232877,Adequate (1-10/month),34.19287671232877,Significantly Below (<50%),100,53.3,57.14
NCT03120091,"Assessment of the Accuracy,Feasibility,Safety of Continuous Glucose Monitoring System",COMPLETED,,22.0,2014-07-01,2015-01-31,3.1293457943925236,Adequate (1-10/month),31.293457943925233,Significantly Below (<50%),100,50.1,47.89
NCT06691191,Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors,RECRUITING,PHASE4,48.0,2025-01-08,2026-12-31,2.0237119113573407,Adequate (1-10/month),20.237119113573407,Significantly Below (<50%),60,41.8,24.445
NCT06045091,To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL,RECRUITING,EARLY_PHASE1,18.0,2023-07-04,2027-09-30,0.35372498386055523,Slow (<1/month),3.537249838605552,Significantly Below (<50%),60,34.4,14.430000000000001
NCT03987191,Insulin Pump to Multiple Daily Injection Transition Clinical Trial,COMPLETED,PHASE4,38.0,2020-01-10,2020-10-08,4.25264705882353,Adequate (1-10/month),42.52647058823529,Significantly Below (<50%),100,53.0,55.80500000000001
NCT01112891,Vitamin D in Pregnancy and Lactation,COMPLETED,PHASE4,225.0,2010-03-01,2013-02-01,6.412921348314607,Adequate (1-10/month),64.12921348314607,Below (50-75%),100,68.0,80.56
NCT01541891,Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome,COMPLETED,PHASE2,30.0,2011-10-01,2012-05-01,4.287323943661972,Adequate (1-10/month),42.87323943661972,Significantly Below (<50%),100,52.4,53.949999999999996
NCT02563691,Stereotactic Radiotherapy for Oligometastatic Prostate Cancer,UNKNOWN,PHASE1,90.0,2014-11-01,2022-12-01,0.9280487804878049,Slow (<1/month),9.28048780487805,Significantly Below (<50%),50,37.2,18.17
NCT06275191,Alternatives to Dental Opioid Prescribing After Tooth Extraction,ENROLLING_BY_INVITATION,NA,38159.0,2024-04-16,2028-12-01,687.3135857988166,Excellent (>50/month),200.0,Exceeded (≥100%),55,86.5,91.97999999999999
NCT03762174,Characteristics of Back Pain Attendances at ED,COMPLETED,,62000.0,2016-08-01,2017-07-31,5184.835164835165,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02476474,GERD Following Laparoscopic Sleeve Gastrectomy,WITHDRAWN,NA,0.0,2023-07-01,2023-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT04860674,A Prospective Study of PD-1 Inhibitor Combined With ICE in the Treatment of Relapsed/Refractory Gray Area Lymphoma,UNKNOWN,PHASE2,20.0,2021-05-01,2024-04-01,0.5711069418386492,Slow (<1/month),5.711069418386492,Significantly Below (<50%),50,31.6,10.905
NCT00805974,Study of the Relationship Between Sleep Quality and Daytime-Nighttime Variations of Blood Pressure and Plasma Glucose Type I,TERMINATED,NA,23.0,2005-10-01,2007-12-01,0.8851074589127688,Slow (<1/month),8.851074589127686,Significantly Below (<50%),10,19.8,5.465
NCT02315274,Pilot Study of Between Visit Interaction to Improve Glycemic Control in Pregnancy With Pre-existing Diabetes,COMPLETED,NA,12.0,2014-06-01,2019-01-01,0.2180776119402985,Slow (<1/month),2.180776119402985,Significantly Below (<50%),100,46.0,34.1
NCT05457374,A Clinical Study of Portal Vein Embolization and Liver Venous Deprivation,UNKNOWN,NA,10.0,2022-03-01,2025-03-01,0.27773722627737224,Slow (<1/month),2.7773722627737225,Significantly Below (<50%),50,30.8,9.745
NCT05093374,Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting,RECRUITING,PHASE4,290.0,2021-03-01,2025-12-31,4.998640996602492,Adequate (1-10/month),49.98640996602492,Significantly Below (<50%),60,61.2,73.43499999999999
NCT01023074,Effects of Training on Central Auditory Function in Multiple Sclerosis,COMPLETED,NA,52.0,2007-10-01,2011-06-01,1.1821359223300971,Adequate (1-10/month),11.821359223300972,Significantly Below (<50%),100,49.2,46.035
NCT01264874,MelaViD: A Trial on Vitamin D Supplementation for Resected Stage II Melanoma Patients,TERMINATED,PHASE3,150.0,2010-05-01,2017-07-01,1.7440794499618029,Adequate (1-10/month),17.44079449961803,Significantly Below (<50%),10,35.0,15.305
NCT05647174,MGPOCUS Assisted Bronchoscopy in Difficult Endotracheal Intubation,NOT_YET_RECRUITING,NA,350.0,2023-08-01,2026-03-01,11.297985153764582,Good (10-50/month),112.97985153764583,Exceeded (≥100%),30,62.0,74.42
NCT03209674,Registry for the Improvement of Postoperative OutcomeS in Cardiac and Thoracic surgEry,UNKNOWN,,8000.0,2012-01-01,2025-12-31,47.62761588108742,Good (10-50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT06471374,Pathophysiology of Circadian Rhythm Delayed Sleep Wake Phase Disorder,RECRUITING,NA,66.0,2024-04-02,2028-07-01,1.2953191489361702,Adequate (1-10/month),12.953191489361702,Significantly Below (<50%),60,38.3,19.785
NCT03078374,MAGENTUM 1 HeartMate 3 LVAS: A Single Center Prospective Controlled Study (MAGENTUM 1),UNKNOWN,NA,15.0,2017-01-11,2022-10-01,0.21857348013403544,Slow (<1/month),2.1857348013403546,Significantly Below (<50%),50,31.2,10.165000000000001
NCT05608174,Comparison of Tracheal Temperature Measured Using Endotracheal Tube (ETT) Thermometer Before and After Neck Hyperextension in Patients Undergoing Laryngeal Microsurgery,UNKNOWN,,56.0,2022-11-01,2023-09-01,5.607368421052632,Adequate (1-10/month),56.073684210526324,Below (50-75%),50,37.8,19.015
NCT07166874,The Impacts of Gluten-free Diet in Patients With Ankylosing Spondylitis,RECRUITING,NA,60.0,2025-01-31,2026-05-31,3.765773195876289,Adequate (1-10/month),37.65773195876289,Significantly Below (<50%),60,42.8,25.929999999999996
NCT03598374,Spontaneous Reproductive Outcomes After Oral Inositol Supplementation in Infertile Polycystic Ovarian Syndrome Women.,UNKNOWN,NA,80.0,2022-01-01,2024-12-31,2.2239269406392697,Adequate (1-10/month),22.239269406392697,Significantly Below (<50%),50,41.4,24.04
NCT07087574,3D Printers for Autonomy in the Care of Inpatients in Continuing and Rehabilitation Care,NOT_YET_RECRUITING,NA,75.0,2026-02-01,2027-09-01,3.956672443674177,Adequate (1-10/month),39.56672443674177,Significantly Below (<50%),30,35.0,15.305
NCT05272774,Stress Recovery Program FOREST+ for Healthcare Workers,COMPLETED,NA,220.0,2022-03-22,2022-10-11,32.98916256157636,Good (10-50/month),200.0,Exceeded (≥100%),100,72.6,83.28
NCT01143974,Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer,COMPLETED,PHASE4,28.0,2010-06-01,2012-06-01,1.1659644322845417,Adequate (1-10/month),11.659644322845418,Significantly Below (<50%),100,47.2,40.035
NCT06714474,Effectiveness of Virtual Simulation Game in Teaching Venous Blood Sampling Skills to Nursing Students,RECRUITING,NA,200.0,2024-11-01,2024-12-31,101.46666666666667,Excellent (>50/month),200.0,Exceeded (≥100%),60,64.0,77.025
NCT02924974,Spinal Morphine in Robotic Assisted Radical Prostatectomy,COMPLETED,PHASE4,160.0,2016-09-01,2018-08-06,6.918181818181818,Adequate (1-10/month),69.18181818181819,Below (50-75%),100,62.8,75.53999999999999
NCT04223674,Serological Screen and Treat Trial for Plasmodium Vivax,UNKNOWN,NA,1133.0,2022-02-09,2023-12-30,50.05590711175617,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT03389074,Evaluation of Optimal Ablation Index for Pulmonary Vein Isolation in Patients With AF Prospective Registry,UNKNOWN,,70.0,2017-01-23,2020-12-31,1.4817802503477053,Adequate (1-10/month),14.81780250347705,Significantly Below (<50%),50,33.9,13.865
NCT00458874,Better Adherence to Therapeutic Lifestyle Change Efforts Trial,COMPLETED,NA,166.0,2007-11-01,2011-04-01,4.052157177225341,Adequate (1-10/month),40.52157177225342,Significantly Below (<50%),100,63.3,76.235
NCT06992674,The R-E-V-I-V-A-L Study,ACTIVE_NOT_RECRUITING,PHASE2,240.0,2025-06-01,2026-12-01,13.331386861313868,Good (10-50/month),133.31386861313868,Exceeded (≥100%),85,69.7,81.73
NCT00527618,Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV,COMPLETED,PHASE4,28.0,2007-12-01,2011-03-01,0.7186509274873525,Slow (<1/month),7.186509274873526,Significantly Below (<50%),100,47.2,40.035
NCT05770518,Biofeedback vs Laryngeal Control Therapy in Management of Paradoxical Vocal Fold Motion,COMPLETED,NA,51.0,2023-03-07,2024-07-30,3.0380430528375735,Adequate (1-10/month),30.380430528375733,Significantly Below (<50%),100,54.1,59.11
NCT06306118,Autoguide Positioning Device for Multiple Stereotactic Biopsies,RECRUITING,,25.0,2024-04-15,2025-10-01,1.4250936329588015,Adequate (1-10/month),14.250936329588015,Significantly Below (<50%),60,33.3,13.200000000000001
NCT00077818,Enoxaparin Versus Unfractionated Heparin in Subjects Who Present to the Emergency Department With Acute Coronary Syndrome (RESCUE),COMPLETED,PHASE4,,2002-06-01,,,Slow (<1/month),,Significantly Below (<50%),100,40.0,21.87
NCT05948618,Improving PRO for Patients with Cancer Using ECAs and Data Visualization,NOT_YET_RECRUITING,NA,100.0,2025-12-01,2026-09-01,11.10948905109489,Good (10-50/month),111.0948905109489,Exceeded (≥100%),30,42.0,24.825
NCT00496418,Peristomal Mesh for Prophylaxis of Parastomal Hernia,COMPLETED,PHASE3,60.0,2007-07-01,2014-11-01,0.681492537313433,Slow (<1/month),6.8149253731343284,Significantly Below (<50%),100,49.8,47.17
NCT05992818,Comparison of DRS-R-98 and 3D-CAM in the Assessment of Postoperative Delirium in Elderly Patients,COMPLETED,,270.0,2023-08-16,2023-12-25,62.738931297709925,Excellent (>50/month),200.0,Exceeded (≥100%),100,79.9,87.315
NCT07136818,From Blueprint to Practice: An Innovative Dynamic 9-Box Grid Improves Exercise Participation and Aerobic Capacity in Graduate Students,COMPLETED,NA,30.0,2024-10-14,2025-01-10,10.377272727272727,Good (10-50/month),103.77272727272728,Exceeded (≥100%),100,57.4,67.05499999999999
NCT06263218,Real-world CMV Outcomes Among Kidney Transplant Recipients in Brazil,ENROLLING_BY_INVITATION,,500.0,2023-10-01,2024-12-29,33.45054945054945,Good (10-50/month),200.0,Exceeded (≥100%),55,79.8,87.27000000000001
NCT06265818,The Effect of Active Breathing Exercises in Stroke Patients With Respiratory Rhythm Disorder,RECRUITING,NA,80.0,2024-03-01,2024-05-01,39.92131147540984,Good (10-50/month),200.0,Exceeded (≥100%),60,49.4,46.42
NCT06397118,Prevention of Malnutrition in Children With Sickle Cell Disease,ACTIVE_NOT_RECRUITING,NA,148.0,2024-11-06,2027-05-31,4.8131623931623935,Adequate (1-10/month),48.13162393162394,Significantly Below (<50%),85,57.3,66.74
NCT00941018,Single and Multiple Ascending Oral Dose Study of RX-10001 in Healthy Volunteers,COMPLETED,PHASE1,56.0,2009-06-01,2009-09-01,18.528695652173912,Good (10-50/month),185.28695652173914,Exceeded (≥100%),100,59.5,71.0
NCT05622318,De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis,SUSPENDED,PHASE2,56.0,2023-08-29,2026-09-15,1.5315723270440254,Adequate (1-10/month),15.315723270440252,Significantly Below (<50%),20,25.5,7.5200000000000005
NCT04717518,Anchoring Patients Pain Scores in the Emergency Department,COMPLETED,,108.0,2020-08-24,2021-11-12,7.387685393258427,Adequate (1-10/month),73.87685393258427,Below (50-75%),100,57.0,66.12
NCT02378818,Characterization of the Motivational Deficit in Schizophrenia and Depression,UNKNOWN,NA,140.0,2014-11-21,2019-01-01,2.83728362183755,Adequate (1-10/month),28.372836218375504,Significantly Below (<50%),50,46.2,35.089999999999996
NCT02891018,Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter in the Treatment of In-stent Restenosis of Coronary Artery Lesion With Paclitaxel Release Coronary Balloon Catheter,UNKNOWN,PHASE3,260.0,2015-12-01,,,Slow (<1/month),,Significantly Below (<50%),50,45.8,33.03
NCT01271218,Effects of Glucosamine and Chondroitin Supplementation in Women With Knee Osteoarthritis Participating in an Exercise and Weight Loss Program,COMPLETED,PHASE4,36.0,2005-11-01,2006-12-01,2.7742784810126584,Adequate (1-10/month),27.74278481012658,Significantly Below (<50%),100,52.9,55.55
NCT03719118,Tailored Therapeutic Model According to the Expression of Genes in Inflammatory Bowel Disease Patients,COMPLETED,NA,215.0,2016-01-01,2018-10-05,6.4926587301587295,Adequate (1-10/month),64.9265873015873,Below (50-75%),100,67.2,79.94
NCT06540118,Food Is Medicine for Patients With Heart Failure,COMPLETED,NA,60.0,2024-10-17,2025-07-28,6.430985915492958,Adequate (1-10/month),64.30985915492957,Below (50-75%),100,54.8,61.095
NCT00592618,Effect of NAC on Sleep Apnea,UNKNOWN,NA,,,,,Slow (<1/month),,Significantly Below (<50%),50,25.0,7.23
NCT04426318,COVID-19 and the Healthy Minds Program for Educators,COMPLETED,NA,698.0,2020-06-14,2021-01-12,100.2222641509434,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT01219218,Extracorporeal Shockwave Therapy for the Treatment of Advanced Angina Pectoris,COMPLETED,PHASE1,33.0,2009-01-01,2012-06-01,0.8055493183640738,Slow (<1/month),8.05549318364074,Significantly Below (<50%),100,47.6,41.775
NCT00570518,Alcohol and Other Psychoactive Substances in Road Traffic - a Case-control Study,UNKNOWN,,4500.0,2007-09-01,2011-10-01,91.87122736418512,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT05925218,Circulating Tumor DNA Collection From Patients With High Grade Gliomas,RECRUITING,,70.0,2022-09-02,2027-09-30,1.1492988133764834,Adequate (1-10/month),11.492988133764834,Significantly Below (<50%),60,36.9,17.735
NCT05454618,The Decision To Enroll In Therapeutic Clinical Trials In A Pediatric Cancer Clinical Network,RECRUITING,,400.0,2022-10-04,2027-06-01,7.15814226925338,Adequate (1-10/month),71.5814226925338,Below (50-75%),60,68.3,80.875
NCT01423890,A Prospective Cohort Study to Evaluate the Oncotype DX® Test in Early Stage Breast Cancer,COMPLETED,NA,1011.0,2012-01-01,2014-02-01,40.386929133858274,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT02290990,"Efficacy Study of ""Imaginative Distention"", a Self Managed Tool to Cope With Fatigue,Insomnia and Stress in pw Insomnia and pw MS",COMPLETED,NA,144.0,2014-09-01,2016-12-01,5.332554744525547,Adequate (1-10/month),53.325547445255474,Below (50-75%),100,61.5,73.905
NCT05193890,Using Next-generation Sequencing in the Diagnosis of Epilepsy and/or Intellectual Disability in a Pediatric Cohorte,COMPLETED,,69.0,2019-06-01,2021-05-31,2.877205479452055,Adequate (1-10/month),28.772054794520553,Significantly Below (<50%),100,53.9,58.34
NCT03494790,Markers of Inflammation and Metabolism in the ER,COMPLETED,,955.0,2017-12-15,2019-08-01,48.93973063973064,Good (10-50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT01349790,Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia,COMPLETED,PHASE3,40.0,2011-10-01,2013-07-01,1.9054773082942098,Adequate (1-10/month),19.0547730829421,Significantly Below (<50%),100,53.2,56.665
NCT00977990,Amplification of Merkel Cell Polyomavirus From Skin Swabs,COMPLETED,,30.0,2009-08-25,2010-05-19,3.4202247191011237,Adequate (1-10/month),34.202247191011246,Significantly Below (<50%),100,50.7,48.915
NCT07046390,TIPS Block vs. IV Analgesia for Postoperative Pain After Knee Arthroscopy,NOT_YET_RECRUITING,NA,52.0,2025-07-20,2026-08-20,3.9971717171717174,Adequate (1-10/month),39.971717171717174,Significantly Below (<50%),30,33.2,12.989999999999998
NCT02717390,Bright by Three (BB3) Effectiveness Study,TERMINATED,NA,100.0,2017-08-01,2019-03-30,5.023102310231024,Adequate (1-10/month),50.23102310231023,Below (50-75%),10,31.0,9.985
NCT06502990,Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy,RECRUITING,PHASE3,15.0,2025-05-23,2026-09-30,0.9224242424242425,Slow (<1/month),9.224242424242423,Significantly Below (<50%),60,34.2,14.305000000000001
NCT00623090,Internet-Based Education for Prostate Cancer Screening,COMPLETED,PHASE3,1893.0,2007-10-01,2011-08-01,41.15922857142857,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT03043690,A Pooled Analysis of the Data From Two Studies of Ammonium Succinate for Menopausal Symptoms,COMPLETED,,227.0,2017-02-11,2017-05-30,63.98037037037037,Excellent (>50/month),200.0,Exceeded (≥100%),100,76.5,85.3
NCT05439590,"Impact of Cottonseed Oil on Oxidative Stress, Inflammation, and Metabolism",COMPLETED,NA,47.0,2022-08-08,2023-11-03,3.165221238938053,Adequate (1-10/month),31.652212389380534,Significantly Below (<50%),100,53.8,58.065
NCT04120090,Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis,UNKNOWN,PHASE3,80.0,2019-07-01,2020-07-01,6.6535519125683065,Adequate (1-10/month),66.53551912568307,Below (50-75%),50,41.4,24.04
NCT05912790,eyeTube in Combination With the eyeWatch Implant,UNKNOWN,NA,15.0,2023-06-06,2024-09-30,0.9473029045643154,Slow (<1/month),9.473029045643155,Significantly Below (<50%),50,31.2,10.165000000000001
NCT03782090,Comparisons of Novel Double-lumen Endobronchial Tube for Blind Lung Isolation Technique With Conventional Double-lumen Endobronchial Tube in Patients Undergoing One-lung Ventilation,COMPLETED,NA,190.0,2018-09-05,2019-01-31,39.078378378378375,Good (10-50/month),200.0,Exceeded (≥100%),100,70.2,81.99499999999999
NCT07021690,The Steno Opti-Bolus-Timing Studies,NOT_YET_RECRUITING,NA,40.0,2025-06-30,2027-06-01,1.736947218259629,Adequate (1-10/month),17.36947218259629,Significantly Below (<50%),30,32.2,11.635
NCT01889290,Methylnaltrexone Pharmacokinetics in Neurointensive Care Patients,COMPLETED,PHASE1,9.0,2014-02-01,2016-06-01,0.3219271445358402,Slow (<1/month),3.219271445358402,Significantly Below (<50%),100,45.7,32.5
NCT00153790,LEAN Project: Weight Loss and Appetite Suppression,COMPLETED,PHASE1,60.0,2005-04-01,2006-05-01,4.6237974683544305,Adequate (1-10/month),46.2379746835443,Significantly Below (<50%),100,54.8,61.095
NCT05850390,Real-time Remote Asthma Monitoring Through Smartphone Voice Analysis,UNKNOWN,,84.0,2021-12-14,2023-11-01,3.721921397379913,Adequate (1-10/month),37.21921397379913,Significantly Below (<50%),50,40.1,22.05
NCT07121790,Mg Alloy DrillPins in Hammertoe Deformity Correction,NOT_YET_RECRUITING,NA,20.0,2025-08-01,2029-12-01,0.38458622867972203,Slow (<1/month),3.84586228679722,Significantly Below (<50%),30,25.6,7.595000000000001
NCT01529190,Pregabalin on Interleukin-6 Levels in Living Donor Kidney,COMPLETED,PHASE2,40.0,2011-03-01,2011-12-01,4.427636363636364,Adequate (1-10/month),44.27636363636364,Significantly Below (<50%),100,53.2,56.665
NCT03814590,"A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults",COMPLETED,PHASE1,1053.0,2019-01-21,2020-11-30,47.20665684830634,Good (10-50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT06164197,Virtual Reality Based Robotic Gait and Balance Trainer,COMPLETED,NA,42.0,2023-08-23,2024-12-31,2.5775806451612904,Adequate (1-10/month),25.775806451612905,Significantly Below (<50%),100,53.4,57.35
NCT02645110,Evaluation of Effectiveness and Mildness of Whole-natural Hand-wash Formulations,UNKNOWN,NA,100.0,2016-01-01,2017-01-01,8.316939890710383,Adequate (1-10/month),83.16939890710383,Met (75-100%),50,43.0,26.465
NCT04999410,Virtual Programming Interval Training for TT Performance,UNKNOWN,NA,140.0,2020-11-20,2021-10-31,12.352463768115943,Good (10-50/month),123.52463768115942,Exceeded (≥100%),50,51.2,50.375
NCT02283710,The Effect of Pentoxifylline on Liver Function Tests in Fatty Liver Disease,COMPLETED,PHASE2,120.0,2013-05-01,2014-05-01,10.007671232876714,Good (10-50/month),100.07671232876714,Exceeded (≥100%),100,64.6,77.59
NCT01432210,Provitamin A Absorption and Conversion With Avocados,COMPLETED,NA,24.0,2011-09-01,2012-03-01,4.014065934065934,Adequate (1-10/month),40.14065934065934,Significantly Below (<50%),100,51.9,52.55499999999999
NCT00842010,Characteristics of Non Diabetic Hyperglycemic Inpatients,COMPLETED,,600.0,2006-03-01,2008-12-01,18.15506958250497,Good (10-50/month),181.55069582504967,Exceeded (≥100%),100,93.3,94.325
NCT06416410,JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation,RECRUITING,PHASE3,392.0,2024-08-07,2027-02-28,12.762010695187167,Good (10-50/month),127.62010695187168,Exceeded (≥100%),60,74.4,84.255
NCT02262910,Study of ES414 in Metastatic Castration-Resistant Prostate Cancer,COMPLETED,PHASE1,35.0,2015-01-01,2019-02-18,0.7060304837640822,Slow (<1/month),7.060304837640823,Significantly Below (<50%),100,47.8,42.42
NCT02533310,Virtual Reality Immersive Method for Spider (Phobia) Exposure Therapy (VIMSE),COMPLETED,NA,100.0,2015-08-01,2019-04-30,2.2251461988304095,Adequate (1-10/month),22.251461988304094,Significantly Below (<50%),100,58.0,68.245
NCT01555710,Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study),UNKNOWN,PHASE3,548.0,2012-05-01,2015-06-01,14.81449378330373,Good (10-50/month),148.14493783303732,Exceeded (≥100%),50,80.0,87.67
NCT01485510,Evaluation of the New Orleans Intervention for Infant Mental Health,COMPLETED,NA,227.0,2011-12-01,2017-08-28,3.2951263710061993,Adequate (1-10/month),32.95126371006199,Significantly Below (<50%),100,68.2,80.77
NCT04107610,Normative Oculomotor and Vestibular Data in Pediatric Population,UNKNOWN,NA,600.0,2021-04-01,2022-08-31,35.32688588007738,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT00637910,Tarceva Italian Lung Optimization tRial,UNKNOWN,PHASE3,850.0,2007-11-01,2013-02-01,13.483064095883273,Good (10-50/month),134.83064095883276,Exceeded (≥100%),50,80.0,87.67
NCT05377710,Evaluation of the Safety and Performance of Glycobone in Sinus Lift,UNKNOWN,NA,40.0,2022-05-16,2022-05-16,40.0,Good (10-50/month),200.0,Exceeded (≥100%),50,28.2,8.469999999999999
NCT05398510,"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Pharmacodynamics of SHR-2010 by Intravenously/Subcutaneously in Healthy Subject",COMPLETED,PHASE1,61.0,2022-06-30,2023-03-10,7.3392885375494075,Adequate (1-10/month),73.39288537549407,Below (50-75%),100,54.9,61.55500000000001
NCT05957510,Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment,RECRUITING,PHASE2,36.0,2023-07-10,2025-12-31,1.2108729281767956,Adequate (1-10/month),12.108729281767955,Significantly Below (<50%),60,35.9,16.445
NCT06643910,A Study on the Safety and Efficacy of BST08 in Treating Advanced Non-Small Cell Lung Cancer,NOT_YET_RECRUITING,NA,12.0,2024-10-24,2027-08-31,0.35089337175792507,Slow (<1/month),3.508933717579251,Significantly Below (<50%),30,25.0,7.23
NCT04348110,Evaluation of Eye Health Benefits of Blueberry Chewable Tablets,COMPLETED,NA,57.0,2020-04-17,2020-12-31,6.725116279069767,Adequate (1-10/month),67.25116279069768,Below (50-75%),100,54.6,60.39
NCT04918810,Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer,TERMINATED,PHASE2,6.0,2022-07-29,2024-11-01,0.2211138014527845,Slow (<1/month),2.2111380145278448,Significantly Below (<50%),10,18.5,4.02
NCT00927810,Long Term Study of Canakinumab (ACZ885) in Patients With Gout,COMPLETED,PHASE2,341.0,2009-06-05,2010-08-04,24.423623529411763,Good (10-50/month),200.0,Exceeded (≥100%),100,82.3,89.115
NCT04462510,To Compare Ilioinguinal/Iliohypogastric Block to Wound Infiltration for Pain Relief After Hernia Repair in Adults,COMPLETED,NA,60.0,2019-03-30,2019-10-25,8.738755980861244,Adequate (1-10/month),87.38755980861245,Met (75-100%),100,59.8,71.61
NCT06112210,Effect of Hyperbaric Oxygen Therapy,COMPLETED,NA,20.0,2023-05-20,2023-06-06,20.0,Good (10-50/month),200.0,Exceeded (≥100%),100,56.6,65.34
NCT02078310,Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia,COMPLETED,PHASE1,35.0,2014-02-01,2014-11-01,3.902564102564103,Adequate (1-10/month),39.025641025641036,Significantly Below (<50%),100,52.8,55.31
NCT02910713,Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation,COMPLETED,NA,185.0,2016-09-30,2016-10-31,181.65806451612903,Excellent (>50/month),200.0,Exceeded (≥100%),100,74.8,84.385
NCT03276013,"Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer",COMPLETED,PHASE2,48.0,2018-05-30,2021-08-26,1.234054054054054,Adequate (1-10/month),12.340540540540541,Significantly Below (<50%),100,48.8,45.184999999999995
NCT07143513,Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients,RECRUITING,,115.0,2025-08-11,2026-06-30,10.837770897832819,Good (10-50/month),108.37770897832819,Exceeded (≥100%),60,50.5,48.515
NCT00314613,Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal,TERMINATED,PHASE4,30.0,2006-04-01,,,Slow (<1/month),,Significantly Below (<50%),10,15.4,2.5100000000000002
NCT01666613,A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD8683 When Administered in Different Ways,WITHDRAWN,PHASE1,0.0,2012-11-01,2013-03-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT05777213,Potential Injection of Human Umbilical Cord Secretome in the Case of Trophic Ulcers (Pre-post Intervention),COMPLETED,PHASE1,27.0,2019-01-01,2023-01-02,0.5621614227086184,Slow (<1/month),5.621614227086184,Significantly Below (<50%),100,47.2,40.035
NCT01492413,Impact of an Online Behavioral Weight Loss Program,COMPLETED,NA,572.0,2008-10-01,2011-12-01,15.062006920415227,Good (10-50/month),150.6200692041523,Exceeded (≥100%),100,95.0,95.7
NCT02206113,Sit to Stand Intervention for Allina Health Employees,COMPLETED,NA,39.0,2013-05-01,2013-11-01,6.451956521739131,Adequate (1-10/month),64.5195652173913,Below (50-75%),100,53.1,56.105000000000004
NCT05792813,Efficacy and Safety of Linggui Yangyuan Paste in Patients With Male Infertility,UNKNOWN,EARLY_PHASE1,162.0,2023-06-01,2024-12-01,8.982295081967214,Adequate (1-10/month),89.82295081967214,Met (75-100%),50,53.0,55.80500000000001
NCT00252213,BELIEVE Study: Nesiritide and Post Myocardial Infarction Left Ventricular Modeling,TERMINATED,PHASE1,24.0,2002-08-01,2006-01-01,0.584915932746197,Slow (<1/month),5.84915932746197,Significantly Below (<50%),10,19.9,5.555000000000001
NCT02511613,"Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration",WITHDRAWN,PHASE2,0.0,2015-07-01,2016-04-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT00469313,Efficacy of Inspiratory Muscle Training on Inspiratory Capacity in Patients With COPD,UNKNOWN,,,2007-05-01,,,Slow (<1/month),,Significantly Below (<50%),50,23.3,6.569999999999999
NCT00856713,Clearance of NRL972 in Patients With Cirrhosis and in Healthy Volunteers,COMPLETED,PHASE1,72.0,2006-03-01,,,Slow (<1/month),,Significantly Below (<50%),100,45.8,33.03
NCT05699213,MRI and Biomarkers for Lung Nodules Detected During Lung Cancer Screening,RECRUITING,,30.0,2023-06-27,2026-08-27,0.7892826274848747,Slow (<1/month),7.892826274848747,Significantly Below (<50%),60,33.7,13.465
NCT03333213,Gua Sha Therapy for Chronic Low Back Pain,COMPLETED,NA,50.0,2009-01-01,2010-12-01,2.1773962804005724,Adequate (1-10/month),21.773962804005727,Significantly Below (<50%),100,54.0,58.72500000000001
NCT00949013,S9313B Study of Tumor Tissue Samples From Women With Early-Stage Breast Cancer Enrolled on Clinical Trial SWOG-9313,COMPLETED,,1600.0,2009-01-01,2009-04-01,541.1555555555556,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT04520113,Kharituwe TB Contact Tracing Study,COMPLETED,NA,10579.0,2020-09-01,2025-03-31,192.59854066985648,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT06706713,Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer,RECRUITING,PHASE2,200.0,2022-04-15,2026-06-30,3.960962914769031,Adequate (1-10/month),39.609629147690306,Significantly Below (<50%),60,54.0,58.72500000000001
NCT05804513,The Effect of Lixisenatide on the Effect of Pituitary Hormones,UNKNOWN,PHASE4,10.0,2023-04-17,2023-12-31,1.1798449612403101,Adequate (1-10/month),11.7984496124031,Significantly Below (<50%),50,30.8,9.745
NCT03992313,Community Versus Facility-based Services to Improve the Screening of Active HCV Infection in Cambodia,COMPLETED,NA,7692.0,2022-04-21,2023-09-23,450.27784615384616,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT02875613,Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer,TERMINATED,PHASE2,6.0,2017-01-01,2019-04-01,0.22273170731707317,Slow (<1/month),2.227317073170732,Significantly Below (<50%),10,18.5,4.02
NCT04455113,Hypophosphatemia Deleteriously Affects Outcome of Septic Shock Patients Admitted to ICU,COMPLETED,,317.0,2018-06-01,2020-06-01,13.200383036935705,Good (10-50/month),132.00383036935705,Exceeded (≥100%),100,78.7,86.835
NCT06757413,Virtual Reality Programme Incorporating Psychology and Physiotherapy for Chronic Low Back Pain,COMPLETED,NA,22.0,2024-11-10,2025-01-31,8.166829268292682,Adequate (1-10/month),81.66829268292683,Met (75-100%),100,51.8,52.17
NCT02741713,Analgesic Benefit of PECS Blocks for Biceps Tenodesis Shoulder Surgery,COMPLETED,PHASE3,40.0,2016-04-01,2017-06-29,2.6819383259911898,Adequate (1-10/month),26.8193832599119,Significantly Below (<50%),100,53.2,56.665
NCT03827213,Exparel Interscalene vs Indwelling Catheter,TERMINATED,PHASE2,23.0,2019-01-22,2021-06-01,0.8131475029036005,Slow (<1/month),8.131475029036004,Significantly Below (<50%),10,19.8,5.465
NCT00215813,Ampligen in Chronic Fatigue Syndrome,TEMPORARILY_NOT_AVAILABLE,,,,,,Slow (<1/month),,Significantly Below (<50%),50,23.3,6.569999999999999
NCT03623113,The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study in Type 1 Diabetes,COMPLETED,NA,63.0,2018-09-28,2022-08-17,1.3514587737843553,Adequate (1-10/month),13.514587737843552,Significantly Below (<50%),100,50.0,47.675
NCT02655913,Safety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung Cancer,COMPLETED,PHASE1,97.0,2015-12-01,2018-08-01,3.031498973305955,Adequate (1-10/month),30.314989733059548,Significantly Below (<50%),100,57.8,67.635
NCT03229213,Interactive Video Game Responses in Cystic Fibrosis,COMPLETED,,55.0,2017-08-30,2019-03-31,2.8965397923875433,Adequate (1-10/month),28.965397923875436,Significantly Below (<50%),100,52.7,55.04
NCT01059513,Hypo-fractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer,COMPLETED,,167.0,2010-01-26,2020-03-19,1.372059379217274,Adequate (1-10/month),13.720593792172739,Significantly Below (<50%),100,56.7,65.53
NCT00860613,Medical Nutrition Therapy Program for Pregnant Women With Diabetes,COMPLETED,NA,162.0,2004-02-01,2008-12-01,2.7939263456090653,Adequate (1-10/month),27.93926345609065,Significantly Below (<50%),100,63.0,75.845
NCT03447613,Retinal Nerve Fiber Layer Thickness and Cerebrospinal Fluid Aβ/Tau,COMPLETED,,86.0,2013-08-01,2014-12-31,5.063520309477757,Adequate (1-10/month),50.63520309477757,Below (50-75%),100,55.2,62.195
NCT00327613,Plasma Levels of Matrix Metalloproteinases (MMPs) and Degree of DNA Fragmentation in Pseudoexfoliation (PEX) Glaucoma,COMPLETED,,60.0,2005-06-01,2008-04-01,1.7646376811594202,Adequate (1-10/month),17.6463768115942,Significantly Below (<50%),100,53.1,56.105000000000004
NCT04820413,Faecal Microbiota Transplantation From Normal Pouch Function Donor in the Treatment of Chronic Pouchitis,COMPLETED,NA,3.0,2021-03-01,2022-03-15,0.24094986807387866,Slow (<1/month),2.409498680738787,Significantly Below (<50%),100,45.2,30.830000000000002
NCT02727413,Inflammatory Mediator Profiles During Heart Valve Replacement Surgery,COMPLETED,,40.0,2016-06-01,2017-02-01,4.969795918367347,Adequate (1-10/month),49.697959183673476,Significantly Below (<50%),100,51.5,51.245
NCT01058213,Nurse Managed Sequential Strength Training and Bicycle Training in Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,PHASE2,354.0,2008-11-01,2013-05-01,6.56258221680877,Adequate (1-10/month),65.6258221680877,Below (50-75%),100,78.3,86.48
NCT06971913,Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia,NOT_YET_RECRUITING,PHASE2,100.0,2025-05-20,2025-12-30,13.589285714285715,Good (10-50/month),135.89285714285714,Exceeded (≥100%),30,42.0,24.825
NCT05507060,Evaluation of the Efficacy of Different Nebulization Techniques,UNKNOWN,NA,96.0,2022-08-01,2022-09-25,53.13163636363637,Excellent (>50/month),200.0,Exceeded (≥100%),50,52.7,55.04
NCT04858360,Inhibition of Non-histaminergic Pruritus Applied Using 3 Different Pruritogens,COMPLETED,NA,22.0,2021-11-15,2022-10-01,2.09275,Adequate (1-10/month),20.927500000000002,Significantly Below (<50%),100,51.8,52.17
NCT06114160,"Knowledge of Pregnant Women Concerning Pertussis, Vaccination Against Pertussis and Cocooning Strategy",UNKNOWN,,500.0,2023-12-01,2024-05-01,100.13157894736842,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT01491360,LaserACE® Procedure Restore Visual Function and Range of Accommodation LaserACE® Procedure,COMPLETED,NA,8.0,2013-12-01,2016-01-01,0.32,Slow (<1/month),3.2,Significantly Below (<50%),100,45.6,32.08
NCT03050060,"Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer",TERMINATED,PHASE2,21.0,2017-06-09,2020-07-12,0.5662001771479186,Slow (<1/month),5.662001771479186,Significantly Below (<50%),10,19.7,5.405
NCT01721460,Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus,COMPLETED,PHASE4,6.0,2012-11-01,2015-06-01,0.19388535031847134,Slow (<1/month),1.9388535031847132,Significantly Below (<50%),100,45.5,31.705
NCT05938660,Effects of Acupressure at Sanyinjiao Point on Primary Dysmenorrhea Among University Students.,UNKNOWN,NA,32.0,2022-11-22,2023-08-01,3.865396825396825,Adequate (1-10/month),38.65396825396825,Significantly Below (<50%),50,37.6,18.845
NCT01869660,Shared Decision Making for Patients With First-admission Schizophrenia,COMPLETED,PHASE2,23.0,2013-06-01,2015-10-01,0.8217370892018779,Slow (<1/month),8.21737089201878,Significantly Below (<50%),100,46.8,38.440000000000005
NCT05198960,AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms,RECRUITING,PHASE3,1308.0,2022-07-13,2027-07-13,21.80477546549836,Good (10-50/month),200.0,Exceeded (≥100%),60,83.0,89.505
NCT05156060,Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer,RECRUITING,PHASE1,64.0,2022-01-24,2026-12-31,1.0811098779134296,Adequate (1-10/month),10.811098779134294,Significantly Below (<50%),60,38.1,19.425
NCT01529060,Phenylbutyrate Therapy for Maple Syrup Urine Disease,COMPLETED,PHASE2,20.0,2013-02-01,2017-12-01,0.34512471655328797,Slow (<1/month),3.4512471655328802,Significantly Below (<50%),100,46.6,37.375
NCT03597360,Low Dose Ionizing Radiation Using CT Scans as a Potential Therapy for Alzheimer's Dementia: A Pilot Study,COMPLETED,NA,4.0,2019-01-08,2020-04-01,0.2711804008908686,Slow (<1/month),2.711804008908686,Significantly Below (<50%),100,45.3,31.169999999999998
NCT05781360,"A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors",TERMINATED,PHASE1,192.0,2023-03-08,2024-05-25,13.163243243243244,Good (10-50/month),131.63243243243244,Exceeded (≥100%),10,43.4,27.265
NCT05085860,Acute Responses to Exercise in Females and Males With Symptomatic Atrial Fibrillation,RECRUITING,NA,36.0,2022-02-08,2026-04-01,0.7242828816920027,Slow (<1/month),7.242828816920027,Significantly Below (<50%),60,35.9,16.445
NCT06177860,Clinical and Atherosclerotic Characteristics of Patients With ACS Associated With Cocaine Use,UNKNOWN,,400.0,2023-11-17,2024-11-30,32.126649076517154,Good (10-50/month),200.0,Exceeded (≥100%),50,70.3,82.09
NCT03103360,Pupillary Pain Index and Reaction to Skin Incision,COMPLETED,,53.0,2018-05-02,2019-11-02,2.938652094717669,Adequate (1-10/month),29.386520947176685,Significantly Below (<50%),100,52.6,54.684999999999995
NCT00574860,EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer,TERMINATED,PHASE3,240.0,2007-12-01,2009-06-01,13.331386861313868,Good (10-50/month),133.31386861313868,Exceeded (≥100%),10,47.2,40.035
NCT04305860,Acceptance of Different Thickeners in Dysphagia,COMPLETED,NA,42.0,2020-02-03,2020-03-03,42.0,Good (10-50/month),200.0,Exceeded (≥100%),100,63.4,76.375
NCT01110460,Prospective Study on Asthma Control,COMPLETED,,2875.0,2009-01-01,2010-11-01,130.81464872944693,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT01709760,A Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With Methotrexate Versus Methotrexate Alone in Patients With RA,UNKNOWN,PHASE3,91.0,2012-11-01,2019-12-01,1.071167826759474,Adequate (1-10/month),10.71167826759474,Significantly Below (<50%),50,37.3,18.35
NCT04807660,Bacteriological Evaluation of Children With Otorrhea,UNKNOWN,,1500.0,2015-10-01,2025-10-01,12.49931563098823,Good (10-50/month),124.99315630988231,Exceeded (≥100%),50,78.3,86.48
NCT00006260,Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer,COMPLETED,PHASE2,36.0,1997-05-01,,,Slow (<1/month),,Significantly Below (<50%),100,42.9,26.145000000000003
NCT03148860,"Impact of Concomitant MTX on Efficacy, Safety and Adherence of Ustekinumab-treatment in Patients With Active PsA",COMPLETED,PHASE3,186.0,2016-12-15,2021-10-21,3.1969734613212877,Adequate (1-10/month),31.96973461321288,Significantly Below (<50%),100,64.9,77.985
NCT06340360,A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA),ACTIVE_NOT_RECRUITING,PHASE2,94.0,2024-04-02,2026-08-01,3.36235017626322,Adequate (1-10/month),33.6235017626322,Significantly Below (<50%),85,53.0,55.80500000000001
NCT03025360,Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion,APPROVED_FOR_MARKETING,,,,,,Slow (<1/month),,Significantly Below (<50%),50,23.3,6.569999999999999
NCT04370860,Optimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion Variants,COMPLETED,,1000.0,2020-05-01,2021-12-31,49.98357963875205,Good (10-50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT04669860,Evaluating the Bacterial and Fungal Microbiome in Patients With Calcium Oxalate Urolithiasis and Renal Cell Carcinoma,SUSPENDED,,90.0,2021-02-24,2028-01-01,1.0949640287769784,Adequate (1-10/month),10.949640287769785,Significantly Below (<50%),20,26.5,7.945
NCT04877860,Pain Treatment in a Breast Cancer Population. PaiNEd Study.,UNKNOWN,NA,72.0,2022-04-04,2024-04-01,3.010549450549451,Adequate (1-10/month),30.105494505494505,Significantly Below (<50%),50,40.8,22.745
NCT00394160,Safety and Pk Study in 1- to 3- Month-Old Children With Bronchiolitis (0476-297),COMPLETED,PHASE2,12.0,2004-12-01,2005-10-01,1.201578947368421,Adequate (1-10/month),12.015789473684212,Significantly Below (<50%),100,46.0,34.1
NCT02765360,EIT Study With COPD and OHS Patients (EIT Step 2),COMPLETED,NA,22.0,2016-05-01,2017-04-30,1.8397802197802198,Adequate (1-10/month),18.3978021978022,Significantly Below (<50%),100,51.8,52.17
NCT06696560,Minimal Invasive Approaches For Aortic Valvular and Subvalvular Surgeries,NOT_YET_RECRUITING,NA,52.0,2024-11-15,2028-01-30,1.351733561058924,Adequate (1-10/month),13.51733561058924,Significantly Below (<50%),30,28.2,8.469999999999999
NCT06028360,Progressive Muscle Relaxation (PMR) in Stress Management Among Physiotherapy Students,UNKNOWN,NA,30.0,2023-10-01,2023-12-31,10.035164835164835,Good (10-50/month),100.35164835164836,Exceeded (≥100%),50,42.4,25.45
NCT05622760,Impact of the Different Information Channels in Reducing Anxiety in Participants of Cervical Cancer Screening,COMPLETED,NA,140.0,2022-05-17,2022-12-28,18.940444444444445,Good (10-50/month),189.40444444444447,Exceeded (≥100%),100,66.2,79.2
NCT03560960,Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,57.0,2020-02-04,2026-11-01,0.7047441104792852,Slow (<1/month),7.047441104792853,Significantly Below (<50%),85,45.1,30.605
NCT06877260,Characterization of Neurocognitive Profiles in Neurodevelopmental Disorders and Epilepsy: a Transdiagnostic Approach,ACTIVE_NOT_RECRUITING,,60.0,2024-11-01,2027-11-01,1.6679452054794521,Adequate (1-10/month),16.67945205479452,Significantly Below (<50%),85,48.6,44.685
NCT01269320,Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease,WITHDRAWN,PHASE4,0.0,2012-01-01,,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT00053820,Interferon Alfa With or Without Interleukin-2 and Fluorouracil in Treating Patients With Advanced Metastatic Kidney Cancer,COMPLETED,PHASE3,670.0,2002-07-01,2006-12-01,12.636183395291203,Good (10-50/month),126.36183395291202,Exceeded (≥100%),100,95.0,95.7
NCT02818920,Neoadjuvant Pembrolizumab,ACTIVE_NOT_RECRUITING,PHASE2,35.0,2017-01-01,2026-03-01,0.3184100418410042,Slow (<1/month),3.184100418410042,Significantly Below (<50%),85,43.3,27.05
NCT05966220,Post Market Clinical Follow-up of Hip Surgery Using FH ORTHO Company Medical Devices.,RECRUITING,NA,800.0,2024-01-08,2038-12-01,4.475647858849476,Adequate (1-10/month),44.756478588494765,Significantly Below (<50%),60,78.0,86.075
NCT06672120,Exercise in Triple- Negative Breast Cancer,RECRUITING,NA,120.0,2025-04-03,2028-12-31,2.670175438596491,Adequate (1-10/month),26.701754385964914,Significantly Below (<50%),60,47.6,41.775
NCT06396520,Neuroimaging of Babies During Natural Sleep to Assess Typical Development and Cerebral Palsy,RECRUITING,,200.0,2024-06-01,2027-12-31,4.654434250764527,Adequate (1-10/month),46.54434250764526,Significantly Below (<50%),60,52.3,53.515
NCT00047320,Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors,COMPLETED,PHASE2,104.0,2004-01-01,2009-02-01,1.7038536060279872,Adequate (1-10/month),17.03853606027987,Significantly Below (<50%),100,58.3,68.99499999999999
NCT04315220,Corestability Training in Overweight Children,COMPLETED,NA,20.0,2020-10-13,2021-03-31,3.6023668639053255,Adequate (1-10/month),36.023668639053255,Significantly Below (<50%),100,51.6,51.644999999999996
NCT01249820,Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease,COMPLETED,PHASE2,26.0,2010-11-01,2013-01-01,0.9992929292929293,Slow (<1/month),9.992929292929293,Significantly Below (<50%),100,47.1,39.64
NCT06669520,Correlation of Blood Serum Renalase and Microcirculation Obstruction in Patients with Acute Myocardial Infarction After Primary Percutaneous Coronary Intervention,RECRUITING,,200.0,2024-08-01,2025-10-01,14.291079812206574,Good (10-50/month),142.91079812206573,Exceeded (≥100%),60,57.3,66.74
NCT05443620,Weight Load PET (WELPET),COMPLETED,NA,10.0,2022-08-01,2024-11-22,0.36066350710900474,Slow (<1/month),3.6066350710900474,Significantly Below (<50%),100,45.8,33.03
NCT01106820,Progressive Resistance Training Versus Relaxation for Breast Cancer Patients During Chemotherapy: Biological Mechanisms and Effects on Fatigue and Quality of Life,COMPLETED,NA,101.0,2010-04-01,2014-10-01,1.8700973236009732,Adequate (1-10/month),18.700973236009734,Significantly Below (<50%),100,58.1,68.595
NCT01177020,The Role of Pro-angiogenic Immune Cells in Human Pregnancies,UNKNOWN,,300.0,2010-08-01,2011-12-01,18.751540041067763,Good (10-50/month),187.51540041067764,Exceeded (≥100%),50,62.3,74.94
NCT04186520,CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies,RECRUITING,PHASE1,100.0,2020-05-18,2028-06-01,1.0367847411444142,Adequate (1-10/month),10.367847411444142,Significantly Below (<50%),60,41.0,23.01
NCT01581320,Phase III Clinical Trial of DP-R206 and Bonvia In Postmenopausal Women With Osteoporosis,COMPLETED,PHASE3,201.0,2011-12-01,2012-09-01,22.24887272727273,Good (10-50/month),200.0,Exceeded (≥100%),100,71.1,82.54
NCT05805020,Cellvizio to Evaluate Margins in Crohn's Ileal Disease,RECRUITING,NA,41.0,2022-03-03,2026-03-01,0.8554078135709391,Slow (<1/month),8.554078135709391,Significantly Below (<50%),60,36.3,17.0
NCT01830920,A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI),COMPLETED,PHASE2,452.0,2013-05-01,2015-09-01,16.129988276670574,Good (10-50/month),161.29988276670574,Exceeded (≥100%),100,91.2,93.605
NCT05894382,Double Helix Design Defocus Lens Spectacle (RACE) for Myopia Control,ACTIVE_NOT_RECRUITING,NA,236.0,2023-06-03,2026-12-31,5.496434583014537,Adequate (1-10/month),54.964345830145376,Below (50-75%),85,64.4,77.37
NCT03573882,Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031,TERMINATED,PHASE3,179.0,2018-06-06,2024-11-12,2.317635048915355,Adequate (1-10/month),23.176350489153553,Significantly Below (<50%),10,37.3,18.35
NCT07245082,Patients With Type 2 Diabetes,RECRUITING,,2000.0,2025-10-09,2028-08-21,58.14708691499523,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT03858582,neoadjuvant_thymic Epithelial Tumor,UNKNOWN,PHASE2,40.0,2019-04-29,2023-04-01,0.8496859734822052,Slow (<1/month),8.496859734822053,Significantly Below (<50%),50,33.2,12.989999999999998
NCT02500082,Triheptanoin (UX007) to Treat Citrate Transporter Deficiency,NO_LONGER_AVAILABLE,,,,,,Slow (<1/month),,Significantly Below (<50%),50,23.3,6.569999999999999
NCT01055782,Colonoscopy Endoguide in Specialist Practice,COMPLETED,NA,1004.0,2009-11-01,2012-06-01,32.409077412513255,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT02349282,The Effect of Calcifediol (Hy.D 25 SD/S) and Vitamin D3 on Muscle Strength in a Frail Elderly Population,COMPLETED,NA,78.0,2014-12-01,2015-12-01,6.504986301369864,Adequate (1-10/month),65.04986301369864,Below (50-75%),100,56.2,64.21
NCT05497882,Computer-Based Learning to Enhance Dementia Care in Prison,COMPLETED,NA,23.0,2023-01-20,2024-05-31,1.4086921529175052,Adequate (1-10/month),14.086921529175052,Significantly Below (<50%),100,46.8,38.440000000000005
NCT04204382,Effects of CKI for Oral Mucositis Caused by Radiotherapy for Head and Neck Cancer,UNKNOWN,PHASE4,144.0,2019-12-12,2022-12-30,3.9347935368043094,Adequate (1-10/month),39.34793536804309,Significantly Below (<50%),50,46.5,36.815
NCT03212482,Patient-ventilator Asynchrony in Patients With Brain Injury,COMPLETED,,100.0,2017-06-15,2020-02-29,3.077856420626896,Adequate (1-10/month),30.778564206268967,Significantly Below (<50%),100,56.3,64.5
NCT00778882,Gene Therapy for Chronic Granulomatous Disease in Korea,WITHDRAWN,PHASE1,0.0,2007-01-01,2010-10-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT01922882,Maternal HIV Disclosure to School Children: RCT of Family-based Intervention,COMPLETED,NA,465.0,2013-05-01,2015-09-01,16.59390386869871,Good (10-50/month),165.93903868698712,Exceeded (≥100%),100,92.2,93.825
NCT04498182,A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease,COMPLETED,PHASE2,369.0,2020-10-26,2021-07-17,42.54681818181818,Good (10-50/month),200.0,Exceeded (≥100%),100,89.5,93.025
NCT03775824,Faecal Analyses in Rheumatoid Arthritis Therapy,COMPLETED,,50.0,2016-08-01,2019-06-01,1.4719535783365572,Adequate (1-10/month),14.719535783365572,Significantly Below (<50%),100,47.3,40.475
NCT03406624,Epigenetic and Molecular Biomarkers in Chronic Low Back Pain and Modic Changes,COMPLETED,,200.0,2018-01-29,2024-05-15,2.649260226283725,Adequate (1-10/month),26.492602262837252,Significantly Below (<50%),100,64.3,77.265
NCT01841424,CO-OP Trial: Community-based Outreach on Obesity in Pregnancy,COMPLETED,NA,46.0,2013-06-01,2017-12-01,0.8517274939172749,Slow (<1/month),8.51727493917275,Significantly Below (<50%),100,48.7,44.93
NCT03510624,Acute Effect of Rebaudioside A on Glucose Excursion During an Oral Glucose Tolerance Test in Type 2 Diabetes Mellitus,COMPLETED,PHASE1,30.0,2018-11-09,2021-04-01,1.0448512585812357,Adequate (1-10/month),10.448512585812356,Significantly Below (<50%),100,47.4,40.98
NCT03465124,Evaluation of Central Macular Thickness in Femtosecond Laser-assisted Cataract Surgery,UNKNOWN,NA,60.0,2018-03-26,2019-04-06,4.857446808510638,Adequate (1-10/month),48.57446808510639,Significantly Below (<50%),50,39.8,21.47
NCT00715624,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin",COMPLETED,PHASE3,496.0,2008-07-01,2011-02-01,15.976973544973546,Good (10-50/month),159.76973544973546,Exceeded (≥100%),100,94.7,94.895
NCT00285324,Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation Necrosis,COMPLETED,,29.0,2006-01-27,2013-08-20,0.3196089790007241,Slow (<1/month),3.1960897900072416,Significantly Below (<50%),100,45.7,32.5
NCT02345824,Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma,UNKNOWN,PHASE1,3.0,2016-03-01,2020-01-01,0.06518201284796575,Slow (<1/month),0.6518201284796574,Significantly Below (<50%),50,30.2,9.245000000000001
NCT02707224,Clinical Trial to Compare the Pharmacokinetics of DP-R208,COMPLETED,PHASE1,40.0,2015-01-01,2015-06-01,8.063576158940398,Adequate (1-10/month),80.63576158940397,Met (75-100%),100,53.2,56.665
NCT05078424,Cognitive Behavioural Therapy for Youths With Depressive and Anxiety Symptoms in Hong Kong,UNKNOWN,NA,128.0,2021-09-29,2024-04-30,4.127457627118645,Adequate (1-10/month),41.27457627118644,Significantly Below (<50%),50,45.2,30.830000000000002
NCT00671424,A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide,COMPLETED,PHASE1,48.0,2008-03-01,2008-05-01,23.9527868852459,Good (10-50/month),200.0,Exceeded (≥100%),100,58.8,69.89999999999999
NCT05095324,The Biomarker Prediction Model of Septic Risk in Infected Patients,UNKNOWN,,1000.0,2021-09-07,2022-09-14,81.82795698924731,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT06420024,ACT for Older Adults Who Hear Voices (HSCED),COMPLETED,NA,2.0,2023-08-02,2024-06-20,0.18848297213622292,Slow (<1/month),1.8848297213622294,Significantly Below (<50%),100,45.2,30.830000000000002
NCT03556124,Transcranial Direct Current Stimulation in Major Depression,COMPLETED,NA,66.0,2018-02-02,2020-05-31,2.3663604240282687,Adequate (1-10/month),23.663604240282687,Significantly Below (<50%),100,55.3,62.36000000000001
NCT07045324,Effect of Vagus Nerve Stimulation on Trapezius Trigger Point,ACTIVE_NOT_RECRUITING,NA,90.0,2025-01-15,2025-06-25,17.01614906832298,Good (10-50/month),170.1614906832298,Exceeded (≥100%),85,57.7,67.51
NCT00154024,Comparison of Vascular Effects After Therapy With Irbesartan and Atorvastatin.,COMPLETED,NA,,2003-03-01,2006-10-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,30.330000000000002
NCT04884724,"Adaptive Dance Exercise Program on Trunk Control, Balance and Functional Mobility in Cerebral Palsy",COMPLETED,NA,27.0,2021-05-20,2021-10-05,5.955652173913044,Adequate (1-10/month),59.55652173913043,Below (50-75%),100,52.2,53.22
NCT05829824,Tobacco Cessation Care for Cancer Patients by Automated Interactive Outreach,RECRUITING,NA,400.0,2023-11-27,2025-06-30,20.956970740103273,Good (10-50/month),200.0,Exceeded (≥100%),60,75.0,84.49
NCT01944124,Exercise and Technology to Reduce Risk in a Rural Population With Metabolic Syndrome,COMPLETED,NA,149.0,2009-11-01,2011-12-01,5.967842105263158,Adequate (1-10/month),59.67842105263158,Below (50-75%),100,61.9,74.265
NCT05295524,Description of the Short-term Effects of KAFTRIO® by Continuous Monitoring With the PHEAL-CR-K Application in Real Life in Patients With Cystic Fibrosis Eligible for KAFTRIO® Treatment,UNKNOWN,NA,50.0,2022-03-14,2023-03-01,4.323863636363637,Adequate (1-10/month),43.23863636363637,Significantly Below (<50%),50,39.0,20.505000000000003
NCT03301324,Intubation Assist Clinical Study,COMPLETED,,66.0,2017-09-12,2017-09-20,66.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,63.6,76.545
NCT02574624,Vitreous Surgery With Intraocular Assistance,TERMINATED,NA,5.0,2015-11-01,2017-09-01,0.22716417910447764,Slow (<1/month),2.271641791044776,Significantly Below (<50%),10,18.4,3.855
NCT02761824,Activity Based Program to Improve Quality of Life Outcomes in Women Diagnosed With Cancer,COMPLETED,NA,71.0,2012-06-01,2014-09-01,2.6292457420924573,Adequate (1-10/month),26.292457420924574,Significantly Below (<50%),100,55.7,63.09
NCT02361424,Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD),COMPLETED,PHASE2,47.0,2013-02-01,2015-06-01,1.6831529411764705,Adequate (1-10/month),16.831529411764706,Significantly Below (<50%),100,53.8,58.065
NCT00591123,Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia,COMPLETED,PHASE2,38.0,2007-12-01,2015-09-01,0.40859060402684566,Slow (<1/month),4.085906040268457,Significantly Below (<50%),100,48.0,42.945
NCT02030223,Transversus Abdominis Plane Block and Inguinal Hernia Repair,COMPLETED,NA,59.0,2014-01-01,2017-12-01,1.255916083916084,Adequate (1-10/month),12.55916083916084,Significantly Below (<50%),100,49.7,46.949999999999996
NCT06764823,Effect of Intracanal Cryotherapy on Postoperative Pain,COMPLETED,NA,60.0,2024-01-03,2025-01-20,4.768668407310705,Adequate (1-10/month),47.68668407310705,Significantly Below (<50%),100,54.8,61.095
NCT01098123,Metabolic Effects of Rowing Multi-races Events,COMPLETED,,45.0,2006-04-01,2006-04-01,45.0,Good (10-50/month),200.0,Exceeded (≥100%),100,41.9,24.585
NCT04961723,HCV Self-testing in Georgia,UNKNOWN,NA,1250.0,2021-12-10,2022-08-01,162.60683760683762,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT00887523,Trial Comparing Prone and Supine Intensity-modulated Radiotherapy (IMRT) After Breast-conserving Surgery in Patients With Large Breast Volume at High Risk for Skin Toxicity and Fibrosis,COMPLETED,NA,100.0,2009-07-01,2021-03-08,0.7132146204311153,Slow (<1/month),7.132146204311153,Significantly Below (<50%),100,53.0,55.80500000000001
NCT06255223,A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy,RECRUITING,PHASE2,35.0,2023-12-15,2026-09-01,1.0750756811301716,Adequate (1-10/month),10.750756811301718,Significantly Below (<50%),60,35.8,16.325
NCT04805723,Effects of Surgery Types in Patients With Pulmonary Nodules,COMPLETED,NA,27.0,2018-07-10,2020-01-01,1.522,Adequate (1-10/month),15.219999999999997,Significantly Below (<50%),100,47.2,40.035
NCT01038323,Drug and Talk Therapy for Fibromyalgia,COMPLETED,PHASE4,58.0,2009-12-01,2012-09-01,1.75673631840796,Adequate (1-10/month),17.5673631840796,Significantly Below (<50%),100,54.6,60.39
NCT02946723,A Study to Compare the Efficacy and Safety of Ultrasound Guided Lead Implantation for Sacral Neuromodulation (SNM) in Subjects With Overactive Bladder (OAB) With X-Ray Guided Technique,UNKNOWN,PHASE1,30.0,2017-02-01,2019-02-01,1.2509589041095892,Adequate (1-10/month),12.509589041095893,Significantly Below (<50%),50,32.4,12.025
NCT00645723,Intravenous Colistin Versus Intravenous Colistin Plus Nebulized Colistin in VAP Due MDR Acinetobacter Baumannii,UNKNOWN,PHASE3,67.0,2008-04-01,2011-04-01,1.8625388127853884,Adequate (1-10/month),18.625388127853885,Significantly Below (<50%),50,40.4,22.34
NCT02087423,A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer,COMPLETED,PHASE2,446.0,2014-02-25,2025-03-26,3.3546429453916478,Adequate (1-10/month),33.54642945391648,Significantly Below (<50%),100,85.7,91.47999999999999
NCT02097823,Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy,COMPLETED,PHASE2,15.0,2014-02-01,2015-03-01,1.1618320610687025,Adequate (1-10/month),11.618320610687023,Significantly Below (<50%),100,46.2,35.089999999999996
NCT04896723,Sexual Dysfunction in Patients With Chronic Liver Disease,UNKNOWN,,300.0,2021-06-01,2022-05-31,25.087912087912088,Good (10-50/month),200.0,Exceeded (≥100%),50,62.3,74.94
NCT04770623,Docetaxel and Irinotecan in Gastric Cancer,COMPLETED,PHASE2,32.0,2021-03-05,2023-01-09,1.4430814814814816,Adequate (1-10/month),14.430814814814816,Significantly Below (<50%),100,47.6,41.775
NCT06962423,AI-driven Automated Biomedical Research,NOT_YET_RECRUITING,NA,40.0,2025-05-15,2026-05-15,3.3358904109589043,Adequate (1-10/month),33.35890410958904,Significantly Below (<50%),30,32.2,11.635
NCT06502223,Impact of Gut Microbiota and Tryptophan Metabolites on Acute Pain in Lumbar Disc Herniation Surgery Patients,COMPLETED,,37.0,2022-01-12,2023-03-15,2.6376580796252926,Adequate (1-10/month),26.37658079625293,Significantly Below (<50%),100,51.3,50.62
NCT01705223,Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan),COMPLETED,PHASE2,150.0,2012-08-01,2015-01-01,5.1710079275198195,Adequate (1-10/month),51.7100792751982,Below (50-75%),100,62.0,74.42
NCT03946423,BAriaTric Surgery After Breast Cancer Treatment (BATS),NOT_YET_RECRUITING,NA,40.0,2026-06-01,2028-02-01,1.996065573770492,Adequate (1-10/month),19.960655737704922,Significantly Below (<50%),30,32.2,11.635
NCT05666323,Increasing Treatment for Obesity Among Underserved Populations,COMPLETED,NA,200.0,2022-03-23,2023-02-08,18.906832298136646,Good (10-50/month),189.06832298136646,Exceeded (≥100%),100,71.0,82.44
NCT04900623,Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study,RECRUITING,PHASE2,145.0,2021-07-02,2032-06-01,1.1070479056935039,Adequate (1-10/month),11.07047905693504,Significantly Below (<50%),60,44.6,29.42
NCT02927223,Atropine in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT),COMPLETED,NA,6.0,2016-10-01,2019-02-01,0.21411488862837047,Slow (<1/month),2.141148886283705,Significantly Below (<50%),100,45.5,31.705
NCT05914623,Effects of High-frequency Repetitive Transcranial Magnetic Stimulation on Cerebral Autoregulation in Patients With Cerebral Small Vessel Disease,RECRUITING,NA,80.0,2023-06-25,2024-07-01,6.5462365591397855,Adequate (1-10/month),65.46236559139786,Below (50-75%),60,44.4,28.95
NCT00609323,Lidocaine and Tetracaine Cream to Treat Postherpetic Neuralgia (PHN),COMPLETED,PHASE2,23.0,2008-01-01,2008-09-01,2.869344262295082,Adequate (1-10/month),28.693442622950815,Significantly Below (<50%),100,51.8,52.17
NCT05232123,Cannabidiol Effects on Cardiovascular System and Exercise Responses,WITHDRAWN,EARLY_PHASE1,0.0,2023-07-01,2024-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT03513523,Study to Assess the Relationship Between Daily Dosing of NRPT and Changes in Liver Fat in Healthy Volunteers,COMPLETED,NA,111.0,2018-04-18,2020-08-17,3.9657746478873244,Adequate (1-10/month),39.65774647887324,Significantly Below (<50%),100,58.9,70.10499999999999
NCT03158623,Wound Additives in Primary Total Joint Athroplasty,COMPLETED,PHASE3,90.0,2016-04-01,2016-12-20,10.416730038022814,Good (10-50/month),104.16730038022814,Exceeded (≥100%),100,62.2,74.74499999999999
NCT07276659,The Contribution of Scenario Writing to Learning Stoma Care in Nursing Education: A Mixed-Methods Quasi-Experimental Intervention Study,RECRUITING,NA,60.0,2025-10-27,2025-12-22,32.614285714285714,Good (10-50/month),200.0,Exceeded (≥100%),60,47.8,42.42
NCT04376359,The Effectiveness of Hyperbaric Oxygen Therapy on Pneumonia Complicating Stroke,UNKNOWN,NA,168.0,2021-06-01,2021-08-01,83.83475409836065,Excellent (>50/month),200.0,Exceeded (≥100%),50,58.4,69.175
NCT01554059,Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients,COMPLETED,PHASE2,25.0,2012-03-01,2014-08-01,0.8618346545866366,Slow (<1/month),8.618346545866364,Significantly Below (<50%),100,47.0,39.33
NCT06201559,Bioequivalence Study Between Two Albendazole 400 mg Tablets in Healthy Adult Participants Under Fed Conditions,COMPLETED,PHASE1,70.0,2023-08-21,2023-09-12,70.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,65.6,78.56
NCT04858659,A Phase 3 Study to Assess the Efficacy and Safety of PK101 in Patients With Knee Osteoarthritis,UNKNOWN,PHASE3,354.0,2021-05-20,2022-03-15,36.03933110367893,Good (10-50/month),200.0,Exceeded (≥100%),50,68.3,80.875
NCT05214859,Enhancing Mother-Child Ties and Psychosocial Wellness Through Arts Among Children With Intellectual Disability and Their Mothers,RECRUITING,NA,154.0,2022-07-09,2025-12-31,3.6882454760031473,Adequate (1-10/month),36.88245476003147,Significantly Below (<50%),60,50.3,48.215
NCT02952859,Impact of Margin-accentuation IRE in Pancreatic Cancer,TERMINATED,,26.0,2017-01-01,2020-02-25,0.6882086956521739,Slow (<1/month),6.882086956521739,Significantly Below (<50%),10,18.4,3.855
NCT03094559,Correlation Between FlowMet™ and Other Gold Standard Assessments in the Management of Critical Limb Ischemia (CLI),WITHDRAWN,NA,0.0,2017-03-07,2018-06-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT00161759,Safety and Efficacy Study of Fibrin Sealant (FS 4IU) for Skin Graft Fixation and Wound Healing in Subjects With Burn Wounds,COMPLETED,PHASE1,40.0,2002-03-01,2004-01-01,1.8146050670640836,Adequate (1-10/month),18.146050670640836,Significantly Below (<50%),100,53.2,56.665
NCT07106359,Initial Testing of a Behavioral Intervention About Genetic Services for Families at Risk of Lynch Syndrome,ENROLLING_BY_INVITATION,NA,185.0,2025-09-15,2027-08-01,8.22102189781022,Adequate (1-10/month),82.21021897810219,Met (75-100%),55,51.3,50.62
NCT05162859,Exercise Training in Heart Failure With Preserved Ejection Fraction - a Long-term Follow-up,COMPLETED,,74.0,2021-12-20,2022-08-19,9.30809917355372,Adequate (1-10/month),93.0809917355372,Met (75-100%),100,59.3,70.815
NCT05712759,Nosocomial Influenza Surveillance of 2022 - 2027 Seasonal Period,WITHDRAWN,,0.0,2025-03-09,2025-03-09,,Slow (<1/month),0.0,Significantly Below (<50%),5,8.2,0.03
NCT03154359,Atomoxetine PBPK-PD Clinical Study,COMPLETED,,51.0,2017-12-12,2022-06-16,0.9425865209471767,Slow (<1/month),9.425865209471766,Significantly Below (<50%),100,47.4,40.98
NCT02980159,Impact of a Triage Liaison Physician,COMPLETED,,69893.0,2016-11-01,2017-06-01,10035.579811320755,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT01667159,Community-Based Integrated Treatment for Adolescents,COMPLETED,PHASE1,114.0,2012-07-01,2017-12-01,1.7534916624557857,Adequate (1-10/month),17.534916624557855,Significantly Below (<50%),100,59.1,70.6
NCT02077959,Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma,TERMINATED,PHASE1,20.0,2014-03-03,2019-05-24,0.31907756813417193,Slow (<1/month),3.190775681341719,Significantly Below (<50%),10,19.6,5.365
NCT01652859,An Bioequivalence Study to Compare Two 2 mg/ml Liposomal Amphotericin B Injections in Healthy Subjects,COMPLETED,PHASE1,36.0,2012-02-01,2012-12-01,3.6047368421052632,Adequate (1-10/month),36.04736842105263,Significantly Below (<50%),100,52.9,55.55
NCT06479759,LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer,RECRUITING,PHASE2,50.0,2024-01-12,2025-12-12,2.1742857142857144,Adequate (1-10/month),21.74285714285714,Significantly Below (<50%),60,42.0,24.825
NCT00966680,How Fast Are we? Speed of General Versus Spinal Anesthesia for Emergency Cesarean Delivery: A Simulation Based Study,COMPLETED,,19.0,2009-09-01,2009-12-01,6.355604395604396,Adequate (1-10/month),63.55604395604395,Below (50-75%),100,49.9,47.425
NCT06034080,Interventions to De-implement Unnecessary Antibiotic Prescribing for Children With Ear Infections,RECRUITING,NA,1566.0,2025-02-03,2029-06-01,30.189385687143762,Good (10-50/month),200.0,Exceeded (≥100%),60,83.0,89.505
NCT05165680,Effect of Aerobic Exercise and Diet on Anthropometric and Hematological Measurements in Obese Anemic Women,UNKNOWN,NA,60.0,2021-07-03,2022-02-01,8.574647887323945,Adequate (1-10/month),85.74647887323944,Met (75-100%),50,44.8,29.845
NCT06427980,Efficacy and Safety of Chinese Herbal HuoXue LiShui Formula for Chronic Subdural Hematoma,NOT_YET_RECRUITING,NA,160.0,2025-02-01,2026-03-28,11.596190476190477,Good (10-50/month),115.96190476190478,Exceeded (≥100%),30,46.8,38.440000000000005
NCT02258880,"Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke",WITHDRAWN,PHASE2,0.0,2014-09-01,2016-05-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT07158580,Opti Gait Wearable Gait Tracker,NOT_YET_RECRUITING,,20.0,2026-02-01,2027-01-01,1.822754491017964,Adequate (1-10/month),18.227544910179642,Significantly Below (<50%),30,28.9,8.709999999999999
NCT01122680,Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma,COMPLETED,PHASE2,105.0,2010-05-01,,,Slow (<1/month),,Significantly Below (<50%),100,48.4,44.22
NCT00511680,Beat the Blues: Treating Depression in African American Elders,COMPLETED,PHASE3,192.0,2008-09-01,2012-06-01,4.269159970781593,Adequate (1-10/month),42.691599707815925,Significantly Below (<50%),100,65.4,78.415
NCT00687180,Mycophenolate vs Azathioprin in Autoimmune Hepatitis,COMPLETED,PHASE4,,,,,Slow (<1/month),,Significantly Below (<50%),100,40.0,21.87
NCT06346080,Molecular Analysis for Gastro-Esophageal Cancer: Multicenter Discrete Choice Experiment,RECRUITING,NA,2200.0,2024-08-01,2026-08-01,91.73698630136987,Excellent (>50/month),200.0,Exceeded (≥100%),60,88.0,92.495
NCT01958580,"Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery",TERMINATED,NA,3.0,2013-09-17,2017-02-24,0.07270700636942676,Slow (<1/month),0.7270700636942675,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT00633880,Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH),COMPLETED,PHASE3,181.0,2008-01-01,2009-09-01,9.047027914614121,Adequate (1-10/month),90.47027914614121,Met (75-100%),100,69.5,81.62
NCT01766180,Cerebrovascular and Cognitive Improvement by Resveratrol (resVida) and Fruitflow-II (CCIRF-II),UNKNOWN,NA,80.0,2013-01-01,2016-02-01,2.1626998223801066,Adequate (1-10/month),21.626998223801067,Significantly Below (<50%),50,41.4,24.04
NCT00031980,Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer,COMPLETED,PHASE2,30.0,2002-03-01,2005-05-01,0.7892826274848747,Slow (<1/month),7.892826274848747,Significantly Below (<50%),100,47.4,40.98
NCT03171480,Use of Nitrous Oxide Donor for Labor Induction in Women With PreEclampsia,COMPLETED,PHASE4,176.0,2017-10-30,2020-07-01,5.494810256410257,Adequate (1-10/month),54.94810256410258,Below (50-75%),100,64.1,77.12
NCT03661580,BA Trial for Co-Occurring Depression and Substance Use,COMPLETED,NA,34.0,2018-09-12,2020-09-30,1.3817890520694258,Adequate (1-10/month),13.81789052069426,Significantly Below (<50%),100,47.7,42.17
NCT00414180,Bupropion SR for Treating Smokeless Tobacco Use,COMPLETED,PHASE3,225.0,2003-08-01,2005-05-01,10.71830985915493,Good (10-50/month),107.18309859154931,Exceeded (≥100%),100,73.0,83.44
NCT02414880,Sugammadex Versus Neostigmine in Patients With Liver Cirrhosis Undergoing Liver Resection,COMPLETED,PHASE4,60.0,2014-12-01,2015-09-01,6.665693430656934,Adequate (1-10/month),66.65693430656934,Below (50-75%),100,54.8,61.095
NCT02820480,Design of an Affordable Gym for Post Stroke Rehabilitation,COMPLETED,,20.0,2015-11-01,2019-08-01,0.44470416362308257,Slow (<1/month),4.447041636230826,Significantly Below (<50%),100,44.9,30.025000000000002
NCT00523380,Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer,COMPLETED,PHASE2,10.0,2007-10-04,2009-01-07,0.6603036876355748,Slow (<1/month),6.603036876355748,Significantly Below (<50%),100,45.8,33.03
NCT00124280,Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC),COMPLETED,PHASE2,85.0,2005-07-01,,,Slow (<1/month),,Significantly Below (<50%),100,46.8,38.440000000000005
NCT04515680,Endocrine Function During Deferasirox Therapy,COMPLETED,,426.0,2016-11-02,2019-01-30,15.833260073260075,Good (10-50/month),158.33260073260072,Exceeded (≥100%),100,87.4,92.28
NCT00307879,Myocardial Regeneration and Angiogenesis in Myocardial Infarction With G-CSF and Intra-Coronary Stem Cell Infusion,TERMINATED,PHASE2,20.0,2004-03-01,2005-02-01,1.8065281899109793,Adequate (1-10/month),18.065281899109795,Significantly Below (<50%),10,24.6,6.959999999999999
NCT06350279,"A Phase I Study to Assess the Safety,Tolerability, PK, PD, and Food Effect of HSK39297 in Healthy Subjects",COMPLETED,PHASE1,96.0,2023-12-25,2024-09-29,10.473978494623656,Good (10-50/month),104.73978494623657,Exceeded (≥100%),100,62.7,75.42
NCT03413579,Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom,COMPLETED,PHASE3,37.0,2015-11-01,2021-02-01,0.5869098488796248,Slow (<1/month),5.869098488796248,Significantly Below (<50%),100,48.0,42.945
NCT04618679,Application of 18F-FDOPA PET in Research of the Association Between HCV Infection and Parkinson's Disease.,UNKNOWN,,100.0,2020-11-02,2021-06-30,12.683333333333334,Good (10-50/month),126.83333333333333,Exceeded (≥100%),50,46.3,35.66
NCT02987179,Identification of Desaturation Episodes by Means of Continuous Measurement of Oxygen Saturation During Hemodialysis,UNKNOWN,,30.0,2016-12-01,2017-12-01,2.5019178082191784,Adequate (1-10/month),25.019178082191786,Significantly Below (<50%),50,35.7,16.18
NCT00963079,Comparison of Transfers of Fresh and Thawed Embryos in High Responder Patients,COMPLETED,NA,100.0,2007-07-01,2010-07-01,2.7773722627737225,Adequate (1-10/month),27.773722627737225,Significantly Below (<50%),100,58.0,68.245
NCT06772779,"A Study of Enlicitide Decanoate (MK-0616), Warfarin, and Lisinopril in Healthy Adult Participants (MK-0616-026)",COMPLETED,PHASE1,36.0,2024-04-01,2024-06-04,17.1225,Good (10-50/month),171.225,Exceeded (≥100%),100,57.9,67.83
NCT00716079,The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial,COMPLETED,NA,2839.0,2008-09-01,2012-12-01,55.68244845360825,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT02831179,"Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor",WITHDRAWN,PHASE1,0.0,2017-12-01,2020-02-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT01455779,Lyrette: Renewing Continence Objective and Subjective Efficacy Study,UNKNOWN,NA,54.0,2011-09-01,2015-07-01,1.1749535382416012,Adequate (1-10/month),11.749535382416012,Significantly Below (<50%),50,34.3,14.39
NCT07296679,The Effect of Hand Massage on Anxiety and Comfort of Bariatric Surgery Patients: A Randomised Controlled Trial,COMPLETED,NA,90.0,2024-04-14,2025-11-20,4.683076923076924,Adequate (1-10/month),46.830769230769235,Significantly Below (<50%),100,57.2,66.465
NCT05633979,Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE1,17.0,2023-02-09,2032-12-31,0.14322723498477719,Slow (<1/month),1.4322723498477719,Significantly Below (<50%),85,41.9,24.585
NCT04886479,Comparing Silicone Hydrogel Contact Lens Wearers to Hydrogel Contact Lens Wearers and Non-lens Wearers,COMPLETED,NA,22.0,2019-03-06,2022-10-07,0.5108161708619375,Slow (<1/month),5.108161708619376,Significantly Below (<50%),100,46.8,38.440000000000005
NCT04400279,The COVID-19 Pandemic and Exercise Study,COMPLETED,NA,334.0,2020-06-01,2020-11-28,56.483111111111114,Excellent (>50/month),200.0,Exceeded (≥100%),100,86.7,92.035
NCT01446679,Special Drug Use-Results Survey of Lipitor Tablets,COMPLETED,,24050.0,2010-09-01,2012-03-01,1338.3583180987202,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT01267279,Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty,COMPLETED,PHASE4,51.0,2005-01-01,2014-12-01,0.4287323943661972,Slow (<1/month),4.287323943661972,Significantly Below (<50%),100,49.1,45.83
NCT06754579,Impact of High-Volume Upper Limb Training on Physical and Cognitive Outcomes,RECRUITING,NA,32.0,2025-01-01,2026-12-30,1.338021978021978,Adequate (1-10/month),13.380219780219779,Significantly Below (<50%),60,35.6,16.03
NCT04722679,A Study to Collect Information on the Characteristics of Elderly Belgian Patients With NVAF That Are Treated With a NOAC for This Indication With a Special Focus on Their Fear of Bleeding While Using a NOAC vs the Clinical Benefit of a NOAC of Thrombosis/Stroke Prevention.,COMPLETED,,103.0,2021-05-11,2022-01-03,13.229198312236289,Good (10-50/month),132.29198312236286,Exceeded (≥100%),100,61.6,74.0
NCT04768179,Safety & Efficacy of Low Dose Aspirin / Ivermectin Combination Therapy for Treatment of Covid-19 Patients,UNKNOWN,PHASE2,490.0,2021-02-19,2021-09-30,66.88609865470852,Excellent (>50/month),200.0,Exceeded (≥100%),50,84.2,90.685
NCT00248079,The Medtronic RESOLUTE Clinical Trial,COMPLETED,PHASE1,139.0,2005-11-01,2011-10-01,1.9588703703703703,Adequate (1-10/month),19.588703703703704,Significantly Below (<50%),100,61.1,73.31
NCT06771479,A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine,RECRUITING,PHASE1,120.0,2025-01-22,2026-05-30,7.4093306288032466,Adequate (1-10/month),74.09330628803245,Below (50-75%),60,47.6,41.775
NCT05445479,Retrospective Study for Identificatiopn of a Link Between Doxycycline and COVID-19 Treatment,WITHDRAWN,,0.0,2022-01-01,2026-01-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT03955796,Performance of a Hydrophilic and a Hydrophobic Intraocular Lens of Similar Design,WITHDRAWN,NA,0.0,2019-05-09,2021-08-03,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT05753696,Azilsartan in Patients With Diabetic Kidney Disease and Hypertension,UNKNOWN,NA,106.0,2023-04-01,2024-12-30,5.049514866979656,Adequate (1-10/month),50.49514866979656,Below (50-75%),50,43.5,27.400000000000002
NCT01237496,Analysis of HBV-Specific Immune Response in Patients With HBeAg Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a (40KD)) - Immunology Sub-Study of ML18253,COMPLETED,PHASE3,17.0,2005-07-01,2009-09-01,0.3397767564018385,Slow (<1/month),3.397767564018385,Significantly Below (<50%),100,46.4,36.26
NCT05541796,Clinical Outcomes Following Implantation of Tecnis Synergy and Symfony Intraocular Lens,COMPLETED,NA,26.0,2022-09-19,2023-12-31,1.6911111111111112,Adequate (1-10/month),16.91111111111111,Significantly Below (<50%),100,52.1,53.03
NCT02438696,"Relative Bioavailability of Two Newly Developed Tablet Formulations (TF2 and iFF)Compared to BI 1060469 TF1 Formulation, Following Oral Administration (Low and High Dose)in Healthy Female Subjects",COMPLETED,PHASE1,29.0,2015-05-01,2015-08-01,9.595217391304349,Adequate (1-10/month),95.95217391304348,Met (75-100%),100,57.3,66.74
NCT04726696,Clarification of Nurses' Expected Role in Health Promotion,UNKNOWN,NA,30.0,2021-02-21,2021-07-01,7.024615384615385,Adequate (1-10/month),70.24615384615383,Below (50-75%),50,37.4,18.62
NCT03173196,Prospective Analysis of Septic Associated Encephalopathy Using the Non-invasive Acoustocerebrography-ACG,COMPLETED,,20.0,2016-06-01,2017-07-30,1.4358490566037736,Adequate (1-10/month),14.358490566037737,Significantly Below (<50%),100,44.9,30.025000000000002
NCT01383096,Study To Investigate The Relative Bioavailability of OZ439 Formulations In Healthy Volunteers,COMPLETED,PHASE1,52.0,2012-04-01,2012-08-01,12.974426229508197,Good (10-50/month),129.74426229508197,Exceeded (≥100%),100,59.2,70.7
NCT06702696,Effect of Aronia Berry Consumption on Inflammatory Parameters,RECRUITING,NA,50.0,2024-11-15,2025-11-15,4.169863013698631,Adequate (1-10/month),41.6986301369863,Significantly Below (<50%),60,42.0,24.825
NCT06467396,Blood Biomarkers to Predict the Prognosis of a Stroke Patient Undergoing Mechanical Thrombectomy,RECRUITING,,400.0,2024-04-09,2025-07-01,27.17857142857143,Good (10-50/month),200.0,Exceeded (≥100%),60,73.3,83.61
NCT01628796,Ultrasound Examination and Guided Injection Into the Acromio-clavicular Joint,UNKNOWN,NA,30.0,2012-07-01,2013-01-01,4.96304347826087,Adequate (1-10/month),49.6304347826087,Significantly Below (<50%),50,37.4,18.62
NCT01410396,Occult Paroxysmal Atrial Fibrillation in Patients With Non-cardioembolic Ischemic Stroke of Determined Mechanism,COMPLETED,,49.0,2010-04-01,2013-05-01,1.3246536412078154,Adequate (1-10/month),13.246536412078152,Significantly Below (<50%),100,47.3,40.475
NCT06796296,Transanal Irrigation for Low Anterior Resection Syndrome,NOT_YET_RECRUITING,NA,94.0,2025-02-01,2029-12-31,1.5949609810479377,Adequate (1-10/month),15.949609810479377,Significantly Below (<50%),30,31.5,10.635
NCT03489096,Cryoballoon Targeting Atrial Fibrosis in Atrial Fibrillation,WITHDRAWN,NA,0.0,2019-10-01,2021-10-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT00903396,Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer,TERMINATED,PHASE2,7.0,2009-09-01,2013-05-01,0.1592526158445441,Slow (<1/month),1.5925261584454409,Significantly Below (<50%),10,18.6,4.25
NCT00609596,A Study To Compare 3 Different Formulations Of Tamsulosin At Steady State.,COMPLETED,PHASE1,24.0,2008-02-26,2008-04-23,12.81684210526316,Good (10-50/month),128.1684210526316,Exceeded (≥100%),100,56.9,65.89500000000001
NCT06802562,Medical Assistance in Dying Requests in Pain Clinic,COMPLETED,,100.0,2021-04-01,2025-01-23,2.185211773151472,Adequate (1-10/month),21.85211773151472,Significantly Below (<50%),100,56.3,64.5
NCT06890962,Citicoline Dose on Energy Drink Efficacy,COMPLETED,NA,34.0,2023-06-09,2023-12-01,5.914057142857143,Adequate (1-10/month),59.140571428571434,Below (50-75%),100,52.7,55.04
NCT05628662,Artificial Pancreas With Carbohydrate Suggestion for Patients With Type 1 Diabetes Prone to Hypoglycemia,COMPLETED,NA,12.0,2021-10-22,2022-04-06,2.2004819277108436,Adequate (1-10/month),22.004819277108435,Significantly Below (<50%),100,51.0,49.714999999999996
NCT04331262,Implementation of an Integrated Care Strategy for Children Contacts of Patients With Tuberculosis,COMPLETED,,163.0,2021-07-26,2023-07-31,6.750639455782314,Adequate (1-10/month),67.50639455782313,Below (50-75%),100,61.4,73.735
NCT04934462,Evaluation of Non-Surgical and Arthroscopic Treatment for Hip Microinstability,RECRUITING,NA,26.0,2021-11-26,2026-01-01,0.528684034736139,Slow (<1/month),5.28684034736139,Significantly Below (<50%),60,35.1,15.384999999999998
NCT05541562,A Practical Nomogram Based on Systemic Inflammatory Markers for Predicting Portal Vein Thrombosis in Patients With Liver Cirrhosis,COMPLETED,,478.0,2013-01-01,2021-01-01,4.979575633127995,Adequate (1-10/month),49.79575633127995,Significantly Below (<50%),100,86.6,92.015
NCT04432662,Darbepoetin in Neonatal Encephalopathy Trial,RECRUITING,PHASE2,150.0,2021-05-28,2024-09-01,3.8305369127516777,Adequate (1-10/month),38.305369127516784,Significantly Below (<50%),60,50.0,47.675
NCT03367962,Detection of Graft Versus Host Disease With [18F]F-AraG,COMPLETED,PHASE1,9.0,2018-05-15,2023-10-21,0.13801511335012595,Slow (<1/month),1.3801511335012593,Significantly Below (<50%),100,45.7,32.5
NCT00787462,Evaluation of Pregabalin in Idiopathic Small Fiber Neuropathy,TERMINATED,NA,3.0,2008-02-01,2013-02-01,0.04998357963875206,Slow (<1/month),0.4998357963875206,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT05067062,Intake Duration Effects of Blackcurrant on Cardiovascular and Metabolic Responses,COMPLETED,NA,15.0,2017-09-01,2018-09-01,1.2509589041095892,Adequate (1-10/month),12.509589041095893,Significantly Below (<50%),100,46.2,35.089999999999996
NCT01997762,Can Resveratrol Improve Insulin Sensitivity and Preserve Beta Cell Function Following Gestational Diabetes?,UNKNOWN,PHASE4,112.0,2014-05-01,2016-12-01,3.6077037037037036,Adequate (1-10/month),36.077037037037044,Significantly Below (<50%),50,44.0,28.249999999999996
NCT05860062,Vitamin D Supplementation in Episodic and Chronic Tension-type Headache,UNKNOWN,NA,20.0,2023-04-18,2023-12-20,2.4747967479674795,Adequate (1-10/month),24.7479674796748,Significantly Below (<50%),50,36.6,17.41
NCT03933462,A Study for the Assessment of the Benefits of a Novel Mesh Nebulizer in the Treatment of Patients With Stable COPD,COMPLETED,NA,21.0,2019-06-12,2019-10-28,4.632173913043478,Adequate (1-10/month),46.32173913043478,Significantly Below (<50%),100,51.7,51.94
NCT06503562,Chronic Nonspecific Neck Pain and Central Nervous System Focused Treatment Program,RECRUITING,NA,30.0,2024-07-10,2025-07-10,2.5019178082191784,Adequate (1-10/month),25.019178082191786,Significantly Below (<50%),60,40.4,22.34
NCT05033262,Our Care Wishes - Dementia,COMPLETED,NA,14.0,2020-10-07,2021-09-08,1.2683333333333333,Adequate (1-10/month),12.683333333333332,Significantly Below (<50%),100,46.1,34.695
NCT03143062,The National Early Warning Score: Preceding Dynamics in the Score for Those Who Suffer an In-hospital Cardiac Arrest,COMPLETED,,381.0,2017-09-30,2018-09-02,34.41436201780416,Good (10-50/month),200.0,Exceeded (≥100%),100,83.8,90.505
NCT03449862,Key Information Can Influence Clinician Ordering of Brain CTs,COMPLETED,NA,167.0,2016-08-31,2018-02-13,9.573408662900189,Adequate (1-10/month),95.73408662900188,Met (75-100%),100,68.4,80.97
NCT05899062,Telerehabilitation-based Exercise Training in Constipated Patients,COMPLETED,NA,32.0,2023-06-01,2024-05-27,2.6982825484764548,Adequate (1-10/month),26.982825484764543,Significantly Below (<50%),100,52.6,54.684999999999995
NCT04548362,Biomarkers of Meats and Potatoes Intake,COMPLETED,NA,12.0,2016-02-15,2016-05-30,3.478857142857143,Adequate (1-10/month),34.78857142857144,Significantly Below (<50%),100,51.0,49.714999999999996
NCT01685762,Metformin for the Treatment of Endometrial Hyperplasia,COMPLETED,EARLY_PHASE1,18.0,2013-01-10,2015-12-01,0.5193554502369668,Slow (<1/month),5.193554502369669,Significantly Below (<50%),100,46.4,36.26
NCT04480762,A Trial of SHR-1703 in Healthy Adults,COMPLETED,PHASE1,42.0,2020-08-04,2021-09-21,3.095593220338983,Adequate (1-10/month),30.95593220338983,Significantly Below (<50%),100,53.4,57.35
NCT00361062,Aggressive Behavior Induced by Selective Serotonin Reuptake Inhibitors (SSRIs) During the First Month of Treatment,COMPLETED,NA,60.0,2006-09-01,2012-03-01,0.9095617529880479,Slow (<1/month),9.095617529880478,Significantly Below (<50%),100,49.8,47.17
NCT02925962,Evaluation of an Electronic CKD Clinical Decision Support System (CDSS) in Clinical Care,COMPLETED,NA,542.0,2017-08-14,2020-06-30,15.697887725975262,Good (10-50/month),156.9788772597526,Exceeded (≥100%),100,95.0,95.7
NCT07297862,Virtual Reality Sickness Questionnaire: Psychometrics in Stroke Patients,ENROLLING_BY_INVITATION,,50.0,2025-07-16,2026-08-16,3.8434343434343434,Adequate (1-10/month),38.43434343434344,Significantly Below (<50%),55,38.8,20.244999999999997
NCT04842162,Study Evaluating Near-infrared Imaging Coupled With Indocyanine Green for Intraoperative Control of Resection Margins in ENT Surgery,RECRUITING,PHASE2,65.0,2020-12-15,2026-11-01,0.9215649743828599,Slow (<1/month),9.215649743828598,Significantly Below (<50%),60,38.2,19.645000000000003
NCT03392662,Hemopatch Performance Evaluation: A Prospective Observational Registry,COMPLETED,,621.0,2017-11-29,2019-01-28,44.47821176470588,Good (10-50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02707562,Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation),COMPLETED,PHASE2,26.0,2016-02-01,2016-11-01,2.8884671532846715,Adequate (1-10/month),28.884671532846717,Significantly Below (<50%),100,52.1,53.03
NCT02478762,Glycemic Objectives of Women With Gestational Diabetes Mellitus,TERMINATED,PHASE3,5.0,2015-03-01,2016-12-01,0.23744149765990638,Slow (<1/month),2.3744149765990636,Significantly Below (<50%),10,18.4,3.855
NCT01454362,Effect of the Electronic Cigarette on Withdrawal Symptoms,COMPLETED,NA,51.0,2013-01-01,2013-03-01,26.312542372881357,Good (10-50/month),200.0,Exceeded (≥100%),100,59.1,70.6
NCT00000262,Effects of Combined Sevoflurane and Nitrous Oxide Inhalation - 14,COMPLETED,NA,20.0,1996-11-01,1999-02-01,0.740632603406326,Slow (<1/month),7.4063260340632615,Significantly Below (<50%),100,46.6,37.375
NCT02634762,Acute Congestive Heart Failure Urgent Care Evaluation,COMPLETED,,1983.0,2011-01-01,2017-12-01,23.896484560570073,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT06023862,A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study),RECRUITING,PHASE2,198.0,2024-01-22,2029-12-31,2.77747465437788,Adequate (1-10/month),27.774746543778804,Significantly Below (<50%),60,53.8,58.065
NCT04683562,Netrin-1 and Placenta Accreta,COMPLETED,NA,34.0,2021-12-01,2022-06-01,5.686593406593407,Adequate (1-10/month),56.86593406593406,Below (50-75%),100,52.7,55.04
NCT02213562,Effect of Chrysanthemum Flower Oil and Its Dose-dependency on Hyperuricemia,COMPLETED,NA,21.0,2014-07-01,2016-03-01,1.049655172413793,Adequate (1-10/month),10.49655172413793,Significantly Below (<50%),100,46.7,37.895
NCT02457962,Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study,ACTIVE_NOT_RECRUITING,,14266.0,2015-04-23,2026-04-01,108.67293293293294,Excellent (>50/month),200.0,Exceeded (≥100%),85,93.8,94.80499999999999
NCT05904262,Peripheral Protective Sensation in Type 2 Diabetes Mellitus,COMPLETED,,42.0,2023-06-06,2023-07-25,26.091428571428573,Good (10-50/month),200.0,Exceeded (≥100%),100,56.7,65.53
NCT03308162,The Kickstart Health Program,COMPLETED,NA,22.0,2017-10-10,2018-08-31,2.060553846153846,Adequate (1-10/month),20.605538461538465,Significantly Below (<50%),100,51.8,52.17
NCT01077362,A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents,COMPLETED,PHASE3,312.0,2010-03-01,2012-11-01,9.730819672131148,Adequate (1-10/month),97.30819672131148,Met (75-100%),100,80.0,87.67
NCT03578562,Targeted Exercise and Changes in Femoroacetabular Impingement in Symptomatic Patients With Acetabular Retroversion,COMPLETED,NA,42.0,2018-11-08,2019-12-17,3.1645544554455447,Adequate (1-10/month),31.64554455445545,Significantly Below (<50%),100,53.4,57.35
NCT02468362,Long Term Outcomes After Laparoscopic Intersphincteric Resection With Total Mesorectal Excision for Low Rectal Cancer.,UNKNOWN,PHASE2,112.0,2014-04-01,2019-10-01,1.6970034843205577,Adequate (1-10/month),16.97003484320558,Significantly Below (<50%),50,44.0,28.249999999999996
NCT06642662,Precision Medicine in the CICU: Identifying Proteomic Biomarkers,NOT_YET_RECRUITING,,60.0,2025-04-15,2027-04-15,2.5019178082191784,Adequate (1-10/month),25.019178082191786,Significantly Below (<50%),30,32.1,11.5
NCT02023762,Deep Sedation Instead of General Anaesthesia in Percutaneous Mitral Valve Repair Using the MitraClip® System,COMPLETED,,21.0,2012-01-01,2013-12-01,0.9132,Slow (<1/month),9.132,Significantly Below (<50%),100,45.0,30.330000000000002
NCT00042562,Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression,COMPLETED,PHASE3,,2002-12-01,2003-12-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,30.330000000000002
NCT05515146,Lymphovascular Abnormalities Under Tattoos,COMPLETED,,19.0,2021-12-01,2022-01-31,9.481311475409836,Adequate (1-10/month),94.81311475409835,Met (75-100%),100,54.9,61.55500000000001
NCT05296746,Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer,RECRUITING,PHASE2,1100.0,2022-05-03,2031-12-01,9.569591311803373,Adequate (1-10/month),95.69591311803374,Met (75-100%),60,83.0,89.505
NCT04943146,An Assessment of Aspirin Plus Prednisone Treatment for Euthyroid Women With Thyroid Autoimmunity,UNKNOWN,,402.0,2021-03-01,2022-03-01,33.525698630136986,Good (10-50/month),200.0,Exceeded (≥100%),50,70.5,82.19999999999999
NCT03998046,Coordinating Pragmatic Primary Care Population Management for Obesity,COMPLETED,NA,80.0,2019-12-16,2021-06-30,4.333096085409253,Adequate (1-10/month),43.330960854092524,Significantly Below (<50%),100,56.4,64.88000000000001
NCT04193046,A Study for the Identification of Biomarker Signatures for Early Detection of Pulmonary Hypertension (PH),COMPLETED,EARLY_PHASE1,907.0,2019-12-16,2022-02-18,34.728402515723275,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT04746846,SCH: Context-aware Freezing of Gait Mitigation in Real-world Setting,COMPLETED,,12.0,2021-06-11,2025-03-10,0.26701754385964915,Slow (<1/month),2.6701754385964915,Significantly Below (<50%),100,44.3,28.715000000000003
NCT02909946,Pathway From Functional Disability to Antimicrobial Resistance in Nursing Home Residents,COMPLETED,NA,246.0,2016-09-15,2018-08-29,10.502440392706871,Good (10-50/month),105.02440392706873,Exceeded (≥100%),100,74.7,84.33500000000001
NCT03095846,Cold Induced Activation of Brown Adipose Tissue in Winter Swimmers,COMPLETED,NA,15.0,2017-04-02,2018-03-01,1.3711711711711714,Adequate (1-10/month),13.711711711711713,Significantly Below (<50%),100,46.2,35.089999999999996
NCT00006246,Busulfan in Treating Children and Adolescents With Refractory CNS Cancer,COMPLETED,PHASE1,28.0,2000-11-01,,,Slow (<1/month),,Significantly Below (<50%),100,42.2,25.155
NCT01890746,A Safety and Efficacy Study of Eltrombopag in Subjects With AML,COMPLETED,PHASE2,148.0,2013-09-05,2017-01-25,3.6390306946688207,Adequate (1-10/month),36.39030694668821,Significantly Below (<50%),100,61.8,74.19
NCT03877146,Calming Alternatives Learned During MRI-Guided Breast Biopsy,COMPLETED,NA,58.0,2018-10-16,2019-06-20,7.147854251012146,Adequate (1-10/month),71.47854251012146,Below (50-75%),100,54.6,60.39
NCT05972746,Telemonitoring Program in the Vulnerable Phase After Hospitalization for Heart Failure,UNKNOWN,NA,110.0,2022-10-07,2023-11-07,8.455555555555556,Adequate (1-10/month),84.55555555555556,Met (75-100%),50,48.8,45.184999999999995
NCT01326546,Therapeutic Hepatitis B Vaccine (Mimogen-based) Joint Entecavir in Treating Chronic Hepatitis B Patients,COMPLETED,PHASE2,378.0,2010-06-01,2014-01-01,8.78345038167939,Adequate (1-10/month),87.8345038167939,Met (75-100%),100,85.2,91.315
NCT05504746,A Phase I Study of SHEN26 Capsule in Healthy Participants,COMPLETED,PHASE1,86.0,2022-08-08,2022-12-11,20.942719999999998,Good (10-50/month),200.0,Exceeded (≥100%),100,61.9,74.265
NCT00446446,PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer),COMPLETED,PHASE2,52.0,2007-10-30,2017-11-29,0.429780070594624,Slow (<1/month),4.29780070594624,Significantly Below (<50%),100,49.2,46.035
NCT05343546,Ideal Timing of Intrauterine Contraception Insertion After Medical Management of First Trimester Incomplete Abortion,UNKNOWN,NA,2076.0,2022-06-01,2025-06-01,57.65824817518248,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT04007146,Systematic Calculation of HyperOxygenation Transit Time,TERMINATED,NA,1.0,2020-03-01,2021-09-01,0.05544626593806922,Slow (<1/month),0.5544626593806923,Significantly Below (<50%),10,18.1,3.105
NCT04622046,A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM,COMPLETED,PHASE3,25.0,2020-11-13,2025-08-21,0.43685419058553393,Slow (<1/month),4.36854190585534,Significantly Below (<50%),100,47.0,39.33
NCT04653246,"Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM",ACTIVE_NOT_RECRUITING,PHASE2,52.0,2021-07-13,2029-01-13,0.5774826705581905,Slow (<1/month),5.774826705581904,Significantly Below (<50%),85,44.7,29.67
NCT05029388,Aerobic Exercise and High-Intensity Interval Training,COMPLETED,NA,78.0,2022-10-03,2024-01-31,4.895505154639175,Adequate (1-10/month),48.95505154639175,Significantly Below (<50%),100,56.2,64.21
NCT01034488,"Pharmacodynamics Aspects Of Porcine Heparin Sodium, Produced by Eurofarma, Compared Heparin Sodium, Produced by APP Pharmaceuticasls, in Patients With Chronic Renal Failure",UNKNOWN,PHASE2,128.0,2010-08-01,2012-02-01,7.09712204007286,Adequate (1-10/month),70.97122040072861,Below (50-75%),50,45.2,30.830000000000002
NCT02470988,Does Disciplined Personal Involvement Precede Change in CBASP?,COMPLETED,NA,13.0,2015-06-01,2016-12-01,0.7208014571949,Slow (<1/month),7.208014571949,Significantly Below (<50%),100,46.0,34.1
NCT00511888,Nebivolol Versus Carvedilol in Patients With Heart Failure,TERMINATED,,160.0,2004-01-01,2007-06-01,3.9056936647955096,Adequate (1-10/month),39.0569366479551,Significantly Below (<50%),10,34.1,14.19
NCT00029588,Reward-Related Processes and Brain Function,COMPLETED,,241.0,2002-01-11,2017-07-24,1.293150008813679,Adequate (1-10/month),12.93150008813679,Significantly Below (<50%),100,62.6,75.325
NCT02382588,Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for the Treatment of Herpes Zoster Keratitis,TERMINATED,PHASE2,8.0,2013-12-10,2020-05-11,0.10389078498293516,Slow (<1/month),1.0389078498293518,Significantly Below (<50%),10,18.6,4.25
NCT01762488,Renal Denervation in Treatment Resistant Hypertension,TERMINATED,PHASE3,8.0,2013-01-01,,,Slow (<1/month),,Significantly Below (<50%),10,13.6,0.8200000000000001
NCT06684288,Efficacy of Access Flap Surgery on Subgingival Peridontopatgogens in Individuals With Periodontitis,COMPLETED,NA,20.0,2021-05-21,2022-02-05,2.3415384615384616,Adequate (1-10/month),23.415384615384614,Significantly Below (<50%),100,51.6,51.644999999999996
NCT03340688,Cerclage for Twins With Short Cervical Length ≤ 15mm,UNKNOWN,NA,200.0,2017-06-22,2025-06-01,2.098586694243364,Adequate (1-10/month),20.985866942433642,Significantly Below (<50%),50,51.0,49.714999999999996
NCT04807088,Effect of Tactile-Kinesthetic Stimulation on Preterm Neonates,COMPLETED,NA,126.0,2015-08-01,2017-07-14,5.37929873772791,Adequate (1-10/month),53.7929873772791,Below (50-75%),100,60.1,72.085
NCT06885788,"Uterine Round Ligament Preservation Vs Resection in Laparoscopic Inguinal Hernia Repair in Women：A Multicenter,Stratified Randomized Controlled Trial",RECRUITING,NA,466.0,2024-09-20,2027-03-01,15.902511210762333,Good (10-50/month),159.0251121076233,Exceeded (≥100%),60,80.3,88.075
NCT03001388,Longitudinal Assessment of Transient Elastography in Cystic Fibrosis,COMPLETED,,141.0,2017-03-08,2023-05-09,1.9050332889480694,Adequate (1-10/month),19.050332889480696,Significantly Below (<50%),100,59.6,71.17999999999999
NCT01324388,A Study of the Effect of LY2189265 on Two Blood Pressure Drugs,COMPLETED,PHASE1,51.0,2011-03-01,2011-08-01,10.146666666666667,Good (10-50/month),101.46666666666665,Exceeded (≥100%),100,59.1,70.6
NCT05320588,A Study in Patients With Advanced Cancers,RECRUITING,PHASE1,332.0,2022-03-25,2027-04-01,5.51340971085652,Adequate (1-10/month),55.13409710856519,Below (50-75%),60,64.6,77.59
NCT06832488,"Food Texture, Eating Rate and Food Intake in Care Home Older Adults.",COMPLETED,NA,30.0,2025-07-29,2025-09-25,15.744827586206897,Good (10-50/month),157.44827586206895,Exceeded (≥100%),100,57.4,67.05499999999999
NCT00060788,Antisocial Behavior: Passing From Parent to Child to Grandchild,UNKNOWN,,663.0,2001-09-01,2005-12-01,13.00368556701031,Good (10-50/month),130.0368556701031,Exceeded (≥100%),50,78.3,86.48
NCT03085888,The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types,COMPLETED,,99481.0,2017-02-28,2024-04-01,1169.6414213982234,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT03239288,"A Randomized, Controlled, Crossover Study to Assess the Glucose and Insulin Excursions of a Test Fiber",COMPLETED,NA,22.0,2017-06-22,2017-07-28,18.60222222222222,Good (10-50/month),186.0222222222222,Exceeded (≥100%),100,56.8,65.69500000000001
NCT03929588,Study of a Hand-held Device Plus Mobile App Versus Standard Eye Care Devices in Measuring Refractive Error of the Eye,COMPLETED,NA,230.0,2019-05-07,2020-03-31,21.280243161094226,Good (10-50/month),200.0,Exceeded (≥100%),100,73.4,83.7
NCT05035888,Prophylactic Norepinephrine and Phenylephrine Boluses for Postspinal Anesthesia Hypotension,COMPLETED,NA,80.0,2022-09-05,2023-01-03,20.293333333333333,Good (10-50/month),200.0,Exceeded (≥100%),100,61.4,73.735
NCT01862588,Renal Resistive Index and Cardiac Output Changes During Resuscitation Predict the Occurrence of Acute Kidney Injury in Septic Shock Patients,UNKNOWN,,40.0,2013-01-01,2014-01-01,3.3358904109589043,Adequate (1-10/month),33.35890410958904,Significantly Below (<50%),50,36.5,17.285
NCT01234688,Effects of Aerobic Training in End Stage Renal Disease Patients,COMPLETED,NA,28.0,2008-06-01,2010-06-01,1.1675616438356167,Adequate (1-10/month),11.675616438356165,Significantly Below (<50%),100,47.2,40.035
NCT04414488,The Impact of Regional Anaesthesia on Hormone Levels in Thoracic Surgery.,COMPLETED,,119.0,2018-05-01,2019-12-01,6.256234887737478,Adequate (1-10/month),62.56234887737479,Below (50-75%),100,57.9,67.83
NCT00487188,A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience,COMPLETED,PHASE4,47.0,2005-11-01,2008-04-01,1.6220861678004534,Adequate (1-10/month),16.220861678004535,Significantly Below (<50%),100,48.8,45.184999999999995
NCT01789788,"A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes Mellitus",COMPLETED,PHASE1,56.0,2013-03-01,2013-09-01,9.264347826086956,Adequate (1-10/month),92.64347826086957,Met (75-100%),100,59.5,71.0
NCT06447688,The Role of Verapamil in Radial Artery Spasm,COMPLETED,PHASE4,150.0,2024-06-05,2024-11-15,28.012269938650306,Good (10-50/month),200.0,Exceeded (≥100%),100,67.0,79.725
NCT05969288,Low Back Pain and Osteopathy in Italian Young People,RECRUITING,,30.0,2023-09-01,2024-06-30,3.0138613861386143,Adequate (1-10/month),30.138613861386137,Significantly Below (<50%),60,38.7,20.145
NCT06473103,Investigation of Standard Excision Surgical Margins Using Two Photon Fluorescence Microscopy,RECRUITING,NA,52.0,2024-10-29,2026-04-01,3.049865125240848,Adequate (1-10/month),30.498651252408482,Significantly Below (<50%),60,42.2,25.155
NCT04485403,The Effect of Ibuprofen on Women With PCOS.,UNKNOWN,PHASE2,20.0,2019-09-01,2021-12-01,0.740632603406326,Slow (<1/month),7.4063260340632615,Significantly Below (<50%),50,31.6,10.905
NCT00486603,"Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme",COMPLETED,PHASE1,92.0,2007-10-29,2014-01-01,1.2413475177304965,Adequate (1-10/month),12.413475177304964,Significantly Below (<50%),100,52.4,53.949999999999996
NCT02479503,Antibiotic Prophylaxis in Adult Heart Transplantation: a French National Survey,COMPLETED,,21.0,2015-03-01,2015-07-01,5.2396721311475405,Adequate (1-10/month),52.3967213114754,Below (50-75%),100,50.0,47.675
NCT04134403,"Steroids, Thiamine and Ascorbic Acid in Septic Shock",UNKNOWN,PHASE3,80.0,2019-12-01,2020-12-01,6.6535519125683065,Adequate (1-10/month),66.53551912568307,Below (50-75%),50,41.4,24.04
NCT04164303,Conservative Management of DeQuervain's Tendinopathy With an Orthopaedic Manual Therapy Approach Emphasizing First CMC Manipulation: A Retrospective Case Series,COMPLETED,,3.0,2016-07-01,2017-12-31,0.16664233576642334,Slow (<1/month),1.6664233576642336,Significantly Below (<50%),100,43.6,27.54
NCT06386003,Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD,NOT_YET_RECRUITING,PHASE2,15.0,2026-03-01,2027-01-01,1.492156862745098,Adequate (1-10/month),14.921568627450982,Significantly Below (<50%),30,25.2,7.359999999999999
NCT04484103,RPCRC Validation Study,UNKNOWN,,275.0,2020-01-01,2020-09-01,34.307377049180324,Good (10-50/month),200.0,Exceeded (≥100%),50,60.3,72.34
NCT05344703,Is Y-Balance Test Predictive of Concussion,UNKNOWN,NA,1000.0,2022-05-04,2025-12-31,22.767389678384443,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT04762303,Spread and Scale of a Polypharmacy App,UNKNOWN,NA,1000.0,2021-08-01,2022-10-31,66.75438596491229,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT02457403,Comparison of Blood Product Use and Bleeding Events During and After Endoscopic or Neurosurgical Procedures in Patients With Cirrhosis and Coagulopathy,COMPLETED,NA,68.0,2015-05-01,2018-11-30,1.5812987012987012,Adequate (1-10/month),15.812987012987012,Significantly Below (<50%),100,50.4,48.355
NCT06903403,Comparing Front-of-package Nutrient Labels,COMPLETED,NA,15582.0,2025-04-01,2025-04-25,15582.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT00698503,A Clinical Investigation of the M2a- 38™ Hip System,TERMINATED,,190.0,2002-01-01,2008-12-01,2.2896278701504356,Adequate (1-10/month),22.896278701504357,Significantly Below (<50%),10,36.5,17.285
NCT01157403,Autologous Transplantation of Mesenchymal Stem Cells for Treatment of Patients With Onset of Type 1 Diabetes,UNKNOWN,PHASE2,80.0,2010-07-01,2014-08-01,1.632171581769437,Adequate (1-10/month),16.321715817694372,Significantly Below (<50%),50,36.4,17.14
NCT02915003,A Partnership Approach to Enhance Health Care Literacy,COMPLETED,NA,248.0,2016-09-20,2017-12-01,17.27487414187643,Good (10-50/month),172.7487414187643,Exceeded (≥100%),100,74.8,84.385
NCT06922903,Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.,NOT_YET_RECRUITING,PHASE3,240.0,2025-04-01,2026-05-01,18.495189873417722,Good (10-50/month),184.9518987341772,Exceeded (≥100%),30,53.2,56.665
NCT02144103,Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration,UNKNOWN,PHASE1,16.0,2014-05-01,2019-01-01,0.2854865181711606,Slow (<1/month),2.8548651817116064,Significantly Below (<50%),50,31.3,10.299999999999999
NCT05490303,HeartGuide: Preliminary Study,UNKNOWN,NA,90.0,2022-09-09,2023-01-01,24.031578947368423,Good (10-50/month),200.0,Exceeded (≥100%),50,47.2,40.035
NCT00311103,Disability of Musculoskeletal Origin in Community-dwelling Elderly,COMPLETED,NA,214.0,2005-10-01,2008-05-01,6.9079109225874875,Adequate (1-10/month),69.07910922587487,Below (50-75%),100,67.1,79.86999999999999
NCT02296203,"Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).",UNKNOWN,PHASE2,27.0,2014-10-01,2018-06-15,0.6074501108647451,Slow (<1/month),6.07450110864745,Significantly Below (<50%),50,32.2,11.635
NCT01867203,Functional and Clinical Impact of CYP3A Genetic Polymorphisms on Statin Therapy,WITHDRAWN,,0.0,2017-08-01,2019-09-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT06451003,Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery,RECRUITING,NA,30.0,2024-07-01,2026-12-31,1.0002190580503834,Adequate (1-10/month),10.002190580503836,Significantly Below (<50%),60,35.4,15.765
NCT07205003,Evaluation of the Link Between Carotid Arterial Wall Viscosity and Major Neurocognitive Disorders,RECRUITING,,140.0,2022-02-15,2026-09-18,2.54272076372315,Adequate (1-10/month),25.427207637231504,Significantly Below (<50%),60,47.5,41.415
NCT06087003,Pediatric Induction Therapy in Kidney Transplantation,COMPLETED,,958.0,2013-03-03,2023-09-30,7.548930882733627,Adequate (1-10/month),75.48930882733626,Met (75-100%),100,88.3,92.705
NCT03727503,Casptesia Versus PICCO in Cardiac Surgical Patients in the ICU,TERMINATED,NA,60.0,2019-03-27,2020-01-01,6.522857142857143,Adequate (1-10/month),65.22857142857143,Below (50-75%),10,27.8,8.32
NCT03190603,Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis,COMPLETED,PHASE4,12.0,2018-06-01,2018-06-05,12.0,Good (10-50/month),120.0,Exceeded (≥100%),100,61.0,73.17
NCT05812703,Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain,NOT_YET_RECRUITING,,50.0,2024-09-27,2026-04-25,2.6469565217391304,Adequate (1-10/month),26.469565217391306,Significantly Below (<50%),30,31.3,10.299999999999999
NCT04577703,First-In-Human Phase I Trial of Ningetinib ( CT053PTSA ) in the Patients With Advanced Solid Tumors,COMPLETED,PHASE1,20.0,2014-02-08,2015-12-10,0.9086567164179106,Slow (<1/month),9.086567164179105,Significantly Below (<50%),100,46.6,37.375
NCT04491903,REBOA for Out-of-hospital Cardiac Arrest,WITHDRAWN,NA,0.0,2020-11-30,2020-11-30,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT01626703,Effect of Depressin Screening and Care Program at Community Health Center,COMPLETED,NA,86.0,2012-06-01,2013-03-01,9.58915750915751,Adequate (1-10/month),95.8915750915751,Met (75-100%),100,61.9,74.265
NCT03718403,Effect of Theophylline in Pseudohypoparathyroidism,RECRUITING,PHASE4,100.0,2019-11-11,2032-04-10,0.6713718570798412,Slow (<1/month),6.713718570798412,Significantly Below (<50%),60,41.0,23.01
NCT06866327,Music for the Mind Study,RECRUITING,NA,18.0,2025-02-24,2025-12-31,1.7674838709677418,Adequate (1-10/month),17.67483870967742,Significantly Below (<50%),60,39.4,20.94
NCT07200427,MELIORA Virtual Coach Intervention for Breast Cancer Prevention,NOT_YET_RECRUITING,NA,2080.0,2025-12-01,2027-04-01,130.27818930041153,Excellent (>50/month),200.0,Exceeded (≥100%),30,79.0,86.96000000000001
NCT04062227,Mindfulness Based Dementia Care Study,COMPLETED,,26.0,2019-01-25,2023-03-02,0.528684034736139,Slow (<1/month),5.28684034736139,Significantly Below (<50%),100,45.4,31.455
NCT07271927,Whole-Body Photobiomodulation for Motor and Cognitive Changes in Parkinson's Disease,RECRUITING,NA,15.0,2025-02-12,2025-12-31,1.4180124223602484,Adequate (1-10/month),14.180124223602483,Significantly Below (<50%),60,34.2,14.305000000000001
NCT00574327,Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry,RECRUITING,,3000.0,2006-01-01,2029-01-01,10.87013450779669,Good (10-50/month),108.70134507796692,Exceeded (≥100%),60,81.3,88.58
NCT03993327,An Imaging Agent (I-124 M5A) in Detecting CEA-Positive Liver Metastases in Patients With Colorectal Cancer,COMPLETED,PHASE1,4.0,2020-07-15,2024-06-04,0.08574647887323944,Slow (<1/month),0.8574647887323945,Significantly Below (<50%),100,45.3,31.169999999999998
NCT02507427,Monitoring and Mapping of Erectile Nerve During RALP (MMEN Study),COMPLETED,PHASE1,30.0,2015-07-26,2018-03-19,0.9443640124095141,Slow (<1/month),9.443640124095142,Significantly Below (<50%),100,47.4,40.98
NCT03447327,Outcome of Single Burr Hole Under Local Anaesthesia in the Management of Chronic Subdural Hematoma,COMPLETED,NA,67.0,2014-03-05,2015-08-28,3.7698336414048064,Adequate (1-10/month),37.698336414048065,Significantly Below (<50%),100,55.4,62.56
NCT06025227,Provide Pre-approval Single Patient Expanded Access (Compassionate Use) of Etrasimod for Patients.,AVAILABLE,,,,,,Slow (<1/month),,Significantly Below (<50%),50,23.3,6.569999999999999
NCT07089927,"Virtual Art Therapy Assisted Re-Integration to Improve Biopsychosocial Outcomes in Adolescent and Young Adult Cancer Survivors, AVATARS Trial",RECRUITING,NA,20.0,2025-07-02,2026-07-15,1.6105820105820106,Adequate (1-10/month),16.105820105820108,Significantly Below (<50%),60,34.6,14.729999999999999
NCT00983827,"Aquatic Treadmill Therapy for Improving Gait, Balance, Fitness and Quality of Life in Stroke Patients",COMPLETED,NA,9.0,2008-05-01,2011-05-01,0.25019178082191784,Slow (<1/month),2.5019178082191784,Significantly Below (<50%),100,45.7,32.5
NCT04522427,Study of Presbyopia-correcting Intraocular Lenses in Eyes With Previous Corneal Refractive Surgery,UNKNOWN,NA,114.0,2020-09-01,2022-08-31,4.760164609053498,Adequate (1-10/month),47.60164609053498,Significantly Below (<50%),50,44.1,28.425
NCT04844827,Pleural Carcinomatosis Tissue Banking,RECRUITING,,100.0,2022-11-17,2025-11-17,2.7773722627737225,Adequate (1-10/month),27.773722627737225,Significantly Below (<50%),60,44.3,28.715000000000003
NCT03319927,Reducing Pesticide Exposures in Child Care Centers,COMPLETED,NA,440.0,2017-10-09,2024-08-01,5.383279742765274,Adequate (1-10/month),53.832797427652736,Below (50-75%),100,85.2,91.315
NCT04040127,Residual Dental Pulp Tissue and Cord Blood Stem Cells,WITHDRAWN,PHASE2,0.0,2019-09-01,2020-02-28,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT05884827,Peroneal Nerve Dysfunction in Epiphyseal Transfer,RECRUITING,,15.0,2023-06-01,2024-09-01,0.9969432314410481,Slow (<1/month),9.969432314410481,Significantly Below (<50%),60,32.5,12.235
NCT04961827,A Self-efficacy Based Dietary Intervention,TERMINATED,NA,68.0,2021-07-29,2022-12-22,4.050724070450098,Adequate (1-10/month),40.50724070450098,Significantly Below (<50%),10,28.4,8.52
NCT07377227,Social COgnition Screening,NOT_YET_RECRUITING,NA,128.0,2026-02-01,2028-12-01,3.7682011605415866,Adequate (1-10/month),37.682011605415866,Significantly Below (<50%),30,39.2,20.715
NCT06088927,Long-term Outcomes of Conduction System Pacing: a National Multicenter Observational Study - NORMAND'HIS / STIMU'HIS,RECRUITING,,2500.0,2023-03-01,2028-03-31,40.98007539041465,Good (10-50/month),200.0,Exceeded (≥100%),60,81.3,88.58
NCT00424827,A Trial of Chemo & Radiation Therapy for Pancreatic Cancer,COMPLETED,PHASE2,11.0,2006-06-01,2014-12-01,0.1078389694041868,Slow (<1/month),1.078389694041868,Significantly Below (<50%),100,45.9,33.495000000000005
NCT00778427,Bioequivalence Study of Metformin Hydrochloride 1000mg Tablets Under Fasting Conditions,COMPLETED,NA,32.0,2006-02-01,2006-04-01,16.50983050847458,Good (10-50/month),165.09830508474576,Exceeded (≥100%),100,57.6,67.36999999999999
NCT04990427,CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM),COMPLETED,PHASE1,6.0,2022-01-10,2023-01-26,0.4793700787401575,Slow (<1/month),4.793700787401575,Significantly Below (<50%),100,45.5,31.705
NCT03968627,Development of a National Protocol for Stroke Rehabilitation in a Multicenter Italian Institution,COMPLETED,,443.0,2017-02-01,2018-02-01,36.944986301369866,Good (10-50/month),200.0,Exceeded (≥100%),100,88.8,92.89
NCT01811927,"The Treatment of Coronary Artery Lesions Using the PRO-Kinetic Energy Cobalt-Chromium, Bare-Metal Stent",TERMINATED,NA,43.0,2013-03-01,2014-10-01,2.2606563039723664,Adequate (1-10/month),22.606563039723664,Significantly Below (<50%),10,26.4,7.865
NCT05845827,Dietary Impact on Continuous Glucose Monitoring,COMPLETED,,30.0,2023-06-20,2023-12-31,4.707216494845361,Adequate (1-10/month),47.07216494845361,Significantly Below (<50%),100,50.7,48.915
NCT07243561,Prospective Clinical Study on Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes for the Treatment of Childhood Autism,RECRUITING,PHASE1,40.0,2025-11-30,2026-07-30,5.031404958677686,Adequate (1-10/month),50.31404958677687,Below (50-75%),60,41.2,23.425
NCT03135561,A Pedometer-based Intervention With and Without Email Counselling in General Practice,COMPLETED,NA,37.0,2015-11-12,2016-12-09,2.8658524173027993,Adequate (1-10/month),28.658524173027995,Significantly Below (<50%),100,53.0,55.80500000000001
NCT00000661,The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient,COMPLETED,PHASE1,8.0,,,,Slow (<1/month),,Significantly Below (<50%),100,40.6,22.575
NCT05602961,A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine Booster,WITHDRAWN,PHASE1,0.0,2023-02-21,2024-09-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT05344261,Effect of Prophylactic TMR and RPNI on Neuroma and Phantom Limb Pain,WITHDRAWN,NA,0.0,2023-03-01,2024-12-30,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT03724461,Effects of Resistance Training With High vs. Light-moderate Loads on Muscle-tendon Function in the Elderly,COMPLETED,NA,55.0,2017-09-01,2020-03-12,1.8138678223185267,Adequate (1-10/month),18.138678223185263,Significantly Below (<50%),100,54.4,59.89
NCT05457361,VAH Versus VA for Salvage Therapy of R/R-AML,UNKNOWN,PHASE3,162.0,2022-03-01,2023-12-31,7.360119402985076,Adequate (1-10/month),73.60119402985075,Below (50-75%),50,48.0,42.945
NCT03853161,High Flow Nasal Cannula Versus Nasal Intermittent Positive Pressure (NIPPV) in Preterm Infants,UNKNOWN,NA,130.0,2018-01-21,2023-07-01,1.9915450427780574,Adequate (1-10/month),19.915450427780577,Significantly Below (<50%),50,45.4,31.455
NCT02631161,Glass Hybrid Versus Composite Restorations of Non-carious Cervical Lesions,COMPLETED,NA,88.0,2015-12-01,2021-02-01,1.418062466913711,Adequate (1-10/month),14.18062466913711,Significantly Below (<50%),100,52.0,52.86
NCT06585761,Effect of Sodium Glucose Co-tansporter 2 Inhibitors (SGLT2I) on Inflammatory and Oxidative Stress Markers Level in Heart Failure Patients,RECRUITING,,60.0,2024-02-15,2025-06-30,3.6455089820359285,Adequate (1-10/month),36.45508982035929,Significantly Below (<50%),60,41.1,23.225
NCT00997061,SCOT Registry: Small Cell Lung Cancer Treatment and Outcome,COMPLETED,,500.0,2009-11-01,2012-02-01,18.51581508515815,Good (10-50/month),185.15815085158152,Exceeded (≥100%),100,93.3,94.325
NCT03539861,Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients,TERMINATED,NA,2.0,2019-09-24,2021-08-04,0.08952941176470589,Slow (<1/month),0.8952941176470589,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT04981561,Safety and Tolerability of GATE-251 in Normal Human Volunteers,COMPLETED,PHASE1,68.0,2016-12-09,2017-12-21,5.4905039787798415,Adequate (1-10/month),54.905039787798415,Below (50-75%),100,55.4,62.56
NCT05001061,Sublingual vs Vaginal Misoprostol for Termination of First Trimesteric Missed Abortion,UNKNOWN,EARLY_PHASE1,288.0,2021-08-03,2021-10-16,118.4691891891892,Excellent (>50/month),200.0,Exceeded (≥100%),50,68.0,80.56
NCT00219661,Effect of Drainage of Subglottic Secretions on Pneumonia Acquired Under Mechanical Ventilation,COMPLETED,PHASE3,440.0,2003-06-01,2006-09-01,11.274074074074075,Good (10-50/month),112.74074074074075,Exceeded (≥100%),100,90.2,93.255
NCT03043261,Effective Management of Emotional Response to Generate Well-Being Post-HF Exacerbation,COMPLETED,NA,3.0,2018-01-29,2018-04-07,1.3429411764705883,Adequate (1-10/month),13.42941176470588,Significantly Below (<50%),100,45.2,30.830000000000002
NCT04223661,"Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy",WITHDRAWN,PHASE2,0.0,2021-12-06,2023-12-31,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT01231061,Spinal met_radiosurgery/SBRT Study,COMPLETED,PHASE2,1.0,2010-11-01,2014-07-01,0.022750373692077726,Slow (<1/month),0.22750373692077724,Significantly Below (<50%),100,45.1,30.605
NCT06984861,A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer,RECRUITING,PHASE2,74.0,2025-05-13,2028-05-01,2.078007380073801,Adequate (1-10/month),20.78007380073801,Significantly Below (<50%),60,43.9,28.12
NCT02954861,A Study to Identify the Incidence of Post Traumatic Stress Symptoms in Patients With Delirium Following Cardiac Surgery,COMPLETED,,406.0,2016-04-07,2018-05-10,16.197431192660552,Good (10-50/month),161.9743119266055,Exceeded (≥100%),100,85.8,91.495
NCT00001061,Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS,COMPLETED,PHASE2,167.0,,1998-03-01,,Slow (<1/month),,Significantly Below (<50%),100,53.4,57.35
NCT03450161,"Hyperalgesia, Persistent Pain, and Fentanyl Dosing in On-Pump Coronary Artery Bypass Grafting",COMPLETED,PHASE4,80.0,2018-05-14,2021-01-09,2.507929969104017,Adequate (1-10/month),25.07929969104017,Significantly Below (<50%),100,56.4,64.88000000000001
NCT05056961,Effects of Large Tidal Volumes Despite Minimal Inspiratory Support in Spontaneously Ventilated Intubated Resuscitation Patients. Pathophysiological Exploratory Study.,UNKNOWN,NA,30.0,2020-06-21,2023-06-25,0.8309372156505914,Slow (<1/month),8.309372156505916,Significantly Below (<50%),50,32.4,12.025
NCT00055861,Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer,COMPLETED,PHASE2,27.0,2002-07-01,,,Slow (<1/month),,Significantly Below (<50%),100,42.2,25.155
NCT06151561,Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines,COMPLETED,PHASE1,24.0,2024-01-05,2024-04-03,8.208539325842697,Adequate (1-10/month),82.08539325842696,Met (75-100%),100,51.9,52.55499999999999
NCT00626561,Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix,TERMINATED,PHASE2,4.0,2008-02-01,2011-07-01,0.09772070626003211,Slow (<1/month),0.977207062600321,Significantly Below (<50%),10,18.3,3.74
NCT02043561,The Effect of Inhibitory Control Processes Induced by Rectal Distension on Impulse Control Measured by Stroop Task Performance and Intertemporal Discounting.,COMPLETED,NA,35.0,2014-12-24,2015-09-07,4.145525291828794,Adequate (1-10/month),41.45525291828795,Significantly Below (<50%),100,52.8,55.31
NCT06954961,A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer,RECRUITING,PHASE3,640.0,2022-09-15,2028-12-31,8.473945193562418,Adequate (1-10/month),84.73945193562417,Met (75-100%),60,83.0,89.505
NCT01680861,Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium,COMPLETED,PHASE3,32.0,2012-11-01,2014-12-01,1.2816842105263158,Adequate (1-10/month),12.816842105263158,Significantly Below (<50%),100,47.6,41.775
NCT00167661,Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal Transplantation,TERMINATED,PHASE1,33.0,2004-06-01,2012-05-01,0.34746454514008995,Slow (<1/month),3.4746454514009,Significantly Below (<50%),10,20.6,5.965
NCT03075761,Physical Activity in Children at Risk of Post-thrombotic Sequelae (PACT),COMPLETED,NA,111.0,2016-11-18,2019-10-10,3.199659090909091,Adequate (1-10/month),31.996590909090912,Significantly Below (<50%),100,58.9,70.10499999999999
NCT04959942,Efficacy of Adding Scapular Stabilization Exercises to Postural Correctional Exercises on on Forward Head Posture,UNKNOWN,NA,60.0,2021-07-15,2021-09-30,23.71948051948052,Good (10-50/month),200.0,Exceeded (≥100%),50,44.8,29.845
NCT03276442,Biorhythms in Metabolic Tissues,UNKNOWN,NA,12.0,2017-08-31,2019-12-31,0.4287323943661972,Slow (<1/month),4.287323943661972,Significantly Below (<50%),50,31.0,9.985
NCT01119742,Clinical Equivalence of Two Generic Butenafine Hydrochloride 1% Creams as Compared to Lotrimin Ultra Cream in Patients With Interdigital Tinea Pedis,TERMINATED,PHASE1,428.0,2010-07-01,2011-07-01,35.69402739726028,Good (10-50/month),200.0,Exceeded (≥100%),10,62.2,74.74499999999999
NCT04256642,Comparison of the Erector Spinae Plane Block Versus Intrathecal Morphine on Post-Cesarean Delivery Analgesia,UNKNOWN,PHASE3,160.0,2020-02-01,2023-01-01,4.573145539906103,Adequate (1-10/month),45.73145539906104,Significantly Below (<50%),50,47.8,42.42
NCT02618642,The Use of i/t Curve in Assessment of Phototherapy Effects,COMPLETED,NA,60.0,2016-02-01,2019-07-01,1.4658105939004815,Adequate (1-10/month),14.658105939004818,Significantly Below (<50%),100,49.8,47.17
NCT04954742,Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH,TERMINATED,PHASE4,30.0,2022-04-13,2025-08-13,0.7497536945812807,Slow (<1/month),7.497536945812806,Significantly Below (<50%),10,20.4,5.885
NCT01379742,Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy,UNKNOWN,PHASE4,240.0,2010-04-01,,,Slow (<1/month),,Significantly Below (<50%),50,44.2,28.549999999999997
NCT01371942,"Mutational Profiling in Colorectal Tumors to Determine Its Role in the Diagnosis, Prognostic Significance and Their Impact in Clinical Management",UNKNOWN,,300.0,2010-05-01,2013-05-01,8.332116788321168,Adequate (1-10/month),83.32116788321167,Met (75-100%),50,57.3,66.74
NCT00160342,Comparison of Estrogen and Methyltestosterone Combination Treatments for Postmenopausal Hot Flushes,COMPLETED,PHASE2,1251.0,2005-06-01,2007-09-01,46.32656934306569,Good (10-50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT05079542,"RCT of BLT Implants Used for Immediate vs Early Placement, Restored With Ceramic Crowns on Titanium Bonding Bases.",UNKNOWN,NA,60.0,2015-10-05,2025-03-03,0.5313936572592377,Slow (<1/month),5.313936572592377,Significantly Below (<50%),50,34.8,15.040000000000001
NCT01212042,Multiplex Microarray Chip-Based Diagnosis of Respiratory Infections,TERMINATED,,129.0,2010-09-01,2016-04-05,1.9220558002936856,Adequate (1-10/month),19.220558002936855,Significantly Below (<50%),10,31.7,11.14
NCT01586442,Comparison of Eplerenone Versus Spironolactone in Heart Failure Patients With Glucose Intolerance or Type 2 Diabetes,COMPLETED,PHASE3,62.0,2012-03-01,2018-07-29,0.8061853908586074,Slow (<1/month),8.061853908586073,Significantly Below (<50%),100,50.0,47.675
NCT03489642,Innovative Pulmonary Rehabilitation Telehealth Program for Improving COPD Patient Outcomes,COMPLETED,NA,12.0,2018-02-15,2021-03-03,0.3284892086330935,Slow (<1/month),3.284892086330935,Significantly Below (<50%),100,46.0,34.1
NCT05785442,Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia,COMPLETED,PHASE2,60.0,2023-03-06,2024-06-28,3.805,Adequate (1-10/month),38.05,Significantly Below (<50%),100,54.8,61.095
NCT01067742,The Natural History of Mucolipidosis Type IV,TERMINATED,,7.0,2009-02-19,2021-07-07,0.04713116567131166,Slow (<1/month),0.47131165671311664,Significantly Below (<50%),10,16.9,2.735
NCT01265342,Efficacy of Nebulised Beclometasone in Viral Wheezing Prophylaxis,COMPLETED,PHASE4,576.0,2010-10-01,2012-10-01,23.985554035567716,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT06280742,Study of Neuroinflammation in Multiple Sclerosis by PET-MRI Imaging Using the Radiotracer ([18F]-DPA-714) : a Multicentre Cohort Study (INFLANET),NOT_YET_RECRUITING,NA,41.0,2025-09-01,2027-11-01,1.5778002528445008,Adequate (1-10/month),15.778002528445006,Significantly Below (<50%),30,27.3,8.155
NCT05251142,Plyometric Training in Volleyball Players With Chronic Knee Pain,UNKNOWN,NA,32.0,2021-12-01,2022-04-10,7.492923076923077,Adequate (1-10/month),74.92923076923076,Below (50-75%),50,37.6,18.845
NCT01591642,"Physical Activity, Functional Fitness and Quality of Life After Coronary Artery Bypass Grafting",COMPLETED,,315.0,2011-01-01,2011-12-01,28.708383233532935,Good (10-50/month),200.0,Exceeded (≥100%),100,78.5,86.785
NCT05232942,Monoclonal Antibody Duration of REsponse in MIgraine After Treatment Interruption,RECRUITING,,200.0,2022-02-15,2024-08-15,6.675438596491229,Adequate (1-10/month),66.75438596491229,Below (50-75%),60,52.3,53.515
NCT05373342,Feasibility Study to Evaluate the Role of a Novel Device in Childbirth,NOT_YET_RECRUITING,,70.0,2026-03-01,2027-03-01,5.837808219178083,Adequate (1-10/month),58.378082191780834,Below (50-75%),30,32.9,12.53
NCT03458442,China OLIMPICS: China Ophthalmic Learning and Improvement Initiative in Cataract Surgery Trial,COMPLETED,NA,32.0,2018-05-09,2020-02-01,1.5388309636650868,Adequate (1-10/month),15.388309636650868,Significantly Below (<50%),100,47.6,41.775
NCT07276542,Clinical Trial Exploring the Outpatient Treatment of Phantom Limb Pain With Ketamine Administration in a Six Month Study With a Minimum Remission Period of 7 Days Between Treatment Session. 25-30 Subjects With an Ongoing History of Significant PLP.--FDA and IRB Approved.,NOT_YET_RECRUITING,PHASE2,30.0,2026-01-15,2026-12-31,2.609142857142857,Adequate (1-10/month),26.091428571428573,Significantly Below (<50%),30,31.4,10.47
NCT01188642,Effects of Physical Training and Nutrition Education on Adipocytokines in Severely Obese Teenagers,COMPLETED,,32.0,2009-03-01,,,Slow (<1/month),,Significantly Below (<50%),100,40.9,22.82
NCT03107442,Exercise and Arterial Stiffness in Systemic Lupus Erythematosus,COMPLETED,NA,58.0,2017-04-12,2017-07-21,17.6552,Good (10-50/month),176.552,Exceeded (≥100%),100,59.6,71.17999999999999
NCT00283842,Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy,TERMINATED,PHASE3,408.0,2006-03-01,2008-06-01,15.090546780072906,Good (10-50/month),150.90546780072904,Exceeded (≥100%),10,60.6,72.785
NCT05978986,Efficiency of Determining the Clinical Class of Chronic Venous Disorders by Artificial Intelligence,RECRUITING,NA,1530.0,2023-08-25,2025-12-15,55.24697508896798,Excellent (>50/month),200.0,Exceeded (≥100%),60,88.0,92.495
NCT03657186,Study to Evaluate Benefit of ProbioSatys™ on Weight Reduction in Overweight Subjects,COMPLETED,NA,236.0,2018-08-31,2019-11-28,15.823436123348019,Good (10-50/month),158.2343612334802,Exceeded (≥100%),100,73.9,83.88
NCT00648986,Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle Nails,COMPLETED,PHASE4,20.0,2005-08-01,2006-12-01,1.2501026694045174,Adequate (1-10/month),12.501026694045175,Significantly Below (<50%),100,46.6,37.375
NCT00030186,Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation,COMPLETED,PHASE2,37.0,2002-01-01,2003-02-01,2.844141414141414,Adequate (1-10/month),28.44141414141414,Significantly Below (<50%),100,53.0,55.80500000000001
NCT00819286,Evaluation of Primary Plating in Sternotomy Patients for Osteosynthesis and Pain,COMPLETED,NA,140.0,2008-11-01,2011-12-01,3.788088888888889,Adequate (1-10/month),37.88088888888888,Significantly Below (<50%),100,61.2,73.43499999999999
NCT01633086,A Study on the Safety and Efficacy of Nitric Oxide Gel in Subjects With Painful Diabetic Neuropathy,COMPLETED,PHASE2,24.0,2012-07-01,2013-02-01,3.397953488372093,Adequate (1-10/month),33.97953488372093,Significantly Below (<50%),100,51.9,52.55499999999999
NCT02384486,Efficacy of Training Programme to Reduce Stress,COMPLETED,NA,67.0,2015-04-01,2015-12-01,8.358524590163935,Adequate (1-10/month),83.58524590163934,Met (75-100%),100,60.4,72.54
NCT00349986,LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus,TERMINATED,PHASE4,4.0,2006-09-01,,,Slow (<1/month),,Significantly Below (<50%),10,13.3,0.8099999999999999
NCT01893086,Impact of Opportunistic Salpingectomy on Ovarian Reserve in Patients Undergoing Laparoscopic Hysterectomy,COMPLETED,PHASE3,68.0,2013-06-01,2015-07-01,2.7235789473684213,Adequate (1-10/month),27.235789473684214,Significantly Below (<50%),100,55.4,62.56
NCT01154686,Working Memory Training in College Students With Attention-Deficit Hyperactivity Disorder/Learning Disabilities,UNKNOWN,NA,30.0,2009-09-01,2010-09-01,2.5019178082191784,Adequate (1-10/month),25.019178082191786,Significantly Below (<50%),50,37.4,18.62
NCT03004586,Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Using a 22 vs 25-Gauge Needle,COMPLETED,NA,61.0,2016-12-16,2020-06-25,1.442766122766123,Adequate (1-10/month),14.427661227661229,Significantly Below (<50%),100,49.9,47.425
NCT00291486,Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer,COMPLETED,PHASE1,19.0,2003-10-01,2012-08-29,0.1776835637480799,Slow (<1/month),1.776835637480799,Significantly Below (<50%),100,46.5,36.815
NCT06158386,Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma,RECRUITING,PHASE2,33.0,2023-11-22,2027-12-31,0.66968,Slow (<1/month),6.6968,Significantly Below (<50%),60,35.6,16.03
NCT01874886,Cannabis Effects on Brain Morphology in Aging,COMPLETED,,60.0,2013-01-01,2019-04-01,0.8007014467338888,Slow (<1/month),8.007014467338887,Significantly Below (<50%),100,48.1,43.275000000000006
NCT06657586,Investigation of the Effectiveness of Neuromuscular Exercise Program Accompanied With Degenerative Meniscal Tear,COMPLETED,NA,50.0,2024-09-01,2025-01-20,10.794326241134751,Good (10-50/month),107.9432624113475,Exceeded (≥100%),100,59.0,70.365
NCT01812486,Dose De-escalation to the Elective Nodal Sites in Head and Neck Cancer,COMPLETED,PHASE3,200.0,2008-05-01,2013-03-01,3.4492917847025497,Adequate (1-10/month),34.492917847025495,Significantly Below (<50%),100,66.0,78.99000000000001
NCT00479986,Effects of Pioglitazone in Type 2 Diabetes Mellitus and Coronary Heart Disease,COMPLETED,PHASE4,92.0,2005-06-01,2006-11-01,5.406332046332047,Adequate (1-10/month),54.06332046332047,Below (50-75%),100,57.4,67.05499999999999
NCT02467686,"Breast Cancer, Sexuality and Black Cohosh",UNKNOWN,PHASE4,60.0,2014-01-01,2017-12-01,1.2772027972027973,Adequate (1-10/month),12.772027972027974,Significantly Below (<50%),50,34.8,15.040000000000001
NCT07187986,Sound Acupuncture in Painful Chemotherapy-Related Neuropathies,COMPLETED,NA,40.0,2022-03-17,2025-07-16,1.0004930156121612,Adequate (1-10/month),10.004930156121612,Significantly Below (<50%),100,48.2,43.665
NCT02227186,"Efficacy Study of School-located Influenza Vaccination Clinics to Increase Influenza Vaccination Rates in Monroe County, New York",COMPLETED,NA,20461.0,2014-08-01,2015-07-31,1711.079230769231,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT06348186,Fascial Tissue Response to Manual Therapy: Implications in Long COVID-19,RECRUITING,NA,30.0,2024-02-01,2025-08-31,1.582668977469671,Adequate (1-10/month),15.826689774696709,Significantly Below (<50%),60,35.4,15.765
NCT02323386,"Kinematic Analysis of a PS, FB Primary Total Knee Arthroplasty (ATTUNE Knee System) Using Dynamic RSA",COMPLETED,NA,20.0,2015-01-01,2016-09-01,0.999671592775041,Slow (<1/month),9.996715927750408,Significantly Below (<50%),100,46.6,37.375
NCT05482386,STREAM Trial - Biomarker,RECRUITING,NA,500.0,2022-11-21,2026-11-01,10.562109646079113,Good (10-50/month),105.62109646079112,Exceeded (≥100%),60,83.0,89.505
NCT02119286,"Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2",COMPLETED,PHASE3,620.0,2013-10-01,2014-04-01,103.6967032967033,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT03109886,Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma,COMPLETED,PHASE2,31.0,2017-07-12,2019-06-20,1.3328248587570621,Adequate (1-10/month),13.32824858757062,Significantly Below (<50%),100,47.5,41.415
NCT06550570,Evaluation of the Impact of Ambulatory Epidural on Maternal Satisfaction During Delivery and Postpartum,RECRUITING,,126.0,2024-07-23,2025-08-23,9.685454545454546,Adequate (1-10/month),96.85454545454546,Met (75-100%),60,51.4,50.92
NCT06445270,Lifestyle Interventions to Improve Glycemic Parameters and Reduce Gestational Diabetes in High-risk Pregnant Individuals,NOT_YET_RECRUITING,NA,100.0,2026-08-01,2031-12-01,1.5626283367556468,Adequate (1-10/month),15.626283367556471,Significantly Below (<50%),30,32.0,11.425
NCT03344770,The Efficacy of Radial Extracorporeal Shockwave Therapy on Knee Osteoarthritis,SUSPENDED,PHASE2,44.0,2017-10-20,2025-10-01,0.46137099552187394,Slow (<1/month),4.61370995521874,Significantly Below (<50%),20,24.5,6.925000000000001
NCT05584670,"A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors",RECRUITING,PHASE1,542.0,2022-11-29,2028-06-28,8.095426889106967,Adequate (1-10/month),80.95426889106967,Met (75-100%),60,78.0,86.075
NCT03537170,"Dietary Assessment and Prevalence of Refeeding Syndrome in High-risk TB Patients in Chhattisgarh, India",COMPLETED,,31.0,2017-11-23,2018-02-14,11.369156626506024,Good (10-50/month),113.69156626506023,Exceeded (≥100%),100,55.8,63.245
NCT02194270,Relative Bioavailability of Ambroxol Hydrochloride of Soft Pastilles Compared to Ambroxol Hydrochloride Syrup in Healthy Male and Female Volunteers,COMPLETED,PHASE1,24.0,2004-09-01,,,Slow (<1/month),,Significantly Below (<50%),100,41.9,24.585
NCT02186470,Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer,COMPLETED,NA,22.0,2016-04-29,2025-09-04,0.19609956076134702,Slow (<1/month),1.96099560761347,Significantly Below (<50%),100,46.8,38.440000000000005
NCT05049070,"Study to Evaluate the Reliability, Validity and Safety of Subjective Mobile Refraction",UNKNOWN,NA,349.0,2021-09-15,2023-06-01,17.0249358974359,Good (10-50/month),170.24935897435898,Exceeded (≥100%),50,67.9,80.36999999999999
NCT01650870,"Safety, Efficacy, and Patient Preference of Split-Dose Crystalline Lactulose as a Preparation for Colonoscopy in Adults",COMPLETED,PHASE2,40.0,2012-07-01,2012-09-01,19.638709677419353,Good (10-50/month),196.38709677419354,Exceeded (≥100%),100,58.2,68.795
NCT03153670,3T MRI in Patients With Deep Brain Stimulation (DBS),RECRUITING,NA,250.0,2017-06-01,2030-12-01,1.543297505576962,Adequate (1-10/month),15.43297505576962,Significantly Below (<50%),60,53.0,55.80500000000001
NCT06436170,The Role of Radial Peripapillary Vessel Density in Irvine-gass Syndrome,COMPLETED,,30.0,2023-07-01,2024-04-29,3.0138613861386143,Adequate (1-10/month),30.138613861386137,Significantly Below (<50%),100,50.7,48.915
NCT06018870,MRI Contrast Clearance Analysis for Glioma Grading and Genotyping,UNKNOWN,,100.0,2023-06-01,2024-06-30,7.706329113924052,Adequate (1-10/month),77.0632911392405,Met (75-100%),50,41.3,23.74
NCT03476070,Adolescent and Young Adult Cancer Patients: Cognitive Toxicity on Survivorship (ACTS),UNKNOWN,,236.0,2018-06-18,2022-09-01,4.6769791666666665,Adequate (1-10/month),46.76979166666667,Significantly Below (<50%),50,52.2,53.22
NCT03793270,Characterization of the Phenotypic Markers of B Cell Lymphocytes in Rheumatoid Arthritis,UNKNOWN,,90.0,2019-01-03,2020-08-20,4.60436974789916,Adequate (1-10/month),46.0436974789916,Significantly Below (<50%),50,40.5,22.46
NCT04439370,Autonomic Regulation of Blood Pressure in Premature and Early Menopausal Women,RECRUITING,,160.0,2019-10-01,2026-12-30,1.839969777106158,Adequate (1-10/month),18.39969777106158,Significantly Below (<50%),60,49.1,45.83
NCT00025870,Studies of Children With Metabolic and Other Genetic Disorders,COMPLETED,,1090.0,2001-10-25,2016-06-23,6.196003734827265,Adequate (1-10/month),61.96003734827264,Below (50-75%),100,88.3,92.705
NCT05882370,"TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study",RECRUITING,PHASE2,30.0,2022-12-01,2025-08-31,0.9095617529880479,Slow (<1/month),9.095617529880478,Significantly Below (<50%),60,35.4,15.765
NCT03860870,Response to Clenbuterol in Humans,COMPLETED,NA,16.0,2019-03-11,2022-12-21,0.35267197682838525,Slow (<1/month),3.526719768283852,Significantly Below (<50%),100,46.3,35.66
NCT05216770,Understanding Disorder-specific Neural Pathophysiology in Laryngeal Dystonia and Voice Tremor,RECRUITING,EARLY_PHASE1,165.0,2022-03-24,2027-08-31,2.5290030211480365,Adequate (1-10/month),25.290030211480364,Significantly Below (<50%),60,51.2,50.375
NCT03151070,Scaling Up an Integrated Approach to Improve Delivery Care in North Guatemala With Stepped Wedge Design,COMPLETED,,32000.0,2013-12-15,2017-03-15,821.3153456998315,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT01747070,"Effect of Cranial Stimulation and Acupuncture on Pain, Functional Capability and Cerebral Function in Osteoarthritis",COMPLETED,NA,60.0,2014-03-01,2016-12-01,1.815506958250497,Adequate (1-10/month),18.155069582504968,Significantly Below (<50%),100,54.8,61.095
NCT04477070,"The Effects of Subgingival Air-polishing, as an Adjunct to Non-surgical Periodontal Treatment on Periodontal Parameters and Patient Satisfaction in Patients With Periodontitis",UNKNOWN,NA,22.0,2020-07-21,2023-10-21,0.564178601516428,Slow (<1/month),5.641786015164279,Significantly Below (<50%),50,31.8,11.19
NCT05867173,Perceptual Consequences of Cochlear Implant Electrode-neuron Interfaces,RECRUITING,NA,200.0,2022-09-16,2027-03-31,3.674109837054919,Adequate (1-10/month),36.74109837054919,Significantly Below (<50%),60,54.0,58.72500000000001
NCT01166373,The Extended Operations And Pelvic Muscle Training In The Management Of Apical Support Loss Study,COMPLETED,NA,285.0,2010-04-01,2016-07-01,3.8,Adequate (1-10/month),38.0,Significantly Below (<50%),100,72.8,83.36
NCT03713073,Clinical and Histological Outcomes of Allogenic Amnion Chorion Membrane in the Healing of Free Gingival Graft Donor Site,COMPLETED,NA,19.0,2016-10-03,2020-01-17,0.4815653621981682,Slow (<1/month),4.815653621981682,Significantly Below (<50%),100,46.5,36.815
NCT07063173,Bioavailability of Ration Items Containing Tart Cherry Extract,RECRUITING,NA,15.0,2024-06-14,2025-12-31,0.808141592920354,Slow (<1/month),8.08141592920354,Significantly Below (<50%),60,34.2,14.305000000000001
NCT01798173,"Environmental, Metabolic and Nutritional Factors of Hepatocellular Carcinoma in Cirrhotic Patients",COMPLETED,NA,1246.0,2008-06-20,2018-01-25,10.8180946948089,Good (10-50/month),108.18094694808902,Exceeded (≥100%),100,95.0,95.7
NCT01934673,"A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Malaysia",COMPLETED,,1668.0,2013-09-01,2013-11-01,832.359344262295,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT01727973,Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy,COMPLETED,PHASE1,14.0,2012-10-01,2013-11-01,1.076161616161616,Adequate (1-10/month),10.761616161616162,Significantly Below (<50%),100,46.1,34.695
NCT03117673,Estimation of Pulmonary Arterial Pressure With Transesophageal Echocardiography: a Pilot Study,UNKNOWN,,39.0,2017-05-01,2020-12-31,0.8859402985074628,Slow (<1/month),8.859402985074627,Significantly Below (<50%),50,31.5,10.635
NCT02363673,The Effect of Individualised Homoeopathic Treatment of Autism Spectrum Disorder in Children,COMPLETED,PHASE2,10.0,2015-02-01,2015-07-01,2.029333333333333,Adequate (1-10/month),20.293333333333333,Significantly Below (<50%),100,50.8,49.18
NCT03778073,Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma,TERMINATED,PHASE1,18.0,2019-04-17,2022-08-01,0.4558402662229617,Slow (<1/month),4.558402662229617,Significantly Below (<50%),10,19.4,5.2299999999999995
NCT03034473,"Translational Validation Study to Examine KFO179-1 Biomarker Scores for the Prediction and Prognosis of Advanced Primary Resectable Rectal Cancer Stages UICC-II-IV, With a 5-Fluorouracil-based Standard Radiochemotherapy Followed by Total Mesorectal Excision.",UNKNOWN,NA,200.0,2011-08-01,2024-08-01,1.2819540955990736,Adequate (1-10/month),12.819540955990735,Significantly Below (<50%),50,46.0,34.1
NCT06830473,KTRSensor Scotland Study: An Observational Study Into Predictors and Diagnosis of Kidney Transplant Rejection,RECRUITING,,200.0,2025-05-16,2027-05-13,8.37414030261348,Adequate (1-10/month),83.7414030261348,Met (75-100%),60,57.3,66.74
NCT05614973,Efficacy and Safety of Percutaneous Liver Biopsy With Needle Tract Plugging on Outpatient Basis,UNKNOWN,NA,122.0,2022-08-02,2023-08-31,9.425583756345178,Adequate (1-10/month),94.25583756345178,Met (75-100%),50,49.8,47.17
NCT01721369,Applicability of Syncope Guidelines in Cataluña,COMPLETED,,581.0,2011-11-01,2013-03-01,36.39020576131688,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT00192569,Australian Trial in Acute Hepatitis C,COMPLETED,PHASE4,167.0,2004-07-01,2010-06-01,2.3523739009717723,Adequate (1-10/month),23.523739009717723,Significantly Below (<50%),100,63.4,76.375
NCT03677869,Effects of Pneumatic Vitreolysis on Macular Hole,COMPLETED,NA,36.0,2018-11-14,2020-07-22,1.7789610389610389,Adequate (1-10/month),17.789610389610388,Significantly Below (<50%),100,52.9,55.55
NCT02905669,Normal Values for Esophageal and Pyloric Impedance Planimetry Under General Anesthesia (NormaFLIP),UNKNOWN,NA,40.0,2017-09-13,2024-05-25,0.4977923139820115,Slow (<1/month),4.977923139820115,Significantly Below (<50%),50,33.2,12.989999999999998
NCT06390969,TBP Survey Among Respiratory Physicians,ENROLLING_BY_INVITATION,,400.0,2024-07-01,2025-02-28,50.31404958677686,Excellent (>50/month),200.0,Exceeded (≥100%),55,76.8,85.42
NCT07066969,Prevalence of Germline Alterations in Actionable Genes in Endometrial Cancer,NOT_YET_RECRUITING,NA,20.0,2026-01-22,2027-04-01,1.4027649769585253,Adequate (1-10/month),14.027649769585251,Significantly Below (<50%),30,25.6,7.595000000000001
NCT06610669,The Prevalence of Hyper-Lp(a)-Emia in the PMMHRI-Lp(a) Registry,RECRUITING,,2000.0,2022-01-01,2028-06-01,25.983781476739225,Good (10-50/month),200.0,Exceeded (≥100%),60,81.3,88.58
NCT04203069,Auto-Adjustable MOBIDERM® Autofit NIGHT-time Compression Armsleeve in the Upper Limb LYMphedema in Maintenance Phase,COMPLETED,NA,63.0,2020-07-01,2024-09-15,1.2477033181522448,Adequate (1-10/month),12.477033181522447,Significantly Below (<50%),100,50.0,47.675
NCT02249169,Developing Novel Microbiota-Targeted Therapies for Irritable Bowel Syndrome,COMPLETED,,84.0,2014-09-19,2017-02-08,2.92893470790378,Adequate (1-10/month),29.289347079037803,Significantly Below (<50%),100,55.1,62.085
NCT01162369,Brief Delirium Assessments in Non-Intensive Care Unit (ICU) Patients,WITHDRAWN,,0.0,2013-07-01,2016-07-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT06708169,Effect of Preemptive Education on the Incidence of Maternal Intraoperative Shivering in Elective Cesarean Delivery,RECRUITING,NA,130.0,2024-12-09,2026-08-31,6.281269841269842,Adequate (1-10/month),62.81269841269842,Below (50-75%),60,48.4,44.22
NCT01250769,Evaluating the Effect of Tooth Cleaning Devices on Oral Health,COMPLETED,NA,170.0,2010-04-01,2010-06-01,84.8327868852459,Excellent (>50/month),200.0,Exceeded (≥100%),100,73.6,83.775
NCT00700869,Evaluation of a New Mechanical Ventilation Weaning Strategy for Patients With Altered Level of Consciousness,COMPLETED,PHASE2,34.0,2008-04-01,2011-09-01,0.8292948717948718,Slow (<1/month),8.292948717948718,Significantly Below (<50%),100,47.7,42.17
NCT02766569,International Registry for ASD Closure by Using the Occlutech®Flex II Device in More Than 2000 Patients,UNKNOWN,,2000.0,2016-07-01,2017-12-01,117.52895752895753,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT02641769,Intra-Testicular Transplantation of Autologous Stem Cells for Treatment of Non-Obstructive Azoospermia Male Infertility.,UNKNOWN,PHASE1,50.0,2014-01-01,2021-01-01,0.5952287837309347,Slow (<1/month),5.952287837309347,Significantly Below (<50%),50,34.0,14.02
NCT00468169,Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer,COMPLETED,PHASE2,110.0,2006-07-01,2012-11-01,1.4463930885529157,Adequate (1-10/month),14.463930885529155,Significantly Below (<50%),100,53.8,58.065
NCT05665569,Effects of Flourish HEC Vaginal Care System on Birth-Related Pelvic Floor Disorders,TERMINATED,NA,1.0,2023-01-30,2023-03-29,0.5248275862068966,Slow (<1/month),5.248275862068966,Significantly Below (<50%),10,18.1,3.105
NCT04529369,"Middle Lobe Only Laser Vaporization or Total Prostate Vaporization of the Prostate, Prospective Cohort Study",NOT_YET_RECRUITING,NA,280.0,2020-10-01,2030-10-01,2.333844468784228,Adequate (1-10/month),23.33844468784228,Significantly Below (<50%),30,51.4,50.92
NCT02167269,Comparison of Minimal Fresh Gas Requirements of Baby EAR and Jackson Rees Anesthetic Circuit,COMPLETED,NA,20.0,2014-05-01,2014-10-01,3.9790849673202615,Adequate (1-10/month),39.790849673202615,Significantly Below (<50%),100,51.6,51.644999999999996
NCT05925569,Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension,ACTIVE_NOT_RECRUITING,NA,12501.0,2024-03-13,2029-12-31,179.58019820670128,Excellent (>50/month),200.0,Exceeded (≥100%),85,95.5,96.55
NCT02909569,Relieving Chronic Itch: Oral Medication,WITHDRAWN,PHASE2,0.0,2018-08-01,2018-10-09,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT06518369,Preoperative Prehabilitation Program For Geriatric Patients in a Rural Healthcare Setting,COMPLETED,,27.0,2024-06-18,2025-06-04,2.3415384615384616,Adequate (1-10/month),23.415384615384617,Significantly Below (<50%),100,50.5,48.515
NCT04542369,Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer,UNKNOWN,PHASE2,15.0,2021-05-01,2025-11-30,0.27275985663082436,Slow (<1/month),2.7275985663082434,Significantly Below (<50%),50,31.2,10.165000000000001
NCT05383469,Efficacy of Active Versus Passive Methods in Chronic Venous Insufficiency,COMPLETED,NA,66.0,2022-09-13,2023-09-02,5.675254237288136,Adequate (1-10/month),56.75254237288135,Below (50-75%),100,55.3,62.36000000000001
NCT04576169,Trial Comparing Treatment Strategies in Triangular Fibrocartilage Complex Ruptures,RECRUITING,NA,204.0,2020-10-27,2035-03-31,1.1787699316628701,Adequate (1-10/month),11.787699316628702,Significantly Below (<50%),60,49.3,46.265
NCT07349069,A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer,NOT_YET_RECRUITING,PHASE3,4800.0,2026-01-01,2034-01-01,50.0041067761807,Excellent (>50/month),200.0,Exceeded (≥100%),30,79.0,86.96000000000001
NCT03957083,Oxytocin at Elective Cesarean Deliveries: A Dose-finding Study in Women With BMI ≥ 40kg/m2,COMPLETED,NA,30.0,2019-06-26,2020-02-04,4.095067264573991,Adequate (1-10/month),40.950672645739914,Significantly Below (<50%),100,52.4,53.949999999999996
NCT00525083,Protein and Phospholipid Analysis of HDL in Patients With Very High Serum Levels of HDL-C,TERMINATED,,19.0,2005-06-01,2014-11-03,0.16803021499128415,Slow (<1/month),1.6803021499128417,Significantly Below (<50%),10,17.9,2.87
NCT01900483,Brain Functions in Patients Before and After Bariatric Surgery,COMPLETED,,24.0,,,,Slow (<1/month),,Significantly Below (<50%),100,40.3,22.21
NCT00241683,Fetal Growth Restriction & Maternal Cardiovascular Risk,COMPLETED,,704.0,2005-08-01,2009-04-01,16.004301717699775,Good (10-50/month),160.04301717699775,Exceeded (≥100%),100,93.3,94.325
NCT01821183,Strength and Strength-ratio of Hip Rotator Muscles at Soccer Players,COMPLETED,,30.0,2013-04-01,2013-08-01,7.485245901639344,Adequate (1-10/month),74.85245901639344,Below (50-75%),100,50.7,48.915
NCT06624683,Exploring the Effect of Footbaths on Increasing the Success Rates in Vitro Fertilization,NOT_YET_RECRUITING,NA,80.0,2024-10-01,2025-10-01,6.6717808219178085,Adequate (1-10/month),66.71780821917808,Below (50-75%),30,35.4,15.765
NCT03776383,Providing Antibiotic Prescribing Feedback to Primary Care Physicians: The Ontario Program To Improve AntiMicrobial USE,COMPLETED,NA,3500.0,2018-12-14,2020-11-30,148.59135285913527,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT01337583,A Safety and Efficacy Trial of Dapivirine Vaginal Ring in Africa,WITHDRAWN,PHASE3,0.0,2011-07-01,2014-07-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT01086683,Rehabilitation of Cancer Survivors in Denmark: The Effect of a Psychosocial Rehabilitation Course,COMPLETED,PHASE2,513.0,2004-05-01,2009-12-01,7.654764705882354,Adequate (1-10/month),76.54764705882353,Met (75-100%),100,90.0,93.17
NCT03524183,Virtual Fitness Buddy Ecosystem,COMPLETED,PHASE2,964.0,2018-08-27,2024-06-30,13.750777881911903,Good (10-50/month),137.507778819119,Exceeded (≥100%),100,95.0,95.7
NCT06742983,Healing Efficacy of Isobutyl Cyanoacrylate High Viscous Solution in Treatment of Traumatic Ulcer in Children,COMPLETED,NA,30.0,2023-08-04,2024-09-20,2.211138014527845,Adequate (1-10/month),22.11138014527845,Significantly Below (<50%),100,52.4,53.949999999999996
NCT03464383,Anxiety and Depression in Epilepsy: A Treatment Study,COMPLETED,PHASE4,69.0,2018-05-07,2019-09-20,4.192335329341318,Adequate (1-10/month),41.92335329341318,Significantly Below (<50%),100,55.5,62.71
NCT00159783,40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857),COMPLETED,PHASE3,218.0,2005-07-01,2007-04-01,10.384851330203443,Good (10-50/month),103.84851330203443,Exceeded (≥100%),100,72.4,83.17999999999999
NCT02919683,Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity,ACTIVE_NOT_RECRUITING,PHASE2,30.0,2016-11-01,2026-12-01,0.24801738185768604,Slow (<1/month),2.4801738185768603,Significantly Below (<50%),85,42.9,26.145000000000003
NCT03292783,"This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001",COMPLETED,PHASE1,45.0,2017-09-18,2021-03-02,1.0862807295796986,Adequate (1-10/month),10.862807295796987,Significantly Below (<50%),100,48.6,44.685
NCT07304583,"The Effect of Playing the Sound of Water and Watching Videos With VR on Urination, Fear, and Pain in Post-Op Children",ENROLLING_BY_INVITATION,NA,1.0,2025-11-01,2026-01-30,0.33822222222222226,Slow (<1/month),3.3822222222222225,Significantly Below (<50%),55,31.6,10.905
NCT06788483,Self-regulated Flipped Classroom Strategy,COMPLETED,NA,110.0,2024-02-01,2024-06-30,22.322666666666667,Good (10-50/month),200.0,Exceeded (≥100%),100,63.8,76.78
NCT06562283,Evaluation of the Reproducibility of a Fatigability Test Fitted to Patients With Spinal Muscular Atrophy,RECRUITING,NA,80.0,2024-12-06,2026-10-01,3.6674698795180722,Adequate (1-10/month),36.674698795180724,Significantly Below (<50%),60,44.4,28.95
NCT06986083,A Study of Changes to Prostate Procedures,RECRUITING,PHASE3,800.0,2025-05-19,2028-05-01,22.589981447124305,Good (10-50/month),200.0,Exceeded (≥100%),60,83.0,89.505
NCT02185183,Oral Administration of AlequelTM for Patients With Inflammatory Bowel Disease (IBD),COMPLETED,PHASE1,22.0,2008-01-01,2010-01-01,0.9161149110807114,Slow (<1/month),9.161149110807115,Significantly Below (<50%),100,46.8,38.440000000000005
NCT00753883,Ezetrol Post-Marketing Study,COMPLETED,PHASE4,40.0,2006-07-01,,,Slow (<1/month),,Significantly Below (<50%),100,43.2,26.840000000000003
NCT01038141,Recto Anal Repair or Milligan Morgans Operation of Grade 3 and 4 Symptomatic Haemorrhoidal Disease,TERMINATED,NA,80.0,2009-11-01,,,Slow (<1/month),,Significantly Below (<50%),10,19.4,5.2299999999999995
NCT06613841,"Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma",RECRUITING,EARLY_PHASE1,15.0,2025-05-01,2026-12-31,0.7497536945812807,Slow (<1/month),7.497536945812806,Significantly Below (<50%),60,34.2,14.305000000000001
NCT01680341,Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine,COMPLETED,PHASE3,272.0,2012-08-31,2013-08-22,23.25752808988764,Good (10-50/month),200.0,Exceeded (≥100%),100,76.8,85.42
NCT01357941,Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE),UNKNOWN,,203.0,2011-09-01,2014-09-01,5.638065693430657,Adequate (1-10/month),56.38065693430657,Below (50-75%),50,49.6,46.785
NCT05454241,CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies,COMPLETED,PHASE2,14.0,2022-09-07,2024-08-31,0.5886187845303867,Slow (<1/month),5.886187845303867,Significantly Below (<50%),100,46.1,34.695
NCT01510041,"Effects of Respiratory Muscle Training and Respiratory Exercise in Exercise Tolerance, Performing Daily Life Activities and Quality of Life of Patients With Chronic Obstructive Pulmonary Disease",UNKNOWN,NA,40.0,2011-01-01,2013-02-01,1.5979002624671919,Adequate (1-10/month),15.979002624671917,Significantly Below (<50%),50,33.2,12.989999999999998
NCT00280241,Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia,COMPLETED,PHASE2,65.0,2004-06-01,2013-01-01,0.6309311224489796,Slow (<1/month),6.309311224489797,Significantly Below (<50%),100,50.2,48.04
NCT05696041,Wrist Stabilizing Exercise Versus Hand Orthotic Intervention for Persons With Hypermobility,COMPLETED,NA,169.0,2014-08-01,2016-01-31,9.387518248175182,Adequate (1-10/month),93.87518248175182,Met (75-100%),100,68.5,81.01
NCT02914041,Kyphotic Measure Using Distance From the Wall,UNKNOWN,,96.0,2016-02-01,2017-08-01,5.342303473491773,Adequate (1-10/month),53.42303473491773,Below (50-75%),50,41.0,23.01
NCT06487741,Efficacy of a Home-based Stretching Program on Fibromyalgia Symptoms: a Randomised Controlled Trial,RECRUITING,NA,58.0,2024-10-31,2026-08-30,2.642994011976048,Adequate (1-10/month),26.429940119760474,Significantly Below (<50%),60,42.6,25.679999999999996
NCT05267041,Joint Thoracic Oncology Research Unit of LYon: Lung cancerS DatabaSE (ULYSSE),RECRUITING,NA,4000.0,2022-05-05,2042-05-05,16.668035592060235,Good (10-50/month),166.68035592060232,Exceeded (≥100%),60,83.0,89.505
NCT06981741,Safety and Efficacy of hUC-MSC for the Treatment of Cartilage Damage in the Knee Joint,RECRUITING,PHASE1,55.0,2025-11-10,2028-11-01,1.540202391904324,Adequate (1-10/month),15.40202391904324,Significantly Below (<50%),60,37.4,18.62
NCT05646641,"Strength Training in Fibromyalgia on Balance, Neuromuscular Performance and Symptoms",COMPLETED,NA,57.0,2024-10-05,2025-08-07,5.670196078431372,Adequate (1-10/month),56.70196078431372,Below (50-75%),100,54.6,60.39
NCT06608641,Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients,ACTIVE_NOT_RECRUITING,PHASE3,490.0,2024-03-19,2025-12-01,23.980064308681673,Good (10-50/month),200.0,Exceeded (≥100%),85,89.7,93.045
NCT00709241,Psychosocial Patterns and Prognosis in Patients With Heart Failure,COMPLETED,,325.0,2007-12-01,2012-12-01,5.4148877941981395,Adequate (1-10/month),54.1488779419814,Below (50-75%),100,74.3,84.205
NCT00076141,Relatively Healthy Male Veterans Observed Over Time to See What Types of Diseases Develop,COMPLETED,,991.0,2002-01-01,2021-01-01,4.3466916426512965,Adequate (1-10/month),43.46691642651297,Significantly Below (<50%),100,88.3,92.705
NCT00980941,"Types of Starch and Their Effect on Blood Glucose, Appetite and Food Intake",COMPLETED,NA,17.0,2007-12-01,2009-06-01,0.9443065693430657,Slow (<1/month),9.443065693430656,Significantly Below (<50%),100,46.4,36.26
NCT03280641,D-dimer In Patients With atRial Fibrillation rEceiving antiCoagulation Therapy,COMPLETED,,1194.0,2015-08-09,2017-09-01,48.2033952254642,Good (10-50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT03573141,Influence of Manual Physical Therapy on Habitual Activity in Knee Osteoarthritis,UNKNOWN,,18.0,2018-01-05,2018-07-31,2.6469565217391304,Adequate (1-10/month),26.469565217391306,Significantly Below (<50%),50,34.8,15.040000000000001
NCT01004354,Vitamin D Supplementation in Psychiatric Illnesses,COMPLETED,NA,12.0,2009-06-01,2010-06-01,1.0007671232876714,Adequate (1-10/month),10.007671232876714,Significantly Below (<50%),100,46.0,34.1
NCT01654354,Comparison of NEOVIST 370 INJ.(Iopromide 768.86mg) With Ultravist 370 INJ.(Iopromide 768.86mg) in Abdominal CT,COMPLETED,,104.0,2012-07-01,2013-12-01,6.111505791505792,Adequate (1-10/month),61.115057915057925,Below (50-75%),100,56.7,65.53
NCT01051154,Effect of Enteral Docosahexaenoic Acid Administration in Children With Acute Lymphoblastic Leukemia,COMPLETED,PHASE2,72.0,2010-09-01,2016-08-01,1.0141971309578899,Adequate (1-10/month),10.141971309578897,Significantly Below (<50%),100,50.8,49.18
NCT06747754,HIV Database (DBHIV)-Establishment of a Database of HIV Patients,NOT_YET_RECRUITING,,4900.0,2025-01-01,2030-12-31,68.10776255707763,Excellent (>50/month),200.0,Exceeded (≥100%),30,77.3,85.67
NCT02149654,Engager Align Post-market Clinical Study,COMPLETED,,27.0,2014-05-01,2017-01-01,0.8420901639344262,Slow (<1/month),8.420901639344262,Significantly Below (<50%),100,45.5,31.705
NCT02817854,PCT REveals Good Recovery After Acute Diverticulitis: the PREGRAD Study,UNKNOWN,,500.0,2016-05-01,2017-07-01,35.72769953051643,Good (10-50/month),200.0,Exceeded (≥100%),50,78.3,86.48
NCT06989554,Tactile Incentiviser Improves Partial Weight Bearing After Lower-Limb Surgery,COMPLETED,NA,34.0,2024-01-01,2025-04-25,2.156166666666667,Adequate (1-10/month),21.561666666666667,Significantly Below (<50%),100,52.7,55.04
NCT00005254,Natural History of Peripheral Arterial Disease,COMPLETED,,,1990-04-01,1995-03-01,,Slow (<1/month),,Significantly Below (<50%),100,43.3,27.05
NCT07166354,Clinical Study of mTOR Inhibitor as a Treatment for Grey Hair (Canities),NOT_YET_RECRUITING,PHASE1,100.0,2025-10-01,2027-09-15,4.263305322128852,Adequate (1-10/month),42.63305322128852,Significantly Below (<50%),30,37.0,17.955
NCT01984554,Observational Study on the Use of IV (Intravenous) Iron Therapy Among Subjects With Iron Deficiency Anemia,COMPLETED,,551.0,2013-09-01,2014-12-01,36.781666666666666,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT00830154,A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering,COMPLETED,PHASE2,321.0,2009-02-01,2011-01-01,13.978884120171674,Good (10-50/month),139.78884120171676,Exceeded (≥100%),100,80.7,88.185
NCT01703754,Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.,TERMINATED,PHASE2,12.0,2013-04-04,2014-08-07,0.7454693877551021,Slow (<1/month),7.45469387755102,Significantly Below (<50%),10,19.0,4.84
NCT02464254,Intervention to Support Participation in Regular Exercise in the Elderly (INSPIRE),UNKNOWN,NA,60.0,2016-04-01,2020-12-30,1.053287197231834,Adequate (1-10/month),10.53287197231834,Significantly Below (<50%),50,34.8,15.040000000000001
NCT01577654,Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer,COMPLETED,PHASE2,203.0,2011-03-01,2015-08-01,3.8285749690210658,Adequate (1-10/month),38.285749690210665,Significantly Below (<50%),100,66.2,79.2
NCT02923154,Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH),COMPLETED,PHASE2,48.0,2016-09-01,2019-04-01,1.5510828025477708,Adequate (1-10/month),15.510828025477705,Significantly Below (<50%),100,48.8,45.184999999999995
NCT00197054,"Safety, Immunogenicity of RTS,S/AS02A, and RTS,S/AS01B Malaria Vaccines in Malaria-experienced Adults.",COMPLETED,PHASE2,255.0,2005-07-01,2006-09-01,18.178454332552693,Good (10-50/month),181.78454332552693,Exceeded (≥100%),100,75.4,84.64500000000001
NCT00232154,A Study To Measure The Level Of Drug In Nasal Tissue And Blood After Taking A Single 2g Dose Or 500mg Tablets For Up To,COMPLETED,PHASE2,72.0,2005-11-01,2006-06-01,10.33811320754717,Good (10-50/month),103.3811320754717,Exceeded (≥100%),100,60.8,72.99
NCT06069154,Ultrasound-Guided Percutaneous Cryoneurolysis to Treat Pain Following Thoracic Trauma,ENROLLING_BY_INVITATION,NA,120.0,2023-10-30,2027-12-01,2.4466175485599466,Adequate (1-10/month),24.466175485599464,Significantly Below (<50%),55,46.1,34.695
NCT04587154,Womens Study to Alleviate Vasomotor Symptoms,COMPLETED,NA,80.0,2020-09-09,2021-07-31,7.492923076923078,Adequate (1-10/month),74.92923076923078,Below (50-75%),100,56.4,64.88000000000001
NCT03970954,Low-dose Interleukin-2 in Women With Unexplained Miscarriages,COMPLETED,PHASE1,18.0,2021-01-05,2024-03-20,0.46830769230769237,Slow (<1/month),4.683076923076924,Significantly Below (<50%),100,46.4,36.26
NCT04103554,Sacubitril/Valsartan in Left Ventricular Assist Device Recipients,ACTIVE_NOT_RECRUITING,PHASE4,60.0,2021-02-05,2025-02-01,1.25353466026081,Adequate (1-10/month),12.535346602608099,Significantly Below (<50%),85,45.3,31.169999999999998
NCT02768805,Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults,COMPLETED,PHASE2,900.0,2016-03-02,2016-11-26,101.84386617100373,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT05526105,Gastric US in ICU Patient,RECRUITING,NA,50.0,2023-02-03,2025-02-03,2.0820793433652534,Adequate (1-10/month),20.820793433652533,Significantly Below (<50%),60,42.0,24.825
NCT03219905,"Does ""Kinesio-taping"" Affect Balance in Healthy Individuals?",COMPLETED,NA,24.0,2014-04-01,2014-06-01,11.97639344262295,Good (10-50/month),119.7639344262295,Exceeded (≥100%),100,56.9,65.89500000000001
NCT04323605,Assistance Program for Outpatients Following an Allogeneic Hematopoietic Stem-cell Transplant,UNKNOWN,NA,50.0,2021-01-01,2022-02-01,3.8434343434343434,Adequate (1-10/month),38.43434343434344,Significantly Below (<50%),50,39.0,20.505000000000003
NCT05669105,Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental Research,UNKNOWN,,200.0,2022-02-19,2024-03-31,7.896238651102465,Adequate (1-10/month),78.96238651102465,Met (75-100%),50,49.3,46.265
NCT04549805,Troponin to Risk Stratify Patients for Computed Tomography Coronary Angiography,COMPLETED,,250.0,2018-12-04,2020-10-06,11.324404761904763,Good (10-50/month),113.24404761904762,Exceeded (≥100%),100,73.3,83.61
NCT01251705,Comparation of Different Devices to Measure Corneal Thickness,UNKNOWN,,70.0,2010-11-01,2011-02-01,23.160869565217393,Good (10-50/month),200.0,Exceeded (≥100%),50,43.9,28.12
NCT05063305,"Probiotics, Immunity, Stress, and QofL",COMPLETED,NA,100.0,2021-09-27,2022-01-27,24.950819672131146,Good (10-50/month),200.0,Exceeded (≥100%),100,63.0,75.845
NCT05470205,Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal,RECRUITING,PHASE3,660.0,2022-11-28,2026-04-30,16.085188150520416,Good (10-50/month),160.85188150520418,Exceeded (≥100%),60,83.0,89.505
NCT06547905,Evaluation of an Ostomy Leakage Detection System,COMPLETED,NA,22.0,2024-07-24,2024-11-15,5.874385964912281,Adequate (1-10/month),58.74385964912281,Below (50-75%),100,51.8,52.17
NCT05840705,Approach Modification for Total Knee Arthroplasty in Morbidly Obese Patients,UNKNOWN,NA,100.0,2018-01-01,2023-06-08,1.534274193548387,Adequate (1-10/month),15.342741935483872,Significantly Below (<50%),50,38.0,19.255
NCT04079205,Home Rehabilitation Using Smart Wearable Exercise and Electrical Stimulation Device After Anterior Cruciate Ligament Reconstruction,TERMINATED,NA,10.0,2018-12-31,2021-06-30,0.33377192982456144,Slow (<1/month),3.3377192982456143,Significantly Below (<50%),10,18.8,4.58
NCT05861505,COLLISION RELAPSE Trial,RECRUITING,PHASE3,360.0,2023-04-24,2028-05-01,5.975136314067612,Adequate (1-10/month),59.75136314067612,Below (50-75%),60,66.8,79.55
NCT00695305,An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks,COMPLETED,PHASE2,83.0,2008-11-01,2010-05-01,4.627326007326007,Adequate (1-10/month),46.27326007326008,Significantly Below (<50%),100,56.6,65.34
NCT04457505,One Year Follow-ups of Patients Admitted to Spanish Intensive Care Units Due to COVID-19,COMPLETED,,8500.0,2020-05-08,2021-12-31,429.8006644518273,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT05676905,Prospective Multicenter Observational Study on the Use of NEOCEMENT® for the Treatment of Bone Defects,TERMINATED,,165.0,2024-11-06,2024-11-06,165.0,Excellent (>50/month),200.0,Exceeded (≥100%),10,24.5,6.925000000000001
NCT05450705,V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071),ACTIVE_NOT_RECRUITING,PHASE3,1500.0,2022-07-22,2029-08-03,17.773452705332815,Good (10-50/month),177.73452705332815,Exceeded (≥100%),85,90.5,93.4
NCT01587105,Improving Care for Children With Complex Needs,COMPLETED,NA,331.0,2010-10-01,2017-09-29,3.943499021526419,Adequate (1-10/month),39.434990215264186,Significantly Below (<50%),100,76.5,85.3
NCT04391205,A Study to Investigate the Possible Causes of Secondary Effects During Use of Peripheral Midline Type Catheter in Patients Hospitalized in Different Care Settings,COMPLETED,,211.0,2017-04-26,2019-02-28,9.543595839524517,Adequate (1-10/month),95.43595839524515,Met (75-100%),100,70.2,81.99499999999999
NCT04652505,"Effect of the COVID-19 Public Health Crisis on the Mental Health and Physical Well-Being of Cancer Patients, the Coping With COVID Study",COMPLETED,,80.0,2020-07-13,2022-01-12,4.443795620437956,Adequate (1-10/month),44.43795620437956,Significantly Below (<50%),100,54.7,60.629999999999995
NCT01427205,Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC),WITHDRAWN,PHASE2,0.0,2013-06-01,,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT06802705,Psychosocial Stress on QOL in Saudi Arabian Patients with Alopecia Areata,COMPLETED,,398.0,2023-10-01,2024-07-01,44.215766423357664,Good (10-50/month),200.0,Exceeded (≥100%),100,90.2,93.255
NCT06333405,Fecal Microbiota Transplantation (FMT) as a Prophylaxis of Necrotizing Enterocolitis (NEC) - Clinical Study,NOT_YET_RECRUITING,NA,20.0,2024-05-01,2025-01-31,2.213818181818182,Adequate (1-10/month),22.13818181818182,Significantly Below (<50%),30,30.6,9.475
NCT03353805,"Hospital Cohort Survey of Public Health Post-attack of July 14, 2016",COMPLETED,,804.0,2017-06-20,2019-10-31,28.358933951332563,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT06971705,fMRI Study on Cerebral Localization and Network Mechanisms of rTMS in Chronic Ankle Instability Treatment,ACTIVE_NOT_RECRUITING,NA,40.0,2025-03-20,2026-10-31,2.0637288135593224,Adequate (1-10/month),20.63728813559322,Significantly Below (<50%),85,48.7,44.93
NCT03846505,Oxytocin to Enhance Alcohol Behavioral Couple Therapy (ABCT),COMPLETED,PHASE2,192.0,2019-05-16,2024-01-31,3.395979081929111,Adequate (1-10/month),33.959790819291115,Significantly Below (<50%),100,65.4,78.415
NCT06449105,The Effect of Mindfulness Compassionate Living Practice on Hemodialysis Patients,NOT_YET_RECRUITING,NA,68.0,2024-06-15,2024-11-15,13.528888888888888,Good (10-50/month),135.2888888888889,Exceeded (≥100%),30,39.4,20.94
NCT03245905,Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL,UNKNOWN,PHASE2,100.0,2017-08-20,2021-12-31,1.9096612296110413,Adequate (1-10/month),19.09661229611041,Significantly Below (<50%),50,43.0,26.465
NCT01293305,Study With Chondroitin Sulfate and Glucosamine Sulfate (in Dosage Capsule and Sachet) in Treating Osteoarthritis,UNKNOWN,PHASE3,320.0,2011-11-01,2012-12-01,24.5979797979798,Good (10-50/month),200.0,Exceeded (≥100%),50,65.6,78.56
NCT06345105,Prospective Evalulation of Artificial Intelligence-assisted Monitoring of Effective Withdrawal Time Versus Standard Withdrawal Time on Adenoma Detected Per Colonoscopy,COMPLETED,,198.0,2023-11-01,2025-01-31,13.188446389496718,Good (10-50/month),131.88446389496718,Exceeded (≥100%),100,69.2,81.28
NCT02250105,Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia,COMPLETED,PHASE2,80.0,2014-09-01,2016-06-01,3.8109546165884196,Adequate (1-10/month),38.1095461658842,Significantly Below (<50%),100,56.4,64.88000000000001
NCT00727805,[Trial of device that is not approved or cleared by the U.S. FDA],WITHHELD,,,,,,Slow (<1/month),,Significantly Below (<50%),50,20.0,5.695
NCT02858505,Impact of One Versus Two Amino Acid Chelated Iron Capsules on Prevention of Iron Deficiency Anemia in Non-anemic Women With Twin Gestations,COMPLETED,PHASE2,120.0,2015-08-01,2016-07-01,10.903880597014927,Good (10-50/month),109.03880597014926,Exceeded (≥100%),100,64.6,77.59
NCT04713605,Cerebral Blood Flow in Neonates During Major Cardiac Surgery.,RECRUITING,,80.0,2022-03-23,2026-01-01,1.7646376811594204,Adequate (1-10/month),17.6463768115942,Significantly Below (<50%),60,42.7,25.77
NCT00156494,Attitudes About Smoking: A Telephone Survey,COMPLETED,,371.0,2004-06-01,,,Slow (<1/month),,Significantly Below (<50%),100,68.0,80.56
NCT07322094,CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer,RECRUITING,PHASE1,60.0,2025-12-10,2028-01-01,2.428723404255319,Adequate (1-10/month),24.287234042553195,Significantly Below (<50%),60,42.8,25.929999999999996
NCT02942394,Treatment of the Postthrombotic Syndrome With the Oblique Stent - TOPOS Study,COMPLETED,,60.0,2016-12-01,2020-12-17,1.236560595802302,Adequate (1-10/month),12.36560595802302,Significantly Below (<50%),100,48.1,43.275000000000006
NCT04031794,ECMO for Critically Ill Patients With Respiratory Failure and/or Circulatory Failure,UNKNOWN,,250.0,2019-07-22,2025-07-31,3.4575193094048164,Adequate (1-10/month),34.57519309404816,Significantly Below (<50%),50,53.3,57.14
NCT01808794,Comparison of Two Different Membranes,COMPLETED,NA,27.0,2013-01-01,2016-01-01,0.7505753424657535,Slow (<1/month),7.505753424657535,Significantly Below (<50%),100,47.2,40.035
NCT01139294,Descriptive Study of Cardiac Output During Rehydration With Recombinant Human Hyaluronidase in Pediatrics,COMPLETED,PHASE4,17.0,2010-02-01,2011-11-01,0.8110971786833856,Slow (<1/month),8.110971786833856,Significantly Below (<50%),100,46.4,36.26
NCT03372694,Efficacy Study of Comprehensive Rehabilitation Program Plus Chemotherapy in Postoperative NSCLC Patients,UNKNOWN,PHASE3,354.0,2016-10-01,2019-12-30,9.09346835443038,Adequate (1-10/month),90.9346835443038,Met (75-100%),50,68.3,80.875
NCT06261294,OncoSweep Cancer Spotlight and Spectrum Product Line,COMPLETED,,109.0,2023-05-29,2025-05-07,4.679774330042313,Adequate (1-10/month),46.797743300423136,Significantly Below (<50%),100,57.1,66.27
NCT00751894,Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5),UNKNOWN,PHASE2,30.0,,,,Slow (<1/month),,Significantly Below (<50%),50,27.4,8.225
NCT02515994,Evaluation of a Johnson & Johnson Vision Care Investigational Contact Lens Compared to a Marketed Monthly Replacement Contact Lens,COMPLETED,NA,224.0,2015-07-01,2015-11-01,55.43544715447154,Excellent (>50/month),200.0,Exceeded (≥100%),100,77.9,85.955
NCT05768594,Omics in Valvular Disease,UNKNOWN,,30.0,2019-11-15,2023-12-13,0.6132975151108127,Slow (<1/month),6.132975151108127,Significantly Below (<50%),50,30.7,9.585
NCT01608594,Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma,COMPLETED,PHASE1,30.0,2013-05-21,2017-02-27,0.662699564586357,Slow (<1/month),6.626995645863571,Significantly Below (<50%),100,47.4,40.98
NCT02999594,Tramadol for Labor Analgesia: a Placebo Controlled Randomised Control Trial,UNKNOWN,PHASE2,86.0,2016-12-01,2018-05-01,5.073333333333333,Adequate (1-10/month),50.73333333333333,Below (50-75%),50,41.9,24.585
NCT05273294,Ultrasound Measurements of Circular Cartilage Transverse Diameter,UNKNOWN,NA,90.0,2022-03-01,2022-07-01,22.455737704918032,Good (10-50/month),200.0,Exceeded (≥100%),50,47.2,40.035
NCT03466866,Reducing Emergency Diabetes Care for Older African Americans,COMPLETED,PHASE3,156.0,2019-01-10,2023-09-30,2.754431554524362,Adequate (1-10/month),27.54431554524362,Significantly Below (<50%),100,62.5,75.21
NCT07265466,"to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban",RECRUITING,PHASE1,96.0,2025-11-17,2026-03-30,21.97172932330827,Good (10-50/month),200.0,Exceeded (≥100%),60,50.7,48.915
NCT03953066,Colostral Milk and Blood IL-6 Levels in Types of Labour,COMPLETED,NA,90.0,2019-06-12,2019-08-20,39.70434782608696,Good (10-50/month),200.0,Exceeded (≥100%),100,62.2,74.74499999999999
NCT06319066,Customized Foot Orthoses With Orthotic Wedges for Plantar Heel Pain,COMPLETED,NA,120.0,2023-04-01,2024-01-31,11.976393442622951,Good (10-50/month),119.76393442622953,Exceeded (≥100%),100,64.6,77.59
NCT02682966,Direct Evaluation of Postoperative Myocardial Injury Using Coronary Computed Tomography Angiography After Non-Cardiac Surgery,UNKNOWN,,354.0,2016-09-01,2020-12-01,6.943144329896907,Adequate (1-10/month),69.43144329896907,Below (50-75%),50,61.7,74.1
NCT01858766,Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection,COMPLETED,PHASE2,379.0,2013-04-01,2014-08-01,23.689445585215605,Good (10-50/month),200.0,Exceeded (≥100%),100,85.3,91.355
NCT01012466,The Physical Effects of Pain Catastrophizing in Labor,COMPLETED,,91.0,2009-06-01,2010-06-01,7.589150684931508,Adequate (1-10/month),75.89150684931508,Met (75-100%),100,55.6,62.905
NCT01771666,Pilot Indocyanine Green Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast Cancer,COMPLETED,PHASE2,23.0,2012-07-01,2015-03-17,0.7079069767441861,Slow (<1/month),7.079069767441862,Significantly Below (<50%),100,46.8,38.440000000000005
NCT05691166,Reducing Falls With Progressive Resistance Training for the Oldest Old Adults With Sarcopenia,ACTIVE_NOT_RECRUITING,NA,241.0,2023-03-30,2028-09-29,3.6497711442786067,Adequate (1-10/month),36.49771144278607,Significantly Below (<50%),85,64.8,77.865
NCT05054166,Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study,COMPLETED,,14.0,2021-05-01,2021-08-30,3.5219834710743805,Adequate (1-10/month),35.21983471074381,Significantly Below (<50%),100,49.5,46.58
NCT00987766,"Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer",COMPLETED,PHASE1,28.0,2009-11-01,2016-10-01,0.3374188440221695,Slow (<1/month),3.374188440221695,Significantly Below (<50%),100,47.2,40.035
NCT00270166,The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy,COMPLETED,PHASE3,201.0,1995-02-01,1998-05-01,5.163240506329115,Adequate (1-10/month),51.632405063291145,Below (50-75%),100,66.1,79.125
NCT02502266,Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer,ACTIVE_NOT_RECRUITING,PHASE2,582.0,2016-05-03,2026-07-16,4.754718196457327,Adequate (1-10/month),47.54718196457327,Significantly Below (<50%),85,85.5,91.42
NCT00126256,Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer,COMPLETED,PHASE3,570.0,2002-02-01,2006-02-01,11.875975359342917,Good (10-50/month),118.75975359342917,Exceeded (≥100%),100,95.0,95.7
NCT00283556,High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma,COMPLETED,PHASE1,30.0,2001-08-01,2008-12-01,0.3408734602463606,Slow (<1/month),3.408734602463606,Significantly Below (<50%),100,47.4,40.98
NCT06784856,"Effects of AR-Based Education on PICC Care Knowledge, Clinical Reasoning, and Learning Engagement in Nurses",COMPLETED,NA,157.0,2024-08-03,2024-11-01,53.10088888888889,Excellent (>50/month),200.0,Exceeded (≥100%),100,72.6,83.28
NCT03299556,Effect of Wearable Health Technology on Patients Treated for Chronic Pain at Geisinger Health System,COMPLETED,,420.0,2017-10-05,2019-11-30,16.265648854961835,Good (10-50/month),162.65648854961833,Exceeded (≥100%),100,86.9,92.085
NCT02692456,Effect of Patient Position on Computerized Tomography Guided Celiac Trunk Neurolysis,COMPLETED,NA,34.0,2015-06-01,2015-12-01,5.65551912568306,Adequate (1-10/month),56.5551912568306,Below (50-75%),100,52.7,55.04
NCT03670056,Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy,ACTIVE_NOT_RECRUITING,PHASE2,25.0,2018-12-06,2025-12-01,0.29819749216300945,Slow (<1/month),2.981974921630094,Significantly Below (<50%),85,42.5,25.585
NCT00368056,Effects of One Evening Dose of 3 mg Eszopiclone on Next Day Driving Ability,COMPLETED,PHASE3,32.0,2005-04-01,2006-06-01,2.2865727699530516,Adequate (1-10/month),22.865727699530517,Significantly Below (<50%),100,52.6,54.684999999999995
NCT01371656,Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation,COMPLETED,PHASE3,624.0,2011-09-01,2017-06-01,9.045028571428572,Adequate (1-10/month),90.45028571428571,Met (75-100%),100,95.0,95.7
NCT06886256,Prehabilitation for Kidney Transplant Candidates,RECRUITING,NA,15.0,2025-03-26,2025-09-30,2.428723404255319,Adequate (1-10/month),24.287234042553195,Significantly Below (<50%),60,39.2,20.715
NCT02143856,Oral Bioavailability of Solid Formulation of GLPG1205 With and Without Food,COMPLETED,PHASE1,12.0,2014-05-01,2014-07-01,5.988196721311475,Adequate (1-10/month),59.88196721311475,Below (50-75%),100,51.0,49.714999999999996
NCT03503656,"""Compuflo®"" in Epidural Space Identification",COMPLETED,,140.0,2017-01-01,2018-04-01,9.366153846153846,Adequate (1-10/month),93.66153846153847,Met (75-100%),100,64.5,77.44
NCT05776056,Methylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints,RECRUITING,PHASE4,70.0,2024-02-05,2027-03-31,1.8528695652173914,Adequate (1-10/month),18.528695652173912,Significantly Below (<50%),60,43.6,27.54
NCT02347956,The Safety and Feasibility of Reduced Port Robotic Distal Gastrectomy Using Single-site for Surgical Treatment of Early Gastric Cancer,COMPLETED,PHASE1,19.0,2015-01-01,2015-11-01,1.9025,Adequate (1-10/month),19.025,Significantly Below (<50%),100,51.5,51.245
NCT06130956,The Effect of a 2-week Preoperative Vegan Diet Versus Omnivorous Diet on the Protein Turnover in the Osteoarthritic Knee,RECRUITING,NA,40.0,2024-10-22,2026-12-01,1.5812987012987014,Adequate (1-10/month),15.812987012987016,Significantly Below (<50%),60,36.2,16.84
NCT04264156,A Safety and Efficacy Study of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age,TERMINATED,PHASE2,12.0,2020-04-18,2021-03-28,1.061860465116279,Adequate (1-10/month),10.61860465116279,Significantly Below (<50%),10,19.0,4.84
NCT03018756,Nebulized Fentanyl in Patients With Mild to Moderate Interstitial Lung Disease and Chronic Dyspnea,COMPLETED,PHASE3,21.0,2017-01-01,2020-11-30,0.447333799860042,Slow (<1/month),4.47333799860042,Significantly Below (<50%),100,46.7,37.895
NCT02357056,Randomized Controlled Evaluation of Robotic Cardiac Surgery Training Modalities,COMPLETED,NA,40.0,2015-04-01,2015-07-01,13.38021978021978,Good (10-50/month),133.8021978021978,Exceeded (≥100%),100,58.2,68.795
NCT06060756,Assessment of the Occurrence of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) in Women Suffering from Endometriosis,NOT_YET_RECRUITING,,80.0,2024-10-01,2026-10-01,3.3358904109589043,Adequate (1-10/month),33.35890410958904,Significantly Below (<50%),30,33.7,13.465
NCT03955822,"Essure Permanent Birth Control, Effectiveness and Safety: A French Survey",COMPLETED,,642.0,2018-07-10,2019-01-16,102.85515789473685,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT00760422,Clinical Evaluation of NIR (Non-Invasive Infrared) Thermometer Performance,COMPLETED,,500.0,2008-12-01,2010-03-01,33.45054945054945,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT04414722,Mechanisms of Probiotics and Antibiotic-Associated Diarrhea,COMPLETED,EARLY_PHASE1,118.0,2021-01-01,2023-05-01,4.225788235294117,Adequate (1-10/month),42.25788235294118,Significantly Below (<50%),100,59.4,70.905
NCT02415322,Cohort Study on Internet Game and Smart Phone Addiction,COMPLETED,,2319.0,2015-05-01,2019-03-01,50.421685714285715,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT06052722,The Relationship of Premenstrual Syndrome and Primary Dysmenorrhea With Severity of Temporomandibular Disorders,UNKNOWN,NA,60.0,2023-10-01,2023-12-31,20.07032967032967,Good (10-50/month),200.0,Exceeded (≥100%),50,44.8,29.845
NCT03460522,Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL,UNKNOWN,PHASE2,65.0,2018-05-02,2025-12-01,0.7142960288808665,Slow (<1/month),7.142960288808665,Significantly Below (<50%),50,35.2,15.445
NCT05947422,CT Quantitative Assessment of Interstitial Lung Disease,RECRUITING,,70.0,2023-12-01,2025-12-30,2.803684210526316,Adequate (1-10/month),28.036842105263162,Significantly Below (<50%),60,41.9,24.585
NCT05071222,Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE),RECRUITING,PHASE1,5.0,2023-07-19,2041-07-19,0.023148288973384033,Slow (<1/month),0.23148288973384035,Significantly Below (<50%),60,33.4,13.29
NCT01585922,Noninvasive Positive Pressure Ventilation in Moderate Acute Respiratory Distress Syndrome,COMPLETED,NA,120.0,2012-07-01,2016-12-01,2.263197026022305,Adequate (1-10/month),22.63197026022305,Significantly Below (<50%),100,59.6,71.17999999999999
NCT05571722,Linezolid or Vancomycin Surgical Site Infection Prophylaxis,RECRUITING,PHASE4,1160.0,2024-11-01,2026-04-03,68.16679536679537,Excellent (>50/month),200.0,Exceeded (≥100%),60,88.0,92.495
NCT06878222,Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC,RECRUITING,PHASE2,35.0,2025-03-15,2030-03-31,0.5783930510314875,Slow (<1/month),5.7839305103148755,Significantly Below (<50%),60,35.8,16.325
NCT06247722,Real World Use of Tocilizumab Biosimilar studY,ACTIVE_NOT_RECRUITING,,600.0,2024-03-05,2026-03-31,24.158730158730158,Good (10-50/month),200.0,Exceeded (≥100%),85,88.8,92.89
NCT02419222,Feasibility of Using Prism Adaptation to Treat Spatial Neglect and Motor Function in Stroke,COMPLETED,NA,30.0,2015-01-01,2016-12-01,1.3045714285714285,Adequate (1-10/month),13.045714285714286,Significantly Below (<50%),100,47.4,40.98
NCT02846922,Catheter Ablation and Rate Control of Atrial Fibrillation in Patients With Heart Failure,COMPLETED,,394.0,2016-08-01,2016-12-01,98.30622950819672,Excellent (>50/month),200.0,Exceeded (≥100%),100,89.9,93.08999999999999
NCT00653822,A Study of Pharmacokinetics and Safety of Alefacept in Caucasian and Japanese Healthy Volunteers,COMPLETED,PHASE1,75.0,2008-03-01,2008-07-01,18.71311475409836,Good (10-50/month),187.1311475409836,Exceeded (≥100%),100,61.0,73.17
NCT00367822,Transdermal Lisuride: a Trial for the Treatment of Patients With Restless Legs Syndrome (RLS),COMPLETED,PHASE3,300.0,,,,Slow (<1/month),,Significantly Below (<50%),100,64.0,77.025
NCT03807622,ClearSight System CHN Study,COMPLETED,,125.0,2018-12-25,2019-10-17,12.85472972972973,Good (10-50/month),128.5472972972973,Exceeded (≥100%),100,63.3,76.235
NCT01970722,"Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer",ACTIVE_NOT_RECRUITING,PHASE1,40.0,2014-05-19,2026-02-03,0.2846189808321646,Slow (<1/month),2.846189808321646,Significantly Below (<50%),85,43.7,27.744999999999997
NCT05267522,Independent Effects of High-cholesterol (High-egg) and High-saturated Fat Diets on LDL-cholesterol,COMPLETED,NA,77.0,2022-03-01,2023-08-31,4.277153284671533,Adequate (1-10/month),42.771532846715324,Significantly Below (<50%),100,56.2,64.21
NCT06497322,Exercise Intervention in Women Diagnosed With Triple-negative Breast Cancer Receiving Oncologic Treatment,NOT_YET_RECRUITING,NA,60.0,2024-09-01,2027-12-31,1.5019736842105262,Adequate (1-10/month),15.019736842105264,Significantly Below (<50%),30,28.8,8.665000000000001
NCT00616122,"Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer",TERMINATED,PHASE1,32.0,2006-03-01,2012-12-01,0.3948439400081071,Slow (<1/month),3.9484394000810705,Significantly Below (<50%),10,20.6,5.965
NCT05263622,Guided Biofilm Therapy for Periodontal Patients.,COMPLETED,NA,20.0,2022-03-22,2022-09-02,3.7121951219512197,Adequate (1-10/month),37.1219512195122,Significantly Below (<50%),100,51.6,51.644999999999996
NCT06493422,Online Interplay Between Deciding and Acting With Mild Cognitive Impairment,RECRUITING,NA,60.0,2025-01-28,2026-06-30,3.525868725868726,Adequate (1-10/month),35.25868725868726,Significantly Below (<50%),60,42.8,25.929999999999996
NCT04019522,American Heart Association- Stroke/Hypoxia Study,UNKNOWN,NA,12.0,2019-07-15,2024-03-01,0.21601419278533412,Slow (<1/month),2.160141927853341,Significantly Below (<50%),50,31.0,9.985
NCT00296322,Trial of Adjuvant Chemotherapy for Gastric Cancer,COMPLETED,PHASE3,528.0,2001-10-01,2010-03-01,5.230172469899122,Adequate (1-10/month),52.30172469899122,Below (50-75%),100,90.0,93.17
NCT01111422,Anti-Oxidant Effect on Peritoneal Membrane in Peritoneal Dialysis (PD) Patients,UNKNOWN,PHASE4,66.0,2010-03-01,2011-12-01,3.139125,Adequate (1-10/month),31.391250000000003,Significantly Below (<50%),50,40.3,22.21
NCT03130322,SLeep and IMagery Correlates (SOMMEIL-IMAGERIE),COMPLETED,NA,51.0,2015-12-09,2018-07-04,1.6550533049040512,Adequate (1-10/month),16.55053304904051,Significantly Below (<50%),100,49.1,45.83
NCT04326322,Methionine Requirements During Healthy Human Pregnancy,ACTIVE_NOT_RECRUITING,NA,69.0,2020-09-14,2025-12-30,1.086580444904294,Adequate (1-10/month),10.865804449042939,Significantly Below (<50%),85,46.0,34.1
NCT00005422,Longitudinal Analysis of Spirometry in Black Children,COMPLETED,,,1992-04-01,1995-03-01,,Slow (<1/month),,Significantly Below (<50%),100,43.3,27.05
NCT05601622,RPVI for Fluid Responsiveness in Children,UNKNOWN,NA,45.0,2022-11-15,2024-10-20,1.9429787234042553,Adequate (1-10/month),19.42978723404255,Significantly Below (<50%),50,38.6,20.015
NCT00373022,Moderate Physical Activity in Helping Patients Recover Physically and Emotionally From Stage II Or Stage III Colorectal Cancer,COMPLETED,NA,45.0,2004-01-01,2006-12-01,1.2861971830985917,Adequate (1-10/month),12.861971830985915,Significantly Below (<50%),100,48.6,44.685
NCT03491722,Surviving a Decade or More After Coronary Revascularization in a Middle Eastern Population,COMPLETED,,1000.0,2018-06-01,2019-06-10,81.3903743315508,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT05586022,Risk Factors for Adverse Outcomes of Endovascular Revascularization in Lower Extremity Arteriosclerosis Occlusion,RECRUITING,,500.0,2022-10-20,2024-12-01,19.689521345407503,Good (10-50/month),196.89521345407505,Exceeded (≥100%),60,81.3,88.58
NCT05848622,Gait Rehabilitation to Treat FastOA,RECRUITING,NA,70.0,2023-06-13,2026-05-01,2.02355175688509,Adequate (1-10/month),20.2355175688509,Significantly Below (<50%),60,43.6,27.54
NCT02501122,Retrospective Analysis in Quality of Care Measures in Pediatric Adenotonsillectomy Patients,COMPLETED,,1000000.0,2015-12-01,2017-01-01,76675.0629722922,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02079922,A Multiple Dose Study Of PF-06678552 In Healthy Subjects,COMPLETED,PHASE1,38.0,2014-03-01,2014-07-01,9.481311475409836,Adequate (1-10/month),94.81311475409835,Met (75-100%),100,58.0,68.245
NCT04822051,The Effect of Psychoeducation Based on Uncertainty In Illness Theory On Schizophrenia Caregivers,COMPLETED,NA,54.0,2019-04-01,2020-08-31,3.1732818532818534,Adequate (1-10/month),31.732818532818534,Significantly Below (<50%),100,54.3,59.62
NCT04955951,Ultrasonographic Response to Polarized Light Therapy in the Treatment of Atopic Dermatitis,TERMINATED,,40.0,2021-07-01,2022-01-15,6.14949494949495,Adequate (1-10/month),61.494949494949495,Below (50-75%),10,24.5,6.925000000000001
NCT07331051,Nutritional Attitudes and Anthropometric Measurements in Relation to Agility in Football Players,COMPLETED,,51.0,2024-01-15,2024-03-15,25.874000000000002,Good (10-50/month),200.0,Exceeded (≥100%),100,57.4,67.05499999999999
NCT06267651,"Value Of ACE Index (Albumin, CRP And Endoscopy) In Predicting Intra Venous Steroid Response In Acute Severe Ulcerative Colitis In Assiut University Hospitals",NOT_YET_RECRUITING,,95.0,2025-01-01,2027-01-01,3.961369863013699,Adequate (1-10/month),39.61369863013699,Significantly Below (<50%),30,34.9,15.215
NCT06096051,Evaluation of 4-Factor PCC in DOAC-associated Intracranial Hemorrhage,UNKNOWN,,100.0,2023-07-13,2024-07-13,8.316939890710383,Adequate (1-10/month),83.16939890710383,Met (75-100%),50,41.3,23.74
NCT05989451,Adaptation of Individual Dialectical Behavior Therapy Intervention for Transdiagnostic Treatment of Emotional Disorders,RECRUITING,NA,250.0,2023-09-01,2026-10-01,6.758436944937833,Adequate (1-10/month),67.58436944937833,Below (50-75%),60,58.0,68.245
NCT06492551,Post-COVID-19 Patients With Trak Tool,COMPLETED,NA,80.0,2022-03-16,2022-10-05,11.996059113300493,Good (10-50/month),119.96059113300494,Exceeded (≥100%),100,61.4,73.735
NCT06266351,EVALUATION of CATS TONOMETER PRISM in LASIK SUBJECTS,COMPLETED,,198.0,2024-02-12,2024-08-01,35.246315789473684,Good (10-50/month),200.0,Exceeded (≥100%),100,69.2,81.28
NCT01868451,"Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma",ACTIVE_NOT_RECRUITING,NA,118.0,2013-05-01,2026-05-01,0.7565122156697557,Slow (<1/month),7.565122156697557,Significantly Below (<50%),85,49.9,47.425
NCT06833151,Ultrasound Measurement of Pleural Line Sliding as a Surrogate Indicator of Lung Volume Change: A Comparative Study With Ventilator Volume Data,ACTIVE_NOT_RECRUITING,,12.0,2025-02-06,2025-12-31,1.113658536585366,Adequate (1-10/month),11.136585365853659,Significantly Below (<50%),85,39.8,21.47
NCT04988451,Family ASL: Longitudinal Study of Deaf Children and Hearing Parents Who Receive Services to Support the Learning of ASL,ACTIVE_NOT_RECRUITING,NA,40.0,2021-07-20,2025-11-30,0.7638644918444165,Slow (<1/month),7.638644918444165,Significantly Below (<50%),85,43.7,27.744999999999997
NCT03650751,Clinical Study on Screening of Nursing Evaluation Indicators of Stroke Patients,UNKNOWN,,300.0,2017-09-01,2019-12-01,11.123020706455542,Good (10-50/month),111.23020706455542,Exceeded (≥100%),50,62.3,74.94
NCT04246151,Oral Vancomycin Versus Probiotics Versus Placebo for Prevention of Clostridium Difficile Infection in Colonized Patients,WITHDRAWN,EARLY_PHASE1,0.0,2022-09-01,2024-09-12,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT01717651,Muscle Atrophy in Patients With Severe Sepsis,TERMINATED,,25.0,2011-12-01,2013-02-01,1.7780373831775702,Adequate (1-10/month),17.7803738317757,Significantly Below (<50%),10,23.3,6.569999999999999
NCT01007851,Single Dose Gonadotropin-releasing Hormone (GnRH) Agonist Administration in the Luteal Phase of GnRH Antagonist Stimulated ICSI-ET Cycles,TERMINATED,PHASE3,,2006-09-01,2007-12-01,,Slow (<1/month),,Significantly Below (<50%),10,18.0,2.92
NCT06112951,A Prospective Randomized Trial of ECP in Subclinical AMR,RECRUITING,NA,80.0,2024-03-01,2027-06-01,2.051558550968829,Adequate (1-10/month),20.51558550968829,Significantly Below (<50%),60,44.4,28.95
NCT04885751,Compare the Effect of Eupatilin and Rebamipide on the Prevention of Gastroenteropathy,UNKNOWN,PHASE4,50.0,2021-06-01,2022-01-31,6.237704918032787,Adequate (1-10/month),62.37704918032786,Below (50-75%),50,39.0,20.505000000000003
NCT01076751,Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients,TERMINATED,,82.0,2010-02-01,2010-10-01,10.314380165289258,Good (10-50/month),103.14380165289259,Exceeded (≥100%),10,32.9,12.53
NCT05069051,Belimumab in Patients with Chronic Lymphocytic Leukemia,ACTIVE_NOT_RECRUITING,PHASE2,120.0,2022-01-19,2027-07-14,1.8245754245754247,Adequate (1-10/month),18.24575424575425,Significantly Below (<50%),85,55.1,62.085
NCT03382951,Development and Validation of an Automated Measurement of Child Screen Media Use: FLASH,COMPLETED,,321.0,2017-10-19,2023-11-27,4.38172197309417,Adequate (1-10/month),43.81721973094171,Significantly Below (<50%),100,74.0,83.985
NCT00186251,High Dose Chemotherapy Followed By PBSC Rescue for HD,COMPLETED,NA,200.0,1998-03-01,2005-07-01,2.2724897349757374,Adequate (1-10/month),22.724897349757374,Significantly Below (<50%),100,66.0,78.99000000000001
NCT00002251,A Multiple Dose Crossover Pharmacokinetics Study to Evaluate the Effects of Food on the Absorption of Oral Ganciclovir,COMPLETED,NA,20.0,,,,Slow (<1/month),,Significantly Below (<50%),100,41.6,24.29
NCT01032551,Vascular Access Decision Aid,COMPLETED,NA,100.0,2010-06-01,2010-12-01,16.633879781420767,Good (10-50/month),166.33879781420765,Exceeded (≥100%),100,63.0,75.845
NCT05400551,Craneofacial Injuries in Rink Hockey Athletes,UNKNOWN,,200.0,2022-09-01,2023-04-30,25.261410788381745,Good (10-50/month),200.0,Exceeded (≥100%),50,54.3,59.62
NCT01317251,Effect of Milk and Cheese on Fecal Fat Excretion and Blood Lipid,COMPLETED,NA,15.0,2011-03-01,2012-09-01,0.8301818181818182,Slow (<1/month),8.301818181818183,Significantly Below (<50%),100,46.2,35.089999999999996
NCT01556451,ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034),COMPLETED,PHASE4,180.0,2012-04-01,2012-10-01,29.940983606557378,Good (10-50/month),200.0,Exceeded (≥100%),100,69.4,81.52000000000001
NCT00422929,Eustachian Tube Growth and Development,COMPLETED,,126.0,2006-08-01,2018-08-24,0.8705038583749433,Slow (<1/month),8.705038583749433,Significantly Below (<50%),100,53.4,57.35
NCT05379829,A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and Inflammation,COMPLETED,PHASE1,24.0,2022-05-30,2024-09-02,0.884455205811138,Slow (<1/month),8.844552058111379,Significantly Below (<50%),100,46.9,38.96
NCT02372929,Relationship Between Endoscopic Ultrasound Staging and Degree of Stricture in Esophageal Cancer,COMPLETED,,100.0,2012-04-01,2014-04-01,4.169863013698631,Adequate (1-10/month),41.6986301369863,Significantly Below (<50%),100,56.3,64.5
NCT04429529,"Safety of TY027, a Treatment for COVID-19, in Humans",COMPLETED,PHASE1,32.0,2020-06-09,2021-01-20,4.329244444444445,Adequate (1-10/month),43.29244444444445,Significantly Below (<50%),100,52.6,54.684999999999995
NCT05551429,Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome,COMPLETED,,60.0,2022-09-22,2024-01-12,3.828930817610063,Adequate (1-10/month),38.289308176100626,Significantly Below (<50%),100,53.1,56.105000000000004
NCT04515329,Tear Film Markers in Dry Eye Syndrome,WITHDRAWN,PHASE4,0.0,2023-12-08,2023-12-08,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT03832829,Clinical Evaluation of Posterior Indirect Resin Composite Restorations With PBE,UNKNOWN,NA,80.0,2018-09-11,2025-09-01,0.9561052218296036,Slow (<1/month),9.561052218296036,Significantly Below (<50%),50,36.4,17.14
NCT04615429,Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19,UNKNOWN,PHASE2,20.0,2020-09-15,2022-02-01,1.2079365079365079,Adequate (1-10/month),12.079365079365079,Significantly Below (<50%),50,31.6,10.905
NCT00191529,Growth Hormone Treatment in Short Children Born Small for Gestational Age,COMPLETED,PHASE3,200.0,2002-12-01,2007-06-01,3.705416920267803,Adequate (1-10/month),37.05416920267803,Significantly Below (<50%),100,66.0,78.99000000000001
NCT04282629,Cerebral Hemodynamic Optimization by Milrinone to Prevent Delayed Cerebral Ischemia,RECRUITING,PHASE2,234.0,2021-07-25,2025-07-01,4.956826722338205,Adequate (1-10/month),49.568267223382044,Significantly Below (<50%),60,56.7,65.53
NCT01888029,Influence of tDCS on Cortical Plasticity in Patients With Mild Cognitive Impairment (MCI),WITHDRAWN,NA,0.0,2013-05-01,2017-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT00915629,Prevention of Recurrent Vulvovaginal Candidiasis With Lactibiane Candisis 5M®,TERMINATED,NA,134.0,2009-06-01,2010-07-01,10.32648101265823,Good (10-50/month),103.26481012658229,Exceeded (≥100%),10,38.7,20.145
NCT00426829,Proton Therapy and Bevacizumab for Primary Liver Tumors,TERMINATED,PHASE1,3.0,2007-05-01,2009-11-01,0.0998032786885246,Slow (<1/month),0.9980327868852459,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT04679129,"Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ASC42 in Healthy Subjects",COMPLETED,PHASE1,64.0,2020-11-30,2021-06-03,10.530594594594595,Good (10-50/month),105.30594594594595,Exceeded (≥100%),100,60.1,72.085
NCT02096029,Tobacco Intervention in Primary Care Treatment Opportunities for Providers,COMPLETED,NA,1278.0,2014-07-01,2018-06-15,26.922020761245676,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT03171129,ADINA vs. High Flow Nasal Cannula Comparison Study,NOT_YET_RECRUITING,NA,40.0,2026-07-01,2027-09-01,2.8515222482435596,Adequate (1-10/month),28.515222482435597,Significantly Below (<50%),30,32.2,11.635
NCT01639729,Effect of Delivery Route on PK of Sufentanil NanoTab,COMPLETED,PHASE1,25.0,2012-07-01,2012-07-01,25.0,Good (10-50/month),200.0,Exceeded (≥100%),100,42.0,24.825
NCT05651529,Acute Oral Ketones or Carbohydrate Supplement Modify Heart Function in Heart Failure?,COMPLETED,NA,20.0,2022-12-16,2025-12-16,0.5554744525547445,Slow (<1/month),5.554744525547445,Significantly Below (<50%),100,46.6,37.375
NCT00043329,"Post Marketing Surveillance Study of Actimmune in Patients With Severe, Malignant Osteopetrosis",COMPLETED,,6.0,2002-01-01,2005-09-01,0.13640029873039583,Slow (<1/month),1.3640029873039583,Significantly Below (<50%),100,43.8,27.965
NCT02969629,The Effects of Apomorphine on Experimental and Clinical Pain in Patients With Chronic Radicular Pain,COMPLETED,PHASE4,59.0,2012-12-01,2014-12-01,2.460219178082192,Adequate (1-10/month),24.60219178082192,Significantly Below (<50%),100,54.7,60.629999999999995
NCT00400829,E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer,COMPLETED,PHASE2,66.0,2006-11-01,2011-01-01,1.32,Adequate (1-10/month),13.200000000000001,Significantly Below (<50%),100,50.3,48.215
NCT03247829,Investigation to Optimize Hemodynamic Management of Left Ventricular Assist Devices Using the CardioMEMS™,COMPLETED,,101.0,2017-08-24,2020-06-30,2.953352545629203,Adequate (1-10/month),29.533525456292033,Significantly Below (<50%),100,56.4,64.88000000000001
NCT01543529,A Pharmacodynamic and Pharmacokinetic Study of RO4917838 in Healthy Volunteers,COMPLETED,PHASE1,25.0,2012-02-28,2012-06-04,7.845360824742269,Adequate (1-10/month),78.45360824742268,Met (75-100%),100,52.0,52.86
NCT03123029,Expanded Access to Venetoclax,AVAILABLE,,,,,,Slow (<1/month),,Significantly Below (<50%),50,23.3,6.569999999999999
NCT05125029,Botulinum Toxin in Raynaud's Phenomenon,RECRUITING,PHASE4,36.0,2022-02-10,2025-12-01,0.7883741007194245,Slow (<1/month),7.883741007194245,Significantly Below (<50%),60,35.9,16.445
NCT02141529,Intraarticular Pulse Radiofrequency to Treat Chronic Knee Pain,COMPLETED,NA,100.0,2014-05-01,2015-12-01,5.257340241796201,Adequate (1-10/month),52.573402417962,Below (50-75%),100,58.0,68.245
NCT00385229,Post Term Pregnancy - Induction of Labor or Monitoring of Pregnancy,COMPLETED,NA,508.0,2002-09-01,2004-07-01,23.11437967115097,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT00348829,Mitral Valve Reconstruction in Chronic Heart Failure (CHF): Identification of Predictors for a Successful Therapy,TERMINATED,PHASE2,5.0,2006-06-01,2012-09-01,0.06663747810858144,Slow (<1/month),0.6663747810858144,Significantly Below (<50%),10,18.4,3.855
NCT02855229,Novel Cross-Species Neurophysiological Assays of Reward and Cognitive Domains,COMPLETED,,222.0,2020-08-15,2021-08-31,17.736692913385827,Good (10-50/month),177.3669291338583,Exceeded (≥100%),100,71.1,82.54
NCT00408629,Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis,COMPLETED,PHASE3,518.0,2006-11-01,2010-03-01,12.96703947368421,Good (10-50/month),129.67039473684213,Exceeded (≥100%),100,95.0,95.7
NCT01549431,Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma,COMPLETED,PHASE1,32.0,2012-01-01,2017-04-01,0.5081272822117893,Slow (<1/month),5.081272822117893,Significantly Below (<50%),100,47.6,41.775
NCT01367431,Xanthohumol and Metabolic Syndrome,COMPLETED,,48.0,2011-08-01,2012-04-01,5.988196721311475,Adequate (1-10/month),59.88196721311475,Below (50-75%),100,52.2,53.22
NCT02608931,"The Safety, Tolerability and Efficacy of Dronabinol, for the Treatment of Nausea and Vomiting in Familial Dysautonomia",WITHDRAWN,PHASE2,0.0,2015-11-01,2019-03-22,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT06350331,Smart Technology Facilitated Patient-centered Venous Thromboembolism Management,ENROLLING_BY_INVITATION,NA,256.0,2024-08-17,2025-11-30,16.58008510638298,Good (10-50/month),165.8008510638298,Exceeded (≥100%),55,62.0,74.42
NCT01046331,Novel Influenza A (H1N1) Surveillance Registry,COMPLETED,,894.0,2009-10-01,2010-10-01,74.55715068493151,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02243631,Effect of Probenecid on Synovial Fluid ATP Levels in CPPD,COMPLETED,EARLY_PHASE1,8.0,2014-10-15,2021-04-08,0.10288128432615125,Slow (<1/month),1.0288128432615125,Significantly Below (<50%),100,45.6,32.08
NCT03919331,Impact of Current Volume Under High-rate Nasal Oxygen Therapy During Acute Hypoxemic Respiratory Failure de Novo,UNKNOWN,NA,60.0,2019-06-01,2021-09-01,2.219198055893074,Adequate (1-10/month),22.19198055893074,Significantly Below (<50%),50,39.8,21.47
NCT04675931,"To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria",COMPLETED,PHASE2,254.0,2022-03-07,2025-08-20,6.126592709984153,Adequate (1-10/month),61.26592709984152,Below (50-75%),100,70.3,82.09
NCT01350531,Interventionist Procedures for Adherence to Weight Loss Recommendations in Black Adolescents,UNKNOWN,NA,200.0,2009-09-01,2014-06-01,3.5109573241061134,Adequate (1-10/month),35.109573241061135,Significantly Below (<50%),50,51.0,49.714999999999996
NCT07379931,Evaluating a Liquid Extract of Carob to Improve Blood Sugar in People With Prediabetes,NOT_YET_RECRUITING,NA,70.0,2026-01-01,2026-04-30,17.905882352941177,Good (10-50/month),179.05882352941177,Exceeded (≥100%),30,39.6,21.115000000000002
NCT00655031,Trial to Evaluate the Use of Pomegranate Concentrate (POMx) for the Prevention of Experimental Rhinovirus Infection,COMPLETED,PHASE2,150.0,2008-04-01,2008-07-01,50.175824175824175,Excellent (>50/month),200.0,Exceeded (≥100%),100,72.0,82.92
NCT03468231,HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC,UNKNOWN,PHASE3,300.0,2018-03-09,2020-03-09,12.49247606019152,Good (10-50/month),124.9247606019152,Exceeded (≥100%),50,64.0,77.025
NCT04053231,Hepatocarcinoma Recurrence on the Liver Study - Part2,NOT_YET_RECRUITING,,3000.0,2019-09-01,2034-05-01,17.05003734129948,Good (10-50/month),170.50037341299478,Exceeded (≥100%),30,72.3,83.065
NCT01743131,Abatacept as GVHD Prophylaxis Phase 2,COMPLETED,PHASE2,186.0,2013-02-01,2024-03-30,1.3894085889570553,Adequate (1-10/month),13.894085889570555,Significantly Below (<50%),100,59.9,71.86
NCT03786731,A Transdiagnostic Sleep and Circadian Treatment for Major Depressive Disorder,UNKNOWN,NA,150.0,2019-01-01,2021-06-01,5.1768707482993195,Adequate (1-10/month),51.76870748299321,Below (50-75%),50,47.0,39.33
NCT07183631,Healing of Intrabony Defects Following Treatment With PRF or EMD,COMPLETED,PHASE4,28.0,2021-09-01,2025-08-25,0.5861898211829436,Slow (<1/month),5.861898211829436,Significantly Below (<50%),100,47.2,40.035
NCT02176031,Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD,COMPLETED,PHASE2,21.0,2015-01-01,2019-02-01,0.42844504021447727,Slow (<1/month),4.284450402144772,Significantly Below (<50%),100,46.7,37.895
NCT04152031,Activity-Aware Prompting to Improve Medication Adherence in Heart Failure Patients,COMPLETED,NA,40.0,2016-10-20,2019-08-05,1.1948969578017665,Adequate (1-10/month),11.948969578017666,Significantly Below (<50%),100,48.2,43.665
NCT07123831,The Effect of Privacy Education With Virtual Reality Application on Children's Privacy Awareness and Saying No Skills,COMPLETED,NA,97.0,2024-11-19,2025-05-30,15.378541666666667,Good (10-50/month),153.78541666666666,Exceeded (≥100%),100,62.8,75.53999999999999
NCT02233231,Smoking Young Asthmatics: Change of Inflammation During Tobacco Cessation and Steroid Treatment,COMPLETED,PHASE4,52.0,2011-08-01,2013-05-01,2.4771205007824726,Adequate (1-10/month),24.77120500782473,Significantly Below (<50%),100,54.2,59.330000000000005
NCT05730231,Clinical Trials of Effects of Time Restricted Eating on Health Parameters in Adults,COMPLETED,NA,108.0,2023-03-03,2024-06-30,6.77839175257732,Adequate (1-10/month),67.78391752577319,Below (50-75%),100,58.6,69.51
NCT01574131,Acute and Long-Term Outcome Investigations of Fenofibrate on Severely Burned Patients,TERMINATED,PHASE4,3.0,2012-05-01,2016-02-01,0.06660831509846828,Slow (<1/month),0.6660831509846827,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT00005131,Atherosclerosis Risk in Communities (ARIC),COMPLETED,,,1985-07-01,2007-01-01,,Slow (<1/month),,Significantly Below (<50%),100,43.3,27.05
NCT03569631,A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome,COMPLETED,PHASE2,30.0,2018-07-09,2020-07-31,1.2127490039840638,Adequate (1-10/month),12.127490039840637,Significantly Below (<50%),100,47.4,40.98
NCT06681831,Single-Port Hysterectomy (R-SPH) Using the Da Vinci SP System in Low-Risk Endometrial Cancer,COMPLETED,NA,15.0,2024-06-26,2024-10-15,4.113513513513514,Adequate (1-10/month),41.13513513513514,Significantly Below (<50%),100,51.2,50.375
NCT04147702,Evaluation of Balance and Trunk Muscle Endurance in Dancers,COMPLETED,NA,80.0,2019-11-01,2021-07-30,3.8229199372056515,Adequate (1-10/month),38.22919937205651,Significantly Below (<50%),100,56.4,64.88000000000001
NCT00154102,Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL),COMPLETED,PHASE3,1221.0,2004-05-01,2011-03-01,14.896689378757515,Good (10-50/month),148.96689378757515,Exceeded (≥100%),100,95.0,95.7
NCT07206602,AI-Guided Left Bundle Branch Area Pacing,NOT_YET_RECRUITING,NA,224.0,2026-01-01,2027-11-01,10.192167414050822,Good (10-50/month),101.92167414050822,Exceeded (≥100%),30,51.9,52.55499999999999
NCT03051802,Feasibility Study of Navigated Endoscopy for the Placement of High Dose Rate Brachytherapy Applicators in the Esophagus and Lung,TERMINATED,NA,1.0,2017-01-27,2018-04-24,0.06734513274336283,Slow (<1/month),0.6734513274336283,Significantly Below (<50%),10,18.1,3.105
NCT06529302,The OPBC-07/microNAC Study,ACTIVE_NOT_RECRUITING,,2000.0,2024-05-15,2025-06-01,159.37172774869111,Excellent (>50/month),200.0,Exceeded (≥100%),85,93.8,94.80499999999999
NCT05614102,"A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors",ACTIVE_NOT_RECRUITING,PHASE1,284.0,2022-11-04,2027-09-09,4.884158192090395,Adequate (1-10/month),48.84158192090396,Significantly Below (<50%),85,68.2,80.77
NCT07102602,"Feasibility of Assessing Muscle Displacement and Muscle Excursion on Muscle Fatigue, With and Without Preventive Strategies",ACTIVE_NOT_RECRUITING,NA,20.0,2024-11-30,2025-11-30,1.6679452054794521,Adequate (1-10/month),16.67945205479452,Significantly Below (<50%),85,47.1,39.64
NCT05541302,Retrospective TMS Therapy for Adults With MDD,COMPLETED,,6456.0,2008-11-01,2022-08-31,38.907273807166895,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT00737802,"In Vivo Anatomy, Physiology, Mechanics and Function of the Lower Esophageal Sphincter",TERMINATED,,4.0,2013-04-12,2017-02-03,0.08740847092605887,Slow (<1/month),0.8740847092605888,Significantly Below (<50%),10,16.7,2.68
NCT01318902,Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis,COMPLETED,PHASE1,27.0,2011-04-27,2018-11-13,0.29810663764961914,Slow (<1/month),2.9810663764961913,Significantly Below (<50%),100,47.2,40.035
NCT00718302,A Multicenter Randomized Trial Comparing Antiglide and Lateral Plate Fixation in Ankle Fractures,COMPLETED,NA,249.0,2008-06-01,2012-12-01,4.61043795620438,Adequate (1-10/month),46.104379562043796,Significantly Below (<50%),100,69.9,81.83
NCT00009802,Calcitriol Plus Paclitaxel in Treating Patients With Advanced Solid Tumors,COMPLETED,PHASE1,45.0,1998-06-01,2005-06-01,0.5357059053578412,Slow (<1/month),5.357059053578412,Significantly Below (<50%),100,48.6,44.685
NCT00891202,A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE),COMPLETED,PHASE3,40.0,2009-11-01,2016-01-01,0.5406749555950267,Slow (<1/month),5.406749555950267,Significantly Below (<50%),100,48.2,43.665
NCT02505802,The Effectiveness of Early Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults,UNKNOWN,PHASE4,30.0,2014-01-01,2017-01-01,0.8332116788321168,Slow (<1/month),8.332116788321168,Significantly Below (<50%),50,32.4,12.025
NCT02694653,Preoperative Cesarean Section Intravenous Acetaminophen and Postoperative Pain Control,UNKNOWN,PHASE1,200.0,2014-10-01,2017-12-01,5.261884183232498,Adequate (1-10/month),52.61884183232498,Below (50-75%),50,51.0,49.714999999999996
NCT04254653,Diabetes Nutrition Education for American Indian and Alaska Native Communities,UNKNOWN,NA,150.0,2020-02-20,2022-05-31,5.494584837545127,Adequate (1-10/month),54.94584837545127,Below (50-75%),50,47.0,39.33
NCT01267253,Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer,COMPLETED,PHASE2,31.0,2011-04-04,2014-02-28,0.889387370405278,Slow (<1/month),8.893873704052782,Significantly Below (<50%),100,47.5,41.415
NCT02946853,Junctional AV Ablation in CRT-D: JAVA-CRT,COMPLETED,NA,26.0,2016-10-01,2020-08-31,0.5534545454545455,Slow (<1/month),5.534545454545455,Significantly Below (<50%),100,47.1,39.64
NCT03820453,Clinical Trial to Investigate the Effectiveness of a Dietary Supplement in Increasing Libido and Sexual Function in Postmenopausal Women.,UNKNOWN,NA,110.0,2018-10-29,2019-08-29,11.014473684210527,Good (10-50/month),110.14473684210526,Exceeded (≥100%),50,48.8,45.184999999999995
NCT02322853,A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors,TERMINATED,PHASE2,8.0,2015-01-01,2017-04-01,0.2966138855054811,Slow (<1/month),2.9661388550548113,Significantly Below (<50%),10,18.6,4.25
NCT00461253,Case-Control-Study on the Breast Cancer Risk of Mirena® Compared With Copper IUDs,COMPLETED,,25565.0,2006-10-01,2014-03-01,287.3702363367799,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT03195153,Effect of Allopurinol on Mono and Co-administration With Statins on Platelets Reactivity on Diabetic Patiets Treated With Aspirin and Insulin,UNKNOWN,PHASE4,200.0,2017-03-28,2017-07-15,55.853211009174316,Excellent (>50/month),200.0,Exceeded (≥100%),50,61.0,73.17
NCT05536453,Retro Comparison of Subsidence Following Interbody Devices in Lumbar Spine,COMPLETED,,465.0,2022-08-16,2025-07-16,13.290704225352114,Good (10-50/month),132.90704225352115,Exceeded (≥100%),100,90.5,93.4
NCT07031453,Observation and Study on the Application of Different Analgesic Regimens in Critically Ill Patients Without Mechanical Ventilation,NOT_YET_RECRUITING,,80.0,2025-06-01,2026-06-01,6.6717808219178085,Adequate (1-10/month),66.71780821917808,Below (50-75%),30,33.7,13.465
NCT01199653,Study Comparing Plate Stabilization to Conservative Treatment in Midshaft Clavicle Fractures,COMPLETED,PHASE2,60.0,2004-08-01,2009-11-01,0.9522419186652764,Slow (<1/month),9.522419186652762,Significantly Below (<50%),100,49.8,47.17
NCT02790853,Multimodal Imaging for Surveillance in Patients With Oral Potentially Malignant Disorders,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,63.0,2016-05-25,2026-05-31,0.5242536905412795,Slow (<1/month),5.242536905412794,Significantly Below (<50%),85,45.5,31.705
NCT02057653,Evaluation of Goal-Directed Intraoperative Hemodynamic Optimization Protocol,COMPLETED,,330.0,2013-11-01,2016-10-01,9.432112676056338,Adequate (1-10/month),94.32112676056339,Met (75-100%),100,79.7,87.22999999999999
NCT00804453,Evaluation of the Biocompatibility of Cartridge Blood Set Versus Standard Blood Line,COMPLETED,NA,16.0,2008-11-01,2008-11-01,16.0,Good (10-50/month),160.0,Exceeded (≥100%),100,41.3,23.74
NCT07153653,Managing Pregnancy Pain With Baduanjin Exercise,RECRUITING,NA,84.0,2025-03-13,2026-06-30,5.394430379746836,Adequate (1-10/month),53.944303797468365,Below (50-75%),60,44.7,29.67
NCT07277153,Clinical Study on the Effect of Tegileridine on Postoperative Pain in Patients Undergoing Abdominal Surgery.,COMPLETED,PHASE4,150.0,2025-10-18,2025-12-14,80.10526315789474,Excellent (>50/month),200.0,Exceeded (≥100%),100,72.0,82.92
NCT00502853,A Pilot Study of MabThera (Rituximab) Evaluated by MRI in Patients With Rheumatoid Arthritis.,COMPLETED,PHASE4,10.0,2007-10-25,2010-07-23,0.3037924151696607,Slow (<1/month),3.037924151696607,Significantly Below (<50%),100,45.8,33.03
NCT04824053,Effects of UNICLA-A2 Dairy Products on Patients At High-risk of Colorectal Cancer Development,RECRUITING,NA,34.0,2022-02-28,2026-12-15,0.5910679611650486,Slow (<1/month),5.910679611650486,Significantly Below (<50%),60,35.7,16.18
NCT01005953,"Comprehensive Collection, Charting, and Communication System",UNKNOWN,,70.0,2009-10-01,2011-08-01,3.1850523168908818,Adequate (1-10/month),31.85052316890882,Significantly Below (<50%),50,38.9,20.325
NCT06075953,DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment,RECRUITING,PHASE2,400.0,2024-02-17,2033-11-01,3.4346967559943584,Adequate (1-10/month),34.34696755994358,Significantly Below (<50%),60,70.0,81.89999999999999
NCT01798953,Surgical Reconstruction in Ulcerative Colitis With Primary Sclerosing Cholangitis,COMPLETED,,175.0,2010-01-01,2013-11-01,3.805,Adequate (1-10/month),38.05,Significantly Below (<50%),100,62.3,74.94
NCT01912053,Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma,COMPLETED,PHASE2,41.0,2013-09-01,2017-11-01,0.82,Slow (<1/month),8.200000000000001,Significantly Below (<50%),100,48.3,43.985
NCT02048553,Tablet-guided Versus Freehand (Tab-Guide) Ventriculostomy : Study Protocol to the Test Accuracy of Ventriculostomy in a Randomized Controlled Trial,UNKNOWN,NA,320.0,2014-03-01,2016-12-01,9.682703777335984,Adequate (1-10/month),96.82703777335983,Met (75-100%),50,65.6,78.56
NCT07100353,"Premature Infants' Developmental Function, Daily Living, Participation, and Quality of Life: A Longitudinal Study",ACTIVE_NOT_RECRUITING,,450.0,2023-10-01,2026-09-30,12.509589041095891,Good (10-50/month),125.09589041095892,Exceeded (≥100%),85,84.8,90.815
NCT05522153,Arista Hemostatic Powder for Total Knee Post Operative Outcomes Study,COMPLETED,PHASE1,61.0,2021-05-01,2023-06-08,2.417760416666667,Adequate (1-10/month),24.17760416666667,Significantly Below (<50%),100,54.9,61.55500000000001
NCT04879953,Effect of the PIPAC on the Survival Rate of Patients With Peritoneal Carcinomatosis of Gastric Origin,COMPLETED,,46.0,2020-02-01,2020-12-31,4.192335329341318,Adequate (1-10/month),41.92335329341317,Significantly Below (<50%),100,52.0,52.86
NCT02932553,BVS Implantation in Patients With Variant Angina and MODerate Coronary Artery Disease,WITHDRAWN,PHASE4,0.0,2017-04-19,2017-04-19,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT03780153,The Norwegian Adult Achondroplasia Study,COMPLETED,,50.0,2017-03-01,2022-03-21,0.8244853737811485,Slow (<1/month),8.244853737811484,Significantly Below (<50%),100,47.3,40.475
NCT02374853,Topical Use of Vancomycin in Reducing Sternal Wound Infection in Cardiac Surgery (SWI Trial),TERMINATED,PHASE2,1037.0,2015-03-01,2019-04-01,21.15702412868633,Good (10-50/month),200.0,Exceeded (≥100%),10,68.0,80.56
NCT02083653,Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer,COMPLETED,PHASE2,254.0,2014-03-06,2017-04-26,6.7408544027898865,Adequate (1-10/month),67.40854402789887,Below (50-75%),100,70.3,82.09
NCT00944437,Continuous Positive Airway Pressure (CPAP) Ventilation Using a Novel Full-Face Mask Versus Conventional Helmet,TERMINATED,NA,23.0,2008-05-01,2010-07-01,0.8851074589127688,Slow (<1/month),8.851074589127686,Significantly Below (<50%),10,19.8,5.465
NCT00128037,Trial of Pre-operative Chemoradiotherapy Followed by Surgical Resection in Pancoast Tumors (JCOG 9806),COMPLETED,PHASE2,75.0,1999-05-01,2006-02-01,0.9250405186385737,Slow (<1/month),9.250405186385736,Significantly Below (<50%),100,51.0,49.714999999999996
NCT05758337,Vibropneumostimulation in the Rehabilitation After Dental Implantation,RECRUITING,NA,100.0,2022-09-01,2025-09-01,2.7773722627737225,Adequate (1-10/month),27.773722627737225,Significantly Below (<50%),60,46.0,34.1
NCT00919737,Study of NPC-08 is to Treat for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme,COMPLETED,PHASE1,24.0,2009-06-01,2011-04-01,1.092017937219731,Adequate (1-10/month),10.920179372197309,Significantly Below (<50%),100,46.9,38.96
NCT03600337,An Integrated Self-Management Intervention for Adolescents With Polycystic Ovary Syndrome,COMPLETED,NA,56.0,2018-06-15,2020-04-01,2.5985365853658537,Adequate (1-10/month),25.985365853658536,Significantly Below (<50%),100,54.5,60.12
NCT06910137,An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC),AVAILABLE,,,,,,Slow (<1/month),,Significantly Below (<50%),50,23.3,6.569999999999999
NCT05199337,Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis,COMPLETED,PHASE1,18.0,2021-11-30,2024-02-14,0.6798014888337469,Slow (<1/month),6.798014888337469,Significantly Below (<50%),100,46.4,36.26
NCT01798537,Simplified Selective Digestive Tract Decontamination for the Prevention of Intensive Care Unit Acquired Infections,UNKNOWN,PHASE2,2400.0,2013-06-01,2015-07-01,96.1263157894737,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT04050137,Therapeutic Exercise to Treat Neuropathic Pain,COMPLETED,NA,5.0,2019-05-02,2020-12-14,0.2570945945945946,Slow (<1/month),2.570945945945946,Significantly Below (<50%),100,45.4,31.455
NCT03446937,Effect of Antenatal Corticosteroids on Neonatal Morbidity.,COMPLETED,NA,150.0,2017-12-01,2019-05-31,8.362637362637363,Adequate (1-10/month),83.62637362637363,Met (75-100%),100,67.0,79.725
NCT00586937,Quality of Life in Lung Cancer Survivors,COMPLETED,,193.0,2005-06-01,2020-01-02,1.1026501501501502,Adequate (1-10/month),11.026501501501503,Significantly Below (<50%),100,58.8,69.89999999999999
NCT00004037,Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer,TERMINATED,PHASE2,,1998-06-01,,,Slow (<1/month),,Significantly Below (<50%),10,13.0,0.38999999999999996
NCT06397937,SDOH-Homecare Intervention Focus Team (SHIFT) Trial to Improve Stroke Outcomes,TERMINATED,NA,22.0,2024-09-17,2025-03-14,3.762247191011236,Adequate (1-10/month),37.62247191011236,Significantly Below (<50%),10,24.8,7.06
NCT04602637,Training Load Management in Three Professional Tennis Players During COVID-19 Lockdown: a Case Series Study,UNKNOWN,,3.0,2019-12-15,2021-01-15,0.2300251889168766,Slow (<1/month),2.3002518891687656,Significantly Below (<50%),50,28.6,8.58
NCT00512837,Mobile Phone Based Structured Intervention,COMPLETED,NA,312.0,2007-11-01,2009-01-01,22.241873536299767,Good (10-50/month),200.0,Exceeded (≥100%),100,80.0,87.67
NCT00741637,Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults,COMPLETED,PHASE2,32.0,2010-07-01,2011-06-01,2.907701492537314,Adequate (1-10/month),29.077014925373135,Significantly Below (<50%),100,52.6,54.684999999999995
NCT04589637,Factors Influencing the Deterioration From Cognitive Decline of Normal Aging to Dementia Among Nursing Home Residents,COMPLETED,,182.0,2018-05-29,2019-05-16,15.738863636363638,Good (10-50/month),157.38863636363638,Exceeded (≥100%),100,67.9,80.36999999999999
NCT04787237,Vetsibular Socket Therapy Versus Buser's Technique,COMPLETED,NA,40.0,2019-01-30,2020-10-31,1.9025,Adequate (1-10/month),19.025,Significantly Below (<50%),100,53.2,56.665
NCT06681337,Universal CAR-T Cell Therapy for Refractory Lupus Nephritis,NOT_YET_RECRUITING,EARLY_PHASE1,10.0,2024-11-25,2025-12-01,0.8204851752021565,Slow (<1/month),8.204851752021565,Significantly Below (<50%),30,24.8,7.06
NCT02448537,A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas,COMPLETED,PHASE2,42.0,2015-08-01,2019-04-01,0.9548020911127708,Slow (<1/month),9.548020911127708,Significantly Below (<50%),100,48.4,44.22
NCT00991237,PRF Treatment for Patients With Chronic Lumbosacral Radicular Pain Compared to Conventional Medical Management,COMPLETED,NA,45.0,2010-02-01,2012-12-01,1.3247582205029016,Adequate (1-10/month),13.247582205029016,Significantly Below (<50%),100,48.6,44.685
NCT05359237,Vincristine Pharmacokinetics in Infants,ACTIVE_NOT_RECRUITING,,83.0,2022-11-16,2025-12-31,2.2143032427695,Adequate (1-10/month),22.143032427695005,Significantly Below (<50%),85,50.5,48.515
NCT02387645,LUDEC Study - Pilot Study of the Lavage of the Uterine Cavity for the Diagnosis of Endometrial Carcinoma,COMPLETED,NA,80.0,2014-05-01,2018-03-01,1.7394285714285715,Adequate (1-10/month),17.394285714285715,Significantly Below (<50%),100,56.4,64.88000000000001
NCT05081245,ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD),ACTIVE_NOT_RECRUITING,PHASE2,150.0,2022-09-13,2026-11-01,3.023841059602649,Adequate (1-10/month),30.238410596026494,Significantly Below (<50%),85,57.5,67.27
NCT06698445,Effect of Short Film Video Training Prepared for Children Undergoing Bone Marrow Aspiration and Biopsy,COMPLETED,NA,60.0,2024-12-19,2026-01-06,4.768668407310705,Adequate (1-10/month),47.68668407310705,Significantly Below (<50%),100,54.8,61.095
NCT02660645,Blue Light Cystoscopy With Cysview® Registry,RECRUITING,,4400.0,2014-04-01,2028-12-01,24.997387084733113,Good (10-50/month),200.0,Exceeded (≥100%),60,81.3,88.58
NCT04713345,VERARE_2 Efficacy of the Observation of Virtual Motor Actions for the Improvement of Gait in Patients With ICU-weakness,ACTIVE_NOT_RECRUITING,NA,68.0,2021-03-26,2025-09-02,1.276940160394818,Adequate (1-10/month),12.76940160394818,Significantly Below (<50%),85,45.9,33.495000000000005
NCT02214745,Demographic Characteristics of Children Suffering From Mental Retardation or Cerebral Palsy in the Israeli Arab Community,UNKNOWN,,400.0,2014-10-01,2017-03-01,13.80498866213152,Good (10-50/month),138.0498866213152,Exceeded (≥100%),50,70.3,82.09
NCT07041645,Bioavailability of Different Vitamin K Vitamers Studied Using 13C-labelled Vitamin K Vitamers,NOT_YET_RECRUITING,NA,20.0,2025-07-01,2031-06-30,0.2779908675799087,Slow (<1/month),2.779908675799087,Significantly Below (<50%),30,25.6,7.595000000000001
NCT02505945,The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease,COMPLETED,PHASE4,152.0,2015-06-01,2018-08-01,3.9990319792566984,Adequate (1-10/month),39.990319792566986,Significantly Below (<50%),100,62.2,74.74499999999999
NCT00149045,Follow up and Observation of Charcot Marie Tooth Disease in Families,COMPLETED,,,2001-11-01,2005-08-01,,Slow (<1/month),,Significantly Below (<50%),100,43.3,27.05
NCT01733745,SYSTANE® Family - Meibomian Deficiency,COMPLETED,NA,26.0,2013-02-01,2013-06-01,6.5953333333333335,Adequate (1-10/month),65.95333333333333,Below (50-75%),100,52.1,53.03
NCT00303745,"Irinotecan With or Without Capecitabine as Second-Line Therapy in Treating Older Patients With Progressive, Metastatic Colorectal Cancer That Cannot Be Removed By Surgery",UNKNOWN,PHASE2,78.0,2006-06-01,,,Slow (<1/month),,Significantly Below (<50%),50,31.2,10.165000000000001
NCT03551145,Patient Perception and Clinical Efficacy of a Collagen Matrix for the Treatment of Peri-implantitis,UNKNOWN,PHASE4,50.0,2017-02-01,2020-03-01,1.3540925266903916,Adequate (1-10/month),13.540925266903914,Significantly Below (<50%),50,34.0,14.02
NCT05525845,Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI,RECRUITING,NA,15.0,2022-09-08,2028-08-01,0.21197771587743733,Slow (<1/month),2.119777158774373,Significantly Below (<50%),60,34.2,14.305000000000001
NCT01208545,Serial Electrophysiologic Monitoring During Administration of Nerve-Toxic Chemotherapeutic Drugs,UNKNOWN,,120.0,2008-07-01,,,Slow (<1/month),,Significantly Below (<50%),50,32.9,12.53
NCT03451045,Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis,COMPLETED,PHASE2,447.0,2017-12-22,2020-06-17,14.985330396475772,Good (10-50/month),149.85330396475774,Exceeded (≥100%),100,90.8,93.51
NCT05801445,Increasing Movement and Exercise in Geriatric Patients Through Large-Scaled Creative Occupation Interventions,COMPLETED,NA,14.0,2023-09-01,2023-11-27,4.898390804597701,Adequate (1-10/month),48.98390804597701,Significantly Below (<50%),100,51.1,50.129999999999995
NCT02986945,Community-Partnered Participatory Development of Mobile Interventions,COMPLETED,NA,30.0,2016-12-01,2017-03-28,7.805128205128206,Adequate (1-10/month),78.05128205128207,Met (75-100%),100,52.4,53.949999999999996
NCT01879345,A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers,COMPLETED,PHASE1,18.0,2004-10-01,2004-12-01,8.982295081967212,Adequate (1-10/month),89.82295081967212,Met (75-100%),100,56.4,64.88000000000001
NCT04255745,The Impact of a Resistance Training Intervention on Blood Pressure Control in Older Adults With Sarcopenia,COMPLETED,NA,91.0,2020-01-27,2025-05-01,1.4419781363872983,Adequate (1-10/month),14.419781363872982,Significantly Below (<50%),100,52.3,53.515
NCT00022945,Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma,COMPLETED,PHASE2,,,,,Slow (<1/month),,Significantly Below (<50%),100,40.0,21.87
NCT06980545,Total Neoadjuvant 6 Cycles of Chemotherapy Versus 3 Cycles in Partial Responder Patients Diagnosed With Epithelial Ovarian Cancer,NOT_YET_RECRUITING,PHASE3,50.0,2025-06-30,2028-05-30,1.4291079812206573,Adequate (1-10/month),14.291079812206576,Significantly Below (<50%),30,28.0,8.38
NCT00935545,Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide in Patients With CNS Tumors,COMPLETED,PHASE1,15.0,2009-07-01,2014-01-01,0.2775683890577508,Slow (<1/month),2.775683890577508,Significantly Below (<50%),100,46.2,35.089999999999996
NCT01776645,Compassion Training and Pain,COMPLETED,NA,56.0,2013-01-01,2013-05-01,14.205333333333334,Good (10-50/month),142.05333333333334,Exceeded (≥100%),100,59.5,71.0
NCT01724645,Beneficial Effects of Korean Traditional Diets in Subjects With Hypertension and Type 2 Diabetes,COMPLETED,NA,48.0,2010-09-01,2011-02-01,9.549803921568628,Adequate (1-10/month),95.49803921568628,Met (75-100%),100,58.8,69.89999999999999
NCT00100945,Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer,COMPLETED,PHASE2,70.0,2005-07-01,2009-10-01,1.3720540888602706,Adequate (1-10/month),13.720540888602706,Significantly Below (<50%),100,50.6,48.705
NCT01572545,Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin of Postmenopausal Women With Low Bone Mass,COMPLETED,NA,91.0,2012-04-01,2013-01-01,10.072872727272728,Good (10-50/month),100.72872727272728,Exceeded (≥100%),100,62.3,74.94
NCT00411645,Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients,COMPLETED,PHASE3,681.0,2006-12-13,2009-05-23,23.2395067264574,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT00922545,Evaluation of a Combined Strategy Addressed to Practitioners and Chronic Obstructive Pulmonary Disease (COPD) Patients to Improve Clinical Control and Quality of Life,UNKNOWN,NA,801.0,2004-04-01,2010-12-01,10.013322381930186,Good (10-50/month),100.13322381930185,Exceeded (≥100%),50,80.0,87.67
NCT03631472,Gala Early Feasibility Study of RheOx,UNKNOWN,NA,21.0,2018-07-06,2024-12-30,0.26983537357534826,Slow (<1/month),2.698353735753482,Significantly Below (<50%),50,31.7,11.14
NCT00471172,Study of Five Different Methods Of Delivering A Lifestyle Modification Program for Weight Loss,COMPLETED,NA,350.0,2004-08-01,2005-05-01,39.02564102564103,Good (10-50/month),200.0,Exceeded (≥100%),100,83.0,89.505
NCT01314872,A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008),COMPLETED,PHASE2,1395.0,2011-03-31,2013-10-10,45.95649350649351,Good (10-50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT00105872,Behavioral Insomnia Therapy in Primary Care,COMPLETED,NA,100.0,2002-03-01,2006-07-01,1.9229311433986103,Adequate (1-10/month),19.2293114339861,Significantly Below (<50%),100,58.0,68.245
NCT01037972,Influence of Whole Body Vibration Compared to Conventional Physiotherapy in Patients With Gonarthrosis,COMPLETED,,40.0,2010-03-01,2011-10-01,2.10293609671848,Adequate (1-10/month),21.0293609671848,Significantly Below (<50%),100,51.5,51.245
NCT05052372,Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib,TERMINATED,,2.0,2021-11-21,2022-12-20,0.15451776649746193,Slow (<1/month),1.5451776649746194,Significantly Below (<50%),10,16.5,2.625
NCT07241572,Evaluation of Perioperative Myocardial Injury in Patients Undergoing Below-Knee Lower Extremity Surgery,RECRUITING,,54.0,2025-09-01,2026-01-10,12.547786259541985,Good (10-50/month),125.47786259541986,Exceeded (≥100%),60,45.7,32.5
NCT07374172,SADT in COPD and Oscillometry in Obstructive Airway Disease in Primary Care. The SCOOP-study,ACTIVE_NOT_RECRUITING,,108.0,2024-05-01,2026-06-01,4.32,Adequate (1-10/month),43.2,Significantly Below (<50%),85,52.5,54.345
NCT06386172,Electronic Decision-support System to Improve Detection and Care of Patients With Chronic Kidney Disease in Stockholm,COMPLETED,NA,65.0,2023-09-09,2025-10-01,2.6276228419654712,Adequate (1-10/month),26.276228419654718,Significantly Below (<50%),100,55.2,62.195
NCT00677872,An Open-Label Study to Evaluate the Safety and Efficacy of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease,TERMINATED,PHASE2,40.0,2008-05-01,,,Slow (<1/month),,Significantly Below (<50%),10,16.2,2.56
NCT05431972,Cardea SOLOTM for Paroxysmal Atrial Fibrillation Diagnosis in ESUS Patients With Left Atrial Enlargement,COMPLETED,NA,257.0,2022-11-01,2024-09-13,11.470791788856307,Good (10-50/month),114.70791788856307,Exceeded (≥100%),100,75.6,84.735
NCT03700372,IMPACT: A Safety and Feasibility Study of the IOWA Approach Cardiac Ablation System,COMPLETED,,7.0,2017-12-13,2021-03-03,0.18119047619047618,Slow (<1/month),1.8119047619047621,Significantly Below (<50%),100,43.9,28.12
NCT03766672,Characterization of the Genetic Profile of Type 2 Endometrial Carcinoma in Martinique,COMPLETED,,30.0,2019-11-22,2024-07-22,0.5359154929577465,Slow (<1/month),5.359154929577465,Significantly Below (<50%),100,45.7,32.5
NCT04581772,A Study to Evaluate the Bioavailability and Safety of DNL343 in Healthy Volunteers,COMPLETED,PHASE1,31.0,2020-12-23,2021-06-04,5.7892024539877305,Adequate (1-10/month),57.892024539877305,Below (50-75%),100,52.5,54.345
NCT05655572,"Comparison Between AOT and Functional Training on Balance, Mobility and Cognition in Diplegic Cerebral Palsy",COMPLETED,NA,46.0,2022-04-01,2023-08-30,2.713643410852713,Adequate (1-10/month),27.13643410852713,Significantly Below (<50%),100,53.7,57.84
NCT07010172,"Fibromyalgia, Cognitive Rehabilitation Software",NOT_YET_RECRUITING,NA,100.0,2025-07-01,2026-08-01,7.686868686868687,Adequate (1-10/month),76.86868686868688,Met (75-100%),30,37.0,17.955
NCT00790595,Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy,COMPLETED,PHASE1,6.0,2006-06-01,,,Slow (<1/month),,Significantly Below (<50%),100,40.5,22.46
NCT03598595,"Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma",ACTIVE_NOT_RECRUITING,PHASE1,31.0,2019-01-28,2026-05-31,0.35210447761194036,Slow (<1/month),3.5210447761194033,Significantly Below (<50%),85,43.0,26.465
NCT05631795,"Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment",COMPLETED,PHASE4,40.0,2022-08-09,2025-06-12,1.1730250481695568,Adequate (1-10/month),11.73025048169557,Significantly Below (<50%),100,48.2,43.665
NCT04897295,Neurobiological Effects of Transcranial Direct Current Stimulation Treatment in Alcohol Use Disorder,NOT_YET_RECRUITING,NA,30.0,2021-12-01,2026-11-30,0.5003835616438356,Slow (<1/month),5.003835616438356,Significantly Below (<50%),30,26.4,7.865
NCT06502795,Quadriceps Strengthening At Different Angles in Patellofemoral Pain,RECRUITING,NA,110.0,2024-10-26,2026-06-01,5.743396226415094,Adequate (1-10/month),57.43396226415095,Below (50-75%),60,46.8,38.440000000000005
NCT03560895,US Prediction of Actual Tube Size and Performance Characteristics of Pediatric Cuffed Vs Un-Cuffed ETT.,COMPLETED,,100.0,2018-06-25,2022-12-01,1.8790123456790122,Adequate (1-10/month),18.790123456790123,Significantly Below (<50%),100,56.3,64.5
NCT02032095,The Desensitization Therapy With GB-0998 for Anti-donor Antibody-positive Recipients.,COMPLETED,PHASE2,17.0,2013-11-01,2015-09-01,0.7735127055306428,Slow (<1/month),7.735127055306427,Significantly Below (<50%),100,46.4,36.26
NCT04569695,A Study of JNJ-70033093 (BMS-986177) in Healthy Chinese Adult Participants,COMPLETED,PHASE1,40.0,2021-03-08,2021-12-16,4.302473498233216,Adequate (1-10/month),43.02473498233216,Significantly Below (<50%),100,53.2,56.665
NCT04002895,What the Body Does to Foliglurax in Healthy Volunteers,COMPLETED,PHASE1,6.0,2019-06-27,2019-08-08,4.348571428571429,Adequate (1-10/month),43.48571428571429,Significantly Below (<50%),100,50.5,48.515
NCT02347995,Resistive Training Combined With Nutritional Therapy After Stroke,ACTIVE_NOT_RECRUITING,NA,93.0,2015-08-24,2026-08-31,0.7033341614906833,Slow (<1/month),7.033341614906834,Significantly Below (<50%),85,47.9,42.64
NCT01375595,Brain Areas Involved in Sound and Spoken Word Memory,TERMINATED,,45.0,2011-05-26,2015-10-30,0.8466007416563659,Slow (<1/month),8.466007416563661,Significantly Below (<50%),10,19.9,5.555000000000001
NCT05207995,The Treatment of Patients With Type 1 Diabetes Mellitus With Autologous Tolerogenic Dendritic Cells,COMPLETED,PHASE1,32.0,2022-03-01,2023-12-26,1.464781954887218,Adequate (1-10/month),14.64781954887218,Significantly Below (<50%),100,47.6,41.775
NCT03369795,Add-on Methotrexate for the Treatment of Schizophrenia,UNKNOWN,PHASE2,100.0,2017-12-15,2020-01-01,4.074966532797858,Adequate (1-10/month),40.74966532797858,Significantly Below (<50%),50,43.0,26.465
NCT05857995,Precision Lung Cancer Survivorship Care Intervention,RECRUITING,NA,300.0,2024-08-16,2027-06-30,8.713740458015266,Adequate (1-10/month),87.13740458015268,Met (75-100%),60,67.0,79.725
NCT00765895,Nortriptyline for Idiopathic Gastroparesis,COMPLETED,PHASE3,130.0,2009-01-01,2012-10-01,2.8905770635500367,Adequate (1-10/month),28.905770635500367,Significantly Below (<50%),100,60.4,72.54
NCT06366295,Comparison of Subgingival Mechanotherapy With and Without the Use of a Perioscope: Clinical Trial,UNKNOWN,NA,26.0,2023-06-01,2024-11-01,1.524932562620424,Adequate (1-10/month),15.249325626204241,Significantly Below (<50%),50,32.1,11.5
NCT01772095,ADVANCE Study: Alzheimer Disease eVAluation iN Clinical PracticE,COMPLETED,,389.0,2013-02-01,2013-11-01,43.374212454212454,Good (10-50/month),200.0,Exceeded (≥100%),100,89.5,93.025
NCT01281995,Effects of Systemically Administered Hydrocortisone on the Immune System in Healthy Volunteers,COMPLETED,,22.0,2011-01-21,2018-08-30,0.2410655147588193,Slow (<1/month),2.410655147588193,Significantly Below (<50%),100,45.1,30.605
NCT00521495,Carpal Tunnel Syndrome and Static Magnetic Field Therapy,UNKNOWN,PHASE2,60.0,2006-09-01,2009-08-01,1.7149295774647888,Adequate (1-10/month),17.14929577464789,Significantly Below (<50%),50,39.8,21.47
NCT06583239,Hub-Based Engagement Navigator Service to Reduce CSC Disengagement,NOT_YET_RECRUITING,NA,555.0,2026-06-01,2029-07-31,14.614359861591696,Good (10-50/month),146.14359861591697,Exceeded (≥100%),30,74.0,83.985
NCT02949739,Prevention of Type 2 Diabetes Amongst South Asians With Central Obesity and Prediabetes,COMPLETED,NA,5244.0,2015-01-01,2022-12-31,54.64818897637795,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT05679739,NEUROprotection Via optimizINg Cerebral Blood Flow afTer cArdiaC arresT (NEURO-INTACT) Study,RECRUITING,NA,49.0,2023-08-29,2026-08-01,1.3965917602996256,Adequate (1-10/month),13.965917602996255,Significantly Below (<50%),60,36.9,17.735
NCT06675539,Validation of the French Version of the Prediction of the Alcohol Withdrawal Severity Scale (PAWSS),RECRUITING,,545.0,2024-11-11,2027-10-01,15.739848197343454,Good (10-50/month),157.39848197343454,Exceeded (≥100%),60,81.3,88.58
NCT00603239,Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin,COMPLETED,PHASE3,165.0,2008-01-01,2009-07-01,9.182084095063985,Adequate (1-10/month),91.82084095063985,Met (75-100%),100,68.2,80.77
NCT03854539,Salivary Alpha Amylase as a Biomarker of Transdermal Vagus Nerve Stimulation,COMPLETED,NA,100.0,2018-03-31,2020-06-08,3.805,Adequate (1-10/month),38.05,Significantly Below (<50%),100,58.0,68.245
NCT01102439,Clopidogrel/Aspirin Interaction Study,COMPLETED,PHASE4,82.0,2010-04-01,2013-02-01,2.40702025072324,Adequate (1-10/month),24.0702025072324,Significantly Below (<50%),100,56.6,65.34
NCT05757739,Randomized Controlled Trial (RCT) of Open Debridement Versus Tenex,RECRUITING,,90.0,2023-02-09,2026-06-01,2.267880794701987,Adequate (1-10/month),22.678807947019866,Significantly Below (<50%),60,43.5,27.400000000000002
NCT04058639,Diabetic Foot Ulcers: Shorter Treatment Period Using Custom Felt Relief?,RECRUITING,NA,74.0,2019-10-01,2026-03-01,0.9613999146393513,Slow (<1/month),9.613999146393512,Significantly Below (<50%),60,38.9,20.325
NCT03266939,Rebalancing the Serotonergic System in Cocaine Dependence,WITHDRAWN,PHASE1,0.0,2018-10-04,2018-10-04,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT01593839,Functioning Disturbance in Chronic Back Pain: Altered Muscle Metabolism,UNKNOWN,,6.0,2012-05-01,2013-12-01,0.31544041450777205,Slow (<1/month),3.15440414507772,Significantly Below (<50%),50,28.8,8.665000000000001
NCT06048939,"Combined Effect of Aerobic and Resistance Training on Physical, Menstrual and Psychological Health of Adolescent Girls.",UNKNOWN,NA,24.0,2023-06-22,2024-01-20,3.446037735849057,Adequate (1-10/month),34.46037735849057,Significantly Below (<50%),50,36.9,17.735
NCT01284439,Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate 0.18% for Ocular Surface Disease in Glaucoma,UNKNOWN,NA,120.0,2011-01-01,2012-02-01,9.224242424242425,Adequate (1-10/month),92.24242424242425,Met (75-100%),50,49.6,46.785
NCT00422539,Efficacy of TCA Effect on Varicella Atrophic Scars,UNKNOWN,PHASE2,100.0,2006-03-01,,,Slow (<1/month),,Significantly Below (<50%),50,33.0,12.695
NCT03846739,Dose-dependent Effects of Oxytocin on the Amygdala and Reward System,COMPLETED,PHASE1,92.0,2017-04-03,2018-12-31,4.396357927786499,Adequate (1-10/month),43.96357927786499,Significantly Below (<50%),100,57.4,67.05499999999999
NCT07035639,Exploring the Role of Baduanjin on Lumbar and Hip Mobility Index in Obese People Based on Infrared Thermography and Meridian Point Specificity,COMPLETED,NA,58.0,2023-10-25,2024-01-10,22.92883116883117,Good (10-50/month),200.0,Exceeded (≥100%),100,59.6,71.17999999999999
NCT06087939,Outcome and Predictors of Mortality of Patients on Prolonged Mechanical Ventilation,NOT_YET_RECRUITING,,323.0,2024-07-15,2024-08-30,213.74173913043478,Excellent (>50/month),200.0,Exceeded (≥100%),30,63.2,76.11
NCT03238339,The Clinical Application and Popularization of Portable Home Noninvasive Ventilator,UNKNOWN,,40.0,2017-09-15,2020-12-30,1.0129783693843593,Adequate (1-10/month),10.129783693843592,Significantly Below (<50%),50,31.5,10.635
NCT05851339,Determinants of Health-related Quality of Life for Patients After Renal Lithotripsy: PNL Versus RIRS,UNKNOWN,,200.0,2021-01-01,2023-08-01,6.462845010615712,Adequate (1-10/month),64.6284501061571,Below (50-75%),50,49.3,46.265
NCT01939639,The Influence of Oxytocin on the Processing of Social Contact,COMPLETED,PHASE1,40.0,2013-03-01,2013-08-01,7.958169934640523,Adequate (1-10/month),79.58169934640523,Met (75-100%),100,53.2,56.665
NCT04959539,Endoscopic Transcanal Tympanoplasty With Attico-antrostomy Versus Endoscopic-assisted Canal Wall up Mastoidectomy in Management of Localized Cholesteatoma: A Randomized Clinical Trial,COMPLETED,NA,40.0,2016-06-01,2020-05-30,0.8345442083618917,Slow (<1/month),8.345442083618918,Significantly Below (<50%),100,48.2,43.665
NCT06099639,Medical Access Program for Patritumab Deruxtecan,NO_LONGER_AVAILABLE,,,,,,Slow (<1/month),,Significantly Below (<50%),50,23.3,6.569999999999999
NCT06705439,A Study of Detection of Paroxysmal Events Utilizing Computer Vision and Machine Learning (USF),RECRUITING,,50.0,2024-11-15,2025-06-01,7.686868686868687,Adequate (1-10/month),76.86868686868688,Met (75-100%),60,40.3,22.21
NCT03771339,Comparison of Quadratus Lumborum Block and Epidural Analgesia Following Kidney Transplant Surgery,COMPLETED,NA,50.0,2018-12-10,2020-01-31,3.6498800959232613,Adequate (1-10/month),36.49880095923261,Significantly Below (<50%),100,54.0,58.72500000000001
NCT03559439,CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies,UNKNOWN,PHASE1,9.0,2018-04-24,2021-12-31,0.20338530066815144,Slow (<1/month),2.0338530066815146,Significantly Below (<50%),50,30.7,9.585
NCT04267939,ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer,TERMINATED,PHASE1,14.0,2020-02-26,2023-12-01,0.3101601164483261,Slow (<1/month),3.101601164483261,Significantly Below (<50%),10,19.1,4.9799999999999995
NCT01174277,Pilot Study: Patients With Chronic Active Graft Versus Host Disease That Have Failed or Not Tolerated Standard Therapy.,COMPLETED,,23.0,2010-08-01,2016-02-01,0.348318407960199,Slow (<1/month),3.48318407960199,Significantly Below (<50%),100,45.2,30.830000000000002
NCT03102177,"Effect of Age, Weight and Sex on Levothyroxine Pharmacokinetics",COMPLETED,EARLY_PHASE1,41.0,2011-05-31,2016-07-26,0.662793414763675,Slow (<1/month),6.627934147636749,Significantly Below (<50%),100,48.3,43.985
NCT05748977,Short Acting Agents Vs Long Acting in Frequent Excerbator COPD Patients,UNKNOWN,EARLY_PHASE1,80.0,2023-02-20,2024-03-20,6.180710659898478,Adequate (1-10/month),61.807106598984774,Below (50-75%),50,41.4,24.04
NCT01283477,Efficacy of Acupuncture for Prophylaxis of Intrathecal Morphine Induced Pruritis in Patients Undergoing Caesarean Delivery,COMPLETED,NA,44.0,2010-10-01,2011-06-01,5.511769547325104,Adequate (1-10/month),55.11769547325104,Below (50-75%),100,53.5,57.555
NCT00134277,Trial Comparing Different Medical Devices for Infragenual Dilatation,COMPLETED,NA,35.0,2004-09-01,2010-04-01,0.5227674190382728,Slow (<1/month),5.227674190382729,Significantly Below (<50%),100,47.8,42.42
NCT06972277,A Randomized Controlled Trial Comparing the Efficacy of Commercial Weight Management Programs,COMPLETED,NA,459.0,2025-05-14,2026-01-09,58.2165,Excellent (>50/month),200.0,Exceeded (≥100%),100,96.7,96.6
NCT03624777,Efficacy of the Stroll Safe Outdoor Fall Prevention Program,COMPLETED,NA,110.0,2019-01-14,2022-05-18,2.7445901639344266,Adequate (1-10/month),27.445901639344267,Significantly Below (<50%),100,58.8,69.89999999999999
NCT04260477,Novel Triple-dose Tuberculosis Retreatment Regimen,RECRUITING,PHASE3,370.0,2021-03-01,2025-09-01,6.8466869300911855,Adequate (1-10/month),68.46686930091185,Below (50-75%),60,67.6,80.15
NCT01462877,A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With Dyslipidemic,COMPLETED,PHASE4,506.0,2011-10-01,2014-03-01,17.46331065759637,Good (10-50/month),174.63310657596372,Exceeded (≥100%),100,95.0,95.7
NCT00480077,Diagnostic Outcome Trial in Heart Failure (DOT-HF Trial),TERMINATED,PHASE4,335.0,2007-03-01,2011-01-01,7.273466476462197,Adequate (1-10/month),72.73466476462197,Below (50-75%),10,49.8,47.17
NCT03697577,CDK and Body Composition Study,RECRUITING,,30.0,2019-01-08,2026-12-01,0.31664355062413313,Slow (<1/month),3.1664355062413314,Significantly Below (<50%),60,33.7,13.465
NCT05703477,The Dynamic Fluctuation of Donor Microbiota Affects the Prognosis of Fecal Microbiota Transplantation for C. Difficile Infection,COMPLETED,NA,60.0,2020-01-01,2022-08-30,1.8790123456790124,Adequate (1-10/month),18.790123456790127,Significantly Below (<50%),100,54.8,61.095
NCT06474377,Clinical Trial of PCV24 in Adults,COMPLETED,PHASE1,170.0,2024-06-21,2025-02-26,20.699199999999998,Good (10-50/month),200.0,Exceeded (≥100%),100,68.6,81.04
NCT05594277,Frailty and Surgery,COMPLETED,,150.0,2020-05-01,2023-10-31,3.5727699530516435,Adequate (1-10/month),35.72769953051643,Significantly Below (<50%),100,60.3,72.34
NCT03109977,Imaging With a New Agent That Finds a Cancer Protein Called HER2,COMPLETED,PHASE1,6.0,2017-03-31,2018-04-12,0.4844562334217507,Slow (<1/month),4.844562334217507,Significantly Below (<50%),100,45.5,31.705
NCT03012477,CISPLATIN + AZD-1775 In Breast Cancer,COMPLETED,PHASE2,34.0,2017-01-18,2020-11-30,0.7329745042492919,Slow (<1/month),7.3297450424929185,Significantly Below (<50%),100,47.7,42.17
NCT01183377,Frequency of Female Athlete Triad Among Elite Female Athlete of Iran in Different Sport in 2007,TERMINATED,,250.0,2006-10-01,2009-03-01,8.628117913832199,Adequate (1-10/month),86.281179138322,Met (75-100%),10,46.3,35.66
NCT06055777,"Study of the Safety, Tolerability, and PK of SZEY-2108 Administered Intravenously to HVs in SAD and MAD Cohorts",TERMINATED,PHASE1,64.0,2023-09-07,2024-05-31,7.296479400749064,Adequate (1-10/month),72.96479400749064,Below (50-75%),10,28.1,8.42
NCT05750277,The Feasibility of Early Time-Restricted Eating in a Student Population,UNKNOWN,NA,16.0,2023-04-19,2023-05-19,16.0,Good (10-50/month),160.0,Exceeded (≥100%),50,41.3,23.74
NCT04026477,Evaluation of Link for Equity (School Staff Population),COMPLETED,NA,1612.0,2019-08-01,2025-09-11,21.97459919390954,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT06703177,A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors,RECRUITING,PHASE1,876.0,2025-02-18,2027-07-01,30.89853997682503,Good (10-50/month),200.0,Exceeded (≥100%),60,83.0,89.505
NCT02141477,Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS),TERMINATED,PHASE1,2.0,2015-05-06,2017-06-22,0.07825192802056556,Slow (<1/month),0.7825192802056556,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT04610177,Prospective Multicenter Study of Artificial Intelligence-assisted Quality Evaluation System for Colonoscopy,UNKNOWN,,5813.0,2020-06-02,2021-12-16,314.85359430604984,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT03024177,A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection,WITHDRAWN,PHASE2,0.0,,,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT04633577,Effect of Intravenous Lidocaine on Propofol Requirements,COMPLETED,NA,40.0,2020-11-20,2020-12-30,30.44,Good (10-50/month),200.0,Exceeded (≥100%),100,58.2,68.795
NCT01096277,Vascular Effects of Sitagliptin in Diabetes Mellitus,UNKNOWN,PHASE4,70.0,2010-10-01,2012-12-01,2.6904040404040406,Adequate (1-10/month),26.9040404040404,Significantly Below (<50%),50,40.6,22.575
NCT04890977,Engaging Pacific Islanders in Mental Health Treatment,UNKNOWN,NA,48.0,2021-07-01,2023-06-30,2.0042798353909466,Adequate (1-10/month),20.042798353909465,Significantly Below (<50%),50,38.8,20.244999999999997
NCT01250977,Effect of Donepezil on Smoking,COMPLETED,PHASE2,30.0,2011-01-11,2011-12-06,2.775683890577508,Adequate (1-10/month),27.756838905775076,Significantly Below (<50%),100,52.4,53.949999999999996
NCT07325877,Supra-papillary Versus Trans-papillary Biliary Stenting in Malignant Peri-hilar Stenosis,NOT_YET_RECRUITING,NA,70.0,2026-03-01,2029-03-01,1.9441605839416058,Adequate (1-10/month),19.441605839416056,Significantly Below (<50%),30,34.6,14.729999999999999
NCT00061477,Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma,COMPLETED,PHASE2,48.0,2002-12-01,2006-09-01,1.0665109489051094,Adequate (1-10/month),10.665109489051094,Significantly Below (<50%),100,48.8,45.184999999999995
NCT00989677,Rheumatoid Arthritis Disease Activity Monitor,COMPLETED,,75.0,2009-01-01,2009-06-01,15.119205298013245,Good (10-50/month),151.19205298013242,Exceeded (≥100%),100,59.3,70.815
NCT04416477,Duration of Immunity 10 Years After a Dose-response Study With Yellow Fever Vaccine - Complementary Study,UNKNOWN,,255.0,2019-04-08,2020-08-31,15.190215264187866,Good (10-50/month),151.90215264187867,Exceeded (≥100%),50,58.7,69.69
NCT06122077,Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening,RECRUITING,,20000.0,2023-11-28,2027-06-15,470.1158301158302,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT03578575,To Investigate the Molecular Mechanism of Traditional Chinese Medicine Constitution Using Next-generation Sequencing in Nasopharyngeal Carcinoma,UNKNOWN,PHASE2,120.0,2018-07-26,2020-07-31,4.96304347826087,Adequate (1-10/month),49.6304347826087,Significantly Below (<50%),50,44.6,29.42
NCT05888675,Clinical Study of Weifuchun Treatment on Gastric Cancer,COMPLETED,EARLY_PHASE1,72.0,2016-07-01,2020-10-01,1.4112556342562783,Adequate (1-10/month),14.112556342562781,Significantly Below (<50%),100,50.8,49.18
NCT03240575,The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus,COMPLETED,PHASE4,302.0,2017-08-14,2019-05-06,14.591873015873016,Good (10-50/month),145.91873015873017,Exceeded (≥100%),100,79.2,87.095
NCT00073775,Epidemiology of Stress and the Metabolic Syndrome,COMPLETED,,3075.0,2003-09-01,2008-08-01,52.117483296213805,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT00550875,Efficacy-safety Study of Sublingual Immunotherapy With Depigmented-polymerized Pollen Extracts to Treat Rhinoconjunctivitis,COMPLETED,PHASE2,90.0,2007-06-01,2009-12-01,2.9973741794310724,Adequate (1-10/month),29.973741794310726,Significantly Below (<50%),100,57.2,66.465
NCT04588675,Stress Cardiac MRI in Ischemic Patients,UNKNOWN,,50.0,2021-11-01,2022-06-01,7.179245283018869,Adequate (1-10/month),71.79245283018868,Below (50-75%),50,37.3,18.35
NCT01572675,A Study of the Patterns of Use of Etoricoxib in France (MK-0663-148),COMPLETED,,547.0,2012-06-01,2015-03-01,16.60087736789631,Good (10-50/month),166.0087736789631,Exceeded (≥100%),100,93.3,94.325
NCT06494475,GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of Age,NOT_YET_RECRUITING,PHASE2,564.0,2024-12-17,2025-06-21,92.30193548387098,Excellent (>50/month),200.0,Exceeded (≥100%),30,79.0,86.96000000000001
NCT05636475,"The Effect Of Machine-Based And Manually Applied Hand Massage On Pain, Anxiety And Gastrointestinal System Functions After Laparoscopic Cholecystectomy Surgery",UNKNOWN,NA,171.0,2022-10-01,2023-09-01,15.53802985074627,Good (10-50/month),155.3802985074627,Exceeded (≥100%),50,53.7,57.84
NCT01194375,A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris,COMPLETED,PHASE2,180.0,2010-09-01,2011-12-01,12.015789473684212,Good (10-50/month),120.15789473684211,Exceeded (≥100%),100,69.4,81.52000000000001
NCT02064075,The Mortality and Changes in Quality of Life of Patients Suffering From SAH With Different Hydration Strategies,COMPLETED,PHASE4,96.0,2013-02-01,2013-10-01,12.075371900826447,Good (10-50/month),120.75371900826448,Exceeded (≥100%),100,62.7,75.42
NCT04748575,Effect of Acai Berry Consumption on Blood Glucose Levels in Healthy Adults,COMPLETED,NA,10.0,2020-11-05,2020-12-29,5.637037037037038,Adequate (1-10/month),56.370370370370374,Below (50-75%),100,50.8,49.18
NCT04996875,(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis,RECRUITING,PHASE2,140.0,2021-11-09,2026-07-01,2.514218289085546,Adequate (1-10/month),25.14218289085546,Significantly Below (<50%),60,49.2,46.035
NCT04695275,Clinical Feature and Microbiology Characteristics of Empyema in Children,UNKNOWN,,100.0,2021-01-06,2022-11-30,4.392496392496392,Adequate (1-10/month),43.924963924963926,Significantly Below (<50%),50,41.3,23.74
NCT03335475,Congenital Heart Disease Physical Activity Lifestyle Study,COMPLETED,NA,60.0,2017-11-07,2021-04-07,1.4646351242983162,Adequate (1-10/month),14.646351242983163,Significantly Below (<50%),100,49.8,47.17
NCT01859975,[Trial of device that is not approved or cleared by the U.S. FDA],WITHHELD,,,,,,Slow (<1/month),,Significantly Below (<50%),50,20.0,5.695
NCT03114475,Effect of CO2 Laser on Enamel White Spot Lesion Formation Around Orthodontic Brackets,COMPLETED,NA,25.0,2016-06-15,2017-09-01,1.7178329571106095,Adequate (1-10/month),17.178329571106097,Significantly Below (<50%),100,52.0,52.86
NCT07137975,Assessment of Bone Volume Using Patient Specific Autogenous Bone Plug Versus Particulate Autogenous Bone for Unilateral Alveolar Ridge Reconstruction,ACTIVE_NOT_RECRUITING,NA,16.0,2025-08-30,2026-09-30,1.22989898989899,Adequate (1-10/month),12.2989898989899,Significantly Below (<50%),85,41.8,24.445
NCT00621075,Correlation OF Hemodynamics in Pulmonary Hypertension With Perfusion Lung Scans,COMPLETED,,50.0,2007-04-01,2008-02-01,4.973856209150327,Adequate (1-10/month),49.73856209150327,Significantly Below (<50%),100,52.3,53.515
NCT03750175,OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -,COMPLETED,,49.0,2018-06-01,2022-12-31,0.8910155316606929,Slow (<1/month),8.910155316606929,Significantly Below (<50%),100,47.3,40.475
NCT03046875,The Biophysical Impact of Transcutaneous Spinal Cord Stimulation Within a Single Session,WITHDRAWN,NA,0.0,2016-10-01,2017-07-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT02333175,Care for Late Stage Parkinsonism,COMPLETED,NA,184.0,2014-09-01,2019-03-31,3.3498564593301436,Adequate (1-10/month),33.49856459330144,Significantly Below (<50%),100,64.7,77.75999999999999
NCT04523675,NAC Supplementation and Soccer Specific Performance,COMPLETED,NA,40.0,2016-04-01,2016-12-01,4.99016393442623,Adequate (1-10/month),49.901639344262286,Significantly Below (<50%),100,53.2,56.665
NCT06278675,Multiple Study of Electroaccpuncture in ARDS,NOT_YET_RECRUITING,NA,264.0,2024-05-10,2026-12-31,8.327626943005182,Adequate (1-10/month),83.27626943005181,Met (75-100%),30,50.1,47.89
NCT00826475,Randomized Trial to Evaluate the Effectiveness of a Mindfulness Based Intervention (MBSR) for Patients Suffering From Migraine,COMPLETED,NA,62.0,2009-01-01,2010-07-01,3.4565567765567766,Adequate (1-10/month),34.56556776556777,Significantly Below (<50%),100,55.0,61.834999999999994
NCT02963675,Incidence of Second Primary Malignancies in Prostate Cancer Patients With Bone Metastases - an Observational Retrospective Cohort Study in Sweden,COMPLETED,,15953.0,2016-11-15,2017-03-31,3570.6567647058823,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT06824675,Point-of-care Ultrasound Teledidactic Teaching for Prehospital Emergency Personnel,COMPLETED,NA,90.0,2025-02-23,2025-05-08,37.02162162162162,Good (10-50/month),200.0,Exceeded (≥100%),100,62.2,74.74499999999999
NCT02577575,Adult Oxytocin Study,COMPLETED,EARLY_PHASE1,120.0,2010-08-01,2015-11-01,1.9044838373305528,Adequate (1-10/month),19.044838373305524,Significantly Below (<50%),100,59.6,71.17999999999999
NCT05115175,Acceptability of Self-Led Mindfulness-Based Intervention,COMPLETED,NA,29.0,2019-07-14,2020-07-17,2.3923035230352308,Adequate (1-10/month),23.92303523035231,Significantly Below (<50%),100,52.3,53.515
NCT05056675,The PENG Block in Elective Hip Surgery and Its Effect on Postoperative Pain and Length of Stay.,COMPLETED,NA,151.0,2022-06-01,2023-11-30,8.402998171846436,Adequate (1-10/month),84.02998171846436,Met (75-100%),100,67.1,79.86999999999999
NCT03148275,"Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery",COMPLETED,PHASE2,44.0,2017-06-20,2023-06-23,0.610464904284412,Slow (<1/month),6.1046490428441205,Significantly Below (<50%),100,48.5,44.47
NCT03786757,Prevention of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant (EARLYmyo-LVT Ⅱ),UNKNOWN,PHASE3,200.0,2019-04-01,2022-12-30,4.447041636230826,Adequate (1-10/month),44.47041636230826,Significantly Below (<50%),50,51.0,49.714999999999996
NCT03206957,"Correlation Between Optic Nerve Vessel Anomalies, Serum Angiogenic Factors and Renal Anomalies in Down Syndrome Children",UNKNOWN,NA,200.0,2017-11-30,2019-06-01,11.10948905109489,Good (10-50/month),111.0948905109489,Exceeded (≥100%),50,56.0,63.71
NCT07145957,Does Undergoing a Prehabilitation Protocol Aimed at Optimizing Scapulothoracic Mobility and Strengthening Improve Internal Rotation After Reverse Shoulder Arthroplasty?,RECRUITING,,64.0,2025-11-06,2028-09-01,1.8914174757281554,Adequate (1-10/month),18.91417475728155,Significantly Below (<50%),60,41.5,24.215
NCT03685357,Correlation Between Idiopathic Parkinson's Disease and Diabetes Mellitus,UNKNOWN,,120.0,2018-07-01,2020-01-01,6.6535519125683065,Adequate (1-10/month),66.53551912568307,Below (50-75%),50,42.9,26.145000000000003
NCT01472757,Clinical Study to Evaluate the Efficacy of VR506 Using a New Inhaler for the Treatment of Asthma,COMPLETED,PHASE2,374.0,2011-10-01,2013-05-01,19.696470588235297,Good (10-50/month),196.96470588235297,Exceeded (≥100%),100,84.9,90.85
NCT04360057,The Impact of Patient Motivational Dialogue (PMD) on Patient Self-advocacy for Hand Hygiene,COMPLETED,NA,63.0,2016-10-01,2018-03-13,3.6320454545454544,Adequate (1-10/month),36.320454545454545,Significantly Below (<50%),100,55.0,61.834999999999994
NCT00502957,Biofeedback Treatment for Functional Constipation,COMPLETED,NA,15.0,2005-03-01,2007-11-01,0.46830769230769237,Slow (<1/month),4.683076923076924,Significantly Below (<50%),100,46.2,35.089999999999996
NCT00644657,The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization,COMPLETED,NA,27.0,2007-03-01,2008-09-01,1.494327272727273,Adequate (1-10/month),14.94327272727273,Significantly Below (<50%),100,47.2,40.035
NCT00796757,A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).,COMPLETED,PHASE2,146.0,2008-12-01,2012-02-01,3.8411754537597234,Adequate (1-10/month),38.41175453759724,Significantly Below (<50%),100,61.7,74.1
NCT03512457,Skin Self-Examination Education During Mammography,COMPLETED,NA,420.0,2018-05-30,2018-10-24,86.97142857142858,Excellent (>50/month),200.0,Exceeded (≥100%),100,93.6,94.77
NCT01345357,Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma,COMPLETED,PHASE1,24.0,2011-05-01,2013-01-01,1.1956792144026187,Adequate (1-10/month),11.956792144026187,Significantly Below (<50%),100,46.9,38.96
NCT00748657,Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary,COMPLETED,PHASE2,36.0,2008-09-22,2013-01-31,0.6883417085427136,Slow (<1/month),6.883417085427136,Significantly Below (<50%),100,47.9,42.64
NCT01431157,Effects of Nocturnal Nasal Oxygen on Biomarkers in Sleep Apnea Patients With Heart Failure,TERMINATED,NA,20.0,2011-11-01,2013-10-01,0.8697142857142858,Slow (<1/month),8.697142857142858,Significantly Below (<50%),10,19.6,5.365
NCT01618357,Pre-Operative Radiation and Veliparib for Breast Cancer,COMPLETED,PHASE1,19.0,2013-07-22,2023-10-17,0.15468307033966303,Slow (<1/month),1.54683070339663,Significantly Below (<50%),100,46.5,36.815
NCT00401557,Mechanisms Relating to the Distinct in Vitro Susceptibility of Human Macrophages to L. Viannia Infection,COMPLETED,,34.0,2006-12-01,2010-04-01,0.850419063270337,Slow (<1/month),8.50419063270337,Significantly Below (<50%),100,46.1,34.695
NCT00246701,Evaluation of Efficacy and Safety of Combined Omacor (Omega-3-acid Ethyl Esters) and Simvastatin Therapy in Hypertriglyceridemic Subjects,COMPLETED,PHASE3,256.0,2005-11-01,2006-06-01,36.75773584905661,Good (10-50/month),200.0,Exceeded (≥100%),100,75.5,84.68
NCT01546701,Buprenorphine in Acute Renal Colic Pain Management,COMPLETED,PHASE4,80.0,2011-03-01,2012-04-01,6.134005037783376,Adequate (1-10/month),61.340050377833755,Below (50-75%),100,56.4,64.88000000000001
NCT06159101,"A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects",UNKNOWN,PHASE1,304.0,2023-11-28,2024-05-28,50.84483516483517,Excellent (>50/month),200.0,Exceeded (≥100%),50,69.3,81.395
NCT00255801,Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma,COMPLETED,PHASE2,37.0,2005-11-01,2017-10-01,0.25879595588235293,Slow (<1/month),2.5879595588235293,Significantly Below (<50%),100,48.0,42.945
NCT02858401,"Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults",COMPLETED,PHASE1,48.0,2015-01-29,2019-02-14,0.9892484766418416,Slow (<1/month),9.892484766418416,Significantly Below (<50%),100,48.8,45.184999999999995
NCT03785301,Effect of FGM on Glucose Control in Diabetic Patients,UNKNOWN,NA,600.0,2018-12-20,2019-12-31,48.57446808510638,Good (10-50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT04214301,An Open-Label Preference Evaluation of BLI800,COMPLETED,PHASE4,40.0,2019-09-24,2019-11-21,20.993103448275864,Good (10-50/month),200.0,Exceeded (≥100%),100,58.2,68.795
NCT00262301,Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema,COMPLETED,PHASE3,75.0,2004-06-01,2009-10-01,1.1719712525667352,Adequate (1-10/month),11.719712525667353,Significantly Below (<50%),100,51.0,49.714999999999996
NCT05440201,Coupling Between Clotting Characteristics in Chronic Hemodialysis Patients and the Hemodialyzer Patency,COMPLETED,NA,20.0,2023-04-19,2023-05-20,19.638709677419353,Good (10-50/month),196.38709677419354,Exceeded (≥100%),100,56.6,65.34
NCT00921401,Improving the Quality of Asthma Care Using the Internet,COMPLETED,PHASE2,408.0,2009-08-01,2013-02-01,9.70275,Adequate (1-10/month),97.0275,Met (75-100%),100,87.6,92.335
NCT00684801,"Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers",COMPLETED,,605.0,2007-08-01,2011-12-01,11.633733417561592,Good (10-50/month),116.33733417561591,Exceeded (≥100%),100,93.3,94.325
NCT01627301,Sympathetic Overactivity in Post-traumatic Stress Disorder,RECRUITING,NA,120.0,2012-07-01,2027-12-01,0.648694725625999,Slow (<1/month),6.48694725625999,Significantly Below (<50%),60,42.6,25.679999999999996
NCT06875401,Long-Term Patient-Reported Maternal Outcomes Following Abdominal Cerclage for the Prevention of Preterm Birth,ENROLLING_BY_INVITATION,,1200.0,2025-03-05,2025-06-01,415.0909090909091,Excellent (>50/month),200.0,Exceeded (≥100%),55,84.8,90.815
NCT00497601,A Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Kala-Azar,COMPLETED,PHASE2,60.0,2007-02-01,2008-07-01,3.53953488372093,Adequate (1-10/month),35.3953488372093,Significantly Below (<50%),100,54.8,61.095
NCT06564701,A Pediatric Comparison of Remote Microphone Technologies,COMPLETED,NA,25.0,2024-08-05,2025-01-16,4.640243902439025,Adequate (1-10/month),46.40243902439025,Significantly Below (<50%),100,52.0,52.86
NCT04586101,iT-based Sports Therapy Application in Haemophilia,COMPLETED,NA,20.0,2018-01-31,2021-12-15,0.4305516265912306,Slow (<1/month),4.305516265912305,Significantly Below (<50%),100,46.6,37.375
NCT01936701,Comparison of the Effect of Hydrophobic Acrylic and Silicone 3-piece IOLs on Posterior Capsule Opacification,COMPLETED,NA,50.0,2011-03-01,2011-08-01,9.947712418300654,Adequate (1-10/month),99.47712418300654,Met (75-100%),100,59.0,70.365
NCT03531801,Referred Pain Areas in Subjects With a Recovered Radius Fracture,COMPLETED,,44.0,2017-10-30,2018-09-03,4.348571428571429,Adequate (1-10/month),43.48571428571428,Significantly Below (<50%),100,51.9,52.55499999999999
NCT06577701,Respiratory Disease Cohort Studies of Chinese Medicine for COPD(RESEARCH-COPD),NOT_YET_RECRUITING,,10000.0,2024-10-01,2027-10-30,270.8185053380783,Excellent (>50/month),200.0,Exceeded (≥100%),30,77.3,85.67
NCT04664101,"REmotely Monitored, Mobile Health-Supported High Intensity Interval Training After COVID-19 Critical Illness (REMM-HIIT-COVID-19)",COMPLETED,NA,13.0,2022-03-02,2023-12-01,0.6192801251956181,Slow (<1/month),6.192801251956182,Significantly Below (<50%),100,46.0,34.1
NCT06312501,Remote Patient Monitoring for Patients With Heart Failure in France,COMPLETED,,20000.0,2018-08-01,2022-12-31,377.4333539987601,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT03544801,Renji Cerebral Small Vessel Disease Corhort Study,UNKNOWN,,300.0,2015-09-29,2020-12-30,4.75872850442939,Adequate (1-10/month),47.58728504429391,Significantly Below (<50%),50,57.3,66.74
NCT03657212,Enhancing Memory Consolidation in Older Adults,TERMINATED,PHASE4,10.0,2018-10-01,2019-01-01,3.3086956521739133,Adequate (1-10/month),33.08695652173913,Significantly Below (<50%),10,23.8,6.76
NCT02661412,Immediate Loading of Implants in the Partially or Completely Edentulous Jaw,ACTIVE_NOT_RECRUITING,,150.0,2015-12-01,2031-12-01,0.7813141683778234,Slow (<1/month),7.813141683778234,Significantly Below (<50%),85,50.8,49.18
NCT07316712,Effect of TECAR (Transfer of Energy Capacitive and Resistive) Therapy on Chronic Supraspinatus Tendinitis,NOT_YET_RECRUITING,NA,46.0,2025-12-30,2026-02-28,23.337333333333333,Good (10-50/month),200.0,Exceeded (≥100%),30,37.7,18.915000000000003
NCT04798612,Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression,UNKNOWN,PHASE2,68.0,2023-08-14,2025-12-01,2.4641904761904763,Adequate (1-10/month),24.641904761904765,Significantly Below (<50%),50,40.4,22.34
NCT03902912,Effect of Prednisolone Treatment on Uterine Natural Killer Cells,RECRUITING,PHASE3,84.0,2019-07-30,2028-04-30,0.7997998123240538,Slow (<1/month),7.9979981232405395,Significantly Below (<50%),60,39.7,21.21
NCT04122612,"Shaping Microbiome in the First 1,000 Days of Life",COMPLETED,,60.0,2018-09-23,2019-10-07,4.818997361477573,Adequate (1-10/month),48.18997361477573,Significantly Below (<50%),100,53.1,56.105000000000004
NCT00000812,"A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection",COMPLETED,PHASE1,36.0,,2000-07-01,,Slow (<1/month),,Significantly Below (<50%),100,42.9,26.145000000000003
NCT02073812,"Evaluating the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Carbavance™ (RPX2014/RPX7009) in Healthy Adult Subjects",COMPLETED,PHASE1,26.0,2014-02-01,2014-04-01,13.414237288135594,Good (10-50/month),134.14237288135595,Exceeded (≥100%),100,57.1,66.27
NCT03003312,Prevalence of Pediatric Urolithiasis in Kashgar Area of Xinjiang in China,UNKNOWN,,4751.0,2016-07-01,2017-06-01,431.7028059701493,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT06579612,The Benefits of Individualized Follow-up With a Sport-Health Professional in the Care of Patients With Chronic Respiratory Diseases,RECRUITING,NA,352.0,2024-11-07,2029-11-07,5.867951807228915,Adequate (1-10/month),58.67951807228916,Below (50-75%),60,66.2,79.2
NCT02833012,"Evaluation of PK of Caprylic Triglyceride Oil, AC-1202, AC-1204, and Axona on Ketone Body Production",COMPLETED,PHASE1,20.0,2016-07-01,2016-12-01,3.9790849673202615,Adequate (1-10/month),39.790849673202615,Significantly Below (<50%),100,51.6,51.644999999999996
NCT04194112,Diagnostic Performance and Predictive Capacity of Immediate Urine Cytology After Transurethral Resection of Non-Muscle Invasive Bladder Cancer; A Prospective Study,COMPLETED,NA,198.0,2015-04-01,2019-09-01,3.7342750929368034,Adequate (1-10/month),37.34275092936804,Significantly Below (<50%),100,65.8,78.745
NCT03146312,Effect of a Multivitamin/Multimineral/Phytochemical Dietary Supplement on Indices of Human Health,COMPLETED,NA,24.0,2017-04-20,2017-06-08,14.909387755102042,Good (10-50/month),149.09387755102043,Exceeded (≥100%),100,56.9,65.89500000000001
NCT03310112,Mindfulness Training in U.S. Army Cohorts,COMPLETED,NA,120.0,2017-10-09,2018-03-27,21.614201183431952,Good (10-50/month),200.0,Exceeded (≥100%),100,64.6,77.59
NCT04250012,Web-based ACT to Support Parents With Children With Chronic and Developmental Conditions,COMPLETED,NA,111.0,2019-01-28,2020-12-15,4.918253275109171,Adequate (1-10/month),49.182532751091706,Significantly Below (<50%),100,58.9,70.10499999999999
NCT06242912,Evidence Development in Cancer Treatment - Real World: PREDiCTrw,RECRUITING,NA,100.0,2024-01-22,2029-01-01,1.6854928017718718,Adequate (1-10/month),16.854928017718716,Significantly Below (<50%),60,46.0,34.1
NCT06176612,"In Patients With Hip Dysplasia, Mid-Term Lower Extremities and Spine After Hip Arthroplasty Natural Course",COMPLETED,NA,33.0,2021-04-15,2024-10-01,0.7940869565217392,Slow (<1/month),7.940869565217393,Significantly Below (<50%),100,47.6,41.775
NCT00671112,Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma,TERMINATED,PHASE1,30.0,2008-06-01,,,Slow (<1/month),,Significantly Below (<50%),10,15.4,2.5100000000000002
NCT00112112,Safety Study to Evaluate FluMist in Immunocompromised Children,COMPLETED,PHASE1,20.0,2005-08-01,2008-05-01,0.6063745019920319,Slow (<1/month),6.063745019920319,Significantly Below (<50%),100,46.6,37.375
NCT05377112,"Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome",COMPLETED,EARLY_PHASE1,11.0,2022-03-29,2022-12-07,1.3234782608695652,Adequate (1-10/month),13.234782608695653,Significantly Below (<50%),100,45.9,33.495000000000005
NCT02588781,Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study,UNKNOWN,PHASE2,23.0,2015-10-01,2023-12-01,0.23470331880657058,Slow (<1/month),2.347033188065706,Significantly Below (<50%),50,31.8,11.19
NCT05045781,"Safety, Tolerability and Pharmacokinetics of Eptinezumab in Healthy Chinese Subjects",COMPLETED,PHASE1,20.0,2021-04-20,2021-07-20,6.69010989010989,Adequate (1-10/month),66.9010989010989,Below (50-75%),100,51.6,51.644999999999996
NCT00811681,Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept,COMPLETED,PHASE3,40.0,2008-12-01,2013-03-01,0.7850419084461637,Slow (<1/month),7.850419084461638,Significantly Below (<50%),100,48.2,43.665
NCT04368481,MIDI (MR Imaging Abnormality Deep Learning Identification),RECRUITING,,30000.0,2019-04-01,2025-03-31,416.7959835691466,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT06672081,Early Catheter-directed Treatment of High Risk Pulmonary Embolism,RECRUITING,NA,315.0,2024-12-27,2027-06-30,10.479344262295083,Good (10-50/month),104.79344262295083,Exceeded (≥100%),60,68.2,80.77
NCT00129181,Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease,COMPLETED,NA,30.0,2005-01-01,2007-01-01,1.2509589041095892,Adequate (1-10/month),12.509589041095893,Significantly Below (<50%),100,47.4,40.98
NCT03875781,Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer,RECRUITING,PHASE3,540.0,2019-06-05,2026-12-05,5.999124087591241,Adequate (1-10/month),59.99124087591241,Below (50-75%),60,78.0,86.075
NCT01438281,Study to Evaluate the Ocular Tolerance of SYL1001 in Healthy Volunteers,COMPLETED,PHASE1,30.0,2011-07-01,2012-06-01,2.717857142857143,Adequate (1-10/month),27.17857142857143,Significantly Below (<50%),100,52.4,53.949999999999996
NCT02248181,Post Marketing Surveillance Study of Sifrol® in Patients With Idiopathic Parkinson's Disease,COMPLETED,,442.0,2004-02-01,,,Slow (<1/month),,Significantly Below (<50%),100,73.7,83.825
NCT01553981,A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma,COMPLETED,PHASE3,40.0,2012-03-01,2014-05-01,1.5393173198482935,Adequate (1-10/month),15.393173198482934,Significantly Below (<50%),100,48.2,43.665
NCT05563181,Evaluation of a Beverage Media Campaign and Added-sugar Warning Labels,COMPLETED,NA,2275.0,2022-10-07,2023-03-10,449.6818181818182,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT05589181,High Dose Buprenorphine (BUP) Induction in the Emergency Department (ED),RECRUITING,PHASE3,140.0,2023-04-06,2026-12-31,3.1220512820512822,Adequate (1-10/month),31.22051282051282,Significantly Below (<50%),60,49.2,46.035
NCT05368181,MAP-guided Preemptive Therapy of aGvHD,UNKNOWN,PHASE2,56.0,2022-05-01,2024-12-31,1.748348717948718,Adequate (1-10/month),17.48348717948718,Significantly Below (<50%),50,39.5,21.044999999999998
NCT00429481,"Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine at Different Viral Concentrations in Healthy Infants",COMPLETED,PHASE2,2464.0,2001-01-01,2003-04-01,91.46848780487805,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT04315181,Prescription Medication Interactions,COMPLETED,PHASE1,11.0,2019-03-25,2023-05-06,0.22278110445775115,Slow (<1/month),2.2278110445775114,Significantly Below (<50%),100,45.9,33.495000000000005
NCT03271281,PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2,COMPLETED,PHASE2,113.0,2017-12-04,2021-12-31,2.3116397849462365,Adequate (1-10/month),23.116397849462366,Significantly Below (<50%),100,59.0,70.365
NCT02146781,A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device,COMPLETED,PHASE1,22.0,2014-06-01,2015-03-01,2.453040293040293,Adequate (1-10/month),24.530402930402932,Significantly Below (<50%),100,51.8,52.17
NCT07195981,VIRTUAL REALITY IN CERVICAL RADICULOPATHY PATIENTS,RECRUITING,NA,42.0,2025-07-01,2025-11-30,8.411052631578947,Adequate (1-10/month),84.11052631578949,Met (75-100%),60,46.4,36.26
NCT06527781,A Study of PD5K3 in Healthy Adult Volunteers,COMPLETED,PHASE1,28.0,2023-11-27,2024-05-20,4.8704,Adequate (1-10/month),48.704,Significantly Below (<50%),100,52.2,53.22
NCT06393881,"A Study to Compare and Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of UI059 and UIC202201",NOT_YET_RECRUITING,PHASE1,66.0,2024-07-03,2024-09-21,25.113,Good (10-50/month),200.0,Exceeded (≥100%),30,39.3,20.810000000000002
NCT02250781,Oral ONC201 in Treating Patients With Advanced Solid Tumors,COMPLETED,PHASE1,58.0,2015-01-12,2018-10-25,1.2775108538350217,Adequate (1-10/month),12.775108538350215,Significantly Below (<50%),100,49.6,46.785
NCT00200681,IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma,COMPLETED,PHASE3,493.0,2005-06-01,2008-06-01,13.692445255474452,Good (10-50/month),136.92445255474453,Exceeded (≥100%),100,94.4,94.865
NCT03540381,"Relation Among HDL Functionality, Neoatherosclerosis and Target Lesion Revascularization",COMPLETED,,181.0,2011-05-01,2017-07-31,2.4133333333333336,Adequate (1-10/month),24.133333333333333,Significantly Below (<50%),100,62.8,75.53999999999999
NCT04533581,Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL),ACTIVE_NOT_RECRUITING,PHASE2,61.0,2020-09-17,2028-05-31,0.6600924280127978,Slow (<1/month),6.600924280127978,Significantly Below (<50%),85,45.4,31.455
NCT07245381,Alendronate to Reduce Pelvic Insufficiency Fractures in Cervical Cancer Patients Undergoing Chemoradiation,NOT_YET_RECRUITING,PHASE1,65.0,2025-12-01,2026-09-01,7.221167883211678,Adequate (1-10/month),72.21167883211679,Below (50-75%),30,34.2,14.305000000000001
NCT03303781,BeSingCardioRehab: CR in Belgium Versus Singapore,COMPLETED,,2792.0,2018-04-01,2021-01-01,84.48159045725646,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT04243681,Combination of Autologous MSC and HSC Infusion in Patients With Decompensated Cirrhosis,COMPLETED,PHASE4,5.0,2019-07-01,2020-09-01,0.35560747663551406,Slow (<1/month),3.5560747663551404,Significantly Below (<50%),100,45.4,31.455
NCT03848481,CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS),COMPLETED,PHASE2,14.0,2020-11-23,2024-10-31,0.296356050069541,Slow (<1/month),2.9635605006954107,Significantly Below (<50%),100,46.1,34.695
NCT07081581,Analgesic Effect of Serratus Plane Block With Adjuvant Agents in Breast Cancer Surgery,COMPLETED,PHASE2,75.0,2022-08-01,2023-03-01,10.768867924528303,Good (10-50/month),107.68867924528303,Exceeded (≥100%),100,61.0,73.17
NCT01964781,The Effect of Topical Administration of Common Drugs on Postoperative Bleeding and Pain,COMPLETED,PHASE4,30.0,2013-08-01,2014-12-01,1.8751540041067762,Adequate (1-10/month),18.751540041067763,Significantly Below (<50%),100,52.4,53.949999999999996
NCT04303481,The Effect of Consuming Enzymes and Prebiotics on Body Composition and Blood Biochemical Index,COMPLETED,NA,88.0,2019-08-10,2019-12-31,18.732307692307693,Good (10-50/month),187.3230769230769,Exceeded (≥100%),100,62.0,74.42
NCT04722081,Virtual Reality for Tibial Eminence Fractures,UNKNOWN,NA,20.0,2015-01-01,2021-03-01,0.27045757441137275,Slow (<1/month),2.7045757441137273,Significantly Below (<50%),50,31.6,10.905
NCT00004381,Phase II Randomized Study of Tin Mesoporphyrin for Neonatal Hyperbilirubinemia,COMPLETED,PHASE2,,1999-12-01,,,Slow (<1/month),,Significantly Below (<50%),100,40.0,21.87
NCT04523519,PrEP Intervention for People Who Inject Substances and Use Methamphetamine,RECRUITING,PHASE4,140.0,2021-04-30,2025-05-01,2.9149110807113545,Adequate (1-10/month),29.149110807113548,Significantly Below (<50%),60,49.2,46.035
NCT02080819,Striatal Effective Connectivity to Predict Treatment Response in Cocaine Misuse,COMPLETED,PHASE2,131.0,2014-02-01,2017-01-21,3.6752442396313363,Adequate (1-10/month),36.75244239631337,Significantly Below (<50%),100,60.5,72.685
NCT02992119,Malaria Vaccine Safety and Immunogenicity Study in Healthy Adults,COMPLETED,PHASE2,193.0,2017-06-04,2018-02-20,22.509272030651342,Good (10-50/month),200.0,Exceeded (≥100%),100,70.4,82.17
NCT06421519,Different Levels of BiPAP,RECRUITING,PHASE1,21.0,2024-05-23,2024-08-01,9.132,Adequate (1-10/month),91.32000000000001,Met (75-100%),60,44.7,29.67
NCT00289419,"Intraarticular Analgesia After Total Hip Arthroplasty, a Randomised Study",COMPLETED,PHASE4,80.0,2005-02-01,2006-03-01,6.196437659033079,Adequate (1-10/month),61.964376590330794,Below (50-75%),100,56.4,64.88000000000001
NCT00903019,Feasibility of Telehealth Problem-Solving Therapy for Depressed Homebound Older Adults,COMPLETED,NA,158.0,2009-06-01,2013-05-01,3.3633006993006993,Adequate (1-10/month),33.633006993007,Significantly Below (<50%),100,62.6,75.325
NCT00138619,Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes,COMPLETED,PHASE3,478.0,2004-11-01,2007-04-01,16.515686719636776,Good (10-50/month),165.15686719636778,Exceeded (≥100%),100,93.2,93.89999999999999
NCT03315819,Anterior Capsulo-labral Reinsertion by Arthroscopic Approach Versus Immobilization,COMPLETED,NA,40.0,2014-03-27,2019-03-26,0.6671780821917808,Slow (<1/month),6.6717808219178085,Significantly Below (<50%),100,48.2,43.665
NCT00973219,Hepatitis B Surface Antigen(HBsAg) Loss in Chronic Hepatitis B Patients With Low Viral Load,COMPLETED,NA,151.0,2009-09-01,2019-10-01,1.248354155350353,Adequate (1-10/month),12.48354155350353,Significantly Below (<50%),100,57.1,66.27
NCT02450019,"Protective Ventilation in Neurosurgery, a Pilot Study",COMPLETED,NA,40.0,2015-05-01,2016-11-01,2.213818181818182,Adequate (1-10/month),22.13818181818182,Significantly Below (<50%),100,53.2,56.665
NCT04591119,Transversus Thoracis Muscle Plane Block for Postoperative Pain in Adult Cardiac Surgery,COMPLETED,NA,75.0,2020-10-20,2020-12-21,36.82258064516129,Good (10-50/month),200.0,Exceeded (≥100%),100,61.0,73.17
NCT00579319,Use of Breast MRI for Local Staging,WITHDRAWN,,0.0,2005-04-01,2009-04-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT04550819,Intraintestinal Extended Biliary Stents Preventing Duodenobiliary Reflux in Patients With Biliary Stricture,UNKNOWN,NA,724.0,2020-10-01,2023-10-01,20.12653881278539,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT00996619,Measuring the Spectrum of Tissues During Endoscopy,UNKNOWN,,100.0,2009-10-01,2010-05-01,14.358490566037737,Good (10-50/month),143.58490566037736,Exceeded (≥100%),50,46.3,35.66
NCT02299219,Teens Taking Charge: Managing Cancer Online,COMPLETED,NA,73.0,2016-01-01,2019-04-01,1.8736256323777405,Adequate (1-10/month),18.736256323777408,Significantly Below (<50%),100,55.8,63.245
NCT06623019,Study of the Validity and Reliability of Two Digital Dynamometers in Older People,COMPLETED,,413.0,2024-12-16,2025-04-15,104.76433333333334,Excellent (>50/month),200.0,Exceeded (≥100%),100,91.4,93.64
NCT05902819,Reconsolidation Blockade of Intrusive Trauma- and Cocaine-related Memories,ACTIVE_NOT_RECRUITING,NA,210.0,2023-05-10,2026-03-14,6.152454282964389,Adequate (1-10/month),61.52454282964389,Below (50-75%),85,62.3,74.94
NCT01107119,Integrated Care Pathways in a Community Setting,COMPLETED,NA,304.0,2009-10-01,2012-10-01,8.443211678832117,Adequate (1-10/month),84.43211678832117,Met (75-100%),100,79.3,87.13
NCT00662519,Neulasta in Type 1 Diabetes,COMPLETED,PHASE1,21.0,2008-04-01,2014-03-01,0.29594444444444445,Slow (<1/month),2.959444444444444,Significantly Below (<50%),100,46.7,37.895
NCT02739919,Bacterial Analysis of Kidney Stones Removed by Percutaneous Nephrolithotomy,COMPLETED,,6.0,2016-06-01,2017-02-24,0.6814925373134328,Slow (<1/month),6.8149253731343284,Significantly Below (<50%),100,43.8,27.965
NCT06214819,Plan to Evaluate Early Endothelialization of a Polymer Free Sirolimus-eluting Coronary Stent System (VIVO ISARTM) Compared With Everolimus-eluting Durable Polymer Stent (XIENCE SkypointTM) in Patients Undergoing Percutaneous Coronary Intervention.,ACTIVE_NOT_RECRUITING,NA,40.0,2024-03-20,2026-05-31,1.5182044887780548,Adequate (1-10/month),15.182044887780549,Significantly Below (<50%),85,43.7,27.744999999999997
NCT04341519,"Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers",UNKNOWN,,1464.0,2020-04-06,2021-12-31,70.29047318611988,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT01558219,Second-line Chemotherapy in Castration Resistant Prostate Cancer,COMPLETED,PHASE2,60.0,2011-11-01,2014-12-01,1.62202486678508,Adequate (1-10/month),16.220248667850797,Significantly Below (<50%),100,49.8,47.17
NCT04587219,"The Study of ""Gam-COVID-Vac"" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older",UNKNOWN,PHASE2,110.0,2020-10-22,2021-04-30,17.623157894736842,Good (10-50/month),176.23157894736843,Exceeded (≥100%),50,48.8,45.184999999999995
NCT01499719,Surgery Checklist and Process Improvement Surrounding Endoscopic Sinus Surgery,COMPLETED,,100.0,2011-12-01,2012-12-01,8.316939890710383,Adequate (1-10/month),83.16939890710383,Met (75-100%),100,56.3,64.5
NCT04905719,Point-of-Care Ultrasound in Primary Care,UNKNOWN,,600.0,2021-06-10,2022-06-30,47.43896103896105,Good (10-50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT04892719,4DX Functional Lung Imaging in the Diagnosis of Chronic Lung Allograft Dysfunction After Lung Transplantation,COMPLETED,NA,18.0,2020-10-28,2022-03-31,1.0557225433526012,Adequate (1-10/month),10.557225433526012,Significantly Below (<50%),100,46.4,36.26
NCT07214519,Permanent Supportive Housing Overdose Prevention-2 Study,NOT_YET_RECRUITING,NA,2940.0,2027-07-01,2031-03-31,65.37151205259313,Excellent (>50/month),200.0,Exceeded (≥100%),30,79.0,86.96000000000001
NCT01919619,Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies,COMPLETED,PHASE2,41.0,2013-11-04,2024-05-03,0.3256039655622228,Slow (<1/month),3.256039655622228,Significantly Below (<50%),100,48.3,43.985
NCT04001530,Half-normal Saline in Atrial Flutter Ablation,COMPLETED,NA,4.0,2018-01-01,2021-01-31,0.10813499111900533,Slow (<1/month),1.0813499111900533,Significantly Below (<50%),100,45.3,31.169999999999998
NCT00189930,An Evaluation of Immunogenicity and Safety of Two Doses of MVA-nef vs. MVA-BN in HIV-1 Infected Patients,COMPLETED,PHASE2,77.0,2005-04-01,2006-12-01,3.848735632183908,Adequate (1-10/month),38.48735632183908,Significantly Below (<50%),100,56.2,64.21
NCT00262730,Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM,COMPLETED,PHASE2,97.0,2006-01-01,2010-04-01,1.9037266279819471,Adequate (1-10/month),19.03726627981947,Significantly Below (<50%),100,57.8,67.635
NCT00938730,A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial Fibrillation,COMPLETED,PHASE2,1280.0,2009-06-01,2010-09-01,85.25864332603939,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT03192930,Inflammatory and Cerebrospinal Biochemical Markers in Blood During Prolonged Hyperbaric Exposure,COMPLETED,,26.0,2017-03-17,2018-01-17,2.58640522875817,Adequate (1-10/month),25.8640522875817,Significantly Below (<50%),100,50.4,48.355
NCT03467230,Performance Assessment of the PMD-200 Under General Anesthesia,COMPLETED,,61.0,2018-03-15,2018-12-12,6.826617647058823,Adequate (1-10/month),68.26617647058823,Below (50-75%),100,53.2,56.665
NCT06624930,Behaviour Change for Cancer Survivors Trial,RECRUITING,NA,236.0,2024-10-03,2029-05-31,4.223303938859495,Adequate (1-10/month),42.233039388594946,Significantly Below (<50%),60,56.9,65.89500000000001
NCT03529630,Breastfeeding Success With the Use of the WHO Syringe Technique for Management of Inverted Nipples in Lactating Women,COMPLETED,NA,54.0,2018-06-01,2020-07-15,2.1209806451612905,Adequate (1-10/month),21.209806451612906,Significantly Below (<50%),100,54.3,59.62
NCT02112630,Boceprevir in End Stage Renal Disease (ESRD),WITHDRAWN,NA,0.0,2013-05-01,2015-02-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT00936130,Bariatric Surgery and Weight Loss on Energy Metabolism and Insulin Sensitivity,COMPLETED,,48.0,2010-09-01,2014-09-01,1.000082135523614,Adequate (1-10/month),10.00082135523614,Significantly Below (<50%),100,47.2,40.035
NCT01133730,Transversalis Fascial Plane Nerve Block in Iliac Crest Bone Graft,COMPLETED,NA,56.0,2010-08-01,2012-12-01,1.9984056271981243,Adequate (1-10/month),19.984056271981242,Significantly Below (<50%),100,54.5,60.12
NCT02444130,Presbyopia Compensation: Looking for Electrophysiological Predictors,COMPLETED,,40.0,2015-02-01,2016-02-01,3.3358904109589043,Adequate (1-10/month),33.35890410958904,Significantly Below (<50%),100,51.5,51.245
NCT06090630,MR Correlated Spectroscopic Imaging for Diagnosing Breast Cancer,COMPLETED,EARLY_PHASE1,83.0,2017-07-31,2023-02-03,1.2551018380526577,Adequate (1-10/month),12.551018380526576,Significantly Below (<50%),100,51.6,51.644999999999996
NCT03007030,Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery,RECRUITING,PHASE2,55.0,2017-04-05,2026-05-01,0.5053425897977664,Slow (<1/month),5.0534258979776645,Significantly Below (<50%),60,37.4,18.62
NCT06852430,Factors Associated With Advanced HIV and Poor Nutrition Among People Living With HIV,NOT_YET_RECRUITING,,100.0,2025-02-22,2027-02-01,4.293370944992947,Adequate (1-10/month),42.93370944992948,Significantly Below (<50%),30,35.3,15.534999999999998
NCT06164730,A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease,RECRUITING,PHASE1,85.0,2024-04-30,2027-08-01,2.1779461279461283,Adequate (1-10/month),21.77946127946128,Significantly Below (<50%),60,44.8,29.845
NCT00270530,Intermittent Preventive Treatment of Malaria in HIV-Seropositive Pregnant Women in Zambia,COMPLETED,PHASE4,454.0,2002-11-01,2004-10-01,19.742514285714286,Good (10-50/month),197.42514285714284,Exceeded (≥100%),100,91.3,93.62
NCT02176330,Does Using a 'Virtual Clinic' in Urogynaecology Improve Patient Experience and Reduce Cost?,COMPLETED,NA,195.0,2008-06-01,2012-08-01,3.9,Adequate (1-10/month),39.0,Significantly Below (<50%),100,65.6,78.56
NCT05113628,Methylene Blue Spray for Identification of Recurrent Laryngeal Nerve and Parathyroid Gland,COMPLETED,NA,80.0,2020-01-15,2021-07-15,4.451919561243145,Adequate (1-10/month),44.519195612431446,Significantly Below (<50%),100,56.4,64.88000000000001
NCT03717428,Preventing Age-Related Weight Gain in the Workplace With Daily Weighing,COMPLETED,NA,280.0,2016-10-01,2019-09-30,7.790859232175503,Adequate (1-10/month),77.90859232175502,Met (75-100%),100,72.4,83.17999999999999
NCT02006628,A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder,COMPLETED,PHASE2,88.0,2014-02-25,2015-01-08,8.450220820189275,Adequate (1-10/month),84.50220820189274,Met (75-100%),100,62.0,74.42
NCT05653128,Food and Nutrition Insecurity During Pregnancy in French Guiana,COMPLETED,,788.0,2023-01-19,2023-09-11,102.07114893617022,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT05173428,The Effect of Motivational Interviews Based on the Transtheoretic Model on Pregnant Women's Smoking Cessation Behaviors,COMPLETED,NA,62.0,2021-12-30,2022-11-30,5.633671641791046,Adequate (1-10/month),56.33671641791045,Below (50-75%),100,55.0,61.834999999999994
NCT02275728,Pelvic Floor Muscle Training With and Without Biofeedback in Women With Stress Urinary Incontinence,UNKNOWN,NA,45.0,2014-05-01,2014-11-01,7.444565217391305,Adequate (1-10/month),74.44565217391305,Below (50-75%),50,38.6,20.015
NCT03216928,"A New Mode of Action of Anti-TNF, Reverse Signaling, in Rheumatoid Arthritis",COMPLETED,NA,33.0,2017-01-01,2020-03-12,0.8615094339622642,Slow (<1/month),8.615094339622642,Significantly Below (<50%),100,47.6,41.775
NCT02163928,Evaluation of Changes in Skin Carotenoid Scores in Medical Students Following Dietary Interventions,COMPLETED,,40.0,2014-06-01,2016-12-14,1.3134843581445523,Adequate (1-10/month),13.134843581445526,Significantly Below (<50%),100,46.5,36.815
NCT02576028,Fascial Manipulation® Associated With Standard Care Versus Standard Post-surgical Care for Total Hip Arthroplasty,COMPLETED,NA,51.0,2011-10-01,2013-07-01,2.4294835680751175,Adequate (1-10/month),24.294835680751177,Significantly Below (<50%),100,54.1,59.11
NCT01965028,Daily Bi-temporal Transcranial Random Noise Stimulation in Tinnitus,COMPLETED,NA,30.0,2013-10-01,2016-01-01,1.110948905109489,Adequate (1-10/month),11.109489051094892,Significantly Below (<50%),100,47.4,40.98
NCT06031428,MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men,RECRUITING,PHASE2,100.0,2024-02-20,2027-11-01,2.254814814814815,Adequate (1-10/month),22.548148148148147,Significantly Below (<50%),60,46.0,34.1
NCT03366428,Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer,COMPLETED,PHASE1,51.0,2017-12-26,2021-02-19,1.348774978279757,Adequate (1-10/month),13.487749782797568,Significantly Below (<50%),100,49.1,45.83
NCT03344328,"Prevalence, Intensity and Consequences of Bortezomib-induced Neuropathic Disorders.",COMPLETED,,67.0,2019-01-15,2020-01-31,5.352965879265092,Adequate (1-10/month),53.52965879265093,Below (50-75%),100,53.7,57.84
NCT02368028,Oral Alkali Production and Caries Prevention in Children (Cross-sectional Component),COMPLETED,,131.0,2015-03-01,2015-09-01,21.67195652173913,Good (10-50/month),200.0,Exceeded (≥100%),100,63.8,76.78
NCT01017328,Effect of Head Rotation on Overlap and Relative Position of Internal Jugular Vein to Carotid Artery in Infants and Children: A Study of the Anatomy Using Ultrasonography,COMPLETED,,120.0,2009-03-01,2009-08-01,23.87450980392157,Good (10-50/month),200.0,Exceeded (≥100%),100,62.9,75.655
NCT05638828,A Study of RD14-01 in Patients With Advanced Solid Tumors,UNKNOWN,EARLY_PHASE1,24.0,2022-12-01,2024-12-01,0.9993980848153216,Slow (<1/month),9.993980848153216,Significantly Below (<50%),50,31.9,11.295
NCT03872128,"The Role of Neuroactive Steroids in Stress, Alcohol Craving and Alcohol Use in Alcohol Use Disorders",COMPLETED,PHASE1,91.0,2018-09-27,2023-08-01,1.5658790276992653,Adequate (1-10/month),15.658790276992654,Significantly Below (<50%),100,52.3,53.515
NCT03019328,Early Peanut Introduction: Translation to Clinical Practice,COMPLETED,,333.0,2016-12-01,2023-03-24,4.39953125,Adequate (1-10/month),43.9953125,Significantly Below (<50%),100,75.0,84.49
NCT04625465,Proximal Effects of Alcohol on Same-Sex Intimate Partner Violence,COMPLETED,NA,474.0,2020-11-12,2023-12-15,12.79127659574468,Good (10-50/month),127.91276595744681,Exceeded (≥100%),100,92.9,93.88
NCT03883165,How do the Neck Muscles Influence Head Acceleration During Sport-associated Impact Events in High School Athletes?,COMPLETED,NA,48.0,2021-01-22,2024-06-10,1.183093117408907,Adequate (1-10/month),11.830931174089068,Significantly Below (<50%),100,48.8,45.184999999999995
NCT04095065,Engineering an Online STI Prevention Program: RCT,COMPLETED,NA,3098.0,2019-07-15,2019-12-31,558.0066272189349,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT04540965,Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects,COMPLETED,PHASE1,22.0,2020-09-22,2020-12-08,8.697142857142858,Adequate (1-10/month),86.97142857142856,Met (75-100%),100,56.8,65.69500000000001
NCT07338565,Magnesium in Gastrointestinal Disease,RECRUITING,,120.0,2025-11-03,2027-12-01,4.818997361477573,Adequate (1-10/month),48.18997361477573,Significantly Below (<50%),60,45.9,33.495000000000005
NCT06249165,VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease,ACTIVE_NOT_RECRUITING,PHASE4,130.0,2024-12-16,2027-02-01,5.0929214929214925,Adequate (1-10/month),50.92921492921493,Below (50-75%),85,55.9,63.42
NCT06054165,Impact of a Clinical Pathway for Pelvic Fragility Fractures,RECRUITING,NA,393.0,2024-01-21,2027-04-27,10.036006711409396,Good (10-50/month),100.36006711409395,Exceeded (≥100%),60,74.4,84.255
NCT02765165,Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM),TERMINATED,PHASE1,26.0,2016-04-01,2020-07-01,0.5099484536082475,Slow (<1/month),5.099484536082474,Significantly Below (<50%),10,20.1,5.81
NCT02493465,Effects of Everolimus in Left Ventricular Hypertrophy After Conversion From Azathioprine: A Pilot Study,UNKNOWN,PHASE4,50.0,2015-07-01,2017-07-01,2.0820793433652534,Adequate (1-10/month),20.820793433652533,Significantly Below (<50%),50,39.0,20.505000000000003
NCT00279565,Buprenorphine Versus Methadone Maintenance in Hepatitis C Patients Receiving Peg-Intron and Rebetol (Study P04279)(TERMINATED),TERMINATED,PHASE4,128.0,2005-08-01,2007-02-01,7.09712204007286,Adequate (1-10/month),70.97122040072861,Below (50-75%),10,33.2,12.989999999999998
NCT05642065,Hip Activation and FSDT,COMPLETED,NA,35.0,2023-01-26,2023-04-28,11.580434782608696,Good (10-50/month),115.80434782608697,Exceeded (≥100%),100,57.8,67.635
NCT03075865,A Cohort Study for Clinical Evaluation of OmniMax MMF System,COMPLETED,,39.0,2017-06-28,2019-06-28,1.626246575342466,Adequate (1-10/month),16.26246575342466,Significantly Below (<50%),100,46.5,36.815
NCT00006265,Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,COMPLETED,PHASE2,60.0,2001-03-01,2005-05-01,1.2,Adequate (1-10/month),12.0,Significantly Below (<50%),100,49.8,47.17
NCT05441865,Cardiovascular Risk Factors and Cognitive Trajectories,COMPLETED,,3372.0,2023-04-01,2024-12-30,160.6317370892019,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT01385865,Effect of Mulberry Leaf Extract on Blood Glucose,COMPLETED,NA,40.0,2011-01-01,2011-10-01,4.46007326007326,Adequate (1-10/month),44.600732600732606,Significantly Below (<50%),100,53.2,56.665
NCT05132465,Liverpool-Heart and BRain Project Stroke Cohort,COMPLETED,,1655.0,2021-10-12,2024-06-10,51.82942386831276,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT03896165,Teaching Parents Reiki for Their Adolescents Receiving Palliative Care,COMPLETED,NA,24.0,2019-07-30,2020-04-24,2.715836431226766,Adequate (1-10/month),27.158364312267658,Significantly Below (<50%),100,51.9,52.55499999999999
NCT02218567,Behavioural Problems in Huntington Disease : Analysis and Enhancement of Caregiver and Patient Experience,TERMINATED,NA,12.0,2014-06-01,2015-12-01,0.6665693430656934,Slow (<1/month),6.665693430656934,Significantly Below (<50%),10,19.0,4.84
NCT07058467,Anterior Cruciate Ligaments: Studying Updates in neuroCognition After Knee Manipulation,RECRUITING,NA,30.0,2025-08-01,2026-05-31,3.0138613861386143,Adequate (1-10/month),30.138613861386137,Significantly Below (<50%),60,40.4,22.34
NCT03885167,Identification of Biomarkers in Spinocerebellar Ataxia 3,COMPLETED,,22.0,2019-02-21,2023-01-04,0.47394196744515216,Slow (<1/month),4.739419674451522,Significantly Below (<50%),100,45.1,30.605
NCT00223067,Induction of Donor-Specific Tolerance in Renal Allograft Recipients (Living Donor) With TAIZ-Monocytes,UNKNOWN,PHASE1,10.0,2005-03-01,2006-05-01,0.7145539906103286,Slow (<1/month),7.145539906103286,Significantly Below (<50%),50,30.8,9.745
NCT02564367,Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction,COMPLETED,PHASE1,30.0,2015-10-06,2020-03-06,0.5661500309981401,Slow (<1/month),5.661500309981402,Significantly Below (<50%),100,47.4,40.98
NCT06672367,Effects of Balance Training with and Without Gaze Stability Exercises on Cognitive Function Balance and Dynamic Postural Stability in Older Adults with Mild Cognitive Impairment,RECRUITING,NA,32.0,2024-07-15,2024-12-30,5.798095238095239,Adequate (1-10/month),57.98095238095239,Below (50-75%),60,40.6,22.575
NCT03803267,Analgesia of Erector Spinae Plane Block Versus Quadratus Lumborum Block,COMPLETED,NA,68.0,2019-05-01,2020-04-01,6.16047619047619,Adequate (1-10/month),61.60476190476191,Below (50-75%),100,55.4,62.56
NCT02440867,Treating Social Cognition With Theta Burst Stimulation; a Pilot Sudy,UNKNOWN,NA,40.0,2015-05-01,2018-12-01,0.9294656488549619,Slow (<1/month),9.294656488549618,Significantly Below (<50%),50,33.2,12.989999999999998
NCT06261567,A Retrospective Chart Review to Investigate Clinical Remission in Patients With Severe Asthma Treated With Biologics in the United Kingdom National Health Service,COMPLETED,,415.0,2024-02-27,2024-08-20,72.18628571428572,Excellent (>50/month),200.0,Exceeded (≥100%),100,91.5,93.67
NCT05004467,Clinical Predictive Effects of Mulligan Treatment in Patients With Chronic Neck Pain,COMPLETED,NA,42.0,2021-08-02,2022-03-18,5.607368421052632,Adequate (1-10/month),56.073684210526324,Below (50-75%),100,53.4,57.35
NCT01159067,Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload,TERMINATED,PHASE2,1.0,2010-07-01,2011-08-09,0.07534653465346534,Slow (<1/month),0.7534653465346536,Significantly Below (<50%),10,18.1,3.105
NCT00960167,A Dose Escalation Trial of Radiation Therapy (RT) for Hepatocellular Carcinoma (HCC),UNKNOWN,PHASE1,20.0,2009-09-01,,,Slow (<1/month),,Significantly Below (<50%),50,26.6,8.01
NCT07331467,Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE,RECRUITING,PHASE1,18.0,2026-01-01,2028-08-01,0.5810392364793213,Slow (<1/month),5.810392364793214,Significantly Below (<50%),60,34.4,14.430000000000001
NCT07055867,"Epidemiological and Clinical Characteristics of Mpox Outbreak in Equateur, the DR Congo (Part1)",ENROLLING_BY_INVITATION,,122.0,2024-08-01,2025-12-31,7.1831334622824,Adequate (1-10/month),71.83133462282399,Below (50-75%),55,44.6,29.42
NCT00150267,A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension,COMPLETED,PHASE3,976.0,2002-02-01,,,Slow (<1/month),,Significantly Below (<50%),100,80.0,87.67
NCT04936867,The CArdiac Imaging RegistrY Study,COMPLETED,,100.0,2017-07-25,2025-01-01,1.1203533308796467,Adequate (1-10/month),11.203533308796468,Significantly Below (<50%),100,51.3,50.62
NCT04067167,Flexi Band Resistance Training Versus EMS Exercise in Patients With the Diagnosis of Malignant Diseases,RECRUITING,NA,100.0,2019-05-01,2026-06-30,1.1631639281620176,Adequate (1-10/month),11.631639281620176,Significantly Below (<50%),60,41.0,23.01
NCT02635867,Clinical Comparison of Vital Pulp Capping Restorative Protocols,COMPLETED,NA,109.0,2015-06-01,2019-08-01,2.18,Adequate (1-10/month),21.8,Significantly Below (<50%),100,58.7,69.69
NCT03375567,Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide Dexamethasone,COMPLETED,NA,28.0,2018-06-04,2022-01-14,0.6456969696969697,Slow (<1/month),6.456969696969697,Significantly Below (<50%),100,47.2,40.035
NCT06743867,The Safety and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy for Peritoneal Metastatic Adenocarcinoma,RECRUITING,PHASE1,30.0,2024-12-11,2026-09-30,1.387841945288754,Adequate (1-10/month),13.878419452887538,Significantly Below (<50%),60,35.4,15.765
NCT04749667,Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis,UNKNOWN,PHASE1,18.0,2021-08-09,2025-01-04,0.44045016077170424,Slow (<1/month),4.404501607717042,Significantly Below (<50%),50,31.4,10.47
NCT00967200,Study of Tissue Samples From Patients With Glioma or Other Brain Tumors,COMPLETED,,180.0,2003-11-01,2015-11-01,1.2501026694045174,Adequate (1-10/month),12.501026694045175,Significantly Below (<50%),100,57.7,67.51
NCT05452200,Lung Cancer Screening Implementation Among Employees at Lyon Hospital,UNKNOWN,NA,600.0,2022-09-21,2024-09-12,25.29639889196676,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT04608500,A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea,COMPLETED,PHASE3,771.0,2017-06-01,2018-07-31,55.22174117647059,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT00626600,A Study to Assess the Safety and Tolerability of Oxycodone Hydrochloride 50mg/mL Administered as an Infusion,TERMINATED,PHASE3,33.0,2008-05-01,2009-06-01,2.5366666666666666,Adequate (1-10/month),25.366666666666664,Significantly Below (<50%),10,25.6,7.595000000000001
NCT06411600,Combination Therapy for BRAF-V600E Metastatic CRCm,RECRUITING,PHASE2,94.0,2024-05-17,2029-05-01,1.5808618784530388,Adequate (1-10/month),15.808618784530385,Significantly Below (<50%),60,40.5,22.46
NCT02419300,Could Colour Dopper Improve the Diagnosis of Retained Placental Fragments After Second Trimester Miscarriage ?,UNKNOWN,,82.0,2015-07-01,2016-04-01,9.076654545454547,Adequate (1-10/month),90.76654545454547,Met (75-100%),50,44.9,30.025000000000002
NCT07160400,A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity,RECRUITING,PHASE1,104.0,2025-09-04,2026-09-30,8.096572890025577,Adequate (1-10/month),80.96572890025577,Met (75-100%),60,46.3,35.66
NCT04985500,ESP/PIF for Sternotomy,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,225.0,2021-07-09,2025-12-31,4.18643031784841,Adequate (1-10/month),41.86430317848411,Significantly Below (<50%),85,63.5,76.465
NCT07168200,A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer,RECRUITING,PHASE3,720.0,2025-10-17,2028-12-01,19.208413672217354,Good (10-50/month),192.08413672217353,Exceeded (≥100%),60,83.0,89.505
NCT01628900,Prospective Study in the Emergency,TERMINATED,PHASE2,23.0,2012-05-01,2013-07-01,1.6434741784037559,Adequate (1-10/month),16.43474178403756,Significantly Below (<50%),10,19.8,5.465
NCT03546907,"Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)",COMPLETED,PHASE2,343.0,2018-07-16,2020-02-21,17.847726495726498,Good (10-50/month),178.47726495726496,Exceeded (≥100%),100,82.4,89.145
NCT03648307,Long Term Effect of Splenectomy on Metabolism,COMPLETED,,154.0,2008-07-01,2018-08-01,1.272810209068694,Adequate (1-10/month),12.72810209068694,Significantly Below (<50%),100,55.7,63.09
NCT04859907,Bone Flap Fixation Systems For Craniotomy Procedures,COMPLETED,NA,60.0,2021-03-19,2023-02-16,2.612875536480687,Adequate (1-10/month),26.12875536480687,Significantly Below (<50%),100,54.8,61.095
NCT04386707,Lot-consistency Clinical Trial of Sabin Strain Inactivated Polio Vaccine,COMPLETED,PHASE3,1300.0,2020-05-11,2020-10-20,244.2716049382716,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT02357407,Development of an Adjustment Assistance Tool Dosage of Fluoroquinolones in a Population Pharmacokinetic Model,COMPLETED,PHASE4,31.0,2015-06-01,2016-12-01,1.7188342440801458,Adequate (1-10/month),17.18834244080146,Significantly Below (<50%),100,52.5,54.345
NCT07167407,[Trial of device that is not approved or cleared by the U.S. FDA],WITHHELD,,,,,,Slow (<1/month),,Significantly Below (<50%),50,20.0,5.695
NCT01045707,"Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes",COMPLETED,PHASE3,530.0,2010-01-01,2010-10-01,59.0959706959707,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT00706407,Uro-NIRS Clinical Study,COMPLETED,NA,42.0,2008-04-01,2010-05-01,1.6822105263157896,Adequate (1-10/month),16.822105263157894,Significantly Below (<50%),100,53.4,57.35
NCT05400707,Triage - Symptoms and Other Predictors in an All-comer Emergency Department Population,RECRUITING,,6467.0,2022-05-17,2026-12-31,116.55149792776793,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT00377507,Catechin Mouth-washing for Removal of Intraoral Bacteria,TERMINATED,NA,36.0,2006-10-01,2013-07-01,0.44455983772819474,Slow (<1/month),4.445598377281947,Significantly Below (<50%),10,20.9,6.075
NCT03202407,Hyperphosphatemia in Children With Chronic Kidney Disease,UNKNOWN,PHASE3,40.0,2017-08-01,2018-12-01,2.500205338809035,Adequate (1-10/month),25.00205338809035,Significantly Below (<50%),50,38.2,19.645000000000003
NCT02378207,"Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents",COMPLETED,PHASE1,84.0,2015-05-01,2016-12-09,4.348571428571429,Adequate (1-10/month),43.48571428571429,Significantly Below (<50%),100,56.7,65.53
NCT01444092,Safety Study of Entocort for Children With Crohn's Disease,COMPLETED,PHASE3,123.0,2011-11-01,2014-09-01,3.6175072463768116,Adequate (1-10/month),36.17507246376812,Significantly Below (<50%),100,59.8,71.61
NCT04512092,The Efficacy of a Compassionate Mind Training Program With Caregivers of Residential Youth Care,UNKNOWN,NA,240.0,2019-05-01,2022-01-30,7.269253731343283,Adequate (1-10/month),72.69253731343282,Below (50-75%),50,54.2,59.330000000000005
NCT06395792,"A Study on Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS) in Children, Teenagers and Adults in Portugal",WITHDRAWN,,0.0,2024-12-01,2025-07-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT05849792,Internet-based Physical Activities Randomized Controlled Trial in Mild/Moderate Depression Participants: SONRIE Project,COMPLETED,NA,80.0,2019-09-01,2020-10-30,5.729882352941177,Adequate (1-10/month),57.29882352941177,Below (50-75%),100,56.4,64.88000000000001
NCT02407392,"""Using Dilute Vinegar to Find Changes in Cells During Endoscopy for Patients With Barrett's Oesophagus"" (The ABBA Study)",COMPLETED,NA,200.0,2015-07-10,2018-02-01,6.497331910352188,Adequate (1-10/month),64.97331910352189,Below (50-75%),100,66.0,78.99000000000001
NCT02147392,Assessment of [11C]ER176 to Image Translocator Protein in Brain and Whole Body of Healthy People,COMPLETED,EARLY_PHASE1,16.0,2014-05-14,2016-06-16,0.6374869109947644,Slow (<1/month),6.374869109947643,Significantly Below (<50%),100,46.3,35.66
NCT02650492,Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma,TERMINATED,NA,2.0,2015-10-01,2019-05-01,0.04654434250764526,Slow (<1/month),0.46544342507645264,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT04110392,Effect of Consumption of Chaya on Lipid Concentration and Antioxidant Status of Patients With Dyslipidemia,COMPLETED,NA,30.0,2019-06-01,2020-12-07,1.6454054054054055,Adequate (1-10/month),16.454054054054055,Significantly Below (<50%),100,47.4,40.98
NCT00225992,Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS),TERMINATED,PHASE2,,2004-02-01,2007-11-01,,Slow (<1/month),,Significantly Below (<50%),10,18.0,2.92
NCT03806192,Feasibility of Partners in Care Program for Caregivers of Patients With Acute Myeloid Leukemia,TERMINATED,NA,12.0,2019-03-16,2020-11-30,0.584448,Slow (<1/month),5.844480000000001,Significantly Below (<50%),10,19.0,4.84
NCT04908592,Efficacy of Dexamethasone in Attenuation of Postinduction Hypotension in Geriatric Patients Undergoing General Anesthesia,COMPLETED,PHASE4,100.0,2021-06-15,2021-09-15,33.08695652173913,Good (10-50/month),200.0,Exceeded (≥100%),100,63.0,75.845
NCT02633592,Seated Evaluation of Anorectal funcTion by High Resolution Anorectal Manometry,COMPLETED,NA,60.0,2014-11-01,2015-11-01,5.003835616438357,Adequate (1-10/month),50.03835616438357,Below (50-75%),100,54.8,61.095
NCT05377892,The Impact of Dietary Protein on the Metabolome,COMPLETED,NA,9.0,2019-11-04,2020-03-05,2.245573770491803,Adequate (1-10/month),22.45573770491803,Significantly Below (<50%),100,50.7,48.915
NCT07048392,Retrieval-Based Word Learning in Developmental Language Disorder During Book Reading II,RECRUITING,NA,32.0,2025-03-01,2026-07-31,1.8841005802707933,Adequate (1-10/month),18.841005802707933,Significantly Below (<50%),60,40.6,22.575
NCT06625892,Investigating the Related Factors and Outcome of Kinesiophobia and the Effects of Multidimensional Interventions in Cardiac Surgery Patients,RECRUITING,NA,245.0,2024-08-14,2026-07-31,10.415921787709497,Good (10-50/month),104.15921787709499,Exceeded (≥100%),60,62.6,75.325
NCT00667992,Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma,COMPLETED,PHASE3,99.0,2008-04-01,2009-05-01,7.629265822784811,Adequate (1-10/month),76.2926582278481,Met (75-100%),100,57.9,67.83
NCT00942292,The Effect of Fish Oils on Human Hepatic Colorectal Metastases,COMPLETED,PHASE2,20.0,2007-05-01,2010-10-01,0.48742994395516415,Slow (<1/month),4.874299439551642,Significantly Below (<50%),100,46.6,37.375
NCT05324436,A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM),COMPLETED,,75.0,2022-01-08,2023-06-30,4.243494423791822,Adequate (1-10/month),42.434944237918224,Significantly Below (<50%),100,54.3,59.62
NCT00920036,Adjunctive Biofeedback Intervention for Operation Iraqi Freedom/Operation Enduring Freedom (OIF-OEF) Post Traumatic Stress Disorder (PTSD),COMPLETED,NA,8.0,2010-02-01,2012-09-01,0.25823966065747617,Slow (<1/month),2.5823966065747617,Significantly Below (<50%),100,45.6,32.08
NCT02851836,Attachment Image Data Set Validation in Adolescent,COMPLETED,NA,133.0,2012-10-01,2013-11-01,10.223535353535354,Good (10-50/month),102.23535353535354,Exceeded (≥100%),100,65.6,78.56
NCT04682236,Study of the Evolution Profile of the Renal Doppler in the Perioperative Hepathic Transplantation,UNKNOWN,,30.0,2020-11-25,2022-05-25,1.6725274725274726,Adequate (1-10/month),16.725274725274726,Significantly Below (<50%),50,35.7,16.18
NCT00502736,A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Malignant Bone Disease.,COMPLETED,PHASE2,13.0,2008-01-01,2009-03-01,0.9311058823529411,Slow (<1/month),9.311058823529413,Significantly Below (<50%),100,46.0,34.1
NCT02812836,3D High Resolution Manometry and Balloon Expulsion Test in Diagnosis of Dyssynergic Defecation in Children,UNKNOWN,NA,100.0,2018-03-01,2019-03-01,8.339726027397262,Adequate (1-10/month),83.3972602739726,Met (75-100%),50,48.0,42.945
NCT00075036,Patient-Provider Trust Among Individuals With End-Stage Kidney Disease,COMPLETED,,113.0,2004-02-27,2019-09-13,0.605904527038929,Slow (<1/month),6.05904527038929,Significantly Below (<50%),100,52.4,53.949999999999996
NCT00669136,Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma,TERMINATED,PHASE1,2.0,2009-06-01,2013-03-01,0.04447041636230826,Slow (<1/month),0.44470416362308257,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT00998036,"Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors",COMPLETED,PHASE1,9.0,2009-09-01,2012-10-01,0.243303730017762,Slow (<1/month),2.4330373001776198,Significantly Below (<50%),100,45.7,32.5
NCT06403436,"A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors",RECRUITING,PHASE1,50.0,2023-11-07,2026-12-01,1.3589285714285715,Adequate (1-10/month),13.589285714285715,Significantly Below (<50%),60,37.0,17.955
NCT04840836,Study of the Implementation of Telehealth-Supported LARC Provision in School-Based Health Centers,COMPLETED,,75.0,2021-04-20,2022-12-31,3.682258064516129,Adequate (1-10/month),36.82258064516129,Significantly Below (<50%),100,54.3,59.62
NCT00523536,Evaluation of a Navigator-Nurse Care Team on the Management of High Blood Pressure and Cardiovascular Disease Risk,COMPLETED,NA,800.0,2007-05-01,2009-08-01,29.589307411907658,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT06244836,Comparison of Two Bundles of Care to Reduce Surgical Site Infection in Colorectal Surgery (CCR-VINCat 2),COMPLETED,NA,32205.0,2011-01-01,2023-01-31,222.14371176070702,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT05899036,Early Feasibility Study of RapidPulseTM Aspiration System for Patients With Acute Ischemic Stroke,COMPLETED,NA,19.0,2024-03-23,2024-10-27,2.65302752293578,Adequate (1-10/month),26.5302752293578,Significantly Below (<50%),100,51.5,51.245
NCT05176236,Pictographic Education Handout on Tracheostomy Care,COMPLETED,NA,38.0,2020-10-01,2021-05-30,4.7996680497925315,Adequate (1-10/month),47.99668049792532,Significantly Below (<50%),100,53.0,55.80500000000001
NCT06528236,Research and Application of Ultrasonic Intelligent Diagnosis System for Ovarian Mass,NOT_YET_RECRUITING,,100000.0,2024-07-30,2029-07-30,1667.0317634173057,Excellent (>50/month),200.0,Exceeded (≥100%),30,77.3,85.67
NCT04913636,Assessing Effects of a Denture Gel on Gum Abrasions,COMPLETED,NA,38.0,2021-06-01,2021-06-29,38.0,Good (10-50/month),200.0,Exceeded (≥100%),100,58.0,68.245
NCT06905236,Kidney Function in Obese Women,COMPLETED,NA,36.0,2024-09-23,2024-12-22,12.176,Good (10-50/month),121.76,Exceeded (≥100%),100,57.9,67.83
NCT00944736,Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's Disease,COMPLETED,PHASE3,12.0,2009-07-01,2013-07-01,0.2500205338809035,Slow (<1/month),2.500205338809035,Significantly Below (<50%),100,46.0,34.1
NCT06140836,A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3),ACTIVE_NOT_RECRUITING,PHASE3,190.0,2023-12-21,2027-03-15,4.901355932203391,Adequate (1-10/month),49.0135593220339,Significantly Below (<50%),85,60.7,72.89999999999999
NCT01042236,Evaluation Of The Ability Of Fesoterodine To Increase Urethral Pressure In Stress Urinary Incontinence Patients,COMPLETED,PHASE2,22.0,2009-01-01,2010-07-01,1.2265201465201465,Adequate (1-10/month),12.265201465201466,Significantly Below (<50%),100,46.8,38.440000000000005
NCT04099836,Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib,TERMINATED,PHASE2,7.0,2020-07-09,2023-06-15,0.19895424836601308,Slow (<1/month),1.9895424836601312,Significantly Below (<50%),10,18.6,4.25
NCT02350036,Placental Protein 13 Serum Endoglin and Uterine Doppler Indeces as Predictors of Pre-eclampsia,COMPLETED,,50.0,2015-01-01,2016-12-01,2.1742857142857144,Adequate (1-10/month),21.74285714285714,Significantly Below (<50%),100,52.3,53.515
NCT03492736,Effects of Melatonin in Untreated Obstructive Sleep Apnea,TERMINATED,EARLY_PHASE1,1.0,2018-04-01,2018-10-01,0.16633879781420766,Slow (<1/month),1.6633879781420766,Significantly Below (<50%),10,18.1,3.105
NCT01031836,A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus.,COMPLETED,PHASE2,30.0,2009-11-25,2016-07-11,0.3773553719008264,Slow (<1/month),3.773553719008264,Significantly Below (<50%),100,47.4,40.98
NCT03026036,Neuroimaging Studies of Reward Processing in Depression,COMPLETED,,123.0,2016-04-01,2021-03-01,2.0858607242339833,Adequate (1-10/month),20.858607242339836,Significantly Below (<50%),100,58.2,68.795
NCT02693236,DC Vaccine Combined With CIK Cells in Patients With Esophagus Cancer,UNKNOWN,PHASE1,30.0,2014-08-01,2016-11-01,1.109599027946537,Adequate (1-10/month),11.09599027946537,Significantly Below (<50%),50,32.4,12.025
NCT03955536,Comparison of the Effects of Different Physiotherapy and Rehabilitation Methods on Open Heart Surgery,UNKNOWN,NA,36.0,2019-02-01,2020-11-30,1.6404790419161677,Adequate (1-10/month),16.404790419161674,Significantly Below (<50%),50,32.9,12.53
NCT06148636,A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,24.0,2023-11-10,2027-12-31,0.4831746031746032,Slow (<1/month),4.831746031746032,Significantly Below (<50%),85,42.4,25.45
NCT05706636,T Central Memory Cells in Early Localized Non-Segmental Vitiligo,COMPLETED,NA,22.0,2023-02-01,2025-04-15,0.8329353233830846,Slow (<1/month),8.329353233830846,Significantly Below (<50%),100,46.8,38.440000000000005
NCT01263236,A Study of LY2940094 in Major Depressive Disorder,COMPLETED,PHASE1,66.0,2010-12-01,2011-09-01,7.332262773722627,Adequate (1-10/month),73.32262773722627,Below (50-75%),100,55.3,62.36000000000001
NCT07237711,Clinical Investigation of Sensovisc,NOT_YET_RECRUITING,NA,75.0,2025-11-25,2026-11-25,6.254794520547946,Adequate (1-10/month),62.54794520547946,Below (50-75%),30,35.0,15.305
NCT00000711,Granulocyte-Macrophage Colony-Stimulating Factor and Zidovudine: A Phase I Study of Concurrent Administration in Patients With AIDS and Severe ARC,COMPLETED,PHASE1,60.0,,1990-05-01,,Slow (<1/month),,Significantly Below (<50%),100,44.8,29.845
NCT01604811,Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia),COMPLETED,PHASE4,206.0,2012-06-01,2013-10-01,12.87605749486653,Good (10-50/month),128.7605749486653,Exceeded (≥100%),100,71.5,82.72
NCT06457711,Blood Pressure and Cardiometabolic Risk (Diet-to-HTN),COMPLETED,NA,50.0,2022-06-22,2023-06-22,4.169863013698631,Adequate (1-10/month),41.6986301369863,Significantly Below (<50%),100,54.0,58.72500000000001
NCT04086511,PANDA: PKU Amino Acid Evaluation,COMPLETED,,37.0,2019-09-10,2023-04-14,0.8584451219512195,Slow (<1/month),8.584451219512196,Significantly Below (<50%),100,46.3,35.66
NCT00347711,Bevacizumab and Retinal Vascular Occlusions,WITHDRAWN,PHASE3,0.0,2006-06-01,2006-06-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT05373511,Assessing Body Posture and Postural Balance Among Young Adults With Bronchial Asthma,COMPLETED,,124.0,2022-02-01,2023-04-22,8.482157303370787,Adequate (1-10/month),84.82157303370786,Met (75-100%),100,63.3,76.235
NCT01797211,Mediterranean Diet and Endothelial Function,COMPLETED,PHASE4,60.0,2010-06-01,2012-05-01,2.609142857142857,Adequate (1-10/month),26.091428571428573,Significantly Below (<50%),100,54.8,61.095
NCT01742611,Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis,COMPLETED,PHASE3,105.0,2013-03-01,2015-04-01,4.2,Adequate (1-10/month),42.0,Significantly Below (<50%),100,58.4,69.175
NCT03859011,Acupuncture Relief for Chronic Neck Pain,COMPLETED,NA,75.0,2022-08-30,2025-05-01,2.3415384615384616,Adequate (1-10/month),23.415384615384617,Significantly Below (<50%),100,56.0,63.71
NCT07341711,Long-term Adaptations of Skeletal Muscle After Hybrid Training.,NOT_YET_RECRUITING,NA,30.0,2026-01-08,2026-12-20,2.639306358381503,Adequate (1-10/month),26.393063583815028,Significantly Below (<50%),30,31.4,10.47
NCT02590211,"Poker, Skills and Associated Problems",COMPLETED,NA,113.0,2016-09-27,2021-03-23,2.09995115995116,Adequate (1-10/month),20.9995115995116,Significantly Below (<50%),100,59.0,70.365
NCT03487211,Comparative Efficacy of Duloxetine vs Escitalopram in Patients With Fibromyalgia,COMPLETED,PHASE2,200.0,2018-04-09,2020-02-26,8.848837209302326,Adequate (1-10/month),88.48837209302326,Met (75-100%),100,71.0,82.44
NCT06071611,Cognitive Frailty and Oxygen-ozone Therapy,COMPLETED,NA,75.0,2019-07-02,2023-11-17,1.427767354596623,Adequate (1-10/month),14.27767354596623,Significantly Below (<50%),100,51.0,49.714999999999996
NCT07090811,Streamlined One-wire Logistics Optimize Transcatheter Aortic Valve Replacement,NOT_YET_RECRUITING,NA,20.0,2025-09-01,2026-04-01,2.871698113207547,Adequate (1-10/month),28.716981132075475,Significantly Below (<50%),30,30.6,9.475
NCT05714111,Radiology Registry on Pancreatic Malignancies,RECRUITING,,1300.0,2022-03-04,2030-03-30,13.423337856173678,Good (10-50/month),134.23337856173677,Exceeded (≥100%),60,81.3,88.58
NCT02711111,Effect of Bone-anchored Protraction on Maxillary Growth in the Young Child,UNKNOWN,NA,20.0,2016-04-01,2021-12-01,0.2941062801932367,Slow (<1/month),2.941062801932367,Significantly Below (<50%),50,31.6,10.905
NCT03861871,Fenfluramine in CDKL5 Deficiency Disorder (CDD),COMPLETED,PHASE2,7.0,2019-10-29,2022-10-24,0.1953070577451879,Slow (<1/month),1.953070577451879,Significantly Below (<50%),100,45.6,32.08
NCT06957171,Assess the Potential of the IVC Distensibility Index as a Predictor of Postoperative Fluid Status in Children.,COMPLETED,,15.0,2024-04-01,2024-08-31,3.0039473684210525,Adequate (1-10/month),30.039473684210527,Significantly Below (<50%),100,49.5,46.58
NCT01705171,Is the Expression of the GLUT5 Specific Fructose Transport Protein Abnormal in Patients With Fructose Intolerance?,COMPLETED,,26.0,2011-12-01,2013-10-01,1.1812537313432836,Adequate (1-10/month),11.812537313432836,Significantly Below (<50%),100,45.4,31.455
NCT04478071,Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19),COMPLETED,PHASE2,448.0,2020-08-22,2022-03-25,23.512275862068964,Good (10-50/month),200.0,Exceeded (≥100%),100,90.8,93.51
NCT05989971,The Effect of Continuous Renal Replacement Therapy on the Efficiency of Extracorporeal CO2 Removal,COMPLETED,,10.0,2023-04-24,2025-12-31,0.309979633401222,Slow (<1/month),3.09979633401222,Significantly Below (<50%),100,44.1,28.425
NCT02954471,Study of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Participants With Early/Metastatic Breast Cancer in Saudi Arabia,COMPLETED,,351.0,2016-10-21,2019-09-17,10.070160226201695,Good (10-50/month),100.70160226201696,Exceeded (≥100%),100,81.4,88.9
NCT01462071,Red Blood Cell Lifespan,TERMINATED,,58.0,2008-05-01,2013-03-01,1.0002946175637395,Adequate (1-10/month),10.002946175637394,Significantly Below (<50%),10,21.0,6.105
NCT03726671,Choline Nutritional Status: Development of a Biomarker Panel,COMPLETED,NA,101.0,2018-11-01,2021-10-20,2.83619926199262,Adequate (1-10/month),28.361992619926202,Significantly Below (<50%),100,58.1,68.595
NCT06459271,Feasibility of CALM in Patients With Ovarian Cancer,RECRUITING,NA,50.0,2024-06-10,2026-08-10,1.9241466498103668,Adequate (1-10/month),19.241466498103666,Significantly Below (<50%),60,42.0,24.825
NCT05187871,Study for Rapid Diagnosis of Postoperative Abdominal Infection,UNKNOWN,,30.0,2021-08-10,2022-12-31,1.7976377952755904,Adequate (1-10/month),17.976377952755904,Significantly Below (<50%),50,35.7,16.18
NCT05472571,Pilot Project of Forest Bathing for Promoting Health,COMPLETED,NA,28.0,2021-05-01,2022-03-15,2.680251572327044,Adequate (1-10/month),26.80251572327044,Significantly Below (<50%),100,52.2,53.22
NCT02594371,"Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer",COMPLETED,PHASE3,402.0,2015-12-02,2022-06-30,5.094454621149043,Adequate (1-10/month),50.944546211490426,Below (50-75%),100,82.2,89.09
NCT03153371,Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks,COMPLETED,,180.0,2016-04-04,2021-08-31,2.7742784810126584,Adequate (1-10/month),27.742784810126587,Significantly Below (<50%),100,62.7,75.42
NCT03020771,"Phase I Study to Evaluate Basic Pharmacodynamic, Pharmacological and Toxicological Effects of the Newly Developed Crimean-Congo Hemorrhagic Fever Vaccine for Humans",COMPLETED,PHASE1,60.0,2014-12-01,2017-06-01,2.0004381161007667,Adequate (1-10/month),20.00438116100767,Significantly Below (<50%),100,54.8,61.095
NCT02416271,The Forteo Alendronate Comparator Trial,COMPLETED,PHASE4,203.0,2001-04-01,2003-05-01,8.130684210526317,Adequate (1-10/month),81.30684210526316,Met (75-100%),100,66.2,79.2
NCT03491371,Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use,COMPLETED,NA,56.0,2015-06-01,2017-02-01,2.7899181669394437,Adequate (1-10/month),27.899181669394434,Significantly Below (<50%),100,54.5,60.12
NCT01779271,Phase 3 Study of Pelubiprofen & Loxoprofen in Patients With Upper Respiratory Tract Infection,COMPLETED,PHASE3,183.0,2013-01-01,,,Slow (<1/month),,Significantly Below (<50%),100,54.6,60.39
NCT03270371,Modulation of Inflammation by Medium Cut Off Membranes,UNKNOWN,NA,50.0,2017-09-01,2019-02-01,2.9382239382239383,Adequate (1-10/month),29.382239382239383,Significantly Below (<50%),50,39.0,20.505000000000003
NCT03490071,Long-term Follow up of Patients With Longstanding Hip and Groin Pain,UNKNOWN,,81.0,2018-01-01,2024-12-31,0.9646478873239437,Slow (<1/month),9.646478873239438,Significantly Below (<50%),50,34.8,15.040000000000001
NCT00435071,The Effect of Surgical Incision Size on Carpal Tunnel Surgery,TERMINATED,NA,100.0,2006-12-01,2008-06-01,5.554744525547445,Adequate (1-10/month),55.54744525547445,Below (50-75%),10,31.0,9.985
NCT06923371,Moms and Babies Health and Well-being,RECRUITING,NA,1250.0,2025-02-28,2027-12-01,37.82306163021869,Good (10-50/month),200.0,Exceeded (≥100%),60,83.0,89.505
NCT01010971,Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older,COMPLETED,PHASE3,671.0,2009-12-01,2010-02-01,329.4393548387097,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT00683371,Microarray Analysis of Sinus Samples From Patients With and Without Chronic Rhinosinusitis,COMPLETED,NA,20.0,2007-10-01,2008-04-30,2.871698113207547,Adequate (1-10/month),28.716981132075475,Significantly Below (<50%),100,51.6,51.644999999999996
NCT02158871,Impact Study of Workplace Mental Health Education on Early Intervention for Healthcare Workers With Mental Health Issues,COMPLETED,NA,216.0,2014-05-01,2016-03-01,9.813492537313433,Adequate (1-10/month),98.13492537313434,Met (75-100%),100,72.3,83.065
NCT06299371,Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations,NOT_YET_RECRUITING,PHASE2,36.0,2024-04-15,2029-04-15,0.60013143483023,Slow (<1/month),6.001314348302301,Significantly Below (<50%),30,26.9,8.09
NCT01181271,Tandem Auto-Allo Transplant for Lymphoma,COMPLETED,PHASE2,42.0,2010-08-01,2016-02-01,0.6360597014925373,Slow (<1/month),6.360597014925373,Significantly Below (<50%),100,48.4,44.22
NCT04104971,Complications of Pediatric Liver Transplantation,UNKNOWN,,45.0,2015-01-01,2021-03-01,0.6085295424255887,Slow (<1/month),6.085295424255887,Significantly Below (<50%),50,31.9,11.295
NCT05077371,Peer Support Program in Cancer Patients Elkar Laguntza,UNKNOWN,NA,120.0,2019-06-01,2024-12-31,1.7905882352941178,Adequate (1-10/month),17.905882352941177,Significantly Below (<50%),50,44.6,29.42
NCT06157944,Physician Reasoning on Diagnostic Cases With Large Language Models,COMPLETED,NA,50.0,2023-11-29,2023-12-30,49.096774193548384,Good (10-50/month),200.0,Exceeded (≥100%),100,64.0,77.025
NCT06654544,Epidemiology of Intracerebral Hemorrhage,NOT_YET_RECRUITING,,60.0,2024-11-30,2025-12-31,4.612121212121212,Adequate (1-10/month),46.121212121212125,Significantly Below (<50%),30,32.1,11.5
NCT01028144,The Active by Choice Today (ACT) Trial to Increase Physical Activity,COMPLETED,PHASE1,1422.0,2004-07-01,2009-05-01,24.52446458923513,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT05762744,Pharmacogenomics of GLP1 Receptor Agonists,TERMINATED,PHASE1,63.0,2016-06-01,2022-10-31,0.8184891165172856,Slow (<1/month),8.184891165172855,Significantly Below (<50%),10,23.0,6.370000000000001
NCT03404544,Impact of Carbetocin Administration on Heart Rate When Given as an Infusion Versus as a Bolus.,COMPLETED,PHASE4,70.0,2018-06-11,2021-01-15,2.245310853530032,Adequate (1-10/month),22.453108535300316,Significantly Below (<50%),100,55.6,62.905
NCT01821144,A School-based Education Programme to Reduce Salt Intake in Children and Their Families,COMPLETED,NA,832.0,2013-03-01,2014-02-01,75.15157270029674,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT04243044,Influence of Transcutaneous Spinal Stimulation Intensity on Spasticity After SCI,COMPLETED,NA,21.0,2022-04-08,2023-12-01,1.061860465116279,Adequate (1-10/month),10.61860465116279,Significantly Below (<50%),100,46.7,37.895
NCT02003144,An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients,COMPLETED,PHASE3,119.0,2015-01-12,2021-07-12,1.526489675516224,Adequate (1-10/month),15.26489675516224,Significantly Below (<50%),100,54.5,60.12
NCT02151344,"Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals",COMPLETED,PHASE1,100.0,2014-05-01,2015-02-01,11.028985507246377,Good (10-50/month),110.28985507246377,Exceeded (≥100%),100,63.0,75.845
NCT04200144,Endoscopic Sleeve Gastroplasty for Obesity and Microbiota Randomized Trial,RECRUITING,NA,60.0,2020-02-04,2025-12-02,0.8582706766917293,Slow (<1/month),8.582706766917294,Significantly Below (<50%),60,37.8,19.015
NCT06974344,Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial),NOT_YET_RECRUITING,PHASE4,80.0,2025-06-01,2030-09-01,1.269655891553702,Adequate (1-10/month),12.696558915537018,Significantly Below (<50%),30,30.4,9.345
NCT03334344,Using Virtual Reality (VR) Models for Preoperative Planning,COMPLETED,NA,92.0,2017-10-24,2019-03-18,5.491137254901961,Adequate (1-10/month),54.91137254901961,Below (50-75%),100,57.4,67.05499999999999
NCT04807244,"Treatment of Deep Carious Lesions With Selective Caries Removal, Partial or Full Pulpotomy",UNKNOWN,NA,249.0,2021-04-01,2025-09-30,4.613244065733415,Adequate (1-10/month),46.13244065733415,Significantly Below (<50%),50,54.9,61.55500000000001
NCT07212244,Analysis of Clinical Outcomes in Patients Undergoing Magnetic Resonance-Guided Focused Ultrasound for Medication-Refractory Tremor,RECRUITING,,240.0,2025-10-01,2032-09-01,2.8910170162247724,Adequate (1-10/month),28.910170162247727,Significantly Below (<50%),60,55.5,62.71
NCT03500744,Erector Spinae Plane Block for Major Gynecologic and Urologic Surgery,TERMINATED,NA,12.0,2019-09-01,2022-08-01,0.34298591549295776,Slow (<1/month),3.429859154929578,Significantly Below (<50%),10,19.0,4.84
NCT06575244,The Effects of a Nurse-led Community-based Sailing Programme on Resilience of School-aged Children With Autism,NOT_YET_RECRUITING,NA,36.0,2025-07-14,2025-09-30,14.04923076923077,Good (10-50/month),140.4923076923077,Exceeded (≥100%),30,36.9,17.735
NCT01980134,The MORDIS Study Clinical Investigational Plan,UNKNOWN,,1200.0,2013-12-01,2016-11-01,34.266416510318955,Good (10-50/month),200.0,Exceeded (≥100%),50,78.3,86.48
NCT05854134,Effectiveness of CC VS Aerobic Exercise for Strengthening and Improving QOL in Post Stroke Patients,UNKNOWN,NA,48.0,2023-04-01,2023-08-31,9.612631578947369,Adequate (1-10/month),96.1263157894737,Met (75-100%),50,43.8,27.965
NCT04651634,MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients,ACTIVE_NOT_RECRUITING,PHASE2,60.0,2021-06-21,2025-12-31,1.1042321644498188,Adequate (1-10/month),11.042321644498186,Significantly Below (<50%),85,45.3,31.169999999999998
NCT02719834,Behavioral Expressions in Alzheimer's Disease,COMPLETED,,4.0,2016-04-01,2018-02-01,0.18146050670640837,Slow (<1/month),1.8146050670640834,Significantly Below (<50%),100,43.7,27.744999999999997
NCT04662034,Performance and Safety of the Cardiac Microcurrent Therapy System,COMPLETED,NA,70.0,2021-02-05,2024-11-13,1.5474219317356575,Adequate (1-10/month),15.474219317356571,Significantly Below (<50%),100,50.6,48.705
NCT07086534,"A Clinical Study of GeminiOne TEER System for the Treatment of Severe, Symptomatic MR.",NOT_YET_RECRUITING,NA,15.0,2025-12-15,2031-05-31,0.22910185649774212,Slow (<1/month),2.291018564977421,Significantly Below (<50%),30,25.2,7.359999999999999
NCT02433834,Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma,COMPLETED,PHASE2,248.0,2015-05-27,2016-03-26,24.832631578947368,Good (10-50/month),200.0,Exceeded (≥100%),100,74.8,84.385
NCT04285034,Cardiovascular Function and Ribavirin PK/PD in Lassa Fever in Lassa Fever,COMPLETED,,158.0,2019-11-26,2021-07-15,8.056147403685094,Adequate (1-10/month),80.56147403685094,Met (75-100%),100,61.0,73.17
NCT06062134,Pericapsular Nerve Group Block: An Imaging Study for Determination of the Spread of the Injectate Using 3-D CT Scan,COMPLETED,NA,10.0,2023-10-18,2023-12-21,4.75625,Adequate (1-10/month),47.5625,Significantly Below (<50%),100,50.8,49.18
NCT06287034,The Role of the Free/Pedunculated Flap in Total Laryngectomy After (Chemo-)Radiotherapy Failure for Laryngeal Carcinoma: Impact on the Risk of Pharyngocutaneous Fistula (PCF),RECRUITING,,102.0,2023-03-21,2025-09-21,3.3933114754098366,Adequate (1-10/month),33.93311475409836,Significantly Below (<50%),60,44.5,29.160000000000004
NCT06634134,Cycling Through the Menstrual Cycle,RECRUITING,,750.0,2024-10-10,2028-01-01,19.380305602716472,Good (10-50/month),193.8030560271647,Exceeded (≥100%),60,81.3,88.58
NCT01532934,The Impact of Psychopathic Traits on the Efficacy of a Substance Use Intervention,COMPLETED,PHASE2,105.0,2009-08-01,2014-07-01,1.7806128133704737,Adequate (1-10/month),17.80612813370474,Significantly Below (<50%),100,58.4,69.175
NCT01525134,Feasibility of a Lateral Flow Urine Lipoarabinomannan (LAM) Test for Diagnosis of Tuberculosis,UNKNOWN,NA,504.0,2011-01-01,2012-04-01,33.64421052631579,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT02311634,A Comparison of Electrical Pudendal Nerve Stimulation and Transvaginal Electrical Stimulation for Urge Incontinence,COMPLETED,NA,120.0,2014-12-01,2016-03-01,8.010526315789473,Adequate (1-10/month),80.10526315789474,Met (75-100%),100,59.6,71.17999999999999
NCT00816634,Efficacy Comparison Study of Combination Regimens to Treat Advanced Esophageal Squamous Cell Carcinoma,UNKNOWN,PHASE2,94.0,2008-10-01,2018-12-01,0.7706329113924051,Slow (<1/month),7.706329113924052,Significantly Below (<50%),50,37.5,18.775
NCT06784934,Mindful Minds: Mindfulness-Based Neurofeedback for Underrepresented College Students,COMPLETED,NA,39.0,2025-01-28,2025-03-25,21.199285714285715,Good (10-50/month),200.0,Exceeded (≥100%),100,58.1,68.595
NCT06133634,Fisetin to Improve Vascular Function in Older Adults,ACTIVE_NOT_RECRUITING,PHASE1,70.0,2023-09-25,2027-03-31,1.6607950116913484,Adequate (1-10/month),16.607950116913482,Significantly Below (<50%),85,46.1,34.695
NCT05262634,Pregnancy Outcome in Women With an Iron Deficiency in the First Trimester,COMPLETED,,713.0,2021-09-01,2022-01-31,142.78763157894736,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT03562234,The CLiFF Study: Change in Liver Function and Fat in Pre-operative Chemotherapy for Colorectal Liver Metastases,UNKNOWN,,35.0,2018-10-22,2020-04-01,2.0216318785578746,Adequate (1-10/month),20.21631878557875,Significantly Below (<50%),50,36.1,16.665
NCT03642834,Study of ICP-105 in Solid Tumors Patients,COMPLETED,PHASE1,21.0,2018-09-21,2021-03-01,0.7166367713004484,Slow (<1/month),7.166367713004485,Significantly Below (<50%),100,46.7,37.895
NCT01717534,Children Immune Functions,COMPLETED,NA,374.0,2012-10-01,2013-07-01,41.701684981684984,Good (10-50/month),200.0,Exceeded (≥100%),100,89.9,93.08999999999999
NCT01453634,"Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018)",WITHDRAWN,PHASE2,0.0,2013-01-01,2013-07-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT04688034,Safety and Tolerability Study of OP-724 in Liver Cirrhosis Patients by HIV/HCV with Hemophilia.,COMPLETED,PHASE1,5.0,2021-03-15,2022-07-05,0.31907756813417193,Slow (<1/month),3.190775681341719,Significantly Below (<50%),100,45.4,31.455
NCT01477034,Vitamin D and Adipose Tissue Inflammation,COMPLETED,NA,18.0,2011-11-01,2013-06-01,0.9479584775086506,Slow (<1/month),9.479584775086506,Significantly Below (<50%),100,46.4,36.26
NCT02745834,The Influence of Dual Task and Gait Speed on Gait Variability in Patients With Chronic Ankle Instability,UNKNOWN,NA,40.0,2015-10-01,2016-10-01,3.3267759562841532,Adequate (1-10/month),33.26775956284153,Significantly Below (<50%),50,38.2,19.645000000000003
NCT02944734,Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension,COMPLETED,PHASE2,392.0,2014-09-01,2015-12-01,26.167719298245615,Good (10-50/month),200.0,Exceeded (≥100%),100,86.4,91.94
NCT00346034,This Study is An Open-Label Trial Of Pregabalin In Patients With Fibromyalgia,COMPLETED,PHASE3,357.0,2006-12-01,2008-02-01,25.44983606557377,Good (10-50/month),200.0,Exceeded (≥100%),100,83.6,90.435
NCT02558634,Thalamic Deep Brain Stimulation for Spasmodic Dysphonia- DEBUSSY Trial,COMPLETED,NA,6.0,2016-01-01,2020-03-01,0.12007889546351086,Slow (<1/month),1.2007889546351087,Significantly Below (<50%),100,45.5,31.705
NCT05533034,Personalized Home Respiratory Rehabilitation Program for Subjects With Systemic Sclerosis With Early Lung Disease,RECRUITING,NA,15.0,2024-04-08,2026-03-01,0.6598265895953758,Slow (<1/month),6.598265895953757,Significantly Below (<50%),60,34.2,14.305000000000001
NCT03822234,A Clinical Trial of Extraperitonealization for Prevention of Parastomal Hernia After Ileal Conduit,COMPLETED,NA,104.0,2019-01-15,2020-03-11,7.519619952494062,Adequate (1-10/month),75.19619952494061,Met (75-100%),100,58.3,68.99499999999999
NCT00886964,Hepatitis B Vaccination (HBV) in HIV Infected Children,COMPLETED,PHASE2,80.0,2009-04-01,2010-05-01,6.165063291139242,Adequate (1-10/month),61.650632911392414,Below (50-75%),100,56.4,64.88000000000001
NCT07113964,QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD),NOT_YET_RECRUITING,PHASE2,79.0,2025-08-30,2029-03-30,1.838501529051988,Adequate (1-10/month),18.38501529051988,Significantly Below (<50%),30,35.3,15.534999999999998
NCT04399564,Temporary vs.Long Term Hemodialysis Catheter on Central Vein Stenosis,UNKNOWN,NA,80.0,2021-05-25,2021-06-01,80.0,Excellent (>50/month),200.0,Exceeded (≥100%),50,51.4,50.92
NCT06669364,A Retrospective Study to Validate BioEP as an Assessment Aid for Seizure Susceptibility,NOT_YET_RECRUITING,,400.0,2025-01-01,2025-03-01,206.3728813559322,Excellent (>50/month),200.0,Exceeded (≥100%),30,69.3,81.395
NCT01746264,Effect of Vitamin D Supplementation on Endothelial Function in Obese Adolescents,COMPLETED,PHASE1,19.0,2012-11-01,2013-12-01,1.4642025316455698,Adequate (1-10/month),14.642025316455697,Significantly Below (<50%),100,46.5,36.815
NCT03047564,Metal Ion Concentration Between Coated and Uncoated TKA,COMPLETED,NA,120.0,2012-02-01,2020-12-01,1.1323000619962802,Adequate (1-10/month),11.323000619962803,Significantly Below (<50%),100,54.6,60.39
NCT02648464,Hydroxychloroquine for the Prevention of Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial,COMPLETED,PHASE4,125.0,2016-02-01,2019-12-31,2.662701189643107,Adequate (1-10/month),26.627011896431068,Significantly Below (<50%),100,60.0,71.97
NCT06813664,ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI),NOT_YET_RECRUITING,PHASE2,60.0,2025-04-01,2026-04-01,5.003835616438357,Adequate (1-10/month),50.03835616438357,Below (50-75%),30,33.8,13.694999999999999
NCT06570564,Upper Versus Lower Limb Exercises on Intermittent Claudication in Diabetic Patients,COMPLETED,NA,60.0,2023-02-20,2024-02-20,5.003835616438357,Adequate (1-10/month),50.03835616438357,Below (50-75%),100,54.8,61.095
NCT07072364,Videos to Aid Decision Making for Fibroid Treatment,RECRUITING,NA,154.0,2025-03-12,2026-03-01,13.24225988700565,Good (10-50/month),132.4225988700565,Exceeded (≥100%),60,55.3,62.36000000000001
NCT01301664,Cartilage Tissue Engineering,AVAILABLE,,,,,,Slow (<1/month),,Significantly Below (<50%),50,23.3,6.569999999999999
NCT00903864,Blood Pressure Monitor Clinical Test (Cuff Range: 22 cm-30 cm),COMPLETED,,85.0,2009-02-01,,,Slow (<1/month),,Significantly Below (<50%),100,45.1,30.605
NCT02600364,Diversion-p64 Post Market Clinical Follow-Up Study to Assess Safety and Effectiveness of the p64 Flow Modulation Device,COMPLETED,,450.0,2015-12-01,2020-06-01,8.332116788321168,Adequate (1-10/month),83.32116788321167,Met (75-100%),100,84.3,90.71000000000001
NCT03564964,Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease,NO_LONGER_AVAILABLE,,,,,,Slow (<1/month),,Significantly Below (<50%),50,23.3,6.569999999999999
NCT03957109,Influence of Anesthesia Methods on Surgical Outcomes and Renal Function,COMPLETED,NA,70.0,2015-09-18,2017-02-10,4.16986301369863,Adequate (1-10/month),41.6986301369863,Significantly Below (<50%),100,55.6,62.905
NCT04150809,A Study to Explore the Role of Gut Flora in ALS,WITHDRAWN,,0.0,2020-03-02,2030-07-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT03385109,The TransEnterix European Patient Registry,RECRUITING,,500.0,2017-07-25,2028-03-01,3.9307851239669422,Adequate (1-10/month),39.307851239669425,Significantly Below (<50%),60,76.3,85.1
NCT05261009,PENG Block Versus LP Block for THA Postop Pain,COMPLETED,PHASE4,154.0,2022-06-13,2023-07-20,11.661094527363185,Good (10-50/month),116.61094527363183,Exceeded (≥100%),100,67.3,80.00500000000001
NCT00366509,Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases,COMPLETED,,157.0,2006-09-18,2016-10-27,1.2944420368364031,Adequate (1-10/month),12.944420368364032,Significantly Below (<50%),100,55.9,63.42
NCT05125809,Setrusumab vs Placebo for Osteogenesis Imperfecta,ACTIVE_NOT_RECRUITING,PHASE2,183.0,2022-02-21,2027-04-01,2.98687399463807,Adequate (1-10/month),29.8687399463807,Significantly Below (<50%),85,60.1,72.085
NCT02967809,Usefulness of an Ultraportative Ultrasound Device in the Management of Intra Hospital Emergencies,COMPLETED,,172.0,2016-10-01,2019-09-01,4.916131455399062,Adequate (1-10/month),49.161314553990614,Significantly Below (<50%),100,62.1,74.595
NCT03173209,Evaluating the Effectiveness of the Calm Moments Cards Program Implemented by School Personnel,COMPLETED,NA,93.0,2015-01-17,2016-10-13,4.458141732283464,Adequate (1-10/month),44.581417322834646,Significantly Below (<50%),100,57.4,67.05499999999999
NCT04521309,SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients,COMPLETED,PHASE1,50.0,2020-06-19,2021-02-08,6.504273504273504,Adequate (1-10/month),65.04273504273506,Below (50-75%),100,54.0,58.72500000000001
NCT01013909,Comparative Safety and Efficacy Study of New Bifonazol Spray vs Terbinafine Solution vs Placebo,COMPLETED,PHASE2,220.0,2009-12-01,2010-05-01,44.34966887417219,Good (10-50/month),200.0,Exceeded (≥100%),100,77.6,85.89
NCT05327309,Role of Propranolol as Compared to Bleomycin in Management of Hemangioma,COMPLETED,NA,90.0,2015-05-08,2018-01-01,2.8272445820433436,Adequate (1-10/month),28.272445820433433,Significantly Below (<50%),100,57.2,66.465
NCT04331509,COVID-19 Symptom Tracker,ACTIVE_NOT_RECRUITING,,10000000.0,2020-03-23,2026-03-23,138931.99452304887,Excellent (>50/month),200.0,Exceeded (≥100%),85,93.8,94.80499999999999
NCT06067009,Feasibility Trial of a Stakeholder-enhanced Lay-navigator-delivered Intervention (ImPart-Multi),COMPLETED,NA,22.0,2024-03-20,2025-02-25,1.9581286549707602,Adequate (1-10/month),19.581286549707606,Significantly Below (<50%),100,51.8,52.17
NCT04611009,Video-supervised Motor and Awareness Training in Writer's Cramp,RECRUITING,PHASE2,54.0,2020-06-26,2027-01-01,0.690655462184874,Slow (<1/month),6.90655462184874,Significantly Below (<50%),60,37.3,18.35
NCT06462209,Effects of Ladder Training Versus Plyometric,RECRUITING,NA,42.0,2024-05-15,2024-07-01,27.201702127659576,Good (10-50/month),200.0,Exceeded (≥100%),60,46.4,36.26
NCT04015609,Psychotherapy Intervention for Latinos With Advanced Cancer,RECRUITING,NA,190.0,2015-04-20,2026-08-31,1.3933028185979284,Adequate (1-10/month),13.933028185979285,Significantly Below (<50%),60,48.2,43.665
NCT03597009,A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion,TERMINATED,PHASE1,1.0,2019-03-06,2020-02-12,0.0887463556851312,Slow (<1/month),0.8874635568513121,Significantly Below (<50%),10,18.1,3.105
NCT00694109,An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia,COMPLETED,PHASE3,144.0,2008-04-01,2014-09-01,1.870034129692833,Adequate (1-10/month),18.70034129692833,Significantly Below (<50%),100,61.5,73.905
NCT03177499,Virtual Imaging-based Early Portal Pressure Gradient (vePPG) (CHESS1702),WITHDRAWN,NA,0.0,2017-08-24,2019-01-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT06392399,Interventions for the Management of Perineal Cancer Pain,NOT_YET_RECRUITING,NA,60.0,2024-06-01,2026-06-01,2.5019178082191784,Adequate (1-10/month),25.019178082191786,Significantly Below (<50%),30,33.8,13.694999999999999
NCT04599699,Integrated Boost to the Dominant Intraprostatic Nodule Based on Ga-68 PSMA PET/MR Study of SBRT With Prostate Cancer,UNKNOWN,NA,20.0,2020-11-01,2023-05-01,0.6682766190998903,Slow (<1/month),6.682766190998903,Significantly Below (<50%),50,31.6,10.905
NCT01911299,Choline Supplementation in Children With Fetal Alcohol Spectrum Disorders,COMPLETED,PHASE2,55.0,2013-05-01,2014-05-01,4.586849315068494,Adequate (1-10/month),45.868493150684934,Significantly Below (<50%),100,54.4,59.89
NCT06762899,Effect of Chronic Mechanical Neck Pain on Isokinetic Characteristics of Rotator Cuff Muscles in Adults,COMPLETED,,66.0,2024-05-01,2024-11-01,10.918695652173913,Good (10-50/month),109.18695652173913,Exceeded (≥100%),100,58.6,69.51
NCT01111799,Does Local Injury of the Endometrium Improve Controlled Ovarian Hyperstimulation (COH) + Intrauterine Insemination (IUI) Outcome?,UNKNOWN,NA,600.0,2010-06-01,2012-10-01,21.411488862837047,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT04431999,Evaluation of a Transfusion Therapy Using Whole Blood in the Management of Coagulopathy in Patients With Acute Traumatic Hemorrhage,COMPLETED,PHASE3,200.0,2021-12-04,2025-10-20,4.299435028248587,Adequate (1-10/month),42.994350282485875,Significantly Below (<50%),100,66.0,78.99000000000001
NCT00331799,Pilot Study of Duloxetine in Psychological Resilience,COMPLETED,PHASE2,18.0,2007-04-01,2008-07-01,1.1989496717724288,Adequate (1-10/month),11.98949671772429,Significantly Below (<50%),100,46.4,36.26
NCT03070899,Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids,COMPLETED,PHASE3,526.0,2017-04-20,2021-04-12,11.019573296627668,Good (10-50/month),110.19573296627667,Exceeded (≥100%),100,95.0,95.7
NCT04756999,The Effect of Foot Reflexology Applied on Dialysis Patients,COMPLETED,NA,40.0,2020-01-12,2021-06-20,2.3192380952380955,Adequate (1-10/month),23.192380952380955,Significantly Below (<50%),100,53.2,56.665
NCT02302599,Mesenchymal Stem Cells to Treat Type 2 Diabetes,COMPLETED,PHASE2,103.0,2013-01-01,2020-12-01,1.084510549982705,Adequate (1-10/month),10.84510549982705,Significantly Below (<50%),100,53.2,56.665
NCT00507299,A Safe Environment for Every Kid (SEEK) I,COMPLETED,NA,660.0,2002-06-01,2006-12-31,12.001433691756272,Good (10-50/month),120.01433691756272,Exceeded (≥100%),100,95.0,95.7
NCT02121899,Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006),TERMINATED,,44.0,2015-04-01,2017-07-31,1.5720187793427232,Adequate (1-10/month),15.720187793427232,Significantly Below (<50%),10,19.9,5.555000000000001
NCT05007899,Alternate Day Versus Daily Oral Iron Therapy in Adolescents,COMPLETED,PHASE4,13.0,2020-12-21,2022-12-22,0.5413406292749658,Slow (<1/month),5.4134062927496585,Significantly Below (<50%),100,46.0,34.1
NCT06432699,Rate of Canine Retraction and Pain Perception Following Micro-osteoperforation- a Split Mouth Clinical Study,COMPLETED,NA,60.0,2024-05-01,2024-12-30,7.51604938271605,Adequate (1-10/month),75.16049382716051,Met (75-100%),100,54.8,61.095
NCT03462199,Evaluating Efficacy of Investigational Products on Spontaneous Bowel Movements in Healthy People With ≤ 3 Complete Weekly Spontaneous Bowel Movements,COMPLETED,NA,240.0,2018-03-23,2020-02-03,10.712023460410558,Good (10-50/month),107.12023460410558,Exceeded (≥100%),100,74.2,84.15
NCT00258999,Predictor of Advanced Sub-Clinical Atherosclerosis (PASA) Study,COMPLETED,NA,600.0,2005-10-01,2007-11-01,24.0,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT05140499,Liposomal Bupivacaine vs Continuous Nerve Catheters for Below the Knee Amputations,TERMINATED,PHASE4,11.0,2022-08-15,2025-12-23,0.273115823817292,Slow (<1/month),2.7311582381729202,Significantly Below (<50%),10,18.9,4.6899999999999995
NCT00654199,Ventricular Asynchrony in Cardiac Surgery Patients,COMPLETED,,20.0,2006-05-01,2009-10-01,0.48742994395516415,Slow (<1/month),4.874299439551642,Significantly Below (<50%),100,44.9,30.025000000000002
NCT02684799,Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination,COMPLETED,PHASE1,48.0,2016-01-31,2016-04-11,20.579154929577463,Good (10-50/month),200.0,Exceeded (≥100%),100,58.8,69.89999999999999
NCT01577199,RCT of Low-dose Clomiphene vs. High Dose Gonadotropin Protocol for IVF Poor Responders,WITHDRAWN,PHASE4,0.0,2012-04-01,2012-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT03495999,Hyperuricemia and Left Ventricular Diastolic Function,TERMINATED,,67.0,2017-08-01,2018-04-03,8.324408163265307,Adequate (1-10/month),83.24408163265306,Met (75-100%),10,26.7,8.065
NCT01965899,Usability Study to Assess the Reveal LINQ Insertable Cardiac Monitor System,COMPLETED,NA,151.0,2013-09-01,2015-09-01,6.296493150684932,Adequate (1-10/month),62.96493150684932,Below (50-75%),100,62.1,74.595
NCT02474199,Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction,COMPLETED,PHASE1,15.0,2016-06-06,2019-12-16,0.3545031055900621,Slow (<1/month),3.545031055900621,Significantly Below (<50%),100,46.2,35.089999999999996
NCT04949399,A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence,COMPLETED,PHASE3,408.0,2021-07-08,2022-12-20,23.433056603773586,Good (10-50/month),200.0,Exceeded (≥100%),100,87.6,92.335
NCT00041132,S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma,COMPLETED,PHASE2,56.0,2002-09-01,2011-06-01,0.5335336463223788,Slow (<1/month),5.335336463223787,Significantly Below (<50%),100,49.5,46.58
NCT00024232,Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer,COMPLETED,PHASE2,,2001-06-01,2004-02-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,30.330000000000002
NCT06288932,Outcome Study of Conventional Steroids Vs. Steroids Combined with Mycopehnolate in Newly Diagnosed Immune Thrombocytopenia Purpura.,COMPLETED,PHASE3,118.0,2023-08-18,2024-08-18,9.813989071038252,Adequate (1-10/month),98.13989071038252,Met (75-100%),100,64.4,77.37
NCT02205632,Relationships Between Macular Pigment Optical Density and Lacquer Cracks in High Myopic Patients.,COMPLETED,NA,39.0,2014-02-01,2014-11-01,4.348571428571429,Adequate (1-10/month),43.485714285714295,Significantly Below (<50%),100,53.1,56.105000000000004
NCT05858632,Immune Spatial Features of Guselkumab Cutaneous Response,RECRUITING,PHASE4,10.0,2023-07-01,2026-06-30,0.2779908675799087,Slow (<1/month),2.779908675799087,Significantly Below (<50%),60,33.8,13.694999999999999
NCT00215332,CHARITE™ vs. ALIF 5-Year Follow-up,COMPLETED,,367.0,2005-03-01,2007-07-01,13.112065727699532,Good (10-50/month),131.1206572769953,Exceeded (≥100%),100,82.7,89.18
NCT07018232,Enhancing Timely Access to Medication Changes: The Role of Pharmacists in Overcoming Transitions of Care Challenges,COMPLETED,,104.0,2024-11-27,2025-05-15,18.732307692307693,Good (10-50/month),187.32307692307694,Exceeded (≥100%),100,61.7,74.1
NCT01770132,Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancreatic Cancer,COMPLETED,PHASE1,12.0,2013-04-19,2018-10-28,0.18101090188305252,Slow (<1/month),1.8101090188305253,Significantly Below (<50%),100,46.0,34.1
NCT03222232,Catheter Salvage in Intestinal Failure Patients,COMPLETED,,715.0,2002-01-01,2015-12-31,4.257550860719875,Adequate (1-10/month),42.57550860719875,Significantly Below (<50%),100,88.3,92.705
NCT03863132,accuRate Evaluation of Benefit With Optimal Medical Treatment With or Without Transcatheter Valve Repair of PARADOXical Low Flow Low Gradient Aortic Stenosis,ACTIVE_NOT_RECRUITING,NA,120.0,2019-07-03,2028-03-01,1.1544879898862201,Adequate (1-10/month),11.544879898862199,Significantly Below (<50%),85,50.1,47.89
NCT02473432,Neuromuscular Electroestimulation and Respiratory Muscle Training in Subacute Stroke,COMPLETED,PHASE4,62.0,2013-12-01,2015-09-01,2.9534898278560253,Adequate (1-10/month),29.534898278560252,Significantly Below (<50%),100,55.0,61.834999999999994
NCT01998932,Predictive of Biomarkers of Healing in Chronic Venous Ulceration of the Lower Limb,COMPLETED,,28.0,2013-11-01,2015-06-01,1.4771577123050261,Adequate (1-10/month),14.77157712305026,Significantly Below (<50%),100,45.6,32.08
NCT06399432,Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors,RECRUITING,NA,36.0,2022-10-18,2026-07-01,0.8105325443786983,Slow (<1/month),8.105325443786983,Significantly Below (<50%),60,35.9,16.445
NCT01247532,Pilot Study of Mindfulness-Based Stress Reduction for Patients With Persistent Cancer-Related Fatigue,COMPLETED,PHASE1,35.0,2010-03-01,2010-10-01,4.978504672897197,Adequate (1-10/month),49.78504672897196,Significantly Below (<50%),100,52.8,55.31
NCT05061732,Helicobacter Pylori Eradication and Follow-up,RECRUITING,PHASE4,4447.0,2021-09-30,2026-06-30,78.06613610149942,Excellent (>50/month),200.0,Exceeded (≥100%),60,88.0,92.495
NCT03759132,Effects of Transcranial Direct Current Stimulation on Postural Control,COMPLETED,PHASE2,18.0,2018-12-01,2020-10-30,0.7838626609442061,Slow (<1/month),7.838626609442061,Significantly Below (<50%),100,46.4,36.26
NCT02174432,Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis,COMPLETED,PHASE2,36.0,2015-08-15,2017-09-03,1.4611200000000002,Adequate (1-10/month),14.611200000000002,Significantly Below (<50%),100,47.9,42.64
NCT00258232,"Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer",COMPLETED,PHASE2,,2002-01-01,2007-08-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,30.330000000000002
NCT00189332,Use of 852A in Metastatic Cutaneous Melanoma.,COMPLETED,PHASE2,28.0,2005-02-01,2006-08-01,1.5610256410256411,Adequate (1-10/month),15.610256410256412,Significantly Below (<50%),100,47.2,40.035
NCT04016532,Personalized Dietary Advice After Discharge From Hospital in Geriatrics: Factors Associated With Improved Nutritional Status and Autonomy,UNKNOWN,NA,338.0,2019-06-25,2023-09-01,6.729051667756704,Adequate (1-10/month),67.29051667756704,Below (50-75%),50,62.0,74.42
NCT01567332,Evaluation of Walking After Repetitive Transcranial Magnetic Stimulation (rTMS) Inhibitory 1Hz in Vascular Hemiplegia,TERMINATED,NA,10.0,2011-09-01,2012-03-01,1.6725274725274726,Adequate (1-10/month),16.725274725274726,Significantly Below (<50%),10,23.8,6.76
NCT01079832,Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies,COMPLETED,PHASE2,50.0,2009-05-01,2012-05-01,1.3886861313868613,Adequate (1-10/month),13.886861313868613,Significantly Below (<50%),100,49.0,45.61
NCT04766632,Contribution of Cerebral 18F-DOPA PET-CT Scan in High-grade Recurrent Gliomas,COMPLETED,NA,16.0,2021-05-18,2025-06-03,0.32974949221394717,Slow (<1/month),3.297494922139472,Significantly Below (<50%),100,46.3,35.66
NCT05213832,Effect of Inhalatory Sedation in Subarachnoid Hemorrhage,COMPLETED,PHASE2,11.0,2020-06-26,2022-12-31,0.36474945533769065,Slow (<1/month),3.6474945533769065,Significantly Below (<50%),100,45.9,33.495000000000005
NCT06772532,A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the Body,COMPLETED,PHASE1,30.0,2025-02-10,2025-06-10,7.61,Adequate (1-10/month),76.1,Met (75-100%),100,52.4,53.949999999999996
NCT01579032,"Pulse Wave Analysis and Velocity in Patients With Chronic Renal Failure: a Cross-sectional Observational Study to Assess Association With Left Ventricular Hypertrophy, Uremic Toxins and Inflammation.",COMPLETED,,90.0,2004-01-01,2012-01-01,0.9375770020533881,Slow (<1/month),9.37577002053388,Significantly Below (<50%),100,50.5,48.515
NCT03726632,Causality of Poisoning of the Elderly: Prospective Study Based on Data From the Poison Control Centre of Bordeaux,COMPLETED,,122.0,2017-04-03,2017-08-02,30.691570247933885,Good (10-50/month),200.0,Exceeded (≥100%),100,63.1,76.03
NCT02691832,Measuring Core Body Temperature Using a Novel Non-invasive Sensor,UNKNOWN,NA,12.0,2016-05-01,2017-08-01,0.7992997811816193,Slow (<1/month),7.992997811816194,Significantly Below (<50%),50,31.0,9.985
NCT02048332,Donor-Derived Viral Specific T-cells (VSTs),RECRUITING,PHASE1,750.0,2014-02-05,2027-01-01,4.844048376830044,Adequate (1-10/month),48.440483768300446,Significantly Below (<50%),60,78.0,86.075
NCT04303832,Exercise Interventions of Eye Muscles Post Strabismus Surgery,COMPLETED,NA,40.0,2018-10-01,2020-02-26,2.373489278752437,Adequate (1-10/month),23.73489278752437,Significantly Below (<50%),100,53.2,56.665
NCT03215732,"Cross Sectional Survey on the Burden and Impacts of Chronic Hepatitis B in the Rural Area of Niakhar, Senegal",COMPLETED,,3119.0,2017-10-19,2019-07-31,146.06516923076924,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT01728532,"Open, Multicentric Trial Evaluating the Efficacy and the Clinical Tolerance of PA0903 as Root Canal Sealer",COMPLETED,NA,26.0,2012-06-01,2016-06-01,0.5417111567419576,Slow (<1/month),5.417111567419576,Significantly Below (<50%),100,47.1,39.64
NCT05131932,Ablation of Esophageal Inlet Patches in Patients Referred for Bravo pH-Testing,UNKNOWN,NA,100.0,2021-12-01,2024-12-01,2.7773722627737225,Adequate (1-10/month),27.773722627737225,Significantly Below (<50%),50,43.0,26.465
NCT06804798,Evaluation of Catheter Associated Urinary Tract Infection Between Metal Alloy Coated Catheter and Conventional Latex Catheter in Critically Ill Patients,COMPLETED,PHASE4,76.0,2023-03-01,2024-11-01,3.7863175122749593,Adequate (1-10/month),37.863175122749595,Significantly Below (<50%),100,56.1,63.99
NCT00229398,Medical and Psychiatric Co-Morbidity Among Treatment Resistant Patients With Major Depression Disorder,COMPLETED,,,1998-11-01,2004-12-01,,Slow (<1/month),,Significantly Below (<50%),100,43.3,27.05
NCT01450098,A Study of LY2484595 in Healthy Subjects,COMPLETED,PHASE1,39.0,2011-10-01,2011-12-01,19.461639344262295,Good (10-50/month),194.61639344262295,Exceeded (≥100%),100,58.1,68.595
NCT06780098,Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I),RECRUITING,PHASE2,144.0,2025-05-28,2032-03-02,1.7746396761133603,Adequate (1-10/month),17.746396761133603,Significantly Below (<50%),60,49.5,46.58
NCT05091398,"Erector Spinae Plane, Paravertebral Versus Intercostal Nerve Block for VATS Surgery",COMPLETED,NA,105.0,2021-11-05,2022-01-10,48.42727272727273,Good (10-50/month),200.0,Exceeded (≥100%),100,68.4,80.97
NCT07058298,GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103),RECRUITING,EARLY_PHASE1,6.0,2025-07-15,2027-09-10,0.23207115628970776,Slow (<1/month),2.3207115628970776,Significantly Below (<50%),60,33.5,13.34
NCT04385498,Primary Care Intervention for PTSD in Ethiopia,COMPLETED,NA,14.0,2023-06-01,2023-10-20,3.0224113475177306,Adequate (1-10/month),30.224113475177305,Significantly Below (<50%),100,51.1,50.129999999999995
NCT05652998,Comparison Between Intralesional Injection of Plasma Rich Platelets and Candida Antigen in Plane Warts,UNKNOWN,PHASE4,30.0,2021-10-15,2023-04-15,1.6694698354661792,Adequate (1-10/month),16.694698354661792,Significantly Below (<50%),50,37.4,18.62
NCT02553798,Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis,COMPLETED,PHASE3,564.0,2015-08-01,2016-12-01,35.18065573770492,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT00100698,Physiologic Growth Hormone Effects in HIV Lipodystrophy,COMPLETED,NA,56.0,2004-01-01,2009-04-01,0.8892227438706313,Slow (<1/month),8.892227438706312,Significantly Below (<50%),100,49.5,46.58
NCT06055998,"Frequency ,Etiology and Prognostic Factors of Acute Transverse Myelitis",NOT_YET_RECRUITING,,50.0,2023-12-01,2026-02-01,1.9192938209331651,Adequate (1-10/month),19.192938209331654,Significantly Below (<50%),30,31.3,10.299999999999999
NCT05376098,An fNIRS Study of Motor Cortical Activation in Stoke Patients,UNKNOWN,,50.0,2022-02-01,2024-07-31,1.6706915477497257,Adequate (1-10/month),16.706915477497258,Significantly Below (<50%),50,37.3,18.35
NCT03978598,Breastfeeding Etonogestrel Implant Study,COMPLETED,PHASE4,150.0,2019-06-03,2024-09-19,2.3596899224806203,Adequate (1-10/month),23.596899224806204,Significantly Below (<50%),100,62.0,74.42
NCT06310798,Inter-organizational Health Planning for Older Adults: Public Dental Care and Municipal Care,NOT_YET_RECRUITING,NA,360.0,2025-03-01,2026-03-01,30.02301369863014,Good (10-50/month),200.0,Exceeded (≥100%),30,62.8,75.53999999999999
NCT00762398,Evaluation of the Accuracy and Precision of the Masimo Labs Pulse-Hemoglobin-Meter Monitor in Surgical Patients,TERMINATED,,40.0,2008-09-01,2011-12-01,1.0266441821247894,Adequate (1-10/month),10.266441821247895,Significantly Below (<50%),10,19.5,5.315
NCT06847698,Single Ascending Dose and Multiple Ascending Dose Study of AVR-48,NOT_YET_RECRUITING,PHASE1,48.0,2025-06-01,2025-11-01,9.549803921568628,Adequate (1-10/month),95.49803921568628,Met (75-100%),30,37.8,19.015
NCT06367998,Effect of Pregabalin on Shoulder Pain in Patients With Central Sensitization After Arthroscopic Rotator Cuff Repair,NOT_YET_RECRUITING,PHASE4,76.0,2024-09-01,2026-05-01,3.8112685337726524,Adequate (1-10/month),38.112685337726525,Significantly Below (<50%),30,35.1,15.384999999999998
NCT05898698,Prospective Case Registry for Wounds,ACTIVE_NOT_RECRUITING,,300.0,2023-03-17,2025-12-17,9.077534791252486,Adequate (1-10/month),90.77534791252484,Met (75-100%),85,72.8,83.36
NCT05252598,Mood and Cognitive Effects of Psilocybin in Healthy Participants,WITHDRAWN,EARLY_PHASE1,0.0,2023-01-01,2023-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT03890198,A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma,TERMINATED,EARLY_PHASE1,2.0,2019-04-22,2020-03-06,0.19084639498432604,Slow (<1/month),1.9084639498432605,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT03288298,Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line,UNKNOWN,EARLY_PHASE1,4.0,2017-11-01,2019-04-01,0.235968992248062,Slow (<1/month),2.3596899224806203,Significantly Below (<50%),50,30.3,9.295
NCT00042198,Treatment of Depression After Coronary Bypass Surgery,COMPLETED,NA,123.0,2001-12-01,2006-08-01,2.1972535211267608,Adequate (1-10/month),21.97253521126761,Significantly Below (<50%),100,59.8,71.61
NCT04910698,Efficacy of Antibiotic Short Course for Bloodstream Infections in Acute Myeloid Leukemia Patients With Febrile Neutropenia,COMPLETED,,104.0,2020-01-01,2020-06-01,20.827368421052633,Good (10-50/month),200.0,Exceeded (≥100%),100,61.7,74.1
NCT06712498,INVESTIGATION OF THE INTRAOPERATIVE AND POSTOPERATIVE EFFECTS OF EXTERNAL OBLIQUE INTERCOSTAL PLAN BLOCK IN PATIENTS UNDERGOING LAPARASCOPIC CHOLESYSTECTOMY OPERATION,COMPLETED,,64.0,2024-11-26,2024-12-30,57.29882352941176,Excellent (>50/month),200.0,Exceeded (≥100%),100,63.5,76.465
NCT01160198,A Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.,COMPLETED,PHASE3,271.0,2010-10-13,2011-02-18,64.4471875,Excellent (>50/month),200.0,Exceeded (≥100%),100,81.7,88.97
NCT01448798,Athermal Nerve-sparing During Robotic-assisted Radical Prostatectomy Using a Hemostatic Matrix.,UNKNOWN,NA,50.0,2011-10-01,2014-01-01,1.8493317132442286,Adequate (1-10/month),18.493317132442286,Significantly Below (<50%),50,39.0,20.505000000000003
NCT04117698,"Multicenter, Randomized Study Evaluating the Value of Antitubercular Treatment During Recurent Anterior Uveitis (URBA)",UNKNOWN,PHASE3,116.0,2019-11-01,2023-05-01,2.765105716523101,Adequate (1-10/month),27.651057165231013,Significantly Below (<50%),50,44.3,28.715000000000003
NCT04269798,The Effect of Functional Electrical Stimulation on Gait and Balance in Children With Hemiplegic Cerebral Palsy,COMPLETED,NA,40.0,2020-02-11,2021-04-15,2.8382284382284384,Adequate (1-10/month),28.382284382284382,Significantly Below (<50%),100,53.2,56.665
NCT02625298,Use of Mineral Trioxide Aggregate in the Treatment of Traumatized Teeth,COMPLETED,PHASE2,24.0,2010-09-01,2016-03-01,0.36382470119521915,Slow (<1/month),3.6382470119521915,Significantly Below (<50%),100,46.9,38.96
NCT00684398,Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I,COMPLETED,,645.0,2008-05-15,2015-11-27,7.134375,Adequate (1-10/month),71.34375,Below (50-75%),100,88.3,92.705
NCT05092698,The Efficacy of Vitamin D Supplementation in Patients With Severe and Extremely Severe COVID-19,COMPLETED,NA,110.0,2020-05-01,2022-01-31,5.231875,Adequate (1-10/month),52.31875,Below (50-75%),100,58.8,69.89999999999999
NCT03536598,Study to Evaluate the Safety and Efficacy of CJ-30060 in Hypertensive Patients With Hyperlipidemia,COMPLETED,PHASE3,203.0,2016-10-14,2017-09-04,19.01329230769231,Good (10-50/month),190.13292307692308,Exceeded (≥100%),100,71.2,82.59
NCT07197398,Preoperative Data and the Spinal Spread of Local Anesthetic in Cesarean Section,RECRUITING,,140.0,2025-09-18,2025-11-30,58.37808219178082,Excellent (>50/month),200.0,Exceeded (≥100%),60,57.5,67.27
NCT05502198,Relevance of Sarcopenia in Advanced Liver Disease,RECRUITING,,150.0,2021-02-01,2030-06-30,1.3288707799767172,Adequate (1-10/month),13.288707799767172,Significantly Below (<50%),60,43.3,27.05
NCT00601263,Safety Study of Chinese Herbal Therapy to Treat Asthma,COMPLETED,PHASE1,35.0,2006-10-01,2008-07-01,1.6672926447574337,Adequate (1-10/month),16.672926447574334,Significantly Below (<50%),100,52.8,55.31
NCT03242863,Effect of Varying Proportions of Low and High Energy Dense Foods Over 5 Days in Preschool Children,COMPLETED,NA,57.0,2017-11-27,2019-05-02,3.330287907869482,Adequate (1-10/month),33.30287907869482,Significantly Below (<50%),100,54.6,60.39
NCT03760263,Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus,COMPLETED,PHASE4,46.0,2020-01-16,2023-11-01,1.0110036101083033,Adequate (1-10/month),10.110036101083034,Significantly Below (<50%),100,48.7,44.93
NCT01658163,Use of 2-octyl-cyanoacrylate Together With a Self-adhering Mesh,COMPLETED,,2.0,2009-06-01,2011-09-01,0.0740632603406326,Slow (<1/month),0.7406326034063261,Significantly Below (<50%),100,43.5,27.400000000000002
NCT04681963,Clinical Characteristics of Acutely Hospitalized Adults With Community-acquired- Pneumonia,COMPLETED,,966.0,2021-03-01,2022-06-01,64.34363238512034,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT07244263,A Study of Zasocitinib in Adults With Hidradenitis Suppurativa,RECRUITING,PHASE2,90.0,2026-01-26,2028-02-22,3.6190224570673712,Adequate (1-10/month),36.19022457067371,Significantly Below (<50%),60,45.2,30.830000000000002
NCT02378363,Representations and Prevention of Cancers in Schools,COMPLETED,,191.0,2012-09-01,2013-11-01,13.647981220657277,Good (10-50/month),136.47981220657277,Exceeded (≥100%),100,68.6,81.04
NCT00865163,LASER: Real Life Antithrombotic Stent Evaluation Registry,COMPLETED,,915.0,2008-11-01,2014-02-01,14.521689259645465,Good (10-50/month),145.21689259645464,Exceeded (≥100%),100,93.3,94.325
NCT03099863,Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Tract Infection,COMPLETED,PHASE4,242.0,2016-04-01,2020-06-01,4.84,Adequate (1-10/month),48.4,Significantly Below (<50%),100,69.4,81.52000000000001
NCT02252263,A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma,COMPLETED,PHASE1,44.0,2014-12-09,2017-10-10,1.2928185328185329,Adequate (1-10/month),12.928185328185329,Significantly Below (<50%),100,48.5,44.47
NCT00034463,ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer,COMPLETED,PHASE1,,,,,Slow (<1/month),,Significantly Below (<50%),100,40.0,21.87
NCT04957563,Clinical Utility of Olfactory Rehabilitation: Treatment for Pacients With Neurosensorial Anosmia,COMPLETED,NA,40.0,2009-10-20,2014-10-20,0.6668127053669223,Slow (<1/month),6.668127053669223,Significantly Below (<50%),100,48.2,43.665
NCT01647763,Hemorrhoidal Artery Ligation and Rectoanal Repair Versus Stapled Hemorrhoidopexy,UNKNOWN,NA,84.0,2011-07-01,2024-12-01,0.5216156670746634,Slow (<1/month),5.216156670746634,Significantly Below (<50%),50,36.7,17.544999999999998
NCT03601663,Exploring the Effect of an Intervention on Women's Physical Activity Behaviour,COMPLETED,NA,49.0,2018-09-01,2019-08-30,4.108980716253444,Adequate (1-10/month),41.08980716253444,Significantly Below (<50%),100,53.9,58.34
NCT00661063,Diabetic Neuropathy Topical Treatment,UNKNOWN,PHASE3,200.0,2008-04-01,2009-06-01,14.291079812206574,Good (10-50/month),142.91079812206573,Exceeded (≥100%),50,56.0,63.71
NCT01292863,The Impact of Delflex on Mesothelial Cell Viability and Peritoneal Transport,WITHDRAWN,NA,0.0,2011-03-01,2012-05-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT03914963,Efficacy of a Fibrin Sealant for the Prevention of Lymphocele After Lymphadenectomy,COMPLETED,PHASE3,82.0,2012-02-01,2016-06-01,1.5778002528445008,Adequate (1-10/month),15.778002528445006,Significantly Below (<50%),100,51.6,51.644999999999996
NCT01117363,Effect of Three Weeks Consumption of Rye Porridge Breakfast,UNKNOWN,NA,26.0,2010-03-01,2010-07-01,6.487213114754098,Adequate (1-10/month),64.87213114754098,Below (50-75%),50,37.1,18.115000000000002
NCT04204863,Status Epilepticus Population Study (STEPS),RECRUITING,,1000.0,2019-04-19,2050-12-01,2.6357260368863105,Adequate (1-10/month),26.357260368863106,Significantly Below (<50%),60,76.3,85.1
NCT01697163,De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors,UNKNOWN,,155.0,2012-10-01,2014-09-01,6.740285714285714,Adequate (1-10/month),67.40285714285714,Below (50-75%),50,45.7,32.5
NCT02354963,Follicular Activation in Poor Responders,COMPLETED,NA,34.0,2014-11-01,2019-12-01,0.5576293103448277,Slow (<1/month),5.5762931034482754,Significantly Below (<50%),100,47.7,42.17
NCT07336563,ENDOCARE-SCREEN: Metabolic Liver Dysfunction Screening Study,NOT_YET_RECRUITING,,10000.0,2026-01-05,2026-10-31,1018.0602006688964,Excellent (>50/month),200.0,Exceeded (≥100%),30,77.3,85.67
NCT06990763,Network Pharmacology Was Applied to Explore the Mechanism of Remimazolam Applied in General Anesthesia for Gynecological Surgeries,NOT_YET_RECRUITING,NA,40.0,2025-06-01,2026-01-01,5.689719626168225,Adequate (1-10/month),56.89719626168225,Below (50-75%),30,32.2,11.635
NCT07164963,Upper Cervical Mobilization vs. Sub-Occipital MET for Neck Pain and FHP,COMPLETED,NA,45.0,2025-09-12,2025-12-01,17.1225,Good (10-50/month),171.225,Exceeded (≥100%),100,58.6,69.51
NCT02830087,Tourniquet Pressure in Primary Total Knee Arthroplasty,TERMINATED,NA,21.0,2016-06-01,2016-09-20,5.758918918918919,Adequate (1-10/month),57.58918918918919,Below (50-75%),10,24.7,6.995
NCT07073287,Efficacy of Cerebello-spinal Direct Current Stimulation (csDCS) on Functional Mobility in Chronic Stroke Patients,RECRUITING,PHASE2,30.0,2024-05-01,2026-08-01,1.110948905109489,Adequate (1-10/month),11.109489051094892,Significantly Below (<50%),60,35.4,15.765
NCT05522387,An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease,ACTIVE_NOT_RECRUITING,PHASE2,11.0,2023-02-21,2024-12-31,0.49313696612665686,Slow (<1/month),4.93136966126657,Significantly Below (<50%),85,41.4,24.04
NCT02420587,AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC),WITHDRAWN,PHASE2,0.0,2014-10-01,,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT01972087,Simulation Training to Improve 911 Dispatcher Identification of Cardiac Arrest,COMPLETED,NA,157.0,2013-09-01,2016-07-01,4.62193423597679,Adequate (1-10/month),46.21934235976789,Significantly Below (<50%),100,62.6,75.325
NCT00666887,Minocycline in Clinically Isolated Syndromes (CIS),COMPLETED,PHASE3,142.0,2009-01-01,2015-07-01,1.8222934232715011,Adequate (1-10/month),18.22293423271501,Significantly Below (<50%),100,61.4,73.735
NCT05951387,Dexmedetomidine Versus Dexmedetomidine with Ketamine in Mechanically Ventilated ARDS Patients,COMPLETED,PHASE4,60.0,2023-06-01,2024-06-05,4.936216216216216,Adequate (1-10/month),49.362162162162164,Significantly Below (<50%),100,54.8,61.095
NCT05560087,Association of PeRiODontal Disease and gUt Microbiome With Coronary artEry Disease (PRODUCE Study),COMPLETED,,450.0,2022-07-01,2024-12-05,15.425675675675677,Good (10-50/month),154.25675675675677,Exceeded (≥100%),100,89.3,93.00500000000001
NCT03794687,The Distal (SnUffbox) Radial artERy Access for Coronary Angiography and Interventions (SUPER-Prospective),COMPLETED,,125.0,2019-04-03,2021-09-15,4.246651785714286,Adequate (1-10/month),42.466517857142854,Significantly Below (<50%),100,58.3,68.99499999999999
NCT05835687,Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors,RECRUITING,PHASE1,48.0,2023-04-27,2028-03-01,0.8254915254237288,Slow (<1/month),8.254915254237288,Significantly Below (<50%),60,36.8,17.630000000000003
NCT01479387,Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in Japan,COMPLETED,,72.0,2008-08-01,2011-02-01,2.3978993435448577,Adequate (1-10/month),23.97899343544858,Significantly Below (<50%),100,54.1,59.11
NCT04962087,Health enSuite Insomnia: an App-based Treatment for Adult Chronic Insomnia,RECRUITING,NA,415.0,2024-08-29,2026-07-01,18.826527570789867,Good (10-50/month),188.26527570789867,Exceeded (≥100%),60,76.2,84.965
NCT07294287,Impact of Microneedling on the Gingival Tissue Surrounding Implant Supported Fixed Restoration.,ACTIVE_NOT_RECRUITING,NA,20.0,2024-10-05,2026-01-05,1.3321663019693655,Adequate (1-10/month),13.321663019693656,Significantly Below (<50%),85,42.1,25.019999999999996
NCT03935087,Improvement of Left Ventricular Ejection Fraction in ICD Patients Undergoing Therapy With Sacubitril/Valsartan,UNKNOWN,,150.0,2018-08-01,2019-06-30,13.711711711711713,Good (10-50/month),137.11711711711715,Exceeded (≥100%),50,50.3,48.215
NCT03376087,Cardiac Rhythm Disturbances in Hard-to-treat Epilepsy Patients Using Loop ECG Recorders,COMPLETED,,193.0,2015-11-16,2019-12-15,3.9428993288590606,Adequate (1-10/month),39.428993288590604,Significantly Below (<50%),100,63.8,76.78
NCT05375487,"The Effect of Natural Carbonated Mineral Water Consumption on Gastrointestinal Transit and on Gut Microbiota in Subjects With Functional Constipation: A Randomized, Placebo-Controlled Pilot Trial",UNKNOWN,NA,60.0,2022-05-01,2022-12-01,8.534579439252337,Adequate (1-10/month),85.34579439252337,Met (75-100%),50,44.8,29.845
NCT06893887,Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma,RECRUITING,NA,300.0,2025-05-22,2028-03-15,8.883268482490273,Adequate (1-10/month),88.83268482490274,Met (75-100%),60,67.0,79.725
NCT04031287,RCDP Natural History Study,UNKNOWN,,75.0,2019-06-18,2021-06-01,3.197478991596639,Adequate (1-10/month),31.97478991596639,Significantly Below (<50%),50,39.3,20.810000000000002
NCT04967287,MyopiaX Treatment for the Reduction of Myopia Progression in Children and Adolescents: Safety and Efficacy Investigation,COMPLETED,NA,124.0,2021-11-16,2024-10-04,3.584577397910731,Adequate (1-10/month),35.84577397910731,Significantly Below (<50%),100,59.9,71.86
NCT05509387,Investigating if a Stronger tDCS Intensity is More Effective for Improving Naming Ability in People Living With Alzheimer's Disease,RECRUITING,NA,42.0,2022-09-01,2026-12-31,0.808141592920354,Slow (<1/month),8.08141592920354,Significantly Below (<50%),60,36.4,17.14
NCT02528487,Predictors of the Long-term Functional Benefits of a Pulmonary Rehabilitation Program?,SUSPENDED,,360.0,2015-05-01,2023-03-01,3.830269136665502,Adequate (1-10/month),38.30269136665502,Significantly Below (<50%),20,53.1,56.105000000000004
NCT00197587,Prevention of Milk-Borne Transmission of HIV-1C in Botswana,COMPLETED,NA,1200.0,2002-08-01,,,Slow (<1/month),,Significantly Below (<50%),100,80.0,87.67
NCT02308787,Retrospective Data Collection of Routine Use With Spectra Optia® for Platelet Depletions,COMPLETED,,12.0,2014-11-01,2015-05-01,2.018121546961326,Adequate (1-10/month),20.18121546961326,Significantly Below (<50%),100,49.3,46.265
NCT02618187,"A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis",COMPLETED,PHASE1,58.0,2016-01-13,2018-01-26,2.373010752688172,Adequate (1-10/month),23.73010752688172,Significantly Below (<50%),100,54.6,60.39
NCT06195787,Improving Emergency Department Testing for Deep Vein Thrombosis,COMPLETED,,458.0,2024-01-01,2025-01-01,38.091584699453556,Good (10-50/month),200.0,Exceeded (≥100%),100,90.0,93.17
NCT00214487,Bifocal Soft Contact Lenses and Their Effect on Myopia Progression in Children and Adolescents.,COMPLETED,NA,78.0,2003-10-01,2006-03-01,2.6919727891156464,Adequate (1-10/month),26.919727891156462,Significantly Below (<50%),100,56.2,64.21
NCT01684293,Occupational Therapy-Based Cognitive Rehabilitation of Cocaine Abusers: A Pilot Study,COMPLETED,NA,50.0,2013-07-01,2019-03-31,0.7251071939018581,Slow (<1/month),7.251071939018582,Significantly Below (<50%),100,49.0,45.61
NCT04999293,Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention,COMPLETED,,1505.0,2021-07-20,2021-08-06,1505.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT04570293,5% Lidocaine-medicated Plaster for the Treatment of Trigeminal Neuralgia,COMPLETED,PHASE4,226.0,2021-05-01,2022-08-26,14.272697095435685,Good (10-50/month),142.72697095435686,Exceeded (≥100%),100,73.1,83.515
NCT00852293,The Connection Between Liver Disease and Chitinase Proteins,UNKNOWN,,200.0,2009-03-01,2014-03-01,3.3340635268346115,Adequate (1-10/month),33.34063526834611,Significantly Below (<50%),50,49.3,46.265
NCT01966393,Closed-loop Control of Glucose Levels (Artificial Pancreas) for 60 Hours in Adults With Type 1 Diabetes,COMPLETED,PHASE2,23.0,2014-04-01,2015-04-01,1.91813698630137,Adequate (1-10/month),19.1813698630137,Significantly Below (<50%),100,51.8,52.17
NCT05322993,Improving Polyp Detection Rate by Artificial Intelligence in Colonoscopy,COMPLETED,NA,5034.0,2021-11-19,2025-06-30,116.17510235026536,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT05581693,A Bioequivalence Study of L04TD2 Compared to Administration of L04RD1 in Healthy Volunteers,COMPLETED,PHASE1,50.0,2022-09-30,2022-11-29,25.366666666666667,Good (10-50/month),200.0,Exceeded (≥100%),100,59.0,70.365
NCT05989893,Mapping of Human Cognition,RECRUITING,NA,75.0,2022-08-01,2027-07-31,1.250958904109589,Adequate (1-10/month),12.50958904109589,Significantly Below (<50%),60,39.0,20.505000000000003
NCT00351793,A Clinical Trial Follow-up Study of the Genesis II Posterior Stabilized Total Knee Replacement,COMPLETED,,186.0,2003-01-01,2021-07-01,0.8380461811722913,Slow (<1/month),8.380461811722913,Significantly Below (<50%),100,58.2,68.795
NCT00788593,"A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)",COMPLETED,PHASE3,82.0,2008-01-01,2009-03-01,5.8731294117647055,Adequate (1-10/month),58.73129411764706,Below (50-75%),100,56.6,65.34
NCT05913193,Oral Nutritional Supplement in Type 2 Diabetes Subjects With or at Risk of Malnutrition,COMPLETED,,231.0,2023-12-15,2025-06-17,12.7848,Good (10-50/month),127.84800000000001,Exceeded (≥100%),100,71.8,82.83
NCT02869893,"MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics",COMPLETED,NA,57.0,2016-08-10,2017-04-06,7.259748953974896,Adequate (1-10/month),72.59748953974896,Below (50-75%),100,54.6,60.39
NCT06902493,Impact of Prior SGLT2 Inhibitors Use on the Development and Progression of Sepsis-Associated Acute Kidney Injury,COMPLETED,,664.0,2024-04-01,2025-03-01,60.515449101796406,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT00321893,Budesonide in Treating Patients With Lung Nodules at High Risk of Developing Lung Cancer,COMPLETED,PHASE2,225.0,2006-01-01,2008-09-01,7.031827515400411,Adequate (1-10/month),70.31827515400411,Below (50-75%),100,68.0,80.56
NCT02063893,Safety Study of Cancer Stem Cell Vaccinie to Treat Breast Cancer,COMPLETED,,40.0,2014-01-01,2015-02-01,3.074747474747475,Adequate (1-10/month),30.747474747474747,Significantly Below (<50%),100,51.5,51.245
NCT00056693,Treatment With SU11248 in Patients With Neuroendocrine Tumors,COMPLETED,PHASE2,107.0,2003-04-01,2006-09-01,2.6077502001601283,Adequate (1-10/month),26.07750200160128,Significantly Below (<50%),100,58.6,69.51
NCT00493493,"Pore Excision, Curettage, and Injection of Cymetra for Pilonidal Disease",UNKNOWN,NA,50.0,2007-01-01,2008-06-01,2.9439071566731143,Adequate (1-10/month),29.439071566731144,Significantly Below (<50%),50,39.0,20.505000000000003
NCT01383993,Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To Less Than 15 Years Old Who Are At High Risk For Systemic Fungal Infection,COMPLETED,PHASE2,21.0,2011-09-01,2013-05-01,1.0513815789473684,Adequate (1-10/month),10.513815789473686,Significantly Below (<50%),100,46.7,37.895
NCT03766893,Medication Maintenance Therapy in Community Pharmacy Settings,COMPLETED,EARLY_PHASE1,11.0,2018-09-01,2018-12-31,2.7672727272727276,Adequate (1-10/month),27.672727272727276,Significantly Below (<50%),100,50.9,49.370000000000005
NCT02062593,Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina,COMPLETED,NA,230.0,2013-12-01,2017-09-01,5.11036496350365,Adequate (1-10/month),51.1036496350365,Below (50-75%),100,68.4,80.97
NCT05701293,A ProspeCtive mUlticenteR Investigation on RENzar Stent Safety and Efficacy in the Treatment of Patients With Femoro-popliteal Disease in Tuscany (CURRENT Registry),RECRUITING,,100.0,2022-12-01,2026-12-01,2.083504449007529,Adequate (1-10/month),20.83504449007529,Significantly Below (<50%),60,44.3,28.715000000000003
NCT03843593,A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery,COMPLETED,,38.0,2019-02-14,2022-12-29,0.818048090523338,Slow (<1/month),8.180480905233381,Significantly Below (<50%),100,46.4,36.26
NCT03830593,Laparoscopic Adrenalectomy for Large Adrenal Tumors.,COMPLETED,,102.0,2019-02-07,2019-07-05,20.978918918918918,Good (10-50/month),200.0,Exceeded (≥100%),100,61.5,73.905
NCT05710393,Hidradenitis - an Analysis of Genetic Traits and Linkages in Families,RECRUITING,,500.0,2019-09-17,2027-12-01,5.078411745078412,Adequate (1-10/month),50.784117450784116,Below (50-75%),60,76.3,85.1
NCT06680193,Therapeutic Effects of the Processing of Positive Memories Technique on Posttrauma Health,COMPLETED,NA,70.0,2022-03-11,2024-06-05,2.608078335373317,Adequate (1-10/month),26.08078335373317,Significantly Below (<50%),100,55.6,62.905
NCT04479293,Post COVID-19 Functional Status in Egypt,UNKNOWN,,400.0,2020-07-01,2020-11-30,80.10526315789474,Excellent (>50/month),200.0,Exceeded (≥100%),50,75.3,84.60499999999999
NCT01017393,Preemptive Low-dose Epidural Ketamine for Preventing Chronic Post-thoracotomy Pain,COMPLETED,NA,209.0,2004-04-01,2005-06-01,14.934178403755869,Good (10-50/month),149.34178403755868,Exceeded (≥100%),100,71.7,82.78999999999999
NCT06866093,"The Study is Observational and Retrospective: Lifestyle, BMI and Activity Physical.",ACTIVE_NOT_RECRUITING,,112.0,2023-09-04,2026-12-31,2.8083031301482704,Adequate (1-10/month),28.083031301482702,Significantly Below (<50%),85,52.8,55.31
NCT05906693,The Quality of Life in Individuals With Parkinson's Disease,COMPLETED,,52.0,2019-01-01,2021-07-13,1.7130735930735932,Adequate (1-10/month),17.13073593073593,Significantly Below (<50%),100,52.5,54.345
NCT06227793,Pragmatic Clinical Trial to Assess the Effectiveness of Pharmaceutical Intervention in Patients With Uncontrolled Asthma,RECRUITING,NA,76.0,2023-08-14,2026-03-30,2.4123461939520334,Adequate (1-10/month),24.123461939520332,Significantly Below (<50%),60,44.1,28.425
NCT00429793,"Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",COMPLETED,PHASE2,60.0,2007-02-01,2012-01-01,1.0174930362116992,Adequate (1-10/month),10.174930362116992,Significantly Below (<50%),100,49.8,47.17
NCT04615793,Effect of Pilates Exercises on Gross Motor Function and Balance,COMPLETED,NA,40.0,2020-11-03,2021-01-31,13.680898876404495,Good (10-50/month),136.80898876404495,Exceeded (≥100%),100,58.2,68.795
NCT03274193,Effects of Yoga Training on Cardiovascular Reactivity to Psychological Stress in Patients With Hypertension,COMPLETED,NA,30.0,2018-03-01,2019-12-31,1.362985074626866,Adequate (1-10/month),13.629850746268657,Significantly Below (<50%),100,47.4,40.98
NCT06895993,Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participants,COMPLETED,PHASE1,84.0,2025-04-07,2025-05-08,82.48258064516129,Excellent (>50/month),200.0,Exceeded (≥100%),100,66.7,79.47999999999999
NCT01866293,Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma,COMPLETED,PHASE1,11.0,2013-05-28,2016-08-18,0.2842444821731749,Slow (<1/month),2.842444821731749,Significantly Below (<50%),100,45.9,33.495000000000005
NCT06304493,REMINDers for Incentive Spirometry in PACU (REMIND-IS in PACU),COMPLETED,NA,240.0,2024-03-25,2024-10-03,38.050000000000004,Good (10-50/month),200.0,Exceeded (≥100%),100,74.2,84.15
NCT03471793,The Australian Colonic Large Sessile Lesion Endoscopic Resection Study,RECRUITING,,5000.0,2017-02-24,2037-02-01,20.90085141444658,Good (10-50/month),200.0,Exceeded (≥100%),60,81.3,88.58
NCT04858893,Application of Machine Learning Method in Validation of Screening Cognitive Test for Parkinsonisms,COMPLETED,,562.0,2017-01-01,2020-08-31,12.785710014947682,Good (10-50/month),127.85710014947682,Exceeded (≥100%),100,93.3,94.325
NCT06235593,Self-care in the Person With Chronic Disease,RECRUITING,NA,400.0,2023-10-01,2024-10-01,33.26775956284153,Good (10-50/month),200.0,Exceeded (≥100%),60,75.0,84.49
NCT05944393,Erector Spine Plane (ESP) Block for Analgesia in Pediatric Scoliosis Surgery,UNKNOWN,NA,50.0,2022-09-08,2023-12-30,3.184100418410042,Adequate (1-10/month),31.84100418410042,Significantly Below (<50%),50,39.0,20.505000000000003
NCT06379321,Evaluation of Outcomes of the Triathlon Hinge Knee (THK) System,RECRUITING,,200.0,2024-05-10,2034-05-10,1.6670317634173057,Adequate (1-10/month),16.670317634173056,Significantly Below (<50%),60,52.3,53.515
NCT00109421,Friendship Based HIV/STI (Sexually Transmitted Infections) Intervention for African American Females,COMPLETED,NA,420.0,2004-11-01,2009-11-01,7.001533406352683,Adequate (1-10/month),70.01533406352684,Below (50-75%),100,83.6,90.435
NCT00947921,Plasty or Prosthesis to Treat Functional Mitral Regurgitation,TERMINATED,NA,20.0,2009-08-01,2017-08-01,0.2083504449007529,Slow (<1/month),2.083504449007529,Significantly Below (<50%),10,19.6,5.365
NCT05895721,Virtual Reality for Generalized Anxiety Disorders,UNKNOWN,NA,80.0,2023-02-21,2024-09-30,4.1485519591141395,Adequate (1-10/month),41.485519591141404,Significantly Below (<50%),50,41.4,24.04
NCT05605821,Influence of Diabetic Control on the Degree of Liver Fibrosis Assessed by Non-invasive Scores in Patients Followed in Diabetology,UNKNOWN,,520.0,2024-01-15,2024-12-30,45.225142857142856,Good (10-50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT00538421,Opioid-potentiated Volative Anaesthetic Vs. Remifentanil And Propofol During Abdominal Aortic Aneurysm Surgery,COMPLETED,PHASE4,193.0,2008-03-01,2013-03-01,3.2173713033954,Adequate (1-10/month),32.173713033954,Significantly Below (<50%),100,65.4,78.415
NCT03752021,The Endocannabinoid System in Human Gestational Tissues in Labor,COMPLETED,,20.0,2019-01-25,2019-07-01,3.877707006369427,Adequate (1-10/month),38.77707006369427,Significantly Below (<50%),100,49.9,47.425
NCT01861821,Analgesic Efficacy of a Multiport Versus Uniport Flexible Catheter for Labor Epidural Analgesia,COMPLETED,NA,650.0,2011-11-01,2013-06-01,34.2318339100346,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT05960721,Low-dose NOAC Versus GDMT After LAAO,RECRUITING,NA,4220.0,2023-07-06,2028-07-30,69.39859535386279,Excellent (>50/month),200.0,Exceeded (≥100%),60,88.0,92.495
NCT06430021,Study of the Value of HPG80 (circulating Progastrin) for the Diagnosis of Neuroendocrine Tumours in Patients with an MEN1 Mutation,RECRUITING,,297.0,2024-06-13,2026-12-01,10.034051054384019,Good (10-50/month),100.34051054384017,Exceeded (≥100%),60,65.1,78.14
NCT01148121,Assessment of Bone Density and Bone Turnover Markers in Patients With Down Syndrome and Comparison to the Ts65Dn Model,COMPLETED,NA,30.0,2010-06-01,2015-08-01,0.4839427662957075,Slow (<1/month),4.839427662957075,Significantly Below (<50%),100,47.4,40.98
NCT01577121,Evaluation of the Use of Indomethacin as Co-treatment in Women With Preterm Labor and High Risk of Intraamniotic Inflammation,COMPLETED,PHASE2,16.0,2012-04-01,2014-09-01,0.5515741789354474,Slow (<1/month),5.515741789354474,Significantly Below (<50%),100,46.3,35.66
NCT06181721,Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes,COMPLETED,NA,20.0,2023-09-05,2024-01-31,4.113513513513514,Adequate (1-10/month),41.13513513513514,Significantly Below (<50%),100,51.6,51.644999999999996
NCT02598921,Screening for Uterine Cavity Abnormalities in Women Scheduled for IVF,COMPLETED,NA,120.0,2014-07-01,2015-10-01,7.992997811816193,Adequate (1-10/month),79.92997811816193,Met (75-100%),100,59.6,71.17999999999999
NCT05088421,A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of BWC0977 in Healthy Volunteers,COMPLETED,PHASE1,44.0,2021-11-05,2023-05-28,2.3538840070298774,Adequate (1-10/month),23.53884007029877,Significantly Below (<50%),100,53.5,57.555
NCT03172221,Clinical Performance of the HRP2 HS-RDT for Malaria Diagnosis in Pregnant Women,COMPLETED,,880.0,2017-07-25,2018-01-31,140.98526315789474,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02582021,WISE CVD - Continuation (WISE HFpEF),RECRUITING,,220.0,2015-11-01,2030-02-01,1.2863618901267768,Adequate (1-10/month),12.863618901267767,Significantly Below (<50%),60,48.9,45.4
NCT01301521,Cinnamon Trial-lIfestyle iNtervention Plus Water-soluble Cinnamon Extract On loweriNg Blood Glucose in Pre-diabetics,COMPLETED,NA,229.0,2013-06-11,2019-04-26,3.2497715617715617,Adequate (1-10/month),32.49771561771561,Significantly Below (<50%),100,68.3,80.875
NCT06777121,"Effects of Exercise or Taping on Pain, Function, Range of Motion, Strength and Kyphosis in Subacromial Pain Syndrome",COMPLETED,NA,75.0,2022-06-06,2024-12-06,2.49781181619256,Adequate (1-10/month),24.978118161925604,Significantly Below (<50%),100,56.0,63.71
NCT07346521,"Endoscopic Screening of Asymptomatic Patients for Helicobacter Pylori, Intestinal Metaplasia, and Barrett's Mucosa During Screening Colonoscopy",RECRUITING,,1000.0,2025-12-16,2026-12-16,83.3972602739726,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT00795821,A Study in Adult Patients With Major Depressive Disorder,COMPLETED,PHASE2,495.0,2008-12-01,2011-03-01,18.375365853658536,Good (10-50/month),183.7536585365854,Exceeded (≥100%),100,94.6,94.88
NCT02828514,Nasal Resonance Change After Endoscopic Endonasal Transsphenoidal Skull Base Surgery: Analysis of Quality of Voice,UNKNOWN,,46.0,2015-09-01,2017-09-01,1.9155129958960329,Adequate (1-10/month),19.15512995896033,Significantly Below (<50%),50,37.0,17.955
NCT00885014,Telephone Cognitive-Behavioral Therapy (CBT) for Subthreshold Depression and Presenteeism in Workplace,COMPLETED,PHASE2,118.0,2009-04-01,2011-09-01,4.067859569648925,Adequate (1-10/month),40.678595696489246,Significantly Below (<50%),100,59.4,70.905
NCT02923414,Comparison of High Versus Escalating Shocks in Cardioverting Atrial Fibrillation,COMPLETED,NA,276.0,2016-09-28,2019-03-08,9.42922558922559,Adequate (1-10/month),94.2922558922559,Met (75-100%),100,77.1,85.5
NCT06540014,The Difference of Weight Gain Tendencies and Obesity During Pregnancy,COMPLETED,,323.0,2022-09-01,2024-06-15,15.056845329249617,Good (10-50/month),150.56845329249614,Exceeded (≥100%),100,79.2,87.095
NCT06631014,Effect of Early Prosthetic Fitting in Patients With Below Knee Amputation,ACTIVE_NOT_RECRUITING,NA,50.0,2023-11-01,2024-12-31,3.5727699530516435,Adequate (1-10/month),35.72769953051643,Significantly Below (<50%),85,49.5,46.58
NCT00539214,Non-interventional Observational Study With Pramipexole: Impact on Non-motor Symptoms in Parkinson's Disease,COMPLETED,,1192.0,2007-03-01,,,Slow (<1/month),,Significantly Below (<50%),100,78.3,86.48
NCT05175014,Mass Campaigns With Fractional Dose Pneumococcal Vaccines in Sub-Saharan Africa (fPCV),COMPLETED,PHASE4,44618.0,2021-12-30,2023-10-03,2115.5325856697823,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT01191814,Comparison of Metal and Plastic Stents for Preoperative Biliary Decompression,COMPLETED,NA,61.0,2010-07-01,2022-10-13,0.41382661020726547,Slow (<1/month),4.138266102072655,Significantly Below (<50%),100,49.9,47.425
NCT07305714,Virtual Reality Educational Intervention for Nursing Students' Day Surgery Patient Counselling,NOT_YET_RECRUITING,NA,60.0,2026-01-30,2027-01-01,5.435714285714286,Adequate (1-10/month),54.35714285714286,Below (50-75%),30,33.8,13.694999999999999
NCT02348814,Development of a Novel Biomarker for Liver Fibrosis,COMPLETED,,25.0,2015-05-01,2019-02-26,0.5447387258410881,Slow (<1/month),5.44738725841088,Significantly Below (<50%),100,45.3,31.169999999999998
NCT06239714,A Study to Evaluate SGB-3403 in Healthy Volunteers and Subjects With Elevated Low-Density Lipoprotein Cholesterol (LDL-C),UNKNOWN,PHASE1,64.0,2024-02-18,2025-05-30,4.171648822269807,Adequate (1-10/month),41.716488222698075,Significantly Below (<50%),50,40.1,22.05
NCT00877214,Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas,ACTIVE_NOT_RECRUITING,PHASE3,1272.0,2009-04-01,2024-12-01,6.7656264197099425,Adequate (1-10/month),67.65626419709943,Below (50-75%),85,85.5,91.42
NCT01522014,Randomized Clinical Trial of Ceramic Bearing Primary Total Hip Arthroplasty,COMPLETED,PHASE4,92.0,1997-11-01,2009-06-01,0.6620520094562649,Slow (<1/month),6.620520094562648,Significantly Below (<50%),100,52.4,53.949999999999996
NCT00713414,Role of Neurotransmission and Functional CNS Networks in Spasmodic Dysphonia,COMPLETED,,37.0,2008-07-09,2016-09-21,0.3759279038718291,Slow (<1/month),3.759279038718291,Significantly Below (<50%),100,46.3,35.66
NCT00289614,Patients With Renal Impairment and Diabetes Undergoing Computed Tomography (CT),COMPLETED,PHASE4,350.0,2006-01-01,2007-04-01,23.415384615384614,Good (10-50/month),200.0,Exceeded (≥100%),100,83.0,89.505
NCT03704714,Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma,SUSPENDED,PHASE1,30.0,2018-11-20,2025-06-11,0.38129436325678495,Slow (<1/month),3.8129436325678503,Significantly Below (<50%),20,23.4,6.7
NCT03355014,BE Study of the Combinations of Gemigliptin/Metformin HCl Extended Release 50/1000mg(25/500mg x 2 Tablets) in Comparison to Each Component Administered Alone,COMPLETED,PHASE1,70.0,2017-12-13,2018-01-12,70.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,65.6,78.56
NCT06567314,Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma,RECRUITING,PHASE2,24.0,2024-12-02,2030-09-01,0.34805145307289187,Slow (<1/month),3.480514530728919,Significantly Below (<50%),60,34.9,15.215
NCT07134114,Occlusal Impact of Hall Crowns in Primary Molars,RECRUITING,NA,60.0,2025-09-15,2026-12-15,4.005263157894737,Adequate (1-10/month),40.05263157894737,Significantly Below (<50%),60,42.8,25.929999999999996
NCT06757114,"A Study on the Efficacy of Immunotherapy, the Occurrence and Severity of Adverse Reactions in Patients with Non-small Cell Lung Cancer in High-altitude Areas",NOT_YET_RECRUITING,,200.0,2025-01-01,2025-06-30,33.82222222222222,Good (10-50/month),200.0,Exceeded (≥100%),30,48.3,43.985
NCT01016314,Efficacy of the Aspen Spinous Process System in Anterior Lumbar Interbody Fusion (ALIF),WITHDRAWN,NA,0.0,2009-11-01,2016-01-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT02115516,Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chemoprophylaxis,COMPLETED,PHASE1,67.0,2014-04-01,2016-04-01,2.7899863201094393,Adequate (1-10/month),27.899863201094394,Significantly Below (<50%),100,55.4,62.56
NCT01015716,"Physical Exercise, Dietary Counseling and Cognitive Behavioral Training as a Combined Intervention to Reduce Weight and Increase Workability in Health Care Workers",COMPLETED,PHASE1,146.0,2009-11-01,2012-05-01,4.873070175438597,Adequate (1-10/month),48.73070175438597,Significantly Below (<50%),100,61.7,74.1
NCT02331316,Drinking Water to Reach or Maintain a Healthier Weight,WITHDRAWN,NA,0.0,2019-01-01,2019-11-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT02618616,A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque Psoriasis,COMPLETED,PHASE2,129.0,2016-01-11,2016-12-22,11.349017341040463,Good (10-50/month),113.49017341040464,Exceeded (≥100%),100,65.3,78.32000000000001
NCT07156916,"A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin Hydrochloride 0.4 mg, Prolonged-release Film-coated Tablets, in Healthy Adult Male Subjects, Under Fasting Conditions",RECRUITING,PHASE1,46.0,2025-09-08,2026-05-01,5.958468085106383,Adequate (1-10/month),59.58468085106383,Below (50-75%),60,41.7,24.36
NCT03102216,"Early Point-Of-Care Blood Tests, ECG & X-rays in the Emergency Department",COMPLETED,NA,1134.0,2017-02-13,2017-06-30,251.96321167883212,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT05145816,Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis,RECRUITING,PHASE1,37.0,2024-02-15,2026-09-01,1.212357373519914,Adequate (1-10/month),12.12357373519914,Significantly Below (<50%),60,36.0,16.564999999999998
NCT04560816,A Study of the Cardiac Effects of ALXN1840 in Healthy Adults,COMPLETED,PHASE1,57.0,2020-07-24,2021-03-24,7.140246913580247,Adequate (1-10/month),71.40246913580248,Below (50-75%),100,54.6,60.39
NCT01425216,Sorafenib for Patients With Extensive Keloids,TERMINATED,PHASE2,60.0,2013-03-01,2013-03-01,60.0,Excellent (>50/month),200.0,Exceeded (≥100%),10,17.8,2.835
NCT03566316,Efficacy/Safety of Telmisartan/Amlodipine/Rosuvastatin in Hypertensive Patients With Hyperlipidemia,COMPLETED,PHASE3,134.0,2015-11-24,2017-06-16,7.156070175438597,Adequate (1-10/month),71.56070175438597,Below (50-75%),100,60.7,72.89999999999999
NCT05768516,Can we Improve Care Pathway in Low Back Pain?,UNKNOWN,NA,124.0,2023-06-05,2024-04-30,11.438060606060606,Good (10-50/month),114.38060606060607,Exceeded (≥100%),50,49.9,47.425
NCT05130216,Genicular Nerve Radiofrequency Ablation for Chronic Knee Pain After Total Knee Arthroplasty,COMPLETED,,5.0,2021-09-22,2025-10-01,0.1035374149659864,Slow (<1/month),1.035374149659864,Significantly Below (<50%),100,43.7,27.744999999999997
NCT04668716,Brain Involvement in Dystrophinopathies Part 2,COMPLETED,,339.0,2021-10-11,2024-06-30,10.39190332326284,Good (10-50/month),103.9190332326284,Exceeded (≥100%),100,80.5,88.12
NCT04594616,Waitlist-Control Trial of Smartphone CBT for Major Depressive Disorder (MDD),WITHDRAWN,NA,0.0,2024-09-01,2027-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT07203716,Preparing Kids for MRI Using VR,NOT_YET_RECRUITING,NA,150.0,2025-10-06,2026-03-31,25.94318181818182,Good (10-50/month),200.0,Exceeded (≥100%),30,46.0,34.1
NCT00643916,Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age,COMPLETED,PHASE2,378.0,2004-12-01,2007-10-01,11.127969052224373,Good (10-50/month),111.27969052224374,Exceeded (≥100%),100,85.2,91.315
NCT07151716,Sedation With Dexmedetomidine-esketamine Combination and Delirium in ICU Patients,RECRUITING,PHASE4,100.0,2025-10-21,2026-10-01,8.823188405797103,Adequate (1-10/month),88.23188405797102,Met (75-100%),60,51.0,49.714999999999996
NCT04571606,Interscalene Catheter vs. Interscalene Liposomal Bupivacaine for Arthroscopic Rotator Cuff Repair,COMPLETED,NA,80.0,2020-10-14,2021-07-02,9.330268199233718,Adequate (1-10/month),93.30268199233717,Met (75-100%),100,61.4,73.735
NCT06018506,A Phase I Study of BR108 in Hematological Malignancies,TERMINATED,PHASE1,8.0,2023-03-18,2024-06-21,0.5282429501084599,Slow (<1/month),5.282429501084599,Significantly Below (<50%),10,18.6,4.25
NCT05857306,"Effect of Olvanil Supplementation on Clinical, Biochemical and Anthropometric Parameters in Obese Adults",UNKNOWN,NA,56.0,2023-02-20,2023-07-31,10.587826086956522,Good (10-50/month),105.87826086956522,Exceeded (≥100%),50,44.5,29.160000000000004
NCT05944406,Enhancing Triage Accuracy: A Clinical Audit of the Manchester Triage System Implementation,COMPLETED,,494.0,2023-03-20,2023-06-10,183.38243902439024,Excellent (>50/month),200.0,Exceeded (≥100%),100,97.9,96.65
NCT05735106,NC/TMD Ratio As a Difficult Airway Predictor in Obese Patients,COMPLETED,,220.0,2021-10-21,2022-05-21,31.58867924528302,Good (10-50/month),200.0,Exceeded (≥100%),100,70.9,82.34
NCT06586606,A Study to Evaluate the Effects of Itraconazole on MK-1708 in Healthy Participants (MK-1708-003),COMPLETED,PHASE1,12.0,2024-10-03,2024-12-10,5.371764705882353,Adequate (1-10/month),53.71764705882352,Below (50-75%),100,51.0,49.714999999999996
NCT02282306,Phone Interview to Prevent Recurring Opioid Overdoses,COMPLETED,NA,30.0,2014-09-01,2015-02-01,5.968627450980392,Adequate (1-10/month),59.68627450980393,Below (50-75%),100,52.4,53.949999999999996
NCT04864106,Comprehensive Preoperative Airway Grading,COMPLETED,NA,13.0,2022-11-06,2023-08-30,1.3323905723905725,Adequate (1-10/month),13.323905723905725,Significantly Below (<50%),100,46.0,34.1
NCT05142306,"A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults",COMPLETED,PHASE1,23.0,2021-12-07,2022-05-31,4.000685714285714,Adequate (1-10/month),40.00685714285714,Significantly Below (<50%),100,51.8,52.17
NCT03798106,A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma,COMPLETED,PHASE2,46.0,2019-04-10,2022-08-10,1.1496223316912972,Adequate (1-10/month),11.496223316912971,Significantly Below (<50%),100,48.7,44.93
NCT03854006,Cryoballoon Pulmonary Vein Isolation: Time-to-Isolation Dependent Freeze Protocols Comparison,UNKNOWN,NA,40.0,2019-05-01,2021-05-01,1.6656634746922026,Adequate (1-10/month),16.656634746922023,Significantly Below (<50%),50,33.2,12.989999999999998
NCT00319306,Real Life Effectiveness in Asthma of Symbicort Single Inhaler Therapy,COMPLETED,PHASE3,550.0,2005-09-01,2006-12-01,36.71491228070175,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT04670406,A Guided Online ACT Intervention Combined With Psychoeducation for People With Spinal Cord Injury,COMPLETED,NA,10.0,2021-05-07,2021-08-23,2.818518518518519,Adequate (1-10/month),28.185185185185187,Significantly Below (<50%),100,50.8,49.18
NCT01965106,Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG),COMPLETED,PHASE2,46.0,2013-12-01,2015-07-01,2.4267590987868286,Adequate (1-10/month),24.26759098786829,Significantly Below (<50%),100,53.7,57.84
NCT05909306,Development of a Partograph E-learning Tool and Evaluation of Its Efficiency in Student Midwives,COMPLETED,NA,93.0,2021-06-01,2021-10-28,18.999463087248323,Good (10-50/month),189.99463087248324,Exceeded (≥100%),100,62.4,75.095
NCT01267006,Blood Levels and Effects of GSK1325756 in Healthy Adult Volunteers Aged 40 to 80 Years Old,COMPLETED,PHASE1,40.0,2010-11-05,2011-01-27,14.669879518072289,Good (10-50/month),146.6987951807229,Exceeded (≥100%),100,58.2,68.795
NCT04162106,Feasibility of the Ultravision™ System in Low Pressure Laparoscopic Cholecystectomy Compared to Airseal® IFS,UNKNOWN,NA,60.0,2019-11-01,2020-02-01,19.85217391304348,Good (10-50/month),198.5217391304348,Exceeded (≥100%),50,44.8,29.845
NCT05702606,Shock Wave Therapy for Management of Spasticity in Patients With Cerebral Palsy,COMPLETED,NA,73.0,2021-06-10,2022-10-03,4.629416666666667,Adequate (1-10/month),46.29416666666666,Significantly Below (<50%),100,55.8,63.245
NCT06320106,Assessment of Navigation Abilities in Children With Cerebral Palsy and Their Peers,RECRUITING,NA,26.0,2023-02-07,2026-12-31,0.5561770906535488,Slow (<1/month),5.561770906535489,Significantly Below (<50%),60,35.1,15.384999999999998
NCT02606006,Inpatient Physical Activity Function Through Enhanced Participation Levels in Animal-Assisted Therapy Programs,WITHDRAWN,NA,0.0,2015-11-01,2018-03-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT01430806,Dronaderone to Prevent Recurrent Implantable Cardioverter Defibrillator (ICD) Shocks,UNKNOWN,NA,20.0,2011-10-01,2015-12-01,0.4,Slow (<1/month),4.0,Significantly Below (<50%),50,31.6,10.905
NCT01562106,Investigating the Use of Fluorescence Imaging in Endometrial Cancer Surgery,COMPLETED,NA,123.0,2012-02-01,2016-08-01,2.278831405964699,Adequate (1-10/month),22.788314059646993,Significantly Below (<50%),100,59.8,71.61
NCT01618006,Multiple Daily Doses Of Aspirin To Overcome Aspirin Hyporesponsiveness Post Cardiac Bypass Surgery,COMPLETED,PHASE2,120.0,2012-01-01,2013-08-01,6.319723183391004,Adequate (1-10/month),63.19723183391004,Below (50-75%),100,59.6,71.17999999999999
NCT05316506,Pain and Hysteroscopy,COMPLETED,NA,70.0,2022-09-01,2023-09-01,5.837808219178083,Adequate (1-10/month),58.378082191780834,Below (50-75%),100,55.6,62.905
NCT07040306,A Clinical Follow-up Study on Drug Therapy for Graves' Disease Patients in China,RECRUITING,,1000.0,2012-11-14,2030-12-01,4.61841905628888,Adequate (1-10/month),46.18419056288879,Significantly Below (<50%),60,76.3,85.1
NCT02178306,Efficacy and Safety of Telmisartan in Hypertensive Patients With Mild/Moderate or Severe Renal Impairment or Requiring Hemodialysis,COMPLETED,PHASE4,82.0,2000-09-01,,,Slow (<1/month),,Significantly Below (<50%),100,46.6,37.375
NCT04778306,Transoral Laser Surgery and Radiotheraphy for Early Stage Laryngeal Squamous Cell Cancer,COMPLETED,NA,261.0,2010-01-01,2019-12-31,2.17607230895645,Adequate (1-10/month),21.7607230895645,Significantly Below (<50%),100,70.9,82.34
NCT00329706,Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID),COMPLETED,NA,710.0,2006-06-01,2017-01-01,5.588931988621671,Adequate (1-10/month),55.889319886216704,Below (50-75%),100,90.0,93.17
NCT04907006,A Food-drug Interaction Study of SY-004 in Healthy Subjects,COMPLETED,PHASE1,24.0,2021-08-31,2021-10-11,17.818536585365855,Good (10-50/month),178.18536585365854,Exceeded (≥100%),100,56.9,65.89500000000001
NCT07038304,The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC),RECRUITING,PHASE2,35.0,2025-01-03,2029-01-03,0.7292265571526352,Slow (<1/month),7.292265571526352,Significantly Below (<50%),60,35.8,16.325
NCT05465304,Effect of Azithromycin in Preventing Premature Labour,COMPLETED,,200.0,2021-10-01,2022-04-30,28.85308056872038,Good (10-50/month),200.0,Exceeded (≥100%),100,69.3,81.395
NCT06881004,Biliary Dilatation National Special Disease Cohort in China,RECRUITING,,6000.0,2025-03-19,2035-03-31,49.84716157205241,Good (10-50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT06288204,Green Propolis Extract and Royal Jelly in Hypertensive Patients and/or With Chronic Kidney Disease,RECRUITING,NA,153.0,2024-10-01,2027-07-31,4.508538238141336,Adequate (1-10/month),45.08538238141336,Significantly Below (<50%),60,50.2,48.04
NCT02420704,Effect of Endometrial Thickness on IVF Outcome,UNKNOWN,,500.0,2014-11-01,2015-12-01,38.53164556962026,Good (10-50/month),200.0,Exceeded (≥100%),50,78.3,86.48
NCT03139604,GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease,COMPLETED,PHASE3,439.0,2017-07-19,2020-07-13,12.259779816513763,Good (10-50/month),122.59779816513763,Exceeded (≥100%),100,90.1,93.24
NCT00001004,A Study of Tumor Necrosis Factor and Human Interferon-gamma in Patients With AIDS Related Complex,COMPLETED,PHASE2,30.0,,1990-02-01,,Slow (<1/month),,Significantly Below (<50%),100,42.4,25.45
NCT02090504,Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome,COMPLETED,PHASE4,127.0,2002-02-01,2009-05-01,1.4610279667422525,Adequate (1-10/month),14.610279667422525,Significantly Below (<50%),100,55.2,62.195
NCT05206604,A First-in-human Study of Multiple Doses of Topically Administered PF-07295324 and PF-07259955,COMPLETED,PHASE1,24.0,2022-02-09,2022-08-12,3.9704347826086956,Adequate (1-10/month),39.70434782608696,Significantly Below (<50%),100,51.9,52.55499999999999
NCT01484704,The Significance of MRI in the Development of Diagnostics and Treatment of Breast Cancer,UNKNOWN,,100.0,2011-02-01,,,Slow (<1/month),,Significantly Below (<50%),50,31.3,10.299999999999999
NCT04672304,Long Term and Permanent Contraceptive,COMPLETED,,1365.0,2020-11-18,2021-01-30,569.186301369863,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT06667804,"The Effect of Laughter Yoga on Blood Glucose Level, Disease Perception and Stress Level in Patients With Type 2 Diabetes",COMPLETED,NA,100.0,2022-07-15,2023-08-15,7.686868686868687,Adequate (1-10/month),76.86868686868688,Met (75-100%),100,58.0,68.245
NCT07052604,Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients,RECRUITING,,300.0,2023-12-15,2025-09-15,14.26875,Good (10-50/month),142.6875,Exceeded (≥100%),60,65.3,78.32000000000001
NCT01777984,Impact of Visceral Fat on the Pathogenesis of Age-related Macular Degeneration,UNKNOWN,,100.0,2009-12-01,2013-12-01,2.083504449007529,Adequate (1-10/month),20.83504449007529,Significantly Below (<50%),50,41.3,23.74
NCT05741684,iCBT and ABM for Reducing Depressive Symptoms in Firefighters,COMPLETED,NA,138.0,2022-04-01,2022-12-01,17.21606557377049,Good (10-50/month),172.1606557377049,Exceeded (≥100%),100,66.0,78.99000000000001
NCT00617084,"Randomized, Two-arm, Non-inferiority Study Comparing Endeavor-Resolute Stent With Abbot Xience-V Stent",COMPLETED,PHASE4,2292.0,2008-04-01,2014-02-01,32.7244277673546,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT01147484,A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer,COMPLETED,PHASE2,47.0,2010-09-02,2015-02-13,0.8804184615384616,Slow (<1/month),8.804184615384617,Significantly Below (<50%),100,48.8,45.184999999999995
NCT02728284,Evaluation of Cardiac Function With Cardio-respiratory Synchronized MRI,SUSPENDED,NA,100.0,2018-03-29,2027-08-01,0.892145369284877,Slow (<1/month),8.92145369284877,Significantly Below (<50%),20,29.0,8.76
NCT06520384,Radiofrequency Applications and Alcoholic Neurolysis of Genicular Nerve for the Treatment of Knee Osteoarthritic Pain,COMPLETED,NA,100.0,2024-07-25,2025-01-05,18.5609756097561,Good (10-50/month),185.609756097561,Exceeded (≥100%),100,63.0,75.845
NCT06018584,Biostimulation After Tooth Extraction,COMPLETED,NA,40.0,2016-11-01,2018-05-01,2.23003663003663,Adequate (1-10/month),22.300366300366303,Significantly Below (<50%),100,53.2,56.665
NCT04929184,Speech Processing in Stuttering,COMPLETED,NA,143.0,2022-04-04,2025-06-16,3.723627031650984,Adequate (1-10/month),37.23627031650984,Significantly Below (<50%),100,61.4,73.735
NCT01885884,Supportive Care Intervention-Pancreas,COMPLETED,NA,60.0,2013-07-01,2015-08-01,2.4,Adequate (1-10/month),24.0,Significantly Below (<50%),100,54.8,61.095
NCT07068984,Assessing Lower Extremity Dynamic Stability in Middle-Aged and Elderly Patients With Patellofemoral Pain Using the Y-Balance Test,COMPLETED,,70.0,2025-03-01,2025-04-10,53.27,Excellent (>50/month),200.0,Exceeded (≥100%),100,63.9,76.9
NCT07076784,Topical Icariin on Acne and Acne Scars,ACTIVE_NOT_RECRUITING,NA,25.0,2023-03-21,2025-12-01,0.7718052738336715,Slow (<1/month),7.718052738336715,Significantly Below (<50%),85,42.5,25.585
NCT06660784,Mechanism of Nitric Oxide on Ventilator-induced Diaphragm Dysfunction with Extracorporeal Membrane Lung Assistance,ACTIVE_NOT_RECRUITING,,80.0,2024-01-16,2025-12-30,3.4106442577030815,Adequate (1-10/month),34.10644257703082,Significantly Below (<50%),85,50.2,48.04
NCT00457184,"Thrombophilia and Migraine, Are They Related?",COMPLETED,,50.0,2004-01-01,2007-06-01,1.2205292702485968,Adequate (1-10/month),12.205292702485968,Significantly Below (<50%),100,47.3,40.475
NCT06626984,Investigation of Novel and Established Therapies in a Human Intravenous Lipopolysaccharide Model of Sepsis,NOT_YET_RECRUITING,PHASE1,65.0,2024-12-01,2026-07-01,3.4291161178509535,Adequate (1-10/month),34.29116117850954,Significantly Below (<50%),30,34.2,14.305000000000001
NCT01346384,Time - Related Cuff Pressure and Volume of the Laryngeal Tube With the Use of Nitrous Oxide,COMPLETED,,75.0,2008-05-01,2009-12-01,3.9430051813471505,Adequate (1-10/month),39.4300518134715,Significantly Below (<50%),100,54.3,59.62
NCT05120284,Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM),ACTIVE_NOT_RECRUITING,PHASE2,40.0,2022-07-01,2026-08-31,0.8,Slow (<1/month),8.0,Significantly Below (<50%),85,43.7,27.744999999999997
NCT05176184,A Deep Learning Method to Predict Difficult Laryngoscopy Using Cervical Spine X-ray Image,UNKNOWN,,367.0,2021-12-01,2022-11-25,31.118328690807804,Good (10-50/month),200.0,Exceeded (≥100%),50,67.7,80.22
NCT06399133,Care Package for Postoperative Constipation,COMPLETED,NA,102.0,2023-01-01,2023-04-03,33.748695652173915,Good (10-50/month),200.0,Exceeded (≥100%),100,63.2,76.11
NCT02625233,Clinical Long-Term Evaluation of Approved and Investigational Contact Lenses,COMPLETED,NA,105.0,2015-10-01,2016-02-01,25.985365853658536,Good (10-50/month),200.0,Exceeded (≥100%),100,63.4,76.375
NCT01307033,A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351),COMPLETED,PHASE3,278.0,2011-03-29,2012-12-04,13.737532467532468,Good (10-50/month),137.37532467532466,Exceeded (≥100%),100,77.2,85.52499999999999
NCT02861833,Identifying Coping Strategies of Patients With Cancerous Wound After a Specific Nursing Accompaniment,UNKNOWN,,100.0,2013-05-01,2017-12-01,1.817313432835821,Adequate (1-10/month),18.17313432835821,Significantly Below (<50%),50,41.3,23.74
NCT04633733,The Study of Pharmacokinetic Interactions Between HL237 and Tacrolimus,UNKNOWN,PHASE1,24.0,2020-08-22,2021-01-01,5.534545454545454,Adequate (1-10/month),55.345454545454544,Below (50-75%),50,36.9,17.735
NCT03030833,Dysfunctional Hemoglobin Pulse Oximetry,COMPLETED,,36.0,2017-02-06,2017-04-30,13.20289156626506,Good (10-50/month),132.0289156626506,Exceeded (≥100%),100,56.2,64.21
NCT00408733,Evaluating a Low-Literacy Discharge Medication Education Tool,COMPLETED,NA,287.0,2007-01-01,2007-08-01,41.208867924528306,Good (10-50/month),200.0,Exceeded (≥100%),100,78.0,86.075
NCT06763133,The Effect of Cold Water Spray Application on Dry Mouth and Thirst Symptoms and Comfort of Patients After Endonasal Endoscopic Surgery After Admission to Intensive Care Unit,COMPLETED,NA,40.0,2024-01-10,2024-12-06,3.6785498489425987,Adequate (1-10/month),36.78549848942599,Significantly Below (<50%),100,53.2,56.665
NCT06341933,Risk Factors for AKI in Patients Undergoing VATS for Pulmonary Resection,RECRUITING,,100.0,2024-04-15,2025-12-15,4.998357963875205,Adequate (1-10/month),49.98357963875205,Significantly Below (<50%),60,44.3,28.715000000000003
NCT04486833,Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib,RECRUITING,PHASE1,158.0,2021-09-03,2029-03-01,1.7578654970760235,Adequate (1-10/month),17.578654970760237,Significantly Below (<50%),60,50.6,48.705
NCT05192733,PRICE Survey Of Extubation Following Infratentorial Craniotomy,COMPLETED,,190.0,2021-11-04,2022-02-15,56.15145631067961,Excellent (>50/month),200.0,Exceeded (≥100%),100,73.5,83.74000000000001
NCT00572533,Intelligent Control Approach to Anemia Management,COMPLETED,NA,62.0,2011-04-01,2012-08-01,3.8673770491803277,Adequate (1-10/month),38.673770491803275,Significantly Below (<50%),100,55.0,61.834999999999994
NCT07193433,A Pilot Effectiveness and Implementation Trial of CSNAT-I in Hong Kong,NOT_YET_RECRUITING,NA,60.0,2025-09-20,2026-05-20,7.547107438016529,Adequate (1-10/month),75.4710743801653,Met (75-100%),30,33.8,13.694999999999999
NCT01057433,Drug-Drug Interaction of Lopinavir/Ritonavir on Pitavastatin,COMPLETED,PHASE4,24.0,2010-01-01,2010-12-01,2.187305389221557,Adequate (1-10/month),21.87305389221557,Significantly Below (<50%),100,51.9,52.55499999999999
NCT02789033,Efficacy of the Combination of Isosorbide Dinitrate Spray and Chitosan in Diabetic Foot Ulcers,COMPLETED,PHASE3,68.0,2015-06-01,2015-08-01,33.93311475409836,Good (10-50/month),200.0,Exceeded (≥100%),100,60.4,72.54
NCT00051233,Treatment of Schizophrenia Through Internet-Based Psychoeducation,COMPLETED,PHASE2,40.0,2003-01-01,2005-01-01,1.6656634746922026,Adequate (1-10/month),16.656634746922023,Significantly Below (<50%),100,48.2,43.665
NCT01023633,OPTIMOX1 in Chinese mCRC Patients,UNKNOWN,PHASE4,300.0,2009-10-01,2015-07-01,4.350643163411148,Adequate (1-10/month),43.506431634111486,Significantly Below (<50%),50,59.0,70.365
NCT05558033,Motor Imagery and Muscle Architecture,UNKNOWN,NA,40.0,2022-11-21,2023-06-15,5.910679611650486,Adequate (1-10/month),59.10679611650485,Below (50-75%),50,38.2,19.645000000000003
NCT04087733,Effectiveness of Liposomial Ozonized-Oil for Cataract Surgery,COMPLETED,PHASE4,200.0,2019-10-01,2020-09-30,16.679452054794524,Good (10-50/month),166.7945205479452,Exceeded (≥100%),100,71.0,82.44
NCT00559533,A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors,COMPLETED,PHASE1,106.0,2007-12-01,2012-11-01,1.7955703951029494,Adequate (1-10/month),17.955703951029495,Significantly Below (<50%),100,58.5,69.34
NCT01190033,Study Of The Efficacy Of Neurolysis In Functional Recovery From Chronic Nonspecific Low Back Pain,UNKNOWN,NA,40.0,2010-08-01,2013-07-01,1.1432863849765258,Adequate (1-10/month),11.43286384976526,Significantly Below (<50%),50,33.2,12.989999999999998
NCT03883633,Reversal of Cognitive Decline (ReCODE) Study,COMPLETED,,30.0,2019-06-30,2020-12-31,1.6603636363636365,Adequate (1-10/month),16.603636363636365,Significantly Below (<50%),100,45.7,32.5
NCT06748833,An App Responding to Behaviour of People to Promote Mental Wellbeing in Anxious Youth,COMPLETED,NA,101.0,2023-09-19,2024-12-03,6.971519274376417,Adequate (1-10/month),69.71519274376418,Below (50-75%),100,58.1,68.595
NCT05312333,Holter Monitoring of Critically-ill Childern in PICU at Sohag University Hospital,UNKNOWN,,100.0,2022-03-09,2023-03-01,8.526610644257705,Adequate (1-10/month),85.26610644257704,Met (75-100%),50,46.3,35.66
NCT02724033,Comparative Study of Superficial Cervical Plexus Block and Nerve of Arnold Block and Incidence of PONV for Inner Ear Surgery,TERMINATED,PHASE4,37.0,2014-05-01,2018-09-01,0.7110353535353535,Slow (<1/month),7.110353535353535,Significantly Below (<50%),10,21.0,6.105
NCT07124533,"Effectiveness of Toothpaste Tablets on Plaque, Gingival Health and Caries Experiences",NOT_YET_RECRUITING,PHASE3,50.0,2026-05-01,2026-12-01,7.112149532710281,Adequate (1-10/month),71.1214953271028,Below (50-75%),30,33.0,12.695
NCT03697733,Comparison Efficiency of Oral Etoricoxib Versus Intravenous Fentanyl on Post Operative Pain in Curettage Under TIVA,COMPLETED,NA,60.0,2018-11-01,2019-05-01,10.09060773480663,Good (10-50/month),100.90607734806629,Exceeded (≥100%),100,59.8,71.61
NCT01709552,Brief Intervention for Substance Use and Partner Abuse Among Females in the ER,COMPLETED,NA,40.0,2012-03-01,2014-11-01,1.248820512820513,Adequate (1-10/month),12.488205128205129,Significantly Below (<50%),100,48.2,43.665
NCT05990452,Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,261.0,2023-08-28,2026-12-30,6.51216393442623,Adequate (1-10/month),65.1216393442623,Below (50-75%),85,66.4,79.36999999999999
NCT01989052,Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma,TERMINATED,PHASE1,9.0,2014-05-01,2016-02-01,0.4273946957878315,Slow (<1/month),4.273946957878315,Significantly Below (<50%),10,18.7,4.455
NCT04695652,A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult,COMPLETED,PHASE2,3854.0,2020-12-30,2021-10-29,387.1807260726073,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT04707352,Impact on Atrial Remodeling of Dapaglifozin in Patients With Heart Failure .,COMPLETED,PHASE3,162.0,2021-02-08,2023-03-26,6.354742268041237,Adequate (1-10/month),63.54742268041237,Below (50-75%),100,63.0,75.845
NCT04257552,Care After Pregnancy Study (CAPS): Engaging Women in Postpartum Care,COMPLETED,NA,128.0,2020-02-03,2021-09-02,6.752720970537262,Adequate (1-10/month),67.52720970537263,Below (50-75%),100,60.2,72.2
NCT00058552,A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer,COMPLETED,PHASE2,129.0,2003-05-01,2004-07-01,9.19615925058548,Adequate (1-10/month),91.96159250585481,Met (75-100%),100,65.3,78.32000000000001
NCT04994652,Video- Or Direct Laryngoscopy for Endotracheal Intubation in Newborns,COMPLETED,NA,214.0,2021-09-04,2023-11-20,8.072069392812887,Adequate (1-10/month),80.72069392812888,Met (75-100%),100,67.1,79.86999999999999
NCT01145352,Enbrel-Juvenile Idiopathic Arthritis (JIA) Use Results Survey [All-Case Surveillance],COMPLETED,,113.0,2009-07-01,2013-10-01,2.214887314874437,Adequate (1-10/month),22.148873148744368,Significantly Below (<50%),100,57.4,67.05499999999999
NCT02853552,Misoprostol as First Aid Measure to Address Excessive Postpartum Bleeding,UNKNOWN,PHASE4,4330.0,2016-10-01,2017-10-01,361.1101369863014,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT01847352,Iron Status and Hypoxic Pulmonary Vascular Responses,COMPLETED,NA,31.0,2013-02-01,2014-04-01,2.2255660377358493,Adequate (1-10/month),22.255660377358492,Significantly Below (<50%),100,52.5,54.345
NCT02276352,Relative Bioavailability of Meloxicam 2 x 7.5 mg Tablets Compared to 15 mg Tablet and Dose Proportionality Over a Dose Range of 7.5 mg and 15 mg in Healthy Volunteers,COMPLETED,PHASE1,18.0,1999-06-01,,,Slow (<1/month),,Significantly Below (<50%),100,41.4,24.04
NCT03369652,Telephone Contact Between Hospital and General Practitioner About Medication Review for Older Patients,COMPLETED,NA,232.0,2017-11-24,2018-11-30,19.035256064690028,Good (10-50/month),190.3525606469003,Exceeded (≥100%),100,73.6,83.775
NCT02502552,Study of Anti-glycan Antibodies Stability in Saint-Etienne IBD Cohort,COMPLETED,,80.0,2013-11-01,2015-10-01,3.4838340486409156,Adequate (1-10/month),34.83834048640916,Significantly Below (<50%),100,54.7,60.629999999999995
NCT07192952,"A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction",NOT_YET_RECRUITING,PHASE3,117.0,2026-04-01,2030-12-30,2.0539100346020764,Adequate (1-10/month),20.539100346020764,Significantly Below (<50%),30,38.4,19.835
NCT04791852,Potential Role of Donor-derived Cell-Free DNA as a Biomarker in Cardiac Allograft Vasculopathy,COMPLETED,,94.0,2019-01-10,2021-04-15,3.4641162227602904,Adequate (1-10/month),34.641162227602905,Significantly Below (<50%),100,55.9,63.42
NCT02237352,Mechanisms of Diabetic Nephropathy in Ecuador,UNKNOWN,,10064.0,2014-09-15,2022-12-01,102.15010336778927,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT05020652,A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis,ACTIVE_NOT_RECRUITING,PHASE2,107.0,2021-11-11,2026-02-01,2.1108749189889826,Adequate (1-10/month),21.108749189889824,Significantly Below (<50%),85,54.1,59.11
NCT03529552,"Evaluation After Reconstruction of the Anterior Cruciate Ligament of the Knee Using the Bioresorbable Interference Screw (SMS): Resorbability, Per- and Post-operative Complications and Articular Functional Recovery.",TERMINATED,NA,40.0,2018-09-17,2019-04-24,5.5598173515981735,Adequate (1-10/month),55.59817351598174,Below (50-75%),10,26.2,7.775
NCT00144352,In-Vivo Response of P. Falciparum to Antimalarial Treatment in HIV-Infected and HIV-Uninfected Adults,COMPLETED,PHASE4,540.0,2002-09-01,2004-07-01,24.570403587443945,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT01147952,The Effect of Exercise on Peripheral Blood Gene Expression in Angina,COMPLETED,NA,60.0,2010-11-01,2014-05-01,1.430227094753328,Adequate (1-10/month),14.302270947533282,Significantly Below (<50%),100,49.8,47.17
NCT02139852,"Capsaicinoid Ingestion, Human Metabolism and Exercise",WITHDRAWN,,0.0,2014-06-01,2016-01-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT01162252,Improving Psoriasis Through Health and Well-Being,COMPLETED,NA,130.0,2010-03-01,2013-12-01,2.8863603209336253,Adequate (1-10/month),28.863603209336254,Significantly Below (<50%),100,60.4,72.54
NCT06860152,Cochlear Implant Speech in Noise Processing,RECRUITING,NA,150.0,2024-11-14,2028-03-31,3.7031630170316303,Adequate (1-10/month),37.031630170316305,Significantly Below (<50%),60,50.0,47.675
NCT01584752,Gore-BioA Fistula Plug to Treat Transsphincteric Fistulas,TERMINATED,,60.0,2011-11-01,2015-11-01,1.2501026694045174,Adequate (1-10/month),12.501026694045175,Significantly Below (<50%),10,21.1,6.140000000000001
NCT03616652,Non-deceptive Application of Placebos in Insomnia,COMPLETED,NA,51.0,2018-10-01,2020-01-31,3.1877618069815195,Adequate (1-10/month),31.8776180698152,Significantly Below (<50%),100,54.1,59.11
NCT03357952,"A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma",COMPLETED,PHASE2,10.0,2017-11-16,2021-11-19,0.20792349726775958,Slow (<1/month),2.079234972677596,Significantly Below (<50%),100,45.8,33.03
NCT06470347,A Real-World Study of Pyrrolitinib Maleate Tablets for HER-2-Positive Early or Locally Advanced Breast Cancer After Adjuvant Trastuzumab Therapy,RECRUITING,PHASE1,67.0,2022-11-01,2025-11-01,1.860839416058394,Adequate (1-10/month),18.60839416058394,Significantly Below (<50%),60,43.4,27.265
NCT06030947,Effectiveness of Micro Connective Tissue Graft for Treatment of Multiple Adjacent Gingival Recession Defects,RECRUITING,NA,30.0,2025-03-01,2026-08-01,1.762934362934363,Adequate (1-10/month),17.62934362934363,Significantly Below (<50%),60,40.4,22.34
NCT05006547,Peroneal Muscles Response to Expected and Unexpected Falls Among Young and Middle-aged Adults Before and After Neuromuscular Training,UNKNOWN,,50.0,2021-07-01,2022-07-01,4.169863013698631,Adequate (1-10/month),41.6986301369863,Significantly Below (<50%),50,37.3,18.35
NCT06453447,Prednisone for CRPS in Distal Radius Fracture,RECRUITING,NA,40.0,2024-10-10,2026-07-01,1.9357710651828297,Adequate (1-10/month),19.3577106518283,Significantly Below (<50%),60,41.2,23.425
NCT04668547,Embryoscopic Evacuation for Induced Abortion,UNKNOWN,NA,10.0,2021-01-01,2021-08-01,1.4358490566037736,Adequate (1-10/month),14.358490566037737,Significantly Below (<50%),50,30.8,9.745
NCT02062047,Full-mouth and Partial-mouth Scaling and Root Planing in Type 2 Diabetic Subjects,COMPLETED,PHASE4,60.0,2007-12-01,2010-04-01,2.143661971830986,Adequate (1-10/month),21.43661971830986,Significantly Below (<50%),100,54.8,61.095
NCT02817347,A Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea,TERMINATED,PHASE1,135.0,2016-06-01,2017-04-13,13.004430379746836,Good (10-50/month),130.04430379746833,Exceeded (≥100%),10,38.8,20.244999999999997
NCT07069647,Artificial Intelligence-Aided Screening for Patients With Diabetic Retinopathy and Age-related Macular Degeneration in Family Medicine and Geriatric Medicine Outpatient Clinics,RECRUITING,NA,4300.0,2025-10-02,2027-12-31,159.62439024390244,Excellent (>50/month),200.0,Exceeded (≥100%),60,88.0,92.495
NCT02670447,"Early Identification of Patients Presenting a First Psychotic Episode, Non Answering to First Line Support Strategies",RECRUITING,,80.0,2025-12-11,2031-04-01,1.2572018585441405,Adequate (1-10/month),12.572018585441405,Significantly Below (<50%),60,37.7,18.915000000000003
NCT04196647,Guideline for Hometitration With Duodopa for Parkinson Patients,COMPLETED,,10.0,2017-03-01,2022-06-30,0.1563430919363123,Slow (<1/month),1.5634309193631228,Significantly Below (<50%),100,44.1,28.425
NCT06517147,Cooling Via Cryogenx Body Cooling Device,NOT_YET_RECRUITING,EARLY_PHASE1,12.0,2024-09-01,2025-07-31,1.096936936936937,Adequate (1-10/month),10.969369369369371,Significantly Below (<50%),30,25.0,7.23
NCT06426147,"L-citrulline to Improve Adverse Outcomes in Admitted Children (EChiLiBRiST, Clinical Trial 2, Inpatients)",RECRUITING,NA,2200.0,2025-12-08,2027-08-01,111.42762063227953,Excellent (>50/month),200.0,Exceeded (≥100%),60,88.0,92.495
NCT04106947,Transition of Care for Patients With Hirschsprung Disease and Anorectal Malformations,UNKNOWN,,1000.0,2019-08-12,2022-08-01,28.055299539170505,Good (10-50/month),200.0,Exceeded (≥100%),50,78.3,86.48
NCT02562547,Evaluation of the Hem-Avert® Perianal Stabilizer Into Routine Clinical Practice,COMPLETED,,799.0,2015-04-01,2015-09-01,158.96444444444444,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT04051047,Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma,WITHDRAWN,EARLY_PHASE1,0.0,2019-11-30,2021-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT06504147,"A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery",RECRUITING,PHASE2,114.0,2024-06-15,2031-02-28,1.4169701919150675,Adequate (1-10/month),14.169701919150674,Significantly Below (<50%),60,42.1,25.019999999999996
NCT00002247,A Randomized Study Comparing the Safety and Efficacy of Two Regimens of Oral Ganciclovir to Intravenous Ganciclovir Maintenance Therapy for Cytomegalovirus Retinitis in People With AIDS Who Have Received Prior Ganciclovir Therapy,COMPLETED,NA,225.0,,,,Slow (<1/month),,Significantly Below (<50%),100,58.0,68.245
NCT00291447,111In-ch806 in Patients With Advanced Tumours Expressing the 806 Antigen,COMPLETED,PHASE1,8.0,2005-05-01,2006-08-10,0.5225751072961373,Slow (<1/month),5.225751072961373,Significantly Below (<50%),100,45.6,32.08
NCT03402347,Ex Vivo Evaluation of Laser Induced Thermal Tissue Damage,COMPLETED,NA,2.0,2019-01-01,2019-06-16,0.3667469879518072,Slow (<1/month),3.6674698795180727,Significantly Below (<50%),100,45.2,30.830000000000002
NCT07206147,Physical Exercise as Treatment Post-stroke Fatigue - a Feasibilty Study.,NOT_YET_RECRUITING,NA,16.0,2026-01-01,2026-06-01,3.225430463576159,Adequate (1-10/month),32.254304635761585,Significantly Below (<50%),30,30.3,9.295
NCT05179447,PROfiling Based Endometrial Cancer Adjuvant Therapy,RECRUITING,NA,590.0,2022-01-24,2027-01-01,9.960953965612868,Adequate (1-10/month),99.60953965612867,Met (75-100%),60,83.0,89.505
NCT06012747,Pain After Cesarean Section - A Danish Multicenter Cohort Study.,COMPLETED,,752.0,2023-09-01,2024-05-31,83.8493772893773,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT04476147,The Impact of Frailty on Thrombosis of Elderly Patients With NVAF （FTE-NVAF）,UNKNOWN,,500.0,2020-08-01,2024-03-01,11.636085626911315,Good (10-50/month),116.36085626911317,Exceeded (≥100%),50,78.3,86.48
NCT00219947,Viral and Host Factors in the Transmission and Pathogenesis of HIV,TERMINATED,,600.0,2000-07-01,2019-03-01,2.6791843919612734,Adequate (1-10/month),26.791843919612734,Significantly Below (<50%),10,61.3,73.56
NCT01071447,Nurse-led Clinic for Patients With Rheumatic Diseases and Biological Treatment,UNKNOWN,NA,100.0,2009-10-01,2012-10-01,2.7773722627737225,Adequate (1-10/month),27.773722627737225,Significantly Below (<50%),50,43.0,26.465
NCT00746447,Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC),COMPLETED,PHASE3,648.0,2005-05-01,2008-03-01,19.058086956521738,Good (10-50/month),190.58086956521737,Exceeded (≥100%),100,95.0,95.7
NCT06274047,PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.,RECRUITING,PHASE3,120.0,2024-09-10,2029-06-30,2.0825541619156214,Adequate (1-10/month),20.825541619156215,Significantly Below (<50%),60,47.6,41.775
NCT07347847,Impact on Mortality of Hospitalisation of a Patient in a Hospital Bed That Does Not Correspond to His Needs After a Visit to the Emergency Department,NOT_YET_RECRUITING,,2766.0,2026-01-01,2026-09-01,346.4898765432099,Excellent (>50/month),200.0,Exceeded (≥100%),30,77.3,85.67
NCT01438047,Optical Frequency Domain Imaging (OFDI) in Dermatology,WITHDRAWN,,0.0,2010-09-01,2012-09-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT05392647,"Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospective，Open-label, Single-arm Study.",UNKNOWN,PHASE2,28.0,2022-07-01,2024-12-31,0.9325164113785558,Slow (<1/month),9.325164113785558,Significantly Below (<50%),50,32.2,11.635
NCT06974747,Immunomodulatory Effect of Pleuran in Children With Recurrent Respiratory Tract Infections,COMPLETED,NA,217.0,2023-09-25,2024-03-31,35.13553191489362,Good (10-50/month),200.0,Exceeded (≥100%),100,72.4,83.17999999999999
NCT06983249,Rhomboid Intercostal and Subserratus Plane Block Versus Quadratus Lumborum Block in Management of Postoperative Pain After Open Nephrectomy,ACTIVE_NOT_RECRUITING,NA,50.0,2025-07-01,2026-09-01,3.5644028103044496,Adequate (1-10/month),35.6440281030445,Significantly Below (<50%),85,49.5,46.58
NCT01455649,Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After Kidney Transplantation in Adults,UNKNOWN,PHASE4,30.0,2011-11-01,2013-11-01,1.249247606019152,Adequate (1-10/month),12.49247606019152,Significantly Below (<50%),50,32.4,12.025
NCT03052049,Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres,COMPLETED,NA,28.0,2017-09-06,2022-09-26,0.46171180931744316,Slow (<1/month),4.617118093174431,Significantly Below (<50%),100,47.2,40.035
NCT04016649,The Mechanical Characterisation of Human Saphenous and Popliteal Vein,RECRUITING,,50.0,2019-01-21,2027-03-21,0.5105669238510567,Slow (<1/month),5.105669238510567,Significantly Below (<50%),60,35.3,15.534999999999998
NCT00242749,IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma,COMPLETED,PHASE2,47.0,2002-12-01,2007-07-01,0.8551583980872685,Slow (<1/month),8.551583980872685,Significantly Below (<50%),100,48.8,45.184999999999995
NCT02745249,Assessing the Feasibility of Integrating Maternal Nutrition Interventions Into an Existing MNCH Platform in Bangladesh,COMPLETED,NA,3500.0,2015-07-01,2016-10-01,232.62008733624455,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT00159549,Long Term Effect of an Education and Training Program for Patients With Chronic Obstructive Pulmonary Disease,COMPLETED,NA,60.0,2000-01-01,2005-12-01,0.8451642757982416,Slow (<1/month),8.451642757982416,Significantly Below (<50%),100,49.8,47.17
NCT00871949,"Safety, Tolerability And Pharmacokinetics Study Of Single Doses Of PNU-100480 In Healthy Adults",COMPLETED,PHASE1,19.0,2009-04-01,2009-08-01,4.740655737704918,Adequate (1-10/month),47.406557377049175,Significantly Below (<50%),100,51.5,51.245
NCT01895049,Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria,COMPLETED,PHASE4,171.0,2013-08-01,2017-03-07,3.9613698630136986,Adequate (1-10/month),39.61369863013699,Significantly Below (<50%),100,63.7,76.655
NCT04704349,Latest Imaging SPECT System Evaluation Phase 1,COMPLETED,NA,68.0,2020-10-05,2021-01-27,18.15719298245614,Good (10-50/month),181.57192982456144,Exceeded (≥100%),100,60.4,72.54
NCT00461149,Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly,COMPLETED,PHASE4,50.0,1995-01-01,2006-12-01,0.34972426470588236,Slow (<1/month),3.4972426470588234,Significantly Below (<50%),100,49.0,45.61
NCT00085449,"Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer",WITHDRAWN,PHASE1,0.0,2006-05-01,2007-01-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT01103349,BI 671800 in Asthmatic Patients on Inhaled Corticosteroids,COMPLETED,PHASE2,243.0,2010-04-20,2011-08-09,15.539747899159664,Good (10-50/month),155.39747899159664,Exceeded (≥100%),100,74.4,84.255
NCT01741649,Clorhexidine Versus Povidone for the Prevention of Surgical Site Infection After Cesarean Section,COMPLETED,NA,800.0,2012-10-01,2013-04-01,133.8021978021978,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT02775149,Dental Erosion in Patients With Gastro-oesophageal Reflux,SUSPENDED,,30.0,2016-11-01,2021-12-01,0.49202586206896554,Slow (<1/month),4.920258620689655,Significantly Below (<50%),20,21.7,6.175
NCT00173849,The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma,UNKNOWN,,100.0,2006-01-01,2006-07-01,16.81767955801105,Good (10-50/month),168.1767955801105,Exceeded (≥100%),50,46.3,35.66
NCT02006849,ACTH Treatment of APOL1- Associated Nephropathy,WITHDRAWN,NA,0.0,2014-01-01,2019-01-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT02876549,G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria,COMPLETED,PHASE4,1000.0,2016-09-01,2018-11-01,38.48293299620734,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT05343949,High Intensity Interval Training and Technologies in COPD,TERMINATED,NA,18.0,2019-05-08,2022-11-25,0.4224518118735544,Slow (<1/month),4.224518118735545,Significantly Below (<50%),10,19.4,5.2299999999999995
NCT03163238,Dexmedetomidine and the Inflammatory Response in Pediatric Cardiac Surgery,UNKNOWN,PHASE2,60.0,2017-05-30,2018-12-01,3.320727272727273,Adequate (1-10/month),33.20727272727273,Significantly Below (<50%),50,39.8,21.47
NCT05290038,ARON-2 Study-Multicentric International Retrospective Study,RECRUITING,,367.0,2022-02-17,2027-09-30,5.446845441248172,Adequate (1-10/month),54.46845441248173,Below (50-75%),60,65.7,78.66499999999999
NCT03380338,The Effect of Exercise on Gut Microbiota in Type 2 Diabetic Patients,COMPLETED,NA,15.0,2016-05-11,2017-06-29,1.1028985507246378,Adequate (1-10/month),11.028985507246377,Significantly Below (<50%),100,46.2,35.089999999999996
NCT04560738,A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male Participants,COMPLETED,PHASE1,8.0,2020-10-15,2021-05-13,1.1596190476190478,Adequate (1-10/month),11.596190476190477,Significantly Below (<50%),100,45.6,32.08
NCT06404138,Recovery From Disability After Geriatric-home Rehabilitation Versus Standard of Care: Pilot Study,COMPLETED,NA,15.0,2024-05-01,2025-07-02,1.0693208430913348,Adequate (1-10/month),10.69320843091335,Significantly Below (<50%),100,46.2,35.089999999999996
NCT03015038,Study of the Immune Response in Colon Adenocarcinoma,COMPLETED,,100.0,2017-02-05,2024-02-05,1.1909233176838812,Adequate (1-10/month),11.90923317683881,Significantly Below (<50%),100,51.3,50.62
NCT03358238,Modeling Mood Course to Detect Markers of Effective Adaptive Interventions,COMPLETED,NA,50.0,2017-11-27,2019-06-19,2.674868189806679,Adequate (1-10/month),26.748681898066785,Significantly Below (<50%),100,54.0,58.72500000000001
NCT02446938,Position of Esophageal Balloon in Patients With Mechanical Ventilation,COMPLETED,,20.0,2015-05-01,2015-09-01,4.949593495934959,Adequate (1-10/month),49.4959349593496,Significantly Below (<50%),100,49.9,47.425
NCT01698138,Prevention of Bladder Dysfunction in Acute Spinal Cord Injury,COMPLETED,PHASE4,20.0,2012-09-01,2020-12-20,0.2007915567282322,Slow (<1/month),2.007915567282322,Significantly Below (<50%),100,46.6,37.375
NCT04204538,Dietary Practices and Metabolic Syndrome in the Young Adult Population of Rwanda,COMPLETED,,1247.0,2021-11-01,2023-12-31,48.04896202531646,Good (10-50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02917538,A Randomized Trial of Contact Force in Atrial Flutter Ablation,COMPLETED,NA,156.0,2016-09-01,2020-06-01,3.468692476260044,Adequate (1-10/month),34.68692476260044,Significantly Below (<50%),100,62.5,75.21
NCT01835938,Clinical Investigation of Erlotinib as an HCV Entry Inhibitor,UNKNOWN,PHASE1,12.0,2013-05-01,2015-05-01,0.5003835616438357,Slow (<1/month),5.003835616438357,Significantly Below (<50%),50,31.0,9.985
NCT00065338,Nutritional Restriction and Activity Thermogenesis,COMPLETED,PHASE1,90.0,2003-06-01,2007-11-01,1.6973977695167288,Adequate (1-10/month),16.97397769516729,Significantly Below (<50%),100,57.2,66.465
NCT03178838,Clinical Study of the Presence of Trichomonas Tenax and Entamoeba Gingivalis in Patients With Periodontitis,COMPLETED,,50.0,2013-12-03,2014-11-11,4.43731778425656,Adequate (1-10/month),44.3731778425656,Significantly Below (<50%),100,52.3,53.515
NCT00665938,Followup of Infants Fed Non-routine Infant Formula,COMPLETED,NA,183.0,2006-10-01,2011-12-01,2.952050874403816,Adequate (1-10/month),29.520508744038153,Significantly Below (<50%),100,64.6,77.59
NCT06618638,Shared Decision Making for Choosing Autosomal DOminant Polycystic Kidney Disease Treatment,RECRUITING,NA,340.0,2024-10-21,2026-09-30,14.597461212976022,Good (10-50/month),145.9746121297602,Exceeded (≥100%),60,70.2,81.99499999999999
NCT00954538,"Safety, Radiation Dosimetry, Biokinetics, and Effectiveness of [18F]MK3328 (MK-3328-001)",COMPLETED,PHASE1,19.0,2009-08-01,2011-05-01,0.9065203761755487,Slow (<1/month),9.065203761755486,Significantly Below (<50%),100,46.5,36.815
NCT04850638,"Drug Interaction Between SHR4640 Tablets and Furosemide Tablets in Healthy Volunteers (Single Center, Single Arm, Open, Self-control)",COMPLETED,PHASE1,18.0,2021-06-28,2021-09-14,7.024615384615385,Adequate (1-10/month),70.24615384615385,Below (50-75%),100,51.4,50.92
NCT00630838,Probiotic Prophylaxis of Hirschprung's Disease Associated Enterocolitis (HAEC),COMPLETED,PHASE2,62.0,2006-09-01,2010-09-01,1.291772758384668,Adequate (1-10/month),12.91772758384668,Significantly Below (<50%),100,50.0,47.675
NCT02274038,Serial [18F]Thymidine (FLT)PET/CT as a Biomarker of Response in Pemetrexed Therapy for Non-Small Cell Lung Cancer,TERMINATED,NA,3.0,2015-03-01,2018-07-01,0.07497536945812808,Slow (<1/month),0.7497536945812807,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT03805438,ED90 of 3% Chloroprocaine for Cervical Cerclage,COMPLETED,PHASE4,47.0,2019-02-07,2020-10-23,2.2927564102564104,Adequate (1-10/month),22.927564102564105,Significantly Below (<50%),100,53.8,58.065
NCT00714038,"CARE - Quality Improvement in Asthma Secondary Prevention in Primary Care, Through Delegation of Consultations to the Nurse.",COMPLETED,,2122.0,2008-05-01,2010-12-01,68.42550847457628,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT01587638,Use of Beta-blockers and Risk of New Onset Diabetes,COMPLETED,,12336.0,2009-04-01,2009-12-01,1538.9665573770492,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT03169738,QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors,WITHDRAWN,PHASE1,0.0,2018-02-01,2021-12-28,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT04983238,Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985,COMPLETED,PHASE1,48.0,2022-01-10,2023-06-26,2.746466165413534,Adequate (1-10/month),27.464661654135337,Significantly Below (<50%),100,53.8,58.065
NCT04139538,Microbiome and Immunogenity of Saliva During Orthodontic Therapy,UNKNOWN,NA,40.0,2019-11-01,2024-10-01,0.6779510022271715,Slow (<1/month),6.779510022271714,Significantly Below (<50%),50,33.2,12.989999999999998
NCT06398158,Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder,RECRUITING,,35.0,2024-07-10,2027-06-30,0.9819354838709677,Slow (<1/month),9.819354838709678,Significantly Below (<50%),60,34.1,14.19
NCT00492258,Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer,COMPLETED,PHASE3,1656.0,2007-06-01,2012-12-01,25.078925373134325,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT01274858,Sensory Mapping and Thermal Thresholds After Thoracic Surgery,COMPLETED,,12.0,2011-01-01,2011-04-01,4.058666666666666,Adequate (1-10/month),40.58666666666667,Significantly Below (<50%),100,49.3,46.265
NCT04007458,Maine Lung Cancer Coalition: Using CHWs for the Annual Lung Cancer Screening Reminder,COMPLETED,NA,396.0,2019-07-16,2019-12-16,78.78588235294117,Excellent (>50/month),200.0,Exceeded (≥100%),100,91.7,93.72500000000001
NCT03447158,Effects of Hyperosmolar Dextrose in Rotator Cuff Disorder With Bursitis,COMPLETED,NA,50.0,2018-07-18,2020-01-23,2.7472924187725636,Adequate (1-10/month),27.472924187725635,Significantly Below (<50%),100,54.0,58.72500000000001
NCT05051358,Therapeutic Endoscopic Ultrasound for Gastrointestinal Disorders: A Multicenter Registry Study,UNKNOWN,,5000.0,2021-02-11,2023-12-10,147.48062015503876,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT04411758,Propolis for Patients With Chronic Kidney Disease.,COMPLETED,NA,24.0,2021-01-12,2023-12-31,0.6745706371191136,Slow (<1/month),6.745706371191136,Significantly Below (<50%),100,46.9,38.96
NCT01547858,Studying Blood Toxicity in Workers Exposed to Formaldehyde,COMPLETED,,708.0,2012-02-09,2020-11-12,6.736955298530791,Adequate (1-10/month),67.3695529853079,Below (50-75%),100,88.3,92.705
NCT00315458,Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension.,TERMINATED,PHASE3,107.0,2003-12-01,2005-03-01,7.1427192982456145,Adequate (1-10/month),71.42719298245615,Below (50-75%),10,31.6,10.905
NCT05042258,"Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis",RECRUITING,PHASE4,40.0,2024-08-12,2025-12-01,2.557983193277311,Adequate (1-10/month),25.57983193277311,Significantly Below (<50%),60,41.2,23.425
NCT06789458,Assessment of Pro-Resolution Mediator Levels in Periodontitis Stage III and IV Before and After Periodontal Therapy,RECRUITING,NA,22.0,2022-10-15,2025-10-14,0.6115799086757991,Slow (<1/month),6.115799086757992,Significantly Below (<50%),60,34.8,15.040000000000001
NCT03475758,Goserelin for Ovarian Protection in Premenopausal Patients Receiving Cyclophosphamide,UNKNOWN,PHASE2,100.0,2018-03-01,2020-03-01,4.164158686730507,Adequate (1-10/month),41.641586867305065,Significantly Below (<50%),50,43.0,26.465
NCT05247658,Use of a Disk of Amniotic Membrane (Visio-AMTRIX) in Postoperative Care After PKR,TERMINATED,PHASE3,9.0,2022-01-25,2022-07-21,1.5477966101694915,Adequate (1-10/month),15.477966101694914,Significantly Below (<50%),10,18.7,4.455
NCT05581758,A Study to Assess the Effect of Food on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants,COMPLETED,PHASE1,14.0,2019-11-14,2019-12-09,14.0,Good (10-50/month),140.0,Exceeded (≥100%),100,56.1,63.99
NCT02425358,Timing for Bone Marrow Mononuclear Cells After Acute Myocardial Infarction,COMPLETED,PHASE2,104.0,2005-02-01,2006-08-01,5.798095238095239,Adequate (1-10/month),57.98095238095239,Below (50-75%),100,58.3,68.99499999999999
NCT02470858,Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects,COMPLETED,PHASE2,18.0,2015-01-01,2015-12-01,1.6404790419161677,Adequate (1-10/month),16.404790419161674,Significantly Below (<50%),100,46.4,36.26
NCT01823458,Behavioral Economics Incentives for Health Management,COMPLETED,NA,152.0,2012-04-01,2014-08-01,5.430610328638498,Adequate (1-10/month),54.306103286384975,Below (50-75%),100,62.2,74.74499999999999
NCT04766658,A Study to Evaluate Effects of Gargle Phonation in Voice,COMPLETED,NA,36.0,2021-01-29,2021-04-15,14.418947368421053,Good (10-50/month),144.18947368421053,Exceeded (≥100%),100,57.9,67.83
NCT00159458,Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer,TERMINATED,PHASE2,7.0,2003-07-01,2006-12-01,0.17060048038430745,Slow (<1/month),1.7060048038430746,Significantly Below (<50%),10,18.6,4.25
NCT02362958,A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer,COMPLETED,PHASE2,159.0,2015-01-09,2020-05-31,2.458080243778568,Adequate (1-10/month),24.580802437785675,Significantly Below (<50%),100,62.7,75.42
NCT03578458,Novel Mobile Application to Assess Dietary Information,COMPLETED,NA,132.0,2018-05-31,2018-11-27,22.322666666666667,Good (10-50/month),200.0,Exceeded (≥100%),100,65.6,78.56
NCT03020758,Effect of Dried Fruit on Cardiometabolic Risk Factors,COMPLETED,NA,55.0,2017-02-01,2018-11-30,2.5100449775112446,Adequate (1-10/month),25.100449775112445,Significantly Below (<50%),100,54.4,59.89
NCT00013858,Environmental Contaminants and Infant Development,COMPLETED,,280.0,1997-01-01,2011-08-01,1.600600938967136,Adequate (1-10/month),16.006009389671362,Significantly Below (<50%),100,65.7,78.66499999999999
NCT02188758,Biomarkers of Iron Homeostasis and Responses to Cystic Fibrosis Pulmonary Exacerbation (CFPE) Treatment,COMPLETED,,20.0,2014-07-01,2018-01-01,0.475625,Slow (<1/month),4.75625,Significantly Below (<50%),100,44.9,30.025000000000002
NCT05077358,Intracorporeal Versus Extracorporeal Anastomosis In Laparoscopic Right Colon Resection,UNKNOWN,NA,241.0,2021-04-05,2024-10-01,5.753756862745099,Adequate (1-10/month),57.53756862745099,Below (50-75%),50,54.3,59.62
NCT02580448,CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448),COMPLETED,PHASE1,175.0,2015-08-01,2019-01-01,4.265012009607687,Adequate (1-10/month),42.65012009607687,Significantly Below (<50%),100,64.0,77.025
NCT03812848,Clinical Pharmacist-led Inpatient Anticoagulation Stewardship Program,COMPLETED,NA,233.0,2018-01-01,2022-06-05,4.3889356435643565,Adequate (1-10/month),43.88935643564357,Significantly Below (<50%),100,68.6,81.04
NCT05799248,Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management,RECRUITING,PHASE3,113.0,2023-04-27,2024-05-28,8.66428211586902,Adequate (1-10/month),86.64282115869017,Met (75-100%),60,52.0,52.86
NCT05963048,Rituxmab Versus IL-6 in Treating ILD,COMPLETED,PHASE2,60.0,2021-12-01,2023-06-01,3.3389396709323584,Adequate (1-10/month),33.389396709323584,Significantly Below (<50%),100,54.8,61.095
NCT05203848,Community Dance Program (CDP) for Older Adults,COMPLETED,NA,54.0,2021-09-09,2022-12-31,3.4388284518828454,Adequate (1-10/month),34.388284518828456,Significantly Below (<50%),100,54.3,59.62
NCT03520348,Safety and Tolerability of the Ophthalmic Gel PRO-167 Versus Corneregel® on Healthy Subjects.,COMPLETED,PHASE1,24.0,2017-10-04,2018-07-16,2.563368421052632,Adequate (1-10/month),25.63368421052632,Significantly Below (<50%),100,51.9,52.55499999999999
NCT04273048,The MOM TO BE Study,TERMINATED,NA,14.0,2020-07-21,2022-06-21,0.6088,Slow (<1/month),6.088,Significantly Below (<50%),10,19.1,4.9799999999999995
NCT07104448,Standardized Perioperative Care Protocol for Lumbar Fusion Surgery,COMPLETED,NA,382.0,2018-01-01,2025-05-01,4.343698169592828,Adequate (1-10/month),43.43698169592828,Significantly Below (<50%),100,80.6,88.14999999999999
NCT02017548,Default Options in Advance Directives,COMPLETED,NA,270.0,2014-01-01,2016-11-01,7.940869565217391,Adequate (1-10/month),79.4086956521739,Met (75-100%),100,71.6,82.755
NCT00838448,Interactions Between Physical Activity and Cannabis Use in Adults,COMPLETED,NA,30.0,2009-01-01,2013-06-01,0.566501240694789,Slow (<1/month),5.66501240694789,Significantly Below (<50%),100,47.4,40.98
NCT04301648,"Impact in Quality of Care of the ""STructural heARt NURSE"" as New Interventional Cardiology Nursing Role in Spain.",UNKNOWN,NA,86.0,2021-11-01,2022-07-01,10.817520661157026,Good (10-50/month),108.17520661157025,Exceeded (≥100%),50,46.9,38.96
NCT04539548,A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract,COMPLETED,PHASE3,65.0,2020-09-04,2023-12-21,1.6447215295095594,Adequate (1-10/month),16.447215295095596,Significantly Below (<50%),100,50.2,48.04
NCT03121248,Outcome of 15 Versus 5 Fractions in Adjuvant Breast Radiotherapy in Women Over 65 Years,ACTIVE_NOT_RECRUITING,NA,144.0,2017-02-15,2026-11-15,1.2312808988764046,Adequate (1-10/month),12.312808988764045,Significantly Below (<50%),85,52.0,52.86
NCT05908448,The True Vie I3 Continuous Glucose Monitoring System in Pediatric Patients With Type 1 Diabetes Mellitus,COMPLETED,,134.0,2024-02-07,2024-11-13,14.567714285714285,Good (10-50/month),145.67714285714285,Exceeded (≥100%),100,64.1,77.12
NCT05085548,ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies,ACTIVE_NOT_RECRUITING,PHASE1,58.0,2021-10-29,2026-01-01,1.1577180327868852,Adequate (1-10/month),11.577180327868852,Significantly Below (<50%),85,45.1,30.605
NCT00276848,Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia,COMPLETED,PHASE3,375.0,1999-07-01,2007-07-01,3.906570841889117,Adequate (1-10/month),39.06570841889117,Significantly Below (<50%),100,80.0,87.67
NCT05142748,Study of Pulmonary Infections (Pneumonia) in Kidney Transplant Recipients Admitted to Hospital,COMPLETED,,132.0,2019-09-01,2020-11-30,8.811578947368421,Adequate (1-10/month),88.11578947368422,Met (75-100%),100,63.9,76.9
NCT05448248,Multicenter Registry Study Of Cerebral Venous Thrombosis In China (RETAIN-CH),COMPLETED,,3276.0,2022-08-20,2023-12-20,204.76681724845997,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT03106948,Delivery of Inhibitors of Lysyl Oxidase (LysoLox) on Serial Angioplasty and Time to Restenosis,UNKNOWN,PHASE2,30.0,2017-02-01,2018-03-01,2.323664122137405,Adequate (1-10/month),23.236641221374047,Significantly Below (<50%),50,37.4,18.62
NCT02789748,"PErsonalized and Adaptive Kinesthetic stImulation Therapy, Based on Cardio-respiratory Holter moNitoring, for Sleep Apnea syndrOmes",COMPLETED,NA,42.0,2016-06-01,2017-10-02,2.6198360655737702,Adequate (1-10/month),26.1983606557377,Significantly Below (<50%),100,53.4,57.35
NCT06642948,AI-based Skeleton Recognition System for Rehabilitation Exercise in Breast Cancer Survivors: A Randomized Controlled Trial,RECRUITING,NA,80.0,2024-10-20,2025-01-01,33.35890410958904,Good (10-50/month),200.0,Exceeded (≥100%),60,49.4,46.42
NCT03382548,Defining Antibiotic Treatment Duration for Ventilator - Associated Lung Infection,COMPLETED,PHASE3,460.0,2018-02-21,2023-03-22,7.548463611859838,Adequate (1-10/month),75.48463611859839,Met (75-100%),100,86.8,92.06
NCT03308448,Traumatic Optic Neuropathy Treatment Trial 2,COMPLETED,PHASE3,93.0,2018-01-06,2023-03-02,1.5050079744816587,Adequate (1-10/month),15.050079744816589,Significantly Below (<50%),100,52.4,53.949999999999996
NCT03294148,Mind-body Treatments for Chronic Back Pain,COMPLETED,NA,151.0,2017-08-07,2019-11-26,5.465445897740785,Adequate (1-10/month),54.65445897740784,Below (50-75%),100,62.1,74.595
NCT00902148,Evaluation of Bioresorbable Sheet to Prevent Intra-Abdominal Adhesions in Colorectal Surgeries,COMPLETED,PHASE4,19.0,2003-12-01,2007-03-01,0.48765598650927494,Slow (<1/month),4.876559865092749,Significantly Below (<50%),100,46.5,36.815
NCT05710055,The Efficacy on Overweight With Oral Supplemenation of Probiotics and Prebiotics,COMPLETED,NA,200.0,2023-02-06,2023-04-30,73.34939759036145,Excellent (>50/month),200.0,Exceeded (≥100%),100,76.0,84.92
NCT01672255,Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM),COMPLETED,EARLY_PHASE1,64.0,2012-10-01,2025-05-01,0.4239738846572361,Slow (<1/month),4.2397388465723616,Significantly Below (<50%),100,50.1,47.89
NCT02155855,Telemedicine for Adolescents With Insulin-dependent Diabetes,COMPLETED,NA,40.0,2014-12-01,2016-12-01,1.6656634746922026,Adequate (1-10/month),16.656634746922023,Significantly Below (<50%),100,48.2,43.665
NCT00630955,Family History Study of Alcohol Consumption Using Memantine,COMPLETED,PHASE2,111.0,2006-06-01,2011-08-01,1.7905882352941176,Adequate (1-10/month),17.905882352941177,Significantly Below (<50%),100,58.9,70.10499999999999
NCT04033055,Antalgic Efficacy of CycloMesh™ Soaked in Ropivacaine Hydrochloride in Uncomplicated Inguinal Hernia.,COMPLETED,NA,304.0,2019-10-31,2024-03-12,5.805370138017566,Adequate (1-10/month),58.05370138017566,Below (50-75%),100,74.3,84.205
NCT04465955,A Study of NGM621 in Participants With Geographic Atrophy,COMPLETED,PHASE2,320.0,2020-07-22,2022-08-16,12.901721854304636,Good (10-50/month),129.01721854304634,Exceeded (≥100%),100,80.6,88.14999999999999
NCT01889355,User Study for Enhanced Meter Feature,COMPLETED,NA,121.0,2014-01-01,2014-03-01,62.427796610169494,Excellent (>50/month),200.0,Exceeded (≥100%),100,69.7,81.73
NCT07218055,Assessment of Music Experiences in Navigating Depression Part 2,RECRUITING,NA,20.0,2025-09-08,2026-08-04,1.844848484848485,Adequate (1-10/month),18.448484848484846,Significantly Below (<50%),60,39.6,21.115000000000002
NCT04670055,A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma,NOT_YET_RECRUITING,EARLY_PHASE1,50.0,2021-01-01,2027-01-01,0.6946599726152443,Slow (<1/month),6.946599726152443,Significantly Below (<50%),30,28.0,8.38
NCT05333055,Aqueous Biomarker Levels in Diabetic Retinopathy and Diabetic Macular Edema,TERMINATED,,107.0,2022-02-10,2024-05-15,3.9479757575757577,Adequate (1-10/month),39.479757575757574,Significantly Below (<50%),10,29.9,9.07
NCT02046655,Corifollitropin Alfa Compared to Daily rFSH in Poor Responders Undergoing ICSI,COMPLETED,PHASE4,80.0,2011-01-01,,,Slow (<1/month),,Significantly Below (<50%),100,46.4,36.26
NCT05646355,Flatbush FHC Proactive Colorectal Cancer Screening and Navigation,COMPLETED,NA,109.0,2023-03-15,2023-12-11,12.24339483394834,Good (10-50/month),122.43394833948341,Exceeded (≥100%),100,63.7,76.655
NCT04074655,Investigating the Effect of Training With a Virtual Reality Driving Simulator,COMPLETED,NA,12.0,2019-09-10,2020-03-01,2.1114450867052024,Adequate (1-10/month),21.114450867052025,Significantly Below (<50%),100,51.0,49.714999999999996
NCT00962455,Feedback Reports and e-Learning in Primary Care Spirometry,COMPLETED,PHASE4,1135.0,2007-11-01,2009-04-01,66.8266924564797,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT05117255,Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity,RECRUITING,NA,256.0,2022-01-04,2027-03-01,4.140616365568544,Adequate (1-10/month),41.40616365568545,Significantly Below (<50%),60,58.5,69.34
NCT05322655,PAthogen Transmission and Health Outcome Models of Enteric Disease,COMPLETED,,286.0,2021-11-15,2024-03-13,10.254228504122498,Good (10-50/month),102.54228504122497,Exceeded (≥100%),100,76.2,84.965
NCT06462755,Perioperative Database of Chinese Elderly Patients for Postoperative Acute Kidney Injury,COMPLETED,,57089.0,2009-01-01,2018-12-31,475.97621473568887,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT00389155,First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy,COMPLETED,PHASE2,34.0,2007-01-01,2008-01-01,2.8355068493150686,Adequate (1-10/month),28.355068493150686,Significantly Below (<50%),100,52.7,55.04
NCT02332226,The PIFBO-study: Person-centred Information to Parents in Paediatric Oncology,COMPLETED,NA,32.0,2015-01-01,2020-01-01,0.5334501642935378,Slow (<1/month),5.334501642935378,Significantly Below (<50%),100,47.6,41.775
NCT01522326,Comparison of Metoclopramide and Ibuprofen for the Treatment of Acute Mountain Sickness,COMPLETED,NA,300.0,2012-03-01,2017-03-30,4.922911051212938,Adequate (1-10/month),49.22911051212939,Significantly Below (<50%),100,74.0,83.985
NCT02367326,Identification of Scores Associated With a Favorable Clinical Response With Thiopurines in IBD Patients,COMPLETED,,400.0,2014-06-01,2017-08-01,10.523768366464996,Good (10-50/month),105.23768366464996,Exceeded (≥100%),100,85.3,91.355
NCT04728126,Menopausal Symptoms and Burnout: Comparison of Occupational Health Issue Among Health Professionals in UMC Hospitals,UNKNOWN,,320.0,2021-09-01,2024-08-01,9.146291079812206,Adequate (1-10/month),91.46291079812208,Met (75-100%),50,63.9,76.9
NCT04630626,Post-Approval Study Protocol for the Simplify Cervical Artificial Disc,COMPLETED,NA,145.0,2021-01-01,2023-04-23,5.242042755344418,Adequate (1-10/month),52.42042755344417,Below (50-75%),100,61.6,74.0
NCT04851626,Hypnotic Intervention for Women With Chronic Pelvic Pain,COMPLETED,NA,14.0,2020-11-02,2020-12-21,8.697142857142858,Adequate (1-10/month),86.97142857142858,Met (75-100%),100,56.1,63.99
NCT04270526,Minimizing Pain During Office Intradetrussor Botox Injection,COMPLETED,PHASE4,85.0,2020-08-15,2023-06-30,2.4665395614871306,Adequate (1-10/month),24.665395614871308,Significantly Below (<50%),100,56.8,65.69500000000001
NCT03897426,Image Based Mobile System for Dietary Assessment and Coaching,COMPLETED,NA,100.0,2016-03-04,2017-08-31,5.585321100917432,Adequate (1-10/month),55.853211009174316,Below (50-75%),100,58.0,68.245
NCT05404126,Balance and Gait in Hearing Impaired Children,UNKNOWN,NA,40.0,2022-05-01,2023-01-30,4.443795620437956,Adequate (1-10/month),44.43795620437956,Significantly Below (<50%),50,38.2,19.645000000000003
NCT06731426,"Multi-session, Personalized Cognitive Bias Modification for Thought-Action-Fusion",RECRUITING,NA,84.0,2024-04-18,2026-05-31,3.3078395860284604,Adequate (1-10/month),33.0783958602846,Significantly Below (<50%),60,44.7,29.67
NCT05712226,Sleepiz One+ Versus Capnography and Electrocardiography,COMPLETED,NA,36.0,2023-02-22,2023-04-06,25.484651162790698,Good (10-50/month),200.0,Exceeded (≥100%),100,57.9,67.83
NCT02442726,Activation of A-delta-fibres and C-fibres in a First Degree Thermal Injury in Volunteers,COMPLETED,NA,18.0,2015-05-01,2015-11-01,2.977826086956522,Adequate (1-10/month),29.77826086956522,Significantly Below (<50%),100,51.4,50.92
NCT05044026,"A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis",COMPLETED,,1012.0,2012-09-20,2022-09-19,8.437491098329225,Adequate (1-10/month),84.37491098329224,Met (75-100%),100,93.3,94.325
NCT02493426,Single Dose Intranasal Oxytocin and Cognitive Effects in Autism,COMPLETED,PHASE2,27.0,2014-05-01,2021-03-31,0.3253681710213777,Slow (<1/month),3.2536817102137774,Significantly Below (<50%),100,47.2,40.035
NCT02775526,"TOT, TVT And Burch Colpo-Suspension for Treatment of Female Mixed Urinary Incontinence",COMPLETED,NA,220.0,2016-05-01,2020-01-10,4.964269829503336,Adequate (1-10/month),49.64269829503336,Significantly Below (<50%),100,67.6,80.15
NCT04927026,"""Where-there-is-no-psychiatrist Integrated Personal Therapy"" Among Community-Dwelling Older Adults",COMPLETED,NA,21.0,2019-09-01,2020-03-31,3.0152830188679247,Adequate (1-10/month),30.152830188679246,Significantly Below (<50%),100,51.7,51.94
NCT02158026,Evaluation of the Role of Follicular Sensitivity Index in the Prediction of Pregnancy in Women Undergoing ICSI/IVF Without Polycystic Ovarian Syndrome,UNKNOWN,,1000.0,2014-06-01,,,Slow (<1/month),,Significantly Below (<50%),50,63.3,76.235
NCT03537326,Study to Detect Oral Administration of Budesonide in Women.,COMPLETED,PHASE1,4.0,2018-05-22,2018-09-10,1.096936936936937,Adequate (1-10/month),10.96936936936937,Significantly Below (<50%),100,45.3,31.169999999999998
NCT03326726,Evaluation 2% Chlorhexidine Gluconate,COMPLETED,PHASE2,30.0,2016-11-16,2016-11-18,30.0,Good (10-50/month),200.0,Exceeded (≥100%),100,62.4,75.095
NCT03316326,"S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer",UNKNOWN,PHASE2,35.0,2017-11-01,2021-12-31,0.7004602235371467,Slow (<1/month),7.0046022353714665,Significantly Below (<50%),50,32.8,12.425
NCT02919826,Dialectical Behaviour Group Therapy for Adults With Intellectual Disabilities,COMPLETED,NA,20.0,2016-08-01,2018-03-01,1.0551126516464473,Adequate (1-10/month),10.551126516464473,Significantly Below (<50%),100,46.6,37.375
NCT00226226,Peripherally Inserted Central Catheter Placement by IV Team Nurses Using the Sonic Flashlight,COMPLETED,PHASE1,230.0,2006-06-01,2007-06-01,19.1813698630137,Good (10-50/month),191.813698630137,Exceeded (≥100%),100,73.4,83.7
NCT04162626,New Families- Innovation and Development of the Child Health Services in Oslo,COMPLETED,NA,428.0,2018-10-08,2021-10-01,11.963562901744721,Good (10-50/month),119.6356290174472,Exceeded (≥100%),100,89.2,92.985
NCT03225326,Effects of Articaine Computer-controlled and Conventional Delivery for Anterior and Middle Superior Alveolar Nerve Block for Tooth Extraction,WITHDRAWN,PHASE4,0.0,2016-12-01,2017-07-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT01952626,Prevention of Intrathecal Morphine Induced Pruritus: Comparison of Ondansetron and Palonosetron,COMPLETED,NA,80.0,2013-04-01,2014-06-01,5.716431924882629,Adequate (1-10/month),57.16431924882629,Below (50-75%),100,56.4,64.88000000000001
NCT00890526,Intervention for Reduced Sound Tolerance,COMPLETED,PHASE1,36.0,2002-07-01,2010-09-01,0.36723860589812335,Slow (<1/month),3.6723860589812336,Significantly Below (<50%),100,47.9,42.64
NCT05720026,Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer,RECRUITING,PHASE3,560.0,2023-01-09,2026-02-21,14.966110623353819,Good (10-50/month),149.66110623353822,Exceeded (≥100%),60,83.0,89.505
NCT04524026,RIOTC: Reducing the Impact of Ovarian Stimulation. Novel Approaches to Luteal Support in IVF-Study 2,COMPLETED,PHASE2,25.0,2018-09-18,2020-11-30,0.9465174129353234,Slow (<1/month),9.465174129353233,Significantly Below (<50%),100,47.0,39.33
NCT03502226,Evaluation of an Inpatient Sexual Risk Behavior Assessment Program,COMPLETED,NA,66.0,2017-01-04,2017-10-29,6.741744966442953,Adequate (1-10/month),67.41744966442953,Below (50-75%),100,55.3,62.36000000000001
NCT04404426,CACOLAC : Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome,COMPLETED,NA,33.0,2020-11-04,2021-05-28,4.90009756097561,Adequate (1-10/month),49.0009756097561,Significantly Below (<50%),100,52.6,54.684999999999995
NCT03233126,A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia,COMPLETED,PHASE3,16.0,2017-07-06,2020-02-17,0.5094560669456067,Slow (<1/month),5.094560669456067,Significantly Below (<50%),100,46.3,35.66
NCT03368378,Early DVC Ligation and Urinary Continence Recovery After RARP,COMPLETED,NA,312.0,2017-11-28,2020-02-10,11.812537313432836,Good (10-50/month),118.12537313432836,Exceeded (≥100%),100,80.0,87.67
NCT02951078,A Study of Comparing Effects of Thulium Laser en Bloc Resection and Electrical Transurethral Resection of the Non-muscle Invasive Bladder Cancer,UNKNOWN,PHASE3,172.0,2017-01-01,,,Slow (<1/month),,Significantly Below (<50%),50,38.8,20.244999999999997
NCT06184178,Implementing the Transcultural Social-Ethical-Care Model -TEC-MED for Older People in the Mediterranean Basin,COMPLETED,NA,20000.0,2023-12-01,2024-01-31,9980.327868852459,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT05519878,Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers,RECRUITING,NA,224.0,2022-11-29,2027-05-25,4.162735042735043,Adequate (1-10/month),41.62735042735043,Significantly Below (<50%),60,55.9,63.42
NCT02346578,Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.,COMPLETED,PHASE2,104.0,2014-12-01,2019-01-22,2.092372769332452,Adequate (1-10/month),20.923727693324523,Significantly Below (<50%),100,58.3,68.99499999999999
NCT02542878,Effect of Myofascial Release by Foam Rolling on Back Muscles Endurance,UNKNOWN,NA,150.0,2015-10-01,2016-02-01,37.12195121951219,Good (10-50/month),200.0,Exceeded (≥100%),50,52.0,52.86
NCT06505278,The Impact of Medication Timing Adjustment on the Effect of Novel Hormonal Therapy,NOT_YET_RECRUITING,PHASE2,70.0,2024-08-01,2025-12-01,4.375359342915811,Adequate (1-10/month),43.753593429158116,Significantly Below (<50%),30,34.6,14.729999999999999
NCT02555878,A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants,COMPLETED,PHASE3,841.0,2015-09-11,2018-08-24,23.747717996289424,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT05254678,Exercise Rehabilitation Via a Mobile Application for Individuals With Breast Cancer Undergoing Chemotherapy,COMPLETED,NA,32.0,2023-09-20,2024-12-30,2.0858244111349036,Adequate (1-10/month),20.858244111349038,Significantly Below (<50%),100,52.6,54.684999999999995
NCT06810778,Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL),RECRUITING,PHASE1,12.0,2025-05-02,2031-06-01,0.16446645655110312,Slow (<1/month),1.644664565511031,Significantly Below (<50%),60,34.0,14.02
NCT02150278,Effectiveness of an Intervention to Reduce Driving Under the Influence of Alcohol Among Drivers,UNKNOWN,NA,120.0,2012-04-01,2014-09-01,4.136806342015856,Adequate (1-10/month),41.36806342015855,Significantly Below (<50%),50,44.6,29.42
NCT02948478,Economic and Social Disparities and Breast Cancer,COMPLETED,,936.0,2016-12-01,2021-02-23,18.441320388349517,Good (10-50/month),184.41320388349516,Exceeded (≥100%),100,93.3,94.325
NCT03684278,"Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial (RAPID-I)",RECRUITING,PHASE2,290.0,2019-05-01,2027-03-31,3.053476305776548,Adequate (1-10/month),30.53476305776548,Significantly Below (<50%),60,61.2,73.43499999999999
NCT06376578,Exercise Interventions for Improving Health in Breast Cancer Survivors,COMPLETED,NA,30.0,2018-09-05,2020-01-30,1.7835937499999999,Adequate (1-10/month),17.8359375,Significantly Below (<50%),100,52.4,53.949999999999996
NCT03428178,Efficacy Study of Gene Therapy for The Treatment of Acute LHON Onset Within Three Months,UNKNOWN,NA,120.0,2018-01-08,2020-12-30,3.360441582336707,Adequate (1-10/month),33.60441582336707,Significantly Below (<50%),50,44.6,29.42
NCT04592978,Personalized Feedback Intervention for Alcohol and Opioid Use Among Adults With Chronic Pain,COMPLETED,NA,206.0,2021-07-30,2025-04-30,4.577109489051095,Adequate (1-10/month),45.771094890510945,Significantly Below (<50%),100,66.5,79.405
NCT05187078,Allis Clamp Versus Single-tooth Tenaculum,COMPLETED,NA,95.0,2017-03-01,2018-03-01,7.922739726027398,Adequate (1-10/month),79.22739726027397,Met (75-100%),100,57.6,67.36999999999999
NCT04591678,Adults With SMA Treated With Nusinersen,COMPLETED,,15.0,2018-10-01,2021-06-25,0.45751503006012023,Slow (<1/month),4.575150300601202,Significantly Below (<50%),100,44.5,29.160000000000004
NCT07179978,Lorazepam and the Risk of Serious Adverse Events,COMPLETED,,12308.0,2008-01-01,2024-10-01,61.23823471722785,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02081378,A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL,COMPLETED,PHASE1,326.0,2014-04-24,2023-03-14,3.0571287738755393,Adequate (1-10/month),30.571287738755395,Significantly Below (<50%),100,76.1,84.94500000000001
NCT01894178,Study Examining Parker-Flex Endotracheal Tube for Obese Patients,COMPLETED,NA,60.0,2013-07-01,2016-10-01,1.5373737373737375,Adequate (1-10/month),15.373737373737374,Significantly Below (<50%),100,49.8,47.17
NCT04923178,A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies,RECRUITING,,1100.0,2022-10-24,2042-12-01,4.559989105270326,Adequate (1-10/month),45.599891052703256,Significantly Below (<50%),60,76.3,85.1
NCT02971878,Comparisons of Human Embryonic Development Using Single Medium With and Without the Addition of Antioxidants,COMPLETED,NA,128.0,2016-11-01,2018-02-01,8.52586433260394,Adequate (1-10/month),85.25864332603939,Met (75-100%),100,65.2,78.23
NCT02904278,Novel Mobile Device Application to Improve Adherence,COMPLETED,NA,26.0,2017-08-10,2019-11-01,0.973480934809348,Slow (<1/month),9.734809348093481,Significantly Below (<50%),100,47.1,39.64
NCT02592278,Prevention of Dental Caries Lesions With Fluoride Varnish in Erupting First Permanent Molars,COMPLETED,PHASE4,180.0,2015-03-01,2016-03-01,14.970491803278689,Good (10-50/month),149.70491803278688,Exceeded (≥100%),100,69.4,81.52000000000001
NCT06904378,Ontegimod and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma,NOT_YET_RECRUITING,PHASE1,61.0,2026-01-30,2029-07-31,1.4529264475743349,Adequate (1-10/month),14.52926447574335,Significantly Below (<50%),30,28.9,8.709999999999999
NCT00406978,"Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients",COMPLETED,PHASE1,24.0,2006-02-01,2014-04-01,0.2450721234485072,Slow (<1/month),2.450721234485072,Significantly Below (<50%),100,46.9,38.96
NCT02236078,Brief Bactericidal Activity of Anti-Tuberculosis Drugs,COMPLETED,PHASE1,18.0,2015-11-01,2020-09-30,0.3052479108635098,Slow (<1/month),3.0524791086350977,Significantly Below (<50%),100,46.4,36.26
NCT02784678,Minimally Invasive Closed Reduction and Internal Fixation With Screws for Distal Radius Fracture,UNKNOWN,NA,60.0,2016-06-01,2018-06-01,2.5019178082191784,Adequate (1-10/month),25.019178082191786,Significantly Below (<50%),50,39.8,21.47
NCT00364078,"Transitoriness in Cancer Patients, Psychosocial Issues in Cancer Care",COMPLETED,,193.0,2006-06-01,2007-08-01,13.790892018779344,Good (10-50/month),137.90892018779343,Exceeded (≥100%),100,68.8,81.105
NCT04251078,Monitoring Mutational Burden in Low Risk MDS Patients Using Sequential Peripheral Blood Samples,RECRUITING,,200.0,2019-01-01,2025-06-30,2.5666104553119733,Adequate (1-10/month),25.666104553119734,Significantly Below (<50%),60,52.3,53.515
NCT01331278,A Comparative Study of Knee Systems,COMPLETED,PHASE4,60.0,2009-09-01,2011-03-01,3.345054945054945,Adequate (1-10/month),33.45054945054945,Significantly Below (<50%),100,54.8,61.095
NCT05796778,Sub Omohyoid Suprascapular Nerve Block Versus Interscalene Nerve Block,UNKNOWN,NA,72.0,2023-04-01,2023-12-01,8.982295081967212,Adequate (1-10/month),89.82295081967212,Met (75-100%),50,45.8,33.03
NCT06961578,SCORE Study: Comparing Surgery and Rigid Collar Treatment for Odontoid Fractures in Adults Over 70,NOT_YET_RECRUITING,NA,322.0,2025-06-01,2028-06-01,8.943138686131388,Adequate (1-10/month),89.43138686131387,Met (75-100%),30,59.8,71.61
NCT06684678,Individualized Automatic Coaching Message for Glycemic Management and Depressive Symptom,NOT_YET_RECRUITING,NA,140.0,2024-11-13,2025-04-30,25.366666666666667,Good (10-50/month),200.0,Exceeded (≥100%),30,45.2,30.830000000000002
NCT04176185,"A Research Study in Chinese People With Allergy to House Dust Mites, Using an Environmental Exposure Chamber",TERMINATED,PHASE3,80.0,2019-11-04,2022-01-19,3.017596034696407,Adequate (1-10/month),30.17596034696407,Significantly Below (<50%),10,29.4,8.84
NCT02517385,Essentiale® Paste in Patients With Gastrointestinal Symptoms in Acute or Chronic Liver Diseases,COMPLETED,PHASE3,147.0,2015-08-01,2016-06-01,14.671081967213116,Good (10-50/month),146.71081967213118,Exceeded (≥100%),100,66.8,79.55
NCT07357285,Safety and Efficacy Evaluation of the iNstroke 4F Thromboaspiration Catheter in Patients With Acute Ischaemic Stroke Due to Primary Distal Medium Vessel Occlusions (DMVO),RECRUITING,NA,57.0,2025-11-27,2026-08-31,6.263826714801445,Adequate (1-10/month),62.63826714801445,Below (50-75%),60,42.6,25.679999999999996
NCT02305485,NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial,UNKNOWN,NA,560.0,2014-11-01,2020-06-01,8.360176557135851,Adequate (1-10/month),83.6017655713585,Met (75-100%),50,80.0,87.67
NCT00068185,A Study of the Pharmacokinetics of Black Cohosh,TERMINATED,PHASE1,12.0,2003-08-01,2008-07-01,0.20338530066815144,Slow (<1/month),2.0338530066815146,Significantly Below (<50%),10,19.0,4.84
NCT01862185,The Effect of Semi-quantitative Procalcitonin Assay to The Adequacy of Empirical Antibiotics and Mortality in Septic Patients,COMPLETED,PHASE3,205.0,2012-12-01,2013-04-01,51.57190082644628,Excellent (>50/month),200.0,Exceeded (≥100%),100,76.4,85.25
NCT00003585,Biological Therapy Plus Chemotherapy in Treating Patients With Metastatic or Recurrent Kidney Cancer,COMPLETED,PHASE1,35.0,1996-08-01,2002-08-01,0.486261980830671,Slow (<1/month),4.86261980830671,Significantly Below (<50%),100,47.8,42.42
NCT02941185,Multi-dose Vitamin D Supplementation in Preterm Infants,COMPLETED,PHASE4,121.0,2014-01-01,2016-12-01,3.458441314553991,Adequate (1-10/month),34.58441314553991,Significantly Below (<50%),100,59.7,71.355
NCT01586585,Back to Functional Life Following Cardiac Surgery,WITHDRAWN,,0.0,2012-05-01,2013-09-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT05828485,Effect of Food on Pharmacokinetics of MY008211A Tablets in Healthy Adult Subjects,COMPLETED,PHASE1,12.0,2022-09-26,2022-10-23,12.0,Good (10-50/month),120.0,Exceeded (≥100%),100,56.0,63.71
NCT04298385,Traction Orthosis for Oblique Proximal Phalangeal Fractures,UNKNOWN,,10.0,2020-03-01,2020-08-01,1.9895424836601308,Adequate (1-10/month),19.895424836601308,Significantly Below (<50%),50,34.1,14.19
NCT06055985,"A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease",COMPLETED,PHASE2,207.0,2023-11-17,2025-04-11,12.330880626223092,Good (10-50/month),123.30880626223093,Exceeded (≥100%),100,71.6,82.755
NCT02868385,Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST),COMPLETED,PHASE3,167.0,2018-10-01,2019-01-14,48.41409523809524,Good (10-50/month),200.0,Exceeded (≥100%),100,73.4,83.7
NCT05998785,Embody Insertional Achilles Tendinopathy,TERMINATED,,8.0,2022-08-02,2024-08-01,0.33358904109589044,Slow (<1/month),3.3358904109589047,Significantly Below (<50%),10,17.0,2.75
NCT01742585,A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis,COMPLETED,PHASE3,163.0,2012-10-01,2014-05-01,8.599168110918546,Adequate (1-10/month),85.99168110918546,Met (75-100%),100,68.0,80.56
NCT03021785,A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular Degeneration,UNKNOWN,PHASE1,36.0,2017-10-18,2018-11-01,2.8913984168865436,Adequate (1-10/month),28.913984168865444,Significantly Below (<50%),50,37.9,19.139999999999997
NCT06821685,Autologous Decidual-like Natural Killer Cells Therapy for Infertility or Adverse Pregnancy History,RECRUITING,PHASE1,14.0,2025-02-13,2027-12-01,0.4173947110675808,Slow (<1/month),4.173947110675808,Significantly Below (<50%),60,34.1,14.19
NCT01951443,Korean Red Ginseng Rg3 Extract on Arterial Stiffness and Blood Pressure,COMPLETED,PHASE1,24.0,2013-08-01,,,Slow (<1/month),,Significantly Below (<50%),100,41.9,24.585
NCT01367743,Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock,COMPLETED,PHASE4,58.0,2011-09-01,2016-08-01,0.9830289532293986,Slow (<1/month),9.830289532293987,Significantly Below (<50%),100,49.6,46.785
NCT01068743,Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered,COMPLETED,PHASE1,24.0,2010-02-01,2010-03-01,24.0,Good (10-50/month),200.0,Exceeded (≥100%),100,56.9,65.89500000000001
NCT04622943,"An Interactive Web Platform to Teach Children Hunting, Shooting and Firearms Safety",COMPLETED,NA,163.0,2021-12-14,2024-05-10,5.6511617312072895,Adequate (1-10/month),56.51161731207288,Below (50-75%),100,63.0,75.845
NCT05612243,Effect of Consumption of a Novel Functional Yogurt on Blood Biomarkers of Healthy Participants,UNKNOWN,NA,21.0,2022-10-17,2022-12-16,10.654,Good (10-50/month),106.53999999999999,Exceeded (≥100%),50,41.7,24.36
NCT01266343,Comparison of Anterior Chamber Paracentesis and Conventional Mannitol Infusion in Patients With Primary Acute Angle-closure Glaucoma,COMPLETED,,60.0,2007-01-01,2009-12-01,1.7149295774647888,Adequate (1-10/month),17.14929577464789,Significantly Below (<50%),100,53.1,56.105000000000004
NCT05209243,START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC,RECRUITING,NA,266.0,2023-01-26,2027-01-01,5.638607242339833,Adequate (1-10/month),56.38607242339834,Below (50-75%),60,59.3,70.815
NCT04394143,Effect of AD128 to Treat Obstructive Sleep Apnea,COMPLETED,PHASE2,15.0,2020-10-20,2021-07-19,1.6786764705882353,Adequate (1-10/month),16.786764705882355,Significantly Below (<50%),100,51.2,50.375
NCT06177743,IRIS-Coroflex NEO Cohort,RECRUITING,,1000.0,2025-01-09,2030-12-31,13.950504124656279,Good (10-50/month),139.50504124656277,Exceeded (≥100%),60,81.3,88.58
NCT04634643,Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD),RECRUITING,,260.0,2021-06-28,2026-01-30,4.7193798449612405,Adequate (1-10/month),47.19379844961241,Significantly Below (<50%),60,57.1,66.27
NCT06004843,The Effects of Remimazolam on the Incidence of Hypoxia During Sedated Hysteroscopy for Assisted Reproduction in Overweight or Obese Patients,NOT_YET_RECRUITING,NA,600.0,2023-08-01,2026-04-01,18.751540041067763,Good (10-50/month),187.51540041067764,Exceeded (≥100%),30,74.0,83.985
NCT04975243,Clinical Evaluation to Assess the Safety and Efficacy of GentleMax Pro™/GentleMax Pro Plus™,UNKNOWN,NA,20.0,2021-03-19,2023-09-30,0.6581621621621622,Slow (<1/month),6.581621621621622,Significantly Below (<50%),50,31.6,10.905
NCT03501043,Assessment of Gait After Dysport Treatment,COMPLETED,PHASE4,11.0,2018-06-11,2019-08-22,0.7662242562929061,Slow (<1/month),7.662242562929062,Significantly Below (<50%),100,45.9,33.495000000000005
NCT07021443,The Effect of GLP-1 Analogues on Liver Steatosis and Fibrosis in Diabetic and Obese Patients in a Clinical Setting,COMPLETED,,50.0,2023-10-09,2025-05-12,2.619621342512909,Adequate (1-10/month),26.196213425129088,Significantly Below (<50%),100,52.3,53.515
NCT01115543,Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism,COMPLETED,PHASE4,32.0,2008-08-01,2009-08-01,2.6687123287671235,Adequate (1-10/month),26.687123287671238,Significantly Below (<50%),100,52.6,54.684999999999995
NCT07368543,Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer,NOT_YET_RECRUITING,PHASE2,216.0,2026-01-16,2028-12-01,6.261942857142858,Adequate (1-10/month),62.61942857142857,Below (50-75%),30,46.3,35.66
NCT00968643,"Spinal Cord Compression. ICORG 05-03, V6",COMPLETED,PHASE3,126.0,2006-01-01,,,Slow (<1/month),,Significantly Below (<50%),100,50.1,47.89
NCT03481543,Effectiveness of Bronchodilator Nebulization With and Without Noninvasive Ventilation in COPD,TERMINATED,NA,11.0,2018-04-10,2020-11-12,0.3535797254487857,Slow (<1/month),3.5357972544878566,Significantly Below (<50%),10,18.9,4.6899999999999995
NCT00907543,Quality of Life in Neoadjuvant Versus Adjuvant Therapy of Esophageal Cancer Treatment Trial,COMPLETED,NA,96.0,2009-04-01,2018-12-31,0.8206234203875316,Slow (<1/month),8.206234203875315,Significantly Below (<50%),100,52.7,55.04
NCT01200043,Metabolic Impact of Fructose Restriction in Obese Children,COMPLETED,NA,54.0,2010-07-01,2014-12-01,1.0184386617100372,Adequate (1-10/month),10.184386617100373,Significantly Below (<50%),100,49.3,46.265
NCT01859143,Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults,COMPLETED,PHASE4,300.0,2013-05-01,2013-12-01,42.67289719626169,Good (10-50/month),200.0,Exceeded (≥100%),100,84.0,90.595
NCT01505543,Proprioceptive Postural Control and Chronic Obstructive Pulmonary Disease (COPD),COMPLETED,,40.0,2012-01-01,2012-09-01,4.99016393442623,Adequate (1-10/month),49.901639344262286,Significantly Below (<50%),100,51.5,51.245
NCT02683343,The Use of Ultrasound to Quantify Muscle Overlying the Carpal Tunnel,WITHDRAWN,,0.0,2016-07-01,2018-07-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT05968443,Dafilon® Suture Material in Patients Undergoing Ophthalmic Surgery,COMPLETED,,200.0,2019-01-08,2022-05-10,4.998357963875205,Adequate (1-10/month),49.98357963875205,Significantly Below (<50%),100,64.3,77.265
NCT01760343,A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor,COMPLETED,PHASE1,16.0,2013-01-01,2013-03-01,8.25491525423729,Adequate (1-10/month),82.54915254237288,Met (75-100%),100,51.3,50.62
NCT05425043,Granulocyte Transfusions After Umbilical Cord Blood Transplant,RECRUITING,NA,40.0,2021-09-14,2026-06-01,0.7074956420685649,Slow (<1/month),7.074956420685649,Significantly Below (<50%),60,36.2,16.84
NCT05819515,Treatment of Gingival Recession Defects Using Platelet-Rich Fibrin With an Allogenic Dermal Matrix,COMPLETED,NA,36.0,2023-04-29,2024-03-27,3.290810810810811,Adequate (1-10/month),32.90810810810812,Significantly Below (<50%),100,52.9,55.55
NCT06756815,Cross Bracing Protocol With And Without Dynamic Neuromuscular Stabilization Training in Athletes,COMPLETED,NA,26.0,2024-04-01,2024-09-30,4.348571428571429,Adequate (1-10/month),43.48571428571428,Significantly Below (<50%),100,52.1,53.03
NCT01747915,"A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.",COMPLETED,PHASE3,219.0,2013-04-03,2019-02-20,3.102075383899488,Adequate (1-10/month),31.02075383899488,Significantly Below (<50%),100,67.5,80.08
NCT04129515,NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis,WITHDRAWN,PHASE1,0.0,2025-10-30,2026-01-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT02700815,Capsaicin + Diclofenac Gel in Acute Back Pain or Neck Pain,COMPLETED,PHASE3,746.0,2016-05-09,2017-07-21,51.84529680365297,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT00104715,Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer,COMPLETED,PHASE3,385.0,2004-10-18,2015-12-15,2.8759263803680986,Adequate (1-10/month),28.759263803680984,Significantly Below (<50%),100,80.8,88.215
NCT06344715,"Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.",RECRUITING,PHASE1,78.0,2022-10-17,2024-10-31,3.187006711409396,Adequate (1-10/month),31.87006711409396,Significantly Below (<50%),60,44.2,28.549999999999997
NCT06515015,"Evaluation of the Feasibility, Safety, and Efficacy of Single-use Endobronchial Silicon Spigots for the Treatment of Refractory Pneumothorax",RECRUITING,NA,10.0,2024-08-01,2026-08-01,0.41698630136986303,Slow (<1/month),4.16986301369863,Significantly Below (<50%),60,33.8,13.694999999999999
NCT00087815,Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain,UNKNOWN,NA,30.0,2003-09-01,2005-06-01,1.4291079812206573,Adequate (1-10/month),14.291079812206572,Significantly Below (<50%),50,32.4,12.025
NCT06303115,CSD231005 Nicotine Pouch Biomarkers of Exposure,COMPLETED,NA,200.0,2024-08-22,2025-01-15,41.6986301369863,Good (10-50/month),200.0,Exceeded (≥100%),100,76.0,84.92
NCT04386915,Study on the Tolerance and Pharmacokinetics of GST-HG141 Tablets,UNKNOWN,PHASE1,104.0,2020-05-18,2021-08-01,7.194909090909091,Adequate (1-10/month),71.94909090909091,Below (50-75%),50,43.3,27.05
NCT06996015,"Effects of SNAGs & CBT on Pain, Craniovertebral Angle & Disability in Non Specific Neck Pain",RECRUITING,NA,32.0,2025-06-10,2025-12-10,5.322841530054645,Adequate (1-10/month),53.22841530054645,Below (50-75%),60,40.6,22.575
NCT04526015,Iliohypogastric and Ilioinguinal Nerve Block for Acute and Chronic Pain Relief After Cesarean Section.,COMPLETED,NA,64.0,2020-09-20,2021-08-01,6.184634920634921,Adequate (1-10/month),61.84634920634922,Below (50-75%),100,55.1,62.085
NCT02609815,Initial Combination of Gemigliptin and Metformin on Microbiota Change,COMPLETED,NA,70.0,2015-11-01,2021-03-15,1.0865884752677206,Adequate (1-10/month),10.865884752677207,Significantly Below (<50%),100,50.6,48.705
NCT05913115,A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer,COMPLETED,PHASE1,6.0,2017-06-12,2018-06-19,0.49096774193548387,Slow (<1/month),4.909677419354839,Significantly Below (<50%),100,45.5,31.705
NCT01472315,"Postmenopausal Women,Treatment of Sleep Apnea and Co-morbidities",COMPLETED,PHASE2,34.0,2000-01-01,2000-11-01,3.3933114754098366,Adequate (1-10/month),33.93311475409836,Significantly Below (<50%),100,52.7,55.04
NCT02638415,The Effect of Hepatic Vein Pressure Gradient(HVPG)-Guided Therapy in Cirrhotic Patients With Esophagogastric Varices,UNKNOWN,PHASE4,500.0,2015-12-01,2018-09-01,15.144278606965173,Good (10-50/month),151.44278606965173,Exceeded (≥100%),50,80.0,87.67
NCT07033715,Exercise in Hereditary ATTR (ATTRv) Amyloidosis,RECRUITING,NA,42.0,2024-10-01,2026-09-30,1.753744855967078,Adequate (1-10/month),17.537448559670782,Significantly Below (<50%),60,41.4,24.04
NCT02429115,"Peer-mentoring, Quality of Life and Caregiver Burden in Patients With Chronic Kidney Disease and Their Caregivers",COMPLETED,NA,241.0,2015-02-12,2018-06-30,5.944927066450567,Adequate (1-10/month),59.44927066450567,Below (50-75%),100,69.3,81.395
NCT06173115,Comparison of a Single Versus Double Perclose Technique for TAVR,RECRUITING,NA,876.0,2023-10-20,2026-06-28,27.154215885947046,Good (10-50/month),200.0,Exceeded (≥100%),60,83.0,89.505
NCT00414115,National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children,RECRUITING,,7000.0,2005-08-01,2029-03-01,24.739347497968186,Good (10-50/month),200.0,Exceeded (≥100%),60,81.3,88.58
NCT06091215,"Combining Broad Based Light (BBL), Fractionated 1927 (MOXI) and Dual Wavelength 2940/1470 (HALO)",COMPLETED,NA,15.0,2024-01-01,2024-12-31,1.2509589041095892,Adequate (1-10/month),12.509589041095893,Significantly Below (<50%),100,46.2,35.089999999999996
NCT00952315,Trial Comparing Three Different Devices for Kidney Stone Removal During Percutaneous Surgery,COMPLETED,NA,270.0,2009-08-01,2017-02-01,2.998467712513681,Adequate (1-10/month),29.98467712513681,Significantly Below (<50%),100,71.6,82.755
NCT01079715,Safety and Efficacy of Propranolol in Newborns With Retinopathy of Prematurity,COMPLETED,PHASE2,52.0,2010-01-01,2012-10-01,1.576573705179283,Adequate (1-10/month),15.765737051792831,Significantly Below (<50%),100,49.2,46.035
NCT06486415,Novel Diagnosis of Ectopic Pregnancy,NOT_YET_RECRUITING,NA,20.0,2024-07-01,2025-04-01,2.221897810218978,Adequate (1-10/month),22.21897810218978,Significantly Below (<50%),30,30.6,9.475
NCT05444335,Screening for Atrial Fibrillation in Elderly Women Older Than 70 Years,ACTIVE_NOT_RECRUITING,NA,120.0,2023-07-15,2026-12-15,2.924579663730985,Adequate (1-10/month),29.24579663730985,Significantly Below (<50%),85,55.1,62.085
NCT05324735,Pentoxifylline for Treatment of Resistant Major Depression,COMPLETED,PHASE1,60.0,2021-12-15,2022-06-04,10.680701754385964,Good (10-50/month),106.80701754385966,Exceeded (≥100%),100,59.8,71.61
NCT06009835,DOTr/DOTa Algorithm Guidance for Refractory Solid Tumors,UNKNOWN,,15.0,2022-08-07,2024-09-01,0.603968253968254,Slow (<1/month),6.03968253968254,Significantly Below (<50%),50,29.5,8.86
NCT05075135,Acceptability and Safety of 3D Printed Wrist-based Splints,COMPLETED,NA,17.0,2021-08-09,2023-07-31,0.7177253814147018,Slow (<1/month),7.177253814147018,Significantly Below (<50%),100,46.4,36.26
NCT05920135,First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI,ACTIVE_NOT_RECRUITING,PHASE1,24.0,2023-09-11,2028-08-01,0.4090481522956327,Slow (<1/month),4.090481522956327,Significantly Below (<50%),85,42.4,25.45
NCT06654635,Ultrasound Guided Rhomboid Intercostal Plane Block Versus Thoracic Erector Spinae Plane Block in Upper Abdominal Surgery,RECRUITING,NA,60.0,2024-01-01,2025-05-01,3.758024691358025,Adequate (1-10/month),37.580246913580254,Significantly Below (<50%),60,42.8,25.929999999999996
NCT03833635,Effects of OMT on Premature Physiological Parameters,UNKNOWN,NA,100.0,2019-03-22,2019-09-30,15.854166666666668,Good (10-50/month),158.54166666666666,Exceeded (≥100%),50,48.0,42.945
NCT03996135,Evaluation of Accuvein in Cirrhotics Patients,UNKNOWN,NA,280.0,2020-06-15,2023-06-30,7.678558558558559,Adequate (1-10/month),76.7855855855856,Met (75-100%),50,57.4,67.05499999999999
NCT01323335,The Relationship Between Uric Acid and Inflammatory Markers,COMPLETED,PHASE1,97.0,2009-03-31,2014-01-31,1.6710130164119978,Adequate (1-10/month),16.710130164119978,Significantly Below (<50%),100,57.8,67.635
NCT00428935,Safety Study of Mini-dystrophin Gene to Treat Duchenne Muscular Dystrophy,COMPLETED,PHASE1,6.0,2006-03-01,2010-07-01,0.11537586860391662,Slow (<1/month),1.153758686039166,Significantly Below (<50%),100,45.5,31.705
NCT04663035,Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC,UNKNOWN,PHASE2,120.0,2020-12-21,2025-12-18,2.0037301151947338,Adequate (1-10/month),20.03730115194734,Significantly Below (<50%),50,44.6,29.42
NCT06260735,Non-invasive Spinal Cord Stimulation After Spinal Cord Injury,RECRUITING,NA,10.0,2023-06-15,2024-11-15,0.5865125240847784,Slow (<1/month),5.865125240847785,Significantly Below (<50%),60,33.8,13.694999999999999
NCT03404635,Monotherapy Anticoagulation To Expedite Home Treatment of Venous Thromboembolism,COMPLETED,,1300.0,2017-08-04,2020-05-08,39.257936507936506,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT01735435,Tight Caloric Balance in Geriatric Patients,COMPLETED,NA,50.0,2010-05-01,2012-03-01,2.271641791044776,Adequate (1-10/month),22.71641791044776,Significantly Below (<50%),100,54.0,58.72500000000001
NCT03356535,Metabolic Signature of Healthy Lifestyle and HCC,COMPLETED,,294.0,2015-08-01,2017-09-15,11.532680412371134,Good (10-50/month),115.32680412371134,Exceeded (≥100%),100,76.9,85.455
NCT00150735,Monotherapy With Levetiracetam in Newly Diagnosed Patients Suffering From Epilepsy,COMPLETED,PHASE3,580.0,2002-06-01,2005-07-01,15.679573712255774,Good (10-50/month),156.7957371225577,Exceeded (≥100%),100,95.0,95.7
NCT01205035,High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia,COMPLETED,PHASE2,6.0,2010-10-01,2012-10-01,0.2498495212038304,Slow (<1/month),2.498495212038304,Significantly Below (<50%),100,45.5,31.705
NCT07315035,QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer,NOT_YET_RECRUITING,PHASE2,74.0,2026-01-01,2030-12-31,1.2342794520547946,Adequate (1-10/month),12.342794520547946,Significantly Below (<50%),30,29.9,9.07
NCT06671535,Effect of Kidney Replacement Therapy with Polymethylmethacrylate Membranes on Pruritus-related Quality of Life in Patients Receiving Maintenance Haemodialysis,RECRUITING,NA,62.0,2025-01-27,2025-10-01,7.640809716599191,Adequate (1-10/month),76.4080971659919,Met (75-100%),60,43.0,26.465
NCT04841135,Blood Microbiota Signature of Alzheimer's Disease,UNKNOWN,NA,120.0,2021-06-03,2026-01-01,2.1833831440526,Adequate (1-10/month),21.833831440526,Significantly Below (<50%),50,44.6,29.42
NCT07266935,Posterior Pericardiotomy for Prevention of POAF After Cardiac Surgery: RCT in Yemen,COMPLETED,NA,210.0,2022-01-01,2024-06-30,7.016904500548848,Adequate (1-10/month),70.16904500548848,Below (50-75%),100,66.8,79.55
NCT05751135,Impact of Focal Muscle Vibration on Bio-psychosocial Outcomes in Cerebral Palsy,COMPLETED,NA,111.0,2023-03-03,2023-11-30,12.42220588235294,Good (10-50/month),124.22205882352941,Exceeded (≥100%),100,63.9,76.9
NCT03663335,"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients",COMPLETED,PHASE2,418.0,2018-11-28,2021-10-29,11.936135084427768,Good (10-50/month),119.36135084427768,Exceeded (≥100%),100,88.4,92.795
NCT04585035,Study to Evaluate D-1553 in Subjects With Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,180.0,2020-10-02,2025-12-01,2.905196182396607,Adequate (1-10/month),29.051961823966067,Significantly Below (<50%),85,59.9,71.86
NCT02710435,REDUCER-I: An Observational Study of the Neovasc Reducer™ System,ACTIVE_NOT_RECRUITING,,400.0,2016-03-01,2028-12-01,2.6139974237870334,Adequate (1-10/month),26.139974237870334,Significantly Below (<50%),85,75.8,84.83500000000001
NCT06366035,LoVE4MUM: Virtual Engagement for Preventing Postpartum Depression,NOT_YET_RECRUITING,NA,64.0,2024-04-22,2024-10-01,12.025679012345678,Good (10-50/month),120.25679012345678,Exceeded (≥100%),30,39.1,20.669999999999998
NCT03468335,2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy,COMPLETED,PHASE3,151.0,2018-03-31,2022-05-31,3.02,Adequate (1-10/month),30.2,Significantly Below (<50%),100,62.1,74.595
NCT03877835,Diaphragm-sparing Nerve Blocks for Shoulder Arthroplasty,COMPLETED,NA,20.0,2019-03-18,2020-08-31,1.1443609022556391,Adequate (1-10/month),11.443609022556391,Significantly Below (<50%),100,46.6,37.375
NCT03511235,Clinical Outcomes in Men With Prostate Cancer Who Selected Active Surveillance Using Prolaris® Testing,COMPLETED,,774.0,2018-03-12,2018-07-31,167.09617021276597,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT06679335,Examining the Effect of Lateralization Imagery Training on EEG Brain Oscillations in Individuals With Chronic Neck Pain,COMPLETED,NA,34.0,2024-12-16,2025-12-01,2.9570285714285713,Adequate (1-10/month),29.570285714285717,Significantly Below (<50%),100,52.7,55.04
NCT05748808,Use of Biofeedback and Virtual Reality as Facilitators of Emotional Recognition in the Treatment of Aggressive Outbursts,RECRUITING,NA,60.0,2024-09-01,2025-09-01,5.003835616438357,Adequate (1-10/month),50.03835616438357,Below (50-75%),60,42.8,25.929999999999996
NCT07245108,The Pro-Chol Study,RECRUITING,,800.0,2024-01-22,2027-04-01,20.903004291845495,Good (10-50/month),200.0,Exceeded (≥100%),60,81.3,88.58
NCT02912208,Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes,ACTIVE_NOT_RECRUITING,PHASE2,174.0,2011-06-11,2026-10-01,0.9473367912716866,Slow (<1/month),9.473367912716867,Significantly Below (<50%),85,54.4,59.89
NCT04866108,A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy,UNKNOWN,PHASE2,49.0,2021-12-08,2024-06-01,1.6463134657836644,Adequate (1-10/month),16.46313465783664,Significantly Below (<50%),50,33.9,13.865
NCT03810508,A Natural History Study of Charcot-Marie-Tooth 4J (CMT4J),TERMINATED,,21.0,2019-07-18,2022-02-15,0.6778791092258749,Slow (<1/month),6.77879109225875,Significantly Below (<50%),10,18.0,2.92
NCT05973708,Comparative Effects of Clamshells and Frog Pump Exercises,COMPLETED,NA,32.0,2023-10-05,2024-03-10,6.204331210191083,Adequate (1-10/month),62.04331210191083,Below (50-75%),100,52.6,54.684999999999995
NCT02773108,Somatic Comorbidities in Psychiatric Patients,COMPLETED,,1061.0,2016-05-01,2018-12-01,34.21275423728814,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT02085408,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,COMPLETED,PHASE3,727.0,2011-02-04,2022-12-21,5.101401567542647,Adequate (1-10/month),51.01401567542647,Below (50-75%),100,90.0,93.17
NCT02588508,"Effectiveness of Warm Packs, Perineal Massage and Hands Off During Labour in the Perineal Outcomes.",UNKNOWN,NA,201.0,2015-04-01,2016-01-01,22.24887272727273,Good (10-50/month),200.0,Exceeded (≥100%),50,56.1,63.99
NCT02307708,Reeducation of Chronic Achilles Tendinopathy by Wearing Shoes Inclined Versus Reeducation by Kinesitherapy,TERMINATED,NA,16.0,2015-01-01,2016-12-01,0.6957714285714286,Slow (<1/month),6.957714285714285,Significantly Below (<50%),10,19.3,5.125
NCT02355808,Do Superfast Broadband and Tailored Interventions Improve Use of E-health and Reduce Health Related Travel?,UNKNOWN,NA,1044.0,2012-10-01,2015-10-01,29.022246575342468,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT00535808,Effect of Strategy for Blood Pressure Control on Cerebral Oxygen Balance During Aortic Coarctation Repair: A Randomized Study,COMPLETED,PHASE2,30.0,2007-10-01,2011-03-01,0.7323175621491581,Slow (<1/month),7.323175621491582,Significantly Below (<50%),100,47.4,40.98
NCT05722925,Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET,ACTIVE_NOT_RECRUITING,PHASE4,50.0,2023-10-04,2026-12-01,1.3188908145580591,Adequate (1-10/month),13.18890814558059,Significantly Below (<50%),85,44.5,29.160000000000004
NCT04647825,NEED: Neuromed Epilepsy EEG Database. A Large EEG Database of Epilepsy Patients for Research Community.,UNKNOWN,,200.0,2021-04-01,2023-01-30,9.10014947683109,Adequate (1-10/month),91.0014947683109,Met (75-100%),50,54.3,59.62
NCT04269525,Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia,UNKNOWN,PHASE2,16.0,2020-02-06,2020-12-30,1.4848780487804878,Adequate (1-10/month),14.848780487804877,Significantly Below (<50%),50,31.3,10.299999999999999
NCT00841425,Airway Responsiveness and Inflammation in Adolescent Elite Swimmers: a 3-Year Prospective Follow-up Study,UNKNOWN,,33.0,2009-02-01,2010-06-01,2.0711752577319587,Adequate (1-10/month),20.711752577319587,Significantly Below (<50%),50,36.0,16.564999999999998
NCT01687725,Renal Denervation in Treatment Resistant Hypertension,COMPLETED,,41.0,2010-11-01,2018-12-01,0.4227777777777778,Slow (<1/month),4.227777777777778,Significantly Below (<50%),100,46.6,37.375
NCT01182025,"A Clinical Trial to Evaluate the Effectiveness and Safety of Xiyanping Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease",UNKNOWN,NA,360.0,2010-06-01,2011-12-01,19.997080291970804,Good (10-50/month),199.97080291970804,Exceeded (≥100%),50,68.8,81.105
NCT03746925,Comparing Short-term Outcomes After Direct Anterior and SuperPATH Hip Arthroplasty Approaches,UNKNOWN,NA,100.0,2019-09-07,2023-04-07,2.3272171253822633,Adequate (1-10/month),23.27217125382263,Significantly Below (<50%),50,43.0,26.465
NCT02509325,Parkinson's KinetiGraph as Tool for DBS Eligibility Assessment,COMPLETED,,38.0,2015-07-01,2016-02-01,5.380093023255815,Adequate (1-10/month),53.800930232558144,Below (50-75%),100,51.4,50.92
NCT02121925,Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up,TERMINATED,,227.0,2014-05-01,2017-07-31,5.821297388374052,Adequate (1-10/month),58.212973883740524,Below (50-75%),10,39.5,21.044999999999998
NCT00353925,Genetic Analysis of African-Americans With High Blood Pressure,COMPLETED,,1000.0,1999-10-05,2007-12-10,10.187416331994646,Good (10-50/month),101.87416331994645,Exceeded (≥100%),100,93.3,94.325
NCT01353625,"Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.",COMPLETED,PHASE1,118.0,2011-04-25,2021-03-12,0.995267387087836,Slow (<1/month),9.95267387087836,Significantly Below (<50%),100,54.4,59.89
NCT05226325,Dexmedetomidine Different Doses as Adjuvant to Entropy-assisted General Anesthesia During Functional Endoscopy Sinus Surgery.,COMPLETED,NA,99.0,2022-02-15,2022-08-02,17.937857142857144,Good (10-50/month),179.37857142857143,Exceeded (≥100%),100,62.9,75.655
NCT02614625,Spectral-domain Optical Coherence Tomography of the Eye,UNKNOWN,,100.0,2014-12-01,2015-12-01,8.339726027397262,Adequate (1-10/month),83.3972602739726,Met (75-100%),50,46.3,35.66
NCT00528125,Laser Acupuncture for Pain Prevention in Neonates,COMPLETED,NA,50.0,2007-09-01,2008-01-01,12.475409836065573,Good (10-50/month),124.75409836065572,Exceeded (≥100%),100,59.0,70.365
NCT05343325,The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC,RECRUITING,PHASE2,25.0,2022-03-09,2027-03-31,0.4117965367965368,Slow (<1/month),4.117965367965367,Significantly Below (<50%),60,35.0,15.305
NCT02740725,The Role of Interactive Binocular Treatment System in Amblyopia Therapy,UNKNOWN,NA,50.0,2014-12-01,,,Slow (<1/month),,Significantly Below (<50%),50,29.0,8.76
NCT00246025,A Study of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With TKR Surgery.,COMPLETED,PHASE2,512.0,2005-10-01,,,Slow (<1/month),,Significantly Below (<50%),100,80.0,87.67
NCT05704725,A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD),COMPLETED,PHASE3,49.0,2023-01-23,2023-03-24,24.859333333333336,Good (10-50/month),200.0,Exceeded (≥100%),100,58.9,70.10499999999999
NCT07175025,The New Empowerment After eXposure to Trauma (NEXT) Study,RECRUITING,NA,106.0,2025-09-15,2028-07-31,3.0729904761904767,Adequate (1-10/month),30.729904761904763,Significantly Below (<50%),60,46.5,36.815
NCT06439225,Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes,RECRUITING,PHASE3,236.0,2024-12-30,2030-03-31,3.747438706311946,Adequate (1-10/month),37.474387063119465,Significantly Below (<50%),60,56.9,65.89500000000001
NCT00152425,"Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).",COMPLETED,PHASE3,392.0,2004-02-01,2005-05-01,26.22523076923077,Good (10-50/month),200.0,Exceeded (≥100%),100,86.4,91.94
NCT06852625,Autologous Tolerogenic Dendritic Cells (ATDC) for Highly Sensitized Kidney Transplant Recipients,NOT_YET_RECRUITING,PHASE1,30.0,2025-05-01,2028-03-01,0.8823188405797101,Slow (<1/month),8.8231884057971,Significantly Below (<50%),30,26.4,7.865
NCT04554576,Escoge Salud (Choose Health): a Chronic Pain Self-Management Program in Middle to Older Age Hispanic Americans,COMPLETED,NA,18.0,2019-02-14,2021-12-31,0.5213320647002855,Slow (<1/month),5.213320647002854,Significantly Below (<50%),100,46.4,36.26
NCT02146976,Postoperative Sleep Quality of Patients Anesthesia With Propofol or Sevoflurane Undergoing Thyroidectomy,COMPLETED,PHASE4,124.0,2014-10-01,2015-10-01,10.341260273972603,Good (10-50/month),103.41260273972604,Exceeded (≥100%),100,64.9,77.985
NCT02750176,Rehabilitation: Closed-Chain Exercises for Rotator Cuff Tears,COMPLETED,EARLY_PHASE1,16.0,2016-04-01,2018-07-01,0.5932277710109622,Slow (<1/month),5.932277710109623,Significantly Below (<50%),100,46.3,35.66
NCT00800176,A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus,COMPLETED,PHASE2,394.0,2009-01-22,2009-10-28,42.98695340501792,Good (10-50/month),200.0,Exceeded (≥100%),100,91.5,93.67
NCT05226676,Long-term Effects of Repetitive TMS in Chronic Neuropathic Pain in People With SCI,WITHDRAWN,NA,0.0,2023-08-01,2023-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT07014176,Nonhealing Diabetic Foot Ulcers Treated With Standard of Care (SOC) Alone or Standard of Care and Amnion-Intermediate-Chorion (AIC),RECRUITING,PHASE4,120.0,2025-07-03,2026-10-31,7.531546391752578,Adequate (1-10/month),75.31546391752578,Met (75-100%),60,47.6,41.775
NCT06464276,Effectiveness and Tolerability of Trimetazidine 80mg Once Daily in Patients With Chronic Coronary Syndrome: The V-GOOD Study,COMPLETED,,800.0,2021-10-31,2022-09-30,72.91017964071857,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT06140576,The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.,NOT_YET_RECRUITING,PHASE1,58.0,2023-11-30,2026-12-31,1.5665661047027508,Adequate (1-10/month),15.665661047027509,Significantly Below (<50%),30,28.6,8.58
NCT06717776,Development of Compensation-Based Problem Solving Therapy,COMPLETED,NA,52.0,2024-09-01,2025-07-01,5.2240264026402645,Adequate (1-10/month),52.24026402640264,Below (50-75%),100,54.2,59.330000000000005
NCT04678076,Bioequivalence of Ketoprofen Oral Gel vs Ketoprofen Lysine Salt as Granules for Oral Solution,COMPLETED,PHASE1,36.0,2018-07-23,2018-08-05,36.0,Good (10-50/month),200.0,Exceeded (≥100%),100,62.9,75.655
NCT03580876,Addition of Azathioprine in IBD Patients With Immunogenic Failure,UNKNOWN,PHASE4,90.0,2018-07-23,2020-06-10,3.9819767441860465,Adequate (1-10/month),39.81976744186046,Significantly Below (<50%),50,42.2,25.155
NCT03041376,Pedometer-Based Walking Intervention in Patients With Chronic Heart Failure With Preserved Ejection Fraction,UNKNOWN,NA,200.0,2017-04-11,2020-01-31,5.939512195121951,Adequate (1-10/month),59.39512195121951,Below (50-75%),50,51.0,49.714999999999996
NCT06193876,"The Effect of Aromatherapy Before Clinical Practice on Stress, Anxiety and Depression in Midwifery Students",COMPLETED,NA,75.0,2023-10-02,2024-06-15,8.883268482490273,Adequate (1-10/month),88.83268482490274,Met (75-100%),100,61.0,73.17
NCT03411317,"Aortic Stenosis: Determinants of Progression, Severity and Left Ventricular Remodeling",ACTIVE_NOT_RECRUITING,,350.0,2017-12-11,2025-12-01,3.6586538461538463,Adequate (1-10/month),36.58653846153846,Significantly Below (<50%),85,71.8,82.83
NCT02797717,Treatment for Classical Hodgkin Lymphoma in Children and Adolescents,RECRUITING,NA,2200.0,2015-11-01,2027-12-01,15.17516428733288,Good (10-50/month),151.75164287332882,Exceeded (≥100%),60,83.0,89.505
NCT04469517,Influence of Hypoxic Induced Factors in Patients With Hereditary Hemorrhagic Telangiectasia,RECRUITING,,100.0,2020-08-10,2026-10-01,1.3571110120374499,Adequate (1-10/month),13.571110120374499,Significantly Below (<50%),60,39.3,20.810000000000002
NCT05512117,Midline Catheters Versus Peripheral Catheters in Internal Medicine Unit,COMPLETED,NA,20.0,2017-02-01,2017-09-30,2.5261410788381746,Adequate (1-10/month),25.261410788381745,Significantly Below (<50%),100,51.6,51.644999999999996
NCT00921817,Body Composition in Infants and Children,COMPLETED,,120.0,2009-05-01,2009-11-01,19.85217391304348,Good (10-50/month),198.5217391304348,Exceeded (≥100%),100,62.9,75.655
NCT02744417,Effect of Smoking Cessation on Clinical and Microbiological Outcomes of the Non-surgical Periodontal Therapy,COMPLETED,NA,63.0,2010-08-01,2014-03-01,1.4661467889908257,Adequate (1-10/month),14.661467889908259,Significantly Below (<50%),100,50.0,47.675
NCT07220317,"This Study Will Examine Shortened Treatment Wear Time for Patients With Mixed Dentition Using AirFlex Aligner, Sequential Dental Aligners.",NOT_YET_RECRUITING,NA,45.0,2026-01-01,2026-12-01,4.1011976047904195,Adequate (1-10/month),41.01197604790419,Significantly Below (<50%),30,32.6,12.31
NCT00547417,To Determine Effect and Safety of Tadalafil Taken by Men of Different Races and With Different Diseases When Needed for Erections,COMPLETED,PHASE3,1933.0,2003-07-01,2004-03-01,241.14967213114753,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT06095817,Project VALOR: Veteran Stress and Wellbeing,TERMINATED,NA,140.0,2023-06-01,2023-10-06,33.55590551181102,Good (10-50/month),200.0,Exceeded (≥100%),10,39.2,20.715
NCT03013517,Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children,UNKNOWN,PHASE3,300.0,2017-01-23,2023-03-01,4.098743267504489,Adequate (1-10/month),40.987432675044886,Significantly Below (<50%),50,59.0,70.365
NCT02111317,A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects,COMPLETED,PHASE1,24.0,2013-10-01,2013-11-01,23.566451612903226,Good (10-50/month),200.0,Exceeded (≥100%),100,56.9,65.89500000000001
NCT02301117,A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment,COMPLETED,PHASE1,43.0,2015-01-01,2019-06-19,0.8030184049079755,Slow (<1/month),8.030184049079756,Significantly Below (<50%),100,48.4,44.22
NCT03447717,Implanted Drop Foot Stimulator for Hemiparetic Patients,COMPLETED,NA,10.0,2012-07-26,2016-02-29,0.23183549124143185,Slow (<1/month),2.318354912414318,Significantly Below (<50%),100,45.8,33.03
NCT04984317,Feasibility of BOTOX Injection on Improving Female Stress Urinary Incontinence,SUSPENDED,EARLY_PHASE1,20.0,2022-02-14,2027-08-01,0.30531594784353056,Slow (<1/month),3.0531594784353056,Significantly Below (<50%),20,22.6,6.329999999999999
NCT00890617,Cryotherapy in Treating Patients With Primary Stage I Non-Small Cell Lung Cancer or Lung Metastasis,COMPLETED,PHASE1,9.0,2009-03-01,2021-05-01,0.06164716471647165,Slow (<1/month),0.6164716471647166,Significantly Below (<50%),100,45.7,32.5
NCT00180817,Longitudinal Study of the Clinical and Haematological Cause of Women With Antiphospholipid Antibodies.,COMPLETED,,250.0,1998-09-01,2005-08-31,2.9773082942097027,Adequate (1-10/month),29.77308294209703,Significantly Below (<50%),100,68.3,80.875
NCT00002917,Paclitaxel in Treating Patients With Early-Stage Bladder Cancer,COMPLETED,PHASE1,,1996-11-01,2004-05-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,30.330000000000002
NCT02476617,Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults,COMPLETED,PHASE3,25.0,2015-06-01,2016-12-01,1.3861566484517307,Adequate (1-10/month),13.861566484517308,Significantly Below (<50%),100,47.0,39.33
NCT04620317,Effects of Synbiotics on FC and Other Contributing Factors,COMPLETED,NA,85.0,2015-01-01,2018-01-01,2.3607664233576644,Adequate (1-10/month),23.607664233576642,Significantly Below (<50%),100,56.8,65.69500000000001
NCT04295317,PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery,ACTIVE_NOT_RECRUITING,PHASE2,65.0,2020-08-01,2025-06-01,1.1210198300283287,Adequate (1-10/month),11.210198300283286,Significantly Below (<50%),85,45.7,32.5
NCT05193617,Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma,ACTIVE_NOT_RECRUITING,PHASE2,104.0,2022-01-20,2027-01-01,1.7519424460431654,Adequate (1-10/month),17.519424460431654,Significantly Below (<50%),85,53.8,58.065
NCT04525417,Rapid Screening Test for Covid-19 Antibodies in Healthcare Workers,COMPLETED,NA,75.0,2020-04-25,2020-10-25,12.475409836065575,Good (10-50/month),124.75409836065575,Exceeded (≥100%),100,61.0,73.17
NCT04244617,Peer-supported Internet Mediated Psychological Treatment,COMPLETED,NA,9.0,2019-03-01,2019-10-30,1.1274074074074074,Adequate (1-10/month),11.274074074074075,Significantly Below (<50%),100,45.7,32.5
NCT02072317,Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer,UNKNOWN,PHASE2,140.0,2013-11-01,2016-03-01,5.007755581668626,Adequate (1-10/month),50.07755581668626,Below (50-75%),50,46.2,35.089999999999996
NCT01465217,Text Messaging to Improve Hypertension Medication Adherence in African Americans,COMPLETED,NA,58.0,2011-03-01,2014-09-01,1.3793125,Adequate (1-10/month),13.793125,Significantly Below (<50%),100,49.6,46.785
NCT06466317,Is There Effect of Adding Honey Intake to Free Walking in Metabolic Syndrome Children,RECRUITING,NA,40.0,2024-06-06,2024-10-01,10.406837606837607,Good (10-50/month),104.0683760683761,Exceeded (≥100%),60,46.2,35.089999999999996
NCT05399017,Clinical Evaluation of EZVent in Hospitalized Mechanically Ventilated Patients,UNKNOWN,NA,22.0,2022-08-01,2022-08-30,22.0,Good (10-50/month),200.0,Exceeded (≥100%),50,41.8,24.445
NCT03884517,Clinical Trial of BAT8003 (for Injection) for Patients With Advanced Epithelial Cancer,TERMINATED,PHASE1,5.0,2019-03-15,2021-02-08,0.21867816091954023,Slow (<1/month),2.1867816091954024,Significantly Below (<50%),10,18.4,3.855
NCT04560517,Remission Factors in Anorexia Nervosa,RECRUITING,,275.0,2021-04-06,2026-10-01,4.1771457085828345,Adequate (1-10/month),41.77145708582835,Significantly Below (<50%),60,58.3,68.99499999999999
NCT02334917,Comparison of Fast-Absorbing Sutures for Mohs Surgery,UNKNOWN,EARLY_PHASE1,100.0,2015-01-01,2015-06-01,20.158940397350992,Good (10-50/month),200.0,Exceeded (≥100%),50,48.0,42.945
NCT06615817,"Intermittent Fasting, Mediterranean Diet and NAFLD",NOT_YET_RECRUITING,NA,60.0,2025-01-01,2027-01-01,2.5019178082191784,Adequate (1-10/month),25.019178082191786,Significantly Below (<50%),30,33.8,13.694999999999999
NCT02919917,Treatment of Post-SCI Hypotension,COMPLETED,PHASE2,66.0,2017-06-01,2021-09-01,1.2936509980682551,Adequate (1-10/month),12.936509980682551,Significantly Below (<50%),100,50.3,48.215
NCT07199140,The Effect of Haptonomy Practice on Body Functionality Appreciation and Childbirth Self-Efficacy in Pregnant Women,NOT_YET_RECRUITING,NA,80.0,2025-11-15,2026-06-15,11.486792452830189,Good (10-50/month),114.8679245283019,Exceeded (≥100%),30,40.4,22.34
NCT05310240,Analysis of the Relevance of Radiologic Parameters on the Outcome After Hip Arthroscopy,COMPLETED,,810.0,2022-02-01,2023-02-01,67.55178082191782,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT00162240,PPAR - Combination With Metformin,COMPLETED,PHASE3,534.0,2003-06-01,2004-05-01,48.52226865671642,Good (10-50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT07095140,Studying the Effects of Nicotine Concentration and Flavor on Alcohol Use in Young Adults,RECRUITING,NA,20.0,2025-09-03,2027-12-31,0.7170789163722026,Slow (<1/month),7.170789163722026,Significantly Below (<50%),60,34.6,14.729999999999999
NCT01887340,Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma,RECRUITING,PHASE2,271.0,2013-06-01,2026-06-01,1.737413647851727,Adequate (1-10/month),17.374136478517272,Significantly Below (<50%),60,59.7,71.355
NCT06359340,Therapy and Peer Support for Patients Taking Medication for Opioid Use Disorder,ACTIVE_NOT_RECRUITING,NA,440.0,2020-03-13,2026-10-31,5.5276929426331,Adequate (1-10/month),55.27692942633099,Below (50-75%),85,80.7,88.185
NCT04366440,De-Implementation of Unnecessary Surgical Antibiotic Prophylaxis in Children,COMPLETED,NA,39363.0,2020-11-01,2024-11-30,804.1675973154362,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT01223040,"An Open-Label, Single-Center Study Evaluating the Effect of Systane Balance on Video Ocular Protection Index (OPI) and Blink Patterns in Patients Diagnosed With Dry Eye",COMPLETED,NA,30.0,2010-08-01,,,Slow (<1/month),,Significantly Below (<50%),100,42.4,25.45
NCT00258440,Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer,TERMINATED,NA,7.0,2003-05-01,2008-09-01,0.10927179487179488,Slow (<1/month),1.0927179487179488,Significantly Below (<50%),10,18.6,4.25
NCT06722040,"Effect and Safety of a Pediatric Triage Track on Hospital Visits and at the Public Medical Helpline 1813, Capital Region, Denmark",COMPLETED,,244000.0,2021-11-01,2023-08-31,11118.802395209581,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT01024140,Open Trial of Escitalopram Treatment for Male Subjects With Posttraumatic Stress Disorder,COMPLETED,NA,16.0,2003-02-01,2004-12-01,0.7280119581464872,Slow (<1/month),7.280119581464872,Significantly Below (<50%),100,46.3,35.66
NCT06896240,Fiber Smoothie Supplement,NOT_YET_RECRUITING,NA,24.0,2026-01-01,2028-01-01,1.0007671232876714,Adequate (1-10/month),10.007671232876714,Significantly Below (<50%),30,25.9,7.704999999999999
NCT05414240,Ibudilast for Treating Alcohol Use Disorder,ACTIVE_NOT_RECRUITING,PHASE2,50.0,2023-01-14,2027-12-31,0.8399558498896247,Slow (<1/month),8.399558498896246,Significantly Below (<50%),85,44.5,29.160000000000004
NCT06628440,Development and Validation of a Mouth Assessment Tool for Orally Intubated Patients in Intensive Care Unit),NOT_YET_RECRUITING,,500.0,2025-11-01,2027-11-01,20.84931506849315,Good (10-50/month),200.0,Exceeded (≥100%),30,72.3,83.065
NCT00496340,Phase II Trial of Pentostatin and Targeted Busulfan,COMPLETED,PHASE2,42.0,2007-07-01,2013-08-01,0.5751147098515519,Slow (<1/month),5.75114709851552,Significantly Below (<50%),100,48.4,44.22
NCT02419040,Treatment of Calcific Tendinitis of the Rotator Cuff,COMPLETED,NA,220.0,2015-04-01,2022-04-01,2.619006648416113,Adequate (1-10/month),26.19006648416113,Significantly Below (<50%),100,67.6,80.15
NCT07056140,Simulation-Based Training for Epidural Analgesia Placement,RECRUITING,NA,86.0,2025-09-12,2027-07-01,3.9845357686453577,Adequate (1-10/month),39.84535768645358,Significantly Below (<50%),60,44.9,30.025000000000002
NCT01109940,Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis,COMPLETED,PHASE2,39.0,2010-04-01,2012-12-01,1.2176,Adequate (1-10/month),12.176,Significantly Below (<50%),100,48.1,43.275000000000006
NCT02836340,"TIBOHCA: Safety, Tolerability and Pharmacokinetics of 2-Iminobiotin (2-IB) After OHCA",TERMINATED,PHASE1,21.0,2016-05-01,2020-04-01,0.44670859538784063,Slow (<1/month),4.4670859538784065,Significantly Below (<50%),10,19.7,5.405
NCT06360640,"A First-in-human Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of APC148 in Healthy Adults",COMPLETED,PHASE1,46.0,2024-09-02,2025-03-10,7.4086772486772485,Adequate (1-10/month),74.08677248677249,Below (50-75%),100,53.7,57.84
NCT06556940,G.I. Pharmacokinetics of LMN-401 in Individuals With Ileostomies,RECRUITING,EARLY_PHASE1,12.0,2024-12-04,2025-12-02,1.0062809917355373,Adequate (1-10/month),10.062809917355372,Significantly Below (<50%),60,34.0,14.02
NCT04012840,Determinant of the Risk of the Becoming Frail in the Non-dependent Elederly,RECRUITING,,2000.0,2018-06-26,2030-12-25,13.336254107338446,Good (10-50/month),133.36254107338445,Exceeded (≥100%),60,81.3,88.58
NCT06285240,Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007),COMPLETED,PHASE1,28.0,2024-03-28,2024-09-23,4.761564245810056,Adequate (1-10/month),47.61564245810057,Significantly Below (<50%),100,52.2,53.22
NCT05144789,Personalized Therapeutic Neuromodulation for Anhedonic Depression,ACTIVE_NOT_RECRUITING,NA,79.0,2022-05-31,2025-06-30,2.1356660746003553,Adequate (1-10/month),21.356660746003552,Significantly Below (<50%),85,51.8,52.17
NCT03436589,The Indiana SNAP-Ed Long-term Study,COMPLETED,NA,575.0,2013-09-21,2015-03-10,32.71588785046729,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT05985889,Comparison of Innovative Rehabilitation Treatments and Examination of Their Effectiveness in Stroke Patients,UNKNOWN,NA,75.0,2023-07-08,2023-08-30,43.07547169811321,Good (10-50/month),200.0,Exceeded (≥100%),50,51.0,49.714999999999996
NCT02331589,Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis,COMPLETED,PHASE4,75.0,2011-08-01,2012-04-01,9.35655737704918,Adequate (1-10/month),93.5655737704918,Met (75-100%),100,61.0,73.17
NCT01775189,"A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Users When ALO-02 Capsules Are Crushed and Snorted",COMPLETED,PHASE1,45.0,2013-02-01,2013-07-01,9.132,Adequate (1-10/month),91.32000000000001,Met (75-100%),100,58.6,69.51
NCT06587789,Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer,RECRUITING,,286.0,2024-01-01,2027-01-01,7.9432846715328465,Adequate (1-10/month),79.43284671532847,Met (75-100%),60,59.2,70.7
NCT05260489,Apollo Remote Observational Sleep Study,WITHDRAWN,,0.0,2022-01-18,2025-10-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT02179489,Surgery With HIPEC in Treating Patients With a High Risk of Developing Colorectal Peritoneal Carcinomatosis,COMPLETED,NA,271.0,2014-11-01,2021-11-30,3.1899613302397527,Adequate (1-10/month),31.899613302397523,Significantly Below (<50%),100,71.7,82.78999999999999
NCT01428089,Suppression of Daytime and Nighttime Luteinizing Hormone Frequency by Progesterone,UNKNOWN,PHASE1,40.0,2011-03-11,2024-12-01,0.24284004786597527,Slow (<1/month),2.4284004786597526,Significantly Below (<50%),50,33.2,12.989999999999998
NCT03362489,Conversion of in Vitro Fertilization Cycles to Intrauterine Inseminations in Patients With a Poor Ovarian Response to Stimulation,COMPLETED,NA,462.0,2018-01-10,2024-03-14,6.236487804878048,Adequate (1-10/month),62.36487804878048,Below (50-75%),100,87.0,92.135
NCT03224689,Evaluation of The Safety And Performance of The Freedom Total Knee® System With The PEEK-OPTIMA Femoral Component,UNKNOWN,NA,34.0,2021-01-01,2024-03-01,0.8960692640692641,Slow (<1/month),8.960692640692642,Significantly Below (<50%),50,32.7,12.370000000000001
NCT02850289,APPROACH Study: Quality of Life and Outcomes Assessment in Participants With Chronic Hepatitis C (CHC) Treated With Pegylated Interferon (PEG-IFN) Alfa-2a and Ribavirin,COMPLETED,,385.0,2006-04-01,2008-10-01,12.822100656455142,Good (10-50/month),128.22100656455143,Exceeded (≥100%),100,84.1,90.64999999999999
NCT00749489,Improving Pain and Function in Hip Fracture,COMPLETED,PHASE3,164.0,2008-11-01,2014-05-01,2.487374190333832,Adequate (1-10/month),24.873741903338317,Significantly Below (<50%),100,63.1,76.03
NCT01307189,Effects of Tiotropium on Walking Capacity in Patients With COPD,COMPLETED,PHASE4,33.0,2005-04-01,2010-08-01,0.5156673511293635,Slow (<1/month),5.156673511293635,Significantly Below (<50%),100,47.6,41.775
NCT03302689,Comparison Levobupivacaine and Ropivacaine for TAP-block After Caesarean Section,UNKNOWN,NA,50.0,2017-09-25,2018-01-01,15.53061224489796,Good (10-50/month),155.3061224489796,Exceeded (≥100%),50,44.0,28.249999999999996
NCT05679089,AssesSment of Early deteCtion basEd oN liquiD Biopsy in Intracranial Tumors,UNKNOWN,,358.0,2022-11-01,2024-06-30,17.953080724876443,Good (10-50/month),179.53080724876443,Exceeded (≥100%),50,67.0,79.725
NCT00005689,Trial of Smoking Cessation Programs in Black Churches,COMPLETED,,,1991-07-01,1995-06-01,,Slow (<1/month),,Significantly Below (<50%),100,43.3,27.05
NCT01836289,High-dose Cyclophosphamide for Severe Refractory Crohn Disease,WITHDRAWN,PHASE1,0.0,2015-03-01,2018-03-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT02422589,"A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors",COMPLETED,PHASE1,33.0,2015-10-23,2017-12-12,1.2861971830985917,Adequate (1-10/month),12.861971830985915,Significantly Below (<50%),100,47.6,41.775
NCT00002289,The Effects of Thymopentin on HIV Infectivity of Blood Cells and Semen in HIV-Infected Patients,COMPLETED,NA,,,,,Slow (<1/month),,Significantly Below (<50%),100,40.0,21.87
NCT06851689,Correlation Between Shoulder Rotation Torque and Hand Grip Strength in University Teaching Staff,NOT_YET_RECRUITING,,46.0,2025-02-28,2025-05-01,22.584516129032256,Good (10-50/month),200.0,Exceeded (≥100%),30,36.0,16.564999999999998
NCT02471989,FODMAPs and Refractory GERD,COMPLETED,NA,31.0,2016-01-05,2018-11-13,0.9047363374880153,Slow (<1/month),9.047363374880153,Significantly Below (<50%),100,47.5,41.415
NCT04470089,A Clinical Trial Investigating the Short-term Relief of Symptoms of Acute Pharyngitis by Treatment With Three Different Doses of MYRAMISTIN™ Oromucosal Spray,TERMINATED,PHASE2,170.0,2020-02-18,2021-12-31,7.587683284457479,Adequate (1-10/month),75.87683284457479,Met (75-100%),10,36.6,17.41
NCT06282068,AI Determine Malignancy of GGO on Chest CT,ENROLLING_BY_INVITATION,,100.0,2024-03-01,2026-02-28,4.175582990397805,Adequate (1-10/month),41.755829903978054,Significantly Below (<50%),55,42.8,25.929999999999996
NCT03750968,Lutein & Zeaxanthin in Pregnancy - Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects,COMPLETED,PHASE2,47.0,2019-09-26,2022-01-31,1.6674592074592074,Adequate (1-10/month),16.674592074592077,Significantly Below (<50%),100,53.8,58.065
NCT04085068,Effect of Dural Release on Women With Back and Neck Pain After Obstetrics and Gynecological Surgery,UNKNOWN,,30.0,2023-10-08,2023-11-11,26.858823529411765,Good (10-50/month),200.0,Exceeded (≥100%),50,40.7,22.675
NCT04833868,Effect of Hippotherapy and Schroth Exercise on Pulmonary Function and Aerobic Capacity in Idiopathic Scoliosis,COMPLETED,NA,45.0,2020-02-20,2021-03-07,3.5952755905511813,Adequate (1-10/month),35.952755905511815,Significantly Below (<50%),100,53.6,57.705
NCT00004568,Study of Inherited Neurological Disorders,RECRUITING,,3500.0,2000-02-18,,,Slow (<1/month),,Significantly Below (<50%),60,66.3,79.3
NCT04460768,An INternational Frontline Ovarian Cancer Real World Management Study,COMPLETED,,989.0,2020-06-27,2020-11-10,221.36147058823528,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT05720468,Exercise for Cognitive Excellence in Parkinson's Disease,RECRUITING,NA,32.0,2023-07-20,2026-01-31,1.0519222462203024,Adequate (1-10/month),10.519222462203023,Significantly Below (<50%),60,35.6,16.03
NCT04420468,Descriptive and Retrospective Analysis of Acute Myocarditis Associated With Pandemic COVID-19 in Children,COMPLETED,,20.0,2020-06-10,2022-05-31,0.8455555555555556,Slow (<1/month),8.455555555555556,Significantly Below (<50%),100,44.9,30.025000000000002
NCT01586468,PILOT STUDY OF THE EFFICACY AND SAFETY OF WF10 IN SUBJECTS SUFFERING FROM PERSISTENT ALLERGIC RHINITIS,COMPLETED,PHASE2,60.0,2010-03-01,2010-11-01,7.454693877551021,Adequate (1-10/month),74.54693877551021,Below (50-75%),100,54.8,61.095
NCT03045068,Platelet Transfusion During Neonatal Open Heart Surgery,COMPLETED,PHASE4,46.0,2017-04-11,2018-11-01,2.4608787346221446,Adequate (1-10/month),24.608787346221444,Significantly Below (<50%),100,53.7,57.84
NCT00945568,Preoperative Oral Supplementation With Branched-Chain Amino Acids (BCAA) Improves Postoperative Quality of Life,COMPLETED,NA,100.0,2007-05-01,2009-06-01,3.9947506561679793,Adequate (1-10/month),39.947506561679795,Significantly Below (<50%),100,58.0,68.245
NCT01353768,Zanamivir Aqueous Solution Compassionate Use Program Retrospective Chart Review Study,COMPLETED,,113.0,2011-07-01,2012-01-01,18.694130434782608,Good (10-50/month),186.9413043478261,Exceeded (≥100%),100,62.4,75.095
NCT00060268,Photodynamic Therapy Using HPPH in Treating Patients With Obstructive Esophageal Tumors,COMPLETED,PHASE1,11.0,1997-01-01,2004-06-01,0.12364844903988183,Slow (<1/month),1.2364844903988184,Significantly Below (<50%),100,45.9,33.495000000000005
NCT03035968,Vojta Therapy in Early Stroke Rehabilitation,COMPLETED,NA,40.0,2015-12-02,2017-07-04,2.099310344827586,Adequate (1-10/month),20.993103448275864,Significantly Below (<50%),100,53.2,56.665
NCT03086668,Fingers Hook Technique to Facilitate Nasotracheal Intubation,COMPLETED,NA,80.0,2017-03-27,2019-11-05,2.555299055613851,Adequate (1-10/month),25.55299055613851,Significantly Below (<50%),100,56.4,64.88000000000001
NCT05314868,Retrospective Evaluation of Photo-oxidized Decellularized Bovine Pericardium in Cardiac Repair or Reconstruction Surgery,TERMINATED,,10.0,2022-03-31,2022-11-30,1.2475409836065574,Adequate (1-10/month),12.475409836065571,Significantly Below (<50%),10,17.1,2.765
NCT00612768,Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens:Bioequivalence of PVP Formulations,COMPLETED,PHASE2,50.0,2008-01-01,2009-10-01,2.3818466353677623,Adequate (1-10/month),23.81846635367762,Significantly Below (<50%),100,54.0,58.72500000000001
NCT02457468,The Coflex®COMMUNITY Study: An Observational Study of Coflex® Interlaminar Technology,COMPLETED,,325.0,2015-06-01,2019-12-01,6.0176399026763985,Adequate (1-10/month),60.176399026763995,Below (50-75%),100,74.3,84.205
NCT02669368,Magnesium Sulfate Effects on Onset and Duration of Low Dose Rocuronium in Patients Undergoing Laparoscopic Cholecystectomy,UNKNOWN,PHASE2,75.0,2015-03-01,,,Slow (<1/month),,Significantly Below (<50%),50,31.0,9.985
NCT01412268,Does Bariatric Surgery Changes Eating Habits and Addiction in Morbid Obesity?,COMPLETED,,35.0,2011-08-01,2012-08-01,2.910928961748634,Adequate (1-10/month),29.10928961748634,Significantly Below (<50%),100,51.1,50.129999999999995
NCT02722668,UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep,COMPLETED,PHASE2,15.0,2017-05-15,2024-02-22,0.1845594179466451,Slow (<1/month),1.8455941794664512,Significantly Below (<50%),100,46.2,35.089999999999996
NCT00002168,A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients,COMPLETED,NA,200.0,,,,Slow (<1/month),,Significantly Below (<50%),100,56.0,63.71
NCT05496868,Add-on Reparixin in Adult Patients With ARDS,COMPLETED,PHASE2,66.0,2022-12-06,2025-04-18,2.325277777777778,Adequate (1-10/month),23.252777777777776,Significantly Below (<50%),100,55.3,62.36000000000001
NCT03709550,Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer,WITHDRAWN,PHASE1,0.0,2021-04-15,2024-04-15,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT04714450,Assessing the Repeatability of a Psychological Stress Test,COMPLETED,NA,24.0,2021-04-23,2023-07-19,0.8941982864137087,Slow (<1/month),8.941982864137088,Significantly Below (<50%),100,46.9,38.96
NCT07241650,Evaluation of the Effects of Different Irrigation Solutions and Activation Methods on Postoperative Pain and Quality of Life in Root Canal Treatment,ACTIVE_NOT_RECRUITING,NA,90.0,2025-11-01,2026-01-01,44.911475409836065,Good (10-50/month),200.0,Exceeded (≥100%),85,62.7,75.42
NCT02778750,Evaluation Of The Pan-microbiome and Host Immune Response in CF,COMPLETED,,12.0,2015-06-05,2020-03-12,0.2096900114810563,Slow (<1/month),2.096900114810563,Significantly Below (<50%),100,44.3,28.715000000000003
NCT05430750,Global Warming Impact of Nitrous Oxide,COMPLETED,PHASE4,102.0,2022-06-29,2023-04-22,10.454141414141414,Good (10-50/month),104.54141414141414,Exceeded (≥100%),100,63.2,76.11
NCT02521350,Determination of Perioperative Acute Kidney Injury Incidence,UNKNOWN,,5000.0,2015-06-01,2016-06-01,415.8469945355191,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT03008850,Shivering Prevention During Cesarean Section by Intrathecal Injection of Magnesium Sulfate,COMPLETED,PHASE2,84.0,2015-06-01,2016-12-01,4.657486338797815,Adequate (1-10/month),46.57486338797815,Significantly Below (<50%),100,56.7,65.53
NCT05094050,Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease,COMPLETED,PHASE1,16.0,2022-01-18,2023-03-17,1.1513947990543736,Adequate (1-10/month),11.513947990543736,Significantly Below (<50%),100,46.3,35.66
NCT00733850,Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer,COMPLETED,PHASE2,85.0,2008-08-01,2014-06-01,1.2147417840375587,Adequate (1-10/month),12.147417840375589,Significantly Below (<50%),100,51.8,52.17
NCT04876950,Post Discharge After Surgery Virtual Care with Remote Automated Monitoring Technology-2 (PVC-RAM-2) Trial,RECRUITING,NA,2000.0,2024-10-04,2026-03-01,118.67446393762185,Excellent (>50/month),200.0,Exceeded (≥100%),60,88.0,92.495
NCT04172350,An Innovative Care-improvement Smartphone-based Perioperative Solution for Women Undergoing Breast Cancer Surgery,UNKNOWN,NA,112.0,2019-11-19,2021-10-31,4.788314606741573,Adequate (1-10/month),47.88314606741573,Significantly Below (<50%),50,44.0,28.249999999999996
NCT00456950,Magnetic Resonance Imaging of the Coronary Vessel Wall,COMPLETED,,75.0,2005-10-01,,,Slow (<1/month),,Significantly Below (<50%),100,44.3,28.715000000000003
NCT01641250,A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia,COMPLETED,PHASE1,44.0,2012-08-01,2015-02-01,1.4653829321663019,Adequate (1-10/month),14.65382932166302,Significantly Below (<50%),100,48.5,44.47
NCT03541850,Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery,ACTIVE_NOT_RECRUITING,PHASE2,92.0,2019-01-29,2027-11-01,0.875697310819262,Slow (<1/month),8.756973108192621,Significantly Below (<50%),85,47.9,42.64
NCT04427150,Affective Prosody Recognition and Auditory Intervention for Children With Autism Spectrum Disorders (ASD),COMPLETED,NA,120.0,2020-09-25,2021-12-31,7.906493506493507,Adequate (1-10/month),79.06493506493507,Met (75-100%),100,59.6,71.17999999999999
NCT01690650,Neonatal Cerebral Oxygenation After Exposure to Oxygen Evaluated With the INVOS Oximeter,COMPLETED,NA,33.0,2012-09-01,2013-08-01,3.0075449101796408,Adequate (1-10/month),30.0754491017964,Significantly Below (<50%),100,52.6,54.684999999999995
NCT02162550,Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus,UNKNOWN,PHASE4,148.0,2014-06-01,2019-09-01,2.3488633993743484,Adequate (1-10/month),23.488633993743484,Significantly Below (<50%),50,46.8,38.440000000000005
NCT04545450,"Effects of Testosterone Plus Dutasteride or Placebo on Muscle Strength, Body Composition and Metabolism in Transmen",COMPLETED,PHASE3,16.0,2008-11-04,2010-10-15,0.6859718309859155,Slow (<1/month),6.859718309859156,Significantly Below (<50%),100,46.3,35.66
NCT04585750,The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE),RECRUITING,PHASE1,300.0,2020-10-29,2027-12-31,3.486827033218786,Adequate (1-10/month),34.868270332187855,Significantly Below (<50%),60,62.0,74.42
NCT04694950,Postoperative Recovery and Comfort in Patients Undergoing Urologic Robotic Surgery,COMPLETED,,30.0,2020-12-30,2021-11-30,2.725970149253732,Adequate (1-10/month),27.259701492537314,Significantly Below (<50%),100,50.7,48.915
NCT01667250,Non-Invasive Neurostimulation for the Prevention of Chronic Migraine,COMPLETED,NA,59.0,2012-10-01,2014-05-01,3.1125823223570195,Adequate (1-10/month),31.125823223570197,Significantly Below (<50%),100,54.7,60.629999999999995
NCT01415050,Safety and Efficacy of Whole-body Vibration as add-on Treatment of Osteoporosis in Post-menopausal Women,COMPLETED,PHASE2,80.0,2009-01-01,2011-07-01,2.6731064763995613,Adequate (1-10/month),26.73106476399561,Significantly Below (<50%),100,56.4,64.88000000000001
NCT03820050,FreeStyle LIbre Flash Glucose Monitoring System Pediatric Accuracy Study,COMPLETED,,144.0,2019-01-29,2019-06-14,32.230588235294114,Good (10-50/month),200.0,Exceeded (≥100%),100,64.9,77.985
NCT07148050,Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells,RECRUITING,PHASE1,21.0,2025-12-22,2044-04-22,0.09546594982078853,Slow (<1/month),0.9546594982078852,Significantly Below (<50%),60,34.7,14.899999999999999
NCT02651350,Efficacy and Safety of Glucocorticosteroid Treatment in the Patients With Chronic Recurrent DILI,COMPLETED,PHASE1,80.0,2015-12-01,2019-07-01,1.8617737003058106,Adequate (1-10/month),18.617737003058103,Significantly Below (<50%),100,56.4,64.88000000000001
NCT01046591,Sleep and Behavior in Children With Cleft Palate,COMPLETED,,82.0,2006-12-01,2011-12-01,1.3669660460021906,Adequate (1-10/month),13.669660460021907,Significantly Below (<50%),100,49.9,47.425
NCT05457491,Novel Antiaging Regenerative Skin Care Regimen Containing Human Platelet Extract (HPE),TERMINATED,PHASE1,56.0,2021-10-01,2022-07-07,6.109820788530467,Adequate (1-10/month),61.09820788530467,Below (50-75%),10,27.5,8.28
NCT06462391,Adapting and Piloting Acceptance and Commitment Therapy (ACT) for Severe Premenstrual Mood Symptoms,ACTIVE_NOT_RECRUITING,NA,50.0,2024-12-01,2026-12-31,2.0026315789473683,Adequate (1-10/month),20.026315789473685,Significantly Below (<50%),85,49.5,46.58
NCT01006291,Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes,COMPLETED,PHASE3,687.0,2009-11-01,2010-09-01,68.7903947368421,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT04825691,ERG Protein Expression in Prostatic Adenocarcinoma and Its Clinicopathological Features,UNKNOWN,,50.0,2021-05-04,2023-05-23,2.0320427236315086,Adequate (1-10/month),20.320427236315087,Significantly Below (<50%),50,37.3,18.35
NCT04893291,Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels,ACTIVE_NOT_RECRUITING,NA,1820.0,2021-11-16,2030-08-30,17.264194453100654,Good (10-50/month),172.64194453100652,Exceeded (≥100%),85,90.5,93.4
NCT00102791,A Stratified Sickle Event Randomized Trial (ASSERT),TERMINATED,PHASE3,297.0,2005-02-01,2007-06-01,10.636094117647058,Good (10-50/month),106.36094117647059,Exceeded (≥100%),10,51.8,52.17
NCT07059091,Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD,NOT_YET_RECRUITING,PHASE2,334.0,2026-02-01,2031-05-01,5.309117493472585,Adequate (1-10/month),53.09117493472585,Below (50-75%),30,55.7,63.09
NCT04425291,Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females,COMPLETED,PHASE3,1680.0,2020-05-28,2021-09-06,109.74077253218884,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT00451191,Botulinum Toxin Injection for the Management of BPH,COMPLETED,PHASE2,134.0,2006-10-01,2009-12-01,3.5254624027657733,Adequate (1-10/month),35.25462402765774,Significantly Below (<50%),100,60.7,72.89999999999999
NCT05197491,Women's Menstruation During the Covid-19 Pandemic,UNKNOWN,,100.0,2022-04-01,2023-12-01,4.998357963875205,Adequate (1-10/month),49.98357963875205,Significantly Below (<50%),50,41.3,23.74
NCT05122091,Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma,RECRUITING,PHASE2,53.0,2021-11-05,2024-11-30,1.4391793041926852,Adequate (1-10/month),14.391793041926851,Significantly Below (<50%),60,37.2,18.17
NCT01709591,Effect of Prenatal Education on Perceptions of Epidural Acceptance,COMPLETED,NA,111.0,2011-06-01,2018-08-01,1.290618792971734,Adequate (1-10/month),12.906187929717342,Significantly Below (<50%),100,53.9,58.34
NCT06749691,Liposomal Irinotecan and Apatinib in ES-SCLC,RECRUITING,PHASE2,30.0,2024-12-28,2027-12-01,0.8550561797752809,Slow (<1/month),8.550561797752811,Significantly Below (<50%),60,35.4,15.765
NCT00726791,Efficacy of rTMS (Repetitive Transcranial Magnetic Stimulation) on Patients With Somatoform Pain Disorder,WITHDRAWN,NA,10.0,2008-04-01,2009-06-01,0.7145539906103286,Slow (<1/month),7.145539906103286,Significantly Below (<50%),5,17.3,2.785
NCT03877991,Bioequivalence Assessment of Cannabidiol (CBD) Administrated in Oral Formulations,RECRUITING,EARLY_PHASE1,12.0,2024-02-19,2025-02-19,0.9980327868852459,Slow (<1/month),9.98032786885246,Significantly Below (<50%),60,34.0,14.02
NCT01929291,Post-marketing Surveillance to Assess the Safety of Boostrix Vaccine Given According to Prescribing Information in Korea,COMPLETED,,682.0,2013-09-23,2016-01-11,24.714380952380953,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT05713591,Transition Care Model for Adolescents With Congenital Heart Disease,UNKNOWN,NA,964.0,2021-05-03,2024-12-31,21.93136023916293,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT05892991,Using Different Amplitude-modulated Frequencies of IFC for the Treatment of Trigger Points,COMPLETED,NA,132.0,2023-10-01,2024-08-01,13.174032786885247,Good (10-50/month),131.7403278688525,Exceeded (≥100%),100,65.6,78.56
NCT07222774,Strengthening Intentions,ACTIVE_NOT_RECRUITING,NA,350.0,2025-10-15,2027-12-01,13.711711711711711,Good (10-50/month),137.11711711711712,Exceeded (≥100%),85,78.5,86.785
NCT00239174,A Multicenter Study to Evaluate the Efficacy and Safety of of Four Doses of SR147778 in Obese Patients,COMPLETED,PHASE2,394.0,2004-11-01,2005-11-01,32.85852054794521,Good (10-50/month),200.0,Exceeded (≥100%),100,86.5,91.97999999999999
NCT04815174,Observational Study of the Clinico-biological Evolution and Standard of Care Offered to Patients With Ebola Virus Disease,COMPLETED,,711.0,2018-08-01,2019-12-31,41.86235976789169,Good (10-50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02871674,Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial,UNKNOWN,NA,60.0,2016-10-01,2017-08-01,6.007894736842105,Adequate (1-10/month),60.078947368421055,Below (50-75%),50,39.8,21.47
NCT01947374,Arthroscopic Autologous Chondrocyte Implantation Versus Microfractures,COMPLETED,PHASE3,48.0,2010-01-01,2015-01-01,0.8001752464403067,Slow (<1/month),8.001752464403067,Significantly Below (<50%),100,48.8,45.184999999999995
NCT03199274,Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer,COMPLETED,PHASE2,104.0,2017-07-01,2025-01-23,1.1457690915671372,Adequate (1-10/month),11.457690915671373,Significantly Below (<50%),100,53.3,57.14
NCT02544074,Validity of the Electronic Self-Administered Gerocognitive Examination (eSAGE),COMPLETED,,69.0,2015-01-01,2024-11-13,0.5827857935627081,Slow (<1/month),5.8278579356270805,Significantly Below (<50%),100,48.9,45.4
NCT05423574,Robotic Trans-Abdominal Retromuscular Umbilical Prosthesis (r-TARUP),COMPLETED,,20.0,2021-01-01,2022-03-01,1.4358490566037736,Adequate (1-10/month),14.358490566037737,Significantly Below (<50%),100,44.9,30.025000000000002
NCT01228474,Single Embryo Transfer vs. Double Embryo Transfer in an Oocyte Donation Programme,TERMINATED,NA,65.0,2010-10-01,2012-12-01,2.4982323232323234,Adequate (1-10/month),24.982323232323232,Significantly Below (<50%),10,28.2,8.469999999999999
NCT05236374,"Effects of Daily Beef Intake, as a Component of a Heart-Healthy Diet on Cellular Zinc",RECRUITING,NA,20.0,2022-10-01,2026-12-31,0.3922680412371134,Slow (<1/month),3.9226804123711343,Significantly Below (<50%),60,34.6,14.729999999999999
NCT06536374,Folate Study in Men With Advanced Prostate Cancer,NOT_YET_RECRUITING,PHASE2,50.0,2026-06-01,2027-12-01,2.7773722627737225,Adequate (1-10/month),27.773722627737225,Significantly Below (<50%),30,33.0,12.695
NCT02815774,SP2086 Pharmacokinetic Study in Renal Insufficiency Patients,COMPLETED,PHASE1,30.0,2014-06-01,2015-01-01,4.267289719626168,Adequate (1-10/month),42.67289719626169,Significantly Below (<50%),100,52.4,53.949999999999996
NCT05795374,Nutritional and Functional Assessment of Patients Undergoing Surgery Due to Gastrointestinal Cancer (NUFAGI).,COMPLETED,,300.0,2022-03-01,2023-12-20,13.857359635811838,Good (10-50/month),138.57359635811838,Exceeded (≥100%),100,77.3,85.67
NCT03435874,"Safety and Immunogenicity of ChAd63 RH5 and MVA RH5 in Adults, Young Children and Infants Living in Tanzania",COMPLETED,PHASE1,63.0,2018-04-12,2019-07-11,4.214769230769231,Adequate (1-10/month),42.14769230769232,Significantly Below (<50%),100,55.0,61.834999999999994
NCT01038674,Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis,COMPLETED,PHASE1,16.0,2010-02-01,2010-12-01,1.6073927392739276,Adequate (1-10/month),16.07392739273927,Significantly Below (<50%),100,46.3,35.66
NCT05869474,Implantation of iodine125-Seeds Combined With Chemotherapy in the Treatment of Metastatic Pancreatic Carcinoma,RECRUITING,NA,206.0,2023-08-01,2027-12-01,3.961238155401137,Adequate (1-10/month),39.612381554011364,Significantly Below (<50%),60,54.5,60.12
NCT04696874,Spectrum of Epididymis and Vas Deferens Anomalies Among Children With Cryptorchidism,COMPLETED,,22.0,2017-09-01,2019-02-28,1.228770642201835,Adequate (1-10/month),12.287706422018351,Significantly Below (<50%),100,45.1,30.605
NCT03381274,Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study,ACTIVE_NOT_RECRUITING,PHASE1,43.0,2018-05-08,2026-04-16,0.451351724137931,Slow (<1/month),4.5135172413793105,Significantly Below (<50%),85,43.9,28.12
NCT00210574,A Pilot Study of Topiramate in Childhood Absence Epilepsy,COMPLETED,PHASE2,12.0,2005-03-01,2006-10-01,0.6308808290155441,Slow (<1/month),6.30880829015544,Significantly Below (<50%),100,46.0,34.1
NCT05431374,Measurement-Based Care Vs. Standard Care for Major Depressive Disorder,COMPLETED,NA,150.0,2022-09-01,2024-01-30,8.848837209302324,Adequate (1-10/month),88.48837209302324,Met (75-100%),100,67.0,79.725
NCT02056574,Safety and Efficacy Study of a Single Dose of NA-1 in Patients Undergoing Endovascular Repair of Ruptured Aneurysms,WITHDRAWN,PHASE2,0.0,2015-11-01,2020-04-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT01744574,"Sex Differences, Hormones & Smoking Cessation",COMPLETED,NA,216.0,2012-12-01,2017-07-27,3.8699470276633314,Adequate (1-10/month),38.69947027663332,Significantly Below (<50%),100,67.3,80.00500000000001
NCT00386074,Iron-fortified Whole Maize Flour Trial,COMPLETED,PHASE2,412.0,2004-05-01,2004-12-01,58.60411214953271,Excellent (>50/month),200.0,Exceeded (≥100%),100,93.0,93.89
NCT06836674,Pediatric Drug Application,COMPLETED,NA,150.0,2023-04-01,2023-06-30,50.733333333333334,Excellent (>50/month),200.0,Exceeded (≥100%),100,72.0,82.92
NCT06059274,Anti-aging Repairing Serum: Efficacy and Tolerability Study,COMPLETED,NA,34.0,2018-03-14,2018-06-07,12.176,Good (10-50/month),121.76,Exceeded (≥100%),100,57.7,67.51
NCT07327918,Effect of Epidural Needle Injection on Catheter Placement Success During Painless Labour,NOT_YET_RECRUITING,PHASE3,216.0,2026-06-28,2027-02-15,28.340689655172415,Good (10-50/month),200.0,Exceeded (≥100%),30,51.3,50.62
NCT01241318,Zambia Chlorhexidine Application Trial,COMPLETED,PHASE2,77535.0,2011-02-01,2013-09-01,2502.826511134677,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT06415318,TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer,RECRUITING,PHASE2,25.0,2024-05-31,2027-12-01,0.5949960906958562,Slow (<1/month),5.9499609069585615,Significantly Below (<50%),60,35.0,15.305
NCT05151718,Multiomic Approach to Radioresistance of Ependymomas in Children and Adolescents,RECRUITING,,370.0,2021-09-30,2025-09-30,7.708966461327858,Adequate (1-10/month),77.08966461327857,Met (75-100%),60,65.9,78.83
NCT05176418,IV Pulsed-Nicotine as a Model of Smoking: The Effects of Dose and Delivery Rate,RECRUITING,EARLY_PHASE1,70.0,2022-09-09,2026-02-01,1.7170024174053184,Adequate (1-10/month),17.170024174053182,Significantly Below (<50%),60,43.6,27.54
NCT05666518,A Study to Learn More About the Safety of the Drug Vericiguat in Japanese People With Chronic Heart Failure Who Will be Receiving Vericiguat Under Real-world Conditions,RECRUITING,,1400.0,2022-08-31,2028-12-31,18.416594641313743,Good (10-50/month),184.16594641313742,Exceeded (≥100%),60,81.3,88.58
NCT03780218,Evaluation of Pulmonary Function in Burn Injury,COMPLETED,,94.0,2019-01-01,2019-10-29,9.506179401993357,Adequate (1-10/month),95.06179401993357,Met (75-100%),100,60.9,73.06
NCT04565418,Exercise to Restore 24h Rhythms in Metabolism,COMPLETED,NA,10.0,2021-01-26,2023-04-24,0.3721271393643032,Slow (<1/month),3.7212713936430317,Significantly Below (<50%),100,45.8,33.03
NCT02329418,Written Document to Assist Family During Decision of Withholding and Withdrawing Life-sustaining Therapies in the Intensive Care Unit,COMPLETED,NA,74.0,2014-09-01,2018-03-01,1.7639467501957713,Adequate (1-10/month),17.639467501957714,Significantly Below (<50%),100,55.9,63.42
NCT06588218,Effect of Watermelon on Gut and Cardiometabolic Health,RECRUITING,NA,36.0,2024-10-13,2026-08-01,1.667945205479452,Adequate (1-10/month),16.67945205479452,Significantly Below (<50%),60,40.9,22.82
NCT05286918,Antibiotic Stewardship in AECOPD Through CRP-Guided Management,NOT_YET_RECRUITING,NA,1184.0,2022-09-01,2026-08-31,24.68558904109589,Good (10-50/month),200.0,Exceeded (≥100%),30,74.0,83.985
NCT01835418,Bedtime Administration of Amlodipine Versus Lisinopril,UNKNOWN,NA,100.0,2013-04-01,,,Slow (<1/month),,Significantly Below (<50%),50,33.0,12.695
NCT02363218,Study on Effectiveness and Safety of Hepatocellular Carcinoma Patients Treated With CyberKnife,UNKNOWN,PHASE2,117.0,2014-05-01,2017-12-01,2.7186870229007636,Adequate (1-10/month),27.18687022900764,Significantly Below (<50%),50,44.4,28.95
NCT02482818,Efficacy of Pregabalin on Chronic Cough,UNKNOWN,PHASE1,40.0,2015-09-01,2021-12-31,0.5264159100734976,Slow (<1/month),5.264159100734977,Significantly Below (<50%),50,33.2,12.989999999999998
NCT04652518,LYT-100 in Post-acute COVID-19 Respiratory Disease,TERMINATED,PHASE2,185.0,2020-12-11,2022-07-18,9.642808219178082,Adequate (1-10/month),96.42808219178082,Met (75-100%),10,42.8,25.929999999999996
NCT00363818,The Association of Platelet Function and Endothelial Function of the Brachial Artery,COMPLETED,,151.0,2006-01-01,2008-03-01,5.818278481012658,Adequate (1-10/month),58.182784810126584,Below (50-75%),100,60.4,72.54
NCT04513418,Effects of Preoperative Enteral Immunonutrition for Esophageal Cancer Patients Given Neoadjuvant Chemoradiotherapy,RECRUITING,PHASE3,244.0,2020-11-10,2028-12-31,2.4982711066263037,Adequate (1-10/month),24.982711066263036,Significantly Below (<50%),60,57.5,67.27
NCT02328118,25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China,UNKNOWN,PHASE2,120.0,2015-02-01,2017-05-01,4.454634146341464,Adequate (1-10/month),44.546341463414635,Significantly Below (<50%),50,44.6,29.42
NCT04796818,An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response,RECRUITING,NA,70.0,2020-08-12,2026-01-31,1.0664664664664665,Adequate (1-10/month),10.664664664664667,Significantly Below (<50%),60,38.6,20.015
NCT01236690,Study of Hepatoma Treated by Perfusing Cinobufacin Through Hepatic Artery Combining Embolotherapy,UNKNOWN,PHASE2,284.0,2010-11-01,2013-11-01,7.887737226277372,Adequate (1-10/month),78.87737226277373,Met (75-100%),50,57.7,67.51
NCT01429090,Bioavailability of Vagantin® Coated Tablets Relative to an Oral Methantheline Bromide Solution,COMPLETED,PHASE1,12.0,1999-10-01,2000-01-01,3.9704347826086956,Adequate (1-10/month),39.70434782608696,Significantly Below (<50%),100,51.0,49.714999999999996
NCT01555190,Combination Therapy With Myo-inositol and Folic Acid Versus Myo-inositol Alone,COMPLETED,NA,50.0,2012-01-01,2013-12-01,2.1742857142857144,Adequate (1-10/month),21.74285714285714,Significantly Below (<50%),100,54.0,58.72500000000001
NCT04369690,"The Psychological, Social, and Economic Impacts of COVID-19",UNKNOWN,,1000.0,2020-04-03,2021-04-03,83.3972602739726,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT05579990,Feasibility of Meal Delivery Postpartum,COMPLETED,NA,11.0,2023-09-27,2025-09-11,0.4683076923076923,Slow (<1/month),4.683076923076924,Significantly Below (<50%),100,45.9,33.495000000000005
NCT02849990,"A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy",COMPLETED,PHASE2,22.0,2017-03-09,2020-12-10,0.48810495626822165,Slow (<1/month),4.881049562682216,Significantly Below (<50%),100,46.8,38.440000000000005
NCT03386890,Clinical Application of Non-invasive Assessment for Staging Liver Steatosis and Liver Fibrosis,UNKNOWN,,400.0,2015-12-01,2018-12-31,10.813499111900533,Good (10-50/month),108.13499111900533,Exceeded (≥100%),50,70.3,82.09
NCT01032590,Internet-Based Weight-Loss Program for Colorectal Cancer Survivors,WITHDRAWN,NA,0.0,2009-07-01,2017-03-02,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT00587990,Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS),TERMINATED,PHASE1,9.0,2007-11-01,2011-06-01,0.20944954128440368,Slow (<1/month),2.094495412844037,Significantly Below (<50%),10,18.7,4.455
NCT00418990,Effect of Vitamins on Academic Performance of School Children,COMPLETED,NA,1600.0,2003-08-01,2005-11-01,59.178614823815316,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT02228590,A Study to Examine APL-130277 in Patients With Parkinson's Disease,COMPLETED,PHASE2,20.0,2014-08-31,2014-11-24,7.16235294117647,Adequate (1-10/month),71.62352941176471,Below (50-75%),100,51.6,51.644999999999996
NCT02032290,Assessment of Coronary Flow Reserve by Doppler Flow Wire in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Differences Between the Loading Dose of Ticagrelor and Clopidogrel,UNKNOWN,PHASE4,88.0,2014-02-01,,,Slow (<1/month),,Significantly Below (<50%),50,32.0,11.425
NCT05321290,Robotic Therapy Program for the Arm After Stroke,COMPLETED,NA,9.0,2015-10-15,2016-11-11,0.6970992366412214,Slow (<1/month),6.970992366412214,Significantly Below (<50%),100,45.7,32.5
NCT05703490,An Innovative Platform for Objective Monitoring of Instrumental Activities of Daily Living,TERMINATED,,64.0,2021-11-01,2024-12-31,1.6852595155709345,Adequate (1-10/month),16.852595155709345,Significantly Below (<50%),10,26.5,7.945
NCT01159990,Antigenic Competition in HIV Preventive Vaccines,COMPLETED,PHASE1,100.0,2011-01-01,2017-04-06,1.3310013117621338,Adequate (1-10/month),13.310013117621338,Significantly Below (<50%),100,53.0,55.80500000000001
NCT00720590,Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors,COMPLETED,NA,30.0,2003-11-01,2006-10-01,0.8574647887323944,Slow (<1/month),8.574647887323945,Significantly Below (<50%),100,47.4,40.98
NCT05230290,Clinical Study of KD6001 in Advanced Solid Tumours,COMPLETED,PHASE1,13.0,2020-09-10,2022-07-26,0.5785380116959065,Slow (<1/month),5.785380116959065,Significantly Below (<50%),100,46.0,34.1
NCT00327990,"Evaluation Of Missed Osteoporosis Diagnoses, And Preference Between Once Monthly Ibandronate And Once Weekly Alendronate",COMPLETED,PHASE4,300.0,2005-04-01,2006-12-01,14.995073891625616,Good (10-50/month),149.95073891625614,Exceeded (≥100%),100,79.0,86.96000000000001
NCT06748690,MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT,RECRUITING,NA,96.0,2024-01-01,2025-12-31,4.0030684931506855,Adequate (1-10/month),40.030684931506855,Significantly Below (<50%),60,45.7,32.5
NCT00495690,Impact of Daily Zinc Supplementation to Infants Born With Low Birth Weight on Death and Severe Disease,COMPLETED,PHASE3,2012.0,2004-11-01,2008-05-01,47.96028191072827,Good (10-50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT02016690,"Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immunocompromised Children With Synagis®",COMPLETED,,312.0,2013-12-01,2015-12-01,13.009972602739728,Good (10-50/month),130.09972602739728,Exceeded (≥100%),100,78.3,86.48
NCT03791697,Telehealth Postop Follow up RCT,UNKNOWN,NA,142.0,2018-07-09,2019-07-31,11.16919896640827,Good (10-50/month),111.6919896640827,Exceeded (≥100%),50,51.4,50.92
NCT00997997,Avelox in Complicated Skin and Skin Structure Infections,COMPLETED,,6127.0,2005-10-01,2008-12-01,161.19782195332758,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT04097197,Factors Influencing Flu Vaccination in Primary Health Care,COMPLETED,NA,197.0,2019-10-14,2020-03-31,35.48331360946746,Good (10-50/month),200.0,Exceeded (≥100%),100,70.8,82.295
NCT05934097,FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma,WITHDRAWN,PHASE1,0.0,2022-12-01,2039-05-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT04754997,Effect of Exercise in Pediatric Hemophilia,UNKNOWN,NA,30.0,2021-01-16,2021-11-30,2.871698113207547,Adequate (1-10/month),28.71698113207547,Significantly Below (<50%),50,37.4,18.62
NCT04543097,Work And Vocational advicE Study - Effectiveness of Adding a Brief Vocational Support Intervention to Usual Primary Care,COMPLETED,NA,130.0,2020-12-23,2025-01-31,2.6381333333333337,Adequate (1-10/month),26.381333333333334,Significantly Below (<50%),100,60.4,72.54
NCT02518997,Effects of Reading to Preterm Infants on Baby and Parents' Well Being,COMPLETED,NA,18.0,2014-10-01,2018-03-01,0.43939053728949484,Slow (<1/month),4.393905372894949,Significantly Below (<50%),100,46.4,36.26
NCT06424197,Colorectal Cancer Screening Intervention Study,COMPLETED,NA,799.0,2023-03-01,2024-08-31,44.30156648451731,Good (10-50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT00663897,Lansoprazole Versus Mosapride for Functional Dyspepsia,COMPLETED,PHASE4,329.0,2008-05-01,2009-09-01,20.52204918032787,Good (10-50/month),200.0,Exceeded (≥100%),100,81.3,88.58
NCT05467397,Feasibility of [11C]Acetate-PET in LAM and TSC,ACTIVE_NOT_RECRUITING,PHASE1,7.0,2021-08-30,2026-06-30,0.12072521246458924,Slow (<1/month),1.2072521246458923,Significantly Below (<50%),85,41.1,23.225
NCT04613297,HLA-G Immuno-Inhibitor Checkpoint Study in Patients With COVID-19 Infection: Molecular and Cellular Assessment,COMPLETED,NA,91.0,2020-10-19,2022-07-19,4.341755485893417,Adequate (1-10/month),43.41755485893417,Significantly Below (<50%),100,57.3,66.74
NCT04008797,A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor,RECRUITING,PHASE1,301.0,2019-07-11,2027-08-31,3.0818836192398256,Adequate (1-10/month),30.81883619239825,Significantly Below (<50%),60,62.1,74.595
NCT06058910,Bilistick Point-of-care System 2.0 Bilirubin Validation,COMPLETED,,80.0,2024-02-01,2024-09-09,11.019004524886878,Good (10-50/month),110.1900452488688,Exceeded (≥100%),100,59.7,71.355
NCT04318210,"Open Label Extension (OLE) of the TDF2 Study, Botswana",COMPLETED,NA,229.0,2012-10-01,2014-07-01,10.925956112852665,Good (10-50/month),109.25956112852666,Exceeded (≥100%),100,73.3,83.61
NCT00000510,Platelet-Inhibitor Drug Trial in Coronary Angioplasty,COMPLETED,PHASE3,,1983-09-01,1988-09-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,30.330000000000002
NCT02821910,Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets,COMPLETED,PHASE1,50.0,2016-07-20,2016-10-31,14.776699029126215,Good (10-50/month),147.76699029126215,Exceeded (≥100%),100,59.0,70.365
NCT04105010,"Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)",COMPLETED,PHASE1,171.0,2019-09-10,2024-02-22,3.2012546125461254,Adequate (1-10/month),32.012546125461256,Significantly Below (<50%),100,63.7,76.655
NCT02584010,Efficacy Study of Two Silicon-based Products to Treat Scars,WITHDRAWN,NA,0.0,2016-01-01,2016-10-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT03590210,Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas,COMPLETED,PHASE2,92.0,2018-06-08,2022-02-12,2.0821412639405206,Adequate (1-10/month),20.821412639405203,Significantly Below (<50%),100,57.4,67.05499999999999
NCT03501810,Study Assessing Safety and Performance of OrtoWell Distractor in Patients Undergoing Spinal Surgery,UNKNOWN,,32.0,2018-04-05,2018-09-30,5.472359550561798,Adequate (1-10/month),54.72359550561797,Below (50-75%),50,35.9,16.445
NCT05718310,Habituation of the Nociceptive Blink Reflex in Experimentally Induced Migraine Attack,UNKNOWN,NA,22.0,2022-11-01,2024-12-01,0.88,Slow (<1/month),8.799999999999999,Significantly Below (<50%),50,31.8,11.19
NCT04007510,California Collaborative Network to Promote Data Driven Care and Improve Outcomes in Early Psychosis,ENROLLING_BY_INVITATION,NA,1329.0,2019-09-10,2026-06-30,16.2795814889336,Good (10-50/month),162.79581488933601,Exceeded (≥100%),55,81.5,88.92999999999999
NCT02344810,"C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer",WITHDRAWN,PHASE1,0.0,2015-03-06,,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT05789810,Manual Pressure and ShotBlocker to Reduce Needle-Related Pain and Fear,COMPLETED,NA,90.0,2022-09-10,2023-02-15,17.339240506329116,Good (10-50/month),173.39240506329114,Exceeded (≥100%),100,62.2,74.74499999999999
NCT06472310,Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR),RECRUITING,,5000.0,2024-06-06,2027-06-30,136.01429848078644,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT06753110,"A Multicenter, Multinational, Cohort Long-term Post-market Clinical Follow-up (PMCF) of the Safety and Efficacy of the Osseoanchored Prostheses for the Rehabilitation of Amputees (OPRA) Implant System When Used for Transhumeral Implantation in Amputee Patients",RECRUITING,NA,70.0,2025-02-19,2026-03-01,5.682133333333334,Adequate (1-10/month),56.821333333333335,Below (50-75%),60,43.6,27.54
NCT03960710,Automatic Segmentation of Polycystic Liver,UNKNOWN,,120.0,2019-04-01,2019-09-01,23.87450980392157,Good (10-50/month),200.0,Exceeded (≥100%),50,47.9,42.64
NCT03495310,"Effect of Mindfulness on Stress, Appetite Hormones and Body Weight of Obese Schoolchildren. Controlled Clinical Trial",COMPLETED,NA,62.0,2018-09-01,2019-08-30,5.199118457300276,Adequate (1-10/month),51.991184573002755,Below (50-75%),100,55.0,61.834999999999994
NCT06966310,Awake Prone Positioning of Patients Suffering Community Acquired Pneumonia Requiring Nasal High Flow Therapy,NOT_YET_RECRUITING,NA,1078.0,2025-05-19,2034-04-01,10.13100339610991,Good (10-50/month),101.31003396109912,Exceeded (≥100%),30,74.0,83.985
NCT00643110,Milk as Treatment for Hypoglycemia,WITHDRAWN,NA,0.0,2008-04-01,2009-01-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT00116610,Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer,COMPLETED,PHASE2,75.0,2005-06-01,2008-03-01,2.2739043824701195,Adequate (1-10/month),22.739043824701195,Significantly Below (<50%),100,56.0,63.71
NCT03421210,Effects of Smoking Environments on Brain Reactivity,COMPLETED,PHASE4,88.0,2018-03-05,2019-12-23,4.071003039513678,Adequate (1-10/month),40.71003039513678,Significantly Below (<50%),100,57.0,66.12
NCT00978510,Study of Health Personnel and the Assistance to Patients With Tuberculosis in Hospital Environment,COMPLETED,,159.0,2004-01-01,2006-12-01,4.544563380281691,Adequate (1-10/month),45.44563380281691,Significantly Below (<50%),100,61.1,73.31
NCT00194610,Botox as a Treatment for Interstitial Cystitis in Women,COMPLETED,PHASE4,20.0,2004-05-01,2010-09-01,0.2630942091616249,Slow (<1/month),2.630942091616249,Significantly Below (<50%),100,46.6,37.375
NCT05406310,Clinical Outcomes of Persistent Atrial Fibrillation Ablation Using Ablation Index-guided Radiofrequency Catheter Ablation in Patients With Continuous Monitoring,WITHDRAWN,,0.0,2024-05-01,2025-06-30,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT06533410,Using the Chinese Indigenization FS Scale in the Diagnosis of Fibromyalgia： Specificity and Sensitivity in Clinical Practice,RECRUITING,,59.0,2024-05-21,2025-05-31,4.789226666666667,Adequate (1-10/month),47.89226666666667,Significantly Below (<50%),60,41.1,23.225
NCT03085810,Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS),TERMINATED,PHASE3,1225.0,2017-03-24,2023-04-27,16.759101123595507,Good (10-50/month),167.59101123595505,Exceeded (≥100%),10,68.0,80.56
NCT06866613,Phase III Trial to Evaluate the Efficacy and Safety in Patients With Ankle Sprains.,COMPLETED,PHASE3,69.0,2025-03-31,2025-10-30,9.860845070422537,Adequate (1-10/month),98.60845070422536,Met (75-100%),100,60.5,72.685
NCT00859313,"An Open-Label Functionality, Safety and Efficacy Study in Patients Undergoing Elective Unilateral Knee Replacement",COMPLETED,PHASE2,30.0,2009-04-01,2009-08-01,7.485245901639344,Adequate (1-10/month),74.85245901639344,Below (50-75%),100,52.4,53.949999999999996
NCT00405613,Aspirin Use and Postoperative Bleeding From Dental Extractions in a Healthy Population,COMPLETED,PHASE2,36.0,2003-05-01,2005-12-01,1.1596190476190475,Adequate (1-10/month),11.596190476190477,Significantly Below (<50%),100,47.9,42.64
NCT02394613,A Phase I Clinical Trial of DARC,UNKNOWN,PHASE1,16.0,2015-05-01,2016-08-01,1.063406113537118,Adequate (1-10/month),10.63406113537118,Significantly Below (<50%),50,31.3,10.299999999999999
NCT00512213,Immunonutrition Versus Standard Enteral Nutrition Before Major Surgery,COMPLETED,NA,154.0,2007-09-01,2010-12-01,3.949250210614996,Adequate (1-10/month),39.492502106149956,Significantly Below (<50%),100,62.3,74.94
NCT01592513,Effect of BIS Monitoring on Propofol Usage During Elective Bronchoscopy,UNKNOWN,NA,80.0,2012-04-01,2012-10-01,13.307103825136613,Good (10-50/month),133.07103825136613,Exceeded (≥100%),50,46.4,36.26
NCT05592613,Next Generation Ingestible Sensors for Medication Adherence Measurement,COMPLETED,PHASE3,15.0,2023-02-06,2024-07-25,0.8534579439252337,Slow (<1/month),8.534579439252337,Significantly Below (<50%),100,46.2,35.089999999999996
NCT04551313,Effectiveness of Social Skills Training Group for Children With Autism Spectrum Disorder,COMPLETED,NA,86.0,2020-10-19,2022-07-27,4.052383900928793,Adequate (1-10/month),40.52383900928793,Significantly Below (<50%),100,56.9,65.89500000000001
NCT01267513,Ambulatory Measurements of Physiological Parameters,UNKNOWN,,200.0,2011-04-01,2012-05-01,15.373737373737374,Good (10-50/month),153.73737373737376,Exceeded (≥100%),50,54.3,59.62
NCT04847713,Early Detection and Follow-Up of Patients With Fabry's Disease,UNKNOWN,,100.0,2021-01-01,2022-12-01,4.354792560801145,Adequate (1-10/month),43.547925608011454,Significantly Below (<50%),50,41.3,23.74
NCT04615013,"NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer",RECRUITING,PHASE1,24.0,2020-11-23,2027-10-31,0.28841689696012635,Slow (<1/month),2.884168969601263,Significantly Below (<50%),60,34.9,15.215
NCT05818813,The Long-term Safety and Effect of Renal Denervation,UNKNOWN,,20.0,2021-04-27,2025-01-01,0.452639405204461,Slow (<1/month),4.52639405204461,Significantly Below (<50%),50,29.9,9.07
NCT03399513,"Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma",COMPLETED,PHASE2,40.0,2018-05-03,2023-12-23,0.5910679611650486,Slow (<1/month),5.910679611650485,Significantly Below (<50%),100,48.2,43.665
NCT02042313,Postoperative Pain Management After Minimally Invasive Esophagectomy,UNKNOWN,PHASE4,58.0,2014-02-01,,,Slow (<1/month),,Significantly Below (<50%),50,29.6,8.885
NCT05380713,......SMARTEST Trial......,COMPLETED,PHASE2,30.0,2022-05-03,2025-12-20,0.6881688018085909,Slow (<1/month),6.881688018085909,Significantly Below (<50%),100,47.4,40.98
NCT04085913,Exparel Injection Effect on Postoperative Opioid Usage,ENROLLING_BY_INVITATION,EARLY_PHASE1,100.0,2019-09-30,2025-07-01,1.4488338886244645,Adequate (1-10/month),14.488338886244644,Significantly Below (<50%),55,39.5,21.044999999999998
NCT05348213,Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma,RECRUITING,PHASE2,76.0,2022-05-16,2025-06-01,2.080431654676259,Adequate (1-10/month),20.804316546762593,Significantly Below (<50%),60,44.1,28.425
NCT02995213,Quantification of UE Use and Effects of Feedback in the Home Setting,COMPLETED,NA,12.0,2015-11-01,2016-12-01,0.9224242424242425,Slow (<1/month),9.224242424242423,Significantly Below (<50%),100,46.0,34.1
NCT07133113,Medium-term Effects of Treatments in Autoimmune Encephalitis,RECRUITING,,200.0,2024-09-01,2027-03-01,6.682766190998903,Adequate (1-10/month),66.82766190998903,Below (50-75%),60,52.3,53.515
NCT03944213,Resting-state Functional Connectivity Throughout a Course of iTBS in Major Depression,UNKNOWN,,60.0,2018-07-23,2024-06-01,0.8534579439252337,Slow (<1/month),8.534579439252337,Significantly Below (<50%),50,33.1,12.814999999999998
NCT06251713,Fluid-removal Guided by VeXUS Score With Usual Care in Patients With Acute Kidney Injury After Cardiac Surgery,RECRUITING,NA,40.0,2024-07-31,2026-07-01,1.7394285714285715,Adequate (1-10/month),17.394285714285715,Significantly Below (<50%),60,41.2,23.425
NCT06436313,DBS Virtual Learning Experience,ACTIVE_NOT_RECRUITING,NA,60.0,2023-09-01,2026-02-01,2.06606334841629,Adequate (1-10/month),20.660633484162897,Significantly Below (<50%),85,50.3,48.215
NCT07125313,Effect of Yoga Training on Cardiovascular and Mental Health Parameters in Hypertensive Patients,NOT_YET_RECRUITING,NA,70.0,2025-08-11,2026-12-20,4.295967741935484,Adequate (1-10/month),42.95967741935484,Significantly Below (<50%),30,34.6,14.729999999999999
NCT04878913,Retrospective Evaluation of Lung Pathology in Subjects With COVID-19,COMPLETED,,35.0,2021-07-07,2021-08-23,22.66808510638298,Good (10-50/month),200.0,Exceeded (≥100%),100,56.1,63.99
NCT00785460,Benfotiamine Prevents Vascular Dysfunction in Healthy Smokers,COMPLETED,PHASE3,20.0,2008-01-01,,,Slow (<1/month),,Significantly Below (<50%),100,41.6,24.29
NCT01614860,Identification of Patient Phenotypes Associated With Elevated Aldosterone Levels,COMPLETED,,90.0,2012-05-01,2014-06-01,3.6,Adequate (1-10/month),36.0,Significantly Below (<50%),100,55.5,62.71
NCT00667160,Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Pediatric Patients With Mild Atopic Dermatitis,COMPLETED,PHASE4,426.0,2002-12-01,2003-11-01,38.70877611940299,Good (10-50/month),200.0,Exceeded (≥100%),100,89.1,92.965
NCT06989060,Nutritional Status in Children With Down Syndrome,NOT_YET_RECRUITING,,75.0,2025-06-01,2026-08-01,5.359154929577465,Adequate (1-10/month),53.591549295774655,Below (50-75%),30,33.3,13.200000000000001
NCT06808360,Supportive and Dignified Maternity Care in Public Health Facilities,COMPLETED,NA,314.0,2019-10-01,2022-03-31,10.48043859649123,Good (10-50/month),104.80438596491229,Exceeded (≥100%),100,80.1,88.02499999999999
NCT01084460,Follow-up of the Natural Course of the Small EUS-suspected Gastric Gastointestinal Stromal Tumors,COMPLETED,,,1997-01-01,2008-12-01,,Slow (<1/month),,Significantly Below (<50%),100,43.3,27.05
NCT04443660,Autophagy/Apoptosis Balance During Pregnancy,COMPLETED,,97.0,2020-12-30,2025-04-07,1.8939576651699808,Adequate (1-10/month),18.93957665169981,Significantly Below (<50%),100,56.1,63.99
NCT06771960,Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC,RECRUITING,,120.0,2025-02-01,2025-12-30,11.002409638554218,Good (10-50/month),110.02409638554215,Exceeded (≥100%),60,50.9,49.370000000000005
NCT03124160,Compare Two Copper IUDs: Mona Lisa NT Cu380 Mini and ParaGard,COMPLETED,PHASE3,1105.0,2017-05-26,2022-06-06,18.310397387044095,Good (10-50/month),183.10397387044094,Exceeded (≥100%),100,95.0,95.7
NCT04326660,SCOPE-Chinese Women Study,COMPLETED,NA,40.0,2020-07-20,2021-12-30,2.306060606060606,Adequate (1-10/month),23.060606060606062,Significantly Below (<50%),100,53.2,56.665
NCT06024460,Non-pharmacological Treatment vs Pharmacological Treatment for Non-acute Lumbar Disc Herniation,RECRUITING,NA,200.0,2023-08-09,2030-12-31,2.253980007404665,Adequate (1-10/month),22.53980007404665,Significantly Below (<50%),60,54.0,58.72500000000001
NCT05452460,"Mindfulness Training, Mental Fatigue, Endurance Performance and Neurocognitive Functions",COMPLETED,NA,53.0,2022-02-17,2023-01-10,4.933700305810398,Adequate (1-10/month),49.33700305810398,Significantly Below (<50%),100,54.2,59.330000000000005
NCT04964960,Pembro+Chemo in Brain Mets,TERMINATED,PHASE2,3.0,2022-05-19,2023-12-19,0.15772020725388602,Slow (<1/month),1.57720207253886,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT04142060,Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC,TERMINATED,PHASE2,34.0,2020-06-01,2022-10-10,1.2020441347270616,Adequate (1-10/month),12.020441347270616,Significantly Below (<50%),10,20.7,6.02
NCT00099060,Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme,COMPLETED,PHASE1,24.0,2004-12-01,2007-11-01,0.6859718309859155,Slow (<1/month),6.859718309859156,Significantly Below (<50%),100,46.9,38.96
NCT04035460,A Pilot Study Comparing Oxygen Delivery Via Helmet Interface Versus High Flow Nasal Cannula,UNKNOWN,NA,1.0,2018-06-01,2022-09-30,0.019241466498103668,Slow (<1/month),0.19241466498103665,Significantly Below (<50%),50,30.1,9.19
NCT03646760,The Improving ATTENDance to Cardiac Rehabilitation Trial,COMPLETED,NA,282.0,2019-03-01,2023-12-31,4.86074745186863,Adequate (1-10/month),48.6074745186863,Significantly Below (<50%),100,72.6,83.28
NCT06654960,Influence of HRS9531 on Pharmacokinetics of Metformin in Healthy Subjects,COMPLETED,PHASE1,20.0,2024-11-05,2024-12-26,11.937254901960785,Good (10-50/month),119.37254901960786,Exceeded (≥100%),100,56.6,65.34
NCT04610060,Power Walking in Cardiac Patients Who Underwent Post-coronary Angioplasty,COMPLETED,NA,24.0,2020-04-07,2020-09-13,4.594716981132075,Adequate (1-10/month),45.947169811320755,Significantly Below (<50%),100,51.9,52.55499999999999
NCT06769620,A First in Human Study of ORT247 in Healthy Volunteers,COMPLETED,PHASE1,44.0,2022-06-06,2023-10-24,2.6521980198019803,Adequate (1-10/month),26.521980198019808,Significantly Below (<50%),100,53.5,57.555
NCT04189120,"The Effect of Ultrasound Guided Superficial, Deep Serratus Plane Blocks and Thoracic Epidural in Thoracotomy",COMPLETED,NA,180.0,2019-04-01,2021-05-16,7.060824742268042,Adequate (1-10/month),70.60824742268042,Below (50-75%),100,64.4,77.37
NCT01420120,"Remedy, Biodegradable Peripheral Stent Registry",COMPLETED,,100.0,2011-01-01,2014-09-01,2.2733383121732635,Adequate (1-10/month),22.733383121732636,Significantly Below (<50%),100,56.3,64.5
NCT04061720,Identifying Effective Treatment for Veterans Unwilling to Quit Smoking,COMPLETED,NA,502.0,2019-11-12,2025-09-26,7.12395337995338,Adequate (1-10/month),71.2395337995338,Below (50-75%),100,90.0,93.17
NCT01867320,Raltegravir for HAM/TSP,COMPLETED,EARLY_PHASE1,19.0,2013-09-05,2018-09-25,0.31330444203683644,Slow (<1/month),3.133044420368364,Significantly Below (<50%),100,46.5,36.815
NCT04221620,Effectiveness of EEG Neurofeedback in Pediatric Occupational Therapy to Improve Executive Functioning,UNKNOWN,NA,30.0,2020-01-01,2021-07-01,1.6694698354661792,Adequate (1-10/month),16.694698354661792,Significantly Below (<50%),50,37.4,18.62
NCT07128420,Microneedle Treatment of Chronic Phase Peyronie's Disease: A Pilot Clinical Trial,ENROLLING_BY_INVITATION,PHASE1,10.0,2025-09-01,2027-09-01,0.41698630136986303,Slow (<1/month),4.16986301369863,Significantly Below (<50%),55,32.3,11.799999999999999
NCT06666920,"Er,Cr:YSGG Laser Bleaching on Tooth Color and Sensitivity",COMPLETED,NA,20.0,2018-10-01,2022-10-01,0.4167008898015058,Slow (<1/month),4.167008898015058,Significantly Below (<50%),100,46.6,37.375
NCT05129020,Neurostimulation to Improve NOWS Outcomes,ACTIVE_NOT_RECRUITING,NA,52.0,2022-07-27,2027-01-31,0.9599029714978776,Slow (<1/month),9.599029714978776,Significantly Below (<50%),85,44.7,29.67
NCT06638320,Hepatitis Delta Virus Infection: Cross-sectional Study in Patients With Chronic Hepatitis B Virus Infection,ACTIVE_NOT_RECRUITING,,2452.0,2024-11-01,2025-12-30,176.03509433962265,Excellent (>50/month),200.0,Exceeded (≥100%),85,93.8,94.80499999999999
NCT01827020,Effect of Ketamine Addition to Lidocaine in Rhinoplasty,COMPLETED,PHASE4,90.0,2013-01-01,2013-03-01,46.433898305084746,Good (10-50/month),200.0,Exceeded (≥100%),100,67.2,79.94
NCT02374320,Exparel as a Nerve Block for Severe Hand Pain,TERMINATED,PHASE2,13.0,2014-11-01,2016-03-01,0.8142386831275721,Slow (<1/month),8.14238683127572,Significantly Below (<50%),10,19.0,4.84
NCT01210820,Feasibility of iFS™ for Intrastromal Arcuate Keratotomy (ISAK) Procedures,COMPLETED,NA,21.0,2010-07-01,2012-06-01,0.9118972895863052,Slow (<1/month),9.118972895863052,Significantly Below (<50%),100,46.7,37.895
NCT02148120,A Study to Evaluate the Acute Bronchodilator Effect of CHF1535 NEXThaler,COMPLETED,PHASE2,60.0,2014-04-01,2014-10-01,9.98032786885246,Adequate (1-10/month),99.80327868852459,Met (75-100%),100,59.8,71.61
NCT05079620,Early Antibiotics After Aspiration in ICU Patients,TERMINATED,PHASE4,5.0,2021-11-30,2024-04-12,0.17615740740740743,Slow (<1/month),1.7615740740740742,Significantly Below (<50%),10,18.4,3.855
NCT04713020,"Application of Educational Intervention on the Knowledge, Depression and Self-efficacy of Patients With Cerebrovascular Accident",COMPLETED,NA,76.0,2021-01-01,2021-08-31,9.559669421487603,Adequate (1-10/month),95.59669421487604,Met (75-100%),100,61.1,73.31
NCT04667520,Testing a Lifestyle Physical Activity Intervention for Women With Depression in Alcohol Treatment,RECRUITING,NA,214.0,2021-05-10,2026-06-30,3.4705167820990943,Adequate (1-10/month),34.705167820990944,Significantly Below (<50%),60,55.1,62.085
NCT05265520,His-Bundle Corrective Pacing in Heart Failure,RECRUITING,NA,120.0,2022-12-02,2027-07-01,2.184688995215311,Adequate (1-10/month),21.846889952153113,Significantly Below (<50%),60,47.6,41.775
NCT05673720,Brain Stimulation and Meditation for Pain After Total Knee Arthroplasty,COMPLETED,NA,24.0,2023-05-15,2024-10-25,1.3810207939508508,Adequate (1-10/month),13.810207939508508,Significantly Below (<50%),100,46.9,38.96
NCT00029120,Evaluation of Age- and Alzheimer's Disease-Related Memory Disorder,COMPLETED,,450.0,2001-12-18,2008-04-21,5.914507772020726,Adequate (1-10/month),59.145077720207254,Below (50-75%),100,84.3,90.71000000000001
NCT07272720,PMCF Investigation of MODULITH® SLX-F2 With StorM-Track in Patients With Kidney Stones,RECRUITING,NA,126.0,2025-12-11,2027-07-01,6.764444444444445,Adequate (1-10/month),67.64444444444445,Below (50-75%),60,48.1,43.275000000000006
NCT02924220,Genetic Susceptibility and Biomarkers in Listeriosis,COMPLETED,,1080.0,2017-02-16,2021-09-30,19.48737403675163,Good (10-50/month),194.8737403675163,Exceeded (≥100%),100,93.3,94.325
NCT06962020,Selection and Efficacy-Influencing Factors of First-Line Biologic Agents in Moderate-to-Severe Ulcerative Colitis,RECRUITING,,400.0,2025-04-30,2025-11-20,59.68627450980392,Excellent (>50/month),200.0,Exceeded (≥100%),60,78.3,86.48
NCT02640820,Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts),UNKNOWN,PHASE2,83.0,2015-12-01,2018-05-01,2.8645351473922904,Adequate (1-10/month),28.645351473922904,Significantly Below (<50%),50,41.6,24.29
NCT02946320,Optimal Predilatation Technique for BVS Implantation,UNKNOWN,PHASE3,45.0,2016-11-01,2017-03-01,11.415000000000001,Good (10-50/month),114.14999999999999,Exceeded (≥100%),50,43.6,27.54
NCT07212920,Validity and Reliability of Video-Based Functional Physiotherapy Assessment of Subacute Knee Injuries,NOT_YET_RECRUITING,NA,138.0,2025-10-01,2026-12-31,9.212105263157895,Adequate (1-10/month),92.12105263157896,Met (75-100%),30,45.0,30.330000000000002
NCT07028320,To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk,COMPLETED,PHASE3,493.0,2021-12-03,2024-05-20,16.692903225806454,Good (10-50/month),166.92903225806455,Exceeded (≥100%),100,94.4,94.865
NCT01962220,Mother Infant Retention for Health: MIR4Health,COMPLETED,NA,680.0,2013-03-01,2015-06-01,25.181508515815086,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT05190120,Adductor Canal Block Versus Femoral Block on Pain and Quadriceps Strength,COMPLETED,PHASE4,132.0,2016-01-01,2022-03-20,1.7700792951541853,Adequate (1-10/month),17.700792951541853,Significantly Below (<50%),100,60.6,72.785
NCT03426020,The Effect of Premedication Type(Pharmalogical and Non Pharmalogical) on Delirium,UNKNOWN,PHASE4,90.0,2018-02-20,2018-06-10,24.905454545454546,Good (10-50/month),200.0,Exceeded (≥100%),50,47.2,40.035
NCT07199920,Implementation of New Multimodal MRI Sequences by Fingerprint to Improve Ischemic Stroke Examination.,NOT_YET_RECRUITING,NA,10.0,2025-10-01,2027-01-01,0.6660831509846827,Slow (<1/month),6.660831509846828,Significantly Below (<50%),30,24.8,7.06
NCT07365020,Feasibility RCT of Culturally Appropriate Physical Activity Strategies for Older Chinese Adults in the UK,COMPLETED,NA,30.0,2024-09-01,2025-09-01,2.5019178082191784,Adequate (1-10/month),25.019178082191786,Significantly Below (<50%),100,52.4,53.949999999999996
NCT05647720,Effect of Maxillary Third Molar Extraction vs. Non-extraction on Distalization of First Molars in a Group of Adolescent Patients,COMPLETED,NA,22.0,2021-02-28,2022-01-15,2.086230529595016,Adequate (1-10/month),20.862305295950158,Significantly Below (<50%),100,51.8,52.17
NCT06012682,Clinical Trials Evaluating the Effect of Metformin Treatment on Function Endometrium in Women Diagnosed With Idiopathic Infertility,NOT_YET_RECRUITING,PHASE2,200.0,2023-08-30,2027-09-30,4.080428954423593,Adequate (1-10/month),40.80428954423593,Significantly Below (<50%),30,45.0,30.330000000000002
NCT05162482,Combination Assessment Trial of COVID-19 Vaccines (COMBAT-COVID),UNKNOWN,PHASE2,1680.0,2022-03-01,2024-06-30,60.02253521126761,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT03636282,Hockey Fans in Training (Hockey FIT): Improving Men's Health Through the Power of Sport,COMPLETED,NA,997.0,2018-11-13,2023-05-03,18.596004901960786,Good (10-50/month),185.96004901960785,Exceeded (≥100%),100,95.0,95.7
NCT00097682,Views of Cancer Patients Regarding Financial Conflicts of Interest,COMPLETED,,300.0,2004-11-18,2007-10-02,8.713740458015266,Adequate (1-10/month),87.13740458015268,Met (75-100%),100,77.3,85.67
NCT03815682,RPTR-147 in Patients With Selected Solid Tumors and Lymphomas,TERMINATED,PHASE1,23.0,2018-10-24,2022-10-11,0.4835082872928177,Slow (<1/month),4.835082872928178,Significantly Below (<50%),10,19.8,5.465
NCT02481882,Baseline Cortical Haemodynamics in MS,UNKNOWN,NA,80.0,2017-01-01,2019-10-01,2.4279162512462613,Adequate (1-10/month),24.27916251246261,Significantly Below (<50%),50,41.4,24.04
NCT07355582,"Injury Incidence, Severity and Burden in Elite Youth Rugby Players",RECRUITING,,400.0,2025-12-18,2026-06-30,62.76288659793815,Excellent (>50/month),200.0,Exceeded (≥100%),60,78.3,86.48
NCT04882982,Caria: Digital Intervention for Menopause Symptom,COMPLETED,NA,150.0,2022-02-01,2022-12-15,14.403785488958992,Good (10-50/month),144.0378548895899,Exceeded (≥100%),100,67.0,79.725
NCT01123382,Electrical Stimulation for Hemiplegic Shoulder Pain,COMPLETED,NA,25.0,2010-01-01,2013-02-01,0.6752440106477374,Slow (<1/month),6.752440106477374,Significantly Below (<50%),100,47.0,39.33
NCT04256382,Dementia Pain Management Educational Program,COMPLETED,NA,285.0,2017-03-27,2020-02-03,8.317737296260786,Adequate (1-10/month),83.17737296260785,Met (75-100%),100,72.8,83.36
NCT05128682,Acute Pudendal Nerve Stimulation On Leak Point Pressure In Women Urodynamic Early Feasibility Study,TERMINATED,NA,4.0,2022-05-24,2022-09-07,1.148679245283019,Adequate (1-10/month),11.48679245283019,Significantly Below (<50%),10,18.3,3.74
NCT07334782,Effects of Vertebral Axial Loading Walking Combined With Core Stabilization Exercises in Individuals With Chronic Low Back Pain,ACTIVE_NOT_RECRUITING,NA,20.0,2026-01-19,2026-07-15,3.43954802259887,Adequate (1-10/month),34.3954802259887,Significantly Below (<50%),85,47.1,39.64
NCT01488682,The Safety and Efficacy of the Harmonic Scalpel in Neck Dissection,UNKNOWN,NA,59.0,2010-01-01,2012-12-01,1.6863474178403757,Adequate (1-10/month),16.86347417840376,Significantly Below (<50%),50,39.7,21.21
NCT04643782,Comparative Study of the ANNE™ One System to Diagnose Obstructive Sleep Apnea,COMPLETED,NA,287.0,2021-05-11,2021-12-27,37.983826086956526,Good (10-50/month),200.0,Exceeded (≥100%),100,78.0,86.075
NCT04957082,Culturally-Targeted COVID-19 Communication and SARS-CoV-2 Antibody Testing Evaluation and Uptake,COMPLETED,NA,666.0,2021-08-04,2022-12-19,40.38454183266933,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT06884982,An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with Lenvatinib,NOT_YET_RECRUITING,PHASE2,30.0,2025-03-13,2028-09-30,0.7040863531225906,Slow (<1/month),7.040863531225907,Significantly Below (<50%),30,26.4,7.865
NCT05560282,Fenfluramine for Adult Dravet Patients,UNKNOWN,PHASE3,15.0,2022-12-10,2024-01-31,1.0949640287769784,Adequate (1-10/month),10.949640287769784,Significantly Below (<50%),50,31.2,10.165000000000001
NCT05913882,Combined Respiratory Training in Persons With ALS,RECRUITING,NA,34.0,2023-08-22,2026-09-30,0.9118590308370045,Slow (<1/month),9.118590308370045,Significantly Below (<50%),60,35.7,16.18
NCT01184482,Lapatinib and Cetuximab in Patients With Solid Tumors,COMPLETED,PHASE1,22.0,2010-06-01,2013-09-01,0.5637037037037037,Slow (<1/month),5.637037037037037,Significantly Below (<50%),100,46.8,38.440000000000005
NCT03166124,A Study of LY900014 in Elderly and Younger Adult Participants With Type 1 Diabetes Mellitus,COMPLETED,PHASE1,80.0,2017-05-24,2017-11-18,13.680898876404495,Good (10-50/month),136.80898876404495,Exceeded (≥100%),100,61.4,73.735
NCT07189624,Effect of Acute Endurance Exercise on the Production of FGF21 and Follistatin in Patients With Hepatocellular Carcinoma,NOT_YET_RECRUITING,NA,12.0,2025-12-01,2029-04-01,0.3001479046836483,Slow (<1/month),3.0014790468364834,Significantly Below (<50%),30,25.0,7.23
NCT06670924,Suturing Techniques for Vesico-urethral Anastomosis,COMPLETED,NA,70.0,2022-02-07,2024-08-16,2.31357220412595,Adequate (1-10/month),23.135722041259502,Significantly Below (<50%),100,55.6,62.905
NCT02812524,Ipilimumab for Head and Neck Cancer Patients,ACTIVE_NOT_RECRUITING,PHASE1,18.0,2016-11-18,2025-12-01,0.16603636363636365,Slow (<1/month),1.6603636363636365,Significantly Below (<50%),85,41.9,24.585
NCT07348224,Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine and Nicotine Analogues,NOT_YET_RECRUITING,NA,24.0,2026-01-31,2026-12-31,2.187305389221557,Adequate (1-10/month),21.87305389221557,Significantly Below (<50%),30,30.9,9.875
NCT04509024,Incidental Auditory Category Training for Language Learning,TERMINATED,NA,106.0,2019-09-01,2023-01-10,2.6296984515077426,Adequate (1-10/month),26.296984515077426,Significantly Below (<50%),10,31.5,10.635
NCT06702124,A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease,RECRUITING,PHASE3,348.0,2023-12-01,2026-04-01,12.433239436619719,Good (10-50/month),124.33239436619718,Exceeded (≥100%),60,70.8,82.295
NCT02676024,Consolidating Tools for Outcomes in Resuscitation,UNKNOWN,NA,456.0,2017-07-05,2019-12-01,15.791399317406144,Good (10-50/month),157.91399317406146,Exceeded (≥100%),50,76.5,85.3
NCT00226824,Safety Study of Galantamine in Tic Disorders,TERMINATED,PHASE4,1.0,2005-09-01,2007-05-01,0.05014827018121911,Slow (<1/month),0.5014827018121911,Significantly Below (<50%),10,18.1,3.105
NCT03820024,MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback,COMPLETED,NA,39.0,2018-09-28,2020-12-23,1.4530722154222766,Adequate (1-10/month),14.530722154222767,Significantly Below (<50%),100,48.1,43.275000000000006
NCT03549624,Standardized Perioperative Management of Patients Operated With Acute Abdominal Surgery in a High-risk Emergency Setting,UNKNOWN,,1435.0,2018-02-26,2023-09-06,21.645887016848366,Good (10-50/month),200.0,Exceeded (≥100%),50,78.3,86.48
NCT00033124,A Behavioral Trial for the Treatment of Methamphetamine Dependence. - 1,UNKNOWN,PHASE2,50.0,2001-07-01,2002-06-01,4.543283582089552,Adequate (1-10/month),45.43283582089552,Significantly Below (<50%),50,39.0,20.505000000000003
NCT05369624,Exercise Capacity in Non-cystic Fibrosis Bronchiectasis After a Pulmonary Rehabilitation Home-based Program,COMPLETED,NA,34.0,2018-05-08,2020-03-14,1.5310059171597634,Adequate (1-10/month),15.310059171597635,Significantly Below (<50%),100,47.7,42.17
NCT06732024,Using Vaccum Assisted Closure of Wound Instead of Primary Closure As Prophylactic Way Against Burst Abdomen,NOT_YET_RECRUITING,NA,100.0,2025-01-01,2026-03-01,7.179245283018869,Adequate (1-10/month),71.79245283018868,Below (50-75%),30,37.0,17.955
NCT05373524,Rheopheresis Mechanism in Hemodialysis Patients With PAD,UNKNOWN,NA,18.0,2022-06-01,2024-05-01,0.7827428571428572,Slow (<1/month),7.827428571428571,Significantly Below (<50%),50,31.4,10.47
NCT04769024,Virtual Reality Intervention for the Reduction of Behavioral and Psychological Symptoms of Dementia,COMPLETED,NA,56.0,2022-12-02,2024-03-04,3.721921397379913,Adequate (1-10/month),37.21921397379913,Significantly Below (<50%),100,54.5,60.12
NCT06945224,A ReaL World Study of DS-8201,ACTIVE_NOT_RECRUITING,,300.0,2024-12-01,2025-06-30,43.27962085308057,Good (10-50/month),200.0,Exceeded (≥100%),85,77.8,85.93499999999999
NCT05718024,Night-time Dexmedetomidine-esketamine Infusion and Sleep Quality in ICU Patients,COMPLETED,PHASE4,174.0,2023-11-01,2025-05-23,9.308541300527242,Adequate (1-10/month),93.08541300527241,Met (75-100%),100,68.9,81.145
NCT04873024,Prevention of Airway Obstruction Events,COMPLETED,NA,15.0,2021-12-01,2022-08-12,1.7976377952755904,Adequate (1-10/month),17.976377952755904,Significantly Below (<50%),100,51.2,50.375
NCT01343524,Changes in Lung Function Based on Differences in Spirometry Equipment Used in Children With Cystic Fibrosis,COMPLETED,,14.0,2010-03-01,2012-01-01,0.6351117734724292,Slow (<1/month),6.351117734724293,Significantly Below (<50%),100,44.5,29.160000000000004
NCT04941924,The ID- RFA Trial: A Trial of Intraductal Radio-frequency Ablation (ID-RFA) Plus Biliary Stenting Versus Biliary Stenting Alone for the Treatment of Malignant Biliary Obstruction.,UNKNOWN,NA,24.0,2022-09-16,2023-10-01,1.9225263157894739,Adequate (1-10/month),19.225263157894737,Significantly Below (<50%),50,36.9,17.735
NCT03183024,Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody,COMPLETED,PHASE4,12.0,2017-09-12,2018-11-06,0.8697142857142858,Slow (<1/month),8.69714285714286,Significantly Below (<50%),100,46.0,34.1
NCT02063724,HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer,COMPLETED,PHASE1,15.0,2014-10-01,2022-09-01,0.15788381742738591,Slow (<1/month),1.578838174273859,Significantly Below (<50%),100,46.2,35.089999999999996
NCT03366324,Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies,UNKNOWN,PHASE1,20.0,2016-05-01,2021-06-01,0.3278406031233172,Slow (<1/month),3.278406031233171,Significantly Below (<50%),50,31.6,10.905
NCT06327724,Belimumab in SLE Synovial Inflammation and Lymph Nodes,RECRUITING,,15.0,2023-09-01,2025-03-01,0.8347349177330896,Slow (<1/month),8.347349177330896,Significantly Below (<50%),60,32.5,12.235
NCT03857724,Three-dimensional Ultrasound Assessment in Cases of Prolapse Surgeries,UNKNOWN,NA,1.0,2019-07-01,2021-09-01,0.038385876418663305,Slow (<1/month),0.38385876418663306,Significantly Below (<50%),50,30.1,9.19
NCT05545124,Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence,UNKNOWN,PHASE2,32.0,2022-11-01,2024-11-01,1.332530779753762,Adequate (1-10/month),13.325307797537622,Significantly Below (<50%),50,32.6,12.31
NCT02273024,Exercise Prior to Allogeneic Hematologic Stem Cell Transplantation,COMPLETED,NA,30.0,2014-10-01,2019-08-01,0.5173937677053825,Slow (<1/month),5.173937677053824,Significantly Below (<50%),100,47.4,40.98
NCT01226524,The Role of Traditional Chinese Medicine in the Treatment of Chronic Childhood Immune Thrombocytopenia (ITP),TERMINATED,PHASE2,7.0,2011-02-01,2014-08-01,0.1668598277212216,Slow (<1/month),1.6685982772122163,Significantly Below (<50%),10,18.6,4.25
NCT03146624,Evaluation of Patients Satisfaction of Attachment Retained Versus Clasp Retained Obturators in Unilateral Total Maxillectomy,COMPLETED,NA,14.0,2015-12-01,2017-03-28,0.8823188405797101,Slow (<1/month),8.8231884057971,Significantly Below (<50%),100,46.1,34.695
NCT00775424,PENNVAX-B With or Without IL-12 or IL-15 as a DNA Vaccine for HIV Infection,COMPLETED,PHASE1,38.0,2008-09-01,2010-06-01,1.8130407523510974,Adequate (1-10/month),18.13040752351097,Significantly Below (<50%),100,53.0,55.80500000000001
NCT05164224,Serum Procalcitonin and Post-cesarean Wound Infection,UNKNOWN,,64.0,2021-01-01,2022-03-01,4.594716981132076,Adequate (1-10/month),45.94716981132076,Significantly Below (<50%),50,38.5,19.895
NCT03252223,Ovarian Response to Recombinant Follicle Stimulating Hormone in Women With PCOS,COMPLETED,PHASE4,33.0,2017-10-02,2021-06-30,0.734835405998537,Slow (<1/month),7.348354059985369,Significantly Below (<50%),100,47.6,41.775
NCT02465723,Detection of Acid Sphingomyelinase/Ceramide Pathway Activation in Radiotherapy Patients Using Intravoxel Incoherent Motion (IVIM) Diffusion-weighted Magnetic Resonance Imaging and Serum Biomarkers,WITHDRAWN,NA,0.0,2015-06-01,,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT02451423,Neoadjuvant Atezolizumab in Localized Bladder Cancer,COMPLETED,PHASE2,23.0,2016-03-29,2023-03-31,0.27369820172009385,Slow (<1/month),2.7369820172009383,Significantly Below (<50%),100,46.8,38.440000000000005
NCT00149123,Low-dose Hydrocortisone in Acutely Burned Patients,COMPLETED,PHASE4,40.0,2005-04-01,2010-10-01,0.6060726729716277,Slow (<1/month),6.060726729716278,Significantly Below (<50%),100,48.2,43.665
NCT02399423,The GlasVEGAS Study (Glasgow Visceral & Ectopic Fat With Weight Gain in South AsianS),COMPLETED,NA,35.0,2015-03-11,2018-07-04,0.8797687861271677,Slow (<1/month),8.797687861271678,Significantly Below (<50%),100,47.8,42.42
NCT03904823,A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC,UNKNOWN,PHASE2,58.0,2019-04-25,2022-12-01,1.3415805471124622,Adequate (1-10/month),13.41580547112462,Significantly Below (<50%),50,34.6,14.729999999999999
NCT03696823,Critical View of Safety in Laparoscopic Cholecystectomy,UNKNOWN,NA,50.0,2018-10-01,2019-11-01,3.8434343434343434,Adequate (1-10/month),38.43434343434344,Significantly Below (<50%),50,39.0,20.505000000000003
NCT01300923,Acamprosate in Youth With Fragile X Syndrome,COMPLETED,PHASE2,14.0,2010-08-01,2011-09-01,1.076161616161616,Adequate (1-10/month),10.761616161616162,Significantly Below (<50%),100,46.1,34.695
NCT00702923,"CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer",TERMINATED,PHASE1,12.0,2008-07-01,2013-03-01,0.2143661971830986,Slow (<1/month),2.143661971830986,Significantly Below (<50%),10,19.0,4.84
NCT06030323,Validation of AI Models to Measure Physical Activity After a Stroke,UNKNOWN,,34.0,2023-06-24,2024-06-24,2.82775956284153,Adequate (1-10/month),28.2775956284153,Significantly Below (<50%),50,36.1,16.665
NCT06785623,Improvement of Depression in Terminal Cancer Patients,NOT_YET_RECRUITING,NA,60.0,2025-01-14,2025-12-31,5.203418803418804,Adequate (1-10/month),52.034188034188034,Below (50-75%),30,33.8,13.694999999999999
NCT04604223,Effect of Pioglitazone on T2DM Patients With COVID-19,UNKNOWN,PHASE4,1506.0,2021-01-18,2021-06-29,282.97925925925927,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT04006223,The Diagnostic Value of Hybrid PET/MR for Systemic Amyloidosis,UNKNOWN,,30.0,2019-03-11,2023-12-31,0.5200455580865604,Slow (<1/month),5.2004555808656034,Significantly Below (<50%),50,30.7,9.585
NCT00224523,Long Term Safety Of GW685698X Via Nasal Biopsy,COMPLETED,PHASE3,125.0,2005-09-01,2007-02-01,7.345559845559846,Adequate (1-10/month),73.45559845559846,Below (50-75%),100,60.0,71.97
NCT00587223,Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB),TERMINATED,PHASE3,1.0,2007-12-01,2008-12-01,0.08316939890710383,Slow (<1/month),0.8316939890710383,Significantly Below (<50%),10,18.1,3.105
NCT00475423,A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.,COMPLETED,PHASE2,122.0,2007-05-01,2011-08-01,2.3912942691564716,Adequate (1-10/month),23.912942691564716,Significantly Below (<50%),100,59.8,71.61
NCT05642923,Post-COVID-19 Chronic Fatigue Syndrome,COMPLETED,PHASE4,528.0,2023-01-08,2025-03-05,20.422261753494283,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT01996423,Impact of Vitamin D Supplementation on Severity of Pediatric Atopic Dermatitis,COMPLETED,NA,101.0,2014-04-01,2014-12-01,12.600163934426229,Good (10-50/month),126.00163934426227,Exceeded (≥100%),100,63.1,76.03
NCT05581459,Muscle Vibration and Joint Position Sense,COMPLETED,NA,45.0,2018-06-06,2018-11-15,8.455555555555556,Adequate (1-10/month),84.55555555555556,Met (75-100%),100,58.6,69.51
NCT03979859,"Evaluate The Safety, Tolerability and Pharmacokinetics Of Multiple Ascending Oral Doses Of WCK 4873 In Healthy Adult Volunteers",COMPLETED,PHASE1,30.0,2013-08-20,2013-12-30,6.918181818181818,Adequate (1-10/month),69.18181818181817,Below (50-75%),100,52.4,53.949999999999996
NCT02861859,Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study,COMPLETED,PHASE3,221.0,2016-12-01,2019-12-23,6.0225962399283794,Adequate (1-10/month),60.22596239928378,Below (50-75%),100,67.7,80.22
NCT07184359,Application of Social Media as a Supporting Tool in the Teaching and Learning Process of Dentistry Students,ENROLLING_BY_INVITATION,NA,90.0,2024-01-14,2026-01-20,3.7172320217096337,Adequate (1-10/month),37.172320217096335,Significantly Below (<50%),55,43.7,27.744999999999997
NCT01710059,Using Mobile Phones to Improve Adherence to Inhaled Steroids,COMPLETED,NA,12.0,2012-12-01,2013-11-01,1.0903880597014926,Adequate (1-10/month),10.903880597014926,Significantly Below (<50%),100,46.0,34.1
NCT02573259,"A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors",COMPLETED,PHASE1,147.0,2016-02-10,2020-11-19,2.5657568807339453,Adequate (1-10/month),25.657568807339455,Significantly Below (<50%),100,61.8,74.19
NCT04785859,Multiparametric Bronchopulmonary Prediction,UNKNOWN,,240.0,2020-12-01,2024-03-01,6.159865092748736,Adequate (1-10/month),61.59865092748736,Below (50-75%),50,52.5,54.345
NCT05788159,"An Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Two-way Crossover, Oralcomparative Pharmacokinetic（PK）Study of Lacosamide Extended-Release Tablets , Adult, Human Subjects Under Fasting Conditions.",UNKNOWN,PHASE1,16.0,2023-04-01,2023-07-31,4.025123966942149,Adequate (1-10/month),40.25123966942149,Significantly Below (<50%),50,36.3,17.0
NCT04913259,Remote Monitoring for Ambulatory Care of Elderly Patients With Cancer,ACTIVE_NOT_RECRUITING,NA,33.0,2021-06-15,2026-06-01,0.5543708609271523,Slow (<1/month),5.543708609271523,Significantly Below (<50%),85,43.1,26.724999999999998
NCT06943859,Ketamine for Opioid Use Disorder,RECRUITING,PHASE2,50.0,2026-01-01,2029-08-31,1.1375186846038863,Adequate (1-10/month),11.375186846038863,Significantly Below (<50%),60,37.0,17.955
NCT01022359,Comparison of Tesio and LifeCath Twin Permanent Dialysis Catheters,COMPLETED,NA,80.0,2008-10-01,2011-09-01,2.2865727699530516,Adequate (1-10/month),22.86572769953052,Significantly Below (<50%),100,56.4,64.88000000000001
NCT07108959,ESPB Versus Perioperative Iv Lidocaine Infusion on Proinflammatory Cytokines in Breast Cancer Surgeries,NOT_YET_RECRUITING,NA,40.0,2025-08-01,2026-12-31,2.3551257253384916,Adequate (1-10/month),23.551257253384918,Significantly Below (<50%),30,32.2,11.635
NCT01648959,Intra Cranial EEG Activity During Dexmedetomidine Sedation,TERMINATED,,5.0,2012-07-01,2014-03-01,0.25032894736842104,Slow (<1/month),2.5032894736842106,Significantly Below (<50%),10,16.7,2.68
NCT01650259,Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus,COMPLETED,,4876.0,2012-07-23,2017-09-14,78.9917189994678,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02803359,Investigation of Human Laryngeal Evoked Brainstem Potentials,COMPLETED,NA,14.0,2016-06-01,2020-07-28,0.28073781291172595,Slow (<1/month),2.8073781291172595,Significantly Below (<50%),100,46.1,34.695
NCT02985359,Impact Evaluation of the WFP-Implemented Nutrition Program in Malawi,COMPLETED,,556.0,2014-01-01,2017-05-01,13.91828947368421,Good (10-50/month),139.18289473684212,Exceeded (≥100%),100,93.3,94.325
NCT07125859,Malnutrition Prevalence and Nutritional Change After Preoperative Nutrition Counseling,RECRUITING,,600.0,2025-07-15,2026-07-01,52.03418803418804,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT03177759,Living With Prostate Cancer (LPC),COMPLETED,,42.0,2016-09-09,2019-08-31,1.1772375690607735,Adequate (1-10/month),11.772375690607735,Significantly Below (<50%),100,46.7,37.895
NCT00481559,Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity,APPROVED_FOR_MARKETING,,,,,,Slow (<1/month),,Significantly Below (<50%),50,23.3,6.569999999999999
NCT04823559,The ThinkCancer! Feasibility Study,UNKNOWN,NA,24.0,2020-02-05,2021-08-01,1.345414364640884,Adequate (1-10/month),13.45414364640884,Significantly Below (<50%),50,31.9,11.295
NCT05223959,Culturally Adapted Psychoeducation for Bipolar Disorder in a Low-resource Setting: A Randomized Controlled Trial,RECRUITING,NA,300.0,2022-06-20,2026-06-01,6.332871012482663,Adequate (1-10/month),63.328710124826635,Below (50-75%),60,62.0,74.42
NCT00689559,Drug Interaction Study Between AZD3480 and Aripiprazole in Healthy Subjects,COMPLETED,PHASE1,52.0,2008-03-01,2009-04-01,3.9971717171717174,Adequate (1-10/month),39.971717171717174,Significantly Below (<50%),100,54.2,59.330000000000005
NCT06352580,Covid-19 Pandemic and Pediatric Dentistry,COMPLETED,,438.0,2022-03-01,2022-06-30,110.18776859504133,Excellent (>50/month),200.0,Exceeded (≥100%),100,93.4,94.75
NCT02329080,New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement,COMPLETED,PHASE2,79.0,2014-12-01,2024-03-22,0.7074904383642249,Slow (<1/month),7.074904383642249,Significantly Below (<50%),100,51.3,50.62
NCT07055880,Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell),NOT_YET_RECRUITING,PHASE2,120.0,2025-07-28,2026-01-15,21.36140350877193,Good (10-50/month),200.0,Exceeded (≥100%),30,43.6,27.54
NCT05010980,Early Detection of Cardiac Amyloidosis,UNKNOWN,,400.0,2021-08-01,2023-09-01,16.0,Good (10-50/month),160.0,Exceeded (≥100%),50,70.3,82.09
NCT04580680,Extracorporeal Blood Purification Therapy in Critically Ill Patients (GlobalARRT),RECRUITING,,1000.0,2020-11-01,2025-09-30,16.96767001114827,Good (10-50/month),169.67670011148272,Exceeded (≥100%),60,81.3,88.58
NCT02682680,Randomized Trial Comparing Colesevelam vs. Ezetimibe,COMPLETED,PHASE4,200.0,2016-01-11,2017-05-25,12.176,Good (10-50/month),121.76,Exceeded (≥100%),100,71.0,82.44
NCT05138380,Hip Osteoarthritis and Foot Orthoses Trial (HOOT),UNKNOWN,NA,28.0,2022-02-01,2025-10-26,0.6253264856933236,Slow (<1/month),6.253264856933235,Significantly Below (<50%),50,32.2,11.635
NCT04996680,Vascular Occlusion for Optimizing Functional Improvement in Patients With Knee Osteoarthritis,COMPLETED,NA,120.0,2021-07-14,2024-02-27,3.81294363256785,Adequate (1-10/month),38.1294363256785,Significantly Below (<50%),100,59.6,71.17999999999999
NCT03725280,Micro RNA Profile in the Ovarian Follicle Fluid of Transgender Men,UNKNOWN,,40.0,2018-11-01,2023-11-01,0.6668127053669223,Slow (<1/month),6.668127053669223,Significantly Below (<50%),50,31.5,10.635
NCT00034580,Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder,COMPLETED,PHASE4,326.0,2001-08-01,2002-08-01,27.18750684931507,Good (10-50/month),200.0,Exceeded (≥100%),100,81.1,88.24499999999999
NCT07230080,Sequential TACE-SBRT Combined With Targeted Immunotherapy for Patients With Intermediate to Advanced Liver Cancer,ACTIVE_NOT_RECRUITING,,17.0,2024-09-01,2025-11-30,1.1373186813186813,Adequate (1-10/month),11.373186813186814,Significantly Below (<50%),85,40.2,22.115000000000002
NCT01351480,Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients,COMPLETED,PHASE3,34.0,2011-06-01,2014-04-01,0.9999613526570048,Slow (<1/month),9.999613526570048,Significantly Below (<50%),100,47.7,42.17
NCT03931980,Robotic Versus Laparoscopic Approach for Rectal Cancer Surgery,COMPLETED,NA,100.0,2019-01-01,2021-06-11,3.4125560538116595,Adequate (1-10/month),34.125560538116595,Significantly Below (<50%),100,58.0,68.245
NCT05438680,Bovine Colostrum in Prevention of Sepsis and Retinopathy of Prematurity,COMPLETED,NA,200.0,2022-06-20,2023-10-01,13.008547008547009,Good (10-50/month),130.08547008547012,Exceeded (≥100%),100,71.0,82.44
NCT04904380,Impact of New Tools of Simulation-enhanced Peer Learning on Neonatal and Maternal Mortality,UNKNOWN,NA,3456.0,2021-10-01,2023-12-30,128.29346341463415,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT03727880,Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma,COMPLETED,PHASE2,28.0,2019-06-04,2025-01-15,0.4153606237816765,Slow (<1/month),4.153606237816765,Significantly Below (<50%),100,47.2,40.035
NCT03985280,Radiofrequency Versus Intraarticular Local Anesthestic and Steroids Injection for Chronic Hip Pain.,UNKNOWN,PHASE4,20.0,2018-06-21,2021-07-30,0.536387665198238,Slow (<1/month),5.3638766519823795,Significantly Below (<50%),50,31.6,10.905
NCT02245880,Tracheal Intubation With Collar Immobilisation : a Comparison of Glidescope and Fastrach,COMPLETED,PHASE4,94.0,2014-04-01,2014-09-01,18.701699346405228,Good (10-50/month),187.0169934640523,Exceeded (≥100%),100,62.5,75.21
NCT03197480,Diabetic Macular Edema Asian Response (DEAR) Study: Biomarkers for Response to Aflibercept in Asian Patients With Center Involving DME,UNKNOWN,PHASE4,36.0,2019-04-17,2021-03-01,1.6021052631578947,Adequate (1-10/month),16.02105263157895,Significantly Below (<50%),50,32.9,12.53
NCT05042180,Virtual Reality-Assisted Cognitive Behavioral Therapy for Alcohol Dependence (CRAVR),UNKNOWN,PHASE2,102.0,2021-10-06,2024-03-01,3.5403420752565564,Adequate (1-10/month),35.403420752565566,Significantly Below (<50%),50,43.2,26.840000000000003
NCT02095080,Determination of the UL of Leucine in Healthy Elderly Men,COMPLETED,NA,6.0,2014-08-01,2015-12-01,0.37503080082135526,Slow (<1/month),3.750308008213553,Significantly Below (<50%),100,45.5,31.705
NCT00909480,Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes,COMPLETED,PHASE4,457.0,2009-05-01,2010-06-01,35.1289898989899,Good (10-50/month),200.0,Exceeded (≥100%),100,91.6,93.695
NCT02357979,Fissure Caries Inhibition Study With Solea CO2-9.3μm Short-pulsed Laser,COMPLETED,NA,60.0,2018-02-08,2020-03-31,2.3355498721227623,Adequate (1-10/month),23.355498721227626,Significantly Below (<50%),100,54.8,61.095
NCT06685679,Melatonin for Pulmonary Hypertension in Full Term Neonates,COMPLETED,PHASE3,40.0,2024-05-15,2025-03-15,4.005263157894737,Adequate (1-10/month),40.05263157894737,Significantly Below (<50%),100,53.2,56.665
NCT05112679,Limb Health and Socket Pressure in Response to Powered Ankle Protheses,COMPLETED,NA,6.0,2021-11-15,2023-07-19,0.2989198036006547,Slow (<1/month),2.9891980360065467,Significantly Below (<50%),100,45.5,31.705
NCT00983879,The Natural History of Infantile Globoid Cell Leukodystrophy,COMPLETED,,6.0,2009-09-01,2014-07-01,0.1035374149659864,Slow (<1/month),1.035374149659864,Significantly Below (<50%),100,43.8,27.965
NCT01226979,Study of High-Dose-Rate Endorectal Brachytherapy (HDRBT) in the Treatment of Locally Advanced Low Rectal Cancer,COMPLETED,NA,16.0,2010-10-26,2018-07-31,0.17179541446208116,Slow (<1/month),1.7179541446208115,Significantly Below (<50%),100,46.3,35.66
NCT03206879,Fecal ESBL Resurgence During Antibiotic Treatment,TERMINATED,,50.0,2016-11-01,2018-12-01,2.0026315789473683,Adequate (1-10/month),20.026315789473685,Significantly Below (<50%),10,25.3,7.414999999999999
NCT02195479,A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma,COMPLETED,PHASE3,706.0,2014-12-09,2024-08-07,6.089725134599036,Adequate (1-10/month),60.89725134599037,Below (50-75%),100,90.0,93.17
NCT06803979,Impact of Delivery Method Elite Athletes.,RECRUITING,,500.0,2025-03-16,2040-01-01,2.816432272390822,Adequate (1-10/month),28.16432272390822,Significantly Below (<50%),60,76.3,85.1
NCT00709579,Physiopathological Study and Pharmacological Modulation of Cutaneous Atrophy's Markers Induced by Glucocorticoids,UNKNOWN,PHASE3,60.0,2008-06-01,2010-08-01,2.3089759797724403,Adequate (1-10/month),23.089759797724398,Significantly Below (<50%),50,39.8,21.47
NCT05351879,Evaluation of a Booster Administration of GAD-alum (Diamyd®) in Individuals With Type 1 Diabetes,COMPLETED,PHASE1,6.0,2022-05-09,2023-08-29,0.3828930817610063,Slow (<1/month),3.828930817610063,Significantly Below (<50%),100,45.5,31.705
NCT01588379,Mothers and Girls Dancing Together Trial,COMPLETED,NA,152.0,2013-01-01,2014-08-01,8.018856152512999,Adequate (1-10/month),80.18856152513,Met (75-100%),100,62.2,74.74499999999999
NCT04564079,An Observational Study to Evaluate the Clinical Utility of the Oncomine Precision Assay Within the Exactis Network,COMPLETED,,100.0,2021-06-01,2023-11-21,3.3709856035437435,Adequate (1-10/month),33.70985603543743,Significantly Below (<50%),100,56.3,64.5
NCT03408379,Impact of Platelet Activation in Intracranial Aneurysm Rupture Risk - PLAQRAN,ACTIVE_NOT_RECRUITING,,230.0,2017-12-20,2033-06-23,1.236087570621469,Adequate (1-10/month),12.36087570621469,Significantly Below (<50%),85,57.2,66.465
NCT06185179,Metformin and Muscle Recovery,RECRUITING,EARLY_PHASE1,50.0,2024-09-01,2030-05-31,0.7254528122020972,Slow (<1/month),7.2545281220209725,Significantly Below (<50%),60,37.0,17.955
NCT02669979,Domiciliary Professional Oral Care for Dependent Elderly,COMPLETED,NA,200.0,2016-01-01,2017-04-01,13.350877192982457,Good (10-50/month),133.50877192982458,Exceeded (≥100%),100,71.0,82.44
NCT00028379,Enhancement of Use-Dependent Plasticity by Somatosensory Stimulation in Chronic Stroke,COMPLETED,NA,52.0,2001-12-01,2005-11-01,1.1061355695317958,Adequate (1-10/month),11.061355695317959,Significantly Below (<50%),100,49.2,46.035
NCT06498479,ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer,RECRUITING,PHASE3,460.0,2024-07-04,2027-05-31,13.197360980207351,Good (10-50/month),131.9736098020735,Exceeded (≥100%),60,79.8,87.27000000000001
NCT06125379,Brief Mindfulness-based Intervention for Indonesian Teacher in Rural Area,ACTIVE_NOT_RECRUITING,NA,80.0,2023-10-15,2025-06-25,3.9340872374798064,Adequate (1-10/month),39.34087237479807,Significantly Below (<50%),85,51.9,52.55499999999999
NCT00228579,Assessment of Changes in Abdominal Fat,COMPLETED,,60.0,2003-06-01,2020-12-01,0.28568747067104644,Slow (<1/month),2.8568747067104643,Significantly Below (<50%),100,48.1,43.275000000000006
NCT01559779,Effect of Gastric Bypass Surgery on Pancreatic Islets and Incretin Function,COMPLETED,,11.0,2010-11-01,2012-12-01,0.44,Slow (<1/month),4.3999999999999995,Significantly Below (<50%),100,44.2,28.549999999999997
NCT06853379,Aromatherapy Versus Diet,NOT_YET_RECRUITING,NA,30.0,2025-03-05,2025-05-10,13.836363636363636,Good (10-50/month),138.36363636363635,Exceeded (≥100%),30,36.4,17.14
NCT05632679,Effect of a Personalized Sound Intervention During Autogenous Gingival Grafts in Adults,UNKNOWN,NA,50.0,2022-05-01,2024-05-01,2.0820793433652534,Adequate (1-10/month),20.820793433652533,Significantly Below (<50%),50,39.0,20.505000000000003
NCT00813579,Study of Prospective Assessment of Living Kidney Donors: Pre and Post Donation,UNKNOWN,,80.0,2008-01-01,2011-01-01,2.221897810218978,Adequate (1-10/month),22.21897810218978,Significantly Below (<50%),50,39.7,21.21
NCT03539679,HEALTH AND EXERCISE IN THE DEFENSE FORCES,UNKNOWN,NA,500.0,2018-05-16,2020-07-01,19.588159588159588,Good (10-50/month),195.88159588159587,Exceeded (≥100%),50,80.0,87.67
NCT05790096,Effectiveness and Safety Study of Filgrastine® in Patientes With Breast Cancer Treated With Myelotoxic Chemotherapy,UNKNOWN,PHASE3,60.0,2023-05-01,2024-12-01,3.148965517241379,Adequate (1-10/month),31.489655172413794,Significantly Below (<50%),50,39.8,21.47
NCT03884296,Response to Live Attenuated Influenza Vaccine in Tonsillar Tissues and Blood,WITHDRAWN,PHASE4,0.0,2019-04-15,2023-11-17,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT05142696,"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab",ACTIVE_NOT_RECRUITING,PHASE1,140.0,2022-07-13,2029-03-23,1.7429856850715748,Adequate (1-10/month),17.429856850715748,Significantly Below (<50%),85,56.7,65.53
NCT07378696,Implementing Evidence-Based Nursing: A Pilot Study of a Leadership and Organizational Change for Implementation,NOT_YET_RECRUITING,NA,300.0,2026-01-01,2027-01-01,25.019178082191782,Good (10-50/month),200.0,Exceeded (≥100%),30,58.0,68.245
NCT01208896,Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma,COMPLETED,PHASE2,32.0,2011-02-03,2017-09-28,0.40102099629477156,Slow (<1/month),4.010209962947715,Significantly Below (<50%),100,47.6,41.775
NCT03741296,REVISITS: Revision Single or Two Stage Surgery,UNKNOWN,NA,110.0,2019-04-01,2022-12-01,2.4988059701492538,Adequate (1-10/month),24.98805970149254,Significantly Below (<50%),50,43.8,27.965
NCT06542796,Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma,RECRUITING,NA,100.0,2024-09-01,2027-05-01,3.131687242798354,Adequate (1-10/month),31.316872427983544,Significantly Below (<50%),60,46.0,34.1
NCT01425996,A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma,TERMINATED,PHASE1,3.0,2011-10-27,2014-10-03,0.0851865671641791,Slow (<1/month),0.8518656716417911,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT06446596,Telerehabilitation-based Exercises vs Standard Home-based Exercise in Low Back Pain,RECRUITING,NA,30.0,2024-11-04,2025-12-01,2.329591836734694,Adequate (1-10/month),23.29591836734694,Significantly Below (<50%),60,40.4,22.34
NCT06935396,Comparison of Physical Function and Quality of Life in Insulin and Non-Insulin Users With Type 2 Diabetes,COMPLETED,,67.0,2019-04-15,2019-11-20,9.31269406392694,Adequate (1-10/month),93.12694063926942,Met (75-100%),100,58.7,69.69
NCT01813396,Prediction of Functional Disability and Clinical Trial in Subjects With Stiff Shoulders,UNKNOWN,NA,45.0,2011-12-01,,,Slow (<1/month),,Significantly Below (<50%),50,28.6,8.58
NCT06832696,Assessment of a Wearable Ultrafiltration Device,NOT_YET_RECRUITING,NA,18.0,2025-11-01,2026-12-31,1.2892235294117647,Adequate (1-10/month),12.892235294117649,Significantly Below (<50%),30,25.4,7.470000000000001
NCT02439996,Different Doses of IVIG for Kawasaki Disease,COMPLETED,PHASE3,404.0,2014-01-01,2016-09-01,12.626036960985626,Good (10-50/month),126.26036960985627,Exceeded (≥100%),100,87.3,92.25
NCT02113696,Intake of Omega 3 in Morbidly Obese Patients,COMPLETED,NA,46.0,2014-05-01,2014-07-01,22.954754098360656,Good (10-50/month),200.0,Exceeded (≥100%),100,58.7,69.69
NCT04592796,Observational Study About Sleep Quality and Its Impact on Daily Life of Nursing-home Residents,COMPLETED,,21.0,2018-12-19,2019-12-19,1.751342465753425,Adequate (1-10/month),17.513424657534248,Significantly Below (<50%),100,50.0,47.675
NCT04339296,Connected Healthcare for Individuals Living at Home With Chronic Conditions,COMPLETED,NA,91.0,2019-03-01,2020-07-31,5.347567567567568,Adequate (1-10/month),53.47567567567568,Below (50-75%),100,57.3,66.74
NCT03577496,Does Aromatherapy Decrease Postoperative Nausea and Vomiting?,COMPLETED,NA,50.0,2018-06-15,2018-12-15,8.316939890710383,Adequate (1-10/month),83.16939890710383,Met (75-100%),100,54.0,58.72500000000001
NCT06649162,A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy,RECRUITING,,10000.0,2024-09-30,2027-03-01,345.12471655328795,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT06789562,F-18 FDG PET/CT and CT in Initial Staging of Non-small Lung Cancer,NOT_YET_RECRUITING,,54.0,2025-01-30,2027-12-31,1.54343661971831,Adequate (1-10/month),15.434366197183099,Significantly Below (<50%),30,26.7,8.065
NCT05523362,Feasibility and Clinical Utility of the Dexcom G6 Continuous Glucose Monitoring Device for Type 2 Diabetes,COMPLETED,NA,56.0,2022-01-15,2023-11-30,2.4921637426900585,Adequate (1-10/month),24.921637426900585,Significantly Below (<50%),100,54.5,60.12
NCT04651062,Detection of Adenomas in Screening Colonoscopy,COMPLETED,NA,1178.0,2017-10-01,2020-04-01,39.27526834611172,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT04003662,Vital Sign Comparison Between Lifelight and Standard of Care - Development,COMPLETED,,9000.0,2018-05-01,2021-05-01,249.96350364963504,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT01915862,Blood Pressure Variability in Acute Ischemic Stroke,COMPLETED,,353.0,2013-08-01,2018-12-01,5.516078028747433,Adequate (1-10/month),55.160780287474346,Below (50-75%),100,76.6,85.35000000000001
NCT05791162,Interest of Follicular Helper Lymphocytes / Regulatory Follicular Helper Lymphocytes Ratio in IgA Nephropathy,RECRUITING,NA,75.0,2023-05-23,2026-05-01,2.1256983240223466,Adequate (1-10/month),21.256983240223466,Significantly Below (<50%),60,44.0,28.249999999999996
NCT07147062,Comparison of the Postoperative Analgesic Effects of RSB and CEB in Pediatric Patients Scheduled for Percutaneous Internal Ring Suturing,RECRUITING,NA,65.0,2025-09-08,2026-02-27,11.503488372093024,Good (10-50/month),115.03488372093025,Exceeded (≥100%),60,48.2,43.665
NCT01710462,"Clinical Study, Multicenter, Randomized With 2 Arms of Pantoprazole + Domperidone and Pantoprazole Isolated at the Gastroesophageal Reflux Disease",WITHDRAWN,PHASE3,0.0,2013-08-01,,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT05467462,Efficacy of Four Different Treatment Regimes on Postpartum Hemorrhage,COMPLETED,NA,300.0,2022-08-01,2023-01-25,51.59322033898305,Excellent (>50/month),200.0,Exceeded (≥100%),100,84.0,90.595
NCT06105762,Ketogenic Diet for Depression,NOT_YET_RECRUITING,NA,120.0,2024-01-01,2027-07-01,2.860454189506656,Adequate (1-10/month),28.604541895066564,Significantly Below (<50%),30,38.6,20.015
NCT03458962,Diagnostic Odyssey: Whole Genome Sequencing (WGS),RECRUITING,,1000.0,2018-02-20,2070-03-01,1.6019366382486055,Adequate (1-10/month),16.019366382486055,Significantly Below (<50%),60,71.3,82.655
NCT07318662,Efficacy and Safety of HMAs Combined With Venetoclax Versus HMAs Alone in ND Int-and H-risk MDS or CMML,ACTIVE_NOT_RECRUITING,,224.0,2020-01-01,2027-03-30,2.577905482041588,Adequate (1-10/month),25.779054820415876,Significantly Below (<50%),85,61.8,74.19
NCT03408262,Clinical Trial of HIV Vaccine Combinations in Healthy Men and Women,COMPLETED,PHASE1,68.0,2017-10-06,2020-02-10,2.415309218203034,Adequate (1-10/month),24.15309218203034,Significantly Below (<50%),100,55.4,62.56
NCT07299162,The Effect of Virtual Reality Therapy on Upper Extremity Functions in Subacute Stroke Patients Receiving Rehabilitation,RECRUITING,NA,38.0,2025-08-15,2026-04-20,4.664193548387097,Adequate (1-10/month),46.64193548387097,Significantly Below (<50%),60,41.0,23.01
NCT02525562,"Stryker NTX Registry Scorpio NRG (Re-""Energize""), Triathlon Total Knee, Triathlon Partial Knee Resurfacing (PKR) With X3 Polyethylene Insert",TERMINATED,NA,237.0,2012-06-28,2020-05-28,2.495427187824282,Adequate (1-10/month),24.954271878242825,Significantly Below (<50%),10,42.0,24.825
NCT00730262,Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme,TERMINATED,PHASE2,40.0,2008-08-01,2010-06-01,1.8200298953662182,Adequate (1-10/month),18.20029895366218,Significantly Below (<50%),10,26.2,7.775
NCT06143462,Vestibular Rehabilitation for Unsteadiness After Intratympanic Gentamicin in Patients With Meniere's Disease,UNKNOWN,NA,48.0,2024-01-01,2024-12-31,4.0030684931506855,Adequate (1-10/month),40.030684931506855,Significantly Below (<50%),50,38.8,20.244999999999997
NCT03504462,Feasibility of Specific Anesthesia of the Forefoot Preserving the Sensitivity of the Heel for Foot Surgery,COMPLETED,NA,27.0,2018-06-25,2019-10-23,1.69459793814433,Adequate (1-10/month),16.945979381443298,Significantly Below (<50%),100,52.2,53.22
NCT01139762,A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms,COMPLETED,PHASE3,696.0,2010-09-01,2012-05-01,34.84578947368421,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT02170246,Analysis of Telmisartan Administered With Antiretroviral Therapy (ART) in Patients With Acute HIV Infection,COMPLETED,PHASE1,21.0,2015-01-28,2018-06-13,0.5188636363636364,Slow (<1/month),5.1886363636363635,Significantly Below (<50%),100,46.7,37.895
NCT04579146,Coronary Artery Disease (CAD) in Patients HIV-infected,UNKNOWN,,60.0,2020-09-07,2023-10-01,1.632171581769437,Adequate (1-10/month),16.321715817694376,Significantly Below (<50%),50,33.1,12.814999999999998
NCT01450046,Vitamin E δ-Tocotrienol Multiple Dose in Healthy Subjects,COMPLETED,PHASE1,18.0,2011-10-01,2016-04-01,0.3332846715328467,Slow (<1/month),3.332846715328467,Significantly Below (<50%),100,46.4,36.26
NCT02265146,ORACLE-NIRS: Lipid cORe Plaque Association With CLinical Events: a Near-InfraRed Spectroscopy Study,WITHDRAWN,,0.0,2014-09-01,2030-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT01803646,AM-101 in the Treatment of Acute Tinnitus 2,COMPLETED,PHASE3,343.0,2014-02-01,2016-06-01,12.269001175088132,Good (10-50/month),122.69001175088133,Exceeded (≥100%),100,82.4,89.145
NCT04389346,A Cone Beam Computed Tomographic Evaluation of Healing of Apicomarginal Defects Using Autologous Platelet Aggregates,UNKNOWN,NA,32.0,2019-07-01,2021-03-01,1.5994745484400656,Adequate (1-10/month),15.994745484400655,Significantly Below (<50%),50,32.6,12.31
NCT00697346,Study of MLN8237 in Participants With Advanced Hematological Malignancies,COMPLETED,PHASE1,58.0,2008-07-11,2016-10-19,0.5842223692918597,Slow (<1/month),5.842223692918597,Significantly Below (<50%),100,49.6,46.785
NCT05520346,Testing a Device for Automatically TRacking Urine and STool in an Inpatient HCT Setting (Project TRUST),RECRUITING,NA,54.0,2023-09-13,2026-06-01,1.657016129032258,Adequate (1-10/month),16.57016129032258,Significantly Below (<50%),60,37.3,18.35
NCT04727346,Evaluation of Post-surgical Improvement in OSA Patients After Imaging of Upper Airway Using CBCT and DISE vs DISE Only,UNKNOWN,,75.0,2021-02-01,2022-07-22,4.259328358208955,Adequate (1-10/month),42.59328358208955,Significantly Below (<50%),50,39.3,20.810000000000002
NCT02968446,Effect of Vitamin D After Application With Valchlor,COMPLETED,EARLY_PHASE1,33.0,2016-11-17,2018-10-01,1.4707467057101027,Adequate (1-10/month),14.707467057101026,Significantly Below (<50%),100,47.6,41.775
NCT03730246,Pain After Cesarean Sectio.,UNKNOWN,,50.0,2018-08-01,2019-07-31,4.181318681318682,Adequate (1-10/month),41.81318681318682,Significantly Below (<50%),50,37.3,18.35
NCT01167946,Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata,COMPLETED,PHASE4,42.0,2003-01-01,2010-07-01,0.4669393718042367,Slow (<1/month),4.669393718042367,Significantly Below (<50%),100,48.4,44.22
NCT00390546,Multicenter Study of Antiarrhythmic Medications for Treatment of Infants With Supraventricular Tachycardia,COMPLETED,PHASE3,72.0,2006-10-01,2011-08-01,1.241745042492918,Adequate (1-10/month),12.417450424929179,Significantly Below (<50%),100,50.8,49.18
NCT05678946,The Effects of Integrated Face-to-face Rehabilitation and Telerehabilitation on the Well-being of Family Caregivers,COMPLETED,,195.0,2022-04-11,2023-08-31,11.707692307692309,Good (10-50/month),117.07692307692308,Exceeded (≥100%),100,68.9,81.145
NCT03636646,Analysis of the Posterior Wall Fracture of the Acetabulum,UNKNOWN,,80.0,2018-08-01,2019-05-01,8.92014652014652,Adequate (1-10/month),89.20146520146521,Met (75-100%),50,44.7,29.67
NCT02976246,Effect of Vitamin K2 (MK7) on Cardiovascular and Bone Disease in Dialysis Patients,COMPLETED,PHASE4,123.0,2016-11-01,,,Slow (<1/month),,Significantly Below (<50%),100,49.8,47.17
NCT01681446,Adjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 Expression,UNKNOWN,PHASE3,296.0,2012-08-01,2019-08-01,3.5251330203442883,Adequate (1-10/month),35.25133020344288,Significantly Below (<50%),50,58.7,69.69
NCT01494246,Effectiveness of an E-mail Tracking Intervention Among the Continued Abstinence of Tobacco Consumption,UNKNOWN,PHASE4,1064.0,2012-12-01,2014-12-01,44.36734246575343,Good (10-50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT05210946,A Single-Arm Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients,UNKNOWN,NA,20.0,2021-12-06,2024-12-06,0.5554744525547445,Slow (<1/month),5.554744525547445,Significantly Below (<50%),50,31.6,10.905
NCT04124146,Long-term Evolution of Patients Suffering From Lumbar Canal Stenosis and Supported by Minimally Invasive Surgery: SUIVISTENO,UNKNOWN,,100.0,2019-12-01,2021-05-01,5.887814313346229,Adequate (1-10/month),58.87814313346229,Below (50-75%),50,41.3,23.74
NCT00802646,The Effects of Combined Spinal Epidurals on Fever During Labor of First-Time Mothers,WITHDRAWN,NA,0.0,2009-06-01,2010-06-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT05108246,Home-Based Dual-Task Training for Older Adults,COMPLETED,NA,16.0,2021-09-01,2022-12-31,1.0021399176954733,Adequate (1-10/month),10.021399176954732,Significantly Below (<50%),100,46.3,35.66
NCT00709046,High Dose Versus Standard Dose Proton Pump Inhibitor (PPI) in High-risk Bleeding Peptic Ulcers After Combined Endoscopic Treatment,UNKNOWN,NA,150.0,2008-01-01,,,Slow (<1/month),,Significantly Below (<50%),50,37.0,17.955
NCT02776046,Individualized Perioperative Open-lung Ventilatory Strategy With High Versus Conventional Inspiratory Oxygen Fraction (iPROVE-O2).,UNKNOWN,NA,756.0,2017-06-01,2019-02-01,37.7256393442623,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT05576246,Airway Occlusion Measured During Non-invasive Ventilation to Assess Respiratory Effort,COMPLETED,NA,12.0,2022-10-30,2025-09-01,0.35224686595949856,Slow (<1/month),3.522468659594985,Significantly Below (<50%),100,46.0,34.1
NCT05524246,Pravastatin as a Prophylactic to Reduce Endothelial Injury in Pediatric Patients With Elevated Body Mass Index,COMPLETED,PHASE1,25.0,2023-01-27,2025-03-05,0.9908854166666667,Slow (<1/month),9.908854166666666,Significantly Below (<50%),100,47.0,39.33
NCT06057246,Individual Determinants of Postprandial Glucose Response in Type 2 Diabetes,UNKNOWN,NA,144.0,2023-05-15,2025-05-01,6.11347280334728,Adequate (1-10/month),61.1347280334728,Below (50-75%),50,46.5,36.815
NCT03857646,The Effect of Lipid Emulsions on Free Fatty Acids and Free Bilirubin in Premature Newborns,COMPLETED,PHASE4,66.0,2019-03-02,2020-06-11,4.302012847965739,Adequate (1-10/month),43.02012847965739,Significantly Below (<50%),100,55.3,62.36000000000001
NCT02716688,S-1 and Radiotherapy for Elderly Esophageal Cancer Patients,WITHDRAWN,PHASE2,0.0,2016-01-01,2020-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT06174688,A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants,COMPLETED,PHASE3,140.0,2023-12-12,2024-09-13,15.440579710144927,Good (10-50/month),154.40579710144925,Exceeded (≥100%),100,66.2,79.2
NCT05818488,The Effect of a Mind-body Exercise Program on Aspects of Attention in Individuals With Anxiety,UNKNOWN,NA,16.0,2024-02-01,2024-12-20,1.5078637770897834,Adequate (1-10/month),15.078637770897835,Significantly Below (<50%),50,31.3,10.299999999999999
NCT01705288,Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study,COMPLETED,EARLY_PHASE1,103.0,2013-01-01,2016-08-24,2.355612321562735,Adequate (1-10/month),23.556123215627352,Significantly Below (<50%),100,58.2,68.795
NCT05724888,Physical Activity and CVD in Adolescents With Type 2 Diabetes,UNKNOWN,NA,40.0,2023-09-01,2023-12-20,11.06909090909091,Good (10-50/month),110.6909090909091,Exceeded (≥100%),50,43.2,26.840000000000003
NCT01333488,Mild Hypothermia and Supplemental Magnesium Sulfate Infusion in Severe Traumatic Brain Injury (TBI) Subjects,TERMINATED,PHASE2,6.0,2011-12-01,2014-06-01,0.20004381161007667,Slow (<1/month),2.0004381161007667,Significantly Below (<50%),10,18.5,4.02
NCT02883088,Relationship Between OCT Coronary Plaque Morphology and Clinical Outcome,UNKNOWN,,1003.0,2013-01-01,2019-12-01,12.09161188118812,Good (10-50/month),120.9161188118812,Exceeded (≥100%),50,78.3,86.48
NCT00621088,A Prospective Randomised Multicenter Study Comparing the Sliding Hip Screw and the Intertan Nail in Trochanteric and Subtrochanteric Femoral Fractures,COMPLETED,NA,500.0,2008-02-01,2010-03-01,20.05270092226614,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT05080088,Retrospective Evaluation of 3 Colonic Adenoma Detection Strategies,COMPLETED,,90.0,2021-04-06,2021-07-08,29.458064516129035,Good (10-50/month),200.0,Exceeded (≥100%),100,60.5,72.685
NCT06965088,Comparison of Recurrence Rate of Keloid After Excision Between Intra-operative Steroid Injection and Steroid With Platelet-rich Plasma Injection Combination Therapy,ACTIVE_NOT_RECRUITING,PHASE2,212.0,2025-04-28,2026-09-30,12.410153846153845,Good (10-50/month),124.10153846153847,Exceeded (≥100%),85,67.5,80.08
NCT05631288,Association of Herpesvirus and Periodontitis,COMPLETED,,100.0,2019-03-01,2022-02-01,2.850187265917603,Adequate (1-10/month),28.50187265917603,Significantly Below (<50%),100,56.3,64.5
NCT03616288,Trial of Thiamine Supplementation in Cambodia,COMPLETED,NA,335.0,2018-08-28,2021-01-28,11.535520361990951,Good (10-50/month),115.35520361990952,Exceeded (≥100%),100,81.8,88.99000000000001
NCT06407388,Ultrasound Findings in Diabetic Pregnancies,RECRUITING,,156.0,2023-06-01,2025-06-01,6.49608755129959,Adequate (1-10/month),64.9608755129959,Below (50-75%),60,48.8,45.184999999999995
NCT06737588,The Addictive Diagnostic Value of Apparent Diffusion Coefficients to bpMRI in the Diagnosis of Prostate Cancer,RECRUITING,,600.0,2024-12-01,2027-03-31,21.487058823529413,Good (10-50/month),200.0,Exceeded (≥100%),60,81.3,88.58
NCT06087588,Pericapsular Nerve Group Block Chemical Neurolysis in Advanced Hip Osteoarthritis,COMPLETED,PHASE4,100.0,2023-10-17,2025-01-14,6.69010989010989,Adequate (1-10/month),66.9010989010989,Below (50-75%),100,58.0,68.245
NCT00241488,DISCOVERY Asia - Crestor in Type IIa and IIb Hypercholesteremia,COMPLETED,PHASE3,1362.0,2003-06-01,2007-02-01,30.91668903803132,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT05158088,Video Laryngoscope Versus USB Borescope in Difficult Intubation,COMPLETED,NA,120.0,2021-12-20,2022-04-01,35.811764705882354,Good (10-50/month),200.0,Exceeded (≥100%),100,64.6,77.59
NCT07061288,"A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia",RECRUITING,PHASE1,48.0,2025-09-03,2027-10-15,1.8926424870466323,Adequate (1-10/month),18.92642487046632,Significantly Below (<50%),60,41.8,24.445
NCT03245788,Effectiveness of Lay Navigators in Meeting Cancer Patients' Non-Clinical Needs: A Pilot Study,COMPLETED,NA,1053.0,2017-02-15,2018-12-31,46.86157894736842,Good (10-50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT00382603,Evaluation of an Investigational Multi-Purpose Disinfecting Solution for the Care of Soft Contact Lenses in Symptomatic Patients,COMPLETED,NA,362.0,2004-08-01,2005-02-01,59.88739130434783,Excellent (>50/month),200.0,Exceeded (≥100%),100,89.0,92.945
NCT00620503,Proellex® Pharmacokinetic Bridging Study II,COMPLETED,PHASE1,12.0,2008-02-29,2008-04-30,5.988196721311475,Adequate (1-10/month),59.88196721311475,Below (50-75%),100,51.0,49.714999999999996
NCT06977503,Electrotherapy Stimulation Together With Life Coaching for the Support of Burnout Symptoms in Healthcare Workers,RECRUITING,NA,40.0,2026-03-01,2027-10-15,2.0532883642495787,Adequate (1-10/month),20.53288364249579,Significantly Below (<50%),60,41.2,23.425
NCT04732403,Ureteral Jets and Patient Positioning Study,COMPLETED,NA,91.0,2021-02-01,2022-03-01,7.048447837150128,Adequate (1-10/month),70.48447837150128,Below (50-75%),100,57.3,66.74
NCT02709603,Hyoscine Butyl Bromide in Reducing Pain During HSG,COMPLETED,PHASE4,200.0,2016-03-01,2016-06-01,66.17391304347827,Excellent (>50/month),200.0,Exceeded (≥100%),100,76.0,84.92
NCT01048203,A Single Dose Metabolism and Mass Balance Study of 14C-ABR-215050 in Healthy Subjects,COMPLETED,PHASE1,6.0,2009-01-01,2009-03-01,3.095593220338983,Adequate (1-10/month),30.955932203389835,Significantly Below (<50%),100,50.5,48.515
NCT00746603,Feasibility Study of Simvastatin in Hodgkin's Lymphoma Survivors,TERMINATED,NA,3.0,2008-01-01,2009-07-01,0.1669469835466179,Slow (<1/month),1.669469835466179,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT00393003,Target-controlled Infusion of Propofol and Remifentanil for Postoperative Sedation Guided by the Bispectral Index,COMPLETED,PHASE4,32.0,2006-09-01,2007-04-01,4.594716981132076,Adequate (1-10/month),45.94716981132076,Significantly Below (<50%),100,52.6,54.684999999999995
NCT06913803,To Find Effectiveness of Stretching Versus Soft Tissue Mobilization in Coccydynia in Postpartum Females,ACTIVE_NOT_RECRUITING,NA,46.0,2025-03-20,2026-02-20,4.155014836795252,Adequate (1-10/month),41.55014836795253,Significantly Below (<50%),85,49.2,46.035
NCT07275203,Concordance of the Biology of Primary Breast Carcinoma and the Biology of Recurrence .,NOT_YET_RECRUITING,,200.0,2026-03-01,2026-10-01,28.448598130841123,Good (10-50/month),200.0,Exceeded (≥100%),30,48.3,43.985
NCT06218303,Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ,RECRUITING,PHASE1,50.0,2024-02-07,2028-08-31,0.9130173965206959,Slow (<1/month),9.130173965206959,Significantly Below (<50%),60,37.0,17.955
NCT01457703,Reproductive Hormonal Alterations in Obesity,COMPLETED,NA,62.0,2010-06-01,2013-07-01,1.6760923623445827,Adequate (1-10/month),16.760923623445827,Significantly Below (<50%),100,55.0,61.834999999999994
NCT03255603,Gastrointestinal Assessment of Three Novel RS4,COMPLETED,NA,40.0,2017-09-01,2018-12-22,2.5526205450733754,Adequate (1-10/month),25.52620545073375,Significantly Below (<50%),100,53.2,56.665
NCT02623803,Perioperative Intravenous Lidocaine Infusion for Patients Undergoing Laparoscopic and Open Pancreatectomies,COMPLETED,PHASE4,48.0,2016-01-01,2018-02-01,1.91748031496063,Adequate (1-10/month),19.1748031496063,Significantly Below (<50%),100,53.8,58.065
NCT05606003,Using a Community-level Just-in-Time Adaptive Intervention to Address COVID-19 Testing Disparities,UNKNOWN,NA,1280.0,2021-06-07,2022-12-30,68.23677758318739,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT03559803,A Prospective Study of Monitoring Immune Response in Locally Advanced Cervix Cancer,UNKNOWN,NA,58.0,2016-10-01,2019-12-01,1.5272664359861592,Adequate (1-10/month),15.272664359861594,Significantly Below (<50%),50,34.6,14.729999999999999
NCT03260803,Oligopin Supplementation and Bone Turnover Markers and Antioxidant Changes in Postmenopausal Osteopenic Women,COMPLETED,PHASE3,43.0,2018-02-01,2019-03-01,3.3305852417302804,Adequate (1-10/month),33.3058524173028,Significantly Below (<50%),100,53.4,57.35
NCT06729203,Effect of Ultrasound Cavitation on Insulin Resistance in Patients with Central Obesity in Female,RECRUITING,NA,52.0,2024-12-01,2025-12-01,4.336657534246576,Adequate (1-10/month),43.36657534246576,Significantly Below (<50%),60,42.2,25.155
NCT02401503,Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG),COMPLETED,PHASE2,66.0,2015-05-06,2024-12-17,0.5718872758326217,Slow (<1/month),5.718872758326217,Significantly Below (<50%),100,50.3,48.215
NCT05920603,Iodine Status of the Indigenous Peoples (Karen) Living in Thailand,COMPLETED,,600.0,2022-08-05,2023-08-04,50.175824175824175,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT06821503,"Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C",NOT_YET_RECRUITING,PHASE1,72.0,2025-02-01,2028-12-01,1.566604717655468,Adequate (1-10/month),15.666047176554681,Significantly Below (<50%),30,29.8,8.98
NCT00173303,The Diagnostic Efficacy of Computer-Aided Detection (CAD) in Full-Field Digital Mammography (FFDM)- A Prospective Study,UNKNOWN,,3000.0,2006-01-01,2008-01-01,125.09589041095892,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT00914303,Study to Evaluate Different Extended Release (ER)-Formulations and Multiple Ascending Dosing of AZD3241,COMPLETED,PHASE1,77.0,2009-06-01,2010-03-01,8.585641025641026,Adequate (1-10/month),85.85641025641027,Met (75-100%),100,61.2,73.43499999999999
NCT00987103,Pharmacokinetic Study to Rectal and Sublingual Administration of Tacrolimus in Future Kidney Transplant Patients,UNKNOWN,PHASE1,18.0,2009-09-01,2011-09-01,0.7505753424657535,Slow (<1/month),7.505753424657535,Significantly Below (<50%),50,31.4,10.47
NCT03295903,Cannabinoid Supplementation on Vascular and Cognitive Function,UNKNOWN,EARLY_PHASE1,24.0,2018-01-01,2021-10-01,0.5336449963476991,Slow (<1/month),5.336449963476991,Significantly Below (<50%),50,31.9,11.295
NCT00003203,Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors,COMPLETED,PHASE2,168.0,1998-03-01,2012-03-01,0.9999843566679704,Slow (<1/month),9.999843566679704,Significantly Below (<50%),100,58.4,69.175
NCT05910203,The Effect of Education Based on Health Belief Model on Smoking Behaviors of Visually Impaired Individuals,RECRUITING,NA,40.0,2023-12-01,2024-12-01,3.3267759562841532,Adequate (1-10/month),33.26775956284153,Significantly Below (<50%),60,41.2,23.425
NCT00537303,Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes,COMPLETED,PHASE4,296.0,2007-10-01,2009-03-01,17.42793036750484,Good (10-50/month),174.27930367504837,Exceeded (≥100%),100,78.7,86.835
NCT06761703,A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss,COMPLETED,,200.0,2024-11-14,2025-01-06,114.8679245283019,Excellent (>50/month),200.0,Exceeded (≥100%),100,74.3,84.205
NCT05126303,Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery,TERMINATED,PHASE2,177.0,2022-03-31,2023-07-12,11.512564102564104,Good (10-50/month),115.12564102564104,Exceeded (≥100%),10,42.2,25.155
NCT05550103,Effect of Serial Remote Ischemic Conditioning on Dynamic Cerebral Autoregulation in Patients With Intravenous Thrombolysis (SRICDCA-IVT),UNKNOWN,NA,60.0,2022-10-01,2023-05-01,8.615094339622642,Adequate (1-10/month),86.15094339622642,Met (75-100%),50,44.8,29.845
NCT04365803,Histology VABB-Histology Post Surgery Pilot Project (BETTY Trial),UNKNOWN,,22.0,2018-06-01,2023-12-31,0.3284355076017656,Slow (<1/month),3.2843550760176554,Significantly Below (<50%),50,30.1,9.19
NCT05087303,Telemedicine for Children With Sickle Cell Disease,RECRUITING,NA,60.0,2022-11-23,2026-01-01,1.6091629955947138,Adequate (1-10/month),16.091629955947138,Significantly Below (<50%),60,37.8,19.015
NCT06531603,Postoperative Analgesic Effectiveness of Bupivacaine With and Without Dexmedetomidine in Patients With Abdominal Surgery,COMPLETED,PHASE2,64.0,2022-02-20,2023-04-20,4.594716981132076,Adequate (1-10/month),45.94716981132076,Significantly Below (<50%),100,55.1,62.085
NCT04284527,The Assessment of Physiotherapy Practice Validation as a Measure in Physiotherapy Student,COMPLETED,,300.0,2020-03-24,2020-06-04,126.83333333333333,Excellent (>50/month),200.0,Exceeded (≥100%),100,82.3,89.115
NCT05732727,Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease,RECRUITING,PHASE3,720.0,2023-03-28,2029-03-01,10.123233256351039,Good (10-50/month),101.23233256351038,Exceeded (≥100%),60,83.0,89.505
NCT07160127,A Clinical Study of Chinese Herbal Formula TJAOA103 in Treating Genitourinary Syndrome of Menopause,NOT_YET_RECRUITING,EARLY_PHASE1,113.0,2025-09-15,2027-09-15,4.711945205479452,Adequate (1-10/month),47.11945205479452,Significantly Below (<50%),30,38.0,19.255
NCT03652727,FX vs. ECG Guidance for PICC Insertion,COMPLETED,NA,120.0,2018-09-04,2019-02-20,21.614201183431952,Good (10-50/month),200.0,Exceeded (≥100%),100,64.6,77.59
NCT05194527,The Detrimental Course of Acute Intestinal Ischemia,UNKNOWN,,120.0,2020-09-15,2024-09-15,2.500205338809035,Adequate (1-10/month),25.00205338809035,Significantly Below (<50%),50,42.9,26.145000000000003
NCT06225427,Gilteritinib for the Treatment of ALK NSCLC,RECRUITING,PHASE1,30.0,2024-07-25,2027-05-01,0.9041584158415843,Slow (<1/month),9.041584158415843,Significantly Below (<50%),60,35.4,15.765
NCT02565927,A Trail of a Novel Tracheal Radioactive Stent for the Malignant Airway Obstruction,UNKNOWN,PHASE2,60.0,2015-05-01,2016-09-01,3.734969325153375,Adequate (1-10/month),37.34969325153374,Significantly Below (<50%),50,39.8,21.47
NCT05033327,Feasibility of an App-based Nutrition & Exercise Program in Cirrhosis,COMPLETED,NA,27.0,2021-04-20,2022-12-31,1.3256129032258064,Adequate (1-10/month),13.256129032258066,Significantly Below (<50%),100,47.2,40.035
NCT03118427,Zero-fluoroscopic Navigation Versus Conventional Fluoroscopic Navigation for Double-chamber Pacemaker Implantation,UNKNOWN,NA,100.0,2013-01-01,2020-12-01,1.0529228640608785,Adequate (1-10/month),10.529228640608787,Significantly Below (<50%),50,38.0,19.255
NCT06099327,Image-based Remote Monitoring in Cardiac Surgery Patients,COMPLETED,,60.0,2024-02-23,2025-02-04,5.263400576368877,Adequate (1-10/month),52.63400576368876,Below (50-75%),100,53.1,56.105000000000004
NCT04077827,TIVA Admnistration and Autologous Fat Transfer in Breast Reconstruction,COMPLETED,NA,46.0,2019-09-01,2020-03-30,6.636208530805687,Adequate (1-10/month),66.36208530805689,Below (50-75%),100,53.7,57.84
NCT03793127,Brown Adipose Tissue Pilot,ACTIVE_NOT_RECRUITING,,24.0,2019-01-23,2025-12-01,0.2917571884984026,Slow (<1/month),2.9175718849840258,Significantly Below (<50%),85,40.8,22.745
NCT06673927,"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of YZJ-1139 in Healthy Participants",COMPLETED,PHASE1,104.0,2017-12-01,2019-03-08,6.852294372294373,Adequate (1-10/month),68.52294372294372,Below (50-75%),100,58.3,68.99499999999999
NCT00461227,Effect of Heredity and Environment on Asthma Development and Severity in Puerto Rican Children,COMPLETED,,1127.0,2006-08-01,2010-06-01,24.5042,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT03943927,Preemptive Pharmacogenetic-guided Metoprolol Management for PostoperativeAtrial Fibrillation in Cardiac Surgery,COMPLETED,NA,107.0,2021-03-05,2022-11-20,5.211328,Adequate (1-10/month),52.11328,Below (50-75%),100,58.6,69.51
NCT07060027,Single vs. Double Tenting Screws for Horizontal Ridge Augmentation.,COMPLETED,NA,16.0,2022-08-01,2024-12-10,0.5650116009280742,Slow (<1/month),5.650116009280742,Significantly Below (<50%),100,46.3,35.66
NCT06892327,BIOmetric MEasurements in Diagnostics: Comparison of EXperts and IA-assisted Residents,COMPLETED,,60.0,2025-04-01,2025-04-01,60.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,43.1,26.724999999999998
NCT07255027,Study on the Efficacy and Safety of Anesthesia-Induced Sleep Therapy for Refractory Insomnia,NOT_YET_RECRUITING,NA,180.0,2025-12-01,2027-08-01,9.011842105263158,Adequate (1-10/month),90.11842105263158,Met (75-100%),30,48.4,44.22
NCT03167827,Effects of Physical Training and Isoflavone Supplementation On Pelvic Floor in Women in the Postmenopausal Period,COMPLETED,PHASE4,22.0,2016-09-01,2017-03-01,3.699889502762431,Adequate (1-10/month),36.998895027624314,Significantly Below (<50%),100,51.8,52.17
NCT03252327,Effects of the Interventions Using Multiple Sensory Integrations on Preterm Infants' Stress-Related Outcomes,COMPLETED,NA,150.0,2017-08-26,2018-11-30,9.904555314533622,Adequate (1-10/month),99.04555314533623,Met (75-100%),100,67.0,79.725
NCT04946227,"Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2')",UNKNOWN,PHASE2,52.0,2021-07-01,2022-12-01,3.055752895752896,Adequate (1-10/month),30.557528957528962,Significantly Below (<50%),50,39.2,20.715
NCT06423027,Nature-Oriented Chatbots on Older Adults' Mental Health,NOT_YET_RECRUITING,NA,60.0,2024-05-01,2025-06-01,4.612121212121212,Adequate (1-10/month),46.121212121212125,Significantly Below (<50%),30,33.8,13.694999999999999
NCT06645327,Utility of the Superior Vena Cava Collapsibility Index (SVC-CI) to Predict Fluid Responsiveness in Patients With Coronary Artery Disease Undergoing Surgical Revascularization,RECRUITING,,120.0,2025-02-24,2029-01-01,2.5961620469083155,Adequate (1-10/month),25.96162046908315,Significantly Below (<50%),60,45.9,33.495000000000005
NCT02365727,Exparel vs Exparel Plus ACB in TKAs,WITHDRAWN,PHASE4,0.0,2015-04-01,2015-08-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT03513627,Microvascular Reactivity of the Gingiva Around Implant Born Crown,UNKNOWN,,20.0,2018-05-28,2020-04-01,0.9032640949554896,Slow (<1/month),9.032640949554898,Significantly Below (<50%),50,29.9,9.07
NCT03825627,From Attention to Behavior: Increasing Behavioral Inhibition,UNKNOWN,NA,76.0,2019-06-01,2020-12-31,3.9955785837651123,Adequate (1-10/month),39.95578583765112,Significantly Below (<50%),50,41.1,23.225
NCT04840927,A Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release (TR) Tablets Compared to an E7386 Immediate Release (IR) Tablet in Healthy Adult Participants,WITHDRAWN,PHASE1,0.0,2021-04-09,2023-05-17,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT01438827,Avanz Phleum Pratense Maintenance Dose,COMPLETED,PHASE2,450.0,2011-09-01,2013-01-01,28.06967213114754,Good (10-50/month),200.0,Exceeded (≥100%),100,91.0,93.56
NCT03893227,Prevalence of Nasal Hyperreactivity in Chronic Upper Airway Inflammation,COMPLETED,,756.0,2019-01-22,2020-12-31,32.457884344146684,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT04343027,Patient Satisfaction in the Orthopedic Surgery Clinic,WITHDRAWN,NA,0.0,2022-08-01,2023-06-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT05022927,A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma,ACTIVE_NOT_RECRUITING,PHASE1,179.0,2021-06-01,2025-12-31,3.2549342891278377,Adequate (1-10/month),32.54934289127837,Significantly Below (<50%),85,59.8,71.61
NCT01928927,Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study),COMPLETED,PHASE2,58.0,2014-01-01,2016-03-01,2.234835443037975,Adequate (1-10/month),22.348354430379747,Significantly Below (<50%),100,54.6,60.39
NCT05575427,Efficacy of Combination Therapy With Minocycline for Treatment of Stenotrophomonas Maltophilia Infections,UNKNOWN,PHASE4,112.0,2022-11-24,2024-11-01,4.815367231638418,Adequate (1-10/month),48.15367231638418,Significantly Below (<50%),50,44.0,28.249999999999996
NCT06393361,Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.,RECRUITING,PHASE2,100.0,2024-06-01,2027-06-01,2.779908675799087,Adequate (1-10/month),27.79908675799087,Significantly Below (<50%),60,46.0,34.1
NCT05206461,Relationship Between Trunk Control and Hand Function and Quality of Life,COMPLETED,,43.0,2020-01-01,2021-12-13,1.838370786516854,Adequate (1-10/month),18.38370786516854,Significantly Below (<50%),100,51.8,52.17
NCT06273761,Evaluation of Medication Management Service,RECRUITING,NA,640.0,2024-02-06,2027-05-01,16.50983050847458,Good (10-50/month),165.09830508474576,Exceeded (≥100%),60,83.0,89.505
NCT05440461,Reliability and Validity Study of Urdu Version of Oxford Knee Score in Patients With Knee Osteoarthritis,COMPLETED,,100.0,2021-05-30,2022-11-20,5.647495361781076,Adequate (1-10/month),56.47495361781076,Below (50-75%),100,56.3,64.5
NCT03838861,An Individualised and Patient-centred Follow-up Program for Women With Gynaecological Cancer,UNKNOWN,NA,200.0,2019-03-01,2025-01-28,2.8185185185185184,Adequate (1-10/month),28.18518518518518,Significantly Below (<50%),50,51.0,49.714999999999996
NCT04937361,Monitoring of MDRO Dynamics and Resistance Mechanisms in a University Hospital Network,UNKNOWN,,12000.0,2021-06-23,2025-06-30,248.82833787465944,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT06533761,Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML,RECRUITING,PHASE1,125.0,2025-04-28,2028-03-15,3.616920152091255,Adequate (1-10/month),36.169201520912544,Significantly Below (<50%),60,48.0,42.945
NCT00009061,Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs,UNKNOWN,PHASE3,624.0,2000-11-01,,,Slow (<1/month),,Significantly Below (<50%),50,65.0,78.065
NCT01046461,"Ramosetron, Aprepitant and Dexamethasone (RAD) in Solid Cancer",UNKNOWN,PHASE2,41.0,2010-01-01,2012-06-01,1.4150113378684808,Adequate (1-10/month),14.150113378684809,Significantly Below (<50%),50,33.3,13.200000000000001
NCT00646061,Pain Control in Renal Colic,COMPLETED,PHASE1,,2007-11-01,2008-12-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,30.330000000000002
NCT01192061,Autonomic Nervous System Activity and Normal Tension Glaucoma,COMPLETED,,97.0,2010-02-01,2011-01-01,8.840359281437125,Adequate (1-10/month),88.40359281437125,Met (75-100%),100,61.1,73.31
NCT03595761,Meningitis With Cerebral Vasculitis in Children,COMPLETED,,17.0,2017-06-01,2017-08-31,5.686593406593407,Adequate (1-10/month),56.86593406593406,Below (50-75%),100,49.7,46.949999999999996
NCT00486161,Acylated Ghrelin Response to Acute Exercise in Obesity,COMPLETED,,16.0,2004-03-01,2006-12-01,0.48461691542288554,Slow (<1/month),4.846169154228855,Significantly Below (<50%),100,44.6,29.42
NCT01643161,Guided Self-Help for Functional Neurological Symptoms,TERMINATED,NA,33.0,2012-04-01,2013-08-01,2.062669404517454,Adequate (1-10/month),20.62669404517454,Significantly Below (<50%),10,25.6,7.595000000000001
NCT05522361,Risdiplam in Patients With Spinal Muscular Atrophy Previously Treated With Nusinersen,ACTIVE_NOT_RECRUITING,PHASE4,10.0,2022-11-06,2026-06-15,0.23113135914958238,Slow (<1/month),2.3113135914958236,Significantly Below (<50%),85,41.3,23.74
NCT06977061,Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression,NOT_YET_RECRUITING,PHASE2,30.0,2025-06-01,2026-09-01,1.9982494529540482,Adequate (1-10/month),19.98249452954048,Significantly Below (<50%),30,31.4,10.47
NCT04941261,Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha),UNKNOWN,PHASE2,1716.0,2021-06-30,2024-03-30,52.02693227091634,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT05157061,GOS to Reduce Symptom Severity in IBS,COMPLETED,NA,153.0,2021-10-26,2024-08-06,4.588492610837439,Adequate (1-10/month),45.88492610837439,Significantly Below (<50%),100,62.2,74.74499999999999
NCT06566261,ABA-101 in Participants With Progressive Multiple Sclerosis,ACTIVE_NOT_RECRUITING,PHASE1,12.0,2024-09-11,2027-02-01,0.4184192439862543,Slow (<1/month),4.184192439862543,Significantly Below (<50%),85,41.5,24.215
NCT06451861,"Randomized Study of ABC-14 Regimen Compared With ""3+7"" Standard Induction Therapy or AB-14 for ND AML",RECRUITING,PHASE2,240.0,2024-08-21,2027-06-30,7.004410354745925,Adequate (1-10/month),70.04410354745924,Below (50-75%),60,57.2,66.465
NCT07174661,Educational Tools for the Improvement of Early Advance Care Planning in Adolescents and Young Adults With Advanced Solid Tumors and High-Grade Brain Tumors,RECRUITING,NA,50.0,2025-09-02,2027-06-30,2.2852852852852856,Adequate (1-10/month),22.852852852852855,Significantly Below (<50%),60,42.0,24.825
NCT06748261,AI-enabled Screening and Diagnosis of Cardiomyopathies Using Coronary CTA,NOT_YET_RECRUITING,,5000.0,2024-12-30,2025-12-30,416.98630136986304,Excellent (>50/month),200.0,Exceeded (≥100%),30,77.3,85.67
NCT03925961,Role of Pre-operative Counseling in the Surgical Patient,TERMINATED,NA,6.0,2019-08-06,2020-09-25,0.43903846153846154,Slow (<1/month),4.390384615384615,Significantly Below (<50%),10,18.5,4.02
NCT02767661,"Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer",ACTIVE_NOT_RECRUITING,PHASE3,240.0,2017-07-19,2024-05-01,2.9481840193704603,Adequate (1-10/month),29.4818401937046,Significantly Below (<50%),85,64.7,77.75999999999999
NCT02100761,CYP 2C19 Polymorphism and Voriconazole Trough Concentration in Chinese Adult Patients,UNKNOWN,,200.0,2014-06-01,2015-06-01,16.679452054794524,Good (10-50/month),166.7945205479452,Exceeded (≥100%),50,54.3,59.62
NCT00168961,Enteral Nutrition in Liver Cirrhosis,COMPLETED,PHASE4,,2003-12-01,2007-06-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,30.330000000000002
NCT05137561,Robotic-arm Assisted 68 Ga PSMA PET/CT Guided Prostate Biopsy Versus MR Directed Cognitive Fusion TRUS Guided Prostate Biopsy (PROBIOP),COMPLETED,PHASE2,217.0,2021-10-25,2024-06-30,6.747170582226762,Adequate (1-10/month),67.47170582226761,Below (50-75%),100,67.4,80.04
NCT02611661,Local Ablative Strategies After Endovascular Radioembolization,TERMINATED,PHASE1,9.0,2016-01-19,2018-02-13,0.3623809523809524,Slow (<1/month),3.6238095238095234,Significantly Below (<50%),10,18.7,4.455
NCT04179461,Personalized Treatment Algorithms for Difficult-to-treat Asthma,COMPLETED,PHASE2,21.0,2018-03-16,2019-10-03,1.1293992932862191,Adequate (1-10/month),11.293992932862192,Significantly Below (<50%),100,46.7,37.895
NCT06594042,Serum Preptin Level and Its Relationship with Bone Mineral Disease in Chronic Kidney Disease Patients,NOT_YET_RECRUITING,,96.0,2025-06-01,2026-09-01,6.394398249452954,Adequate (1-10/month),63.94398249452955,Below (50-75%),30,35.0,15.305
NCT05411042,Benefits of Digital Dance Game by Older Adults,COMPLETED,NA,60.0,2020-08-31,2022-03-20,3.226855123674912,Adequate (1-10/month),32.26855123674912,Significantly Below (<50%),100,54.8,61.095
NCT03396042,Natural History Study of CEP290-Related Retinal Degeneration,COMPLETED,,26.0,2017-12-17,2022-05-06,0.49434103685196756,Slow (<1/month),4.943410368519675,Significantly Below (<50%),100,45.4,31.455
NCT03970642,Video Directly Observed Therapy (VDOT) to Improve Medication Adherence,TERMINATED,NA,35.0,2019-05-27,2020-04-15,3.2882716049382714,Adequate (1-10/month),32.882716049382715,Significantly Below (<50%),10,25.8,7.670000000000001
NCT05557942,Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL),TERMINATED,PHASE3,186.0,2022-11-02,2024-08-08,8.778046511627906,Adequate (1-10/month),87.78046511627907,Met (75-100%),10,42.9,26.145000000000003
NCT02262442,Effect of the Topical Application of Anaesthetics With EnkFiberoptic Atomizer During the Bronchoscopy,UNKNOWN,PHASE4,60.0,2014-10-01,2016-08-01,2.725970149253732,Adequate (1-10/month),27.259701492537314,Significantly Below (<50%),50,39.8,21.47
NCT03757442,Peripheral Perfusion Index in Acute Surgical Patients,COMPLETED,,1338.0,2019-02-01,2020-01-01,121.9422754491018,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT04356742,Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control,COMPLETED,PHASE3,198.0,2020-05-26,2022-02-23,9.446896551724139,Adequate (1-10/month),94.46896551724139,Met (75-100%),100,70.8,82.295
NCT02986542,Comparison of Success Rates of Femoral Artery Catheterization,COMPLETED,NA,65.0,2016-12-01,2018-04-02,4.062833675564682,Adequate (1-10/month),40.62833675564682,Significantly Below (<50%),100,55.2,62.195
NCT00923442,Biology Studies of Hematologic Cancers,ENROLLING_BY_INVITATION,,550.0,2004-02-24,,,Slow (<1/month),,Significantly Below (<50%),55,64.8,77.865
NCT03884842,Dupilumab on Airway Hyper-responsiveness and Ventilation Heterogeneity in Patients With Asthma.,COMPLETED,PHASE3,24.0,2019-07-01,2023-01-17,0.5637037037037037,Slow (<1/month),5.637037037037037,Significantly Below (<50%),100,46.9,38.96
NCT04967742,"A Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine",COMPLETED,PHASE1,50.0,2021-08-05,2021-10-31,17.49425287356322,Good (10-50/month),174.94252873563218,Exceeded (≥100%),100,59.0,70.365
NCT03129542,Midodrine Hydrochloride in Early Sepsis,COMPLETED,PHASE1,33.0,2017-08-30,2020-05-15,1.0156926188068758,Adequate (1-10/month),10.15692618806876,Significantly Below (<50%),100,47.6,41.775
NCT01413542,Pharmacogenetics of Ace Inhibitor-Associated Angioedema,COMPLETED,NA,44.0,2011-11-01,2014-07-01,1.3765262076053444,Adequate (1-10/month),13.765262076053444,Significantly Below (<50%),100,48.5,44.47
NCT01781442,A Post Marketing Surveillance As Required By Philippine Food And Drug Administration,WITHDRAWN,,0.0,2013-06-01,2015-06-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT00140842,Neuroendocrine Modulation of Metabolic Effects in Overweight Adolescents,COMPLETED,,47.0,2005-05-01,2007-06-01,1.88,Adequate (1-10/month),18.8,Significantly Below (<50%),100,52.1,53.03
NCT04664842,Effects of Manual Therapy and Exercise Training of Diaphragm in Patients With Chronic Neck Pain,COMPLETED,NA,126.0,2020-08-01,2021-09-15,9.354731707317073,Adequate (1-10/month),93.54731707317073,Met (75-100%),100,65.1,78.14
NCT05425342,iECG: Recording Chest Leads Using a Smartwatch With a Digital Image Processing Algorithm,COMPLETED,NA,50.0,2020-12-12,2021-03-23,15.06930693069307,Good (10-50/month),150.6930693069307,Exceeded (≥100%),100,59.0,70.365
NCT05318742,Panretinal Photocoagulation During Vitrectomy for Diabetic Vitreous Hemorrhage,UNKNOWN,NA,150.0,2022-02-15,2024-01-15,6.532188841201717,Adequate (1-10/month),65.32188841201717,Below (50-75%),50,47.0,39.33
NCT01178242,Salivary Gland Transplantation in the Treatment of Dry Eye in Patients With Stevens-Johnson Syndrome.,COMPLETED,NA,19.0,2008-12-01,2010-12-01,0.7922739726027398,Slow (<1/month),7.922739726027397,Significantly Below (<50%),100,46.5,36.815
NCT07284342,A Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/Foscarbidopa,RECRUITING,,103.0,2025-11-17,2027-01-01,7.647121951219512,Adequate (1-10/month),76.47121951219512,Met (75-100%),60,44.6,29.42
NCT04803786,"A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study of XYWAV in Narcolepsy",COMPLETED,,110.0,2021-04-09,2022-02-24,10.431152647975079,Good (10-50/month),104.3115264797508,Exceeded (≥100%),100,62.1,74.595
NCT02922686,Penicillin for the Emergency Department Outpatient Treatment of CELLulitis,UNKNOWN,PHASE4,414.0,2016-12-01,2019-12-01,11.50882191780822,Good (10-50/month),115.08821917808221,Exceeded (≥100%),50,73.1,83.515
NCT01405586,MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer,UNKNOWN,PHASE3,299.0,2011-03-01,2024-11-01,1.8224989987985583,Adequate (1-10/month),18.22498998798558,Significantly Below (<50%),50,58.9,70.10499999999999
NCT05491486,"Mindfulness, Empathy and the Oxytocinergic System in Persons With Schizophrenia",UNKNOWN,NA,60.0,2022-06-15,2023-07-15,4.6237974683544305,Adequate (1-10/month),46.2379746835443,Significantly Below (<50%),50,39.8,21.47
NCT01356186,Pilot Trial of Inpatient Cognitive Therapy for the Prevention of Suicide in Military Personnel,COMPLETED,NA,36.0,2008-07-01,2018-12-01,0.288,Slow (<1/month),2.88,Significantly Below (<50%),100,47.9,42.64
NCT00604786,The Effect of Omalizumab on Responses to Cat Allergen Challenge,COMPLETED,NA,18.0,2007-07-01,2009-01-01,0.9962181818181819,Slow (<1/month),9.96218181818182,Significantly Below (<50%),100,46.4,36.26
NCT03949686,Erector Spinae Plane Block for Congenital Hip Dislocation Surgery,COMPLETED,NA,60.0,2019-04-22,2020-02-01,6.40842105263158,Adequate (1-10/month),64.0842105263158,Below (50-75%),100,54.8,61.095
NCT04151186,A Clinical Study on the Safety and Efficacy of CAR-T Therapy for the TM4SF1- and EpCAM-positive Solid Tumors,UNKNOWN,NA,72.0,2019-11-20,2021-11-20,2.9981942544459645,Adequate (1-10/month),29.98194254445965,Significantly Below (<50%),50,40.8,22.745
NCT05711186,Structured Shared Decision Making for Patients Undergoing SAVR or TAVR,RECRUITING,NA,140.0,2023-04-17,2026-05-30,3.7415276558384547,Adequate (1-10/month),37.415276558384555,Significantly Below (<50%),60,49.2,46.035
NCT06705686,Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer,NOT_YET_RECRUITING,PHASE1,40.0,2025-09-30,2028-03-30,1.3350877192982458,Adequate (1-10/month),13.350877192982457,Significantly Below (<50%),30,27.2,8.115
NCT01194986,Evaluation of Histamine H3 Receptor Radioligand [11C]AZ12807110 and Histamine H3 Receptor Occupancy of AZD5213 After Oral Administration,COMPLETED,PHASE1,13.0,2010-11-01,2011-06-01,1.8666037735849057,Adequate (1-10/month),18.66603773584906,Significantly Below (<50%),100,51.0,49.714999999999996
NCT07180186,Microbiota and Probiotic Therapy in Ulcerative Colitis Patients,COMPLETED,,70.0,2022-01-01,2024-05-01,2.503877790834313,Adequate (1-10/month),25.03877790834313,Significantly Below (<50%),100,53.9,58.34
NCT00758186,Randomized Trial of Colonic Stents as a Bridge to Surgery,COMPLETED,PHASE3,40.0,2004-10-01,2008-06-01,0.9093353248693055,Slow (<1/month),9.093353248693054,Significantly Below (<50%),100,48.2,43.665
NCT02650986,Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1,ACTIVE_NOT_RECRUITING,PHASE1,15.0,2017-07-14,2032-07-14,0.0833363752509582,Slow (<1/month),0.8333637525095821,Significantly Below (<50%),85,41.7,24.36
NCT02492386,Bioabsorbable Everolimus-Eluting Stents for Internal Pudendal Artery-Related Arteriogenic Erectile Dysfunction,UNKNOWN,PHASE2,15.0,2015-07-01,2017-03-01,0.7497536945812807,Slow (<1/month),7.497536945812806,Significantly Below (<50%),50,31.2,10.165000000000001
NCT05752786,"Evaluation of the ""Eat Less Meat"" One-month Challenge",COMPLETED,NA,366.0,2023-02-01,2023-06-18,81.32145985401459,Excellent (>50/month),200.0,Exceeded (≥100%),100,89.3,93.00500000000001
NCT05761886,Rural Area Pharmacist Intervention for Diabetes,COMPLETED,NA,87.0,2023-05-16,2025-03-26,3.894529411764706,Adequate (1-10/month),38.94529411764706,Significantly Below (<50%),100,57.0,66.12
NCT02277886,Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and Sleep Disturbances,UNKNOWN,PHASE4,340.0,2014-11-01,2016-06-01,17.905882352941177,Good (10-50/month),179.0588235294118,Exceeded (≥100%),50,67.2,79.94
NCT00132886,Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure,COMPLETED,PHASE2,140.0,2004-12-01,2006-12-01,5.837808219178083,Adequate (1-10/month),58.378082191780834,Below (50-75%),100,61.2,73.43499999999999
NCT00169286,Organized Self-management Support for Chronic Depression,COMPLETED,NA,104.0,2003-07-01,2005-06-01,4.516062767475035,Adequate (1-10/month),45.16062767475035,Significantly Below (<50%),100,58.3,68.99499999999999
NCT02721186,Effectiveness of Mass Drug Administration for Reducing Seasonal Malaria Transmission in Zanzibar,COMPLETED,NA,22500.0,2016-04-30,2017-09-30,1322.2007722007722,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT06534086,Virtual Reality for Urological Procedures,COMPLETED,NA,100.0,2024-06-06,2024-11-01,20.56756756756757,Good (10-50/month),200.0,Exceeded (≥100%),100,63.0,75.845
NCT05535686,Methotrexate Adherence in Rheumatoid Arthritis Patients,COMPLETED,,300.0,2021-01-01,2022-01-01,25.019178082191782,Good (10-50/month),200.0,Exceeded (≥100%),100,77.3,85.67
NCT05455086,"Free-Base Nicotine or Nicotine Salt e-Liquids in Current E-Cigarette Smokers, PeloPET Study",COMPLETED,NA,21.0,2022-03-23,2023-06-26,1.3896521739130436,Adequate (1-10/month),13.896521739130435,Significantly Below (<50%),100,46.7,37.895
NCT00136786,Effect of Memantine Versus Bupropion on Smoking Relapse in Nicotine-Dependent Individuals - 3,COMPLETED,PHASE1,25.0,2006-12-01,2009-05-01,0.86281179138322,Slow (<1/month),8.6281179138322,Significantly Below (<50%),100,47.0,39.33
NCT01046786,Safety and Feasibility of Umbilical Cord Blood Cell Transplant Into Injured Spinal Cord,COMPLETED,PHASE1,8.0,2010-01-01,2013-12-01,0.1702937062937063,Slow (<1/month),1.702937062937063,Significantly Below (<50%),100,45.6,32.08
NCT06160570,"IMRT Versus 3DCRT for Locally Advanced Rectal Cancer, Prospective Phase II Study.",COMPLETED,NA,75.0,2018-10-01,2021-01-31,2.676436107854631,Adequate (1-10/month),26.764361078546305,Significantly Below (<50%),100,56.0,63.71
NCT06707870,Comparison of Cervical Retraction Exercise and Facet Oscillatory Mobilization in Chronic Mechanical Neck Pain,RECRUITING,NA,32.0,2024-05-01,2024-12-13,4.310088495575221,Adequate (1-10/month),43.100884955752214,Significantly Below (<50%),60,40.6,22.575
NCT03234270,Changes in Aviators' Body Core Temperature Measurements at F-35,UNKNOWN,NA,10.0,2017-07-01,2017-12-01,1.9895424836601308,Adequate (1-10/month),19.895424836601308,Significantly Below (<50%),50,35.8,16.325
NCT05362370,"Stryker PEEK Customized Implant: A Prospective Post Market Follow Up to Evaluate Safety, Performance and Effectiveness",RECRUITING,,110.0,2023-02-01,2027-12-30,1.8674846625766872,Adequate (1-10/month),18.67484662576687,Significantly Below (<50%),60,45.1,30.605
NCT01266070,TKI 258 in Von Hippel-Lindau Syndrome (VHL),TERMINATED,PHASE2,6.0,2012-11-01,2015-12-01,0.16234666666666667,Slow (<1/month),1.6234666666666668,Significantly Below (<50%),10,18.5,4.02
NCT07109570,"Surface Electrical Myography, Oxygen Consumption, Effort, and Weaning in the Mechanically Ventilated Patient in the Intensive Care Unit",RECRUITING,,60.0,2025-07-08,2029-06-01,1.2825842696629213,Adequate (1-10/month),12.825842696629215,Significantly Below (<50%),60,36.1,16.665
NCT03880370,RELATIONSHIP OF LUMBOPELVIC MUSCULATURE WITH FUNCTIONAL TESTS IN NON-PROFESSIONAL ATHLETES WITH LUMBAR DISC HERNIATION,UNKNOWN,,60.0,2019-04-01,2019-12-31,6.665693430656934,Adequate (1-10/month),66.65693430656934,Below (50-75%),50,38.1,19.425
NCT05687370,Modified Dynamic Needle Tip Positioning vs Conventional Long-axis In-plane in Radial Artery Cannulation,COMPLETED,NA,124.0,2023-01-15,2023-03-26,53.922285714285714,Excellent (>50/month),200.0,Exceeded (≥100%),100,69.9,81.83
NCT04942470,Effect of Aloe Vera and Propolis on Wound Healing in Pressure Injuries,COMPLETED,NA,66.0,2021-03-11,2022-06-11,4.396148796498906,Adequate (1-10/month),43.96148796498906,Significantly Below (<50%),100,55.3,62.36000000000001
NCT03005470,Technology for Innovative Monitoring of Cardiovascular Prevention: a RCT,UNKNOWN,PHASE3,231.0,2017-01-01,2019-02-01,9.24,Adequate (1-10/month),92.4,Met (75-100%),50,58.5,69.34
NCT05273970,Electrochemical and Electrophysiological Study,ENROLLING_BY_INVITATION,NA,10.0,2022-09-07,2027-02-01,0.1893034825870647,Slow (<1/month),1.8930348258706466,Significantly Below (<50%),55,32.3,11.799999999999999
NCT03296670,Efficacy of Intracoronary Infusion of Different Medicine in STEMI Patients With CSFP,COMPLETED,PHASE4,57.0,2015-08-01,2017-08-31,2.28,Adequate (1-10/month),22.8,Significantly Below (<50%),100,54.6,60.39
NCT07127770,A Study to Understand How the Body Processes [14C]PF-07104091 in Healthy Participants,COMPLETED,PHASE1,9.0,2025-08-28,2025-11-07,3.8585915492957747,Adequate (1-10/month),38.585915492957746,Significantly Below (<50%),100,50.7,48.915
NCT01427270,Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain,COMPLETED,PHASE3,455.0,2011-08-01,2014-10-01,11.970786516853932,Good (10-50/month),119.70786516853933,Exceeded (≥100%),100,91.4,93.64
NCT07195370,Testing YAG Laser Iridotomy for Primary Angle-Closure Glaucoma,ACTIVE_NOT_RECRUITING,NA,150.0,2025-05-01,2026-01-01,18.636734693877553,Good (10-50/month),186.3673469387755,Exceeded (≥100%),85,62.5,75.21
NCT03698370,Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer,COMPLETED,PHASE2,27.0,2020-12-15,2022-02-11,1.9429787234042553,Adequate (1-10/month),19.429787234042557,Significantly Below (<50%),100,52.2,53.22
NCT04850573,Effects of Equine Assisted Activities on Veterans With Post-traumatic Stress Disorder,COMPLETED,NA,9.0,2021-06-21,2023-06-16,0.3778758620689655,Slow (<1/month),3.7787586206896555,Significantly Below (<50%),100,45.7,32.5
NCT05023473,Comparison Between Pericapsular Nerve Group Block (PENG) and Morphine Infusion,COMPLETED,NA,36.0,2022-04-01,2022-09-01,7.16235294117647,Adequate (1-10/month),71.62352941176471,Below (50-75%),100,52.9,55.55
NCT04278573,Intralesional Vitamin D Injection for Treatment of Common Warts,COMPLETED,PHASE2,77.0,2020-10-20,2023-04-04,2.6159375000000002,Adequate (1-10/month),26.159375,Significantly Below (<50%),100,56.2,64.21
NCT05440773,Emptying Malaria Reservoirs to Accelerate Malaria Elimination in High Transmission Settings,UNKNOWN,NA,112.0,2023-04-01,2024-02-01,11.141437908496732,Good (10-50/month),111.41437908496732,Exceeded (≥100%),50,49.0,45.61
NCT01232673,Autologous Bone Marrow Stem Cell Transfer in Patients With Chronical Critical Limb Ischemia and Diabetic Foot,COMPLETED,PHASE2,96.0,2008-10-01,2010-12-01,3.6943615676359043,Adequate (1-10/month),36.94361567635904,Significantly Below (<50%),100,57.7,67.51
NCT01259973,"Typical Versus Atypical Antipsychotics; Occupation of Striatal Receptors and the Appearance of Extrapyramidal Symptomatology, in Healthy Volunteers",UNKNOWN,PHASE1,24.0,2011-02-01,2011-12-01,2.4110891089108915,Adequate (1-10/month),24.110891089108915,Significantly Below (<50%),50,36.9,17.735
NCT00148473,Oral Versus Vaginal Misoprostol for Induction of Labor,COMPLETED,PHASE2,180.0,2000-03-01,2001-10-01,9.46321243523316,Adequate (1-10/month),94.6321243523316,Met (75-100%),100,69.4,81.52000000000001
NCT00320073,Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors,COMPLETED,PHASE1,41.0,2006-08-01,2010-01-01,0.9992313851080865,Slow (<1/month),9.992313851080866,Significantly Below (<50%),100,48.3,43.985
NCT05599373,Optimal rTMS for Cognitive Deficits and Negative Symptoms in Schizophrenia,UNKNOWN,NA,90.0,2020-01-01,2023-12-31,1.8764383561643838,Adequate (1-10/month),18.76438356164384,Significantly Below (<50%),50,42.2,25.155
NCT06027073,Biologics and Sublingual Immunotherapy,NOT_YET_RECRUITING,PHASE4,150.0,2024-05-01,2028-03-01,3.2614285714285716,Adequate (1-10/month),32.614285714285714,Significantly Below (<50%),30,41.0,23.01
NCT05834673,VICTORION-ASCERTAIN: Implementation Study (v-ASCERTAIN),TERMINATED,NA,6.0,2023-11-17,2024-12-19,0.4588944723618091,Slow (<1/month),4.5889447236180905,Significantly Below (<50%),10,18.5,4.02
NCT05565573,Medroxyprogesterone Acetate vs LNG-IUS in Early-stage Endometrioid Carcinoma and Atypical Hyperplasia Patients,UNKNOWN,PHASE2,148.0,2022-11-01,2025-11-01,4.11051094890511,Adequate (1-10/month),41.105109489051095,Significantly Below (<50%),50,46.8,38.440000000000005
NCT06231173,Effects of Visual Feedback Therapy on Post Burn Children,COMPLETED,NA,36.0,2023-12-01,2024-02-05,16.60363636363636,Good (10-50/month),166.03636363636366,Exceeded (≥100%),100,57.9,67.83
NCT00100373,RSV Challenge in Healthy Adults,COMPLETED,NA,13.0,2004-09-01,2005-05-01,1.635206611570248,Adequate (1-10/month),16.35206611570248,Significantly Below (<50%),100,46.0,34.1
NCT05703373,Increasing Access to Multiple Micronutrient Supplementation - A Pilot Intervention at up to 15 Clinics in Botswana,ENROLLING_BY_INVITATION,NA,1200.0,2024-07-09,2026-07-01,50.59279778393352,Excellent (>50/month),200.0,Exceeded (≥100%),55,86.5,91.97999999999999
NCT07043673,Plasma Concentrations of the Non-protein-bound Form of Vancomycin,COMPLETED,,77.0,2022-06-17,2025-03-01,2.372348178137652,Adequate (1-10/month),23.723481781376517,Significantly Below (<50%),100,54.5,60.12
NCT05232773,Rotator Cuff Surgery in Athletes: From Rehabilitation to Return to Sport,UNKNOWN,,42.0,2022-01-31,2023-07-30,2.3458348623853214,Adequate (1-10/month),23.458348623853215,Significantly Below (<50%),50,36.7,17.544999999999998
NCT07299773,Evaluation of Patients With Hypertensive Disorders of Pregnancy: An Ambispective Observational Study,NOT_YET_RECRUITING,,120.0,2026-01-01,2027-12-01,5.225751072961374,Adequate (1-10/month),52.25751072961374,Below (50-75%),30,36.9,17.735
NCT06292273,Bupivacaine With Dexmedetomidine Versus Bupivacaine Alone for Transversus Abdominis Plane Block in Caesarean Section,COMPLETED,NA,60.0,2023-10-10,2024-02-20,13.732330827067669,Good (10-50/month),137.3233082706767,Exceeded (≥100%),100,59.8,71.61
NCT06961773,Bone Metabolism in Premenopausal Exercising Women,ENROLLING_BY_INVITATION,NA,22.0,2024-12-05,2026-06-15,1.20229802513465,Adequate (1-10/month),12.0229802513465,Significantly Below (<50%),55,33.3,13.200000000000001
NCT06898073,Dual-task Training During Curved Walking in Stroke Patients,RECRUITING,NA,60.0,2025-03-12,2026-07-31,3.609486166007905,Adequate (1-10/month),36.094861660079054,Significantly Below (<50%),60,42.8,25.929999999999996
NCT03619473,Standard Motorcycle Child Safety Helmet Initiative (MCHI) Program,UNKNOWN,NA,2000.0,2016-01-01,2018-12-31,55.59817351598174,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT00617773,"Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",COMPLETED,PHASE2,31.0,2008-05-01,2012-06-01,0.6324664879356569,Slow (<1/month),6.324664879356569,Significantly Below (<50%),100,47.5,41.415
NCT01163773,Milk Consumption and the Metabolic Syndrome in Menopausal Women,COMPLETED,NA,29.0,2004-10-01,2006-06-01,1.451907894736842,Adequate (1-10/month),14.519078947368422,Significantly Below (<50%),100,47.3,40.475
NCT01035073,Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort Syndrome,COMPLETED,PHASE4,22.0,2006-04-01,2009-05-01,0.5947424511545293,Slow (<1/month),5.947424511545293,Significantly Below (<50%),100,46.8,38.440000000000005
NCT02544373,CPAP to Treat Cognitive Dysfunction in MS,COMPLETED,NA,135.0,2015-11-12,2021-06-25,2.0026315789473688,Adequate (1-10/month),20.026315789473685,Significantly Below (<50%),100,60.8,72.99
NCT01430169,Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease,COMPLETED,PHASE2,20.0,2011-09-01,2011-11-01,9.98032786885246,Adequate (1-10/month),99.80327868852457,Met (75-100%),100,56.6,65.34
NCT06684769,A Chitosan Brush and Enamel Matrix Derivative for Non-surgical Treatment of Furcations,RECRUITING,NA,40.0,2024-11-15,2026-11-01,1.7005586592178772,Adequate (1-10/month),17.005586592178773,Significantly Below (<50%),60,41.2,23.425
NCT00115869,Hutchinson Smoking Prevention Project,COMPLETED,PHASE3,8388.0,1984-09-01,1999-08-01,46.875476409032494,Good (10-50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT01093469,Comparing Aquaphor to Atopiclair and EpiCeram in Children With Mild to Moderate Atopic Dermatitis,COMPLETED,PHASE4,39.0,2009-09-01,2010-02-01,7.759215686274509,Adequate (1-10/month),77.5921568627451,Met (75-100%),100,53.1,56.105000000000004
NCT00555269,Membrane Blue Versus Infracyanine Green,COMPLETED,,30.0,2004-10-01,2005-12-01,2.143661971830986,Adequate (1-10/month),21.43661971830986,Significantly Below (<50%),100,50.7,48.915
NCT02221869,A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy,COMPLETED,PHASE3,106.0,2014-10-01,2019-01-25,2.0460621433100825,Adequate (1-10/month),20.46062143310083,Significantly Below (<50%),100,58.5,69.34
NCT05380869,POCT PCT in Outpatient LRTI,COMPLETED,NA,114.0,2020-04-01,2021-04-30,8.807512690355331,Adequate (1-10/month),88.0751269035533,Met (75-100%),100,64.1,77.12
NCT01189669,n-3 Polyunsaturated Fatty Acids (PUFA) Supplementation in Young Women With Polycystic Ovary Syndrome (PCOS),COMPLETED,NA,25.0,2007-09-01,2008-07-01,2.5032894736842106,Adequate (1-10/month),25.032894736842103,Significantly Below (<50%),100,52.0,52.86
NCT03822169,Choline Uptake Study,COMPLETED,NA,18.0,2019-02-05,2019-02-19,18.0,Good (10-50/month),180.0,Exceeded (≥100%),100,56.4,64.88000000000001
NCT05040269,"Serum Levels of Vitamin D,Calcium and Magnesium in Preschool Recurrent Wheezers",UNKNOWN,,30.0,2021-05-01,2022-05-01,2.5019178082191784,Adequate (1-10/month),25.019178082191786,Significantly Below (<50%),50,35.7,16.18
NCT04391569,Randomized Therapy In Status Epilepticus,COMPLETED,PHASE3,100.0,2020-12-09,2024-04-28,2.462783171521036,Adequate (1-10/month),24.62783171521036,Significantly Below (<50%),100,58.0,68.245
NCT07332169,The Efficacy of Non-invasive Brain Stimulation on Cognitive Functions in Patients With Chronic Obstructive Pulmonary Disease: Double-Blinded Randomised Controlled Trial,NOT_YET_RECRUITING,NA,24.0,2026-01-20,2028-11-30,0.6991004784688994,Slow (<1/month),6.991004784688995,Significantly Below (<50%),30,25.9,7.704999999999999
NCT00747669,Pharmacokinetic Study of Synera™ in Neonates and Infants,SUSPENDED,PHASE4,11.0,2008-09-01,2013-04-01,0.20014345487148835,Slow (<1/month),2.0014345487148835,Significantly Below (<50%),20,21.9,6.23
NCT00000169,The Collaborative Longitudinal Evaluation of Ethnicity and Refractive Error (CLEERE) Study,UNKNOWN,,,1999-04-01,,,Slow (<1/month),,Significantly Below (<50%),50,23.3,6.569999999999999
NCT05885269,Comparative Efficacy of Tacrolimus and Clobetasol Propionate in Alopecia Areata,COMPLETED,PHASE1,70.0,2022-11-01,2023-04-30,11.837777777777777,Good (10-50/month),118.37777777777778,Exceeded (≥100%),100,60.6,72.785
NCT05625269,The Effect of Education and Follow-up Program in Patients Undergoing TAVI,COMPLETED,NA,60.0,2022-12-18,2023-12-15,5.045303867403315,Adequate (1-10/month),50.453038674033145,Below (50-75%),100,54.8,61.095
NCT04841369,Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i),COMPLETED,PHASE3,3420.0,2021-04-13,2022-09-20,198.29485714285715,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT06089369,Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion,NOT_YET_RECRUITING,PHASE3,360.0,2024-06-01,2026-11-30,12.015789473684212,Good (10-50/month),120.15789473684211,Exceeded (≥100%),30,62.8,75.53999999999999
NCT02385669,A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma,TERMINATED,PHASE1,3.0,2015-04-01,2019-09-18,0.05599019006744329,Slow (<1/month),0.5599019006744328,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT02342769,Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany,COMPLETED,,403.0,2015-02-19,2018-10-28,9.107141796585005,Adequate (1-10/month),91.07141796585005,Met (75-100%),100,85.6,91.465
NCT05352269,Safety and Tolerability of FMT Capsules in Healthy Volunteers,UNKNOWN,PHASE1,36.0,2022-04-21,2022-10-01,6.7229447852760735,Adequate (1-10/month),67.22944785276074,Below (50-75%),50,37.9,19.139999999999997
NCT05753969,"The Efficacy of ""Mindtesion""is Measuring Attentional and the Startle Response Dysregulation in Children and Adolescents Suffering From Attention Deficit Disorder: With and Without Medication.",UNKNOWN,NA,200.0,2021-02-23,2024-02-28,5.534545454545455,Adequate (1-10/month),55.34545454545455,Below (50-75%),50,51.0,49.714999999999996
NCT01713569,Feasibility Study: Histological Characterization After Treatment With the Ulthera® System,TERMINATED,NA,2.0,2012-10-01,2013-10-01,0.16679452054794522,Slow (<1/month),1.6679452054794524,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT03250169,Neurofilaments for NEDA Assessing in MS,TERMINATED,,21.0,2017-08-01,2022-01-28,0.38954296160877516,Slow (<1/month),3.895429616087752,Significantly Below (<50%),10,18.0,2.92
NCT02930369,Effects of Different Area of Internal Limiting Membrane Peeling (ILM) Peeling on Anatomical Outcomes in Macular Hole Surgery,COMPLETED,PHASE4,128.0,2015-06-01,2016-10-01,7.984262295081967,Adequate (1-10/month),79.84262295081966,Met (75-100%),100,60.2,72.2
NCT01048983,Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC),WITHDRAWN,PHASE1,0.0,,,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT07229183,Family Planning Counseling and Simulation,COMPLETED,NA,96.0,2025-05-06,2025-05-28,96.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,67.7,80.22
NCT06193083,DEprescribing: Perceptions of PAtients Living With Advanced Cancer,RECRUITING,,325.0,2024-02-28,2026-12-29,9.558454106280193,Adequate (1-10/month),95.58454106280193,Met (75-100%),60,67.3,80.00500000000001
NCT06576583,Implantation of Engineered Cartilage Grafts for Treatment of Patellofemoral Osteoarthritis Versus Surgical Comparators.,RECRUITING,PHASE2,150.0,2025-07-15,2030-01-01,2.7995095033721644,Adequate (1-10/month),27.99509503372164,Significantly Below (<50%),60,50.0,47.675
NCT02010983,Achalasia and Dysplasia,UNKNOWN,NA,80.0,2013-10-01,2025-12-01,0.547974797479748,Slow (<1/month),5.479747974797481,Significantly Below (<50%),50,36.4,17.14
NCT02328183,Efficacy of Polymyxin B Against Infections Caused by Extensively Drug-resistant (XDR) Gram-Negative Bacteria,UNKNOWN,PHASE4,100.0,2014-12-01,2015-11-01,9.086567164179105,Adequate (1-10/month),90.86567164179104,Met (75-100%),50,48.0,42.945
NCT03843983,Effect of Thermal Pulsation System (Lipiflow) Treatment for Ocular Surface Disease Due to Meibomian Gland Dysfunction,COMPLETED,NA,20.0,2019-03-25,2020-10-13,1.0718309859154929,Adequate (1-10/month),10.718309859154928,Significantly Below (<50%),100,46.6,37.375
NCT01883583,Pilot Study of Contrast-Enhanced Ultrasound of Transplanted Kidney,UNKNOWN,NA,10.0,2013-06-01,2015-12-01,0.33340635268346114,Slow (<1/month),3.3340635268346115,Significantly Below (<50%),50,30.8,9.745
NCT04366583,Argon Plasma Coagulation vs Hemoclipping for Bleeding Peptic Ulcers,COMPLETED,PHASE4,166.0,2012-02-09,2016-04-25,3.2875992192582957,Adequate (1-10/month),32.875992192582956,Significantly Below (<50%),100,63.3,76.235
NCT04256083,Metabolomic and Proteomic Profiles of Amniotic Fluid Embolism,COMPLETED,,20.0,2021-06-24,2021-10-25,4.949593495934959,Adequate (1-10/month),49.4959349593496,Significantly Below (<50%),100,49.9,47.425
NCT06737783,Thoracic Mobility Exercises Impact in Tibio Femoral Arthritis Patients,COMPLETED,NA,32.0,2024-12-03,2025-06-10,5.153862433862434,Adequate (1-10/month),51.53862433862434,Below (50-75%),100,52.6,54.684999999999995
NCT03260283,Assessment of Subarachnoid Anesthesia With Low Dose of Pethidine and Combination of Ropivacaine With Fentanyl for Urologic Surgical Operations.,COMPLETED,PHASE2,104.0,2017-08-16,2019-12-31,3.651395617070358,Adequate (1-10/month),36.51395617070358,Significantly Below (<50%),100,58.3,68.99499999999999
NCT01604083,European Transfusion Practice and Outcome Study,COMPLETED,,6066.0,2013-04-01,2013-12-01,756.7583606557376,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT05943483,To Establish the Traditional Chinese Medicine Based Intelligent Personal Health Care System,COMPLETED,,1918.0,2020-08-01,2022-07-31,80.0876817558299,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT03416283,Remote Monitoring and Social Support for Hypertension Management,COMPLETED,NA,250.0,2018-05-20,2019-10-26,14.522900763358779,Good (10-50/month),145.2290076335878,Exceeded (≥100%),100,75.0,84.49
NCT04144283,Role of Sleep on Motor Learning in Parkinson's Disease and Healthy Older Adults,UNKNOWN,NA,80.0,2019-11-15,2023-12-01,1.648747461069736,Adequate (1-10/month),16.48747461069736,Significantly Below (<50%),50,36.4,17.14
NCT02588183,PV Cryoablation Efficacy (COR ADVANCE Study),COMPLETED,NA,25.0,2015-08-01,2018-03-22,0.7894190871369295,Slow (<1/month),7.894190871369296,Significantly Below (<50%),100,47.0,39.33
NCT05692583,Correlation Between EPB Entrapment Test and Ultrasound Wrist Findings in Patients With deQuervain's Disease,COMPLETED,,39.0,2020-11-01,2022-07-08,1.9334853420195441,Adequate (1-10/month),19.33485342019544,Significantly Below (<50%),100,51.5,51.245
NCT04122183,Internet Auditory Rehabilitation: Follow-up to Adult Hearing Screening,COMPLETED,NA,31.0,2021-08-17,2023-12-30,1.0909132947976878,Adequate (1-10/month),10.909132947976879,Significantly Below (<50%),100,47.5,41.415
NCT06224283,Radiomics Compared With Conventional Response Criteria for Predicting Progression of Desmoid Tumor After Cryoablation,RECRUITING,,21.0,2024-02-20,2026-10-31,0.6496341463414634,Slow (<1/month),6.496341463414634,Significantly Below (<50%),60,33.0,12.695
NCT03372083,Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis,COMPLETED,PHASE4,44.0,2018-01-16,2019-12-05,1.9467441860465116,Adequate (1-10/month),19.46744186046512,Significantly Below (<50%),100,53.5,57.555
NCT03136783,New Tumor Models in Three Dimensions and in a Human Skin Environment for Personalized Melanoma Therapy,UNKNOWN,NA,8.0,2017-03-22,2019-09-22,0.2664332603938731,Slow (<1/month),2.664332603938731,Significantly Below (<50%),50,30.6,9.475
NCT01162083,Identifying an Ideal Cardiopulmonary Exercise Test Parameter,COMPLETED,,100.0,2010-10-01,2013-05-01,3.227995758218452,Adequate (1-10/month),32.27995758218452,Significantly Below (<50%),100,56.3,64.5
NCT05706883,Clinical and Molecular Findings in Patients With Cervical/Supraclavicular Metastasis From Non-small-cell Lung Cancer (NSCLC),COMPLETED,,348.0,2023-01-01,2023-11-30,31.811171171171175,Good (10-50/month),200.0,Exceeded (≥100%),100,81.2,88.265
NCT01964183,Post-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of Tolterodine,COMPLETED,PHASE4,24.0,2013-06-01,2013-08-01,11.97639344262295,Good (10-50/month),119.7639344262295,Exceeded (≥100%),100,56.9,65.89500000000001
NCT05038683,Holbæk Obesity Treatment (HOT) Versus Conventional Obesity Treatment (COT) in Children With Overweight or Obesity.,RECRUITING,NA,554.0,2022-10-26,2027-01-01,11.036492146596858,Good (10-50/month),110.36492146596859,Exceeded (≥100%),60,83.0,89.505
NCT01935583,Intervention to Promote Survivor Resilience and Adjustment: Efficacy Evaluation,COMPLETED,NA,164.0,2013-01-01,2017-09-30,2.88064627813041,Adequate (1-10/month),28.8064627813041,Significantly Below (<50%),100,63.1,76.03
NCT02094183,The Interaction Between Appetite Hormones,COMPLETED,NA,58.0,2011-09-01,2014-04-01,1.8722375397667022,Adequate (1-10/month),18.722375397667022,Significantly Below (<50%),100,54.6,60.39
NCT07309783,Lung EIT Image Guide Ventilation in ARDS,NOT_YET_RECRUITING,NA,574.0,2025-12-20,2029-06-20,13.671799687010955,Good (10-50/month),136.71799687010954,Exceeded (≥100%),30,74.0,83.985
NCT02329483,Monitoring the Early Follicular Phase With Androstenedione in Low-dose Step-up Ovulation Induction in High Responders,UNKNOWN,,50.0,2014-12-01,2015-06-01,8.362637362637363,Adequate (1-10/month),83.62637362637363,Met (75-100%),50,42.3,25.295
NCT02737241,HoLEP (50W) vs. HoLEP (100W) for Treatment of BPH,COMPLETED,NA,121.0,2015-06-01,2018-02-01,3.7738114754098357,Adequate (1-10/month),37.738114754098355,Significantly Below (<50%),100,59.7,71.355
NCT01655641,Study of Tranexamic Acid for Reducing Blood Requirement in Patients Undergoing Major Gastro-intestinal Surgery,UNKNOWN,PHASE2,118.0,2012-07-01,2014-07-01,4.920438356164384,Adequate (1-10/month),49.20438356164384,Significantly Below (<50%),50,44.4,28.95
NCT04558541,A Developmental Framework For Linking Phonological And Morpho-syntactic Sequential Pattern Rules In DLD: Production,RECRUITING,NA,400.0,2022-08-07,2026-12-31,7.576851275668949,Adequate (1-10/month),75.76851275668949,Met (75-100%),60,70.0,81.89999999999999
NCT04827641,Severity Grading of Unexpected Events in Pediatric Surgery,UNKNOWN,,670.0,2017-01-01,2023-07-01,8.59814502529511,Adequate (1-10/month),85.9814502529511,Met (75-100%),50,78.3,86.48
NCT03482141,Clinical Utility of Prenatal Whole Exome Sequencing,COMPLETED,NA,316.0,2017-08-01,2022-05-13,5.509186712485682,Adequate (1-10/month),55.09186712485682,Below (50-75%),100,75.3,84.60499999999999
NCT04078841,Treating Post-Lyme Disease Syndrome With Acetogenins,COMPLETED,PHASE1,30.0,2019-07-01,2020-01-30,4.287323943661972,Adequate (1-10/month),42.87323943661972,Significantly Below (<50%),100,52.4,53.949999999999996
NCT06798441,Determination of the Oral Irritation Potential of a Fluoride Rinse in Children,COMPLETED,NA,161.0,2025-01-20,2025-02-20,158.0916129032258,Excellent (>50/month),200.0,Exceeded (≥100%),100,72.9,83.39
NCT03319641,PSMA-PET Imaging for Advanced ACC/SDC,COMPLETED,NA,25.0,2017-10-25,2018-05-14,3.7860696517412937,Adequate (1-10/month),37.86069651741293,Significantly Below (<50%),100,52.0,52.86
NCT06054841,Reshaping Postpartum Follow-up,COMPLETED,NA,157.0,2023-05-22,2025-03-01,7.363759630200308,Adequate (1-10/month),73.63759630200309,Below (50-75%),100,62.6,75.325
NCT06417541,Autopsy and Photon Counting Computed Tomography to Evaluate Thromboses Related to Central Venous Catheters,RECRUITING,,75.0,2025-01-16,2028-06-01,1.8530844155844155,Adequate (1-10/month),18.530844155844157,Significantly Below (<50%),60,42.3,25.295
NCT00477841,Self-Expandable Esophageal Radiation Stent:a Randomized Controlled Trial in Patients With Advanced Esophageal Cancer,COMPLETED,PHASE2,60.0,2004-04-01,2006-12-01,1.8751540041067762,Adequate (1-10/month),18.751540041067763,Significantly Below (<50%),100,54.8,61.095
NCT06582641,Evaluation of Peer Group Connection - Middle School,RECRUITING,NA,1400.0,2024-09-01,2028-09-14,28.91180461329715,Good (10-50/month),200.0,Exceeded (≥100%),60,83.0,89.505
NCT05602441,Living Together With Chronic Disease: Informal Support for Diabetes Management in Vietnam (VALID),UNKNOWN,NA,229.0,2021-01-12,2023-05-31,8.021588032220944,Adequate (1-10/month),80.21588032220943,Met (75-100%),50,53.3,57.14
NCT02681341,Vascular Post Market Review,COMPLETED,,10.0,2016-02-01,2017-09-21,0.5090301003344482,Slow (<1/month),5.090301003344482,Significantly Below (<50%),100,44.1,28.425
NCT01209741,Bioavailability of Variably Aged MK-0974 Tablets (MK-0974-038)(COMPLETED),COMPLETED,PHASE1,48.0,2007-10-01,2007-11-01,47.13290322580645,Good (10-50/month),200.0,Exceeded (≥100%),100,63.8,76.78
NCT04792541,Hyaluronan in the Treatment of Residual Pockets in Periodontitis Patients.,COMPLETED,NA,66.0,2016-12-01,2021-02-08,1.3130980392156864,Adequate (1-10/month),13.130980392156863,Significantly Below (<50%),100,50.3,48.215
NCT01246141,The Comparison of Tricuspid Replacement and Repair in Patients With Combined Heart Valve Disease,COMPLETED,,68.0,1998-01-01,2010-04-01,0.4627587748714509,Slow (<1/month),4.627587748714509,Significantly Below (<50%),100,48.8,45.184999999999995
NCT00758641,Platelet Rich Plasma to Treat Plantar Fasciitis,COMPLETED,PHASE4,115.0,2009-09-01,2016-01-01,1.5134457414613058,Adequate (1-10/month),15.13445741461306,Significantly Below (<50%),100,54.2,59.330000000000005
NCT00693641,Efficiency of a Jellyfish Sting Inhibitor Sun Lotion and Protocols for Jellyfish Sting Pain Relief,COMPLETED,PHASE4,39.0,2008-07-01,2011-06-01,1.1147042253521127,Adequate (1-10/month),11.147042253521128,Significantly Below (<50%),100,48.1,43.275000000000006
NCT00863941,A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting Conditions,COMPLETED,PHASE1,28.0,2004-06-01,2004-07-01,28.0,Good (10-50/month),200.0,Exceeded (≥100%),100,57.2,66.465
NCT04734041,Integrative Medicine for Hypermobility Spectrum Disorder and Ehlers-Danlos Syndromes (IMforHSDandEDS),COMPLETED,NA,20.0,2020-12-23,2021-07-02,3.187434554973822,Adequate (1-10/month),31.87434554973822,Significantly Below (<50%),100,51.6,51.644999999999996
NCT06496841,Transnasal Versus Suprazygomatic SPG Block in Persistant Idiopathic Facial Pain,COMPLETED,,40.0,2022-10-01,2023-04-02,6.6535519125683065,Adequate (1-10/month),66.53551912568307,Below (50-75%),100,51.5,51.245
NCT03881241,Safety Study of Treatment of Leg Fractures,TERMINATED,,2.0,2019-09-20,2020-03-24,0.32731182795698927,Slow (<1/month),3.2731182795698928,Significantly Below (<50%),10,16.5,2.625
NCT03912441,First-In-Human Study to Evaluate Safety And Pharmacokinetics of Single Escalating Doses of BCD-147 (Bispecific Anti-HER2/HER2 Antibody) in Healthy Subjects,COMPLETED,PHASE1,15.0,2019-01-30,2019-09-30,1.8790123456790124,Adequate (1-10/month),18.790123456790127,Significantly Below (<50%),100,51.2,50.375
NCT02852941,Assessment of Volumetric Hemodynamic Parameters and Nutritional Status in Stable Renal Transplant Recipients,COMPLETED,,80.0,2016-07-01,2016-08-01,78.55483870967741,Excellent (>50/month),200.0,Exceeded (≥100%),100,64.7,77.75999999999999
NCT01356641,Antibiotic Treatment Alone for Acute Simple Appendicitis in Children,COMPLETED,NA,50.0,2012-09-01,2017-01-01,0.9614655716993051,Slow (<1/month),9.61465571699305,Significantly Below (<50%),100,49.0,45.61
NCT02715141,Molecular Stool Testing for Colorectal Cancer Surveillance,COMPLETED,,3966.0,2015-10-01,2020-12-15,63.472681388012624,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02262741,"A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer",COMPLETED,PHASE1,71.0,2014-10-15,2017-09-21,2.016082089552239,Adequate (1-10/month),20.160820895522384,Significantly Below (<50%),100,55.7,63.09
NCT01095341,Postoperative Hyperthyroidism,COMPLETED,,57.0,2008-04-01,2009-04-01,4.7536438356164386,Adequate (1-10/month),47.53643835616439,Significantly Below (<50%),100,52.9,55.55
NCT01620541,Comparing Ankle Fusion to Ankle Replacement,ACTIVE_NOT_RECRUITING,,516.0,2012-05-01,2027-05-01,2.867294633077766,Adequate (1-10/month),28.67294633077766,Significantly Below (<50%),85,83.8,90.505
NCT04726254,The JULI Registry--Hemp and Cannabis Observational Registry,UNKNOWN,,2000.0,2021-08-01,2025-02-15,47.04791344667697,Good (10-50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT07358754,The Relationship Between Serum S100B and Brain-Derived Neurotrophic Factor,NOT_YET_RECRUITING,,60.0,2026-02-01,2026-04-30,20.754545454545454,Good (10-50/month),200.0,Exceeded (≥100%),30,37.1,18.115000000000002
NCT04159454,"PITA-HF: Feasibility, Safety, and Tolerability",COMPLETED,NA,8.0,2020-11-20,2023-02-01,0.3032627646326277,Slow (<1/month),3.032627646326277,Significantly Below (<50%),100,45.6,32.08
NCT00386854,Metabolic Study of Concentric and Eccentric Muscle Training,COMPLETED,NA,40.0,2003-04-01,2003-08-01,9.98032786885246,Adequate (1-10/month),99.80327868852457,Met (75-100%),100,58.2,68.795
NCT07387354,Pacritinib With Aza for Upfront Myelodysplastic Syndrome,NOT_YET_RECRUITING,PHASE1,25.0,2026-02-01,2027-01-01,2.2784431137724552,Adequate (1-10/month),22.78443113772455,Significantly Below (<50%),30,31.0,9.985
NCT03391154,Efficacy of Low Dose Levothyroxine During Pregnancy,COMPLETED,PHASE3,180.0,2017-05-01,2020-08-30,4.502218570254725,Adequate (1-10/month),45.02218570254725,Significantly Below (<50%),100,64.4,77.37
NCT06459154,The Effectiveness of Mixed Reality as Interventional Tool for the Improvement on Quality of Life for People With Parkinson´s Disease.,RECRUITING,NA,15.0,2023-08-20,2025-12-20,0.5352872215709261,Slow (<1/month),5.352872215709262,Significantly Below (<50%),60,34.2,14.305000000000001
NCT04043754,Platelet-rich Fibrin and Autogenous Bone vs Membrane and Autogenous Bone in Intrabony Defects,COMPLETED,NA,44.0,2018-06-10,2023-07-15,0.7196990865126277,Slow (<1/month),7.196990865126277,Significantly Below (<50%),100,48.5,44.47
NCT01129154,Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC),UNKNOWN,PHASE2,17.0,2010-08-01,2012-07-01,0.7392571428571428,Slow (<1/month),7.392571428571429,Significantly Below (<50%),50,31.4,10.47
NCT04480554,"Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1",RECRUITING,PHASE2,225.0,2023-01-30,2025-06-30,7.76530612244898,Adequate (1-10/month),77.6530612244898,Met (75-100%),60,56.0,63.71
NCT00193154,OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma,COMPLETED,PHASE2,63.0,2003-02-01,2014-03-01,0.4739792387543253,Slow (<1/month),4.739792387543253,Significantly Below (<50%),100,50.0,47.675
NCT02057354,Neuroimaging Study of Exercise and Memory Function,COMPLETED,NA,190.0,2014-04-01,2018-03-01,4.044475524475525,Adequate (1-10/month),40.44475524475525,Significantly Below (<50%),100,65.2,78.23
NCT03163654,Novel Porcine Dermal Matrix in the Treatment of Multiple Adjacent Gingival Recessions,COMPLETED,NA,16.0,2014-12-01,2016-09-01,0.761,Slow (<1/month),7.61,Significantly Below (<50%),100,46.3,35.66
NCT04048954,Use of a Smartphone Application on the Detection of Complications Related to Smoking,COMPLETED,,5671.0,2019-05-30,2020-06-01,469.0903260869565,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02165605,HylaCare in the Treatment of Acute Skin Changes in Patients Undergoing Radiotherapy for Breast Cancer,COMPLETED,NA,28.0,2012-08-01,2015-12-01,0.7003451109285128,Slow (<1/month),7.003451109285128,Significantly Below (<50%),100,47.2,40.035
NCT04670705,Relationship of CP and AP,COMPLETED,,1022.0,2010-01-01,2020-10-01,7.924014263881813,Adequate (1-10/month),79.24014263881813,Met (75-100%),100,88.3,92.705
NCT03136705,Healthy Combine Study,COMPLETED,PHASE1,39.0,2016-02-03,2017-12-01,1.7798500749625188,Adequate (1-10/month),17.79850074962519,Significantly Below (<50%),100,53.1,56.105000000000004
NCT00140205,Pharmacokinetics of Leptin Administration During Fasting,COMPLETED,PHASE1,15.0,2001-02-01,2016-12-01,0.0789692148045659,Slow (<1/month),0.789692148045659,Significantly Below (<50%),100,46.2,35.089999999999996
NCT05691205,Identifying Optimal PEEP After Lung Transplantation,COMPLETED,NA,47.0,2023-01-31,2025-03-15,1.8484237726098194,Adequate (1-10/month),18.484237726098193,Significantly Below (<50%),100,53.8,58.065
NCT06710405,The Effect of Intraoperative Intravenous Lidocaine Infusion on Postoperative Pain and Recovery in Children (< 7 Years Old) Undergoing Thoracoscopic Surgery,RECRUITING,PHASE4,80.0,2024-12-09,2026-12-31,3.2382978723404254,Adequate (1-10/month),32.38297872340426,Significantly Below (<50%),60,44.4,28.95
NCT06974305,PET/MRI/EEG Imaging Study in Epilepsy,RECRUITING,,30.0,2023-09-21,2025-11-30,1.1400749063670412,Adequate (1-10/month),11.40074906367041,Significantly Below (<50%),60,33.7,13.465
NCT02962505,Continuous Regional Analysis Device for Neonate Lung,COMPLETED,,200.0,2016-11-01,2019-03-03,7.145539906103287,Adequate (1-10/month),71.45539906103286,Below (50-75%),100,64.3,77.265
NCT01921205,Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures,COMPLETED,PHASE3,404.0,2013-08-29,2017-01-24,9.885659163987139,Adequate (1-10/month),98.85659163987138,Met (75-100%),100,87.3,92.25
NCT04298905,Leveraging mHealth to Enable and Adapt CHW Strategies to Improve TB/HIV Patient Outcomes in SA,ACTIVE_NOT_RECRUITING,NA,62.0,2022-03-10,2026-12-31,1.0741491178144564,Adequate (1-10/month),10.741491178144564,Significantly Below (<50%),85,45.5,31.705
NCT07083505,A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer,NOT_YET_RECRUITING,PHASE2,60.0,2025-08-15,2026-12-31,3.631013916500994,Adequate (1-10/month),36.310139165009936,Significantly Below (<50%),30,33.8,13.694999999999999
NCT03663205,A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer,COMPLETED,PHASE3,334.0,2018-07-23,2023-04-26,5.849804372842348,Adequate (1-10/month),58.498043728423475,Below (50-75%),100,76.7,85.385
NCT04040205,Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration,RECRUITING,PHASE2,44.0,2019-10-07,2027-06-01,0.47937007874015747,Slow (<1/month),4.7937007874015745,Significantly Below (<50%),60,36.5,17.285
NCT06618105,Bronchoprovocation Study to Demonstrate the Pharmacodynamic Bioequivalence of Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) of Macleods Pharmaceuticals Ltd,NOT_YET_RECRUITING,PHASE3,144.0,2024-10-15,2025-05-31,19.225263157894737,Good (10-50/month),192.2526315789474,Exceeded (≥100%),30,45.5,31.705
NCT00554905,Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma,UNKNOWN,PHASE4,180.0,2006-10-01,2009-06-01,5.6254620123203285,Adequate (1-10/month),56.25462012320329,Below (50-75%),50,49.4,46.42
NCT01471405,One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma,COMPLETED,,54.0,2012-01-01,2013-08-01,2.8438754325259517,Adequate (1-10/month),28.43875432525952,Significantly Below (<50%),100,52.7,55.04
NCT06130605,Subjects Perceived as Embarrassing During a Consultation in General Medical Practice,UNKNOWN,,2000.0,2023-12-01,2024-06-01,332.6775956284153,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT03473405,Air Barrier System for the Reduction of Airborne Colony Forming Units During Total Knee Arthroplasty,UNKNOWN,NA,40.0,2019-02-01,2019-07-01,8.117333333333333,Adequate (1-10/month),81.17333333333333,Met (75-100%),50,38.2,19.645000000000003
NCT05340205,Blood Loss During Cesarean Delivery in Placenta Previa Patients,COMPLETED,PHASE4,81.0,2022-05-04,2023-01-05,10.022926829268293,Good (10-50/month),100.22926829268293,Exceeded (≥100%),100,61.5,73.905
NCT06200805,ai Chi Reduces Insomnia in College Students: Exploring Inflammatory Factor Roles,COMPLETED,NA,90.0,2024-05-15,2024-07-20,41.50909090909091,Good (10-50/month),200.0,Exceeded (≥100%),100,62.2,74.74499999999999
NCT01128205,Nationwide Assessment of Cardiovascular Risk Factors: in Chinese Patients With Type 2 Diabetes,COMPLETED,,25000.0,2010-06-01,2011-06-01,2084.931506849315,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT00749905,Low Fiber Diet for Bowel Preparation for Colon Capsule Examination,TERMINATED,PHASE2,75.0,2009-01-01,2009-12-01,6.835329341317365,Adequate (1-10/month),68.35329341317366,Below (50-75%),10,29.0,8.76
NCT00188305,A Randomized Trial of Cancer Risk and Health Education in Relatives of Colorectal Cancer Patients,COMPLETED,PHASE3,252.0,2005-01-01,2009-08-01,4.5851046025104605,Adequate (1-10/month),45.8510460251046,Significantly Below (<50%),100,70.2,81.99499999999999
NCT05594394,Improving Charge Nurse Conflict Resolution Communication Using Artificial Intelligence,COMPLETED,,35.0,2022-09-19,2023-08-29,3.097093023255814,Adequate (1-10/month),30.970930232558143,Significantly Below (<50%),100,51.1,50.129999999999995
NCT00185094,"A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin",COMPLETED,PHASE4,60.0,2004-02-01,2005-07-01,3.53953488372093,Adequate (1-10/month),35.3953488372093,Significantly Below (<50%),100,54.8,61.095
NCT05771194,Analysis of Postoperative Ocular Surface Changes and Intervention Effect After PPV in MGD Dry Eye Patients,COMPLETED,PHASE4,40.0,2021-02-01,2022-07-02,2.3596899224806203,Adequate (1-10/month),23.5968992248062,Significantly Below (<50%),100,53.2,56.665
NCT00218894,"The Influence of Vision on Balance, Gait and Falls",COMPLETED,,148.0,2004-01-01,2009-12-01,2.084738546968996,Adequate (1-10/month),20.847385469689957,Significantly Below (<50%),100,60.2,72.2
NCT07327294,A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor,NOT_YET_RECRUITING,PHASE1,150.0,2026-01-31,2028-06-30,5.182746878547106,Adequate (1-10/month),51.82746878547106,Below (50-75%),30,41.0,23.01
NCT04850794,Evaluation of an Interdisciplinary Decision Guide for Infant Feeding Assessment,COMPLETED,NA,56.0,2021-07-14,2022-02-08,8.156172248803829,Adequate (1-10/month),81.56172248803828,Met (75-100%),100,54.5,60.12
NCT00766194,Nasopharyngeal Pressure Measurement During Neonatal Nasal Respiratory Support,TERMINATED,,20.0,2007-05-01,2012-12-01,0.2982851543361098,Slow (<1/month),2.9828515433610976,Significantly Below (<50%),10,17.9,2.87
NCT04079894,Physical Activity in the Elderly Spine Patient,COMPLETED,,206.0,2019-06-26,2023-02-01,4.764924012158055,Adequate (1-10/month),47.64924012158055,Significantly Below (<50%),100,64.8,77.865
NCT03779594,Acetazolamide for Treating NPH in Shunt-candidates Patients,UNKNOWN,PHASE2,15.0,2018-12-01,2019-12-01,1.2509589041095892,Adequate (1-10/month),12.509589041095893,Significantly Below (<50%),50,31.2,10.165000000000001
NCT05690594,Long-term Outcomes of Patients Treated for Bladder Exstrophy by Questionnaires.,COMPLETED,,42.0,2023-04-20,2023-07-13,15.22,Good (10-50/month),152.2,Exceeded (≥100%),100,56.7,65.53
NCT02097394,The Clinical Study on Combizym and Bifidobacteri to Prevent the Recurrence of Colon Polyps,UNKNOWN,PHASE4,200.0,2013-06-01,2020-06-01,2.3809151349237387,Adequate (1-10/month),23.80915134923739,Significantly Below (<50%),50,51.0,49.714999999999996
NCT00003594,Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer,COMPLETED,PHASE3,1691.0,1998-10-01,2004-10-01,23.482682481751823,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT06590194,PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC),NOT_YET_RECRUITING,PHASE1,96.0,2024-09-10,2026-08-31,4.058666666666666,Adequate (1-10/month),40.58666666666667,Significantly Below (<50%),30,36.7,17.544999999999998
NCT02064894,Oral Analgesic Utilization for CHildhood Musculoskeletal Injuries,COMPLETED,NA,501.0,2013-07-08,2015-06-22,21.359159663865547,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT05612594,"Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study",RECRUITING,PHASE4,164.0,2024-03-27,2027-09-01,3.984166001596169,Adequate (1-10/month),39.84166001596169,Significantly Below (<50%),60,51.1,50.129999999999995
NCT02500394,Biomarker Guided Intervention for Prevention of Acute Kidney Injury,COMPLETED,NA,135.0,2015-06-01,2017-01-01,7.085172413793104,Adequate (1-10/month),70.85172413793104,Below (50-75%),100,60.8,72.99
NCT03098394,Use of a Rapid Test for Gonorrhea & Chlamydia for Women Presenting With Possible Sexually Transmitted Infections,TERMINATED,NA,64.0,2018-09-24,2023-06-20,1.1261040462427745,Adequate (1-10/month),11.261040462427745,Significantly Below (<50%),10,23.1,6.404999999999999
NCT01188694,Enhancing Extinction Learning in Post Traumatic Stress Disorder (PTSD),COMPLETED,PHASE2,42.0,2009-09-01,2013-04-01,0.9774311926605506,Slow (<1/month),9.774311926605506,Significantly Below (<50%),100,48.4,44.22
NCT04099394,Pain & Aging: Combined Interventions for Fitness in the Community Study,ACTIVE_NOT_RECRUITING,NA,280.0,2019-10-30,2025-01-31,4.439166666666667,Adequate (1-10/month),44.391666666666666,Significantly Below (<50%),85,67.9,80.36999999999999
NCT02388594,A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients,COMPLETED,PHASE1,14.0,2015-04-01,2019-03-01,0.29801398601398604,Slow (<1/month),2.9801398601398605,Significantly Below (<50%),100,46.1,34.695
NCT07112066,Multimodality Cardiac Imaging for Disease Progression in ATTR-CM,RECRUITING,NA,50.0,2025-10-20,2027-06-01,2.5840407470288627,Adequate (1-10/month),25.84040747028863,Significantly Below (<50%),60,42.0,24.825
NCT05065866,Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy,COMPLETED,PHASE1,14.0,2021-11-18,2024-04-24,0.47990990990990995,Slow (<1/month),4.7990990990991,Significantly Below (<50%),100,46.1,34.695
NCT07030166,A Machine Learning Prediction Model for Postoperative Acute Kidney Injury in Non-Cardiac Surgery Patients,RECRUITING,,2500.0,2025-07-01,2026-12-31,138.86861313868613,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT00774566,PV-Isolation With the Cryoballoon Versus RF:a Randomized Controlled Prospective Non-inferiority Trial (FreezeAF),COMPLETED,PHASE4,322.0,2008-10-01,2014-12-01,4.3524333925399645,Adequate (1-10/month),43.524333925399645,Significantly Below (<50%),100,75.8,84.83500000000001
NCT02512666,Non Invasive Optical Imaging of WBC Count,COMPLETED,NA,45.0,2015-09-01,2017-09-01,1.8738714090287278,Adequate (1-10/month),18.738714090287278,Significantly Below (<50%),100,53.6,57.705
NCT03741166,Blood Collection Sub-Study for CRC Screening in Individuals 45-49 at Average Risk for CRC.,COMPLETED,,871.0,2018-11-08,2019-04-05,179.1435135135135,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT05454566,"A Study Evaluating the Safety, Tolerability, and Activity of ICM-203 in Subjects With Knee Osteoarthritis.",NOT_YET_RECRUITING,PHASE1,18.0,2025-11-15,2027-11-01,0.7652513966480448,Slow (<1/month),7.6525139664804485,Significantly Below (<50%),30,25.4,7.470000000000001
NCT01705366,Clinical Outcomes of Knee Replacement,TERMINATED,,316.0,2012-10-01,2018-09-19,4.414428636989445,Adequate (1-10/month),44.14428636989445,Significantly Below (<50%),10,46.6,37.375
NCT02965066,Clinical Study Investigating Safety and Performance of a New Urinary Intermittent Catheter in Healthy Volunteers,COMPLETED,NA,28.0,2016-09-01,2016-11-01,13.972459016393442,Good (10-50/month),139.7245901639344,Exceeded (≥100%),100,57.2,66.465
NCT05017766,NCCR AntiResist:: New Approaches to Combat Antibiotic-resistant Bacteria,RECRUITING,,8000.0,2020-12-03,2028-12-01,83.3972602739726,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT01969266,A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food,COMPLETED,PHASE1,8.0,2013-10-01,2013-11-01,7.855483870967742,Adequate (1-10/month),78.55483870967743,Met (75-100%),100,50.6,48.705
NCT01116466,Clinical Study to Evaluate the Implantation of the ActiGait Drop Foot Stimulator System,COMPLETED,NA,5.0,2009-08-01,2010-03-01,0.7179245283018868,Slow (<1/month),7.179245283018869,Significantly Below (<50%),100,45.4,31.455
NCT02402166,"Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder",COMPLETED,PHASE2,24.0,2015-04-15,2016-06-30,1.6528506787330317,Adequate (1-10/month),16.52850678733032,Significantly Below (<50%),100,46.9,38.96
NCT05282966,Assessment of QSant™ for Underlying Allograft Rejection,NOT_YET_RECRUITING,,4000.0,2023-03-01,2026-10-01,92.94656488549619,Excellent (>50/month),200.0,Exceeded (≥100%),30,77.3,85.67
NCT00498966,Ph II Study of Perifosine for Patients With Carcinoma of the Kidney,COMPLETED,PHASE2,50.0,2007-07-01,2011-10-01,0.9800386349001933,Slow (<1/month),9.800386349001933,Significantly Below (<50%),100,49.0,45.61
NCT00937066,Cost-effectiveness Study of Symbicort as Maintenance and Reliever Therapy (SMART),COMPLETED,,1000.0,,,,Slow (<1/month),,Significantly Below (<50%),100,78.3,86.48
NCT03202966,Early Intervention Therapy for Children With Delayed Development: Enabling Access in India's Rural Communities,COMPLETED,NA,1050.0,2017-07-01,2019-07-30,42.1106719367589,Good (10-50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT04434066,Outcomes on Abdominal Versus Vaginal Morcellation At Time of Hysterectomy,COMPLETED,NA,46.0,2020-01-08,2024-11-05,0.7942370958593308,Slow (<1/month),7.942370958593306,Significantly Below (<50%),100,48.7,44.93
NCT04440566,O-GlcNAcylation Role in the Pathophysiology of Systemic Lupus Erythematosus,COMPLETED,NA,50.0,2020-10-13,2022-02-14,3.1124744376278124,Adequate (1-10/month),31.12474437627812,Significantly Below (<50%),100,54.0,58.72500000000001
NCT05214066,Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT,UNKNOWN,PHASE2,60.0,2019-02-01,2022-08-01,1.430227094753328,Adequate (1-10/month),14.302270947533282,Significantly Below (<50%),50,34.8,15.040000000000001
NCT01436656,A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma,COMPLETED,PHASE1,107.0,2011-09-05,2022-11-07,0.7981083067875521,Slow (<1/month),7.98108306787552,Significantly Below (<50%),100,53.6,57.705
NCT04049656,Confirmatory Study of HFVI Guided Analgesic Administration in Surgical Subjects,COMPLETED,NA,5.0,2020-10-08,2024-01-09,0.12811447811447813,Slow (<1/month),1.2811447811447811,Significantly Below (<50%),100,45.4,31.455
NCT03797456,A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL),COMPLETED,PHASE2,111.0,2019-04-01,2024-02-06,1.9067945823927765,Adequate (1-10/month),19.067945823927765,Significantly Below (<50%),100,58.9,70.10499999999999
NCT03272256,Phase 1 Study of IM156 in Patients With Advanced Solid Tumor and Lymphoma,COMPLETED,PHASE1,22.0,2017-10-09,2020-07-28,0.6546236559139785,Slow (<1/month),6.5462365591397855,Significantly Below (<50%),100,46.8,38.440000000000005
NCT04539756,Writing Activities and Emotions,COMPLETED,NA,250.0,2020-09-08,2020-11-20,104.24657534246575,Excellent (>50/month),200.0,Exceeded (≥100%),100,80.0,87.67
NCT04960956,Glycosylation of Exosomes in Prostate and Urothelial Carcinoma,TERMINATED,,13.0,2016-10-13,2017-02-02,3.533214285714286,Adequate (1-10/month),35.332142857142856,Significantly Below (<50%),10,22.4,6.29
NCT05612256,Electrical Impedance Tomography for Identification of Optimal Positive End-expiratory Pressure in Newborn Infants,RECRUITING,,86.0,2022-12-10,2026-12-01,1.8029201101928376,Adequate (1-10/month),18.029201101928376,Significantly Below (<50%),60,43.2,26.840000000000003
NCT06458556,Transvaginal Radiofrequency Ablation for Overactive Bladder,COMPLETED,NA,17.0,2023-06-19,2024-05-30,1.495606936416185,Adequate (1-10/month),14.95606936416185,Significantly Below (<50%),100,46.4,36.26
NCT04868656,Implementing a Hospital-Based Walking Program (STRIDE): Function QUERI 2.0,COMPLETED,NA,35.0,2021-06-01,2024-01-26,1.099484004127967,Adequate (1-10/month),10.99484004127967,Significantly Below (<50%),100,47.8,42.42
NCT04317456,AChild - Austrian Children With Hearing Impairment - Longitudinal Database,UNKNOWN,,450.0,2019-09-01,2025-08-01,6.338732068486812,Adequate (1-10/month),63.38732068486812,Below (50-75%),50,69.3,81.395
NCT07206056,"An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)",RECRUITING,PHASE1,188.0,2025-10-15,2030-12-17,3.0294970884065644,Adequate (1-10/month),30.29497088406564,Significantly Below (<50%),60,53.0,55.80500000000001
NCT00641056,Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3),COMPLETED,PHASE3,467.0,2008-04-01,2009-11-01,24.551778929188256,Good (10-50/month),200.0,Exceeded (≥100%),100,92.4,93.845
NCT02009956,EXCELLA Post-Approval Study,COMPLETED,NA,57.0,2014-02-26,2016-06-01,2.1005811138014527,Adequate (1-10/month),21.005811138014526,Significantly Below (<50%),100,54.6,60.39
NCT02107456,Effect of Dry Needling on Myofascial Trigger Point,COMPLETED,NA,33.0,2012-07-01,2013-06-01,2.998567164179105,Adequate (1-10/month),29.985671641791043,Significantly Below (<50%),100,52.6,54.684999999999995
NCT01164956,Methylphenidate for Cancer-Related Fatigue,TERMINATED,PHASE1,3.0,2011-07-01,2013-03-01,0.14995073891625615,Slow (<1/month),1.4995073891625614,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT04665856,Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,PHASE3,123.0,2020-12-21,2026-06-30,1.8562816063460585,Adequate (1-10/month),18.562816063460584,Significantly Below (<50%),85,55.3,62.36000000000001
NCT00822822,Evaluation of Patient Functionality and Utility of Web-Based Personal Health History and Risk Assess,COMPLETED,,17.0,2006-03-01,2009-11-01,0.3858911260253542,Slow (<1/month),3.8589112602535427,Significantly Below (<50%),100,44.7,29.67
NCT02779322,Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic One Anastomosis Gastric Bypass,UNKNOWN,NA,20.0,2015-06-01,2025-06-01,0.16665754174650974,Slow (<1/month),1.6665754174650973,Significantly Below (<50%),50,31.6,10.905
NCT01862822,Position of Children During Urine Collection: Evaluation Study,COMPLETED,NA,803.0,2013-06-01,2017-12-01,14.868199513381995,Good (10-50/month),148.68199513381995,Exceeded (≥100%),100,95.0,95.7
NCT04705922,Relative Bioavailability Study and Food Effect Study of TT-00420 (Tinengotinib) Capsule and Tablet Formulations in Healthy Volunteers,COMPLETED,PHASE1,24.0,2020-12-29,2021-07-23,3.5464077669902916,Adequate (1-10/month),35.46407766990291,Significantly Below (<50%),100,51.9,52.55499999999999
NCT00681122,CARIATIDE (Compliance of ARomatase Inhibitors AssessmenT In Daily Practice Through Educational Approach),COMPLETED,,2600.0,2008-05-01,2011-05-01,72.27762557077627,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT01474122,Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients,TERMINATED,PHASE3,265.0,2011-12-01,2014-02-01,10.172257250945776,Good (10-50/month),101.72257250945775,Exceeded (≥100%),10,49.2,46.035
NCT04622722,Efficacy and Safety of Diabetes-specific Formula in Patients With Type 2 Diabetes Mellitus,COMPLETED,NA,30.0,2018-08-22,2020-05-16,1.442654028436019,Adequate (1-10/month),14.42654028436019,Significantly Below (<50%),100,47.4,40.98
NCT06700122,Clinical Comparative Evaluation of the Use of Photodynamic Therapy in Conjunction With the Use of Vitamin D in Management Stage II Grade B Periodontitis Patients,RECRUITING,NA,24.0,2025-06-01,2025-06-15,24.0,Good (10-50/month),200.0,Exceeded (≥100%),60,49.9,47.425
NCT04560322,Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL,RECRUITING,PHASE2,40.0,2020-10-19,2027-03-01,0.5239242685025818,Slow (<1/month),5.239242685025818,Significantly Below (<50%),60,36.2,16.84
NCT00438022,Identifying Risk Factors for Eczema Herpeticum in Individuals With Atopic Dermatitis,COMPLETED,,240.0,2006-03-01,2010-01-01,5.210841654778887,Adequate (1-10/month),52.10841654778887,Below (50-75%),100,67.5,80.08
NCT06194422,Psychiatric Comorbidities in Children With Generalized Epilepsy,UNKNOWN,,62.0,2023-12-30,2025-03-24,4.193955555555556,Adequate (1-10/month),41.939555555555565,Significantly Below (<50%),50,38.3,19.785
NCT03808922,Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study,RECRUITING,PHASE3,274.0,2019-05-23,2025-08-31,3.638987783595114,Adequate (1-10/month),36.38987783595114,Significantly Below (<50%),60,59.9,71.86
NCT00883922,Central Venous Saturation (ScvO2) Monitoring in Pediatric Patients Undergoing Cardiac Surgery,COMPLETED,,70.0,2007-03-01,2010-03-01,1.9441605839416058,Adequate (1-10/month),19.441605839416056,Significantly Below (<50%),100,53.9,58.34
NCT00458822,Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis,COMPLETED,PHASE2,40.0,2007-02-01,2015-03-01,0.4127457627118644,Slow (<1/month),4.127457627118644,Significantly Below (<50%),100,48.2,43.665
NCT04286022,Specific Neurotechnical Strength Training (NeuroTraining),COMPLETED,NA,34.0,2023-01-01,2023-10-31,3.415709570957096,Adequate (1-10/month),34.15709570957096,Significantly Below (<50%),100,52.7,55.04
NCT00002322,A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients,COMPLETED,PHASE2,,,,,Slow (<1/month),,Significantly Below (<50%),100,40.0,21.87
NCT03227822,Short Spot Versus Long Lesion Stenting as Best Treatment for Extensive Occlusive SFA Disease,TERMINATED,NA,3.0,2013-07-01,2015-02-01,0.15744827586206897,Slow (<1/month),1.5744827586206895,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT02414022,Economic Analysis of Alliance A041202 CLL Study,ACTIVE_NOT_RECRUITING,,55.0,2015-04-15,2026-04-09,0.4172981056829511,Slow (<1/month),4.172981056829511,Significantly Below (<50%),85,43.2,26.840000000000003
NCT07242222,Erdosteine in the Treatment of Nonalcoholic Fatty Liver Disease,RECRUITING,PHASE1,50.0,2025-11-20,2026-11-20,4.169863013698631,Adequate (1-10/month),41.6986301369863,Significantly Below (<50%),60,42.0,24.825
NCT00548522,Pancreatic Islet Mass in Pregnancy in Type 1 Diabetes,TERMINATED,,12.0,2007-08-01,2013-12-01,0.15785652549697493,Slow (<1/month),1.5785652549697493,Significantly Below (<50%),10,17.3,2.785
NCT01512251,BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma,COMPLETED,PHASE1,8.0,2012-06-09,2017-03-21,0.13947308132875144,Slow (<1/month),1.3947308132875145,Significantly Below (<50%),100,45.6,32.08
NCT00555451,"Safety, Pharmacokinetics and Potential Activity of HE3286 in Obese Adult Subjects",COMPLETED,PHASE1,66.0,2007-10-01,2009-09-01,2.865962910128388,Adequate (1-10/month),28.65962910128388,Significantly Below (<50%),100,55.3,62.36000000000001
NCT01845051,Is There a Comorbidity Between Migraine and Allergic Rhinitis?,COMPLETED,,80.0,2012-11-01,2013-03-01,20.293333333333333,Good (10-50/month),200.0,Exceeded (≥100%),100,59.7,71.355
NCT03624751,Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment,RECRUITING,,300.0,2018-06-30,2030-06-30,2.0835044490075294,Adequate (1-10/month),20.83504449007529,Significantly Below (<50%),60,60.3,72.34
NCT01126151,Parent Interventions to Prevent Student Drinking,COMPLETED,NA,1900.0,2006-07-01,2012-09-01,25.659272404614022,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT05366751,A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor,TERMINATED,PHASE2,97.0,2022-06-03,2024-09-10,3.55744578313253,Adequate (1-10/month),35.574457831325304,Significantly Below (<50%),10,30.8,9.745
NCT01607151,Safety and Feasibility Study of Targeted Temperature Management After ICH,UNKNOWN,PHASE1,50.0,2013-01-01,2016-06-01,1.2205292702485968,Adequate (1-10/month),12.205292702485968,Significantly Below (<50%),50,34.0,14.02
NCT05390151,Laser Assisted Treatment of Fistula In Ano,RECRUITING,NA,176.0,2022-03-01,2026-03-01,3.666967830253251,Adequate (1-10/month),36.66967830253251,Significantly Below (<50%),60,52.1,53.03
NCT01646151,A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension,COMPLETED,,2580.0,2012-05-01,2013-04-01,234.43343283582092,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT03988751,Real-time Location System Feasibility Study,COMPLETED,NA,22.0,2019-06-06,2022-08-19,0.5723760683760685,Slow (<1/month),5.723760683760684,Significantly Below (<50%),100,46.8,38.440000000000005
NCT03917251,The Effects of Trans Venous Cardiac Pacing on Coronary Microvascular Function and Hemodynamics,WITHDRAWN,NA,0.0,2021-10-07,2021-10-07,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT00691951,Effects of Budesonide & Budesonide/Formoterol on Smoking Asthmatic Subjects,COMPLETED,PHASE3,,,,,Slow (<1/month),,Significantly Below (<50%),100,40.0,21.87
NCT05212051,"Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active AS",UNKNOWN,PHASE2,120.0,2021-12-10,2023-01-11,9.201007556675064,Adequate (1-10/month),92.01007556675063,Met (75-100%),50,49.6,46.785
NCT04676451,Femtosecond Laser Assisted Keratotomies for the Management of Corneal Astigmatism,COMPLETED,NA,94.0,2018-05-14,2024-03-22,1.3377092099111734,Adequate (1-10/month),13.377092099111735,Significantly Below (<50%),100,52.5,54.345
NCT04887051,The Effects of Respiratory-based Telerehabilitaion in Patients With MS,UNKNOWN,NA,100.0,2021-04-16,2021-08-30,22.38235294117647,Good (10-50/month),200.0,Exceeded (≥100%),50,48.0,42.945
NCT05768451,Ultrasound Radiomics for Predicting Breast Cancer and Axillary Lymph Node Metastasis,UNKNOWN,,200.0,2023-04-01,2025-08-31,6.894677236693092,Adequate (1-10/month),68.94677236693092,Below (50-75%),50,49.3,46.265
NCT01111851,Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183),COMPLETED,PHASE1,16.0,2010-04-01,2010-10-01,2.6614207650273225,Adequate (1-10/month),26.614207650273226,Significantly Below (<50%),100,51.3,50.62
NCT01496651,PCI vs. CABG in the Treatment of Unprotected Left Main Stenosis,ACTIVE_NOT_RECRUITING,NA,1201.0,2008-11-06,2025-12-31,5.836277139208174,Adequate (1-10/month),58.36277139208173,Below (50-75%),85,85.5,91.42
NCT02487251,Effectiveness of Differing Levels of Support for Family Mealtimes on Obesity Prevention Among Head Start Preschools,COMPLETED,NA,810.0,2015-09-02,2020-10-01,13.28469827586207,Good (10-50/month),132.84698275862067,Exceeded (≥100%),100,95.0,95.7
NCT00873951,Influence of Protein Hydrolysis on Dietary Protein Digestibility and Metabolism in Healthy Subjects,COMPLETED,NA,26.0,2006-01-01,2008-01-01,1.084164383561644,Adequate (1-10/month),10.84164383561644,Significantly Below (<50%),100,47.1,39.64
NCT02792751,Does the Use of Bispectral Index Reduce the Oxidative Stress in Endoscopic Retrograde Cholangiopancreatography?,COMPLETED,NA,50.0,2014-05-01,2015-10-01,2.9382239382239383,Adequate (1-10/month),29.382239382239383,Significantly Below (<50%),100,54.0,58.72500000000001
NCT06380751,"Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer",RECRUITING,PHASE3,500.0,2024-08-01,2030-10-18,6.707800793301014,Adequate (1-10/month),67.07800793301014,Below (50-75%),60,78.0,86.075
NCT03437551,Prevalence of DRP and DME Among Type 1 Diabetics Treated With Long-term Intensified Insulin Therapy,COMPLETED,,150.0,2012-09-01,2014-12-01,5.561510353227771,Adequate (1-10/month),55.61510353227771,Below (50-75%),100,60.3,72.34
NCT01748851,XELOX Versus FOLFOX for Advanced Gastric Cancer (AGC),TERMINATED,PHASE3,42.0,2012-12-01,2014-09-01,2.0007511737089203,Adequate (1-10/month),20.007511737089203,Significantly Below (<50%),10,26.4,7.865
NCT00308451,A 30 Day Acute Efficacy and Safety Study of Chromium Picolinate + Biotin on Glycemic Control in Overweight or Obese Subjects With T2DM,COMPLETED,NA,40.0,2003-11-01,2004-04-01,8.010526315789473,Adequate (1-10/month),80.10526315789474,Met (75-100%),100,53.2,56.665
NCT01028651,A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension,COMPLETED,,13.0,2011-01-01,2013-04-01,0.4819975639464068,Slow (<1/month),4.819975639464069,Significantly Below (<50%),100,44.4,28.95
NCT00160251,"Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)",COMPLETED,PHASE2,357.0,2005-09-01,2007-07-01,16.26808383233533,Good (10-50/month),162.6808383233533,Exceeded (≥100%),100,83.6,90.435
NCT00578929,Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients,COMPLETED,PHASE3,2388.0,2007-09-01,,,Slow (<1/month),,Significantly Below (<50%),100,80.0,87.67
NCT02567929,Assessment of the Anesthetic Effect on the Activity of Immune Cell in Patient With Breast Cancer,COMPLETED,NA,218.0,2016-03-01,2016-12-01,24.130618181818182,Good (10-50/month),200.0,Exceeded (≥100%),100,72.4,83.17999999999999
NCT02985229,Acceptability and Feasibility of Medical Abortion in Singapore,COMPLETED,PHASE3,130.0,2016-10-01,2017-07-01,14.495238095238097,Good (10-50/month),144.95238095238096,Exceeded (≥100%),100,65.4,78.415
NCT06591429,Smoldering Inflammation in MS,RECRUITING,,25.0,2024-06-19,2027-06-30,0.6880650994575046,Slow (<1/month),6.880650994575046,Significantly Below (<50%),60,33.3,13.200000000000001
NCT03143829,Promoting Cancer Symptom Management in Older Adults,COMPLETED,NA,80.0,2016-08-11,2018-08-31,3.2469333333333337,Adequate (1-10/month),32.46933333333333,Significantly Below (<50%),100,56.4,64.88000000000001
NCT00699829,Mohs Versus Traditional Surgery - Basal-Cell Carcinomas (BCC),UNKNOWN,,450.0,2008-06-01,,,Slow (<1/month),,Significantly Below (<50%),50,59.3,70.815
NCT01213329,Immunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab,TERMINATED,PHASE4,52.0,2006-02-01,2009-04-01,1.3704588744588744,Adequate (1-10/month),13.704588744588744,Significantly Below (<50%),10,22.2,6.2700000000000005
NCT06263829,HCV Tappt Adherence Study,RECRUITING,NA,30.0,2024-06-01,2026-04-01,1.3650224215246636,Adequate (1-10/month),13.650224215246636,Significantly Below (<50%),60,35.4,15.765
NCT03540329,Comparison Between Internal and External Distractors in Osteogenesis,UNKNOWN,NA,30.0,2018-08-01,2020-10-01,1.153030303030303,Adequate (1-10/month),11.530303030303031,Significantly Below (<50%),50,32.4,12.025
NCT00926029,Compare the Clinical Efficacy of Prototype Toothpastes,COMPLETED,PHASE3,98.0,2008-01-01,2008-04-01,32.78153846153846,Good (10-50/month),200.0,Exceeded (≥100%),100,62.8,75.53999999999999
NCT04109729,Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer,ACTIVE_NOT_RECRUITING,PHASE1,39.0,2020-09-16,2026-04-30,0.5785380116959065,Slow (<1/month),5.785380116959065,Significantly Below (<50%),85,43.6,27.54
NCT05884229,The Effect of SPI (Surgical Pleth Index) - Guided Anaesthesia on Opioid Consumption in Gastric Sleeve Surgery,UNKNOWN,NA,40.0,2023-01-01,2024-01-01,3.3358904109589043,Adequate (1-10/month),33.35890410958904,Significantly Below (<50%),50,38.2,19.645000000000003
NCT00552929,A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Caucasian Participants. Part B (P05974),COMPLETED,PHASE2,102.0,2005-10-04,2006-09-15,8.97364161849711,Adequate (1-10/month),89.7364161849711,Met (75-100%),100,63.2,76.11
NCT03292029,Pilot Medical Evaluation of the T50 Test,COMPLETED,NA,776.0,2017-09-22,2020-03-04,26.42219239373602,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT02306629,Study to Compare Properties of Epratuzumab When Given as an Injection Under the Skin or Directly Into the Blood,COMPLETED,PHASE1,42.0,2014-11-01,2015-04-01,8.466754966887418,Adequate (1-10/month),84.66754966887416,Met (75-100%),100,58.4,69.175
NCT03310229,Pulmonary Hypertension in Haemodialysis Patients :Frequency and Risk Factors,COMPLETED,,80.0,2018-12-01,2019-12-02,6.6535519125683065,Adequate (1-10/month),66.53551912568307,Below (50-75%),100,54.7,60.629999999999995
NCT02777229,Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings,COMPLETED,PHASE3,616.0,2016-07-01,2021-07-01,10.268915662650603,Good (10-50/month),102.68915662650603,Exceeded (≥100%),100,95.0,95.7
NCT00259129,Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients,COMPLETED,PHASE1,53.0,2005-08-01,2008-03-01,1.7108377518557796,Adequate (1-10/month),17.108377518557795,Significantly Below (<50%),100,54.2,59.330000000000005
NCT06031129,Butorphanol in Pain Following Ablation for Hepatic Tumor,COMPLETED,NA,300.0,2023-03-01,2023-08-09,56.72049689440994,Excellent (>50/month),200.0,Exceeded (≥100%),100,84.0,90.595
NCT02852629,Assessment of a Tool for Decision Making in Case of Worsening Condition of Cancer Patients,COMPLETED,,483.0,2014-02-01,2016-03-31,18.634372623574144,Good (10-50/month),186.34372623574146,Exceeded (≥100%),100,92.0,93.78999999999999
NCT06608329,A Relative Bioavailability and Food Effect Study of HDM1002 in Healthy Subjects,NOT_YET_RECRUITING,PHASE1,33.0,2024-10-01,2024-12-01,16.467540983606558,Good (10-50/month),164.67540983606557,Exceeded (≥100%),30,36.6,17.41
NCT05966129,A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Acute Pain Trial),COMPLETED,NA,1602.0,2021-03-10,2024-03-25,43.89278127812782,Good (10-50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT03580629,Pilot Study of the Liver Live Donor Champion Program,COMPLETED,NA,76.0,2018-09-18,2025-11-29,0.8799695701787752,Slow (<1/month),8.799695701787751,Significantly Below (<50%),100,51.1,50.129999999999995
NCT04130529,Better Sleep in Psychiatric Care - Bipolar,UNKNOWN,NA,85.0,2019-10-01,2025-06-01,1.249951690821256,Adequate (1-10/month),12.49951690821256,Significantly Below (<50%),50,36.8,17.630000000000003
NCT00554229,A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases,COMPLETED,PHASE3,896.0,2007-11-01,2011-08-01,19.9227465303141,Good (10-50/month),199.227465303141,Exceeded (≥100%),100,95.0,95.7
NCT06041529,Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension,RECRUITING,PHASE4,250.0,2023-10-18,2025-10-28,10.269905533063428,Good (10-50/month),102.69905533063428,Exceeded (≥100%),60,63.0,75.845
NCT02953431,Increased Lung Volume as Controller Therapy for Asthma,COMPLETED,NA,60.0,2018-05-07,2023-12-31,0.8848837209302325,Slow (<1/month),8.848837209302324,Significantly Below (<50%),100,49.8,47.17
NCT03196531,A Study to Assess the Bioequivalence of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared With Clarityne Tablets,COMPLETED,PHASE1,108.0,2017-11-07,2018-03-31,22.83,Good (10-50/month),200.0,Exceeded (≥100%),100,63.6,76.545
NCT07184931,An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease,RECRUITING,PHASE3,980.0,2025-10-01,2029-05-14,22.582286146858443,Good (10-50/month),200.0,Exceeded (≥100%),60,83.0,89.505
NCT02582931,MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer,COMPLETED,PHASE1,10.0,2015-12-02,2018-12-13,0.27497741644083107,Slow (<1/month),2.7497741644083105,Significantly Below (<50%),100,45.8,33.03
NCT05448131,ERT in Pompe Disease: Elucidation of Molecular Structures Contributing to Enzyme Uptake and Immunoreactivity,UNKNOWN,,50.0,2023-02-01,2024-10-07,2.478827361563518,Adequate (1-10/month),24.78827361563518,Significantly Below (<50%),50,37.3,18.35
NCT05831631,Characterization of Circulating and Tumor-infiltrating Immune Cells in Malignant Brain Tumors,RECRUITING,,200.0,2022-08-01,2029-08-01,2.3809151349237387,Adequate (1-10/month),23.80915134923739,Significantly Below (<50%),60,52.3,53.515
NCT05712031,Combined Tooth-implant Supported Prostheses,COMPLETED,NA,78.0,2015-07-03,2022-09-09,0.9045028571428572,Slow (<1/month),9.045028571428572,Significantly Below (<50%),100,51.2,50.375
NCT03472131,Unilateral Posterolateral Approach for Spondylodiskitis,COMPLETED,NA,20.0,2004-01-01,2016-12-01,0.12903772785078424,Slow (<1/month),1.2903772785078425,Significantly Below (<50%),100,46.6,37.375
NCT03902431,Translating the ABCS Into HIV Care,COMPLETED,NA,4277.0,2019-09-26,2024-05-31,76.18015213575191,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT04132531,Effect of Weight Loss Surgery on Stem Cells.,COMPLETED,,38.0,2018-05-01,2019-08-13,2.4663539445628997,Adequate (1-10/month),24.663539445628995,Significantly Below (<50%),100,51.4,50.92
NCT03309631,Clinical Validation of ThyroidPrint: A Gene Expression Signature for Diagnosis of Indeterminate Thyroid Nodules,UNKNOWN,,1500.0,2016-03-01,2018-06-30,53.654524089306705,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT04314531,Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2),ACTIVE_NOT_RECRUITING,PHASE3,296.0,2020-07-01,2026-01-01,4.482706467661691,Adequate (1-10/month),44.827064676616914,Significantly Below (<50%),85,69.2,81.28
NCT07093931,Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer,NOT_YET_RECRUITING,PHASE4,468.0,2025-08-01,2030-08-01,7.80170865279299,Adequate (1-10/month),78.0170865279299,Met (75-100%),30,66.4,79.36999999999999
NCT02519231,Copper IUD Treatment Observation Study,COMPLETED,PHASE4,34.0,2016-02-01,2017-11-01,1.6196557120500783,Adequate (1-10/month),16.196557120500785,Significantly Below (<50%),100,47.7,42.17
NCT01506531,Silo Versus Primary Closure for Gastroschisis,COMPLETED,NA,38.0,2011-08-01,2018-04-01,0.4750390143737167,Slow (<1/month),4.7503901437371665,Significantly Below (<50%),100,48.0,42.945
NCT00967031,Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases,COMPLETED,PHASE2,45.0,2009-04-01,,,Slow (<1/month),,Significantly Below (<50%),100,43.6,27.54
NCT05451602,HEC169096 in Participants With Advanced Solid Tumors,RECRUITING,PHASE1,456.0,2022-10-21,2027-08-30,7.824487034949268,Adequate (1-10/month),78.24487034949269,Met (75-100%),60,74.5,84.28999999999999
NCT04285502,Comparison of Postoperative Drain Insertion Versus No Drain Insertion In Total Laparoscopic Hysterectomy,UNKNOWN,NA,100.0,2020-03-01,2021-02-01,9.032640949554898,Adequate (1-10/month),90.32640949554897,Met (75-100%),50,48.0,42.945
NCT05315102,Effects of Intensive Chiropractic Care to Usual Care for Children With Cerebral Palsy.,COMPLETED,NA,39.0,2022-04-07,2022-10-01,6.707118644067797,Adequate (1-10/month),67.07118644067796,Below (50-75%),100,53.1,56.105000000000004
NCT05205902,TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides,NOT_YET_RECRUITING,PHASE3,78.0,2022-02-01,2031-02-01,0.7223364770307271,Slow (<1/month),7.223364770307272,Significantly Below (<50%),30,30.2,9.245000000000001
NCT03045302,"Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly",TERMINATED,PHASE2,4.0,2017-01-26,2017-06-02,0.9587401574803149,Slow (<1/month),9.587401574803149,Significantly Below (<50%),10,18.3,3.74
NCT03699202,Anti-RSV Study in Chinese Patients (ASCENT),UNKNOWN,PHASE2,160.0,2019-03-29,2020-06-30,10.610893246187365,Good (10-50/month),106.10893246187365,Exceeded (≥100%),50,52.8,55.31
NCT02234102,Eagle AF (Atrial Fibrillation) - Endoscopically Guided Laser Ablation of Persistent Atrial Fibrillation,UNKNOWN,NA,160.0,2014-08-01,2017-06-01,4.705700483091787,Adequate (1-10/month),47.05700483091787,Significantly Below (<50%),50,47.8,42.42
NCT05715502,Focal Salvage Brachytherapy Study (FocaSaBra),RECRUITING,NA,100.0,2022-05-01,2028-12-31,1.2495894909688012,Adequate (1-10/month),12.495894909688012,Significantly Below (<50%),60,41.0,23.01
NCT05053802,"Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial",RECRUITING,PHASE2,146.0,2021-03-21,2027-09-30,1.8641946308724833,Adequate (1-10/month),18.641946308724833,Significantly Below (<50%),60,49.7,46.949999999999996
NCT05883202,Effect of the Abutment-Prosthesis Connection on Marginal Bone Loss and Gingival Sealing Around Dental Implants,ACTIVE_NOT_RECRUITING,NA,40.0,2023-07-10,2026-07-01,1.1201471941122356,Adequate (1-10/month),11.201471941122355,Significantly Below (<50%),85,43.7,27.744999999999997
NCT03731702,Optimization of Collection Methods for Studies of the Human Microbiota,WITHDRAWN,,0.0,2018-11-01,2020-10-27,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT00453102,Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma,COMPLETED,PHASE2,18.0,2006-02-01,2015-02-01,0.16669303316093703,Slow (<1/month),1.6669303316093704,Significantly Below (<50%),100,46.4,36.26
NCT07235202,A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy,RECRUITING,PHASE1,45.0,2025-12-24,2028-12-22,1.2521023765996344,Adequate (1-10/month),12.521023765996345,Significantly Below (<50%),60,36.6,17.41
NCT03788902,OT and Social Cognition in Children With ADHD: Impact of MPH,COMPLETED,NA,90.0,2014-02-01,2017-01-01,2.5723943661971833,Adequate (1-10/month),25.72394366197183,Significantly Below (<50%),100,57.2,66.465
NCT01897402,"Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine",COMPLETED,PHASE2,525.0,2013-07-01,2014-12-01,30.851351351351354,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT00866502,A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease,COMPLETED,PHASE1,12.0,2009-03-01,2011-03-01,0.5003835616438357,Slow (<1/month),5.003835616438357,Significantly Below (<50%),100,46.0,34.1
NCT07202702,Modulation of Motor Learning Via tDCS in a Dexterous Video Game Task,RECRUITING,NA,52.0,2025-03-03,2026-03-03,4.336657534246576,Adequate (1-10/month),43.36657534246576,Significantly Below (<50%),60,42.2,25.155
NCT06174402,Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis,ACTIVE_NOT_RECRUITING,PHASE2,184.0,2023-08-21,2026-12-31,4.561042345276873,Adequate (1-10/month),45.610423452768735,Significantly Below (<50%),85,60.2,72.2
NCT00847002,Flexitouch Treatment for Venous Ulcers,TERMINATED,NA,8.0,2007-09-01,2010-08-01,0.22865727699530516,Slow (<1/month),2.286572769953052,Significantly Below (<50%),10,18.6,4.25
NCT06141902,The Effects of Jing Si Herbal Tea on Physical and Psychological Symptoms in Peripheral Blood Hematopoietic Stem Cell Donors,ENROLLING_BY_INVITATION,NA,80.0,2025-09-18,2027-12-31,2.919904076738609,Adequate (1-10/month),29.19904076738609,Significantly Below (<50%),55,42.9,26.145000000000003
NCT02789202,Diammine Silver Fluoride in Arresting Enamel Caries Lesions on Babies' Occlusal Surfaces,UNKNOWN,NA,100.0,2014-10-01,2020-08-01,1.4284373533552324,Adequate (1-10/month),14.284373533552325,Significantly Below (<50%),50,38.0,19.255
NCT05418153,Synergy Lens Outcomes Evaluation,COMPLETED,,52.0,2022-03-14,2022-11-22,6.256442687747036,Adequate (1-10/month),62.56442687747036,Below (50-75%),100,52.5,54.345
NCT05294653,Atherosclerotic Cardiovascular Risk in Childhood and Teen-age Onset Diabetes,NOT_YET_RECRUITING,,300.0,2022-06-01,2027-01-01,5.451940298507463,Adequate (1-10/month),54.51940298507463,Below (50-75%),30,51.3,50.62
NCT02550353,Changes Between Lenticule Extraction and Femtosecond Laser-assisted Laser in Situ Keratomileusis,COMPLETED,NA,75.0,2015-09-01,2016-05-01,9.395061728395062,Adequate (1-10/month),93.95061728395063,Met (75-100%),100,61.0,73.17
NCT05094453,Borescope Visually Assisted Intubation Through Fekry Intubating Airway,COMPLETED,,35.0,2020-06-01,2021-07-10,2.637128712871287,Adequate (1-10/month),26.371287128712872,Significantly Below (<50%),100,51.1,50.129999999999995
NCT01719653,A Comparison of 5 Low Volume Bowel Preparations,COMPLETED,PHASE4,1079.0,2012-10-01,2014-09-01,46.92108571428572,Good (10-50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT05848453,"Safety, Tolerability, and Pharmacokinetics of BAP5191 in Healthy Adults Following Topical Application of Repeat Doses",COMPLETED,PHASE1,24.0,2023-03-28,2024-03-07,2.1175652173913044,Adequate (1-10/month),21.175652173913047,Significantly Below (<50%),100,51.9,52.55499999999999
NCT06913153,Tianjin Diabetes and Health Cohort Study,COMPLETED,,396983.0,2009-01-01,2024-12-31,2068.1435084716754,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT03122353,BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis,COMPLETED,PHASE1,699.0,2017-04-11,2017-11-15,97.60348623853211,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT01853553,Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD),COMPLETED,PHASE3,61.0,2013-07-01,2017-01-01,1.45065625,Adequate (1-10/month),14.506562500000001,Significantly Below (<50%),100,49.9,47.425
NCT01135953,Methods to Enhance Transcranial Direct Stimulation (tDCS),COMPLETED,NA,24.0,2010-01-01,2010-07-01,4.036243093922652,Adequate (1-10/month),40.36243093922652,Significantly Below (<50%),100,51.9,52.55499999999999
NCT03837353,A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1,TERMINATED,PHASE1,18.0,2019-04-01,2022-09-20,0.43211356466876977,Slow (<1/month),4.321135646687697,Significantly Below (<50%),10,19.4,5.2299999999999995
NCT05900453,Novel Strategies for Personalized Clinical Decisions in Knee Arthroplasty,COMPLETED,,675.0,2018-05-15,2022-12-30,12.157988165680473,Good (10-50/month),121.57988165680476,Exceeded (≥100%),100,93.3,94.325
NCT02162953,Stem Cell Models of Best Disease and Other Retinal Degenerative Diseases.,COMPLETED,,48.0,2014-02-01,2022-12-31,0.44888479262672815,Slow (<1/month),4.488847926267281,Significantly Below (<50%),100,47.2,40.035
NCT05568953,An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity,UNKNOWN,PHASE2,70.0,2022-09-28,2025-10-01,1.9388535031847134,Adequate (1-10/month),19.388535031847134,Significantly Below (<50%),50,40.6,22.575
NCT06815653,Digital Intervention for Psychedelic Preparation (DIPP): Comparing Meditation and Music-Based Programs,RECRUITING,PHASE1,40.0,2025-03-01,2026-12-01,1.9025,Adequate (1-10/month),19.025,Significantly Below (<50%),60,41.2,23.425
NCT01299753,Catecholamine Blockade Post-burn,UNKNOWN,NA,80.0,2011-02-01,2023-12-31,0.5163698049194233,Slow (<1/month),5.163698049194233,Significantly Below (<50%),50,36.4,17.14
NCT02903953,Clinical Research Outside of Teaching Hospitals (RECHNONU),COMPLETED,,129.0,2012-01-01,2013-05-01,8.079753086419753,Adequate (1-10/month),80.79753086419754,Met (75-100%),100,58.7,69.69
NCT00319553,"Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®",COMPLETED,PHASE4,647.0,2006-05-01,2008-12-01,20.840931216931217,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT06720753,Real-time Examination of Skills and Coping Use in Teen's Everyday Lives,RECRUITING,NA,200.0,2024-07-29,2029-03-31,3.568581477139508,Adequate (1-10/month),35.68581477139508,Significantly Below (<50%),60,54.0,58.72500000000001
NCT03184753,Genetically Modified T Cells Against Ovarian Cancer,RECRUITING,PHASE1,100.0,2025-05-01,2029-12-31,1.7853372434017598,Adequate (1-10/month),17.853372434017597,Significantly Below (<50%),60,46.0,34.1
NCT02989753,Effects of Two Herbal Dietary Supplements on Lipid Metabolism in Moderate Hypercholesterolemia and Hypertriglyceridemia,COMPLETED,PHASE1,40.0,2017-01-01,2018-07-01,2.23003663003663,Adequate (1-10/month),22.300366300366303,Significantly Below (<50%),100,53.2,56.665
NCT01070953,EZETROL® Re-examination Study (MK0653-175)(COMPLETED),COMPLETED,,4467.0,2005-01-01,2010-07-01,67.75061285500747,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02541253,A Study to Evaluate the Efficacy and Safety of 'GC3110A(QIV)' in Healthy Children,COMPLETED,PHASE3,543.0,2015-09-01,2016-06-01,60.324525547445255,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT02295553,Ketamine and Propofol for Upper Endoscopy,COMPLETED,PHASE4,56.0,2013-07-01,2016-12-01,1.3648038430744596,Adequate (1-10/month),13.648038430744597,Significantly Below (<50%),100,49.5,46.58
NCT06966037,Uric Acid Levels and Migraine in Children,COMPLETED,,2.0,2019-08-01,2025-04-01,0.029410628019323672,Slow (<1/month),0.2941062801932367,Significantly Below (<50%),100,43.5,27.400000000000002
NCT00557037,A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer,COMPLETED,PHASE2,60.0,2007-11-01,2009-11-01,2.498495212038304,Adequate (1-10/month),24.98495212038304,Significantly Below (<50%),100,54.8,61.095
NCT03316937,Comparison of the Effect of Teflon vs Non-Teflon Hand Scalers in the Maintenance of Peri-Implant Tissue,COMPLETED,NA,13.0,2018-01-10,2019-06-06,0.7728906249999999,Slow (<1/month),7.7289062500000005,Significantly Below (<50%),100,46.0,34.1
NCT02895737,PROTECT TAVI - Prospective Randomized Outcome Study in TAVI Patients Undergoing Periprocedural Embolic Cerebral Protection With the Sentinel™ Device,UNKNOWN,NA,328.0,2016-12-28,2022-06-01,5.040040383644624,Adequate (1-10/month),50.40040383644624,Below (50-75%),50,61.2,73.43499999999999
NCT03960437,The Effect of Etelcalcetide on CKD-MBD,COMPLETED,PHASE2,22.0,2018-09-06,2020-11-19,0.8319006211180124,Slow (<1/month),8.319006211180122,Significantly Below (<50%),100,46.8,38.440000000000005
NCT07266337,CD19/BCMA CAR-T for SLE,NOT_YET_RECRUITING,EARLY_PHASE1,24.0,2025-12-10,2037-12-31,0.16588555858310625,Slow (<1/month),1.6588555858310625,Significantly Below (<50%),30,25.9,7.704999999999999
NCT04752137,Intraoperative Tumor Margin Identification With ICG Dye Imaging,RECRUITING,PHASE2,100.0,2022-05-25,2026-10-01,1.9144654088050317,Adequate (1-10/month),19.144654088050313,Significantly Below (<50%),60,46.0,34.1
NCT05837637,The Vietnamese Smell Identification Test in the Diagnosis of Parkinson's Disease,UNKNOWN,,218.0,2023-05-05,2025-09-01,7.806964705882353,Adequate (1-10/month),78.06964705882353,Met (75-100%),50,50.8,49.18
NCT02717637,Oxycodone in Serum After Postoperative Oral Oxycodone in Caesarean Sections Under Spinal Anesthesia,COMPLETED,,50.0,2016-02-01,2017-04-01,3.581176470588235,Adequate (1-10/month),35.811764705882354,Significantly Below (<50%),100,52.3,53.515
NCT03326037,Study of The Association of Mutations in The NPHS2 Gene and Nephrotic Syndrome in Children and Adults in Middle East,UNKNOWN,,150.0,2016-10-01,2020-06-01,3.4100074682598955,Adequate (1-10/month),34.10007468259896,Significantly Below (<50%),50,45.3,31.169999999999998
NCT00953537,Predicting Response to Capecitabine in Women With Metastatic Breast Cancer,COMPLETED,NA,303.0,2009-01-01,2011-02-01,12.12,Good (10-50/month),121.2,Exceeded (≥100%),100,79.2,87.095
NCT06669637,Amplify EP Registry,NOT_YET_RECRUITING,,1100.0,2024-11-22,2026-12-01,45.30987821380244,Good (10-50/month),200.0,Exceeded (≥100%),30,77.3,85.67
NCT03892837,Clinical Study on Autologous Platelet-rich Plasma (PRP) Treatment for Refractory Benign Airway Stenosis,UNKNOWN,NA,24.0,2019-04-01,2021-04-01,0.9993980848153216,Slow (<1/month),9.993980848153216,Significantly Below (<50%),50,31.9,11.295
NCT03968237,Measures to Improve Outcomes After an Opioid Overdose,UNKNOWN,,200.0,2019-08-01,2021-06-01,9.086567164179105,Adequate (1-10/month),90.86567164179104,Met (75-100%),50,54.3,59.62
NCT04109937,External Beam Radiation Therapy Post Surgery in Patients With Lower Extremity Bone Metastases Randomized Efficacy Trial,WITHDRAWN,NA,0.0,2020-10-01,2026-10-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT01563237,Safety and Performance of Miami InnFocus Drainage Implant (MIDI Arrow) Glaucoma Drainage Implant,COMPLETED,NA,69.0,2011-06-01,2017-01-01,1.0290837824595787,Adequate (1-10/month),10.290837824595787,Significantly Below (<50%),100,50.5,48.515
NCT01006837,Hypothermia in the Trauma Patient - When do Trauma Patients Get Cold?,COMPLETED,,60.0,2009-10-01,2014-08-01,1.034787535410765,Adequate (1-10/month),10.347875354107648,Significantly Below (<50%),100,48.1,43.275000000000006
NCT06777537,Neoadjuvant Chemotherapy with or Without Talniflumate for the Treatment of Breast Cancer,NOT_YET_RECRUITING,PHASE4,200.0,2025-06-01,2030-12-01,3.0303633648581387,Adequate (1-10/month),30.30363364858139,Significantly Below (<50%),30,45.0,30.330000000000002
NCT03869437,RCT Cefiderocol vs BAT for Treatment of Gram Negative BSI,COMPLETED,PHASE2,513.0,2019-10-28,2024-01-29,10.04872586872587,Good (10-50/month),100.4872586872587,Exceeded (≥100%),100,95.0,95.7
NCT05849337,The Lóa Study: a Brief Digital Intervention for Women with Intrusive Memories in the SAGA Cohort,RECRUITING,NA,380.0,2023-10-30,2025-11-30,15.180052493438321,Good (10-50/month),151.80052493438322,Exceeded (≥100%),60,73.4,83.7
NCT05549037,Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC,RECRUITING,PHASE3,210.0,2022-09-23,2025-12-31,5.34928870292887,Adequate (1-10/month),53.4928870292887,Below (50-75%),60,54.8,61.095
NCT05547737,"Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer",UNKNOWN,,500.0,2022-09-21,2025-09-21,13.886861313868613,Good (10-50/month),138.86861313868613,Exceeded (≥100%),50,78.3,86.48
NCT06197737,Specific Modified Exercise Program for Patients Having Chronic Asthma,COMPLETED,NA,78.0,2023-03-01,2024-01-01,7.759215686274509,Adequate (1-10/month),77.5921568627451,Met (75-100%),100,56.2,64.21
NCT00299637,Changes in Blood Flow in MCA of Fetuses to Mothers Having Clinical Chorioamnionitis,UNKNOWN,,34.0,2006-10-01,2007-12-01,2.4294835680751175,Adequate (1-10/month),24.294835680751177,Significantly Below (<50%),50,36.1,16.665
NCT02904837,Mental Practice Combined With Physical Practice to Improve the Gait Performance of People With Parkinson's Disease,COMPLETED,NA,20.0,2015-03-01,2017-12-01,0.605168986083499,Slow (<1/month),6.05168986083499,Significantly Below (<50%),100,46.6,37.375
NCT03874637,FemPulse Therapy First-in-Human Experience,COMPLETED,NA,15.0,2017-02-14,2017-05-17,4.96304347826087,Adequate (1-10/month),49.6304347826087,Significantly Below (<50%),100,51.2,50.375
NCT06960837,Ultrasound Simulation Case-based Workshop Implementation and Impact Assessment,RECRUITING,NA,100.0,2025-03-06,2026-12-31,4.5774436090225565,Adequate (1-10/month),45.774436090225564,Significantly Below (<50%),60,46.0,34.1
NCT02764437,AsthMatic Inflammation and Neurocircuitry Activation (MINA),COMPLETED,,43.0,2016-07-28,2020-03-31,0.9753502235469449,Slow (<1/month),9.75350223546945,Significantly Below (<50%),100,46.8,38.440000000000005
NCT01021137,Vestibular Consequences of Blast-related Mild Traumatic Brain Injury (TBI),COMPLETED,,140.0,2011-05-01,2017-12-01,1.771238570241064,Adequate (1-10/month),17.71238570241064,Significantly Below (<50%),100,59.5,71.0
NCT01023737,Hydroxychloroquine + Vorinostat in Advanced Solid Tumors,COMPLETED,PHASE1,72.0,2009-11-01,2023-01-08,0.45508305647840536,Slow (<1/month),4.550830564784054,Significantly Below (<50%),100,50.8,49.18
NCT03249337,Glanatec(R) for Descemet Stripping in Fuch's Endothelial Dystrophy,RECRUITING,PHASE4,30.0,2017-12-06,2021-12-01,0.6271978021978022,Slow (<1/month),6.271978021978023,Significantly Below (<50%),60,35.4,15.765
NCT05922137,Oriental Intervention for Enhanced Neurocognitive Health (ORIENT) Diet in Patients With Intracranial / Carotid Stenosis,RECRUITING,NA,120.0,2023-05-01,2027-05-31,2.4498993963782696,Adequate (1-10/month),24.498993963782695,Significantly Below (<50%),60,47.6,41.775
NCT03999437,SINGLE-APPLICATION TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION BUTENAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION FOR THE TREATMENT OF TINEA PEDIS,UNKNOWN,PHASE2,42.0,2019-01-02,2020-01-03,3.493114754098361,Adequate (1-10/month),34.9311475409836,Significantly Below (<50%),50,38.4,19.835
NCT03426137,Relieving Acute Pain (RAP) Study: A Pilot Study,TERMINATED,PHASE2,3.0,2018-09-17,2020-01-21,0.18598778004073319,Slow (<1/month),1.8598778004073322,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT01984645,Primary-care-provider Identification And Notification,COMPLETED,NA,7023.0,2012-09-01,2015-07-01,206.9507454017425,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT05882045,A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease,ACTIVE_NOT_RECRUITING,PHASE3,1800.0,2023-05-30,2026-05-01,51.3514526710403,Excellent (>50/month),200.0,Exceeded (≥100%),85,95.5,96.55
NCT00087945,Blood Levels of Abacavir in HIV Infected Adolescents,COMPLETED,NA,30.0,2004-07-01,2004-12-01,5.968627450980392,Adequate (1-10/month),59.68627450980393,Below (50-75%),100,52.4,53.949999999999996
NCT05455645,The Therapeutic Effect of Targeted Intrinsic Foot Muscles Exercises in Plantar Fasciitis,UNKNOWN,NA,64.0,2022-08-30,2023-08-30,5.337424657534247,Adequate (1-10/month),53.374246575342475,Below (50-75%),50,40.1,22.05
NCT01723345,Does Omega-3 Polyunsaturated Fatty Acids (PUFAs) Pretreatment Improve Outcomes in Patients Undergoing Percutaneous Coronary Intervention (PCI)?,UNKNOWN,PHASE3,90.0,2012-02-01,2013-04-01,6.4461176470588235,Adequate (1-10/month),64.46117647058824,Below (50-75%),50,42.2,25.155
NCT04401345,Effect of Glycopyrrolate on Vasopressors Requirement for Non-elective Caesarean Section Under Spinal Anaesthesia,COMPLETED,PHASE4,258.0,2020-06-01,2021-01-31,32.186557377049176,Good (10-50/month),200.0,Exceeded (≥100%),100,75.6,84.735
NCT01788345,Prospective Trial of the Bilevel Positive Airway Pressure (by Boussignac) in Emergency Department of Non-invasive Patients Presenting With Acute Hypercapnic Respiratory Failure,UNKNOWN,NA,44.0,2013-02-01,2013-12-01,4.4203300330033,Adequate (1-10/month),44.20330033003301,Significantly Below (<50%),50,38.5,19.895
NCT00054145,"Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer",COMPLETED,PHASE2,,2003-06-01,,,Slow (<1/month),,Significantly Below (<50%),100,40.0,21.87
NCT06572345,Low EnerGy DiEt iN Adolescents With Obesity and Type 2 Diabetes: The LEGEND Study,RECRUITING,NA,73.0,2025-06-30,2026-12-31,4.047577413479053,Adequate (1-10/month),40.475774134790534,Significantly Below (<50%),60,43.8,27.965
NCT05391945,Effects of Thyroidectomy on Obstructive Sleep Apnea in Patients Suffering From Goiters,RECRUITING,,100.0,2022-09-01,2026-12-01,1.9613402061855671,Adequate (1-10/month),19.61340206185567,Significantly Below (<50%),60,44.3,28.715000000000003
NCT01681745,Probe Configuration and Time-Temperature Dose Ranging for Understanding of Skin Lesion Effects,COMPLETED,NA,30.0,2012-06-01,2015-04-01,0.8831721470019344,Slow (<1/month),8.831721470019344,Significantly Below (<50%),100,47.4,40.98
NCT00511745,Safety of Rabeprazole in Patients Under Multiple Treatments,TERMINATED,,2157.0,,2002-11-01,,Slow (<1/month),,Significantly Below (<50%),10,51.3,50.62
NCT05911945,Failed Insertion of Ureteral Access Sheath During Flexible Ureterorenoscopy,COMPLETED,NA,48.0,2020-09-10,2021-12-01,3.2687248322147653,Adequate (1-10/month),32.68724832214765,Significantly Below (<50%),100,53.8,58.065
NCT07283445,[Trial of device that is not approved or cleared by the U.S. FDA],WITHHELD,,,,,,Slow (<1/month),,Significantly Below (<50%),50,20.0,5.695
NCT02481245,BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study,RECRUITING,PHASE2,30.0,2018-01-11,2026-02-28,0.30747474747474746,Slow (<1/month),3.074747474747475,Significantly Below (<50%),60,35.4,15.765
NCT00266045,D-dimer Levels During and After Anticoagulation in Patients With a Previous Venous Thromboembolism: Effects on the Risk of Recurrence,COMPLETED,,355.0,2005-08-01,2008-12-01,8.872085385878488,Adequate (1-10/month),88.72085385878489,Met (75-100%),100,81.7,88.97
NCT03716245,Clinical Significance of Supraclavicular Lymph Node Dissection for Breast Cancer,COMPLETED,NA,180.0,2019-02-27,2024-01-20,3.0644295302013425,Adequate (1-10/month),30.644295302013425,Significantly Below (<50%),100,64.4,77.37
NCT06403345,A Feasiblity Study of Green Activity Program for People Living With Memory Challenges,RECRUITING,NA,40.0,2024-07-17,2026-08-30,1.5731266149870802,Adequate (1-10/month),15.731266149870804,Significantly Below (<50%),60,36.2,16.84
NCT04166045,Evaluation of Peripheral Nerve Stimulation for Acute Treatment of Migraine Pain,COMPLETED,NA,20.0,2020-06-12,2021-04-29,1.8965732087227416,Adequate (1-10/month),18.96573208722742,Significantly Below (<50%),100,51.6,51.644999999999996
NCT05815745,"""Physiological vs Right Ventricular Pacing Outcome Trial Evaluated for bradyCardia Treatment"" (PROTECT-HF)",RECRUITING,NA,2600.0,2023-06-05,2029-12-04,33.33782645324347,Good (10-50/month),200.0,Exceeded (≥100%),60,83.0,89.505
NCT02758145,Promotion of Influenza Vaccination in Healthcare Workers During the Recruitment Visit,COMPLETED,NA,379.0,2016-04-01,2018-04-01,15.80378082191781,Good (10-50/month),158.0378082191781,Exceeded (≥100%),100,85.3,91.355
NCT05008445,Study of LM-102 in Patients With Advance Solid Tumors,TERMINATED,PHASE1,11.0,2021-10-06,2023-02-28,0.6565490196078432,Slow (<1/month),6.565490196078431,Significantly Below (<50%),10,18.9,4.6899999999999995
NCT02613845,"Predictors for Postoperative Delirium After Cardiac Surgery in Adults: a One-year, Single Center, Observational Cohort Study",COMPLETED,,656.0,2013-01-01,2016-04-01,16.836964586846545,Good (10-50/month),168.36964586846545,Exceeded (≥100%),100,93.3,94.325
NCT02973945,High Flow Nasal Cannula and Aerobic Capacity Training,UNKNOWN,NA,60.0,2017-07-01,2019-05-01,2.730044843049327,Adequate (1-10/month),27.300448430493272,Significantly Below (<50%),50,39.8,21.47
NCT05763745,Bedside Ultrasonic Assessment for Gastric Content in Patients With Upper GI Bleeding Undergoing Endoscopy,COMPLETED,,50.0,2023-02-10,2025-04-03,1.9438058748403577,Adequate (1-10/month),19.438058748403577,Significantly Below (<50%),100,52.3,53.515
NCT02441972,Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics,UNKNOWN,PHASE1,200.0,2012-01-01,2020-12-01,1.869204789683758,Adequate (1-10/month),18.692047896837582,Significantly Below (<50%),50,51.0,49.714999999999996
NCT00477672,A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis,COMPLETED,PHASE3,298.0,2007-06-01,2009-07-01,11.92,Good (10-50/month),119.19999999999999,Exceeded (≥100%),100,78.8,86.86
NCT02200172,The Preventative Role of Exogenous Melatonin Administration in Patients With Advanced Cancer Who Are at Risk of Delirium: a Feasibility Study,COMPLETED,PHASE2,60.0,2014-12-01,2016-04-01,3.7503080082135525,Adequate (1-10/month),37.503080082135526,Significantly Below (<50%),100,54.8,61.095
NCT00777972,Bioequivalence Study of Fosinopril Sodium/ Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fasting Conditions,COMPLETED,NA,34.0,2003-03-01,2003-04-01,33.3858064516129,Good (10-50/month),200.0,Exceeded (≥100%),100,57.7,67.51
NCT00213772,Risk Factors of Porphyria Cutanea Tarda (PCT),COMPLETED,,280.0,1999-05-01,,,Slow (<1/month),,Significantly Below (<50%),100,60.7,72.89999999999999
NCT00095472,Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease,COMPLETED,PHASE1,18.0,2004-11-01,2007-08-24,0.5340350877192983,Slow (<1/month),5.340350877192983,Significantly Below (<50%),100,46.4,36.26
NCT00345072,A Menopause Interactive Decision Aid System,UNKNOWN,NA,296.0,2003-07-01,,,Slow (<1/month),,Significantly Below (<50%),50,48.7,44.93
NCT06075472,The Effect of Inspiratory Muscle Training on Balance and Postural Control in Multiple Sclerosis Patients,COMPLETED,NA,29.0,2023-03-06,2024-06-26,1.8467782426778243,Adequate (1-10/month),18.467782426778243,Significantly Below (<50%),100,52.3,53.515
NCT02561572,"The Effect of Acupuncture on Pre-operative Anxiety Levels in Neurosurgical Patients: a Randomised, Controlled Trail",COMPLETED,NA,128.0,2015-10-01,2016-04-01,21.29136612021858,Good (10-50/month),200.0,Exceeded (≥100%),100,65.2,78.23
NCT03725072,"Human Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Evobrutinib",COMPLETED,PHASE1,6.0,2018-10-30,2018-12-05,5.073333333333333,Adequate (1-10/month),50.73333333333333,Below (50-75%),100,50.5,48.515
NCT07037472,Photoacoustic/Ultrasound Imaging in Patients of Dermatomyositis With Calcinosis Cutis: Characteristic Findings and Treatment Response Evaluation,RECRUITING,NA,100.0,2024-01-01,2028-12-31,1.6670317634173057,Adequate (1-10/month),16.670317634173056,Significantly Below (<50%),60,46.0,34.1
NCT00451672,The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism,UNKNOWN,PHASE4,25.0,2007-01-01,2007-12-01,2.2784431137724552,Adequate (1-10/month),22.78443113772455,Significantly Below (<50%),50,37.0,17.955
NCT02373072,"A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease",COMPLETED,PHASE1,18.0,2015-03-01,2016-03-01,1.497049180327869,Adequate (1-10/month),14.970491803278687,Significantly Below (<50%),100,46.4,36.26
NCT01335672,Survival After First Myocardial Infarction in Patients With and Without Chronic Obstructive Pulmonary Disease,COMPLETED,,2100000.0,2011-03-01,2014-12-01,46625.82056892779,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT05184972,Coverage and Validity of the Swedish Registry of Cardiopulmonary Resuscitation Regarding In-hospital Cardiac Arrest,COMPLETED,,1109.0,2022-03-10,2023-09-06,61.94121100917432,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT05348772,A First-In-Human Phase 1b Study of AmnioPul-02 in COVID-19 / Other LRTI,COMPLETED,PHASE1,6.0,2022-10-10,2023-02-09,1.4970491803278687,Adequate (1-10/month),14.970491803278687,Significantly Below (<50%),100,45.5,31.705
NCT06193772,Increasing Treatment Response Rates in Depressed Adolescents Via Feedback-Informed IPDT,COMPLETED,NA,35.0,2024-01-26,2024-12-31,3.133529411764706,Adequate (1-10/month),31.33529411764706,Significantly Below (<50%),100,52.8,55.31
NCT00160472,Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms,COMPLETED,NA,110.0,2004-03-01,2009-01-01,1.8949632144878326,Adequate (1-10/month),18.949632144878322,Significantly Below (<50%),100,58.8,69.89999999999999
NCT01113372,Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor - Optimize Trial,COMPLETED,PHASE4,3119.0,2010-04-01,2015-07-01,49.526531038080336,Good (10-50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT03658772,Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer,COMPLETED,PHASE1,54.0,2018-09-20,2023-03-07,1.009060773480663,Adequate (1-10/month),10.09060773480663,Significantly Below (<50%),100,49.3,46.265
NCT04264572,Project MiNT: Assessing the Impact of Food & Video-Based Nutrition Education on Patients With Poorly Controlled Diabetes,COMPLETED,NA,600.0,2020-01-21,2025-05-09,9.438759689922481,Adequate (1-10/month),94.38759689922482,Met (75-100%),100,95.0,95.7
NCT02662972,Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Trigeminal Neuralgia. Safety Issues.,COMPLETED,PHASE1,10.0,2016-05-01,2018-11-01,0.33304157549234137,Slow (<1/month),3.330415754923414,Significantly Below (<50%),100,45.8,33.03
NCT06289972,"Development,Validity and Reliability of a Caregiver Version of the Breathlessness Beliefs Questionnaire",COMPLETED,,42.0,2024-02-20,2024-07-11,9.003380281690141,Adequate (1-10/month),90.03380281690141,Met (75-100%),100,56.7,65.53
NCT03632772,Comparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURP,UNKNOWN,PHASE2,130.0,2018-08-01,2019-07-31,10.871428571428572,Good (10-50/month),108.71428571428572,Exceeded (≥100%),50,50.4,48.355
NCT07143695,Parasternal Intercostal Muscle Thickening as an Additive Weaning Criterion,RECRUITING,NA,200.0,2025-09-01,2026-08-31,16.725274725274726,Good (10-50/month),167.25274725274727,Exceeded (≥100%),60,59.0,70.365
NCT02996695,Safety and Efficacy of Sanaria's PfSPZ-CVac in Malian Adults,COMPLETED,PHASE1,62.0,2017-04-06,2018-06-22,4.269864253393665,Adequate (1-10/month),42.698642533936656,Significantly Below (<50%),100,55.0,61.834999999999994
NCT06337695,VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients With Cancer,NOT_YET_RECRUITING,PHASE2,298.0,2024-07-01,2026-12-01,10.273069082672707,Good (10-50/month),102.73069082672708,Exceeded (≥100%),30,57.8,67.635
NCT03556995,Suggesting Score Scale for Risk of Bleeding in Bariatric Surgery,COMPLETED,,9044.0,2013-01-01,2018-01-31,148.32939655172416,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02134795,A Pilot Study of a Non-Invasive Neuromodulation Device for Treatment of Parkinson's Disease,TERMINATED,NA,6.0,2014-05-01,2014-09-01,1.4848780487804878,Adequate (1-10/month),14.848780487804877,Significantly Below (<50%),10,18.5,4.02
NCT03221595,Multicenter RCT of SSRF in Non Flail Patients,COMPLETED,NA,110.0,2018-01-02,2020-01-01,4.593141289437586,Adequate (1-10/month),45.93141289437585,Significantly Below (<50%),100,58.8,69.89999999999999
NCT05309395,Food Prescriptions to Promote Affordable Diets,RECRUITING,PHASE3,720.0,2021-08-21,2027-06-01,10.387109004739338,Good (10-50/month),103.8710900473934,Exceeded (≥100%),60,83.0,89.505
NCT02037295,Investigation of the Gut Microbiota in Regulating Nutrient Absorption in Humans,COMPLETED,PHASE2,27.0,2014-01-14,2019-03-29,0.4325684210526316,Slow (<1/month),4.325684210526316,Significantly Below (<50%),100,47.2,40.035
NCT03751995,POEM (Practice of Embracing Each Moment) Study (Delivery Science),COMPLETED,NA,142.0,2018-10-31,2020-04-29,7.916630036630037,Adequate (1-10/month),79.16630036630038,Met (75-100%),100,61.4,73.735
NCT02601495,Latent Structure of Multi-level Assessments and Predictors of Outcomes for Women in Recovery,ACTIVE_NOT_RECRUITING,,100.0,2015-11-01,2028-11-01,0.6409770477995368,Slow (<1/month),6.409770477995368,Significantly Below (<50%),85,46.8,38.440000000000005
NCT01805895,A Pilot Study of Minocycline in Intracerebral Hemorrhage Patients,COMPLETED,PHASE1,16.0,2013-02-01,2016-12-01,0.34813438170121513,Slow (<1/month),3.4813438170121516,Significantly Below (<50%),100,46.3,35.66
NCT06926595,Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention,NOT_YET_RECRUITING,PHASE2,41.0,2026-02-01,2031-10-01,0.6035009671179885,Slow (<1/month),6.035009671179885,Significantly Below (<50%),30,27.3,8.155
NCT01426295,Pharmaco-economic Study of a New Medical Device Performed From the Perspective of the Hospital,COMPLETED,PHASE2,92.0,2011-04-01,2014-04-01,2.555182481751825,Adequate (1-10/month),25.55182481751825,Significantly Below (<50%),100,57.4,67.05499999999999
NCT03566095,"Voices for Food: Food Policy Councils, Food Security and Healthy Food Choices",COMPLETED,NA,1735.0,2014-08-01,2018-03-15,39.949621785173974,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT02028195,Effectiveness and Cost-effectiveness of the Check Your Health Preventive Programme,UNKNOWN,NA,11000.0,2013-05-01,2019-12-01,139.22661122661123,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT00153595,EWO1 in Persistent Allergic Rhinitis Patients,UNKNOWN,PHASE2,60.0,2004-11-01,,,Slow (<1/month),,Significantly Below (<50%),50,29.8,8.98
NCT01636895,Evaluation of SP Resistance and Effectiveness of IPTp in Nigeria,UNKNOWN,PHASE4,600.0,2011-01-01,2013-02-01,23.968503937007878,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT04131595,Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects,COMPLETED,PHASE1,45.0,2019-10-07,2020-07-22,4.739792387543253,Adequate (1-10/month),47.39792387543253,Significantly Below (<50%),100,53.6,57.705
NCT05604495,Screening for Cystic Fibrosis and Cystic Fibrosis Related Disorders in Chinese Adults With Bronchiectasis,RECRUITING,,1000.0,2022-09-07,2024-12-31,35.981087470449175,Good (10-50/month),200.0,Exceeded (≥100%),60,81.3,88.58
NCT01824095,Chiropractic Care and a Specific Regimen of Nutritional Supplementation for Patients With Acute Ankle Sprain,TERMINATED,PHASE3,73.0,2013-01-01,2015-06-01,2.5222701475595914,Adequate (1-10/month),25.222701475595915,Significantly Below (<50%),10,28.8,8.665000000000001
NCT03580395,Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer,UNKNOWN,PHASE2,200.0,2017-06-01,2022-12-01,3.0303633648581387,Adequate (1-10/month),30.30363364858139,Significantly Below (<50%),50,51.0,49.714999999999996
NCT02273895,"The Use of EEG in Alzheimer's Disease, With and Without Scopolamine - A Pilot Study",COMPLETED,NA,29.0,2004-04-01,2010-01-01,0.4201618277010947,Slow (<1/month),4.2016182770109465,Significantly Below (<50%),100,47.3,40.475
NCT07125495,The Effect of an Suction Toothbrush on the Development of Ventilator-Associated Pneumonia,ACTIVE_NOT_RECRUITING,NA,90.0,2025-02-01,2025-12-20,8.50807453416149,Adequate (1-10/month),85.0807453416149,Met (75-100%),85,57.7,67.51
NCT03296995,"Accuracy, Feasibility and Acceptance of CGM Lupus",UNKNOWN,NA,30.0,2017-07-01,2019-10-01,1.110948905109489,Adequate (1-10/month),11.109489051094892,Significantly Below (<50%),50,32.4,12.025
NCT06938295,"Comparing Diagnostic Accuracy of High-end Intestinal Ultrasound Versus Mid-end Ultrasound With Tandem Ileo-colonoscopy in Inflammatory Bowel Disease : a Paired, Validating Confirmatory Study",RECRUITING,NA,500.0,2024-09-14,2025-10-30,37.0316301703163,Good (10-50/month),200.0,Exceeded (≥100%),60,83.0,89.505
NCT02242695,Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis,COMPLETED,PHASE4,150.0,2014-11-01,2016-04-01,8.831721470019344,Adequate (1-10/month),88.31721470019343,Met (75-100%),100,67.0,79.725
NCT02113995,"Clinical Evaluation, Organic Response in Obesity Patients Subjected to Vertical Videolaparoscopy Gastroplasty With or Without Perioperative Cares Recommended by the Acerto Project. Randomized Study.",COMPLETED,NA,20.0,2012-04-01,2012-10-01,3.3267759562841532,Adequate (1-10/month),33.26775956284153,Significantly Below (<50%),100,51.6,51.644999999999996
NCT07278895,Dural Puncture Epidural vs Standard Epidural Analgesia in Labor,RECRUITING,NA,102.0,2026-01-20,2026-03-30,44.998260869565215,Good (10-50/month),200.0,Exceeded (≥100%),60,56.2,64.21
NCT03381339,Powertoothbrushing for Treating Gingivitis,COMPLETED,NA,55.0,2017-12-05,2019-06-25,2.9527336860670195,Adequate (1-10/month),29.527336860670196,Significantly Below (<50%),100,54.4,59.89
NCT02360839,The Use of FNA and FNB in the Optimization of EUS-assisted Tissue Sampling,COMPLETED,NA,1000.0,2009-07-01,2022-12-31,6.173190022307848,Adequate (1-10/month),61.73190022307848,Below (50-75%),100,90.0,93.17
NCT02728739,Incidence of Significant Mitral Regurgitation in Acute Heart Failure Patients,COMPLETED,NA,500.0,2016-06-06,2018-02-01,25.15702479338843,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT04326439,AflacLL1901 (CHOA-AML),TERMINATED,PHASE2,8.0,2020-01-24,2022-03-15,0.3118053777208707,Slow (<1/month),3.118053777208707,Significantly Below (<50%),10,18.6,4.25
NCT00582439,The Use of RIA to Harvest Bone Graft for Treatment of Non-unions and Fractures,COMPLETED,NA,21.0,2007-01-01,2009-09-01,0.6563039014373717,Slow (<1/month),6.563039014373717,Significantly Below (<50%),100,46.7,37.895
NCT02290639,Brief Cognitive Behavioral Treatment of Deployment-Related PTSD Symptoms in Primary Care Settings,COMPLETED,NA,74.0,2012-12-01,2015-11-01,2.115079812206573,Adequate (1-10/month),21.15079812206573,Significantly Below (<50%),100,55.9,63.42
NCT03907839,Effects of Combined Cognitive Rehabilitation in COPD Patients,COMPLETED,NA,60.0,2016-12-15,2019-03-15,2.227317073170732,Adequate (1-10/month),22.273170731707317,Significantly Below (<50%),100,54.8,61.095
NCT02636439,Exercise Intolerance in Elderly Patients With HFpEF(Heart Failure With Preserved Ejection Fraction),COMPLETED,NA,88.0,2015-08-01,2021-07-21,1.2282072443833103,Adequate (1-10/month),12.282072443833103,Significantly Below (<50%),100,52.0,52.86
NCT01108939,Study of Iron Absorption and Utilization in Asymptomatic Malaria,COMPLETED,EARLY_PHASE1,23.0,2009-02-01,2010-04-01,1.6512264150943397,Adequate (1-10/month),16.5122641509434,Significantly Below (<50%),100,46.8,38.440000000000005
NCT00481039,Sickle Cell Anemia in an Arab Bedouin Village in the Northern Israel,COMPLETED,,300.0,2007-05-01,2008-12-01,15.744827586206897,Good (10-50/month),157.44827586206895,Exceeded (≥100%),100,77.3,85.67
NCT04878939,Evaluation of Incisors' Position Following Anterior Segment Retraction,COMPLETED,NA,30.0,2019-02-04,2020-12-13,1.3469026548672567,Adequate (1-10/month),13.46902654867257,Significantly Below (<50%),100,47.4,40.98
NCT03018639,Impact of Therapist Change on Dropout in a Naturalistic Sample of Inpatients With Borderline Pathology Receiving DBT,COMPLETED,,89.0,2012-12-01,2016-08-01,2.0232710978342046,Adequate (1-10/month),20.23271097834205,Significantly Below (<50%),100,55.5,62.71
NCT03170739,Effects of Dexmedetomidine and Dopamine on Renal Function After Major Surgery,UNKNOWN,PHASE4,180.0,2017-06-06,2019-12-01,6.034361233480176,Adequate (1-10/month),60.34361233480177,Below (50-75%),50,49.4,46.42
NCT01037439,Comparison of Modified With Conventional Adaptive Servoventilation Processes,COMPLETED,NA,20.0,2008-06-01,2009-12-01,1.110948905109489,Adequate (1-10/month),11.10948905109489,Significantly Below (<50%),100,46.6,37.375
NCT01047839,"Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries",COMPLETED,PHASE3,100.0,2010-01-01,2013-08-01,2.3272171253822633,Adequate (1-10/month),23.27217125382263,Significantly Below (<50%),100,58.0,68.245
NCT02806739,Soy Supplementation and Gestational Diabetes,COMPLETED,EARLY_PHASE1,40.0,2013-01-01,2016-09-01,0.9093353248693055,Slow (<1/month),9.093353248693054,Significantly Below (<50%),100,48.2,43.665
NCT04197739,Fixed-dose Amikacin for Elderly UTI,UNKNOWN,PHASE4,200.0,2019-12-01,2021-12-01,8.328317373461013,Adequate (1-10/month),83.28317373461013,Met (75-100%),50,51.0,49.714999999999996
NCT06472739,The Effect of GM-CSF to Preventing Oral Mucositis for Patients With Nasopharyngeal Carcinoma Receiving Radiotherapy,RECRUITING,PHASE2,138.0,2023-09-15,2024-11-15,9.83775175644028,Adequate (1-10/month),98.37751756440282,Met (75-100%),60,54.0,58.72500000000001
NCT06524739,"Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS",TERMINATED,PHASE3,16.0,2024-08-28,2025-07-11,1.5364037854889592,Adequate (1-10/month),15.364037854889592,Significantly Below (<50%),10,19.3,5.125
NCT02736539,Clinical Trial of CBS-2004 in Prevention of Travelers' Diarrhea,WITHDRAWN,PHASE3,0.0,2017-04-15,2019-02-28,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT03848039,Impact on Disease Relapse of HPV Vaccination in Women Treated With LEEP for Cervical Intraepithelial Neoplasia. HOPE9,NOT_YET_RECRUITING,PHASE3,1220.0,2020-12-01,2028-05-01,13.713737075332348,Good (10-50/month),137.1373707533235,Exceeded (≥100%),30,74.0,83.985
NCT04808739,Adalimumab Biosimilar in Clinical Practice,COMPLETED,,604.0,2020-06-01,2021-02-28,67.59470588235294,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT06307639,Seminal Levels of PGK2 and ACRV1 as Predictors of Micro-TESE Results in NOA,NOT_YET_RECRUITING,,64.0,2024-04-01,2026-04-01,2.6687123287671235,Adequate (1-10/month),26.687123287671238,Significantly Below (<50%),30,32.5,12.235
NCT04160039,Early Cycle Ergometry for Critically-Ill Liver Failure Patients in a Transplant Intensive Care Unit,TERMINATED,NA,97.0,2019-11-10,2022-09-01,2.87785575048733,Adequate (1-10/month),28.778557504873298,Significantly Below (<50%),10,30.8,9.745
NCT02409277,Redesigning Ambulatory Care Delivery to Enhance Asthma Control in Children,COMPLETED,NA,926.0,2013-08-01,2016-12-31,22.586089743589742,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT03512977,Is Sphenopalatine Ganglion Block Treatment Effective on Postspinal Headaches,COMPLETED,NA,20.0,2017-12-01,2018-06-15,3.1061224489795918,Adequate (1-10/month),31.06122448979592,Significantly Below (<50%),100,51.6,51.644999999999996
NCT03471377,Improving Planned Surgical Case Duration Accuracy by Leveraging the EHR and Predictive Modeling,COMPLETED,,683.0,2018-03-05,2022-03-15,14.13359619306594,Good (10-50/month),141.3359619306594,Exceeded (≥100%),100,93.3,94.325
NCT05479877,A Comparative Clinical and Radiographic Study of Collagen Based Pulpotomy Versus Biodentine Pulpotomy in Children With Cariously Exposed Vital Primary Molars,UNKNOWN,EARLY_PHASE1,40.0,2022-09-01,2023-10-01,3.082531645569621,Adequate (1-10/month),30.825316455696207,Significantly Below (<50%),50,38.2,19.645000000000003
NCT06553677,Clinical Evaluation of Tunneled Coronally Advanced Flap v.s Coronally Advanced Flap With Graft for Gingival Recession,RECRUITING,NA,22.0,2024-08-01,2025-09-01,1.6911111111111112,Adequate (1-10/month),16.91111111111111,Significantly Below (<50%),60,39.8,21.47
NCT07246577,"The VGR GCA Cohort: Ultrasound, Biopsy and Biomarkers - Novel Methods for Diagnosis, Monitoring and Prognosis in Giant Cell Arteritis.",NOT_YET_RECRUITING,,340.0,2025-12-01,2029-12-01,7.083915126625599,Adequate (1-10/month),70.83915126625598,Below (50-75%),30,54.5,60.12
NCT01244477,Neuroimaging the Impact of Treatment on Neural Substrates of Trust in Post-Traumatic Stress Disorder (PTSD),COMPLETED,NA,61.0,2011-05-16,2018-06-30,0.713620292083013,Slow (<1/month),7.13620292083013,Significantly Below (<50%),100,49.9,47.425
NCT01737177,Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL,COMPLETED,PHASE2,42.0,2012-07-31,2017-02-02,0.7762477231329691,Slow (<1/month),7.76247723132969,Significantly Below (<50%),100,48.4,44.22
NCT04513977,Geriatric Oncology SuPportive Clinic for ELderly,RECRUITING,NA,200.0,2020-08-19,2025-09-01,3.310494834148994,Adequate (1-10/month),33.10494834148994,Significantly Below (<50%),60,54.0,58.72500000000001
NCT04395677,A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene,UNKNOWN,PHASE2,173.0,2020-07-07,2025-12-31,2.6291163255117325,Adequate (1-10/month),26.291163255117322,Significantly Below (<50%),50,48.8,45.184999999999995
NCT00001177,Study of Premenstrual Syndrome and Premenstrual Dysphoria,RECRUITING,,1600.0,1984-03-09,,,Slow (<1/month),,Significantly Below (<50%),60,66.3,79.3
NCT03334877,Prediction of Preterm Labor in Asymptomatic High Risk Women,COMPLETED,,220.0,2015-05-15,2017-10-01,7.697471264367816,Adequate (1-10/month),76.97471264367816,Met (75-100%),100,65.9,78.83
NCT03653377,Human Papilloma Virus Vaccination in Girls With Cystic Fibrosis (VACCIN-HPV-MUC2),COMPLETED,,81.0,2018-12-17,2019-04-30,18.400298507462686,Good (10-50/month),184.00298507462685,Exceeded (≥100%),100,59.8,71.61
NCT06686277,Effects Of Gong's Versus Mulligan Mobilization In Patients With Adhesive Capsulitis,RECRUITING,NA,60.0,2024-04-24,2025-02-24,5.968627450980392,Adequate (1-10/month),59.68627450980393,Below (50-75%),60,42.8,25.929999999999996
NCT06850077,Comparison of Prefrontal Hemodynamic Responses and Balance Control Differences Based on Head Posture and Task Difficulty in Cognitive-Balance Tasks,COMPLETED,,38.0,2025-04-27,2025-10-20,6.572272727272727,Adequate (1-10/month),65.72272727272728,Below (50-75%),100,51.4,50.92
NCT05823077,Effects of Aromatherapy Massage in Menopausal Women With Knee Osteoarthritis,COMPLETED,NA,60.0,2023-05-24,2023-08-13,22.548148148148147,Good (10-50/month),200.0,Exceeded (≥100%),100,59.8,71.61
NCT03336177,Understanding Low Gynecological Cancer Delay and Help-seeking Behavior in Older Patients.,COMPLETED,,12.0,2017-10-30,2018-07-27,1.3528888888888888,Adequate (1-10/month),13.528888888888888,Significantly Below (<50%),100,44.3,28.715000000000003
NCT03735277,"Evaluation of the Safety and Efficacy of Hemacord HPC, Cord Blood in Subjects With Acute Ischemic Stroke",UNKNOWN,PHASE1,10.0,2021-03-06,2022-07-01,0.6315352697095437,Slow (<1/month),6.315352697095436,Significantly Below (<50%),50,30.8,9.745
NCT03160677,Blood Pressure Target in Acute Stroke to Reduce hemorrhaGe After Endovascular Therapy,COMPLETED,NA,320.0,2017-06-21,2020-01-31,10.210482180293502,Good (10-50/month),102.104821802935,Exceeded (≥100%),100,80.6,88.14999999999999
NCT05113277,Development and Evaluation of a Tonic Immobility Focused Psychoeducational Intervention,COMPLETED,NA,51.0,2021-09-27,2022-05-31,6.310731707317073,Adequate (1-10/month),63.107317073170734,Below (50-75%),100,54.1,59.11
NCT02274077,Transverse Abdominal Plane Anesthesia for Abdominal Wall Reconstruction,WITHDRAWN,PHASE4,0.0,2016-01-01,2017-06-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT01072877,Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) Incompetence,COMPLETED,PHASE3,279.0,2010-12-01,2012-11-01,12.115206847360913,Good (10-50/month),121.15206847360913,Exceeded (≥100%),100,77.3,85.67
NCT06808477,A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD),RECRUITING,PHASE1,198.0,2025-02-27,2027-02-06,8.500874471086037,Adequate (1-10/month),85.00874471086037,Met (75-100%),60,58.8,69.89999999999999
NCT02361177,Role of Oxytocin in Telling and Detecting Lies,WITHDRAWN,EARLY_PHASE1,0.0,2016-01-01,2016-04-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT05927077,Chemometers to Determine the Environmental and Human Exposome by Mixtures of Pollutants,NOT_YET_RECRUITING,,250.0,2023-09-01,2026-03-31,8.07855626326964,Adequate (1-10/month),80.78556263269638,Met (75-100%),30,47.3,40.475
NCT00617877,Antihypertensive Response to Losartan and Genetic Polymorphisms,COMPLETED,NA,800.0,2005-03-01,2009-06-01,15.680618158403092,Good (10-50/month),156.80618158403092,Exceeded (≥100%),100,95.0,95.7
NCT05050877,Risk Factors and Prognosis of Adverse Cardiovascular and Kidney Events After Coronary Intervention II,COMPLETED,,184855.0,2000-06-01,2020-12-31,748.4685022612397,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT05808777,Validation of the ICH Score for the Prediction of 12-month Functional Outcome in Patients With Primary Intracerebral Hemorrhage,COMPLETED,,100.0,2019-06-24,2022-06-23,2.779908675799087,Adequate (1-10/month),27.79908675799087,Significantly Below (<50%),100,56.3,64.5
NCT06729177,Single Case Research Design: Teacher Outcomes,COMPLETED,NA,4.0,2024-08-23,2025-09-30,0.3021339950372208,Slow (<1/month),3.0213399503722083,Significantly Below (<50%),100,45.3,31.169999999999998
NCT00572377,Alprostadil (FemLife Gel) in the Treatment of Female Sexual Arousal Disorder,TERMINATED,PHASE1,10.0,2007-05-01,2008-03-01,0.998032786885246,Slow (<1/month),9.980327868852461,Significantly Below (<50%),10,18.8,4.58
NCT03221777,Atrial Fibrillation Occurring Transiently With Stress (AFOTS),COMPLETED,,281.0,2017-03-01,2022-11-30,4.073161904761905,Adequate (1-10/month),40.73161904761905,Significantly Below (<50%),100,70.8,82.295
NCT05784077,PRevalence of Obstructive Sleep apnoEa and Reduction of Promoters in AF,UNKNOWN,,343.0,2020-01-01,2025-01-31,5.62246634356489,Adequate (1-10/month),56.22466343564889,Below (50-75%),50,60.8,72.99
NCT00662077,Study Of The Efficacy And Security Of Ibandronate For Osteoporosis Treatment In A HIV-Infected Patients Cohort,WITHDRAWN,PHASE4,0.0,,,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT06247475,Generating Fast and Slow for Entree Level Medical Knowledge,UNKNOWN,,120.0,2024-02-01,2024-06-01,30.188429752066117,Good (10-50/month),200.0,Exceeded (≥100%),50,47.9,42.64
NCT04883775,Study of a New Technique for Imaging Pancreatic Cancer,COMPLETED,PHASE1,4.0,2021-05-10,2025-01-27,0.08966126656848307,Slow (<1/month),0.8966126656848308,Significantly Below (<50%),100,45.3,31.169999999999998
NCT04444375,"Plantar Pain, Balance and Foot Function in Individuals With Diabetes Mellitus",COMPLETED,,54.0,2017-12-01,2018-05-30,9.132,Adequate (1-10/month),91.32000000000001,Met (75-100%),100,57.7,67.51
NCT05537675,Semi-automated Segmentation Methods of SSTR PET for Dosimetry Prediction,COMPLETED,,20.0,2022-10-01,2022-11-30,10.146666666666667,Good (10-50/month),101.46666666666665,Exceeded (≥100%),100,54.9,61.55500000000001
NCT04127175,Breast Density Measurements in Digital Mammography and Breast Tomosynthesis Systems of Different Pixel Size,UNKNOWN,,300.0,2019-10-01,2020-08-01,29.94098360655738,Good (10-50/month),200.0,Exceeded (≥100%),50,62.3,74.94
NCT05861375,Liver Biomarkers in Anorexia Nervosa,UNKNOWN,,50.0,2023-06-23,2025-06-30,2.062330623306233,Adequate (1-10/month),20.623306233062333,Significantly Below (<50%),50,37.3,18.35
NCT05332275,A Media Parenting Prevention Intervention,RECRUITING,NA,120.0,2025-05-12,2025-12-31,15.677253218884122,Good (10-50/month),156.77253218884118,Exceeded (≥100%),60,52.6,54.684999999999995
NCT05694975,Efficacy of Megadose Vitamin C in Severe and Critical Ill COVID-19 Patients.,UNKNOWN,PHASE2,608.0,2023-01-13,2023-06-01,133.14762589928057,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT05416775,Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer,RECRUITING,PHASE1,168.0,2022-08-15,2026-06-30,3.614077738515901,Adequate (1-10/month),36.14077738515901,Significantly Below (<50%),60,51.4,50.92
NCT01826175,Comparison of Ticagrelor Versus Clopidogrel on Residual Thrombus Burden During PCI: an OCT Study,WITHDRAWN,PHASE4,0.0,2013-05-01,2014-05-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT06481475,A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines,RECRUITING,PHASE2,174.0,2025-01-09,2025-10-01,19.98701886792453,Good (10-50/month),199.87018867924527,Exceeded (≥100%),60,56.9,65.89500000000001
NCT01627275,Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant,COMPLETED,PHASE1,28.0,2012-06-01,2017-08-03,0.4512016940179989,Slow (<1/month),4.512016940179989,Significantly Below (<50%),100,47.2,40.035
NCT07096375,"Coupling of IPACK Block With Adductor Canal Block Versus Adductor Canal Block Alone on Pain, Functional Recovery and Inflammatory Response After Knee Replacement",NOT_YET_RECRUITING,NA,50.0,2025-09-20,2026-09-28,4.080428954423593,Adequate (1-10/month),40.80428954423593,Significantly Below (<50%),30,33.0,12.695
NCT00856375,"NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer",COMPLETED,PHASE2,83.0,2008-12-01,2014-12-01,1.1531355545413056,Adequate (1-10/month),11.531355545413057,Significantly Below (<50%),100,51.6,51.644999999999996
NCT03958175,The Alouette Test in Parkinson Disease,COMPLETED,,38.0,2015-11-01,2016-04-01,7.61,Adequate (1-10/month),76.1,Met (75-100%),100,51.4,50.92
NCT04463875,"Magnesium, Vitamin B2, Feverfew, Andrographis Paniculata and Coenzyme Q10 for Episodic Migraine Prophylaxis",COMPLETED,,113.0,2018-04-01,2020-05-31,4.348571428571429,Adequate (1-10/month),43.48571428571429,Significantly Below (<50%),100,57.4,67.05499999999999
NCT01026675,Early Screening for Gestational Diabetes Mellitus,COMPLETED,,1442.0,2009-04-01,2013-05-01,29.43962441314554,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT07095075,A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases,RECRUITING,EARLY_PHASE1,36.0,2025-10-14,2029-12-31,0.712046783625731,Slow (<1/month),7.12046783625731,Significantly Below (<50%),60,35.9,16.445
NCT01100775,Effects of Galantamine on Cognition,COMPLETED,PHASE2,12.0,2010-05-01,2014-08-21,0.23221869040050858,Slow (<1/month),2.3221869040050858,Significantly Below (<50%),100,46.0,34.1
NCT01515475,Hyperopia Treatment Study 1 (HTS1) - Glasses vs Observation,COMPLETED,NA,249.0,2012-02-23,2018-02-01,3.492884792626728,Adequate (1-10/month),34.92884792626728,Significantly Below (<50%),100,69.9,81.83
NCT06698575,"A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes",ACTIVE_NOT_RECRUITING,PHASE1,146.0,2024-12-08,2026-01-01,11.424781491002571,Good (10-50/month),114.24781491002571,Exceeded (≥100%),85,62.2,74.74499999999999
NCT05241275,Xenon MRI and Progressive ILD,ACTIVE_NOT_RECRUITING,PHASE2,60.0,2022-07-19,2026-08-31,1.2143617021276596,Adequate (1-10/month),12.143617021276597,Significantly Below (<50%),85,45.3,31.169999999999998
NCT04561375,Assessing the Effects of Sublingual Sufentanil 30 µg on Postoperative Recovery,TERMINATED,PHASE4,61.0,2020-12-11,2022-07-01,3.2748500881834217,Adequate (1-10/month),32.74850088183421,Significantly Below (<50%),10,27.9,8.344999999999999
NCT04301375,Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial),NOT_YET_RECRUITING,PHASE2,27.0,2020-06-15,2027-07-15,0.3178190255220418,Slow (<1/month),3.178190255220418,Significantly Below (<50%),30,26.2,7.775
NCT06760975,Effects of Vestibular Habituation and Ocular Reflex Exercises on Vertigo,NOT_YET_RECRUITING,NA,50.0,2024-12-31,2025-08-01,7.145539906103287,Adequate (1-10/month),71.45539906103286,Below (50-75%),30,33.0,12.695
NCT02777775,Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.,COMPLETED,,71.0,2016-05-01,2025-06-01,0.6513682941531043,Slow (<1/month),6.5136829415310435,Significantly Below (<50%),100,49.0,45.61
NCT06593275,Pain Perception in Protection of the Palatal Donor Area After Harvesting a Free Gingival Graft Using Flowable Resin Versus a Self-adhesive Dressing,NOT_YET_RECRUITING,NA,30.0,2024-10-30,2029-12-15,0.48782051282051286,Slow (<1/month),4.8782051282051295,Significantly Below (<50%),30,26.4,7.865
NCT03812575,The Use of Fractionated Exhaled Nitric Oxide in the Diagnosis and Assessment of Disease Activity of Eosinophilic Esophagitis (Pilot),COMPLETED,,80.0,2019-01-31,2020-06-01,5.00041067761807,Adequate (1-10/month),50.0041067761807,Below (50-75%),100,54.7,60.629999999999995
NCT05355857,Creation of a Probabilistic Atlas of Normal Cerebral Uptake of 18F-FDG in PET/MRI.,COMPLETED,NA,39.0,2022-08-10,2023-03-23,5.276266666666667,Adequate (1-10/month),52.76266666666668,Below (50-75%),100,53.1,56.105000000000004
NCT02261857,3D-Printed CPAP Masks for Children With Obstructive Sleep Apnea,COMPLETED,EARLY_PHASE1,8.0,2013-09-01,2017-09-01,0.16668035592060232,Slow (<1/month),1.666803559206023,Significantly Below (<50%),100,45.6,32.08
NCT06524557,Exploration of Noninvasive Differential Diagnosis of Benign and Malignant Liver Tumors,RECRUITING,,200.0,2018-01-01,2025-12-30,2.0849315068493155,Adequate (1-10/month),20.84931506849315,Significantly Below (<50%),60,52.3,53.515
NCT05981157,Anrotinib and Tirelizumab in First-line Treatment of RM-NPC,UNKNOWN,PHASE2,27.0,2023-06-01,2025-12-30,0.8715588547189821,Slow (<1/month),8.715588547189821,Significantly Below (<50%),50,32.2,11.635
NCT04244357,[Trial of device that is not approved or cleared by the U.S. FDA],WITHHELD,,,,,,Slow (<1/month),,Significantly Below (<50%),50,20.0,5.695
NCT04964557,"A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia",COMPLETED,PHASE2,411.0,2021-07-07,2022-07-15,33.54112600536193,Good (10-50/month),200.0,Exceeded (≥100%),100,87.9,92.36999999999999
NCT01428557,BREATHE Registry - I Brazilian Registry of Heart Failure,COMPLETED,,3013.0,2011-03-01,2019-09-01,29.528564069542824,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT03178357,"""Cardiac Rehabilitation in Patients With Hypertrophic Cardiomyopathy"".",UNKNOWN,NA,60.0,2017-07-10,2020-12-01,1.4729032258064516,Adequate (1-10/month),14.729032258064517,Significantly Below (<50%),50,34.8,15.040000000000001
NCT02900157,Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors,COMPLETED,PHASE1,42.0,2016-08-09,2020-01-23,1.0130586370839938,Adequate (1-10/month),10.130586370839936,Significantly Below (<50%),100,48.4,44.22
NCT02181257,Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts,ACTIVE_NOT_RECRUITING,PHASE3,280.0,2015-01-01,2028-12-01,1.6768050363958293,Adequate (1-10/month),16.76805036395829,Significantly Below (<50%),85,67.9,80.36999999999999
NCT04534257,Prospective Registry to Investigate the Safety and Efficacy of the Treatment With the Selution Sirolimus Drug Coated Balloon in TASC C and D Atheroma-occlusive Infra-Inguinal Disease in Patients With Chronic Limb Threatening Ischemia From Singapore,UNKNOWN,NA,75.0,2020-09-09,2022-05-20,3.6941747572815538,Adequate (1-10/month),36.94174757281554,Significantly Below (<50%),50,41.0,23.01
NCT02338557,Effect of Motor Relearning Programme and Mirror Therapy Along for Improving Hand Function In Patients With Stroke.,COMPLETED,NA,12.0,2010-01-01,2011-07-01,0.6690109890109891,Slow (<1/month),6.690109890109891,Significantly Below (<50%),100,46.0,34.1
NCT04677257,Coronary Physiology Testing in Acute Coronary Syndromes,COMPLETED,NA,130.0,2020-11-02,2022-12-31,5.015462610899873,Adequate (1-10/month),50.154626108998734,Below (50-75%),100,60.4,72.54
NCT00248157,Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy,TERMINATED,PHASE3,105.0,2005-11-01,2006-05-01,17.658563535911604,Good (10-50/month),176.58563535911603,Exceeded (≥100%),10,36.4,17.14
NCT00786357,Sleep Enhancement Training Study for Experienced Shiftworkers,COMPLETED,PHASE1,32.0,2008-11-01,2010-01-01,2.2865727699530516,Adequate (1-10/month),22.865727699530517,Significantly Below (<50%),100,52.6,54.684999999999995
NCT04763057,Indirect Pulp Treatment in Primary Teeth,UNKNOWN,NA,88.0,2021-04-01,2022-10-01,4.888175182481752,Adequate (1-10/month),48.88175182481751,Significantly Below (<50%),50,42.0,24.825
NCT07196657,The Efficacy and Safety of Pregabalin and Crisugabalin in Patients With Fibromyalgia,RECRUITING,NA,1116.0,2025-09-30,2027-08-31,48.530057142857146,Good (10-50/month),200.0,Exceeded (≥100%),60,88.0,92.495
NCT04287257,PEMF in the Treatment of Fresh Distal Radius Fractures,UNKNOWN,NA,50.0,2020-03-01,2022-03-01,2.0849315068493155,Adequate (1-10/month),20.84931506849315,Significantly Below (<50%),50,39.0,20.505000000000003
NCT02096757,The Use of Fish Oil to Reduce Inflammation Caused by a Peripheral Vascular Intervention,COMPLETED,NA,8.0,2014-06-01,2017-03-01,0.24254980079681276,Slow (<1/month),2.4254980079681276,Significantly Below (<50%),100,45.6,32.08
NCT04206501,OptiVol for Precision Medical Management of Heart Failure,TERMINATED,NA,7.0,2020-02-05,2022-11-20,0.20910696761530911,Slow (<1/month),2.0910696761530914,Significantly Below (<50%),10,18.6,4.25
NCT01416701,Vitamin D and Chronic Obstructive Lung Disease,WITHDRAWN,PHASE4,0.0,2011-09-01,2013-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT04144101,Etoricoxib vs Aceclofenac in the Treatment of Patients With Rheumatoid Arthritis,COMPLETED,PHASE4,40.0,2007-03-01,2007-07-31,8.010526315789473,Adequate (1-10/month),80.10526315789474,Met (75-100%),100,53.2,56.665
NCT01395901,Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients,COMPLETED,PHASE3,670.0,2011-06-01,2012-04-01,66.86819672131148,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT00193401,Weekly Topotecan in the First-line Treatment of Elderly Patients With Small Cell Lung Cancer,COMPLETED,PHASE2,40.0,2002-08-01,2004-11-01,1.4794653705953829,Adequate (1-10/month),14.794653705953827,Significantly Below (<50%),100,48.2,43.665
NCT01133301,Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder,COMPLETED,PHASE2,30.0,1998-08-01,2001-10-01,0.7892826274848747,Slow (<1/month),7.892826274848747,Significantly Below (<50%),100,47.4,40.98
NCT03353701,30-to-90 Day Challenge: Effects of Alcohol Cessation on Health Outcomes,COMPLETED,NA,57.0,2017-12-11,2024-01-01,0.7843942133815552,Slow (<1/month),7.843942133815553,Significantly Below (<50%),100,49.6,46.785
NCT01353001,Effect of Weight Loss on Cardiovascular Disease Risk Factors in Obese Women,COMPLETED,NA,24.0,2011-04-01,2011-07-01,8.028131868131869,Adequate (1-10/month),80.28131868131868,Met (75-100%),100,51.9,52.55499999999999
NCT01432301,Uridine Triacetate as Antidote for Patients at Excess Risk of 5-FU Toxicity Due to Overdosage or Impaired Elimination,APPROVED_FOR_MARKETING,,,,,,Slow (<1/month),,Significantly Below (<50%),50,23.3,6.569999999999999
NCT07071701,A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target Population,COMPLETED,,19267.0,2022-07-02,2024-04-05,912.111166407465,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT00444301,"Pain Assessment, Incidence & Nature in Heart Failure",COMPLETED,,349.0,2006-06-01,2007-12-01,19.386058394160585,Good (10-50/month),193.86058394160582,Exceeded (≥100%),100,81.3,88.58
NCT04233801,A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin,COMPLETED,PHASE3,219.0,2020-04-15,2022-03-10,9.6057060518732,Adequate (1-10/month),96.057060518732,Met (75-100%),100,72.5,83.23
NCT03137901,"Agreement and Precision of Capstesia, a New Smarphone Application for PPV and CO Monitoring",COMPLETED,,40.0,2017-05-10,2017-06-30,23.87450980392157,Good (10-50/month),200.0,Exceeded (≥100%),100,56.5,65.18
NCT00968201,Chronic Asthma Study in 2- to 5-Year-Old Patients (MK0476-072 ),COMPLETED,PHASE3,689.0,1997-12-01,2001-03-01,17.683946037099496,Good (10-50/month),176.83946037099497,Exceeded (≥100%),100,95.0,95.7
NCT04391101,Convalescent Plasma for the Treatment of Severe SARS-CoV-2 (COVID-19),UNKNOWN,PHASE3,231.0,2020-06-01,2021-12-01,12.831459854014598,Good (10-50/month),128.31459854014597,Exceeded (≥100%),50,58.5,69.34
NCT00172601,Mobilization Techniques in Patients With Frozen Shoulder: a Randomized Multiple-Treatment Trial,UNKNOWN,NA,30.0,2005-08-01,,,Slow (<1/month),,Significantly Below (<50%),50,27.4,8.225
NCT02506101,"Randomized, Split-body, Single-blinded Clinical Trial of NB-UVB Treatment for Vitiligo",TERMINATED,NA,2.0,2015-07-01,2016-10-04,0.13206073752711497,Slow (<1/month),1.3206073752711498,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT00175201,Cost Efficacy of a Clinical Pathway to Patients Undergoing Hip and Knee Replacement Surgery,COMPLETED,NA,247.0,2005-05-01,2008-12-31,5.610955223880597,Adequate (1-10/month),56.10955223880597,Below (50-75%),100,69.8,81.785
NCT06884501,Let's Increase Fuerza (Strength) Through Exercise and Diet,NOT_YET_RECRUITING,NA,90.0,2025-09-01,2026-09-01,7.505753424657535,Adequate (1-10/month),75.05753424657536,Met (75-100%),30,36.2,16.84
NCT02993601,Feasibility Study of a New Peripheral Oedema Monitor for Heart Failure,COMPLETED,,70.0,2017-01-15,2017-06-13,14.300671140939597,Good (10-50/month),143.006711409396,Exceeded (≥100%),100,58.9,70.10499999999999
NCT07036601,Phase II Study of THDBH120 Injection in Overweight or Obese Subjects,RECRUITING,PHASE2,276.0,2025-01-06,2026-03-11,19.583776223776223,Good (10-50/month),195.83776223776223,Exceeded (≥100%),60,65.1,78.14
NCT00366301,The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes,TERMINATED,PHASE4,500.0,2006-08-01,2009-04-01,15.626283367556468,Good (10-50/month),156.2628336755647,Exceeded (≥100%),10,68.0,80.56
NCT03273101,Sit-to-stand Training in Stroke Patient,COMPLETED,NA,52.0,2015-01-01,2018-05-01,1.3017105263157895,Adequate (1-10/month),13.017105263157896,Significantly Below (<50%),100,49.2,46.035
NCT06003101,"Effect of PRP, PPP, & BMAC on Functional Outcomes Following Hip Arthroscopy for Acetabular Labral Pathologies",RECRUITING,PHASE3,160.0,2023-08-30,2045-08-30,0.6060726729716277,Slow (<1/month),6.060726729716278,Significantly Below (<50%),60,45.8,33.03
NCT02044601,Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT),WITHDRAWN,PHASE1,0.0,2014-06-01,,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT00629512,Prevention of Gastric Ulcers,COMPLETED,PHASE3,504.0,2001-03-01,2002-12-01,23.9715,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT05219812,A Study to Learn How Safe BAY2395840 is and How Well it Works in Participants Who Have Diabetic Nerve Pain,COMPLETED,PHASE2,80.0,2022-02-16,2022-11-21,8.759712230215827,Adequate (1-10/month),87.59712230215828,Met (75-100%),100,61.4,73.735
NCT03381612,"Prevalence of Female Circumcision Among Young Women in Beni-Suef, Egypt",COMPLETED,,3353.0,2017-04-03,2017-07-15,990.9254368932039,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT00005812,Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma,TERMINATED,PHASE2,12.0,2000-01-01,2004-05-01,0.23089759797724402,Slow (<1/month),2.30897597977244,Significantly Below (<50%),10,19.0,4.84
NCT00912912,Sunitinib Malate in Refractory Germ Cell Tumors,TERMINATED,PHASE2,5.0,2009-05-01,2014-12-01,0.07460784313725491,Slow (<1/month),0.746078431372549,Significantly Below (<50%),10,18.4,3.855
NCT04987112,Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors,UNKNOWN,PHASE1,36.0,2022-01-20,2024-12-30,1.019386046511628,Adequate (1-10/month),10.193860465116279,Significantly Below (<50%),50,32.9,12.53
NCT06643312,TPAD for Recovery of Standing After Severe SCI,RECRUITING,NA,50.0,2024-10-22,2028-01-01,1.3053173241852487,Adequate (1-10/month),13.05317324185249,Significantly Below (<50%),60,37.0,17.955
NCT03037112,Resetting the Default: Improving Provider-patient Communication to Reduce Antibiotic Misuse,COMPLETED,NA,1600.0,2017-03-03,2019-04-30,61.807106598984774,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT01427712,Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis,COMPLETED,,24.0,2011-08-01,2018-03-01,0.3038935108153078,Slow (<1/month),3.038935108153078,Significantly Below (<50%),100,45.3,31.169999999999998
NCT00836212,Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring,UNKNOWN,PHASE4,12.0,2008-03-01,2009-04-01,0.9224242424242425,Slow (<1/month),9.224242424242423,Significantly Below (<50%),50,31.0,9.985
NCT06240312,Optic Nerve Head Strain as Biomarker for Glaucoma,RECRUITING,NA,130.0,2024-07-01,2028-01-31,3.0230710466004584,Adequate (1-10/month),30.230710466004577,Significantly Below (<50%),60,48.4,44.22
NCT01321112,Search for Transcriptional Biomarkers in a Conversion Protocol From Calcineurin Inhibitors to Mycophenolate Mofetil,UNKNOWN,NA,40.0,2011-02-01,2014-03-01,1.0832740213523133,Adequate (1-10/month),10.832740213523131,Significantly Below (<50%),50,33.2,12.989999999999998
NCT05426512,Effect of Mechanical Loading on vBMD and Geometry in Patients With Primary Hyperparathyroidism,COMPLETED,,120.0,2016-01-05,2020-12-08,2.030461367426348,Adequate (1-10/month),20.30461367426348,Significantly Below (<50%),100,57.9,67.83
NCT04045912,Reaching Adolescent Girls and Young Women Through Girl-Friendly Drug Vendors,COMPLETED,NA,20.0,2019-07-22,2020-03-11,2.612875536480687,Adequate (1-10/month),26.128755364806867,Significantly Below (<50%),100,51.6,51.644999999999996
NCT05365412,Clinicopathological Characteristics of Colon Cancer in Young Age,RECRUITING,,1400.0,2019-01-01,2025-12-01,16.870942201108473,Good (10-50/month),168.70942201108474,Exceeded (≥100%),60,81.3,88.58
NCT05192512,Clinical Trial of the TQB2928 Injection in Patients With Advanced Cancers,UNKNOWN,PHASE1,180.0,2022-01-24,2025-01-01,5.106430568499534,Adequate (1-10/month),51.06430568499535,Below (50-75%),50,49.4,46.42
NCT01084512,Chest Wall Kinematics and Respiratory Muscle Action During Supine Breathing in Individuals With and Without Spinal Cord Injury,COMPLETED,,50.0,2005-07-01,2008-07-01,1.3886861313868613,Adequate (1-10/month),13.886861313868613,Significantly Below (<50%),100,47.3,40.475
NCT01390012,Oral Versus Intravenous Dexamethasone,COMPLETED,PHASE3,30.0,2011-08-01,2012-10-01,2.1386416861826696,Adequate (1-10/month),21.3864168618267,Significantly Below (<50%),100,52.4,53.949999999999996
NCT00000512,Familial Atherosclerosis Treatment Study,COMPLETED,PHASE3,146.0,1984-01-01,1989-08-01,2.17961745953899,Adequate (1-10/month),21.796174595389896,Significantly Below (<50%),100,61.7,74.1
NCT01170312,Arthroscopic Surgery and Platelet Rich Plasma In Rotator Cuff Tear Evaluation,COMPLETED,NA,25.0,2010-09-01,2012-08-01,1.0871428571428572,Adequate (1-10/month),10.87142857142857,Significantly Below (<50%),100,47.0,39.33
NCT06713512,InvEstigating oeStrogen Signalling and the Effect upoN the exTracelluar Matrix In pAtients With Obstructive Lung Disease,RECRUITING,,100.0,2024-12-01,2028-11-01,2.127183787561146,Adequate (1-10/month),21.27183787561146,Significantly Below (<50%),60,44.3,28.715000000000003
NCT03239912,Treatment of Class II Malocclusion Combined With Low-level Laser,COMPLETED,NA,40.0,2017-07-16,2019-02-15,2.10293609671848,Adequate (1-10/month),21.0293609671848,Significantly Below (<50%),100,53.2,56.665
NCT01624012,Non-invasive Ventilation With Neurally Adjusted Ventilatory Assist Versus Nasal Continuous Airway Pressure in Premature Infants,COMPLETED,NA,40.0,2011-08-01,2016-05-01,0.7017867435158501,Slow (<1/month),7.017867435158502,Significantly Below (<50%),100,48.2,43.665
NCT02536612,"Empower, Nudge: Increasing Dual Protection in South Africa",COMPLETED,NA,100.0,2015-05-01,2016-06-01,7.66750629722922,Adequate (1-10/month),76.6750629722922,Met (75-100%),100,58.0,68.245
NCT04113512,Yoga Nasal Irrigation in the Treatment of Chronic Tension Type Headache,COMPLETED,NA,98.0,2019-03-15,2019-07-26,22.429473684210524,Good (10-50/month),200.0,Exceeded (≥100%),100,62.8,75.53999999999999
NCT01696812,Web-based International Multi-Center Clinical Study for Parkinson's Disease,UNKNOWN,NA,136.0,2014-11-01,2020-12-01,1.8631143114311433,Adequate (1-10/month),18.63114311431143,Significantly Below (<50%),50,45.9,33.495000000000005
NCT03804112,TransIent Perivascular Inflammation of the Carotid Artery (TIPIC) Syndrome: Clinical and Radiological Follow-up,COMPLETED,,47.0,2018-12-17,2020-02-18,3.342710280373832,Adequate (1-10/month),33.427102803738315,Significantly Below (<50%),100,52.1,53.03
NCT03596112,The Difference in Wound Size Reduction Comparing Two Frequently Used Wound Dressings in Everyday Care,COMPLETED,NA,77.0,2018-09-01,2020-05-31,3.673793103448276,Adequate (1-10/month),36.73793103448276,Significantly Below (<50%),100,56.2,64.21
NCT01131312,Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS),COMPLETED,PHASE3,5060.0,2008-02-20,2009-02-05,438.82165242165246,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT01999712,Right Ventricular Failure After Implantation of Left Ventricular Assist Devices,COMPLETED,,83.0,2013-07-01,2017-12-31,1.5368126520681265,Adequate (1-10/month),15.368126520681265,Significantly Below (<50%),100,50.0,47.675
NCT01643512,Heritability of Fatty Liver as Measured by MRI: a Cross Sectional Study of Twins and Family Members,UNKNOWN,,500.0,2011-08-01,2021-08-01,4.166438543662744,Adequate (1-10/month),41.664385436627434,Significantly Below (<50%),50,73.3,83.61
NCT03918512,Development and Validation of a Questionnaire for Assessing Activity Limitation in Patients With Lumbar Spinal Stenosis : The Cochin L3S Questionnaire,UNKNOWN,,200.0,2020-03-01,2021-03-01,16.679452054794524,Good (10-50/month),166.7945205479452,Exceeded (≥100%),50,54.3,59.62
NCT02630212,The Relationship Between ALDH2 and Aortic Dissection,UNKNOWN,,400.0,2015-12-01,2019-12-01,8.334017796030116,Adequate (1-10/month),83.34017796030116,Met (75-100%),50,65.3,78.32000000000001
NCT07186712,The Incidence of Early Trauma Induced Coagulopathy and Hyperfibrinolysis in Severely Injured Trauma Patients in the Emergency Room: a Retrospective Cohort Study,COMPLETED,,263.0,2025-05-25,2025-10-20,54.0927027027027,Excellent (>50/month),200.0,Exceeded (≥100%),100,79.4,87.155
NCT00556712,"A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)",COMPLETED,PHASE3,889.0,2006-01-01,2010-11-01,15.332101983002833,Good (10-50/month),153.32101983002832,Exceeded (≥100%),100,95.0,95.7
NCT06120881,Precision Dosing of Metformin in Youth With T2D,RECRUITING,EARLY_PHASE1,20.0,2024-04-25,2026-12-31,0.6212244897959184,Slow (<1/month),6.212244897959184,Significantly Below (<50%),60,34.6,14.729999999999999
NCT04933981,Benefit of Expanded Surveillance of Nursing Homes During the COVID-19 Pandemic,COMPLETED,,1587.0,2020-10-15,2021-06-30,187.24139534883722,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT04904081,Feasibility of Use of Indocyanine Green in Pediatric Colorectal Surgery,RECRUITING,PHASE3,12.0,2021-06-16,2024-07-01,0.3287848784878488,Slow (<1/month),3.287848784878488,Significantly Below (<50%),60,34.0,14.02
NCT04367181,DCS Study in Extremely Premature Newborns,COMPLETED,NA,100.0,2019-03-15,2023-05-31,1.9791937581274381,Adequate (1-10/month),19.791937581274382,Significantly Below (<50%),100,58.0,68.245
NCT03485781,Propofol-induced EEG Changes in Hypoxic Brain Injury,COMPLETED,,102.0,2017-10-12,2019-07-10,4.88188679245283,Adequate (1-10/month),48.8188679245283,Significantly Below (<50%),100,56.5,65.18
NCT06207981,Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA,RECRUITING,PHASE3,310.0,2024-02-26,2030-02-01,4.354591601292109,Adequate (1-10/month),43.54591601292109,Significantly Below (<50%),60,62.8,75.53999999999999
NCT04970381,An Exploratory stuDy of effectIveneSs and Safety of rivarOxaban in Patients With Left VEntricular Thrombus (R-DISSOLVE),COMPLETED,NA,75.0,2020-09-27,2022-10-30,2.99213630406291,Adequate (1-10/month),29.9213630406291,Significantly Below (<50%),100,56.0,63.71
NCT04413981,Evaluation the Preoperative Anxiety Level of the Surgeons,COMPLETED,,100.0,2020-07-28,2021-12-31,5.842610364683302,Adequate (1-10/month),58.42610364683301,Below (50-75%),100,56.3,64.5
NCT04865081,Clinical Evaluation of an Aerosol Protective Intubation Device on Videolaryngoscopic Intubation Difficulty,UNKNOWN,NA,60.0,2021-04-19,2021-07-01,25.019178082191782,Good (10-50/month),200.0,Exceeded (≥100%),50,44.8,29.845
NCT03139981,A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis,COMPLETED,PHASE1,36.0,2017-04-12,2017-12-05,4.6237974683544305,Adequate (1-10/month),46.23797468354431,Significantly Below (<50%),100,52.9,55.55
NCT03033381,"A Comparison of Testicular Volume and Blood Flow in Patients With Inguinal Hernia, Hydrocele, and Cord Cyst",COMPLETED,NA,23.0,2016-04-01,2016-08-01,5.738688524590164,Adequate (1-10/month),57.38688524590163,Below (50-75%),100,51.8,52.17
NCT05396781,Acceptability and Performance of a Mobile Optical Biopsy Technology for Gastrointestinal Cancer Screening,COMPLETED,PHASE2,41.0,2022-01-13,2022-01-20,41.0,Good (10-50/month),200.0,Exceeded (≥100%),100,63.3,76.235
NCT00256581,Imaging Studies With GE C-Hawk Gamma Camera Compared to Routine Clinical Exam,COMPLETED,,34.0,2005-11-01,2007-06-01,1.7936915077989604,Adequate (1-10/month),17.936915077989603,Significantly Below (<50%),100,51.1,50.129999999999995
NCT01321281,A Study to Determine if Aquamin Modulates Inflammatory Biomarkers in the Blood of Osteoarthritis and Healthy Subjects,COMPLETED,PHASE2,36.0,2011-03-01,2012-05-01,2.5663700234192035,Adequate (1-10/month),25.66370023419204,Significantly Below (<50%),100,52.9,55.55
NCT02002481,Comparison of the Quality of CPR by Professional Helpers (Emergency Physicians / Paramedics) During Flights,UNKNOWN,NA,50.0,2013-12-01,2015-12-01,2.0849315068493155,Adequate (1-10/month),20.84931506849315,Significantly Below (<50%),50,39.0,20.505000000000003
NCT04273581,The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19,UNKNOWN,PHASE2,40.0,2020-02-18,2020-05-30,11.937254901960785,Good (10-50/month),119.37254901960786,Exceeded (≥100%),50,43.2,26.840000000000003
NCT01299519,Progressive Weight Loss and Metabolic Health,COMPLETED,NA,59.0,2011-02-01,2016-04-01,0.9522587486744434,Slow (<1/month),9.522587486744435,Significantly Below (<50%),100,49.7,46.949999999999996
NCT05024019,Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery,UNKNOWN,PHASE2,95.0,2021-08-21,2025-08-21,1.9793292265571527,Adequate (1-10/month),19.793292265571527,Significantly Below (<50%),50,42.6,25.679999999999996
NCT01137019,Optical Coherence Tomography Assessment of Intimal Tissue and Malapposition,UNKNOWN,PHASE3,80.0,2010-10-01,2014-12-01,1.6,Adequate (1-10/month),16.0,Significantly Below (<50%),50,36.4,17.14
NCT04337619,Project Activate: Mindfulness and Acceptance Based Behavioral Treatment for Weight Loss,COMPLETED,NA,285.0,2019-08-15,2024-11-07,4.539717425431712,Adequate (1-10/month),45.39717425431711,Significantly Below (<50%),100,72.8,83.36
NCT01939119,Body-fluid Balance and Drinking Habits in Patients With Retinal Vascular Occlusion,UNKNOWN,,30.0,2013-01-01,2013-12-01,2.734131736526946,Adequate (1-10/month),27.341317365269457,Significantly Below (<50%),50,35.7,16.18
NCT02161419,RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer,TERMINATED,PHASE2,142.0,2014-07-30,2016-05-25,6.49996992481203,Adequate (1-10/month),64.99969924812031,Below (50-75%),10,34.4,14.430000000000001
NCT03050619,Characteristics of Empagliflozin Initiators,COMPLETED,,31908.0,2016-09-10,2016-10-14,28567.044705882352,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT05788419,Sonographic Study of Hip Joint in Hockey Players,COMPLETED,,60.0,2022-10-01,2023-04-30,8.655924170616114,Adequate (1-10/month),86.55924170616115,Met (75-100%),100,58.1,68.595
NCT07263919,Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC),RECRUITING,PHASE2,90.0,2025-12-19,2031-12-01,1.2607455131155085,Adequate (1-10/month),12.607455131155088,Significantly Below (<50%),60,40.2,22.115000000000002
NCT04627519,Effectiveness and Safety of Rhea Health Tone® as add-on Therapy for COVID-19 in Hospitalized Adults in Indonesia,UNKNOWN,NA,85.0,2020-12-09,2021-09-01,9.727067669172932,Adequate (1-10/month),97.27067669172932,Met (75-100%),50,46.8,38.440000000000005
NCT06325319,Effect of Community Engagement Using M-Mama Champions,NOT_YET_RECRUITING,NA,120.0,2024-03-01,2024-05-01,59.88196721311475,Excellent (>50/month),200.0,Exceeded (≥100%),30,48.6,44.685
NCT02895919,Bedside Inoculation of Ascitic Fluid in Diagnostic Paracentesis,WITHDRAWN,,0.0,2016-08-22,2018-08-19,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT03737019,Effects of Acceptance and Commitment Therapy in Primary Health Care,COMPLETED,NA,700.0,2018-10-31,2021-08-30,20.6073500967118,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT05583019,Atopic Dermatitis With Accelerometry and Polysomnography (ADAP),COMPLETED,,88.0,2022-10-27,2023-05-11,13.666938775510205,Good (10-50/month),136.66938775510204,Exceeded (≥100%),100,60.4,72.54
NCT02296619,The Effects of Transversus Abdominis Plane Block in Patients Undergoing Total Abdominal Hysterectomy,COMPLETED,PHASE4,66.0,2014-09-01,2016-02-01,3.8784555984555986,Adequate (1-10/month),38.78455598455599,Significantly Below (<50%),100,55.3,62.36000000000001
NCT06070519,A Dynamic Evaluation of Chronic Heart Failure Prognosis: the MECKI Score,RECRUITING,NA,400.0,2023-05-01,2026-05-01,11.10948905109489,Good (10-50/month),111.0948905109489,Exceeded (≥100%),60,75.0,84.49
NCT00112619,"Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors",TERMINATED,PHASE1,19.0,2005-08-01,,,Slow (<1/month),,Significantly Below (<50%),10,14.5,0.84
NCT05987319,Feasibility Study to Collect and Assess Safety Data for a Radiofrequency Microneedling Device for Electrocoagulation and Hemostasis of Soft Tissues for Dermatologic Conditions,RECRUITING,NA,20.0,2023-07-24,2024-08-01,1.6278074866310162,Adequate (1-10/month),16.278074866310163,Significantly Below (<50%),60,34.6,14.729999999999999
NCT06179719,EEG-fMRI Experiments During Anesthesia Induction With Propofol,RECRUITING,NA,35.0,2023-09-10,2026-09-10,0.9720802919708029,Slow (<1/month),9.720802919708028,Significantly Below (<50%),60,35.8,16.325
NCT01784419,Short Term Effects of Ivacaftor in Non-G551D Cystic Fibrosis Patients,COMPLETED,NA,10.0,2013-10-01,2015-12-01,0.38482932996207336,Slow (<1/month),3.8482932996207335,Significantly Below (<50%),100,45.8,33.03
NCT03574519,Project Step II: The Effects of Incentives and Feedback on Promoting Walking Within Overweight and Obese Adults,COMPLETED,NA,61.0,2017-06-01,2018-01-30,7.641316872427984,Adequate (1-10/month),76.41316872427984,Met (75-100%),100,54.9,61.55500000000001
NCT00649519,Fasting Study of Amlodipine and Benazepril HCl Capsules 10 mg/20 mg to Lotrel® Capsules 10 mg/20 mg,COMPLETED,PHASE1,54.0,2004-05-01,2004-05-01,54.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,44.3,28.715000000000003
NCT04299919,The AI Prognostic Assessment and Pathological Basis Research of Early HCC After Minimally Invasive Treatment,UNKNOWN,,1200.0,2007-04-01,2024-06-30,5.798095238095238,Adequate (1-10/month),57.980952380952374,Below (50-75%),50,73.3,83.61
NCT00401219,Study Comparing Bioavailability of 3 New Formulations of Premarin/MPA With Premarin/MPA (PREMPRO) Reference Formulation,COMPLETED,PHASE1,,2006-11-01,2007-02-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,30.330000000000002
NCT06158919,A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer,RECRUITING,NA,58.0,2023-11-20,2026-11-20,1.610875912408759,Adequate (1-10/month),16.10875912408759,Significantly Below (<50%),60,37.6,18.845
NCT03647319,Noninvasive Dual-mode Stimulation Therapy for Neurorehabilitation in Post-stroke Cognitive Impairment,COMPLETED,NA,29.0,2013-04-11,2016-11-10,0.6743773873185638,Slow (<1/month),6.743773873185638,Significantly Below (<50%),100,47.3,40.475
NCT01351519,A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors,TERMINATED,PHASE2,16.0,2011-05-01,2015-01-01,0.3631916480238628,Slow (<1/month),3.6319164802386283,Significantly Below (<50%),10,19.3,5.125
NCT01872819,Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay,COMPLETED,NA,16.0,2013-08-02,2014-11-17,1.0318644067796612,Adequate (1-10/month),10.31864406779661,Significantly Below (<50%),100,46.3,35.66
NCT00990730,Atherosclerosis in Rheumatoid Arthritis,COMPLETED,,80.0,2009-09-01,2011-06-01,3.8169278996865206,Adequate (1-10/month),38.16927899686521,Significantly Below (<50%),100,54.7,60.629999999999995
NCT06091930,A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6,RECRUITING,PHASE1,97.0,2024-02-16,2028-09-10,1.7701918465227817,Adequate (1-10/month),17.701918465227816,Significantly Below (<50%),60,45.8,33.03
NCT01110330,"An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis, Commonly Known as Athlete's Foot",TERMINATED,PHASE3,583.0,2007-07-01,2008-10-01,38.747860262008736,Good (10-50/month),200.0,Exceeded (≥100%),10,68.0,80.56
NCT06267430,Learning by Heart: The Effectiveness of an EF Training Program for Pre-schoolers With a Severe CHD,RECRUITING,NA,141.0,2024-05-01,2027-12-31,3.205407020164302,Adequate (1-10/month),32.05407020164302,Significantly Below (<50%),60,49.3,46.265
NCT06184230,Persistence of Hepatitis A Antibody in Healthy Adults ~32 Years Post Vaccination.,UNKNOWN,PHASE4,300.0,2024-01-01,2025-06-01,17.66344294003869,Good (10-50/month),176.63442940038686,Exceeded (≥100%),50,64.0,77.025
NCT00689130,ADVANCE: Assessment for Defining Variability in Anesthesia Through Novel Clinical EEG,COMPLETED,,120.0,2008-05-01,2008-10-01,23.87450980392157,Good (10-50/month),200.0,Exceeded (≥100%),100,62.9,75.655
NCT07083830,ECP-DL Cell Infusion for Induction in Living Donor Kidney (LDK) Transplants,NOT_YET_RECRUITING,PHASE1,24.0,2025-09-30,2028-08-25,0.6892075471698114,Slow (<1/month),6.892075471698113,Significantly Below (<50%),30,25.9,7.704999999999999
NCT00026130,Combination Chemotherapy and Radiation Therapy in Treating Patients With Pancreatic Cancer,COMPLETED,PHASE2,81.0,2001-09-01,2010-06-01,0.771718309859155,Slow (<1/month),7.7171830985915495,Significantly Below (<50%),100,51.5,51.245
NCT03196830,CAR-T for R/R B-NHL,UNKNOWN,PHASE2,10.0,2017-06-01,2021-05-31,0.20849315068493152,Slow (<1/month),2.084931506849315,Significantly Below (<50%),50,30.8,9.745
NCT03935230,Uncontrolled Donation After Circulatory Determination of Death (uDCDD),COMPLETED,,1111.0,2016-05-01,2016-08-01,367.59608695652173,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT04924530,Effect of Lactose on Blood Lipids,COMPLETED,NA,26.0,2021-06-07,2023-07-21,1.0225322997416022,Adequate (1-10/month),10.225322997416022,Significantly Below (<50%),100,47.1,39.64
NCT00309530,Randomized Study on Adjuvant Chemotherapy and Adjuvant Chemo-Immunotherapy in Colon Carcinoma Dukes C,COMPLETED,PHASE3,598.0,1990-10-01,,,Slow (<1/month),,Significantly Below (<50%),100,80.0,87.67
NCT04034030,Repeated Oscillatory TMS Therapy of the Epileptogenic Cortical Area in Children With Focal CSWS,RECRUITING,NA,10.0,2019-08-01,2026-07-31,0.11909233176838811,Slow (<1/month),1.1909233176838812,Significantly Below (<50%),60,33.8,13.694999999999999
NCT01683630,"Comparison of Epidemiology and Clinical Outcomes of Influenza A & B Cases in Manitoba, Canada",COMPLETED,,1849.0,2012-04-01,2012-09-01,367.8664052287582,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT04197830,Evaluation of Acute Post-thrombectomy Complications for Stroke,COMPLETED,,361.0,2020-01-15,2020-03-31,144.59,Excellent (>50/month),200.0,Exceeded (≥100%),100,87.2,92.21000000000001
NCT07098130,Comparative Study of Two Ultrasound-guided Percutaneous Neuromodulation Protocols on Maximal Handgrip Strength.,COMPLETED,NA,86.0,2025-08-01,2025-11-27,22.185084745762712,Good (10-50/month),200.0,Exceeded (≥100%),100,61.9,74.265
NCT05990530,Allogeneic Transplantation of Expanded Pancreatic Islet Cells,UNKNOWN,PHASE2,6.0,2023-02-22,2025-08-01,0.204983164983165,Slow (<1/month),2.04983164983165,Significantly Below (<50%),50,30.5,9.395000000000001
NCT06727630,A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma,RECRUITING,PHASE1,40.0,2024-03-14,2025-10-30,2.046386554621849,Adequate (1-10/month),20.46386554621849,Significantly Below (<50%),60,41.2,23.425
NCT07212530,EmoTIChealth: Promoting Adolescent Health Through a Serious Game.,NOT_YET_RECRUITING,NA,600.0,2025-12-01,2027-08-30,28.671899529042385,Good (10-50/month),200.0,Exceeded (≥100%),30,74.0,83.985
NCT02944630,Psychotherapy for Patients With Psoriasis: Effects in Quality of Life,UNKNOWN,NA,120.0,2016-10-01,2020-01-01,3.0773378264532436,Adequate (1-10/month),30.773378264532436,Significantly Below (<50%),50,44.6,29.42
NCT07265830,Building Adaptive School-based Interventions for Caries,NOT_YET_RECRUITING,PHASE3,1200.0,2026-09-01,2030-06-01,26.682249817384953,Good (10-50/month),200.0,Exceeded (≥100%),30,74.0,83.985
NCT00535730,ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED),COMPLETED,PHASE3,473.0,2007-06-01,2008-02-01,58.76783673469388,Excellent (>50/month),200.0,Exceeded (≥100%),100,97.8,96.64
NCT05495230,OPTIMA FORMA Phase 3,COMPLETED,NA,842.0,2023-01-01,2024-09-01,42.086174055829225,Good (10-50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT04074330,A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma,TERMINATED,PHASE1,38.0,2019-10-15,2023-04-26,0.8973778122575641,Slow (<1/month),8.97377812257564,Significantly Below (<50%),10,21.0,6.105
NCT01767428,Pharmacokinetic Study to Compare Two Formulations of Paracetamol,COMPLETED,PHASE1,30.0,2010-04-01,2010-04-01,30.0,Good (10-50/month),200.0,Exceeded (≥100%),100,42.4,25.45
NCT01118728,Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis,TERMINATED,PHASE2,223.0,2010-06-01,2011-12-01,12.387080291970802,Good (10-50/month),123.87080291970803,Exceeded (≥100%),10,45.8,33.03
NCT01794728,How the Elderly Live With Pain in Heart Failure,COMPLETED,,56.0,2012-07-01,2013-07-01,4.670246575342467,Adequate (1-10/month),46.70246575342466,Significantly Below (<50%),100,52.8,55.31
NCT04184128,Detrusor Underactivity and Bladder Outlet Obstruction in Women With Cystocele,COMPLETED,,623.0,2010-11-01,2018-09-30,6.561979238754326,Adequate (1-10/month),65.61979238754326,Below (50-75%),100,88.3,92.705
NCT01803828,REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrs,COMPLETED,PHASE4,120.0,2014-05-01,2019-07-01,1.93577106518283,Adequate (1-10/month),19.3577106518283,Significantly Below (<50%),100,59.6,71.17999999999999
NCT02663128,A Study of Lanabecestat (LY3314814) in Healthy Participants,COMPLETED,PHASE1,18.0,2016-01-31,2016-03-31,9.132000000000001,Adequate (1-10/month),91.32000000000001,Met (75-100%),100,56.4,64.88000000000001
NCT04926428,In Situ Thrombolysis With tPA and Inflow Perfusion Analysis in Patient With Severe Covid-19 Infection,COMPLETED,NA,15.0,2020-12-25,2021-03-30,4.806315789473684,Adequate (1-10/month),48.06315789473684,Significantly Below (<50%),100,51.2,50.375
NCT03491228,Anaemetro I.V. Infusion 500mg Drug Use Investigation,COMPLETED,,107.0,2015-07-01,2017-08-01,4.274383202099738,Adequate (1-10/month),42.74383202099738,Significantly Below (<50%),100,56.9,65.89500000000001
NCT06204328,Combined Effects of mHealth Psychoeducational and Benson Relaxation Technique Among Female Informal Caregivers of Cancer Patients in Bangladesh,COMPLETED,NA,102.0,2024-10-01,2025-03-31,17.154033149171273,Good (10-50/month),171.5403314917127,Exceeded (≥100%),100,63.2,76.11
NCT04866628,Clinical Trials of Two Helichrysum Infusions in Adults,COMPLETED,NA,30.0,2021-05-06,2021-06-19,20.754545454545454,Good (10-50/month),200.0,Exceeded (≥100%),100,57.4,67.05499999999999
NCT00258128,Effect of Salicylate on Glucose Metabolism in Insulin Resistance States,COMPLETED,PHASE1,17.0,2000-01-01,2008-05-01,0.1700558659217877,Slow (<1/month),1.7005586592178772,Significantly Below (<50%),100,46.4,36.26
NCT02121028,Mechanisms of Early Recurrence in Intracranial Atherosclerotic Disease,COMPLETED,,105.0,2015-05-01,2020-12-31,1.5433124094640271,Adequate (1-10/month),15.433124094640272,Significantly Below (<50%),100,51.7,51.94
NCT00115128,Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors,COMPLETED,,309.0,2003-11-01,2007-09-01,6.718542857142857,Adequate (1-10/month),67.18542857142857,Below (50-75%),100,73.1,83.515
NCT03636828,Gastric Emptying Time of a Rice-based Meal,UNKNOWN,,10.0,2018-10-15,2018-12-27,4.16986301369863,Adequate (1-10/month),41.698630136986296,Significantly Below (<50%),50,34.1,14.19
NCT01703728,Controlled Ovarian Stimulation by HP-hMG for IVF / ICSI Cycles: Study on Ovarian Hyper Stimulation Syndrome in a Cohort of Women From 18 to 36 Years Old.,COMPLETED,,455.0,2012-11-01,2014-05-01,25.366666666666667,Good (10-50/month),200.0,Exceeded (≥100%),100,89.7,93.045
NCT01936428,Prospective Study of the Perception of Palliative Care by Relatives of Patients Treated in Oncology,COMPLETED,NA,20.0,2013-01-01,2013-05-01,5.073333333333333,Adequate (1-10/month),50.73333333333333,Below (50-75%),100,51.6,51.644999999999996
NCT00652028,Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Pediatrics Subjects,COMPLETED,PHASE2,69.0,2008-11-01,2010-04-01,4.0704651162790695,Adequate (1-10/month),40.7046511627907,Significantly Below (<50%),100,55.5,62.71
NCT03084328,Vitamin D Replacement in Nonalcoholic Fatty Liver Disease,COMPLETED,,48.0,2012-01-20,2017-03-10,0.7788486140724947,Slow (<1/month),7.788486140724945,Significantly Below (<50%),100,47.2,40.035
NCT02638428,Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy,UNKNOWN,PHASE2,90.0,2015-12-01,2023-12-01,0.9375770020533881,Slow (<1/month),9.37577002053388,Significantly Below (<50%),50,37.2,18.17
NCT01802528,Clinical Effectiveness of Obturator Externus Muscle Injection in Chronic Pelvic Pain Patients,COMPLETED,,23.0,2012-03-01,2012-12-01,2.545890909090909,Adequate (1-10/month),25.458909090909092,Significantly Below (<50%),100,50.2,48.04
NCT05446428,Evaluation of Type I IFN Level and Disease Activity in SLE Patients,UNKNOWN,,70.0,2022-08-01,2024-07-31,2.9189041095890413,Adequate (1-10/month),29.189041095890417,Significantly Below (<50%),50,38.9,20.325
NCT04618328,A Study of ATRA in the Treatment of ITP,UNKNOWN,PHASE2,80.0,2020-11-01,2021-10-01,7.291017964071856,Adequate (1-10/month),72.91017964071857,Below (50-75%),50,41.4,24.04
NCT00376428,Interest of Gentamicin-induced Readthrough in Cystic Fibrosis Patients,TERMINATED,PHASE2,20.0,2003-01-01,2005-06-01,0.6902494331065759,Slow (<1/month),6.9024943310657605,Significantly Below (<50%),10,19.6,5.365
NCT06985628,Alleviating Dyspnea With Non-Invasive Neuromodulation,RECRUITING,NA,8.0,2024-11-18,2025-12-01,0.6442328042328043,Slow (<1/month),6.442328042328042,Significantly Below (<50%),60,33.6,13.375
NCT02854228,PITUItary Carcinoma or Aggressive Tumors REgistry -Lyon,UNKNOWN,,1300.0,2007-02-01,2020-12-01,7.832937450514649,Adequate (1-10/month),78.32937450514649,Met (75-100%),50,73.3,83.61
NCT06085365,Effects of Immunonutrition on the Improvement of Postoperative Adjuvant Chemotherapy Related Adverse Reactions in Patients With Gastrointestinal Tumors,UNKNOWN,PHASE3,324.0,2023-07-24,2024-12-31,18.750114068441064,Good (10-50/month),187.50114068441067,Exceeded (≥100%),50,65.9,78.83
NCT00456365,Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD),COMPLETED,PHASE3,110.0,2006-11-01,2012-10-01,1.5494678389634429,Adequate (1-10/month),15.494678389634428,Significantly Below (<50%),100,53.8,58.065
NCT01244165,Study of Cytrix Use in Pelvic Floor Prolapse Treatment,COMPLETED,PHASE4,45.0,2002-01-01,2006-10-01,0.7899653979238755,Slow (<1/month),7.899653979238755,Significantly Below (<50%),100,48.6,44.685
NCT06869265,Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia,RECRUITING,PHASE2,56.0,2025-05-01,2029-04-01,1.1912229210342418,Adequate (1-10/month),11.912229210342417,Significantly Below (<50%),60,37.5,18.775
NCT05218265,Criteria and Potential Predictors of Severity in Patients With COVID-19,COMPLETED,,202.0,2020-03-01,2021-07-30,11.916434108527131,Good (10-50/month),119.16434108527132,Exceeded (≥100%),100,69.5,81.62
NCT03811665,Stereotactic Body Radiation Therapy Versus Radiofrequency Ablation for Small Renal Masses,UNKNOWN,NA,24.0,2019-10-01,2022-12-30,0.6159865092748736,Slow (<1/month),6.159865092748737,Significantly Below (<50%),50,31.9,11.295
NCT05701865,Biphasic Effects of Acute Alcohol Intoxication on Bystander Intervention,RECRUITING,NA,192.0,2023-03-09,2024-12-31,8.815203619909504,Adequate (1-10/month),88.15203619909502,Met (75-100%),60,58.4,69.175
NCT03536065,"Post-Discharge Opioid Reduction Intervention for Open, Laparoscopic, and Endoscopic Surgery",COMPLETED,NA,443.0,2017-08-01,2019-03-01,23.370745233968808,Good (10-50/month),200.0,Exceeded (≥100%),100,90.4,93.305
NCT00825565,Study of Alwextin® Cream in Treating Epidermolysis Bullosa,COMPLETED,PHASE2,8.0,2009-02-01,2010-11-01,0.3816927899686521,Slow (<1/month),3.816927899686521,Significantly Below (<50%),100,45.6,32.08
NCT02854865,Specke Tracking Echocardiography And Filling Pressures,UNKNOWN,,30.0,2015-01-01,2018-12-01,0.6386013986013986,Slow (<1/month),6.386013986013987,Significantly Below (<50%),50,30.7,9.585
NCT07164365,Effect of an Interdisciplinary Shared Decision-Making Intervention on Decisional Conflict in Advanced Cancer Patients Receiving Third-Line Therapy,ACTIVE_NOT_RECRUITING,NA,62.0,2025-08-10,2026-04-01,8.065299145299146,Adequate (1-10/month),80.65299145299146,Met (75-100%),85,50.5,48.515
NCT03116165,Cognitive-Behavioural Therapy as a Preventive Treatment for Post Traumatic Stress Disorder,TERMINATED,NA,352.0,2017-04-18,2017-12-11,45.2104641350211,Good (10-50/month),200.0,Exceeded (≥100%),10,61.2,73.43499999999999
NCT06232265,An Observational Study on Predicting the Efficacy of Immunotherapy for NSCLC Based on LIRAscore,RECRUITING,,108.0,2023-09-22,2026-08-01,3.1489655172413795,Adequate (1-10/month),31.489655172413794,Significantly Below (<50%),60,45.0,30.330000000000002
NCT01133665,Cetuximab and Lenalidomide in Head and Neck,COMPLETED,PHASE2,42.0,2010-02-01,2012-08-01,1.401842105263158,Adequate (1-10/month),14.018421052631581,Significantly Below (<50%),100,48.4,44.22
NCT05203965,"Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant",RECRUITING,EARLY_PHASE1,80.0,2022-05-17,2026-07-31,1.5854166666666667,Adequate (1-10/month),15.854166666666666,Significantly Below (<50%),60,39.4,20.94
NCT02272465,Prehospital Resuscitation On Helicopter Study,COMPLETED,,1049.0,2015-01-01,2015-12-01,95.60347305389222,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT00315965,Development of a New Method for Steady-State Measurement of NO Lung Diffusing Capacity in Healthy Subjects,UNKNOWN,PHASE1,107.0,2006-07-01,2007-09-01,7.627822014051522,Adequate (1-10/month),76.27822014051523,Met (75-100%),50,43.6,27.54
NCT02876965,Change on Sleep Quality of Patients With Fibromyalgia Subjected to a Protocol Based on Physical Exercise and Stretching,COMPLETED,NA,40.0,2016-08-01,2017-03-01,5.743396226415094,Adequate (1-10/month),57.43396226415095,Below (50-75%),100,53.2,56.665
NCT07138365,Clinical and Biochemical Effects Of Cryotherapy Protocols On Mandibular Premolars With Symptomatic Apical Periodontitis,COMPLETED,NA,30.0,2024-06-01,2025-06-01,2.5019178082191784,Adequate (1-10/month),25.019178082191786,Significantly Below (<50%),100,52.4,53.949999999999996
NCT00354965,Pharmacokinetic Profiles Of Amoxicillin 2000 mg And Clavulanate 125 mg In Adolescent Patients,COMPLETED,PHASE1,52.0,2006-01-19,2007-04-02,3.613881278538813,Adequate (1-10/month),36.13881278538813,Significantly Below (<50%),100,54.2,59.330000000000005
NCT04855565,ALY688-SR in Generally Healthy Overweight or Obese Adults,TERMINATED,PHASE1,8.0,2021-05-19,2021-08-03,3.2042105263157894,Adequate (1-10/month),32.04210526315789,Significantly Below (<50%),10,23.6,6.7250000000000005
NCT02271165,Subcutaneous Immunoglobulin (Hizentra) in Patients With Dermatomyositis: A Proof of Concept Study,TERMINATED,EARLY_PHASE1,2.0,2014-11-01,2017-03-02,0.07145539906103286,Slow (<1/month),0.7145539906103286,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT03530865,Assessment of the Variations in the Root Canal System of the Permanent Mandibular First and Second Molars Among Egyptian Population Using Cone Beam Computed Tomography,UNKNOWN,,384.0,2018-06-01,2018-10-01,95.8111475409836,Excellent (>50/month),200.0,Exceeded (≥100%),50,74.1,84.10499999999999
NCT00919165,Assessment of Cognitive Function in Patients Undergoing Carotid Artery Stent Placement,COMPLETED,,19.0,2007-12-01,2017-04-20,0.16871645274212368,Slow (<1/month),1.687164527421237,Significantly Below (<50%),100,44.9,30.025000000000002
NCT03251365,Intrabdominal Hyperthermic Chemotherapy and Pancreatic Cancer,UNKNOWN,PHASE2,42.0,2017-07-27,2024-12-31,0.47106853352984523,Slow (<1/month),4.710685335298453,Significantly Below (<50%),50,33.4,13.29
NCT04465565,Fluids Administration During Combined Clonidine-Arginine Growth Hormone Stimulation Test,WITHDRAWN,NA,0.0,2020-12-01,2022-08-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT01461265,Safety and Efficacy of Cryoablation for the Palliation of Painful Bone Metastases,COMPLETED,PHASE1,29.0,2011-11-01,2015-04-01,0.7079069767441861,Slow (<1/month),7.079069767441862,Significantly Below (<50%),100,47.3,40.475
NCT02878265,The Effect of Vitamin A With and Without Zinc and Multivitamin Supplementation on Malaria Morbidity in Ghanaian Children,COMPLETED,PHASE3,547.0,2011-11-01,2012-12-01,42.04717171717172,Good (10-50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT05502965,Specific Dietary Pattern for Crohn's Disease Patients Following Surgery,RECRUITING,NA,35.0,2022-09-17,2026-06-30,0.7709117221418235,Slow (<1/month),7.709117221418235,Significantly Below (<50%),60,35.8,16.325
NCT06799065,"First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer",RECRUITING,PHASE1,90.0,2025-03-21,2027-08-30,3.0713004484304935,Adequate (1-10/month),30.713004484304935,Significantly Below (<50%),60,45.2,30.830000000000002
NCT07013565,Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL,ACTIVE_NOT_RECRUITING,PHASE2,20.0,2025-08-07,2030-07-01,0.3403018446059251,Slow (<1/month),3.403018446059251,Significantly Below (<50%),85,42.1,25.019999999999996
NCT06496165,Remimazolam Besylate and Propofol Sedation on Hemodynamic for Coronary Artery Bypass Graft Patients,NOT_YET_RECRUITING,NA,338.0,2024-07-15,2026-12-31,11.444627363737487,Good (10-50/month),114.44627363737487,Exceeded (≥100%),30,61.0,73.17
NCT05682365,Online Personalized Intervention for the Prevention of Anxiety.,UNKNOWN,NA,2000.0,2023-01-30,2024-08-31,105.14680483592402,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT01531465,High Flow Nasal Cannula Versus Nasal Continuous Positive Airway Pressure,COMPLETED,NA,20.0,2011-06-01,2013-01-01,1.049655172413793,Adequate (1-10/month),10.496551724137932,Significantly Below (<50%),100,46.6,37.375
NCT05477667,Study of Let-7a and miRNA-124 in Cases of Non-Hodgkin's Lymphoma and Acute Leukemia,UNKNOWN,NA,100.0,2022-10-01,2023-04-30,14.42654028436019,Good (10-50/month),144.26540284360192,Exceeded (≥100%),50,48.0,42.945
NCT07024667,Clinical and Molecular Study to Evaluate the Effect of the Pixel CO2 Laser (FemiLiftTM) for the Treatment of Vulvo-Vaginal Atrophy,RECRUITING,NA,20.0,2022-09-02,2027-12-31,0.312846865364851,Slow (<1/month),3.12846865364851,Significantly Below (<50%),60,34.6,14.729999999999999
NCT02856867,Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN),WITHDRAWN,PHASE2,0.0,2016-12-01,,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT01458067,"A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency",COMPLETED,PHASE1,30.0,2011-11-10,2016-02-25,0.5823979591836735,Slow (<1/month),5.823979591836735,Significantly Below (<50%),100,47.4,40.98
NCT02782767,Comparison of Continuous Wound Catheter Infusion Versus Continuous Epidural Infusion in Abdominal Surgery,COMPLETED,NA,40.0,2016-05-01,2017-01-01,4.969795918367347,Adequate (1-10/month),49.697959183673476,Significantly Below (<50%),100,53.2,56.665
NCT01367067,Prediction of Claustrophobia During MR Imaging,COMPLETED,,8000.0,2010-01-01,2011-06-01,471.937984496124,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT00723567,A Novel Mutation of the Spectrin Gene,COMPLETED,,12.0,2008-02-01,2008-12-01,1.201578947368421,Adequate (1-10/month),12.015789473684212,Significantly Below (<50%),100,44.3,28.715000000000003
NCT06260267,A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis,WITHDRAWN,PHASE1,0.0,2024-03-12,2026-01-15,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT05735067,The Impact of Body Weight on Clinical and Immunological Outcomes in Relapse-Remitting Multiple Sclerosis Patients,UNKNOWN,,138.0,2022-02-01,2025-07-30,3.2946823529411766,Adequate (1-10/month),32.946823529411766,Significantly Below (<50%),50,44.4,28.95
NCT06544967,Differences Between Male and Femal Fetal Brain Biometry by Ultrasound,RECRUITING,,500.0,2024-06-01,2025-06-01,41.6986301369863,Good (10-50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT04277767,The Role of Ophthalmologic Tests and EEG Imaging in Alzheimer's Disease,UNKNOWN,,60.0,2022-09-01,2023-07-01,6.027722772277229,Adequate (1-10/month),60.277227722772274,Below (50-75%),50,38.1,19.425
NCT01398267,A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril,COMPLETED,PHASE1,55.0,2011-08-01,2012-10-01,3.9208430913348944,Adequate (1-10/month),39.20843091334895,Significantly Below (<50%),100,54.4,59.89
NCT00458367,"RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain Information on the Safety and Efficacy of Risperidone When Used in Routine Clinical Practice",COMPLETED,,5296.0,2002-06-01,2006-10-01,101.8384333543904,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02538367,Phase 1/2a Trial of YH12852 in Healthy Subjects and Patients With Functional Constipation,COMPLETED,PHASE1,120.0,2015-08-01,2016-09-01,9.201007556675064,Adequate (1-10/month),92.01007556675063,Met (75-100%),100,64.6,77.59
NCT00315367,A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties,COMPLETED,PHASE4,26.0,2004-09-01,2007-10-01,0.7035022222222221,Slow (<1/month),7.035022222222222,Significantly Below (<50%),100,47.1,39.64
NCT07379567,BREVOC Study: Exhaled VOCs for High-Risk Chest Pain in the ED,NOT_YET_RECRUITING,,6000.0,2026-03-01,2027-12-31,272.5970149253732,Excellent (>50/month),200.0,Exceeded (≥100%),30,77.3,85.67
NCT03309267,Serratus Anterior Plane Block Versus Intercostal Block,COMPLETED,,42.0,2017-10-06,2017-11-03,42.0,Good (10-50/month),200.0,Exceeded (≥100%),100,61.7,74.1
NCT04191967,Thermocoagulation for Treatment of Precancerous Cervical Lesions,COMPLETED,NA,379.0,2019-09-25,2021-11-30,14.475232120451693,Good (10-50/month),144.75232120451693,Exceeded (≥100%),100,85.3,91.355
NCT06453967,Impact of Blood Glucose Levels on in ICU Morbidity and Mortality in Patients With Acute Decompensated Heart Failure,NOT_YET_RECRUITING,,96.0,2024-07-01,2025-09-30,6.40842105263158,Adequate (1-10/month),64.0842105263158,Below (50-75%),30,35.0,15.305
NCT00514267,An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors,COMPLETED,PHASE1,32.0,2007-05-01,2010-03-01,0.9411400966183575,Slow (<1/month),9.411400966183574,Significantly Below (<50%),100,47.6,41.775
NCT00486967,Insulin Resistance : Heart Failure,COMPLETED,,147.0,2006-08-01,2008-07-31,6.129698630136987,Adequate (1-10/month),61.29698630136987,Below (50-75%),100,60.1,72.085
NCT05681767,Motivational Multicomponent Lifestyle Interventions as a Supportive Treatment for Depression in Primary Health Care,RECRUITING,NA,210.0,2022-11-21,2026-12-31,4.258760826115923,Adequate (1-10/month),42.587608261159225,Significantly Below (<50%),60,54.8,61.095
NCT05198167,Efficacy of HOFA Versus Hydrocolloid Dressings in the Prevention of PUs in Critically Ill Prone Patients,UNKNOWN,NA,262.0,2021-06-12,2023-06-12,10.925041095890412,Good (10-50/month),109.25041095890413,Exceeded (≥100%),50,61.0,73.17
NCT05653167,VR as a Facilitator for Participation in Society Among Persons With MHD/SUD,UNKNOWN,,124.0,2022-03-01,2024-12-01,3.752047713717694,Adequate (1-10/month),37.52047713717693,Significantly Below (<50%),50,43.3,27.05
NCT02162667,Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer,COMPLETED,PHASE3,562.0,2014-06-01,2018-10-01,10.80687302590019,Good (10-50/month),108.06873025900188,Exceeded (≥100%),100,95.0,95.7
NCT04898400,Eosinophils in Human Adipose Tissue,COMPLETED,NA,4.0,2021-06-01,2022-08-26,0.26997782705099777,Slow (<1/month),2.6997782705099778,Significantly Below (<50%),100,45.3,31.169999999999998
NCT06203600,"Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial",RECRUITING,PHASE2,224.0,2024-06-24,2027-10-31,5.570718954248366,Adequate (1-10/month),55.70718954248366,Below (50-75%),60,55.9,63.42
NCT02126800,Rapid Medical Donation Programme for Breast Cancer,UNKNOWN,,60.0,2014-03-01,2019-03-01,1.0002190580503834,Adequate (1-10/month),10.002190580503836,Significantly Below (<50%),50,33.1,12.814999999999998
NCT01976000,Influence of CT 3D on the Learning Curve of Laparoscopic Colorectal Resection,COMPLETED,,120.0,2012-01-01,2014-01-01,4.996990424076608,Adequate (1-10/month),49.96990424076608,Significantly Below (<50%),100,57.9,67.83
NCT04785300,ALSENLITE: Senolytics for Alzheimer's Disease,ACTIVE_NOT_RECRUITING,PHASE1,20.0,2022-07-06,2026-06-01,0.42692847124824684,Slow (<1/month),4.269284712482468,Significantly Below (<50%),85,42.1,25.019999999999996
NCT02251600,A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular Dystrophy,COMPLETED,PHASE1,24.0,2014-12-01,2015-10-01,2.403157894736842,Adequate (1-10/month),24.031578947368423,Significantly Below (<50%),100,51.9,52.55499999999999
NCT05219500,Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).,ACTIVE_NOT_RECRUITING,PHASE2,115.0,2021-12-16,2026-07-31,2.0738151658767774,Adequate (1-10/month),20.738151658767777,Significantly Below (<50%),85,54.7,60.629999999999995
NCT03508700,A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD,COMPLETED,PHASE3,93.0,2018-04-19,2019-09-30,5.351455576559547,Adequate (1-10/month),53.514555765595475,Below (50-75%),100,57.4,67.05499999999999
NCT01432600,Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide,COMPLETED,PHASE1,80.0,2011-11-01,2016-08-01,1.4035734870317003,Adequate (1-10/month),14.035734870317004,Significantly Below (<50%),100,51.4,50.92
NCT03784300,A Safety Study of PTI-125 in Healthy Volunteers,COMPLETED,PHASE1,24.0,2017-08-18,2018-03-27,3.3057013574660634,Adequate (1-10/month),33.05701357466064,Significantly Below (<50%),100,51.9,52.55499999999999
NCT02878200,"RHOST-cRCT, Reactive Household-based Self-administered Treatment Against Residual Malaria Transmission",COMPLETED,NA,2236.0,2016-11-04,2020-07-16,50.41765925925926,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT02515500,Cigarette Reduction Using the Quitbit Digital Lighter and Mobile Application for Smoking Cessation: a Randomized Controlled Trial,COMPLETED,NA,124.0,2016-06-01,2018-06-01,5.1706301369863015,Adequate (1-10/month),51.70630136986302,Below (50-75%),100,59.9,71.86
NCT06147700,Identifying Molecular Determinants of Infertility in Men (MODIFY),COMPLETED,,100.0,2023-10-11,2024-06-30,11.574144486692017,Good (10-50/month),115.74144486692015,Exceeded (≥100%),100,61.3,73.56
NCT00517400,Deep Transcranial Magnetic Stimulation (TMS)- Treatment for Post Traumatic Stress Disorder,COMPLETED,PHASE1,30.0,2008-02-01,2011-07-01,0.7329052969502408,Slow (<1/month),7.329052969502409,Significantly Below (<50%),100,47.4,40.98
NCT06563700,Novel Lenses for Myopia Progression Trial,ACTIVE_NOT_RECRUITING,NA,300.0,2024-08-16,2027-07-31,8.46339202965709,Adequate (1-10/month),84.6339202965709,Met (75-100%),85,74.5,84.28999999999999
NCT03182400,Neurophysiological Study of Sensory and Cognitive Processes in Healthy Children and Adults,RECRUITING,NA,450.0,2017-06-14,2027-06-01,3.7642209398186317,Adequate (1-10/month),37.642209398186324,Significantly Below (<50%),60,74.0,83.985
NCT01937000,[Trial of device that is not approved or cleared by the U.S. FDA],WITHHELD,,,,,,Slow (<1/month),,Significantly Below (<50%),50,20.0,5.695
NCT04743700,"""Effects of Piezocision vs Micro-osteoperforations on the Rate of Maxillary Canine Retraction",UNKNOWN,NA,20.0,2020-12-25,2021-12-01,1.7853372434017598,Adequate (1-10/month),17.853372434017597,Significantly Below (<50%),50,36.6,17.41
NCT02948400,Virtual Reality by Mobile Phone: Improving Child Pedestrian Safety,COMPLETED,NA,500.0,2016-12-01,2022-12-20,6.886877828054299,Adequate (1-10/month),68.868778280543,Below (50-75%),100,90.0,93.17
NCT03824600,Physiological Patterns of Coronary Artery Disease,COMPLETED,,117.0,2017-11-24,2019-09-30,5.276266666666667,Adequate (1-10/month),52.76266666666667,Below (50-75%),100,57.7,67.51
NCT04842500,Translational Research to Inform Interventions for Challenging Behavior,COMPLETED,NA,86.0,2021-08-01,2024-05-14,2.5740806293018683,Adequate (1-10/month),25.740806293018682,Significantly Below (<50%),100,56.9,65.89500000000001
NCT00780507,Fecal Biomarker Study for Patients With Ulcerative Colitis,COMPLETED,,89.0,2007-08-01,2009-07-01,3.8702285714285716,Adequate (1-10/month),38.70228571428571,Significantly Below (<50%),100,55.5,62.71
NCT00006307,Epidemiology of Body Mass Index Rebound,COMPLETED,,,2000-08-01,2006-07-01,,Slow (<1/month),,Significantly Below (<50%),100,43.3,27.05
NCT00126607,Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer,TERMINATED,PHASE2,35.0,2005-07-01,,,Slow (<1/month),,Significantly Below (<50%),10,15.8,2.54
NCT04343807,Effectiveness of Ultrasound Guided PECS Block on Opioid Consumption and Patient Satisfaction Through Adequate Pain Control Following Breast Cancer Surgery.,COMPLETED,NA,70.0,2023-11-01,2025-03-30,4.13747572815534,Adequate (1-10/month),41.3747572815534,Significantly Below (<50%),100,55.6,62.905
NCT05301907,Survey Among Healthcare Professionals and MS Patients to Assess Their Understanding of RMP Materials,COMPLETED,,335.0,2021-12-02,2025-05-16,8.086756542426645,Adequate (1-10/month),80.86756542426645,Met (75-100%),100,75.1,84.56
NCT05253807,Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration,COMPLETED,PHASE2,8.0,2022-04-29,2023-08-16,0.5137552742616034,Slow (<1/month),5.137552742616034,Significantly Below (<50%),100,45.6,32.08
NCT00640107,Evaluation and Optimization of Ultrasound and/or MRI Hardware and Software,RECRUITING,,30.0,2007-10-01,2030-09-01,0.10909090909090909,Slow (<1/month),1.090909090909091,Significantly Below (<50%),60,33.7,13.465
NCT04607707,Women's Satisfaction and Adherence to Vulvovaginal Atrophy Treatments,COMPLETED,,831.0,2020-07-07,2021-04-30,85.17050505050506,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT04462107,Longitudinal Study Evaluating Recovery After Scheduled Cesarean Delivery,COMPLETED,,66.0,2021-02-01,2021-11-01,7.35912087912088,Adequate (1-10/month),73.5912087912088,Below (50-75%),100,53.6,57.705
NCT02363907,Observational Study to Evaluate the Effectiveness and Safety of the Dexcom G4 Continuous Glucose Monitoring System in Pediatrics,COMPLETED,,30.0,2012-09-01,2012-10-01,30.0,Good (10-50/month),200.0,Exceeded (≥100%),100,55.7,63.09
NCT04042207,Diabeloop for Highly Unstable Type 1 Diabetes,COMPLETED,NA,7.0,2019-09-03,2021-03-22,0.3764664310954064,Slow (<1/month),3.764664310954064,Significantly Below (<50%),100,45.6,32.08
NCT00121407,Visudyne® in Occult (VIO),COMPLETED,PHASE3,364.0,2002-03-01,2005-08-01,8.871224979983987,Adequate (1-10/month),88.71224979983987,Met (75-100%),100,84.1,90.64999999999999
NCT02711007,Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy,COMPLETED,PHASE2,37.0,2016-03-01,2018-01-08,1.66117994100295,Adequate (1-10/month),16.6117994100295,Significantly Below (<50%),100,48.0,42.945
NCT00879307,Brain Derived Neurotrophic Factor as a Predictor of Response to Treatment in Bipolar Depression and Mania: 16-weeks Follow-up With Quetiapine XR,UNKNOWN,PHASE3,100.0,2009-03-01,2011-09-01,3.3304157549234135,Adequate (1-10/month),33.304157549234134,Significantly Below (<50%),50,43.0,26.465
NCT04297007,Pectoral Nerve Block Type-II and Rhomboid Intercostal Block for Pain Management Following Mastectomy Surgery,COMPLETED,NA,90.0,2020-03-23,2021-02-20,8.202395209580839,Adequate (1-10/month),82.02395209580838,Met (75-100%),100,57.2,66.465
NCT02987907,"The Impact on Therapeutic Effect and Tolerance of Treatment for Patients With Hepatocellular Carcinoma in Transcatheter Arterial Chemoembolization (TACE) of Dexamethasone Application: A Random, Double-blind, Controlled, Clinical Trial.",UNKNOWN,PHASE3,220.0,2016-08-01,2019-08-01,6.115799086757992,Adequate (1-10/month),61.15799086757991,Below (50-75%),50,52.6,54.684999999999995
NCT03805607,IV Ketorolac on Platelet Function Post-Cesarean Delivery,COMPLETED,PHASE4,40.0,2021-01-18,2024-03-30,1.0433590402742074,Adequate (1-10/month),10.433590402742075,Significantly Below (<50%),100,48.2,43.665
NCT02807207,To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects,COMPLETED,PHASE1,42.0,2014-10-01,2014-12-01,20.958688524590162,Good (10-50/month),200.0,Exceeded (≥100%),100,58.4,69.175
NCT05626907,Does What You Eat Affect Your Brain,COMPLETED,NA,36.0,2023-01-13,2025-06-30,1.2189543937708567,Adequate (1-10/month),12.189543937708567,Significantly Below (<50%),100,47.9,42.64
NCT05690607,Small Volume Blood Testing Validity and Acceptability for HIV-1 and Hepatitis B (TINIES for BBVs),UNKNOWN,,300.0,2023-01-23,2024-01-22,25.087912087912088,Good (10-50/month),200.0,Exceeded (≥100%),50,62.3,74.94
NCT03153007,Study of Subjects With Diabetic Foot Ulcer (DFU),COMPLETED,,1.0,2017-08-11,2017-12-06,0.26017094017094017,Slow (<1/month),2.6017094017094022,Significantly Below (<50%),100,43.4,27.265
NCT00001307,Positron Emission Tomography to Measure Pain and Pain Control,COMPLETED,,273.0,1992-08-01,2005-08-01,1.7502358887952822,Adequate (1-10/month),17.502358887952823,Significantly Below (<50%),100,70.2,81.99499999999999
NCT03692507,Effects of Nutritional Preconditioning on the Patient's Outcomes After Surgery,UNKNOWN,NA,20.0,2021-07-30,2022-12-30,1.1752895752895753,Adequate (1-10/month),11.752895752895755,Significantly Below (<50%),50,31.6,10.905
NCT03770507,Gas Exchange Kinetics and Work Load During Exercise,WITHDRAWN,NA,0.0,2016-04-25,2016-04-25,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT03962907,Preoperative Decolonization and Surgical Site Infections in Orthopaedic Surgery - 2 Year Outcome in Prosthetic Surgery,COMPLETED,PHASE4,1318.0,2019-01-01,2020-06-30,73.47970695970696,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT02933307,Continuous Monitoring on the General Ward,COMPLETED,NA,90.0,2015-04-01,2016-09-01,5.278612716763006,Adequate (1-10/month),52.786127167630056,Below (50-75%),100,57.2,66.465
NCT07193407,INOPASE - Performance and Safety Study of a Personalised SNM System,NOT_YET_RECRUITING,NA,10.0,2025-12-15,2026-06-28,1.5610256410256411,Adequate (1-10/month),15.610256410256412,Significantly Below (<50%),30,24.8,7.06
NCT01248507,Predictive Questionnaires for Risk of Acute COPD (Chronic Obstructive Pulmonary Disease) Exacerbations,COMPLETED,,634.0,2011-01-01,2013-04-01,23.506650426309378,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT00566007,The Effect of Ozone Therapy for Lumbar Herniated Disc,TERMINATED,PHASE2,156.0,2008-12-01,2014-03-01,2.4784133611691024,Adequate (1-10/month),24.784133611691022,Significantly Below (<50%),10,35.5,15.950000000000001
NCT04949607,Traumatic Brain Injury and the Gut Microbiome,COMPLETED,NA,23.0,2021-07-28,2022-06-08,2.222603174603175,Adequate (1-10/month),22.22603174603175,Significantly Below (<50%),100,51.8,52.17
NCT02773407,Nepal Undifferentiated Febrile Illness Trial,COMPLETED,PHASE3,330.0,2016-05-23,2019-08-04,8.600342465753425,Adequate (1-10/month),86.00342465753424,Met (75-100%),100,81.4,88.9
NCT05004207,Study of Oro-cecal Transit Time in Healthy Subjects Using Scintigraphy and Lactulose Hydrogen Breath Test.,UNKNOWN,,50.0,2021-07-01,2022-01-31,7.112149532710281,Adequate (1-10/month),71.1214953271028,Below (50-75%),50,37.3,18.35
NCT06824792,Optimal Standard Treatment Selection for Solid Tumor Patients by Biologically-informed Multi-agent System,NOT_YET_RECRUITING,PHASE4,3000.0,2025-03-01,2030-02-28,50.03835616438356,Excellent (>50/month),200.0,Exceeded (≥100%),30,79.0,86.96000000000001
NCT05676892,Effects of Intravenous Ibuprofen on Acute Pain After Laparoscopic Cholecystectomy,UNKNOWN,NA,140.0,2023-03-01,2023-12-31,13.972459016393444,Good (10-50/month),139.72459016393447,Exceeded (≥100%),50,51.2,50.375
NCT02647892,Optimal Lidocaine Buffering to Reduce Injection Pain in Local Anesthesia,TERMINATED,PHASE4,70.0,2016-01-08,2021-11-05,1.0013157894736842,Adequate (1-10/month),10.013157894736842,Significantly Below (<50%),10,23.6,6.7250000000000005
NCT00758992,Peripheral Blood Stem Cells Obtained From Normal Volunteers for Studying Retroviral Vector Mediated Gene Transfer Into Primitive Hematopoietic Cells and Vector Mediated Transgene Expression in Mature Hematopoietic Lineages,COMPLETED,,14.0,2006-10-01,2015-07-01,0.1333834115805947,Slow (<1/month),1.3338341158059468,Significantly Below (<50%),100,44.5,29.160000000000004
NCT04856592,Clinical Outcomes of IVUS-guided Stenting Using the Boston Scientific Vici® Venous Stent System in Treating Patients With Chronic Non-malignant Iliofemoral Vein Obstruction,WITHDRAWN,NA,0.0,2021-12-31,2023-12-31,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT07348692,Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age,RECRUITING,PHASE3,896.0,2026-01-20,2028-01-19,37.41322359396433,Good (10-50/month),200.0,Exceeded (≥100%),60,83.0,89.505
NCT02961192,Social Incentives to Improve Diabetes,COMPLETED,NA,361.0,2017-02-13,2020-01-27,10.193729128014843,Good (10-50/month),101.93729128014843,Exceeded (≥100%),100,83.9,90.56
NCT05184192,Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction,COMPLETED,PHASE2,68.0,2022-01-10,2023-08-29,3.473020134228188,Adequate (1-10/month),34.73020134228188,Significantly Below (<50%),100,55.4,62.56
NCT01367392,Effectiveness and Safety of CT-guided Needle Placement in the Liver With the Aid of the ActiSight Needle Guidance System,COMPLETED,PHASE4,20.0,2011-06-01,2012-01-01,2.8448598130841125,Adequate (1-10/month),28.448598130841123,Significantly Below (<50%),100,51.6,51.644999999999996
NCT02303392,Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma,COMPLETED,PHASE1,34.0,2015-06-09,2022-04-18,0.4131576846307386,Slow (<1/month),4.131576846307385,Significantly Below (<50%),100,47.7,42.17
NCT00005492,"Pooled Analysis of NHANES I/II--Race, Gender, and CHD",COMPLETED,,,1997-08-01,2000-07-01,,Slow (<1/month),,Significantly Below (<50%),100,43.3,27.05
NCT00645892,Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis,COMPLETED,PHASE2,32.0,2003-11-01,,,Slow (<1/month),,Significantly Below (<50%),100,42.6,25.679999999999996
NCT00215592,"Open Label, Zonegran (Zonisamide) In Partial Onset Seizures",COMPLETED,PHASE4,1000.0,2005-10-01,,,Slow (<1/month),,Significantly Below (<50%),100,80.0,87.67
NCT00716092,The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients,COMPLETED,PHASE2,121.0,2008-07-01,,,Slow (<1/month),,Significantly Below (<50%),100,49.7,46.949999999999996
NCT06296992,"Type 1 Diabetes, Exercise and Mentoring Trial",RECRUITING,NA,60.0,2025-02-01,2027-05-01,2.23003663003663,Adequate (1-10/month),22.3003663003663,Significantly Below (<50%),60,42.8,25.929999999999996
NCT05201092,A Study Investigating Lu AG06466 in Healthy Men,COMPLETED,PHASE1,6.0,2022-01-05,2022-02-19,4.058666666666666,Adequate (1-10/month),40.58666666666667,Significantly Below (<50%),100,50.5,48.515
NCT04930692,"A Prospective Single-center Cohort Study ""Preoperative Identification of Sentinel Lymph Nodes Using Contrast-enhanced CT Lymphography in Breast Cancer Patients""",UNKNOWN,NA,31.0,2022-10-01,2023-08-01,3.104078947368421,Adequate (1-10/month),31.04078947368421,Significantly Below (<50%),50,37.5,18.775
NCT00907192,Self Reported Deviations From Opioid Analgesic Prescription,COMPLETED,,201.0,2009-05-01,2012-06-01,5.428961845607809,Adequate (1-10/month),54.289618456078095,Below (50-75%),100,64.4,77.37
NCT03345992,Benefit of Clarithromycin in Patients With Severe Infections Through Modulation of the Immune System,COMPLETED,PHASE3,110.0,2017-12-15,2020-12-19,3.044,Adequate (1-10/month),30.440000000000005,Significantly Below (<50%),100,58.8,69.89999999999999
NCT03550092,Analysis of Brain Activity to Uncover Brain-behavior Relationships Related to Therapy Outcomes in Aphasia,COMPLETED,NA,23.0,2018-09-25,2023-12-31,0.36407696307852316,Slow (<1/month),3.6407696307852317,Significantly Below (<50%),100,46.8,38.440000000000005
NCT06816992,ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC,RECRUITING,PHASE1,76.0,2025-02-27,2027-05-01,2.9173266078184112,Adequate (1-10/month),29.173266078184113,Significantly Below (<50%),60,44.1,28.425
NCT06140992,PaCIFiC-CUP Classifies Cancer of Unknown Primary,RECRUITING,,120.0,2023-07-01,2025-12-31,3.9964989059080964,Adequate (1-10/month),39.96498905908096,Significantly Below (<50%),60,45.9,33.495000000000005
NCT06826092,Metformin for the Treatment of mCRC Patients Undergoing FOLFIRI Plus Target Therapy,RECRUITING,PHASE2,110.0,2022-10-31,2025-12-31,2.8940363007778735,Adequate (1-10/month),28.940363007778735,Significantly Below (<50%),60,46.8,38.440000000000005
NCT02758392,A Study to Evaluate Safety and Tolerability of JNJ-61178104 in Healthy Participants,COMPLETED,PHASE1,54.0,2016-04-01,2017-01-01,5.977309090909092,Adequate (1-10/month),59.77309090909092,Below (50-75%),100,54.3,59.62
NCT04609592,"Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery",RECRUITING,PHASE1,10.0,2021-03-17,2027-09-01,0.12903772785078424,Slow (<1/month),1.2903772785078425,Significantly Below (<50%),60,33.8,13.694999999999999
NCT04742192,"Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung Cancer",COMPLETED,,601.0,2021-03-04,2022-11-30,28.764842767295598,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT06216236,Effects of Physical Fitness Using a Kinect Interventional System,COMPLETED,NA,64.0,2024-02-03,2025-12-03,2.912047832585949,Adequate (1-10/month),29.120478325859487,Significantly Below (<50%),100,55.1,62.085
NCT07309536,"Mediterranean Diet Uptake and Nutrition on Child Health, Inflammation, and Early-life Symbiosis (MUNCHIES) Study",NOT_YET_RECRUITING,NA,30.0,2026-02-01,2027-11-01,1.4313479623824452,Adequate (1-10/month),14.31347962382445,Significantly Below (<50%),30,26.4,7.865
NCT02157636,A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma,COMPLETED,PHASE1,30.0,2014-07-15,2016-11-08,1.0781582054309329,Adequate (1-10/month),10.781582054309329,Significantly Below (<50%),100,47.4,40.98
NCT04552236,Evaluation of Liver Stiffness by Ultrasound Elastography for Predicting Early HCC Recurrence After Treatment,UNKNOWN,,100.0,2021-01-01,2022-02-01,7.686868686868687,Adequate (1-10/month),76.86868686868688,Met (75-100%),50,41.3,23.74
NCT04784936,Identification of Stroke at the Emergency Medical Dispatch Center,COMPLETED,,179.0,2010-09-01,2013-10-30,4.717541125541126,Adequate (1-10/month),47.175411255411255,Significantly Below (<50%),100,62.7,75.42
NCT07296536,Expert Consensus on the Use of Isotretinoin in Rejuvenation: A Delphi Study,ENROLLING_BY_INVITATION,,15.0,2026-01-25,2027-09-01,0.7818493150684932,Slow (<1/month),7.818493150684931,Significantly Below (<50%),55,31.0,9.985
NCT07260136,Cervical Spine Abnormalities in Down Syndrome,ACTIVE_NOT_RECRUITING,,50.0,2025-10-23,2026-12-30,3.515011547344111,Adequate (1-10/month),35.150115473441105,Significantly Below (<50%),85,47.8,42.42
NCT00905736,Influence of Microcurrent Parameters on Effectiveness in Treatment of Chronic Tennis Elbow,COMPLETED,PHASE2,24.0,2009-04-01,2009-12-01,2.9940983606557374,Adequate (1-10/month),29.940983606557374,Significantly Below (<50%),100,51.9,52.55499999999999
NCT00787436,Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using THALIDOMIDE,WITHDRAWN,PHASE3,0.0,2006-05-01,2010-01-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT06853236,Functional Incremental Stepping in Place Test (F-IST) Validation,RECRUITING,,60.0,2024-07-02,2026-02-28,3.0138613861386143,Adequate (1-10/month),30.138613861386137,Significantly Below (<50%),60,41.1,23.225
NCT00509236,Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1),COMPLETED,PHASE3,129.0,2007-10-19,2011-03-14,3.1616425120772944,Adequate (1-10/month),31.616425120772945,Significantly Below (<50%),100,60.3,72.34
NCT05485636,Degenerative Lumbar Scoliosis,UNKNOWN,,640.0,2022-08-01,2024-08-01,26.65061559507524,Good (10-50/month),200.0,Exceeded (≥100%),50,78.3,86.48
NCT01346436,Value of Robotic Rectopexy for the Treatment of Complex Pelvic Floor Dysfunction,UNKNOWN,PHASE4,50.0,2011-04-01,2020-05-01,0.45871006630500305,Slow (<1/month),4.58710066305003,Significantly Below (<50%),50,34.0,14.02
NCT01423136,Remote Electrocardiographic (ECG) ST-Monitoring (PROSE 3)in Post-op Patients,COMPLETED,,89.0,2010-10-01,2012-10-01,3.706101231190151,Adequate (1-10/month),37.06101231190151,Significantly Below (<50%),100,55.5,62.71
NCT04508036,Ductus Arteriosus Closure and D-Dimer and Fibrinogen Levels,UNKNOWN,,100.0,2019-03-14,2023-12-31,1.7364517969195665,Adequate (1-10/month),17.364517969195667,Significantly Below (<50%),50,41.3,23.74
NCT05750836,Assessment and Prevention of Caregiver Burden in Oncology,NOT_YET_RECRUITING,NA,250.0,2023-07-01,2027-06-01,5.317959468902865,Adequate (1-10/month),53.179594689028654,Below (50-75%),30,49.0,45.61
NCT01076036,CorPath™ 200: Robotically-Assisted Percutaneous Coronary Intervention (PCI),COMPLETED,PHASE2,8.0,2010-02-01,2010-05-01,2.736179775280899,Adequate (1-10/month),27.361797752808986,Significantly Below (<50%),100,50.6,48.705
NCT02442336,A Web-Based Multimedia Intervention for Head and Neck Cancer Patients,COMPLETED,NA,80.0,2012-06-15,2020-11-18,0.7911630929174789,Slow (<1/month),7.91163092917479,Significantly Below (<50%),100,51.4,50.92
NCT02106936,Depotentiation in People With Focal Hand Dystonia,TERMINATED,,6.0,2014-03-05,2017-06-20,0.1518204488778055,Slow (<1/month),1.5182044887780548,Significantly Below (<50%),10,16.8,2.715
NCT02337036,Pharmacokinetic of Tacrolimus in Paediatric Liver Transplant Patients,UNKNOWN,NA,80.0,2013-12-01,2020-12-01,0.9523660539694956,Slow (<1/month),9.523660539694955,Significantly Below (<50%),50,36.4,17.14
NCT01316536,Music Therapy is Associated With Decreased Pain and Agitation in Intubated ICU Patients,TERMINATED,NA,5.0,2010-04-01,2013-12-01,0.11358208955223882,Slow (<1/month),1.135820895522388,Significantly Below (<50%),10,18.4,3.855
NCT03622736,Influence of the Radiological Stage on the Efficiency of Viscosupplementation in Basal Thumb Arthritis,COMPLETED,,122.0,2016-03-01,2017-08-01,7.16926640926641,Adequate (1-10/month),71.6926640926641,Below (50-75%),100,58.1,68.595
NCT06858436,SGLT2 Inhibitor Utilization Re-perfusion Therapy,NOT_YET_RECRUITING,PHASE4,150.0,2026-01-23,2027-10-31,7.06811145510836,Adequate (1-10/month),70.6811145510836,Below (50-75%),30,41.0,23.01
NCT04933136,Radial Artery Occlusion and Dual Artery Hemostasis After Transradial Approach.,RECRUITING,,500.0,2022-12-12,2025-12-31,13.650224215246636,Good (10-50/month),136.50224215246638,Exceeded (≥100%),60,81.3,88.58
NCT06021236,Efficacy of a Mindfulness-Based Intervention in Patients With Cardiovascular Implantable Electronic Device,ENROLLING_BY_INVITATION,NA,68.0,2024-01-01,2025-12-30,2.8393964334705077,Adequate (1-10/month),28.393964334705075,Significantly Below (<50%),55,41.9,24.585
NCT02282436,Substudy : Patients With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease,UNKNOWN,,20.0,2012-05-01,2018-05-01,0.2778639890460977,Slow (<1/month),2.7786398904609775,Significantly Below (<50%),50,29.9,9.07
NCT03634436,The PK/PD Study of A Single Subcutaneous Injection of SHR-1209 in Healthy Subjects,COMPLETED,PHASE1,32.0,2018-08-30,2019-05-28,3.5943911439114395,Adequate (1-10/month),35.94391143911439,Significantly Below (<50%),100,52.6,54.684999999999995
NCT01662336,Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program,COMPLETED,,173.0,2012-06-01,2016-06-01,3.6044626967830253,Adequate (1-10/month),36.044626967830254,Significantly Below (<50%),100,62.2,74.74499999999999
NCT04812236,Clinical Study on Wuling Powder in Treating Metabolic Syndrome of Spleen Deficiency and Dampness,UNKNOWN,PHASE4,320.0,2021-04-01,2023-05-01,12.816842105263158,Good (10-50/month),128.16842105263157,Exceeded (≥100%),50,65.6,78.56
NCT01329536,The Occurrence of the ApoE4 Allele in Agitated In-Patients With Late-Onset Alzheimer's Disease,COMPLETED,,50.0,2010-12-01,2011-10-01,5.006578947368421,Adequate (1-10/month),50.065789473684205,Below (50-75%),100,52.3,53.515
NCT03825211,Continuous Versus Discontinuous Suture in the Perineals Lesions,COMPLETED,NA,134.0,2016-11-01,2018-12-31,5.163240506329115,Adequate (1-10/month),51.632405063291145,Below (50-75%),100,60.7,72.89999999999999
NCT03940911,Fatigue and Skeletal Muscle Impact in Severe Axial Spondyloarthritis,NOT_YET_RECRUITING,NA,122.0,2025-06-01,2029-06-01,2.5418754277891855,Adequate (1-10/month),25.418754277891853,Significantly Below (<50%),30,38.8,20.244999999999997
NCT04308811,Autologous Platelet-Rich Plasma in the Management of Asherman Syndrome,COMPLETED,PHASE2,60.0,2019-08-10,2020-02-20,9.414432989690722,Adequate (1-10/month),94.14432989690722,Met (75-100%),100,59.8,71.61
NCT04746911,Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216),COMPLETED,PHASE2,10.0,2021-03-01,2022-05-11,0.6981651376146789,Slow (<1/month),6.9816513761467895,Significantly Below (<50%),100,45.8,33.03
NCT00902811,Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria,UNKNOWN,PHASE4,600.0,2008-12-01,2009-12-01,50.038356164383565,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT04902911,Point of Care Evaluation of Novir 2019-nCoV Immunoglobulin G/ Immunoglobulin M (IgG/IgM) Antibody Test (Collodial Gold),TERMINATED,,91.0,2021-04-13,2022-08-17,5.6416293279022405,Adequate (1-10/month),56.41629327902241,Below (50-75%),10,28.6,8.58
NCT02250911,Care For The Cancer Caregiver: A Meaning-Based Workshop To Help Manage Caregiver Burden,COMPLETED,NA,88.0,2014-09-01,2018-08-01,1.8732307692307693,Adequate (1-10/month),18.732307692307696,Significantly Below (<50%),100,57.0,66.12
NCT03908411,The Effect of Paratracheal Pressure on the Glottic View,COMPLETED,NA,140.0,2019-09-05,2020-02-28,24.213636363636365,Good (10-50/month),200.0,Exceeded (≥100%),100,66.2,79.2
NCT04466111,"Observational, Post Market Study in Treating Chronic Upper Extremity Limb Pain",COMPLETED,,58.0,2020-09-08,2023-03-09,1.9358771929824563,Adequate (1-10/month),19.358771929824563,Significantly Below (<50%),100,53.0,55.80500000000001
NCT04602611,Impact Of Nurse Navigation Program on Outcomes in Patients With GI Cancers,COMPLETED,NA,228.0,2020-11-03,2023-08-10,6.87160396039604,Adequate (1-10/month),68.7160396039604,Below (50-75%),100,68.2,80.77
NCT02081911,Total Knee Arthroplasty Utilizing Adductor Canal Block: Effect on Quadriceps Sparing,TERMINATED,NA,33.0,2014-02-01,2015-12-01,1.5037724550898204,Adequate (1-10/month),15.0377245508982,Significantly Below (<50%),10,20.6,5.965
NCT02386111,A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma,TERMINATED,PHASE1,17.0,2015-05-01,2017-11-03,0.5643184296619411,Slow (<1/month),5.6431842966194115,Significantly Below (<50%),10,19.4,5.2299999999999995
NCT05667311,Autonomic Function in Patients With COPD,COMPLETED,,26.0,2016-07-01,2018-12-31,0.866856516976999,Slow (<1/month),8.66856516976999,Significantly Below (<50%),100,45.4,31.455
NCT04423211,Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging,RECRUITING,PHASE3,804.0,2020-10-08,2032-12-31,5.478791134989926,Adequate (1-10/month),54.78791134989927,Below (50-75%),60,78.0,86.075
NCT01035411,AZD9668 Relative Bioavailability,COMPLETED,PHASE1,15.0,2009-11-01,2009-12-01,15.0,Good (10-50/month),150.0,Exceeded (≥100%),100,56.2,64.21
NCT03241511,Novel PAradigm to Improve Inflammatory Burden in ESRD (rePAIR): A Pilot and Feasibility Randomized Controlled Trial,COMPLETED,NA,66.0,2017-11-07,2020-12-01,1.7937857142857143,Adequate (1-10/month),17.937857142857144,Significantly Below (<50%),100,55.3,62.36000000000001
NCT04628871,"Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX",ACTIVE_NOT_RECRUITING,,13.0,2020-11-03,2030-01-01,0.11826658696951585,Slow (<1/month),1.1826658696951586,Significantly Below (<50%),85,39.9,21.695
NCT06140771,A Clinical Study to Assess the Gingivitis Effects of Various Dentifrices,COMPLETED,NA,115.0,2021-10-20,2022-02-06,32.11559633027523,Good (10-50/month),200.0,Exceeded (≥100%),100,64.2,77.18
NCT02301871,The Effect of Soft Tissue Mobilization in Myofascial Neck Pain,COMPLETED,NA,33.0,2013-07-01,2014-05-01,3.304342105263158,Adequate (1-10/month),33.04342105263158,Significantly Below (<50%),100,52.6,54.684999999999995
NCT03353571,"A Prospective Evaluation of the Catheter Science C3 ""Umbrella Catheter.""",UNKNOWN,NA,50.0,2017-08-31,2018-03-01,8.362637362637363,Adequate (1-10/month),83.62637362637363,Met (75-100%),50,44.0,28.249999999999996
NCT01646671,Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive Patients,COMPLETED,PHASE3,35.0,2012-07-01,2013-02-01,4.955348837209303,Adequate (1-10/month),49.55348837209302,Significantly Below (<50%),100,52.8,55.31
NCT04949971,A Comparative Study of High and Low Tidal Volume in Preventing Hypoxemia in Patients With Mechanical Ventilation After Cervical Spinal Cord Injury,UNKNOWN,,50.0,2021-04-03,2022-12-31,2.389324960753532,Adequate (1-10/month),23.89324960753532,Significantly Below (<50%),50,37.3,18.35
NCT05749471,Sex Dysfunction and Chronic Venous Disease,UNKNOWN,,600.0,2019-01-01,2023-04-30,11.559493670886077,Good (10-50/month),115.59493670886076,Exceeded (≥100%),50,78.3,86.48
NCT01654471,Validation of the Korean Version of the Walking Impairment Questionnaire in Patients With Peripheral Arterial Disease,COMPLETED,,47.0,2012-08-01,2014-09-01,1.88,Adequate (1-10/month),18.8,Significantly Below (<50%),100,52.1,53.03
NCT00373971,"Preventing Loss of Weight, Fat Free Mass and Activities of Daily Living",COMPLETED,NA,252.0,1995-11-01,1998-07-01,7.883741007194245,Adequate (1-10/month),78.83741007194246,Met (75-100%),100,70.2,81.99499999999999
NCT02217371,Role of Circadian and Homeostatic Systems in the Regulation of Wakefulness in Adult Patients With Attention Deficit Disorder With or Without Hyperactivity,COMPLETED,NA,19.0,2014-09-02,2017-08-01,0.5435714285714286,Slow (<1/month),5.435714285714285,Significantly Below (<50%),100,46.5,36.815
NCT01051271,Prophylaxis Against Metoclopramide-Induced Akathisia,COMPLETED,NA,225.0,2009-07-01,2009-11-01,55.68292682926829,Excellent (>50/month),200.0,Exceeded (≥100%),100,78.0,86.075
NCT01170871,Ixabepilone and Pemetrexed/Solid Tumors,WITHDRAWN,PHASE1,0.0,,,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT05169671,"Safety, Tolerability, and Pharmacokinetics Study of ATH-1020",COMPLETED,PHASE1,32.0,2022-03-30,2022-09-09,5.975950920245399,Adequate (1-10/month),59.759509202454,Below (50-75%),100,52.6,54.684999999999995
NCT05684744,Roflumilast Versus Methotrexate in Psoriasis,COMPLETED,PHASE2,30.0,2023-01-09,2023-05-14,7.3056,Adequate (1-10/month),73.056,Below (50-75%),100,52.4,53.949999999999996
NCT05075044,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People Aged ≥18 Years With HIV Infected,UNKNOWN,PHASE4,400.0,2021-10-08,2022-12-30,27.17857142857143,Good (10-50/month),200.0,Exceeded (≥100%),50,72.0,82.92
NCT01073644,Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients,TERMINATED,,3.0,2010-02-01,2010-04-01,1.5477966101694915,Adequate (1-10/month),15.477966101694918,Significantly Below (<50%),10,16.6,2.645
NCT02465944,A Pilot Study of FFP104 in Subjects With Crohn's Disease,UNKNOWN,PHASE1,24.0,2016-01-01,2017-12-01,1.0436571428571428,Adequate (1-10/month),10.436571428571428,Significantly Below (<50%),50,31.9,11.295
NCT01333644,The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk,COMPLETED,,270.0,2010-04-01,2014-12-01,4.8204105571847515,Adequate (1-10/month),48.20410557184751,Significantly Below (<50%),100,69.9,81.83
NCT01230944,Conventional Nissen Fundoplication Versus Laparoscopic Nissen Fundoplication,COMPLETED,NA,110.0,2004-12-01,2009-08-01,1.9650234741784038,Adequate (1-10/month),19.65023474178404,Significantly Below (<50%),100,58.8,69.89999999999999
NCT06467344,Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR),RECRUITING,PHASE1,15.0,2024-06-11,2030-12-01,0.19314720812182742,Slow (<1/month),1.9314720812182742,Significantly Below (<50%),60,34.2,14.305000000000001
NCT06615544,Clinical Evaluation of a New Dual-cure Universal Adhesive,ACTIVE_NOT_RECRUITING,NA,45.0,2024-11-04,2031-04-01,0.5856348867037195,Slow (<1/month),5.856348867037196,Significantly Below (<50%),85,44.1,28.425
NCT05868044,REsponse to Combined SONS and ONS in Chronic Cluster HeadachE,ACTIVE_NOT_RECRUITING,NA,5.0,2023-05-02,2026-04-30,0.13912248628884827,Slow (<1/month),1.3912248628884827,Significantly Below (<50%),85,40.9,22.82
NCT05791344,Intra-procedural ECG Changes During TAVR,TERMINATED,,43.0,2023-06-21,2024-12-31,2.3415384615384616,Adequate (1-10/month),23.415384615384617,Significantly Below (<50%),10,24.8,7.06
NCT05050344,Moya Moya Syndrome With or Withtout Sickle Cell Disease,UNKNOWN,,50.0,2021-05-01,2022-12-01,2.6286701208981005,Adequate (1-10/month),26.286701208981,Significantly Below (<50%),50,37.3,18.35
NCT04323644,Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg),UNKNOWN,,1000.0,2020-01-01,2020-09-30,111.5018315018315,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT02598544,Endocrine Regulation of Lipolysis in Obesity and Diabetes,COMPLETED,NA,55.0,2013-05-01,2015-04-01,2.391714285714286,Adequate (1-10/month),23.917142857142856,Significantly Below (<50%),100,54.4,59.89
NCT02861144,The Hanapū Study: Incentivized Partnerships to Reduce Diabetes Disparities,COMPLETED,NA,107.0,2011-02-01,2013-11-01,3.2441035856573706,Adequate (1-10/month),32.441035856573706,Significantly Below (<50%),100,58.6,69.51
NCT00826644,Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient,COMPLETED,PHASE3,147.0,2009-01-01,2013-02-01,2.9991152815013407,Adequate (1-10/month),29.991152815013404,Significantly Below (<50%),100,61.8,74.19
NCT05479344,My Journey: A Brief Contextual Behavioural Intervention Based on Meaning and Connection,COMPLETED,NA,106.0,2022-08-15,2023-04-15,13.278353909465022,Good (10-50/month),132.78353909465022,Exceeded (≥100%),100,63.5,76.465
NCT02018744,Nellix® Registry Study: EVAS-Global,UNKNOWN,,300.0,2013-10-01,2022-06-30,2.859110832811522,Adequate (1-10/month),28.591108328115215,Significantly Below (<50%),50,57.3,66.74
NCT02062944,SRL (Sirolimus) Withdrawal,COMPLETED,NA,21.0,2013-03-01,2020-07-01,0.23861142217245243,Slow (<1/month),2.386114221724524,Significantly Below (<50%),100,46.7,37.895
NCT03373344,Remediation of Emotional Processing Deficits in MS,COMPLETED,NA,39.0,2016-11-01,2020-03-01,0.9762828947368422,Slow (<1/month),9.76282894736842,Significantly Below (<50%),100,48.1,43.275000000000006
NCT02192944,Comparison of the ECG Effects Related to Pharmacokinetic Profile of Chloroquine and Piperaquine,COMPLETED,PHASE4,16.0,2014-07-01,2015-09-01,1.140608899297424,Adequate (1-10/month),11.40608899297424,Significantly Below (<50%),100,46.3,35.66
NCT04855344,Deep Brain Stimulation Therapy and Intestinal Microbiota,UNKNOWN,,30.0,2021-04-15,2022-12-31,1.46112,Adequate (1-10/month),14.611199999999998,Significantly Below (<50%),50,30.7,9.585
NCT02972944,Laparoscopic Cholecystectomy or Conservative Treatment in the Acute Cholecystitis of Elderly Patients,UNKNOWN,NA,200.0,2016-10-01,2021-12-01,3.22628510863805,Adequate (1-10/month),32.2628510863805,Significantly Below (<50%),50,51.0,49.714999999999996
NCT01921244,Shared Decision Making to Improve Care and Outcomes for Children With Autism,COMPLETED,NA,142.0,2013-08-01,2015-07-01,6.183805436337625,Adequate (1-10/month),61.83805436337626,Below (50-75%),100,61.4,73.735
NCT05974644,Southeastern ATTR Amyloidosis Consortium: SEATTRAC Family Registry,NOT_YET_RECRUITING,,1000.0,2026-02-01,2030-12-01,17.256235827664398,Good (10-50/month),172.562358276644,Exceeded (≥100%),30,72.3,83.065
NCT05228444,Managing Sleep-wake Disruption Due to Hospitalisation: the Circadian Care Project,UNKNOWN,NA,50.0,2020-10-28,2023-01-28,1.8515815085158152,Adequate (1-10/month),18.515815085158152,Significantly Below (<50%),50,39.0,20.505000000000003
NCT03801044,Lung Ultrasound in PD Patients,COMPLETED,,23.0,2018-05-01,2018-09-01,5.692032520325203,Adequate (1-10/month),56.920325203252034,Below (50-75%),100,50.2,48.04
NCT05890144,"RCT of Intensive, Brief, and Control Indigenous Cultural Safety Training Interventions for Health Care Providers",COMPLETED,NA,58.0,2018-03-01,2022-04-05,1.1801604278074866,Adequate (1-10/month),11.801604278074867,Significantly Below (<50%),100,49.6,46.785
NCT02896634,Analysis by Clinical Mass Spectrometry of Bloodstains,COMPLETED,,160.0,2015-10-01,2018-09-01,4.5688555347091935,Adequate (1-10/month),45.688555347091935,Significantly Below (<50%),100,61.1,73.31
NCT06124534,Bilateral Occipital Nerve Field Stimulation for the Treatment of dtCCH,SUSPENDED,NA,10.0,2023-10-19,2025-03-30,0.5765151515151515,Slow (<1/month),5.765151515151516,Significantly Below (<50%),20,21.8,6.205
NCT05041634,Physical Activity for People With Behavioral Diagnoses,COMPLETED,NA,8.0,2019-07-01,2019-12-16,1.4495238095238097,Adequate (1-10/month),14.495238095238097,Significantly Below (<50%),100,45.6,32.08
NCT03194334,"Creatine, Carnitine and Carnosine in Vegetarians",COMPLETED,NA,40.0,2012-12-01,2013-06-01,6.69010989010989,Adequate (1-10/month),66.9010989010989,Below (50-75%),100,53.2,56.665
NCT02914834,Acupuncture for Individuals With Stable Angina,TERMINATED,NA,27.0,2019-05-15,2020-03-16,2.6858823529411766,Adequate (1-10/month),26.85882352941176,Significantly Below (<50%),10,25.2,7.359999999999999
NCT06601634,Predictors of Axial Pain Improvement After Anterior Cervical Discectomy and Fusion,RECRUITING,,60.0,2024-11-17,2027-12-01,1.6468890892696122,Adequate (1-10/month),16.468890892696123,Significantly Below (<50%),60,36.1,16.665
NCT06371534,A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults,RECRUITING,PHASE1,228.0,2024-04-12,2025-04-01,19.60542372881356,Good (10-50/month),196.0542372881356,Exceeded (≥100%),60,61.2,73.43499999999999
NCT03733834,SD vs. NSD Therapy in Elderly AML,UNKNOWN,,1000.0,2018-10-08,2021-09-01,28.74409820585458,Good (10-50/month),200.0,Exceeded (≥100%),50,78.3,86.48
NCT01738334,Effects Of The Mindfulness Meditation Practices On Cognition,COMPLETED,PHASE3,40.0,2012-02-01,2012-05-01,13.52888888888889,Good (10-50/month),135.2888888888889,Exceeded (≥100%),100,58.2,68.795
NCT06647134,A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy,RECRUITING,,20.0,2024-09-11,2028-03-31,0.4693909020817271,Slow (<1/month),4.693909020817271,Significantly Below (<50%),60,32.9,12.53
NCT06985134,Comparative Efficacy and Safety of Thalidomide and Sulfasalazine in Moderate to Severe Ankylosing Spondylitis: A Real-World Study From Bangladesh,COMPLETED,PHASE3,93.0,2017-01-01,2018-12-31,3.883292181069959,Adequate (1-10/month),38.83292181069959,Significantly Below (<50%),100,57.4,67.05499999999999
NCT05748834,Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer,RECRUITING,PHASE2,36.0,2023-07-24,2026-07-01,1.021286113699907,Adequate (1-10/month),10.212861136999068,Significantly Below (<50%),60,35.9,16.445
NCT05887934,Bone-Lead Level Associations With Brain and Mental Health,ENROLLING_BY_INVITATION,,500.0,2023-08-17,2027-05-01,11.249076127124908,Good (10-50/month),112.49076127124908,Exceeded (≥100%),55,79.8,87.27000000000001
NCT06652334,Comparison of Spinal Anesthesia and Erector Spinae Plane Block in Critically Adult Patients Undergoing Femur Surgery,COMPLETED,,40.0,2024-10-20,2025-06-01,5.435714285714286,Adequate (1-10/month),54.35714285714286,Below (50-75%),100,51.5,51.245
NCT00453934,Patient Preference of h-Patch vs. Pen or Needle/Syringe as Insulin Administration Device,TERMINATED,PHASE4,11.0,2007-05-01,2007-09-01,2.7222764227642275,Adequate (1-10/month),27.222764227642276,Significantly Below (<50%),10,23.9,6.78
NCT00197834,Study of Depakote for Behavioral and Psychological Symptoms in Dementia,UNKNOWN,PHASE1,20.0,2004-03-01,,,Slow (<1/month),,Significantly Below (<50%),50,26.6,8.01
NCT05211934,Relationship Between Postoperative Delirium and Heart Function in Valvular Surgery,UNKNOWN,,300.0,2022-01-01,2024-07-01,10.013157894736842,Good (10-50/month),100.13157894736844,Exceeded (≥100%),50,62.3,74.94
NCT00837434,Anti-TNF Agents for the Treatment of Rheumatoid Arthritis,COMPLETED,PHASE4,63.0,2009-03-01,2014-01-01,1.0852971137521223,Adequate (1-10/month),10.852971137521223,Significantly Below (<50%),100,50.0,47.675
NCT01603134,Bioequivalence Study of Allopurinol 300 mg Tablets USP Under Fasting Condition,COMPLETED,PHASE1,32.0,2007-11-01,2008-04-01,6.408421052631579,Adequate (1-10/month),64.08421052631579,Below (50-75%),100,52.6,54.684999999999995
NCT04220034,Autoantibodies Prevalence During Checkpoint Inhibitor Treatment,COMPLETED,,183.0,2020-01-15,2025-11-28,2.5981902985074625,Adequate (1-10/month),25.981902985074623,Significantly Below (<50%),100,63.0,75.845
NCT06554834,Effects of Osteopathic Technique on Autonomic Nervous System Activity,RECRUITING,NA,109.0,2024-06-20,2024-11-10,23.202517482517482,Good (10-50/month),200.0,Exceeded (≥100%),60,51.7,51.94
NCT03724734,Trial of Adaptive Deep Brain Stimulation,UNKNOWN,NA,15.0,2019-10-01,2020-05-01,2.143661971830986,Adequate (1-10/month),21.43661971830986,Significantly Below (<50%),50,36.2,16.84
NCT04871334,"Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma",UNKNOWN,PHASE1,76.0,2021-02-07,2022-12-31,3.343121387283237,Adequate (1-10/month),33.43121387283237,Significantly Below (<50%),50,41.1,23.225
NCT01993264,Fetal Cardiac Strain Imaging Research,COMPLETED,,60.0,2013-10-01,2020-11-03,0.7051737451737452,Slow (<1/month),7.051737451737453,Significantly Below (<50%),100,48.1,43.275000000000006
NCT02413164,Multimodal Physical Therapy Program in Schizophrenia,COMPLETED,NA,50.0,2017-03-01,2018-05-01,3.5727699530516435,Adequate (1-10/month),35.72769953051643,Significantly Below (<50%),100,54.0,58.72500000000001
NCT03685864,Suture Embedding Acupuncture for Chronic Low Back Pain,COMPLETED,NA,51.0,2018-10-12,2023-12-13,0.8222669491525424,Slow (<1/month),8.222669491525425,Significantly Below (<50%),100,49.1,45.83
NCT05343364,"A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease",COMPLETED,PHASE1,24.0,2022-05-09,2023-06-13,1.8264,Adequate (1-10/month),18.264,Significantly Below (<50%),100,51.9,52.55499999999999
NCT01533064,Response of Psychiatric Outpatients to the Great East Japan Earthquake,COMPLETED,,328.0,2011-03-01,2011-05-01,163.6773770491803,Excellent (>50/month),200.0,Exceeded (≥100%),100,84.6,90.765
NCT05388864,Building Resilient Families,RECRUITING,NA,340.0,2022-05-24,2027-05-01,5.740210759844704,Adequate (1-10/month),57.40210759844704,Below (50-75%),60,65.2,78.23
NCT03653364,"Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms",COMPLETED,PHASE3,49.0,2019-01-23,2023-04-03,0.9742390594382757,Slow (<1/month),9.742390594382758,Significantly Below (<50%),100,48.9,45.4
NCT06335264,Screening for Heart Failure Using a Multimodal Wearable Device,COMPLETED,,56.0,2024-01-15,2025-08-31,2.86976430976431,Adequate (1-10/month),28.6976430976431,Significantly Below (<50%),100,52.8,55.31
NCT00860964,A Study of Prevention and Treatment of Postmenopausal Osteoporosis in Chinese Women,COMPLETED,PHASE4,221.0,1998-02-01,2006-12-01,2.0859658914728683,Adequate (1-10/month),20.859658914728683,Significantly Below (<50%),100,67.7,80.22
NCT03514264,Clinical Applicability of PBSCIMMO as a Single Material in Endodontic Obturations,UNKNOWN,NA,70.0,2017-11-09,2019-02-26,4.49535864978903,Adequate (1-10/month),44.9535864978903,Significantly Below (<50%),50,40.6,22.575
NCT04968964,"Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing",RECRUITING,NA,55.0,2022-03-07,2029-09-30,0.6057163531114328,Slow (<1/month),6.057163531114327,Significantly Below (<50%),60,37.4,18.62
NCT03189264,Percutaneous Nephrolithotomy for Treatment of Kidney Stones Greater Than 2 cm,UNKNOWN,NA,70.0,2017-05-10,2017-09-30,14.900699300699301,Good (10-50/month),149.006993006993,Exceeded (≥100%),50,45.6,32.08
NCT06753864,"A Single-center, Open, Randomized, Single-dose, Cross-over Bioequivalence Study to Evaluate the Effects of the Test Formulation Abalparatide Injection and the Reference Formulation Abalparatide Injection (Tymlos®) in Healthy Adult Subjects",NOT_YET_RECRUITING,PHASE1,32.0,2025-01-02,2025-05-01,8.185546218487396,Adequate (1-10/month),81.85546218487396,Met (75-100%),30,31.6,10.905
NCT05592964,The Effect of Oral Fluid Administration 1 Hour Before Surgery on Preoperative Anxiety and Gastric Volume in Pediatrics,COMPLETED,,90.0,2022-03-04,2022-08-30,15.305027932960895,Good (10-50/month),153.05027932960894,Exceeded (≥100%),100,60.5,72.685
NCT04771364,"Impact of ""ASAP"" Multidisciplinary Optimization Care Protocol on Clinical Outcome in Elderly Inpatients for Hip Fracture",COMPLETED,,800.0,2017-01-01,2022-12-31,11.119634703196349,Good (10-50/month),111.19634703196348,Exceeded (≥100%),100,93.3,94.325
NCT07193264,Impact of Chronic and Acute Caffeine Intake on the Hematopoietic System,NOT_YET_RECRUITING,NA,100.0,2025-10-01,2028-06-01,3.1252566735112937,Adequate (1-10/month),31.252566735112943,Significantly Below (<50%),30,37.0,17.955
NCT05251064,Orthopaedic Surgical Wound Closure Comparison Study,COMPLETED,NA,56.0,2019-04-23,2022-01-20,1.6995413758723827,Adequate (1-10/month),16.995413758723828,Significantly Below (<50%),100,54.5,60.12
NCT05231564,Hybrid Training and Middle Age,COMPLETED,NA,15.0,2019-11-01,2020-02-01,4.96304347826087,Adequate (1-10/month),49.6304347826087,Significantly Below (<50%),100,51.2,50.375
NCT04931264,Clinical Trial of YuWell YE660D Blood Pressure Monitor in General Population According to the ISO 81060-2:2018,COMPLETED,NA,92.0,2021-09-01,2022-03-08,14.896170212765957,Good (10-50/month),148.96170212765958,Exceeded (≥100%),100,62.4,75.095
NCT07259564,A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD),NOT_YET_RECRUITING,PHASE2,120.0,2025-12-19,2026-06-09,21.23720930232558,Good (10-50/month),200.0,Exceeded (≥100%),30,43.6,27.54
NCT01820364,LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma,TERMINATED,PHASE2,15.0,2013-11-01,2015-03-01,0.9414432989690722,Slow (<1/month),9.414432989690722,Significantly Below (<50%),10,19.2,5.055
NCT03207464,Molecular Imaging of NET Using [C-11]MRB-PET in MS,RECRUITING,PHASE1,19.0,2017-10-10,2026-12-31,0.17167111902641732,Slow (<1/month),1.7167111902641734,Significantly Below (<50%),60,34.5,14.52
NCT05691764,Effect of Cyclosporine and Remote Ischemic Preconditioning in Reperfusion Ischemia Injury on Tetralogy Fallot Patients With Correction Surgery,COMPLETED,NA,40.0,2020-09-01,2022-09-01,1.6679452054794521,Adequate (1-10/month),16.67945205479452,Significantly Below (<50%),100,53.2,56.665
NCT01885364,Esmolol Pretreatment on Pain During Injection of Propofol,COMPLETED,NA,120.0,2015-06-01,2015-12-01,19.96065573770492,Good (10-50/month),199.60655737704917,Exceeded (≥100%),100,64.6,77.59
NCT05871164,"Longitudinal, Prospective, French, Multicenter Cohort Study on Pancreatic Radiofrequency",RECRUITING,,200.0,2023-06-12,2030-05-01,2.4206759443339965,Adequate (1-10/month),24.206759443339962,Significantly Below (<50%),60,52.3,53.515
NCT01133964,Dairy Proteins and Postprandial Appetite Regulation and Energy Expenditure,COMPLETED,NA,22.0,2008-10-01,2009-12-01,1.5720187793427232,Adequate (1-10/month),15.720187793427232,Significantly Below (<50%),100,46.8,38.440000000000005
NCT01253564,A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases,COMPLETED,PHASE2,24.0,2010-11-22,2012-03-14,1.5283682008368202,Adequate (1-10/month),15.283682008368201,Significantly Below (<50%),100,46.9,38.96
NCT04262609,Faecal Incontinence in Prostate Cancer Survivors Treated Whith Radiotherapy,ACTIVE_NOT_RECRUITING,,200.0,2019-07-01,2025-12-01,2.596162046908316,Adequate (1-10/month),25.961620469083158,Significantly Below (<50%),85,59.8,71.61
NCT02813109,Urine Biomarkers for Renal Function Monitoring in Preterm Infants,COMPLETED,,83.0,2016-06-01,2017-03-02,9.22087591240876,Adequate (1-10/month),92.20875912408759,Met (75-100%),100,60.0,71.97
NCT06385509,A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months,ACTIVE_NOT_RECRUITING,PHASE4,110.0,2024-05-10,2026-03-01,5.073333333333333,Adequate (1-10/month),50.73333333333333,Below (50-75%),85,54.3,59.62
NCT04312009,Losartan for Patients With COVID-19 Requiring Hospitalization,COMPLETED,PHASE2,205.0,2020-04-13,2021-02-01,21.22517006802721,Good (10-50/month),200.0,Exceeded (≥100%),100,71.4,82.695
NCT02694809,The PROMISE Study: Duavee in Women With DCIS,COMPLETED,PHASE2,142.0,2017-01-01,2024-06-19,1.5856493030080705,Adequate (1-10/month),15.856493030080705,Significantly Below (<50%),100,56.4,64.88000000000001
NCT01861509,BP-C1 in Metastatic Breast Cancer Patients,COMPLETED,PHASE1,10.0,2014-01-19,2016-01-20,0.41641586867305064,Slow (<1/month),4.164158686730506,Significantly Below (<50%),100,45.8,33.03
NCT04458909,Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer,TERMINATED,PHASE3,15.0,2020-12-09,2023-08-15,0.46639427987742593,Slow (<1/month),4.663942798774259,Significantly Below (<50%),10,19.2,5.055
NCT02581709,An Intervention Programme to Reduce Cognitive Impairment Due to Cancer,TERMINATED,NA,15.0,2016-05-01,2017-10-01,0.8814671814671815,Slow (<1/month),8.814671814671815,Significantly Below (<50%),10,19.2,5.055
NCT04261309,BACk Pain in Elders in Norway (BACE-N),COMPLETED,,452.0,2017-01-15,2022-03-15,7.299140583554377,Adequate (1-10/month),72.99140583554376,Below (50-75%),100,84.5,90.745
NCT02551809,"Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients",COMPLETED,PHASE2,43.0,2015-10-01,2018-08-01,1.2646570048309178,Adequate (1-10/month),12.646570048309178,Significantly Below (<50%),100,48.4,44.22
NCT01952509,A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) Treatment in Patients With Rheumatoid Arthritis,COMPLETED,,169.0,2013-10-01,2016-09-01,4.825853658536586,Adequate (1-10/month),48.25853658536586,Significantly Below (<50%),100,61.9,74.265
NCT01127009,"Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia",COMPLETED,PHASE1,3.0,2010-07-01,2014-05-01,0.06522857142857143,Slow (<1/month),0.6522857142857142,Significantly Below (<50%),100,45.2,30.830000000000002
NCT04520009,EHR Embedded Comparative Effectiveness Studies--CPS,COMPLETED,NA,37.0,2020-10-23,2021-10-27,3.0522493224932252,Adequate (1-10/month),30.522493224932255,Significantly Below (<50%),100,53.0,55.80500000000001
NCT01231009,The Role of Corticosteroids and Vestibular Exercises in Recovery of Vestibular Neuritis,UNKNOWN,EARLY_PHASE1,40.0,2010-01-01,2013-01-01,1.110948905109489,Adequate (1-10/month),11.10948905109489,Significantly Below (<50%),50,33.2,12.989999999999998
NCT04683809,Effects of a Telerehabilitation Approach in Children With Cystic Fibrosis,UNKNOWN,NA,30.0,2021-01-01,2021-06-01,6.047682119205298,Adequate (1-10/month),60.476821192052974,Below (50-75%),50,37.4,18.62
NCT00883909,ARI103094-Follow-Up Study for REDUCE Study Subjects,COMPLETED,,2795.0,2009-04-09,2010-12-29,135.26200317965024,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT00805909,NI-0401 in Patients With Acute Renal Allograft Rejection,COMPLETED,PHASE1,12.0,2007-08-01,2009-01-01,0.7038150289017341,Slow (<1/month),7.0381502890173415,Significantly Below (<50%),100,46.0,34.1
NCT01328899,Feasibility Study of PneumRx's Lung Volume Reduction Coil (LVRC),COMPLETED,PHASE1,60.0,2009-12-01,2013-01-01,1.6205856255545699,Adequate (1-10/month),16.205856255545697,Significantly Below (<50%),100,49.8,47.17
NCT02350699,Control Study of Nautilus BrainPulse for the Detection of Concussion,COMPLETED,,22.0,2015-01-01,2015-05-01,5.580666666666667,Adequate (1-10/month),55.80666666666667,Below (50-75%),100,50.1,47.89
NCT03475199,Evaluation of Personalised Support Program Effectiveness in Sperm Quality Improvement,UNKNOWN,NA,75.0,2018-02-13,2019-12-01,3.4801829268292686,Adequate (1-10/month),34.801829268292686,Significantly Below (<50%),50,41.0,23.01
NCT02218099,"A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease",COMPLETED,PHASE1,55.0,2013-09-16,2014-09-09,4.676536312849162,Adequate (1-10/month),46.76536312849162,Significantly Below (<50%),100,54.4,59.89
NCT06991699,A Novel Digitally Driven Approach for Gummy Smile Solution Using Milled Sub-nasal Stent,COMPLETED,NA,10.0,2024-02-08,2025-04-08,0.7162352941176471,Slow (<1/month),7.162352941176471,Significantly Below (<50%),100,45.8,33.03
NCT02731599,The Effects of Treadmill Training With Visual and Auditory Cues on Gait Parameters in Parkinsonian Patients in Advanced Stages of Disease.,UNKNOWN,NA,150.0,2014-06-01,2017-06-01,4.166058394160584,Adequate (1-10/month),41.660583941605836,Significantly Below (<50%),50,47.0,39.33
NCT00684099,Docetaxel/Pemetrexed as 1st Line Treatment in Patients With Non Small Cell Lung Cancer (NSCLC),COMPLETED,PHASE1,70.0,2006-05-01,2009-05-01,1.9441605839416058,Adequate (1-10/month),19.441605839416056,Significantly Below (<50%),100,55.6,62.905
NCT03905499,Robot Assisted Physical Therapy for Pseudoparalysis in Massive Rotator Cuff Tear,AVAILABLE,,,,,,Slow (<1/month),,Significantly Below (<50%),50,23.3,6.569999999999999
NCT04138199,A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients After Switching From Kaletra in the Routine Clinical Settings of Russian Federation,TERMINATED,,239.0,2019-11-01,2020-07-08,29.10064,Good (10-50/month),200.0,Exceeded (≥100%),10,45.5,31.705
NCT06596499,Outcomes of a Novel Magnetically Levitated LVAD: a Multicenter Analysis,COMPLETED,,75.0,2022-06-01,2024-08-01,2.882575757575758,Adequate (1-10/month),28.825757575757578,Significantly Below (<50%),100,54.3,59.62
NCT00669799,"Topical Antibiotic Use In Chronic Rhinosinusitis A Double-Blinded, Randomized, Placebo Controlled Study",WITHDRAWN,NA,0.0,2008-03-01,2010-01-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT05462899,"Purpose in Life, Goals, and Expectations",NOT_YET_RECRUITING,,150.0,2025-12-01,2027-09-01,7.145539906103287,Adequate (1-10/month),71.45539906103286,Below (50-75%),30,39.3,20.810000000000002
NCT02411799,Instrumented Thoracic and Lumbar Arthrodesis Supplemented by the Implanet Jazz SystemTMd,TERMINATED,,154.0,2015-04-01,2021-06-30,2.0542331288343556,Adequate (1-10/month),20.542331288343558,Significantly Below (<50%),10,33.7,13.465
NCT01214499,"Prospective, Controlled and Randomized Clinical Trial on Cardiac Cell Regeneration With Laser and Autologous Bone Marrow Stem Cells, in Patients With Coronary Disease and Refractory Angina",UNKNOWN,PHASE2,20.0,2010-10-01,2012-10-01,0.8328317373461013,Slow (<1/month),8.328317373461012,Significantly Below (<50%),50,31.6,10.905
NCT02145299,The Lumen Study: Comparing Devices for Patients With Symptomatic Femoro-popliteal Chronic Total Occlusion (CTO),TERMINATED,PHASE2,8.0,2014-05-01,2015-06-01,0.614949494949495,Slow (<1/month),6.14949494949495,Significantly Below (<50%),10,18.6,4.25
NCT02263599,Conservative Treatment For Ventral Hernia,COMPLETED,,2089.0,2014-09-01,2015-04-01,299.9488679245283,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT04551599,A Study of the Effects of Food and Age on Danicopan,COMPLETED,PHASE1,27.0,2020-02-21,2021-02-03,2.3617241379310348,Adequate (1-10/month),23.617241379310343,Significantly Below (<50%),100,52.2,53.22
NCT05826899,A Stable Isotope Study to Evaluate the Bioavailability of an Oat Protein-based Iron Delivery System,COMPLETED,NA,52.0,2023-04-03,2024-02-29,4.767710843373494,Adequate (1-10/month),47.67710843373494,Significantly Below (<50%),100,54.2,59.330000000000005
NCT00619099,A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS),COMPLETED,PHASE2,67.0,2008-05-01,,,Slow (<1/month),,Significantly Below (<50%),100,45.4,31.455
NCT02179099,Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB Patients,TERMINATED,PHASE1,3.0,2014-07-01,2016-02-01,0.15744827586206897,Slow (<1/month),1.5744827586206895,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT06740799,Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment,RECRUITING,PHASE1,12.0,2024-09-30,2026-03-01,0.7065377176015475,Slow (<1/month),7.065377176015475,Significantly Below (<50%),60,34.0,14.02
NCT07068399,Use of Shock Wave Therapy for Neo-Vascularisation in Non-critical Coronary Artery Disease: Validation by Quantitative Cardiac MRI Perfusion,RECRUITING,NA,100.0,2020-09-01,2026-01-01,1.5626283367556468,Adequate (1-10/month),15.626283367556471,Significantly Below (<50%),60,41.0,23.01
NCT01248299,Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.,TERMINATED,PHASE2,105.0,2011-01-01,2017-01-01,1.4581204379562043,Adequate (1-10/month),14.581204379562044,Significantly Below (<50%),10,26.4,7.865
NCT00977899,Phase 1 Study of the Safety and Immunogenicity of a Malaria Transmission-blocking Pfs25-Pfs25 Conjugate Vaccine,WITHDRAWN,PHASE1,0.0,2009-08-20,2013-03-05,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT02597699,Use of Ultiva ® Associated With Xylocaine ® in the Procedures of Feticide,COMPLETED,PHASE3,66.0,2015-12-18,2019-05-06,1.6267530364372471,Adequate (1-10/month),16.26753036437247,Significantly Below (<50%),100,50.3,48.215
NCT06571799,Study Evaluating the Efficacy and Safety of BENEV Exosome Regenerative Complex+ for Self-perceived Thinning Hair,COMPLETED,NA,30.0,2024-09-03,2025-03-27,4.454634146341464,Adequate (1-10/month),44.546341463414635,Significantly Below (<50%),100,52.4,53.949999999999996
NCT00881699,Testing an HIV Prevention Intervention for Psychiatric Patients in Brazil,COMPLETED,PHASE3,460.0,2006-09-01,2011-08-01,7.800779944289694,Adequate (1-10/month),78.00779944289694,Met (75-100%),100,86.8,92.06
NCT06313099,Parameters of the General Health Status of Prison Officers,COMPLETED,,141.0,2021-01-01,2021-03-02,71.534,Excellent (>50/month),200.0,Exceeded (≥100%),100,69.6,81.675
NCT01635699,Effect of Modified Fujita Technique Uvulopalatoplasty on Oxidative DNA Damage Levels in Patients With Obstructive Sleep Apnea SyndromE (OSAS),COMPLETED,,49.0,2008-06-01,2011-03-01,1.487098703888335,Adequate (1-10/month),14.87098703888335,Significantly Below (<50%),100,47.3,40.475
NCT04702399,Hyaluronic Acid for the Prevention of Endocavitary Synechiae After Myomectomy,UNKNOWN,NA,76.0,2021-02-01,2022-05-01,5.09568281938326,Adequate (1-10/month),50.95682819383261,Below (50-75%),50,41.1,23.225
NCT00265499,"The Internal Thoracic Artery Skeletonization Study: A Paired, Within-Patient Comparison",COMPLETED,NA,48.0,,,,Slow (<1/month),,Significantly Below (<50%),100,43.8,27.965
NCT04374799,Heparin vs Placebo for Cardiac Catheterization,RECRUITING,PHASE3,3600.0,2020-10-05,2026-12-01,48.74733096085409,Good (10-50/month),200.0,Exceeded (≥100%),60,88.0,92.495
NCT03011099,Improving Gait Performance in Individuals With Spinal Cord Injuries: an Intervention Using Robotic Exoskeletons,COMPLETED,NA,12.0,2014-01-01,2016-03-01,0.4623797468354431,Slow (<1/month),4.6237974683544305,Significantly Below (<50%),100,46.0,34.1
NCT05029999,"CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer",RECRUITING,PHASE1,30.0,2022-04-20,2026-04-20,0.6250513347022587,Slow (<1/month),6.250513347022587,Significantly Below (<50%),60,35.4,15.765
NCT00219999,Hepatitis C Virus and the Humoral Immune System,COMPLETED,,161.0,2001-09-01,2013-05-01,1.1504319248826291,Adequate (1-10/month),11.504319248826294,Significantly Below (<50%),100,56.2,64.21
NCT03043599,Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer,COMPLETED,PHASE1,21.0,2017-02-13,2023-11-16,0.25911633563032027,Slow (<1/month),2.591163356303203,Significantly Below (<50%),100,46.7,37.895
NCT05676099,TSC Biosample Repository and Natural History Database,RECRUITING,,5000.0,2016-01-01,2050-12-01,11.934446796832118,Good (10-50/month),119.34446796832117,Exceeded (≥100%),60,81.3,88.58
NCT06218199,Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts,RECRUITING,PHASE4,80.0,2021-07-08,2026-12-31,1.2163836163836164,Adequate (1-10/month),12.163836163836166,Significantly Below (<50%),60,39.4,20.94
NCT05624099,Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.,RECRUITING,PHASE2,75.0,2023-08-01,2027-12-31,1.4153750774953504,Adequate (1-10/month),14.153750774953503,Significantly Below (<50%),60,39.0,20.505000000000003
NCT01779999,Early Detection of PICC-related Deep Vein Thrombosis by US Surveillance: an Effective Approach for Secondary Prevention?,COMPLETED,,150.0,2010-06-01,2012-06-01,6.24623803009576,Adequate (1-10/month),62.4623803009576,Below (50-75%),100,60.3,72.34
NCT01339299,Study to Examine Effect of Recombinant Luteinizing Hormone (r-Lh) and Recombinant Human Chorionic Gonadotropin (r-hCG) for Ovarian Stimulation in Assisted Reproduction Techniques (ART),COMPLETED,PHASE4,100.0,2009-10-01,2012-07-01,3.03187250996016,Adequate (1-10/month),30.318725099601597,Significantly Below (<50%),100,58.0,68.245
NCT03258632,Improving Outcomes Among Medical/Surgical Inpatients With Alcohol Use Disorders,COMPLETED,NA,155.0,2018-09-01,2022-05-31,3.4489766081871345,Adequate (1-10/month),34.489766081871345,Significantly Below (<50%),100,62.4,75.095
NCT06870032,Pulmonary Rehabilitation and Quality of Life in Children With Chronic Lung Diseases: A Multidisciplinary Approach,COMPLETED,NA,400.0,2022-11-01,2023-12-30,28.716981132075475,Good (10-50/month),200.0,Exceeded (≥100%),100,87.0,92.135
NCT04034732,MBRP on Reducing Craving and Addictive Behaviour in Adults,RECRUITING,NA,80.0,2019-08-15,2024-08-31,1.3213239283776452,Adequate (1-10/month),13.213239283776455,Significantly Below (<50%),60,39.4,20.94
NCT01150032,Bone Quality Lyon Orleans,UNKNOWN,,1605.0,2010-09-20,2025-05-01,9.15424395727937,Adequate (1-10/month),91.5424395727937,Met (75-100%),50,78.3,86.48
NCT02271932,Multi-institutional Trial of Non-operative Management of Appendicitis,UNKNOWN,,1076.0,2014-10-01,2023-11-01,9.871440626883665,Adequate (1-10/month),98.71440626883665,Met (75-100%),50,78.3,86.48
NCT06265532,Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect,ACTIVE_NOT_RECRUITING,PHASE1,22.0,2024-02-07,2026-03-25,0.8618790218790219,Slow (<1/month),8.618790218790219,Significantly Below (<50%),85,42.3,25.295
NCT01904032,Sunshine 2 Study for Women With Diabetes,COMPLETED,PHASE2,265.0,2013-11-21,2018-08-31,4.625344036697248,Adequate (1-10/month),46.253440366972484,Significantly Below (<50%),100,71.2,82.59
NCT01098032,RenalGuard System and Contrast Media,COMPLETED,PHASE3,294.0,2009-01-01,2011-12-01,8.411052631578947,Adequate (1-10/month),84.11052631578947,Met (75-100%),100,78.5,86.785
NCT00241332,Postoperative Pain After Orthopedic Surgery: Does it Help to Give Fentanyl Before Start of Remifentanil Based Anesthesia?,COMPLETED,PHASE3,100.0,2005-10-01,2006-07-01,11.150183150183151,Good (10-50/month),111.50183150183153,Exceeded (≥100%),100,63.0,75.845
NCT00457132,The Effect of Neuromuscular Training on Osteoarthritis: A Comparative Prospective Randomized Study,COMPLETED,NA,60.0,2005-09-01,2006-02-01,11.937254901960785,Good (10-50/month),119.37254901960786,Exceeded (≥100%),100,59.8,71.61
NCT05365932,Evaluation of an Intra Auricular Device as a Treatment for Painful Temporo-Mandibular Disorders,COMPLETED,NA,10.0,2018-11-29,2019-12-10,0.8095744680851064,Slow (<1/month),8.095744680851064,Significantly Below (<50%),100,45.8,33.03
NCT01506232,"Brain Activity Flow Patterns Analysis Using Evoked Response Potentials in Youth With ADHD, Bipolar Disorder, or Autism Spectrum Disorders: A Preliminary Study",TERMINATED,,1.0,2011-03-01,2012-11-01,0.04981996726677578,Slow (<1/month),0.49819967266775783,Significantly Below (<50%),10,16.4,2.595
NCT06257732,Different Exercise Modalities in the Treatment of NAFLD and Their Impact on Myokines,UNKNOWN,NA,144.0,2024-01-05,2024-10-15,15.434366197183099,Good (10-50/month),154.34366197183098,Exceeded (≥100%),50,51.5,51.245
NCT00164632,No More Falls Injury Prevention Study,COMPLETED,NA,552.0,2001-10-01,,,Slow (<1/month),,Significantly Below (<50%),100,80.0,87.67
NCT01631032,Effect of Qi-tonifying Chinese Herbal Products for Treatment of Allergic Rhinitis,COMPLETED,PHASE3,112.0,2012-07-01,2013-12-01,6.581621621621622,Adequate (1-10/month),65.81621621621623,Below (50-75%),100,59.0,70.365
NCT04141332,Specific Language Impairment (SLI) in Children May Caused by Epileptic Brain Activity,COMPLETED,,160.0,2018-02-01,2019-03-01,12.392875318066158,Good (10-50/month),123.92875318066159,Exceeded (≥100%),100,66.1,79.125
NCT02842632,Evaluation of Simulator Training on TEE Performance in Residents,COMPLETED,NA,54.0,2016-04-01,2017-09-01,3.1732818532818534,Adequate (1-10/month),31.732818532818534,Significantly Below (<50%),100,54.3,59.62
NCT00190632,To Evaluate the Safety in Patients Taking Duloxetine for Stress Urinary Incontinence,COMPLETED,PHASE3,600.0,2001-03-01,2006-04-01,9.835218093699515,Adequate (1-10/month),98.35218093699515,Met (75-100%),100,95.0,95.7
NCT04127032,Internet-Delivered Cognitive Behaviour Therapy for Public Safety Personnel,RECRUITING,NA,250.0,2019-12-01,2028-03-31,2.5008215576733486,Adequate (1-10/month),25.008215576733484,Significantly Below (<50%),60,58.0,68.245
NCT06818032,Avocado and Postprandial Responses,RECRUITING,NA,30.0,2025-03-01,2026-06-01,1.9982494529540482,Adequate (1-10/month),19.98249452954048,Significantly Below (<50%),60,40.4,22.34
NCT01616732,Testosterone and Weight Loss,COMPLETED,PHASE2,100.0,2013-04-01,2015-12-01,3.1252566735112937,Adequate (1-10/month),31.252566735112943,Significantly Below (<50%),100,58.0,68.245
NCT03544632,Acellular Adipose Tissue (AAT) for Soft Tissue Reconstruction,ENROLLING_BY_INVITATION,PHASE2,15.0,2018-06-21,2026-09-30,0.15104201124710553,Slow (<1/month),1.5104201124710552,Significantly Below (<50%),55,32.7,12.370000000000001
NCT06010732,In Situ Comparison of the Remineralization Potential of Optimized Fluoride Dentifrice With Control Fluoride Dentifrice,COMPLETED,PHASE3,52.0,2023-10-02,2024-02-22,11.069090909090908,Good (10-50/month),110.69090909090909,Exceeded (≥100%),100,59.2,70.7
NCT00875732,Choosing the Right Pacing Mode in Heart Failure - The CHOICE Trial,COMPLETED,NA,22.0,2009-09-01,2011-01-01,1.3751129363449692,Adequate (1-10/month),13.751129363449694,Significantly Below (<50%),100,46.8,38.440000000000005
NCT00403832,Acrylate Intraocular Lenses in Cataract Surgery of Uveitis Patients,COMPLETED,NA,60.0,2005-08-01,2007-02-01,3.3267759562841532,Adequate (1-10/month),33.26775956284153,Significantly Below (<50%),100,54.8,61.095
NCT01503632,Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission,ACTIVE_NOT_RECRUITING,PHASE3,570.0,2012-02-21,2029-12-31,2.6599417445960447,Adequate (1-10/month),26.599417445960448,Significantly Below (<50%),85,85.5,91.42
NCT04899232,Antithrombin III in Infectious Disease Caused by COVID-19,TERMINATED,PHASE2,52.0,2021-07-06,2022-03-31,5.906268656716418,Adequate (1-10/month),59.06268656716418,Below (50-75%),10,27.2,8.115
NCT06522932,PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy,RECRUITING,PHASE1,32.0,2024-10-23,2027-01-31,1.1735903614457832,Adequate (1-10/month),11.73590361445783,Significantly Below (<50%),60,35.6,16.03
NCT05901532,Nasal Irrigation With Chinese Herbal Medicine as an Adjunctive Treatment in Allergic Rhinitis,COMPLETED,PHASE2,38.0,2020-11-01,2023-02-28,1.3624499411071849,Adequate (1-10/month),13.62449941107185,Significantly Below (<50%),100,48.0,42.945
NCT02453932,Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia,COMPLETED,PHASE3,543.0,2013-10-01,2017-05-01,12.63678899082569,Good (10-50/month),126.3678899082569,Exceeded (≥100%),100,95.0,95.7
NCT02126098,Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis,UNKNOWN,,100.0,2014-05-01,2017-12-01,2.3236641221374046,Adequate (1-10/month),23.236641221374047,Significantly Below (<50%),50,41.3,23.74
NCT01827098,A Clinical Study to Compare Two Revascularization Protocols to Treat Non-vital Teeth With Incomplete Root Formation,COMPLETED,NA,45.0,2012-10-01,2023-06-07,0.35114073314534733,Slow (<1/month),3.5114073314534733,Significantly Below (<50%),100,48.6,44.685
NCT05788198,Integrated Depression Care,RECRUITING,NA,150.0,2023-04-25,2024-09-30,8.713740458015266,Adequate (1-10/month),87.13740458015268,Met (75-100%),60,55.0,61.834999999999994
NCT03444298,A Study of Gamma Tocopherol-enriched Supplement on Lower Airway Responses to Inhaled Wood Smoke in Healthy Adults,COMPLETED,PHASE2,16.0,2018-06-08,2023-03-06,0.28120092378752887,Slow (<1/month),2.8120092378752886,Significantly Below (<50%),100,46.3,35.66
NCT03085498,Sportcheck Follow-Up,COMPLETED,,280.0,2017-11-01,2018-10-01,25.518562874251497,Good (10-50/month),200.0,Exceeded (≥100%),100,75.7,84.785
NCT05077098,Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer,ACTIVE_NOT_RECRUITING,PHASE1,8.0,2021-08-12,2028-07-01,0.09682703777335985,Slow (<1/month),0.9682703777335985,Significantly Below (<50%),85,41.1,23.225
NCT03033498,"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease",COMPLETED,PHASE1,29.0,2017-05-17,2019-06-08,1.1738829787234042,Adequate (1-10/month),11.738829787234044,Significantly Below (<50%),100,47.3,40.475
NCT05025098,Precision Therapy Versus Standard Therapy in AML and MDS in Elderly,RECRUITING,PHASE2,36.0,2021-06-22,2027-06-10,0.5029095915557595,Slow (<1/month),5.029095915557596,Significantly Below (<50%),60,35.9,16.445
NCT07079098,"Trial of Oligometastasis SBRT With Immediate, Simulation-Free Treatment Delivery (OLIGO-SWIFT)",NOT_YET_RECRUITING,PHASE1,15.0,2025-12-01,2026-02-01,7.364516129032258,Adequate (1-10/month),73.64516129032258,Below (50-75%),30,30.2,9.245000000000001
NCT03758898,The Effect of Chest Physiotherapy After Bariatric Surgery,COMPLETED,NA,148.0,2018-05-05,2019-04-15,13.05831884057971,Good (10-50/month),130.5831884057971,Exceeded (≥100%),100,66.8,79.55
NCT01291498,High Intensity Focused Ultrasound (HIFU) for Parathyroid Adenoma,TERMINATED,NA,1.0,2011-04-01,2013-06-01,0.03843434343434344,Slow (<1/month),0.3843434343434344,Significantly Below (<50%),10,18.1,3.105
NCT00683098,Long-term Results After Endoscopic Total Extraperitoneal Repair of Recurrent Inguinal Hernia,COMPLETED,,300.0,2008-06-01,2008-12-01,49.9016393442623,Good (10-50/month),200.0,Exceeded (≥100%),100,82.3,89.115
NCT02770898,Improving Family Holistic Health in Probationers,COMPLETED,NA,463.0,2015-07-01,2017-07-01,19.280054719562244,Good (10-50/month),192.80054719562244,Exceeded (≥100%),100,92.0,93.78999999999999
NCT06561698,High-dose Dual Therapy and Minocycline-cotaining Quadruple Therapy for Helicobacter Pylori Infection,RECRUITING,PHASE4,200.0,2024-08-21,2026-08-30,8.238159675236806,Adequate (1-10/month),82.38159675236807,Met (75-100%),60,54.0,58.72500000000001
NCT07380698,The Effect of Dose and Storage Conditions of Indocyanine Green on Efficacy and Cost in Sentinel Lymph Node Mapping in Gynecological Cancer,RECRUITING,,30.0,2025-10-03,2026-09-03,2.725970149253732,Adequate (1-10/month),27.259701492537314,Significantly Below (<50%),60,38.7,20.145
NCT03624998,The Effects of Cognitive Functioning on Gait Rehabilitation,UNKNOWN,NA,40.0,2018-04-03,2020-04-02,1.6679452054794521,Adequate (1-10/month),16.67945205479452,Significantly Below (<50%),50,38.2,19.645000000000003
NCT07097298,Empathy and (Self-)Compassion in Parkinson's Disease Patients and Caregivers,RECRUITING,NA,30.0,2025-11-06,2027-07-01,1.5169435215946845,Adequate (1-10/month),15.169435215946844,Significantly Below (<50%),60,35.4,15.765
NCT00736398,Fusion Assessment Clinical Trial,COMPLETED,,50.0,2008-08-01,,,Slow (<1/month),,Significantly Below (<50%),100,42.3,25.295
NCT06036498,Evaluation of Cerebral Blood Flow and Cerebral Oxygenation With Transcranial Doppler and NIRS in Laparoscopic Cholecystectomy Cases,UNKNOWN,,40.0,2023-01-18,2024-06-26,2.3192380952380955,Adequate (1-10/month),23.192380952380955,Significantly Below (<50%),50,36.5,17.285
NCT05975398,China Research for Severe Spontaneous Intracerebral Hemorrhage（CRISIH）,UNKNOWN,,450.0,2022-07-01,2025-12-31,10.709929632525412,Good (10-50/month),107.0992963252541,Exceeded (≥100%),50,74.3,84.205
NCT06618898,Orofacial Pain in Woodwind and Cello Musicians in German Orchestras,COMPLETED,,245.0,2024-11-04,2025-01-26,89.85301204819277,Excellent (>50/month),200.0,Exceeded (≥100%),100,77.9,85.955
NCT07254598,Myotensive Extraocular Muscle Techniques Added to Manual Therapy for Migraine Without Aura,NOT_YET_RECRUITING,NA,84.0,2026-01-08,2027-03-01,6.131798561151079,Adequate (1-10/month),61.317985611510785,Below (50-75%),30,35.7,16.18
NCT02428998,Safety for 24 Weeks Intake of Korean Red Ginseng in Adults,COMPLETED,NA,1000.0,2014-09-01,2017-04-01,32.27995758218452,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT03442998,Walking Green: Developing an Evidence-base for Nature Prescriptions,COMPLETED,NA,24.0,2017-07-14,2019-04-01,1.1670287539936104,Adequate (1-10/month),11.670287539936103,Significantly Below (<50%),100,46.9,38.96
NCT01799863,Artificial Tears Versus Preservative Free Ketorolac Trometamol 0.45% for Acute Viral Conjunctivitis,COMPLETED,PHASE2,50.0,2012-06-01,2013-03-01,5.575091575091576,Adequate (1-10/month),55.750915750915766,Below (50-75%),100,54.0,58.72500000000001
NCT04974463,Predicting Chronic Opioid Use Following Lower Extremity Joint Arthroplasty,UNKNOWN,,1000.0,2021-07-19,2023-12-31,34.011173184357546,Good (10-50/month),200.0,Exceeded (≥100%),50,78.3,86.48
NCT05521763,Influenza Vaccine Uptake Among Healthcare Workers,UNKNOWN,NA,3000.0,2022-03-12,2023-02-12,270.9792284866469,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT05113563,Investigation of TEST (Transcranial Electric Stimulation Therapy) for Chronic Pain,COMPLETED,NA,6.0,2023-01-02,2024-01-17,0.48063157894736847,Slow (<1/month),4.806315789473684,Significantly Below (<50%),100,45.5,31.705
NCT01324063,A Randomized Phase III Study of Intensive Consolidation With High Dose Cytosine Arabinoside in Acute Myelogenous Leukemia (AML-8B),COMPLETED,PHASE3,160.0,1986-11-01,,,Slow (<1/month),,Significantly Below (<50%),100,52.8,55.31
NCT01252563,Amlodipine 10mg Drug Use Investigation,COMPLETED,,14141.0,2010-12-01,2012-10-01,642.4657313432837,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT05532163,A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS),TERMINATED,PHASE4,1.0,2023-01-23,2023-10-09,0.11752895752895753,Slow (<1/month),1.1752895752895753,Significantly Below (<50%),10,18.1,3.105
NCT03229863,"An Examination of Infants' Microbiome, Nutrition, and Development Study.",ACTIVE_NOT_RECRUITING,NA,102.0,2017-04-18,2027-03-10,0.8593634099086631,Slow (<1/month),8.59363409908663,Significantly Below (<50%),85,48.7,44.93
NCT00547963,Brief Counseling to Reduce Injuries Among Emergency Department Patients Who Report Alcohol and Substance Use,UNKNOWN,PHASE2,554.0,2003-12-01,2008-12-01,9.230301039956213,Adequate (1-10/month),92.30301039956214,Met (75-100%),50,80.0,87.67
NCT06535763,Impact and Influence of the Use of Hypnosis Adapted to People With Severe Stage Neurocognitive Disorder (HAPNeSS) on the Professional Practices of EHPAD (Establishment for Dependent Elderly People) Caregivers With Elderly Residents,NOT_YET_RECRUITING,,36.0,2024-09-01,2025-03-01,6.054364640883978,Adequate (1-10/month),60.54364640883978,Below (50-75%),30,30.2,9.245000000000001
NCT05211063,"Effects of CROCUVIS+® on Computer Vision Syndrome, Sleep and Mood Disorders",COMPLETED,NA,100.0,2022-10-21,2023-05-05,15.53061224489796,Good (10-50/month),155.3061224489796,Exceeded (≥100%),100,63.0,75.845
NCT02907463,EDWARDS INTUITY Elite Valve System,COMPLETED,,280.0,2016-02-01,2017-12-01,12.740209267563527,Good (10-50/month),127.40209267563527,Exceeded (≥100%),100,75.7,84.785
NCT02668263,Investigating the Use of Drains and (Internal) Quilting Sutures on Seroma Formation Following Mastectomy,UNKNOWN,NA,120.0,2015-11-01,2016-11-01,9.98032786885246,Adequate (1-10/month),99.80327868852459,Met (75-100%),50,49.6,46.785
NCT04610463,Evaluation of the Severity of Right to Left Shunt in PFO Patients After Systemic Embolism,UNKNOWN,NA,150.0,2020-09-25,2023-12-01,3.9294320137693637,Adequate (1-10/month),39.29432013769364,Significantly Below (<50%),50,47.0,39.33
NCT03043287,"Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC)",COMPLETED,,420.0,2017-05-12,2019-09-30,14.67830080367394,Good (10-50/month),146.7830080367394,Exceeded (≥100%),100,86.9,92.085
NCT03573687,Effects of Protein Timing and Resistance Exercise on Fat Metabolism,COMPLETED,NA,13.0,2017-03-20,2018-02-28,1.1470144927536232,Adequate (1-10/month),11.470144927536232,Significantly Below (<50%),100,46.0,34.1
NCT02001987,A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy,COMPLETED,PHASE3,139.0,2014-01-01,2015-12-01,6.0531616595135915,Adequate (1-10/month),60.531616595135915,Below (50-75%),100,61.1,73.31
NCT06902987,Efficacy and Safety of Upatinib in the Treatment of Active Anal Fistulas in Crohn's Disease,RECRUITING,PHASE1,27.0,2024-01-17,2026-12-30,0.7624118738404453,Slow (<1/month),7.624118738404453,Significantly Below (<50%),60,35.2,15.445
NCT02337387,A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women,TERMINATED,PHASE1,28.0,2015-01-01,2015-03-01,14.446101694915255,Good (10-50/month),144.46101694915257,Exceeded (≥100%),10,30.2,9.245000000000001
NCT04240587,Intranasal Neurostimulation for the Treatment of Neurosensory Abnormalities in CL Wearers (INTAC),WITHDRAWN,NA,0.0,2020-03-23,2021-11-03,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT05124587,Prediction for Critical Outcomes of Patients With COVID-19,UNKNOWN,,600.0,2021-09-01,2022-12-01,40.05263157894737,Good (10-50/month),200.0,Exceeded (≥100%),50,78.3,86.48
NCT04232787,Southeast Asian Brugada Syndrome Cohort,UNKNOWN,,750.0,2016-01-28,2023-01-01,9.023715415019764,Adequate (1-10/month),90.23715415019764,Met (75-100%),50,78.3,86.48
NCT04279587,Camp Based Multi-component Intervention for Families of Young Children With Type 1 Diabetes,TERMINATED,NA,3.0,2019-08-19,2023-02-13,0.07167974882260596,Slow (<1/month),0.7167974882260596,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT00837187,Bioavailability of Dexmedetomidine After Intranasal Administration,COMPLETED,PHASE1,7.0,2009-03-01,2009-05-01,3.4931147540983605,Adequate (1-10/month),34.9311475409836,Significantly Below (<50%),100,50.6,48.705
NCT04668287,Improving Students' Self-esteem With an Online Intervention,COMPLETED,NA,33.0,2020-11-11,2020-12-18,27.14918918918919,Good (10-50/month),200.0,Exceeded (≥100%),100,57.6,67.36999999999999
NCT06433687,Evaluation of the HekaHeart Platform in Medication Management for Heart Failure Patients,WITHDRAWN,,0.0,2025-10-01,2026-10-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT03352687,Diaphragmatic Paralysis After Ultrasound Block of the Suprascapular Nerve for Shoulder Surgery,COMPLETED,NA,84.0,2018-02-02,2019-02-28,6.539539641943735,Adequate (1-10/month),65.39539641943735,Below (50-75%),100,56.7,65.53
NCT04300387,Chronic Kidney Disease at Northeast Taiwan: Biomarker and Multidisciplinary Care,UNKNOWN,NA,8000.0,2011-03-01,2024-12-01,48.47133757961783,Good (10-50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT05626387,An RCT of Mycophenolate Mofetil (MMF) in Fibrotic Hypersensitivity Pneumonitis,UNKNOWN,PHASE4,144.0,2022-11-23,2025-10-23,4.115830985915493,Adequate (1-10/month),41.15830985915493,Significantly Below (<50%),50,46.5,36.815
NCT06215287,Survey to Assess Physicians' Knowledge of Exjade Posology and Biological Monitoring Recommendations as Described in the Educational Materials,COMPLETED,,400.0,2024-01-12,2024-02-15,358.11764705882354,Excellent (>50/month),200.0,Exceeded (≥100%),100,90.3,93.28
NCT06072287,The Living With a Long-Term Condition Study,UNKNOWN,,600.0,2023-06-28,2024-01-10,93.18367346938776,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT00004987,Treatment of Advanced AIDS Patients With Dextrin Sulfate,UNKNOWN,PHASE1,,1999-10-01,,,Slow (<1/month),,Significantly Below (<50%),50,25.0,7.23
NCT06728787,Robot-assisted Walking Treatment in Hereditary Spastic Paraplegia (HSP),RECRUITING,,50.0,2012-01-01,2026-12-31,0.2778386272362176,Slow (<1/month),2.778386272362176,Significantly Below (<50%),60,35.3,15.534999999999998
NCT01667887,Plating of Distal Femur Fractures by Far Cortical Locking Using MotionLoc Screws,COMPLETED,,33.0,2011-04-01,2013-01-01,1.5671138845553823,Adequate (1-10/month),15.67113884555382,Significantly Below (<50%),100,46.0,34.1
NCT00002987,Combination Chemotherapy Given With Radiation Therapy or Radiation Therapy Alone in Treating Patients With Early-Stage Hodgkin's Disease,UNKNOWN,PHASE3,400.0,1997-01-01,,,Slow (<1/month),,Significantly Below (<50%),50,57.0,66.12
NCT05290987,Efficacy of ADW S-100 Ionized Water Nasal Spray in Decreasing SARS-Cov-2 Viral Load.,TERMINATED,NA,13.0,2022-01-14,2022-11-08,1.3279194630872484,Adequate (1-10/month),13.279194630872485,Significantly Below (<50%),10,19.0,4.84
NCT00414687,"Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension",COMPLETED,PHASE2,63.0,1998-07-01,2001-05-01,1.8528695652173912,Adequate (1-10/month),18.528695652173912,Significantly Below (<50%),100,55.0,61.834999999999994
NCT01260987,Fractional CO2 Laser Assisted Photodynamic Therapy,COMPLETED,PHASE2,47.0,2010-10-01,2012-08-01,2.1353432835820896,Adequate (1-10/month),21.353432835820897,Significantly Below (<50%),100,53.8,58.065
NCT04690387,"Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection",COMPLETED,PHASE1,27.0,2020-12-07,2021-01-15,21.073846153846155,Good (10-50/month),200.0,Exceeded (≥100%),100,57.2,66.465
NCT01552187,COlchicine for Prevention of the Post-pericardiotomy Syndrome and Post-operative Atrial Fibrillation (COPPS-2 Trial),UNKNOWN,PHASE3,360.0,2012-03-01,2014-07-01,12.861971830985917,Good (10-50/month),128.61971830985917,Exceeded (≥100%),50,68.8,81.105
NCT05496387,Effect of Neuromobılızatıon on Stiffness of Scıatıc Nerve,COMPLETED,NA,36.0,2022-10-15,2022-11-15,35.34967741935484,Good (10-50/month),200.0,Exceeded (≥100%),100,57.9,67.83
NCT00822887,Dose Escalation Study of Vandetanib With Hypofractionated Stereotactic Radiotherapy in Recurrent Malignant Gliomas,COMPLETED,PHASE1,13.0,2007-03-01,2011-01-01,0.2822539229671897,Slow (<1/month),2.822539229671897,Significantly Below (<50%),100,46.0,34.1
NCT06676787,Evaluating the Impact of Demand-Side Incentives (DSI) on Zero Dose Burden and Immunisation Coverage in Nigeria,RECRUITING,EARLY_PHASE1,100000.0,2024-08-29,2025-12-31,6224.948875255624,Excellent (>50/month),200.0,Exceeded (≥100%),60,88.0,92.495
NCT05257993,"Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer",RECRUITING,PHASE1,30.0,2022-03-30,2026-06-01,0.5992125984251969,Slow (<1/month),5.992125984251969,Significantly Below (<50%),60,35.4,15.765
NCT03093493,Genetics of Ehlers-Danlos Syndrome,COMPLETED,,334.0,2017-08-25,2025-04-03,3.659812814974802,Adequate (1-10/month),36.59812814974802,Significantly Below (<50%),100,75.1,84.56
NCT02947893,"Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease",UNKNOWN,PHASE2,42.0,2017-01-01,2020-02-01,1.135417406749556,Adequate (1-10/month),11.35417406749556,Significantly Below (<50%),50,33.4,13.29
NCT02777593,"Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 2",ACTIVE_NOT_RECRUITING,NA,250.0,2016-09-06,2027-12-01,1.8547404338289057,Adequate (1-10/month),18.54740433828906,Significantly Below (<50%),85,65.5,78.48
NCT00702793,Safety and Tolerability of Varenicline in Schizophrenia (SATOVA),WITHDRAWN,PHASE4,0.0,2008-04-01,2012-05-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT04692493,RA-PRO PRAGMATIC TRIAL,RECRUITING,PHASE3,924.0,2021-09-22,2028-12-31,10.585833646970269,Good (10-50/month),105.85833646970269,Exceeded (≥100%),60,83.0,89.505
NCT04761393,Characterizing Matrix Metalloproteinase-12 (MMP12) in Sputum,RECRUITING,,45.0,2022-11-29,2025-01-01,1.792931937172775,Adequate (1-10/month),17.929319371727747,Significantly Below (<50%),60,39.9,21.695
NCT05367193,3D Visualization System for Vitreoretinal Diseases in Highly Myopic Eyes,COMPLETED,NA,40.0,2022-10-07,2023-03-16,7.61,Adequate (1-10/month),76.1,Met (75-100%),100,53.2,56.665
NCT06983093,"Effects of Rain Stick and Musical Egg on Pain, Fear and Anxiety",NOT_YET_RECRUITING,NA,120.0,2025-12-31,2025-12-31,120.0,Excellent (>50/month),200.0,Exceeded (≥100%),30,28.6,8.58
NCT04358393,"A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS",UNKNOWN,PHASE1,69.0,2020-12-04,2025-12-30,1.1341036717062636,Adequate (1-10/month),11.341036717062634,Significantly Below (<50%),50,35.5,15.950000000000001
NCT05962593,Different Inflammatory Biomarkers With Surgical Removal of Mandibular Third Molars,UNKNOWN,NA,124.0,2023-06-01,2024-06-01,10.313005464480874,Good (10-50/month),103.13005464480874,Exceeded (≥100%),50,49.9,47.425
NCT01311193,Circadian Sleep-wake Cycles and Light Therapy in Borderline Personality Disorder,COMPLETED,NA,,,,,Slow (<1/month),,Significantly Below (<50%),100,40.0,21.87
NCT00000793,A Phase II/III Double-Blind Study of Amitriptyline and Mexiletine for Painful Neuropathy in HIV Infection,COMPLETED,PHASE2,240.0,,1997-10-01,,Slow (<1/month),,Significantly Below (<50%),100,59.2,70.7
NCT03418493,A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis,COMPLETED,PHASE1,63.0,2018-01-30,2019-07-29,3.518752293577982,Adequate (1-10/month),35.187522935779825,Significantly Below (<50%),100,55.0,61.834999999999994
NCT03807193,Self-selected or Predetermined Internet-based Treatment for Generalized Anxiety Disorder With Different Types of Support,COMPLETED,NA,85.0,2019-02-12,2020-12-10,3.879160419790105,Adequate (1-10/month),38.79160419790105,Significantly Below (<50%),100,56.8,65.69500000000001
NCT06919393,"""Triple Negative"" Adult B-cell Acute Lymphoblastic Leukemia - TRINEG-ALL",RECRUITING,,60.0,2019-10-23,2026-01-01,0.8074270557029177,Slow (<1/month),8.074270557029177,Significantly Below (<50%),60,36.1,16.665
NCT01374893,Physical Training in Hospitalized Elderly,COMPLETED,NA,260.0,2011-09-01,2014-10-01,7.028774422735347,Adequate (1-10/month),70.28774422735347,Below (50-75%),100,70.8,82.295
NCT04341493,Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19,TERMINATED,PHASE4,44.0,2020-04-06,2020-12-30,4.9976119402985075,Adequate (1-10/month),49.97611940298507,Significantly Below (<50%),10,26.5,7.945
NCT03163693,The Effects of Dexmedetomidine on cTnI and GP-BB in Patients Undergoing OPCABG,UNKNOWN,NA,40.0,2016-02-01,2017-05-01,2.676043956043956,Adequate (1-10/month),26.760439560439565,Significantly Below (<50%),50,38.2,19.645000000000003
NCT03392493,Robot-assisted Hand Rehabilitation for Patients With Stroke,COMPLETED,NA,25.0,2018-02-01,2018-06-30,5.10738255033557,Adequate (1-10/month),51.07382550335571,Below (50-75%),100,52.0,52.86
NCT06964893,The Effect of Early Postoperative Pain on Postoperative Delirium (POD) in Elderly Patients Undergoing Abdominal Surgery,COMPLETED,,3389.0,2020-04-01,2023-04-30,91.78039145907474,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02479893,"Cold Snare,Hot Snare and APC Polypectomy for the Complete Removal of Small Left Sided Colon Polyps",COMPLETED,,108.0,2015-01-01,2020-03-10,1.7348390501319262,Adequate (1-10/month),17.348390501319262,Significantly Below (<50%),100,57.0,66.12
NCT03493893,"10 Year Review of the Experience of the PFNA ,TFNA the Affixus Nail",COMPLETED,,800.0,2006-09-01,2016-09-01,6.666301669860389,Adequate (1-10/month),66.6630166986039,Below (50-75%),100,88.3,92.705
NCT01874093,IMPACT- 24Bt Post Mech. Thrombectomy and/or rtPA TRIAL IMPlant Augmenting Cerebral Blood Flow 24 Hours From Stroke Onset,TERMINATED,PHASE3,27.0,2013-05-01,2018-06-01,0.44258481421647816,Slow (<1/month),4.4258481421647815,Significantly Below (<50%),10,20.2,5.845000000000001
NCT05627193,Comparing Patient Satisfaction in Post-operative Breast Surgery Patients Having Physical Clinic and Tele Clinic Follow up: A Randomized Controlled Trial,COMPLETED,NA,194.0,2023-01-01,2023-12-10,17.216793002915452,Good (10-50/month),172.16793002915455,Exceeded (≥100%),100,70.5,82.19999999999999
NCT02308293,The Role of Endogenous Lactate in Brain Preservation and Counterregulatory Defenses Against Hypoglycemia,COMPLETED,NA,30.0,2015-01-01,2016-07-01,1.6694698354661792,Adequate (1-10/month),16.694698354661792,Significantly Below (<50%),100,52.4,53.949999999999996
NCT06466993,Influence of Relaxing Breathing Before Each Station of an Objective Structured Clinical Examination,NOT_YET_RECRUITING,NA,400.0,2024-09-05,2024-12-17,118.21359223300972,Excellent (>50/month),200.0,Exceeded (≥100%),30,71.0,82.44
NCT06013293,Evaluation of Postoperative Pain With Resin Based Sealer vs Zinc Oxide Eugenol Based Sealer After Single Visit Endodontic,UNKNOWN,NA,100.0,2022-10-01,2023-09-01,9.086567164179105,Adequate (1-10/month),90.86567164179104,Met (75-100%),50,48.0,42.945
NCT02371993,Asthma in the Elderly: A Study of Choline Supplementation,COMPLETED,PHASE3,30.0,2015-01-01,2015-06-01,6.047682119205298,Adequate (1-10/month),60.476821192052974,Below (50-75%),100,52.4,53.949999999999996
NCT00551993,Laparoscopic Versus Robotic Assisted Laparoscopic Sacrocolpopexy for Vaginal Prolapse,COMPLETED,NA,78.0,2006-09-01,2011-11-01,1.2582511923688395,Adequate (1-10/month),12.582511923688394,Significantly Below (<50%),100,51.2,50.375
NCT04987593,Characterisation of the Gut Microbiota in Term Infants After Maternal Supplementation of Probiotics,COMPLETED,NA,23.0,2021-08-01,2022-06-30,2.1024624624624626,Adequate (1-10/month),21.02462462462463,Significantly Below (<50%),100,51.8,52.17
NCT01654393,Triage Nurse Initiated Radiographs According to OAR,UNKNOWN,NA,142.0,2012-07-01,2013-02-01,20.104558139534884,Good (10-50/month),200.0,Exceeded (≥100%),50,51.4,50.92
NCT00485693,Dose-Ranging Study for Prolonged Postoperative Analgesia in Subject Undergoing Total Knee Arthroplasty,COMPLETED,PHASE2,138.0,2007-06-01,2009-08-01,5.303939393939394,Adequate (1-10/month),53.03939393939394,Below (50-75%),100,61.0,73.17
NCT05608993,RELAX: Reducing Length of Antibiotics for Children With Ear Infections,ACTIVE_NOT_RECRUITING,NA,500.0,2024-04-01,2027-10-01,11.90923317683881,Good (10-50/month),119.09233176838812,Exceeded (≥100%),85,90.5,93.4
NCT07350993,Effect of Music on Dental Anxiety in Children: Turkish Validation of the CEDAM,COMPLETED,NA,78.0,2024-04-22,2025-02-21,7.784655737704918,Adequate (1-10/month),77.8465573770492,Met (75-100%),100,56.2,64.21
NCT07020793,Green Subthreshold Laser Therapy for Chronic Central Serous Chorioretinopathy.,COMPLETED,,12.0,2024-06-01,2025-03-30,1.2095364238410595,Adequate (1-10/month),12.095364238410596,Significantly Below (<50%),100,44.3,28.715000000000003
NCT04931693,PECs Block for Pacemaker Insertion in Children,COMPLETED,PHASE4,40.0,2021-12-20,2022-08-20,5.010699588477366,Adequate (1-10/month),50.10699588477367,Below (50-75%),100,53.2,56.665
NCT06401993,"Peripheral-central Correlation Study on the Treatment of Chronic Tinnitus With ""Dao qi Tong Luo"" Based on the Theory of ""Connecting the Two Ears to the Brain""",RECRUITING,NA,87.0,2024-05-04,2026-12-01,2.81432518597237,Adequate (1-10/month),28.1432518597237,Significantly Below (<50%),60,45.0,30.330000000000002
NCT04771793,Physical Restraint of Critically Ill Patients,COMPLETED,,992.0,2021-09-01,2023-03-14,54.01874776386404,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT04099693,A Prospective Randomized Study of General Anesthesia Versus Anesthetist Administered Sedation for ERCP,UNKNOWN,,204.0,2019-09-08,2022-05-20,6.304324873096447,Adequate (1-10/month),63.04324873096447,Below (50-75%),50,49.7,46.949999999999996
NCT04418193,Patient Preference Trial for COVID-19 (PPT-COVID),WITHDRAWN,,0.0,2020-04-06,2021-02-04,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT03592693,"Vitamin C, Hydrocortisone and Thiamine for Septic Shock",TERMINATED,PHASE2,24.0,2018-09-06,2023-01-16,0.45860640301318273,Slow (<1/month),4.586064030131827,Significantly Below (<50%),10,19.9,5.555000000000001
NCT04748393,"Risk, Predictors, Impact and Outcome of Anticoagulation-associated Abnormal Menstrual Bleeding",TERMINATED,,90.0,2018-09-01,2021-02-01,3.0990950226244345,Adequate (1-10/month),30.990950226244347,Significantly Below (<50%),10,28.5,8.540000000000001
NCT04929821,"UNITY-B A Prospective, Multicentric, Single-arm Study to Evaluate the Safety and Efficacy of the UNITY-B Biodegradable Balloon-Expandable Biliary Stent System in Subjects With Biliary Strictures",UNKNOWN,NA,100.0,2017-10-16,2024-06-01,1.2578512396694215,Adequate (1-10/month),12.578512396694213,Significantly Below (<50%),50,38.0,19.255
NCT04522921,Childhood Obesity - Prevention of Diabetes Through Changed Eating Patterns,ACTIVE_NOT_RECRUITING,NA,211.0,2020-10-01,2032-12-31,1.4355923111309792,Adequate (1-10/month),14.35592311130979,Significantly Below (<50%),85,57.4,67.05499999999999
NCT01891721,Evaluating Two Types of Cognitive Training in Veterans With Schizophrenia,COMPLETED,NA,105.0,2013-11-21,2018-06-30,1.9002378121284187,Adequate (1-10/month),19.002378121284185,Significantly Below (<50%),100,58.4,69.175
NCT03324321,Feasibility of Improving Cerebral Autoregulation in Acute Intracerebral Haemorrhage,COMPLETED,NA,18.0,2017-10-08,2018-07-15,1.9568571428571429,Adequate (1-10/month),19.56857142857143,Significantly Below (<50%),100,51.4,50.92
NCT04476121,Use of PRF in Treatment of Dry Socket.,UNKNOWN,NA,30.0,2019-01-01,2021-07-01,1.0013157894736842,Adequate (1-10/month),10.013157894736842,Significantly Below (<50%),50,32.4,12.025
NCT06177821,Rezum for 30-80ml Patients With Moderate-severe LUTS to Study Surgical Principles for Median Lobe Enlargement,RECRUITING,NA,44.0,2024-06-03,2025-12-30,2.329321739130435,Adequate (1-10/month),23.29321739130435,Significantly Below (<50%),60,41.5,24.215
NCT00931021,Smoking Cessation Treatment for Head and Neck Cancer Patients,TERMINATED,EARLY_PHASE1,7.0,2009-07-01,2012-12-01,0.17060048038430745,Slow (<1/month),1.7060048038430746,Significantly Below (<50%),10,18.6,4.25
NCT06543121,Validation And Turkish Cross-Cultural Adaptation of Stroke Knowledge Test,COMPLETED,,200.0,2024-09-01,2025-04-03,28.448598130841123,Good (10-50/month),200.0,Exceeded (≥100%),100,69.3,81.395
NCT01345721,Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine,COMPLETED,PHASE3,205.0,2011-05-01,2011-09-01,50.733333333333334,Excellent (>50/month),200.0,Exceeded (≥100%),100,76.4,85.25
NCT00559221,FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML,UNKNOWN,PHASE2,37.0,2004-12-01,2008-06-01,0.8812832550860721,Slow (<1/month),8.81283255086072,Significantly Below (<50%),50,33.0,12.695
NCT01653821,Surgical Removal of Carotid Body in Patients With Systolic Heart Failure,COMPLETED,NA,10.0,2012-08-01,2013-11-01,0.6660831509846827,Slow (<1/month),6.660831509846828,Significantly Below (<50%),100,45.8,33.03
NCT00996021,Study to Assess Cardiac Conduction of GSK1349572,COMPLETED,PHASE1,42.0,2009-09-01,2009-12-01,14.04923076923077,Good (10-50/month),140.4923076923077,Exceeded (≥100%),100,58.4,69.175
NCT03800121,Study of Exosomes in Monitoring Patients With Sarcoma (EXOSARC),COMPLETED,,34.0,2018-11-19,2024-11-19,0.47215328467153284,Slow (<1/month),4.721532846715328,Significantly Below (<50%),100,46.1,34.695
NCT00357721,Atazanavir Twice Daily,COMPLETED,PHASE1,18.0,2006-06-01,2006-09-01,5.955652173913044,Adequate (1-10/month),59.55652173913044,Below (50-75%),100,51.4,50.92
NCT00192621,Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects,COMPLETED,PHASE4,50.0,2004-11-01,2006-12-01,2.0026315789473683,Adequate (1-10/month),20.026315789473685,Significantly Below (<50%),100,54.0,58.72500000000001
NCT06183021,The Effect of Cryotherapy on the Outcome of Pulpotomy and Root Canal Treatment,RECRUITING,NA,144.0,2023-12-13,2025-12-01,6.096467315716273,Adequate (1-10/month),60.96467315716273,Below (50-75%),60,49.5,46.58
NCT01839721,Impact of Probiotics BIFILACT® on Diarrhea in Patients Treated With Pelvic Radiation,COMPLETED,PHASE3,246.0,2006-12-01,2010-12-01,5.125420944558521,Adequate (1-10/month),51.25420944558522,Below (50-75%),100,69.7,81.73
NCT04069221,Absolute BA and OZ439 PK Effect of Different OZ439 Dose Volumes and Cobicistat Co-administration Study,COMPLETED,PHASE1,26.0,2017-02-28,2017-05-30,8.697142857142858,Adequate (1-10/month),86.97142857142856,Met (75-100%),100,57.1,66.27
NCT06099821,KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade,RECRUITING,PHASE2,39.0,2023-10-25,2026-12-31,1.0207738607050731,Adequate (1-10/month),10.20773860705073,Significantly Below (<50%),60,36.1,16.665
NCT00027521,Electroporation Therapy With Bleomycin in Treating Patients With Pancreatic Cancer,WITHDRAWN,PHASE1,0.0,2000-12-01,,,Slow (<1/month),0.0,Significantly Below (<50%),5,9.8,0.22
NCT05431621,Establishment of Molecular Classification Models for Early Diagnosis of Digestive System Cancers,COMPLETED,,2430.0,2020-11-15,2023-07-31,74.8676113360324,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02438514,Biological Biomarkers in MOMS Partnership,TERMINATED,,20.0,2014-11-01,2019-11-01,0.33340635268346114,Slow (<1/month),3.3340635268346115,Significantly Below (<50%),10,17.9,2.87
NCT01737814,Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC),COMPLETED,PHASE3,388.0,2013-05-01,,,Slow (<1/month),,Significantly Below (<50%),100,71.0,82.44
NCT06066814,To Study the Role of Plasma Von Willebrand Factor Antigen (vWF) to A Disintegrin-like and Metalloproteinase With Thrombospondin Type-1 Motifs 13 (ADAMTS-13) Activity Ratio as a Predictor of Development of Extrahepatic Organ Failure in Acute on Chronic Liver Failure (ACLF) Patients.,UNKNOWN,,50.0,2023-10-07,2023-12-31,17.905882352941177,Good (10-50/month),179.05882352941177,Exceeded (≥100%),50,42.3,25.295
NCT05527314,Effect of Remimazolam vs Sevoflurane Anesthesia on Incidence of Emergence Agitation and Complications in Children Undergoing Ophthalmic Surgery,COMPLETED,NA,110.0,2022-08-23,2023-02-07,19.93095238095238,Good (10-50/month),199.30952380952382,Exceeded (≥100%),100,63.8,76.78
NCT03550014,Effectiveness of Physical Therapy Interventions for Low Back Pain Targeting the Low Back Only or Low Back Plus Hips,COMPLETED,NA,76.0,2018-07-02,2021-01-14,2.4956202804746495,Adequate (1-10/month),24.9562028047465,Significantly Below (<50%),100,56.1,63.99
NCT04383314,Targeting Hyaluronan Accumulation Through Exercise in T2DM,COMPLETED,NA,30.0,2021-09-01,2024-08-31,0.8339726027397261,Slow (<1/month),8.33972602739726,Significantly Below (<50%),100,47.4,40.98
NCT03002714,Blood Pressure Reactivity After Resistance Exercise in Older Women,COMPLETED,NA,10.0,2014-10-01,2015-05-01,1.4358490566037736,Adequate (1-10/month),14.358490566037737,Significantly Below (<50%),100,45.8,33.03
NCT03695614,Cognitive Remediation Therapy for Participants With Late-Life Schizophrenia,COMPLETED,NA,34.0,2018-10-24,2020-03-12,2.0494257425742575,Adequate (1-10/month),20.494257425742575,Significantly Below (<50%),100,52.7,55.04
NCT01186614,"Refractory Out-Of-Hospital Cardiac Arrest Treated With Mechanical CPR, Hypothermia, ECMO and Early Reperfusion",UNKNOWN,PHASE1,24.0,2010-11-01,2014-12-01,0.48997987927565395,Slow (<1/month),4.899798792756539,Significantly Below (<50%),50,31.9,11.295
NCT00194714,Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab,COMPLETED,PHASE1,22.0,2016-05-01,2023-05-22,0.25986806363989134,Slow (<1/month),2.5986806363989134,Significantly Below (<50%),100,46.8,38.440000000000005
NCT06165614,Artesunate Pessaries (Vaginal Inserts) for Cervical Precancer in Kenya,COMPLETED,PHASE1,17.0,2024-03-04,2025-04-10,1.28726368159204,Adequate (1-10/month),12.872636815920396,Significantly Below (<50%),100,46.4,36.26
NCT05121714,"Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464",COMPLETED,PHASE1,59.0,2020-12-17,2021-05-18,11.815526315789473,Good (10-50/month),118.15526315789475,Exceeded (≥100%),100,59.7,71.355
NCT02753114,Prehospital Analgesia With Intra-Nasal Ketamine,COMPLETED,PHASE4,120.0,2017-11-06,2018-05-24,18.355778894472362,Good (10-50/month),183.5577889447236,Exceeded (≥100%),100,64.6,77.59
NCT05942014,Correlation of Children's Electronic Screen Time Exposure and Dental Anxiety and Behavior,UNKNOWN,,211.0,2023-09-01,2024-10-01,16.21929292929293,Good (10-50/month),162.1929292929293,Exceeded (≥100%),50,55.2,62.195
NCT00000914,A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks,COMPLETED,NA,800.0,,2000-06-01,,Slow (<1/month),,Significantly Below (<50%),100,80.0,87.67
NCT00890214,Prostacyclin's Effect on Platelet Responsiveness,COMPLETED,PHASE4,23.0,2007-09-01,2008-05-01,2.881152263374486,Adequate (1-10/month),28.811522633744858,Significantly Below (<50%),100,51.8,52.17
NCT03039114,Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102),COMPLETED,PHASE1,26.0,2017-02-15,2021-03-30,0.5262234042553192,Slow (<1/month),5.2622340425531915,Significantly Below (<50%),100,47.1,39.64
NCT07289516,"Effect Of Lıstenıng to Musıc on Women Gıvıng Bırth By Cesarean Sectıon: Paın, Comfort And Attachment",COMPLETED,NA,62.0,2023-03-15,2024-05-15,4.4198594847775174,Adequate (1-10/month),44.19859484777518,Significantly Below (<50%),100,55.0,61.834999999999994
NCT03554616,Efficacy of Three Novel Bi-treated Long Lasting Insecticidal Nets,COMPLETED,NA,4200.0,2019-02-01,2023-02-01,87.50718685831622,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT01565616,Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease,COMPLETED,PHASE2,22.0,2012-03-01,2016-06-30,0.42331226295828067,Slow (<1/month),4.233122629582807,Significantly Below (<50%),100,46.8,38.440000000000005
NCT03303716,ASXL-Related Disorders Natural History Study,RECRUITING,,200.0,2017-09-20,2037-09-01,0.8355750754872359,Slow (<1/month),8.35575075487236,Significantly Below (<50%),60,47.3,40.475
NCT06023316,mGain - sEMG-based Gamified Therapy for Improved Upper Limb Rehabilitation,UNKNOWN,NA,30.0,2023-08-08,2024-03-01,4.433009708737864,Adequate (1-10/month),44.33009708737864,Significantly Below (<50%),50,37.4,18.62
NCT03263416,Study Evaluating Treatment Adherence in Patients Treated With Oral Targeted Therapy in Oncology Supported by a Dedicated and Coordinated Follow-up Compared to Standard Follow-up.,COMPLETED,NA,186.0,2017-07-24,2022-01-25,3.439756986634265,Adequate (1-10/month),34.39756986634265,Significantly Below (<50%),100,64.9,77.985
NCT00812916,European Carto® XP REgistry for Validating Specialized CFAE SOftware,COMPLETED,,206.0,2008-09-01,2010-12-01,7.637807551766139,Adequate (1-10/month),76.37807551766139,Met (75-100%),100,64.8,77.865
NCT00006216,Vaccine Therapy and Ganciclovir in Treating Patients With Mesothelioma,UNKNOWN,PHASE1,,1997-08-01,,,Slow (<1/month),,Significantly Below (<50%),50,25.0,7.23
NCT03776916,Application of Simethicone in Esophagogastroscopy,COMPLETED,NA,311.0,2019-05-01,2019-08-31,77.59704918032787,Excellent (>50/month),200.0,Exceeded (≥100%),100,84.9,90.85
NCT06362616,Preoperative Accelerated Partial Breast Irradiation in Patients With Locally Recurrent or Second Primary Breast Cancer,RECRUITING,NA,31.0,2024-04-12,2027-04-11,0.8625594149908593,Slow (<1/month),8.625594149908594,Significantly Below (<50%),60,35.5,15.950000000000001
NCT02106416,Use of PET/MRI Tracer to Further Understanding of Prostate Cancer Development,COMPLETED,NA,21.0,2013-08-01,2016-04-01,0.6563039014373717,Slow (<1/month),6.563039014373717,Significantly Below (<50%),100,46.7,37.895
NCT03653416,Efficacy of Ipack Block and Surgeon's Joint Infiltration in Total Knee Arthroplasty,COMPLETED,PHASE4,99.0,2018-03-01,2019-08-01,5.817683397683398,Adequate (1-10/month),58.17683397683398,Below (50-75%),100,57.9,67.83
NCT05758116,Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients,RECRUITING,PHASE2,20.0,2022-07-07,2026-07-07,0.4167008898015058,Slow (<1/month),4.167008898015058,Significantly Below (<50%),60,34.6,14.729999999999999
NCT04047316,Development and Validation of a New Digital Dermatoscope in the United States,COMPLETED,,60.0,2019-08-27,2020-04-15,7.872413793103449,Adequate (1-10/month),78.72413793103448,Met (75-100%),100,53.1,56.105000000000004
NCT02045316,"The Expression of Aquaporin 3, 8 and 9 in Placenta in Normal and Preeclamptic Pregnancies: Perinatal and Neonatal Outcomes.",UNKNOWN,,210.0,2014-03-01,2014-07-01,52.39672131147541,Excellent (>50/month),200.0,Exceeded (≥100%),50,60.1,72.085
NCT06589206,Three-Dimensional Assessment of Dentoskeletal Changes Associated With a Modified Twin Block Appliance,NOT_YET_RECRUITING,NA,30.0,2024-10-01,2025-10-30,2.317766497461929,Adequate (1-10/month),23.17766497461929,Significantly Below (<50%),30,31.4,10.47
NCT05568706,A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.,COMPLETED,PHASE2,186.0,2022-11-29,2025-06-23,6.042518676627535,Adequate (1-10/month),60.42518676627535,Below (50-75%),100,64.9,77.985
NCT01174706,Impact of Information Prescriptions on Medication Adherence in Emergency Department (ED) Patients,COMPLETED,NA,3940.0,2010-11-01,2011-12-01,303.62936708860764,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT00271206,Effect of Progesterone on Smoking Behavior in Male and Female Smokers,COMPLETED,PHASE1,65.0,2004-09-01,2008-09-01,1.354277891854894,Adequate (1-10/month),13.54277891854894,Significantly Below (<50%),100,50.2,48.04
NCT06972706,"Efficacy and Safety of Shatavari in Women Sexual Wellness: A Prospective, Randomized, Double-Blind, Three-arm, Parallel, Placebo-Controlled Study",COMPLETED,NA,51.0,2024-10-26,2025-02-28,12.41952,Good (10-50/month),124.1952,Exceeded (≥100%),100,59.1,70.6
NCT06190106,Experiences of Psychotherapeutic Outcomes in Women Victims of Domestic Violence,UNKNOWN,NA,15.0,2023-11-15,2024-04-10,3.1061224489795918,Adequate (1-10/month),31.06122448979592,Significantly Below (<50%),50,36.2,16.84
NCT06000306,MRD Monitoring by Digital Droplet PCR in the Early Period After Allo-HSCT to Predict Patients at High Risk of Relapse,COMPLETED,,192.0,2018-01-01,2023-07-31,2.869160530191458,Adequate (1-10/month),28.69160530191458,Significantly Below (<50%),100,63.7,76.655
NCT02531906,"Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During Chemoradiation",COMPLETED,PHASE1,60.0,2015-04-24,2018-06-14,1.5923278116826505,Adequate (1-10/month),15.923278116826506,Significantly Below (<50%),100,49.8,47.17
NCT03789006,Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney Transplantation,UNKNOWN,PHASE4,300.0,2018-03-21,2024-03-21,4.166058394160584,Adequate (1-10/month),41.660583941605836,Significantly Below (<50%),50,59.0,70.365
NCT00684606,Transcervical Foley Catheter With or Without Oxytocin for Induction of Labor,UNKNOWN,NA,120.0,2008-05-01,2010-05-01,5.003835616438357,Adequate (1-10/month),50.03835616438357,Below (50-75%),50,44.6,29.42
NCT05459506,Investigating Development of Autoimmunity in Post-Acute COVID-19 Syndrome (PACS),UNKNOWN,,120.0,2021-06-25,2024-03-25,3.6382470119521915,Adequate (1-10/month),36.38247011952191,Significantly Below (<50%),50,42.9,26.145000000000003
NCT05549206,A Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in Chinese People,UNKNOWN,NA,350.0,2023-04-01,2024-04-01,29.10928961748634,Good (10-50/month),200.0,Exceeded (≥100%),50,68.0,80.56
NCT00574106,A Study to Evaluate the Effect of Far Infrared Radiation for Cancer Treatment,UNKNOWN,PHASE1,3.0,2008-02-01,2009-10-01,0.15019736842105263,Slow (<1/month),1.5019736842105265,Significantly Below (<50%),50,30.2,9.245000000000001
NCT01234506,Oxidative Stress and Nutritional Supplementation Intervention Study,COMPLETED,PHASE2,21.0,2010-10-01,2013-07-01,0.6366932270916336,Slow (<1/month),6.366932270916335,Significantly Below (<50%),100,46.7,37.895
NCT01127906,Study To Assess The Effect Of PF-04531083 On Heat Pain In Healthy Volunteers With Ultraviolet Light Sensitized Skin,COMPLETED,PHASE1,36.0,2010-06-01,2010-09-01,11.911304347826087,Good (10-50/month),119.11304347826088,Exceeded (≥100%),100,57.9,67.83
NCT06630806,A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma,RECRUITING,PHASE1,82.0,2024-10-30,2029-05-14,1.5063850331925168,Adequate (1-10/month),15.063850331925169,Significantly Below (<50%),60,39.6,21.115000000000002
NCT02860806,"Safety, Tolerability, Pharmacokinetic and Absolute Bioavailability Study of JNJ-63623872 Administered as an Intravenous Infusion and a 600-Milligram (mg) Oral Dose in Healthy Adults",COMPLETED,PHASE1,66.0,2016-08-08,2017-06-10,6.565490196078431,Adequate (1-10/month),65.65490196078431,Below (50-75%),100,55.3,62.36000000000001
NCT00006006,Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed,COMPLETED,PHASE2,38.0,2000-08-01,,,Slow (<1/month),,Significantly Below (<50%),100,43.0,26.465
NCT02078206,Early Neurocognitive Rehabilitation in Intensive Care,COMPLETED,NA,72.0,2015-11-01,2020-09-01,1.2410419026047566,Adequate (1-10/month),12.410419026047565,Significantly Below (<50%),100,50.8,49.18
NCT03345706,Selective Cerebral Hypothermia Trial - Under Extracorporeal Cardiopulmonary Resuscitation (SHOT-ECPR),UNKNOWN,NA,20.0,2017-10-11,2019-07-01,0.9694267515923567,Slow (<1/month),9.694267515923567,Significantly Below (<50%),50,31.6,10.905
NCT05824806,Knee Osteoarthritis Treatment With Platelet-rich Plasma,NOT_YET_RECRUITING,PHASE3,90.0,2024-08-01,2026-07-01,3.9193133047210305,Adequate (1-10/month),39.1931330472103,Significantly Below (<50%),30,36.2,16.84
NCT00095706,Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF),COMPLETED,PHASE1,50.0,2003-06-01,2012-01-01,0.48533163265306123,Slow (<1/month),4.853316326530613,Significantly Below (<50%),100,49.0,45.61
NCT03192904,Comparison of Energy Instruments and Stapling Device to Dissect Intersegmental Plane in Segmentectomy,TERMINATED,NA,70.0,2017-06-01,2018-06-09,5.71260053619303,Adequate (1-10/month),57.1260053619303,Below (50-75%),10,28.6,8.58
NCT05111704,Short-term Effects of Postural Taping on Pain and Neck Posture,COMPLETED,NA,26.0,2018-01-16,2021-10-01,0.5845199409158051,Slow (<1/month),5.84519940915805,Significantly Below (<50%),100,47.1,39.64
NCT06900504,"""The Effect of Sleep Hygiene Training Given to Heart Failure Patients on Their HospitalAcquired Insomnia Level""",NOT_YET_RECRUITING,NA,34.0,2025-06-30,2026-05-30,3.098682634730539,Adequate (1-10/month),30.986826347305385,Significantly Below (<50%),30,31.7,11.14
NCT02520804,Normal Saline Versus Balance Salt Solution Resuscitation on Kidney Function,UNKNOWN,NA,107.0,2014-11-01,2017-10-01,3.0582910798122067,Adequate (1-10/month),30.58291079812207,Significantly Below (<50%),50,43.6,27.54
NCT06591104,Metabolic Phenotypes of Obesity and Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus,NOT_YET_RECRUITING,,71.0,2024-10-01,2025-10-01,5.921205479452055,Adequate (1-10/month),59.212054794520554,Below (50-75%),30,33.0,12.695
NCT04049604,IDENTIFY Study: Natural History of Maternal Neoplasia,RECRUITING,NA,320.0,2019-12-23,2029-04-30,2.8515222482435596,Adequate (1-10/month),28.515222482435597,Significantly Below (<50%),60,63.6,76.545
NCT02008604,Influence of Stroke on the Composition of Intestinal Microbiota,COMPLETED,,24.0,2014-06-01,2018-04-01,0.5218285714285714,Slow (<1/month),5.218285714285714,Significantly Below (<50%),100,45.3,31.169999999999998
NCT05415904,Hantavirus Nephropathy in North-Eastern France : Severity Risk Factors and Prognostic Tools,COMPLETED,,101.0,2022-05-20,2024-07-31,3.8286924034869245,Adequate (1-10/month),38.286924034869244,Significantly Below (<50%),100,56.4,64.88000000000001
NCT01493804,Noninvasive Study of Brain Connectivity With EEG and NIRS,COMPLETED,,5.0,2011-11-08,2017-09-01,0.0716572504708098,Slow (<1/month),0.716572504708098,Significantly Below (<50%),100,43.7,27.744999999999997
NCT07109804,Cuneiform Nucleus (CnF) Deep Brain Stimulation for Gait Facilitation Following Spinal Cord Injury,RECRUITING,NA,6.0,2025-11-30,2026-12-31,0.46121212121212124,Slow (<1/month),4.612121212121211,Significantly Below (<50%),60,33.5,13.34
NCT04626804,Remember Stuff: A Dyadic-focused Technology to Support Persons With Alzheimer's Disease in the Community,COMPLETED,NA,30.0,2020-10-27,2022-12-31,1.148679245283019,Adequate (1-10/month),11.486792452830189,Significantly Below (<50%),100,47.4,40.98
NCT05655104,Effects of the Couplet Care in Neonatal Intensive Care Unit,UNKNOWN,,30.0,2023-01-01,2023-12-01,2.734131736526946,Adequate (1-10/month),27.341317365269457,Significantly Below (<50%),50,35.7,16.18
NCT01729104,Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma,TERMINATED,PHASE1,18.0,2013-04-25,2018-10-03,0.27575239053850026,Slow (<1/month),2.7575239053850025,Significantly Below (<50%),10,19.4,5.2299999999999995
NCT04149704,Videos for Advance Care Planning in Young Adults,COMPLETED,NA,102.0,2019-12-13,2022-05-05,3.5524942791762015,Adequate (1-10/month),35.52494279176201,Significantly Below (<50%),100,58.2,68.795
NCT02273804,Topiramate and Severe Obesity,COMPLETED,PHASE3,18.0,2016-06-01,2018-01-23,0.9116805324459234,Slow (<1/month),9.116805324459234,Significantly Below (<50%),100,46.4,36.26
NCT02944604,The Efficacy and Safety of PEG-rhG-CSF（Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy,COMPLETED,PHASE4,240.0,2016-09-08,2017-09-30,18.877519379844962,Good (10-50/month),188.77519379844964,Exceeded (≥100%),100,74.2,84.15
NCT03350204,Biomechanical Osteoarthritis Outcomes in Meniscectomy Patients,COMPLETED,NA,30.0,2017-11-01,2020-09-20,0.8664136622390892,Slow (<1/month),8.664136622390892,Significantly Below (<50%),100,47.4,40.98
NCT02409004,Effects of Rifampin on the Pharmacokinetics of Ataluren,COMPLETED,PHASE1,15.0,2015-02-01,2015-03-01,15.0,Good (10-50/month),150.0,Exceeded (≥100%),100,56.2,64.21
NCT00791804,Phase II Study of Inhaled AeroLEF for Analgesia After ACL Knee Surgery,COMPLETED,PHASE2,19.0,2004-02-01,2004-12-01,1.9025,Adequate (1-10/month),19.025,Significantly Below (<50%),100,51.5,51.245
NCT04816604,Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH),ACTIVE_NOT_RECRUITING,PHASE2,74.0,2021-04-05,2027-12-01,0.9265981077745783,Slow (<1/month),9.265981077745783,Significantly Below (<50%),85,46.4,36.26
NCT02975804,RCT on Interactive Computer Play on Trunk Control in CP,COMPLETED,NA,18.0,2017-10-01,2018-09-30,1.5052747252747254,Adequate (1-10/month),15.052747252747253,Significantly Below (<50%),100,46.4,36.26
NCT01492504,Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial,COMPLETED,,1850.0,2012-02-07,2018-03-19,25.230286738351257,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT05620784,Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP,RECRUITING,PHASE3,138.0,2023-03-01,2024-08-01,8.093872832369943,Adequate (1-10/month),80.93872832369942,Met (75-100%),60,49.0,45.61
NCT03666884,The Comparison of 50% AS Versus PFAT+ 0.05 % COE in Severe Dry Eye Syndrome,COMPLETED,PHASE4,36.0,2015-10-10,2016-10-25,2.876220472440945,Adequate (1-10/month),28.76220472440945,Significantly Below (<50%),100,52.9,55.55
NCT03518684,Obstetrical Gel Use to Shorten Labor and Prevent Lower Genital Tract Trauma,COMPLETED,PHASE4,160.0,2018-04-03,2019-06-30,10.751434878587196,Good (10-50/month),107.51434878587196,Exceeded (≥100%),100,67.8,80.285
NCT01212484,Carbidopa for the Treatment of Nausea and Vomiting in Familial Dysautonomia,COMPLETED,PHASE3,12.0,2009-12-01,2012-10-01,0.35292753623188405,Slow (<1/month),3.529275362318841,Significantly Below (<50%),100,46.0,34.1
NCT01883284,Action of Epigenetic Modifiers in Cystic Fibrosis Treatment,COMPLETED,NA,39.0,2012-01-01,2014-11-01,1.1470144927536232,Adequate (1-10/month),11.470144927536232,Significantly Below (<50%),100,48.1,43.275000000000006
NCT07145684,"Culturally Tailored Nutrition Therapy to Improve Dietary Adherence of Type 2 Diabetes Patients in Benin, Africa",NOT_YET_RECRUITING,NA,60.0,2025-10-02,2026-10-30,4.64732824427481,Adequate (1-10/month),46.47328244274809,Significantly Below (<50%),30,33.8,13.694999999999999
NCT06516484,"Ropustin for Refractory Aplastic Anaemia After Radiotherapy - a Single-centre, Prospective, Open-label, Single-arm Study",NOT_YET_RECRUITING,PHASE4,40.0,2024-07-30,2025-12-31,2.3460500963391135,Adequate (1-10/month),23.46050096339114,Significantly Below (<50%),30,32.2,11.635
NCT05700084,Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors,RECRUITING,PHASE1,84.0,2023-06-09,2025-04-09,3.8163582089552244,Adequate (1-10/month),38.163582089552236,Significantly Below (<50%),60,44.7,29.67
NCT00925184,Students' View: Survey of Medical Education in Taiwan,UNKNOWN,,370.0,2008-07-01,2009-11-01,23.07950819672131,Good (10-50/month),200.0,Exceeded (≥100%),50,67.9,80.36999999999999
NCT06399484,"In Patients With Carpal Tunnel Syndrome, Median Nerve Conduction is Evaluated After Nerve Mobilizations",NOT_YET_RECRUITING,NA,30.0,2024-06-15,2024-12-15,4.99016393442623,Adequate (1-10/month),49.90163934426229,Significantly Below (<50%),30,31.4,10.47
NCT05819684,A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors,RECRUITING,PHASE1,133.0,2023-04-18,2026-05-30,3.557574692442883,Adequate (1-10/month),35.57574692442883,Significantly Below (<50%),60,48.6,44.685
NCT07052084,Systematic Adjunction of Vasopressine in Septic Shock,NOT_YET_RECRUITING,PHASE3,120.0,2026-01-01,2028-02-01,4.8,Adequate (1-10/month),48.0,Significantly Below (<50%),30,38.6,20.015
NCT04855084,Occlusal Relationship Assesment of Monolithic Zirconia FDPs,COMPLETED,NA,14.0,2018-05-24,2018-08-27,4.485894736842106,Adequate (1-10/month),44.858947368421056,Significantly Below (<50%),100,51.1,50.129999999999995
NCT03159884,The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV),UNKNOWN,PHASE4,300.0,2015-10-01,2018-12-01,7.892826274848747,Adequate (1-10/month),78.92826274848747,Met (75-100%),50,59.0,70.365
NCT02710084,Piloting Treatment With Intranasal Oxytocin in Phelan-McDermid Syndrome,COMPLETED,PHASE2,18.0,2016-04-29,2020-07-29,0.3530412371134021,Slow (<1/month),3.530412371134021,Significantly Below (<50%),100,46.4,36.26
NCT02353884,Multi-modality MRI Study on Prediction for Mild Cognitive Impairment Conversion,COMPLETED,,150.0,2010-01-01,2012-12-01,4.287323943661972,Adequate (1-10/month),42.87323943661973,Significantly Below (<50%),100,60.3,72.34
NCT06035484,Effect of Seat Height and Angle on Wheelchair Foot Propulsion,COMPLETED,NA,31.0,2023-04-20,2023-10-30,4.889326424870466,Adequate (1-10/month),48.89326424870467,Significantly Below (<50%),100,52.5,54.345
NCT00867984,Torsion Optimization to Reduce Symptoms and Improve Outcomes in Non-responders,UNKNOWN,PHASE3,60.0,2009-03-01,2017-01-01,0.637932238910234,Slow (<1/month),6.379322389102341,Significantly Below (<50%),50,34.8,15.040000000000001
NCT05882084,"Oral Supplementation of Astaxanthin on Skin Photoaging, Hydration and Elasticity",UNKNOWN,NA,24.0,2023-07-24,2023-12-31,4.566,Adequate (1-10/month),45.660000000000004,Significantly Below (<50%),50,36.9,17.735
NCT05529784,Dupilumab in the Treatment of Severe Uncontrolled CRSwNP: a Multicentre Observational Real-life Study (DUPIREAL),UNKNOWN,,600.0,2021-10-06,2023-10-01,25.191724137931033,Good (10-50/month),200.0,Exceeded (≥100%),50,78.3,86.48
NCT04236284,Management of Chronic Pain and PTSD in Gulf War Veterans With tDCS+Prolonged Exposure,COMPLETED,NA,21.0,2020-01-15,2021-11-23,0.9428318584070797,Slow (<1/month),9.428318584070798,Significantly Below (<50%),100,46.7,37.895
NCT02899884,Characterisation and Epidemiology of Breakthrough Cancer Pain in Spain,COMPLETED,,3765.0,2016-11-14,2018-07-16,188.18817733990147,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT03285984,Ability of Four Toothpastes to Remove Plaque,COMPLETED,NA,56.0,2012-03-27,2012-05-08,40.586666666666666,Good (10-50/month),200.0,Exceeded (≥100%),100,59.5,71.0
NCT00795184,Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy,COMPLETED,NA,122.0,2008-11-01,2010-02-01,8.12621444201313,Adequate (1-10/month),81.26214442013129,Met (75-100%),100,59.8,71.61
NCT02825784,A Multicenter Study to Evaluate the Nutritional Suitability of Renastart,COMPLETED,NA,12.0,2017-01-06,2019-10-31,0.3553307392996109,Slow (<1/month),3.553307392996109,Significantly Below (<50%),100,46.0,34.1
NCT01142284,"Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers, Endothelial Function and Safety",COMPLETED,PHASE2,80.0,2010-05-19,2012-12-18,2.5796610169491525,Adequate (1-10/month),25.79661016949153,Significantly Below (<50%),100,56.4,64.88000000000001
NCT06415084,Prevalence of Hyperemesis Gravidarum,RECRUITING,,604.0,2025-05-01,2026-12-01,31.75433506044905,Good (10-50/month),200.0,Exceeded (≥100%),60,81.3,88.58
NCT04569084,Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS,TERMINATED,PHASE3,384.0,2020-11-13,2023-09-29,11.13234285714286,Good (10-50/month),111.32342857142858,Exceeded (≥100%),10,58.7,69.69
NCT04909684,Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for NSCLC,UNKNOWN,PHASE3,750.0,2020-11-18,2024-11-01,15.810249307479227,Good (10-50/month),158.10249307479225,Exceeded (≥100%),50,80.0,87.67
NCT07149233,Effectiveness of Inspiratory Muscle Training on Sleep in Patients With Obstructive Sleep Apnea,ENROLLING_BY_INVITATION,NA,30.0,2025-03-11,2026-02-20,2.639306358381503,Adequate (1-10/month),26.393063583815028,Significantly Below (<50%),55,38.9,20.325
NCT03193333,PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM),TERMINATED,PHASE3,51.0,2017-11-06,2024-10-30,0.6088,Slow (<1/month),6.088,Significantly Below (<50%),10,22.1,6.254999999999999
NCT02423733,Can E-therapies Reduce Waiting Lists in Secondary Mental Health Care? A Randomized Controlled Trial,UNKNOWN,NA,110.0,2015-04-01,2019-05-31,2.2014464168310326,Adequate (1-10/month),22.014464168310326,Significantly Below (<50%),50,43.8,27.965
NCT02262533,Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects,COMPLETED,PHASE1,15.0,2007-06-01,2007-06-01,15.0,Good (10-50/month),150.0,Exceeded (≥100%),100,41.2,23.425
NCT04843033,A Study to Investigate Safety and Tolerability of SH3809 Tablet in Patients With Advanced Solid Tumors,UNKNOWN,PHASE1,55.0,2021-04-02,2023-12-01,1.7206577595066805,Adequate (1-10/month),17.206577595066804,Significantly Below (<50%),50,39.4,20.94
NCT05942833,Quality of Life in Acute Complicated and Chronic Recurrent Left-sided Diverticulitis,RECRUITING,NA,136.0,2023-01-16,2027-07-01,2.544462200368777,Adequate (1-10/month),25.444622003687765,Significantly Below (<50%),60,48.9,45.4
NCT04221633,R34 Family Navigator Enhancing Early Engagement,UNKNOWN,NA,297.0,2019-12-11,2021-10-30,13.12145137880987,Good (10-50/month),131.21451378809869,Exceeded (≥100%),50,63.8,76.78
NCT01261533,"Flexibility, Efficacy, and Safety of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment",UNKNOWN,PHASE1,122.0,2010-09-01,2014-06-01,2.7126953981008035,Adequate (1-10/month),27.12695398100804,Significantly Below (<50%),50,44.8,29.845
NCT03791333,A Multi-center Clinical Study on the Status of Trauma Evaluating Ability in Patients With Multiple Trauma,UNKNOWN,,3600.0,2019-01-01,2021-12-31,100.07671232876713,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT05567133,Risk Indicators of Sarcoidosis Evolution-Unified Protocol,RECRUITING,,200.0,2023-01-10,2030-03-30,2.309559939301973,Adequate (1-10/month),23.09559939301973,Significantly Below (<50%),60,52.3,53.515
NCT05073133,Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (OFELIA),COMPLETED,PHASE4,16.0,2021-11-04,2023-08-08,0.7586292834890966,Slow (<1/month),7.586292834890967,Significantly Below (<50%),100,46.3,35.66
NCT03645733,Evaluation of the Effect of Cooled Haemodialysis on Cognitive Function in Patients Suffering With End-stage KD,UNKNOWN,NA,90.0,2017-12-20,2020-10-31,2.6191204588910133,Adequate (1-10/month),26.191204588910132,Significantly Below (<50%),50,42.2,25.155
NCT02483533,Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202,TERMINATED,PHASE3,100.0,2015-06-01,2016-02-26,11.274074074074074,Good (10-50/month),112.74074074074072,Exceeded (≥100%),10,36.0,16.564999999999998
NCT06084533,CS1P1 PET Studies of Neuroinflammation in Parkinson Disease,ENROLLING_BY_INVITATION,,80.0,2024-01-10,2029-02-28,1.2980810234541578,Adequate (1-10/month),12.980810234541575,Significantly Below (<50%),55,36.2,16.84
NCT00025233,Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix,COMPLETED,PHASE2,50.0,2002-04-01,2009-07-01,0.574773413897281,Slow (<1/month),5.7477341389728105,Significantly Below (<50%),100,49.0,45.61
NCT00878033,Autonomic Dysfunction and Inflammation in Chronic Hemodialysis Patients,COMPLETED,,45.0,2009-04-01,2010-12-01,2.2492610837438423,Adequate (1-10/month),22.49261083743842,Significantly Below (<50%),100,51.9,52.55499999999999
NCT00150033,Health-Related Quality of Life for Thyroid Patients,COMPLETED,,1200.0,2005-05-01,2007-10-01,41.368063420158556,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT01899833,Efficacy and Saftey Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD),NOT_YET_RECRUITING,PHASE2,60.0,2025-05-10,2026-04-01,5.602453987730061,Adequate (1-10/month),56.02453987730062,Below (50-75%),30,33.8,13.694999999999999
NCT02785133,Safety and Feasibility of Polychromatic Light Emitting Diode for Peripheral Catheter Illumination During Peripheral Intravenous Delivery of Normal Saline,COMPLETED,NA,3063.0,2014-12-01,2016-10-01,139.160776119403,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT06455033,Manual Diaphragm Release on Stepping Reaction Time in Chronic Obstructive Pulmonary Disease,ACTIVE_NOT_RECRUITING,NA,60.0,2024-08-22,2025-11-15,4.058666666666667,Adequate (1-10/month),40.58666666666667,Significantly Below (<50%),85,50.3,48.215
NCT03935633,Short-term Clinical Study of CN128 in Thalassemia Patients,COMPLETED,PHASE1,16.0,2018-12-03,2019-12-17,1.2850659630606862,Adequate (1-10/month),12.850659630606861,Significantly Below (<50%),100,46.3,35.66
NCT02844933,Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi Syndrome,TERMINATED,PHASE2,7.0,2018-05-09,2019-07-31,0.475625,Slow (<1/month),4.75625,Significantly Below (<50%),10,18.6,4.25
NCT02634333,Anti-VEGF Treatment for Prevention of PDR/DME,COMPLETED,PHASE3,399.0,2016-01-01,2022-05-11,5.230645994832042,Adequate (1-10/month),52.306459948320416,Below (50-75%),100,81.9,89.01
NCT03073252,The Acute Effect of Egg-Based High Protein Meal on Hypertensive Response to Exercise,COMPLETED,NA,31.0,2017-01-01,2017-06-30,5.242444444444445,Adequate (1-10/month),52.424444444444454,Below (50-75%),100,52.5,54.345
NCT02304952,Eccentric Exercise or Radiofrequent Microtenotomy as Treatment of Lateral Epicondylalgia,UNKNOWN,NA,100.0,2014-09-01,2018-09-01,2.083504449007529,Adequate (1-10/month),20.83504449007529,Significantly Below (<50%),50,43.0,26.465
NCT06528652,"Evaluation of Injury Profile, Core Stability and Balance in Female Hip-Hop Dancers",COMPLETED,,65.0,2024-09-19,2025-05-17,8.244166666666667,Adequate (1-10/month),82.44166666666666,Met (75-100%),100,53.5,57.555
NCT00728052,A Human Volunteer Study Investigating Single Oral Doses of GSK598809 in Otherwise Healthy Smokers,COMPLETED,PHASE1,18.0,2008-06-09,2008-08-19,7.7171830985915495,Adequate (1-10/month),77.17183098591549,Met (75-100%),100,51.4,50.92
NCT06631352,Outcomes and Prognostic Factors in Hepatopancreatoduodenectomy,COMPLETED,,50.0,2000-01-01,2024-05-31,0.17068520802960638,Slow (<1/month),1.7068520802960636,Significantly Below (<50%),100,47.3,40.475
NCT06511752,Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia,RECRUITING,EARLY_PHASE1,120.0,2024-05-21,2030-12-01,1.5315723270440251,Adequate (1-10/month),15.315723270440252,Significantly Below (<50%),60,42.6,25.679999999999996
NCT01210352,"Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects",COMPLETED,PHASE3,61.0,2010-12-13,2017-10-06,0.7460184813177984,Slow (<1/month),7.4601848131779835,Significantly Below (<50%),100,49.9,47.425
NCT03344952,Improvement on GMFCS Level of Patients With Cerebral Palsy Treated by Repeated Botulinum Toxin-A,COMPLETED,,503.0,2017-11-20,2018-11-09,43.252316384180794,Good (10-50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT00929552,Effect of Fish Oil on Markers of the Metabolic Syndrome in Overweight Adolescent Boys,COMPLETED,NA,78.0,2007-11-01,2009-06-01,4.107820069204153,Adequate (1-10/month),41.07820069204153,Significantly Below (<50%),100,56.2,64.21
NCT02726152,Polymer Clips Versus Endoloops for Closure of the Appendiceal Stump During Emergency Laparoscopic Appendicectomy,UNKNOWN,NA,150.0,2016-08-01,2017-09-01,11.530303030303031,Good (10-50/month),115.30303030303031,Exceeded (≥100%),50,52.0,52.86
NCT06243952,Brain Controlled Spinal Cord Stimulation In Participants With Spinal Cord Injury For Lower Limb Rehabilitation,RECRUITING,NA,3.0,2024-05-03,2030-07-01,0.04058666666666667,Slow (<1/month),0.4058666666666667,Significantly Below (<50%),60,33.2,12.989999999999998
NCT06635252,"Statins, Cholesterol and Cognitive Decline in Alzheimer's",COMPLETED,,2000.0,2025-01-01,2025-03-01,1031.864406779661,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT07168252,Developing a Physiology-Pharmacodynamic Model of Rocuronium Dose and Cardiac Output to Investigate the Onset Time of Neuromuscular Relaxation,NOT_YET_RECRUITING,PHASE4,32.0,2025-12-01,2026-12-31,2.4660253164556964,Adequate (1-10/month),24.660253164556963,Significantly Below (<50%),30,31.6,10.905
NCT05929352,Song-making In a Group (SING),RECRUITING,NA,200.0,2022-10-14,2026-05-31,4.594716981132075,Adequate (1-10/month),45.947169811320755,Significantly Below (<50%),60,54.0,58.72500000000001
NCT01911052,The Impact of Telephone and Short Message System Based Education on Bowel Preparation for Colonoscopy,COMPLETED,PHASE3,390.0,2013-07-01,2014-02-01,55.21674418604651,Excellent (>50/month),200.0,Exceeded (≥100%),100,91.2,93.605
NCT03341052,Characterization of Bile Acid Pathway in Obesity,COMPLETED,NA,16.0,2017-11-14,2021-10-09,0.3417824561403509,Slow (<1/month),3.417824561403509,Significantly Below (<50%),100,46.3,35.66
NCT07356752,Prediction of Lung Transplant Outcome,ACTIVE_NOT_RECRUITING,NA,4200.0,2025-06-17,2031-06-01,58.780689655172424,Excellent (>50/month),200.0,Exceeded (≥100%),85,95.5,96.55
NCT06254352,Clinical Risk Scores in Prediction Outcome of Acute UGIT Bleeding in Non Cirrhotic Patients,UNKNOWN,,100.0,2024-03-01,2024-11-30,11.10948905109489,Good (10-50/month),111.0948905109489,Exceeded (≥100%),50,46.3,35.66
NCT00621452,"Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma",COMPLETED,PHASE1,12.0,2007-08-01,,,Slow (<1/month),,Significantly Below (<50%),100,41.0,23.01
NCT02571452,Brief Behavioral Insomnia Treatment Study,COMPLETED,NA,93.0,2016-01-06,2019-06-30,2.227317073170732,Adequate (1-10/month),22.27317073170732,Significantly Below (<50%),100,57.4,67.05499999999999
NCT02134652,Ability of Bedside Ultrasound to Predict Progression of Severity of Disease in Dengue Fever,WITHDRAWN,,0.0,2015-01-01,2016-06-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT04065152,Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma,UNKNOWN,PHASE2,20.0,2021-01-01,2024-02-01,0.5406749555950267,Slow (<1/month),5.406749555950267,Significantly Below (<50%),50,31.6,10.905
NCT04615052,Home-based Exercise in COVID-19 Survivors,UNKNOWN,NA,50.0,2020-09-26,2022-09-30,2.0735694822888284,Adequate (1-10/month),20.735694822888284,Significantly Below (<50%),50,39.0,20.505000000000003
NCT05276752,Short- and Long-term Health Adverse Outcomes Associated With Nutrition Disorders and Nutrition Related Conditions in Hospitalized Older People,UNKNOWN,,224.0,2021-10-12,2022-12-31,15.322606741573034,Good (10-50/month),153.22606741573034,Exceeded (≥100%),50,56.3,64.5
NCT05960552,Perioperative Rescue Transesophageal Echocardiography in Intensive and Critical Status,UNKNOWN,NA,6.0,2023-08-01,2025-12-31,0.20684031710079276,Slow (<1/month),2.0684031710079274,Significantly Below (<50%),50,30.5,9.395000000000001
NCT00722852,Study of Safety and Efficacy of Diractin® for the Treatment of Osteoarthritis (OA) of the Knee,COMPLETED,PHASE3,555.0,2008-06-01,2009-04-01,55.57302631578948,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT02194647,Anti-osteoporosis Medication Monitoring and Management Service,ACTIVE_NOT_RECRUITING,,500.0,2014-07-01,2026-07-01,3.4725074150125486,Adequate (1-10/month),34.72507415012549,Significantly Below (<50%),85,83.8,90.505
NCT02624947,A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization,COMPLETED,PHASE3,4636.0,2015-12-01,2019-07-12,106.99002274450342,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT01397747,Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer,COMPLETED,,12776.0,2011-06-01,2013-05-01,555.5734857142858,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT04780347,Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer,UNKNOWN,PHASE2,92.0,2020-12-15,2023-02-25,3.491870324189526,Adequate (1-10/month),34.91870324189526,Significantly Below (<50%),50,42.4,25.45
NCT01209247,Emergence of Fluoroquinolone Resistance in Commensal Flora,COMPLETED,NA,571.0,2010-10-01,2012-12-01,21.946010101010103,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT01841047,Assessment of Helical Tomotherapy Radiotherapy (54 Gy) Followed by Surgery in Retro-peritoneal Liposarcoma,COMPLETED,NA,48.0,2009-01-20,2018-12-19,0.4036243093922652,Slow (<1/month),4.036243093922652,Significantly Below (<50%),100,48.8,45.184999999999995
NCT04983147,The Effect of Training Given to Women With Obesity Patients According to the Health Belief Model,COMPLETED,NA,128.0,2017-04-01,2018-12-02,6.387409836065574,Adequate (1-10/month),63.87409836065575,Below (50-75%),100,60.2,72.2
NCT01218347,"Influence of Organic Anion Transporting Polypeptide1B1(OATP1B1) Genotype on Rosuvastatin PK, PD and Lipid Profiles",COMPLETED,PHASE4,34.0,2010-10-01,2010-12-01,16.96655737704918,Good (10-50/month),169.6655737704918,Exceeded (≥100%),100,57.7,67.51
NCT03406247,Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma,RECRUITING,PHASE2,140.0,2018-02-12,2027-11-01,1.2007889546351085,Adequate (1-10/month),12.007889546351084,Significantly Below (<50%),60,44.2,28.549999999999997
NCT03975647,A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer,ACTIVE_NOT_RECRUITING,PHASE3,466.0,2019-10-02,2029-03-10,4.11518421816072,Adequate (1-10/month),41.15184218160719,Significantly Below (<50%),85,82.8,89.19500000000001
NCT00398047,"Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes",TERMINATED,PHASE2,3.0,2006-09-01,2009-09-01,0.08332116788321167,Slow (<1/month),0.8332116788321168,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT02671747,"Pilot: Mind Over Matter: Healthy Bowels, Healthy Bladder",COMPLETED,NA,56.0,2015-08-01,2016-10-01,3.9921311475409835,Adequate (1-10/month),39.92131147540984,Significantly Below (<50%),100,54.5,60.12
NCT03571347,Self Help Plus for Asylum Seekers and Refugees in Europe,COMPLETED,NA,459.0,2018-09-01,2020-12-31,16.399014084507044,Good (10-50/month),163.9901408450704,Exceeded (≥100%),100,91.7,93.72500000000001
NCT00663949,Assessment of the Effect of Captopril Versus Combination of Captopril and Pentoxifylline on Reducing Proteinuria in Type 2 Diabetic Nephropathy,COMPLETED,PHASE2,70.0,2006-02-01,2008-01-01,3.048354792560801,Adequate (1-10/month),30.48354792560801,Significantly Below (<50%),100,55.6,62.905
NCT00925249,Comparison of the Tuberculin Skin Test (TST) and QuantiFERON ®-TB Gold Test (QFT-G) In Patients With Rheumatoid Arthritis Being Considered for Anti-TNF-Alpha Therapy,UNKNOWN,,90.0,2009-05-01,2011-06-01,3.6,Adequate (1-10/month),36.0,Significantly Below (<50%),50,40.5,22.46
NCT06897449,The Effects of Positive Psychological Interventions on Chinese Collegiate Student-athletes,COMPLETED,NA,122.0,2023-08-10,2023-12-10,30.439999999999998,Good (10-50/month),200.0,Exceeded (≥100%),100,64.8,77.865
NCT07301749,A Clinical Study Evaluating the Safety and Efficacy of the VCFix Spinal System for Treatment of Vertebral Compression Fractures.,RECRUITING,NA,103.0,2025-11-04,2028-12-31,2.719271465741544,Adequate (1-10/month),27.19271465741544,Significantly Below (<50%),60,46.2,35.089999999999996
NCT01029249,Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults,COMPLETED,,500.0,2010-01-01,2013-05-01,12.516447368421053,Good (10-50/month),125.16447368421053,Exceeded (≥100%),100,93.3,94.325
NCT02517749,Out Patient Talc Slurry Via Indwelling Pleural Catheter for Malignant Pleural Effusion Vs Usual Inpatient Management,COMPLETED,NA,142.0,2015-08-01,2020-03-01,2.582126642771804,Adequate (1-10/month),25.821266427718037,Significantly Below (<50%),100,61.4,73.735
NCT05433649,Effects of Therapeutic Exercise With Elastic Bands on Strength and Pain in Women With Non-specific Neck Pain.,COMPLETED,NA,35.0,2022-07-01,2022-10-01,11.580434782608696,Good (10-50/month),115.80434782608697,Exceeded (≥100%),100,57.8,67.635
NCT06744049,Transfer Direct System as a New Method for Embryo Transfer,RECRUITING,NA,80.0,2024-10-21,2025-08-01,8.574647887323943,Adequate (1-10/month),85.74647887323943,Met (75-100%),60,49.4,46.42
NCT03774849,PicoWay™ 730 Resolve Fusion for Benign Pigmented Lesions and Wrinkles,COMPLETED,NA,115.0,2018-12-05,2020-11-12,4.944350282485876,Adequate (1-10/month),49.44350282485876,Significantly Below (<50%),100,59.2,70.7
NCT03767049,Readmissions of Lung Transplant Patients in ICU.,COMPLETED,,153.0,2012-08-01,2016-06-30,3.259146256123163,Adequate (1-10/month),32.59146256123163,Significantly Below (<50%),100,60.6,72.785
NCT05390749,"Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL",RECRUITING,PHASE2,50.0,2022-04-11,2026-04-01,1.0489317711922812,Adequate (1-10/month),10.489317711922812,Significantly Below (<50%),60,37.0,17.955
NCT04531449,EXhaled Hydrogen Peroxide As a Marker of Lung Disease Study - Conformité Européenne (European Conformity),COMPLETED,,27.0,2019-06-06,2019-10-09,6.5750399999999996,Adequate (1-10/month),65.7504,Below (50-75%),100,50.5,48.515
NCT06003049,A Study to Evaluate Safety and Efficacy of BOTOX in Adults With Moderate COPD,COMPLETED,PHASE2,40.0,2023-10-01,2024-07-10,4.302473498233216,Adequate (1-10/month),43.02473498233216,Significantly Below (<50%),100,53.2,56.665
NCT06945549,Evaluation of Intestinal Lesions and Disease Activity in Inflammatory Bowel Disease Based on 18F-FAPI PET Imaging,RECRUITING,,30.0,2025-04-25,2027-12-31,0.9318367346938776,Slow (<1/month),9.318367346938777,Significantly Below (<50%),60,33.7,13.465
NCT03253549,"The SMArTVIEW, CoVeRed",COMPLETED,NA,572.0,2018-03-21,2021-11-15,13.042456928838952,Good (10-50/month),130.42456928838953,Exceeded (≥100%),100,95.0,95.7
NCT00396149,"Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy (Tablets) With Recombinant Bet v1",COMPLETED,PHASE1,57.0,2006-11-01,2007-06-01,8.18433962264151,Adequate (1-10/month),81.8433962264151,Met (75-100%),100,54.6,60.39
NCT02032849,Air-impingement Manipulation to Clear Subglottic Secretion Compared With Drainage Tube in Prolonged Intubated Patients,UNKNOWN,NA,240.0,2014-02-01,2016-12-01,7.065377176015475,Adequate (1-10/month),70.65377176015475,Below (50-75%),50,54.2,59.330000000000005
NCT06747949,A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS),RECRUITING,PHASE3,844.0,2025-02-25,2029-12-11,14.680777142857144,Good (10-50/month),146.80777142857144,Exceeded (≥100%),60,83.0,89.505
NCT02082249,"An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications",COMPLETED,PHASE3,30.0,2014-03-10,2019-10-31,0.44308588064046583,Slow (<1/month),4.430858806404658,Significantly Below (<50%),100,47.4,40.98
NCT02591849,GLP-1 Effects on Insulin and Glucagon in PTDM,COMPLETED,NA,24.0,2014-10-01,2015-03-01,4.838145695364238,Adequate (1-10/month),48.381456953642385,Significantly Below (<50%),100,51.9,52.55499999999999
NCT06491849,Evaluation of Peri-implant Conditions of Orthodontic Mini Implants,COMPLETED,,60.0,2021-03-04,2023-09-20,1.9638709677419355,Adequate (1-10/month),19.638709677419357,Significantly Below (<50%),100,53.1,56.105000000000004
NCT05254249,Clinical Trial of Probiotic Supplementation in Psoriasis Vulgaris,UNKNOWN,PHASE1,75.0,2022-02-07,2022-10-01,9.673728813559322,Adequate (1-10/month),96.73728813559322,Met (75-100%),50,46.0,34.1
NCT00448149,Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer,COMPLETED,PHASE1,55.0,2006-12-01,2009-06-01,1.8337349397590361,Adequate (1-10/month),18.337349397590362,Significantly Below (<50%),100,54.4,59.89
NCT01125449,Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease,WITHDRAWN,PHASE2,0.0,2020-01-01,2020-06-30,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT04761549,"3D, Dynamic and Mechanically-informed Decision Making in AIS",ENROLLING_BY_INVITATION,NA,100.0,2021-01-19,2026-01-01,1.6836283185840708,Adequate (1-10/month),16.83628318584071,Significantly Below (<50%),55,44.5,29.160000000000004
NCT04907149,Evaluation of Mass Balance and Absolute Bioavailability of GLPG3970,COMPLETED,PHASE1,6.0,2021-06-07,2021-07-12,5.218285714285714,Adequate (1-10/month),52.182857142857145,Below (50-75%),100,50.5,48.515
NCT06651749,Hemodynamic Effects of a High Dose Versus Low Dose Propofol During Induction of Anesthesia.,RECRUITING,NA,70.0,2024-11-01,2025-03-31,14.205333333333334,Good (10-50/month),142.0533333333333,Exceeded (≥100%),60,48.6,44.685
NCT03350438,"Participation in Occupations and Perception of Quality of Life, Comparing Adults With and Without PTSD",UNKNOWN,,80.0,2018-01-01,2018-10-30,8.063576158940398,Adequate (1-10/month),80.63576158940397,Met (75-100%),50,39.7,21.21
NCT00593138,Study of Dopamine Transporter Receptor Occupancy With Long-acting Dex-methylphenidate,COMPLETED,PHASE1,23.0,2006-12-01,2009-12-01,0.6387956204379562,Slow (<1/month),6.387956204379562,Significantly Below (<50%),100,46.8,38.440000000000005
NCT01422538,Ultherapy™ Treatment Following Sculptra® Treatment,COMPLETED,NA,30.0,2011-05-01,2012-09-01,1.8674846625766874,Adequate (1-10/month),18.67484662576687,Significantly Below (<50%),100,52.4,53.949999999999996
NCT04998838,Stop Hep B @ Birth,UNKNOWN,NA,110.0,2018-07-01,2023-06-30,1.8347397260273972,Adequate (1-10/month),18.347397260273972,Significantly Below (<50%),50,43.8,27.965
NCT00707538,A Phase I Study in Healthy Volunteers to Assess Dosimetry and Safety Following Injection of BMS747158 at Stress,COMPLETED,PHASE1,12.0,2008-06-01,2008-10-01,2.9940983606557374,Adequate (1-10/month),29.940983606557374,Significantly Below (<50%),100,51.0,49.714999999999996
NCT00911638,Comparison of Ways to Prepare Patients for Decisions About Joint Replacement Surgery,COMPLETED,NA,343.0,2008-05-01,2017-05-01,3.1764283541223004,Adequate (1-10/month),31.764283541223005,Significantly Below (<50%),100,77.4,85.835
NCT04576338,"""Neighborhood Disadvantage, Sleep and Vascular Health""",COMPLETED,,55.0,2020-01-11,2023-12-31,1.1546206896551725,Adequate (1-10/month),11.546206896551725,Significantly Below (<50%),100,47.7,42.17
NCT04235738,Cognitive Impairment in Older Emergency Department Users and Associated Adverse Outcomes,ACTIVE_NOT_RECRUITING,,4724.0,2020-01-17,2025-02-01,78.06653637350706,Excellent (>50/month),200.0,Exceeded (≥100%),85,93.8,94.80499999999999
NCT03245138,Endoscopic Third Ventriculostomy Versus Ventriculo-peritoneal Shunting in Idiopathic Normal Pressure Hydrocephalus,UNKNOWN,NA,100.0,2016-06-01,2020-12-01,1.8515815085158152,Adequate (1-10/month),18.515815085158152,Significantly Below (<50%),50,43.0,26.465
NCT01474538,Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy,COMPLETED,PHASE3,122.0,2011-12-01,2013-02-01,8.676822429906542,Adequate (1-10/month),86.76822429906542,Met (75-100%),100,64.8,77.865
NCT03775538,Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study,COMPLETED,PHASE1,15.0,2018-07-05,2020-07-08,0.6220708446866485,Slow (<1/month),6.220708446866485,Significantly Below (<50%),100,46.2,35.089999999999996
NCT02092038,Preoperative Chemoradiation for Glioblastoma,COMPLETED,PHASE1,1.0,2014-11-01,2015-07-01,0.12578512396694216,Slow (<1/month),1.2578512396694215,Significantly Below (<50%),100,45.1,30.605
NCT01328938,GCPGC in Chemotherapy-induced Neutropenia,COMPLETED,PHASE2,177.0,2010-10-01,2013-05-01,5.71355249204666,Adequate (1-10/month),57.135524920466594,Below (50-75%),100,64.2,77.18
NCT00750438,Effect of Fibre Products on Appetite and Weight,COMPLETED,NA,60.0,2008-09-01,2012-10-01,1.2249496981891348,Adequate (1-10/month),12.249496981891348,Significantly Below (<50%),100,49.8,47.17
NCT00360438,Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS,COMPLETED,PHASE1,18.0,2006-07-01,2007-04-01,1.9997080291970804,Adequate (1-10/month),19.997080291970804,Significantly Below (<50%),100,51.4,50.92
NCT03405038,Prone Position Impact in ARDS Patients on the Incidence of Central Venous Catheter Colonization,COMPLETED,,202.0,2017-11-02,2019-01-01,14.46795294117647,Good (10-50/month),144.67952941176472,Exceeded (≥100%),100,69.5,81.62
NCT05267938,Microneedle Pretreatment as a Strategy to Improve the Effectiveness of Topical Anesthetics Formulations,COMPLETED,PHASE1,30.0,2019-08-01,2020-01-30,5.0175824175824175,Adequate (1-10/month),50.17582417582418,Below (50-75%),100,52.4,53.949999999999996
NCT02368938,Prognosis in the Elderly Chinese: the Northern Shanghai Study,UNKNOWN,,5000.0,2014-08-01,,,Slow (<1/month),,Significantly Below (<50%),50,63.3,76.235
NCT03221738,Smartphone-Administered App Treatment for Adults With Body Dysmorphic Disorder,COMPLETED,NA,10.0,2017-07-24,2019-01-18,0.5605893186003683,Slow (<1/month),5.605893186003684,Significantly Below (<50%),100,45.8,33.03
NCT02615938,Hydroxychloroquine (HCQ) in Pediatric Interstitial Lung Disease (ILD),TERMINATED,PHASE2,35.0,2015-08-21,2020-09-09,0.5771397616468039,Slow (<1/month),5.77139761646804,Significantly Below (<50%),10,20.8,6.055
NCT02117258,Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma,COMPLETED,PHASE2,167.0,2014-04-01,2017-03-01,4.773220657276996,Adequate (1-10/month),47.73220657276996,Significantly Below (<50%),100,63.4,76.375
NCT00601458,Bunionectomy Study (0000-063),COMPLETED,PHASE1,100.0,2007-07-01,2008-01-01,16.543478260869566,Good (10-50/month),165.43478260869566,Exceeded (≥100%),100,63.0,75.845
NCT00464958,One Year Extension Study To Protocol C2/5/TZ:MS-05,TERMINATED,PHASE1,10.0,2008-01-01,2008-12-01,0.9086567164179106,Slow (<1/month),9.086567164179105,Significantly Below (<50%),10,18.8,4.58
NCT06472258,Efficacy of Only IV Artesunate Versus IV Artesunate Plus IV Quinine in the Treatment of Severe Malaria in Children: A Comparative Study,COMPLETED,NA,104.0,2023-03-01,2023-06-30,26.163305785123967,Good (10-50/month),200.0,Exceeded (≥100%),100,63.3,76.235
NCT05057858,The Women TDF-FTC Benchmark Study,ACTIVE_NOT_RECRUITING,PHASE2,72.0,2022-04-25,2025-01-31,2.1656916996047433,Adequate (1-10/month),21.656916996047432,Significantly Below (<50%),85,51.3,50.62
NCT02894658,Lipiflow Versus Warm Compresses in Parkinson's Disease,WITHDRAWN,NA,0.0,2016-08-01,2023-10-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT06573658,Neurophysiological Changes After Perturbation-based Training in Older Adults,RECRUITING,NA,88.0,2024-04-18,2026-10-14,2.946886688668867,Adequate (1-10/month),29.468866886688673,Significantly Below (<50%),60,45.0,30.330000000000002
NCT02869958,Digital Action Plan for Asthma Attacks,COMPLETED,NA,280.0,2016-11-03,2020-04-29,6.695365278868814,Adequate (1-10/month),66.95365278868815,Below (50-75%),100,72.4,83.17999999999999
NCT03097458,Enhancing Adjustment to Parental Cancer: Short-term Counselling for Families,COMPLETED,NA,11.0,2017-02-04,2019-09-01,0.3565921192758254,Slow (<1/month),3.565921192758254,Significantly Below (<50%),100,45.9,33.495000000000005
NCT06216158,Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma,RECRUITING,PHASE3,411.0,2024-04-05,2029-06-01,6.6440998406797664,Adequate (1-10/month),66.44099840679768,Below (50-75%),60,70.9,82.34
NCT05180448,Sharing Digital Self-Monitoring Data With Others to Enhance Long-Term Weight Loss,COMPLETED,NA,322.0,2022-01-03,2025-07-30,7.516625766871166,Adequate (1-10/month),75.16625766871167,Met (75-100%),100,75.8,84.83500000000001
NCT06035848,Components of Metabolic Derangement and Paracentesis for Determination of Surgery in Preterm Neonates With Necrotizing Enterocolitis.,TERMINATED,NA,117.0,2022-02-01,2023-06-30,6.928949416342413,Adequate (1-10/month),69.28949416342414,Below (50-75%),10,32.4,12.025
NCT02216448,Arthroscopy Simulator Training vs OR Training Knee,WITHDRAWN,NA,0.0,2014-09-01,2017-12-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT01702948,Studying Nicotine Addiction With Transcranial Magnetic Stimulation,COMPLETED,,46.0,2012-09-10,2017-10-03,0.7572958355868037,Slow (<1/month),7.572958355868035,Significantly Below (<50%),100,47.0,39.33
NCT01712048,Submucosal Injection EMR vs. Underwater EMR for Colorectal Polyps,COMPLETED,NA,170.0,2012-09-01,2019-12-01,1.954967888175293,Adequate (1-10/month),19.54967888175293,Significantly Below (<50%),100,63.6,76.545
NCT00893048,The Use of Oral Steroids in the Treatment of Cellulitis,WITHDRAWN,PHASE2,0.0,2010-01-15,2010-08-31,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT01441648,Influence of Cosmetic Color Tinted Contact Lenses on the Ocular Surface,COMPLETED,,14.0,2011-12-01,2013-12-01,0.5829822161422709,Slow (<1/month),5.829822161422709,Significantly Below (<50%),100,44.5,29.160000000000004
NCT04869748,Perfetti Method on Upper Extremity Spasticity of Stroke Patient,COMPLETED,NA,14.0,2018-11-15,2019-07-25,1.691111111111111,Adequate (1-10/month),16.91111111111111,Significantly Below (<50%),100,51.1,50.129999999999995
NCT02011048,"Giant Ventral Incisional Hernia: Abdominal Wall Function, Respiratory Performance and Quality of Life",COMPLETED,,36.0,2013-11-01,2016-03-01,1.2877085781433608,Adequate (1-10/month),12.877085781433609,Significantly Below (<50%),100,46.2,35.089999999999996
NCT01188148,Series Studies of Bipolar Disorder-Valproate add-on Memantine,COMPLETED,PHASE2,219.0,2009-08-01,2012-10-01,5.761763180639585,Adequate (1-10/month),57.61763180639585,Below (50-75%),100,67.5,80.08
NCT03844048,An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial,ACTIVE_NOT_RECRUITING,PHASE3,165.0,2019-09-06,2026-02-01,2.1464102564102565,Adequate (1-10/month),21.464102564102568,Significantly Below (<50%),85,58.7,69.69
NCT02792348,Change of Urinary Metabolic Profile Secondary to a Congenital Urine Flow Impairment (UFI) by Nuclear Magnetic Resonance (NMR) and Metabolomics Analysis,UNKNOWN,,200.0,2011-02-01,2016-12-01,2.8582159624413146,Adequate (1-10/month),28.58215962441315,Significantly Below (<50%),50,49.3,46.265
NCT05056948,Artificial Intelligence Designed Single Tooth Dental Prostheses,COMPLETED,,250.0,2021-09-01,2025-05-30,5.566934893928311,Adequate (1-10/month),55.669348939283104,Below (50-75%),100,68.3,80.875
NCT03989648,Adequacy of Exsanguination Between Esmarch Bandages and Simple Leg Elevation in Total Knee Arthroplasty,UNKNOWN,NA,100.0,2019-06-01,2022-12-01,2.379984362783425,Adequate (1-10/month),23.799843627834246,Significantly Below (<50%),50,43.0,26.465
NCT02817048,Tubeless VATS for Peripheral Lung Nodule,UNKNOWN,NA,100.0,2016-06-01,2017-09-01,6.660831509846827,Adequate (1-10/month),66.60831509846827,Below (50-75%),50,43.0,26.465
NCT01145248,Comparison of Biliary Forceps Biopsy and Brush Cytology,COMPLETED,NA,43.0,2006-01-01,2009-07-01,1.0249960845732184,Adequate (1-10/month),10.249960845732184,Significantly Below (<50%),100,48.4,44.22
NCT03768648,Cognition and MRI Markers in MS Patients With Aubagio® Treatment,COMPLETED,NA,75.0,2019-05-21,2023-02-23,1.6615720524017468,Adequate (1-10/month),16.61572052401747,Significantly Below (<50%),100,51.0,49.714999999999996
NCT03552848,Mesenchymal Stem Cells for Multiple Organ Dysfuntion Syndrome After Surgical Repaire of Acute Type A Aortic Dissection,UNKNOWN,NA,60.0,2018-07-01,2019-12-01,3.525868725868726,Adequate (1-10/month),35.25868725868726,Significantly Below (<50%),50,39.8,21.47
NCT00623948,Implanted Gluteal Stimulation System for Pressure Sore Prevention,WITHDRAWN,NA,0.0,2012-09-01,2014-08-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT03863548,French Observational Study of Complications Associated With Anticoagulants and Antiplatelet Treatment in Retina/Vitreous Surgery,COMPLETED,,748.0,2019-01-08,2019-07-19,118.58916666666667,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT03743948,NIPD of CFTC by WGA Coupled to Mini-exome Sequencing,UNKNOWN,NA,18.0,2018-12-19,2019-12-30,1.4572340425531916,Adequate (1-10/month),14.572340425531916,Significantly Below (<50%),50,31.4,10.47
NCT03071848,A Study to Evaluate Safety and Effectiveness of Bevacizumab in Combination With Paclitaxel and Cisplatin/Carboplatin or Toptecan in Participants With Advanced Cervical Cancer,COMPLETED,,84.0,2017-04-06,2017-12-20,9.910697674418603,Adequate (1-10/month),99.10697674418604,Met (75-100%),100,60.1,72.085
NCT06295848,The Effects of Cardiac Rehabilitation Programme in Hypertensive Rheumatoid Arthritis Patients,RECRUITING,NA,40.0,2022-12-15,2024-06-15,2.221897810218978,Adequate (1-10/month),22.21897810218978,Significantly Below (<50%),60,41.2,23.425
NCT02206048,Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix,COMPLETED,NA,9.0,2015-10-02,2021-04-21,0.1350887573964497,Slow (<1/month),1.3508875739644972,Significantly Below (<50%),100,45.7,32.5
NCT07064148,The Effects of Self-Myofascial Release on Physical Fitness and Swing Performance in Male Collegiate Golfers in China,ENROLLING_BY_INVITATION,NA,30.0,2025-08-01,2025-10-02,14.729032258064516,Good (10-50/month),147.29032258064515,Exceeded (≥100%),55,43.9,28.12
NCT05212948,A Study of S-268019 for the Prevention of COVID-19,COMPLETED,PHASE3,9902.0,2021-12-25,2023-07-19,527.8754465849387,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT03418948,Comparison of AMR and ADR Between Endocuff Vision-assisted and Conventional Colonoscopy: a Multicenter Randomized Trial,UNKNOWN,NA,708.0,2017-12-08,2019-11-01,31.09887445887446,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT00215748,Reduced Dexamethasone Pre-Medication Dose in Elderly Patients Receiving Weekly Docetaxel,TERMINATED,PHASE2,40.0,2004-08-01,2007-04-01,1.251387461459404,Adequate (1-10/month),12.51387461459404,Significantly Below (<50%),10,21.2,6.16
NCT05872048,Evaluation of Periodontal Distractor in Acceleration of Canine Retraction,COMPLETED,NA,16.0,2022-07-01,2023-01-30,2.2865727699530516,Adequate (1-10/month),22.865727699530517,Significantly Below (<50%),100,51.3,50.62
NCT05012748,The Effects of Ketogenic Diet on the Heart and Brain,COMPLETED,NA,11.0,2020-06-01,2022-10-31,0.3796371882086168,Slow (<1/month),3.796371882086168,Significantly Below (<50%),100,45.9,33.495000000000005
NCT05826548,Financial Abilities in Neurological Diseases. Development of a Telerehabilitation Program: FINAGE,RECRUITING,NA,140.0,2021-03-11,2025-02-17,2.961501042390549,Adequate (1-10/month),29.615010423905485,Significantly Below (<50%),60,49.2,46.035
NCT03517748,Evaluation of the Efficacy and Safety of DM05 Versus Optive™ on the Treatment of Moderate to Severe Ocular Dryness,COMPLETED,NA,80.0,2016-12-01,2018-03-30,5.031404958677686,Adequate (1-10/month),50.31404958677687,Below (50-75%),100,56.4,64.88000000000001
NCT06254248,Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma,NOT_YET_RECRUITING,PHASE2,50.0,2026-01-01,2030-01-01,1.0417522245037645,Adequate (1-10/month),10.417522245037645,Significantly Below (<50%),30,28.0,8.38
NCT04028648,Generation of Prediction Equations for BIA of the Elderly,COMPLETED,,150.0,2019-01-22,2020-01-08,13.00854700854701,Good (10-50/month),130.0854700854701,Exceeded (≥100%),100,65.3,78.32000000000001
NCT01604148,Retrospective Review a Comprehensive Case Database of HoLEP Procedure Performed by a Single Surgeon,COMPLETED,,300.0,2011-07-01,2011-07-01,300.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,62.3,74.94
NCT03217448,The Efficacy and Safety of Dabigatran Etexilate for the Treatment of Cerebral Venous Thrombosis,UNKNOWN,PHASE3,80.0,2017-10-30,2019-01-01,5.689719626168225,Adequate (1-10/month),56.89719626168225,Below (50-75%),50,41.4,24.04
NCT02450448,The Detection of Circulating Tumor Cells (CTCs) in Patients With Renal Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment,COMPLETED,,60.0,2013-06-01,2015-12-01,2.0004381161007667,Adequate (1-10/month),20.00438116100767,Significantly Below (<50%),100,53.1,56.105000000000004
NCT04997148,Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS),COMPLETED,,116.0,2021-08-11,2023-09-14,4.621780104712042,Adequate (1-10/month),46.21780104712042,Significantly Below (<50%),100,57.6,67.36999999999999
NCT00679848,Transoral Gastric Volume Reduction as an Intervention for Weight Management,COMPLETED,PHASE1,18.0,2008-05-01,2010-11-01,0.5994748358862144,Slow (<1/month),5.994748358862145,Significantly Below (<50%),100,46.4,36.26
NCT06156748,CT Imaging for Guiding PA-TACE for HCC,COMPLETED,,1770.0,2019-10-01,2025-06-30,25.668794664125777,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT03227055,Cardiovascular Comorbidity in Children With Chronic Kidney Disease,COMPLETED,,155.0,2016-12-30,2019-12-31,4.30492700729927,Adequate (1-10/month),43.0492700729927,Significantly Below (<50%),100,60.7,72.89999999999999
NCT06083155,The NetherLands Registry of Invasive Coronary Vasomotor Function Testing (NL-CFT),ENROLLING_BY_INVITATION,,2000.0,2020-10-15,2035-10-01,11.142020497803808,Good (10-50/month),111.42020497803809,Exceeded (≥100%),55,79.8,87.27000000000001
NCT04879355,Spinal Needles in Ultrasound-guided Fine Needle Aspirations From Thyroid Nodules,UNKNOWN,NA,350.0,2021-11-01,2023-11-01,14.594520547945207,Good (10-50/month),145.94520547945206,Exceeded (≥100%),50,68.0,80.56
NCT03324555,Study of ORIC-101 in Healthy Adult Subjects,COMPLETED,PHASE1,24.0,2017-10-19,2017-12-18,12.176,Good (10-50/month),121.76,Exceeded (≥100%),100,56.9,65.89500000000001
NCT00824655,Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children,COMPLETED,PHASE3,234.0,2009-03-01,2010-06-01,15.586345733041576,Good (10-50/month),155.86345733041577,Exceeded (≥100%),100,73.7,83.825
NCT00893555,Pharmacologic Optimization of Voriconazole,COMPLETED,PHASE3,189.0,2009-04-01,2017-01-01,2.0314830508474575,Adequate (1-10/month),20.314830508474575,Significantly Below (<50%),100,65.1,78.14
NCT00967655,"Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer",UNKNOWN,PHASE2,54.0,2009-07-01,,,Slow (<1/month),,Significantly Below (<50%),50,29.3,8.825
NCT06928155,Inclusive Rehabilitation: Virtual Reality as a Tool to Improve the Quality of Life of Dependent Persons,RECRUITING,NA,172.0,2025-06-01,2025-12-28,24.931809523809527,Good (10-50/month),200.0,Exceeded (≥100%),60,56.8,65.69500000000001
NCT04320355,Exploring the Effects of Soft Tissue Manual Therapy on Caesarean Section Scar,COMPLETED,NA,51.0,2020-01-09,2020-11-20,4.912784810126582,Adequate (1-10/month),49.12784810126582,Significantly Below (<50%),100,54.1,59.11
NCT00919555,Combination Therapy in Amyotrophic Lateral Sclerosis (ALS),COMPLETED,PHASE1,28.0,2008-06-01,2012-03-01,0.6225858290723156,Slow (<1/month),6.225858290723156,Significantly Below (<50%),100,47.2,40.035
NCT00213655,URO-BCG-4 : Bladder Tumors Immunotherapy,COMPLETED,,146.0,2004-06-01,2013-12-01,1.2807608069164265,Adequate (1-10/month),12.807608069164267,Significantly Below (<50%),100,55.0,61.834999999999994
NCT05190055,Evaluation of Treatment Effect of Minimally Invasive Spinal Fusion Surgery,UNKNOWN,NA,73.0,2015-03-25,2023-02-26,0.7675716753022452,Slow (<1/month),7.675716753022452,Significantly Below (<50%),50,35.8,16.325
NCT05395455,"Gingival Crevicular Fluid, Salivary, and Serum Biomarkers Levels in Periodontal Treatment",COMPLETED,NA,75.0,2018-11-12,2020-01-23,5.224256292906179,Adequate (1-10/month),52.242562929061776,Below (50-75%),100,56.0,63.71
NCT03578055,BDD With UDCA Therapy After Laparoscopic Cholecystectomy,UNKNOWN,PHASE3,172.0,2018-04-24,2019-12-31,8.49948051948052,Adequate (1-10/month),84.9948051948052,Met (75-100%),50,53.8,58.065
NCT03991455,Evaluation of Safety and Efficacy of the Apyx™ Device for the Repair of Pelvic Organ Prolapse (POP),COMPLETED,NA,17.0,2019-10-25,2022-05-01,0.5630903155603918,Slow (<1/month),5.630903155603917,Significantly Below (<50%),100,46.4,36.26
NCT02957955,Cardiovascular Prehabilitation in Patients Awaiting Heart Transplantation (PREHAB HTx Study),COMPLETED,NA,6.0,2018-05-01,2020-02-02,0.28448598130841124,Slow (<1/month),2.8448598130841125,Significantly Below (<50%),100,45.5,31.705
NCT02925455,Contralaterally Controlled FES for Hand Opening in Hemiplegic Cerebral Palsy,COMPLETED,NA,15.0,2016-10-16,2020-04-30,0.353405572755418,Slow (<1/month),3.53405572755418,Significantly Below (<50%),100,46.2,35.089999999999996
NCT02935855,ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON),COMPLETED,PHASE4,300.0,2015-09-01,2019-09-01,6.250513347022587,Adequate (1-10/month),62.50513347022587,Below (50-75%),100,74.0,83.985
NCT00802555,Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC),COMPLETED,PHASE1,21.0,2009-01-01,2011-12-01,0.6007894736842105,Slow (<1/month),6.007894736842105,Significantly Below (<50%),100,46.7,37.895
NCT04936555,The Effect of Self-Acupressure Application on Functional Composite and Quality of Life in Multiple Sclerosis Patients,COMPLETED,NA,60.0,2021-05-01,2021-07-15,24.352,Good (10-50/month),200.0,Exceeded (≥100%),100,59.8,71.61
NCT06201455,Evaluation of Phacogoniotomy in Medically-controlled POAG,RECRUITING,NA,100.0,2023-09-28,2029-12-31,1.331583552055993,Adequate (1-10/month),13.315835520559933,Significantly Below (<50%),60,41.0,23.01
NCT06227455,Efficacy of Customized Zirconia Sheet vs PTFE as a Non-resorbable Barrier in Maxillary Alveolar Ridge Augmentation,COMPLETED,NA,14.0,2023-02-01,2024-11-01,0.6669170579029734,Slow (<1/month),6.669170579029735,Significantly Below (<50%),100,46.1,34.695
NCT04693455,ZD03 Capsule Study,COMPLETED,PHASE1,48.0,2019-11-06,2020-04-27,8.44578034682081,Adequate (1-10/month),84.4578034682081,Met (75-100%),100,58.8,69.89999999999999
NCT07387055,Effect of Artificial Intelligence on Assessing Dental Anxiety in Children,COMPLETED,,171.0,2024-08-01,2024-11-30,43.01851239669422,Good (10-50/month),200.0,Exceeded (≥100%),100,72.0,82.92
NCT04335955,Platelet Indices in Prediction of Mortality in Critically Ill Septic Patients,COMPLETED,,54.0,2020-05-01,2020-11-30,7.7171830985915495,Adequate (1-10/month),77.1718309859155,Met (75-100%),100,52.7,55.04
NCT03438955,Phase I Drug-drug Interaction of Omega-3 and Atorvastatin,UNKNOWN,PHASE1,48.0,2018-02-01,2018-08-31,6.924739336492891,Adequate (1-10/month),69.24739336492893,Below (50-75%),50,38.8,20.244999999999997
NCT06001255,ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors,RECRUITING,PHASE2,120.0,2024-01-18,2025-12-31,5.123141654978962,Adequate (1-10/month),51.23141654978962,Below (50-75%),60,47.6,41.775
NCT01100255,Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD),COMPLETED,PHASE2,15.0,2010-04-01,2015-12-01,0.22057971014492753,Slow (<1/month),2.205797101449275,Significantly Below (<50%),100,46.2,35.089999999999996
NCT00147355,Toxicity Substudy of Evaluation of Subcutaneous Proleukin in a Randomised International Trial (ESPRIT): TOXIL-2 Substudy,TERMINATED,PHASE3,28.0,2005-11-01,2008-12-01,0.7569449378330373,Slow (<1/month),7.569449378330373,Significantly Below (<50%),10,20.2,5.845000000000001
NCT04403555,Ivermectin as a Novel Therapy in COVID-19 Treatment,COMPLETED,PHASE2,164.0,2020-06-01,2020-12-01,27.279562841530055,Good (10-50/month),200.0,Exceeded (≥100%),100,68.1,80.715
NCT00040755,BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy,COMPLETED,PHASE2,68.0,2002-05-01,,,Slow (<1/month),,Significantly Below (<50%),100,45.4,31.455
NCT05164055,Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase),ACTIVE_NOT_RECRUITING,PHASE4,17.0,2022-07-11,2026-09-30,0.3355901426718548,Slow (<1/month),3.3559014267185474,Significantly Below (<50%),85,41.9,24.585
NCT03818555,Sebacia Postmarket Study of Real-World Use,UNKNOWN,NA,125.0,2019-01-01,2021-06-01,4.314058956916099,Adequate (1-10/month),43.140589569161,Significantly Below (<50%),50,45.0,30.330000000000002
NCT05655455,Dance and Movement Therapy Techniques in Elderly People,COMPLETED,NA,16.0,2022-02-12,2023-06-12,1.0042061855670104,Adequate (1-10/month),10.042061855670102,Significantly Below (<50%),100,46.3,35.66
NCT06012955,Study on the Effect of Target-controlled Infusion for General Anesthesia in Cardiac Surgery,UNKNOWN,,2000.0,2023-08-30,2024-06-30,199.6065573770492,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT06557655,Caffeinate Chewing Gum on Ice Hockey Performance,COMPLETED,NA,14.0,2024-02-05,2024-04-30,5.01364705882353,Adequate (1-10/month),50.13647058823529,Below (50-75%),100,51.1,50.129999999999995
NCT04698655,Influence of Osteoarthritis Information on Treatment Beliefs,COMPLETED,NA,735.0,2021-03-24,2021-04-05,735.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT01771926,Lifestyle Modification and Potato Consumption,COMPLETED,NA,107.0,2013-02-01,2016-06-01,2.678519736842105,Adequate (1-10/month),26.785197368421056,Significantly Below (<50%),100,58.6,69.51
NCT02922426,An Insulin Sensitivity Study in Healthy Subjects,COMPLETED,PHASE1,60.0,2016-09-01,2017-07-20,5.6720496894409935,Adequate (1-10/month),56.72049689440993,Below (50-75%),100,54.8,61.095
NCT05649826,Automated Ultrasound Cardiac Guidance Tool,RECRUITING,,200.0,2023-02-01,2027-05-01,3.9277419354838714,Adequate (1-10/month),39.27741935483871,Significantly Below (<50%),60,52.3,53.515
NCT03663426,Impact of Opioid Free Anesthesia on Outcome After Hip Arthroplasty by Direct Anterior Approach.,COMPLETED,NA,42.0,2019-03-01,2019-11-01,5.218285714285715,Adequate (1-10/month),52.182857142857145,Below (50-75%),100,53.4,57.35
NCT06600126,Supporting Evidence-based Responses to Emotional Needs in Emphysema,RECRUITING,NA,750.0,2024-09-30,2028-03-05,18.23482428115016,Good (10-50/month),182.3482428115016,Exceeded (≥100%),60,83.0,89.505
NCT03079726,Use of Device Data to Predict Frailty in Individuals,COMPLETED,,50.0,2017-09-07,2018-03-01,8.697142857142858,Adequate (1-10/month),86.97142857142856,Met (75-100%),100,57.3,66.74
NCT04655326,Probiotic Therapy for Children and Adults With Autism Spectrum Disorder,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,350.0,2020-10-15,2024-12-15,7.0,Adequate (1-10/month),70.0,Below (50-75%),85,73.5,83.74000000000001
NCT00148226,ICIBS Trial - Improving Patient Information About Bowel Cancer Screening - a Decision Aid Trial,COMPLETED,PHASE2,,2003-11-01,2005-09-01,,Slow (<1/month),,Significantly Below (<50%),100,45.0,30.330000000000002
NCT00283426,"Efficacy and Safety Study of Soluble Beta-1,3/1,6-Glucan in Thermal Burns",TERMINATED,PHASE1,10.0,2006-01-01,2007-03-01,0.7179245283018868,Slow (<1/month),7.179245283018869,Significantly Below (<50%),10,18.8,4.58
NCT05827926,A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults,COMPLETED,PHASE1,1758.0,2023-04-14,2024-12-03,89.33809682804674,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT06233526,Individualized Treatment of Pediatric R/R AML Based on Transcriptomic Profile and in Vitro Drug Sensitivity Test,RECRUITING,NA,60.0,2024-01-01,2025-12-31,2.5019178082191784,Adequate (1-10/month),25.019178082191786,Significantly Below (<50%),60,42.8,25.929999999999996
NCT06033326,Validation of the French Version of the Lithium Knowledge Test (LKT),UNKNOWN,,300.0,2023-09-30,2025-10-10,12.323886639676113,Good (10-50/month),123.23886639676114,Exceeded (≥100%),50,62.3,74.94
NCT06279026,UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma,RECRUITING,NA,15.0,2024-04-01,2027-07-01,0.384991568296796,Slow (<1/month),3.84991568296796,Significantly Below (<50%),60,34.2,14.305000000000001
NCT03213626,Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma,TERMINATED,PHASE2,7.0,2017-10-13,2019-11-18,0.2781723237597912,Slow (<1/month),2.7817232375979115,Significantly Below (<50%),10,18.6,4.25
NCT02029326,Biomarker Analysis in Metastatic Colorectal Cancer Treated With Cetuximab,COMPLETED,,30.0,2010-02-01,2015-08-26,0.4494094488188976,Slow (<1/month),4.494094488188976,Significantly Below (<50%),100,45.7,32.5
NCT02938026,"Changes of Diet, Physical Activity and Sleep Pattern and Their Effects on Glycemic and Weight Control in Hong Kong Chinese Obese Patients With Type 2 Diabetes After Bariatric Surgery Compared to Telephone Intensive Lifestyle Counselling",COMPLETED,NA,141.0,2016-05-01,2018-03-01,6.4156053811659195,Adequate (1-10/month),64.15605381165919,Below (50-75%),100,61.3,73.56
NCT06762626,Comparing FET Guided by ERA Vs Standard Timing in Patients with Recurrent Implantation Failure,RECRUITING,NA,734.0,2025-02-15,2028-06-30,18.15025182778229,Good (10-50/month),181.50251827782293,Exceeded (≥100%),60,83.0,89.505
NCT01077726,A Study of Xeloda (Capecitabine) in Breast Cancer Patients With Central Nervous System (CNS) Progression,COMPLETED,PHASE2,3.0,2010-01-01,2010-12-01,0.27341317365269463,Slow (<1/month),2.734131736526946,Significantly Below (<50%),100,45.2,30.830000000000002
NCT00214526,Asthma Intervention Research (AIR) Trial,COMPLETED,NA,112.0,2002-11-01,2006-07-01,2.5480418535127054,Adequate (1-10/month),25.480418535127054,Significantly Below (<50%),100,59.0,70.365
NCT01856426,Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects,COMPLETED,PHASE1,28.0,2013-06-01,2015-10-01,1.0003755868544602,Adequate (1-10/month),10.003755868544602,Significantly Below (<50%),100,47.2,40.035
NCT00319878,Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia,UNKNOWN,PHASE1,52.0,2006-05-01,2009-12-01,1.2083053435114504,Adequate (1-10/month),12.083053435114504,Significantly Below (<50%),50,34.2,14.305000000000001
NCT07148778,Effectiveness of Chatbot-Supported Web Program in Postpartum Care,NOT_YET_RECRUITING,NA,102.0,2025-10-01,2026-12-01,7.288450704225353,Adequate (1-10/month),72.88450704225352,Below (50-75%),30,37.2,18.17
NCT04971278,Evaluating the Impact of a Supportive Care Program,COMPLETED,,1201.0,2019-11-07,2022-09-22,34.81756190476191,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT01439178,Acute Changes in Intraocular Cytokines After Intravitreal Bevacizumab,UNKNOWN,NA,28.0,2011-08-01,2011-11-01,9.264347826086956,Adequate (1-10/month),92.64347826086957,Met (75-100%),50,42.2,25.155
NCT02000778,EC17 for Intraoperative Imaging in Occult Ovarian Cancer,COMPLETED,PHASE1,10.0,2013-11-01,2014-11-12,0.8095744680851064,Slow (<1/month),8.095744680851064,Significantly Below (<50%),100,45.8,33.03
NCT06336278,Relationship Between Central Sensitization and Kinesiophobia in Knee Osteoarthritis,COMPLETED,,84.0,2022-10-01,2023-12-01,6.002253521126761,Adequate (1-10/month),60.022535211267616,Below (50-75%),100,55.1,62.085
NCT05999578,Contribution of Hypnosis on Image Quality in Cardiac MRI,RECRUITING,NA,90.0,2025-04-15,2027-05-01,3.6723860589812336,Adequate (1-10/month),36.72386058981233,Significantly Below (<50%),60,45.2,30.830000000000002
NCT03295578,"Blood Glucose, Cognition and Wellbeing @ Work",COMPLETED,NA,45.0,2017-10-02,2017-12-22,16.91111111111111,Good (10-50/month),169.11111111111111,Exceeded (≥100%),100,58.6,69.51
NCT03316885,Post-Market Clinical Investigation of the Clareon® IOL,COMPLETED,NA,245.0,2018-03-14,2021-09-23,5.785725368502716,Adequate (1-10/month),57.85725368502715,Below (50-75%),100,69.6,81.675
NCT00384085,"Insulin Glargine ""All to Target"" Trial",COMPLETED,PHASE4,588.0,2006-05-01,2010-03-01,12.7848,Good (10-50/month),127.84800000000001,Exceeded (≥100%),100,95.0,95.7
NCT01873885,"Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension",COMPLETED,PHASE1,20.0,2013-06-01,2014-03-01,2.23003663003663,Adequate (1-10/month),22.300366300366303,Significantly Below (<50%),100,51.6,51.644999999999996
NCT05706285,Comparing Intrathecal Morphine With Erector Spina Plane Block in Open Gastrectomy Surgery,COMPLETED,,63.0,2023-02-15,2024-02-01,5.463589743589744,Adequate (1-10/month),54.63589743589744,Below (50-75%),100,53.4,57.35
NCT03884985,"Eye Movements, Visual Perception and Attention",COMPLETED,NA,155.0,2018-01-01,2024-02-01,2.1234023402340236,Adequate (1-10/month),21.234023402340235,Significantly Below (<50%),100,62.4,75.095
NCT02621385,Study to Assess the Effect of Multiple Doses of Tradipitant on CYP3A4 Using Midazolam as a Substrate in Healthy Subjects,COMPLETED,PHASE1,24.0,2015-11-01,,,Slow (<1/month),,Significantly Below (<50%),100,41.9,24.585
NCT01789385,Anesthesia for Deep Brain Stimulation,COMPLETED,PHASE4,26.0,2013-02-01,2013-04-01,13.414237288135594,Good (10-50/month),134.14237288135595,Exceeded (≥100%),100,57.1,66.27
NCT06413043,Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy,NOT_YET_RECRUITING,NA,78.0,2024-05-06,2025-11-05,4.332700729927007,Adequate (1-10/month),43.32700729927007,Significantly Below (<50%),30,35.2,15.445
NCT00160043,Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.,COMPLETED,PHASE2,112.0,2005-03-01,2008-11-01,2.5423415361670396,Adequate (1-10/month),25.423415361670397,Significantly Below (<50%),100,59.0,70.365
NCT07354243,International Neuromodulation Registry,NOT_YET_RECRUITING,,1000.0,2026-01-05,2026-12-31,84.55555555555556,Excellent (>50/month),200.0,Exceeded (≥100%),30,77.3,85.67
NCT00217243,Evoked Fields After Median and Ulnar Stimulation,COMPLETED,,60.0,2005-06-01,2007-06-01,2.5019178082191784,Adequate (1-10/month),25.019178082191786,Significantly Below (<50%),100,53.1,56.105000000000004
NCT06966843,Dantrolene in Statin-induced Myopathy,NOT_YET_RECRUITING,PHASE2,23.0,2027-10-01,2030-03-01,0.7937868480725624,Slow (<1/month),7.937868480725624,Significantly Below (<50%),30,25.8,7.670000000000001
NCT04178343,Tomotherapy for Leptomeningeal Metastases,COMPLETED,NA,103.0,2014-09-01,2018-10-24,2.070885072655218,Adequate (1-10/month),20.708850726552182,Significantly Below (<50%),100,58.2,68.795
NCT01764243,Safety and Efficacy of MT-4666,COMPLETED,PHASE2,450.0,2012-11-01,2015-07-01,14.092592592592593,Good (10-50/month),140.92592592592595,Exceeded (≥100%),100,91.0,93.56
NCT00940043,Monitoring of the Inflammatory Response of Patients With Premature Rupture of Membranes With Bedside Tests,COMPLETED,,60.0,2008-09-01,2009-12-01,4.005263157894737,Adequate (1-10/month),40.05263157894737,Significantly Below (<50%),100,53.1,56.105000000000004
NCT06444243,Psilocybin-assisted Therapy for Alcohol Use Disorder,NOT_YET_RECRUITING,PHASE2,90.0,2024-09-01,2025-12-01,6.007894736842106,Adequate (1-10/month),60.078947368421055,Below (50-75%),30,36.2,16.84
NCT02328443,Evaluation and Validation of Metabolic Markers for the Assessment of CYP3A Activity and Prediction of DDI,COMPLETED,PHASE1,24.0,2014-01-01,2015-04-01,1.6056263736263736,Adequate (1-10/month),16.056263736263737,Significantly Below (<50%),100,46.9,38.96
NCT01118143,Oral Health Literacy Tailored Communication,COMPLETED,NA,179.0,2010-06-01,2012-02-01,8.932393442622951,Adequate (1-10/month),89.32393442622953,Met (75-100%),100,69.3,81.395
NCT07102043,Glucose Metabolism in Cystic Fibrosis Related Diabetes (CFRD),NOT_YET_RECRUITING,,30.0,2026-04-01,2028-12-01,0.9366153846153847,Slow (<1/month),9.366153846153848,Significantly Below (<50%),30,24.7,6.995
NCT00238043,Cohort Study to Determine the Long-Term Safety and Efficacy of Biogeneric Epoetin Treatment for Renal Anemia,UNKNOWN,PHASE3,2000.0,2005-08-01,2011-04-01,29.42484291928468,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT00230243,Historical Control Study of Refractory IFI or Patients Intolerant to Standard Antifungal Therapy in Patients With Invasive Fungal Infections (Study P02387),COMPLETED,,330.0,1997-03-01,2002-09-01,4.9976119402985075,Adequate (1-10/month),49.97611940298507,Significantly Below (<50%),100,74.7,84.33500000000001
NCT06549543,High-Intensity Laser Therapy: Effectiveness on Knee Osteoarthritis Patients,COMPLETED,NA,43.0,2022-04-01,2024-02-01,1.9507004470938898,Adequate (1-10/month),19.5070044709389,Significantly Below (<50%),100,53.4,57.35
NCT00855543,Phospholipase A2 Producing Bacteria and Pre-Term Labor,COMPLETED,,60.0,2009-08-01,2010-12-01,3.7503080082135525,Adequate (1-10/month),37.503080082135526,Significantly Below (<50%),100,53.1,56.105000000000004
NCT04794543,Effects of Using E-Cigarettes on Lungs in People With HIV (HBS Ancillary),COMPLETED,,23.0,2022-04-01,2023-12-04,1.1439869281045751,Adequate (1-10/month),11.439869281045752,Significantly Below (<50%),100,45.2,30.830000000000002
NCT06419543,Paradoxical Reactions of Remimazolam in Pediatric Painless Gastrointestinal Endoscopy,COMPLETED,NA,333.0,2024-05-20,2024-10-01,75.64567164179104,Excellent (>50/month),200.0,Exceeded (≥100%),100,86.6,92.015
NCT07018843,Mitochondrial Assessment in Critical Ill Patients in Intensive Care,NOT_YET_RECRUITING,,20.0,2025-07-01,2026-03-01,2.505349794238683,Adequate (1-10/month),25.053497942386834,Significantly Below (<50%),30,28.9,8.709999999999999
NCT00257543,SALT: Alternative Donor Bone Marrow and Cord Blood Transplantation for High Risk Sickle Cell Disease,TERMINATED,EARLY_PHASE1,3.0,2006-01-01,2012-08-01,0.037986688851913475,Slow (<1/month),0.37986688851913475,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT04884243,"Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction",COMPLETED,PHASE2,92.0,2021-09-05,2023-08-17,3.9387904360056263,Adequate (1-10/month),39.38790436005626,Significantly Below (<50%),100,57.4,67.05499999999999
NCT04426643,Treatment of Urinary Incontinence in Men After Prostatectomy With Autologous Adipose-derived Mesenchymal Stem Cells,COMPLETED,PHASE1,10.0,2020-08-01,2021-03-31,1.2578512396694215,Adequate (1-10/month),12.578512396694217,Significantly Below (<50%),100,45.8,33.03
NCT05506943,"A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)",ACTIVE_NOT_RECRUITING,PHASE2,150.0,2023-01-09,2025-12-01,4.319772942289498,Adequate (1-10/month),43.19772942289499,Significantly Below (<50%),85,57.5,67.27
NCT01783743,Identification of TT Cases by Community Treatment Assistants: An Assessment,COMPLETED,NA,27473.0,2013-02-01,2013-12-01,2759.9937953795384,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT02289443,a 10-year Follow-up Study of a Randomized Clinical Trial,COMPLETED,,104.0,2012-09-01,2014-01-01,6.5005338809034905,Adequate (1-10/month),65.00533880903492,Below (50-75%),100,56.7,65.53
NCT01129843,Directly Observed Iron Supplementation to Treat Anemia,COMPLETED,NA,1000.0,2010-05-01,2011-05-01,83.3972602739726,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT05618743,NSPT on Calprotectin and Periostin Levels,UNKNOWN,NA,45.0,2021-06-30,2022-12-31,2.4950819672131153,Adequate (1-10/month),24.95081967213115,Significantly Below (<50%),50,38.6,20.015
NCT05320315,Protective Effect Assessment of Foto Ultra Isdin Solar Allergy Fusion Fluid on the UVA Induced PLE,COMPLETED,NA,15.0,2021-02-25,2021-06-08,4.433009708737864,Adequate (1-10/month),44.33009708737864,Significantly Below (<50%),100,51.2,50.375
NCT02691715,Intrauterine Saline Washing for Detection Endometrial Disease in Patients With Abnormal Uterine Bleeding,UNKNOWN,NA,400.0,2016-01-01,2016-06-01,80.10526315789474,Excellent (>50/month),200.0,Exceeded (≥100%),50,77.0,85.475
NCT07152015,"Multiple Sclerosis, Sarcopenia and Respiration",NOT_YET_RECRUITING,,40.0,2025-09-05,2025-09-20,40.0,Good (10-50/month),200.0,Exceeded (≥100%),30,40.5,22.46
NCT04255615,Use of Artificial Intelligence for Clinical Assessment of Assisted Reproductive Techniques and IVF Outcomes,RECRUITING,NA,4000.0,2020-02-12,2029-09-30,34.610574189880616,Good (10-50/month),200.0,Exceeded (≥100%),60,83.0,89.505
NCT02362815,Ultrasound Assessment of Clear Liquid Intake During Labour,COMPLETED,NA,156.0,2014-01-29,2018-01-30,3.248043775649795,Adequate (1-10/month),32.48043775649795,Significantly Below (<50%),100,62.5,75.21
NCT06284915,Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers,COMPLETED,PHASE3,840.0,2024-03-19,2025-11-14,42.26380165289256,Good (10-50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT03106415,Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer,COMPLETED,PHASE1,23.0,2017-09-27,2022-05-19,0.41305014749262536,Slow (<1/month),4.130501474926254,Significantly Below (<50%),100,46.8,38.440000000000005
NCT01580215,Long Term Follow up Investigation of Endobronchial Valves in Emphysema,TERMINATED,,628.0,2012-07-01,2016-09-01,12.551753118844386,Good (10-50/month),125.51753118844387,Exceeded (≥100%),10,66.3,79.3
NCT06643715,"Research of the Application of Pancreatic Cancer Screening Artificial Intelligence Model ""PANDAPro""",COMPLETED,NA,82536.0,2024-04-01,2024-08-01,20593.408524590162,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT00006015,"Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer",TERMINATED,PHASE2,26.0,2000-05-01,2003-02-01,0.7867196819085487,Slow (<1/month),7.867196819085487,Significantly Below (<50%),10,20.1,5.81
NCT05620615,Intensive Drug Therapy for Ischemic Stroke,UNKNOWN,,42.0,2018-07-01,2023-12-01,0.6460232440626579,Slow (<1/month),6.460232440626578,Significantly Below (<50%),50,31.7,11.14
NCT01227915,Effectiveness Comparison Between the Drugs TOBRACORT® and TOBRADEX® in Reducing the Signs and Symptoms of Acute Bacterial Conjunctivitis,UNKNOWN,PHASE3,70.0,2011-02-01,,,Slow (<1/month),,Significantly Below (<50%),50,30.6,9.475
NCT00765115,A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.,COMPLETED,PHASE1,27.0,2006-07-01,2007-09-01,1.9247775175644029,Adequate (1-10/month),19.24777517564403,Significantly Below (<50%),100,52.2,53.22
NCT06099015,Cera™ Vascular Plug System Post-Market Clinical Follow-Up,RECRUITING,,132.0,2024-06-21,2026-06-01,5.659267605633803,Adequate (1-10/month),56.59267605633803,Below (50-75%),60,46.9,38.96
NCT06658015,[Trial of device that is not approved or cleared by the U.S. FDA],WITHHELD,,,,,,Slow (<1/month),,Significantly Below (<50%),50,20.0,5.695
NCT04338815,Exoskeleton Variability Optimization,TERMINATED,NA,9.0,2022-01-31,2025-03-28,0.2378125,Slow (<1/month),2.378125,Significantly Below (<50%),10,18.7,4.455
NCT02037815,Correlation of Measured and Calculated Serum Osmolality During Hyperosmolar Drugs Infusion in Patients After Craniotomy,COMPLETED,PHASE4,35.0,2014-01-01,2014-06-01,7.055629139072848,Adequate (1-10/month),70.55629139072848,Below (50-75%),100,52.8,55.31
NCT02711215,Patient Stratification and Treatment Response Prediction in Neuropharmacotherapy Using Hybrid Positron Emmission Tomography/Magnetic Resconance Imaging (PET/MR),UNKNOWN,PHASE4,80.0,2015-05-01,2020-01-01,1.427432590855803,Adequate (1-10/month),14.27432590855803,Significantly Below (<50%),50,36.4,17.14
NCT00975715,"Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures",COMPLETED,PHASE2,99.0,2009-09-01,2012-10-01,2.676341030195382,Adequate (1-10/month),26.763410301953815,Significantly Below (<50%),100,57.9,67.83
NCT02170415,Development of a Personalised Care Plan Designed to Reduce Chronic Post-Operative Pain Following Breast Surgery,UNKNOWN,NA,154.0,2014-06-01,2018-02-01,3.495719612229679,Adequate (1-10/month),34.95719612229679,Significantly Below (<50%),50,47.3,40.475
NCT01852435,R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B,UNKNOWN,PHASE3,648.0,2013-05-01,2018-02-01,11.355854922279795,Good (10-50/month),113.55854922279794,Exceeded (≥100%),50,80.0,87.67
NCT05510635,"The Effectiveness of Bibliotherapy on Emotional Distress, Coping Strategies and Resilience of Adolescents With Cancer",COMPLETED,NA,27.0,2022-11-30,2023-07-26,3.45327731092437,Adequate (1-10/month),34.5327731092437,Significantly Below (<50%),100,52.2,53.22
NCT00972335,"Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma",TERMINATED,PHASE2,18.0,2010-01-01,2014-07-01,0.33369062119366627,Slow (<1/month),3.3369062119366624,Significantly Below (<50%),10,19.4,5.2299999999999995
NCT03402035,"Shock, Whole Blood, and Assessment of TBI S.W.A.T. (LITES TO 2)",COMPLETED,,1051.0,2018-05-01,2022-03-02,22.835431834403998,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT00217035,Glutamine Enriched Total Parenteral Feeding and Proline Metabolism in Severely Burned Patients,WITHDRAWN,,0.0,1997-08-01,2010-01-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT06554535,Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung Cancer,NOT_YET_RECRUITING,PHASE2,43.0,2024-10-01,2027-10-01,1.1953607305936074,Adequate (1-10/month),11.953607305936075,Significantly Below (<50%),30,27.4,8.225
NCT00305708,"Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission",COMPLETED,PHASE1,40.0,2000-08-01,2004-07-01,0.8514685314685315,Slow (<1/month),8.514685314685314,Significantly Below (<50%),100,48.2,43.665
NCT00833508,Effect of Preoperative Chemoradiotherapy on Exercise Capacity as Measured by Cardiopulmonary Exercise Testing,COMPLETED,NA,40.0,2009-01-01,2011-10-01,1.2139581256231307,Adequate (1-10/month),12.139581256231304,Significantly Below (<50%),100,48.2,43.665
NCT07025408,Phase II Clinical Trial of KJ101in the Treatment of Deep II Degree Burns,RECRUITING,PHASE2,144.0,2025-06-16,2026-08-29,9.98487471526196,Adequate (1-10/month),99.84874715261958,Met (75-100%),60,54.5,60.12
NCT03833908,Evaluation of the Performance of MAF-1217 on Cataract Surgery,COMPLETED,NA,46.0,2018-11-20,2019-06-17,6.699712918660287,Adequate (1-10/month),66.99712918660288,Below (50-75%),100,53.7,57.84
NCT05586308,Incentive-based and Media Literacy Informed Approaches to Improve Vaping Cessation,COMPLETED,NA,40.0,2023-12-07,2025-06-30,2.132399299474606,Adequate (1-10/month),21.32399299474606,Significantly Below (<50%),100,53.2,56.665
NCT02676908,Optimum Duration of Compression Stockings After Endovenous Varicose Vein Surgery,UNKNOWN,NA,110.0,2016-09-01,2019-08-01,3.1469924812030072,Adequate (1-10/month),31.469924812030076,Significantly Below (<50%),50,43.8,27.965
NCT01205308,Plant Stanols and Type 1 Diabetes,COMPLETED,NA,24.0,2010-01-01,2011-03-01,1.7230188679245284,Adequate (1-10/month),17.230188679245284,Significantly Below (<50%),100,51.9,52.55499999999999
NCT03558308,CBCR for Executive Functions in Patients With ABI in the Chronic Phase,COMPLETED,NA,72.0,2018-08-01,2021-07-01,2.0579154929577466,Adequate (1-10/month),20.579154929577467,Significantly Below (<50%),100,55.8,63.245
NCT05026008,"A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SR1375",COMPLETED,PHASE1,72.0,2021-09-30,2023-03-30,4.014065934065934,Adequate (1-10/month),40.14065934065935,Significantly Below (<50%),100,55.8,63.245
NCT07008508,Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study,ACTIVE_NOT_RECRUITING,,300.0,2025-05-15,2032-05-01,3.591034211561148,Adequate (1-10/month),35.910342115611485,Significantly Below (<50%),85,67.8,80.285
NCT06615908,Treatment of Persisting Symptoms After Concussion With Psilocybin Assisted Therapy,RECRUITING,PHASE1,40.0,2025-05-27,2027-03-30,1.811904761904762,Adequate (1-10/month),18.11904761904762,Significantly Below (<50%),60,41.2,23.425
NCT03785808,"Reducing Insulin, Growth Hormones, and Tumors",TERMINATED,NA,3.0,2018-12-21,2019-08-05,0.40229074889867844,Slow (<1/month),4.022907488986784,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT07199608,Subcision With CO₂ Laser or PRP vs Subcision Alone in Atrophic Acne Scars,NOT_YET_RECRUITING,NA,42.0,2025-11-01,2027-01-01,3.0011267605633805,Adequate (1-10/month),30.011267605633808,Significantly Below (<50%),30,32.4,12.025
NCT06345625,Gait and Postural Balance Analysis During Head-motion Perturbed Standing and Walking in Older Adults,RECRUITING,,100.0,2024-05-07,2028-01-01,2.2818590704647677,Adequate (1-10/month),22.81859070464768,Significantly Below (<50%),60,44.3,28.715000000000003
NCT05946525,Ventilatory Variables in Subjects With Acute Respiratory Distress Syndrome Due to COVID-19,COMPLETED,,110.0,2023-02-10,2023-02-10,110.0,Excellent (>50/month),200.0,Exceeded (≥100%),100,47.1,39.64
NCT00270725,Impact of Anti-HIV Treatment on Labor Productivity and Costs in South Africa,WITHDRAWN,,0.0,2005-07-01,2005-07-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,8.2,0.03
NCT01959425,Oral Anticoagulation Therapy Pilot Study,TERMINATED,PHASE4,80.0,2013-04-17,2019-10-07,1.030118443316413,Adequate (1-10/month),10.30118443316413,Significantly Below (<50%),10,24.4,6.890000000000001
NCT05851625,Efficacy of Ear Acupuncture in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients,COMPLETED,NA,64.0,2023-10-16,2024-04-30,9.889137055837564,Adequate (1-10/month),98.89137055837564,Met (75-100%),100,60.1,72.085
NCT00285025,Study of the Effect of SR57667B in Patients With Alzheimer's Disease,COMPLETED,PHASE2,500.0,2005-03-01,2005-09-01,82.71739130434783,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT04848025,Treatment of Central Airway Stenoses Using Computer-Assisted Customized 3d Stents TATUM,RECRUITING,NA,30.0,2021-06-17,2025-12-01,0.5609336609336609,Slow (<1/month),5.609336609336609,Significantly Below (<50%),60,35.4,15.765
NCT05394025,COVID-19 Observational Research Collaboratory,COMPLETED,,479.0,2022-05-18,2024-06-01,19.571489932885907,Good (10-50/month),195.71489932885905,Exceeded (≥100%),100,91.7,93.72500000000001
NCT06161025,"A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",RECRUITING,PHASE2,860.0,2024-02-27,2030-04-30,11.614196983141083,Good (10-50/month),116.14196983141085,Exceeded (≥100%),60,83.0,89.505
NCT02723825,Study of Prognostic Factors of the Distal Epiphysis of the Tibia Fracture Prognosis,NOT_YET_RECRUITING,NA,200.0,2016-03-01,2026-12-01,1.5502928444104915,Adequate (1-10/month),15.502928444104915,Significantly Below (<50%),30,40.0,21.87
NCT04547725,Complete Cytoreduction Followed by IP and Systemic Chemotherapies for Gastric Cancer With Peritoneal Carcinomatosis,RECRUITING,NA,48.0,2020-09-16,2028-09-16,0.500041067761807,Slow (<1/month),5.00041067761807,Significantly Below (<50%),60,36.8,17.630000000000003
NCT05828225,Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of Refractory Myasthenia Gravis,RECRUITING,PHASE1,9.0,2023-04-30,2026-04-20,0.25226519337016573,Slow (<1/month),2.5226519337016575,Significantly Below (<50%),60,33.7,13.465
NCT06514625,"Sleep Quality in Carpal Tunnel Syndrome, Splinting and Kinesiotaping",COMPLETED,NA,90.0,2022-11-01,2023-11-01,7.505753424657535,Adequate (1-10/month),75.05753424657536,Met (75-100%),100,57.2,66.465
NCT02678325,The Basel Enteral High Protein Study,TERMINATED,NA,25.0,2016-05-21,2019-12-31,0.5769522365428356,Slow (<1/month),5.769522365428355,Significantly Below (<50%),10,20.0,5.695
NCT06800625,Manual Versus Sonic-powered Toothbrushing for Plaque Reduction in Patients with Peri-implant Mucositis,COMPLETED,,41.0,2023-04-15,2024-06-15,2.9228103044496487,Adequate (1-10/month),29.22810304449649,Significantly Below (<50%),100,51.6,51.644999999999996
NCT03267225,Genetic Determinants of Clindamycin/Rifampin Interaction,COMPLETED,,84.0,2016-01-01,2021-04-15,1.324163645779389,Adequate (1-10/month),13.24163645779389,Significantly Below (<50%),100,50.1,47.89
NCT07303725,Intra-procedural Spectral CT for Image-guided Embolization and Ablation in Interventional Oncology,RECRUITING,,30.0,2025-02-01,2026-09-01,1.582668977469671,Adequate (1-10/month),15.826689774696709,Significantly Below (<50%),60,33.7,13.465
NCT00156325,Escitalopram as a Mood Stabilizer for Bipolar II Disorder,COMPLETED,PHASE2,10.0,2004-02-01,2005-02-01,0.8316939890710383,Slow (<1/month),8.316939890710383,Significantly Below (<50%),100,45.8,33.03
NCT04853225,Investigation of Chronic Obstructive Pulmonary Disease (COPD) Phenotypes and Endotypes in China,COMPLETED,,2005.0,2020-04-22,2024-06-25,40.02111475409836,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT05195125,Use of Direct Peritoneal Resuscitation in High-risk Liver Transplant Recipients,UNKNOWN,PHASE1,15.0,2022-02-01,2023-12-01,0.6835329341317365,Slow (<1/month),6.835329341317364,Significantly Below (<50%),50,31.2,10.165000000000001
NCT01604525,Tailored Web and Peer Email Cessation Counseling for College Smokers,COMPLETED,NA,1699.0,2011-05-01,2011-11-01,281.0736956521739,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT06944925,A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD),RECRUITING,PHASE1,98.0,2025-05-08,2027-03-31,4.310867052023122,Adequate (1-10/month),43.108670520231215,Significantly Below (<50%),60,45.8,33.03
NCT02708225,The Influence of Medical Clowns on the Performance of Pulmonary Function Tests Among Preschooler Children,UNKNOWN,NA,200.0,2016-03-01,2017-10-01,10.514680483592402,Good (10-50/month),105.146804835924,Exceeded (≥100%),50,56.0,63.71
NCT03965325,FOcUs on Colorectal CAncer oUtcomes: Long-Term Study,UNKNOWN,,133.0,2019-06-07,2025-06-06,1.8477955271565498,Adequate (1-10/month),18.4779552715655,Significantly Below (<50%),50,44.0,28.249999999999996
NCT01060176,Three Dose Regimen of Tranexamic Acid in Cardiac Surgery,UNKNOWN,NA,600.0,2010-02-01,2019-12-01,5.087465181058496,Adequate (1-10/month),50.87465181058496,Below (50-75%),50,75.0,84.49
NCT04160676,"Therapy With Hydrocortisone, Ascorbic Acid, Thamine in Patients With Sepsis",COMPLETED,NA,80.0,2019-12-01,2021-07-26,4.0384742951907135,Adequate (1-10/month),40.384742951907135,Significantly Below (<50%),100,56.4,64.88000000000001
NCT07053176,Impact of Local Lidocaine Paravertebral Cervical Injection on Cervicogenic Dizziness Symptoms,ENROLLING_BY_INVITATION,PHASE4,42.0,2025-08-01,2025-09-15,28.410666666666668,Good (10-50/month),200.0,Exceeded (≥100%),55,44.9,30.025000000000002
NCT02191176,Study to Investigate Safety With Special Emphasis on ECG Effects and Tolerability After Oral Doses of Dextromethorphan Hydrobromide Monohydrate in Healthy Male and Female Subjects,COMPLETED,PHASE1,48.0,2009-06-01,,,Slow (<1/month),,Significantly Below (<50%),100,43.8,27.965
NCT07283276,Effect of Functional Core Stability Training or Cognitive Training on Balance and Postural Control in Chronic Ankle Instability,RECRUITING,NA,45.0,2025-08-15,2026-03-01,6.918181818181819,Adequate (1-10/month),69.18181818181817,Below (50-75%),60,41.6,24.29
NCT04089176,Carbetocin Versus Oxytocin for Prevention of Postcesarean Hemorrhage in Pregnancy With High Risk for PPH,COMPLETED,EARLY_PHASE1,120.0,2019-02-01,2019-05-31,30.695798319327732,Good (10-50/month),200.0,Exceeded (≥100%),100,64.6,77.59
NCT02392676,Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations,WITHDRAWN,PHASE3,0.0,2016-07-01,2019-06-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT04945876,Exercise Adherence and Optimal Nutrition Post Rehabilitation Among People With Parkinson's Disease,COMPLETED,NA,100.0,2021-04-30,2023-06-28,3.8580481622306717,Adequate (1-10/month),38.58048162230672,Significantly Below (<50%),100,58.0,68.245
NCT05218876,Effects of Moderate and High-intensity Exercise During Chemotherapy on Muscle Cells in Women With Breast Cancer,COMPLETED,NA,80.0,2016-12-08,2022-11-30,1.1155290884104443,Adequate (1-10/month),11.155290884104446,Significantly Below (<50%),100,51.4,50.92
NCT00094276,Intervention for Improving Asthma Care for Minority Children in Head Start,COMPLETED,NA,336.0,2004-09-01,2009-06-01,5.89840830449827,Adequate (1-10/month),58.984083044982704,Below (50-75%),100,76.9,85.455
NCT05729776,Evaluation of the Glucose Metrics After Eating Pizza Margherita in Hybrid Closed Loop Users,COMPLETED,,32.0,2022-12-01,2023-02-07,14.32470588235294,Good (10-50/month),143.24705882352941,Exceeded (≥100%),100,55.9,63.42
NCT00550576,Antibodies to Digoxin for Bipolar Disorder,COMPLETED,PHASE2,18.0,2007-10-01,2009-02-01,1.1204907975460123,Adequate (1-10/month),11.204907975460124,Significantly Below (<50%),100,46.4,36.26
NCT05862376,Nutritional Status and Iodized Salt Use Among School-aged Children,COMPLETED,,367.0,2021-04-01,2021-09-30,61.38175824175824,Excellent (>50/month),200.0,Exceeded (≥100%),100,87.7,92.36
NCT03985176,Delayed Cerebral Ischaemia and Coagulation Alterations After Aneurysmal Subarachnoid Haemorrhage,UNKNOWN,,62.0,2019-06-10,2025-12-31,0.7876794657762939,Slow (<1/month),7.876794657762938,Significantly Below (<50%),50,33.3,13.200000000000001
NCT03933176,Absence of Liner Following the Selective Caries Removal (ALFSCaRe),WITHDRAWN,NA,0.0,2019-06-30,2024-09-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT00076076,The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023),COMPLETED,PHASE3,822.0,2003-12-01,2005-06-01,45.66,Good (10-50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT00177476,Enhancing Exercise Participation in Overweight Adults,COMPLETED,PHASE1,225.0,2003-09-01,2006-05-01,7.039054470709147,Adequate (1-10/month),70.39054470709148,Below (50-75%),100,68.0,80.56
NCT07142876,Evaluation Of Liver Resection Using Harmonic Scalpel Versus Cavitron Ultrasonic Surgical Aspirator (CUSA).,NOT_YET_RECRUITING,NA,50.0,2025-08-22,2026-12-30,3.074747474747475,Adequate (1-10/month),30.747474747474747,Significantly Below (<50%),30,33.0,12.695
NCT07011576,A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC),RECRUITING,PHASE2,60.0,2025-09-29,2027-06-01,2.994098360655738,Adequate (1-10/month),29.94098360655738,Significantly Below (<50%),60,42.8,25.929999999999996
NCT05433376,SOLSTICE Trial in China,UNKNOWN,NA,20.0,2021-04-15,2022-11-26,1.0318644067796612,Adequate (1-10/month),10.31864406779661,Significantly Below (<50%),50,31.6,10.905
NCT06966076,Effect of Callisthenic Training on Mobility and ADL Performance in Spastic Diplegic Cerebral Palsy Patients,COMPLETED,NA,32.0,2024-09-12,2025-05-02,4.198620689655173,Adequate (1-10/month),41.98620689655173,Significantly Below (<50%),100,52.6,54.684999999999995
NCT03409276,"Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults",COMPLETED,PHASE1,60.0,2018-03-16,2020-10-22,1.920504731861199,Adequate (1-10/month),19.20504731861199,Significantly Below (<50%),100,54.8,61.095
NCT02664376,Prevalence of Sarcopenia and Its Geriatric Features,COMPLETED,,834.0,2016-01-01,2018-01-18,33.93978609625668,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT06552117,ElastoMRI Evaluation of Hepatic Metastases in Colorectal Cancer ( MetaIRM),NOT_YET_RECRUITING,NA,50.0,2024-08-10,2027-06-30,1.444022770398482,Adequate (1-10/month),14.44022770398482,Significantly Below (<50%),30,28.0,8.38
NCT03818217,Effects of a Robot on Physical and Psychosocial Outcomes of Persons With Dementia and Their Social Environment at Home,COMPLETED,NA,64.0,2019-05-06,2020-06-30,4.627458432304038,Adequate (1-10/month),46.27458432304037,Significantly Below (<50%),100,55.1,62.085
NCT04871217,68Ga-NODAGA-RGD PET in Patients With an Occluded Coronary Artery,UNKNOWN,NA,60.0,2018-12-04,2023-12-01,1.0018650575973669,Adequate (1-10/month),10.01865057597367,Significantly Below (<50%),50,34.8,15.040000000000001
NCT00990717,Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies,COMPLETED,PHASE1,8.0,2005-03-01,2012-07-01,0.09089958939902949,Slow (<1/month),0.9089958939902949,Significantly Below (<50%),100,45.6,32.08
NCT03023917,The Study on Umbilical Cord Milking to Prevent and Decrease the Severity of Anemia in Preterms,COMPLETED,NA,284.0,2017-06-30,2019-12-31,9.458380743982495,Adequate (1-10/month),94.58380743982495,Met (75-100%),100,77.7,85.91499999999999
NCT03814317,Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension,RECRUITING,PHASE2,10.0,2020-01-30,2026-07-29,0.12833052276559867,Slow (<1/month),1.2833052276559869,Significantly Below (<50%),60,33.8,13.694999999999999
NCT01865617,"Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia",COMPLETED,PHASE1,204.0,2013-05-22,2021-03-26,2.167455497382199,Adequate (1-10/month),21.67455497382199,Significantly Below (<50%),100,66.3,79.3
NCT06608017,Study of Yupingfeng Powder Treating Allergic Rhinitis (AR),NOT_YET_RECRUITING,PHASE2,140.0,2024-10-01,2025-10-31,10.788860759493671,Good (10-50/month),107.8886075949367,Exceeded (≥100%),30,45.2,30.830000000000002
NCT05698017,Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA),ACTIVE_NOT_RECRUITING,PHASE1,10.0,2022-11-07,2026-02-19,0.25366666666666665,Slow (<1/month),2.5366666666666666,Significantly Below (<50%),85,41.3,23.74
NCT01361217,"The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity",COMPLETED,NA,10.0,2011-09-01,2012-06-01,1.110948905109489,Adequate (1-10/month),11.10948905109489,Significantly Below (<50%),100,45.8,33.03
NCT06740617,Evaluation Of Balance And Ankle Proprioception In Calcaneal Spur Patients,NOT_YET_RECRUITING,,52.0,2024-12-25,2025-01-30,43.96888888888889,Good (10-50/month),200.0,Exceeded (≥100%),30,41.5,24.215
NCT05105217,Evaluation of Slit2 in Systemic Lupus Erythematosus and Systemic Sclerosis Patients,UNKNOWN,,85.0,2021-12-01,2023-02-01,6.059484777517564,Adequate (1-10/month),60.594847775175644,Below (50-75%),50,40.1,22.05
NCT00249717,Group-Based Contingency Management for Substance Abuse Treatment - 1,COMPLETED,NA,312.0,2005-05-01,2010-01-01,5.566987104337632,Adequate (1-10/month),55.66987104337632,Below (50-75%),100,75.0,84.49
NCT04919317,Combination Dexamethasone and Bupivacaine Pain Control in Reduction Mammaplasty,COMPLETED,PHASE2,56.0,2017-09-29,2020-11-25,1.478438855160451,Adequate (1-10/month),14.784388551604511,Significantly Below (<50%),100,49.5,46.58
NCT05147740,Study to Assess Switching to B/F/TAF in Treatment Experienced People With HIV Who Are at Least 65 Years of Age,UNKNOWN,PHASE4,50.0,2021-07-01,2022-12-01,2.9382239382239383,Adequate (1-10/month),29.382239382239383,Significantly Below (<50%),50,39.0,20.505000000000003
NCT02225340,"Relationships Between Plasma PCSK9 Levels, LDL-cholesterol Concentrations and Lipoprotein (a) Levels in Familial Hypercholesterolemia",COMPLETED,,348.0,2014-01-01,2014-04-01,117.70133333333334,Excellent (>50/month),200.0,Exceeded (≥100%),100,86.2,91.52
NCT06078540,A Mobile Health (mHealth) Strategy for Improving Blood Pressure Control Among Adult Hypertensive African Americans,RECRUITING,NA,30.0,2023-10-27,2026-10-01,0.8534579439252337,Slow (<1/month),8.534579439252337,Significantly Below (<50%),60,35.4,15.765
NCT04770740,Randomized Controlled Clinical Trial to Investigate Effects of Vitamin K2 in COVID-19,COMPLETED,NA,40.0,2021-02-22,2022-03-01,3.2731182795698928,Adequate (1-10/month),32.73118279569893,Significantly Below (<50%),100,53.2,56.665
NCT04723940,Or v IV Antibiotics for Infection,UNKNOWN,PHASE3,308.0,2021-01-25,2023-01-25,12.843178082191782,Good (10-50/month),128.4317808219178,Exceeded (≥100%),50,64.6,77.59
NCT03507140,Microbiota Study in Liver Transplanted Patients,COMPLETED,,64.0,2019-04-16,2024-03-27,1.0781184283342558,Adequate (1-10/month),10.781184283342556,Significantly Below (<50%),100,48.5,44.47
NCT02975440,Drug-drug Interaction Study Between Orally Administered Rifampicin and Vilaprisan,COMPLETED,PHASE1,12.0,2016-11-10,2017-04-11,2.403157894736842,Adequate (1-10/month),24.031578947368423,Significantly Below (<50%),100,51.0,49.714999999999996
NCT03113240,Trial of Enteral Glutamine on Intestinal Permeability in Critically Ill Patients,COMPLETED,PHASE3,60.0,2017-04-01,2017-10-01,9.98032786885246,Adequate (1-10/month),99.80327868852459,Met (75-100%),100,59.8,71.61
NCT00166140,Heparin Responses in Pediatric Patients Undergoing Cardiopulmonary Bypass.,COMPLETED,,125.0,2002-12-01,2006-05-01,3.051323175621492,Adequate (1-10/month),30.51323175621492,Significantly Below (<50%),100,58.3,68.99499999999999
NCT05299840,Impact of Using the Oncogramme® Device to Select the First Line of Treatment for Patients With Metastatic Colorectal Cancer,RECRUITING,NA,450.0,2023-06-07,2028-12-01,6.835329341317366,Adequate (1-10/month),68.35329341317366,Below (50-75%),60,74.0,83.985
NCT00020540,Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer,COMPLETED,PHASE1,,2001-03-01,,,Slow (<1/month),,Significantly Below (<50%),100,40.0,21.87
NCT04034940,"Correlations Between Oxidative Stress Biomarkers, h-FABP and Left Ventricular Dysfunction in Patients With Acute Myocardial Infarction Undergoing Primary PCI",UNKNOWN,NA,200.0,2019-08-01,2020-08-01,16.633879781420767,Good (10-50/month),166.33879781420765,Exceeded (≥100%),50,56.0,63.71
NCT03201640,VR for Preoperative Anxiety in Children,COMPLETED,NA,39.0,2017-09-18,2019-04-30,2.015551782682513,Adequate (1-10/month),20.15551782682513,Significantly Below (<50%),100,53.1,56.105000000000004
NCT03196440,Sensitivity of Basic Taste in Elderly,COMPLETED,,280.0,2015-07-07,2019-08-29,5.629590488771466,Adequate (1-10/month),56.29590488771466,Below (50-75%),100,70.7,82.25
NCT01390740,Observatory of Screening Aneurysms of the Abdominal Aorta During Echocardiography. National Epidemiological Survey,COMPLETED,,1412.0,2011-05-01,2011-09-01,349.4413008130081,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT05704140,Vienna Vascular Access Studied on Exchange of Dialysis Catheters for Shunts Where Feasible,UNKNOWN,,400.0,2022-12-15,2023-06-01,72.47619047619048,Excellent (>50/month),200.0,Exceeded (≥100%),50,75.3,84.60499999999999
NCT04292340,Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19,UNKNOWN,,15.0,2020-02-01,2020-12-31,1.367065868263473,Adequate (1-10/month),13.670658682634729,Significantly Below (<50%),50,29.5,8.86
NCT05320640,"Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors",UNKNOWN,PHASE1,100.0,2022-03-30,2025-04-01,2.7723132969034614,Adequate (1-10/month),27.723132969034616,Significantly Below (<50%),50,43.0,26.465
NCT01000740,A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa,COMPLETED,PHASE4,59.0,2009-08-01,2010-04-01,7.390781893004116,Adequate (1-10/month),73.90781893004116,Below (50-75%),100,54.7,60.629999999999995
NCT02381340,ACE Stapler Sub Study,COMPLETED,,10.0,2012-06-01,2014-03-01,0.47711598746081507,Slow (<1/month),4.771159874608151,Significantly Below (<50%),100,44.1,28.425
NCT03449940,Penile Fracture: A Comparison of Erectile Function After Immediate Repair Versus Delayed Repair,COMPLETED,NA,46.0,2015-01-01,2017-12-01,1.3147793427230048,Adequate (1-10/month),13.147793427230049,Significantly Below (<50%),100,48.7,44.93
NCT01771640,Intrathecal Transplantation of Mesenchymal Stem Cell in Patients With ALS,COMPLETED,PHASE1,8.0,2013-08-01,2014-12-01,0.500041067761807,Slow (<1/month),5.000410677618071,Significantly Below (<50%),100,45.6,32.08
NCT02294240,Effect of Energy Dense Biscuits in Undernourished Women on Birth Weight of Their Neonates,UNKNOWN,NA,224.0,2014-09-01,2016-03-01,12.465374771480805,Good (10-50/month),124.65374771480803,Exceeded (≥100%),50,57.9,67.83
NCT02420340,Using The HOPES Program in Transition Care,COMPLETED,NA,12.0,2014-09-01,,,Slow (<1/month),,Significantly Below (<50%),100,41.0,23.01
NCT07088640,Single Step Protocol and Multi-step Warming Protocol for Blastocyst FET,RECRUITING,NA,816.0,2025-08-13,2027-03-01,43.962902654867264,Good (10-50/month),200.0,Exceeded (≥100%),60,88.0,92.495
NCT02304640,"Prevalence, Severity and Determinants of Cancer-related Fatigue (CRF) in Asian Breast Cancer Patients",UNKNOWN,,194.0,2014-10-01,2020-12-01,2.6211096316023084,Adequate (1-10/month),26.21109631602308,Significantly Below (<50%),50,48.9,45.4
NCT02434640,"Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1128688 After Multiple Oral Administrations in Healthy Women",COMPLETED,PHASE1,51.0,2015-04-01,2016-04-01,4.241639344262295,Adequate (1-10/month),42.416393442622955,Significantly Below (<50%),100,54.1,59.11
NCT04028440,γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL),UNKNOWN,EARLY_PHASE1,6.0,2019-10-01,2022-03-31,0.20026315789473687,Slow (<1/month),2.0026315789473688,Significantly Below (<50%),50,30.5,9.395000000000001
NCT04781140,Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD,RECRUITING,PHASE4,286.0,2024-03-19,2026-06-01,10.8281592039801,Good (10-50/month),108.28159203980098,Exceeded (≥100%),60,65.9,78.83
NCT07326540,Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex,NOT_YET_RECRUITING,PHASE3,248.0,2026-03-20,2028-03-30,10.18774628879892,Good (10-50/month),101.8774628879892,Exceeded (≥100%),30,53.8,58.065
NCT00480389,Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal,COMPLETED,PHASE2,19.0,2007-05-01,2013-03-01,0.27140309713749416,Slow (<1/month),2.7140309713749415,Significantly Below (<50%),100,46.5,36.815
NCT03186989,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease",COMPLETED,PHASE1,46.0,2017-10-12,2022-05-12,0.8369635385534968,Slow (<1/month),8.369635385534968,Significantly Below (<50%),100,48.7,44.93
NCT00965289,High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell Lymphoma,COMPLETED,PHASE2,42.0,2002-04-01,2009-06-01,0.4883422459893048,Slow (<1/month),4.883422459893048,Significantly Below (<50%),100,48.4,44.22
NCT02603289,One Week Aligner Evaluation,COMPLETED,,287.0,2015-09-01,2020-08-01,4.8642984409799555,Adequate (1-10/month),48.64298440979955,Significantly Below (<50%),100,71.3,82.655
NCT04133389,Believing People Can Change: A Randomized Controlled Trial of an Incremental Theory Intervention in Adolescence,COMPLETED,NA,576.0,2019-10-15,2020-03-06,122.61146853146853,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT01413789,Measurement and Comparison of the Occlusive and Hydrating Capacity of Three Silicone Gels and One Gel Cream,COMPLETED,NA,55.0,2011-06-01,2012-07-01,4.227777777777778,Adequate (1-10/month),42.27777777777778,Significantly Below (<50%),100,54.4,59.89
NCT04748289,ICU Cockpit Apps: Interventional Study With First ICU Cockpit Software Applications,SUSPENDED,NA,1000.0,2021-03-01,2027-01-01,14.27767354596623,Good (10-50/month),142.7767354596623,Exceeded (≥100%),20,71.0,82.44
NCT05034289,Promoting INformed Approaches in Precision Oncology and ImmuNoTherapy,COMPLETED,NA,81.0,2021-07-12,2023-05-19,3.647396449704142,Adequate (1-10/month),36.47396449704142,Significantly Below (<50%),100,56.5,65.18
NCT02748889,Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer,TERMINATED,PHASE1,1.0,2016-03-01,2017-05-09,0.07013824884792627,Slow (<1/month),0.7013824884792627,Significantly Below (<50%),10,18.1,3.105
NCT06007989,Assessing the Relationship Between Hypoxia and the Immune Environment in Myeloma Patients (CHIME),UNKNOWN,,10.0,2023-11-01,2024-08-01,1.110948905109489,Adequate (1-10/month),11.10948905109489,Significantly Below (<50%),50,29.1,8.799999999999999
NCT06295289,"Hybrid Closed-loop Insulin Delivery System in Perioperative Diabetic Patients: an Open-label, Randomized Controlled Trial",COMPLETED,NA,54.0,2023-10-16,2024-12-31,3.7189140271493213,Adequate (1-10/month),37.189140271493216,Significantly Below (<50%),100,54.3,59.62
NCT07292389,Examining Valence-based Effects in Self-Monitoring Feedback Messages,NOT_YET_RECRUITING,NA,127.0,2026-01-01,2027-06-01,7.492015503875969,Adequate (1-10/month),74.92015503875969,Below (50-75%),30,39.2,20.715
NCT05799989,Catheter Dislocation and the Influence of Different Catheter Fixation in Pediatric Patients,UNKNOWN,,100.0,2023-06-01,2024-04-30,9.113772455089821,Adequate (1-10/month),91.1377245508982,Met (75-100%),50,46.3,35.66
NCT02898389,Influence of Chronic Vascular Diseases on Transcranial Doppler Profiles in Critically Ill Patients,COMPLETED,,91.0,2016-06-14,2018-09-14,3.3698783454987833,Adequate (1-10/month),33.69878345498783,Significantly Below (<50%),100,55.6,62.905
NCT01504789,Part II: Exercise in Hispanic Breast Cancer Survivors,ACTIVE_NOT_RECRUITING,NA,53.0,2012-02-07,2026-02-28,0.3141811100292113,Slow (<1/month),3.1418111002921125,Significantly Below (<50%),85,44.7,29.67
NCT00005489,"Salt Sensitivity, Cardiovascular and Metabolic Disease",COMPLETED,,,1998-01-01,2001-12-01,,Slow (<1/month),,Significantly Below (<50%),100,43.3,27.05
NCT00635089,Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis,COMPLETED,PHASE3,190.0,2008-07-01,2012-01-01,4.521970289288507,Adequate (1-10/month),45.21970289288507,Significantly Below (<50%),100,65.2,78.23
NCT05089968,Ventilation Associated Pneumonia and Covid-19,COMPLETED,,268.0,2020-01-24,2021-01-08,23.308342857142858,Good (10-50/month),200.0,Exceeded (≥100%),100,74.8,84.385
NCT04494568,Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Rectal Endometriosis,COMPLETED,NA,60.0,2020-08-27,2022-11-30,2.2138181818181817,Adequate (1-10/month),22.138181818181817,Significantly Below (<50%),100,54.8,61.095
NCT04573868,"National Study ""AEC COVID-19""",UNKNOWN,,1000.0,2020-03-01,2020-09-30,142.91079812206573,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT00155168,Quantitative Analysis of SMN1 and SMN2 Gene Based on DHPLC System,UNKNOWN,,500.0,2004-04-01,,,Slow (<1/month),,Significantly Below (<50%),50,63.3,76.235
NCT05024968,Sintilimab in Cancer of Unknown Primary,COMPLETED,PHASE2,12.0,2021-08-26,2025-04-03,0.2775683890577508,Slow (<1/month),2.7756838905775076,Significantly Below (<50%),100,46.0,34.1
NCT05427968,Comparison of Hypotension During Spinal Anaesthesia for C-section,COMPLETED,,38.0,2021-12-01,2022-02-01,18.656774193548387,Good (10-50/month),186.56774193548387,Exceeded (≥100%),100,56.4,64.88000000000001
NCT04514068,Effect of Electroacupuncture on P6 Acupoint on Hypertensive Patients.,UNKNOWN,NA,150.0,2020-09-01,2021-04-30,18.946058091286307,Good (10-50/month),189.46058091286312,Exceeded (≥100%),50,52.0,52.86
NCT07058168,The Effect of Labor Diet During the Delivery Process,COMPLETED,NA,94.0,2022-02-01,2022-06-30,19.203758389261743,Good (10-50/month),192.03758389261745,Exceeded (≥100%),100,62.5,75.21
NCT06578468,End-Tidal Oxygen for Intubation in the Emergency Department,RECRUITING,NA,1400.0,2024-08-05,2025-12-31,83.0721247563353,Excellent (>50/month),200.0,Exceeded (≥100%),60,88.0,92.495
NCT05139368,Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer,ACTIVE_NOT_RECRUITING,NA,22.0,2021-11-11,2027-06-26,0.32619581100828055,Slow (<1/month),3.2619581100828055,Significantly Below (<50%),85,42.3,25.295
NCT05901168,Acute Responses of Active Video Games and Traditional Exercise Program in in Patients With Pulmonary Hypertension,COMPLETED,NA,16.0,2023-08-01,2024-05-30,1.6073927392739276,Adequate (1-10/month),16.07392739273927,Significantly Below (<50%),100,46.3,35.66
NCT07102368,A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany,RECRUITING,,400.0,2025-08-18,2029-01-15,9.772070626003211,Adequate (1-10/month),97.7207062600321,Met (75-100%),60,73.3,83.61
NCT02279368,Nursing Led Interdisciplinary Intervention in Prevention of Girl Child Mortality and Maltreatment,COMPLETED,NA,134.0,2013-09-01,2014-10-01,10.32648101265823,Good (10-50/month),103.26481012658229,Exceeded (≥100%),100,65.7,78.66499999999999
NCT01007968,Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function,COMPLETED,PHASE1,25.0,2010-03-01,2012-11-01,0.7797131147540983,Slow (<1/month),7.797131147540982,Significantly Below (<50%),100,47.0,39.33
NCT05058768,Omics Sequencing of Exosomes in Body Fluids of Patients With Acute Lung Injury,UNKNOWN,,180.0,2022-05-06,2024-12-16,5.73738219895288,Adequate (1-10/month),57.37382198952879,Below (50-75%),50,47.7,42.17
NCT01700868,Practice Based Nutrition Intervention-2,COMPLETED,NA,15.0,2014-07-01,2015-07-01,1.2509589041095892,Adequate (1-10/month),12.509589041095893,Significantly Below (<50%),100,46.2,35.089999999999996
NCT03163368,Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors,ACTIVE_NOT_RECRUITING,EARLY_PHASE1,25.0,2017-05-09,2025-11-01,0.24564234990316333,Slow (<1/month),2.4564234990316334,Significantly Below (<50%),85,42.5,25.585
NCT00404768,"The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor",COMPLETED,PHASE2,93.0,2007-10-12,2011-07-07,2.0754545454545457,Adequate (1-10/month),20.754545454545458,Significantly Below (<50%),100,57.4,67.05499999999999
NCT01626768,Medtronic Market-Released DF4 Lead Imaging,COMPLETED,,37.0,2012-06-01,2013-05-01,3.3720958083832335,Adequate (1-10/month),33.720958083832336,Significantly Below (<50%),100,51.3,50.62
NCT02586168,The Effect of Gemcabene on Insulin Sensitivity in Nondiabetic Subjects,COMPLETED,PHASE2,53.0,2001-07-01,2001-10-01,17.53608695652174,Good (10-50/month),175.3608695652174,Exceeded (≥100%),100,59.2,70.7
NCT05981768,Study to Evaluate Effect of Food on Bioavailability of Single 3 mg Tablet and Pharmacokinetics (PK) of Multiple 3 mg Doses in Healthy Adult Smokers,COMPLETED,PHASE1,30.0,2023-08-08,2023-09-21,20.754545454545454,Good (10-50/month),200.0,Exceeded (≥100%),100,57.4,67.05499999999999
NCT05717868,Self-Mobilization Versus Kinesio-Taping on the Cervical Region in Electronic Device Users,UNKNOWN,NA,32.0,2022-11-16,2023-06-01,4.944568527918782,Adequate (1-10/month),49.44568527918782,Significantly Below (<50%),50,37.6,18.845
NCT02211768,Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1,COMPLETED,PHASE1,10.0,2014-12-08,2019-12-30,0.16471861471861474,Slow (<1/month),1.647186147186147,Significantly Below (<50%),100,45.8,33.03
NCT01967368,Safety and Efficacy of Intradermal Trivalent Influenza Vaccination in Institutionalized Older Adults,UNKNOWN,PHASE4,100.0,2013-10-01,2015-06-01,5.006578947368421,Adequate (1-10/month),50.065789473684205,Below (50-75%),50,43.0,26.465
NCT03002168,Determining Lipid Content in Stool After Alpha-cyclodextrin,COMPLETED,NA,8.0,2017-01-20,2017-06-05,1.7905882352941176,Adequate (1-10/month),17.905882352941177,Significantly Below (<50%),100,50.6,48.705
NCT01852968,Hippocampal Metabolism and Function in Patients With Type 1 Diabetes,COMPLETED,,57.0,2013-05-01,2017-10-31,1.0554014598540147,Adequate (1-10/month),10.554014598540146,Significantly Below (<50%),100,47.9,42.64
NCT03761368,Remote Ischemic Preconditioning and Contrast Induced - Acute Kidney Injury in Patients Undergoing Elective PCI,COMPLETED,NA,101.0,2015-03-01,2018-06-30,2.5262448644207067,Adequate (1-10/month),25.26244864420707,Significantly Below (<50%),100,58.1,68.595
NCT03073668,Pericardial Resection to Treat Heart Failure,COMPLETED,NA,23.0,2017-03-20,2019-02-02,1.0235672514619882,Adequate (1-10/month),10.235672514619884,Significantly Below (<50%),100,46.8,38.440000000000005
NCT00928668,Efficacy (Bronchoprotection) and Safety of Orally Inhaled BI 1744 CL in Patients With Intermittent Asthma,COMPLETED,PHASE2,32.0,2006-01-01,,,Slow (<1/month),,Significantly Below (<50%),100,42.6,25.679999999999996
NCT04702568,A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH),TERMINATED,PHASE2,19.0,2020-12-18,2023-10-04,0.5670196078431373,Slow (<1/month),5.670196078431373,Significantly Below (<50%),10,19.5,5.315
NCT04255550,Hemodynamic Monitoring and Correlation Between Electrical Cardiometry and Esophageal Doppler in Patients Undergoing Major Abdominal Surgery,COMPLETED,,35.0,2019-04-09,2020-12-30,1.6884310618066563,Adequate (1-10/month),16.88431061806656,Significantly Below (<50%),100,51.1,50.129999999999995
NCT03276650,Admission of Adult-onset Still Disease Patients in the ICU,COMPLETED,,45.0,2017-09-01,2018-08-01,4.1011976047904195,Adequate (1-10/month),41.01197604790419,Significantly Below (<50%),100,51.9,52.55499999999999
NCT02559050,Nasal Reconstruction Using a Customized 3D-printed Nasal Stent for Congenital Arhinia,COMPLETED,,1.0,2013-05-01,2013-12-01,0.14224299065420562,Slow (<1/month),1.422429906542056,Significantly Below (<50%),100,43.4,27.265
NCT07356050,Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease,RECRUITING,,130.0,2025-03-13,2028-12-31,2.8489560835133187,Adequate (1-10/month),28.489560835133187,Significantly Below (<50%),60,46.7,37.895
NCT06195150,Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer,RECRUITING,,3.0,2023-11-08,2025-10-31,0.12630705394190872,Slow (<1/month),1.263070539419087,Significantly Below (<50%),60,31.6,10.905
NCT05148650,Impact of Balanced Crystalloid and Colloid Infusion on Haemostasis in Healthy Male Volunteers,UNKNOWN,NA,25.0,2021-02-16,2021-12-01,2.642361111111111,Adequate (1-10/month),26.42361111111111,Significantly Below (<50%),50,37.0,17.955
NCT01087450,The Effect of Erythropietin on Microcircualtory Alteration in Intensive Care Unit Patients With Severe Sepsis,TERMINATED,,22.0,2009-08-12,2018-03-07,0.21402364972834773,Slow (<1/month),2.1402364972834773,Significantly Below (<50%),10,18.1,3.105
NCT02686450,[Trial of device that is not approved or cleared by the U.S. FDA],WITHHELD,,,,,,Slow (<1/month),,Significantly Below (<50%),50,20.0,5.695
NCT03076450,Evaluation of POC Lung Ultrasound Combined With Pressure-volume Curve to Titration Adjust PEEP for ARDS Lung Recruitment,UNKNOWN,NA,30.0,2017-03-01,2018-09-01,1.6633879781420766,Adequate (1-10/month),16.633879781420767,Significantly Below (<50%),50,32.4,12.025
NCT00948350,Anesthesia for Awake Fiberoptic Intubation,COMPLETED,NA,120.0,2009-01-01,2014-01-01,2.0004381161007667,Adequate (1-10/month),20.00438116100767,Significantly Below (<50%),100,59.6,71.17999999999999
NCT04809350,Human Milk Fortification With Adjustable Versus Targeted Method,UNKNOWN,NA,52.0,2023-11-10,2025-05-31,2.7867605633802817,Adequate (1-10/month),27.867605633802818,Significantly Below (<50%),50,39.2,20.715
NCT07284550,Smartphone Based Digital Screening for Aortic Valve Stenosis,NOT_YET_RECRUITING,,500.0,2025-12-01,2029-11-01,10.63591893780573,Good (10-50/month),106.35918937805731,Exceeded (≥100%),30,72.3,83.065
NCT02490150,Corifollitropin Alfa on D5 Versus D7 After Contraceptive Pill,COMPLETED,PHASE4,70.0,2015-02-01,2016-06-01,4.3843621399176955,Adequate (1-10/month),43.84362139917696,Significantly Below (<50%),100,55.6,62.905
NCT02513550,A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis,COMPLETED,PHASE3,1257.0,2015-08-01,2017-08-03,52.200654843110506,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT04150250,Cholera Anti-Secretory Treatment Trial,COMPLETED,PHASE2,47.0,2019-11-04,2020-07-27,5.378496240601503,Adequate (1-10/month),53.78496240601503,Below (50-75%),100,53.8,58.065
NCT03774550,Atrial Fibrillation Ablation: Radiofrequency or Cryoablation?,COMPLETED,,206.0,2019-01-25,2019-05-01,65.31916666666667,Excellent (>50/month),200.0,Exceeded (≥100%),100,74.8,84.385
NCT03391050,A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma,TERMINATED,PHASE1,3.0,2018-01-18,2018-08-08,0.4520792079207921,Slow (<1/month),4.520792079207921,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT01548950,Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension,COMPLETED,NA,50.0,2011-09-01,2020-03-01,0.4903350515463918,Slow (<1/month),4.903350515463917,Significantly Below (<50%),100,49.0,45.61
NCT03891550,Micro-elimination of Hepatitis C Virus Infection in Uremics,UNKNOWN,PHASE3,135.0,2019-05-13,2024-04-15,2.2842690383546413,Adequate (1-10/month),22.842690383546415,Significantly Below (<50%),50,45.8,33.03
NCT04794491,An Interventional Safety Switch Study (Segue Study) of XYWAV in Narcolepsy,COMPLETED,PHASE4,62.0,2021-03-22,2022-11-15,3.1298175787728026,Adequate (1-10/month),31.298175787728027,Significantly Below (<50%),100,55.0,61.834999999999994
NCT00562991,Monitoring Asthma Treatment Using Exhaled Nitric Oxide,COMPLETED,,99.0,2007-10-01,2009-12-01,3.805,Adequate (1-10/month),38.05,Significantly Below (<50%),100,56.3,64.5
NCT00471991,Valette (Combined Oral Contraceptive SH T04769G and SH D00659AF) Low Ovulation Inhibition,COMPLETED,PHASE2,60.0,2007-04-01,2007-12-01,7.485245901639344,Adequate (1-10/month),74.85245901639344,Below (50-75%),100,54.8,61.095
NCT05470491,"Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...",RECRUITING,PHASE1,265.0,2023-01-26,2027-07-30,4.900729040097206,Adequate (1-10/month),49.00729040097205,Significantly Below (<50%),60,59.2,70.7
NCT03498391,A Study of Human Multi-Sensory Integration,SUSPENDED,PHASE2,40.0,2018-07-30,2023-05-01,0.7013824884792627,Slow (<1/month),7.0138248847926254,Significantly Below (<50%),20,24.2,6.825
NCT02115191,2-octyl Cyanoacrylate for Closure of Urethrocutaneous Fistula.,COMPLETED,PHASE3,42.0,2014-04-01,2015-03-01,3.8277844311377245,Adequate (1-10/month),38.277844311377244,Significantly Below (<50%),100,53.4,57.35
NCT01692691,Dacarbazine and Carmustine in Metastatic Melanoma,TERMINATED,PHASE2,1.0,2012-08-01,2014-10-01,0.038482932996207336,Slow (<1/month),0.3848293299620733,Significantly Below (<50%),10,18.1,3.105
NCT07202091,Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig),RECRUITING,PHASE2,900.0,2025-05-06,2027-03-31,39.475504322766575,Good (10-50/month),200.0,Exceeded (≥100%),60,83.0,89.505
NCT02893891,Metabolic Changes After Bariatric Surgery,COMPLETED,NA,150.0,2012-03-01,2017-12-01,2.173250832936697,Adequate (1-10/month),21.73250832936697,Significantly Below (<50%),100,62.0,74.42
NCT02087891,Stress Free Now in a Corporate Call Center,COMPLETED,NA,161.0,2011-05-01,2012-09-01,10.022167689161556,Good (10-50/month),100.22167689161554,Exceeded (≥100%),100,67.9,80.36999999999999
NCT02663791,Alcohol Consumption and Arterial Stiffness: A Longitudinal Study of Pulse Wave Velocity in the Whitehall II Cohort,COMPLETED,,10308.0,2016-01-01,2016-06-01,2064.3126315789473,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT04669691,A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine,COMPLETED,PHASE2,420.0,2020-12-19,2022-04-15,26.52448132780083,Good (10-50/month),200.0,Exceeded (≥100%),100,88.6,92.825
NCT02767791,Auriculotherapy and Acupuncture's Treatment for Chemotherapy-induced Nausea and Vomiting (CINV),COMPLETED,NA,116.0,2016-05-04,2021-06-07,1.8984086021505377,Adequate (1-10/month),18.984086021505377,Significantly Below (<50%),100,59.3,70.815
NCT02078791,Discomfort and Psychosocial Difficulties in Fibromyalgia,COMPLETED,PHASE4,66.0,2012-07-01,2014-02-01,3.463862068965517,Adequate (1-10/month),34.63862068965517,Significantly Below (<50%),100,55.3,62.36000000000001
NCT01181791,Effects of Lactobacillus Reuteri in Premature Infants,TERMINATED,NA,65.0,2010-07-01,2017-07-01,0.7737974188502151,Slow (<1/month),7.737974188502152,Significantly Below (<50%),10,23.2,6.444999999999999
NCT06293391,The Effect of Patient Position Changes on Advanced Cardiac Indices in Cancer Surgery,COMPLETED,,80.0,2023-02-01,2024-02-05,6.5994579945799465,Adequate (1-10/month),65.99457994579947,Below (50-75%),100,54.7,60.629999999999995
NCT02623491,"Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55375515 in Healthy Participants",COMPLETED,PHASE1,175.0,2015-11-01,2016-09-01,17.465573770491805,Good (10-50/month),174.65573770491807,Exceeded (≥100%),100,69.0,81.185
NCT06458491,Urinary Symptoms After Posterior Tibial Nerve Stimulation,COMPLETED,,100.0,2024-03-01,2024-05-31,33.45054945054945,Good (10-50/month),200.0,Exceeded (≥100%),100,61.3,73.56
NCT03965091,A Study to Test the Effectiveness and Safety of Fremanezumab on Participants With Fibromyalgia,TERMINATED,PHASE2,189.0,2019-07-31,2022-01-19,6.371162790697675,Adequate (1-10/month),63.71162790697675,Below (50-75%),10,38.1,19.425
NCT06341491,The Study of Delay Discounting Among Beneficiaries of the Pé-de-Meia Program,NOT_YET_RECRUITING,,120.0,2024-04-01,2025-12-01,5.998029556650246,Adequate (1-10/month),59.98029556650245,Below (50-75%),30,36.9,17.735
NCT06433791,Evaluation of Ascorbate-Meglumine Therapeutic for SRS,ENROLLING_BY_INVITATION,PHASE1,12.0,2024-09-09,2025-09-09,1.0007671232876714,Adequate (1-10/month),10.007671232876714,Significantly Below (<50%),55,32.5,12.235
NCT06137391,Effectiveness of Pulpotomy in Carious First Permanent Molar,UNKNOWN,NA,96.0,2024-01-01,2025-12-01,4.174628571428571,Adequate (1-10/month),41.74628571428571,Significantly Below (<50%),50,42.7,25.77
NCT06793891,Effects of Ashwagandha Extract on Stress Levels,RECRUITING,NA,60.0,2024-10-21,2025-04-30,9.562303664921465,Adequate (1-10/month),95.62303664921465,Met (75-100%),60,47.8,42.42
NCT02579291,Dry Needling in Patients Who Had Experience Stroke,COMPLETED,NA,30.0,2015-10-01,2016-05-01,4.287323943661972,Adequate (1-10/month),42.87323943661972,Significantly Below (<50%),100,52.4,53.949999999999996
NCT01307891,"Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer",COMPLETED,PHASE2,64.0,2011-03-01,2017-06-01,0.8529597197898424,Slow (<1/month),8.529597197898424,Significantly Below (<50%),100,50.1,47.89
NCT01045291,Pacing for Heart Failure With Preserved Ejection Fraction,COMPLETED,NA,22.0,2010-06-01,2013-01-01,0.7086560846560847,Slow (<1/month),7.086560846560847,Significantly Below (<50%),100,46.8,38.440000000000005
NCT04041791,A Study to Compare Different Antibiotics and Different Modes of Fluid Treatment for Children With Severe Pneumonia,COMPLETED,PHASE3,4392.0,2019-08-19,2024-04-05,79.0611945594323,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT02960191,Functional Neuroimaging and Genetic Vulnerability to Suicidal Behavior,TERMINATED,NA,95.0,2008-12-01,2012-03-01,2.438279932546375,Adequate (1-10/month),24.382799325463747,Significantly Below (<50%),10,30.6,9.475
NCT06017791,Management of Excess Gingival Display Using Tunnel Technique With 3D Designed PEEK Shell: A Case Series,RECRUITING,NA,10.0,2023-11-08,2026-02-01,0.3730392156862745,Slow (<1/month),3.7303921568627456,Significantly Below (<50%),60,33.8,13.694999999999999
NCT02431091,Evaluation of the Role of OCT in the Detection of HIV-associated Neurocognitive Disorder,COMPLETED,NA,55.0,2015-04-01,2022-03-01,0.6627870150435472,Slow (<1/month),6.627870150435472,Significantly Below (<50%),100,49.4,46.42
NCT02382991,Assessment of Disability Compensation With the C-LEG COMPACT 2 Knee (Ref. 3C60 et 3C60=ST),COMPLETED,NA,35.0,2015-03-01,2015-11-01,4.348571428571429,Adequate (1-10/month),43.48571428571429,Significantly Below (<50%),100,52.8,55.31
NCT03845491,ASSIST Registry Studying Various Operator Techniques,COMPLETED,,1492.0,2019-01-24,2023-01-25,31.064623803009578,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT00426374,Assessment of Asymptomatic Heart Disease in Children With HIV,UNKNOWN,NA,,2007-01-01,,,Slow (<1/month),,Significantly Below (<50%),50,25.0,7.23
NCT06683274,Bascom Cleft Lift for Primary Wound Healing in Complex and Recurrent Sacrococcygeal Pilonidal Sinus Disease,RECRUITING,,58.0,2025-02-20,2027-04-01,2.292883116883117,Adequate (1-10/month),22.928831168831174,Significantly Below (<50%),60,41.0,23.01
NCT02528474,Comparison of Optical Coherence Tomographic Findings After Balloon Angioplasty With Two Different Paclitaxel-Coated Balloons for the Treatment of In-Stent Restenosis in Drug-Eluting Stents,TERMINATED,NA,24.0,2015-09-30,2017-04-20,1.2861971830985914,Adequate (1-10/month),12.861971830985915,Significantly Below (<50%),10,19.9,5.555000000000001
NCT03610074,"Relieve the Patient's Thirst, Refresh the Mouth First (ICU-MIC)",COMPLETED,NA,26.0,2018-04-23,2019-03-08,2.4810031347962385,Adequate (1-10/month),24.810031347962383,Significantly Below (<50%),100,52.1,53.03
NCT06251674,Efficacy of Ultrasound-guided Transverse Carpal Ligament Release for Carpal Tunnel Syndrome,COMPLETED,NA,60.0,2020-01-01,2023-12-30,1.2518163125428377,Adequate (1-10/month),12.518163125428378,Significantly Below (<50%),100,49.8,47.17
NCT04858074,Study to Investigate the Effect of Hypoestes Rosea Powder in Parkinson's Disease,COMPLETED,PHASE1,19.0,2022-01-03,2022-12-31,1.5976795580110497,Adequate (1-10/month),15.976795580110497,Significantly Below (<50%),100,46.5,36.815
NCT06995274,Umbilical Cord Blood Therapy in a Child With Eosinophilic Duodenitis and Autism Spectrum Disorder: a Case Study,NOT_YET_RECRUITING,NA,1.0,2025-06-01,2025-12-31,0.14291079812206572,Slow (<1/month),1.4291079812206573,Significantly Below (<50%),30,24.1,6.805
NCT04880174,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel Following mRNA COVID-19 Vaccination,ACTIVE_NOT_RECRUITING,NA,500.0,2021-03-22,2028-07-01,5.7261098570353655,Adequate (1-10/month),57.26109857035365,Below (50-75%),85,85.5,91.42
NCT00085774,Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma,COMPLETED,PHASE3,24.0,2004-06-30,2004-09-30,7.940869565217391,Adequate (1-10/month),79.40869565217392,Met (75-100%),100,51.9,52.55499999999999
NCT05788874,Study of 18F-FAPI Applied to Gastrointestinal Cancer,UNKNOWN,,50.0,2023-05-01,2024-12-01,2.6241379310344826,Adequate (1-10/month),26.241379310344826,Significantly Below (<50%),50,37.3,18.35
NCT00181974,Efficacy of a Fibrin Sealant in Burn Surgery,COMPLETED,NA,25.0,2000-03-01,2007-11-01,0.2716886826133524,Slow (<1/month),2.7168868261335235,Significantly Below (<50%),100,47.0,39.33
NCT05730374,"Benson's Relaxation Technique, Music Therapy for Children With Thalassemia",COMPLETED,NA,120.0,2022-08-01,2023-04-30,13.429411764705883,Good (10-50/month),134.29411764705884,Exceeded (≥100%),100,64.6,77.59
NCT01513174,Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone,COMPLETED,PHASE1,186.0,2011-08-01,2016-07-01,3.1524721603563473,Adequate (1-10/month),31.52472160356347,Significantly Below (<50%),100,64.9,77.985
NCT01405274,Impact of Physiotherapy Intervention for Children With Ankle Sprains,COMPLETED,NA,170.0,2011-07-01,2018-06-01,2.0478037198258803,Adequate (1-10/month),20.478037198258807,Significantly Below (<50%),100,63.6,76.545
NCT00033774,Stem Cell Collection for Adult Volunteers,TERMINATED,,136.0,2002-04-29,2022-08-19,0.5581555885128758,Slow (<1/month),5.5815558851287586,Significantly Below (<50%),10,27.2,8.115
NCT03994874,Peritoneal Ultrafiltration in Cardio Renal Syndrome.,RECRUITING,PHASE1,84.0,2025-04-16,2027-06-01,3.2950515463917527,Adequate (1-10/month),32.950515463917526,Significantly Below (<50%),60,44.7,29.67
NCT00458718,Efficacy and Safety of Rimonabant as an Aid to Smoking Cessation With or Without Nicotine Patch,COMPLETED,PHASE3,755.0,2004-09-01,2005-07-01,75.84884488448846,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT05107518,Children Participation Assessment Scale,COMPLETED,,250.0,2024-01-01,2025-01-01,20.792349726775956,Good (10-50/month),200.0,Exceeded (≥100%),100,73.3,83.61
NCT05268718,Au-Ag-Cu2O NG With PTT Anti Drug-resistant Microbial Keratitis,UNKNOWN,EARLY_PHASE1,20.0,2021-08-01,2024-07-01,0.5716431924882629,Slow (<1/month),5.71643192488263,Significantly Below (<50%),50,31.6,10.905
NCT06941818,HS-IT101 Injection in the Treatment of Advanced Melanoma,ENROLLING_BY_INVITATION,PHASE1,10.0,2025-07-10,2027-05-30,0.44179970972423804,Slow (<1/month),4.417997097242381,Significantly Below (<50%),55,32.3,11.799999999999999
NCT02783118,Using a Smartphone App to Reduce Cognitive Vulnerability and Mild Depressive Symptoms,COMPLETED,NA,255.0,2016-05-01,2017-12-01,13.406217616580312,Good (10-50/month),134.06217616580312,Exceeded (≥100%),100,75.4,84.64500000000001
NCT01381718,Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor,COMPLETED,PHASE2,112.0,2011-08-01,2016-08-01,1.8660536398467433,Adequate (1-10/month),18.660536398467436,Significantly Below (<50%),100,59.0,70.365
NCT04451018,Evaluation of Macro and Microcirculatory Arterial Condition of the Upper Limb in Insufficiently Renal Patients,UNKNOWN,,300.0,2020-06-17,2025-06-17,5.001095290251917,Adequate (1-10/month),50.010952902519165,Below (50-75%),50,57.3,66.74
NCT04019418,Carbohydrate Intake and Gut Hormone Release During Exercise,COMPLETED,NA,12.0,2019-02-21,2020-02-12,1.026067415730337,Adequate (1-10/month),10.26067415730337,Significantly Below (<50%),100,46.0,34.1
NCT04471818,Ketamine or Placebo in Patients With Major Depression and Advanced Cancer,COMPLETED,PHASE1,19.0,2019-09-19,2023-07-30,0.41018439716312055,Slow (<1/month),4.101843971631205,Significantly Below (<50%),100,46.5,36.815
NCT03426618,A Real-World Observational Study for the Safety and Efficacy of Baraclude in Korean Pediatric Patients With Chronic Hepatitis B,COMPLETED,,1.0,2018-01-12,2019-03-13,0.07162352941176471,Slow (<1/month),0.7162352941176471,Significantly Below (<50%),100,43.4,27.265
NCT03925818,Low Dose Bismuth Versus Lactobacillus Reuteri for H. Pylori Eradication,TERMINATED,NA,99.0,2017-08-29,2018-12-23,6.265197505197505,Adequate (1-10/month),62.65197505197505,Below (50-75%),10,30.9,9.875
NCT07361718,Comparison Between Two Medical Devices for the Reconditioning of Lungs Intended for Transplantation,NOT_YET_RECRUITING,NA,20.0,2026-01-01,2028-06-30,0.6682766190998903,Slow (<1/month),6.682766190998903,Significantly Below (<50%),30,25.6,7.595000000000001
NCT02577718,Safety and Effectiveness of Novel Nitroglycerin Based Catheter Lock Solution,COMPLETED,PHASE1,60.0,2015-11-01,2016-10-01,5.451940298507464,Adequate (1-10/month),54.51940298507463,Below (50-75%),100,54.8,61.095
NCT01201018,Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R for Cancer Treatment,COMPLETED,PHASE1,7.0,2011-01-01,2012-05-01,0.4384362139917696,Slow (<1/month),4.384362139917696,Significantly Below (<50%),100,45.6,32.08
NCT05458518,Caesarean Wound Dressing Removal Study,COMPLETED,NA,294.0,2022-08-01,2024-12-31,10.135175537938846,Good (10-50/month),101.35175537938845,Exceeded (≥100%),100,78.5,86.785
NCT00348218,Pilot Study of Neurovision to Improve Vision and Slow Myopia Progression in Children With Myopia,COMPLETED,PHASE1,30.0,2006-06-01,2009-04-01,0.8823188405797101,Slow (<1/month),8.8231884057971,Significantly Below (<50%),100,47.4,40.98
NCT02594618,Energy Metabolism and Cost of Physical Activities Using Whole Body Calorimeter,COMPLETED,,20.0,2014-08-01,2016-04-01,0.999671592775041,Slow (<1/month),9.996715927750408,Significantly Below (<50%),100,44.9,30.025000000000002
NCT03182218,Periprocedural Direct Oral Anticoagulant Management,COMPLETED,,1100.0,2015-02-01,2018-06-01,27.536184210526315,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT06382818,Personalization of Breast Radiotherapy According to Loco-regional Recurrence Risk and Toxicity Probability,NOT_YET_RECRUITING,NA,854.0,2025-03-06,2038-03-06,5.475096882898063,Adequate (1-10/month),54.75096882898063,Below (50-75%),30,69.0,81.185
NCT06577818,Sustained Inflation and Chest Compression vs 3:1 C:V Ratio in Asphyxiated Newborns,NOT_YET_RECRUITING,NA,554.0,2026-01-01,2033-07-01,6.159152666179693,Adequate (1-10/month),61.591526661796934,Below (50-75%),30,69.0,81.185
NCT02633618,Analgecine for the Treatment of Neuropathic Pain,COMPLETED,PHASE3,135.0,2005-08-01,2005-12-01,33.68360655737705,Good (10-50/month),200.0,Exceeded (≥100%),100,65.8,78.745
NCT07360418,"Evaluating the Durability of Closure for Diabetic Foot Ulcers Following a Randomized, Controlled, Modified Platform Trial.",RECRUITING,,50.0,2025-10-16,2027-10-01,2.128671328671329,Adequate (1-10/month),21.286713286713287,Significantly Below (<50%),60,40.3,22.21
NCT00218218,"Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia",COMPLETED,PHASE2,48.0,2002-06-01,2005-02-01,1.4970491803278687,Adequate (1-10/month),14.970491803278687,Significantly Below (<50%),100,48.8,45.184999999999995
NCT05145218,A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer,UNKNOWN,PHASE3,405.0,2021-09-28,2024-12-01,10.627758620689654,Good (10-50/month),106.27758620689656,Exceeded (≥100%),50,72.4,83.17999999999999
NCT00626418,The Effects of Aplindore on the Treatment of Signs and Symptoms of Restless Legs Syndrome,COMPLETED,PHASE2,24.0,2008-02-01,,,Slow (<1/month),,Significantly Below (<50%),100,41.9,24.585
NCT00510718,A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer,COMPLETED,PHASE1,140.0,2007-07-23,2018-04-02,1.0910394265232974,Adequate (1-10/month),10.910394265232975,Significantly Below (<50%),100,56.2,64.21
NCT04044690,"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)",TERMINATED,PHASE3,134.0,2019-10-21,2024-12-02,2.1824291064740504,Adequate (1-10/month),21.824291064740503,Significantly Below (<50%),10,33.7,13.465
NCT05612490,Furosemide Stress Test to Predict Successful Liberation From RRT,COMPLETED,,52.0,2023-01-17,2025-07-09,1.7509734513274338,Adequate (1-10/month),17.50973451327434,Significantly Below (<50%),100,52.5,54.345
NCT06921590,A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects,ACTIVE_NOT_RECRUITING,PHASE1,6.0,2025-05-09,2025-12-01,0.8866019417475729,Slow (<1/month),8.866019417475728,Significantly Below (<50%),85,41.0,23.01
NCT00772590,Antiretroviral Therapy Intensification With Raltegravir or Addition of Hyper-immune Bovine Colostrum in HIV-1 Infected Patients With Suboptimal CD4+ T Cell Response,COMPLETED,PHASE4,75.0,2009-03-01,2011-06-01,2.7773722627737225,Adequate (1-10/month),27.77372262773723,Significantly Below (<50%),100,56.0,63.71
NCT04134390,"Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study",COMPLETED,PHASE2,25.0,2020-02-17,2023-11-22,0.5538573508005823,Slow (<1/month),5.538573508005823,Significantly Below (<50%),100,47.0,39.33
NCT07146490,Effects of Different Types of Exercise on Irisin and Cognitive Performance (Exercise-Irisin),COMPLETED,NA,12.0,2025-06-10,2025-08-05,6.522857142857143,Adequate (1-10/month),65.22857142857143,Below (50-75%),100,51.0,49.714999999999996
NCT01533090,Evaluation of Reduced-volume PEG Bowel Preparation Administered the Same Day of Colonoscopy,COMPLETED,NA,162.0,2010-04-01,2010-11-01,23.04336448598131,Good (10-50/month),200.0,Exceeded (≥100%),100,68.0,80.56
NCT05674890,SmartSystem Virtual Reality Headset Perimeter Versus Humphrey HFA-III Perimeter,COMPLETED,NA,52.0,2023-01-03,2023-06-01,10.623355704697987,Good (10-50/month),106.23355704697988,Exceeded (≥100%),100,59.2,70.7
NCT00001390,Salivary Evaluation in Healthy Volunteers,COMPLETED,,173.0,1993-10-26,2018-09-20,0.5790126443100605,Slow (<1/month),5.790126443100604,Significantly Below (<50%),100,57.2,66.465
NCT02631590,Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma,COMPLETED,PHASE2,24.0,2016-07-05,2021-03-05,0.4287323943661972,Slow (<1/month),4.287323943661972,Significantly Below (<50%),100,46.9,38.96
NCT05052190,Patient Portal Flu Vaccine Reminders_RCT 4,TERMINATED,NA,239567.0,2021-10-14,2022-04-01,43150.411124260354,Excellent (>50/month),200.0,Exceeded (≥100%),10,73.0,83.44
NCT02476890,Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014),COMPLETED,PHASE2,36.0,2015-10-28,2016-10-20,3.061005586592179,Adequate (1-10/month),30.610055865921794,Significantly Below (<50%),100,52.9,55.55
NCT00797290,Photon/Proton Radiation Therapy for Carcinoma of the Nasopharynx,TERMINATED,,9.0,2008-06-01,2015-07-01,0.10593967517401393,Slow (<1/month),1.0593967517401393,Significantly Below (<50%),10,17.1,2.765
NCT00451490,The Effect of Agomelatine or Fluoxentine on Heart Rate Variability in Patients With Major Depressive Disorder,WITHDRAWN,NA,24.0,2006-10-01,2007-12-01,1.7149295774647888,Adequate (1-10/month),17.14929577464789,Significantly Below (<50%),5,23.4,6.7
NCT03096990,A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium,COMPLETED,,106.0,2017-04-21,2018-12-27,5.246569105691057,Adequate (1-10/month),52.46569105691058,Below (50-75%),100,56.8,65.69500000000001
NCT00633490,Study of Apatinib as an Inhibitor of Tumor Angiogenesis,UNKNOWN,PHASE1,18.0,2007-07-01,2008-06-01,1.6307142857142858,Adequate (1-10/month),16.30714285714286,Significantly Below (<50%),50,31.4,10.47
NCT02319590,"Anti-Angiotensin-Receptor 1 (ATR1)-, Anti-Endothelin-Receptor A (ETRA)-Antibodies and T Cells in Cardiomyopathy",COMPLETED,,80.0,2014-12-01,2020-12-01,1.110948905109489,Adequate (1-10/month),11.10948905109489,Significantly Below (<50%),100,49.7,46.949999999999996
NCT04168190,A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001),COMPLETED,PHASE1,600.0,2019-12-06,2021-07-12,31.273972602739725,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT02330497,Efficacy and Safety of Radiofrequency Ablation in Pancreatic Neuroendocrine and Cystic Tumor,COMPLETED,NA,30.0,2015-02-01,2017-02-01,1.249247606019152,Adequate (1-10/month),12.49247606019152,Significantly Below (<50%),100,47.4,40.98
NCT05468697,A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024),ACTIVE_NOT_RECRUITING,PHASE1,60.0,2022-08-10,2026-07-21,1.2674531575294936,Adequate (1-10/month),12.674531575294933,Significantly Below (<50%),85,45.3,31.169999999999998
NCT06469697,Zanzibar Arts for Children's Eyesight Pilot Trial,COMPLETED,NA,1295.0,2024-01-15,2024-12-11,119.09305135951662,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT06483997,"Diet, Hepcidin, and Chemotherapy RDI",ACTIVE_NOT_RECRUITING,,100.0,2024-08-16,2026-07-01,4.450292397660819,Adequate (1-10/month),44.50292397660819,Significantly Below (<50%),85,51.8,52.17
NCT06568497,Dairy and Vegan Cheese: Effect on Satiety and Blood Glucose,RECRUITING,NA,52.0,2024-08-04,2025-12-31,3.0795330739299613,Adequate (1-10/month),30.795330739299615,Significantly Below (<50%),60,42.2,25.155
NCT03982797,Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis,UNKNOWN,PHASE2,306.0,2019-05-17,2022-03-03,9.12305582761998,Adequate (1-10/month),91.2305582761998,Met (75-100%),50,64.5,77.44
NCT06755697,Comparative Efficacy of Intra-articular vs. MRI-guided Extra-articular Dextrose Injections in Knee Osteoarthritis Management,RECRUITING,NA,60.0,2025-01-23,2028-12-31,1.2700973574408903,Adequate (1-10/month),12.700973574408902,Significantly Below (<50%),60,37.8,19.015
NCT04046497,Artificial Intelligence to Measure Adherence to Oral Medication,RECRUITING,PHASE4,200.0,2020-11-20,2024-12-31,4.053262316910786,Adequate (1-10/month),40.53262316910786,Significantly Below (<50%),60,54.0,58.72500000000001
NCT02559297,Effects of Sevoflurane and Desflurane on Treg,COMPLETED,PHASE2,40.0,2015-08-10,2017-06-03,1.836500754147813,Adequate (1-10/month),18.36500754147813,Significantly Below (<50%),100,53.2,56.665
NCT05945797,Effects of Dexamethasone on Common Bile Duct Cannulation Time,COMPLETED,NA,80.0,2023-08-01,2024-05-16,8.426297577854672,Adequate (1-10/month),84.26297577854672,Met (75-100%),100,61.4,73.735
NCT06970197,The Effect of Simulation and Out-of-Class Educational Activities on Sustainability Among Nursing Students,COMPLETED,NA,72.0,2025-02-10,2025-12-01,7.45469387755102,Adequate (1-10/month),74.54693877551021,Below (50-75%),100,55.8,63.245
NCT00409097,Effect of Rosiglitazone on ADMA in Critical Illness,UNKNOWN,PHASE3,30.0,2006-04-01,2007-12-01,1.4995073891625614,Adequate (1-10/month),14.995073891625612,Significantly Below (<50%),50,32.4,12.025
NCT05034497,Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases,ACTIVE_NOT_RECRUITING,PHASE1,18.0,2021-12-06,2026-06-30,0.32868626274745055,Slow (<1/month),3.286862627474505,Significantly Below (<50%),85,41.9,24.585
NCT00858897,Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study A,COMPLETED,NA,10.0,2007-06-01,2009-02-01,0.4981996726677578,Slow (<1/month),4.981996726677577,Significantly Below (<50%),100,45.8,33.03
NCT05772897,Parenting Skills Group for Mothers With Postpartum Depression,RECRUITING,NA,750.0,2023-08-03,2035-06-01,5.284722222222222,Adequate (1-10/month),52.847222222222214,Below (50-75%),60,78.0,86.075
NCT07093697,A Study to Evaluate the Efficacy and Safety of DW5121 Compared to DW51211 and DW51212,COMPLETED,PHASE3,273.0,2024-03-28,2025-05-27,19.553223529411763,Good (10-50/month),195.53223529411764,Exceeded (≥100%),100,76.8,85.42
NCT06087497,The Z Stitch Early Bed Rest Assessment Study,RECRUITING,NA,200.0,2024-01-01,2025-05-01,12.526748971193417,Good (10-50/month),125.26748971193418,Exceeded (≥100%),60,59.0,70.365
NCT02626897,A Comparison of Accelerometers for Measuring Daily Activity in Sarcoid,UNKNOWN,NA,12.0,2016-01-01,2016-05-01,3.0188429752066117,Adequate (1-10/month),30.18842975206612,Significantly Below (<50%),50,36.0,16.564999999999998
NCT01673997,"Bioequivalence Study of Metoprolol Succinate ER Tablets, 200 mg Under Fasting Conditions",COMPLETED,PHASE1,48.0,2010-12-01,2011-01-01,47.13290322580645,Good (10-50/month),200.0,Exceeded (≥100%),100,63.8,76.78
NCT04545697,mHealth ElectroNic COnsultation REcording (mENCORE) in Advanced Prostate Cancer,COMPLETED,NA,27.0,2020-09-18,2021-02-28,5.042208588957055,Adequate (1-10/month),50.42208588957055,Below (50-75%),100,52.2,53.22
NCT03686410,Therapeutic Educational Intervention and Fibromyalgia: a Mixed Methods Research,UNKNOWN,NA,64.0,2020-01-15,2024-11-15,1.1031483578708947,Adequate (1-10/month),11.031483578708947,Significantly Below (<50%),50,35.1,15.384999999999998
NCT00478010,"Making Decisions About Participating in a Cancer Clinical Trial for Patients With Stage II, Stage III, or Stage IV Pancreatic Cancer or Stage III or Stage IV Colon Cancer or Rectal Cancer",COMPLETED,NA,205.0,2007-01-19,2008-09-29,10.081098546042004,Good (10-50/month),100.81098546042004,Exceeded (≥100%),100,71.4,82.695
NCT04626310,Mapping Aspects of Psychotherapy in Dialectical Behavior Therapy,COMPLETED,NA,84.0,2020-10-26,2023-02-06,3.069579831932773,Adequate (1-10/month),30.69579831932773,Significantly Below (<50%),100,56.7,65.53
NCT00615810,ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial,COMPLETED,PHASE4,159.0,2008-03-01,2010-01-01,7.213055141579732,Adequate (1-10/month),72.13055141579731,Below (50-75%),100,62.7,75.42
NCT03083210,Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET,UNKNOWN,PHASE4,28.0,2017-07-05,2020-02-01,0.9057598299681191,Slow (<1/month),9.05759829968119,Significantly Below (<50%),50,32.2,11.635
NCT06244810,Comparison of Two Types of Lingual Fixed Retainer Fabricated,COMPLETED,NA,42.0,2025-02-15,2025-03-10,42.0,Good (10-50/month),200.0,Exceeded (≥100%),100,63.4,76.375
NCT02105610,Volatile Anesthetics to Reduce Mortality in Cardiac Surgery,COMPLETED,PHASE4,5400.0,2014-04-14,2018-09-01,102.67083073079327,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT02988310,Comparison of Gait Characteristics in Individuals With Above and Below Knee Limb Loss,UNKNOWN,,39.0,2016-12-01,2017-01-01,38.29548387096774,Good (10-50/month),200.0,Exceeded (≥100%),50,41.5,24.215
NCT01425710,Non-invasive Evaluation of Fluid Status and Cardiac Output During Operative Treatment of Pheochromcytoma,COMPLETED,,15.0,2011-08-01,2013-07-01,0.6522857142857142,Slow (<1/month),6.522857142857143,Significantly Below (<50%),100,44.5,29.160000000000004
NCT01251510,Bile Acid-induced GLP-secretion. A Study in Cholecystectomized Subjects,COMPLETED,,20.0,2010-10-01,2011-06-01,2.505349794238683,Adequate (1-10/month),25.053497942386834,Significantly Below (<50%),100,49.9,47.425
NCT00485810,Examining Rapid Acting Intra-Muscular Olanzapine in Japanese Patients With Schizophrenia,COMPLETED,PHASE1,31.0,2004-06-01,2004-11-01,6.167581699346405,Adequate (1-10/month),61.67581699346405,Below (50-75%),100,52.5,54.345
NCT04437810,To Study Efficacy of Albumin in Cirrhosis With Spontaneous Bacterial Peritonitis at Low Risk for AKI Development,UNKNOWN,NA,100.0,2020-07-08,2022-04-30,4.605143721633888,Adequate (1-10/month),46.05143721633888,Significantly Below (<50%),50,43.0,26.465
NCT00416910,Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemia,TERMINATED,PHASE3,83.0,1999-07-01,2007-09-01,0.8466890080428955,Slow (<1/month),8.466890080428955,Significantly Below (<50%),10,24.6,6.959999999999999
NCT03009110,Preventing Adverse Incisional Outcomes at Cesarean Multicenter Trial,TERMINATED,NA,1624.0,2017-02-08,2019-11-13,49.04222222222222,Good (10-50/month),200.0,Exceeded (≥100%),10,73.0,83.44
NCT04799210,Human Factors Actual-Use Clinical Protocol,TERMINATED,NA,3.0,2021-09-16,2021-12-13,1.0377272727272728,Adequate (1-10/month),10.377272727272729,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT06194110,Comparing Stationary and Mobile Ergospirometry,COMPLETED,,20.0,2023-09-30,2024-07-30,2.0026315789473683,Adequate (1-10/month),20.026315789473685,Significantly Below (<50%),100,49.9,47.425
NCT03791710,Effect of Autologous Fat Grafting on Acute Burn Wound Healing,COMPLETED,PHASE3,100.0,2019-03-14,2020-01-31,9.424148606811146,Adequate (1-10/month),94.24148606811147,Met (75-100%),100,63.0,75.845
NCT04320810,Developing Metagenomic Approaches to Identify the Causes of Pediatric Infectious Diseases,RECRUITING,,1000.0,2020-01-01,2025-12-30,13.899543378995435,Good (10-50/month),138.99543378995435,Exceeded (≥100%),60,81.3,88.58
NCT01641510,PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic Variants,COMPLETED,PHASE3,70.0,2013-10-01,2019-02-01,1.0932786044125193,Adequate (1-10/month),10.932786044125193,Significantly Below (<50%),100,50.6,48.705
NCT03622710,Effects of Walking Training on Different Surfaces on Walking Ability in Ambulatory Patients With Spinal Cord Injury,COMPLETED,NA,72.0,2017-07-01,2019-01-16,3.8859574468085105,Adequate (1-10/month),38.85957446808511,Significantly Below (<50%),100,55.8,63.245
NCT02109510,Comparative Study of Nonintubated Anesthesia Versus Intubated General Anesthesia in Single Port Thoracoscopic Bullectomy,COMPLETED,NA,40.0,2012-11-01,2013-11-01,3.3358904109589043,Adequate (1-10/month),33.35890410958904,Significantly Below (<50%),100,53.2,56.665
NCT04219410,Assessment of a Modified Minimally Invasive Esophagectomy,COMPLETED,,142.0,2013-01-01,2016-08-31,3.2305530642750373,Adequate (1-10/month),32.30553064275038,Significantly Below (<50%),100,59.7,71.355
NCT03782610,Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes,ACTIVE_NOT_RECRUITING,,675.0,2019-04-01,2026-06-01,7.848357524828113,Adequate (1-10/month),78.48357524828113,Met (75-100%),85,83.8,90.505
NCT00887510,Metabolic Effects of Antihypertensive Drugs on People With Metabolic Syndrome (The MEAD Study),COMPLETED,PHASE4,24.0,2007-05-01,2009-11-01,0.7984262295081967,Slow (<1/month),7.984262295081967,Significantly Below (<50%),100,46.9,38.96
NCT02300610,Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer,COMPLETED,PHASE1,10.0,2015-02-11,2019-04-19,0.19921465968586388,Slow (<1/month),1.9921465968586387,Significantly Below (<50%),100,45.8,33.03
NCT01154010,PEMF: an Adjunct Therapy for Anterior Uveitis,COMPLETED,NA,18.0,2009-08-01,2015-04-01,0.2648235862735621,Slow (<1/month),2.6482358627356213,Significantly Below (<50%),100,46.4,36.26
NCT05564013,Developing a Virtual Reality (VR)-Based Prototype for Perioperative Care - a Proof of Concept Study,UNKNOWN,NA,160.0,2022-10-01,2023-09-01,14.53850746268657,Good (10-50/month),145.38507462686567,Exceeded (≥100%),50,52.8,55.31
NCT03841513,Minimally Invasive Burch Colposuspension to Reduce Occult Stress Incontinence,COMPLETED,NA,50.0,2019-01-29,2022-09-27,1.1383694839192222,Adequate (1-10/month),11.383694839192222,Significantly Below (<50%),100,49.0,45.61
NCT04661813,Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV,COMPLETED,NA,81.0,2021-03-01,2023-01-15,3.5994744525547446,Adequate (1-10/month),35.994744525547446,Significantly Below (<50%),100,56.5,65.18
NCT00570713,An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer,COMPLETED,PHASE2,155.0,2007-12-01,2009-12-01,6.454445964432285,Adequate (1-10/month),64.54445964432284,Below (50-75%),100,62.4,75.095
NCT05756413,Birth to Three - Cavity Free,ACTIVE_NOT_RECRUITING,NA,634.0,2023-03-01,2027-03-31,12.943635144198526,Good (10-50/month),129.43635144198524,Exceeded (≥100%),85,90.5,93.4
NCT04535713,"GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma",RECRUITING,PHASE2,260.0,2020-09-30,2025-12-31,4.126381647549531,Adequate (1-10/month),41.263816475495304,Significantly Below (<50%),60,58.8,69.89999999999999
NCT06804213,Student Wellness 2.0,COMPLETED,NA,83.0,2025-01-27,2025-05-29,20.70918032786885,Good (10-50/month),200.0,Exceeded (≥100%),100,61.6,74.0
NCT07329413,Effect of Anterior Disc Displacement With Reduction on Postoperative Pain After Root Canal Treatment,COMPLETED,NA,70.0,2025-03-10,2025-07-14,16.91111111111111,Good (10-50/month),169.11111111111111,Exceeded (≥100%),100,60.6,72.785
NCT01813513,Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004),COMPLETED,PHASE1,42.0,2013-01-01,2013-07-01,7.063425414364641,Adequate (1-10/month),70.63425414364642,Below (50-75%),100,53.4,57.35
NCT02076113,Cervical Spondylotic Myelopathy Surgical Trial,ACTIVE_NOT_RECRUITING,NA,269.0,2014-04-01,2025-12-30,1.9082638079701704,Adequate (1-10/month),19.082638079701702,Significantly Below (<50%),85,67.0,79.725
NCT03005613,Sacrospinous Ligament Fixation vs Ischial Spine Fascia Fixation,COMPLETED,NA,76.0,2017-01-15,2023-02-01,1.0477536231884057,Adequate (1-10/month),10.477536231884057,Significantly Below (<50%),100,51.1,50.129999999999995
NCT05943613,Efficacy of Intrathecal Clonidine Versus Neostigmine as Adjuvants to Bupivacaine on Postoperative Maternal and Fetal Outcomes After Elective Cesarean Section,UNKNOWN,PHASE1,111.0,2023-12-01,2025-11-30,4.62854794520548,Adequate (1-10/month),46.2854794520548,Significantly Below (<50%),50,43.9,28.12
NCT03703713,Colloid Osmotic Pressure and Osmolality in Hyponatremia,TERMINATED,,1.0,2018-10-09,2020-12-31,0.037395577395577397,Slow (<1/month),0.3739557739557739,Significantly Below (<50%),10,16.4,2.595
NCT06338813,Digital Manometry for Intra-Abdominal Pressure Measurement in Ileus,COMPLETED,NA,30.0,2022-10-30,2023-03-01,7.485245901639344,Adequate (1-10/month),74.85245901639344,Below (50-75%),100,52.4,53.949999999999996
NCT01544413,Quality Control Study of Laparoscopic Sentinel Node Biopsy in Early Gastric Cancer,COMPLETED,NA,112.0,2012-02-01,2014-09-01,3.6153552492046663,Adequate (1-10/month),36.153552492046664,Significantly Below (<50%),100,59.0,70.365
NCT00874913,Study of Ocular Blood Flow in Patients With Glaucoma and/or Obstructive Sleep Apnea Syndrome (OSAS),UNKNOWN,NA,90.0,2006-09-01,2014-01-01,1.022620380739082,Adequate (1-10/month),10.226203807390817,Significantly Below (<50%),50,37.2,18.17
NCT04881513,The Change of the Structure and Function of Taste Buds After the Otosclerosis Surgery,UNKNOWN,NA,50.0,2020-01-01,2022-01-01,2.0820793433652534,Adequate (1-10/month),20.820793433652533,Significantly Below (<50%),50,39.0,20.505000000000003
NCT00180713,Simvastatin as a Treatment for Pulmonary Hypertension,COMPLETED,PHASE1,42.0,2005-10-01,2009-05-01,0.9774311926605506,Slow (<1/month),9.774311926605506,Significantly Below (<50%),100,48.4,44.22
NCT05101213,"Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients",RECRUITING,PHASE1,30.0,2023-01-06,2027-01-31,0.614535666218035,Slow (<1/month),6.14535666218035,Significantly Below (<50%),60,35.4,15.765
NCT00770913,Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis,COMPLETED,PHASE2,337.0,2008-10-01,2010-03-01,19.880387596899226,Good (10-50/month),198.80387596899226,Exceeded (≥100%),100,82.0,89.05499999999999
NCT01110213,Goal Setting and Lifestyle,COMPLETED,NA,43.0,2006-08-01,2007-08-01,3.586082191780822,Adequate (1-10/month),35.860821917808224,Significantly Below (<50%),100,53.4,57.35
NCT06120413,18F-LN1 PET/CT in Urothelial Carcinomas,UNKNOWN,,30.0,2023-11-01,2024-10-01,2.725970149253732,Adequate (1-10/month),27.259701492537314,Significantly Below (<50%),50,35.7,16.18
NCT03819413,Clinical Patterns of Neuromyelitis Optica Spectrum Disorders in Assiut University Hospital,COMPLETED,,90.0,2019-02-15,2020-08-30,4.87473309608541,Adequate (1-10/month),48.74733096085409,Significantly Below (<50%),100,55.5,62.71
NCT04776213,Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension),COMPLETED,PHASE4,280.0,2021-02-23,2023-06-20,10.062809917355374,Good (10-50/month),100.62809917355374,Exceeded (≥100%),100,77.4,85.835
NCT04264260,Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment,COMPLETED,PHASE2,42.0,2019-12-24,2025-05-30,0.6443951612903226,Slow (<1/month),6.443951612903226,Significantly Below (<50%),100,48.4,44.22
NCT02682160,Pilot Study to Evaluate Daily Protein's Intake Following Bariatric Surgery by Using the Software Protein Assistant,COMPLETED,NA,38.0,2015-06-01,2016-10-01,2.370327868852459,Adequate (1-10/month),23.703278688524588,Significantly Below (<50%),100,53.0,55.80500000000001
NCT06219460,Comparison of Two Types of Face Mask Ventilation in Obese Patients,COMPLETED,NA,108.0,2022-01-01,2023-12-01,4.7031759656652365,Adequate (1-10/month),47.03175965665237,Significantly Below (<50%),100,58.6,69.51
NCT00121160,Health SMART (Stress Management and Relaxation Training) to Improve Vaccine Immune Response,COMPLETED,PHASE1,126.0,2005-09-01,2010-07-01,2.1742857142857144,Adequate (1-10/month),21.742857142857144,Significantly Below (<50%),100,60.1,72.085
NCT00706160,Language Mapping in Patients With Epilepsy,COMPLETED,,153.0,2008-06-13,2013-04-04,2.652232346241458,Adequate (1-10/month),26.522323462414576,Significantly Below (<50%),100,60.6,72.785
NCT05357560,A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21,ACTIVE_NOT_RECRUITING,PHASE1,107.0,2023-07-10,2025-06-01,4.706763005780347,Adequate (1-10/month),47.06763005780347,Significantly Below (<50%),85,54.1,59.11
NCT00372060,MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED),COMPLETED,PHASE3,134.0,2006-08-21,2008-02-05,7.6528330206379,Adequate (1-10/month),76.528330206379,Met (75-100%),100,60.7,72.89999999999999
NCT04442360,The Impact of Information Sources on Mental Health During the COVID-19 Pandemic,UNKNOWN,,4000.0,2020-06-22,2020-07-13,4000.0,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT02255760,Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults,COMPLETED,PHASE1,56.0,2014-09-04,2015-04-20,7.476491228070176,Adequate (1-10/month),74.76491228070175,Below (50-75%),100,54.5,60.12
NCT01701960,Effect of Local Anesthetic on Hemodynamic Measures During Nasal Surgery,WITHDRAWN,,0.0,2012-11-01,2014-08-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT05183360,A Study in Healthy Japanese and Chinese Men to Test How Well Different Doses of BI 706321 Are Tolerated,TERMINATED,PHASE1,48.0,2022-02-07,2024-08-08,1.6003504928806134,Adequate (1-10/month),16.003504928806134,Significantly Below (<50%),10,21.8,6.205
NCT01245660,A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy,TERMINATED,EARLY_PHASE1,3.0,2011-01-01,2011-10-01,0.33450549450549455,Slow (<1/month),3.3450549450549456,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT05429060,A Prospective Evaluation of Hemorrhoidal Surgery Outcome in Istanbul,UNKNOWN,,2000.0,2022-06-01,2024-05-31,83.3972602739726,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT00004160,Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed,COMPLETED,PHASE1,72.0,2000-02-01,2004-05-01,1.4130754352030948,Adequate (1-10/month),14.130754352030946,Significantly Below (<50%),100,50.8,49.18
NCT01278160,Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756,COMPLETED,PHASE4,179.0,2011-01-01,2011-09-01,22.422880658436217,Good (10-50/month),200.0,Exceeded (≥100%),100,69.3,81.395
NCT03309020,PREVAIL VII: Cataract Surgery in Ebola Survivors,COMPLETED,NA,37.0,2017-09-21,2019-08-01,1.6587334315169369,Adequate (1-10/month),16.587334315169368,Significantly Below (<50%),100,48.0,42.945
NCT05208320,Effectiveness of Community Health Workers in Hypertension Adherence,COMPLETED,NA,537.0,2020-11-03,2022-02-18,34.631949152542376,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT02527720,Changing Impulsivity With Mindful Breathing Therapy to Reduce Problem Drinking,COMPLETED,NA,10.0,2015-06-01,2016-12-01,0.5544626593806923,Slow (<1/month),5.544626593806922,Significantly Below (<50%),100,45.8,33.03
NCT05253820,Long-term Radial Artery Occlusion in Coronary Diagnosis and Intervention Via Distal Radial Approach (CONDITION),COMPLETED,NA,801.0,2022-03-01,2023-08-01,47.070347490347494,Good (10-50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT02595320,Capecitabine in Metastatic Breast and GI Cancers,UNKNOWN,PHASE2,200.0,2015-10-05,2023-12-01,2.0436388049681105,Adequate (1-10/month),20.436388049681103,Significantly Below (<50%),50,51.0,49.714999999999996
NCT06661720,Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer,RECRUITING,PHASE3,1040.0,2025-03-14,2037-11-01,6.859718309859155,Adequate (1-10/month),68.59718309859156,Below (50-75%),60,78.0,86.075
NCT05236582,Herombopag for Chemotherapy-induced Thrombocytopenia,RECRUITING,PHASE2,50.0,2022-03-14,2025-12-31,1.0965417867435159,Adequate (1-10/month),10.965417867435159,Significantly Below (<50%),60,37.0,17.955
NCT06572982,"Extension Study, Pilot, Compassionate Use of Azacitidine 300 mg Film Coated Tablets for Acute Myeloid Leukaemia (AML) Patients",ACTIVE_NOT_RECRUITING,NA,20.0,2025-04-29,2026-05-01,1.6588555858310627,Adequate (1-10/month),16.588555858310627,Significantly Below (<50%),85,42.1,25.019999999999996
NCT05709782,Phase II Cohort of Spinal Stereotactic Radiotherapy in Patients Using a MR LINAC,RECRUITING,PHASE2,40.0,2023-05-09,2026-01-31,1.2200400801603206,Adequate (1-10/month),12.200400801603205,Significantly Below (<50%),60,36.2,16.84
NCT05835882,Blood Salvage From Liver Donors: a Feasibility Pilot Study,COMPLETED,NA,10.0,2023-06-01,2025-06-30,0.4005263157894737,Slow (<1/month),4.005263157894737,Significantly Below (<50%),100,45.8,33.03
NCT02935582,PSOREAL - Managing PSOriasis in the REAL World,COMPLETED,,1214.0,2017-01-01,2020-12-30,25.328416723783416,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT06007482,A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors,COMPLETED,PHASE1,12.0,2023-09-26,2025-02-18,0.7148336594911937,Slow (<1/month),7.148336594911937,Significantly Below (<50%),100,46.0,34.1
NCT05890482,"A Scalable, Community-based Program for War and Refugee Trauma",UNKNOWN,NA,200.0,2022-05-15,2024-12-31,6.335067637877211,Adequate (1-10/month),63.35067637877211,Below (50-75%),50,51.0,49.714999999999996
NCT06704282,Assessing the Impact of VR-Based Observational Mindfulness Meditation on Stress Reduction in Adults,NOT_YET_RECRUITING,NA,34.0,2024-11-25,2025-02-23,11.499555555555556,Good (10-50/month),114.99555555555557,Exceeded (≥100%),30,36.7,17.544999999999998
NCT00092482,Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED),COMPLETED,PHASE3,3882.0,2002-06-28,2008-08-15,52.75360714285714,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT03298282,Integrated Coronary Multicenter Imaging Registry,UNKNOWN,,180.0,2017-10-10,2021-09-30,3.7761543762922125,Adequate (1-10/month),37.76154376292212,Significantly Below (<50%),50,47.7,42.17
NCT00002482,Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer,UNKNOWN,PHASE1,,1991-06-01,,,Slow (<1/month),,Significantly Below (<50%),50,25.0,7.23
NCT01909882,Effect of Family Member's Massage Therapy on the Vital Signs and Glasgow Coma Scale Score,COMPLETED,NA,180.0,2007-08-01,2013-05-01,2.6091428571428574,Adequate (1-10/month),26.091428571428573,Significantly Below (<50%),100,64.4,77.37
NCT03746782,Apixaban + DAPT in Lowering Platelet Reactivity and Thrombin Generation,COMPLETED,,40.0,2018-07-10,2019-11-08,2.505349794238683,Adequate (1-10/month),25.053497942386834,Significantly Below (<50%),100,51.5,51.245
NCT00065182,Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer,COMPLETED,PHASE2,399.0,2003-08-14,2007-08-30,8.223127962085309,Adequate (1-10/month),82.23127962085309,Met (75-100%),100,81.9,89.01
NCT06657482,"Effects of Delayed School Start Times on Sleep, Mental Health, and Academic Performance Among Norwegian Adolescents",RECRUITING,NA,200.0,2023-08-15,2025-06-30,8.887591240875912,Adequate (1-10/month),88.87591240875912,Met (75-100%),60,59.0,70.365
NCT00118482,Clinical Trial for the Prevention of Vasovagal Syncope,COMPLETED,PHASE4,213.0,2005-05-01,2011-07-01,2.879094138543517,Adequate (1-10/month),28.790941385435172,Significantly Below (<50%),100,67.0,79.725
NCT07018882,Evaluation of the Efficacy and Safety of the Sullivan Cochlear Implant.,NOT_YET_RECRUITING,NA,25.0,2025-06-01,2026-12-31,1.3166089965397925,Adequate (1-10/month),13.166089965397926,Significantly Below (<50%),30,26.0,7.735
NCT05006482,"Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial",RECRUITING,PHASE3,668.0,2023-03-21,2027-09-17,12.391176112126754,Good (10-50/month),123.91176112126755,Exceeded (≥100%),60,83.0,89.505
NCT04336982,A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia,TERMINATED,PHASE1,22.0,2020-08-05,2024-04-05,0.500134428678118,Slow (<1/month),5.00134428678118,Significantly Below (<50%),10,19.8,5.465
NCT06023082,"A Single-Group Study to Examine the Efficacy of a Gut Health Supplement to Increase Metabolism, Improve Gut Health, and Support Weight Management",COMPLETED,NA,120.0,2023-07-26,2023-11-26,29.697560975609754,Good (10-50/month),200.0,Exceeded (≥100%),100,64.6,77.59
NCT02262182,Interest of Positive Expiratory Pressure (PEP) Delivery by EzPAP® After Cardiac Surgery in the Management of Postoperative Atelectasis,COMPLETED,NA,80.0,2014-11-01,2016-09-01,3.6346268656716423,Adequate (1-10/month),36.34626865671642,Significantly Below (<50%),100,56.4,64.88000000000001
NCT00573482,A Cafeteria Based Study of Weight Gain Prevention,COMPLETED,NA,106.0,2002-09-01,2007-02-01,1.9991573729863694,Adequate (1-10/month),19.991573729863696,Significantly Below (<50%),100,58.5,69.34
NCT03822182,Single Shot Liposomal Bupivicaine in Rotator Cuff Surgery,COMPLETED,PHASE4,78.0,2018-10-24,2020-01-22,5.218285714285714,Adequate (1-10/month),52.18285714285715,Below (50-75%),100,56.2,64.21
NCT00070382,Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer,COMPLETED,PHASE3,14.0,2003-08-01,,,Slow (<1/month),,Significantly Below (<50%),100,41.1,23.225
NCT00108082,The CLEVER Study - Coreg And Left Ventricular Mass Regression,COMPLETED,PHASE3,287.0,2005-01-01,2008-08-01,6.679113149847096,Adequate (1-10/month),66.79113149847096,Below (50-75%),100,73.0,83.44
NCT05529524,Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL),COMPLETED,,6.0,2022-11-07,2024-01-22,0.4141496598639456,Slow (<1/month),4.141496598639456,Significantly Below (<50%),100,43.8,27.965
NCT06329024,The Impact of Myofascial Release Therapy on Dysphagia in Post-stroke Patients,NOT_YET_RECRUITING,NA,80.0,2024-03-01,2024-12-01,8.855272727272729,Adequate (1-10/month),88.55272727272728,Met (75-100%),30,40.4,22.34
NCT00111124,Enbrel® in Psoriatic Arthritis,COMPLETED,PHASE4,,,,,Slow (<1/month),,Significantly Below (<50%),100,40.0,21.87
NCT07083024,"Infection, Prevention and Control: A Multifaceted Approach to Preventing Hospital Acquired Infections Principal",COMPLETED,NA,50.0,2023-01-05,2025-05-23,1.7514384349827388,Adequate (1-10/month),17.514384349827385,Significantly Below (<50%),100,54.0,58.72500000000001
NCT07202624,The Effectiveness of Intracuff Dexmedetomidine in Preventing Postoperative Sore Throat Following Prone Surgery,COMPLETED,PHASE2,4.0,2025-02-10,2025-10-01,0.5225751072961373,Slow (<1/month),5.225751072961373,Significantly Below (<50%),100,45.3,31.169999999999998
NCT02995824,Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients,COMPLETED,,271.0,2002-01-01,2019-12-31,1.2550190171915412,Adequate (1-10/month),12.55019017191541,Significantly Below (<50%),100,65.0,78.065
NCT05234424,Flow Rate Impact on Arterial Carbon Dioxide During THRIVE,TERMINATED,NA,1.0,2022-02-08,2024-05-13,0.0368969696969697,Slow (<1/month),0.36896969696969695,Significantly Below (<50%),10,18.1,3.105
NCT03790124,Post-dural Puncture Headache: A Retrospective Study,COMPLETED,,50.0,2019-02-01,2019-03-30,26.701754385964914,Good (10-50/month),200.0,Exceeded (≥100%),100,57.3,66.74
NCT02070224,"Evaluation of the Prognostic Value of Biological Markers, Coll2-1 and Coll2-1NO2 in Patients With Symptomatic Knee Osteoarthritis",COMPLETED,NA,120.0,2014-01-01,2019-02-01,1.967043618739903,Adequate (1-10/month),19.67043618739903,Significantly Below (<50%),100,59.6,71.17999999999999
NCT01957124,Treatment of the Hypertensive Leg Ulcers by PRF Application,TERMINATED,PHASE4,10.0,2013-10-01,2017-07-01,0.22235208181154129,Slow (<1/month),2.223520818115413,Significantly Below (<50%),10,18.8,4.58
NCT05802524,Neurophysiological Evaluation of Residual Cognitive Functions in Patients With Severe Alterations of Consciousness,COMPLETED,,20.0,2020-06-14,2022-06-14,0.8339726027397261,Slow (<1/month),8.33972602739726,Significantly Below (<50%),100,44.9,30.025000000000002
NCT03644524,Heat Therapy and Cardiometabolic Health in Obese Women,COMPLETED,NA,20.0,2015-09-08,2018-07-01,0.592794547224927,Slow (<1/month),5.92794547224927,Significantly Below (<50%),100,46.6,37.375
NCT03952624,Patient-Centered Assessment of Symptoms and Outcomes,RECRUITING,,692.0,2019-09-13,2026-07-01,8.483479661699558,Adequate (1-10/month),84.83479661699558,Met (75-100%),60,81.3,88.58
NCT06546124,Treatment of Upper Trapezius Muscle Myofascial Pain Syndrome,COMPLETED,NA,80.0,2024-08-11,2025-04-01,10.451502145922747,Good (10-50/month),104.51502145922747,Exceeded (≥100%),100,61.4,73.735
NCT03042624,"Efficacy of Fermented Rice Flour for the Treatment of Atopic Dermatitis: Randomized, Double-blind Controlled Trial",UNKNOWN,NA,50.0,2017-01-24,2017-05-31,11.984251968503937,Good (10-50/month),119.84251968503936,Exceeded (≥100%),50,44.0,28.249999999999996
NCT00762424,Effect of Tamsulosin on Stone Expulsion and Pain Resolution in ED Patients With Ureterolithiasis,COMPLETED,NA,53.0,2007-06-01,2011-01-01,1.2315419847328244,Adequate (1-10/month),12.315419847328245,Significantly Below (<50%),100,49.2,46.035
NCT01953224,STEP AND GO: A Study of Technology-based Exercise Promotion,COMPLETED,NA,40.0,2014-09-01,2016-11-01,1.5373737373737375,Adequate (1-10/month),15.373737373737374,Significantly Below (<50%),100,48.2,43.665
NCT06166524,Pulsed-field Ablation for Patients With Asymptomatic Non-paroxysmal Atrial Fibrillation,UNKNOWN,PHASE2,124.0,2024-01-01,2025-12-31,5.1706301369863015,Adequate (1-10/month),51.70630136986302,Below (50-75%),50,44.9,30.025000000000002
NCT04685824,Visual Telerehabilitation in AMD Patients,TERMINATED,NA,16.0,2021-09-15,2023-10-06,0.6485219707057257,Slow (<1/month),6.485219707057258,Significantly Below (<50%),10,19.3,5.125
NCT05495724,Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable,UNKNOWN,PHASE2,176.0,2021-07-23,2025-07-01,3.7230298818624044,Adequate (1-10/month),37.23029881862404,Significantly Below (<50%),50,49.1,45.83
NCT01426724,"Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease",WITHDRAWN,NA,0.0,2011-09-01,2013-08-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT05558124,CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML,RECRUITING,PHASE1,18.0,2023-02-16,2027-04-01,0.3640664451827243,Slow (<1/month),3.640664451827243,Significantly Below (<50%),60,34.4,14.430000000000001
NCT00118924,Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults,COMPLETED,PHASE1,28.0,2005-07-01,2007-07-01,1.1675616438356167,Adequate (1-10/month),11.675616438356165,Significantly Below (<50%),100,47.2,40.035
NCT05598424,CST1 Predictive Model of Oral Glucocorticoid Therapy Sensitivity for Chronic Rhinosinusitis With Polyps,UNKNOWN,PHASE4,150.0,2022-11-22,2025-11-01,4.247441860465116,Adequate (1-10/month),42.47441860465116,Significantly Below (<50%),50,47.0,39.33
NCT06215924,The Effects of Postisometric Relaxation Technique in Female Patients With Dyssynergic Defecation,UNKNOWN,NA,42.0,2024-01-15,2024-12-31,3.6423931623931627,Adequate (1-10/month),36.42393162393163,Significantly Below (<50%),50,38.4,19.835
NCT01946724,"In-hospital and Long-term Outcomes for Percutaneous Chronic Total Coronary Occlusion Revascularization in a High-volume, Multi-operator Program",COMPLETED,,500.0,2013-08-01,2017-05-24,10.933908045977011,Good (10-50/month),109.33908045977012,Exceeded (≥100%),100,93.3,94.325
NCT02602223,Comparison of Amnion Chorion Membrane vs. Dense Polytetrafluoroethylene Membrane in Ridge Preservation Procedures,COMPLETED,PHASE2,9.0,2012-09-01,2014-12-01,0.33369062119366627,Slow (<1/month),3.3369062119366624,Significantly Below (<50%),100,45.7,32.5
NCT00831623,Study of Hypofractionated Proton Beam Radiation Therapy for Prostate Cancer,COMPLETED,NA,167.0,2009-02-17,2019-07-18,1.3367026032079938,Adequate (1-10/month),13.367026032079938,Significantly Below (<50%),100,58.4,69.175
NCT05490823,Validation of a Smartphone App for Anemia Screening Among General Population,UNKNOWN,NA,1000.0,2018-12-01,2022-12-01,20.83504449007529,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT04155723,Impact of a Task Delegation to ICU Nurses for Midlines' Placement,COMPLETED,,310.0,2019-11-06,2023-06-01,7.24205679201842,Adequate (1-10/month),72.4205679201842,Below (50-75%),100,73.1,83.515
NCT02660723,Impact of Aging on Cytokine Production by Innate Immune Cells,COMPLETED,NA,50.0,2016-02-01,2018-06-01,1.7884841363102235,Adequate (1-10/month),17.884841363102232,Significantly Below (<50%),100,54.0,58.72500000000001
NCT05588323,Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids,RECRUITING,PHASE1,24.0,2023-01-04,2026-06-15,0.5807313195548489,Slow (<1/month),5.80731319554849,Significantly Below (<50%),60,34.9,15.215
NCT06504823,"The Effect of Light Level Applied During Breastfeeding on Maternal Stress, Anxiety, Psychological Well-being and Breastfeeding Motivation",NOT_YET_RECRUITING,NA,60.0,2024-07-22,2024-08-02,60.0,Excellent (>50/month),200.0,Exceeded (≥100%),30,43.8,27.965
NCT05798923,A Phase 2a Study of LAM-001 for the Treatment of Pulmonary Hypertension,ACTIVE_NOT_RECRUITING,PHASE2,10.0,2023-04-03,2027-09-30,0.18549664838513102,Slow (<1/month),1.8549664838513102,Significantly Below (<50%),85,41.3,23.74
NCT07028723,Relationship Between Proprioceptive Flexibility and the Occurrence of Lower Limb Ligament Injury in Pivot-contact Sports,RECRUITING,NA,150.0,2025-06-30,2028-01-01,4.99016393442623,Adequate (1-10/month),49.9016393442623,Significantly Below (<50%),60,50.0,47.675
NCT02064023,Comparison of Insulin Pump and MDI for Pregestational Diabetes During Pregnancy,TERMINATED,NA,2.0,2014-04-01,2015-12-04,0.09947712418300654,Slow (<1/month),0.9947712418300654,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT02812823,Comparison of Anorectal Manometry and 3D Manometry in Diagnosis of Functional Disorders in Children,UNKNOWN,NA,100.0,2018-03-01,2019-03-01,8.339726027397262,Adequate (1-10/month),83.3972602739726,Met (75-100%),50,48.0,42.945
NCT00987623,Clinical Evaluation of Two Daily Disposable Lenses in Neophytes,COMPLETED,NA,326.0,2009-08-01,2009-12-01,81.33967213114754,Excellent (>50/month),200.0,Exceeded (≥100%),100,86.1,91.51
NCT04753723,The Use of a Platform Wound Device for Reducing Infection,COMPLETED,PHASE4,48.0,2021-02-08,2022-05-25,3.1021656050955415,Adequate (1-10/month),31.02165605095541,Significantly Below (<50%),100,53.8,58.065
NCT01757223,Administration of AdVEGF-All6A+ to Myocardium of Individuals With Diffuse CAD Via Minimally Invasive Surgery,WITHDRAWN,PHASE1,0.0,2020-12-01,2030-10-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT01163123,"Seroepidemiology of Japanese Encephalitis Virus Infection in Hualien, Taiwan",UNKNOWN,,312.0,2010-05-01,2010-12-01,44.37981308411215,Good (10-50/month),200.0,Exceeded (≥100%),50,68.3,80.875
NCT07154823,A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies,RECRUITING,,550.0,2026-01-27,2035-11-01,4.696213183730715,Adequate (1-10/month),46.962131837307155,Significantly Below (<50%),60,76.3,85.1
NCT01287923,Assessment of Blood Biomarkers by DNA Microarrays in Patients With Aggressive Lymphoma BMS_LyTrans,COMPLETED,,326.0,2011-02-21,2017-09-01,4.16251677852349,Adequate (1-10/month),41.6251677852349,Significantly Below (<50%),100,74.4,84.255
NCT02415023,A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer,COMPLETED,PHASE1,34.0,2014-11-09,2017-03-31,1.1855211912943873,Adequate (1-10/month),11.855211912943874,Significantly Below (<50%),100,47.7,42.17
NCT00134823,Improving Pediatric Safety and Quality With Health Care Information Technology,COMPLETED,NA,5420.0,2005-03-01,2008-09-01,128.894375,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT02957123,Intranasal Inhalations of Bioactive Factors Produced by M2 Macrophages in Patients With Organic Brain Syndrome,COMPLETED,PHASE1,30.0,2016-03-01,2020-09-01,0.5551367781155016,Slow (<1/month),5.551367781155016,Significantly Below (<50%),100,47.4,40.98
NCT01211223,Effects of the Variation in the Time of Systemic Administration of Metronidazole and Amoxicillin Associated to the Non-surgical Therapy of Chronic Periodontitis.,COMPLETED,PHASE4,42.0,2010-01-01,2014-03-01,0.8411052631578948,Slow (<1/month),8.411052631578947,Significantly Below (<50%),100,48.4,44.22
NCT03733223,"Relationships Among FVIII, t-PA/PAI-1, and MMP-9 Levels and Intracranial Hemorrhage Complications After Thrombolysis With Alteplase in Patients With Acute Ischemic Stroke: Protocol for a Multicenter Retrospective Study",UNKNOWN,,350.0,2018-10-12,2020-12-01,13.641485275288092,Good (10-50/month),136.41485275288093,Exceeded (≥100%),50,66.3,79.3
NCT05975723,MIND Diet and Cognitive Function in Adults With MCI,UNKNOWN,NA,240.0,2023-07-26,2025-08-01,9.912618724559023,Adequate (1-10/month),99.12618724559023,Met (75-100%),50,59.2,70.7
NCT00986323,Efficacy Study of Temperature Controlled Laminar Airflow (TLA)-Treatment in Perennial Allergic Asthma,COMPLETED,PHASE3,312.0,2008-04-01,2010-02-01,14.153919523099852,Good (10-50/month),141.53919523099853,Exceeded (≥100%),100,80.0,87.67
NCT03283423,Image-guided Lymphadanectomy in AMIGO,TERMINATED,NA,11.0,2018-10-25,2020-03-20,0.653984375,Slow (<1/month),6.53984375,Significantly Below (<50%),10,18.9,4.6899999999999995
NCT06788223,Intraoperative Identification of Parathyroid Adenomas Using PTeye™ and FLUOBEAM® LX: a Prospective Cohort Study,ACTIVE_NOT_RECRUITING,,40.0,2024-11-01,2025-01-31,13.38021978021978,Good (10-50/month),133.8021978021978,Exceeded (≥100%),85,52.0,52.86
NCT05785923,Low-Risk Chest Pain Echo Study,UNKNOWN,NA,70.0,2023-04-05,2023-11-30,8.915481171548118,Adequate (1-10/month),89.15481171548117,Met (75-100%),50,45.6,32.08
NCT04095923,A Social Media Game to Increase Physical Activity Among Older Adult Women,ACTIVE_NOT_RECRUITING,NA,300.0,2019-12-01,2026-02-28,4.003507233669444,Adequate (1-10/month),40.03507233669444,Significantly Below (<50%),85,69.5,81.62
NCT04930159,Social Interventions for Support During Treatment for Endometrial Cancer and Recurrence,ACTIVE_NOT_RECRUITING,NA,252.0,2021-09-01,2030-10-31,2.291867343890051,Adequate (1-10/month),22.91867343890051,Significantly Below (<50%),85,65.7,78.66499999999999
NCT00914459,Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients,COMPLETED,PHASE4,37.0,2009-12-01,2016-04-01,0.48693471681798534,Slow (<1/month),4.8693471681798535,Significantly Below (<50%),100,48.0,42.945
NCT06527859,Correlation Between Levothyroxine and Blood Th17/Treg in Pregnant Women With Normal-high TSH and Positive TPOAb,TERMINATED,,64.0,2022-04-06,2024-06-05,2.4629077117572695,Adequate (1-10/month),24.62907711757269,Significantly Below (<50%),10,26.5,7.945
NCT05812859,Vaginal Orthosis Use After Vaginal Reconstructive Surgery,ACTIVE_NOT_RECRUITING,NA,30.0,2024-01-29,2026-07-01,1.033031674208145,Adequate (1-10/month),10.330316742081449,Significantly Below (<50%),85,42.9,26.145000000000003
NCT01684059,Study the Effect of Oral Zinc Supplementation on Enzymes of Nitric Oxide Pathway,COMPLETED,,60.0,2011-07-01,2012-07-01,4.99016393442623,Adequate (1-10/month),49.90163934426229,Significantly Below (<50%),100,53.1,56.105000000000004
NCT00494559,The Effect of Pioglitazone on Neointima Volume and Inflammatory Markers,COMPLETED,PHASE4,240.0,2007-07-01,2015-07-01,2.500205338809035,Adequate (1-10/month),25.00205338809035,Significantly Below (<50%),100,69.2,81.28
NCT05285059,Implicit Learning in Epileptic Children,RECRUITING,,40.0,2023-03-21,2026-03-21,1.110948905109489,Adequate (1-10/month),11.10948905109489,Significantly Below (<50%),60,34.5,14.52
NCT01850459,Extracellular Signal-Related Kinase Biomarker Development in Autism,COMPLETED,,213.0,2013-01-01,2015-08-01,6.882929936305732,Adequate (1-10/month),68.82929936305732,Below (50-75%),100,65.4,78.415
NCT05604859,Evaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome(SFTS),UNKNOWN,PHASE4,350.0,2022-08-19,2024-06-30,15.644640234948605,Good (10-50/month),156.44640234948605,Exceeded (≥100%),50,68.0,80.56
NCT00005359,Genetics of Asthma and Bronchial Hyperresponsiveness,COMPLETED,,,1994-07-01,2008-05-01,,Slow (<1/month),,Significantly Below (<50%),100,43.3,27.05
NCT04172259,ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC,ACTIVE_NOT_RECRUITING,PHASE2,156.0,2019-01-10,2026-09-30,1.6839148936170212,Adequate (1-10/month),16.83914893617021,Significantly Below (<50%),85,58.0,68.245
NCT00294359,"The MAX Study: Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer",COMPLETED,PHASE2,333.0,2005-06-01,2007-07-01,13.337526315789475,Good (10-50/month),133.37526315789475,Exceeded (≥100%),100,81.6,88.94999999999999
NCT01615159,Maintenance of Recommended Sodium Intake,COMPLETED,NA,55.0,2012-06-01,2014-09-01,2.0367396593673965,Adequate (1-10/month),20.367396593673966,Significantly Below (<50%),100,54.4,59.89
NCT02633059,"Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma",COMPLETED,PHASE1,33.0,2015-12-30,2022-11-01,0.40212970376301044,Slow (<1/month),4.021297037630104,Significantly Below (<50%),100,47.6,41.775
NCT01201980,An Epidemiological Study to Evaluate Standard Daily Practice in Managing Patients With Arterial Hypertension,COMPLETED,,300.0,2010-12-01,2011-12-01,25.019178082191782,Good (10-50/month),200.0,Exceeded (≥100%),100,77.3,85.67
NCT07045480,Prevention of Pressure Ulcers by Effleurage With RIVADOUCE VEGETABLE SKINCARE OIL in Patients at Risk of Pressure Ulcers,RECRUITING,,252.0,2025-04-04,2026-01-31,25.40026490066225,Good (10-50/month),200.0,Exceeded (≥100%),60,61.5,73.905
NCT04540380,Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH,ACTIVE_NOT_RECRUITING,PHASE1,20.0,2021-09-01,2027-06-01,0.29004287756074326,Slow (<1/month),2.9004287756074323,Significantly Below (<50%),85,42.1,25.019999999999996
NCT02433080,Diet and Physical Activity in Uterine Cancer Survivors,COMPLETED,NA,60.0,2015-04-01,2016-06-01,4.277283372365339,Adequate (1-10/month),42.7728337236534,Significantly Below (<50%),100,54.8,61.095
NCT07001280,A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE),RECRUITING,,200.0,2025-07-21,2030-08-31,3.2608462774504554,Adequate (1-10/month),32.60846277450455,Significantly Below (<50%),60,52.3,53.515
NCT06323980,INHANCE Stemless Reverse Shoulder IDE,RECRUITING,NA,168.0,2025-03-04,2028-09-29,3.918712643678161,Adequate (1-10/month),39.18712643678161,Significantly Below (<50%),60,51.4,50.92
NCT06265480,FallFitness Fallprevention Program for Older Adults,RECRUITING,NA,100.0,2024-03-01,2025-12-31,4.543283582089552,Adequate (1-10/month),45.43283582089552,Significantly Below (<50%),60,46.0,34.1
NCT06611280,Deuterium Metabolic Imaging in People with Multiple Sclerosis,RECRUITING,,20.0,2024-10-01,2026-05-01,1.0551126516464473,Adequate (1-10/month),10.551126516464473,Significantly Below (<50%),60,32.9,12.53
NCT03941080,Gut Microbiome Dynamics in Metastasized or Irresectable Colorectal Cancer,RECRUITING,,300.0,2020-09-09,2026-01-01,4.707216494845361,Adequate (1-10/month),47.072164948453604,Significantly Below (<50%),60,60.3,72.34
NCT03983980,Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002),COMPLETED,PHASE3,515.0,2019-06-06,2020-05-29,43.78938547486034,Good (10-50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT00641680,Rhinocort Aqua Versus Placebo and Fluticasone Propionate,COMPLETED,PHASE3,750.0,2003-04-01,2003-07-01,250.87912087912088,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT05085080,Chinese Neonatal Extracorporeal Life Support Registry (Chi-NELS),WITHDRAWN,,0.0,2024-01-01,2025-12-31,,Slow (<1/month),0.0,Significantly Below (<50%),5,13.2,0.6
NCT00301080,D-cycloserine in the Management of Chemotherapy-Induced Peripheral Neuropathic Pain,TERMINATED,PHASE3,7.0,2006-02-01,2008-05-01,0.2598536585365854,Slow (<1/month),2.5985365853658537,Significantly Below (<50%),10,18.6,4.25
NCT04705480,Pregabalin vs. Gabapentin on Reducing Opioid Usage,COMPLETED,PHASE4,109.0,2021-04-12,2024-12-13,2.474243102162565,Adequate (1-10/month),24.742431021625656,Significantly Below (<50%),100,58.7,69.69
NCT04877080,CD19 and BCMA Targeted Fast Dual CAR-T for CD19+ Refractory/Relapsed B-NHL,WITHDRAWN,PHASE1,0.0,2021-05-05,2023-12-31,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT03995680,Efficacy and Safety of a New Chewable Versus the Swallowable Tablet of Mebendazole Against Hookworm,COMPLETED,PHASE2,397.0,2019-07-12,2019-10-09,135.7829213483146,Excellent (>50/month),200.0,Exceeded (≥100%),100,91.8,93.755
NCT02482779,Smartphone Application-Based Vital Sign Monitors,COMPLETED,,120.0,2015-01-01,2015-07-01,20.18121546961326,Good (10-50/month),200.0,Exceeded (≥100%),100,62.9,75.655
NCT04502979,Learning to Love Mealtime Together,COMPLETED,NA,71.0,2017-09-26,2019-04-25,3.752152777777778,Adequate (1-10/month),37.52152777777778,Significantly Below (<50%),100,55.7,63.09
NCT00436579,Sorafenib in Treating Patients With Advanced Solid Tumors,TERMINATED,PHASE1,110.0,2007-01-01,,,Slow (<1/month),,Significantly Below (<50%),10,21.8,6.205
NCT00089479,A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer,COMPLETED,PHASE3,2611.0,2002-08-01,2012-05-01,22.31924740241505,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT05167279,A Study of JS026 and JS026 Together With JS016 for Treatment of COVID-19,COMPLETED,PHASE1,48.0,2021-12-16,2022-12-08,4.092773109243698,Adequate (1-10/month),40.92773109243698,Significantly Below (<50%),100,53.8,58.065
NCT06465979,Perception of Speech in Context by Listeners With Healthy and Impaired Hearing,RECRUITING,NA,680.0,2023-09-19,2027-08-31,14.354507628294035,Good (10-50/month),143.54507628294039,Exceeded (≥100%),60,83.0,89.505
NCT06624579,Prognostic Value of Confocal Endomicroscopy in Ulcerative Colitis: the CONF-UC Study,NOT_YET_RECRUITING,NA,26.0,2024-10-01,2026-06-01,1.3017105263157895,Adequate (1-10/month),13.017105263157896,Significantly Below (<50%),30,26.1,7.75
NCT05045079,Rhythm Control and Potential Early Surgery for Tricuspid Regurgitation,COMPLETED,NA,4.0,2022-01-20,2023-08-09,0.2151236749116608,Slow (<1/month),2.1512367491166082,Significantly Below (<50%),100,45.3,31.169999999999998
NCT03303079,Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine,COMPLETED,PHASE2,571.0,2017-12-19,2019-11-30,24.446188466947962,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT02539979,A Trial of Intravenous Paracetamol vs. Placebo in Patients Receiving Radiofrequency Ablation of the Medial Branch Facet Nerve,UNKNOWN,NA,50.0,2015-08-01,,,Slow (<1/month),,Significantly Below (<50%),50,29.0,8.76
NCT00856479,A Randomized Controlled Cost Study of Infuse BMP 2 vs Iliac Crest Autograft for Non Union of Long Bone Fractures,WITHDRAWN,PHASE4,0.0,2009-03-01,2013-03-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT02364479,Treatment of Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein,COMPLETED,PHASE4,150.0,2014-02-10,2016-08-28,4.909677419354839,Adequate (1-10/month),49.096774193548384,Significantly Below (<50%),100,62.0,74.42
NCT04478279,A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors,ACTIVE_NOT_RECRUITING,PHASE1,125.0,2020-07-01,2025-12-01,1.922688226376958,Adequate (1-10/month),19.22688226376958,Significantly Below (<50%),85,55.5,62.71
NCT05047679,The Effectiveness of Pain Neuroscience Education in At-risk Patients Following Surgery for Lumbar Radiculopathy,TERMINATED,NA,6.0,2021-09-30,2023-10-16,0.24482573726541557,Slow (<1/month),2.4482573726541554,Significantly Below (<50%),10,18.5,4.02
NCT04842279,FACE-Q in Facial Reconstructive Surgery: A Prospective Database,UNKNOWN,,300.0,2021-04-20,2022-04-20,25.019178082191782,Good (10-50/month),200.0,Exceeded (≥100%),50,62.3,74.94
NCT03605979,Continuous Glucose Monitoring and Hypoglycemia Unawareness in Type 1 Diabetes,COMPLETED,,11.0,2012-07-01,2013-06-01,0.9995223880597016,Slow (<1/month),9.995223880597015,Significantly Below (<50%),100,44.2,28.549999999999997
NCT05880979,Engaging Together for Healthy Relationships,COMPLETED,NA,102.0,2023-07-01,2024-12-01,5.98242774566474,Adequate (1-10/month),59.8242774566474,Below (50-75%),100,58.2,68.795
NCT00844779,Molecular Investigation of Non Alcoholic Fatty Liver Diseases in Obese Patients,UNKNOWN,,90.0,2009-02-01,2011-01-01,3.9193133047210305,Adequate (1-10/month),39.1931330472103,Significantly Below (<50%),50,40.5,22.46
NCT02903979,Impact of Different Restorative Treatments for Deep Caries Lesion in Primary Teeth,COMPLETED,NA,108.0,2016-11-01,2020-05-01,2.5744087705559906,Adequate (1-10/month),25.74408770555991,Significantly Below (<50%),100,58.6,69.51
NCT04240379,Metacognition Assessment in Patient With Multiple Sclerosis,COMPLETED,,80.0,2020-06-11,2022-04-08,3.656456456456457,Adequate (1-10/month),36.56456456456457,Significantly Below (<50%),100,54.7,60.629999999999995
NCT00628979,Addressing Help-Seeking Barriers in Developing an Intensive Treatment for Veterans With Panic Disorder,COMPLETED,NA,23.0,2008-03-01,2009-07-01,1.437618069815195,Adequate (1-10/month),14.376180698151952,Significantly Below (<50%),100,46.8,38.440000000000005
NCT00708279,Study of Osteopathic Manipulation in the Management of Angina,COMPLETED,NA,1.0,2007-08-01,2008-07-01,0.09086567164179106,Slow (<1/month),0.9086567164179105,Significantly Below (<50%),100,45.1,30.605
NCT04354779,Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.,COMPLETED,,3301.0,2020-05-11,2020-09-28,717.7317142857142,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02127879,Intensive Transcranial Magnetic Stimulation for Negative Symptoms in Schizophrenia,UNKNOWN,NA,40.0,2014-05-01,2016-10-01,1.3773755656108597,Adequate (1-10/month),13.7737556561086,Significantly Below (<50%),50,33.2,12.989999999999998
NCT03971396,The Chest Physiotherapy and Breathing Exercises Management of Patients Following Open Heart Surgery: a National Survey of Practice in Turkey.,COMPLETED,,21.0,2019-04-30,2019-06-30,10.479344262295081,Good (10-50/month),104.7934426229508,Exceeded (≥100%),100,55.0,61.834999999999994
NCT01266096,PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study,ACTIVE_NOT_RECRUITING,NA,10.0,2011-01-01,2026-12-01,0.05236538792361948,Slow (<1/month),0.5236538792361948,Significantly Below (<50%),85,41.3,23.74
NCT03409796,Assessment of Immune Activation and Tolerance in Celiac Disease During Gluten Challenge,COMPLETED,NA,16.0,2018-04-24,2019-05-02,1.3057372654155497,Adequate (1-10/month),13.057372654155497,Significantly Below (<50%),100,46.3,35.66
NCT04136496,Evaluation of a Novel Axillary Lymph Node Ink Localization Technique: A Feasibility Study,WITHDRAWN,NA,0.0,2020-01-02,2023-06-19,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT04061096,Local Anesthesia in Molar Teeth With Molar Incisor Hypomineralization,COMPLETED,NA,38.0,2014-09-01,2018-05-01,0.8645142002989537,Slow (<1/month),8.645142002989537,Significantly Below (<50%),100,48.0,42.945
NCT05818696,Uncertainty and Firearms: Obtaining Secure Storage,RECRUITING,NA,100.0,2023-06-26,2025-11-01,3.543655413271246,Adequate (1-10/month),35.43655413271246,Significantly Below (<50%),60,46.0,34.1
NCT06555796,"Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer",ACTIVE_NOT_RECRUITING,PHASE1,50.0,2024-09-23,2028-12-02,0.9941214892227302,Slow (<1/month),9.941214892227302,Significantly Below (<50%),85,44.5,29.160000000000004
NCT04345796,Pharmacological Reduction of Right Ventricular Enlargement,COMPLETED,PHASE3,56.0,2021-02-15,2024-06-03,1.4158139534883722,Adequate (1-10/month),14.158139534883722,Significantly Below (<50%),100,49.5,46.58
NCT05693896,Treating Binge Eating and Obesity Digitally in Black Women,RECRUITING,NA,60.0,2025-01-15,2026-12-01,2.6662773722627735,Adequate (1-10/month),26.662773722627737,Significantly Below (<50%),60,42.8,25.929999999999996
NCT07140796,Effects of Hip Blood Flow Restriction and Shockwave Therapy on Q-Angle and Plantar Pressure in Adults With Genu Varum,NOT_YET_RECRUITING,NA,14.0,2025-09-10,2026-01-01,3.771327433628319,Adequate (1-10/month),37.71327433628319,Significantly Below (<50%),30,30.1,9.19
NCT04942496,A 96-hour Patch Test Study Using Healthy Human Volunteers to Assess the Skin Irritation Potential of 11 Topically Applied Formulations,UNKNOWN,PHASE4,44.0,2021-06-01,2021-07-01,44.0,Good (10-50/month),200.0,Exceeded (≥100%),50,48.5,44.47
NCT05137496,Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome,UNKNOWN,PHASE3,40.0,2022-06-01,2024-06-01,1.6656634746922026,Adequate (1-10/month),16.656634746922023,Significantly Below (<50%),50,33.2,12.989999999999998
NCT00431496,A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD),COMPLETED,PHASE4,71.0,2006-09-01,2009-10-01,1.9193960923623445,Adequate (1-10/month),19.193960923623447,Significantly Below (<50%),100,55.7,63.09
NCT00362596,"A Randomized Controlled Trial of Acyclovir Among HIV and HSV-2 Co-Infected Women, Chiang Rai, Thailand",COMPLETED,PHASE4,67.0,2005-01-01,2005-08-01,9.620188679245283,Adequate (1-10/month),96.20188679245284,Met (75-100%),100,60.4,72.54
NCT03868696,Ultrasound Directed Reduction of Colles Type Distal Radial Fractures in ED (UDiReCT),COMPLETED,NA,48.0,2019-10-07,2020-07-06,5.352087912087913,Adequate (1-10/month),53.52087912087913,Below (50-75%),100,53.8,58.065
NCT06583096,College Student Stress: Transitions Over Time,COMPLETED,NA,120.0,2024-10-01,2024-11-27,64.08421052631579,Excellent (>50/month),200.0,Exceeded (≥100%),100,69.6,81.675
NCT03305796,Detection of Cholesteatoma Using Diffusion Magnetic Resonance Imaging,UNKNOWN,,30.0,2017-11-01,2019-02-01,1.9982494529540482,Adequate (1-10/month),19.98249452954048,Significantly Below (<50%),50,35.7,16.18
NCT06104696,Comprehensive Geriatric Assessment in Kidney Transplantation,RECRUITING,,1000.0,2020-01-02,2040-01-02,4.167008898015059,Adequate (1-10/month),41.67008898015058,Significantly Below (<50%),60,76.3,85.1
NCT06150196,Brain Health & Wellness Classes for Veterans With Traumatic Brain Injury,RECRUITING,NA,80.0,2023-05-01,2026-09-14,1.9766233766233767,Adequate (1-10/month),19.766233766233764,Significantly Below (<50%),60,44.4,28.95
NCT01492296,Endoscopy With Short Fasting,COMPLETED,NA,115.0,2011-03-01,2011-11-01,14.288163265306123,Good (10-50/month),142.88163265306125,Exceeded (≥100%),100,64.2,77.18
NCT06642896,Quantitative Pupillometry in Brain Injury Children : Variation After Osmotherapy,RECRUITING,,90.0,2024-11-11,2028-04-01,2.214713015359741,Adequate (1-10/month),22.14713015359741,Significantly Below (<50%),60,43.5,27.400000000000002
NCT05879796,Envafolimab Combined With Endostar and Concurrent Chemoradiotherapy for Locally Advanced Primary Cervical Cancer,NOT_YET_RECRUITING,,30.0,2023-05-16,2026-05-16,0.8332116788321168,Slow (<1/month),8.332116788321168,Significantly Below (<50%),30,24.7,6.995
NCT04434196,A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,COMPLETED,PHASE1,16.0,2020-12-21,2024-05-21,0.390569366479551,Slow (<1/month),3.90569366479551,Significantly Below (<50%),100,46.3,35.66
NCT05492396,Evaluation of Healing Following Open Gluteus Medius Repair With Biointegrative Implant,ACTIVE_NOT_RECRUITING,,30.0,2022-08-01,2026-01-01,0.7311449159327462,Slow (<1/month),7.311449159327463,Significantly Below (<50%),85,41.2,23.425
NCT07273396,"Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer",NOT_YET_RECRUITING,PHASE1,53.0,2026-01-01,2030-08-31,0.9473399882560188,Slow (<1/month),9.473399882560187,Significantly Below (<50%),30,28.2,8.469999999999999
NCT06731296,General Surgery Patients at the Intensive Care Unit,NOT_YET_RECRUITING,,1000.0,2026-08-01,2029-01-01,34.43438914027149,Good (10-50/month),200.0,Exceeded (≥100%),30,72.3,83.065
NCT05355896,[Trial of device that is not approved or cleared by the U.S. FDA],WITHHELD,,,,,,Slow (<1/month),,Significantly Below (<50%),50,20.0,5.695
NCT03851796,Parent Involvement in Adolescent Obesity Treatment,COMPLETED,NA,418.0,2019-05-23,2024-10-26,6.416500252143218,Adequate (1-10/month),64.16500252143219,Below (50-75%),100,83.4,90.405
NCT06008496,"Patient Reported Outcomes, Postoperative Pain and Pain Relief After Day Case Surgery (POPPY)",COMPLETED,,7839.0,2024-01-15,2025-07-01,447.6907317073171,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT03092596,Integrated Care (iCare) at Mount Sinai to Improve Substance Use Diagnosis and Treatment Practices in HIV Clinic Settings,COMPLETED,NA,3358.0,2017-02-02,2020-06-30,82.16842443729904,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT04126096,Negative Predictive Value and NIC of Beta-Lactam Antibiotics.,COMPLETED,NA,747.0,2019-09-20,2023-01-06,18.885946843853823,Good (10-50/month),188.85946843853822,Exceeded (≥100%),100,95.0,95.7
NCT00710996,Blue Light Intraocular Lenses (IOLs) and Photostress,COMPLETED,,58.0,2008-01-01,2008-10-01,6.443503649635036,Adequate (1-10/month),64.43503649635036,Below (50-75%),100,53.0,55.80500000000001
NCT06973096,CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy,RECRUITING,PHASE1,9.0,2025-07-18,2042-07-01,0.04424418604651163,Slow (<1/month),0.44244186046511635,Significantly Below (<50%),60,33.7,13.465
NCT06462196,"Natural History of Depression, Bipolar Disorder and Suicide Risk",RECRUITING,,500.0,2024-09-09,2030-06-01,7.278813964610234,Adequate (1-10/month),72.78813964610235,Below (50-75%),60,76.3,85.1
NCT00938262,A Study to Evaluate the Effect of Ketoconazole and Rifampicin on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers,COMPLETED,PHASE1,24.0,2009-04-01,2009-08-01,5.988196721311475,Adequate (1-10/month),59.88196721311475,Below (50-75%),100,51.9,52.55499999999999
NCT02025062,Comprehensive Geriatric Assessment and Head and Neck Elderly Cancer Patients,COMPLETED,NA,499.0,2013-09-01,2020-09-01,5.940383261634729,Adequate (1-10/month),59.40383261634729,Below (50-75%),100,89.9,93.08999999999999
NCT07036562,Time-restricted Eating and High-intensity Interval Training for Metabolic Health in Adults With Overweight/Obesity,RECRUITING,NA,100.0,2025-09-11,2027-07-01,4.62613981762918,Adequate (1-10/month),46.2613981762918,Significantly Below (<50%),60,46.0,34.1
NCT01653262,Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV),COMPLETED,PHASE3,29.0,2012-07-01,2013-11-01,1.8089344262295082,Adequate (1-10/month),18.089344262295082,Significantly Below (<50%),100,52.3,53.515
NCT03091062,Evaluation of an Airway Clearance System,COMPLETED,NA,9.0,2017-03-30,2018-02-02,0.8866019417475729,Slow (<1/month),8.866019417475728,Significantly Below (<50%),100,45.7,32.5
NCT03895762,"Observational Study of Efficacy, Safety and Tolerability of Fentanyl in Korean Cancer Patients",COMPLETED,,143.0,2017-07-04,2019-06-28,6.01232044198895,Adequate (1-10/month),60.12320441988951,Below (50-75%),100,59.8,71.61
NCT04875962,"A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)",COMPLETED,PHASE1,31.0,2019-05-06,2020-02-19,3.2651903114186855,Adequate (1-10/month),32.65190311418686,Significantly Below (<50%),100,52.5,54.345
NCT02169362,Applying Platelet Rich Plasma (PRP) Gel to Acute Deep Partial Thickness Thermal Injuries,UNKNOWN,PHASE1,36.0,2014-07-01,2018-05-01,0.7827428571428572,Slow (<1/month),7.827428571428571,Significantly Below (<50%),50,32.9,12.53
NCT01514162,Post-Approval Study Protocol of the St. Jude Medical Trifecta Valve,COMPLETED,NA,245.0,2012-02-01,2014-10-01,7.664748201438849,Adequate (1-10/month),76.6474820143885,Met (75-100%),100,69.6,81.675
NCT01521962,Study of Combination Therapy With SYR-322,COMPLETED,PHASE3,67.0,2012-02-01,2013-03-01,5.176345177664975,Adequate (1-10/month),51.76345177664975,Below (50-75%),100,55.4,62.56
NCT05629962,SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19,COMPLETED,PHASE3,2285.0,2022-11-25,2024-05-30,126.00615942028985,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT01744262,A Comparison of Totally Intravenous and Inhalation Anesthesia for Intraocular Pressure During Robot-Assisted Laparoscopic Radical Prostatectomy,COMPLETED,NA,66.0,2011-05-01,2012-03-01,6.587016393442624,Adequate (1-10/month),65.87016393442624,Below (50-75%),100,55.3,62.36000000000001
NCT01741662,Prevalence of Psychocognitive Impairments in Adolescents Surviving Childhood Leukemia : LEA-PsyCog,UNKNOWN,NA,170.0,2013-07-01,2016-06-01,4.8544090056285185,Adequate (1-10/month),48.544090056285185,Significantly Below (<50%),50,48.6,44.685
NCT01989962,E4E-Health Professional Education for Improving Care for Canadian Aboriginal Populations,UNKNOWN,PHASE2,860.0,2014-02-01,2016-11-01,26.074103585657372,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT02782962,Accuracy of a Diagnostic Algorithm for the Differential Diagnosis of Vertigo in the ED: the STANDING.,COMPLETED,,350.0,2014-12-01,2016-03-01,23.364035087719298,Good (10-50/month),200.0,Exceeded (≥100%),100,81.3,88.58
NCT03306862,Effect of Peas in Soup on Blood Glucose Control,ACTIVE_NOT_RECRUITING,NA,24.0,2017-11-08,2025-01-01,0.27980084258904636,Slow (<1/month),2.798008425890464,Significantly Below (<50%),85,42.4,25.45
NCT03759262,Ultra-high Dose Vitamin D for HSCT,COMPLETED,PHASE1,33.0,2018-12-10,2020-05-10,1.9429787234042555,Adequate (1-10/month),19.429787234042557,Significantly Below (<50%),100,52.6,54.684999999999995
NCT01156662,Efficacy of Thrombosuction in Primary Percutaneous Coronary Intervention of Acute Myocardial Infarction,UNKNOWN,PHASE4,1400.0,2009-03-01,2014-04-01,22.9488422186322,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT00704262,Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds,COMPLETED,PHASE2,33.0,2008-05-01,2009-12-01,1.7349222797927462,Adequate (1-10/month),17.34922279792746,Significantly Below (<50%),100,52.6,54.684999999999995
NCT00095862,Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers,TERMINATED,PHASE1,24.0,2004-11-01,,,Slow (<1/month),,Significantly Below (<50%),10,14.9,2.4899999999999998
NCT02672462,Renal Denervation for the Treatment of Hypertension: A Pilot Safety and Efficacy Study,UNKNOWN,NA,20.0,2015-12-01,,,Slow (<1/month),,Significantly Below (<50%),50,26.6,8.01
NCT07214662,"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer",RECRUITING,PHASE1,136.0,2026-01-12,2029-07-01,3.2700157977883095,Adequate (1-10/month),32.700157977883094,Significantly Below (<50%),60,48.9,45.4
NCT06545162,"Safety, Tolerability, and Pharmacokinetics of a Single or Multiple Ascending Doses of CPX101",RECRUITING,PHASE1,80.0,2024-12-04,2025-12-20,6.391601049868767,Adequate (1-10/month),63.91601049868767,Below (50-75%),60,44.4,28.95
NCT03227562,Is Initial Response to Low Dose Risperidone Predictive for Outcome in Anxiety?,TERMINATED,PHASE3,120.0,2017-09-01,2021-12-01,2.3536082474226805,Adequate (1-10/month),23.536082474226806,Significantly Below (<50%),10,32.6,12.31
NCT00493246,Safety and Pharmacokinetic (PK) Study of Intravenous (IV) Acetaminophen Administration in Pediatric Inpatients,COMPLETED,PHASE1,75.0,2007-06-01,2008-11-01,4.398843930635838,Adequate (1-10/month),43.98843930635839,Significantly Below (<50%),100,56.0,63.71
NCT06871046,Phase III Trial to Assess the Safety and Efficacy of TK-254RX in Patients With Contusions,COMPLETED,PHASE3,221.0,2025-02-20,2025-10-01,30.16699551569507,Good (10-50/month),200.0,Exceeded (≥100%),100,72.7,83.325
NCT06893146,Protocol for a Quasi-experimental Controlled Study to Reduce Sedentary Lifestyle in Patients With Type 2 Diabetes,NOT_YET_RECRUITING,NA,169.0,2025-07-01,2026-07-01,14.094136986301372,Good (10-50/month),140.9413698630137,Exceeded (≥100%),30,47.5,41.415
NCT06546046,Analysis of the Efficacy and Stability of a Wearable ECG Monitor,NOT_YET_RECRUITING,NA,100.0,2024-09-09,2025-03-30,15.06930693069307,Good (10-50/month),150.6930693069307,Exceeded (≥100%),30,42.0,24.825
NCT05394246,Fluorescent-labeled IgG for Liver Tumor Detection,UNKNOWN,NA,60.0,2022-05-20,2025-06-30,1.6063324538258577,Adequate (1-10/month),16.063324538258577,Significantly Below (<50%),50,34.8,15.040000000000001
NCT03442946,International Nutrition Survey 2018,COMPLETED,,280.0,2018-03-01,2019-12-31,12.721194029850748,Good (10-50/month),127.21194029850747,Exceeded (≥100%),100,75.7,84.785
NCT05061446,Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis,COMPLETED,PHASE2,54.0,2021-09-10,2023-10-06,2.1742857142857144,Adequate (1-10/month),21.742857142857144,Significantly Below (<50%),100,54.3,59.62
NCT06725446,Uterine Niche Symptoms and US and Hystroscopic Findings,ACTIVE_NOT_RECRUITING,,70.0,2023-04-18,2025-12-30,2.15886524822695,Adequate (1-10/month),21.588652482269506,Significantly Below (<50%),85,49.4,46.42
NCT07020546,Ovarian PRP Injections for Improved Embryo Quality Using Embryo Quality Score,RECRUITING,NA,180.0,2025-07-08,2026-08-30,13.108133971291867,Good (10-50/month),131.0813397129187,Exceeded (≥100%),60,57.4,67.05499999999999
NCT04300946,Time Prediction and Cerebellum: Magnetic Transcranial Stimulation (TMS) in Healthy Volunteers,RECRUITING,,48.0,2021-10-10,2025-10-01,1.0062809917355373,Adequate (1-10/month),10.062809917355372,Significantly Below (<50%),60,35.2,15.445
NCT02734446,To Evaluate the Efficacy of Supplementation With L. Reuteri + Vit. D3 in Asthmatic Children,COMPLETED,PHASE3,52.0,2014-04-01,2016-03-01,2.261257142857143,Adequate (1-10/month),22.612571428571428,Significantly Below (<50%),100,54.2,59.330000000000005
NCT01191346,Radiation Planning Study for High Grade Brain Tumors,COMPLETED,,24.0,2010-06-01,2013-03-01,0.7276494023904383,Slow (<1/month),7.276494023904383,Significantly Below (<50%),100,45.3,31.169999999999998
NCT00407446,PDE5-Inhibition With Sildenafil in Chronic Heart Failure,COMPLETED,PHASE3,40.0,2004-01-01,2005-02-01,3.067002518891688,Adequate (1-10/month),30.670025188916878,Significantly Below (<50%),100,53.2,56.665
NCT04702646,Patient and Colonoscopy Cleansing Quality Agreement,COMPLETED,,1011.0,2021-02-17,2021-09-30,136.77706666666668,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT01122446,Diabetes Prevention - Immune Tolerance,COMPLETED,PHASE2,50.0,2009-04-01,2016-12-01,0.5433773652267048,Slow (<1/month),5.433773652267047,Significantly Below (<50%),100,49.0,45.61
NCT05308446,Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation,ACTIVE_NOT_RECRUITING,PHASE2,84.0,2022-07-19,2026-02-28,1.9370909090909092,Adequate (1-10/month),19.37090909090909,Significantly Below (<50%),85,52.2,53.22
NCT00357188,Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects,COMPLETED,PHASE1,22.0,2006-07-01,2006-09-01,10.801290322580645,Good (10-50/month),108.01290322580645,Exceeded (≥100%),100,56.8,65.69500000000001
NCT01459588,"Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease",COMPLETED,PHASE3,315.0,2011-10-01,2012-02-15,69.98978102189781,Excellent (>50/month),200.0,Exceeded (≥100%),100,85.2,91.315
NCT04795388,Development of an Artificial Intelligence Algorithm,UNKNOWN,,589.0,2020-08-01,2023-12-31,14.37783480352847,Good (10-50/month),143.77834803528472,Exceeded (≥100%),50,78.3,86.48
NCT06463288,Comparison of Jacobson Relaxation Technique and Pranayama Technique in Patients With COPD,COMPLETED,NA,30.0,2023-07-20,2023-12-10,6.386013986013986,Adequate (1-10/month),63.86013986013985,Below (50-75%),100,52.4,53.949999999999996
NCT04296188,Erector Spina Plane Block vs Serratus Anterior Plane Block for Postoperative Mastectomy Pain,UNKNOWN,NA,60.0,2020-03-18,2021-03-15,5.045303867403315,Adequate (1-10/month),50.453038674033145,Below (50-75%),50,39.8,21.47
NCT01900288,Home Parenteral Nutrition (HPN) Families' Mobile Distance Connections to Care Research,COMPLETED,NA,121.0,2012-08-01,2016-12-23,2.2948535825545173,Adequate (1-10/month),22.94853582554517,Significantly Below (<50%),100,59.7,71.355
NCT00055588,Nervous System Function in Normal Volunteers During Cycling Training,COMPLETED,PHASE1,60.0,2003-03-04,2008-05-20,0.9592436974789916,Slow (<1/month),9.592436974789917,Significantly Below (<50%),100,49.8,47.17
NCT06699888,Effect of Cervicothoracic Junction Manipulation on Craniovertebral Angle and Proprioception in Forward Head Posture,COMPLETED,NA,36.0,2024-06-01,2025-04-16,3.4352351097178686,Adequate (1-10/month),34.35235109717868,Significantly Below (<50%),100,52.9,55.55
NCT02750488,18793 - Human Photoallergy Test,COMPLETED,NA,54.0,2016-05-09,2016-07-01,31.01433962264151,Good (10-50/month),200.0,Exceeded (≥100%),100,59.3,70.815
NCT02131688,Phase I Study of Mitoxantrone Hydrochloride Liposome Injection,UNKNOWN,PHASE1,30.0,2013-05-01,2015-10-01,1.034201585503964,Adequate (1-10/month),10.342015855039637,Significantly Below (<50%),50,32.4,12.025
NCT02898688,P3+ Intervention Phase,COMPLETED,NA,2200.0,2017-06-12,2020-07-06,59.792857142857144,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT01346488,Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment),COMPLETED,,2088.0,2011-06-01,2016-01-01,37.94550447761194,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT03200288,A Study to Evaluate the Clinical Performance and Safety of an Intra-articular Hyaluronic Acid in Knee Osteoarthritis,COMPLETED,PHASE3,692.0,2017-06-29,2018-10-30,43.164918032786886,Good (10-50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT02030288,Relational Agent for Alcohol Screening and Treatment,COMPLETED,NA,178.0,2015-02-19,2018-10-23,4.0374962742175855,Adequate (1-10/month),40.37496274217586,Significantly Below (<50%),100,64.2,77.18
NCT05208788,Urinary Biomarkers in Paediatric Kidney Transplantation (pKTx),COMPLETED,,186.0,2021-06-01,2023-02-01,9.281704918032787,Adequate (1-10/month),92.81704918032788,Met (75-100%),100,68.2,80.77
NCT00203788,Improving Work Outcome in People With Recent-onset Schizophrenia,COMPLETED,PHASE4,87.0,1999-05-01,2006-12-01,0.9557127390833635,Slow (<1/month),9.557127390833635,Significantly Below (<50%),100,52.0,52.86
NCT00034788,A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX,TERMINATED,PHASE3,84.0,2000-12-01,2004-02-01,2.209991356957649,Adequate (1-10/month),22.09991356957649,Significantly Below (<50%),10,29.7,8.92
NCT01305603,Ultrasound-guided Dual TAP Block: Magnetic Resonance (MR) Evaluation of the Distribution of Local Anesthetic,COMPLETED,NA,10.0,2011-02-01,2013-04-01,0.3853164556962026,Slow (<1/month),3.853164556962026,Significantly Below (<50%),100,45.8,33.03
NCT05396703,TOETVA Feasibility and Complications - Single Center First Experience,COMPLETED,,18.0,2019-10-22,2023-06-19,0.4101197604790419,Slow (<1/month),4.101197604790419,Significantly Below (<50%),100,44.8,29.845
NCT01633203,Observational Study of Perioperative Chemotherapy in Gastric Cancer,COMPLETED,,61.0,2010-08-01,2018-12-01,0.61,Slow (<1/month),6.1,Significantly Below (<50%),100,48.2,43.665
NCT02042703,Imaging Lens Deposits in Exfoliation Syndrome,TERMINATED,,4.0,2014-02-01,2015-09-01,0.21102253032928944,Slow (<1/month),2.1102253032928946,Significantly Below (<50%),10,16.7,2.68
NCT06019403,Association Between a Healthy Lifestyle Behavior and Musculoskeletal Pain,COMPLETED,,1188.0,2023-11-16,2024-05-16,198.69626373626375,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02570503,Postoperative Pain Control After Periarticular Injection During Total Knee Arthroplasty,TERMINATED,PHASE4,64.0,2015-10-01,2021-02-11,0.9939591836734695,Slow (<1/month),9.939591836734694,Significantly Below (<50%),10,23.1,6.404999999999999
NCT05447403,Effect of Chewing Gum and WeChat Enhanced Instructions on the Bowel Preparation Quality in Patients With Constipation,COMPLETED,NA,115.0,2022-02-24,2023-08-30,6.341666666666667,Adequate (1-10/month),63.416666666666664,Below (50-75%),100,59.2,70.7
NCT06027203,Transperineal Versus Transrectal Prostate Biopsy,COMPLETED,,923.0,2023-04-15,2023-07-18,298.8948936170213,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT00919503,Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders,COMPLETED,PHASE2,98.0,2009-07-31,2020-06-10,0.7519838669019411,Slow (<1/month),7.519838669019411,Significantly Below (<50%),100,52.8,55.31
NCT02731703,"Conventional, Overdenture and Palateless Overdenture Oral Health Impact Comparison Study",COMPLETED,,14.0,2016-04-01,2023-01-04,0.172604293236128,Slow (<1/month),1.72604293236128,Significantly Below (<50%),100,44.5,29.160000000000004
NCT05239403,Association Between Gut Microbiome and Dietary Determinants and Vaccine Response,RECRUITING,,1000.0,2021-08-24,2027-02-28,15.114200595829198,Good (10-50/month),151.14200595829197,Exceeded (≥100%),60,81.3,88.58
NCT06651203,"Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study",NOT_YET_RECRUITING,,460.0,2024-11-01,2029-11-01,7.668346111719606,Adequate (1-10/month),76.68346111719606,Met (75-100%),30,64.1,77.12
NCT03267303,A Study to Evaluate the Safety and Efficacy of TS-091 in Patients with Narcolepsy,COMPLETED,PHASE2,53.0,2017-10-31,2019-08-08,2.497399380804954,Adequate (1-10/month),24.97399380804954,Significantly Below (<50%),100,54.2,59.330000000000005
NCT02625103,The Significance of Deviation in Time From the 12-hour Standard Serum-clozapine Monitoring.,COMPLETED,PHASE4,48.0,2015-09-01,2016-02-01,9.549803921568628,Adequate (1-10/month),95.49803921568628,Met (75-100%),100,58.8,69.89999999999999
NCT05743803,Observance of Preoperative Fasting Time a Before-and-after Sensitization Campaign to Fasting Guidelines Study,COMPLETED,,364.0,2023-02-27,2023-08-20,63.67908045977012,Excellent (>50/month),200.0,Exceeded (≥100%),100,87.5,92.305
NCT01708603,P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis,TERMINATED,PHASE3,1831.0,2012-08-01,2015-10-01,48.2142214532872,Good (10-50/month),200.0,Exceeded (≥100%),10,73.0,83.44
NCT04802603,Dose-Escalated Spine SbRT for Localized Metastasis to the Spinal Column,RECRUITING,NA,60.0,2021-03-14,2029-12-31,0.5682638456751711,Slow (<1/month),5.682638456751712,Significantly Below (<50%),60,37.8,19.015
NCT05320003,Assessment of Balance in Patients With Pes Planus,UNKNOWN,NA,40.0,2022-04-06,2022-05-15,31.22051282051282,Good (10-50/month),200.0,Exceeded (≥100%),50,43.2,26.840000000000003
NCT00838903,Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes,COMPLETED,PHASE3,1049.0,2009-02-01,2013-04-01,21.007605263157895,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT04294303,Use of Telemonitoring System in Heart Failure Patients,COMPLETED,NA,50.0,2016-02-03,2020-01-29,1.0453296703296704,Adequate (1-10/month),10.453296703296704,Significantly Below (<50%),100,49.0,45.61
NCT02476903,Viscosupplementation in the Hip Following Hip Arthroscopy,UNKNOWN,NA,,2015-06-01,,,Slow (<1/month),,Significantly Below (<50%),50,25.0,7.23
NCT06107803,"A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia",COMPLETED,PHASE1,17.0,2023-10-13,2024-01-12,5.686593406593407,Adequate (1-10/month),56.86593406593406,Below (50-75%),100,51.4,50.92
NCT03890627,Thoracic Bio-reactance Measurement of Cardiac Output in Pulmonary Hypertension,COMPLETED,,60.0,2019-05-21,2022-05-31,1.651356238698011,Adequate (1-10/month),16.51356238698011,Significantly Below (<50%),100,48.1,43.275000000000006
NCT03604627,Study of Coronary Calcium Score as a Marker of Post-radiation Vascular Dysplasia in Adults Treated During Childhood for Cancer With Mediastinal Irradiation,RECRUITING,NA,500.0,2018-06-14,2028-09-01,4.078242229367631,Adequate (1-10/month),40.78242229367631,Significantly Below (<50%),60,78.0,86.075
NCT03041727,"Physiotherapist Approach to Shoulder's Diseases, Differences Between Fascial Manipulation and Standard Exercises",COMPLETED,NA,70.0,2017-02-01,2021-08-01,1.29768574908648,Adequate (1-10/month),12.976857490864798,Significantly Below (<50%),100,50.6,48.705
NCT06140927,Effect of Ketamine on Intraoperative Motor Evoked Potentials,RECRUITING,PHASE3,20.0,2023-12-01,2026-12-01,0.5554744525547445,Slow (<1/month),5.554744525547445,Significantly Below (<50%),60,34.6,14.729999999999999
NCT06335927,HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC,RECRUITING,PHASE2,45.0,2023-05-11,2026-05-10,1.2509589041095892,Adequate (1-10/month),12.509589041095893,Significantly Below (<50%),60,36.6,17.41
NCT04817527,Edaravone Dexborneol for Treatment of Acute Ischemic Stroke With Endovascular Therapy in Extended Time Windows,UNKNOWN,PHASE2,200.0,2021-10-01,2022-12-31,13.350877192982457,Good (10-50/month),133.50877192982458,Exceeded (≥100%),50,56.0,63.71
NCT04544527,The Risk Factors of Cardiovascular Disease in Elderly Diabetic Patients: A Prospective Cohort Study,RECRUITING,,10000.0,2020-09-01,2031-12-31,73.5621072982117,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT07352527,New Clinical Decision Support Score Based on Steroid Hormone Profiling in the Diagnosis of MACS,RECRUITING,,291.0,2025-11-19,2027-05-01,16.77659090909091,Good (10-50/month),167.7659090909091,Exceeded (≥100%),60,64.6,77.59
NCT02084927,Hyperbaric Oxygen Therapy Can Improve Neurological State Post Meningioma Removal Surgery,UNKNOWN,PHASE1,62.0,2014-04-01,,,Slow (<1/month),,Significantly Below (<50%),50,30.0,9.145
NCT04609527,Management of Placenta Accreta Spectrum,UNKNOWN,PHASE2,30.0,2020-10-16,2021-12-31,2.0707482993197277,Adequate (1-10/month),20.707482993197278,Significantly Below (<50%),50,37.4,18.62
NCT06174727,International Registry of Intra-arterial and Endosaccular Flow Diverters (IRF),RECRUITING,,5000.0,2023-10-01,2026-06-01,156.26283367556468,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT03247127,Memory Preservation of Hippocampal Avoidance Whole Brain Radiotherapy,UNKNOWN,NA,30.0,2017-03-27,2020-12-31,0.6641454545454546,Slow (<1/month),6.641454545454546,Significantly Below (<50%),50,32.4,12.025
NCT06299527,Telerehabilitation in Patients With Fibromyalgia,COMPLETED,NA,66.0,2023-05-27,2024-01-27,8.200163265306124,Adequate (1-10/month),82.00163265306124,Met (75-100%),100,55.3,62.36000000000001
NCT04393727,Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19,TERMINATED,PHASE2,1.0,2020-05-01,2020-09-30,0.20026315789473684,Slow (<1/month),2.0026315789473683,Significantly Below (<50%),10,18.1,3.105
NCT00385827,A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC),TERMINATED,PHASE2,106.0,2006-11-01,2008-11-01,4.414008207934337,Adequate (1-10/month),44.140082079343365,Significantly Below (<50%),10,31.5,10.635
NCT01964027,The Study of Irinotecan Plus Epirubicin as the Second-line Chemoregime for Advanced Gastric Cancer,UNKNOWN,PHASE2,40.0,2013-10-01,2014-12-01,2.8582159624413146,Adequate (1-10/month),28.582159624413144,Significantly Below (<50%),50,38.2,19.645000000000003
NCT02638727,Assessment of Short-term Effect of L-Citrulline on Endothelial Function and Vasodilation in Known CAD Patients,UNKNOWN,NA,30.0,2015-12-01,2016-02-01,14.729032258064516,Good (10-50/month),147.29032258064515,Exceeded (≥100%),50,42.4,25.45
NCT06883227,Investigating Health Impacts of Exposure to Harmful Algal Blooms,RECRUITING,,400.0,2024-10-14,2030-10-14,5.557279780921954,Adequate (1-10/month),55.572797809219544,Below (50-75%),60,68.3,80.875
NCT04434027,The Effects of Natural Sugars in Breast Milk on Healthy Infant Growth and Development,COMPLETED,,221.0,2016-07-01,2022-08-01,3.0275607560756077,Adequate (1-10/month),30.27560756075608,Significantly Below (<50%),100,66.0,78.99000000000001
NCT02326727,Influence of Epidural Analgesia on Natural Killer Cell (NK) Activity After Colonic Cancer Surgery,UNKNOWN,NA,30.0,2015-04-01,2017-05-01,1.2,Adequate (1-10/month),12.0,Significantly Below (<50%),50,32.4,12.025
NCT02855827,Constitution of a Cohort for Monitoring Patients Candidating for Ovarian Tissue Autograft,RECRUITING,,240.0,2013-05-01,2025-10-01,1.6105820105820106,Adequate (1-10/month),16.105820105820104,Significantly Below (<50%),60,50.5,48.515
NCT03846661,Nationwide Long-term Outcome Surveillance of Physiomesh® vs. Other Meshes in Laparoscopic Incisional Hernia Repair,COMPLETED,NA,3338.0,2010-01-01,2019-02-01,30.623484026522004,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT05332561,Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE),RECRUITING,PHASE2,240.0,2023-06-29,2030-12-01,2.6938053097345134,Adequate (1-10/month),26.93805309734514,Significantly Below (<50%),60,57.2,66.465
NCT05596461,New Techniques for Diagnosis and Treatment of Cognitive Impairment in Affective Disorder,UNKNOWN,NA,90.0,2022-01-01,2024-10-01,2.7286852589641435,Adequate (1-10/month),27.286852589641438,Significantly Below (<50%),50,42.2,25.155
NCT02081261,Predicting Acute Kidney Injury After Coronary Artery Bypass Graft,COMPLETED,,877.0,2014-01-01,2016-02-01,35.08,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT04582461,Role of Preoperative Multislice Computed Tomography in Whipple's Operation.,UNKNOWN,,100.0,2021-01-01,2022-02-01,7.686868686868687,Adequate (1-10/month),76.86868686868688,Met (75-100%),50,41.3,23.74
NCT06702761,Prevalence and Severity of Depression Among Cardiothoracic Surgery Healthcare Workers in Baghdad: A PHQ-9 Cross-Sectional Study,RECRUITING,,200.0,2024-12-01,2025-05-15,36.8969696969697,Good (10-50/month),200.0,Exceeded (≥100%),60,57.3,66.74
NCT04000061,Heart Failure-USB: Prediction and Progression,RECRUITING,,6000.0,2019-06-13,2026-12-31,66.22189992748369,Excellent (>50/month),200.0,Exceeded (≥100%),60,86.3,91.725
NCT00549861,Characterization of Irreversible Myocardial Injury in Cardiomyopathies by Contrast-enhanced CMR,COMPLETED,NA,40.0,2007-09-01,2008-08-01,3.6346268656716423,Adequate (1-10/month),36.34626865671642,Significantly Below (<50%),100,53.2,56.665
NCT00071461,Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis,COMPLETED,PHASE2,158.0,2003-08-01,2010-05-01,1.9511237322515214,Adequate (1-10/month),19.511237322515214,Significantly Below (<50%),100,62.6,75.325
NCT07355361,Huaier Granule and Proteinuria,NOT_YET_RECRUITING,PHASE2,120.0,2026-01-15,2028-06-15,4.141496598639455,Adequate (1-10/month),41.414965986394556,Significantly Below (<50%),30,38.6,20.015
NCT05158361,Acupuncture for Overactive Bladder in Adults,RECRUITING,NA,110.0,2022-03-08,2024-12-31,3.254033041788144,Adequate (1-10/month),32.540330417881435,Significantly Below (<50%),60,46.8,38.440000000000005
NCT04549961,123 nutritionDay in Worldwide ICUs: An International Audit and Registry on Nutrition and Outcome.,UNKNOWN,,35000.0,2007-01-01,2025-12-01,154.20466058763932,Excellent (>50/month),200.0,Exceeded (≥100%),50,83.3,90.11
NCT06541561,Efficacy of TEAS on Postoperative Pain and Recovery in Patients Undergoing Pancreatectomy,NOT_YET_RECRUITING,NA,132.0,2025-07-16,2026-09-30,9.111292517006802,Adequate (1-10/month),91.11292517006804,Met (75-100%),30,44.6,29.42
NCT05606861,Mindfulness Based Interventions in Pediatric Nurses,COMPLETED,NA,29.0,2018-11-20,2019-01-30,12.433239436619719,Good (10-50/month),124.33239436619718,Exceeded (≥100%),100,57.3,66.74
NCT05570461,Efficacy of Modified Constraint-Induced Movement Therapy on the Upper Limb Function of Sub-acute Stroke Patients in Peshawar Pakistan,UNKNOWN,NA,46.0,2022-11-04,2023-09-25,4.308430769230769,Adequate (1-10/month),43.084307692307696,Significantly Below (<50%),50,38.7,20.145
NCT04154761,Resection of the Inferior Vena Cava Due to Tumor Involvement,COMPLETED,,13.0,2019-01-31,2019-10-01,1.6284773662551442,Adequate (1-10/month),16.28477366255144,Significantly Below (<50%),100,44.4,28.95
NCT06325761,A Study to Evaluate the Food Effects on Pharmacokinetics of SY-5007 Tablets in Healthy Subjects,NOT_YET_RECRUITING,PHASE1,28.0,2024-04-01,2024-05-01,28.0,Good (10-50/month),200.0,Exceeded (≥100%),30,36.2,16.84
NCT04595461,Effect of Patient Education Videos on Perioperative Anxiety in Patients Undergoing Endoscopic Sinus Surgery,COMPLETED,NA,80.0,2017-05-01,2020-05-01,2.221897810218978,Adequate (1-10/month),22.21897810218978,Significantly Below (<50%),100,56.4,64.88000000000001
NCT03687242,Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia,COMPLETED,PHASE2,11.0,2018-09-06,2019-08-09,0.9935905044510387,Slow (<1/month),9.935905044510388,Significantly Below (<50%),100,45.9,33.495000000000005
NCT06776042,Upper Airway Inflammation and Olfaction: Mechanisms of Loss and Recovery,RECRUITING,NA,140.0,2023-05-22,2026-09-30,3.47318663406683,Adequate (1-10/month),34.73186634066829,Significantly Below (<50%),60,49.2,46.035
NCT06579742,A Clinical Trial to Examine the Efficacy of a Supplement to Support Healthy Hair and Skin,ACTIVE_NOT_RECRUITING,NA,50.0,2024-06-07,2024-12-31,7.3526570048309186,Adequate (1-10/month),73.52657004830918,Below (50-75%),85,49.5,46.58
NCT01115842,Vitamin D and Inflammatory Cytokine Levels After Acute Myocardial Infraction (MI),UNKNOWN,PHASE4,50.0,2010-06-01,2011-01-01,7.112149532710281,Adequate (1-10/month),71.1214953271028,Below (50-75%),50,39.0,20.505000000000003
NCT02839642,"Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy",COMPLETED,PHASE3,106.0,2016-07-26,2022-11-17,1.3998438177874186,Adequate (1-10/month),13.998438177874187,Significantly Below (<50%),100,53.5,57.555
NCT04783142,A Study to Evaluate the Influence of Diet on GI Health,COMPLETED,NA,20.0,2021-06-11,2023-03-27,0.9308868501529053,Slow (<1/month),9.308868501529052,Significantly Below (<50%),100,46.6,37.375
NCT05281042,Home OCT Repeatability and Reproducibility of Automatic Fluid Quantification Study,COMPLETED,,20.0,2021-09-13,2022-01-05,5.340350877192983,Adequate (1-10/month),53.40350877192983,Below (50-75%),100,49.9,47.425
NCT03951142,Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label Losartan Study,UNKNOWN,PHASE2,165.0,2019-10-01,2024-12-31,2.61866527632951,Adequate (1-10/month),26.186652763295097,Significantly Below (<50%),50,48.2,43.665
NCT01474642,Phase II Trial of XP Versus XG in Advanced Esophageal Squamous Cell Carcinoma,COMPLETED,PHASE2,64.0,2008-09-01,2014-05-01,0.9420502901353967,Slow (<1/month),9.420502901353967,Significantly Below (<50%),100,50.1,47.89
NCT04836442,PFI Hazardous Drinkers With Subclinical PTSD,UNKNOWN,NA,100.0,2022-07-01,2023-07-01,8.339726027397262,Adequate (1-10/month),83.3972602739726,Met (75-100%),50,48.0,42.945
NCT04385342,FSH Followed by HMG vs FSH Plus HMG in IVF,UNKNOWN,PHASE4,530.0,2020-06-30,2022-08-31,20.370202020202022,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT05119842,"APrevent-VOIS-Implant-002 - a Two-Part, Open-Label, Non-Randomized Multicenter Study",RECRUITING,NA,30.0,2019-11-13,2026-09-01,0.3676328502415459,Slow (<1/month),3.676328502415459,Significantly Below (<50%),60,35.4,15.765
NCT06946342,WATERinMOTION Aquatic Exercise Program Compared to Land-Based Rehabilitation on Low-Back Pain Relief and Quality of Life,ACTIVE_NOT_RECRUITING,NA,90.0,2025-01-25,2025-05-30,21.9168,Good (10-50/month),200.0,Exceeded (≥100%),85,57.7,67.51
NCT01052142,Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma,COMPLETED,PHASE1,12.0,2009-09-01,2012-03-01,0.40052631578947373,Slow (<1/month),4.0052631578947375,Significantly Below (<50%),100,46.0,34.1
NCT05271942,Tilt and Tumble vs Divide and Conquer - a Unique Comparison of the Two Cataract Surgery Methods,UNKNOWN,NA,1000.0,2021-09-08,2023-12-01,37.3955773955774,Good (10-50/month),200.0,Exceeded (≥100%),50,80.0,87.67
NCT00442442,Clinical Evaluation of Mosquito Coils to Control Malaria in China,UNKNOWN,PHASE3,8000.0,2007-04-01,2007-12-01,998.0327868852459,Excellent (>50/month),200.0,Exceeded (≥100%),50,85.0,91.07499999999999
NCT06471842,Study of the Prevalence of Pediatric Eating Disorders in Inherited Metabolic Diseases With Dietary Treatment,RECRUITING,,200.0,2024-08-21,2026-08-01,8.574647887323945,Adequate (1-10/month),85.74647887323945,Met (75-100%),60,57.3,66.74
NCT04698642,"A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat",COMPLETED,PHASE2,43.0,2020-02-03,2020-11-12,4.625159010600707,Adequate (1-10/month),46.25159010600707,Significantly Below (<50%),100,53.4,57.35
NCT00282542,Hepatocyte Transplantation as a Life Support Bridge,WITHDRAWN,NA,0.0,2000-05-01,2006-01-01,,Slow (<1/month),0.0,Significantly Below (<50%),5,14.8,1.6650000000000003
NCT03347942,Effects of the Administered Time of Meal on the Treatment of Overweight and Obesity,UNKNOWN,NA,110.0,2017-08-10,2018-07-01,10.302769230769231,Good (10-50/month),103.0276923076923,Exceeded (≥100%),50,48.8,45.184999999999995
NCT04099342,Enhanced Spatial Targeting in ECT Utilizing FEAST,SUSPENDED,NA,20.0,2022-04-01,2026-06-30,0.39252095422308186,Slow (<1/month),3.925209542230819,Significantly Below (<50%),20,22.6,6.329999999999999
NCT01634542,An Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia,COMPLETED,,1433.0,2011-02-01,2014-12-01,31.179785561115082,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT00313586,"Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia",COMPLETED,PHASE2,197.0,2006-08-01,2013-07-01,2.3739825811559783,Adequate (1-10/month),23.739825811559783,Significantly Below (<50%),100,65.8,78.745
NCT04633486,Endoscopically One-year Follow-up in Patients After Small-bowel Transplantation,COMPLETED,,15.0,2012-04-01,2019-11-15,0.1640086206896552,Slow (<1/month),1.6400862068965516,Significantly Below (<50%),100,44.5,29.160000000000004
NCT00665886,Compact Closed System Versus Mounted Open System (COSMOS),COMPLETED,PHASE4,1200.0,2008-03-01,2009-04-01,92.24242424242425,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT01597986,Drug Interaction Study of Isavuconazole and Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone,COMPLETED,PHASE1,24.0,2012-04-01,2012-06-01,11.97639344262295,Good (10-50/month),119.7639344262295,Exceeded (≥100%),100,56.9,65.89500000000001
NCT01506986,Helicobacter Eradication Aspirin Trial,COMPLETED,PHASE4,30024.0,2012-03-01,2022-03-16,249.2311317152986,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT00278486,Hematopoietic Stem Cell Transplantation in Autoimmune-Related Retinopathy(ARRON),TERMINATED,PHASE1,2.0,2004-08-01,2012-04-01,0.021742857142857144,Slow (<1/month),0.21742857142857142,Significantly Below (<50%),10,18.2,3.4799999999999995
NCT00911586,Pharmacokinetic Study to Determine Time to Steady-state,COMPLETED,PHASE2,15.0,2009-07-01,2010-01-01,2.481521739130435,Adequate (1-10/month),24.81521739130435,Significantly Below (<50%),100,51.2,50.375
NCT00463086,Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis in HIV-infected Persons,COMPLETED,NA,1368.0,2007-11-01,2011-11-01,28.502340862422997,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT03846986,Postprandial Glycemia in Apple Products,COMPLETED,NA,59.0,2019-02-28,2020-06-12,3.8211914893617025,Adequate (1-10/month),38.21191489361703,Significantly Below (<50%),100,54.7,60.629999999999995
NCT06315686,The Dynamic Monitoring of Cerebrospinal Fluid ctDNA,RECRUITING,PHASE2,20.0,2022-09-29,2024-12-31,0.7388349514563107,Slow (<1/month),7.388349514563107,Significantly Below (<50%),60,34.6,14.729999999999999
NCT02498886,IHAT Absorption Kinetics,COMPLETED,EARLY_PHASE1,34.0,2015-08-01,2016-03-01,4.858967136150235,Adequate (1-10/month),48.589671361502354,Significantly Below (<50%),100,52.7,55.04
NCT01080586,Bioequivalence Study of Cyclosporine 100mg Capsule Under Fed Condition,COMPLETED,NA,36.0,2007-09-01,2007-10-01,36.0,Good (10-50/month),200.0,Exceeded (≥100%),100,57.9,67.83
NCT06328686,Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases,RECRUITING,EARLY_PHASE1,10.0,2024-09-05,2027-12-31,0.2511551155115512,Slow (<1/month),2.511551155115512,Significantly Below (<50%),60,33.8,13.694999999999999
NCT04048486,Children Born From IVM-CAPA vs IVF or Natural Conception,COMPLETED,,66.0,2019-08-07,2019-12-15,15.454153846153845,Good (10-50/month),154.54153846153844,Exceeded (≥100%),100,58.6,69.51
NCT06240286,"Comparing Manual and Neurocognitive Skills-While Sitting, Standing, Walking on a Treadmill and Using a Stepper.",COMPLETED,NA,44.0,2015-10-01,2015-11-01,43.20516129032258,Good (10-50/month),200.0,Exceeded (≥100%),100,63.5,76.465
NCT04043286,The Effects of Dis/Reconnection of Implant Abutments on Peri-implant Bone Levels,COMPLETED,NA,19.0,2019-09-30,2023-09-18,0.399144237405107,Slow (<1/month),3.9914423740510707,Significantly Below (<50%),100,46.5,36.815
NCT02718586,"Serum Level of Myokines and Protein Energy Wasting, Inflammation and Atherosclerosis in Hemodialysis Patients",COMPLETED,,170.0,2016-03-01,2016-12-01,18.817454545454545,Good (10-50/month),188.1745454545455,Exceeded (≥100%),100,66.9,79.60000000000001
NCT02832986,Herpes Zoster Prevalence in Frailty Consultations,COMPLETED,,1245.0,2015-01-01,2016-06-01,73.30328820116056,Excellent (>50/month),200.0,Exceeded (≥100%),100,98.3,97.505
NCT02268786,Single Embryo TrAnsfeR of Euploid Embryo,COMPLETED,NA,661.0,2014-09-01,2016-12-31,23.616009389671362,Good (10-50/month),200.0,Exceeded (≥100%),100,95.0,95.7
NCT04732286,A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy,TERMINATED,PHASE3,100.0,2021-05-04,2024-04-26,2.797794117647059,Adequate (1-10/month),27.977941176470587,Significantly Below (<50%),10,31.0,9.985
NCT04296786,Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study,UNKNOWN,PHASE2,52.0,2019-11-01,2024-12-01,0.8523855681206246,Slow (<1/month),8.523855681206244,Significantly Below (<50%),50,34.2,14.305000000000001
NCT01750970,Endoscopic Resection of Bladder Tumors,COMPLETED,NA,68.0,2009-11-01,2013-12-01,1.3882763246143528,Adequate (1-10/month),13.88276324614353,Significantly Below (<50%),100,50.4,48.355
NCT02723370,Implementation of Evidence Based Practices for Colonoscopy: The Strategies to Improve Colonoscopy Study,COMPLETED,NA,46184.0,2013-05-01,2016-12-01,1073.161038167939,Excellent (>50/month),200.0,Exceeded (≥100%),100,100.0,99.185
NCT05825170,Evaluation of a HA Dermal Filler in the Treatment of Lip Deformity,RECRUITING,NA,20.0,2023-12-08,2027-06-15,0.47377431906614786,Slow (<1/month),4.737743190661479,Significantly Below (<50%),60,34.6,14.729999999999999
NCT03998670,Base-in Prism Spectacles for Intermittent Exotropia,COMPLETED,NA,61.0,2019-09-01,2020-07-30,5.576096096096097,Adequate (1-10/month),55.76096096096097,Below (50-75%),100,54.9,61.55500000000001
NCT01095770,Left Atrial Ablation With Permanent Pacemaker or ImplanTable Loop Recorder Follow-UP,UNKNOWN,NA,50.0,2010-04-01,2012-11-01,1.6105820105820106,Adequate (1-10/month),16.105820105820108,Significantly Below (<50%),50,34.0,14.02
NCT04939870,Assessment of Protein Modification in Chronic Kidney Disease - Selected Clinical and Biochemical Aspects,COMPLETED,,195.0,2015-01-01,2019-01-10,4.03795918367347,Adequate (1-10/month),40.3795918367347,Significantly Below (<50%),100,63.9,76.9
NCT00961870,Effect of Radius on Alpha Motor Neuron Excitability,COMPLETED,NA,80.0,2009-09-01,2009-12-01,26.76043956043956,Good (10-50/month),200.0,Exceeded (≥100%),100,61.4,73.735
NCT04393870,Focusing on Maryam's Flower at Labor,COMPLETED,NA,124.0,2019-05-01,2020-01-31,13.725672727272729,Good (10-50/month),137.2567272727273,Exceeded (≥100%),100,64.9,77.985
NCT06317870,Pericapsular Nerve Block Versus Intrathecal Morphine for Analgesia After Primary Hip Arthroplasty,RECRUITING,NA,80.0,2024-09-10,2027-05-01,2.528764278296989,Adequate (1-10/month),25.28764278296989,Significantly Below (<50%),60,44.4,28.95
NCT04311970,Pilot Study of Esocheck in Eosinophilic Esophagitis,COMPLETED,NA,12.0,2020-08-05,2021-08-23,0.9537336814621411,Slow (<1/month),9.537336814621412,Significantly Below (<50%),100,46.0,34.1
NCT04703270,Understanding COVID-19 Infection in Pregnant Women and Their Babies,COMPLETED,,881.0,2021-01-04,2023-09-30,26.844484484484486,Good (10-50/month),200.0,Exceeded (≥100%),100,93.3,94.325
NCT06419270,"Cardiovascular, Renal, and Skeletal Complications in Patients With Post-Surgical Hypoparathyroidism",COMPLETED,,100.0,2024-05-26,2025-06-30,7.61,Adequate (1-10/month),76.1,Met (75-100%),100,56.3,64.5
